
APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

24th EDITION

THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF PHARMACEUTICAL SCIENCE
OFFICE OF GENERIC DRUGS

2004

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2003.

24th EDITION



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF PHARMACEUTICAL SCIENCE
OFFICE OF GENERIC DRUGS

2004

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
APPROVED DRUG PRODUCTS
with
Therapeutic Equivalence Evaluations

CONTENTS

		PAGE
PREFACE TO TWENTY FOURTH EDITION		v
1.	INTRODUCTION	vii
1.1	Content and Exclusion	vii
1.2	Therapeutic Equivalence-Related Terms	vii
1.3	Statistical Criteria for Bioequivalence	ix
1.4	Reference Listed Drug	x
1.5	General Policies and Legal Status	xi
1.6	Practitioner/User Responsibilities	xii
1.7	Therapeutic Equivalence Evaluations Codes	xiii
1.8	Description of Special Situations	xx
1.9	Therapeutic Equivalence Code Change for a Drug Entity	xxi
1.10	Change of the Therapeutic Equivalence Evaluation for a Single Product	xxii
1.11	Availability of Internal Policy and Procedure Guides	xxii
1.12	Discontinued Section	xxii
2.	HOW TO USE THE DRUG PRODUCTS LISTS	2-1
2.1	Key Sections for Using the Drug Product Lists	2-1
2.2	Drug Product Illustration	2-3
2.3	Therapeutic Equivalence Evaluations Illustration	2-4
DRUG PRODUCT LISTS		
	Prescription Drug Product List	3-1
	OTC Drug Product List	4-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	5-1
	Discontinued Drug Product List	6-1
	Orphan Products Designations and Approvals List	7-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	8-1
APPENDICES		
	A. Product Name Index	A-1
	B. Product Name Index Listed by Applicant	B-1
	C. Uniform Terms	C-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		AD1
	A. Patent and Exclusivity Lists	ADA1
	B. Patent and Exclusivity Terms	ADB1

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
APPROVED DRUG PRODUCTS
with
Therapeutic Equivalence Evaluations

PREFACE TO TWENTY FOURTH EDITION

The publication, *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act). Drugs on the market approved only on the basis of safety (covered by the ongoing Drug Efficacy Study Implementation [DESI] review [e.g., Donnatal® Tablets and Librax® Capsules] or pre-1938 drugs [e.g., Phenobarbital Tablets]) are not included in this publication. The main criterion for the inclusion of any product is that the product is the subject of an application with an effective approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products on the List is independent of any current regulatory action through administrative or judicial means against a drug product. In addition, the List contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the Act.

Background of the Publication. To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state stating FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The List was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the Act.

The therapeutic equivalence evaluations in the List reflect FDA's application of specific criteria to the multisource prescription drug products on the List approved under Section 505 of the Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the code appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register* on October 31, 1980 (45 FR 72582). The first publication, October 1980, of the final version of the List incorporated

FDA data supplied by DrugPatentWatch.com

appropriate corrections and additions. Each subsequent edition has included the new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act (1984 Amendments). The 1984 Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The *Approved Drug Products with Therapeutic Equivalence Evaluations* publication and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that qualify under the 1984 Amendments for periods of exclusivity (during which ANDAs or applications described in Section 505(b)(2) of the Act for those drugs may not be submitted for a specified period of time and, if allowed to be submitted, would be tentatively approved) and provides patent information concerning the listed drugs which also may delay the approval of ANDAs or Section 505(b)(2) applications. The *Addendum* also provides additional information that may be helpful to those submitting a new drug application to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Director, Division of Labeling and Program Support HFD-610, Office of Generic Drugs, Center for Drug and Evaluation and Research, 7500 Standish Place, Rockville, MD 20855. Comments received are publicly available to the extent allowable under the Freedom of Information regulations.

FDA data supplied by DrugPatentWatch.com

1. INTRODUCTION

1.1 Content and Exclusion

The List is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. This publication also includes indices of prescription and OTC drug products by trade or established name (if no trade name exists) and by applicant name (holder of the approved application). All established names for active ingredients generally conform to official compendial names or *United States Adopted Names* (USAN) as prescribed in (21 CFR 299.4(e)). The latter list includes applicants' names as abbreviated in this publication; in addition, a list of uniform terms is provided. An *Addendum* contains drug patent and exclusivity information for the Prescription and OTC Drug Product Lists, and for the Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research.

This publication also includes additional information, such as Orphan Drug Product Designations and other data that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research because the main purpose of the publication was to provide information to states regarding FDA's recommendation as to which generic prescription drug products were acceptable candidates for drug product selection. The 1984 Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required.

Under the 1984 Amendments, some drug products were given tentative approvals. Prior to the effective date, the Agency will not include drug products with tentative approval in the List; however, they are available in the *FDA Drug Product Approvals List* on the Internet World Wide Web. When the tentative approval becomes a full approval through a subsequent action letter to the application holder, the Agency will list the drug product and the final, effective approval date in the appropriate approved drug product list.

Distributors or repackagers of products on the List are not identified. Because distributors or repackagers are not required to notify FDA when they shift their sources of supply from one approved manufacturer to another, it is not possible to maintain complete information linking product approval with the distributor or repackager handling the products.

1.2 Therapeutic Equivalence-Related Terms

Pharmaceutical Equivalents. Drug products are considered pharmaceutical equivalents if they contain the same active ingredient(s), are of the same dosage form, route of administration and are identical in strength or concentration (e.g., chlordiazepoxide hydrochloride, 5mg capsules). Pharmaceutically equivalent drug products are formulated to contain the same amount of active ingredient in the same dosage form and to meet the same or compendial or other applicable standards (i.e., strength, quality, purity, and identity), but they may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration time, and, within certain limits, labeling.

FDA data supplied by DrugPatentWatch.com

Pharmaceutical Alternatives. Drug products are considered pharmaceutical alternatives if they contain the same therapeutic moiety, but are different salts, esters, or complexes of that moiety, or are different dosage forms or strengths (e.g., tetracycline hydrochloride, 250mg capsules vs. tetracycline phosphate complex, 250mg capsules; quinidine sulfate, 200mg tablets vs. quinidine sulfate, 200mg capsules). Data are generally not available for FDA to make the determination of tablet to capsule bioequivalence. Different dosage forms and strengths within a product line by a single manufacturer are thus pharmaceutical alternatives, as are extended-release products when compared with immediate- or standard-release formulations of the same active ingredient.

Therapeutic Equivalents. Drug products are considered to be therapeutic equivalents only if they are pharmaceutical equivalents and if they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

FDA classifies as therapeutically equivalent those products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; and (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. *The concept of therapeutic equivalence, as used to develop the List, applies only to drug products containing the same active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., propoxyphene hydrochloride vs. pentazocine hydrochloride for the treatment of pain).* Any drug product in the List repackaged and/or distributed by other than the application holder is considered to be therapeutically equivalent to the application holder's drug product even if the application holder's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, distributors or repackagers of an application holder's drug product are considered to have the same code as the application holder. Therapeutic equivalence determinations are not made for unapproved, off-label indications.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time and minor aspects of labeling (e.g., the presence of specific pharmacokinetic information) and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a particular brand be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product will produce the same clinical effect and safety profile as the prescribed product.

Bioavailability. This term means the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.

Bioequivalent Drug Products. This term describes pharmaceutical equivalent or pharmaceutical alternative products that display comparable bioavailability when studied under similar experimental conditions. Section 505 (j)(7)(B) of the Act describes one set of conditions under which a test and reference listed drug (see Section 1.4) shall be considered bioequivalent:

> the rate and extent of absorption of the test drug do not show a significant difference from the rate and extent of absorption of the reference drug when administered at the same molar dose of

FDA data supplied by DrugPatentWatch.com

the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or

the extent of absorption of the test drug does not show a significant difference from the extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the reference drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

Bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.

1.3 Statistical Criteria for Bioequivalence

Under the Drug Price Competition and Patent Term Restoration Act of 1984, manufacturers seeking approval to market a generic drug product must submit data demonstrating that the drug product is bioequivalent to the pioneer (innovator) drug product. A major premise underlying the 1984 law is that bioequivalent drug products are therapeutically equivalent, and therefore, interchangeable.

Bioavailability refers to the rate and extent to which the active ingredient or therapeutic ingredient is absorbed from a drug product and becomes available at the site of drug action (Federal Food, Drug and Cosmetic Act, section 505(j)(8)). Bioequivalence refers to equivalent release of the same drug substance from two or more drug products or formulations. This leads to an equivalent rate and extent of absorption from these formulations. Underlying the concept of bioequivalence is the thesis that, if a drug product contains a drug substance that is chemically identical and is delivered to the site of action at the same rate and extent as another drug product, then it is equivalent and can be substituted for that drug product. Methods used to define bioequivalence can be found in 21 CFR 320.24, and include (1) pharmacokinetic (PK) studies, (2) pharmacodynamic (PD) studies, (3) comparative clinical trials, and (4) in-vitro studies. The choice of study used is based on the site of action of the drug and the ability of the study design to compare drug delivered to that site by the two products.

The standard bioequivalence (PK) study is conducted using a two-treatment crossover study design in a limited number of volunteers, usually 24 to 36 adults. Alternately, a four-period, replicate design crossover study may also be used. Single doses of the test and reference drug products are administered and blood or plasma levels of the drug are measured over time. Pharmacokinetic parameters characterizing rate and extent of drug absorption are evaluated statistically. The PK parameters of interest are the resulting area under the plasma concentration-time curve (AUC), calculated to the last measured concentration ($AUC_{(0-t)}$) and extrapolated to infinity ($AUC_{(0-inf)}$), for extent of absorption; and the maximum or peak drug concentrations (Cmax), for rate of absorption. Crossover studies may not be practical in drugs with a long half-life in the body, and a parallel study design may be used instead. Alternate study methods, such as in-vitro studies or equivalence studies with clinical or pharmacodynamic endpoints, are used for drug products where plasma concentrations are not useful to determine delivery of the drug substance to the site of activity (such as inhalers, nasal sprays and topical products applied to the skin).

The statistical methodology for analyzing these bioequivalence studies is

FDA data supplied by DrugPatentWatch.com

called the two one-sided test procedure. Two situations are tested with this statistical methodology. The first of the two one-sided tests determines whether a generic product (test), when substituted for a brand-name product (reference) is significantly less bioavailable. The second of the two one-sided tests determines whether a brand-name product when substituted for a generic product is significantly less bioavailable. Based on the opinions of FDA medical experts, a difference of greater than 20% for each of the above tests was determined to be significant, and therefore, undesirable for all drug products. Numerically, this is expressed as a limit of test-product average/reference-product average of 80% for the first statistical test and a limit of reference-product average/test-product average of 80% for the second statistical test. By convention, all data is expressed as a ratio of the average response (AUC and Cmax) for test/reference, so the limit expressed in the second statistical test is 125% (reciprocal of 80%).

For statistical reasons, all data is log-transformed prior to conducting statistical testing. In practice, these statistical tests are carried out using an analysis of variance procedure (ANOVA) and calculating a 90% confidence interval for each pharmacokinetic parameter (Cmax and AUC). The confidence interval for both pharmacokinetic parameters, AUC and Cmax, must be entirely within the 80% to 125% boundaries cited above. Because the mean of the study data lies in the center of the 90% confidence interval, the mean of the data is usually close to 100% (a test/reference ratio of 1). Different statistical criteria are sometimes used when bioequivalence is demonstrated through comparative clinical trials, pharmacodynamic studies, or comparative in-vitro methodology.

The bioequivalence methodology and criteria described above simultaneously control for both, differences in the average response between test and reference, as well as the precision with which the average response in the population is estimated. This precision depends on the within-subject (normal volunteer or patient) variability in the pharmacokinetic parameters (AUC and Cmax) of the two products and on the number of subjects in the study. The width of the 90% confidence interval is a reflection in part of the within-subject variability of the test and reference products in the bioequivalence study. A test product with no differences in the average response when compared to the reference might still fail to pass the bioequivalence criteria if the variability of one or both products is high and the bioequivalence study has insufficient statistical power (i.e., insufficient number of subjects). Likewise, a test product with low variability may pass the bioequivalence criteria, when there are somewhat larger differences in the average response.

This system of assessing bioequivalence of generic products assures that these substitutable products do not deviate substantially in in-vivo performance from the reference product. The Office of Generic Drugs has conducted two surveys to quantify the differences between generic and brand name products. The first survey included 224 bioequivalence studies submitted in approved applications during 1985 and 1986. The observed average differences between reference and generic products for AUC was 3.5% (JAMA, Sept. 4, 1987, Vol. 258, No. 9). The second survey included 127 bioequivalence studies submitted to the agency in 273 ANDAs approved in 1997. The three measures reviewed include $AUC_{(0-t)}$, $AUC_{(0-inf)}$, and Cmax. The observed average differences between the reference and generic products were $\pm$ 3.47% (SD 2.84) for $AUC_{(0-t)}$, $\pm$ 3.25% (SD 2.97) for $AUC_{(0-inf)}$, and $\pm$ 4.29% (SD 3.72) for Cmax (JAMA, Dec. 1, 1999, Vol. 282, No. 21).

The primary concern from the regulatory point of view is the protection of the patient against approval of products that are not bioequivalent. The current practice of carrying out two one-sided tests at the 0.05 level of significance ensures that there is no more than a 5% chance that a generic product that is not truly equivalent to the reference will be approved.

1.4 Reference Listed Drug

A reference listed drug (21 CFR 314.94(a)(3)) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.

FDA data supplied by DrugPatentWatch.com

FDA has identified in the Prescription Drug Product and OTC Drug Product Lists those reference listed drugs to which the *in vivo* bioequivalence and, in some instances, the *in vitro* bioequivalence of the applicant's product is compared. By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. Such variations could result if generic drugs were compared to different reference listed drugs. However, in some instances when listed drugs are approved for a single drug product, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. A firm wishing to market a generic version of a listed drug that is not designated as the reference listed drug may petition the Agency through the Citizen Petition procedure (see 21 CFR 10.25(a) and CFR 10.30). When the Citizen Petition is approved, the second listed drug will be designated as an additional reference listed drug and the petitioner may submit an Abbreviated New Drug Application citing the designated reference listed drug. Section 1.7, *Therapeutic Equivalence Evaluations Codes Products meeting necessary bioequivalence requirements* explains the ***(AB, AB1, AB2, AB3...*** coding system for multisource drug products listed under the same heading with two reference listed drugs.

In addition, there are two situations in which two listed drugs that have been shown to be bioequivalent to each other may both be designated as reference listed drugs. The first situation occurs when the *in vivo* determination of bioequivalence is self-evident and a waiver of the *in vivo* bioequivalence may be granted. The second situation occurs when the bioequivalence of two listed products may be determined through *in vitro* methodology. The reference listed drug is identified by the symbol "+" in the Prescription and Over-the-Counter (OTC) Drug Product Lists. These identified reference listed drugs represent the best judgment of the Division of Bioequivalence at this time. The Prescription and OTC Drug Product Lists identify reference drugs for oral dosage forms, injectables, ophthalmics, otics, and topical products. It is recommended that a firm planning to conduct an *in vivo* bioequivalence study, or planning to manufacture a batch of a drug product for which an *in vivo* waiver of bioequivalence will be requested, contact the Division of Bioequivalence, Office of Generic Drugs, to confirm the appropriate reference listed drug.

1.5 General Policies and Legal Status

The List contains public information and advice. It does not mandate the drug products which may be purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the List sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, intended to reduce the cost of drugs to consumers. To the extent that the List identifies drug products approved under Section 505 of the Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the List does not necessarily mean that the drug product is either in violation of Section 505 of the Act, or that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion is based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

FDA data supplied by DrugPatentWatch.com

1.6 Practitioner/User Responsibilities

Professional care and judgment should be exercised in using the List. Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have equivalent clinical effect and no difference in their potential for adverse effects when used under the conditions of their labeling. However, these products may differ in other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. There may also be better stability of one product over another under adverse storage conditions, or allergic reactions in rare cases due to a coloring or a preservative ingredient, as well as differences in cost to the patient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the physician's specification of that product is appropriate. Pharmacists must also be familiar with the expiration dates/times and labeling directions for storage of the different products, particularly for reconstituted products, to assure that patients are properly advised when one product is substituted for another.

Multisource and single-source drug products. FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the Act, which in most instances means those pharmaceutical equivalents available from more than one manufacturer. For such products, a therapeutic equivalence code is included and, in addition, product information is highlighted in bold face and underlined. Those products with approved applications that are single-source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included on the List, but no therapeutic equivalence code is included with such products. Any drug product in the List repackaged and/or distributed by other than the application holder is considered to be therapeutically equivalent to the application holder's drug product even if the application holder's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, although not identified in the List, distributors or repackagers of an application holder's drug product are considered to have the same code as the application holder. The details of these codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*.

Products on the List are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product. The applicant may have had its product manufactured by a contract manufacturer and may simply be distributing the product for which it has obtained approval. In most instances, however, the manufacturer of the product is also the applicant. The name of the manufacturer is permitted by regulation to appear on the label, even when the manufacturer is not the marketer.

Although the products on the List are identified by the names of the applicants, circumstances, such as changing corporate ownership, have sometimes made identification of the applicant difficult. The Agency believes, based on continuing document review and communication with firms, that the applicant designations on the List are, in most cases, correct.

To relate firm name information on a product label to that on the List, the following should be noted: the applicant's name always appears on the List. This applies whether the applicant (firm name on the Form FDA 356h in the application) is the marketer (firm name in largest letters on the label)

FDA data supplied by DrugPatentWatch.com

or not. However, the applicant's name may not always appear on the label of the product.

If the applicant is the marketer, its name appears on the List and on the label; if the applicant is not the marketer, and the Agency is aware of a corporate relationship (e.g., parent and subsidiary) between the applicant and the marketer, the name of the applicant appears on the List and both firm names may appear on the label. Firms with known corporate relationships are displayed in Appendix B. If there is no known corporate relationship between the applicant and the marketer, the applicant's name appears on the List; however, unless the applicant is the manufacturer, packager, or distributor, the applicant's name may not appear on the label. In this case, the practitioner, from labeling alone, will not be able to relate the marketed product to an applicant cited in the List, and hence to a specific approved drug product. In such cases, to assure that the product in question is the subject of an approved application, the firm named on the label should be contacted.

To relate trade name (proprietary name) information on a product label to that on the List, the following should be noted: if the applicant is the marketer, its name appears on the List and on the label; if the Agency is aware of a corporate relationship between the applicant and the marketer, the trade name (proprietary name) of the drug product (established drug name if no trade name exists) appears on the List. If a corporate relationship exists between an application holder and a marketer and both firms are distributing the drug product, the FDA reserves the right to select the trade name of either the marketer or the application holder to appear on the List. If there is no known corporate relationship between the applicant and the marketer, the established drug name appears on the List.

Every product on the List is subject at all times to regulatory action. From time to time, approved products may be found in violation of one or more provisions of the Act. In such circumstances, the Agency will commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product on the List. The main criterion for inclusion of a product is that it has an application with an effective approval that has not been withdrawn for safety or efficacy reasons. FDA believes that retention of a violative product on the List will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the data upon which the Agency's assessment of whether a product meets the criteria for therapeutic equivalence was made.

1.7 Therapeutic Equivalence Evaluations Codes

The coding system for therapeutic equivalence evaluations is constructed to allow users to determine quickly whether the Agency has evaluated a particular approved product as therapeutically equivalent to other pharmaceutically equivalent products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With few exceptions, the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter as follows:

A Drug products that FDA considers to be <u>therapeutically equivalent</u> to other pharmaceutically equivalent products, i.e., drug products for which:

(1) there are no known or suspected bioequivalence problems. These are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form; or

(2) actual or potential bioequivalence problems have been resolved with

FDA data supplied by DrugPatentWatch.com

adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

B Drug products that FDA at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products, i.e.,

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC, BD, BE, BN, BP, BR, BS, BT, BX,** or **B***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

"A" CODES

Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.

"A" products are those for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bio- equivalence. Drug products designated with an **"A"** code fall under one of two main policies:

(1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is presumed and considered self-evident based on other data in the application for some dosage forms (e.g., solutions) or satisfied for solid oral dosage forms by a showing that an acceptable *in vitro* dissolution standard is met. A therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA, AN, AO, AP,** or **AT,** depending on the dosage form, as described below); or

(2) for those DESI drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products in a dosage form presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional. For example, pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution. An FDA evaluation that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in the labeling of that product.

The Agency will use notes in this publication to point out special situations such as potential differences between two drug products that have

FDA data supplied by DrugPatentWatch.com

been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Special Situations*.

For example, in rare instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. Such differences may be due to patent or exclusivity rights associated with such use. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note will be added to Section 1.8.

Also, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts and esters of the same therapeutic moiety are regarded as pharmaceutical alternatives. For the purpose of this publication, such products are not considered to be therapeutically equivalent. There are no instances in this List where pharmaceutical alternatives are evaluated or coded with regard to therapeutic equivalence. Anhydrous and hydrated entities, as well as different polymorphs, are considered pharmaceutical equivalents and must meet the same standards and, where necessary, as in the case of ampicillin/ampicillin trihydrate, their equivalence is supported by appropriate bioavailability/bioequivalence studies.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives may differ among some therapeutically equivalent drug products. Differences in preservatives and other inactive ingredients do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

AA Products in conventional dosage forms not presenting bioequivalence problems

Products coded as **AA** contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

FDA data supplied by DrugPatentWatch.com

AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements

Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents)* generally will be coded **AB** if a study is submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1, AB2, AB3, etc.**). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. For example, Adalat® CC (Miles) and Procardia XL® (Pfizer), extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved, Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. The generic drug products bioequivalent to Adalat® CC would be assigned a rating of **AB1** and those bioequivalent to Procardia XL® would be assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or repackagers are not included in the List, they are considered therapeutically equivalent to the application holder's drug product if the application holder's drug product is rated either with an **AB** or three-character code or is single source in the List. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

AN Solutions and powders for aerosolization

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in any of several delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon *in vitro* methodology, if bioequivalence needs to be demonstrated by *in vivo* methodology then the drug products will be coded **AB**.

AO Injectable oil solutions

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

FDA data supplied by DrugPatentWatch.com

AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, *Injectable; Injection*. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are all considered to be pharmaceutically and therapeutically equivalent provided they are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included on the List (e.g., dextrose injection 5%, dextrose injection 10%, sodium chloride injection 0.9%) since these products are on the market without FDA approval and the FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

The strength of parenteral drugs products is defined as the total drug content of the container. Until recently the strength of liquid parenteral drug products in the Orange Book have not been displayed. The concentration of the liquid parenteral drug product in the Orange Book has been shown as xmg/ml. The amount of dry powder or freeze dried powder in a container has always been identified as the strength.

With the finalization of the Waxman-Hatch amendments that characterized each strength of a drug product as a listed drug it became evident that the format of the Orange Book should be changed to reflect each strength of a parenteral solution. To this end the OGD has started to display the strength of all new approvals of parenteral solutions. Previously we would have displayed only the concentration of an approved parenteral solution, e.g. 50mg/ml. If this drug product had a 20 ml and 60 ml container approved the two products would be shown as 1Gm / 20ml (50mg/ml) and 3Gm / 60ml (50mg/ml).

AT Topical products

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including solutions, creams, ointments, gels, lotions, pastes, sprays, and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate

FDA data supplied by DrugPatentWatch.com

bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate bioequivalence data, and **BT** in the absence of such data.

"B" CODES

Drug products that FDA, at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products.

"B" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a **"B"** code fall under one of three main policies:

(1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bio- equivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or

(2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or

(3) the drug products are under regulatory review.

The specific coding definitions and policies for the **"B"** sub-codes are as follows:

B* Drug products requiring further FDA investigation and review to determine therapeutic equivalence

The code **B*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

BC Extended-release dosage forms (capsules, injectables and tablets)

Extended-release tablets are formulated in such a manner as to make the contained medicament available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because firms developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

FDA data supplied by DrugPatentWatch.com

BD Active ingredients and dosage forms with documented bioequivalence problems

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

BE Delayed-release oral dosage forms

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of "enteric" coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach.
Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

BN Products in aerosol-nebulizer drug delivery systems

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore, the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard, such products are coded AB.

BP Active ingredients and dosage forms with potential bioequivalence problems

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate *in vivo* bioequivalence data are submitted, such products are coded AB. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence, such products would be coded AB.

BR Suppositories or enemas that deliver drugs for systemic absorption

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bio-equivalent only if *in vivo* evidence of

FDA data supplied by DrugPatentWatch.com

bioequivalence is available. In those cases where *in vivo* evidence is available, the product is coded **AB**. If such evidence is not available, the products are coded **BR**.

BS Products having drug standard deficiencies

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

BT Topical products with bioequivalence issues

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, ointments, gels, lotions, pastes, and sprays, as well as suppositories not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

BX Drug products for which the data are insufficient to determine therapeutic equivalence

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

1.8 Description of Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. Following is a description of those special situations:

Amino Acid and Protein Hydrolysate Injections. These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be considered therapeutically equivalent.

Follitropin Alfa and Beta. Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

Gaviscon®. Gaviscon® is an OTC product which has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test which is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon® 's activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate

FDA data supplied by DrugPatentWatch.com

and alginic acid. Therefore, *all ANDAs which cite Gaviscon® tablets as the listed drug must contain the inactive ingredients sodium bicarbonate and alginic acid.* A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

Patent Certification(s) Reference Listed Drug based upon a suitability petition. An abbreviated new drug application that refers to a Reference Listed Drug (RLD) approved pursuant to a suitability petition must demonstrate that the proposed product is bioequivalent to the RLD, and it must include appropriate patent certification(s) and an exclusivity statement with respect to the listed drug which served as the basis for the approved suitability petition.

Waived exclusivity. If a new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (Act) qualifies for exclusivity under sections 505(c)(3)(D) and 505(j)(5)(D), the exclusivity is listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, the FDA will delay the approval of a 505(b)(2) application or an abbreviated new drug application (ANDA) under section 505(j) of the Act until the expiration of the exclusivity. If the listed drug is also protected by one or more patents, the approval date for the 505(b)(2) application or ANDA will be determined by the latest expiring patent or exclusivity listed in the Orange Book.
However, the holder of the NDA may waiver its exclusivity as to any or all 505(b)(2) and ANDA applications referencing the protected drug product. If an NDA sponsor waivers its right to the exclusivity protection, qualified 505(b)(2) or ANDA applications may be approved without regard to the NDA holder's exclusivity. An NDA for which the holder has waived its exclusivity as to all 505(b)(2) and ANDA applications will be coded with a W in the Patent and Exclusivity Section of the Orange Book and be referred to this section. The applicant referencing this listed drug should indicate in the exclusivity statement that the holder of the listed drug has waived its exclusivity.

1.9 Therapeutic Equivalence Code Change for a Drug Entity

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multi-source drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of drug products in the List (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific drug entity and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying a bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of drugs, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comment. Comments, along with scientific data, may be sent to the Director, Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, (MPN-2) HFD-650, 7500 Standish Place, Rockville, MD 20855. The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submission is an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. These submissions should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of

FDA data supplied by DrugPatentWatch.com

calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and such submissions are discouraged. Copies of supporting reports published in the scientific literature or unpublished material, however, are welcome.

1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The aforementioned procedure does not apply to a change in a single drug product code. For example, a change in a single drug product's code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

1.11 Availability of Internal Policy and Procedure Guides

The Office of Generic Drugs maintains internal policy and procedure guides. Although these guides are designed for Office personnel and are subject to change without public notice, they are available to members of the public who may wish to know more about the Office's policies and procedures. Copies of these guides may be obtained from the FDA, Center for Drug Evaluation and Research, HFD-240, Office of Training and Communications, Division of Drug Information, 5600 Fishers Lane, Rockville, MD 20857. The Agency welcomes public comment on the policies, procedures, and practices employed in the approval of generic drugs. Such comments may be sent to the Director, Office of Generic Drugs, (MPN-2) HFD-600, 7500 Standish Place, Rockville, MD 20855.

1.12 Discontinued Section

Those drug products in the Discontinued Section of the Orange Book in which a determination has already been made that the products were not marketed or withdrawn for safety or efficacy reasons have been designated by the symbol "*". Those drug products with the symbol "*" are only reflective of citizen petitions approved since 1995.

The identification of these drug products in the Discontinued Section of the Orange Book with the symbol "*" should avoid the submission of multiple citizen petitions for the same drug product.

FDA data supplied by DrugPatentWatch.com

2. HOW TO USE THE DRUG PRODUCT LISTS

2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

Illustrations. The annotated *Drug Product Illustration*, see Section 2.2, and the *Therapeutic Equivalence Evaluations Illustration*, see Section 2.3, are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

Drug Product Lists. The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, application holders, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982.

The Discontinued Product List, arranged alphabetically by active ingredient(s), contain product identification information (dosage form, product name, strength, and application number).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with **"A"** and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form heading. The OTC Drug Product List, Discontinued Drug Product List, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly. The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing, are for military use, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the 12th Cumulative Supplement of the 23rd Edition List have been added to the Discontinued Drug Product List appearing in the 24th Edition. In addition, approved drug products that are not in the commercial distribution channel

FDA data supplied by DrugPatentWatch.com

e.g. approved drug products in applications for export only are also listed in the Discontinued Section of the Orange Book.

Orphan Drug Product Designations. Drugs and biologicals that have been granted Orphan Designation pursuant to Section 526 as amended by the Orphan Drug Act [P.L. 97-414, January 4, 1983] are listed in Section 3.5.

Product Name Index *(Prescription and OTC Drug Product Lists)*. This is an index of drug products by established or trade name. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.


Product Name Index Listed by Applicant *(Prescription and OTC Drug Product Lists)*. This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

Uniform Terms. To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.


FDA data supplied by DrugPatentWatch.com

2.2 DRUG PRODUCT ILLUSTRATION


SINGLE INGREDIENT



MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION



WITH CROSS-REFERENCE




THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

FDA data supplied by DrugPatentWatch.com

2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **"A"**) UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **A"**) AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH **"B"**) AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A **"B"**) ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE *INTRODUCTION.*



NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

FDA data supplied by DrugPatentWatch.com

ABACAVIR SULFATE

SOLUTION; ORAL				
ZIAGEN				
+ GLAXOSMITHKLINE	EQ 20MG BASE/ML		N20978 001	DEC 17, 1998
TABLET; ORAL				
ZIAGEN				
+ GLAXOSMITHKLINE	EQ 300MG BASE		N20977 001	DEC 17, 1998

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL				
TRIZIVIR				
+ GLAXOSMITHKLINE	EQ 300MG BASE;150MG;300MG		N21205 001	NOV 14, 2000

ABARELIX

INJECTABLE; INTRAMUSCULAR				
PLENAXIS				
+ PRAECIS	100MG/VIAL		N21320 001	NOV 25, 2003

ACARBOSE

TABLET; ORAL				
PRECOSE				
BAYER PHARMS	25MG		N20482 004	MAY 29, 1997
	50MG		N20482 001	SEP 06, 1995
+	100MG		N20482 002	SEP 06, 1995

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL					
ACEBUTOLOL HCL					
AB MYLAN	**EQ 200MG BASE**		**N74288 001**	APR 24, 1995
AB	**EQ 400MG BASE**		**N74288 002**	APR 24, 1995

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL					
ACEBUTOLOL HCL					
AB PAR PHARM	**EQ 200MG BASE**		**N75047 001**	DEC 30, 1999
AB	**EQ 400MG BASE**		**N75047 002**	DEC 30, 1999
AB WATSON LABS	**EQ 200MG BASE**		**N74007 001**	OCT 18, 1995
AB	**EQ 400MG BASE**		**N74007 002**	OCT 18, 1995
SECTRAL				
AB ESP PHARMA	**EQ 200MG BASE**		**N18917 001**	DEC 28, 1984
AB +	**EQ 400MG BASE**		**N18917 003**	DEC 28, 1984

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL				
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE				
+ MIKART	150MG;180MG;30MG		N81096 001	OCT 26, 1990

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL					
BUCET					
AB MALLINCKRODT	**650MG;50MG**		**N88991 001**	JUN 28, 1985
PHRENILIN FORTE					
AB + AMARIN PHARMS	**650MG;50MG**		**N88831 001**	JUN 19, 1985
TENCON					
AB MALLINCKRODT	**650MG;50MG**		**N89405 001**	MAY 15, 1990
TABLET; ORAL					
BUTAPAP					
AB MIKART	**325MG;50MG**		**N89987 001**	OCT 26, 1992
AB	**650MG;50MG**		**N89988 001**	OCT 26, 1992
PHRENILIN					
AB + AMARIN PHARMS	**325MG;50MG**		**N87811 001**	JUN 19, 1985

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

		SEDAPAP		
AB	+ MAYRAND	650MG;50MG	**N88944 001**	OCT 17, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

		ACETAMINOPHEN, BUTALBITAL, AND CAFFEINE		
AB	+ MIKART	325MG;50MG;40MG	**N89007 001**	MAR 17, 1986
		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE		
AB	WEST WARD	500MG;50MG;40MG	**N40261 001**	OCT 28, 1998
		ESGIC-PLUS		
AB	+ MIKART	500MG;50MG;40MG	**N40085 001**	MAR 28, 1996

SOLUTION; ORAL

		ACETAMINOPHEN AND BUTALBITAL AND CAFFEINE		
	+ MIKART	325MG/15ML;50MG/15ML; 40MG/15ML	N40387 001	JAN 31, 2003

TABLET; ORAL

		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE		
AB	ABLE	325MG;50MG;40MG	**N40390 001**	JUL 23, 2001
AB		500MG;50MG;40MG	**N40394 001**	JUL 23, 2001
AB	MALLINCKRODT	325MG;50MG;40MG	**N87804 001**	JAN 24, 1985
AB	MIKART	325MG;50MG;40MG	**N89175 001**	JAN 21, 1987
	+	750MG;50MG;40MG	N40496 001	DEC 23, 2003
AB	VINTAGE PHARMS	325MG;50MG;40MG	**N40511 001**	AUG 27, 2003
AB		500MG;50MG;40MG	**N40513 001**	AUG 25, 2003
AB	WATSON LABS	500MG;50MG;40MG	**N40267 001**	JUL 30, 1998
AB	WEST WARD	325MG;50MG;40MG	**N89718 001**	JUN 12, 1995
		BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE		
AB	WEST WARD	500MG;50MG;40MG	**N40336 001**	AUG 18, 1999

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

		BUTALBITAL, APAP, AND CAFFEINE		
AB	AXIOM PHARM	325MG;50MG;40MG	**N89536 001**	FEB 16, 1988
		ESGIC-PLUS		
AB	+ MIKART	500MG;50MG;40MG	**N89451 001**	MAY 23, 1988
		FIORICET		
AB	+ WATSON PHARMS	325MG;50MG;40MG	**N88616 001**	NOV 09, 1984

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

		ACETAMINOPHEN, BUTALBITAL, CAFFEINE, AND CODEINE PHOSPHATE		
AB	VINTAGE PHARMS	325MG;50MG;40MG;30MG	**N75929 001**	APR 22, 2002
		BUTALBITAL; ACETAMINOPHEN; AND CAFFEINE WITH CODEINE PHOSPHATE		
AB	WEST WARD	325MG;50MG;40MG;30MG	**N75618 001**	MAR 23, 2001
		BUTALBITAL; ACETAMINOPHEN; CAFFEINE AND CODEINE PHOSPHATE		
AB	ABLE	325MG;50MG;40MG;30MG	**N76528 001**	AUG 21, 2003
		FIORICET W/ CODEINE		
AB	+ WATSON PHARMS	325MG;50MG;40MG;30MG	**N20232 001**	JUL 30, 1992
		PHRENILIN WITH CAFFEINE AND CODEINE		
AB	AMARIN PHARMS	325MG;50MG;40MG;30MG	**N74911 001**	AUG 22, 2001

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

		ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE		
	+ MIKART	356.4MG;30MG;16MG	N40109 001	AUG 26, 1997

TABLET; ORAL

		ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE		
	+ MIKART	712.8MG;60MG;32MG	N40316 001	APR 28, 1999

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

		ACETAMINOPHEN AND CODEINE PHOSPHATE		
AA	+	ALPHARMA	120MG/5ML;12MG/5ML	N85861 001
AA		CLONMEL	120MG/5ML;12MG/5ML	N40098 001 SEP 20, 1996
AA		HI TECH PHARMA	120MG/5ML;12MG/5ML	N40119 001 APR 26, 1996
AA		MIKART	120MG/5ML;12MG/5ML	N89450 001 OCT 27, 1992
AA		MORTON GROVE	120MG/5ML;12MG/5ML	N87006 001
AA		PHARM ASSOC	120MG/5ML;12MG/5ML	N87508 001
		ACETAMINOPHEN W/ CODEINE		
AA		ROXANE	120MG/5ML;12MG/5ML	N86366 001

SUSPENSION; ORAL

		ACETAMINOPHEN AND CODEINE PHOSPHATE		
AA		AMARIN PHARMS	120MG/5ML;12MG/5ML	N86024 001
		CAPITAL AND CODEINE		
AA		ALPHARMA	120MG/5ML;12MG/5ML	N85883 001

TABLET; ORAL

		ACETAMINOPHEN AND CODEINE PHOSPHATE		
AA		ABLE	300MG;30MG	N40452 001 AUG 01, 2002
AA			300MG;60MG	N40459 001 AUG 01, 2002
AA		ANDRX PHARMS	300MG;15MG	N40443 001 JAN 22, 2003
AA			300MG;30MG	N40443 002 JAN 22, 2003
AA			300MG;60MG	N40443 003 JAN 22, 2003
AA	+	DURAMED PHARMS BARR	300MG;15MG	N40223 001 NOV 18, 1997
AA			300MG;30MG	N40223 002 NOV 18, 1997
AA			300MG;60MG	N40223 003 NOV 18, 1997
AA		MALLINCKRODT	300MG;15MG	N40419 001 MAY 31, 2001
AA			300MG;30MG	N40419 002 MAY 31, 2001
AA			300MG;60MG	N40419 003 MAY 31, 2001
AA		MIKART	300MG;30MG	N89238 001 FEB 25, 1986

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

		ACETAMINOPHEN AND CODEINE PHOSPHATE		
	+	MIKART	650MG;30MG	N89231 001 MAR 03, 1986
	+		650MG;60MG	N89363 001 SEP 09, 1991
AA		MUTUAL PHARM	300MG;15MG	N89671 001 FEB 10, 1988
AA			300MG;30MG	N89672 001 FEB 10, 1988
AA			300MG;60MG	N89673 001 FEB 10, 1988
AA		PHARMERAL	300MG;30MG	N87762 001 DEC 10, 1982
AA		RANBAXY	300MG;60MG	N87083 001
AA		SANDOZ	300MG;30MG	N81250 001 JUL 16, 1992
AA			300MG;60MG	N81249 001 JUL 16, 1992
AA		TEVA	300MG;15MG	N88627 001 MAR 06, 1985
AA			300MG;30MG	N88628 001 MAR 06, 1985
AA			300MG;60MG	N88629 001 MAR 06, 1985
AA		VINTAGE PHARMS	300MG;15MG	N89990 001 SEP 30, 1988
AA			300MG;30MG	N89805 001 SEP 30, 1988
AA			300MG;60MG	N89828 001 SEP 30, 1988
AA		WATSON LABS	300MG;15MG	N89997 001 DEC 28, 1994
AA			300MG;30MG	N89998 001 DEC 28, 1994
AA			300MG;60MG	N89999 001 DEC 28, 1994
		ACETAMINOPHEN W/ CODEINE NO. 3		
AA		ROXANE	300MG;30MG	N84656 001
		ACETAMINOPHEN W/ CODEINE PHOSPHATE #3		
AA		RANBAXY	300MG;30MG	N85868 001
		CODRIX		
	+	ANDRX PHARMS	500MG;15MG	N40447 001 FEB 26, 2003
	+		500MG;30MG	N40441 001 MAR 27, 2003

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL				
	CODRIX			
	+ ANDRX PHARMS	500MG;60MG	N40488 001	MAR 28, 2003
	TYLENOL W/ CODEINE NO. 3			
AA	+ ORTHO MCNEIL PHARM	300MG;30MG	N85055 003	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL				
	ACETAMINOPHEN AND HYDROCODONE BITARTRATE			
AA	CENT PHARMS	500MG;5MG	N88898 001	MAR 27, 1985
	ALLAY			
AA	IVAX PHARMS	500MG;5MG	N89907 001	JAN 13, 1989
	HYDROCET			
AA	MALLINCKRODT	500MG;5MG	N89006 001	AUG 09, 1985
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA	MALLINCKRODT	500MG;5MG	N88956 001	JUL 19, 1985
AA	MIKART	500MG;5MG	N81067 001	NOV 30, 1989
AA		500MG;5MG	N81068 001	NOV 30, 1989
AA		500MG;5MG	N81069 001	NOV 30, 1989
AA		500MG;5MG	N81070 001	NOV 30, 1989
AA		500MG;5MG	N89008 001	FEB 21, 1986
	LORCET-HD			
AA	+ MALLINCKRODT	500MG;5MG	N87336 001	JUL 08, 1982
SOLUTION; ORAL				
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA	KV PHARM	500MG/15ML;7.5MG/15ML	N40366 001	JAN 23, 2002
AA	MALLINCKRODT	500MG/15ML;7.5MG/15ML	N40418 001	JUN 27, 2001
AA	+	500MG/15ML;10MG/15ML	N40508 001	AUG 29, 2003
AA	MIKART	500MG/15ML;5MG/15ML	N81226 001	OCT 27, 1992

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL				
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA	+ MIKART	500MG/15ML;5MG/15ML	N89557 001	APR 29, 1992
AA	+	500MG/15ML;7.5MG/15ML	N81051 001	AUG 28, 1992
	+	325MG/15ML;7.5MG/15ML	N40482 001	SEP 25, 2003
AA	PHARM ASSOC	500MG/15ML;7.5MG/15ML	N40182 001	MAR 13, 1998
AA	VINTAGE PHARMS	500MG/15ML;7.5MG/15ML	N40520 001	OCT 30, 2003
TABLET; ORAL				
	ANEXSIA			
AA	MALLINCKRODT	500MG;5MG	N89160 001	APR 23, 1987
AA		750MG;10MG	N40468 001	OCT 31, 2002
	ANEXSIA 5/325			
AA	MALLINCKRODT	325MG;5MG	N40409 001	OCT 20, 2000
	ANEXSIA 7.5/325			
AA	MALLINCKRODT	325MG;7.5MG	N40405 001	SEP 08, 2000
	ANEXSIA 7.5/650			
AA	MALLINCKRODT	650MG;7.5MG	N89725 001	SEP 30, 1987
	CO-GESIC			
AA	SCHWARZ PHARMA	500MG;5MG	N87757 001	MAY 03, 1982
	HY-PHEN			
AA	ASCHER	500MG;5MG	N87677 001	MAY 03, 1982
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA	ABLE	325MG;5MG	N40478 001	NOV 08, 2002
AA		325MG;7.5MG	N40464 001	OCT 23, 2002
AA		325MG;10MG	N40464 002	OCT 23, 2002
AA		500MG;5MG	N40477 001	NOV 06, 2002
AA		500MG;7.5MG	N40490 001	MAY 21, 2003
AA		500MG;10MG	N40473 001	NOV 06, 2002

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

		HYDROCODONE BITARTRATE AND ACETAMINOPHEN		
AA	ABLE	650MG;7.5MG	N40474 001	JAN 02, 2003
AA		650MG;10MG	N40476 001	OCT 23, 2002
AA		750MG;7.5MG	N40469 001	OCT 25, 2002
AA	ANDRX PHARMS	500MG;5MG	N40493 001	MAY 28, 2003
AA		660MG;10MG	N40495 001	MAY 28, 2003
AA		750MG;7.5MG	N40494 001	MAY 28, 2003
AA	AXIOM PHARM	500MG;5MG	N40236 001	SEP 25, 1997
AA		650MG;7.5MG	N40240 002	NOV 26, 1997
AA		650MG;10MG	N40240 001	NOV 26, 1997
AA		750MG;7.5MG	N40236 002	SEP 25, 1997
AA	BARR	500MG;2.5MG	N40307 001	JUL 26, 2000
AA		500MG;5MG	N40308 001	JUL 26, 2000
AA		500MG;7.5MG	N40307 002	JUL 26, 2000
AA		500MG;10MG	N40309 001	JUL 26, 2000
AA		650MG;7.5MG	N40307 003	JUL 26, 2000
AA		650MG;10MG	N40307 004	JUL 26, 2000
AA		750MG;7.5MG	N40308 002	JUL 26, 2000
AA	ENDO PHARMS	500MG;5MG	N40281 001	SEP 30, 1998
AA		500MG;7.5MG	N40280 001	SEP 30, 1998
AA		650MG;7.5MG	N40280 002	SEP 30, 1998
AA		650MG;10MG	N40280 003	SEP 30, 1998
AA		750MG;7.5MG	N40281 002	SEP 30, 1998

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

			HYDROCODONE BITARTRATE AND ACETAMINOPHEN		
	+	ENDO PHARMS	400MG;5MG	N40288 001	NOV 27, 1998
	+		400MG;7.5MG	N40288 002	NOV 27, 1998
	+		400MG;10MG	N40288 003	NOV 27, 1998
AA		EON	500MG;5MG	N40149 001	JAN 27, 1997
AA			750MG;7.5MG	N40149 002	JAN 27, 1997
AA		IVAX PHARMS	500MG;5MG	N89696 001	APR 21, 1988
AA		MALLINCKRODT	325MG;10MG	N40400 001	JUL 26, 2000
AA			500MG;5MG	N40084 002	JUN 01, 1995
AA			500MG;7.5MG	N40201 001	FEB 27, 1998
AA			500MG;10MG	N40201 002	FEB 27, 1998
AA			650MG;10MG	N40084 004	OCT 16, 1996
AA	+		660MG;10MG	N40084 003	JUL 29, 1996
AA			750MG;7.5MG	N40084 001	JUN 01, 1995
AA		MIKART	325MG;7.5MG	N40432 001	JAN 22, 2003
AA	+		500MG;2.5MG	N89698 001	AUG 25, 1989
AA			500MG;5MG	N89271 001	JUL 16, 1986
AA			500MG;5MG	N89697 001	JAN 28, 1992
AA	+		500MG;7.5MG	N89699 001	AUG 25, 1989
AA	+		650MG;7.5MG	N89689 001	JUN 29, 1988
AA	+		650MG;10MG	N81223 001	MAY 29, 1992
AA		UCB	500MG;10MG	N40210 001	AUG 13, 1997
AA			650MG;7.5MG	N40134 001	NOV 21, 1996

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

		HYDROCODONE BITARTRATE AND ACETAMINOPHEN	
AA	VINTAGE PHARMS	325MG;10MG	N40355 001 MAY 31, 2000
AA		500MG;2.5MG	N40144 002 APR 25, 1997
AA		500MG;5MG	N89831 001 SEP 07, 1988
AA		500MG;5MG	N89971 001 DEC 02, 1988
AA		500MG;7.5MG	N40144 001 FEB 22, 1996
AA		500MG;10MG	N40356 001 MAY 31, 2000
AA		650MG;7.5MG	N40155 001 APR 14, 1997
AA		650MG;10MG	N40143 001 FEB 22, 1996
AA		660MG;10MG	N40358 001 MAY 31, 2000
AA		750MG;7.5MG	N40157 001 APR 12, 1996
AA	WATSON LABS	325MG;10MG	N40248 002 APR 28, 2000
AA		500MG;2.5MG	N40123 003 MAR 04, 1996
AA		500MG;2.5MG	N81079 001 AUG 30, 1991
AA		500MG;5MG	N40122 001 MAR 04, 1996
AA		500MG;5MG	N89883 001 DEC 01, 1988
AA		500MG;7.5MG	N40123 004 MAR 04, 1996
AA		500MG;7.5MG	N81080 001 AUG 30, 1991
AA		500MG;10MG	N40148 002 FEB 14, 1997
AA		650MG;7.5MG	N40094 001 SEP 29, 1995
AA		650MG;7.5MG	N40123 001 MAR 04, 1996
AA		650MG;10MG	N40094 002 SEP 29, 1995
AA		650MG;10MG	N40123 002 MAR 04, 1996

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

			HYDROCODONE BITARTRATE AND ACETAMINOPHEN	
AA		WATSON LABS	660MG;10MG	N40094 003 AUG 08, 2000
AA			750MG;7.5MG	N40122 002 MAR 04, 1996
AA			750MG;7.5MG	N81083 001 AUG 30, 1991
AA	+		750MG;10MG	N40094 004 MAR 22, 1999
		LORTAB		
AA		MALLINCKRODT	500MG;5MG	N87722 001 JUL 09, 1982
AA	+	UCB	500MG;10MG	N40100 001 JAN 26, 1996
		NORCO		
AA	+	WATSON LABS	325MG;5MG	N40099 001 JUN 25, 1997
AA	+		325MG;7.5MG	N40148 003 SEP 12, 2000
AA	+		325MG;10MG	N40148 001 FEB 14, 1997
		VICODIN		
AA	+	ABBOTT	500MG;5MG	N88058 001 JAN 07, 1983
		VICODIN ES		
AA	+	ABBOTT	750MG;7.5MG	N89736 001 DEC 09, 1988
		VICODIN HP		
AA		ABBOTT	660MG;10MG	N40117 001 SEP 23, 1996

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

	OXYCODONE AND ACETAMINOPHEN		
AA	AMIDE PHARM	500MG;5MG	N40199 001 DEC 30, 1998
AA	AXIOM PHARM	500MG;5MG	N40219 001 JAN 22, 1998
AA	BARR	500MG;5MG	N40304 001 OCT 02, 2000
AA	DURAMED PHARMS BARR	500MG;5MG	N40289 001 MAR 16, 1999
AA	ENDO PHARMS	500MG;5MG	N40303 001 DEC 30, 1999

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

	OXYCODONE AND ACETAMINOPHEN			
AA	MALLINCKRODT	500MG;5MG	**N40257 001**	AUG 04, 1998
AA	VINTAGE PHARMS	500MG;5MG	**N40106 001**	JUL 30, 1996
AA	WATSON LABS	500MG;5MG	**N40234 001**	OCT 30, 1997
	ROXILOX			
AA	ROXANE	500MG;5MG	**N40061 001**	JUL 03, 1995
	TYLOX			
AA	+ ORTHO MCNEIL PHARM	500MG;5MG	**N88790 001**	DEC 12, 1984

SOLUTION; ORAL

	ROXICET			
	ROXANE	325MG/5ML;5MG/5ML	N89351 001	DEC 03, 1986

TABLET; ORAL

	OXYCET			
AA	MALLINCKRODT	325MG;5MG	**N87463 001**	DEC 07, 1983
	OXYCODONE AND ACETAMINOPHEN			
AA	AMIDE PHARM	325MG;5MG	**N40203 001**	MAR 15, 1999
AA	BARR	325MG;5MG	**N87406 001**	
AA	DURAMED PHARMS BARR	325MG;5MG	**N40272 001**	JUN 30, 1998
AA	VINTAGE PHARMS	325MG;5MG	**N40105 001**	JUL 30, 1996
AA	WATSON LABS	325MG;5MG	**N40171 001**	OCT 30, 1997
AA		325MG;7.5MG	**N40535 001**	SEP 05, 2003
AA		325MG;10MG	**N40535 002**	SEP 05, 2003
AA		500MG;7.5MG	**N40371 001**	DEC 29, 2000
AA		650MG;10MG	**N40371 002**	DEC 29, 2000
	PERCOCET			
AA	ENDO PHARMS	325MG;5MG	**N40330 002**	JUN 25, 1999
AA	+	325MG;5MG	**N85106 002**	

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

	PERCOCET			
AA	+ ENDO PHARMS	325MG;7.5MG	**N40434 001**	NOV 23, 2001
AA	+	325MG;10MG	**N40434 002**	NOV 23, 2001
AA	+	500MG;7.5MG	**N40341 001**	JUL 26, 1999
AA	+	650MG;10MG	**N40341 002**	JUL 26, 1999
	+	325MG;2.5MG	N40330 001	JUN 25, 1999
	ROXICET			
AA	ROXANE	325MG;5MG	**N87003 001**	
	ROXICET 5/500			
	+ ROXANE	500MG;5MG	N89775 001	JAN 12, 1989

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

	ACETAMINOPHEN AND PENTAZOCINE HCL			
AB	AMIDE PHARM	650MG;EQ 25MG BASE	**N76202 001**	AUG 02, 2002
	PENTAZOCINE HCL AND ACETAMINOPHEN			
AB	WATSON LABS	650MG;EQ 25MG BASE	**N74699 001**	MAR 24, 2000
	TALACEN			
AB	+ SANOFI SYNTHELABO	650MG;EQ 25MG BASE	**N18458 001**	SEP 23, 1982

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

	PROPOXYPHENE HCL AND ACETAMINOPHEN			
AA	MYLAN	650MG;65MG	**N83978 001**	
AA	SANDOZ	650MG;65MG	**N89959 001**	JUL 18, 1989
AA	VINTAGE PHARMS	650MG;65MG	**N40507 001**	JUL 30, 2003
AA	WATSON LABS	650MG;65MG	**N40139 001**	DEC 16, 1996
	WYGESIC			
AA	+ WOMEN FIRST HLTHCARE	650MG;65MG	**N84999 001**	

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

	DARVOCET A500			
	+ AAIPHARMA	500MG;100MG	N76429 001	SEP 10, 2003
	DARVOCET-N 100			
AB	+ AAIPHARMA LLC	650MG;100MG	N17122 002	
	DARVOCET-N 50			
AB	AAIPHARMA LLC	325MG;50MG	N17122 001	
	PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN			
AB	ABLE	650MG;100MG	N75838 001	JUL 11, 2001
AB	HALSEY	650MG;100MG	N70615 001	MAR 21, 1986
AB		650MG;100MG	N70771 001	MAR 21, 1986
AB		650MG;100MG	N70775 001	MAR 21, 1986
AB	IVAX PHARMS	650MG;100MG	N70146 001	AUG 02, 1985
AB	MALLINCKRODT	650MG;100MG	N75738 001	FEB 02, 2001
AB	MYLAN	650MG;100MG	N70145 001	JUN 12, 1985
AB		650MG;100MG	N72195 001	FEB 16, 1988
AB	PUREPAC PHARM	650MG;100MG	N70910 001	JAN 02, 1987
AB	SANDOZ	650MG;100MG	N70443 001	JAN 23, 1986
AB	TEVA	650MG;100MG	N74119 001	DEC 19, 1994
AB	VINTAGE PHARMS	325MG;50MG	N74843 002	FEB 15, 2001
AB		650MG;100MG	N74843 001	FEB 12, 1997

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

	ULTRACET			
	+ ORTHO MCNEIL PHARM	325MG;37.5MG	N21123 001	AUG 15, 2001

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

	DIAMOX			
	+ DURAMED PHARMS BARR	500MG	N12945 003	APR 25, 1995

TABLET; ORAL

	ACETAZOLAMIDE			
AB	LANNETT	250MG	N84840 001	
AB	MUTUAL PHARM	125MG	N89752 001	JUN 22, 1988
AB		250MG	N89753 001	JUN 22, 1988
AB	TARO	125MG	N40195 001	MAY 28, 1997
AB		250MG	N40195 002	MAY 28, 1997
AB	WATSON LABS	250MG	N88882 001	OCT 22, 1985
	DIAMOX			
AB	DURAMED PHARMS BARR	125MG	N08943 001	
AB	+	250MG	N08943 002	

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

	ACETAZOLAMIDE SODIUM			
AP	ABBOTT	EQ 500MG BASE/VIAL	N40108 001	OCT 30, 1995
AP	BEDFORD	EQ 500MG BASE/VIAL	N40089 001	FEB 28, 1995
	DIAMOX			
AP	+ DURAMED PHARMS BARR	EQ 500MG BASE/VIAL	N09388 001	DEC 05, 1990

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

	ACETIC ACID 0.25% IN PLASTIC CONTAINER			
AT	ABBOTT	250MG/100ML	N17656 001	
AT	B BRAUN	250MG/100ML	N18161 001	
AT	BAXTER HLTHCARE	250MG/100ML	N18523 001	FEB 19, 1982

SOLUTION/DROPS; OTIC

	ACETASOL			
AT	ALPHARMA	2%	N87146 001	

FDA data supplied by DrugPatentWatch.com

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

	ACETIC ACID			
AT	MORTON GROVE	2%	**N40166 001**	JUL 26, 1996
AT	TARO	2%	**N88638 001**	SEP 06, 1984
	VOSOL			
AT	+ MEDPOINTE PHARM HLC	2%	**N12179 001**	

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

	ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE		
+	BAUSCH AND LOMB	2%;0.79%	N40063 001 FEB 25, 1994

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

	ACETASOL HC			
AT	ALPHARMA	2%;1%	**N87143 001**	JAN 13, 1982
	HYDROCORTISONE AND ACETIC ACID			
AT	MORTON GROVE	2%;1%	**N40168 001**	AUG 30, 1996
AT	TARO	2%;1%	**N88759 001**	MAR 04, 1985
	VOSOL HC			
AT	+ MEDPOINTE PHARM HLC	2%;1%	**N12770 001**	

ACETOHEXAMIDE

TABLET; ORAL

	ACETOHEXAMIDE			
AB	BARR	250MG	**N70869 001**	FEB 09, 1987
AB	+	500MG	**N70870 001**	FEB 09, 1987
AB	WATSON LABS	250MG	**N71893 001**	NOV 25, 1987
AB		500MG	**N71894 001**	NOV 25, 1987

ACETOHYDROXAMIC ACID

TABLET; ORAL

	LITHOSTAT		
+	MISSION PHARMA	250MG	N18749 001 MAY 31, 1983

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

	MIOCHOL		
+	NOVARTIS	20MG/VIAL	N16211 001
	MIOCHOL-E		
+	NOVARTIS	20MG/VIAL	N20213 001 SEP 22, 1993

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

	ACETYLCYSTEINE			
AN	ABBOTT	10%	**N73664 001**	AUG 30, 1994
AN		20%	**N74037 001**	AUG 30, 1994
AN	BEDFORD	10%	**N72323 001**	APR 30, 1992
AN		20%	**N72324 001**	APR 30, 1992
AN	LUITPOLD	10%	**N72489 001**	JUL 28, 1995
AN		20%	**N72547 001**	JUL 28, 1995
AN	MAYNE PHARMA USA	10%	**N71364 001**	MAY 01, 1989
AN		10%	**N71365 002**	JAN 18, 2002
AN		20%	**N71364 002**	JAN 18, 2002
AN		20%	**N71365 001**	MAY 01, 1989
AN	ROXANE	10%	**N72621 001**	SEP 30, 1992
AN		20%	**N72622 001**	SEP 30, 1992
	MUCOMYST			
AN	+ APOTHECON	10%	**N13601 002**	
AN	+	20%	**N13601 001**	

FDA data supplied by DrugPatentWatch.com

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

	MUCOSIL-10			
AN	DEY	10%	N70575 001	OCT 14, 1986
	MUCOSIL-20			
AN	DEY	20%	N70576 001	OCT 14, 1986

ACITRETIN

CAPSULE; ORAL

	SORIATANE			
	HLR	10MG	N19821 001	OCT 28, 1996
+		25MG	N19821 002	OCT 28, 1996

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

	SEMPREX-D			
+	CELLTECH PHARMS	8MG;60MG	N19806 001	MAR 25, 1994

ACYCLOVIR

CAPSULE; ORAL

	ACYCLOVIR			
AB	AAIPHARMA LLC	200MG	N74833 001	APR 22, 1997
AB	APOTHECON	200MG	N74889 001	OCT 31, 1997
AB	CLONMEL HLTHCARE	200MG	N74872 001	APR 22, 1997
AB	COPLEY PHARM	200MG	N74914 001	NOV 26, 1997
AB	GENPHARM	200MG	N74977 001	APR 13, 1998
AB	IVAX PHARMS	200MG	N74674 001	APR 22, 1997
AB	MYLAN	200MG	N74727 001	APR 22, 1997
AB	PUREPAC PHARM	200MG	N74906 001	AUG 26, 1997

ACYCLOVIR

CAPSULE; ORAL

	ACYCLOVIR			
AB	RANBAXY	200MG	N74975 001	SEP 30, 1998
AB	STASON	200MG	N75090 001	JAN 26, 1999
AB	TEVA	200MG	N74578 001	APR 22, 1997
AB		200MG	N74828 001	APR 22, 1997
AB	WATSON LABS	200MG	N75101 001	APR 15, 1998
	ZOVIRAX			
AB	+ GLAXOSMITHKLINE	200MG	N18828 001	JAN 25, 1985

CREAM; TOPICAL

	ZOVIRAX			
	+ GLAXOSMITHKLINE	5%	N21478 001	DEC 30, 2002

OINTMENT; TOPICAL

	ZOVIRAX			
	+ GLAXOSMITHKLINE	5%	N18604 001	MAR 29, 1982

SUSPENSION; ORAL

	ACYCLOVIR			
AB	ALPHARMA	200MG/5ML	N74738 001	APR 28, 1997
	ZOVIRAX			
AB	+ GLAXOSMITHKLINE	200MG/5ML	N19909 001	DEC 22, 1989

TABLET; ORAL

	ACYCLOVIR			
AB	AAIPHARMA LLC	400MG	N74946 001	NOV 19, 1997
AB		800MG	N74946 002	NOV 19, 1997
AB	APOTHECON	400MG	N74891 001	OCT 31, 1997
AB		800MG	N74891 002	OCT 31, 1997
AB	CARLSBAD	400MG	N75382 001	APR 30, 1999

FDA data supplied by DrugPatentWatch.com

ACYCLOVIR

TABLET; ORAL

	ACYCLOVIR			
AB	CARLSBAD	**800MG**	**N75382 002**	APR 30, 1999
AB	COPLEY PHARM	**400MG**	**N75021 001**	MAR 18, 1998
AB		**800MG**	**N75021 002**	MAR 18, 1998
AB	GENPHARM	**400MG**	**N74976 001**	APR 13, 1998
AB		**800MG**	**N74976 002**	APR 13, 1998
AB	IVAX PHARMS	**400MG**	**N74836 001**	APR 22, 1997
AB		**800MG**	**N74836 002**	APR 22, 1997
AB	MYLAN	**400MG**	**N75211 001**	SEP 28, 1998
AB		**800MG**	**N75211 002**	SEP 28, 1998
AB	PUREPAC PHARM	**400MG**	**N74870 001**	JUN 05, 1997
AB		**800MG**	**N74870 002**	JUN 05, 1997
AB	RANBAXY	**400MG**	**N74980 001**	SEP 30, 1998
AB		**800MG**	**N74980 002**	SEP 30, 1998
AB	TEVA	**400MG**	**N74556 002**	APR 22, 1997
AB		**800MG**	**N74556 003**	APR 22, 1997
	ZOVIRAX			
AB	GLAXOSMITHKLINE	**400MG**	**N20089 001**	APR 30, 1991
AB +		**800MG**	**N20089 002**	APR 30, 1991

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

	ACYCLOVIR			
AP	ABBOTT	**EQ 50MG BASE/ML**	**N75114 001**	JUL 26, 1999
AP	GENSIA SICOR PHARMS	**EQ 50MG BASE/ML**	**N75627 001**	MAR 28, 2001

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE

+	BAXTER HLTHCARE	EQ 500MG BASE/VIAL	N74885 001	DEC 19, 1997
		EQ 1GM BASE/VIAL	N74885 002	DEC 19, 1997
	ACYCLOVIR SODIUM			
AP	ABBOTT	**EQ 500MG BASE/VIAL**	**N74663 001**	APR 22, 1997
AP		**EQ 500MG BASE/VIAL**	**N74758 001**	APR 22, 1997
AP		**EQ 1GM BASE/VIAL**	**N74663 002**	APR 22, 1997
AP		**EQ 1GM BASE/VIAL**	**N74758 002**	APR 22, 1997
AP +	AM PHARM PARTNERS	**EQ 50MG BASE/ML**	**N74930 001**	MAY 13, 1998
AP		**EQ 500MG BASE/VIAL**	**N75015 001**	APR 30, 1998
AP	BAXTER HLTHCARE	**EQ 500MG BASE/VIAL**	**N74913 001**	OCT 15, 1997
AP		**EQ 1GM BASE/VIAL**	**N74913 002**	OCT 15, 1997
AP	BEDFORD	**EQ 500MG BASE/VIAL**	**N74596 002**	APR 22, 1997
AP		**EQ 1GM BASE/VIAL**	**N74596 001**	APR 22, 1997
AP	GENSIA SICOR PHARMS	**EQ 500MG BASE/VIAL**	**N74969 001**	AUG 26, 1997
AP		**EQ 1GM BASE/VIAL**	**N74969 002**	AUG 26, 1997
+	MAYNE PHARMA USA	EQ 25MG BASE/ML	N74720 001	APR 22, 1997
AP	MERIDIAN MEDCL TECHN	**EQ 50MG BASE/ML**	**N75065 001**	FEB 25, 1999
	ZOVIRAX			
AP +	GLAXOSMITHKLINE	**EQ 500MG BASE/VIAL**	**N18603 001**	OCT 22, 1982
AP +		**EQ 1GM BASE/VIAL**	**N18603 002**	JUN 29, 1989

ADAPALENE

CREAM; TOPICAL

	DIFFERIN			
+	GALDERMA LABS LP	0.1%	N20748 001	MAY 26, 2000

FDA data supplied by DrugPatentWatch.com

ADAPALENE

GEL; TOPICAL
DIFFERIN
+ GALDERMA LABS LP 0.1% N20380 001 MAY 31, 1996

SOLUTION; TOPICAL
DIFFERIN
+ GALDERMA LABS LP 0.1% N20338 001 MAY 31, 1996

ADEFOVIR DIPIVOXIL

TABLET; ORAL
HEPSERA
+ GILEAD 10MG N21449 001 SEP 20, 2002

ADENOSINE

INJECTABLE; INJECTION
ADENOCARD
+ FUJISAWA HLTHCARE 3MG/ML N19937 002 OCT 30, 1989

ADENOSCAN
+ FUJISAWA HLTHCARE 3MG/ML N20059 001 MAY 18, 1995

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION
TROVAN PRESERVATIVE FREE
PFIZER EQ 200MG BASE/VIAL N20760 001 DEC 18, 1997
+ EQ 300MG BASE/VIAL N20760 002 DEC 18, 1997

ALBENDAZOLE

TABLET; ORAL
ALBENZA
+ GLAXOSMITHKLINE 200MG N20666 001 JUN 11, 1996

ALBUMIN HUMAN

INJECTABLE; INJECTION
OPTISON
+ AMERSHAM HLTH 10MG/ML N20899 001 DEC 31, 1997

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125
MALLINCKRODT 10 uCi/ML N17844 001

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION
MEGATOPE
ISO TEX 0.5mCi/VIAL N17837 001
1mCi/VIAL N17837 002

ALBUTEROL

AEROSOL, METERED; INHALATION
ALBUTEROL
AB ARMSTRONG PHARMS **0.09MG/INH** **N72273 001** AUG 14, 1996
AB GENPHARM **0.09MG/INH** **N73045 001** AUG 19, 1997
AB IVAX PHARMS **0.09MG/INH** **N73272 001** DEC 28, 1995
AB PLIVA **0.09MG/INH** **N74072 001** AUG 01, 1996

PROVENTIL
BN + SCHERING 0.09MG/INH N17559 001
VENTOLIN
AB + GLAXOSMITHKLINE **0.09MG/INH** **N18473 001**

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION
PROVENTIL-HFA
BX + 3M EQ 0.09MG BASE/INH N20503 001 AUG 15, 1996

VENTOLIN HFA
BX + GLAXOSMITHKLINE EQ 0.09MG BASE/INH N20983 001 APR 19, 2001

FDA data supplied by DrugPatentWatch.com

ALBUTEROL SULFATE

SOLUTION; INHALATION

	ACCUNEB			
	+ DEY	EQ 0.021% BASE	N20949 002	APR 30, 2001
	+	EQ 0.042% BASE	N20949 001	APR 30, 2001
	ALBUTEROL SULFATE			
AN	ALPHARMA	**EQ 0.083% BASE**	**N73533 001**	SEP 26, 1995
AN	BAUSCH AND LOMB	**EQ 0.083% BASE**	**N75358 001**	MAR 29, 2000
AN		**EQ 0.5% BASE**	**N75050 001**	JUN 18, 1998
AN	BREATH LTD	**EQ 0.083% BASE**	**N76370 001**	NOV 24, 2003
AN	DEY	**EQ 0.083% BASE**	**N72652 001**	FEB 21, 1992
AN	HI TECH PHARMA	**EQ 0.083% BASE**	**N75063 001**	FEB 09, 1999
AN		**EQ 0.5% BASE**	**N74543 001**	JAN 15, 1998
AN	IVAX PHARMS	**EQ 0.083% BASE**	**N75343 001**	NOV 09, 1999
AN	MORTON GROVE	**EQ 0.083% BASE**	**N75394 001**	NOV 22, 1999
AN	NEPHRON	**EQ 0.083% BASE**	**N74880 001**	SEP 17, 1997
AN		**EQ 0.5% BASE**	**N75664 001**	JUN 26, 2001
AN	NOVEX	**EQ 0.5% BASE**	**N76391 001**	APR 01, 2003
AN	ROXANE	**EQ 0.083% BASE**	**N75129 001**	FEB 13, 2001
	PROVENTIL			
AN	+ SCHERING	**EQ 0.083% BASE**	**N19243 002**	JAN 14, 1987
AN	+	**EQ 0.5% BASE**	**N19243 001**	JAN 14, 1987

SYRUP; ORAL

	ALBUTEROL SULFATE			
AA	ALPHARMA	**EQ 2MG BASE/5ML**	**N74454 001**	SEP 25, 1995
AA	HI TECH PHARMA	**EQ 2MG BASE/5ML**	**N74749 001**	JAN 30, 1998
AA	TEVA	**EQ 2MG BASE/5ML**	**N73419 001**	MAR 30, 1992

ALBUTEROL SULFATE

SYRUP; ORAL

	ALBUTEROL SULFATE			
AA	UDL	**EQ 2MG BASE/5ML**	**N75262 001**	MAR 30, 1999

TABLET; ORAL

	ALBUTEROL SULFATE			
AB	MUTUAL PHARM	**EQ 2MG BASE**	**N72636 001**	DEC 05, 1989
AB		**EQ 4MG BASE**	**N72637 001**	DEC 05, 1989
AB	+ MYLAN	**EQ 2MG BASE**	**N72893 001**	JAN 17, 1991
AB	+	**EQ 4MG BASE**	**N72894 001**	JAN 17, 1991
AB	PLIVA	**EQ 2MG BASE**	**N72316 001**	DEC 05, 1989
AB		**EQ 4MG BASE**	**N72317 001**	DEC 05, 1989
AB	SANDOZ	**EQ 2MG BASE**	**N72151 001**	DEC 05, 1989
AB		**EQ 4MG BASE**	**N72152 001**	DEC 05, 1989
AB	TEVA	**EQ 2MG BASE**	**N72619 001**	DEC 05, 1989
AB		**EQ 2MG BASE**	**N72779 001**	JUN 25, 1993
AB		**EQ 2MG BASE**	**N72938 001**	MAR 30, 1990
AB		**EQ 4MG BASE**	**N72620 001**	DEC 05, 1989
AB		**EQ 4MG BASE**	**N72780 001**	JUN 25, 1993
AB		**EQ 4MG BASE**	**N72939 001**	MAR 30, 1990
AB	WATSON LABS	**EQ 2MG BASE**	**N72629 001**	JAN 31, 1991
AB		**EQ 2MG BASE**	**N72764 001**	AUG 28, 1991
AB		**EQ 4MG BASE**	**N72630 001**	JAN 31, 1991
AB		**EQ 4MG BASE**	**N72765 001**	AUG 28, 1991

TABLET, EXTENDED RELEASE; ORAL

	ALBUTEROL SULFATE			
AB	PLIVA	**EQ 4MG BASE**	**N76130 002**	SEP 26, 2002

FDA data supplied by DrugPatentWatch.com

ALBUTEROL SULFATE

TABLET, EXTENDED RELEASE; ORAL

	ALBUTEROL SULFATE			
AB	PLIVA	**EQ 8MG BASE**	**N76130 003**	SEP 26, 2002
	VOLMAX			
AB	+ MURO	**EQ 4MG BASE**	**N19604 002**	DEC 23, 1992
AB	+	**EQ 8MG BASE**	**N19604 001**	DEC 23, 1992

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

	COMBIVENT			
	+ BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH; 0.018MG/INH	N20291 001	OCT 24, 1996

SOLUTION; INHALATION

	DUONEB			
	+ DEY	EQ 0.083% BASE;0.017%	N20950 001	MAR 21, 2001

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

	ACLOVATE			
	+ GLAXOSMITHKLINE	0.05%	N18707 001	DEC 14, 1982

OINTMENT; TOPICAL

	ACLOVATE			
	+ GLAXOSMITHKLINE	0.05%	N18702 001	DEC 14, 1982

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

	ALCOHOL 10% AND DEXTROSE 5%			
	+ B BRAUN	10ML/100ML;5GM/100ML	N04589 006	
	ALCOHOL 5% AND DEXTROSE 5%			
AP	+ B BRAUN	**5ML/100ML;5GM/100ML**	**N04589 004**	
	ALCOHOL 5% IN D5-W			
AP	ABBOTT	**5ML/100ML;5GM/100ML**	**N83263 001**	

ALENDRONATE SODIUM

SOLUTION; ORAL

	FOSAMAX			
	+ MERCK	EQ 70MG ACID/75ML	N21575 001	SEP 17, 2003

TABLET; ORAL

	FOSAMAX			
	MERCK	EQ 5MG BASE	N20560 003	APR 25, 1997
		EQ 10MG BASE	N20560 001	SEP 29, 1995
		EQ 35MG BASE	N20560 004	OCT 20, 2000
		EQ 40MG BASE	N20560 002	SEP 29, 1995
	+	EQ 70MG BASE	N20560 005	OCT 20, 2000

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

	ALFENTA			
AP	+ AKORN	**EQ 0.5MG BASE/ML**	**N19353 001**	DEC 29, 1986
	ALFENTANIL			
AP	ABBOTT	**EQ 0.5MG BASE/ML**	**N75221 001**	OCT 28, 1999

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	UROXATRAL			
	+ SANOFI SYN RES	10MG	N21287 001	JUN 12, 2003

ALGLUCERASE

INJECTABLE; INJECTION

	CEREDASE			
	+ GENZYME	80 UNITS/ML	N20057 003	APR 05, 1991

FDA data supplied by DrugPatentWatch.com

ALITRETINOIN

GEL; TOPICAL
PANRETIN
+ LIGAND — EQ 0.1% BASE — N20886 001 FEB 02, 1999

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL

AB	MUTUAL PHARM	**100MG**	**N71449 001**	JAN 09, 1987
AB		**300MG**	**N71450 001**	JAN 09, 1987
AB	MYLAN	**100MG**	**N18659 001**	OCT 24, 1986
AB		**300MG**	**N18659 002**	OCT 24, 1986
AB	PAR PHARM	**100MG**	**N70150 001**	DEC 10, 1985
AB		**300MG**	**N70147 001**	DEC 10, 1985
AB	SANDOZ	**100MG**	**N70268 001**	DEC 31, 1985
AB		**300MG**	**N70269 001**	DEC 31, 1985
AB	VINTAGE PHARMS	**100MG**	**N75798 001**	JUN 27, 2003
AB		**300MG**	**N75798 002**	JUN 27, 2003
AB	WATSON LABS	**100MG**	**N18832 002**	SEP 28, 1984
AB		**300MG**	**N18877 001**	SEP 28, 1984

LOPURIN

AB	BASF	**100MG**	**N71586 001**	APR 02, 1987
AB		**300MG**	**N71587 001**	APR 02, 1987

ZYLOPRIM

AB	PROMETHEUS LABS	**100MG**	**N16084 001**	
AB	+	**300MG**	**N16084 002**	

ALLOPURINOL SODIUM

INJECTABLE; INJECTION
ALOPRIM
+ DSM PHARMS — EQ 500MG BASE/VIAL — N20298 001 MAY 17, 1996

ALMOTRIPTAN MALATE

TABLET; ORAL
AXERT

JANSSEN ORTHO	EQ 6.25MG BASE	N21001 001	MAY 07, 2001
+	EQ 12.5MG BASE	N21001 002	MAY 07, 2001

ALOSETRON HYDROCHLORIDE

TABLET; ORAL
LOTRONEX

GLAXOSMITHKLINE	EQ 0.5MG BASE	N21107 002	DEC 23, 2003
+	EQ 1MG BASE	N21107 001	FEB 09, 2000

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION
INFUVITE ADULT
+ SABEX 2002 — 2 IU/ML;40MG/ML;12 UGM/ML;40 IU/ML; 1 UGM/ML;3MG/ML;120 UGM/ML;8MG/ML; 1.2MG/ML;0.72MG/ML;1.2MG/ML; 660 IU/ML;0.03MG/ML — N21163 001 MAY 18, 2000

INJECTABLE; IV (INFUSION)
INFUVITE ADULT
+ SABEX 2002 — 2 IU/ML;40MG/ML;12 UGM/ML;40 IU/ML; 1 UGM/ML;3MG/ML;120 UGM/ML;8MG/ML; 1.2MG/ML;0.72MG/ML;1.2MG/ML; 660 IU/ML;30 UGM/ML — N21559 001 JUN 16, 2003

FDA data supplied by DrugPatentWatch.com

ALPRAZOLAM

CONCENTRATE; ORAL

	ALPRAZOLAM			
	+ ROXANE	1MG/ML	N74312 001	OCT 31, 1993

TABLET; ORAL

	ALPRAZOLAM			
AB	ALPHAPHARM	**0.25MG**	**N74046 001**	OCT 19, 1993
AB		**0.5MG**	**N74046 002**	OCT 19, 1993
AB		**1MG**	**N74046 003**	OCT 19, 1993
AB		**2MG**	**N74046 004**	MAY 07, 1997
AB	IVAX PHARMS	**0.25MG**	**N74294 001**	JUL 29, 1994
AB		**0.5MG**	**N74294 002**	JUL 29, 1994
AB		**1MG**	**N74294 003**	JUL 29, 1994
AB		**2MG**	**N74294 004**	JUL 29, 1994
AB	MYLAN	**0.25MG**	**N74215 001**	JAN 27, 1994
AB		**0.5MG**	**N74215 002**	JAN 27, 1994
AB		**1MG**	**N74215 003**	JAN 27, 1994
AB		**2MG**	**N74215 004**	JAN 27, 1994
AB	PUREPAC PHARM	**0.25MG**	**N74342 001**	OCT 31, 1993
AB		**0.5MG**	**N74342 002**	OCT 31, 1993
AB		**1MG**	**N74342 003**	OCT 31, 1993
AB		**2MG**	**N74342 004**	OCT 31, 1993
AB	SANDOZ	**0.25MG**	**N74112 001**	DEC 29, 1995
AB		**0.5MG**	**N74112 002**	DEC 29, 1995
AB		**1MG**	**N74112 003**	DEC 29, 1995
AB		**2MG**	**N74909 001**	MAR 25, 1998

ALPRAZOLAM

TABLET; ORAL

	ALPRAZOLAM			
AB	TEVA	**0.25MG**	**N74085 001**	FEB 16, 1994
AB		**0.5MG**	**N74085 002**	FEB 16, 1994
AB		**1MG**	**N74085 003**	FEB 16, 1994
AB		**2MG**	**N74085 004**	FEB 26, 1996
AB	WATSON LABS	**0.25MG**	**N74456 001**	AUG 31, 1995
AB		**0.25MG**	**N74479 001**	JAN 21, 1997
AB		**0.5MG**	**N74456 002**	AUG 31, 1995
AB		**0.5MG**	**N74479 002**	JAN 21, 1997
AB		**1MG**	**N74456 003**	AUG 31, 1995
AB		**1MG**	**N74479 003**	JAN 21, 1997
	XANAX			
AB	PHARMACIA AND UPJOHN	**0.25MG**	**N18276 001**	NOV 27, 1985
AB		**0.5MG**	**N18276 002**	
AB	+	**1MG**	**N18276 003**	
AB		**2MG**	**N18276 004**	

TABLET, EXTENDED RELEASE; ORAL

	XANAX XR			
	PHARMACIA AND UPJOHN	0.5MG	N21434 001	JAN 17, 2003
		1MG	N21434 002	JAN 17, 2003
		2MG	N21434 003	JAN 17, 2003
	+	3MG	N21434 004	JAN 17, 2003

ALPROSTADIL

INJECTABLE; INJECTION

	ALPROSTADIL			
AP	BEDFORD	**0.5MG/ML**	**N74815 001**	JAN 20, 1998

FDA data supplied by DrugPatentWatch.com

ALPROSTADIL

INJECTABLE; INJECTION

	ALPROSTADIL			
AP	GENSIA SICOR PHARMS	**0.5MG/ML**	**N75196 001**	
			APR 30, 1999	
	CAVERJECT			
AP	PHARMACIA AND UPJOHN	**0.01MG/VIAL**	**N20379 001**	
			JUL 06, 1995	
AP	+	**0.02MG/VIAL**	**N20379 002**	
			JUL 06, 1995	
AP	+	**0.04MG/VIAL**	**N20379 004**	
			MAY 19, 1997	
		0.005MG/VIAL	N20379 003	
			JUN 27, 1996	
		0.01MG/VIAL	N21212 001	
			JUN 11, 2002	
		0.02MG/VIAL	N21212 002	
			JUN 11, 2002	
	EDEX			
AP	SCHWARZ PHARMA	**0.01MG/VIAL**	**N20649 002**	
			JUN 12, 1997	
AP		**0.02MG/VIAL**	**N20649 003**	
			JUN 12, 1997	
AP	+	**0.04MG/VIAL**	**N20649 004**	
			JUN 12, 1997	
	+	0.01MG/VIAL	N20649 005	
			JUL 30, 1998	
	+	0.02MG/VIAL	N20649 006	
			JUL 30, 1998	
	+	0.04MG/VIAL	N20649 007	
			JUL 30, 1998	
	PROSTIN VR PEDIATRIC			
AP	+ PHARMACIA AND UPJOHN	**0.5MG/ML**	**N18484 001**	

SUPPOSITORY; URETHRAL

	MUSE		
	VIVUS	0.125MG	N20700 001
			NOV 19, 1996
		0.25MG	N20700 002
			NOV 19, 1996
		0.5MG	N20700 003
			NOV 19, 1996
	+	1MG	N20700 004
			NOV 19, 1996

ALTRETAMINE

CAPSULE; ORAL

	HEXALEN			
	+ MGI PHARMA INC	50MG		N19926 001
				DEC 26, 1990

ALUMINUM ACETATE; *MULTIPLE*

SEE ACETIC ACID, GLACIAL; ALUMINUM ACETATE

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

	AMANTADINE HCL			
AB	SANDOZ	**100MG**		**N71293 001**
				FEB 18, 1987
AB	+ USL PHARMA	**100MG**		**N70589 001**
				AUG 05, 1986

SYRUP; ORAL

	AMANTADINE HCL		
AA	ALPHARMA	**50MG/5ML**	**N72655 001**
			OCT 30, 1990
AA	CAROLINA MEDCL	**50MG/5ML**	**N75819 001**
			SEP 11, 2002
AA	COPLEY PHARM	**50MG/5ML**	**N73115 001**
			AUG 23, 1991
AA	HI TECH PHARMA	**50MG/5ML**	**N74170 001**
			OCT 28, 1994
AA	MIKART	**50MG/5ML**	**N74028 001**
			JUN 28, 1993
AA	MORTON GROVE	**50MG/5ML**	**N75060 001**
			DEC 24, 1998
AA	PHARM ASSOC	**50MG/5ML**	**N74509 001**
			JUL 17, 1995
	SYMMETREL		
AA	+ ENDO PHARMS	**50MG/5ML**	**N16023 002**

TABLET; ORAL

	AMANTADINE HCL		
AB	USL PHARMA	**100MG**	**N76186 001**
			DEC 16, 2002
	SYMMETREL		
AB	+ ENDO PHARMS	**100MG**	**N18101 001**

FDA data supplied by DrugPatentWatch.com

AMBENONIUM CHLORIDE

TABLET; ORAL
MYTELASE
+ SANOFI SYNTHELABO 10MG N10155 002

AMCINONIDE

CREAM; TOPICAL
AMCINONIDE
AB ALTANA **0.1%** **N76065 001** MAY 15, 2003
AB TARO PHARM INDS **0.1%** **N76229 001** MAY 31, 2002
CYCLOCORT
AB + FUJISAWA HLTHCARE **0.1%** **N18116 002**

LOTION; TOPICAL
AMCINONIDE
AB ALTANA **0.1%** **N76329 001** NOV 06, 2002
CYCLOCORT
AB + FUJISAWA HLTHCARE **0.1%** **N19729 001** JUN 13, 1988

OINTMENT; TOPICAL
AMCINONIDE
AB ALTANA **0.1%** **N76096 001** NOV 19, 2002
AB TARO PHARM INDS **0.1%** **N76367 001** MAR 19, 2003
CYCLOCORT
AB + FUJISAWA HLTHCARE **0.1%** **N18498 001**

AMIFOSTINE

INJECTABLE; INJECTION
ETHYOL
+ MEDIMMUNE ONCOLOGY 500MG/VIAL N20221 001 DEC 08, 1995

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN SULFATE
AP ABBOTT **EQ 50MG BASE/ML** **N63263 001** NOV 30, 1994

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN SULFATE
AP ABBOTT **EQ 250MG BASE/ML** **N63264 001** NOV 30, 1994
AP **EQ 250MG BASE/ML** **N64098 001** JUN 26, 1995
EQ 62.5MG BASE/ML N63283 001 OCT 31, 1994
AP BEDFORD **EQ 50MG BASE/ML** **N63313 001** APR 11, 1994
AP **EQ 250MG BASE/ML** **N63315 001** APR 11, 1994
AP GENSIA SICOR PHARMS **EQ 50MG BASE/ML** **N64045 001** SEP 28, 1993
AP **EQ 250MG BASE/ML** **N64045 002** SEP 28, 1993
AP MAYNE PHARMA USA **EQ 50MG BASE/ML** **N63350 001** JUL 30, 1993
AP **EQ 250MG BASE/ML** **N63350 002** JUL 30, 1993

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
ABBOTT EQ 500MG BASE/100ML N64146 001 APR 02, 1997

AMIKIN
AP + APOTHECON **EQ 50MG BASE/ML** **N62311 001**
AP + **EQ 250MG BASE/ML** **N62311 002**

AMILORIDE HYDROCHLORIDE

TABLET; ORAL
AMILORIDE HCL
AB PAR PHARM **5MG** **N70346 001** JAN 22, 1986
MIDAMOR
AB + MERCK **5MG** **N18200 001**

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE
AB BARR **EQ 5MG ANHYDROUS;50MG** **N71111 001** MAY 10, 1988
AB MYLAN **EQ 5MG ANHYDROUS;50MG** **N73209 001** OCT 31, 1991

FDA data supplied by DrugPatentWatch.com

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	AMILORIDE HCL AND HYDROCHLOROTHIAZIDE			
AB	SANDOZ	**EQ 5MG ANHYDROUS;50MG**	**N73357 001**	NOV 27, 1991
AB	TEVA	**EQ 5MG ANHYDROUS;50MG**	**N70795 001**	APR 17, 1988
AB	WATSON LABS	**EQ 5MG ANHYDROUS;50MG**	**N73334 001**	JUL 19, 1991
	HYDRO-RIDE			
AB	PAR PHARM	**EQ 5MG ANHYDROUS;50MG**	**N70347 001**	DEC 25, 1990
	MODURETIC 5-50			
AB	+ MERCK	**EQ 5MG ANHYDROUS;50MG**	**N18201 001**	

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE			
FRESENIUS KABI	5.2% (5.2GM/100ML)	N18901 001	APR 06, 1984
AMINOSYN 10%			
ABBOTT	10% (10GM/100ML)	N17673 003	
AMINOSYN 10% (PH6)			
ABBOTT	10% (10GM/100ML)	N17673 008	NOV 18, 1985
AMINOSYN 3.5%			
ABBOTT	3.5% (3.5GM/100ML)	N17789 004	
AMINOSYN 5%			
ABBOTT	5% (5GM/100ML)	N17673 001	
AMINOSYN 7% (PH6)			
ABBOTT	7% (7GM/100ML)	N17673 006	NOV 18, 1985
AMINOSYN 8.5% (PH6)			
ABBOTT	8.5% (8.5GM/100ML)	N17673 007	NOV 18, 1985
AMINOSYN II 10%			
ABBOTT	10% (10GM/100ML)	N19438 005	APR 03, 1986
AMINOSYN II 10% IN PLASTIC CONTAINER			
ABBOTT	10% (10GM/100ML)	N20015 001	DEC 19, 1991
AMINOSYN II 15% IN PLASTIC CONTAINER			
ABBOTT	15% (15GM/100ML)	N20041 001	DEC 19, 1991
AMINOSYN II 7%			
ABBOTT	7% (7GM/100ML)	N19438 003	APR 03, 1986

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN II 8.5%			
ABBOTT	8.5% (8.5GM/100ML)	N19438 004	APR 03, 1986
AMINOSYN-HBC 7%			
ABBOTT	7% (7GM/100ML)	N19374 001	JUL 12, 1985
AMINOSYN-HF 8%			
ABBOTT	8% (8GM/100ML)	N20345 001	APR 04, 1996
AMINOSYN-PF 10%			
ABBOTT	10% (10GM/100ML)	N19492 002	OCT 17, 1986
AMINOSYN-PF 7%			
ABBOTT	7% (7GM/100ML)	N19398 001	SEP 06, 1985
AMINOSYN-RF 5.2%			
ABBOTT	5.2% (5.2GM/100ML)	N18429 001	
BRANCHAMIN 4% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4% (4GM/100ML)	N18684 001	SEP 28, 1984
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER			
CLINTEC NUTR	15% (15GM/100ML)	N20512 001	AUG 30, 1996
FREAMINE HBC 6.9%			
B BRAUN	6.9% (6.9GM/100ML)	N16822 006	MAY 17, 1983
FREAMINE III 10%			
B BRAUN	10% (10GM/100ML)	N16822 005	
FREAMINE III 8.5%			
B BRAUN	8.5% (8.5GM/100ML)	N16822 004	
HEPATAMINE 8%			
B BRAUN	8% (8GM/100ML)	N18676 001	AUG 03, 1982
HEPATASOL 8%			
BAXTER HLTHCARE	8% (8GM/100ML)	N20360 001	APR 04, 1996
NEPHRAMINE 5.4%			
B BRAUN	5.4% (5.4GM/100ML)	N17766 001	
NOVAMINE 11.4%			
FRESENIUS KABI	11.4% (11.4GM/100ML)	N17957 003	AUG 09, 1982
NOVAMINE 15%			
FRESENIUS KABI	15% (15GM/100ML)	N17957 004	NOV 28, 1986
PREMASOL 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	EQ 10% (10GM/100ML)	N75880 002	JUN 19, 2003

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS

INJECTABLE; INJECTION

PREMASOL 6% IN PLASTIC CONTAINER
BAXTER HLTHCARE EQ 6% (6GM/100ML) N75880 001 JUN 19, 2003

PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER
\+ BAXTER HLTHCARE 20% (20GM/100ML) N20849 001 AUG 26, 1998

RENAMIN W/O ELECTROLYTES
BAXTER HLTHCARE 6.5% (6.5GM/100ML) N17493 007 OCT 15, 1982

TRAVASOL 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 10% (10MG/100ML) N18931 003 AUG 23, 1984

TRAVASOL 10% W/O ELECTROLYTES
BAXTER HLTHCARE 10% (10GM/100ML) N17493 006

TRAVASOL 5.5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5.5% (5.5GM/100ML) N18931 001 AUG 23, 1984

TRAVASOL 5.5% W/O ELECTROLYTES
BAXTER HLTHCARE 5.5% (5.5GM/100ML) N17493 004

TRAVASOL 8.5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 8.5% (8.5GM/100ML) N18931 002 AUG 23, 1984

TRAVASOL 8.5% W/O ELECTROLYTES
BAXTER HLTHCARE 8.5% (8.5GM/100ML) N17493 005

TROPHAMINE
\+ B BRAUN 6% (6GM/100ML) N19018 001 JUL 20, 1984

TROPHAMINE 10%
\+ B BRAUN 10% (10GM/100ML) N19018 003 SEP 07, 1988

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PROCALAMINE
B BRAUN 3%;26MG/100ML;3GM/100ML;54MG/100ML; 41MG/100ML;150MG/100ML;200MG/100ML; 120MG/100ML N18582 001 MAY 08, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
ABBOTT 3.5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML N19683 001 NOV 07, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER
ABBOTT 4.25%;36.8MG/100ML;20GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML N19683 002 NOV 07, 1988

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
ABBOTT 4.25%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML N19683 003 NOV 07, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
\+ BAXTER HLTHCARE 2.75%;33MG/100ML;10GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML N20678 002 MAR 26, 1997

CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
\+ BAXTER HLTHCARE 2.75%;33MG/100ML;25GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML N20678 005 MAR 26, 1997

CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER
\+ BAXTER HLTHCARE 2.75%;33MG/100ML;5GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML N20678 001 MAR 26, 1997

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%;33MG/100ML;10GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 009 MAR 26, 1997

CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%;33MG/100ML;20GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 011 MAR 26, 1997

CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%;33MG/100ML;25GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 012 MAR 26, 1997

CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%;33MG/100ML;5GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 008 MAR 26, 1997

CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;10GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 016 MAR 26, 1997

CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;15GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 017 MAR 26, 1997

CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;20GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 018 MAR 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;25GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 019 MAR 26, 1997

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;35GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 021 MAR 26, 1997

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT 3.5%;25GM/100ML N19681 001 NOV 01, 1988

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 3.5%;5GM/100ML N19681 002 NOV 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER
ABBOTT 4.25%;10GM/100ML N19681 004 NOV 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
ABBOTT 4.25%;20GM/100ML N19681 005 NOV 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT 4.25%;25GM/100ML N19681 003 NOV 01, 1988

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER
ABBOTT 5%;25GM/100ML N19681 006 NOV 01, 1988

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;10GM/100ML N20734 002 SEP 29, 1997

CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;25GM/100ML N20734 005 SEP 29, 1997

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;5GM/100ML N20734 001 SEP 29, 1997
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;10GM/100ML N20734 008 SEP 29, 1997
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;20GM/100ML N20734 010 SEP 29, 1997
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;25GM/100ML N20734 011 SEP 29, 1997
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;5GM/100ML N20734 007 SEP 29, 1997
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;10GM/100ML N20734 014 SEP 29, 1997
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;15GM/100ML N20734 015 SEP 29, 1997
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;20GM/100ML N20734 016 SEP 29, 1997
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;25GM/100ML N20734 017 SEP 29, 1997
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5%;35GM/100ML N20734 018 SEP 29, 1997
TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;10GM/100ML N19520 002 SEP 23, 1988
TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;15GM/100ML N19520 003 SEP 23, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION
TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;20GM/100ML N19520 004 SEP 23, 1988
TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;25GM/100ML N19520 005 SEP 23, 1988
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 2.75%;5GM/100ML N19520 001 SEP 23, 1988
TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;10GM/100ML N19520 007 SEP 23, 1988
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;15GM/100ML N19520 008 SEP 23, 1988
TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;20GM/100ML N19520 009 SEP 23, 1988
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;25GM/100ML N19520 010 SEP 23, 1988
TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 4.25%;5GM/100ML N19520 006 SEP 23, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 3.5%;5GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML N19682 001 NOV 01, 1988
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER
ABBOTT 4.25%;5GM/100ML;30MG/100ML; 97MG/100ML;120MG/100ML; 49.3MG/100ML N19682 002 NOV 01, 1988

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE — 2.75%;10GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML — N20147 002 OCT 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE — 2.75%;15GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML — N20147 003 OCT 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE — 2.75%;20GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML — N20147 004 OCT 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE — 2.75%;25GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML — N20147 005 OCT 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE — 2.75%;5GM/100ML;51MG/100ML; 261MG/100ML;216MG/100ML; 112MG/100ML — N20147 001 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE — 4.25%;10GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML — N20147 007 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER
BAXTER HLTHCARE — 4.25%;15GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML — N20147 008 OCT 23, 1995

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER
BAXTER HLTHCARE — 4.25%;20GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML — N20147 009 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
BAXTER HLTHCARE — 4.25%;25GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML — N20147 010 OCT 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE — 4.25%;5GM/100ML;51MG/100ML; 261MG/100ML;297MG/100ML; 77MG/100ML — N20147 006 OCT 23, 1995

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES
B BRAUN — 8.5%;110MG/100ML;230MG/100ML; 10MG/100ML;440MG/100ML; 690MG/100ML — N16822 007 JUL 01, 1988

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M
ABBOTT — 3.5%;21MG/100ML;40MG/100ML; 128MG/100ML;234MG/100ML — N17789 003

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
FREAMINE III 3% W/ ELECTROLYTES
B BRAUN 3%;54MG/100ML;40MG/100ML; 150MG/100ML;200MG/100ML; 120MG/100ML N16822 003

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN II 10% W/ ELECTROLYTES
ABBOTT 10%;102MG/100ML;45MG/100ML; 522MG/100ML;410MG/100ML N19437 004 APR 03, 1986

AMINOSYN II 8.5% W/ ELECTROLYTES
ABBOTT 8.5%;102MG/100ML;45MG/100ML; 522MG/100ML;410MG/100ML N19437 005 APR 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
BAXTER HLTHCARE 3.5%;51MG/100ML;131MG/100ML; 218MG/100ML;35MG/100ML N20177 001 OCT 23, 1995

TRAVASOL 3.5% W/ ELECTROLYTES
BAXTER HLTHCARE 3.5%;51MG/100ML;131MG/100ML; 218MG/100ML;35MG/100ML N17493 003

TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
BAXTER HLTHCARE 5.5%;102MG/100ML;522MG/100ML; 431MG/100ML;224MG/100ML N20173 001 OCT 27, 1995

TRAVASOL 5.5% W/ ELECTROLYTES
BAXTER HLTHCARE 5.5%;102MG/100ML;522MG/100ML; 431MG/100ML;224MG/100ML N17493 001

TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER
BAXTER HLTHCARE 8.5%;102MG/100ML;522MG/100ML; 594MG/100ML;154MG/100ML N20173 002 OCT 27, 1995

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
TRAVASOL 8.5% W/ ELECTROLYTES
BAXTER HLTHCARE 8.5%;102MG/100ML;522MG/100ML; 594MG/100ML;154MG/100ML N17493 002

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN 7% W/ ELECTROLYTES
ABBOTT 7%;102MG/100ML;522MG/100ML; 410MG/100ML N17789 002

AMINOSYN 8.5% W/ ELECTROLYTES
ABBOTT 8.5%;102MG/100ML;522MG/100ML; 410MG/100ML N17673 005

AMINOCAPROIC ACID

INJECTABLE; INJECTION

	AMICAR			
AP	+ XANODYNE PHARM	**250MG/ML**	**N15229 002**	
	AMINOCAPROIC ACID			
AP	ABBOTT	**250MG/ML**	**N70888 001**	JUN 16, 1988
AP	LUITPOLD	**250MG/ML**	**N71192 001**	DEC 01, 1987
	AMINOCAPROIC ACID IN PLASTIC CONTAINER			
AP	ABBOTT	**250MG/ML**	**N70010 001**	MAR 09, 1987

SYRUP; ORAL

	AMICAR			
AA	+ XANODYNE PHARM	**1.25GM/5ML**	**N15230 002**	
	AMINOCAPROIC ACID			
AA	MIKART	**1.25GM/5ML**	**N74759 001**	SEP 02, 1998

TABLET; ORAL

	AMICAR			
AB	+ XANODYNE PHARM	**500MG**	**N15197 001**	
	AMINOCAPROIC			
AB	MIKART	**500MG**	**N75602 001**	MAY 24, 2001

FDA data supplied by DrugPatentWatch.com

AMINOGLUTETHIMIDE

TABLET; ORAL
CYTADREN
+ NOVARTIS 250MG N18202 001

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION
AMINOHIPPURATE SODIUM
+ MERCK 20% N05619 001

AMINOLEVULINIC ACID HYDROCHLORIDE

SOLUTION; TOPICAL
LEVULAN
+ DUSA 20% N20965 001 DEC 03, 1999

AMINOPHYLLINE

INJECTABLE; INJECTION
AMINOPHYLLINE

AP	ABBOTT	**25MG/ML**	**N87242 001** OCT 26, 1983
AP	+	**25MG/ML**	**N87601 001** JUL 23, 1982
AP	GENSIA SICOR PHARMS	**25MG/ML**	**N81142 001** SEP 25, 1991
AP	INTL MEDICATION	**25MG/ML**	**N87209 001** FEB 01, 1982
AP	LUITPOLD	**25MG/ML**	**N87240 001**
AP		**25MG/ML**	**N87600 001**
AP	PHARMA SERVE NY	**25MG/ML**	**N87392 001** DEC 15, 1983

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

+ ABBOTT	100MG/100ML	N88147 002 MAY 03, 1983
+	200MG/100ML	N88147 003 MAY 03, 1983

SOLUTION; ORAL
AMINOPHYLLINE

AA	+ ROXANE	**105MG/5ML**	**N88126 001** AUG 19, 1983

AMINOPHYLLINE

SOLUTION; ORAL
AMINOPHYLLINE DYE FREE

AA	+ ALPHARMA	**105MG/5ML**	**N87727 001** APR 16, 1982

SUPPOSITORY; RECTAL
TRUPHYLLINE

G AND W LABS	250MG	N85498 001 MAR 23, 1983
+	500MG	N85498 002 JAN 03, 1983

TABLET; ORAL
AMINOPHYLLINE

AB	+ ROXANE	**100MG**	**N87500 001** FEB 09, 1982
AB	+	**200MG**	**N87501 001** FEB 09, 1982
AB	WEST WARD	**100MG**	**N84540 001**
AB		**200MG**	**N85003 001**

AMINOSALICYLATE SODIUM

TABLET; ORAL
SODIUM P.A.S.
+ LANNETT 500MG N80138 002

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE; ORAL
PASER
+ JACOBUS 4GM/PACKET N74346 001 JUN 30, 1994

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
AMIODARONE HCL

AP	ABBOTT	**50MG/ML**	**N75955 001** OCT 18, 2002
AP	AM PHARM PARTNERS	**50MG/ML**	**N75761 001** OCT 15, 2002
AP	APOTEX	**50MG/ML**	**N76394 001** APR 25, 2003

FDA data supplied by DrugPatentWatch.com

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HCL

AP	BEDFORD	50MG/ML	N76018 001	OCT 15, 2002
AP	BEDFORD LABS	50MG/ML	N76299 001	OCT 24, 2002
AP	BEN VENUE	50MG/ML	N76088 001	OCT 15, 2002
AP	BIONICHE (CANADA)	50MG/ML	N76217 001	OCT 15, 2002
AP	MAYNE PHARMA USA	50MG/ML	N76108 001	OCT 15, 2002
AP	SICOR PHARMS	50MG/ML	N76163 001	SEP 05, 2003

CORDARONE

AP +	WYETH PHARMS INC	50MG/ML	N20377 001	AUG 03, 1995

TABLET; ORAL

AMIODARONE HCL

AB	ALPHAPHARM	200MG	N75188 001	FEB 24, 1999
AB	BARR	200MG	N75389 001	JAN 25, 2001
AB	COPLEY PHARM	200MG	N74739 001	NOV 30, 1998
AB	EON	200MG	N75315 001	DEC 23, 1998
AB		400MG	N75315 002	JUN 30, 2000
AB	TARO	200MG	N75424 001	MAR 30, 2001
AB +		400MG	N76362 001	NOV 29, 2002
		100MG	N75424 002	DEC 18, 2002
		300MG	N76362 002	DEC 02, 2003
AB	TEVA	200MG	N74895 001	APR 16, 1999

CORDARONE

AB	WYETH PHARMS INC	200MG	N18972 001	DEC 24, 1985

PACERONE

AB	UPSHER SMITH	200MG	N75135 001	APR 30, 1998

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ELAVIL

+	ASTRAZENECA	10MG/ML	N12704 001	

TABLET; ORAL

AMITRIPTYLINE HCL

AB	MUTUAL PHARM	10MG	N89398 001	JUL 14, 1987
AB		25MG	N89399 001	JUL 14, 1987
AB		50MG	N89400 001	JUL 14, 1987
AB		75MG	N89401 001	JUL 14, 1987
AB		100MG	N89402 001	JUL 14, 1987
AB		150MG	N89403 001	JUL 14, 1987
AB	MYLAN	10MG	N86157 001	
AB		25MG	N86010 001	
AB		50MG	N86009 001	
AB		75MG	N86011 001	
AB		100MG	N86158 001	
AB		150MG	N86153 001	
AB	PLIVA	10MG	N88883 001	SEP 26, 1984
AB		25MG	N88884 001	SEP 26, 1984
AB		50MG	N88885 001	SEP 26, 1984
AB		75MG	N88886 001	SEP 26, 1984
AB		100MG	N88887 001	SEP 26, 1984
AB		150MG	N88888 001	SEP 26, 1984
AB	SANDOZ	10MG	N85969 001	
AB		25MG	N85966 001	
AB		50MG	N85968 001	
AB		75MG	N85971 001	
AB		100MG	N85967 001	
AB		150MG	N85970 001	
AB	TEVA	10MG	N84910 003	
AB		25MG	N85031 001	
AB		50MG	N85032 001	
AB		100MG	N85836 001	

FDA data supplied by DrugPatentWatch.com

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

		AMITRIPTYLINE HYDROCHLORIDE		
AB		VINTAGE PHARMS	10MG	N40218 001 SEP 11, 1997
AB			25MG	N40218 002 SEP 11, 1997
AB			50MG	N40218 003 SEP 11, 1997
AB			75MG	N40218 004 SEP 11, 1997
AB			100MG	N40218 005 SEP 11, 1997
AB			150MG	N40218 006 SEP 11, 1997
		ELAVIL		
AB		ASTRAZENECA	10MG	N12703 001
AB	+		25MG	N12703 003
AB			50MG	N12703 004
AB			75MG	N12703 005
AB			100MG	N12703 006
AB			150MG	N12703 007

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

		CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL		
AB		MYLAN	EQ 12.5MG BASE;5MG	N71296 001 DEC 10, 1986
AB			EQ 25MG BASE;10MG	N71297 001 DEC 10, 1986
AB		PAR PHARM	EQ 12.5MG BASE;5MG	N72277 001 MAY 09, 1988
AB			EQ 25MG BASE;10MG	N72278 001 MAY 09, 1988
AB		WATSON LABS	EQ 12.5MG BASE;5MG	N72052 001 DEC 16, 1988
AB			EQ 25MG BASE;10MG	N72053 001 DEC 16, 1988
		LIMBITROL		
AB		VALEANT PHARM INTL	EQ 12.5MG BASE;5MG	N16949 001
		LIMBITROL DS		
AB	+	VALEANT PHARM INTL	EQ 25MG BASE;10MG	N16949 002

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

		PERPHENAZINE AND AMITRIPTYLINE HCL		
AB		MYLAN	10MG;2MG	N70336 001 NOV 10, 1988
AB			10MG;4MG	N71442 001 NOV 10, 1988
AB			25MG;2MG	N70337 001 NOV 10, 1988
AB	+		25MG;4MG	N70338 001 NOV 10, 1988
AB	+		50MG;4MG	N71443 001 NOV 10, 1988
AB		SANDOZ	10MG;2MG	N71062 001 NOV 27, 1987
AB			10MG;4MG	N71862 001 DEC 21, 1987
AB			25MG;2MG	N71063 001 NOV 27, 1987
AB			25MG;4MG	N71064 001 NOV 27, 1987
AB			50MG;4MG	N71863 001 DEC 21, 1987
AB		WATSON LABS	10MG;2MG	N73007 001 OCT 17, 1991
AB			10MG;4MG	N73009 001 OCT 17, 1991
AB			25MG;2MG	N73008 001 OCT 17, 1991
AB			25MG;4MG	N73010 001 OCT 17, 1991

AMLEXANOX

PASTE; DENTAL

		APHTHASOL		
	+	ACCESS PHARMS	5%	N20511 001 DEC 17, 1996

AMLODIPINE BESYLATE

TABLET; ORAL

		NORVASC		
		PFIZER	EQ 2.5MG BASE	N19787 001 JUL 31, 1992

FDA data supplied by DrugPatentWatch.com

AMLODIPINE BESYLATE

TABLET; ORAL

NORVASC				
PFIZER	EQ 5MG BASE	N19787 002 JUL 31, 1992		
+	EQ 10MG BASE	N19787 003 JUL 31, 1992		

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

LOTREL				
NOVARTIS	EQ 2.5MG BASE;10MG	N20364 002 MAR 03, 1995		
	EQ 5MG BASE;10MG	N20364 003 MAR 03, 1995		
	EQ 5MG BASE;20MG	N20364 004 MAR 03, 1995		
+	EQ 10MG BASE;20MG	N20364 005 JUN 20, 2002		

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER			
+ ABBOTT	5MEQ/ML	N88366 001 JUN 13, 1984	

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE				
AB CLAY PARK	**EQ 12% BASE**	**N75774 001** MAY 01, 2002		
AB TARO	**EQ 12% BASE**	**N75883 001** APR 10, 2003		
LAC-HYDRIN				
AB + WESTWOOD SQUIBB	**EQ 12% BASE**	**N20508 001** AUG 29, 1996		

LOTION; TOPICAL

AMMONIUM LACTATE				
AB PADDOCK	**EQ 12% BASE**	**N75575 001** JUN 11, 2002		

AMMONIUM LACTATE

LOTION; TOPICAL

LAC-HYDRIN				
AB + WESTWOOD SQUIBB	**EQ 12% BASE**	**N19155 001** APR 24, 1985		

AMOXAPINE

TABLET; ORAL

AMOXAPINE				
AB SANDOZ	**25MG**	**N72943 001** JUN 28, 1991		
AB	**50MG**	**N72944 001** JUN 28, 1991		
AB	**100MG**	**N72878 001** JUN 28, 1991		
AB	**150MG**	**N72879 001** JUN 28, 1991		
AB WATSON LABS	**25MG**	**N72418 001** MAY 11, 1989		
AB	**25MG**	**N72688 001** AUG 28, 1992		
AB	**50MG**	**N72419 001** MAY 11, 1989		
AB	**50MG**	**N72689 001** AUG 28, 1992		
AB	**100MG**	**N72420 001** MAY 11, 1989		
AB	**100MG**	**N72690 001** AUG 28, 1992		
AB +	**150MG**	**N72421 001** MAY 11, 1989		
AB	**150MG**	**N72691 001** AUG 28, 1992		

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN				
AB BIOCHEMIE	**250MG**	**N64076 001** SEP 30, 1994		
AB	**500MG**	**N64076 002** SEP 30, 1994		
AB CLONMEL	**250MG**	**N62884 001** FEB 25, 1988		

FDA data supplied by DrugPatentWatch.com

AMOXICILLIN

CAPSULE; ORAL

	AMOXICILLIN			
AB	CLONMEL	500MG	N62881 001	
			FEB 25, 1988	
AB	CONSOLIDATED PHARM	250MG	N62058 001	
AB		500MG	N62058 002	
AB	RANBAXY	250MG	N65016 001	
			APR 08, 1999	
AB		500MG	N65016 002	
			APR 08, 1999	
AB	TEVA	250MG	N61926 001	
AB		250MG	N62853 001	
			DEC 22, 1987	
AB		500MG	N61926 003	
AB		500MG	N62854 001	
			DEC 22, 1987	
	AMOXIL			
AB	GLAXOSMITHKLINE	250MG	N62216 001	
AB	+	500MG	N62216 004	
	TRIMOX			
AB	APOTHECON	250MG	N61885 001	
AB		500MG	N61885 002	

FOR SUSPENSION; ORAL

	AMOXICILLIN			
AB	CLONMEL	125MG/5ML	N62927 001	
			NOV 25, 1988	
AB		250MG/5ML	N62927 002	
			NOV 25, 1988	
AB	CONSOLIDATED PHARM	125MG/5ML	N62059 001	
AB		250MG/5ML	N62059 002	
AB	RANBAXY	200MG/5ML	N65113 001	
			NOV 29, 2002	
AB		400MG/5ML	N65113 002	
			NOV 29, 2002	
AB	TEVA	125MG/5ML	N61931 001	
AB		125MG/5ML	N62946 001	
			NOV 01, 1988	
AB		200MG/5ML	N65119 001	
			DEC 04, 2002	
AB		250MG/5ML	N61931 002	
AB		250MG/5ML	N63001 001	
			JAN 06, 1989	
AB		400MG/5ML	N65119 002	
			DEC 04, 2002	
	AMOXICILLIN PEDIATRIC			
AB	TEVA	50MG/ML	N61931 003	
			DEC 01, 1982	

AMOXICILLIN

FOR SUSPENSION; ORAL

	AMOXIL			
AB	GLAXOSMITHKLINE	125MG/5ML	N62226 001	
AB		200MG/5ML	N50760 001	
			APR 15, 1999	
AB	+	250MG/5ML	N62226 002	
AB		50MG/ML	N62226 005	
AB	+	400MG/5ML	N50760 002	
			APR 15, 1999	
	LAROTID			
AB	GLAXOSMITHKLINE	125MG/5ML	N62226 003	
AB		250MG/5ML	N62226 004	
	TRIMOX			
AB	APOTHECON	125MG/5ML	N62885 001	
			MAR 08, 1988	
AB		250MG/5ML	N62885 002	
			MAR 08, 1988	

TABLET; ORAL

	AMOXICILLIN			
AB	RANBAXY	500MG	N65059 001	
			NOV 24, 2000	
AB		875MG	N65059 002	
			NOV 24, 2000	
AB	TEVA	500MG	N65056 001	
			SEP 18, 2000	
AB		875MG	N65056 002	
			SEP 18, 2000	
	AMOXIL			
AB	GLAXOSMITHKLINE	500MG	N50754 002	
			JUL 10, 1998	
AB	+	875MG	N50754 001	
			JUL 10, 1998	

TABLET, CHEWABLE; ORAL

	AMOXICILLIN			
AB	CLONMEL	125MG	N64139 001	
			JAN 29, 1996	
AB		250MG	N64139 002	
			JAN 29, 1996	
AB	RANBAXY	125MG	N65021 001	
			DEC 23, 1999	
AB		200MG	N65060 001	
			NOV 29, 2000	
AB		250MG	N65021 002	
			DEC 23, 1999	

FDA data supplied by DrugPatentWatch.com

AMOXICILLIN

TABLET, CHEWABLE; ORAL

	AMOXICILLIN			
AB	RANBAXY	400MG	N65060 002	NOV 29, 2000
AB	TEVA	125MG	N64013 002	SEP 11, 1995
AB		125MG	N64031 001	DEC 19, 1996
AB		250MG	N64013 001	DEC 22, 1992
AB		250MG	N64031 002	DEC 19, 1996
	AMOXIL			
AB	GLAXOSMITHKLINE	125MG	N50542 002	
AB		200MG	N50761 001	APR 15, 1999
AB		250MG	N50542 001	
AB +		400MG	N50761 002	APR 15, 1999

TABLET, FOR SUSPENSION; ORAL

	DISPERMOX			
	RANBAXY	200MG	N65080 002	AUG 11, 2003
	+	400MG	N65080 001	AUG 11, 2003
	+	600MG	N65159 001	DEC 04, 2003

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS; ORAL

	PREVPAC			
	+ TAP PHARM	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A, 30MG	N50757 001	DEC 02, 1997

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

	AMOXICILLIN AND CLAVULANATE POTASSIUM			
AB	LEK PHARMS	200MG/5ML; EQ 28.5MG BASE/5ML	N65098 001	DEC 16, 2002

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

	AMOXICILLIN AND CLAVULANATE POTASSIUM			
AB	LEK PHARMS	400MG/5ML; EQ 57MG BASE/5ML	N65098 002	DEC 16, 2002
AB	RANBAXY	200MG/5ML; EQ 28.5MG BASE/5ML	N65132 001	MAR 19, 2003
AB		400MG/5ML; EQ 57MG BASE/5ML	N65132 002	MAR 19, 2003
AB	SANDOZ	200MG/5ML; EQ 28.5MG BASE/5ML	N65066 001	JUN 05, 2002
AB		400MG/5ML; EQ 57MG BASE/5ML	N65066 002	JUN 05, 2002
	AUGMENTIN '125'			
	GLAXOSMITHKLINE	125MG/5ML; EQ 31.25MG BASE/5ML	N50575 001	AUG 06, 1984
	AUGMENTIN '200'			
AB	GLAXOSMITHKLINE	200MG/5ML; EQ 28.5MG BASE/5ML	N50725 001	MAY 31, 1996
	AUGMENTIN '250'			
	+ GLAXOSMITHKLINE	250MG/5ML; EQ 62.5MG BASE/5ML	N50575 002	AUG 06, 1984
	AUGMENTIN '400'			
AB	GLAXOSMITHKLINE	400MG/5ML; EQ 57MG BASE/5ML	N50725 002	MAY 31, 1996
	AUGMENTIN ES-600			
	+ GLAXOSMITHKLINE	600MG/5ML; EQ 42.9MG BASE/5ML	N50755 001	JUN 22, 2001

TABLET; ORAL

	AMOXICILLIN AND CLAVULANATE POTASSIUM			
AB	LEK PHARMS	875MG;EQ 125MG BASE	N65093 001	NOV 21, 2002
AB	RANBAXY	500MG;EQ 125MG BASE	N65109 001	NOV 04, 2002
AB		875MG;EQ 125MG BASE	N65102 001	SEP 17, 2002

FDA data supplied by DrugPatentWatch.com

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

	AMOXICILLIN AND CLAVULANATE POTASSIUM			
AB	SANDOZ	**500MG;EQ 125MG BASE**	**N65064 001**	MAR 15, 2002
AB		**875MG;EQ 125MG BASE**	**N65063 001**	MAR 14, 2002
AB	TEVA	**500MG;EQ 125MG BASE**	**N65101 001**	OCT 30, 2002
AB		**875MG;EQ 125MG BASE**	**N65096 001**	OCT 29, 2002
	AMOXICILLIN AND CLAVULANATE POTSSSIUM			
AB	LEK PHARMS	**500MG;EQ 125MG BASE**	**N65117 001**	NOV 27, 2002
	AUGMENTIN '250'			
	GLAXOSMITHKLINE	250MG;EQ 125MG BASE	N50564 001	AUG 06, 1984
	AUGMENTIN '500'			
AB	GLAXOSMITHKLINE	**500MG;EQ 125MG BASE**	**N50564 002**	AUG 06, 1984
	AUGMENTIN '875'			
AB	+ GLAXOSMITHKLINE	**875MG;EQ 125MG BASE**	**N50720 001**	FEB 13, 1996

TABLET, CHEWABLE; ORAL

	AMOXICILLIN AND CLAVULANATE POTASSIUM			
AB	RANBAXY	**200MG;EQ 28.5MG BASE**	**N65161 001**	DEC 03, 2003
AB		**400MG;EQ 57MG BASE**	**N65161 002**	DEC 03, 2003
AB	SANDOZ	**200MG;EQ 28.5MG BASE**	**N65065 001**	APR 18, 2002
AB		**400MG;EQ 57MG BASE**	**N65065 002**	APR 18, 2002
	AUGMENTIN '125'			
	GLAXOSMITHKLINE	125MG;EQ 31.25MG BASE	N50597 001	JUL 22, 1985
	AUGMENTIN '200'			
AB	GLAXOSMITHKLINE	**200MG;EQ 28.5MG BASE**	**N50726 001**	MAY 31, 1996
	AUGMENTIN '250'			
	+ GLAXOSMITHKLINE	250MG;EQ 62.5MG BASE	N50597 002	JUL 22, 1985
	AUGMENTIN '400'			
AB	+ GLAXOSMITHKLINE	**400MG;EQ 57MG BASE**	**N50726 002**	MAY 31, 1996

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET, EXTENDED RELEASE; ORAL

	AUGMENTIN XR		
	+ GLAXOSMITHKLINE	1GM;62.5MG	N50785 001 SEP 25, 2002

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

	ADDERALL XR 10		
	SHIRE LABS	2.5MG;2.5MG;2.5MG;2.5MG	N21303 001 OCT 11, 2001
	ADDERALL XR 15		
	SHIRE LABS	3.75MG;3.75MG;3.75MG; 3.75MG	N21303 006 MAY 22, 2002
	ADDERALL XR 20		
	SHIRE LABS	5MG;5MG;5MG;5MG	N21303 002 OCT 11, 2001
	ADDERALL XR 25		
	SHIRE LABS	6.25MG;6.25MG;6.25MG; 6.25MG	N21303 004 MAY 22, 2002
	ADDERALL XR 30		
	+ SHIRE LABS	7.5MG;7.5MG;7.5MG;7.5MG	N21303 003 OCT 11, 2001
	ADDERALL XR 5		
	SHIRE LABS	1.25MG;1.25MG;1.25MG; 1.25MG	N21303 005 MAY 22, 2002

TABLET; ORAL

	ADDERALL 10		
AB	SHIRE LABS	**2.5MG;2.5MG;2.5MG;2.5MG**	**N11522 007** FEB 13, 1996
	ADDERALL 12.5		
AB	SHIRE LABS	**3.125MG;3.125MG;3.125MG; 3.125MG**	**N11522 012** AUG 31, 2000
	ADDERALL 15		
AB	SHIRE LABS	**3.75MG;3.75MG;3.75MG; 3.75MG**	**N11522 013** AUG 31, 2000
	ADDERALL 20		
AB	SHIRE LABS	**5MG;5MG;5MG;5MG**	**N11522 008** FEB 13, 1996

FDA data supplied by DrugPatentWatch.com

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

	ADDERALL 30			
AB	+ SHIRE LABS	7.5MG;7.5MG;7.5MG;7.5MG	**N11522 010**	MAY 12, 1997
	ADDERALL 5			
AB	SHIRE LABS	1.25MG;1.25MG;1.25MG; 1.25MG	**N11522 009**	MAY 12, 1997
	ADDERALL 7.5			
AB	SHIRE LABS	1.875MG;1.875MG;1.875MG; 1.875MG	**N11522 011**	AUG 31, 2000
	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE			
AB	ABRIKA PHARMS	1.25MG;1.25MG;1.25MG; 1.25MG	**N40472 001**	SEP 30, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	**N40472 002**	SEP 30, 2003
AB		5MG;5MG;5MG;5MG	**N40472 003**	SEP 30, 2003
AB		7.5MG;7.5MG;7.5MG;7.5MG	**N40472 004**	SEP 30, 2003
AB	BARR	1.25MG;1.25MG;1.25MG; 1.25MG	**N40422 001**	FEB 11, 2002
AB		1.875MG;1.875MG;1.875MG; 1.875MG	**N40422 005**	MAR 19, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	**N40422 002**	FEB 11, 2002
AB		3.125MG;3.125MG;3.125MG; 3.125MG	**N40422 006**	MAR 19, 2003
AB		3.75MG;3.75MG;3.75MG; 3.75MG	**N40422 007**	MAR 19, 2003
AB		5MG;5MG;5MG;5MG	**N40422 003**	FEB 11, 2002
AB		7.5MG;7.5MG;7.5MG;7.5MG	**N40422 004**	FEB 11, 2002
AB	COREPHARMA	1.25MG;1.25MG;1.25MG; 1.25MG	**N40444 001**	JUN 19, 2002

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE			
AB	COREPHARMA	2.5MG;2.5MG;2.5MG;2.5MG	**N40444 002**	JUN 19, 2002
AB		5MG;5MG;5MG;5MG	**N40444 003**	JUN 19, 2002
AB		7.5MG;7.5MG;7.5MG;7.5MG	**N40444 004**	JUN 19, 2002
AB	EON	1.25MG;1.25MG;1.25MG; 1.25MG	**N40470 001**	SEP 27, 2002
AB		2.5MG;2.5MG;2.5MG;2.5MG	**N40439 001**	JUN 14, 2002
AB		5MG;5MG;5MG;5MG	**N40439 002**	JUN 14, 2002
AB		7.5MG;7.5MG;7.5MG;7.5MG	**N40439 003**	JUN 14, 2002
AB	MALLINCKRODT	1.25MG;1.25MG;1.25MG; 1.25MG	**N40440 001**	OCT 07, 2003
AB		1.875MG;1.875MG;1.875MG; 1.875MG	**N40440 002**	OCT 07, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	**N40440 003**	OCT 07, 2003
AB		3.125MG;3.125MG;3.125MG; 3.125MG	**N40440 004**	OCT 07, 2003
AB		3.75MG;3.75MG;3.75MG; 3.75MG	**N40440 005**	OCT 07, 2003
AB		5MG;5MG;5MG;5MG	**N40440 006**	OCT 07, 2003
AB		7.5MG;7.5MG;7.5MG;7.5MG	**N40440 007**	OCT 07, 2003
AB	MUTUAL PHARM	1.25MG;1.25MG;1.25MG; 1.25MG	**N40480 001**	SEP 09, 2003
AB		1.875MG;1.875MG;1.875MG; 1.875MG	**N40480 002**	SEP 09, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	**N40480 003**	SEP 09, 2003

FDA data supplied by DrugPatentWatch.com

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	MUTUAL PHARM	3.125MG;3.125MG;3.125MG; 3.125MG	**N40480 004** SEP 09, 2003
AB		3.75MG;3.75MG;3.75MG; 3.75MG	**N40480 005** SEP 09, 2003
AB		5MG;5MG;5MG;5MG	**N40480 006** SEP 09, 2003
AB		7.5MG;7.5MG;7.5MG;7.5MG	**N40480 007** SEP 09, 2003
AB	WATSON LABS	1.25MG;1.25MG;1.25MG; 1.25MG	**N40456 001** MAY 06, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	**N40456 002** MAY 06, 2003
AB		5MG;5MG;5MG;5MG	**N40456 003** MAY 06, 2003
AB		7.5MG;7.5MG;7.5MG;7.5MG	**N40456 004** MAY 06, 2003

AMPHETAMINE SULFATE; *MULTIPLE*
SEE AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

AMPHOTERICIN B

CREAM; TOPICAL
FUNGIZONE

+	APOTHECON	3%	N50314 001

INJECTABLE; INJECTION
AMPHOTERICIN B

AP	GENSIA SICOR PHARMS	**50MG/VIAL**	**N64062 001** MAR 31, 1995
AP	PHARMA TEK	**50MG/VIAL**	**N63206 001** APR 29, 1992

FUNGIZONE

AP +	APOTHECON	**50MG/VIAL**	**N60517 001**

INJECTABLE, LIPID COMPLEX; INJECTION
ABELCET

+	ENZON	5MG/ML	N50724 001 NOV 20, 1995

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION
AMPHOTEC

+	INTERMUNE PHARMS	50MG/VIAL	N50729 001 NOV 22, 1996
+		100MG/VIAL	N50729 002 NOV 22, 1996

INJECTABLE, LIPOSOMAL; INJECTION
AMBISOME

+	FUJISAWA HLTHCARE	50MG/VIAL	N50740 001 AUG 11, 1997

LOTION; TOPICAL
FUNGIZONE

+	APOTHECON	3%	N60570 001

AMPICILLIN SODIUM

INJECTABLE; INJECTION
AMPICILLIN SODIUM

AP	+	APOTHECON	**EQ 125MG BASE/VIAL**	**N61395 001**
AP	+		**EQ 250MG BASE/VIAL**	**N61395 002**
AP	+		**EQ 500MG BASE/VIAL**	**N61395 003**
AP	+		**EQ 1GM BASE/VIAL**	**N61395 004**
AP			**EQ 1GM BASE/VIAL**	**N62738 001** FEB 19, 1987
AP	+		**EQ 2GM BASE/VIAL**	**N61395 005**
AP			**EQ 2GM BASE/VIAL**	**N62738 002** FEB 19, 1987
AP	+		**EQ 10GM BASE/VIAL**	**N61395 006**
AP		IBI	**EQ 250MG BASE/VIAL**	**N62719 001** MAY 12, 1987
AP			**EQ 500MG BASE/VIAL**	**N62719 003** MAY 12, 1987
AP			**EQ 1GM BASE/VIAL**	**N62719 002** MAY 12, 1987

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION
AMPICILLIN AND SULBACTAM

AP		ESI LEDERLE	**EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL**	**N65074 001** MAR 19, 2002

FDA data supplied by DrugPatentWatch.com

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP		ESI LEDERLE	EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	N65074 002 MAR 19, 2002
AP			EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	N65076 001 MAR 19, 2002

UNASYN

AP	+	PFIZER	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	N50608 002 DEC 31, 1986
AP	+		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	N50608 001 DEC 31, 1986
AP	+		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	N50608 005 DEC 10, 1993
			EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	N62901 001 NOV 23, 1988

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

AB		CLONMEL	EQ 250MG BASE	N62883 001 FEB 25, 1988
AB			EQ 500MG BASE	N62882 001 FEB 25, 1988
AB		CONSOLIDATED PHARM	EQ 250MG BASE	N61602 001
AB			EQ 500MG BASE	N61602 002
AB		TEVA	EQ 250MG BASE	N61502 001
AB			EQ 500MG BASE	N61502 002

PRINCIPEN

AB		APOTHECON	EQ 250MG BASE	N61392 001
AB			EQ 250MG BASE	N62888 001 MAR 04, 1988
AB			EQ 500MG BASE	N61392 002
AB	+		EQ 500MG BASE	N62888 002 MAR 04, 1988

TOTACILLIN

AB		GLAXOSMITHKLINE	EQ 250MG BASE	N62212 001
AB			EQ 500MG BASE	N62212 002

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

AB		CLONMEL	EQ 125MG BASE/5ML	N62982 001 FEB 10, 1989
AB			EQ 250MG BASE/5ML	N62982 002 FEB 10, 1989
AB		CONSOLIDATED PHARM	EQ 125MG BASE/5ML	N61601 001
AB			EQ 250MG BASE/5ML	N61601 002
AB		PUREPAC PHARM	EQ 250MG BASE/5ML	N61980 002
AB		TEVA	EQ 125MG BASE/5ML	N61370 001
AB			EQ 250MG BASE/5ML	N61370 002

PRINCIPEN

AB		APOTHECON	EQ 125MG BASE/5ML	N61394 002
AB	+		EQ 250MG BASE/5ML	N61394 003
			EQ 100MG BASE/ML	N61394 001

AMPRENAVIR

CAPSULE; ORAL

AGENERASE

	GLAXOSMITHKLINE	50MG	N21007 001 APR 15, 1999
+		150MG	N21007 002 APR 15, 1999

SOLUTION; ORAL

AGENERASE

+	GLAXOSMITHKLINE	15MG/ML	N21039 001 APR 15, 1999

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

	SHIRE LABS	EQ 0.5MG BASE	N20333 001 MAR 14, 1997
+		EQ 1MG BASE	N20333 002 MAR 14, 1997

ANASTROZOLE

TABLET; ORAL

ARIMIDEX

+	ASTRAZENECA	1MG	N20541 001 DEC 27, 1995

FDA data supplied by DrugPatentWatch.com

ANISINDIONE

TABLET; ORAL			
MIRADON			
+ SCHERING	50MG	N10909 003	

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC			
IOPIDINE			
+ ALCON	EQ 0.5% BASE	N20258 001	JUL 30, 1993
+	EQ 1% BASE	N19779 001	DEC 31, 1987

APREPITANT

CAPSULE; ORAL			
EMEND			
MERCK	80MG	N21549 001	MAR 26, 2003
+	125MG	N21549 002	MAR 26, 2003

APROTININ BOVINE

INJECTABLE; INJECTION			
TRASYLOL			
+ BAYER PHARMS	10,000KIU/ML	N20304 001	DEC 29, 1993

ARGATROBAN

INJECTABLE; INJECTION			
ARGATROBAN			
+ ENCYSIVE	100MG/ML	N20883 001	JUN 30, 2000

ARGININE HYDROCHLORIDE

INJECTABLE; INJECTION			
R-GENE 10			
+ PHARMACIA AND UPJOHN	10GM/100ML	N16931 001	

ARIPIPRAZOLE

TABLET; ORAL			
ABILIFY			
OTSUKA	2MG	N21436 006	NOV 15, 2002
	5MG	N21436 005	NOV 15, 2002
	10MG	N21436 001	NOV 15, 2002
	15MG	N21436 002	NOV 15, 2002
	20MG	N21436 003	NOV 15, 2002
+	30MG	N21436 004	NOV 15, 2002

ARSENIC TRIOXIDE

INJECTABLE; INJECTION			
TRISENOX			
+ CELL THERAP	1MG/ML	N21248 001	SEP 25, 2000

ARTICAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION			
SEPTOCAINE			
+ DEPROCO	4%;EQ 0.01MG BASE/ML	N20971 001	APR 03, 2000

ASCORBIC ACID; *MULTIPLE*

SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

FDA data supplied by DrugPatentWatch.com

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

	INFUVITE PEDIATRIC			
+	SABEX 2002	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL; 0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL; 17MG/VIAL;1MG/VIAL;1.4MG/VIAL; 1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL; 0.2MG/VIAL	N21265 001 FEB 21, 2001	

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

	M.V.I. PEDIATRIC			
+	AAIPHARMA LLC	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL; 5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL; 17MG/VIAL;0.2MG/VIAL;1MG/VIAL; 1.4MG/VIAL;EQ 1.2MG BASE/VIAL; 0.7MG/VIAL;7MG/VIAL	N18920 001 SEP 21, 2000	

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

	M.V.I.-12			
+	AAIPHARMA LLC	10MG/ML;0.006MG/ML;0.5 UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML; 0.4MG/ML;0.36MG/ML;0.3MG/ML; 330 UNITS/ML;1 IU/ML	N08809 004 AUG 08, 1985	

ASPIRIN; *MULTIPLE*

SEE ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

		FIORINAL			
AB	+	WATSON PHARMS	325MG;50MG;40MG		**N17534 005** APR 16, 1986
		LANORINAL			
AB		LANNETT	325MG;50MG;40MG		**N86996 002** OCT 11, 1985

TABLET; ORAL

		ASPIRIN AND CAFFEINE W/ BUTALBITAL			
AB		PUREPAC PHARM	325MG;50MG;40MG		**N86710 002** AUG 23, 1983
		BUTAL COMPOUND			
AB		SANDOZ	325MG;50MG;40MG		**N86398 002** APR 06, 1984
		BUTALBITAL W/ ASPIRIN & CAFFEINE			
AB		PHARMERAL	325MG;50MG;40MG		**N87048 002** DEC 09, 1983
		BUTALBITAL, ASPIRIN AND CAFFEINE			
AB		WEST WARD	325MG;50MG;40MG		**N86162 002** FEB 16, 1984
		FIORINAL			
AB	+	WATSON PHARMS	325MG;50MG;40MG		**N17534 003** APR 16, 1986

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

		BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE		
AB		ANABOLIC	325MG;50MG;40MG;30MG	**N75231 001** NOV 30, 2001
AB		ENDO PHARMS	325MG;50MG;40MG;30MG	**N75351 001** MAR 05, 1999
AB		STEVENS J	325MG;50MG;40MG;30MG	**N74951 001** AUG 31, 1998
AB		WATSON LABS	325MG;50MG;40MG;30MG	**N74359 001** AUG 31, 1995
		FIORINAL W/CODEINE NO 3		
AB	+	WATSON PHARMS	325MG;50MG;40MG;30MG	**N19429 003** OCT 26, 1990

FDA data supplied by DrugPatentWatch.com

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

	SYNALGOS-DC			
+	WOMEN FIRST HLTHCARE	356.4MG;30MG;16MG	N11483 004	SEP 06, 1983

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

	INVAGESIC			
AB	SANDOZ	**385MG;30MG;25MG**	**N74817 001**	NOV 27, 1996
	INVAGESIC FORTE			
AB	SANDOZ	**770MG;60MG;50MG**	**N74817 002**	NOV 27, 1996
	NORGESIC			
AB	3M	**385MG;30MG;25MG**	**N13416 003**	OCT 27, 1982
	NORGESIC FORTE			
AB +	3M	**770MG;60MG;50MG**	**N13416 004**	OCT 27, 1982
	ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE			
AB	EON	**385MG;30MG;25MG**	**N74654 001**	DEC 31, 1996
AB		**770MG;60MG;50MG**	**N74654 002**	DEC 31, 1996
AB	STEVENS J	**385MG;30MG;25MG**	**N74988 001**	APR 30, 1999
AB		**770MG;60MG;50MG**	**N74988 002**	APR 30, 1999
	ORPHENGESIC			
AB	PAR PHARM	**385MG;30MG;25MG**	**N75141 001**	MAY 29, 1998
	ORPHENGESIC FORTE			
AB	PAR PHARM	**770MG;60MG;50MG**	**N75141 002**	MAY 29, 1998

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

	DARVON COMPOUND			
+	AAIPHARMA LLC	389MG;32.4MG;32MG	N10996 006	MAR 08, 1983
	DARVON COMPOUND-65			
AA +	AAIPHARMA LLC	**389MG;32.4MG;65MG**	**N10996 007**	MAR 08, 1983

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

	PROPOXYPHENE COMPOUND 65			
AA	TEVA	**389MG;32.4MG;65MG**	**N89025 001**	MAR 29, 1985

ASPIRIN; CARISOPRODOL

TABLET; ORAL

	CARISOPRODOL AND ASPIRIN			
AB	AMIDE PHARM	**325MG;200MG**	**N40252 001**	DEC 10, 1997
AB	EON	**325MG;200MG**	**N40116 001**	APR 25, 1996
AB	PAR PHARM	**325MG;200MG**	**N89594 001**	MAR 31, 1989
	SOMA COMPOUND			
AB +	MEDPOINTE PHARM HLC	**325MG;200MG**	**N12365 005**	JUL 11, 1983

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

	CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE			
AB	AMIDE PHARM	**325MG;200MG;16MG**	**N40283 001**	DEC 29, 1998
AB	EON	**325MG;200MG;16MG**	**N40118 001**	APR 16, 1996
	SOMA COMPOUND W/ CODEINE			
AB +	MEDPOINTE PHARM HLC	**325MG;200MG;16MG**	**N12366 002**	JUL 11, 1983

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

	AGGRENOX			
+	BOEHRINGER INGELHEIM	25MG;200MG	N20884 001	NOV 22, 1999

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

	AZDONE			
+	CENT PHARMS	500MG;5MG	N89420 001	JAN 25, 1988

FDA data supplied by DrugPatentWatch.com

ASPIRIN; MEPROBAMATE

TABLET; ORAL
EQUAGESIC
\+ WOMEN FIRST HLTHCARE 325MG;200MG — N11702 003 DEC 29, 1983

ASPIRIN; METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL AND ASPIRIN

AB	+ IVAX PHARMS	**325MG;400MG**	**N87211 001**	DEC 22, 1982
AB	PAR PHARM	**325MG;400MG**	**N89657 001**	NOV 04, 1988
AB	STEVENS J	**325MG;400MG**	**N81145 001**	JAN 31, 1995

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL
OXYCODONE AND ASPIRIN

AA	AXIOM PHARM	**325MG;4.5MG;0.38MG**	**N40260 001**	JUL 17, 1998
AA	HALSEY	**325MG;4.5MG;0.38MG**	**N87794 001**	MAY 26, 1982
AA	WATSON LABS	**325MG;4.5MG;0.38MG**	**N40255 001**	FEB 27, 1998

PERCODAN

AA	+ ENDO PHARMS	**325MG;4.5MG;0.38MG**	**N07337 006**	

PERCODAN-DEMI

AA	+ ENDO PHARMS	**325MG;2.25MG;0.19MG**	**N07337 005**	

ASPIRIN; PRAVASTATIN SODIUM

TABLET; ORAL
PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB	81MG,N/A;N/A,20MG	N21387 001	JUN 24, 2003
	81MG,N/A;N/A,40MG	N21387 002	JUN 24, 2003
	81MG,N/A;N/A,80MG	N21387 003	JUN 24, 2003
	325MG,N/A;N/A,20MG	N21387 004	JUN 24, 2003

ASPIRIN; PRAVASTATIN SODIUM

TABLET, TABLET; ORAL
PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB	325MG,N/A;N/A,40MG	N21387 005	JUN 24, 2003
+	325MG,N/A;N/A,80MG	N21387 006	JUN 24, 2003

ATAZANAVIR SULFATE

CAPSULE; ORAL
REYATAZ

BRISTOL MYERS SQUIBB	EQ 100MG BASE	N21567 001	JUN 20, 2003
	EQ 150MG BASE	N21567 002	JUN 20, 2003
+	EQ 200MG BASE	N21567 003	JUN 20, 2003

ATENOLOL

INJECTABLE; INJECTION
TENORMIN

+ ASTRAZENECA	0.5MG/ML	N19058 001	SEP 13, 1989

TABLET; ORAL
ATENOLOL

AB	CLONMEL HLTHCARE	**25MG**	**N74099 001**	APR 28, 1992
AB		**50MG**	**N73542 001**	DEC 19, 1991
AB		**100MG**	**N73543 001**	DEC 19, 1991
AB	COPLEY PHARM	**50MG**	**N74120 001**	FEB 24, 1995
AB		**100MG**	**N74120 002**	FEB 24, 1995
AB	IPR	**25MG**	**N73646 001**	JUL 31, 1992
AB		**50MG**	**N72303 001**	JUL 15, 1988
AB		**100MG**	**N72304 001**	JUL 15, 1988
AB	MARTEC	**50MG**	**N74127 001**	FEB 21, 1995

FDA data supplied by DrugPatentWatch.com

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	MARTEC	**100MG**	**N74127 002** FEB 21, 1995
AB	MUTUAL PHARM	**25MG**	**N74499 001** JUL 30, 1997
AB		**50MG**	**N73475 001** MAR 30, 1993
AB		**100MG**	**N73476 001** MAR 30, 1993
AB	MYLAN	**50MG**	**N73456 001** JAN 24, 1992
AB		**100MG**	**N73457 001** JAN 24, 1992
		25MG	N73457 002 APR 26, 1999
AB	PLIVA	**25MG**	**N74101 001** JUL 17, 1997
AB		**50MG**	**N74101 002** JUL 17, 1997
AB		**100MG**	**N74101 003** JUL 17, 1997
AB	SANDOZ	**25MG**	**N74052 001** MAY 01, 1992
AB		**25MG**	**N74265 001** FEB 28, 1994
AB		**50MG**	**N73025 001** SEP 17, 1991
AB		**50MG**	**N74265 002** FEB 28, 1994
AB		**100MG**	**N73026 001** SEP 17, 1991
AB		**100MG**	**N74265 003** FEB 28, 1994
AB	SCS	**50MG**	**N73676 001** OCT 30, 1992
AB		**100MG**	**N73676 002** OCT 30, 1992
AB	TEVA	**50MG**	**N73315 001** MAY 28, 1993
AB		**50MG**	**N74056 001** JAN 18, 1995
AB		**100MG**	**N73316 001** MAY 28, 1993
AB		**100MG**	**N74056 002** JAN 18, 1995

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	WATSON LABS	**50MG**	**N73352 001** DEC 27, 1991
AB		**100MG**	**N73353 001** DEC 27, 1991

TENORMIN

AB	ASTRAZENECA	**25MG**	**N18240 004** APR 09, 1990
AB		**50MG**	**N18240 001**
AB	+	**100MG**	**N18240 002**

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB	IPR	**50MG;25MG**	**N72301 001** MAY 31, 1990
AB		**100MG;25MG**	**N72302 001** MAY 31, 1990
AB	MARTEC	**50MG;25MG**	**N74404 001** MAY 14, 1998
AB		**100MG;25MG**	**N74404 002** MAY 14, 1998
AB	MUTUAL PHARM	**50MG;25MG**	**N73581 001** APR 29, 1993
AB		**100MG;25MG**	**N73582 001** APR 29, 1993
AB	MYLAN	**50MG;25MG**	**N74203 001** OCT 31, 1993
AB		**100MG;25MG**	**N74203 002** OCT 31, 1993
AB	PLIVA	**50MG;25MG**	**N74107 001** SEP 24, 1997
AB		**100MG;25MG**	**N74107 002** SEP 24, 1997
AB	WATSON LABS	**50MG;25MG**	**N73665 001** JUL 02, 1992
AB		**100MG;25MG**	**N73665 002** JUL 02, 1992

TENORETIC 100

AB	+ ASTRAZENECA	**100MG;25MG**	**N18760 001** JUN 08, 1984

TENORETIC 50

AB	ASTRAZENECA	**50MG;25MG**	**N18760 002** JUN 08, 1984

FDA data supplied by DrugPatentWatch.com

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL				
STRATTERA				
LILLY	10MG		N21411 002	NOV 26, 2002
	18MG		N21411 003	NOV 26, 2002
	25MG		N21411 004	NOV 26, 2002
	40MG		N21411 005	NOV 26, 2002
+	60MG		N21411 006	NOV 26, 2002

ATORVASTATIN CALCIUM

TABLET; ORAL				
LIPITOR				
PFIZER	EQ 10MG BASE		N20702 001	DEC 17, 1996
	EQ 20MG BASE		N20702 002	DEC 17, 1996
	EQ 40MG BASE		N20702 003	DEC 17, 1996
+	EQ 80MG BASE		N20702 004	APR 07, 2000

ATOVAQUONE

SUSPENSION; ORAL				
MEPRON				
+ GLAXOSMITHKLINE	750MG/5ML		N20500 001	FEB 08, 1995
TABLET; ORAL				
MEPRON				
+ GLAXOSMITHKLINE	250MG		N20259 001	NOV 25, 1992

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL				
MALARONE				
+ GLAXOSMITHKLINE	250MG;100MG		N21078 001	JUL 14, 2000

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL				
MALARONE PEDIATRIC				
+ GLAXOSMITHKLINE	62.5MG;25MG		N21078 002	JUL 14, 2000

ATRACURIUM BESYLATE

INJECTABLE; INJECTION				
ATRACURIUM BESYLATE				
AP ABBOTT	**10MG/ML**		**N74632 001**	DEC 23, 1996
AP BAXTER HLTHCARE CORP	**10MG/ML**		**N74753 001**	JAN 23, 1997
AP BEDFORD	**10MG/ML**		**N74901 001**	JUL 18, 1997
AP ESI LEDERLE	**10MG/ML**		**N74824 001**	SEP 30, 1997
AP GENSIA SICOR PHARMS	**10MG/ML**		**N74784 001**	JUN 11, 1997
AP MARSAM PHARMS LLC	**10MG/ML**		**N74945 001**	JUL 28, 1998
AP MAYNE PHARMA USA	**10MG/ML**		**N74740 001**	MAR 28, 1997
ATRACURIUM BESYLATE PRESERVATIVE FREE				
AP ABBOTT	**10MG/ML**		**N74633 001**	DEC 23, 1996
AP	**10MG/ML**		**N74639 001**	MAR 25, 1997
AP BAXTER HLTHCARE CORP	**10MG/ML**		**N74768 001**	JAN 23, 1997
AP BEDFORD	**10MG/ML**		**N74900 001**	JUL 18, 1997
AP ESI LEDERLE	**10MG/ML**		**N74825 001**	SEP 30, 1997
AP MARSAM PHARMS LLC	**10MG/ML**		**N74944 001**	JUL 28, 1998
AP MAYNE PHARMA USA	**10MG/ML**		**N74741 001**	MAR 28, 1997
TRACRIUM				
AP + ABBOTT	**10MG/ML**		**N18831 002**	JUN 20, 1985
TRACRIUM PRESERVATIVE FREE				
AP + ABBOTT	**10MG/ML**		**N18831 001**	NOV 23, 1983

FDA data supplied by DrugPatentWatch.com

ATROPINE

INJECTABLE; INJECTION
ATROPEN
+ MERIDIAN MEDCL TECHN EQ 0.5MG SULFATE/0.7ML N17106 003 JUN 19, 2003
+ EQ 1MG SULFATE/0.7ML N17106 002 JUN 19, 2003
+ EQ 2MG SULFATE/0.7ML N17106 001

ATROPINE SULFATE

INJECTABLE; IM-IV-SC
ATROPINE SULFATE ANSYR PLASTIC SYRINGE
ABBOTT 0.05MG/ML N21146 002 JUL 09, 2001
+ 0.1MG/ML N21146 001 JUL 09, 2001

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL
MOTOFEN
+ AMARIN PHARMS 0.025MG;1MG N17744 002

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENOXYLATE HCL W/ ATROPINE SULFATE
SCHERER RP 0.025MG;2.5MG N86440 001

SOLUTION; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE
AA ROXANE **0.025MG/5ML;2.5MG/5ML** **N87708 001** MAY 03, 1982

LOMOTIL
AA + GD SEARLE LLC **0.025MG/5ML;2.5MG/5ML** **N12699 001**

TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE
AA ABLE **0.025MG;2.5MG** **N40395 001** NOV 27, 2000
AA LANNETT **0.025MG;2.5MG** **N85372 001**
AA MYLAN **0.025MG;2.5MG** **N85762 001**
AA PAR PHARM **0.025MG;2.5MG** **N40357 001** MAY 02, 2000

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
DIPHENOXYLATE HCL W/ ATROPINE SULFATE
AA EON **0.025MG;2.5MG** **N86173 001**
AA IVAX PHARMS **0.025MG;2.5MG** **N86727 001**
LOMOTIL
AA + GD SEARLE LLC **0.025MG;2.5MG** **N12462 001**
LONOX
AA SANDOZ **0.025MG;2.5MG** **N85311 002**

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
ENLON-PLUS
+ BAXTER HLTHCARE CORP 0.14MG/ML;10MG/ML N19677 001 NOV 06, 1991
+ 0.14MG/ML;10MG/ML N19678 001 NOV 06, 1991

AURANOFIN

CAPSULE; ORAL
RIDAURA
+ PROMETHEUS LABS 3MG N18689 001 MAY 24, 1985

AZATADINE MALEATE

TABLET; ORAL
OPTIMINE
+ SCHERING 1MG N17601 001

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
TRINALIN
+ SCHERING 1MG;120MG N18506 001 MAR 23, 1982

FDA data supplied by DrugPatentWatch.com

AZATHIOPRINE

TABLET; ORAL

	AZASAN			
AB	AAIPHARMA LLC	**50MG**	**N75252 001**	JUN 07, 1999
		25MG	N75252 002	FEB 03, 2003
		75MG	N75252 003	FEB 03, 2003
		100MG	N75252 004	FEB 03, 2003
	AZATHIOPRINE			
AB	GENPHARM	**50MG**	**N75568 001**	DEC 13, 1999
AB	ROXANE	**50MG**	**N74069 001**	FEB 16, 1996
	IMURAN			
AB	+ PROMETHEUS LABS	**50MG**	**N16324 001**	

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

	AZATHIOPRINE SODIUM			
AP	BEDFORD	**EQ 100MG BASE/VIAL**	**N74419 001**	MAR 31, 1995
	IMURAN			
AP	+ PROMETHEUS LABS	**EQ 100MG BASE/VIAL**	**N17391 001**	

AZELAIC ACID

CREAM; TOPICAL

AZELEX			
+	ALLERGAN	20%	N20428 001 SEP 13, 1995

GEL; TOPICAL

FINACEA			
+	BERLEX	15%	N21470 001 DEC 24, 2002

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OPTIVAR			
+	MEDPOINTE PHARM HLC	0.05%	N21127 001 MAY 22, 2000

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

ASTELIN			
+	MEDPOINTE PHARM HLC	EQ 0.125MG BASE/SPRAY	N20114 001 NOV 01, 1996

AZITHROMYCIN

CAPSULE; ORAL

ZITHROMAX			
+	PFIZER	EQ 250MG BASE	N50670 001 NOV 01, 1991

FOR SUSPENSION; ORAL

ZITHROMAX			
+	PFIZER	EQ 1GM BASE/PACKET	N50693 001 SEP 28, 1994
		EQ 100MG BASE/5ML	N50710 001 OCT 19, 1995
+		EQ 200MG BASE/5ML	N50710 002 OCT 19, 1995

INJECTABLE; INJECTION

ZITHROMAX			
+	PFIZER	EQ 500MG BASE/VIAL	N50733 001 JAN 30, 1997

TABLET; ORAL

ZITHROMAX			
	PFIZER	EQ 250MG BASE	N50711 001 JUL 18, 1996
		EQ 500MG BASE	N50784 001 MAY 24, 2002
+		EQ 600MG BASE	N50730 001 JUN 12, 1996

AZTREONAM

INJECTABLE; INJECTION

AZACTAM IN PLASTIC CONTAINER			
+	BRISTOL MYERS SQUIBB	20MG/ML	N50632 002 MAY 24, 1989
+		40MG/ML	N50632 001 MAY 24, 1989

FDA data supplied by DrugPatentWatch.com

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION; ORAL

	SPECTROBID			
+	PFIZER	125MG/5ML	N50556 001	MAR 23, 1982

TABLET; ORAL

	SPECTROBID			
+	PFIZER	400MG	N50520 001	

BACITRACIN

INJECTABLE; INJECTION

	BACIIM			
AP	PHARMA TEK	**50,000 UNITS/VIAL**	**N64153 001**	MAY 09, 1997
	BACITRACIN			
AP	AM PHARM PARTNERS	**50,000 UNITS/VIAL**	**N65116 001**	DEC 03, 2002
AP +	PHARMACIA AND UPJOHN	**50,000 UNITS/VIAL**	**N60733 002**	
		10,000 UNITS/VIAL	N60733 001	

OINTMENT; OPHTHALMIC

	BACITRACIN		
+	ALTANA	500 UNITS/GM	N61212 001

POWDER; FOR RX COMPOUNDING

	BACI-RX		
AA	PHARMA TEK	**5,000,000 UNITS/BOT**	**N61580 001**
	BACITRACIN		
AA	APOTHEKERNES	**5,000,000 UNITS/BOT**	**N61699 001**

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE		
+	PHARMADERM	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62166 002

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	CORTISPORIN			
AT +	MONARCH PHARMS	**400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N50416 002**	
	NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE			
AT	BAUSCH AND LOMB	**400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N64068 001**	OCT 30, 1995

OINTMENT; TOPICAL

	CORTISPORIN			
+	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM	N50168 002	MAY 04, 1984

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	BACITRACIN-NEOMYCIN-POLYMYXIN			
AT	ALTANA	**400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N60764 002**	
	NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC			
AT	BAUSCH AND LOMB	**400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N64064 001**	OCT 30, 1995
	NEOSPORIN			
AT +	MONARCH PHARMS	**400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N50417 001**	

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	BACITRACIN ZINC AND POLYMYXIN B SULFATE			
AT	AKORN	**500 UNITS/GM; 10,000 UNITS/GM**	**N64028 001**	JAN 30, 1995
AT	ALTANA	**500 UNITS/GM; 10,000 UNITS/GM**	**N65022 001**	FEB 27, 2002
AT	BAUSCH AND LOMB	**500 UNITS/GM; 10,000 UNITS/GM**	**N64046 001**	JAN 26, 1995

FDA data supplied by DrugPatentWatch.com

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
POLYSPORIN
AT + MONARCH PHARMS — 500 UNITS/GM; 10,000 UNITS/GM — N61229 001

BACLOFEN

INJECTABLE; INTRATHECAL
LIORESAL
+ MEDTRONIC — 0.05MG/ML — N20075 003 NOV 07, 1996
+ — 0.5MG/ML — N20075 001 JUN 17, 1992
+ — 2MG/ML — N20075 002 JUN 17, 1992

TABLET; ORAL
BACLOFEN
AB IVAX PHARMS — 10MG — N72234 001 JUL 21, 1988
AB + — 20MG — N72235 001 JUL 21, 1988
AB USL PHARMA — 10MG — N74584 001 AUG 19, 1996
AB — 20MG — N74584 002 AUG 19, 1996
AB WATSON LABS — 10MG — N72824 001 SEP 18, 1991
AB — 10MG — N73092 001 JAN 28, 1994
AB — 20MG — N72825 001 SEP 18, 1991

TABLET, ORALLY DISINTEGRATING; ORAL
KEMSTRO
SCHWARZ PHARMA — 10MG — N21589 001 OCT 30, 2003
+ — 20MG — N21589 002 OCT 30, 2003

BALSALAZIDE DISODIUM

CAPSULE; ORAL
COLAZAL
+ SALIX PHARMS — 750MG — N20610 001 JUL 18, 2000

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION
QVAR 40
+ 3M — 0.04MG/INH — N20911 002 SEP 15, 2000
QVAR 80
+ 3M — 0.08MG/INH — N20911 001 SEP 15, 2000
VANCERIL
BN + SCHERING — 0.042MG/INH — N17573 001
VANCERIL DOUBLE STRENGTH
+ SCHERING — 0.084MG/INH — N20486 001 DEC 24, 1996

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL
BECONASE AQ
BN + GLAXOSMITHKLINE — EQ 0.042MG DIPROP/SPRAY — N19389 001 JUL 27, 1987
VANCENASE AQ
BN + SCHERING — EQ 0.042MG DIPROP/SPRAY — N19589 001 DEC 23, 1987

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL
LOTENSIN
NOVARTIS — 5MG — N19851 001 JUN 25, 1991
— 10MG — N19851 002 JUN 25, 1991
— 20MG — N19851 003 JUN 25, 1991
+ — 40MG — N19851 004 JUN 25, 1991

BENAZEPRIL HYDROCHLORIDE; *MULTIPLE*
SEE AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
LOTENSIN HCT
NOVARTIS 5MG;6.25MG N20033 001 MAY 19, 1992
10MG;12.5MG N20033 002 MAY 19, 1992
20MG;12.5MG N20033 004 MAY 19, 1992
+ 20MG;25MG N20033 003 MAY 19, 1992

BENDROFLUMETHIAZIDE

TABLET; ORAL
NATURETIN-5
+ APOTHECON 5MG N12164 002

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL
CORZIDE
KING PHARMS 5MG;40MG N18647 001 MAY 25, 1983
+ 5MG;80MG N18647 002 MAY 25, 1983

BENZONATATE

CAPSULE; ORAL
BENZONATATE
AA BANNER PHARMACAPS **100MG** **N81297 001** JAN 29, 1993

TESSALON
AA + FOREST LABS **100MG** **N11210 001**
+ 200MG N11210 003 JUN 25, 1999

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL
BENZACLIN
+ DERMIK LABS 5%;EQ 1% BASE N50756 001 DEC 21, 2000

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL
DUAC
+ STIEFEL 5%;EQ 1% BASE N50741 001 AUG 26, 2002

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL
BENZAMYCIN
+ DERMIK LABS 5%;3% N50557 001 OCT 26, 1984

BENZAMYCIN PAK
+ DERMIK LABS 5%;3% N50769 001 NOV 27, 2000

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL
DIDREX
+ PHARMACIA AND UPJOHN 50MG N12427 002

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
EMETE-CON
+ PFIZER EQ 50MG BASE/VIAL N16820 001

BENZTROPINE MESYLATE

INJECTABLE; INJECTION
COGENTIN
+ MERCK 1MG/ML N12015 001

TABLET; ORAL
BENZTROPINE MESYLATE
AA COREPHARMA **0.5MG** **N72264 001** FEB 27, 1989
AA **1MG** **N72265 001** FEB 27, 1989
AA **2MG** **N72266 001** FEB 27, 1989
AA MUTUAL PHARM **1MG** **N81264 001** JAN 23, 1992

FDA data supplied by DrugPatentWatch.com

BENZTROPINE MESYLATE

TABLET; ORAL
BENZTROPINE MESYLATE

AA		MUTUAL PHARM	2MG	**N81265 001** JAN 23, 1992
AA	+	PAR PHARM	0.5MG	**N88877 001** APR 11, 1985
AA	+		1MG	**N88894 001** APR 11, 1985
AA	+		2MG	**N88895 001** APR 11, 1985
AA		PLIVA	0.5MG	**N89058 001** AUG 10, 1988
AA			1MG	**N89059 001** AUG 10, 1988
AA			2MG	**N89060 001** AUG 10, 1988
AA		USL PHARMA	0.5MG	**N40103 001** DEC 12, 1996
AA			1MG	**N40103 002** DEC 12, 1996
AA			2MG	**N40103 003** DEC 12, 1996

BENZYL PENICILLOYL-POLYLYSINE

INJECTABLE; INJECTION
PRE-PEN

+	HOLLISTER STIER LABS	60 UMOLAR	N50114 001

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL
VASCOR

+	ORTHO MCNEIL PHARM	200MG	N19002 001 DEC 28, 1990

BERACTANT

SUSPENSION; INTRATRACHEAL
SURVANTA

+	ROSS LABS	25MG/ML	N20032 001 JUL 01, 1991

BETAINE, ANHYDROUS

FOR SOLUTION; ORAL
CYSTADANE

+	ORPHAN MEDCL	1GM/SCOOPFUL	N20576 001 OCT 25, 1996

BETAMETHASONE

SYRUP; ORAL
CELESTONE

+	SCHERING	0.6MG/5ML	N14215 002

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
CELESTONE SOLUSPAN

+	SCHERING	3MG/ML;EQ 3MG BASE/ML	N14602 001

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL
ALPHATREX

AB	+	SAVAGE LABS	EQ 0.05% BASE	**N19138 001** JUN 26, 1984

BETAMETHASONE DIPROPIONATE

AB	ALPHARMA US PHARM	EQ 0.05% BASE	**N70885 001** FEB 03, 1987
AB	FOUGERA	EQ 0.05% BASE	**N19137 001** JUN 26, 1984
AB	TARO	EQ 0.05% BASE	**N71143 001** JUN 17, 1987
AB		EQ 0.05% BASE	**N73552 001** APR 30, 1992
AB	TEVA	EQ 0.05% BASE	**N71476 001** AUG 10, 1987

CREAM, AUGMENTED; TOPICAL
BETAMETHASONE DIPROPIONATE

AB	ALTANA	EQ 0.05% BASE	**N76215 001** DEC 09, 2003
AB	CLAY PARK	EQ 0.05% BASE	**N76592 001** DEC 09, 2003
AB	TARO	EQ 0.05% BASE	**N76543 001** DEC 09, 2003

FDA data supplied by DrugPatentWatch.com

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED; TOPICAL

DIPROLENE AF				
AB	+ SCHERING	EQ 0.05% BASE	N19555 001	APR 27, 1987

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE				
AB	ALTANA	EQ 0.05% BASE	N75276 001	MAY 13, 2003
AB	TARO	EQ 0.05% BASE	N76508 001	DEC 02, 2003
DIPROLENE				
AB	+ SCHERING	EQ 0.05% BASE	N19408 002	NOV 22, 1991

LOTION; TOPICAL

ALPHATREX				
AB	SAVAGE LABS	EQ 0.05% BASE	N70273 001	AUG 12, 1985
BETAMETHASONE DIPROPIONATE				
AB	ALPHARMA	EQ 0.05% BASE	N70281 001	JUL 31, 1985
AB	CLAY PARK	EQ 0.05% BASE	N72538 001	JAN 31, 1990
AB	COPLEY PHARM	EQ 0.05% BASE	N71882 001	JUN 06, 1988
AB	FOUGERA	EQ 0.05% BASE	N70275 001	AUG 12, 1985
AB	TARO	EQ 0.05% BASE	N72276 001	AUG 24, 1988
AB		EQ 0.05% BASE	N74272 001	SEP 30, 1994
AB	TEVA	EQ 0.05% BASE	N71467 001	AUG 10, 1987
DIPROSONE				
AB	+ SCHERING	EQ 0.05% BASE	N17781 001	

LOTION, AUGMENTED; TOPICAL

DIPROLENE				
+	SCHERING	EQ 0.05% BASE	N19716 001	AUG 01, 1988

OINTMENT; TOPICAL

ALPHATREX				
AB	SAVAGE LABS	EQ 0.05% BASE	N19143 001	SEP 04, 1984

BETAMETHASONE DIPROPIONATE

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE				
AB	ALPHARMA US PHARM	EQ 0.05% BASE	N71012 001	FEB 03, 1987
AB	+ FOUGERA	EQ 0.05% BASE	N19141 001	SEP 04, 1984
AB	TARO	EQ 0.05% BASE	N74271 001	SEP 15, 1994
AB	TEVA	EQ 0.05% BASE	N71477 001	AUG 10, 1987

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE				
AB	ALPHARMA US PHARM	EQ 0.05% BASE	N74304 001	AUG 31, 1995
AB	ALTANA	EQ 0.05% BASE	N75373 001	JUN 22, 1999
DIPROLENE				
AB	+ SCHERING	EQ 0.05% BASE	N18741 001	JUL 27, 1983

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE				
AB	ALPHARMA US PHARM	EQ 0.05% BASE;1%	N76002 001	AUG 02, 2002
AB	ALTANA	EQ 0.05% BASE;1%	N75502 001	JUN 05, 2001
AB	TARO	EQ 0.05% BASE;1%	N75673 001	MAY 29, 2001
LOTRISONE				
AB	+ SCHERING	EQ 0.05% BASE;1%	N18827 001	JUL 10, 1984

LOTION; TOPICAL

LOTRISONE				
+	SCHERING PLOUGH RES	EQ 0.05% BASE;1%	N20010 001	DEC 08, 2000

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE SODIUM PHOSPHATE			
AP	STERIS	EQ 3MG BASE/ML	N85738 001

FDA data supplied by DrugPatentWatch.com

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

	CELESTONE			
AP	+ SCHERING	**EQ 3MG BASE/ML**	**N17561 001**	

BETAMETHASONE SODIUM PHOSPHATE; *MULTIPLE*
SEE BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

BETAMETHASONE VALERATE

AEROSOL; TOPICAL

	LUXIQ			
	+ CONNETICS	EQ 0.12% BASE	N20934 001	FEB 28, 1999

CREAM; TOPICAL

	BETA-VAL			
AB	TEVA	**EQ 0.1% BASE**	**N18642 001**	MAR 24, 1983
	BETADERM			
AB	ROACO	**EQ 0.1% BASE**	**N18839 001**	JUN 30, 1983
	BETAMETHASONE VALERATE			
AB	+ FOUGERA	**EQ 0.1% BASE**	**N18861 001**	AUG 31, 1983
AB	TARO	**EQ 0.1% BASE**	**N70062 001**	MAY 14, 1985
	BETATREX			
AB	SAVAGE LABS	**EQ 0.1% BASE**	**N18862 001**	AUG 31, 1983
	DERMABET			
AB	TARO	**EQ 0.1% BASE**	**N72041 001**	JAN 06, 1988
	VALNAC			
AB	ALPHARMA US PHARM	**EQ 0.1% BASE**	**N70050 001**	OCT 10, 1984

LOTION; TOPICAL

	BETA-VAL			
AB	TEVA	**EQ 0.1% BASE**	**N70072 001**	JUN 27, 1985
	BETAMETHASONE VALERATE			
AB	ALPHARMA	**EQ 0.1% BASE**	**N70052 001**	JUL 31, 1985
AB	COPLEY PHARM	**EQ 0.1% BASE**	**N71883 001**	APR 22, 1988

BETAMETHASONE VALERATE

LOTION; TOPICAL

	BETAMETHASONE VALERATE			
AB	+ FOUGERA	**EQ 0.1% BASE**	**N18866 001**	AUG 31, 1983
	BETATREX			
AB	SAVAGE LABS	**EQ 0.1% BASE**	**N18867 001**	AUG 31, 1983

OINTMENT; TOPICAL

	BETA-VAL			
AB	TEVA	**EQ 0.1% BASE**	**N70069 001**	DEC 19, 1985
	BETAMETHASONE VALERATE			
AB	ALPHARMA US PHARM	**EQ 0.1% BASE**	**N70051 001**	OCT 10, 1984
AB	+ FOUGERA	**EQ 0.1% BASE**	**N18865 001**	AUG 31, 1983
	BETATREX			
AB	SAVAGE LABS	**EQ 0.1% BASE**	**N18863 001**	AUG 31, 1983

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	BETAXOLOL			
AT	AKORN	**EQ 0.5% BASE**	**N75386 001**	JUN 30, 2000
AT	NOVEX	**EQ 0.5% BASE**	**N75446 001**	SEP 28, 2000
	BETAXOLOL HCL			
AT	BAUSCH AND LOMB	**EQ 0.5% BASE**	**N75630 001**	APR 12, 2001
	BETOPTIC			
AT	+ ALCON	**EQ 0.5% BASE**	**N19270 001**	AUG 30, 1985

SUSPENSION/DROPS; OPHTHALMIC

	BETOPTIC S			
	+ ALCON	EQ 0.25% BASE	N19845 001	DEC 29, 1989

TABLET; ORAL

	BETAXOLOL HCL			
AB	AMIDE PHARM	**10MG**	**N75541 001**	OCT 22, 1999

FDA data supplied by DrugPatentWatch.com

BETAXOLOL HYDROCHLORIDE

TABLET; ORAL

	BETAXOLOL HCL			
AB	AMIDE PHARM	**20MG**	**N75541 002**	OCT 22, 1999
	KERLONE			
AB	LOREX	**10MG**	**N19507 001**	OCT 27, 1989
AB +		**20MG**	**N19507 002**	OCT 27, 1989

BETHANECHOL CHLORIDE

TABLET; ORAL

	BETHANECHOL CHLORIDE			
AA	WOCKHARDT	**5MG**	**N40532 001**	SEP 29, 2003
AA		**10MG**	**N40533 001**	SEP 29, 2003
AA		**25MG**	**N40534 001**	SEP 29, 2003
AA		**50MG**	**N40518 001**	SEP 29, 2003
	URECHOLINE			
AA +	ODYSSEY PHARMS	**5MG**	**N89095 001**	DEC 19, 1985
AA +		**10MG**	**N88440 001**	MAY 29, 1984
AA +		**25MG**	**N88441 001**	MAY 29, 1984
AA +		**50MG**	**N89096 001**	DEC 19, 1985

BEXAROTENE

CAPSULE; ORAL

	TARGRETIN		
+	LIGAND	75MG	N21055 001 DEC 29, 1999

GEL; TOPICAL

	TARGRETIN		
+	LIGAND	1%	N21056 001 JUN 28, 2000

BICALUTAMIDE

TABLET; ORAL

	CASODEX		
+	ASTRAZENECA	50MG	N20498 001 OCT 04, 1995

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

	LUMIGAN		
+	ALLERGAN	0.03%	N21275 001 MAR 16, 2001

BIOTIN; *MULTIPLE*

SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

BIPERIDEN HYDROCHLORIDE

TABLET; ORAL

	AKINETON		
+	ABBOTT	2MG	N12003 001

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

	HELIDAC		
+	PROMETHEUS LABS	262.4MG,N/A,N/A;N/A,250MG,N/A;N/A, N/A,500MG	N50719 001 AUG 15, 1996

FDA data supplied by DrugPatentWatch.com

BISOPROLOL FUMARATE

TABLET; ORAL

	BISOPROLOL FUMARATE			
AB	COPLEY PHARM	5MG	N75644 001	JUN 26, 2001
AB		10MG	N75644 002	JUN 26, 2001
AB	EON	5MG	N75643 001	NOV 16, 2000
AB		10MG	N75643 002	NOV 16, 2000
AB	MUTUAL PHARM	5MG	N75474 001	OCT 25, 2002
AB		10MG	N75474 002	OCT 25, 2002
	ZEBETA			
AB	DURAMED PHARMS BARR	5MG	N19982 002	JUL 31, 1992
AB +		10MG	N19982 001	JUL 31, 1992

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE			
AB	EON	2.5MG;6.25MG	N75579 001	SEP 25, 2000
AB		5MG;6.25MG	N75579 002	SEP 25, 2000
AB		10MG;6.25MG	N75579 003	SEP 25, 2000
AB	IVAX PHARMS	2.5MG;6.25MG	N75632 001	SEP 27, 2000
AB		5MG;6.25MG	N75632 002	SEP 27, 2000
AB		10MG;6.25MG	N75632 003	SEP 27, 2000
AB	MYLAN	2.5MG;6.25MG	N75768 001	SEP 25, 2000
AB		5MG;6.25MG	N75768 002	SEP 25, 2000
AB		10MG;6.25MG	N75768 003	SEP 25, 2000
AB	PUREPAC PHARM	2.5MG;6.25MG	N75672 001	SEP 25, 2000
AB		5MG;6.25MG	N75672 002	SEP 25, 2000

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE			
AB	PUREPAC PHARM	10MG;6.25MG	N75672 003	SEP 25, 2000
AB	SANDOZ	2.5MG;6.25MG	N75527 001	SEP 25, 2000
AB		5MG;6.25MG	N75527 003	SEP 25, 2000
AB		10MG;6.25MG	N75527 002	SEP 25, 2000
AB	TEVA	2.5MG;6.25MG	N75686 001	JAN 19, 2001
AB		5MG;6.25MG	N75686 002	JAN 19, 2001
AB		10MG;6.25MG	N75686 003	JAN 19, 2001
AB	WATSON LABS	2.5MG;6.25MG	N75469 001	SEP 25, 2000
AB		5MG;6.25MG	N75469 002	SEP 25, 2000
AB		10MG;6.25MG	N75469 003	SEP 25, 2000
	ZIAC			
AB	DURAMED PHARMS BARR	2.5MG;6.25MG	N20186 003	MAR 26, 1993
AB		5MG;6.25MG	N20186 001	MAR 26, 1993
AB +		10MG;6.25MG	N20186 002	MAR 26, 1993

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

	ANGIOMAX			
+	MEDICINES CO	250MG/VIAL	N20873 001	DEC 15, 2000

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

	BLENOXANE			
AP +	BRISTOL MYERS SQUIBB	EQ 15 UNITS BASE/VIAL	N50443 001	SEP 07, 1995
AP +		EQ 30 UNITS BASE/VIAL	N50443 002	SEP 07, 1995

FDA data supplied by DrugPatentWatch.com

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

	BLEOMYCIN			
AP	BEDFORD	**EQ 15 UNITS BASE/VIAL**	**N65042 002** OCT 17, 2001	
AP		**EQ 30 UNITS BASE/VIAL**	**N65042 001** OCT 17, 2001	
AP	GENSIA SICOR PHARMS	**EQ 15 UNITS BASE/VIAL**	**N65033 001** JUN 27, 2000	
AP		**EQ 30 UNITS BASE/VIAL**	**N65033 002** JUN 27, 2000	
AP	MAYNE PHARMA USA	**EQ 15 UNITS BASE/VIAL**	**N65031 001** MAR 10, 2000	
AP		**EQ 30 UNITS BASE/VIAL**	**N65031 002** MAR 10, 2000	
	BLEOMYCIN SULFATE			
AP	GENSIA SICOR PHARMS	**EQ 15 UNITS BASE/VIAL**	**N64084 001** JUN 01, 1996	
AP		**EQ 30 UNITS BASE/VIAL**	**N64084 002** JUN 01, 1996	

BORTEZOMIB

INJECTABLE; INTRAVENOUS

	VELCADE			
+	MILLENNIUM PHARMS	3.5MG/VIAL	N21602 001 MAY 13, 2003	

BOSENTAN

TABLET; ORAL

	TRACLEER			
	ACTELION	62.5MG	N21290 001 NOV 20, 2001	
+		125MG	N21290 002 NOV 20, 2001	

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

	BRETYLIUM TOSYLATE			
AP	+ ABBOTT	**50MG/ML**	**N19033 001** APR 29, 1986	
AP	INTL MEDICATION	**50MG/ML**	**N70119 001** APR 29, 1986	

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

	BRETYLIUM TOSYLATE			
AP	LUITPOLD	**50MG/ML**	**N70891 001** JUL 26, 1988	
	BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ ABBOTT	**200MG/100ML**	**N19008 002** APR 29, 1986	
AP	+	**400MG/100ML**	**N19008 003** APR 29, 1986	
AP	+ B BRAUN	**200MG/100ML**	**N19121 002** APR 29, 1986	
AP	+	**400MG/100ML**	**N19121 003** APR 29, 1986	
	+	100MG/100ML	N19121 001 APR 29, 1986	
	BRETYLIUM TOSYLATE IN PLASTIC CONTAINER			
AP	+ ABBOTT	**50MG/ML**	**N19030 001** APR 29, 1986	

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

	ALPHAGAN P			
+	ALLERGAN	0.15%	N21262 001 MAR 16, 2001	
	BRIMONIDINE TARTRATE			
AT	ALCON	**0.2%**	**N76254 001** SEP 16, 2003	
AT	+ BAUSCH AND LOMB	**0.2%**	**N76260 001** MAY 28, 2003	

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC

	AZOPT			
+	ALCON	1%	N20816 001 APR 01, 1998	

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

	PARLODEL			
+	NOVARTIS	EQ 5MG BASE	N17962 002 MAR 01, 1982	

FDA data supplied by DrugPatentWatch.com

BROMOCRIPTINE MESYLATE

TABLET; ORAL

	BROMOCRIPTINE MESYLATE			
AB	LEK PHARMS	**EQ 2.5MG BASE**	**N74631 001**	JAN 13, 1998
	PARLODEL			
AB	+ NOVARTIS	**EQ 2.5MG BASE**	**N17962 001**	

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL

	AMBENYL			
AA	+ FORREST LABS	**12.5MG/5ML;10MG/5ML**	**N09319 006**	JAN 10, 1984
	MYBANIL			
AA	MORTON GROVE	**12.5MG/5ML;10MG/5ML**	**N88626 001**	OCT 12, 1984

BROMPHENIRAMINE MALEATE

ELIXIR; ORAL

	BROMPHENIRAMINE MALEATE		
	+ KV PHARM	2MG/5ML	N85466 001

INJECTABLE; INJECTION

	BROMPHENIRAMINE MALEATE		
	+ STERIS	10MG/ML	N83821 001

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

	BROMFED-DM			
AA	VERUM PHARMS	**2MG/5ML;10MG/5ML;30MG/5ML**	**N89681 001**	DEC 22, 1988
	MYPHETANE DX			
AA	+ MORTON GROVE	**2MG/5ML;10MG/5ML;30MG/5ML**	**N88811 001**	JUN 07, 1985

BUDESONIDE

CAPSULE; ORAL

	ENTOCORT EC			
	+ ASTRAZENECA	3MG	N21324 001	OCT 02, 2001

BUDESONIDE

POWDER, METERED; INHALATION

	PULMICORT		
	+ ASTRAZENECA	0.16MG/INH	N20441 002 JUN 24, 1997

SPRAY, METERED; NASAL

	RHINOCORT		
	ASTRAZENECA	0.032MG/INH	N20746 001 OCT 01, 1999
	+	0.064MG/INH	N20746 002 OCT 01, 1999

SUSPENSION; INHALATION

	PULMICORT RESPULES		
	ASTRAZENECA	0.25MG/2ML	N20929 001 AUG 08, 2000
	+	0.5MG/2ML	N20929 002 AUG 08, 2000

BUMETANIDE

INJECTABLE; INJECTION

	BUMETANIDE			
AP	ABBOTT	**0.25MG/ML**	**N74160 001**	OCT 30, 1997
AP		**0.25MG/ML**	**N74332 001**	OCT 31, 1994
AP	BEDFORD	**0.25MG/ML**	**N74441 001**	JAN 27, 1995
AP	GENSIA SICOR PHARMS	**0.25MG/ML**	**N74613 001**	NOV 18, 1997
	BUMEX			
AP	+ ROCHE	**0.25MG/ML**	**N18226 001**	FEB 28, 1983

TABLET; ORAL

	BUMETANIDE			
AB	EON	**0.5MG**	**N74700 001**	NOV 21, 1996
AB		**1MG**	**N74700 002**	NOV 21, 1996
AB		**2MG**	**N74700 003**	NOV 21, 1996
AB	IVAX PHARMS	**0.5MG**	**N74225 001**	APR 24, 1995

FDA data supplied by DrugPatentWatch.com

BUMETANIDE

TABLET; ORAL

	BUMETANIDE			
AB	IVAX PHARMS	1MG	**N74225 002**	APR 24, 1995
AB		2MG	**N74225 003**	APR 24, 1995
	BUMEX			
AB	ROCHE	0.5MG	**N18225 002**	FEB 28, 1983
AB		1MG	**N18225 001**	FEB 28, 1983
AB	+	2MG	**N18225 003**	JUN 14, 1985

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	BUPIVACAINE HCL			
AP	ABBOTT	0.25%	**N18053 002**	
AP		0.25%	**N70583 001**	FEB 17, 1987
AP		0.25%	**N70586 001**	MAR 03, 1987
AP		0.25%	**N70590 001**	FEB 17, 1987
AP		0.5%	**N18053 001**	
AP		0.5%	**N70584 001**	FEB 17, 1986
AP		0.5%	**N70597 001**	MAR 03, 1987
AP		0.5%	**N70609 001**	MAR 03, 1987
AP		0.75%	**N18053 003**	
AP		0.75%	**N70585 001**	MAR 03, 1987
AP		0.75%	**N70587 001**	MAR 03, 1987
	BUPIVACINE HCL PRESERVATIVE FREE			
AP	INTL MEDICATED	0.25%	**N76012 001**	JAN 09, 2002
AP		0.5%	**N76012 002**	JAN 09, 2002
AP		0.75%	**N76012 003**	JAN 09, 2002
	MARCAINE HCL			
AP	+ ABBOTT	0.25%	**N16964 001**	

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	MARCAINE HCL		
AP	+ ABBOTT	0.5%	**N16964 006**
	MARCAINE HCL PRESERVATIVE FREE		
AP	+ ABBOTT	0.25%	**N16964 012**
AP	+	0.5%	**N16964 005**
AP	+	0.75%	**N16964 009**
	SENSORCAINE		
AP	ASTRAZENECA	0.25%	**N18304 001**
AP		0.25%	**N70552 001** MAY 21, 1986
AP		0.5%	**N18304 002**
AP		0.5%	**N70553 001** MAY 21, 1986
AP		0.75%	**N18304 003**
AP		0.75%	**N70554 001** MAY 21, 1986

INJECTABLE; SPINAL

	BUPIVACAINE		
AP	ABBOTT	0.75%	**N71810 001** DEC 11, 1987
	MARCAINE		
AP	+ ABBOTT	0.75%	**N18692 001** MAY 04, 1984
	SENSORCAINE		
AP	ASTRAZENECA	0.75%	**N71202 001** APR 15, 1987

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

	BUPIVACAINE HCL AND EPINEPHRINE		
+	ABBOTT	0.25%;0.005MG/ML	N71165 001 JUN 16, 1988
		0.25%;0.005MG/ML	N71166 001 JUN 16, 1988
		0.25%;0.005MG/ML	N71167 001 JUN 16, 1988
+		0.5%;0.005MG/ML	N71168 001 JUN 16, 1988
		0.5%;0.005MG/ML	N71169 001 JUN 16, 1988
		0.5%;0.005MG/ML	N71170 001 JUN 16, 1988

FDA data supplied by DrugPatentWatch.com

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

	BUPIVACAINE HCL AND EPINEPHRINE			
	+ ABBOTT	0.75%;0.005MG/ML	N71171 001	JUN 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

	MARCAINE HCL W/ EPINEPHRINE			
AP	+ ABBOTT	**0.25%;0.0091MG/ML**	**N16964 004**	
AP	+	**0.5%;0.0091MG/ML**	**N16964 008**	
	MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE			
AP	+ ABBOTT	**0.25%;0.0091MG/ML**	**N16964 013**	
AP	+	**0.5%;0.0091MG/ML**	**N16964 007**	
AP	+	**0.75%;0.0091MG/ML**	**N16964 010**	
	SENSORCAINE			
AP	ASTRAZENECA	**0.25%;0.0091MG/ML**	**N70966 001**	OCT 13, 1987
AP		**0.25%;0.0091MG/ML**	**N70967 001**	OCT 13, 1987
AP		**0.5%;0.0091MG/ML**	**N18304 004**	SEP 02, 1983
AP		**0.5%;0.0091MG/ML**	**N70968 001**	OCT 13, 1987
AP		**0.75%;0.0091MG/ML**	**N18304 005**	SEP 02, 1983

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	DUOCAINE			
	+ AMPHASTAR	EQ 0.375% (37.5MG/10ML); EQ 1% (100MG/10ML)	N21496 001	MAY 23, 2003

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

	BUPRENEX			
AP	+ RECKITT BENCKISER	**EQ 0.3MG BASE/ML**	**N18401 001**	
	BUPRENORPHINE HCL			
AP	ABBOTT	**EQ 0.3MG BASE/ML**	**N74137 001**	JUN 03, 1996

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

	SUBUTEX			
	RECKITT BENCKISER	EQ 2MG BASE	N20732 002	OCT 08, 2002
	+	EQ 8MG BASE	N20732 003	OCT 08, 2002

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

	SUBOXONE			
	RECKITT BENCKISER	2MG;0.5MG	N20733 001	OCT 08, 2002
	+	8MG;2MG	N20733 002	OCT 08, 2002

BUPROPION HYDROCHLORIDE

TABLET; ORAL

	BUPROPION HCL			
AB	EON	**75MG**	**N75613 002**	OCT 10, 2000
AB		**100MG**	**N75613 001**	OCT 10, 2000
AB	MYLAN	**75MG**	**N75491 001**	APR 17, 2000
AB		**100MG**	**N75491 002**	APR 17, 2000
AB	SANDOZ	**75MG**	**N75584 001**	FEB 07, 2000
AB		**100MG**	**N75584 002**	FEB 07, 2000
AB	TEVA	**75MG**	**N75310 001**	NOV 29, 1999
AB		**100MG**	**N75310 002**	NOV 29, 1999
	WELLBUTRIN			
AB	GLAXOSMITHKLINE	**75MG**	**N18644 002**	DEC 30, 1985
AB	+	**100MG**	**N18644 003**	DEC 30, 1985

TABLET, EXTENDED RELEASE; ORAL

	BUPROPRION HCL			
AB	EON	**100MG**	**N75932 001**	NOV 25, 2003

FDA data supplied by DrugPatentWatch.com

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	WELLBUTRIN SR			
AB	GLAXOSMITHKLINE	**100MG**	**N20358 002**	OCT 04, 1996
		50MG	N20358 001	OCT 04, 1996
	+	150MG	N20358 003	OCT 04, 1996
		200MG	N20358 004	JUN 14, 2002
	WELLBUTRIN XL			
	+ SMITHKLINE BEECHAM	150MG	N21515 001	AUG 28, 2003
		300MG	N21515 002	AUG 28, 2003
	ZYBAN			
	+ GLAXOSMITHKLINE	150MG	N20711 003	MAY 14, 1997

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

	BUSPAR			
AB	BRISTOL MYERS SQUIBB	**5MG**	**N18731 001**	SEP 29, 1986
AB		**10MG**	**N18731 002**	SEP 29, 1986
AB		**15MG**	**N18731 003**	APR 22, 1996
AB	+	**30MG**	**N18731 004**	APR 22, 1996
	BUSPIRONE HCL			
AB	EGIS	**5MG**	**N75119 001**	MAR 14, 2002
AB		**10MG**	**N75119 002**	MAR 14, 2002
AB		**15MG**	**N75119 003**	JAN 23, 2003
AB	KV PHARM	**5MG**	**N75572 001**	FEB 27, 2002
AB		**10MG**	**N75572 002**	FEB 27, 2002
AB		**15MG**	**N75572 003**	FEB 27, 2002
AB	MYLAN	**5MG**	**N75272 001**	MAR 01, 2002

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

	BUSPIRONE HCL			
AB	MYLAN	**10MG**	**N75272 002**	MAR 01, 2002
AB		**15MG**	**N75272 003**	MAR 28, 2001
AB		**30MG**	**N76008 001**	JUN 28, 2001
AB	PAR PHARM	**5MG**	**N75467 001**	FEB 28, 2002
AB		**7.5MG**	**N75467 002**	MAR 28, 2001
AB		**10MG**	**N75467 003**	FEB 28, 2002
AB		**15MG**	**N75467 004**	FEB 28, 2002
AB	PHARMEX PRODS	**5MG**	**N75388 001**	MAY 09, 2002
AB		**10MG**	**N75388 002**	MAY 09, 2002
AB		**15MG**	**N75388 003**	MAY 09, 2002
AB	SANDOZ	**5MG**	**N75413 001**	MAR 19, 2002
AB		**10MG**	**N75413 002**	MAR 19, 2002
AB		**15MG**	**N75413 003**	MAR 19, 2002
AB	TEVA	**5MG**	**N75022 001**	FEB 28, 2002
AB		**10MG**	**N75022 002**	FEB 28, 2002
AB		**15MG**	**N75022 003**	FEB 28, 2002
AB	TORPHARM	**5MG**	**N75521 001**	APR 05, 2002
AB		**10MG**	**N75521 002**	APR 05, 2002
AB		**15MG**	**N75521 003**	APR 05, 2002
AB	WATSON LABS	**5MG**	**N74253 001**	MAR 28, 2001
AB		**10MG**	**N74253 002**	MAR 28, 2001
AB		**15MG**	**N74253 003**	MAR 13, 2002

FDA data supplied by DrugPatentWatch.com

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

	BUSPIRONE HCL			
AB	ZENITH GOLDLINE	**5MG**	**N75385 001**	MAR 01, 2002
AB		**10MG**	**N75385 002**	MAR 01, 2002
AB		**15MG**	**N75385 003**	MAR 01, 2002

BUSULFAN

INJECTABLE; INJECTION

BUSULFEX			
+ ESP PHARMA	6MG/ML	N20954 001	FEB 04, 1999

TABLET; ORAL

MYLERAN			
+ GLAXOSMITHKLINE	2MG	N09386 001	

BUTABARBITAL SODIUM

ELIXIR; ORAL

BUTISOL SODIUM			
+ MEDPOINTE PHARM HLC	30MG/5ML	N85380 001	

TABLET; ORAL

	BUTABARBITAL			
AA	BUNDY	**30MG**	**N85550 001**	
	BUTISOL SODIUM			
AA	+ MEDPOINTE PHARM HLC	**30MG**	**N00793 004**	
	+	50MG	N00793 003	
	SODIUM BUTABARBITAL			
	MARSHALL PHARMA	16.2MG	N83524 001	
		32.4MG	N83858 001	

BUTALBITAL; *MULTIPLE*

SEE ACETAMINOPHEN; BUTALBITAL
SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE
SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
SEE ASPIRIN; BUTALBITAL; CAFFEINE
SEE ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX			
+ BERTEK PHARMS	1%	N20524 001	OCT 18, 1996
MENTAX-TC			
+ BERTEK	1%	N21408 001	OCT 17, 2002

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

GYNAZOLE-1			
+ KV PHARM	2%	N19881 001	FEB 07, 1997

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

	BUTORPHANOL TARTRATE			
AP	ABBOTT	**1MG/ML**	**N75559 001**	MAR 20, 2000
AP		**2MG/ML**	**N75559 002**	MAR 20, 2000
AP	APOTEX	**2MG/ML**	**N75697 001**	OCT 23, 2001
AP	BEDFORD	**2MG/ML**	**N75046 001**	AUG 12, 1998
AP	MERIDIAN MEDCL TECHN	**1MG/ML**	**N75342 001**	NOV 04, 1999
AP		**2MG/ML**	**N75342 002**	NOV 04, 1999
	BUTORPHANOL TARTRATE PRESERVATIVE FREE			
AP	ABBOTT	**1MG/ML**	**N74620 001**	JAN 22, 1997
AP		**1MG/ML**	**N74626 001**	JAN 23, 1997
AP		**2MG/ML**	**N74620 002**	JAN 22, 1997
AP		**2MG/ML**	**N74626 002**	JAN 23, 1997
AP	APOTEX	**1MG/ML**	**N75695 001**	OCT 23, 2001
AP		**2MG/ML**	**N75695 002**	OCT 23, 2001

FDA data supplied by DrugPatentWatch.com

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP	BEDFORD	**1MG/ML**	**N75045 001** AUG 12, 1998	
AP		**2MG/ML**	**N75045 002** AUG 12, 1998	
AP	MAYNE PHARMA USA	**1MG/ML**	**N75170 001** SEP 28, 1998	
AP		**2MG/ML**	**N75170 002** SEP 28, 1998	

STADOL

AP	+ APOTHECON	**2MG/ML**	**N17857 004**	

STADOL PRESERVATIVE FREE

AP	+ APOTHECON	**1MG/ML**	**N17857 001**	
AP	+	**2MG/ML**	**N17857 002**	

SPRAY, METERED; NASAL

BUTORPHANOL TARTRATE

AB	MYLAN	**1MG/SPRAY**	**N75759 001** AUG 08, 2001	
AB	NOVEX	**1MG/SPRAY**	**N75499 001** DEC 04, 2002	
AB	ROXANE	**1MG/SPRAY**	**N75824 001** MAR 12, 2002	

STADOL

AB	+ BRISTOL MYERS SQUIBB	**1MG/SPRAY**	**N19890 001** DEC 12, 1991	

CABERGOLINE

TABLET; ORAL

DOSTINEX

+	PHARMACIA AND UPJOHN	0.5MG	N20664 001 DEC 23, 1996	

CAFFEINE; *MULTIPLE*

SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE
SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
SEE ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE
SEE ASPIRIN; BUTALBITAL; CAFFEINE
SEE ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
SEE ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE
SEE ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE
SEE ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

CAFERGOT

+	NOVARTIS	100MG;2MG	N09000 002	

TABLET; ORAL

ERCATAB

+	SANDOZ	100MG;1MG	N84294 001	

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS, ORAL

CAFCIT

+	MEAD JOHNSON	EQ 10MG BASE/ML	N20793 001 SEP 21, 1999	

CALCIPOTRIENE

CREAM; TOPICAL

DOVONEX

+	BRISTOL MYERS SQUIBB	0.005%	N20554 001 JUL 22, 1996	

OINTMENT; TOPICAL

DOVONEX

+	BRISTOL MYERS SQUIBB	0.005%	N20273 001 DEC 29, 1993	

SOLUTION; TOPICAL

DOVONEX

+	BRISTOL MYERS SQUIBB	0.005%	N20611 001 MAR 03, 1997	

CALCITONIN, SALMON

INJECTABLE; INJECTION

CALCIMAR

AP	+ AVENTIS	**200 IU/ML**	**N17769 001**	

MIACALCIN

AP	+ NOVARTIS	**200 IU/ML**	**N17808 002** MAR 29, 1991	

SPRAY, METERED; NASAL

MIACALCIN

+	NOVARTIS	200 IU/SPRAY	N20313 002 AUG 17, 1995	

FDA data supplied by DrugPatentWatch.com

CALCITRIOL

CAPSULE; ORAL

	CALCITRIOL			
AB	TEVA	0.25 UGM	N75765 001	OCT 12, 2001
AB		0.5 UGM	N75765 002	OCT 12, 2001
	ROCALTROL			
AB	ROCHE	0.25 UGM	N18044 001	
AB +		0.5 UGM	N18044 002	

INJECTABLE; INJECTION

	CALCIJEX			
AP +	ABBOTT	0.001MG/ML	N18874 001	SEP 25, 1986
AP +		0.002MG/ML	N18874 002	SEP 25, 1986
	CALCITRIOL			
AP	AAIPHARMA LLC	0.001MG/ML	N75766 001	FEB 20, 2003
AP		0.002MG/ML	N75766 002	FEB 20, 2003
AP	AM PHARM PARTNERS	0.001MG/ML	N75836 001	DEC 31, 2002
AP		0.002MG/ML	N75836 002	DEC 31, 2002
AP	GENSIA SICOR PHARMS	0.001MG/ML	N75823 001	MAR 31, 2003
AP		0.002MG/ML	N75823 002	MAR 31, 2003
AP	LUITPOLD	0.001MG/ML	N75746 001	SEP 26, 2003
AP		0.002MG/ML	N75746 002	SEP 26, 2003
AP	LYNE	0.001MG/ML	N76206 001	SEP 17, 2003

SOLUTION; ORAL

	CALCITRIOL			
AA	ROXANE	1 UGM/ML	N76242 001	JUL 18, 2003
	ROCALTROL			
AA +	ROCHE	1 UGM/ML	N21068 001	NOV 20, 1998

CALCIUM ACETATE

CAPSULE; ORAL

	PHOSLO GELCAPS			
+	NABI	EQ 169MG CALCIUM	N21160 003	APR 02, 2001

TABLET; ORAL

	PHOSLO			
+	NABI	EQ 169MG CALCIUM	N19976 001	DEC 10, 1990

CALCIUM ACETATE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

CALCIUM CHLORIDE

INJECTABLE; INJECTION
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

+	ABBOTT	100MG/ML	N21117 001	JAN 28, 2000

CALCIUM CHLORIDE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

	BSS PLUS			
AT	ALCON	0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML	N18469 001	

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

ENDOSOL EXTRA

AT AKORN **0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML** **N20079 001** NOV 27, 1991

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML N19864 001 JUN 10, 1993

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN 35MG/100ML;5GM/100ML;30MG/100ML; 74MG/100ML;640MG/100ML;500MG/100ML; 74MG/100ML N19867 001 DEC 20, 1993

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 37MG/100ML;5GM/100ML;30MG/100ML; 119MG/100ML;161MG/100ML;94MG/100ML; 138MG/100ML N17390 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER

B BRAUN 510MG/100ML;30GM/100ML;200MG/100ML; 9.2GM/100ML;9.6GM/100ML N18807 001 AUG 26, 1983

510MG/100ML;30GM/100ML;200MG/100ML; 9.4GM/100ML;11GM/100ML N18807 003 AUG 26, 1983

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

B BRAUN 510MG/100ML;50GM/100ML;200MG/100ML; 9.2GM/100ML;9.6GM/100ML N18807 002 AUG 26, 1983

510MG/100ML;50GM/100ML;200MG/100ML; 9.4GM/100ML;11GM/100ML N18807 004 AUG 26, 1983

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL **25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML** **N18379 002**

AT **25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML** **N18883 001** NOV 30, 1984

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL **25.7MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML** **N18883 004** NOV 30, 1984

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL **18.4MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML** **N20171 001** AUG 19, 1992

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL **25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML** **N18379 003**

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N18883 002** NOV 30, 1984

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18883 005** NOV 30, 1984

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 18.4MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20171 002** AUG 19, 1992

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;3.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N18379 007** JUN 24, 1988

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N18379 001**

AT 25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N18883 003** NOV 30, 1984

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18883 006** NOV 30, 1984

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 18.4MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20171 003** AUG 19, 1992

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18379 004** JUL 07, 1982

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18379 005** JUL 07, 1982

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18379 008** JUN 24, 1988

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT FRESENIUS MEDCL 25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N18379 006** JUL 07, 1982

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN 26MG/100ML;1.5GM/100ML;5MG/100ML; 530MG/100ML;450MG/100ML N18460 007 JAN 29, 1986

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN 26MG/100ML;2.5GM/100ML;5MG/100ML; 530MG/100ML;450MG/100ML N18460 005 NOV 02, 1983

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN 26MG/100ML;4.25GM/100ML;5MG/100ML; 530MG/100ML;450MG/100ML N18460 009 JAN 29, 1986

DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 001**

DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 003**

DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 002**

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20183 001** DEC 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20183 002** DEC 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20183 003** DEC 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20183 004** DEC 04, 1992

DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 007** JUL 09, 1984

DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 008** JUL 09, 1984

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;3.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 010** NOV 18, 1985

DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML **N17512 009** JUL 09, 1984

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 18.3MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N17512 004**

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20163 001** DEC 04, 1992

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N17512 005**

AT 25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20163 002** DEC 04, 1992

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N17512 011** NOV 18, 1985

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT BAXTER HLTHCARE 25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N17512 006**

AT 25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20163 003** DEC 04, 1992

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT FRESENIUS 18.4MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20374 001** JUN 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT FRESENIUS 18.4MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20374 002** JUN 13, 1994

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT FRESENIUS 18.4MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML **N20374 003** JUN 13, 1994

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	FRESENIUS	18.4MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N20374 004 JUN 13, 1994

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

ELLIOTTS B SOLUTION

+	QOL MEDCL	0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML; 1.9MG/ML;7.3MG/ML; 0.2MG/ML	N20577 001 SEP 27, 1996

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML; 380MG/100ML;600MG/100ML	N18258 001

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML	N18254 001

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML	N18256 001
AP		33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML	N20000 001 APR 17, 1992
AP	BAXTER HLTHCARE	33MG/100ML;5GM/100ML;30MG/100ML; 860MG/100ML	N16695 001

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	10MG/100ML;2.5GM/100ML;15MG/100ML; 300MG/100ML;160MG/100ML	N19634 001 FEB 24, 1988

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML	N17608 001

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML	N19634 003 FEB 24, 1988

LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML	N16679 001

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML; 600MG/100ML;310MG/100ML	N19367 002 APR 05, 1985
	20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML	N19367 003 APR 05, 1985

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML	N19367 006 APR 05, 1985

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML	N19685 002 OCT 17, 1988
AP		20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML	N19685 008 OCT 17, 1988
AP	BAXTER HLTHCARE	20MG/100ML;5GM/100ML;179MG/100ML; 600MG/100ML;310MG/100ML	N19367 004 APR 05, 1985
AP		20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML	N19367 005 APR 05, 1985

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;254MG/100ML; 600MG/100ML;310MG/100ML**	**N19367 007** APR 05, 1985

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	**20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML**	**N19685 004** OCT 17, 1988
AP	BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;328MG/100ML; 600MG/100ML;310MG/100ML**	**N19367 008** APR 05, 1985

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML; 600MG/100ML;310MG/100ML	N19367 001 APR 05, 1985

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

ABBOTT	16.5MG/ML;25.4MG/ML;74.6MG/ML; 121MG/ML;16.1MG/ML	N18895 001 JUL 20, 1984

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

B BRAUN	35MG/100ML;30MG/100ML;74MG/100ML; 640MG/100ML;500MG/100ML; 74MG/100ML	N19718 001 SEP 29, 1989

SOLUTION; IRRIGATION

BSS

+ ALCON	0.48MG/ML;0.3MG/ML;0.75MG/ML; 3.9MG/ML;6.4MG/ML; 1.7MG/ML	N20742 001 DEC 10, 1997

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

BAXTER HLTHCARE	36.8MG/100ML;30.5MG/100ML; 74.6MG/100ML;640MG/100ML; 496MG/100ML;89.6MG/100ML	N17438 001

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	**17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML**	**N75323 001** APR 21, 2000

PLEGISOL IN PLASTIC CONTAINER

AT	+ ABBOTT	**17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML**	**N18608 001** FEB 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	**33MG/100ML;30MG/100ML; 860MG/100ML**	**N18251 001**
AP	B BRAUN	**33MG/100ML;30MG/100ML; 860MG/100ML**	**N18721 001** NOV 09, 1982
AP		**33MG/100ML;30MG/100ML; 860MG/100ML**	**N20002 001** APR 17, 1992
AP	BAXTER HLTHCARE	**33MG/100ML;30MG/100ML; 860MG/100ML**	**N16693 001**

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT	ABBOTT	**33MG/100ML;30MG/100ML; 860MG/100ML**	**N17635 001**
AT	B BRAUN	**33MG/100ML;30MG/100ML; 860MG/100ML**	**N18156 001**
AT	BAXTER HLTHCARE	**33MG/100ML;30MG/100ML; 860MG/100ML**	**N18495 001** FEB 19, 1982

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER

AP	ABBOTT	**20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML**	**N17641 001**
AP	B BRAUN	**20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML**	**N19632 001** FEB 29, 1988
AP	BAXTER HLTHCARE	**20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML**	**N16682 001**

SOLUTION; IRRIGATION
LACTATED RINGER'S IN PLASTIC CONTAINER

AT	ABBOTT	**20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML**	**N19416 001** JAN 17, 1986
AT	B BRAUN	**20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML**	**N18681 001** DEC 27, 1982
AT	BAXTER HLTHCARE	**20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML**	**N18494 001** FEB 19, 1982
AT		**20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML**	**N18921 001** APR 03, 1984
AT		**20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML**	**N19933 001** AUG 29, 1989

CALFACTANT

SUSPENSION; INTRATRACHEAL
INFASURF PRESERVATIVE FREE

+	ONY	35MG/ML	N20521 001 JUL 01, 1998

CANDESARTAN CILEXETIL

TABLET; ORAL
ATACAND

	ASTRAZENECA	4MG	N20838 001 JUN 04, 1998
		8MG	N20838 002 JUN 04, 1998

CANDESARTAN CILEXETIL

TABLET; ORAL
ATACAND

	ASTRAZENECA	16MG	N20838 003 JUN 04, 1998
+		32MG	N20838 004 JUN 04, 1998

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
ATACAND HCT

	ASTRAZENECA	16MG;12.5MG	N21093 001 SEP 05, 2000
+		32MG;12.5MG	N21093 002 SEP 05, 2000

CAPECITABINE

TABLET; ORAL
XELODA

	HLR	150MG	N20896 001 APR 30, 1998
+		500MG	N20896 002 APR 30, 1998

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION
CAPASTAT SULFATE

+	LILLY	EQ 1GM BASE/VIAL	N50095 001

CAPTOPRIL

TABLET; ORAL
CAPOTEN

AB	PAR PHARM	**12.5MG**	**N18343 005** JAN 17, 1985
AB		**25MG**	**N18343 002**
AB		**50MG**	**N18343 001**
AB	+	**100MG**	**N18343 003**
	CAPTOPRIL		
AB	APOTHECON	**12.5MG**	**N74472 001** MAR 31, 1995

FDA data supplied by DrugPatentWatch.com

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	APOTHECON	25MG	**N74472 002** MAR 31, 1995
AB		50MG	**N74472 003** MAR 31, 1995
AB		100MG	**N74472 004** MAR 31, 1995
AB	CLONMEL HLTHCARE	12.5MG	**N74423 001** FEB 13, 1996
AB		25MG	**N74423 002** FEB 13, 1996
AB		50MG	**N74423 003** FEB 13, 1996
AB		100MG	**N74423 004** FEB 13, 1996
AB	COPLEY PHARM	12.5MG	**N74462 001** FEB 13, 1996
AB		25MG	**N74462 002** FEB 13, 1996
AB		50MG	**N74462 003** FEB 13, 1996
AB		100MG	**N74462 004** FEB 13, 1996
AB	EGIS PHARMS	12.5MG	**N74748 004** MAY 29, 1997
AB		25MG	**N74748 002** MAY 29, 1997
AB		50MG	**N74748 001** MAY 29, 1997
AB		100MG	**N74748 003** MAY 29, 1997
AB	ENDO LABS	12.5MG	**N74418 001** FEB 13, 1996
AB		25MG	**N74418 002** FEB 13, 1996
AB		50MG	**N74418 003** FEB 13, 1996
AB		100MG	**N74418 004** FEB 13, 1996
AB	EON	12.5MG	**N74519 001** FEB 13, 1996
AB		25MG	**N74519 002** FEB 13, 1996
AB		50MG	**N74519 003** FEB 13, 1996

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	EON	100MG	**N74519 004** FEB 13, 1996
AB	HALLMARK PHARMS	12.5MG	**N74477 001** FEB 13, 1996
AB		25MG	**N74477 002** FEB 13, 1996
AB		50MG	**N74477 003** FEB 13, 1996
AB		100MG	**N74477 004** FEB 13, 1996
AB	IVAX PHARMS	12.5MG	**N74590 004** AUG 30, 1996
AB		25MG	**N74590 002** AUG 30, 1996
AB		50MG	**N74590 001** AUG 30, 1996
AB		100MG	**N74590 003** AUG 30, 1996
AB	MYLAN	12.5MG	**N74434 001** FEB 13, 1996
AB		25MG	**N74434 002** FEB 13, 1996
AB		50MG	**N74434 003** FEB 13, 1996
AB		100MG	**N74434 004** FEB 13, 1996
AB	PAR PHARM	12.5MG	**N74493 001** FEB 13, 1996
AB		25MG	**N74493 002** FEB 13, 1996
AB		50MG	**N74493 003** FEB 13, 1996
AB		100MG	**N74493 004** FEB 13, 1996
AB	SANDOZ	12.5MG	**N74363 001** NOV 09, 1995
AB		12.5MG	**N74481 001** FEB 13, 1996
AB		25MG	**N74363 002** NOV 09, 1995
AB		25MG	**N74481 002** FEB 13, 1996
AB		50MG	**N74363 003** NOV 09, 1995

FDA data supplied by DrugPatentWatch.com

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	SANDOZ	50MG	**N74481 003**	FEB 13, 1996
AB		100MG	**N74363 004**	NOV 09, 1995
AB		100MG	**N74481 004**	FEB 13, 1996
AB	STASON	12.5MG	**N74677 004**	MAY 30, 1997
AB		25MG	**N74677 002**	MAY 30, 1997
AB		50MG	**N74677 001**	MAY 30, 1997
AB		100MG	**N74677 003**	MAY 30, 1997
AB	TEVA	12.5MG	**N74322 001**	FEB 13, 1996
AB		12.5MG	**N74433 001**	FEB 13, 1996
AB		12.5MG	**N74483 001**	FEB 13, 1996
AB		25MG	**N74322 002**	FEB 13, 1996
AB		25MG	**N74433 002**	FEB 13, 1996
AB		25MG	**N74483 002**	FEB 13, 1996
AB		50MG	**N74322 003**	FEB 13, 1996
AB		50MG	**N74433 003**	FEB 13, 1996
AB		50MG	**N74483 003**	FEB 13, 1996
AB		100MG	**N74322 004**	FEB 13, 1996
AB		100MG	**N74433 004**	FEB 13, 1996
AB		100MG	**N74483 004**	FEB 13, 1996
AB	TORPHARM	12.5MG	**N74737 001**	OCT 28, 1998
AB		25MG	**N74737 002**	OCT 28, 1998
AB		50MG	**N74737 003**	OCT 28, 1998

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	TORPHARM	100MG	**N74737 004**	OCT 28, 1998
AB	WATSON LABS	12.5MG	**N74386 001**	MAY 23, 1996
AB		12.5MG	**N74451 001**	FEB 13, 1996
AB		12.5MG	**N74576 001**	APR 23, 1996
AB		25MG	**N74386 002**	MAY 23, 1996
AB		25MG	**N74451 002**	FEB 13, 1996
AB		25MG	**N74576 002**	APR 23, 1996
AB		50MG	**N74386 003**	MAY 23, 1996
AB		50MG	**N74451 003**	FEB 13, 1996
AB		50MG	**N74576 003**	APR 23, 1996
AB		100MG	**N74386 004**	MAY 23, 1996
AB		100MG	**N74451 004**	FEB 13, 1996
AB		100MG	**N74576 004**	APR 23, 1996
AB	WEST WARD	12.5MG	**N74505 001**	FEB 13, 1996
AB		25MG	**N74505 002**	FEB 13, 1996
AB		50MG	**N74505 003**	FEB 13, 1996
AB		100MG	**N74505 004**	FEB 13, 1996
AB	WOCKHARDT	12.5MG	**N74532 001**	MAR 28, 1997
AB		25MG	**N74532 002**	MAR 28, 1997
AB		50MG	**N74532 003**	MAR 28, 1997
AB		100MG	**N74532 004**	MAR 28, 1997

FDA data supplied by DrugPatentWatch.com

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	CAPOZIDE 25/15			
AB	APOTHECON	25MG;15MG	N18709 001	OCT 12, 1984
	CAPOZIDE 25/25			
AB	+ APOTHECON	25MG;25MG	N18709 002	OCT 12, 1984
	CAPOZIDE 50/15			
AB	+ APOTHECON	50MG;15MG	N18709 004	OCT 12, 1984
	CAPOZIDE 50/25			
AB	APOTHECON	50MG;25MG	N18709 003	OCT 12, 1984
	CAPTOPRIL AND HYDROCHLOROTHIAZIDE			
AB	ENDO LABS	25MG;15MG	N74788 001	DEC 29, 1997
AB		25MG;25MG	N74788 002	DEC 29, 1997
AB		50MG;15MG	N74788 004	DEC 29, 1997
AB		50MG;25MG	N74788 003	DEC 29, 1997
AB	IVAX PHARMS	25MG;15MG	N75055 001	JUN 18, 1998
AB		25MG;25MG	N75055 002	JUN 18, 1998
AB		50MG;15MG	N75055 004	JUN 18, 1998
AB		50MG;25MG	N75055 003	JUN 18, 1998
AB	MYLAN	25MG;15MG	N74896 001	DEC 29, 1997
AB		25MG;25MG	N74896 002	DEC 29, 1997
AB		50MG;15MG	N74896 004	DEC 29, 1997
AB		50MG;25MG	N74896 003	DEC 29, 1997
AB	TEVA	25MG;15MG	N74827 001	DEC 29, 1997
AB		25MG;25MG	N74827 002	DEC 29, 1997
AB		50MG;15MG	N74827 004	DEC 29, 1997
AB		50MG;25MG	N74827 003	DEC 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

	CARBASTAT			
AT	NOVARTIS	0.01%	N73677 001	APR 28, 1995
	MIOSTAT			
AT	+ ALCON	0.01%	N16968 001	

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

	CARBATROL			
	+ SHIRE PHARM	100MG	N20712 003	SEP 30, 1997
	+	200MG	N20712 001	SEP 30, 1997
	+	300MG	N20712 002	SEP 30, 1997

SUSPENSION; ORAL

	CARBAMAZEPINE			
AB	MORTON GROVE	100MG/5ML	N75714 001	JUN 05, 2002
AB	TARO	100MG/5ML	N75875 001	DEC 21, 2000
	TEGRETOL			
AB	+ NOVARTIS	100MG/5ML	N18927 001	DEC 18, 1987

TABLET; ORAL

	CARBAMAZEPINE			
AB	APOTEX	200MG	N75948 001	FEB 27, 2002
AB	INWOOD LABS	200MG	N70231 001	AUG 14, 1986
AB	PLIVA	200MG	N71479 001	JUL 24, 1987
AB	PUREPAC PHARM	200MG	N71696 001	NOV 09, 1987
AB	TARO	200MG	N74649 001	OCT 03, 1996
	EPITOL			
AB	TEVA	200MG	N70541 001	SEP 17, 1986
	TEGRETOL			
AB	+ NOVARTIS	200MG	N16608 001	

FDA data supplied by DrugPatentWatch.com

CARBAMAZEPINE

TABLET; ORAL

	TERIL			
AB	TARO	**200MG**	**N76525 001**	SEP 26, 2003

TABLET, CHEWABLE; ORAL

	CARBAMAZEPINE			
AB	CARACO	**100MG**	**N75712 001**	JUL 05, 2001
AB	TARO PHARM INDS	**100MG**	**N75687 001**	OCT 24, 2000
+		200MG	N75687 002	JUL 29, 2002
AB	WARNER CHILCOTT	**100MG**	**N71940 001**	FEB 01, 1988
	EPITOL			
AB	TEVA	**100MG**	**N73524 001**	JUL 29, 1992
	TEGRETOL			
AB	+ NOVARTIS	**100MG**	**N18281 001**	

TABLET, EXTENDED RELEASE; ORAL

TEGRETOL-XR			
NOVARTIS	100MG	N20234 001	MAR 25, 1996
	200MG	N20234 002	MAR 25, 1996
+	400MG	N20234 003	MAR 25, 1996

CARBENICILLIN INDANYL SODIUM

TABLET; ORAL

GEOCILLIN			
+ PFIZER	EQ 382MG BASE	N50435 001	

CARBIDOPA

TABLET; ORAL

LODOSYN			
+ BRISTOL MYERS SQUIBB	25MG	N17830 001	

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

STALEVO 100			
ORION PHARMA INC	25MG;200MG;100MG	N21485 002	JUN 11, 2003
STALEVO 150			
+ ORION PHARMA INC	37.5MG;200MG;150MG	N21485 003	JUN 11, 2003
STALEVO 50			
ORION PHARMA INC	12.5MG;200MG;50MG	N21485 001	JUN 11, 2003

CARBIDOPA; LEVODOPA

TABLET; ORAL

	CARBIDOPA AND LEVODOPA			
AB	PUREPAC PHARM	**10MG;100MG**	**N74260 001**	SEP 03, 1993
AB		**25MG;100MG**	**N74260 002**	SEP 03, 1993
AB		**25MG;250MG**	**N74260 003**	SEP 03, 1993
AB	SANDOZ	**10MG;100MG**	**N73586 001**	JUN 29, 1995
AB		**25MG;100MG**	**N73587 001**	JUN 29, 1995
AB		**25MG;250MG**	**N73620 001**	JUN 29, 1995
AB	TEVA	**10MG;100MG**	**N73618 001**	AUG 28, 1992
AB		**25MG;100MG**	**N73589 001**	AUG 28, 1992
AB		**25MG;250MG**	**N73607 001**	AUG 28, 1992
	SINEMET			
AB	BRISTOL MYERS SQUIBB	**10MG;100MG**	**N17555 001**	
AB		**25MG;100MG**	**N17555 003**	
AB	+	**25MG;250MG**	**N17555 002**	

TABLET, EXTENDED RELEASE; ORAL

	CARBIDOPA AND LEVODOPA			
AB	MYLAN	**25MG;100MG**	**N75091 002**	APR 21, 2000
AB		**50MG;200MG**	**N75091 001**	SEP 30, 1999
	SINEMET CR			
AB	BRISTOL MYERS SQUIBB	**25MG;100MG**	**N19856 002**	DEC 24, 1992

FDA data supplied by DrugPatentWatch.com

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL
SINEMET CR
AB + BRISTOL MYERS SQUIBB 50MG;200MG N19856 001 MAY 30, 1991

CARBINOXAMINE MALEATE

SOLUTION; ORAL
CARBINOXAMINE MALEATE
+ MIKART 4MG/5ML N40458 001 APR 25, 2003

TABLET; ORAL
CARBINOXAMINE MALEATE
+ MIKART 4MG N40442 001 MAR 19, 2003

CARBOPLATIN

INJECTABLE; INJECTION
PARAPLATIN
+ BRISTOL MYERS SQUIBB 50MG/VIAL N19880 001 MAR 03, 1989
+ 150MG/VIAL N19880 002 MAR 03, 1989
+ 450MG/VIAL N19880 003 MAR 03, 1989

INJECTABLE; IV (INFUSION)
PARAPLATIN
+ BRISTOL MYERS SQUIBB EQ 50MG /5ML(10MG/ML) N20452 001 JUL 14, 2003
+ EQ 150MG /15ML(10MG/ML) N20452 002 JUL 14, 2003
+ EQ 450MG /45ML(10MG/ML) N20452 003 JUL 14, 2003

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION
HEMABATE
+ PHARMACIA AND UPJOHN EQ 0.25MG BASE/ML N17989 001

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL
AA ABLE 350MG N40421 001 JUN 21, 2001
AA AMIDE PHARM 350MG N40188 001 MAR 07, 1997
AA COREPHARMA 350MG N40397 001 SEP 21, 2000
AA MUTUAL PHARM 350MG N89346 001 OCT 17, 1991
AA SANDOZ 350MG N81025 001 APR 13, 1989
AA VINTAGE PHARMS 350MG N40245 001 SEP 08, 1997
AA WATSON LABS 350MG N40152 001 DEC 03, 1996
AA 350MG N86179 001
AA 350MG N87499 001 APR 20, 1982
AA WEST WARD 350MG N40124 001 JAN 24, 1996

SOMA
AA + MEDPOINTE PHARM HLC 350MG N11792 001

CARISOPRODOL; *MULTIPLE*
SEE ASPIRIN; CARISOPRODOL
SEE ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

CARMUSTINE

IMPLANT; INTRACRANIAL
GLIADEL
+ GUILFORD PHARMS 7.7MG N20637 001 SEP 23, 1996

INJECTABLE; INJECTION
BICNU
+ BRISTOL 100MG/VIAL N17422 001

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
CARTEOLOL HCL
AT ALCON 1% N75476 001 JAN 03, 2000

FDA data supplied by DrugPatentWatch.com

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	CARTEOLOL HCL			
AT	BAUSCH AND LOMB	**1%**	**N75546 001**	
			JAN 20, 2000	
AT	NOVEX	**1%**	**N76097 001**	
			FEB 06, 2002	
	OCUPRESS			
AT	+ NOVARTIS	**1%**	**N19972 001**	
			MAY 23, 1990	

TABLET; ORAL

	CARTROL		
	ABBOTT	2.5MG	N19204 001
			DEC 28, 1988
	+	5MG	N19204 002
			DEC 28, 1988

CARVEDILOL

TABLET; ORAL

	COREG		
	GLAXOSMITHKLINE	3.125MG	N20297 004
			MAY 29, 1997
		6.25MG	N20297 003
			SEP 14, 1995
	+	12.5MG	N20297 002
			SEP 14, 1995
		25MG	N20297 001
			SEP 14, 1995

CASPOFUNGIN ACETATE

INJECTABLE; IV (INFUSION)

	CANCIDAS		
	+ MERCK RES	50MG/VIAL	N21227 001
			JAN 26, 2001
	+	70MG/VIAL	N21227 002
			JAN 26, 2001

CEFACLOR

CAPSULE; ORAL

	CECLOR		
AB	LILLY	**EQ 250MG BASE**	**N50521 001**

CEFACLOR

CAPSULE; ORAL

	CECLOR		
AB	+ LILLY	**EQ 500MG BASE**	**N50521 002**
	CEFACLOR		
AB	CEPH INTL	**EQ 250MG BASE**	**N62205 001**
AB		**EQ 500MG BASE**	**N62205 002**
AB	IVAX PHARMS	**EQ 250MG BASE**	**N64061 001**
			APR 27, 1995
AB		**EQ 500MG BASE**	**N64061 002**
			APR 27, 1995
AB	MARSAM PHARMS LLC	**EQ 250MG BASE**	**N64148 001**
			MAY 23, 1996
AB		**EQ 500MG BASE**	**N64148 002**
			MAY 23, 1996
AB	RANBAXY	**EQ 250MG BASE**	**N64156 001**
			AUG 28, 1997
AB		**EQ 500MG BASE**	**N64156 002**
			AUG 28, 1997
AB	TEVA	**EQ 250MG BASE**	**N64145 001**
			JUN 24, 1996
AB		**EQ 500MG BASE**	**N64145 002**
			JUN 24, 1996

FOR SUSPENSION; ORAL

	CECLOR		
AB	LILLY	**EQ 125MG BASE/5ML**	**N50522 001**
AB		**EQ 125MG BASE/5ML**	**N62206 001**
AB		**EQ 187MG BASE/5ML**	**N62206 003**
			APR 20, 1988
AB	+	**EQ 250MG BASE/5ML**	**N50522 002**
AB		**EQ 250MG BASE/5ML**	**N62206 002**
AB	+	**EQ 375MG BASE/5ML**	**N62206 004**
			APR 20, 1988
	CEFACLOR		
AB	IVAX PHARMS	**EQ 375MG BASE/5ML**	**N64070 001**
			APR 28, 1995
AB	MARSAM PHARMS LLC	**EQ 125MG BASE/5ML**	**N64204 001**
			FEB 18, 1998
AB		**EQ 187MG BASE/5ML**	**N64205 001**
			FEB 18, 1998
AB		**EQ 250MG BASE/5ML**	**N64206 001**
			FEB 18, 1998
AB		**EQ 375MG BASE/5ML**	**N64207 001**
			FEB 18, 1998
AB	RANBAXY	**EQ 125MG BASE/5ML**	**N64166 001**
			OCT 02, 1997

FDA data supplied by DrugPatentWatch.com

CEFACLOR

FOR SUSPENSION; ORAL

	CEFACLOR			
AB	RANBAXY	**EQ 187MG BASE/5ML**	**N64165 001**	OCT 02, 1997
AB		**EQ 250MG BASE/5ML**	**N64164 001**	OCT 02, 1997
AB		**EQ 375MG BASE/5ML**	**N64155 001**	OCT 02, 1997

TABLET, CHEWABLE; ORAL

RANICLOR			
RANBAXY	EQ 125MG BASE	N65092 001	DEC 22, 2003
	EQ 187MG BASE	N65092 002	DEC 22, 2003
	EQ 250MG BASE	N65092 003	DEC 22, 2003
+	EQ 375MG BASE	N65092 004	DEC 22, 2003

TABLET, EXTENDED RELEASE; ORAL

	CECLOR CD			
AB	+ LILLY	**EQ 500MG BASE**	**N50673 002**	JUN 28, 1996
	CEFACLOR			
AB	IVAX PHARMS	**EQ 500MG BASE**	**N65057 001**	JAN 05, 2001
AB	TEVA	**EQ 500MG BASE**	**N65058 002**	SEP 04, 2002
		EQ 375MG BASE	N65058 001	SEP 04, 2002

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

	CEFADROXIL			
AB	APOTHECON	**EQ 500MG BASE**	**N62291 001**	
AB	IVAX PHARMS	**EQ 500MG BASE**	**N62766 001**	MAR 03, 1987
AB	RANBAXY	**EQ 500MG BASE**	**N65015 001**	JUN 22, 1999
	DURICEF			
AB	+ WARNER CHILCOTT	**EQ 500MG BASE**	**N50512 001**	

FOR SUSPENSION; ORAL

	CEFADROXIL			
AB	RANBAXY	**EQ 125MG BASE/5ML**	**N65115 001**	MAR 26, 2003

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

	CEFADROXIL			
AB	RANBAXY	**EQ 250MG BASE/5ML**	**N65115 002**	MAR 26, 2003
AB		**EQ 500MG BASE/5ML**	**N65115 003**	MAR 26, 2003
	DURICEF			
AB	+ WARNER CHILCOTT	**EQ 500MG BASE/5ML**	**N50527 001**	
AB		**EQ 125MG BASE/5ML**	**N50527 002**	
AB		**EQ 250MG BASE/5ML**	**N50527 003**	

TABLET; ORAL

	CEFADROXIL			
AB	RANBAXY	**EQ 1GM BASE**	**N65018 001**	APR 23, 1999
	DURICEF			
AB	+ WARNER CHILCOTT	**EQ 1GM BASE**	**N50528 001**	

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

MANDOL			
+ LILLY	EQ 1GM BASE/VIAL	N50504 002	
+	EQ 2GM BASE/VIAL	N50504 003	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	ANCEF			
AP	+ GLAXOSMITHKLINE	**EQ 500MG BASE/VIAL**	**N50461 002**	
AP	+	**EQ 1GM BASE/VIAL**	**N50461 003**	
AP	+	**EQ 5GM BASE/VIAL**	**N50461 004**	
AP	+	**EQ 10GM BASE/VIAL**	**N50461 005**	
	ANCEF IN PLASTIC CONTAINER			
	+ BAXTER HLTHCARE	EQ 10MG BASE/ML	N63002 001	MAR 28, 1991
	+	EQ 20MG BASE/ML	N63002 002	MAR 28, 1991
	CEFAZOLIN AND DEXTROSE			
	+ B BRAUN	EQ 500MG BASE/VIAL	N50779 001	JUL 27, 2000
	+	EQ 1GM BASE/VIAL	N50779 002	JUL 27, 2000
	CEFAZOLIN SODIUM			
AP	AM PHARM PARTNERS	**EQ 500MG BASE/VIAL**	**N64169 001**	AUG 14, 1998

FDA data supplied by DrugPatentWatch.com

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	AM PHARM PARTNERS	EQ 1GM BASE/VIAL	N64169 002	AUG 14, 1998
AP		EQ 10GM BASE/VIAL	N64170 001	MAR 18, 1998
AP		EQ 20GM BASE/VIAL	N64170 002	MAR 18, 1998
AP	APOTHECON	EQ 500MG BASE/VIAL	N62831 001	DEC 09, 1988
AP		EQ 1GM BASE/VIAL	N62831 002	DEC 09, 1988
AP		EQ 10GM BASE/VIAL	N62831 003	SEP 25, 1992
AP	GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N64033 001	OCT 31, 1993
AP	HANFORD GC	EQ 1GM BASE/VIAL	N63207 001	DEC 27, 1991
AP		EQ 1GM BASE/VIAL	N63208 001	DEC 27, 1991
AP		EQ 10GM BASE/VIAL	N63209 001	DEC 27, 1991
AP		EQ 500MG BASE/VIAL	N63214 001	DEC 27, 1991
AP		EQ 500MG BASE/VIAL	N63216 001	DEC 27, 1991
AP	HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	N65047 001	SEP 18, 2001
AP		EQ 1GM BASE/VIAL	N65047 002	SEP 18, 2001
AP	MARSAM PHARMS LLC	EQ 1GM BASE/VIAL	N62988 003	DEC 29, 1989
AP		EQ 5GM BASE/VIAL	N62989 001	DEC 29, 1989
AP		EQ 10GM BASE/VIAL	N62989 002	DEC 29, 1989
AP		EQ 20GM BASE/VIAL	N62989 003	DEC 29, 1989
AP		EQ 250MG BASE/VIAL	N62988 001	DEC 29, 1989
AP		EQ 500MG BASE/VIAL	N62988 002	DEC 29, 1989

KEFZOL

AP	+ LILLY	EQ 250MG BASE/VIAL	N61773 001	
AP		EQ 500MG BASE/VIAL	N61773 002	
AP		EQ 1GM BASE/VIAL	N61773 003	
AP		EQ 10GM BASE/VIAL	N61773 004	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

KEFZOL

AP	+ LILLY	EQ 20GM BASE/VIAL	N61773 005	SEP 08, 1987

CEFDINIR

CAPSULE; ORAL

OMNICEF

	+ ABBOTT	300MG	N50739 001	DEC 04, 1997

FOR SUSPENSION; ORAL

OMNICEF

	+ ABBOTT	125MG/5ML	N50749 001	DEC 04, 1997

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

	+ PURDUE PHARMA LP	200MG	N21222 001	AUG 29, 2001

CEFEPIME HYDROCHLORIDE (ARGININE FORMULATION)

INJECTABLE; INJECTION

MAXIPIME

	+ BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N50679 001	JAN 18, 1996
	+	EQ 1GM BASE/VIAL	N50679 002	JAN 18, 1996
	+	EQ 2GM BASE/VIAL	N50679 003	JAN 18, 1996

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION

CEFOBID

	+ PFIZER	EQ 1GM BASE/VIAL	N50551 001	NOV 18, 1982
	+	EQ 2GM BASE/VIAL	N50551 002	NOV 18, 1982

FDA data supplied by DrugPatentWatch.com

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION

	CEFOBID			
	+ PFIZER	EQ 10GM BASE/VIAL	N50551 003	MAR 05, 1990
	CEFOBID IN PLASTIC CONTAINER			
	+ PFIZER	EQ 20MG BASE/ML	N50613 002	JUL 31, 1987
	+	EQ 40MG BASE/ML	N50613 001	JUL 23, 1986

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

	CEFOTAXIME			
AP	AM PHARM PARTNERS	**EQ 500MG BASE/VIAL**	**N64200 001**	MAR 24, 2000
AP		**EQ 1GM BASE/VIAL**	**N64200 002**	MAR 24, 2000
AP		**EQ 2GM BASE/VIAL**	**N64200 003**	MAR 24, 2000
AP		**EQ 10GM BASE/VIAL**	**N64201 001**	MAR 24, 2000
	+	EQ 20GM BASE/VIAL	N64201 002	MAR 24, 2000
AP	HIKMA	**EQ 500MG BASE/VIAL**	**N65072 001**	NOV 20, 2002
AP		**EQ 1GM BASE/VIAL**	**N65072 002**	NOV 20, 2002
AP		**EQ 2GM BASE/VIAL**	**N65072 003**	NOV 20, 2002
AP		**EQ 10GM BASE/VIAL**	**N65071 001**	NOV 20, 2002
	CEFOTAXIME SODIUM			
AP	LUPIN	**EQ 500MG BASE/VIAL**	**N65124 001**	SEP 24, 2003
AP		**EQ 1GM BASE/VIAL**	**N65124 002**	SEP 24, 2003
AP		**EQ 2GM BASE/VIAL**	**N65124 003**	SEP 24, 2003
	CLAFORAN			
AP	+ AVENTIS PHARMS	**EQ 500MG BASE/VIAL**	**N50547 001**	
AP	+	**EQ 1GM BASE/VIAL**	**N50547 002**	
AP		**EQ 1GM BASE/VIAL**	**N62659 001**	JAN 13, 1987
AP	+	**EQ 2GM BASE/VIAL**	**N50547 003**	

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

	CLAFORAN			
AP	AVENTIS PHARMS	**EQ 2GM BASE/VIAL**	**N62659 002**	JAN 13, 1987
AP	+	**EQ 10GM BASE/VIAL**	**N50547 004**	DEC 29, 1983
	CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER			
	+ AVENTIS PHARMS	EQ 20MG BASE/ML	N50596 002	MAY 20, 1985
	+	EQ 40MG BASE/ML	N50596 004	MAY 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN			
+ ASTRAZENECA	EQ 1GM BASE/VIAL	N50588 001	DEC 27, 1985
	EQ 1GM BASE/VIAL	N63293 001	APR 29, 1993
+	EQ 2GM BASE/VIAL	N50588 002	DEC 27, 1985
	EQ 2GM BASE/VIAL	N63293 002	APR 29, 1993
+	EQ 10GM BASE/VIAL	N50588 003	APR 25, 1988
CEFOTAN IN PLASTIC CONTAINER			
+ ASTRAZENECA	EQ 20MG BASE/ML	N50694 002	JUL 30, 1993
+	EQ 40MG BASE/ML	N50694 001	JUL 30, 1993

CEFOXITIN SODIUM

INJECTABLE; INJECTION

	CEFOXITIN			
AP	AM PHARM PARTNERS	**EQ 1GM BASE/VIAL**	**N65012 001**	JUL 03, 2000
AP		**EQ 2GM BASE/2VIAL**	**N65012 002**	JUL 03, 2000
AP		**EQ 10GM BASE/VIAL**	**N65011 001**	JUL 03, 2000
AP	BAXTER HLTHCARE	**EQ 10GM BASE/VIAL**	**N65050 001**	SEP 11, 2000

FDA data supplied by DrugPatentWatch.com

CEFOXITIN SODIUM

INJECTABLE; INJECTION

	CEFOXITIN			
AP	ESI LEDERLE	**EQ 1GM BASE/VIAL**	**N65051 001**	SEP 11, 2000
AP		**EQ 2GM BASE/VIAL**	**N65051 002**	SEP 11, 2000
	MEFOXIN			
AP	+ MERCK	**EQ 1GM BASE/VIAL**	**N50517 001**	
AP		**EQ 1GM BASE/VIAL**	**N62757 001**	JAN 08, 1987
AP	+	**EQ 2GM BASE/VIAL**	**N50517 002**	
AP		**EQ 2GM BASE/VIAL**	**N62757 002**	JAN 08, 1987
AP	+	**EQ 10GM BASE/VIAL**	**N50517 003**	
	MEFOXIN IN PLASTIC CONTAINER			
	+ MERCK	EQ 20MG BASE/ML	N63182 001	JAN 25, 1993
	+	EQ 40MG BASE/ML	N63182 002	JAN 25, 1993

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

	CEFPODOXIME PROXETIL			
AB	RANBAXY	**EQ 50MG BASE/5ML**	**N65082 001**	MAY 31, 2002
AB		**EQ 100MG BASE/5ML**	**N65082 002**	MAY 31, 2002
	VANTIN			
AB	PHARMACIA AND UPJOHN	**EQ 50MG BASE/5ML**	**N50675 001**	AUG 07, 1992
AB	+	**EQ 100MG BASE/5ML**	**N50675 002**	AUG 07, 1992

TABLET; ORAL

	CEFPODOXIME PROXETIL			
AB	RANBAXY	**EQ 100MG BASE**	**N65083 001**	AUG 20, 2003
AB		**EQ 200MG BASE**	**N65083 002**	AUG 20, 2003
	VANTIN			
AB	PHARMACIA AND UPJOHN	**EQ 100MG BASE**	**N50674 001**	AUG 07, 1992
AB	+	**EQ 200MG BASE**	**N50674 002**	AUG 07, 1992

CEFPROZIL

FOR SUSPENSION; ORAL

	CEFZIL			
	BRISTOL MYERS SQUIBB	125MG/5ML	N50665 001	DEC 23, 1991
	+	250MG/5ML	N50665 002	DEC 23, 1991

TABLET; ORAL

	CEFZIL			
	BRISTOL MYERS SQUIBB	250MG	N50664 001	DEC 23, 1991
	+	500MG	N50664 002	DEC 23, 1991

CEFTAZIDIME

INJECTABLE; INJECTION

	FORTAZ			
AP	+ GLAXOSMITHKLINE	**500MG/VIAL**	**N50578 001**	JUL 19, 1985
AP	+	**1GM/VIAL**	**N50578 002**	JUL 19, 1985
AP	+	**2GM/VIAL**	**N50578 003**	JUL 19, 1985
AP	+	**6GM/VIAL**	**N50578 004**	JUL 19, 1985
	TAZICEF			
AP	ABBOTT	**500MG/VIAL**	**N62662 001**	MAR 06, 1986
AP		**1GM/VIAL**	**N62662 002**	MAR 06, 1986
AP		**1GM/VIAL**	**N64032 001**	OCT 31, 1993
AP		**2GM/VIAL**	**N62662 003**	MAR 06, 1986
AP		**2GM/VIAL**	**N64032 002**	OCT 31, 1993
AP		**6GM/VIAL**	**N62662 004**	MAR 06, 1986
	TAZIDIME			
AP	LILLY	**500MG/VIAL**	**N62640 001**	NOV 20, 1985
AP		**1GM/VIAL**	**N62640 002**	NOV 20, 1985
AP		**1GM/VIAL**	**N62655 001**	NOV 20, 1985

FDA data supplied by DrugPatentWatch.com

CEFTAZIDIME

INJECTABLE; INJECTION

	TAZIDIME			
AP	LILLY	**2GM/VIAL**	**N62640 003**	NOV 20, 1985
AP		**2GM/VIAL**	**N62655 002**	NOV 20, 1985

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION

	CEPTAZ			
	+ GLAXOSMITHKLINE	1GM/VIAL	N50646 002	SEP 27, 1990
	+	2GM/VIAL	N50646 003	SEP 27, 1990
	+	10GM/VIAL	N50646 004	SEP 27, 1990

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

	CEFTAZIDIME SODIUM IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	**EQ 20MG BASE/ML**	**N63221 002**	APR 29, 1993
AP		**EQ 40MG BASE/ML**	**N63221 003**	APR 29, 1993
	+	EQ 10MG BASE/ML	N63221 001	APR 29, 1993
	FORTAZ IN PLASTIC CONTAINER			
AP	+ GLAXOSMITHKLINE	**EQ 20MG BASE/ML**	**N50634 002**	APR 28, 1989
AP	+	**EQ 40MG BASE/ML**	**N50634 003**	APR 28, 1989

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

	CEDAX			
	+ BIOVAIL	EQ 400MG BASE	N50685 002	DEC 20, 1995

FOR SUSPENSION; ORAL

	CEDAX			
	BIOVAIL	EQ 90MG BASE/5ML	N50686 001	DEC 20, 1995

CEFTIBUTEN DIHYDRATE

FOR SUSPENSION; ORAL

	CEDAX			
	+ BIOVAIL	EQ 180MG BASE/5ML	N50686 002	DEC 20, 1995

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

	CEFIZOX			
	+ FUJISAWA HLTHCARE	EQ 1GM BASE/VIAL	N50560 002	SEP 15, 1983
		EQ 1GM BASE/VIAL	N63294 002	MAR 31, 1994
	+	EQ 2GM BASE/VIAL	N50560 003	SEP 15, 1983
		EQ 2GM BASE/VIAL	N63294 003	MAR 31, 1994
		EQ 10GM BASE/VIAL	N50560 005	MAR 19, 1993
	CEFIZOX IN PLASTIC CONTAINER			
	+ FUJISAWA HLTHCARE	EQ 20MG BASE/ML	N50589 003	APR 13, 1995
	+	EQ 40MG BASE/ML	N50589 004	APR 13, 1995

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

	CEFTRIAXONE			
AP	LUPIN	**EQ 250MG BASE/VIAL**	**N65125 001**	SEP 30, 2003
AP		**EQ 500MG BASE/VIAL**	**N65125 002**	SEP 30, 2003
AP		**EQ 1GM BASE/VIAL**	**N65125 003**	SEP 30, 2003
AP		**EQ 2GM BASE/VIAL**	**N65125 004**	SEP 30, 2003
	ROCEPHIN			
AP	+ HLR	**EQ 250MG BASE/VIAL**	**N50585 001**	DEC 21, 1984
AP	+	**EQ 500MG BASE/VIAL**	**N50585 002**	DEC 21, 1984
AP	+	**EQ 1GM BASE/VIAL**	**N50585 003**	DEC 21, 1984

FDA data supplied by DrugPatentWatch.com

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

	ROCEPHIN			
AP +	HLR	**EQ 2GM BASE/VIAL**	**N50585 004**	DEC 21, 1984

INJECTABLE; INJECTION

ROCEPHIN			
HLR	EQ 250MG BASE/VIAL	N63239 001	AUG 13, 1993
	EQ 500MG BASE/VIAL	N63239 002	AUG 13, 1993
	EQ 1GM BASE/VIAL	N62654 002	APR 30, 1987
	EQ 1GM BASE/VIAL	N63239 003	AUG 13, 1993
	EQ 2GM BASE/VIAL	N62654 003	APR 30, 1987
+	EQ 10GM BASE/VIAL	N50585 005	DEC 21, 1984
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER			
+ HLR	EQ 20MG BASE/ML	N50624 002	FEB 11, 1987
+	EQ 40MG BASE/ML	N50624 003	FEB 11, 1987

CEFUROXIME AXETIL

TABLET; ORAL

	CEFUROXIME AXETIL			
AB	APOTEX	**EQ 500MG BASE**	**N65069 002**	OCT 02, 2002
AB	BIOCHEMIE US	**EQ 250MG BASE**	**N65126 001**	OCT 28, 2003
AB		**EQ 500MG BASE**	**N65126 002**	OCT 28, 2003
AB	LUPIN	**EQ 250MG BASE**	**N65135 001**	JUL 25, 2003
AB		**EQ 500MG BASE**	**N65135 002**	JUL 25, 2003
AB	RANBAXY	**EQ 125MG BASE**	**N65043 003**	FEB 15, 2002
AB		**EQ 125MG BASE**	**N65118 001**	APR 25, 2003
AB		**EQ 250MG BASE**	**N65043 002**	FEB 15, 2002
AB		**EQ 250MG BASE**	**N65118 002**	APR 25, 2003
AB		**EQ 500MG BASE**	**N65043 001**	FEB 15, 2002
AB		**EQ 500MG BASE**	**N65118 003**	APR 25, 2003

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

CEFTIN			
GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N50672 001	JUN 30, 1994
+	EQ 250MG BASE/5ML	N50672 002	APR 29, 1997

TABLET; ORAL

	CEFTIN			
AB	GLAXOSMITHKLINE	**EQ 125MG BASE**	**N50605 001**	DEC 28, 1987
AB		**EQ 250MG BASE**	**N50605 002**	DEC 28, 1987
AB +		**EQ 500MG BASE**	**N50605 003**	DEC 28, 1987
	CEFUROXIME AXETIL			
AB	APOTEX	**EQ 250MG BASE**	**N65069 001**	OCT 02, 2002

CEFUROXIME SODIUM

INJECTABLE; IM-IV

	CEFUROXIME			
AB	AM PHARM PARTNERS	**EQ 750MG BASE/VIAL**	**N65001 001**	MAY 30, 2001
AB	TEVA	**EQ 750MG BASE/VIAL**	**N64192 002**	APR 16, 1998
	CEFUROXIME SODIUM			
AB	HANFORD GC	**EQ 750MG BASE/VIAL**	**N64125 001**	MAY 30, 1997
AB	MARSAM PHARMS LLC	**EQ 750MG BASE/VIAL**	**N64035 001**	FEB 26, 1993
	KEFUROX			
AB	LILLY	**EQ 750MG BASE/VIAL**	**N62591 001**	JAN 10, 1986
	ZINACEF			
AB +	GLAXOSMITHKLINE	**EQ 750MG BASE/VIAL**	**N50558 002**	OCT 19, 1983

FDA data supplied by DrugPatentWatch.com

CEFUROXIME SODIUM

INJECTABLE; INJECTION

	CEFUROXIME			
AP	AM PHARM PARTNERS	EQ 1.5GM BASE/VIAL	**N65001 002**	MAY 30, 2001
AP	HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	**N65048 001**	JAN 09, 2004
AP		EQ 1.5GM BASE/VIAL	**N65048 002**	JAN 09, 2004
AP	TEVA	EQ 1.5GM BASE/VIAL	**N64192 001**	APR 16, 1998
AP		EQ 7.5GM BASE/VIAL	**N64191 001**	APR 16, 1998
	CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER			
	+ B BRAUN	EQ 15MG BASE/ML	N50780 001	FEB 21, 2001
	+	EQ 30MG BASE/ML	N50780 002	FEB 21, 2001
	CEFUROXIME SODIUM			
AP	AM PHARM PARTNERS	EQ 7.5GM BASE/VIAL	**N65002 001**	SEP 28, 1998
AP	HANFORD GC	EQ 1.5GM BASE/VIAL	**N64125 002**	MAY 30, 1997
AP		EQ 7.5GM BASE/VIAL	**N64124 001**	MAY 30, 1997
AP	MARSAM PHARMS LLC	EQ 1.5GM BASE/VIAL	**N64035 002**	FEB 26, 1993
AP		EQ 7.5GM BASE/VIAL	**N64036 001**	FEB 26, 1993
	KEFUROX			
AP	LILLY	EQ 1.5GM BASE/VIAL	**N62591 002**	JAN 10, 1986
AP		EQ 1.5GM BASE/VIAL	**N62592 002**	JAN 10, 1986
AP		EQ 7.5GM BASE/VIAL	**N62591 003**	DEC 17, 1987
	ZINACEF			
AP	+ GLAXOSMITHKLINE	EQ 1.5GM BASE/VIAL	**N50558 003**	OCT 19, 1983
AP	+	EQ 7.5GM BASE/VIAL	**N50558 004**	OCT 23, 1986
	ZINACEF IN PLASTIC CONTAINER			
	+ GLAXOSMITHKLINE	EQ 15MG BASE/ML	N50643 001	APR 28, 1989
	+	EQ 30MG BASE/ML	N50643 002	APR 28, 1989

CEFUROXIME SODIUM

INJECTABLE; INTRAVENOUS

	KEFUROX			
AP	LILLY	EQ 750MG BASE/VIAL	**N62592 001**	JAN 10, 1986

CELECOXIB

CAPSULE; ORAL

CELEBREX			
GD SEARLE LLC	100MG		N20998 001 DEC 31, 1998
	200MG		N20998 002 DEC 31, 1998
+	400MG		N20998 003 AUG 29, 2002

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL

CALCIBIND			
+ MISSION PHARMA	300GM/BOT		N18757 003 OCT 16, 1984

CEPHALEXIN

CAPSULE; ORAL

	CEPHALEXIN			
AB	APOTHECON	EQ 250MG BASE	**N63063 001**	SEP 29, 1989
AB		EQ 250MG BASE	**N63186 001**	DEC 30, 1994
AB		EQ 500MG BASE	**N63063 002**	SEP 29, 1989
AB		EQ 500MG BASE	**N63186 002**	DEC 30, 1994
AB	BARR	EQ 250MG BASE	**N62773 001**	JUN 26, 1987
AB		EQ 500MG BASE	**N62775 001**	APR 22, 1987
AB	CEPH INTL	EQ 250MG BASE	**N62118 001**	
AB		EQ 500MG BASE	**N62118 002**	
AB	IVAX PHARMS	EQ 250MG BASE	**N61969 001**	
AB		EQ 500MG BASE	**N61969 002**	

FDA data supplied by DrugPatentWatch.com

CEPHALEXIN

CAPSULE; ORAL

	CEPHALEXIN			
AB	LABS ATRAL	EQ 250MG BASE	N62713 001	JUL 15, 1988
AB		EQ 500MG BASE	N62713 002	JUL 15, 1988
AB	MJ PHARMS	EQ 250MG BASE	N62791 001	JUN 11, 1987
AB		EQ 500MG BASE	N62791 002	JUN 11, 1987
AB	RANBAXY	EQ 250MG BASE	N65007 001	SEP 16, 1999
AB		EQ 500MG BASE	N65007 002	SEP 16, 1999
AB	STEVENS J	EQ 250MG BASE	N62870 001	MAR 17, 1988
AB	TEVA	EQ 250MG BASE	N62702 001	FEB 13, 1987
AB		EQ 250MG BASE	N62760 001	APR 24, 1987
AB		EQ 500MG BASE	N62702 002	FEB 13, 1987
AB		EQ 500MG BASE	N62761 001	APR 24, 1987
	KEFLEX			
AB	LILLY	EQ 250MG BASE	N50405 002	
AB	+	EQ 500MG BASE	N50405 003	

FOR SUSPENSION; ORAL

	CEPHALEXIN			
AB	BARR	EQ 250MG BASE/5ML	N62777 001	AUG 06, 1987
AB	CEPH INTL	EQ 125MG BASE/5ML	N62117 002	
AB	+	EQ 250MG BASE/5ML	N62117 003	
	+	EQ 100MG BASE/ML	N62117 001	
AB	RANBAXY	EQ 125MG BASE/5ML	N65081 001	JUL 27, 2001
AB		EQ 250MG BASE/5ML	N65081 002	JUL 27, 2001
AB	TEVA	EQ 125MG BASE/5ML	N62703 001	FEB 13, 1987
AB		EQ 125MG BASE/5ML	N62767 001	JUN 16, 1987
AB		EQ 250MG BASE/5ML	N62703 002	FEB 13, 1987
AB		EQ 250MG BASE/5ML	N62768 001	JUN 16, 1987

CEPHALEXIN

TABLET; ORAL

	CEPHALEXIN			
AB	TEVA	EQ 250MG BASE	N63023 001	JAN 12, 1989
		EQ 500MG BASE	N63024 001	JAN 12, 1989
	KEFLET			
AB	LILLY	EQ 250MG BASE	N50440 003	FEB 26, 1987

TABLET, FOR SUSPENSION; ORAL

PANIXINE DISPERDOSE			
RANBAXY	EQ 125MG BASE	N65100 002	SEP 11, 2003
+	EQ 250MG BASE	N65100 001	SEP 11, 2003

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL

KEFTAB			
+ LILLY	EQ 500MG BASE	N50614 002	OCT 29, 1987

CEPHRADINE

CAPSULE; ORAL

	ANSPOR			
AB	GLAXOSMITHKLINE	250MG	N61859 001	
AB		500MG	N61859 002	
	CEPHRADINE			
AB	TEVA	250MG	N62683 001	JAN 09, 1987
AB		500MG	N62683 002	JAN 09, 1987
	VELOSEF			
AB	APOTHECON	250MG	N61764 001	
AB	+	500MG	N61764 002	

FOR SUSPENSION; ORAL

ANSPOR			
AB	GLAXOSMITHKLINE	125MG/5ML	N61866 001
AB		250MG/5ML	N61866 002
	CEPHRADINE		
AB	TEVA	125MG/5ML	N62693 001 JAN 09, 1987

FDA data supplied by DrugPatentWatch.com

CEPHRADINE

FOR SUSPENSION; ORAL

	CEPHRADINE			
AB	TEVA	**250MG/5ML**	**N62693 002**	
			JAN 09, 1987	
	VELOSEF '125'			
AB	+ APOTHECON	**125MG/5ML**	**N61763 001**	
	VELOSEF '250'			
AB	+ APOTHECON	**250MG/5ML**	**N61763 002**	

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

	ZYRTEC		
	+ PFIZER	5MG/5ML	N20346 001
			SEP 27, 1996

TABLET; ORAL

	ZYRTEC		
	PFIZER	5MG	N19835 001
			DEC 08, 1995
	+	10MG	N19835 002
			DEC 08, 1995

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	ZYRTEC-D 12 HOUR		
	+ PFIZER	5MG;120MG	N21150 001
			AUG 10, 2001

CETRORELIX

INJECTABLE; INJECTION

	CETROTIDE		
	+ SERONO INC	EQ 0.25MG BASE/ML	N21197 001
			AUG 11, 2000
	+	EQ 3MG BASE/ML	N21197 002
			AUG 11, 2000

CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

FOR SUSPENSION; INTRATRACHEAL

	EXOSURF NEONATAL		
	+ GLAXOSMITHKLINE	12MG/VIAL;108MG/VIAL; 8MG/VIAL	N20044 001
			AUG 02, 1990

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

	EVOXAC		
	+ DAIICHI	EQ 30MG BASE	N20989 002
			JAN 11, 2000

CHLORAMBUCIL

TABLET; ORAL

	LEUKERAN		
	+ SMITHKLINE BEECHAM	2MG	N10669 002

CHLORAMPHENICOL

OINTMENT; OPHTHALMIC

	CHLORAMPHENICOL		
AT	+ ALTANA	**1%**	**N60133 001**

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

	CHLORAMPHENICOL SODIUM SUCCINATE		
AP	AM PHARM PARTNERS	**EQ 1GM BASE/VIAL**	**N62365 001**
			AUG 25, 1982
	CHLOROMYCETIN		
AP	+ PARKEDALE	**EQ 1GM BASE/VIAL**	**N50155 001**

CHLORDIAZEPOXIDE; *MULTIPLE*
SEE AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

	CHLORDIAZEPOXIDE HCL		
AB	BARR	**5MG**	**N84768 001**

FDA data supplied by DrugPatentWatch.com

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

	CHLORDIAZEPOXIDE HCL			
AB	BARR	10MG	N83116 001	
AB		25MG	N84769 001	
AB	USL PHARMA	10MG	N84623 001	
AB	WATSON LABS	5MG	N86383 001	
AB		10MG	N86294 001	
AB		25MG	N86382 001	
	LIBRIUM			
AB	VALEANT PHARM INTL	5MG	N85461 001	
AB		10MG	N85472 001	
AB	+	25MG	N85475 001	

INJECTABLE; INJECTION

	LIBRIUM		
	+ VALEANT PHARM INTL	100MG/AMP	N12301 001

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

	CHLORHEXIDINE GLUCONATE		
AT	ALPHARMA	0.12%	N74291 001 DEC 28, 1995
AT	HI TECH PHARMA	0.12%	N74356 001 MAY 07, 1996
AT	NOVEX	0.12%	N75561 001 NOV 14, 2000
AT	TEVA	0.12%	N74522 001 DEC 15, 1995
	PERIDEX		
AT	+ ZILA	0.12%	N19028 001 AUG 13, 1986
	PERIOGARD		
AT	COLGATE	0.12%	N73695 001 JAN 14, 1994

TABLET; DENTAL

	PERIOCHIP		
	+ DEXCEL PHARMA	2.5MG	N20774 001 MAY 15, 1998

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CHLOROPROCAINE HCL		
AP	ABBOTT	2%	N87447 001 APR 16, 1982
AP		3%	N87446 001 APR 16, 1982
AP	BEDFORD	2%	N40273 001 SEP 09, 1998
AP		3%	N40273 002 SEP 09, 1998
	NESACAINE		
	+ ASTRAZENECA	1%	N09435 001
		2%	N09435 002
	NESACAINE-MPF		
AP	+ ASTRAZENECA	2%	N09435 006 MAY 02, 1996
AP	+	3%	N09435 007 MAY 02, 1996

CHLOROQUINE PHOSPHATE

TABLET; ORAL

	ARALEN		
AA	+ SANOFI SYNTHELABO	EQ 300MG BASE	N06002 001
	CHLOROQUINE PHOSPHATE		
AA	IMPAX LABS	EQ 150MG BASE	N80880 001
AA		EQ 300MG BASE	N40516 001 AUG 29, 2003
AA	+ WEST WARD	EQ 150MG BASE	N83082 001
AA		EQ 300MG BASE	N83082 002 SEP 17, 1999

CHLOROTHIAZIDE

SUSPENSION; ORAL

	DIURIL		
	+ MERCK	250MG/5ML	N11870 001

TABLET; ORAL

	CHLOROTHIAZIDE		
AB	MYLAN	250MG	N84388 001
AB		500MG	N84217 001
AB	WEST WARD	250MG	N86028 001 JUL 14, 1982

FDA data supplied by DrugPatentWatch.com

CHLOROTHIAZIDE

TABLET; ORAL

	CHLOROTHIAZIDE			
AB	WEST WARD	**500MG**	**N87736 001**	JUL 14, 1982
	DIURIL			
AB	MERCK	**250MG**	**N11145 004**	
AB	+	**500MG**	**N11145 002**	

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

	DIUPRES-250			
BP	MERCK	250MG;0.125MG	N11635 003	AUG 26, 1987
	DIUPRES-500			
BP	+ MERCK	500MG;0.125MG	N11635 006	AUG 26, 1987

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

	DIURIL		
	+ MERCK	EQ 500MG BASE/VIAL	N11145 005

CHLOROXINE

SHAMPOO; TOPICAL

	CAPITROL		
	+ WESTWOOD SQUIBB	2%	N17594 001

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

	CHLORPHENIRAMINE MALEATE			
AA	MARSHALL PHARMA	**4MG**	**N83286 001**	
AA	TABLICAPS	**4MG**	**N83394 001**	

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

	TUSSIONEX			
	+ CELLTECH PHARMS	EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML	N19111 001	DEC 31, 1987

CHLORPROMAZINE

SUPPOSITORY; RECTAL

	THORAZINE		
	+ GLAXOSMITHKLINE	25MG	N09149 024
	+	100MG	N09149 033

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	THORAZINE		
	+ GLAXOSMITHKLINE	200MG	N11120 019
	+	300MG	N11120 020

CONCENTRATE; ORAL

	CHLORPROMAZINE HCL			
AA	ALPHARMA	**100MG/ML**	**N86863 001**	
AA	PHARM ASSOC	**30MG/ML**	**N40231 001**	DEC 30, 1999
AA		**100MG/ML**	**N40224 001**	JAN 26, 1999
	CHLORPROMAZINE HCL INTENSOL			
AA	ROXANE	**30MG/ML**	**N88157 001**	APR 27, 1983
AA		**100MG/ML**	**N88158 001**	APR 27, 1983
	SONAZINE			
AA	SANDOZ	**30MG/ML**	**N80983 004**	
AA		**100MG/ML**	**N80983 005**	
	THORAZINE			
AA	+ GLAXOSMITHKLINE	**30MG/ML**	**N09149 032**	
AA	+	**100MG/ML**	**N09149 043**	

INJECTABLE; INJECTION

	CHLORPROMAZINE HCL		
AP	BAXTER HLTHCARE	**25MG/ML**	**N83329 001**
	THORAZINE		
AP	+ GLAXOSMITHKLINE	**25MG/ML**	**N09149 011**

FDA data supplied by DrugPatentWatch.com

CHLORPROMAZINE HYDROCHLORIDE

SYRUP; ORAL

	SONAZINE			
AA	SANDOZ	**10MG/5ML**	**N83040 001**	
	THORAZINE			
AA	+ GLAXOSMITHKLINE	**10MG/5ML**	**N09149 022**	

TABLET; ORAL

	CHLORPROMAZINE HCL			
BP	SANDOZ	10MG	N80439 001	
BP		25MG	N80439 002	
BP		50MG	N80439 003	
BP		100MG	N80439 004	
BP		200MG	N80439 005	
BP	USL PHARMA	10MG	N83386 001	
BP		25MG	N84112 001	
BP		50MG	N84113 001	
BP		100MG	N84114 001	
BP		200MG	N84115 001	
	THORAZINE			
BP	+ GLAXOSMITHKLINE	10MG	N09149 002	
BP		25MG	N09149 007	
BP		50MG	N09149 013	
BP	+	100MG	N09149 018	
BP		200MG	N09149 020	

CHLORPROPAMIDE

TABLET; ORAL

	CHLORPROPAMIDE			
AB	MYLAN	**100MG**	**N88548 001**	JUN 01, 1984
AB		**250MG**	**N88549 001**	JUN 01, 1984
AB	PAR PHARM	**100MG**	**N88175 001**	FEB 27, 1984
AB		**250MG**	**N88176 001**	FEB 27, 1984
AB	PLIVA	**100MG**	**N88921 001**	APR 12, 1985
AB		**250MG**	**N88922 001**	APR 12, 1985
AB	SANDOZ	**100MG**	**N88725 001**	AUG 31, 1984
AB		**250MG**	**N88726 001**	AUG 31, 1984

CHLORPROPAMIDE

TABLET; ORAL

	CHLORPROPAMIDE			
AB	WATSON LABS	**100MG**	**N88852 001**	SEP 26, 1984
AB		**250MG**	**N88826 001**	SEP 26, 1984
	DIABINESE			
AB	PFIZER	**100MG**	**N11641 003**	
AB	+	**250MG**	**N11641 006**	

CHLORTHALIDONE

TABLET; ORAL

	CHLORTHALIDONE			
AB	MYLAN	**25MG**	**N87180 001**	
AB	+	**50MG**	**N86831 001**	
AB	PLIVA	**25MG**	**N88902 001**	SEP 19, 1985
AB		**50MG**	**N88903 001**	SEP 19, 1985
	THALITONE			
	+ MONARCH PHARMS	15MG	N19574 001	DEC 20, 1988

CHLORTHALIDONE; *MULTIPLE*
SEE ATENOLOL; CHLORTHALIDONE

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

	CLORPRES			
AB	MYLAN	**15MG;0.1MG**	**N71323 001**	FEB 09, 1987
AB		**15MG;0.2MG**	**N71324 001**	FEB 09, 1987
	+	15MG;0.3MG	N71325 001	FEB 09, 1987

CHLORZOXAZONE

TABLET; ORAL

	CHLORZOXAZONE			
AA	AMIDE PHARM	**250MG**	**N88928 001**	MAY 08, 1987

FDA data supplied by DrugPatentWatch.com

CHLORZOXAZONE

TABLET; ORAL

	CHLORZOXAZONE			
AA	AMIDE PHARM	500MG	N40113 001	SEP 29, 1995
AA	BARR	500MG	N89895 001	MAY 04, 1988
AA	MUTUAL PHARM	500MG	N89970 001	SEP 27, 1990
AA	OHM LABS	250MG	N81298 001	DEC 29, 1993
AA		500MG	N81299 001	DEC 29, 1993
AA	PAR PHARM	250MG	N87981 001	SEP 20, 1983
AA	SANDOZ	250MG	N89852 001	MAY 04, 1988
AA		500MG	N89853 001	MAY 04, 1988
AA	TEVA	500MG	N89859 001	MAY 04, 1988
AA	WATSON LABS	500MG	N40137 001	AUG 09, 1996
AA		500MG	N81040 001	AUG 22, 1989
	PARAFON FORTE DSC			
AA +	ORTHO MCNEIL PHARM	500MG	N11529 002	JUN 15, 1987
	STRIFON FORTE DSC			
AA	FERNDALE LABS	500MG	N81008 001	DEC 23, 1988

CHOLECALCIFEROL; *MULTIPLE*

SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

CHOLESTYRAMINE

POWDER; ORAL

	CHOLESTYRAMINE			
AB	COPLEY PHARM	EQ 4GM RESIN/PACKET	N74554 001	OCT 02, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74554 002	OCT 02, 1996
AB	EON	EQ 4GM RESIN/PACKET	N74557 001	AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74557 002	AUG 15, 1996
AB	IVAX PHARMS	EQ 4GM RESIN/PACKET	N74771 001	JUL 09, 1997
AB		EQ 4GM RESIN/SCOOPFUL	N74771 002	JUL 09, 1997
AB	TEVA	EQ 4GM RESIN/PACKET	N74347 001	MAY 28, 1998
AB		EQ 4GM RESIN/SCOOPFUL	N74347 002	MAY 28, 1998
	CHOLESTYRAMINE LIGHT			
AB	COPLEY PHARM	EQ 4GM RESIN/PACKET	N74555 001	SEP 30, 1998
AB		EQ 4GM RESIN/SCOOPFUL	N74555 002	SEP 30, 1998
AB	EON	EQ 4GM RESIN/PACKET	N74558 001	AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74558 002	AUG 15, 1996
AB	TEVA	EQ 4GM RESIN/PACKET	N74348 001	MAY 28, 1998
AB		EQ 4GM RESIN/SCOOPFUL	N74348 002	MAY 28, 1998
	LOCHOLEST			
AB	EON	EQ 4GM RESIN/PACKET	N74561 001	AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74561 002	AUG 15, 1996
	LOCHOLEST LIGHT			
AB	EON	EQ 4GM RESIN/PACKET	N74562 001	AUG 15, 1996
AB		EQ 4GM RESIN/SCOOPFUL	N74562 002	AUG 15, 1996
	PREVALITE			
AB	UPSHER SMITH	EQ 4GM RESIN/PACKET	N73263 001	FEB 22, 1996
	QUESTRAN			
AB +	BRISTOL MYERS	EQ 4GM RESIN/PACKET	N16640 001	
AB		EQ 4GM RESIN/SCOOPFUL	N16640 003	

FDA data supplied by DrugPatentWatch.com

CHOLESTYRAMINE

POWDER; ORAL
QUESTRAN LIGHT
AB BRISTOL MYERS — EQ 4GM RESIN/PACKET — N19669 001 DEC 05, 1988
AB — EQ 4GM RESIN/SCOOPFUL — N19669 003 DEC 05, 1988

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION
OVIDREL
+ SERONO INC — 0.25MG/VIAL — N21149 001 SEP 20, 2000

INJECTABLE; SUBCUTANEOUS
OVIDREL
+ SERONO INC — EQ 0.25MG /0.5ML0.5MG/ML — N21149 002 OCT 06, 2003

CHROMIC CHLORIDE

INJECTABLE; INJECTION
CHROMIC CHLORIDE IN PLASTIC CONTAINER
+ ABBOTT — EQ 0.004MG CHROMIUM/ML — N18961 001 JUN 26, 1986

CHROMIC PHOSPHATE, P-32

INJECTABLE; INJECTION
PHOSPHOCOL P32
+ MALLINCKRODT — 5mCi/ML — N17084 001

CICLOPIROX

CREAM; TOPICAL
LOPROX
+ MEDICIS — 0.77% — N18748 001 DEC 30, 1982

GEL; TOPICAL
LOPROX
+ MEDICIS — 0.77% — N20519 001 JUL 21, 1997

CICLOPIROX

SHAMPOO; TOPICAL
LOPROX
+ MEDICIS — 1% — N21159 001 FEB 28, 2003

SOLUTION; TOPICAL
PENLAC
+ DERMIK LABS — 8% — N21022 001 DEC 17, 1999

SUSPENSION; TOPICAL
LOPROX
+ MEDICIS — 0.77% — N19824 001 DEC 30, 1988

CIDOFOVIR

INJECTABLE; INJECTION
VISTIDE
+ GILEAD — EQ 75MG BASE/ML — N20638 001 JUN 26, 1996

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION
PRIMAXIN
+ MERCK — EQ 250MG BASE/VIAL; 250MG/VIAL — N50587 001 NOV 26, 1985
EQ 250MG BASE/VIAL; 250MG/VIAL — N62756 001 JAN 08, 1987
+ EQ 500MG BASE/VIAL; 500MG/VIAL — N50587 002 NOV 26, 1985
EQ 500MG BASE/VIAL; 500MG/VIAL — N50630 001 DEC 14, 1990
EQ 500MG BASE/VIAL; 500MG/VIAL — N62756 002 JAN 08, 1987
+ EQ 750MG BASE/VIAL; 750MG/VIAL — N50630 002 DEC 14, 1990

FDA data supplied by DrugPatentWatch.com

CILOSTAZOL

TABLET; ORAL
PLETAL

+	OTSUKA	50MG	N20863 001	JAN 15, 1999
+		100MG	N20863 002	JAN 15, 1999

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	CLONMEL HLTHCARE	300MG	**N74340 001**	JUN 23, 1995
AB		400MG	**N74340 002**	JUN 23, 1995
AB		800MG	**N74339 001**	JUN 23, 1995
AB	ENDO PHARMS	200MG	**N74281 001**	MAY 17, 1994
AB		300MG	**N74281 002**	MAY 17, 1994
AB		400MG	**N74281 003**	MAY 17, 1994
AB		800MG	**N74329 001**	MAY 17, 1994
AB	IVAX PHARMS	200MG	**N74401 001**	MAY 30, 1995
AB		200MG	**N74424 001**	JUL 28, 1995
AB		300MG	**N74401 002**	MAY 30, 1995
AB		300MG	**N74424 002**	JUL 28, 1995
AB		400MG	**N74401 003**	MAY 30, 1995
AB		400MG	**N74424 003**	JUL 28, 1995
AB		800MG	**N74402 001**	MAY 30, 1995
AB		800MG	**N74424 004**	JUL 28, 1995
AB	LEK PHARMS	300MG	**N74250 002**	JUN 29, 1995
AB		400MG	**N74250 003**	JUN 29, 1995

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	LEK PHARMS	800MG	**N74250 004**	JUN 29, 1995
AB	MYLAN	200MG	**N74246 001**	MAY 17, 1994
AB		300MG	**N74246 002**	MAY 17, 1994
AB		400MG	**N74246 003**	MAY 17, 1994
AB		800MG	**N74246 004**	MAY 17, 1994
AB	PLIVA	200MG	**N74568 001**	FEB 27, 1997
AB		300MG	**N74568 002**	FEB 27, 1997
AB		400MG	**N74568 003**	FEB 27, 1997
AB		800MG	**N74566 001**	FEB 27, 1997
AB	SANDOZ	200MG	**N74100 001**	JAN 31, 1995
AB		200MG	**N74506 001**	JAN 24, 1996
AB		300MG	**N74100 002**	JAN 31, 1995
AB		300MG	**N74506 002**	JAN 24, 1996
AB		400MG	**N74100 003**	JAN 31, 1995
AB		400MG	**N74506 003**	JAN 24, 1996
AB		800MG	**N74100 004**	JAN 31, 1995
AB		800MG	**N74506 004**	JAN 24, 1996
AB	TEVA	200MG	**N74151 001**	MAY 17, 1994
AB		200MG	**N74365 001**	FEB 28, 1995
AB		300MG	**N74151 002**	MAY 17, 1994
AB		300MG	**N74365 002**	FEB 28, 1995
AB		400MG	**N74151 003**	MAY 17, 1994

FDA data supplied by DrugPatentWatch.com

CIMETIDINE

TABLET; ORAL

	CIMETIDINE			
AB	TEVA	400MG	N74365 003	FEB 28, 1995
AB		800MG	N74365 004	FEB 28, 1995
AB		800MG	N74463 001	MAY 17, 1994
AB	TORPHARM	200MG	N74890 001	DEC 18, 1998
AB		300MG	N74890 002	DEC 18, 1998
AB		400MG	N74890 003	DEC 18, 1998
AB		800MG	N74890 004	DEC 18, 1998
AB	WATSON LABS	200MG	N74349 001	AUG 30, 1996
AB		300MG	N74349 002	AUG 30, 1996
AB		400MG	N74349 003	AUG 30, 1996
AB		800MG	N74316 001	FEB 28, 1996
	TAGAMET			
AB	GLAXOSMITHKLINE	200MG	N17920 002	
AB		300MG	N17920 003	
AB		400MG	N17920 004	DEC 14, 1983
AB +		800MG	N17920 005	APR 30, 1986

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CIMETIDINE HCL			
AP	ABBOTT	EQ 300MG BASE/2ML	N74296 001	MAR 28, 1997
AP		EQ 300MG BASE/2ML	N74344 001	JAN 31, 1995
AP		EQ 300MG BASE/2ML	N74345 001	JAN 31, 1995
AP		EQ 300MG BASE/2ML	N74412 001	MAR 28, 1997
AP		EQ 300MG BASE/2ML	N74422 001	JAN 31, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CIMETIDINE HCL			
AP	CLONMEL HLTHCARE	EQ 300MG BASE/2ML	N74428 001	APR 25, 1996
AP	ENDO PHARMS	EQ 300MG BASE/2ML	N74005 001	AUG 31, 1994
AP	GENSIA SICOR PHARMS	EQ 300MG BASE/2ML	N74252 001	NOV 26, 1997
AP	LUITPOLD	EQ 300MG BASE/2ML	N74353 001	DEC 20, 1994
	CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	ABBOTT	EQ 6MG BASE/ML	N74269 001	DEC 27, 1994
+		EQ 90MG BASE/100ML	N74468 005	DEC 29, 1994
+		EQ 120MG BASE/100ML	N74468 006	DEC 29, 1994
+		EQ 180MG BASE/100ML	N74468 003	DEC 29, 1994
+		EQ 240MG BASE/100ML	N74468 004	DEC 29, 1994
+		EQ 360MG BASE/100ML	N74468 001	DEC 29, 1994
+		EQ 480MG BASE/100ML	N74468 002	DEC 29, 1994
	TAGAMET			
AP +	GLAXOSMITHKLINE	EQ 300MG BASE/2ML	N17939 002	
	TAGAMET HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP +	GLAXOSMITHKLINE	EQ 6MG BASE/ML	N19434 001	OCT 31, 1985

SOLUTION; ORAL

	CIMETIDINE HCL			
AA +	ALPHARMA	EQ 300MG BASE/5ML	N74176 001	JUN 01, 1994
AA	COPLEY PHARM	EQ 300MG BASE/5ML	N74859 001	JUL 09, 1998
AA	DURAMED PHARMS BARR	EQ 300MG BASE/5ML	N75110 001	JUN 18, 1998
AA	ENDO PHARMS	EQ 300MG BASE/5ML	N74251 001	DEC 22, 1994
AA	HI TECH PHARMA	EQ 300MG BASE/5ML	N74664 001	OCT 28, 1997
AA	MORTON GROVE	EQ 300MG BASE/5ML	N74757 001	OCT 17, 1997
AA	NOVEX	EQ 300MG BASE/5ML	N75560 001	MAR 15, 2000

FDA data supplied by DrugPatentWatch.com

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL
CIMETIDINE HCL

AA	PHARM ASSOC	EQ 300MG BASE/5ML	N74553 001 JAN 27, 1997
AA	ROXANE	EQ 300MG BASE/5ML	N74541 001 AUG 05, 1997
AA	TEVA	EQ 300MG BASE/5ML	N74610 001 SEP 26, 1996

CIPROFLOXACIN

FOR SUSPENSION; ORAL
CIPRO

	BAYER PHARMS	250MG/5ML	N20780 001 SEP 26, 1997
+		500MG/5ML	N20780 002 SEP 26, 1997

INJECTABLE; INJECTION
CIPRO

+	BAYER PHARMS	10MG/ML	N19847 001 DEC 26, 1990

CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

+	BAYER PHARMS	200MG/100ML	N19857 001 DEC 26, 1990

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL
CIPRO XR

+	BAYER PHARMS	425.2MG;EQ 574.9MG BASE	N21473 002 AUG 28, 2003

TABLET, EXTENDED RELEASE; ORAL
CIPRO XR

+	BAYER PHARMS	212.6MG;EQ 287.5MG BASE	N21473 001 DEC 13, 2002

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS; OTIC
CIPRODEX

+	ALCON	0.3%;0.1%	N21537 001 JUL 18, 2003

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC
CILOXAN

+	ALCON	EQ 0.3% BASE	N20369 001 MAR 30, 1998

SOLUTION/DROPS; OPHTHALMIC
CILOXAN

+	ALCON	EQ 0.3% BASE	N19992 001 DEC 31, 1990

TABLET; ORAL
CIPRO

	BAYER PHARMS	EQ 100MG BASE	N19537 001 APR 08, 1996
		EQ 250MG BASE	N19537 002 OCT 22, 1987
		EQ 500MG BASE	N19537 003 OCT 22, 1987
+		EQ 750MG BASE	N19537 004 OCT 22, 1987

CIPROFLOXACIN HYDROCHLORIDE; *MULTIPLE*
SEE CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC
CIPRO HC

+	ALCON	EQ 0.2% BASE;1%	N20805 001 FEB 10, 1998

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION
NIMBEX

+	ABBOTT	EQ 2MG BASE/ML	N20551 001 DEC 15, 1995

NIMBEX PRESERVATIVE FREE

+	ABBOTT	EQ 2MG BASE/ML	N20551 003 DEC 15, 1995
+		EQ 10MG BASE/ML	N20551 002 DEC 15, 1995

FDA data supplied by DrugPatentWatch.com

CISPLATIN

INJECTABLE; INJECTION

	CISPLATIN			
AP	AM PHARM PARTNERS	1MG/ML	N74735 001	JUL 16, 1999
AP	BEDFORD	1MG/ML	N75036 001	NOV 07, 2000
AP		10MG/VIAL	N74713 001	NOV 14, 2000
AP		50MG/VIAL	N74713 002	NOV 14, 2000
AP	GENSIA SICOR PHARMS	1MG/ML	N74814 001	MAY 16, 2000
AP	PHARMACHEMIE	1MG/ML	N74656 001	MAY 16, 2000
	PLATINOL			
AP	+ BRISTOL MYERS	10MG/VIAL	N18057 001	
AP	+	50MG/VIAL	N18057 002	
	PLATINOL-AQ			
AP	+ BRISTOL MYERS	1MG/ML	N18057 004	NOV 08, 1988

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL

	CELEXA			
	+ FOREST LABS	EQ 10MG BASE/5ML	N21046 001	DEC 22, 1999

TABLET; ORAL

	CELEXA			
	FOREST LABS	EQ 10MG BASE	N20822 001	APR 27, 2000
		EQ 20MG BASE	N20822 002	JUL 17, 1998
	+	EQ 40MG BASE	N20822 003	JUL 17, 1998

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION; IRRIGATION

	RENACIDIN			
	UNITED GUARDIAN	6.602GM/100ML;198MG/100ML; 3.177GM/100ML	N19481 001	OCT 02, 1990

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION

	IRRIGATING SOLUTION G IN PLASTIC CONTAINER			
AT	BAXTER HLTHCARE	3.24GM/100ML;380MG/100ML; 430MG/100ML	N18519 001	JUN 22, 1982
	UROLOGIC G IN PLASTIC CONTAINER			
AT	ABBOTT	3.24GM/100ML;380MG/100ML; 430MG/100ML	N18904 001	MAY 27, 1983

CLADRIBINE

INJECTABLE; INJECTION

	CLADRIBINE			
AP	BEDFORD	1MG/ML	N75405 001	FEB 28, 2000
	LEUSTATIN			
AP	+ ORTHO BIOTECH	1MG/ML	N20229 001	FEB 26, 1993

CLARITHROMYCIN

FOR SUSPENSION; ORAL

	BIAXIN			
	ABBOTT	125MG/5ML	N50698 001	DEC 23, 1993
	+	250MG/5ML	N50698 002	DEC 23, 1993

TABLET; ORAL

	BIAXIN			
	+ ABBOTT	250MG	N50662 001	OCT 31, 1991
	+	500MG	N50662 002	OCT 31, 1991

TABLET, EXTENDED RELEASE; ORAL

	BIAXIN XL			
	+ ABBOTT	500MG	N50775 001	MAR 03, 2000

CLARITHROMYCIN; *MULTIPLE*
SEE AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

FDA data supplied by DrugPatentWatch.com

CLAVULANATE POTASSIUM; *MULTIPLE*
SEE AMOXICILLIN; CLAVULANATE POTASSIUM

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION
TIMENTIN
\+ GLAXOSMITHKLINE — EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL — N50590 001 APR 01, 1985
EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL — N62691 001 DEC 19, 1986
\+ EQ 200MG BASE/VIAL; EQ 3GM BASE/VIAL — N50590 002 APR 01, 1985
\+ EQ 1GM BASE/VIAL; EQ 30GM BASE/VIAL — N50590 003 AUG 18, 1987

TIMENTIN IN PLASTIC CONTAINER
\+ GLAXOSMITHKLINE — EQ 100MG BASE/100ML; EQ 3GM BASE/100ML — N50658 001 DEC 15, 1989

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE

AA	ALPHARMA	**EQ 0.5MG BASE/5ML**	**N74075 001** OCT 31, 1993
AA	COPLEY PHARM	**EQ 0.5MG BASE/5ML**	**N73095 001** APR 21, 1992
AA	MORTON GROVE	**EQ 0.5MG BASE/5ML**	**N74863 001** MAR 13, 1998
AA	NOVEX	**EQ 0.5MG BASE/5ML**	**N75703 001** NOV 27, 2000
AA	SILARX	**EQ 0.5MG BASE/5ML**	**N74884 001** DEC 17, 1997
AA +	TEVA	**EQ 0.5MG BASE/5ML**	**N73399 001** JUN 30, 1994

TABLET; ORAL
CLEMASTINE FUMARATE

AB	SANDOZ	**2.68MG**	**N73459 001** OCT 31, 1993
AB	TEVA	**2.68MG**	**N73283 001** JAN 31, 1992

CLEMASTINE FUMARATE

TABLET; ORAL
TAVIST

AB +	NOVARTIS	**2.68MG**	**N17661 001**

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLEOCIN HCL

AB	PHARMACIA AND UPJOHN	**EQ 75MG BASE**	**N50162 001**
AB		**EQ 150MG BASE**	**N50162 002**
AB +		**EQ 300MG BASE**	**N50162 003** APR 14, 1988

CLINDAMYCIN HCL

AB	RANBAXY	**EQ 150MG BASE**	**N65061 001** FEB 02, 2001
AB		**EQ 300MG BASE**	**N65061 002** FEB 02, 2001
AB	TEVA	**EQ 75MG BASE**	**N63027 001** SEP 20, 1989
AB		**EQ 150MG BASE**	**N63029 001** SEP 20, 1989
AB	WATSON LABS	**EQ 150MG BASE**	**N63083 001** JUL 31, 1991
AB		**EQ 300MG BASE**	**N63083 002** MAR 18, 2003

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL
CLEOCIN
PHARMACIA AND UPJOHN — EQ 75MG BASE/5ML — N62644 001 APR 07, 1986

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL
CLEOCIN
\+ PHARMACIA AND UPJOHN — EQ 2% BASE — N50680 002 MAR 02, 1998

GEL; TOPICAL
CLEOCIN T

AB +	PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N50615 001** JAN 07, 1987

FDA data supplied by DrugPatentWatch.com

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

	CLINDAGEL			
BT	GALDERMA LABS LP	EQ 1% BASE	N50782 001	NOV 27, 2000
	CLINDAMYCIN PHOSPHATE			
AB	ALTANA	**EQ 1% BASE**	**N64160 001**	JAN 28, 2000

INJECTABLE; INJECTION

	CLEOCIN PHOSPHATE			
AP	+ PHARMACIA AND UPJOHN	**EQ 150MG BASE/ML**	**N50441 001**	
AP		**EQ 150MG BASE/ML**	**N62803 001**	OCT 16, 1987
	CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ PHARMACIA AND UPJOHN	**EQ 6MG BASE/ML**	**N50639 001**	AUG 30, 1989
AP	+	**EQ 12MG BASE/ML**	**N50639 002**	AUG 30, 1989
AP	+	**EQ 18MG BASE/ML**	**N50639 003**	APR 10, 1991
	CLINDAMYCIN PHOSPHATE			
AP	ABBOTT	**EQ 150MG BASE/ML**	**N62800 001**	JUL 24, 1987
AP		**EQ 150MG BASE/ML**	**N62801 001**	JUL 24, 1987
AP	BAXTER HLTHCARE	**EQ 150MG BASE/ML**	**N62889 001**	APR 25, 1988
	CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%			
AP	+ AM PHARM PARTNERS	**EQ 900MG BASE/100ML**	**N50635 001**	DEC 22, 1989
	CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ BAXTER HLTHCARE	**EQ 6MG BASE/ML**	**N50648 001**	DEC 29, 1989
AP	+	**EQ 900MG BASE/100ML**	**N50648 003**	DEC 29, 1989
AP	+	**EQ 12MG BASE/ML**	**N50648 002**	DEC 29, 1989

LOTION; TOPICAL

	CLEOCIN T			
AB	+ PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N50600 001**	MAY 31, 1989
	CLINDAMYCIN PHOSPHATE			
AB	ALTANA	**EQ 1% BASE**	**N65067 001**	JAN 31, 2002

SOLUTION; TOPICAL

	CLEOCIN T			
AT	+ PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N50537 001**	

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL

	CLINDA-DERM			
AT	PADDOCK	**EQ 1% BASE**	**N63329 001**	SEP 30, 1992
	CLINDAMYCIN PHOSPHATE			
AT	ALPHARMA	**EQ 1% BASE**	**N62811 001**	SEP 01, 1988
AT	CLAY PARK	**EQ 1% BASE**	**N64050 001**	NOV 30, 1995
AT	FOUGERA	**EQ 1% BASE**	**N64159 001**	JUN 05, 1997
AT	MORTON GROVE	**EQ 1% BASE**	**N63304 001**	JUL 15, 1997
AT	STIEFEL	**EQ 1% BASE**	**N64108 001**	SEP 27, 1996

SUPPOSITORY; VAGINAL

	CLEOCIN			
	+ PHARMACIA AND UPJOHN	100MG	N50767 001	AUG 13, 1999

SWAB; TOPICAL

	CLEOCIN			
AT	PHARMACIA AND UPJOHN	**EQ 1% BASE**	**N50537 002**	FEB 22, 1994
	CLINDAMYCIN PHOSPHATE			
AT	CLAY PARK	**EQ 1% BASE**	**N65049 001**	MAY 25, 2000
	CLINDETS			
AT	STIEFEL	**EQ 1% BASE**	**N64136 001**	SEP 30, 1996

CLINDAMYCIN PHOSPHATE; *MULTIPLE*
SEE BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

CLOBETASOL PROPIONATE

AEROSOL; TOPICAL

	OLUX FOAM			
	+ CONNETICS	0.05%	N21142 001	MAY 26, 2000

CREAM; TOPICAL

	CLOBETASOL PROPIONATE			
AB1	ALPHARMA US PHARM	**0.05%**	**N74139 001**	AUG 03, 1994

FDA data supplied by DrugPatentWatch.com

CLOBETASOL PROPIONATE

CREAM; TOPICAL

	CLOBETASOL PROPIONATE			
AB1	COPLEY PHARM	0.05%	**N74087 001** FEB 16, 1994	
AB1	FOUGERA	0.05%	**N74392 001** SEP 30, 1996	
AB1	STIEFEL	0.05%	**N75338 001** FEB 09, 2001	
AB2		0.05%	**N75733 001** AUG 22, 2001	
AB1	TARO	0.05%	**N74249 001** JUL 08, 1996	
	CLOBETASOL PROPIONATE (EMOLLIENT)			
AB2	ALTANA	0.05%	**N75430 001** MAY 26, 1999	
AB2	TARO	0.05%	**N75633 001** MAY 17, 2000	
	CORMAX			
AB1	HEALTHPOINT	0.05%	**N74220 001** MAY 16, 1997	
	EMBELINE E			
AB2	HEALTHPOINT	0.05%	**N75325 001** DEC 24, 1998	
	TEMOVATE			
AB1 +	GLAXOSMITHKLINE	0.05%	**N19322 001** DEC 27, 1985	
	TEMOVATE E			
AB2 +	GLAXOSMITHKLINE	0.05%	**N20340 001** JUN 17, 1994	

GEL; TOPICAL

	CLOBETASOL PROPIONATE			
AB	ALTANA	0.05%	**N75368 001** FEB 15, 2000	
AB	STIEFEL	0.05%	**N75027 001** OCT 31, 1997	
AB	TARO	0.05%	**N75279 001** MAY 28, 1999	
	EMBELINE			
AB	HEALTHPOINT	0.05%	**N76141 001** APR 12, 2002	
	TEMOVATE			
AB +	GLAXOSMITHKLINE	0.05%	**N20337 001** APR 29, 1994	

LOTION; TOPICAL

	CLOBEX		
+	GALDERMA LABS LP	0.05%	N21535 001 JUL 24, 2003

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL

	CLOBETASOL PROPIONATE			
AB	ALPHARMA US PHARM	0.05%	**N74128 001** AUG 03, 1994	
AB	COPLEY PHARM	0.05%	**N74089 001** FEB 16, 1994	
AB	FOUGERA	0.05%	**N74407 001** FEB 23, 1996	
AB	STIEFEL	0.05%	**N75057 001** AUG 12, 1998	
AB	TARO	0.05%	**N74248 001** JUL 12, 1996	
	EMBELINE			
AB	HEALTHPOINT	0.05%	**N74221 001** MAR 31, 1995	
	TEMOVATE			
AB +	GLAXOSMITHKLINE	0.05%	**N19323 001** DEC 27, 1985	

SOLUTION; TOPICAL

	CLOBETASOL PROPIONATE			
AT	ALPHARMA US PHARM	0.05%	**N74331 001** DEC 15, 1995	
AT	ALTANA	0.05%	**N75391 001** FEB 08, 1999	
AT	MORTON GROVE	0.05%	**N75205 001** NOV 13, 1998	
AT	TARO	0.05%	**N75224 001** NOV 16, 1998	
AT		0.05%	**N75363 001** DEC 29, 2000	
	EMBELINE			
AT	DPT	0.05%	**N74222 001** DEC 06, 1995	
	TEMOVATE			
AT +	GLAXOSMITHKLINE	0.05%	**N19966 001** FEB 22, 1990	

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

	CLODERM		
+	HEALTHPOINT	0.1%	N17765 001

FDA data supplied by DrugPatentWatch.com

CLOFAZIMINE

CAPSULE; ORAL

LAMPRENE

	NOVARTIS	50MG	N19500 002 DEC 15, 1986

CLOFIBRATE

CAPSULE; ORAL

CLOFIBRATE

AB	BANNER PHARMACAPS	**500MG**	**N73396 001** MAR 20, 1992
AB	TEVA	**500MG**	**N72600 001** JUL 25, 1991
AB	USL PHARMA	**500MG**	**N70531 001** JUN 16, 1986

CLOMIPHENE CITRATE

TABLET; ORAL

CLOMID

AB	+ AVENTIS PHARMS	50MG	N16131 002

CLOMIPHENE CITRATE

AB	PAR PHARM	50MG	N75528 001 AUG 30, 1999

MILOPHENE

AB	MILEX	50MG	N72196 001 DEC 20, 1988

SEROPHENE

AB	SERONO	50MG	N18361 001 MAR 22, 1982

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

AB	TYCO HLTHCARE	25MG	N19906 001 DEC 29, 1989
AB	+	50MG	N19906 002 DEC 29, 1989
AB		75MG	N19906 003 DEC 29, 1989

CLOMIPRAMINE HCL

AB	MYLAN	25MG	N74947 001 APR 30, 1998

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HCL

AB	MYLAN	50MG	N74947 002 APR 30, 1998
AB		75MG	N74947 003 APR 30, 1998
AB	SANDOZ	25MG	N74364 001 MAR 29, 1996
AB		25MG	N74953 001 JUN 25, 1997
AB		50MG	N74364 002 MAR 29, 1996
AB		50MG	N74953 002 JUN 25, 1997
AB		75MG	N74364 003 MAR 29, 1996
AB		75MG	N74953 003 JUN 25, 1997
AB	TARO	25MG	N74694 001 DEC 31, 1996
AB		50MG	N74694 002 DEC 31, 1996
AB		75MG	N74694 003 DEC 31, 1996
AB	TEVA	25MG	N74849 001 APR 04, 1997
AB		25MG	N74958 001 AUG 26, 1997
AB		50MG	N74849 002 APR 04, 1997
AB		50MG	N74958 002 AUG 26, 1997
AB		75MG	N74849 003 APR 04, 1997
AB		75MG	N74958 003 AUG 26, 1997
AB	WATSON LABS	25MG	N74600 001 NOV 27, 1996
AB		25MG	N74751 001 SEP 30, 1998
AB		50MG	N74600 002 NOV 27, 1996
AB		50MG	N74751 002 SEP 30, 1998
AB		75MG	N74600 003 NOV 27, 1996

FDA data supplied by DrugPatentWatch.com

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

	CLOMIPRAMINE HCL		
AB	WATSON LABS	75MG	N74751 003 SEP 30, 1998

CLONAZEPAM

TABLET; ORAL

	CLONAZEPAM		
AB	ALPHAPHARM	0.5MG	N74940 001 OCT 30, 1997
AB		1MG	N74940 002 OCT 30, 1997
AB		2MG	N74940 003 OCT 30, 1997
AB	CARACO	0.5MG	N75423 001 APR 27, 2001
AB		1MG	N75423 002 APR 27, 2001
AB		2MG	N75423 003 APR 27, 2001
AB	EON	0.5MG	N74979 001 AUG 29, 1997
AB		1MG	N74979 002 AUG 29, 1997
AB		2MG	N74979 003 AUG 29, 1997
AB	MYLAN	0.5MG	N75150 001 OCT 05, 1998
AB		1MG	N75150 002 OCT 05, 1998
AB		2MG	N75150 003 OCT 05, 1998
AB	PUREPAC PHARM	0.5MG	N74869 001 OCT 31, 1996
AB		1MG	N74869 002 OCT 31, 1996
AB		2MG	N74869 003 OCT 31, 1996
AB	SANDOZ	0.5MG	N74925 001 SEP 30, 1997
AB		1MG	N74925 002 SEP 30, 1997
AB		2MG	N74925 003 SEP 30, 1997

CLONAZEPAM

TABLET; ORAL

	CLONAZEPAM		
AB	TEVA	0.5MG	N74569 001 SEP 10, 1996
AB		0.5MG	N74920 001 AUG 04, 1998
AB		1MG	N74569 002 SEP 10, 1996
AB		1MG	N74920 002 AUG 04, 1998
AB		2MG	N74569 003 SEP 10, 1996
AB		2MG	N74920 003 AUG 04, 1998
AB	TORPHARM	0.5MG	N75468 001 OCT 06, 2000
AB		1MG	N75468 002 OCT 06, 2000
AB		2MG	N75468 003 OCT 06, 2000
AB	WATSON LABS	0.5MG	N74964 001 DEC 30, 1997
AB		1MG	N74964 002 DEC 30, 1997
AB		2MG	N74964 003 DEC 30, 1997

	KLONOPIN		
AB	ROCHE	0.5MG	N17533 001
AB	+	1MG	N17533 002
AB		2MG	N17533 003

TABLET, ORALLY DISINTEGRATING; ORAL

	KLONOPIN RAPIDLY DISINTEGRATING	
	ROCHE	0.125MG N20813 001 DEC 23, 1997
		0.25MG N20813 002 DEC 23, 1997
		0.5MG N20813 003 DEC 23, 1997
	+	1MG N20813 004 DEC 23, 1997
		2MG N20813 005 DEC 23, 1997

FDA data supplied by DrugPatentWatch.com

CLONIDINE

FILM, EXTENDED RELEASE; TRANSDERMAL

CATAPRES-TTS-1

BOEHRINGER INGELHEIM 0.1MG/24HR N18891 001 OCT 10, 1984

CATAPRES-TTS-2

BOEHRINGER INGELHEIM 0.2MG/24HR N18891 002 OCT 10, 1984

CATAPRES-TTS-3

\+ BOEHRINGER INGELHEIM 0.3MG/24HR N18891 003 OCT 10, 1984

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURACLON

\+ AAIPHARMA 0.1MG/ML N20615 001 OCT 02, 1996

TABLET; ORAL

CATAPRES

AB	BOEHRINGER INGELHEIM	**0.1MG**	**N17407 001**
AB		**0.2MG**	**N17407 002**
AB	+	**0.3MG**	**N17407 003**

CLONIDINE HCL

AB	CLONMEL HLTHCARE	**0.1MG**	**N71783 001** APR 05, 1988
AB		**0.2MG**	**N71784 001** APR 05, 1988
AB		**0.3MG**	**N71785 001** APR 05, 1988
AB	HALSEY	**0.1MG**	**N70925 001** SEP 04, 1987
AB	MYLAN	**0.1MG**	**N70315 001** JUN 09, 1987
AB		**0.2MG**	**N70316 001** JUN 09, 1987
AB		**0.3MG**	**N70317 001** JUN 09, 1987
AB	PUREPAC PHARM	**0.1MG**	**N70974 001** DEC 16, 1986
AB		**0.2MG**	**N70975 001** DEC 16, 1986
AB		**0.3MG**	**N70976 001** DEC 16, 1986
AB	SANDOZ	**0.1MG**	**N70887 001** AUG 31, 1988

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HCL

AB	SANDOZ	**0.2MG**	**N70886 001** AUG 31, 1988
AB		**0.3MG**	**N71294 001** AUG 31, 1988
AB	WATSON LABS	**0.1MG**	**N70965 001** JUL 08, 1986
AB		**0.2MG**	**N70964 001** JUL 08, 1986
AB		**0.3MG**	**N70963 001** JUL 08, 1986

CLONIDINE HYDROCHLORIDE; *MULTIPLE*

SEE CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

CLOPIDOGREL BISULFATE

TABLET; ORAL

PLAVIX

\+ SANOFI SYNTHELABO EQ 75MG BASE N20839 001 NOV 17, 1997

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

AB	MYLAN	**3.75MG**	**N71509 001** OCT 19, 1987
AB		**7.5MG**	**N71510 001** OCT 19, 1987
AB	+	**15MG**	**N71511 001** OCT 19, 1987
AB	SANDOZ	**3.75MG**	**N72219 001** AUG 26, 1988
AB		**7.5MG**	**N72220 001** AUG 26, 1988
AB		**15MG**	**N72112 001** AUG 26, 1988

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

AB	ABLE	**3.75MG**	**N71780 001** JUN 26, 1987

FDA data supplied by DrugPatentWatch.com

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

	CLORAZEPATE DIPOTASSIUM			
AB	ABLE	7.5MG	N71781 001	
			JUN 26, 1987	
AB		15MG	N71782 001	
			JUN 26, 1987	
AB	MYLAN	3.75MG	N71856 001	
			JUL 17, 1987	
AB		7.5MG	N71857 001	
			JUL 17, 1987	
AB		15MG	N71858 001	
			JUL 17, 1987	
AB	SANDOZ	7.5MG	N72513 001	
			MAY 11, 1990	
AB		15MG	N72514 001	
			MAY 11, 1990	
AB	TARO	3.75MG	N75731 003	
			APR 27, 2000	
AB		7.5MG	N75731 002	
			APR 27, 2000	
AB		15MG	N75731 001	
			APR 27, 2000	
AB	WATSON LABS	3.75MG	N71852 001	
			FEB 09, 1988	
AB		7.5MG	N71853 001	
			FEB 09, 1988	
AB		15MG	N71854 001	
			FEB 09, 1988	
	GEN-XENE			
AB	ALRA	3.75MG	N71787 001	
			APR 26, 1988	
AB		7.5MG	N71788 001	
			APR 26, 1988	
AB		15MG	N71789 001	
			APR 26, 1988	
	TRANXENE			
AB	OVATION PHARMS	3.75MG	N17105 006	
AB		7.5MG	N17105 007	
AB	+	15MG	N17105 008	
	TRANXENE SD			
	OVATION PHARMS	11.25MG	N17105 005	
	+	22.5MG	N17105 004	

CLOTRIMAZOLE

CREAM; TOPICAL

	CLOTRIMAZOLE		
AB	TARO	1%	N72640 001
			AUG 31, 1993
	LOTRIMIN		
AB	+ SCHERING PLOUGH	1%	N17619 001
	MYCELEX		
BT	BAYER PHARMS	1%	N18183 001

LOTION; TOPICAL

LOTRIMIN		
+ SCHERING	1%	N18813 001
		FEB 17, 1984

SOLUTION; TOPICAL

	CLOTRIMAZOLE		
AT	TARO	1%	N74580 001
			JUL 29, 1996
AT	TEVA	1%	N73306 001
			FEB 28, 1995
	LOTRIMIN		
AT	+ SCHERING PLOUGH	1%	N17613 001
	MYCELEX		
AT	+ BAYER PHARMS	1%	N18181 001

TROCHE/LOZENGE; ORAL

MYCELEX		
+ BAYER PHARMS	10MG	N18713 001
		JUN 17, 1983

CLOTRIMAZOLE; *MULTIPLE*
SEE BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CLOXACILLIN SODIUM

CAPSULE; ORAL

	CLOXACILLIN SODIUM		
AB	TEVA	EQ 250MG BASE	N62240 001
AB		EQ 500MG BASE	N62240 002
	CLOXAPEN		
AB	GLAXOSMITHKLINE	EQ 250MG BASE	N61806 001
AB	+	EQ 500MG BASE	N61806 002

FOR SOLUTION; ORAL

CLOXACILLIN SODIUM		
+ TEVA	EQ 125MG BASE/5ML	N62268 001

FDA data supplied by DrugPatentWatch.com

CLOZAPINE

TABLET; ORAL

	CLOZAPINE			
AB	CARACO	25MG	N75713 001	NOV 15, 2002
AB		100MG	N75713 002	NOV 15, 2002
AB	IVAX PHARMS	25MG	N74949 001	NOV 26, 1997
AB	+	100MG	N74949 002	NOV 26, 1997
		12.5MG	N74949 003	JUL 31, 2003
AB	MYLAN	25MG	N75417 001	MAY 27, 1999
AB		100MG	N75417 002	MAY 27, 1999
	CLOZARIL			
AB	NOVARTIS	25MG	N19758 001	SEP 26, 1989
AB		100MG	N19758 002	SEP 26, 1989

COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

N/A; N/A

	RUBRATOPE-57 KIT		
	BRACCO	N/A;N/A;N/A;N/A	N16089 001

CODEINE PHOSPHATE; *MULTIPLE*

SEE ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE
SEE ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
SEE ACETAMINOPHEN; CODEINE PHOSPHATE
SEE ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
SEE ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE
SEE BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PROMETH VC W/ CODEINE			
AA	+ ALPHARMA	10MG/5ML;5MG/5ML; 6.25MG/5ML	N88764 001	OCT 31, 1984

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PROMETHAZINE VC W/ CODEINE			
AA	MORTON GROVE	10MG/5ML;5MG/5ML; 6.25MG/5ML	N88896 001	JAN 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PROMETH W/ CODEINE			
AA	+ ALPHARMA	10MG/5ML;6.25MG/5ML	N88763 001	OCT 31, 1984
	PROMETHAZINE HCL AND CODEINE PHOSPHATE			
AA	HI TECH PHARMA	10MG/5ML;6.25MG/5ML	N40151 001	AUG 26, 1997
AA	PHARM ASSOC	10MG/5ML;6.25MG/5ML	N89647 001	DEC 22, 1988
	PROMETHAZINE W/ CODEINE			
AA	MORTON GROVE	10MG/5ML;6.25MG/5ML	N88875 001	DEC 17, 1984

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

	TRIACIN-C			
AA	ALPHARMA	10MG/5ML;30MG/5ML; 1.25MG/5ML	N88704 001	MAR 22, 1985
	TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE			
AA	+ MORTON GROVE	10MG/5ML;30MG/5ML; 1.25MG/5ML	N88833 001	NOV 16, 1984

COLCHICINE; PROBENECID

TABLET; ORAL

	COL-PROBENECID		
BP	+ WATSON LABS	0.5MG;500MG	N84279 001
	PROBENECID AND COLCHICINE		
BP	IVAX PHARMS	0.5MG;500MG	N83734 001

FDA data supplied by DrugPatentWatch.com

COLESEVELAM HYDROCHLORIDE

TABLET; ORAL
WELCHOL
+ SANKYO 625MG N21176 001 MAY 26, 2000

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL
COLESTID
PHARMACIA AND UPJOHN 5GM/SCOOPFUL N17563 003 SEP 22, 1995
+ 5GM/PACKET N17563 004 SEP 22, 1995

FLAVORED COLESTID
+ PHARMACIA AND UPJOHN 5GM/PACKET N17563 001
5GM/SCOOPFUL N17563 002

TABLET; ORAL
COLESTID
+ PHARMACIA AND UPJOHN 1GM N20222 001 JUL 19, 1994

COLFOSCERIL PALMITATE; *MULTIPLE*
SEE CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION
COLISTIMETHATE
AP PHARMA TEK **EQ 150MG BASE/VIAL** **N64216 001** FEB 26, 1999

COLY-MYCIN M
AP + PARKEDALE **EQ 150MG BASE/VIAL** **N50108 002**

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC
COLY-MYCIN S
+ PARKEDALE EQ 3MG BASE/ML;10MG/ML; EQ 3.3MG BASE/ML;0.5MG/ML N50356 001

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE
COPPER T MODEL TCU 380A
+ FEI 309MG/COPPER N18680 001 NOV 15, 1984

CORTICORELIN OVINE TRIFLUTATE

INJECTABLE; INJECTION
ACTHREL
+ FERRING EQ 0.1MG BASE/VIAL N20162 001 MAY 23, 1996

CORTICOTROPIN

INJECTABLE; INJECTION
H.P. ACTHAR GEL
+ QUESTCOR PHARMS 80 UNITS/ML N08372 008

CORTISONE ACETATE

TABLET; ORAL
CORTISONE ACETATE
BP + PHARMACIA AND UPJOHN 25MG N08126 001
5MG N08126 003
10MG N08126 004
BP WEST WARD 25MG N80776 002

COSYNTROPIN

INJECTABLE; INJECTION
CORTROSYN
+ AMPHASTAR 0.25MG/VIAL N16750 001

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION
INTAL
+ AVENTIS 0.8MG/INH N18887 001 DEC 05, 1985

SOLUTION; INHALATION
CROMOLYN SODIUM
AN ALPHARMA **10MG/ML** **N75067 001** JUL 19, 1999

FDA data supplied by DrugPatentWatch.com

CROMOLYN SODIUM

SOLUTION; INHALATION

	CROMOLYN SODIUM			
AN	BAUSCH AND LOMB	**10MG/ML**	**N75585 001**	DEC 21, 2000
AN	DEY	**10MG/ML**	**N74209 001**	APR 26, 1994
AN	IVAX PHARMS	**10MG/ML**	**N75271 001**	JAN 18, 2000
AN	MORTON GROVE	**10MG/ML**	**N75346 001**	OCT 25, 1999
AN	NOVEX	**10MG/ML**	**N75333 001**	APR 30, 2002
AN	ROXANE	**10MG/ML**	**N75175 001**	SEP 30, 1999
AN	WARRICK PHARMS	**10MG/ML**	**N75437 001**	APR 21, 2000
	INTAL			
AN +	AVENTIS PHARMS	**10MG/ML**	**N18596 001**	MAY 28, 1982

SOLUTION, CONCENTRATE; ORAL

	GASTROCROM			
+	CELLTECH PHARMS	100MG/5ML	N20479 001	FEB 29, 1996

SOLUTION/DROPS; OPHTHALMIC

	CROLOM			
AT	BAUSCH AND LOMB	**4%**	**N74443 001**	JAN 30, 1995
	CROMOLYN SODIUM			
AT	AKORN	**4%**	**N74706 001**	APR 29, 1998
AT	ALCON	**4%**	**N75282 001**	JUN 16, 1999
AT	NOVEX	**4%**	**N75615 001**	JAN 26, 2001
	OPTICROM			
AT +	ALLERGAN	**4%**	**N18155 001**	OCT 03, 1984

CROTAMITON

CREAM; TOPICAL

	EURAX			
+	WESTWOOD SQUIBB	10%	N06927 001	

CROTAMITON

LOTION; TOPICAL

	CROTAN			
AT	SUMMERS	**10%**	**N87204 001**	
	EURAX			
AT +	WESTWOOD SQUIBB	**10%**	**N09112 003**	

CUPRIC CHLORIDE

INJECTABLE; INJECTION

	CUPRIC CHLORIDE IN PLASTIC CONTAINER			
+	ABBOTT	EQ 0.4MG COPPER/ML	N18960 001	JUN 26, 1986

CYANOCOBALAMIN

GEL, METERED; NASAL

	NASCOBAL			
+	QUESTCOR PHARMS	0.5MG/INH	N19722 001	NOV 05, 1996

INJECTABLE; INJECTION

	CYANOCOBALAMIN			
AP	AM PHARM PARTNERS	**0.1MG/ML**	**N80557 002**	
AP	LUITPOLD	**1MG/ML**	**N80737 001**	
AP	PHARMAFORCE	**1MG/ML**	**N40451 001**	SEP 23, 2003
AP	STERIS	**0.1MG/ML**	**N80573 002**	
AP		**1MG/ML**	**N80573 001**	
	RUBRAMIN PC			
AP +	BRISTOL MYERS SQUIBB	**1MG/ML**	**N06799 010**	APR 28, 1988
	VIBISONE			
AP	AM PHARM PARTNERS	**1MG/ML**	**N80557 003**	

CYANOCOBALAMIN; *MULTIPLE*

SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

FDA data supplied by DrugPatentWatch.com

CYANOCOBALAMIN; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

CYANOCOBALAMIN, CO-57

CAPSULE; ORAL

RUBRATOPE-57			
BRACCO		0.5-1 uCi	N16089 002

CYANOCOBALAMIN, CO-57; *MULTIPLE*
SEE COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HCL				
AB	HALSEY		10MG	N73541 001 MAY 23, 1995
AB	MYLAN		10MG	N73144 001 MAY 30, 1991
AB	PLIVA		10MG	N74421 001 SEP 29, 1995
AB	SANDOZ		10MG	N72854 001 NOV 19, 1991
AB			10MG	N73683 001 FEB 26, 1993
AB	WATSON LABS		10MG	N71611 001 MAY 03, 1989
AB			10MG	N73143 001 NOV 27, 1991
AB			10MG	N74436 001 NOV 30, 1994
FLEXERIL				
AB	+	MCNEIL CONS SPECLT	10MG	N17821 002
			5MG	N17821 001

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE				
AT		AKORN	1%	N40164 001 JAN 13, 1997
AT			2%	N40165 001 JAN 13, 1997
CYCLOGYL				
AT	+	ALCON	0.5%	N84109 001
AT	+		1%	N84110 001
AT	+		2%	N84108 001
CYCLOPENTOLATE HCL				
AT		ALCON UNIVERSAL	1%	N89162 001 JAN 24, 1991
PENTOLAIR				
AT		BAUSCH AND LOMB	1%	N40075 001 APR 29, 1994

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOMYDRIL				
	+	ALCON	0.2%;1%	N84300 001

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE				
AP		BAXTER HLTHCARE	1GM/VIAL	N88374 001 SEP 24, 1986
AP			100MG/VIAL	N88371 001 JUL 03, 1986
AP			200MG/VIAL	N88372 001 JUL 03, 1986
AP			500MG/VIAL	N88373 001 JUL 03, 1986
LYOPHILIZED CYTOXAN				
AP	+	BRISTOL MYERS SQUIBB	100MG/VIAL	N12142 006 DEC 05, 1985
AP	+		200MG/VIAL	N12142 007 DEC 10, 1985
AP	+		500MG/VIAL	N12142 008 JAN 04, 1984
AP	+		1GM/VIAL	N12142 010 SEP 24, 1985

FDA data supplied by DrugPatentWatch.com

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

	LYOPHILIZED CYTOXAN			
AP	+ BRISTOL MYERS SQUIBB	2GM/VIAL	N12142 009	DEC 10, 1984
	NEOSAR			
AP	GENSIA SICOR PHARMS	100MG/VIAL	N87442 001	FEB 16, 1982
AP		200MG/VIAL	N87442 002	FEB 16, 1982
AP		500MG/VIAL	N87442 003	FEB 16, 1982
AP		1GM/VIAL	N87442 004	JUL 08, 1983
AP		2GM/VIAL	N87442 005	MAR 30, 1989

TABLET; ORAL

	CYCLOPHOSPHAMIDE			
AB	ROXANE	25MG	N40032 001	AUG 17, 1999
AB		50MG	N40032 002	AUG 17, 1999
	CYTOXAN			
AB	BRISTOL MYERS SQUIBB	25MG	N12141 002	
AB	+	50MG	N12141 001	

CYCLOSERINE

CAPSULE; ORAL

	SEROMYCIN			
	+ LILLY	250MG	N60593 001	

CYCLOSPORINE

CAPSULE; ORAL

	CYCLOSPORINE			
AB1	EON	25MG	N65017 002	JAN 13, 2000
AB1		100MG	N65017 001	JAN 13, 2000
AB1	PLIVA	25MG	N65044 002	DEC 20, 2000
AB1		100MG	N65044 001	DEC 20, 2000

CYCLOSPORINE

CAPSULE; ORAL

	CYCLOSPORINE			
AB2	TORPHARM	25MG	N65040 001	MAY 09, 2002
AB2		100MG	N65040 002	MAY 09, 2002
	GENGRAF			
AB1	ABBOTT	25MG	N65003 001	MAY 12, 2000
AB1		100MG	N65003 003	MAY 12, 2000
BX		50MG	N65003 002	MAY 12, 2000
	NEORAL			
AB1	NOVARTIS	25MG	N50715 001	JUL 14, 1995
AB1	+	100MG	N50715 002	JUL 14, 1995
	SANDIMMUNE			
AB2	NOVARTIS	25MG	N50625 001	MAR 02, 1990
AB2	+	100MG	N50625 002	MAR 02, 1990
BX		50MG	N50625 003	NOV 23, 1992

EMULSION; OPHTHALMIC

	RESTASIS			
	+ ALLERGAN	0.05%	N50790 001	DEC 23, 2002

INJECTABLE; INJECTION

	CYCLOSPORINE			
AP	BEDFORD	50MG/ML	N65004 001	OCT 29, 1999
AP	PHARMAFORCE	50MG/ML	N65151 001	OCT 07, 2003
	SANDIMMUNE			
AP	+ NOVARTIS	50MG/ML	N50573 001	NOV 14, 1983

SOLUTION; ORAL

	CYCLOSPORINE			
AB	ABBOTT	100MG/ML	N65025 001	MAR 03, 2000
AB	PLIVA	100MG/ML	N65054 001	DEC 18, 2001

FDA data supplied by DrugPatentWatch.com

CYCLOSPORINE

SOLUTION; ORAL

		NEORAL			
AB	+	NOVARTIS	100MG/ML	N50716 001	JUL 14, 1995
		SANDIMMUNE			
BX	+	NOVARTIS	100MG/ML	N50574 001	NOV 14, 1983

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

		CYPROHEPTADINE HCL			
AA		ALPHARMA	2MG/5ML	N86833 001	
		PERIACTIN			
AA	+	MERCK	2MG/5ML	N13220 002	

TABLET; ORAL

		CYPROHEPTADINE HCL			
AA		ABC HOLDING	4MG	N88212 001	MAY 26, 1983
AA		COREPHARMA	4MG	N40537 001	SEP 30, 2003
AA	+	IVAX PHARMS	4MG	N87056 001	
AA		PAR PHARM	4MG	N87129 001	
AA		PLIVA	4MG	N88205 001	JUL 26, 1983

CYSTEAMINE BITARTRATE

CAPSULE; ORAL

		CYSTAGON			
		MYLAN	EQ 50MG BASE	N20392 001	AUG 15, 1994
	+		EQ 150MG BASE	N20392 002	AUG 15, 1994

CYTARABINE

INJECTABLE; INJECTION

		CYTARABINE			
AP		BEDFORD	1GM/VIAL	N74245 001	AUG 31, 1994
AP			2GM/VIAL	N74245 002	AUG 31, 1994

CYTARABINE

INJECTABLE; INJECTION

		CYTARABINE			
AP		BEDFORD	100MG/VIAL	N71471 001	AUG 02, 1989
AP			500MG/VIAL	N71472 001	AUG 02, 1989
	+	MAYNE PHARMA USA	20MG/ML	N71868 001	JUN 04, 1990
	+		20MG/ML	N72168 001	AUG 31, 1990
	+		20MG/ML	N72945 001	FEB 28, 1994
	+		100MG/ML	N75383 001	NOV 22, 1999
		CYTOSAR-U			
AP		SICOR PHARMS	100MG/VIAL	N75206 001	DEC 30, 1998
AP	+		500MG/VIAL	N75206 002	DEC 30, 1998
AP	+		1GM/VIAL	N75206 004	DEC 30, 1998
AP	+		2GM/VIAL	N75206 003	DEC 30, 1998

INJECTABLE, LIPOSOMAL; INJECTION

		DEPOCYT			
	+	SKYEPHARMA	10MG/ML	N21041 001	APR 01, 1999

DACARBAZINE

INJECTABLE; INJECTION

		DACARBAZINE			
AP		AM PHARM PARTNERS	100MG/VIAL	N75371 001	AUG 27, 1999
AP			200MG/VIAL	N75371 002	AUG 27, 1999
AP		BEDFORD	200MG/VIAL	N75812 001	JUN 15, 2001
AP			500MG/VIAL	N75812 002	OCT 31, 2002
AP		GENSIA SICOR PHARMS	200MG/VIAL	N75259 002	AUG 27, 1998
AP	+		500MG/VIAL	N75259 001	SEP 22, 2000

FDA data supplied by DrugPatentWatch.com

DACARBAZINE

INJECTABLE; INJECTION

	DACARBAZINE			
AP	MAYNE PHARMA USA	**200MG/VIAL**	**N75940 001**	OCT 18, 2001
	DTIC-DOME			
AP	+ BAYER PHARMS	**100MG/VIAL**	**N17575 001**	
AP	+	**200MG/VIAL**	**N17575 002**	

DACTINOMYCIN

INJECTABLE; INJECTION

	COSMEGEN		
	+ MERCK	0.5MG/VIAL	N50682 001

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

	SYNERCID		
	+ KING PHARMS	350MG/VIAL;150MG/VIAL	N50748 001 SEP 21, 1999

DALTEPARIN SODIUM

INJECTABLE; INJECTION

	FRAGMIN		
	+ PHARMACIA AND UPJOHN	10,000 IU/ML	N20287 004 JAN 30, 1998
	+	2,500 IU/0.2ML	N20287 001 DEC 22, 1994
	+	5,000 IU/0.2ML	N20287 003 MAR 18, 1996

DANAZOL

CAPSULE; ORAL

	DANAZOL			
AB	BARR	**50MG**	**N74582 003**	MAY 29, 1998
AB		**100MG**	**N74582 002**	MAY 29, 1998
AB		**200MG**	**N74582 001**	AUG 09, 1996
	DANOCRINE			
AB	SANOFI SYNTHELABO	**50MG**	**N17557 003**	

DANAZOL

CAPSULE; ORAL

	DANOCRINE			
AB	SANOFI SYNTHELABO	**100MG**	**N17557 004**	
AB	+	**200MG**	**N17557 002**	

DANTROLENE SODIUM

CAPSULE; ORAL

	DANTRIUM		
	PROCTER AND GAMBLE	25MG	N17443 001
		50MG	N17443 003
	+	100MG	N17443 002

INJECTABLE; INJECTION

	DANTRIUM		
	+ PROCTER AND GAMBLE	20MG/VIAL	N18264 001

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	REV-EYES		
	+ ANGELINI	0.5%	N19849 001 DEC 31, 1990

DAPSONE

TABLET; ORAL

	DAPSONE		
	JACOBUS	25MG	N86841 001
	+	100MG	N86842 001

DAPTOMYCIN

INJECTABLE; IV (INFUSION)

	CUBICIN		
	CUBIST	250MG/VIAL	N21572 001 SEP 12, 2003
	+	500MG/VIAL	N21572 002 SEP 12, 2003

FDA data supplied by DrugPatentWatch.com

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION

	DAUNOXOME			
+	GILEAD	EQ 2MG BASE/ML	N50704 002	APR 08, 1996

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

	CERUBIDINE			
AP	+ BEDFORD	**EQ 20MG BASE/VIAL**	**N64103 001**	FEB 03, 1995
	DAUNORUBICIN HCL			
AP	+ BEDFORD	**EQ 5MG BASE/ML**	**N50731 001**	JAN 30, 1998
AP	BIGMAR	**EQ 20MG BASE/VIAL**	**N65000 001**	MAY 25, 1999
AP	GENSIA SICOR PHARMS	**EQ 5MG BASE/ML**	**N65035 001**	JAN 24, 2000
AP		**EQ 20MG BASE/VIAL**	**N64212 001**	JUN 23, 1998
	+	EQ 50MG BASE/VIAL	N64212 002	MAY 03, 1999
AP	SUPERGEN	**EQ 5MG BASE/VIAL**	**N65034 001**	NOV 20, 2001

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

	DESFERAL			
+	NOVARTIS	500MG/VIAL	N16267 001	
+		2GM/VIAL	N16267 002	MAY 25, 2000

DELAVIRDINE MESYLATE

TABLET; ORAL

	RESCRIPTOR			
	AGOURON	100MG	N20705 001	APR 04, 1997
+		200MG	N20705 002	JUL 14, 1999

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

	DECLOMYCIN			
	ESP PHARMA	150MG	N50261 002	
+		300MG	N50261 003	

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL

	ENDURONYL		
	ABBOTT	0.25MG;5MG	N12775 001
	ENDURONYL FORTE		
+	ABBOTT	0.5MG;5MG	N12775 002

DESFLURANE

LIQUID; INHALATION

	SUPRANE		
	BAXTER HLTHCARE CORP	99.9%	N20118 001 SEP 18, 1992

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

	DESIPRAMINE HCL			
AB	EON	**10MG**	**N74430 001**	FEB 09, 1996
AB		**25MG**	**N71601 001**	JUN 05, 1987
AB		**50MG**	**N71588 001**	JUN 05, 1987
AB		**75MG**	**N71602 001**	OCT 05, 1987
AB		**100MG**	**N71766 001**	OCT 05, 1987
AB		**150MG**	**N74430 002**	FEB 09, 1996
AB	PLIVA	**25MG**	**N71800 001**	DEC 08, 1987
AB		**50MG**	**N71801 001**	DEC 08, 1987
AB		**75MG**	**N71802 001**	DEC 08, 1987
AB		**100MG**	**N71803 001**	MAY 29, 1997

FDA data supplied by DrugPatentWatch.com

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

		DESIPRAMINE HCL		
AB		PLIVA	**150MG**	**N71804 001** MAY 29, 1997
AB		SANDOZ	**10MG**	**N72099 001** MAY 24, 1988
AB			**25MG**	**N72100 001** MAY 24, 1988
AB			**50MG**	**N72101 001** MAY 24, 1988
AB			**75MG**	**N72102 001** JUN 20, 1988
AB			**100MG**	**N72103 001** JUN 20, 1988
AB			**150MG**	**N72104 001** JUN 20, 1988
		NORPRAMIN		
AB		AVENTIS PHARMS	**10MG**	**N14399 007** FEB 11, 1982
AB			**25MG**	**N14399 001**
AB	+		**50MG**	**N14399 003**
AB			**75MG**	**N14399 004**
AB	+		**100MG**	**N14399 005**
AB			**150MG**	**N14399 006**

DESIRUDIN

INJECTABLE; SUBCUTANEOUS

		IPRIVASK		
	+	AVENTIS PHARMS	15MG/VIAL	N21271 001 APR 04, 2003

DESLORATADINE

TABLET; ORAL

		CLARINEX		
	+	SCHERING PLOUGH	5MG	N21165 001 DEC 21, 2001

TABLET, ORALLY DISINTEGRATING; ORAL

		CLARINEX		
	+	SCHERING	5MG	N21312 001 JUN 26, 2002

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

		DDAVP		
AP	+	AVENTIS	**0.004MG/ML**	**N18938 001** MAR 30, 1984
	+		0.015MG/ML	N18938 002 APR 25, 1995
		DESMOPRESSIN ACETATE		
AP		ABBOTT	**0.004MG/ML**	**N75220 001** AUG 28, 2000
AP		BEDFORD	**0.004MG/ML**	**N74575 001** FEB 18, 2000
AP		GENSIA SICOR PHARMS	**0.004MG/ML**	**N74888 001** OCT 15, 1997
		DESMOPRESSIN ACETATE PRESERVATIVE FREE		
AP		BEDFORD	**0.004MG/ML**	**N74574 001** FEB 18, 2000

SOLUTION; NASAL

		DDAVP		
	+	AVENTIS	0.01%	N17922 001

SPRAY, METERED; NASAL

		DDAVP (NEEDS NO REFRIGERATION)		
AB	+	AVENTIS	**0.01MG/SPRAY**	**N17922 003** AUG 07, 1996
		DESMOPRESSIN ACETATE		
AB	+	BAUSCH AND LOMB	**0.01MG/SPRAY**	**N74830 001** JAN 25, 1999
		MINIRIN		
AB	+	FERRING	**0.01MG/SPRAY**	**N21333 001** SEP 16, 2002
		STIMATE		
	+	AVENTIS BEHRING	0.15MG/SPRAY	N20355 001 MAR 07, 1994

TABLET; ORAL

		DDAVP		
		AVENTIS	0.1MG	N19955 001 SEP 06, 1995
	+		0.2MG	N19955 002 SEP 06, 1995

FDA data supplied by DrugPatentWatch.com

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

	DESOGESTREL AND ETHINYL ESTRADIOL			
AB	DURAMED PHARMS BARR	0.15MG;0.03MG	**N75256 001** AUG 12, 1999	

TABLET; ORAL-28

	CYCLESSA			
+	ORGANON USA INC	0.1MG,0.125MG,0.15MG;0.025MG, 0.025MG,0.025MG	N21090 001 DEC 20, 2000	
	DESOGEN			
AB	ORGANON USA INC	0.15MG;0.03MG	**N20071 002** DEC 10, 1992	
	DESOGESTREL AND ETHINYL ESTRADIOL			
AB	DURAMED PHARMS BARR	0.15MG;0.03MG	**N75256 002** AUG 12, 1999	
	KARIVA			
AB	BARR	0.15MG,N/A;0.02MG,0.01MG	**N75863 001** APR 05, 2002	
	MIRCETTE			
AB +	ORGANON USA INC	0.15MG,N/A;0.02MG,0.01MG	**N20713 001** APR 22, 1998	
	ORTHO-CEPT			
AB +	ORTHO MCNEIL PHARM	0.15MG;0.03MG	**N20301 002** DEC 14, 1992	

DESONIDE

CREAM; TOPICAL

	DESONIDE			
AB	COPLEY PHARM	0.05%	**N74027 001** SEP 28, 1992	
AB	TARO	0.05%	**N73548 001** JUN 30, 1992	
	DESOWEN			
AB	GALDERMA LABS LP	0.05%	**N19048 001** DEC 14, 1984	
	TRIDESILON			
AB +	CLAY PARK	0.05%	**N17010 001**	

LOTION; TOPICAL

	DESONIDE			
AB	ALTANA	0.05%	**N75860 001** MAR 19, 2002	
	DESOWEN			
AB +	GALDERMA LABS LP	0.05%	**N72354 001** JAN 24, 1992	

DESONIDE

OINTMENT; TOPICAL

	DESONIDE			
AB	ALTANA	0.05%	**N75751 001** MAR 12, 2001	
AB	TARO	0.05%	**N74254 001** AUG 03, 1994	
	DESOWEN			
AB	GALDERMA LABS LP	0.05%	**N71425 001** JUN 15, 1988	
	TRIDESILON			
AB +	CLAY PARK	0.05%	**N17426 001**	

DESOXIMETASONE

CREAM; TOPICAL

	DESOXIMETASONE			
AB	CLAY PARK	0.25%	**N76510 001** JUL 01, 2003	
AB	TARO	0.05%	**N73210 001** NOV 30, 1990	
AB		0.25%	**N73193 001** NOV 30, 1990	
	TOPICORT			
AB +	MEDICIS	0.25%	**N17856 001**	
	TOPICORT LP			
AB +	MEDICIS	0.05%	**N18309 001**	

GEL; TOPICAL

	DESOXIMETASONE			
AB	TARO	0.05%	**N74904 001** JUL 14, 1998	
	TOPICORT			
AB +	MEDICIS	0.05%	**N18586 001** MAR 29, 1982	

OINTMENT; TOPICAL

	DESOXIMETASONE			
AB	TARO	0.25%	**N74286 001** JUN 07, 1996	
	TOPICORT			
AB +	MEDICIS	0.25%	**N18763 001** SEP 30, 1983	

FDA data supplied by DrugPatentWatch.com

DEXAMETHASONE

CONCENTRATE; ORAL

	DEXAMETHASONE INTENSOL			
	+ ROXANE	1MG/ML	N88252 001	SEP 01, 1983

ELIXIR; ORAL

	DEXAMETHASONE			
AA	ALPHARMA	**0.5MG/5ML**	**N84754 001**	
	HEXADROL			
AA	+ ORGANON USA INC	**0.5MG/5ML**	**N12674 001**	
	MYMETHASONE			
AA	MORTON GROVE	**0.5MG/5ML**	**N88254 001**	JUL 27, 1983

SOLUTION; ORAL

	DEXAMETHASONE			
	+ ROXANE	0.5MG/5ML	N88248 001	SEP 01, 1983

SUSPENSION/DROPS; OPHTHALMIC

	MAXIDEX			
	+ ALCON	0.1%	N13422 001	

TABLET; ORAL

	DECADRON			
AB	MERCK	**0.5MG**	**N11664 001**	
AB	+	**0.75MG**	**N11664 002**	
AB		**1.5MG**	**N11664 003**	
AB		**4MG**	**N11664 005**	
BP		0.25MG	N11664 004	
BP	+	6MG	N11664 006	JUL 30, 1982
	DEXAMETHASONE			
BP	PAR PHARM	0.25MG	N88149 001	APR 28, 1983
BP		0.5MG	N88148 001	APR 28, 1983
BP		0.75MG	N88160 001	APR 28, 1983
BP		1.5MG	N88237 001	APR 28, 1983
BP		4MG	N88238 001	APR 28, 1983
BP		6MG	N88481 001	NOV 28, 1983
AB	ROXANE	**0.5MG**	**N84611 001**	
AB		**0.75MG**	**N84613 001**	

DEXAMETHASONE

TABLET; ORAL

	DEXAMETHASONE			
AB	ROXANE	**1.5MG**	**N84610 001**	
AB		**4MG**	**N84612 001**	
BP		6MG	N88316 001	SEP 15, 1983
		1MG	N88306 001	SEP 15, 1983
		2MG	N87916 001	AUG 26, 1982
	HEXADROL			
BP	ORGANON USA	4MG	N12675 010	

DEXAMETHASONE; *MULTIPLE*

SEE CIPROFLOXACIN; DEXAMETHASONE

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	MAXITROL		
AT	+ FALCON PHARMS	**0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N50065 002**
	NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE		
AT	BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N64063 001** JUL 25, 1994
AT	FOUGERA	**0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM**	**N62938 001** JUL 31, 1989

SUSPENSION/DROPS; OPHTHALMIC

	DEXACIDIN		
AT	NOVARTIS	**0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N62544 001** OCT 29, 1984
	DEXASPORIN		
AT	BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N64135 001** SEP 13, 1995
	MAXITROL		
AT	ALCON	**0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N62341 001** MAY 22, 1984
AT	+ FALCON PHARMS	**0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N50023 002**

FDA data supplied by DrugPatentWatch.com

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

	NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE			
AT	ALCON UNIVERSAL	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62721 001	NOV 17, 1986

DEXAMETHASONE; TOBRAMYCIN

OINTMENT; OPHTHALMIC

	TOBRADEX			
	+ ALCON	0.1%;0.3%	N50616 001	SEP 28, 1988

SUSPENSION/DROPS; OPHTHALMIC

	TOBRADEX			
AB	+ ALCON	0.1%;0.3%	N50592 001	AUG 18, 1988
	TOBRAMYCIN AND DEXAMETHASONE			
AB	BAUSCH AND LOMB	0.1%;0.3%	N64134 001	OCT 27, 1999

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

	DEXAMETHASONE			
AP	BAXTER HLTHCARE	EQ 4MG PHOSPHATE/ML	N84282 001	
AP	ELKINS SINN	EQ 10MG PHOSPHATE/ML	N87702 001	SEP 07, 1982
	DEXAMETHASONE SODIUM PHOSPHATE			
AP	AM PHARM	EQ 10MG PHOSPHATE/ML	N40491 001	APR 11, 2003
AP	AM PHARM PARTNERS	EQ 4MG PHOSPHATE/ML	N84916 001	
AP	+ GENSIA SICOR PHARMS	EQ 10MG PHOSPHATE/ML	N81126 001	AUG 31, 1990
AP	+ LUITPOLD	EQ 4MG PHOSPHATE/ML	N87440 001	JUL 21, 1982

SOLUTION/DROPS; OPHTHALMIC, OTIC

	DECADRON			
AT	+ MERCK	EQ 0.1% PHOSPHATE	N11984 001	
	DEXAMETHASONE SODIUM PHOSPHATE			
AT	ALCON UNIVERSAL	EQ 0.1% PHOSPHATE	N88771 001	JAN 16, 1985
AT	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	N40069 001	JUL 26, 1996

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

	MYLARAMINE			
	+ MORTON GROVE	2MG/5ML	N88251 001	MAR 23, 1984

TABLET; ORAL

	DEXCHLORPHENIRAMINE MALEATE			
	+ PLIVA	2MG	N88682 001	JAN 17, 1986

DEXMEDETOMIDINE

INJECTABLE; INJECTION

	PRECEDEX			
	+ ABBOTT	EQ 100 UGM BASE/ML	N21038 001	DEC 17, 1999

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

	FOCALIN			
	NOVARTIS	2.5MG	N21278 001	NOV 13, 2001
		5MG	N21278 002	NOV 13, 2001
	+	10MG	N21278 003	NOV 13, 2001

DEXPANTHENOL; *MULTIPLE*

SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FDA data supplied by DrugPatentWatch.com

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

ZINECARD

+	PHARMACIA AND UPJOHN	EQ 250MG BASE/VIAL	N20212 001	MAY 26, 1995
+		EQ 500MG BASE/VIAL	N20212 002	MAY 26, 1995

DEXTROAMPHETAMINE SACCHARATE; *MULTIPLE*
SEE AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

AB	GLAXOSMITHKLINE	5MG	**N17078 001**	
AB		10MG	**N17078 002**	
AB	+	15MG	**N17078 003**	

DEXTROAMPHETAMINE SULFATE

AB	BARR	5MG	**N76137 001**	JAN 18, 2002
AB		10MG	**N76137 002**	JAN 18, 2002
AB		15MG	**N76137 003**	JAN 18, 2002
AB	MALLINCKRODT	5MG	**N76353 001**	MAY 06, 2003
AB		10MG	**N76353 002**	MAY 06, 2003
AB		15MG	**N76353 003**	MAY 06, 2003

TABLET; ORAL

DEXEDRINE

AA	GLAXOSMITHKLINE	5MG	**N84935 001**

DEXTROAMPHETAMINE SULFATE

AA	BARR	5MG	**N40361 001**	JAN 31, 2001
AA		10MG	**N40361 002**	JAN 31, 2001
AA	ENDO PHARMS	5MG	**N40299 001**	MAY 13, 1999
AA	KV PHARM	5MG	**N40365 001**	OCT 31, 2002

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA	KV PHARM	10MG	**N40367 001**	OCT 31, 2002
AA	MALLINCKRODT	5MG	**N40436 001**	JAN 29, 2002
AA		10MG	**N40436 002**	JAN 29, 2002

DEXTROSTAT

AA	+ SHIRE RICHWOOD	5MG	**N84051 001**	
AA	+	10MG	**N84051 002**	

DEXTROAMPHETAMINE SULFATE; *MULTIPLE*
SEE AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

DEXTROMETHORPHAN HYDROBROMIDE; *MULTIPLE*
SEE BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH W/ DEXTROMETHORPHAN

AA	+ ALPHARMA	15MG/5ML;6.25MG/5ML	**N88762 001**	OCT 31, 1984

PROMETHAZINE HCL AND DEXTROMETHORPHAN HYDROBROMIDE

AA	HI TECH PHARMA	15MG/5ML;6.25MG/5ML	**N40027 001**	JUL 31, 1996

PROMETHAZINE W/ DEXTROMETHORPHAN

AA	MORTON GROVE	15MG/5ML;6.25MG/5ML	**N88864 001**	JAN 04, 1985

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

AP	ABBOTT	10GM/100ML	**N18080 001**	
AP	B BRAUN	10GM/100ML	**N18046 001**	
AP		10GM/100ML	**N19626 004**	FEB 02, 1988
AP	BAXTER HLTHCARE	10GM/100ML	**N16694 001**	

DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML	N18358 001

FDA data supplied by DrugPatentWatch.com

DEXTROSE

INJECTABLE; INJECTION

	DEXTROSE 20% IN PLASTIC CONTAINER		
AP	ABBOTT	20GM/100ML	N18564 001 MAR 23, 1982
AP	BAXTER HLTHCARE	20GM/100ML	N17521 004
	DEXTROSE 25%		
	ABBOTT	250MG/ML	N19445 002 NOV 23, 1998
	DEXTROSE 30% IN PLASTIC CONTAINER		
AP	ABBOTT	30GM/100ML	N19345 001 JAN 26, 1985
AP	BAXTER HLTHCARE	30GM/100ML	N17521 003
	DEXTROSE 40% IN PLASTIC CONTAINER		
AP	ABBOTT	40GM/100ML	N18562 001 MAR 23, 1982
AP	BAXTER HLTHCARE	40GM/100ML	N17521 002
	DEXTROSE 5% IN PLASTIC CONTAINER		
AP	ABBOTT	5GM/100ML	N19466 001 JUL 15, 1985
AP		5GM/100ML	N19479 001 SEP 17, 1985
AP		50MG/ML	N16367 002
AP		50MG/ML	N19222 001 JUL 13, 1984
AP	B BRAUN	5GM/100ML	N16730 001
AP		50MG/ML	N16730 002
AP		5GM/100ML	N19626 002 FEB 02, 1988
AP	BAXTER HLTHCARE	5GM/100ML	N16673 001
AP		50MG/ML	N16673 003 OCT 30, 1985
AP		5GM/100ML	N20179 001 DEC 07, 1992
AP		50MG/ML	N20179 002 DEC 07, 1992
AP	DHL	5GM/100ML	N19971 001 SEP 28, 1995
	DEXTROSE 50% IN PLASTIC CONTAINER		
AP	ABBOTT	50GM/100ML	N18563 001 MAR 23, 1982
AP		50GM/100ML	N19894 001 DEC 26, 1989
AP	BAXTER HLTHCARE	50GM/100ML	N17521 001
AP		50GM/100ML	N20047 001 JUL 02, 1991
	DEXTROSE 60% IN PLASTIC CONTAINER		
AP	ABBOTT	60GM/100ML	N19346 001 JAN 25, 1985

DEXTROSE

INJECTABLE; INJECTION

	DEXTROSE 60% IN PLASTIC CONTAINER		
AP	BAXTER HLTHCARE	60GM/100ML	N17521 005 MAR 26, 1982
	DEXTROSE 70% IN PLASTIC CONTAINER		
AP	ABBOTT	70GM/100ML	N18561 001 MAR 23, 1982
AP		70GM/100ML	N19893 001 DEC 26, 1989
AP	BAXTER HLTHCARE	70GM/100ML	N17521 006 MAR 26, 1982
AP		70GM/100ML	N20047 003 JUL 02, 1991

DEXTROSE; *MULTIPLE*

SEE ALCOHOL; DEXTROSE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

DEXTROSE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;21MG/100ML;128MG/100ML; 234MG/100ML N17610 001

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;32MG/100ML;128MG/100ML; 234MG/100ML N17385 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML N19873 001 JUN 10, 1993
ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML N19025 001 DEC 27, 1984

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION
IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;53MG/100ML;100MG/100ML; 100MG/100ML;180MG/100ML;280MG/100ML; 16MG/100ML N19515 001 MAY 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;31MG/100ML;141MG/100ML; 20MG/100ML;12MG/100ML; 260MG/100ML N17484 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;30MG/100ML;141MG/100ML; 15MG/100ML;260MG/100ML; 25MG/100ML N19513 001 MAY 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;30MG/100ML;97MG/100ML; 220MG/100ML;140MG/100ML N19844 001 JUN 10, 1993
ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;30MG/100ML;97MG/100ML; 220MG/100ML;140MG/100ML N18273 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML N19843 001** AUG 09, 1993
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML N18274 001**

FDA data supplied by DrugPatentWatch.com

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;30MG/100ML;37MG/100ML; 222MG/100ML;526MG/100ML; 502MG/100ML N17609 001

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **5GM/100ML;30MG/100ML;37MG/100ML; 368MG/100ML;526MG/100ML; 502MG/100ML** **N17451 001**

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER
AP BRISTOL MYERS SQUIBB **5GM/100ML;75MG/100ML** **N17634 004**
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER
AP BRISTOL MYERS SQUIBB **5GM/100ML;150MG/100ML** **N17634 001**
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER
AP BRISTOL MYERS SQUIBB **5GM/100ML;224MG/100ML** **N17634 003**
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
AP BRISTOL MYERS SQUIBB **5GM/100ML;300MG/100ML** **N17634 002**
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;75MG/100ML** **N18744 001** NOV 09, 1982
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;150MG/100ML** **N18744 002** NOV 09, 1982
AP **5GM/100ML;150MG/100ML** **N19699 004** SEP 29, 1989
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML N18744 003 NOV 09, 1982
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;300MG/100ML** **N18744 004** NOV 09, 1982
AP **5GM/100ML;300MG/100ML** **N19699 006** SEP 29, 1989

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;149MG/100ML N18371 001
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER
AP ABBOTT **5GM/100ML;224MG/100ML** **N18371 003**
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;298MG/100ML N18371 002

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION
IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;111MG/100ML;256MG/100ML; 146MG/100ML;207MG/100ML N19514 001 MAY 08, 1986

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML N19870 001 JUN 10, 1993
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML N18270 001

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;205MG/100ML;100MG/100ML; 120MG/100ML;220MG/100ML N18840 001 JUN 29, 1983

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ

AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML; 200MG/100ML	N18037 006	APR 13, 1982
AP		5GM/100ML;150MG/100ML; 200MG/100ML	N18037 007	APR 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)

AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML; 200MG/100ML	N18037 004	

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ

AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML; 200MG/100ML	N18037 008	APR 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)

AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML; 200MG/100ML	N18037 001	

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ

AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML; 200MG/100ML	N18037 005	APR 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ

AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML; 200MG/100ML	N18037 009	APR 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ

AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML; 200MG/100ML	N18037 002	

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)

AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML; 200MG/100ML	N18037 003	

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML; 330MG/100ML	N18629 005	MAR 23, 1982

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML; 330MG/100ML	N18629 002	MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML; 330MG/100ML	N18629 003	MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML; 330MG/100ML	N18629 004	MAR 23, 1982
AP		5GM/100ML;300MG/100ML; 330MG/100ML	N18629 006	MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML; 330MG/100ML	N18629 007	MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML; 330MG/100ML	N18629 008	MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML; 330MG/100ML	N18629 001	MAR 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML; 450MG/100ML	N18008 010	

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;37MG/100ML; 200MG/100ML	N19630 031	FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML;37MG/100ML; 450MG/100ML	N19630 037	FEB 17, 1988

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;37MG/100ML;900MG/100ML N19630 043 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML;110MG/100ML N19630 001 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML;200MG/100ML N19630 007 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML;330MG/100ML N19630 013 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML;450MG/100ML N19630 019 FEB 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML;900MG/100ML N19630 025 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;75MG/100ML;200MG/100ML N19630 032 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;75MG/100ML;450MG/100ML N19630 038 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;75MG/100ML;900MG/100ML N19630 044 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;75MG/100ML;300MG/100ML N19630 049 MAY 07, 1992

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;75MG/100ML;110MG/100ML N19630 002 FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;75MG/100ML;200MG/100ML** **N19630 008** FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;75MG/100ML;330MG/100ML** **N19630 014** FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;75MG/100ML;450MG/100ML** **N19630 020** FEB 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;75MG/100ML;900MG/100ML** **N19630 026** FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML;200MG/100ML N19630 033 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML;450MG/100ML N19630 039 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML;900MG/100ML N19630 045 FEB 17, 1988

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;110MG/100ML; 300MG/100ML N19630 050 MAY 07, 1992

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML; 110MG/100ML N19630 003 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML; 200MG/100ML N19630 009 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML; 330MG/100ML N19630 015 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML; 450MG/100ML N19630 021 FEB 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML; 900MG/100ML N19630 027 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML; 200MG/100ML N19630 034 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML; 450MG/100ML N19630 040 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML; 900MG/100ML N19630 046 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;150MG/100ML; 300MG/100ML N19630 051 MAY 07, 1992

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;150MG/100ML; 110MG/100ML N19630 004 FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;150MG/100ML; 200MG/100ML N19630 010** FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;150MG/100ML; 330MG/100ML N19630 016** FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;150MG/100ML; 450MG/100ML N19630 022** FEB 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;150MG/100ML; 900MG/100ML N19630 028** FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML; 200MG/100ML N19630 035 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML; 450MG/100ML N19630 041 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML; 900MG/100ML N19630 047 FEB 17, 1988

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	B BRAUN	3.3GM/100ML;220MG/100ML; 300MG/100ML	N19630 052 MAY 07, 1992

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;220MG/100ML; 110MG/100ML	N19630 005 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;220MG/100ML; 200MG/100ML	N19630 011 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;220MG/100ML; 330MG/100ML	N19630 017 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;220MG/100ML; 450MG/100ML	N19630 023 FEB 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;220MG/100ML; 900MG/100ML	N19630 029 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;300MG/100ML; 200MG/100ML	N19630 036 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;300MG/100ML; 450MG/100ML	N19630 042 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;300MG/100ML; 900MG/100ML	N19630 048 FEB 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	B BRAUN	3.3GM/100ML;300MG/100ML; 300MG/100ML	N19630 053 MAY 07, 1992

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;300MG/100ML; 110MG/100ML	N19630 006 FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;300MG/100ML; 200MG/100ML**	**N19630 012** FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;300MG/100ML; 330MG/100ML**	**N19630 018** FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;300MG/100ML; 450MG/100ML**	**N19630 024** FEB 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	**5GM/100ML;300MG/100ML; 900MG/100ML**	**N19630 030** FEB 17, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;74.5MG/100ML; 225MG/100ML	N18365 002 JUL 05, 1983
		5GM/100ML;149MG/100ML; 225MG/100ML	N18365 006 MAR 28, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;74.5MG/100ML; 300MG/100ML	N18876 001 JAN 17, 1986
		5GM/100ML;149MG/100ML; 300MG/100ML	N18876 006 MAR 28, 1988

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;74.5MG/100ML; 450MG/100ML	N18362 005 MAR 28, 1988
AP		5GM/100ML;74.5MG/100ML; 450MG/100ML	N18362 009 JUL 05, 1983
AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML; 450MG/100ML	N18008 005 APR 28, 1982
AP		5GM/100ML;150MG/100ML; 450MG/100ML	N18008 006 APR 28, 1982

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;74.5MG/100ML; 900MG/100ML	N19691 002 MAR 24, 1988
AP		5GM/100ML;149MG/100ML; 900MG/100ML	N19691 004 MAR 24, 1988
AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML; 900MG/100ML	N19308 004 APR 05, 1985
AP		5GM/100ML;150MG/100ML; 900MG/100ML	N19308 002 APR 05, 1985

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;224MG/100ML; 225MG/100ML	N18365 008 MAR 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;224MG/100ML; 300MG/100ML	N18876 007 MAR 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;224MG/100ML; 450MG/100ML	N18362 006 MAR 28, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;224MG/100ML; 900MG/100ML	N19691 006 MAR 24, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;149MG/100ML; 225MG/100ML	N18365 001
		5GM/100ML;298MG/100ML; 225MG/100ML	N18365 009 MAR 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;298MG/100ML; 300MG/100ML	N18876 008 MAR 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;149MG/100ML; 450MG/100ML	N18362 010 JUL 05, 1983
AP		5GM/100ML;298MG/100ML; 450MG/100ML	N18362 007 MAR 28, 1988
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML; 450MG/100ML	N18008 007 APR 28, 1982

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;149MG/100ML; 900MG/100ML	N19691 005 MAR 24, 1988
AP		5GM/100ML;298MG/100ML; 900MG/100ML	N19691 008 MAR 24, 1988
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML; 900MG/100ML	N19308 005 APR 05, 1985
AP		5GM/100ML;300MG/100ML; 900MG/100ML	N19308 003 APR 05, 1985

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;149MG/100ML; 300MG/100ML	N18876 002 JAN 17, 1986

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;224MG/100ML; 225MG/100ML	N18365 003 JUL 05, 1983

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;224MG/100ML; 300MG/100ML	N18876 003 JAN 17, 1986

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;224MG/100ML; 450MG/100ML	N18362 002
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML; 450MG/100ML	N18008 008 APR 28, 1982

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;224MG/100ML; 900MG/100ML	N19691 007 MAR 24, 1988
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML; 900MG/100ML	N19308 006 APR 05, 1985

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;298MG/100ML; 225MG/100ML	N18365 004 JUL 05, 1983

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;298MG/100ML; 300MG/100ML	N18876 004 MAR 28, 1988

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;298MG/100ML; 450MG/100ML	N18362 003
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML; 450MG/100ML	N18008 009 APR 28, 1982

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;298MG/100ML; 900MG/100ML	N19691 009 MAR 24, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML; 900MG/100ML	N19308 007 APR 05, 1985

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;74.5MG/100ML; 225MG/100ML	N18365 005 MAR 28, 1988
		5GM/100ML;149MG/100ML; 225MG/100ML	N18365 007 MAR 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	ABBOTT	5GM/100ML;74.5MG/100ML; 300MG/100ML	N18876 005 MAR 28, 1988
		5GM/100ML;149MG/100ML; 300MG/100ML	N18876 009 MAR 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;74.5MG/100ML; 450MG/100ML	N18362 008 MAR 28, 1988
AP		5GM/100ML;149MG/100ML; 450MG/100ML	N18362 004 MAR 28, 1988
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML; 450MG/100ML	N18008 004

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	5GM/100ML;74.5MG/100ML; 900MG/100ML	N19691 001 MAR 24, 1988
AP		5GM/100ML;149MG/100ML; 900MG/100ML	N19691 003 MAR 24, 1988
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML; 900MG/100ML	N19308 001 APR 05, 1985

FDA data supplied by DrugPatentWatch.com

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML N19631 011
FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;200MG/100ML N19631 012
FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;330MG/100ML N19631 013
FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;450MG/100ML N19631 014
FEB 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP B BRAUN **10GM/100ML;900MG/100ML** **N19631 015**
FEB 24, 1988

AP BAXTER HLTHCARE **10GM/100ML;900MG/100ML** **N16696 001**

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 2.5GM/100ML;110MG/100ML N19631 001
FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 2.5GM/100ML;200MG/100ML N19631 002
FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 2.5GM/100ML;330MG/100ML N19631 003
FEB 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP ABBOTT **2.5GM/100ML;450MG/100ML** **N18096 001**
AP B BRAUN **2.5GM/100ML;450MG/100ML** **N19631 004**
FEB 24, 1988

AP BAXTER HLTHCARE **2.5GM/100ML;450MG/100ML** **N16697 001**

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 2.5GM/100ML;900MG/100ML N19631 005
FEB 24, 1988

DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;300MG/100ML N19631 016
JAN 19, 1990

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML N19631 006
FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;200MG/100ML** **N19631 007**
FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;225MG/100ML N17606 001

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
ABBOTT 5GM/100ML;300MG/100ML N17799 001

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;330MG/100ML** **N19631 008**
FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP ABBOTT **5GM/100ML;450MG/100ML** **N17607 001**
AP B BRAUN **5GM/100ML;450MG/100ML** **N19631 009**
FEB 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP ABBOTT **5GM/100ML;900MG/100ML** **N17585 001**
AP B BRAUN **5GM/100ML;900MG/100ML** **N19631 010**
FEB 24, 1988

DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **5GM/100ML;200MG/100ML** **N16689 001**

DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **5GM/100ML;330MG/100ML** **N16687 001**

DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **5GM/100ML;450MG/100ML** **N16683 001**

DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **5GM/100ML;900MG/100ML** **N16678 001**

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

HYPAQUE
AP + AMERSHAM HLTH **30%** **N16403 002**
AP + **60%** **N16403 001**

RENO-60
AP + BRACCO **60%** **N10040 016**

RENO-DIP
AP + BRACCO **30%** **N10040 012**

SOLUTION; URETERAL

RENO-30
BRACCO 30% N10040 021

SOLUTION; URETHRAL

CYSTOGRAFIN
AT BRACCO **30%** **N10040 018**

CYSTOGRAFIN DILUTE
BRACCO 18% N10040 022
NOV 09, 1982

HYPAQUE-CYSTO
AT AMERSHAM HLTH **30%** **N16403 003**

FDA data supplied by DrugPatentWatch.com

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

	HYPAQUE-76			
AP	AMERSHAM HLTH	**66%;10%**	**N86505 001**	
	MD-76R			
AP	+ MALLINCKRODT	**66%;10%**	**N19292 001**	SEP 29, 1989
	RENOCAL-76			
AP	BRACCO	**66%;10%**	**N89347 001**	JUN 01, 1988
	RENOGRAFIN-60			
	+ BRACCO	52%;8%	N10040 006	
	RENOGRAFIN-76			
AP	+ BRACCO	**66%;10%**	**N10040 001**	

SOLUTION; ORAL, RECTAL

	GASTROGRAFIN			
AA	+ BRACCO	**66%;10%**	**N11245 003**	
	MD-GASTROVIEW			
AA	MALLINCKRODT	**66%;10%**	**N87388 001**	

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION; INTRAUTERINE

	SINOGRAFIN		
	BRACCO	52.7%;26.8%	N11324 002

DIATRIZOATE SODIUM

FOR SOLUTION; ORAL, RECTAL

	HYPAQUE		
	AMERSHAM HLTH	100%	N11386 001

INJECTABLE; INJECTION

	HYPAQUE		
	+ AMERSHAM HLTH	50%	N09561 001

DIATRIZOATE SODIUM; *MULTIPLE*
SEE DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

DIAZEPAM

CONCENTRATE; ORAL

	DIAZEPAM INTENSOL			
	+ ROXANE	5MG/ML	N71415 001	APR 03, 1987

GEL; RECTAL

	DIASTAT			
	XCEL PHARMS	2.5MG/0.5ML	N20648 001	JUL 29, 1997
		5MG/ML	N20648 002	JUL 29, 1997
		10MG/2ML	N20648 003	JUL 29, 1997
		15MG/3ML	N20648 004	JUL 29, 1997
		+ 20MG/4ML	N20648 005	JUL 29, 1997

INJECTABLE; INJECTION

	DIAZEPAM			
AP	+ ABBOTT	**5MG/ML**	**N71583 001**	OCT 13, 1987
AP		**5MG/ML**	**N71584 001**	OCT 13, 1987
AP		**5MG/ML**	**N72079 001**	DEC 20, 1988
AP	BAXTER HLTHCARE	**5MG/ML**	**N71309 001**	JUL 17, 1987
AP		**5MG/ML**	**N71310 001**	JUL 17, 1987
AP	MARSAM PHARMS LLC	**5MG/ML**	**N72370 001**	JAN 29, 1993
AP		**5MG/ML**	**N72397 001**	JAN 29, 1993
AP	STERIS	**5MG/ML**	**N70296 001**	FEB 12, 1986

SOLUTION; ORAL

	DIAZEPAM		
	+ ROXANE	5MG/5ML	N70928 001 APR 03, 1987

TABLET; ORAL

	DIAZEPAM			
AB	BARR	**2MG**	**N70152 001**	NOV 01, 1985

FDA data supplied by DrugPatentWatch.com

DIAZEPAM

TABLET; ORAL

DIAZEPAM

AB	BARR	5MG	**N70153 001** NOV 01, 1985
AB		10MG	**N70154 001** NOV 01, 1985
AB	CLONMEL HLTHCARE	2MG	**N70226 001** SEP 26, 1985
AB	IVAX PHARMS	2MG	**N71307 001** DEC 10, 1986
AB		5MG	**N71321 001** DEC 10, 1986
AB		10MG	**N71322 001** DEC 10, 1986
AB	MYLAN	2MG	**N70323 001** SEP 04, 1985
AB		5MG	**N70324 001** SEP 04, 1985
AB		10MG	**N70325 001** SEP 04, 1985
AB	PAR PHARM	2MG	**N70462 001** FEB 25, 1986
AB		5MG	**N70463 001** FEB 25, 1986
AB		10MG	**N70464 001** FEB 25, 1986
AB	PUREPAC PHARM	2MG	**N70781 001** MAR 19, 1986
AB		5MG	**N70706 001** MAR 19, 1986
AB		10MG	**N70707 001** MAR 19, 1986
AB	SANDOZ	2MG	**N70302 001** DEC 20, 1985
AB		5MG	**N70303 001** DEC 20, 1985
AB		10MG	**N70304 001** DEC 20, 1985
AB	WATSON LABS	2MG	**N71134 001** FEB 03, 1987
AB		5MG	**N71135 001** FEB 03, 1987
AB		10MG	**N71136 001** FEB 03, 1987

VALIUM

AB	ROCHE	2MG	**N13263 002**
AB		5MG	**N13263 004**

DIAZEPAM

TABLET; ORAL

VALIUM

AB	+ ROCHE	10MG	**N13263 006**

DIAZOXIDE

INJECTABLE; INJECTION

HYPERSTAT

+	SCHERING	15MG/ML	N16996 001

SUSPENSION; ORAL

PROGLYCEM

+	BAKER NORTON	50MG/ML	N17453 001

DICLOFENAC POTASSIUM

TABLET; ORAL

CATAFLAM

AB	+ NOVARTIS	50MG	**N20142 002** NOV 24, 1993

DICLOFENAC POTASSIUM

AB	EON	50MG	**N75582 001** FEB 23, 2001
AB	MUTUAL PHARM	50MG	**N75470 001** FEB 21, 2002
AB	MYLAN	50MG	**N75463 001** JUL 26, 1999
AB	SANDOZ	50MG	**N75229 001** NOV 20, 1998
AB	TEVA	50MG	**N75219 001** AUG 06, 1998
AB	WATSON LABS	50MG	**N75152 001** NOV 27, 1998

DICLOFENAC SODIUM

GEL; TOPICAL

SOLARAZE

+	BIOGLAN PHARMA	3%	N21005 001 OCT 16, 2000

SOLUTION/DROPS; OPHTHALMIC

VOLTAREN

+	NOVARTIS	0.1%	N20037 001 MAR 28, 1991

FDA data supplied by DrugPatentWatch.com

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

AB	ALPHAPHARM	50MG	N75281 002	FEB 12, 2002
AB		75MG	N75281 003	FEB 12, 2002
AB	CARLSBAD	25MG	N75185 002	NOV 13, 1998
AB		50MG	N75185 003	NOV 13, 1998
AB		75MG	N75185 001	NOV 13, 1998
AB	COPLEY PHARM	25MG	N74459 001	JUN 25, 1997
AB		50MG	N74459 002	JUN 25, 1997
AB		75MG	N74459 003	JUN 25, 1997
AB	MARTEC	50MG	N74986 001	FEB 26, 1999
AB		75MG	N74986 002	FEB 26, 1999
AB	PLIVA	50MG	N74432 002	JUL 29, 1999
AB		75MG	N74432 003	JUL 29, 1999
AB	PUREPAC PHARM	50MG	N74514 001	MAR 26, 1996
AB		75MG	N74514 002	MAR 26, 1996
AB	ROXANE	25MG	N74391 001	JUN 29, 1995
AB		50MG	N74391 002	JUN 29, 1995
AB		75MG	N74391 003	JUN 29, 1995
AB	SANDOZ	25MG	N74376 001	SEP 28, 1995
AB		50MG	N74376 002	SEP 28, 1995
AB		75MG	N74394 001	NOV 30, 1995
AB	TEVA	50MG	N74723 001	MAR 30, 1999
AB		75MG	N74390 001	AUG 15, 1996

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

VOLTAREN

AB	+ NOVARTIS	25MG	N19201 001	JUL 28, 1988
AB	+	50MG	N19201 002	JUL 28, 1988
AB	+	75MG	N19201 003	JUL 28, 1988

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

AB	BIOVAIL	100MG	N75492 001	FEB 11, 2000
AB	DEXCEL LTD	100MG	N76201 001	NOV 06, 2002
AB	MYLAN	100MG	N76152 001	DEC 13, 2001
AB	PUREPAC PHARM	100MG	N75910 001	JAN 07, 2002

VOLTAREN-XR

AB	+ NOVARTIS	100MG	N20254 001	MAR 08, 1996

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

ARTHROTEC

+	GD SEARLE LLC	50MG;0.2MG	N20607 001	DEC 24, 1997
+		75MG;0.2MG	N20607 002	DEC 24, 1997

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DICLOXACILLIN SODIUM

AB	APOTHECON	EQ 250MG BASE	N61454 001	
AB	+	EQ 500MG BASE	N61454 003	
		EQ 125MG BASE	N61454 002	
AB	TEVA	EQ 250MG BASE	N62286 001	JUN 03, 1982
AB		EQ 500MG BASE	N62286 002	JUN 03, 1982

FOR SUSPENSION; ORAL

DICLOXACILLIN SODIUM

+	APOTHECON	EQ 62.5MG BASE/5ML	N61455 001	

FDA data supplied by DrugPatentWatch.com

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

	BENTYL			
AB	+ AXCAN SCANDIPHARM	10MG	**N07409 003**	OCT 15, 1984
	DICYCLOMINE HCL			
AB	LANNETT	10MG	**N84285 001**	
AB	MYLAN	10MG	**N40319 001**	SEP 07, 1999
AB	WATSON LABS	10MG	**N85082 001**	JUN 19, 1986
AB	WEST WARD	10MG	**N40204 001**	FEB 28, 1997

INJECTABLE; INJECTION

	BENTYL			
AP	+ AXCAN SCANDIPHARM	10MG/ML	**N08370 001**	OCT 15, 1984
	BENTYL PRESERVATIVE FREE			
AP	+ AXCAN SCANDIPHARM	10MG/ML	**N08370 002**	OCT 15, 1984
	DICYCLOMINE HCL (PRESERVATIVE-FREE)			
AP	BEDFORD	10MG/ML	**N40465 001**	JUN 30, 2003

SYRUP; ORAL

	BENTYL			
	+ AXCAN SCANDIPHARM	10MG/5ML	N07961 002	OCT 15, 1984

TABLET; ORAL

	BENTYL			
AB	+ AXCAN SCANDIPHARM	20MG	**N07409 001**	OCT 15, 1984
	DICYCLOMINE HCL			
AB	LANNETT	20MG	**N40230 001**	FEB 26, 1999
AB	MYLAN	20MG	**N40317 001**	SEP 07, 1999
AB	WATSON LABS	20MG	**N85223 001**	JUL 30, 1986
AB	WEST WARD	20MG	**N40161 001**	OCT 01, 1996

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

	VIDEX EC			
	+ BRISTOL MYERS SQUIBB	125MG	N21183 001	OCT 31, 2000
	+	200MG	N21183 002	OCT 31, 2000
	+	250MG	N21183 003	OCT 31, 2000
	+	400MG	N21183 004	OCT 31, 2000

FOR SOLUTION; ORAL

	VIDEX			
	BRISTOL MYERS SQUIBB	10MG/ML	N20156 001	OCT 09, 1991
		100MG/PACKET	N20155 003	OCT 09, 1991
		167MG/PACKET	N20155 004	OCT 09, 1991
	+	250MG/PACKET	N20155 005	OCT 09, 1991

TABLET, CHEWABLE; ORAL

	VIDEX			
	+ BRISTOL MYERS SQUIBB	25MG	N20154 002	OCT 09, 1991
		50MG	N20154 003	OCT 09, 1991
		100MG	N20154 004	OCT 09, 1991
		150MG	N20154 005	OCT 09, 1991
		200MG	N20154 006	OCT 28, 1999

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

	DIETHYLPROPION HCL			
AA	ABC HOLDING	25MG	**N88267 001**	AUG 25, 1983
AA		25MG	**N88268 001**	AUG 25, 1983
	TENUATE			
AA	+ AVENTIS PHARMS	25MG	**N11722 002**	

FDA data supplied by DrugPatentWatch.com

DIETHYLPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	TENUATE DOSPAN				
+	AVENTIS PHARMS	75MG	N12546 001		

DIFENOXIN HYDROCHLORIDE; *MULTIPLE*

SEE ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

DIFLORASONE DIACETATE

CREAM; TOPICAL

	DIFLORASONE DIACETATE				
AB1	ALTANA	**0.05%**	**N75187 001** MAR 30, 1998		
AB2		**0.05%**	**N76263 001** DEC 20, 2002		
AB1	TARO	**0.05%**	**N75508 001** APR 24, 2000		
	FLORONE				
BX +	PHARMACIA AND UPJOHN	0.05%	N17741 001		
	FLORONE E				
AB2 +	PHARMACIA AND UPJOHN	**0.05%**	**N19259 001** AUG 28, 1985		
	PSORCON				
AB1 +	DERMIK LABS	**0.05%**	**N20205 001** NOV 20, 1992		

OINTMENT; TOPICAL

	DIFLORASONE DIACETATE				
AB	ALTANA	**0.05%**	**N75374 001** APR 27, 1999		
AB	TARO	**0.05%**	**N75331 001** MAY 14, 1999		
	FLORONE				
+	PHARMACIA AND UPJOHN	0.05%	N17994 001		
	PSORCON				
AB +	PHARMACIA AND UPJOHN	**0.05%**	**N19260 001** AUG 28, 1985		

DIFLUNISAL

TABLET; ORAL

	DIFLUNISAL				
AB	ROXANE	**250MG**	**N73562 001** NOV 27, 1992	**AB** ROXANE	**500MG** **N73563 001** NOV 27, 1992
				AB SANDOZ	**500MG** **N74604 001** JUN 10, 1996
				AB TEVA	**250MG** **N73679 001** JUL 31, 1992
				AB	**500MG** **N73673 001** JUL 31, 1992
				AB WATSON LABS	**250MG** **N74400 001** JUL 17, 1997
				AB	**500MG** **N74400 002** JUL 17, 1997
				DOLOBID	
				AB MERCK	**250MG** **N18445 001** APR 19, 1982
				AB +	**500MG** **N18445 002** APR 19, 1982

DIGOXIN

CAPSULE; ORAL

	LANOXICAPS		
	SMITHKLINE BEECHAM	0.05MG	N18118 002 JUL 26, 1982
		0.1MG	N18118 003 JUL 26, 1982
+		0.2MG	N18118 001 JUL 26, 1982

INJECTABLE; INJECTION

	DIGOXIN		
AP	ABBOTT	**0.25MG/ML**	**N40093 001** MAY 16, 1996
AP		**0.25MG/ML**	**N40206 001** AUG 28, 1998
AP	ELKINS SINN	**0.25MG/ML**	**N83391 001**
AP	SABEX 2002	**0.25MG/ML**	**N40481 001** AUG 21, 2003
	DIGOXIN PEDIATRIC		
AP	ABBOTT	**0.1MG/ML**	**N40092 001** APR 25, 1996
	LANOXIN		
AP +	GLAXOSMITHKLINE	**0.25MG/ML**	**N09330 002**
	LANOXIN PEDIATRIC		
AP +	GLAXOSMITHKLINE	**0.1MG/ML**	**N09330 004**

FDA data supplied by DrugPatentWatch.com

DIGOXIN

TABLET; ORAL

	DIGOXIN			
AB	AMIDE PHARM	0.125MG	N40282 001	DEC 23, 1999
AB		0.25MG	N40282 002	DEC 23, 1999
AB	CARACO	0.125MG	N76363 001	JAN 31, 2003
AB		0.25MG	N76363 002	JAN 31, 2003
AB	STEVENS J	0.125MG	N76268 001	JUL 26, 2002
AB		0.25MG	N76268 002	JUL 26, 2002
	LANOXIN			
AB	SMITHKLINE BEECHAM	0.125MG	N20405 002	SEP 30, 1997
AB +		0.25MG	N20405 004	SEP 30, 1997

DIHYDROCODEINE BITARTRATE; *MULTIPLE*

SEE ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE
SEE ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

	D.H.E. 45			
AP +	XCEL PHARMS	1MG/ML	N05929 001	
	DIHYDROERGOTAMINE MESYLATE			
AP	BEDFORD	1MG/ML	N40453 001	JUN 09, 2003
AP	PADDOCK	1MG/ML	N40475 001	APR 28, 2003

SPRAY, METERED; NASAL

	MIGRANAL			
+	XCEL PHARM	0.5MG/INH	N20148 001	DEC 08, 1997

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	CARDIZEM CD			
AB3 +	BIOVAIL	120MG	N20062 001	AUG 10, 1992
AB3 +		180MG	N20062 002	DEC 27, 1991
AB3 +		240MG	N20062 003	DEC 27, 1991
AB3 +		300MG	N20062 004	DEC 27, 1991
BC +		360MG	N20062 005	AUG 24, 1999
	CARDIZEM SR			
AB1 +	AVENTIS PHARMS	60MG	N19471 001	JAN 23, 1989
AB1 +		90MG	N19471 002	JAN 23, 1989
AB1 +		120MG	N19471 003	JAN 23, 1989
	CARTIA XT			
AB3	ANDRX PHARMS	120MG	N74752 002	JUL 09, 1998
AB3		180MG	N74752 001	JUL 09, 1998
AB3		240MG	N74752 003	JUL 09, 1998
AB3		300MG	N74752 004	JUL 09, 1998
	DILACOR XR			
AB2 +	WATSON LABS	120MG	N20092 001	MAY 29, 1992
AB2 +		180MG	N20092 002	MAY 29, 1992
AB2 +		240MG	N20092 003	MAY 29, 1992
	DILTIAZEM HCL			
AB2	ANDRX	120MG	N74852 001	OCT 10, 1997
AB2		180MG	N74852 002	OCT 10, 1997
AB2		240MG	N74852 003	OCT 10, 1997
AB1	BIOVAIL	60MG	N74845 001	SEP 15, 1999
AB1		90MG	N74845 002	SEP 15, 1999

FDA data supplied by DrugPatentWatch.com

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	DILTIAZEM HCL			
AB3	BIOVAIL	120MG	**N20939 001**	JAN 28, 2000
AB1		120MG	**N74845 003**	SEP 15, 1999
AB3		120MG	**N75116 001**	DEC 23, 1999
AB3		180MG	**N20939 002**	JAN 28, 2000
AB3		180MG	**N75116 002**	DEC 23, 1999
AB3		240MG	**N20939 003**	JAN 28, 2000
AB3		240MG	**N75116 003**	DEC 23, 1999
AB3		300MG	**N20939 004**	JAN 28, 2000
AB3		300MG	**N75116 004**	DEC 23, 1999
AB1	MYLAN	60MG	**N74910 001**	MAY 02, 1997
AB1		90MG	**N74910 002**	MAY 02, 1997
AB1		120MG	**N74910 003**	MAY 02, 1997
AB2		120MG	**N75124 002**	MAR 18, 1998
AB2		180MG	**N75124 003**	MAR 18, 1998
AB2		240MG	**N75124 001**	MAR 18, 1998
AB3	PUREPAC PHARM	120MG	**N74984 001**	DEC 20, 1999
AB3		180MG	**N74984 002**	DEC 20, 1999
AB3		240MG	**N74984 003**	DEC 20, 1999
AB3		300MG	**N74984 004**	DEC 20, 1999
AB1	TEVA	60MG	**N74079 001**	NOV 30, 1993
AB1		90MG	**N74079 002**	NOV 30, 1993
AB1		120MG	**N74079 003**	NOV 30, 1993

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	DILTIAZEM HCL			
AB2	TORPHARM	120MG	**N74943 003**	DEC 19, 2000
AB2		180MG	**N74943 002**	DEC 19, 2000
AB2		240MG	**N74943 001**	AUG 06, 1998
	TAZTIA XT			
AB4	ANDRX PHARMS	120MG	**N75401 001**	APR 10, 2003
AB4		180MG	**N75401 002**	APR 10, 2003
AB4		240MG	**N75401 003**	APR 10, 2003
AB4		300MG	**N75401 004**	APR 10, 2003
AB4		360MG	**N75401 005**	APR 10, 2003
	TIAZAC			
AB4	BIOVAIL	120MG	**N20401 001**	SEP 11, 1995
AB4		180MG	**N20401 002**	SEP 11, 1995
AB4		240MG	**N20401 003**	SEP 11, 1995
AB4		300MG	**N20401 004**	SEP 11, 1995
AB4		360MG	**N20401 005**	SEP 11, 1995
+		420MG	N20401 006	OCT 16, 1998

INJECTABLE; INJECTION

	CARDIZEM			
AP +	AVENTIS PHARMS	100MG/VIAL	**N20792 001**	SEP 05, 1997
AP +	BIOVAIL	5MG/ML	**N20027 001**	OCT 24, 1991
+		25MG/VIAL	N20027 003	AUG 18, 1995
	DILTIAZEM HCL			
AP	ABBOTT	5MG/ML	**N74941 001**	APR 15, 1998
AP		5MG/ML	**N75004 001**	FEB 16, 2000

FDA data supplied by DrugPatentWatch.com

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

		DILTIAZEM HCL			
AP		ABBOTT	**100MG/VIAL**	**N75853 001** DEC 17, 2002
AP		APOTEX	**5MG/ML**	**N75375 001** SEP 30, 1999
AP	+	BEDFORD	**5MG/ML**	**N74617 001** FEB 28, 1996
AP		GENSIA SICOR PHARMS	**5MG/ML**	**N74894 001** AUG 26, 1997
	+		10MG/ML	N74894 002 APR 19, 2002
AP		INTL MEDICATION	**5MG/ML**	**N75749 001** NOV 21, 2001
AP		MERIDIAN MEDCL TECHN	**5MG/ML**	**N75106 001** APR 29, 1999
AP		TAYLOR PHARMA	**5MG/ML**	**N75086 001** APR 09, 1998

TABLET; ORAL

		CARDIZEM		
AB		AVENTIS PHARMS	**30MG**	**N18602 001** NOV 05, 1982
AB			**60MG**	**N18602 002** NOV 05, 1982
AB			**90MG**	**N18602 003** DEC 08, 1986
AB	+		**120MG**	**N18602 004** DEC 08, 1986
		DILTIAZEM HCL		
AB		CLONMEL HLTHCARE	**30MG**	**N74093 001** NOV 05, 1992
AB			**60MG**	**N74093 002** NOV 05, 1992
AB			**90MG**	**N74093 003** NOV 05, 1992
AB			**120MG**	**N74093 004** NOV 05, 1992
AB		COPLEY PHARM	**30MG**	**N74067 001** NOV 05, 1992
AB			**60MG**	**N74067 002** NOV 05, 1992
AB			**90MG**	**N74067 003** NOV 05, 1992
AB			**120MG**	**N74067 004** NOV 05, 1992

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL

		DILTIAZEM HCL		
AB		IVAX PHARMS	**30MG**	**N74168 001** MAR 03, 1995
AB			**60MG**	**N74168 002** MAR 03, 1995
AB			**90MG**	**N74168 003** MAR 03, 1995
AB			**120MG**	**N74168 004** MAR 03, 1995
AB		MYLAN	**30MG**	**N73185 001** NOV 05, 1992
AB			**60MG**	**N73186 001** NOV 05, 1992
AB			**90MG**	**N72837 001** NOV 05, 1992
AB			**120MG**	**N72838 001** NOV 05, 1992
AB		TEVA	**30MG**	**N74185 001** MAY 31, 1995
AB			**60MG**	**N74185 002** MAY 31, 1995
AB			**90MG**	**N74185 003** MAY 31, 1995
AB			**120MG**	**N74185 004** MAY 31, 1995

TABLET, EXTENDED RELEASE; ORAL

	CARDIZEM LA		
+	BIOVAIL	120MG	N21392 001 FEB 06, 2003
+		180MG	N21392 002 FEB 06, 2003
+		240MG	N21392 003 FEB 06, 2003
+		300MG	N21392 004 FEB 06, 2003
+		360MG	N21392 005 FEB 06, 2003
+		420MG	N21392 006 FEB 06, 2003

FDA data supplied by DrugPatentWatch.com

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE; ORAL
TECZEM
+ BIOVAIL — EQ 180MG HCL;5MG — N20507 001 OCT 04, 1996

DIMENHYDRINATE

INJECTABLE; INJECTION
DIMENHYDRINATE
+ STERIS — 50MG/ML — N80615 001

DIMERCAPROL

INJECTABLE; INJECTION
BAL
+ AKORN — 10% — N05939 001

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL
DIMETHYL SULFOXIDE
AT BIONICHE (CANADA) — **50%** — **N76185 001** NOV 29, 2002

RIMSO-50
AT + EDWARDS LIFESCIENCES — **50%** — **N17788 001**

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS
IMAGENT
+ IMCOR — 0.92MG/VIAL;0.092MG/VIAL — N21191 001 MAY 31, 2002

DINOPROSTONE

GEL; ENDOCERVICAL
PREPIDIL
+ PHARMACIA AND UPJOHN — 0.5MG/3GM — N19617 001 DEC 09, 1992

INSERT, EXTENDED RELEASE; VAGINAL
CERVIDIL
+ CONTROLLED THERAP — 10MG — N20411 001 MAR 30, 1995

DINOPROSTONE

SUPPOSITORY; VAGINAL
PROSTIN E2
+ PHARMACIA AND UPJOHN — 20MG — N17810 001

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

AA		BARR	**50MG**	**N80738 001**
AA		HALSEY	**25MG**	**N84506 001**
AA		LNK	**25MG**	**N87977 001** JAN 27, 1983
AA			**50MG**	**N87978 001** JAN 27, 1983
AA		MK LABS	**25MG**	**N83087 001**
AA			**50MG**	**N83087 002**
AA		MUTUAL PHARM	**25MG**	**N89488 001** JAN 02, 1987
AA			**50MG**	**N89489 001** JAN 02, 1987
AA	+	SANDOZ	**25MG**	**N80832 001**
AA	+		**50MG**	**N80832 002**
AA		VALEANT PHARM INTL	**50MG**	**N80592 001**
AA		WATSON LABS	**25MG**	**N80728 001**
AA			**50MG**	**N80727 001**

ELIXIR; ORAL
DIPHENHYDRAMINE HCL

AA		MK LABS	**12.5MG/5ML**	**N83088 002**
AA		PHARM ASSOC	**12.5MG/5ML**	**N87513 001** FEB 10, 1982
AA	+	ROXANE	**12.5MG/5ML**	**N80643 001**

INJECTABLE; INJECTION
BENADRYL

AP	+	PARKE DAVIS	**50MG/ML**	**N06146 002**

BENADRYL PRESERVATIVE FREE

AP	+	PARKE DAVIS	**50MG/ML**	**N09486 001**

DIPHENHYDRAMINE HCL

AP		ABBOTT	**50MG/ML**	**N40140 001** NOV 20, 1998
AP		AM PHARM PARTNERS	**50MG/ML**	**N40466 001** MAY 28, 2002
AP		BAXTER HLTHCARE	**50MG/ML**	**N80817 002**
AP		STERIS	**50MG/ML**	**N80873 002**
	+		10MG/ML	N80873 001

FDA data supplied by DrugPatentWatch.com

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	DIPHENHYDRAMINE HCL PRESERVATIVE FREE				
AP	INTL MEDICATION	50MG/ML	N84094 001		
AP	STERIS	50MG/ML	N80873 003		

DIPHENOXYLATE HYDROCHLORIDE; *MULTIPLE*
SEE ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	AKPRO				
AT	AKORN	0.1%	N74382 001 SEP 29, 1995		
	DIPIVEFRIN HCL				
AT	BAUSCH AND LOMB	0.1%	N74188 001 MAY 19, 1995		
AT	FALCON PHARMS	0.1%	N73636 001 JUN 30, 1994		
	PROPINE				
AT +	ALLERGAN	0.1%	N18239 001		

DIPYRIDAMOLE

INJECTABLE; INJECTION

	DIPYRIDAMOLE				
AP	ABBOTT	5MG/ML	N74601 001 DEC 19, 1997		
AP	AM PHARM PARTNERS	5MG/ML	N74956 001 SEP 30, 1998		
AP	APOTEX	5MG/ML	N75769 001 NOV 27, 2002		
AP +	BEDFORD	5MG/ML	N74939 001 APR 13, 1998		
AP	ELKINS SINN	5MG/ML	N74521 001 OCT 18, 1996		
AP	GENSIA SICOR PHARMS	5MG/ML	N74952 001 NOV 26, 1997		

TABLET; ORAL

	DIPYRIDAMOLE				
AB	BARR	25MG	N87184 001 OCT 03, 1990		

DIPYRIDAMOLE

TABLET; ORAL

	DIPYRIDAMOLE				
AB	BARR	50MG	N87716 001 OCT 03, 1990		
AB		75MG	N87717 001 OCT 03, 1990		
AB	CLONMEL HLTHCARE	50MG	N89000 001 FEB 05, 1991		
AB	PUREPAC PHARM	25MG	N89425 001 JUL 12, 1990		
AB	SANDOZ	25MG	N86944 002 APR 16, 1991		
AB		50MG	N87562 001 FEB 25, 1992		
AB		75MG	N87561 001 FEB 25, 1992		
AB	WATSON LABS	50MG	N87160 001 JUN 07, 1996		
	PERSANTINE				
AB	BOEHRINGER INGELHEIM	25MG	N12836 003 DEC 22, 1986		
AB +		50MG	N12836 004 FEB 06, 1987		
AB		75MG	N12836 005 FEB 06, 1987		

DIPYRIDAMOLE; *MULTIPLE*
SEE ASPIRIN; DIPYRIDAMOLE

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

	DYNABAC				
+	LILLY RES LABS	250MG	N50678 001 JUN 19, 1995		

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

	DISOPYRAMIDE PHOSPHATE				
AB	IVAX PHARMS	EQ 100MG BASE	N70186 001 NOV 18, 1985		
AB		EQ 150MG BASE	N70187 001 NOV 18, 1985		

FDA data supplied by DrugPatentWatch.com

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

	DISOPYRAMIDE PHOSPHATE			
AB	SANDOZ	EQ 100MG BASE	N70470 001	DEC 10, 1985
AB		EQ 150MG BASE	N70471 001	DEC 10, 1985
AB	TEVA	EQ 100MG BASE	N70101 001	FEB 22, 1985
AB		EQ 150MG BASE	N70102 001	FEB 22, 1985
AB	WATSON LABS	EQ 100MG BASE	N70173 001	MAY 31, 1985
AB		EQ 150MG BASE	N70174 001	MAY 31, 1985
	NORPACE			
AB	GD SEARLE LLC	EQ 100MG BASE	N17447 001	
AB +		EQ 150MG BASE	N17447 002	

CAPSULE, EXTENDED RELEASE; ORAL

	DISOPYRAMIDE PHOSPHATE			
AB	KV PHARM	EQ 150MG BASE	N71200 001	DEC 15, 1987
	NORPACE CR			
AB +	GD SEARLE LLC	EQ 150MG BASE	N18655 002	*JUL 20, 1982*
		EQ 100MG BASE	N18655 001	JUL 20, 1982

DISULFIRAM

TABLET; ORAL

	ANTABUSE			
+	ODYSSEY PHARMS	250MG	N88482 001	DEC 08, 1983

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

	DEPAKOTE			
+	ABBOTT	EQ 125MG VALPROIC ACID	N19680 001	SEP 12, 1989

TABLET, DELAYED RELEASE; ORAL

	DEPAKOTE			
+	ABBOTT	EQ 125MG VALPROIC ACID	N18723 003	OCT 26, 1984

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

	DEPAKOTE			
+	ABBOTT	EQ 250MG VALPROIC ACID	N18723 001	MAR 10, 1983
+		EQ 500MG VALPROIC ACID	N18723 002	MAR 10, 1983

TABLET, EXTENDED RELEASE; ORAL

	DEPAKOTE ER			
	ABBOTT	EQ 250MG VALPROIC ACID	N21168 002	MAY 31, 2002
+		EQ 500MG VALPROIC ACID	N21168 001	AUG 04, 2000

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	DOBUTAMINE HCL			
AP	ABBOTT	EQ 1.25GM BASE/100ML	N74634 001	SEP 27, 1996
AP		EQ 12.5MG BASE/ML	N74086 001	NOV 29, 1993
AP		EQ 12.5MG BASE/ML	N74292 001	FEB 16, 1995
AP	BEDFORD	EQ 12.5MG BASE/ML	N74277 001	OCT 31, 1994
AP	GENSIA SICOR PHARMS	EQ 12.5MG BASE/ML	N74206 001	OCT 19, 1993
AP	LUITPOLD	EQ 12.5MG BASE/ML	N74545 001	JUN 25, 1998
AP	MARSAM PHARMS LLC	EQ 12.5MG BASE/ML	N74279 001	FEB 18, 1998
AP		EQ 12.5MG BASE/ML	N74995 001	MAR 31, 1998
AP	STERIS	EQ 12.5MG BASE/ML	N74114 001	NOV 30, 1993
	DOBUTAMINE HCL IN DEXTROSE 5%			
AP +	ABBOTT	EQ 50MG BASE/100ML	N20269 001	OCT 19, 1993
AP +		EQ 100MG BASE/100ML	N20269 002	OCT 19, 1993
AP +		EQ 200MG BASE/100ML	N20269 003	OCT 19, 1993
	DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP +	ABBOTT	EQ 50MG BASE/100ML	N20201 003	OCT 19, 1993

FDA data supplied by DrugPatentWatch.com

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+ ABBOTT	**EQ 100MG BASE/100ML**	**N20201 002** OCT 19, 1993
AP	+	**EQ 200MG BASE/100ML**	**N20201 001** OCT 19, 1993
AP	+	**EQ 400MG BASE/100ML**	**N20201 006** JUL 07, 1994
AP	+ BAXTER HLTHCARE	**EQ 50MG BASE/100ML**	**N20255 001** OCT 19, 1993
AP	+	**EQ 100MG BASE/100ML**	**N20255 003** OCT 19, 1993
AP	+	**EQ 200MG BASE/100ML**	**N20255 004** OCT 19, 1993
AP	+	**EQ 400MG BASE/100ML**	**N20255 005** OCT 19, 1993

DOBUTREX

AP	+ LILLY	**EQ 12.5MG BASE/ML**	**N17820 002**

DOCETAXEL

INJECTABLE; INJECTION
TAXOTERE

	+ AVENTIS PHARMS	EQ 40MG BASE/ML	N20449 001 MAY 14, 1996

DOFETILIDE

CAPSULE; ORAL
TIKOSYN

	PFIZER	0.125MG	N20931 001 OCT 01, 1999
		0.25MG	N20931 002 OCT 01, 1999
	+	0.5MG	N20931 003 OCT 01, 1999

DOLASETRON MESYLATE MONOHYDRATE

INJECTABLE; INJECTION
ANZEMET

	+ AVENTIS PHARMS	EQ 100MG BASE/5ML	N20624 001 SEP 11, 1997

DOLASETRON MESYLATE MONOHYDRATE

INJECTABLE; INJECTION
ANZEMET

	AVENTIS PHARMS	EQ 12.5MG BASE/0.625ML	N20624 002 SEP 11, 1997
	+	EQ 500MG BASE/25ML	N20624 003 DEC 11, 2001

TABLET; ORAL
ANZEMET

	AVENTIS PHARMS	EQ 50MG BASE	N20623 001 SEP 11, 1997
	+	EQ 100MG BASE	N20623 002 SEP 11, 1997

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL
ARICEPT

	EISAI MEDCL RES	5MG	N20690 002 NOV 25, 1996
	+	10MG	N20690 001 NOV 25, 1996

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL

AP	+ ABBOTT	**80MG/100ML**	**N18132 002** FEB 04, 1982
AP	+	**160MG/100ML**	**N18132 003** FEB 04, 1982
AP	+	**40MG/ML**	**N18132 001**
AP		**40MG/ML**	**N74403 001** MAY 23, 1996
AP	+	**80MG/ML**	**N18132 004** JUL 09, 1982
AP	GENSIA SICOR PHARMS	**40MG/ML**	**N72999 001** OCT 23, 1991
AP		**80MG/ML**	**N73000 001** OCT 23, 1991
AP	+ INTL MEDICATION	**40MG/ML**	**N18014 001**
AP	LUITPOLD	**40MG/ML**	**N70799 001** FEB 11, 1987
AP		**80MG/ML**	**N70820 001** FEB 11, 1987

FDA data supplied by DrugPatentWatch.com

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

		DOPAMINE HCL			
AP		LUITPOLD	**160MG/ML**	**N70826 001** FEB 11, 1987	
		DOPAMINE HCL AND DEXTROSE 5%			
AP	+	B BRAUN	**80MG/100ML**	**N19099 002** OCT 15, 1986	
AP	+		**320MG/100ML**	**N19099 004** OCT 15, 1986	
		DOPAMINE HCL AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+	B BRAUN	**160MG/100ML**	**N19099 003** OCT 15, 1986	
	+		40MG/100ML	N19099 001 OCT 15, 1986	
		DOPAMINE HCL IN DEXTROSE 5%			
AP	+	ABBOTT	**1.6MG/ML**	**N20542 001** AUG 30, 1995	
		DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+	ABBOTT	**80MG/100ML**	**N18826 001** SEP 30, 1983	
AP	+		**160MG/100ML**	**N18826 002** SEP 30, 1983	
AP	+		**320MG/100ML**	**N18826 003** SEP 30, 1983	
AP	+	BAXTER HLTHCARE	**80MG/100ML**	**N19615 001** MAR 27, 1987	
AP	+		**160MG/100ML**	**N19615 002** MAR 27, 1987	
AP	+		**320MG/100ML**	**N19615 003** MAR 27, 1987	
	+		640MG/100ML	N19615 004 MAR 27, 1987	
		INTROPIN			
AP	+	MAYNE PHARMA USA	**40MG/ML**	**N17395 001**	
AP	+		**80MG/ML**	**N17395 002**	
AP	+		**160MG/ML**	**N17395 003**	

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

		TRUSOPT		
	+	MERCK	EQ 2% BASE	N20408 001 DEC 09, 1994

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

		COSOPT		
	+	MERCK	EQ 2% BASE;EQ 0.5% BASE	N20869 001 APR 07, 1998

DOXACURIUM CHLORIDE

INJECTABLE; INJECTION

		NUROMAX		
	+	ABBOTT	EQ 1MG BASE/ML	N19946 001 MAR 07, 1991

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

		DOPRAM		
AP	+	BAXTER HLTHCARE CORP	**20MG/ML**	**N14879 001**
		DOXAPRAM HCL		
AP		BEDFORD	**20MG/ML**	**N76266 001** JAN 10, 2003
AP		STERIS	**20MG/ML**	**N73529 001** JAN 30, 1992

DOXAZOSIN MESYLATE

TABLET; ORAL

		CARDURA		
AB	+	PFIZER	**EQ 1MG BASE**	**N19668 001** NOV 02, 1990
AB			**EQ 2MG BASE**	**N19668 002** NOV 02, 1990
AB			**EQ 4MG BASE**	**N19668 003** NOV 02, 1990
AB			**EQ 8MG BASE**	**N19668 004** NOV 02, 1990
		DOXAZOSIN MESYLATE		
AB		EON	**EQ 1MG BASE**	**N75646 001** OCT 18, 2000
AB			**EQ 2MG BASE**	**N75646 002** OCT 18, 2000
AB			**EQ 4MG BASE**	**N75646 003** OCT 18, 2000
AB			**EQ 8MG BASE**	**N75646 004** OCT 18, 2000

FDA data supplied by DrugPatentWatch.com

DOXAZOSIN MESYLATE

TABLET; ORAL

	DOXAZOSIN MESYLATE		
AB	GENPHARM	EQ 1MG BASE	N75466 001 OCT 18, 2000
AB		EQ 2MG BASE	N75466 002 OCT 18, 2000
AB		EQ 4MG BASE	N75466 003 OCT 18, 2000
AB		EQ 8MG BASE	N75466 004 OCT 18, 2000
AB	IVAX PHARMS	EQ 1MG BASE	N75453 001 OCT 18, 2000
AB		EQ 2MG BASE	N75453 002 OCT 18, 2000
AB		EQ 4MG BASE	N75453 003 OCT 18, 2000
AB		EQ 8MG BASE	N75453 004 OCT 18, 2000
AB	KV PHARM	EQ 1MG BASE	N75609 001 OCT 18, 2000
AB		EQ 2MG BASE	N75609 002 OCT 18, 2000
AB		EQ 4MG BASE	N75609 003 OCT 18, 2000
AB		EQ 8MG BASE	N75609 004 OCT 18, 2000
AB	MYLAN	EQ 1MG BASE	N75509 001 OCT 19, 2000
AB		EQ 2MG BASE	N75509 002 OCT 19, 2000
AB		EQ 4MG BASE	N75509 003 OCT 19, 2000
AB		EQ 8MG BASE	N75509 004 OCT 19, 2000
AB	PLIVA	EQ 1MG BASE	N75750 001 JUN 08, 2001
AB		EQ 2MG BASE	N75750 002 JUN 08, 2001
AB		EQ 4MG BASE	N75750 003 JUN 08, 2001
AB		EQ 8MG BASE	N75750 004 JUN 08, 2001
AB	PUREPAC PHARM	EQ 1MG BASE	N75574 001 OCT 18, 2000
AB		EQ 2MG BASE	N75574 002 OCT 18, 2000

DOXAZOSIN MESYLATE

TABLET; ORAL

	DOXAZOSIN MESYLATE		
AB	PUREPAC PHARM	EQ 4MG BASE	N75574 003 OCT 18, 2000
AB		EQ 8MG BASE	N75574 004 OCT 18, 2000
AB	SANDOZ	EQ 1MG BASE	N75432 001 OCT 18, 2000
AB		EQ 2MG BASE	N75432 002 OCT 18, 2000
AB		EQ 4MG BASE	N75432 003 OCT 18, 2000
AB		EQ 8MG BASE	N75432 004 OCT 18, 2000
AB	TEVA	EQ 1MG BASE	N75353 001 JAN 12, 2001
AB		EQ 1MG BASE	N75536 001 OCT 18, 2000
AB		EQ 2MG BASE	N75353 002 JAN 12, 2001
AB		EQ 2MG BASE	N75536 002 OCT 18, 2000
AB		EQ 4MG BASE	N75353 003 JAN 12, 2001
AB		EQ 4MG BASE	N75536 003 OCT 18, 2000
AB		EQ 8MG BASE	N75353 004 JAN 12, 2001
AB		EQ 8MG BASE	N75536 004 OCT 18, 2000
AB	TORPHARM	EQ 1MG BASE	N75580 001 OCT 18, 2000
AB		EQ 2MG BASE	N75580 002 OCT 18, 2000
AB		EQ 4MG BASE	N75580 003 OCT 18, 2000
AB		EQ 8MG BASE	N75580 004 OCT 18, 2000
AB	WATSON LABS	EQ 1MG BASE	N75426 001 OCT 18, 2000
AB		EQ 2MG BASE	N75426 002 OCT 18, 2000
AB		EQ 4MG BASE	N75426 003 OCT 18, 2000
AB		EQ 8MG BASE	N75426 004 OCT 18, 2000

FDA data supplied by DrugPatentWatch.com

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HCL				
AB	MYLAN	EQ 10MG BASE	N70789 001	MAY 13, 1986
AB		EQ 25MG BASE	N70790 001	MAY 13, 1986
AB		EQ 50MG BASE	N70791 001	MAY 13, 1986
AB		EQ 75MG BASE	N70792 001	MAY 13, 1986
AB		EQ 100MG BASE	N70793 001	MAY 13, 1986
AB	PAR PHARM	EQ 10MG BASE	N71697 001	NOV 09, 1987
AB		EQ 25MG BASE	N71437 001	NOV 09, 1987
AB		EQ 50MG BASE	N71595 001	NOV 09, 1987
AB		EQ 75MG BASE	N71608 001	NOV 09, 1987
AB		EQ 100MG BASE	N71422 001	NOV 09, 1987
AB		EQ 150MG BASE	N71669 001	NOV 09, 1987
AB	SANDOZ	EQ 10MG BASE	N71487 001	MAR 02, 1987
AB		EQ 25MG BASE	N70827 001	MAY 15, 1986
AB		EQ 50MG BASE	N70828 001	MAY 15, 1986
AB		EQ 75MG BASE	N70825 001	MAY 15, 1986
AB		EQ 100MG BASE	N71562 001	MAR 02, 1987
AB	WATSON LABS	EQ 10MG BASE	N71485 001	APR 30, 1987
AB		EQ 10MG BASE	N72985 001	MAR 29, 1991
AB		EQ 25MG BASE	N71486 001	APR 30, 1987
AB		EQ 25MG BASE	N72986 001	MAR 29, 1991
AB		EQ 50MG BASE	N71238 001	APR 30, 1987
AB		EQ 50MG BASE	N72987 001	MAR 29, 1991

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HCL				
AB	WATSON LABS	EQ 75MG BASE	N71326 001	APR 30, 1987
AB		EQ 100MG BASE	N71239 001	APR 30, 1987
SINEQUAN				
AB	PFIZER	EQ 10MG BASE	N16798 003	
AB	+	EQ 25MG BASE	N16798 001	
AB		EQ 50MG BASE	N16798 002	
AB		EQ 75MG BASE	N16798 006	
AB	+	EQ 100MG BASE	N16798 005	
AB		EQ 150MG BASE	N16798 007	

CONCENTRATE; ORAL

DOXEPIN HCL				
AA	COPLEY PHARM	EQ 10MG BASE/ML	N71609 001	NOV 09, 1987
AA	MORTON GROVE	EQ 10MG BASE/ML	N71918 001	JUL 20, 1988
AA	SILARX	EQ 10MG BASE/ML	N74721 001	DEC 29, 1998
SINEQUAN				
AA	+ PFIZER	EQ 10MG BASE/ML	N17516 001	

CREAM; TOPICAL

ZONALON				
+	BIOGLAN PHARMS	5%	N20126 001	APR 01, 1994

DOXERCALCIFEROL

CAPSULE; ORAL

HECTOROL				
+	BONE CARE	2.5 UGM	N20862 001	JUN 09, 1999

INJECTABLE; INJECTION

HECTOROL				
+	BONE CARE	2 UGM/ML	N21027 001	APR 06, 2000

FDA data supplied by DrugPatentWatch.com

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

	ADRIAMYCIN PFS			
AP	+ PHARMACIA AND UPJOHN	2MG/ML	N50629 001	
			DEC 23, 1987	
AP	+	200MG/100ML	N50629 002	
			MAY 03, 1988	
AP		2MG/ML	N63165 001	
			JAN 30, 1991	
AP		200MG/100ML	N63165 002	
			JAN 30, 1991	
	ADRIAMYCIN RDF			
AP	+ PHARMACIA AND UPJOHN	10MG/VIAL	N50467 001	
AP	+	20MG/VIAL	N50467 003	
			MAY 20, 1985	
AP	+	50MG/VIAL	N50467 002	
	DOXORUBICIN HCL			
AP	AM PHARM PARTNERS	2MG/ML	N63277 001	
			OCT 26, 1995	
AP	BEDFORD	2MG/ML	N62975 001	
			MAR 17, 1989	
AP		200MG/100ML	N64097 001	
			SEP 13, 1994	
AP		10MG/VIAL	N62921 001	
			MAR 17, 1989	
AP		20MG/VIAL	N62921 002	
			MAR 17, 1989	
AP		50MG/VIAL	N62921 003	
			MAR 17, 1989	
AP	GENSIA SICOR PHARMS	2MG/ML	N64140 001	
			JUL 28, 1995	
AP		200MG/100ML	N64140 002	
			JUL 28, 1995	
AP	PHARMACHEMIE	2MG/ML	N63336 001	
			FEB 28, 1995	
AP		200MG/100ML	N63336 004	
			FEB 28, 1995	
AP		10MG/VIAL	N63097 001	
			MAY 21, 1990	
AP		20MG/VIAL	N63097 002	
			MAY 21, 1990	
AP		50MG/VIAL	N63097 003	
			MAY 21, 1990	
	RUBEX			
AP	BRISTOL MYERS SQUIBB	10MG/VIAL	N62926 001	
			APR 13, 1989	
AP		50MG/VIAL	N62926 002	
			APR 13, 1989	

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

	RUBEX		
	BRISTOL MYERS SQUIBB	100MG/VIAL	N62926 003
			APR 13, 1989

INJECTABLE, LIPOSOMAL; INJECTION

	DOXIL		
+	ALZA	2MG/ML	N50718 001
			NOV 17, 1995

DOXYCYCLINE

CAPSULE; ORAL

	DOXYCYCLINE		
AB	AXIOM PHARM	EQ 50MG BASE	N65041 001
			APR 28, 2000
AB		EQ 100MG BASE	N65041 002
			APR 28, 2000
AB	EON	EQ 50MG BASE	N65032 001
			JUN 30, 2000
AB		EQ 100MG BASE	N65032 002
			JUN 30, 2000
AB	PAR PHARM	EQ 50MG BASE	N65055 001
			DEC 01, 2000
AB		EQ 100MG BASE	N65055 002
			DEC 01, 2000
AB	RANBAXY	EQ 50MG BASE	N65053 001
			NOV 22, 2000
AB		EQ 100MG BASE	N65053 002
			NOV 22, 2000
+		EQ 75MG BASE	N65053 003
			SEP 10, 2003
	MONODOX		
AB	OCLASSEN	EQ 50MG BASE	N50641 002
			FEB 10, 1992
AB +		EQ 100MG BASE	N50641 001
			DEC 29, 1989

FOR SUSPENSION; ORAL

	VIBRAMYCIN		
+	PFIZER	EQ 25MG BASE/5ML	N50006 001

TABLET; ORAL

	DOXYCYCLINE		
	PAR PHARM	EQ 50MG BASE	N65070 001
			DEC 15, 2000

FDA data supplied by DrugPatentWatch.com

DOXYCYCLINE

TABLET; ORAL
DOXYCYCLINE

	PAR PHARM	EQ 75MG BASE	N65070 003 DEC 30, 2002
+		EQ 100MG BASE	N65070 002 DEC 15, 2000

DOXYCYCLINE CALCIUM

SUSPENSION; ORAL
VIBRAMYCIN

+	PFIZER	EQ 50MG BASE/5ML	N50480 001

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
DOXYCYCLINE HYCLATE

AB	AXIOM PHARM	**EQ 50MG BASE**	**N61717 001**
AB		**EQ 100MG BASE**	**N61717 002**
AB	IVAX PHARMS	**EQ 50MG BASE**	**N62500 001** SEP 11, 1984
AB		**EQ 100MG BASE**	**N62500 002** SEP 11, 1984
AB	MUTUAL PHARM	**EQ 50MG BASE**	**N62675 001** JUL 10, 1986
AB		**EQ 100MG BASE**	**N62676 001** JUL 10, 1986
AB	MYLAN	**EQ 50MG BASE**	**N62337 001** MAR 29, 1982
AB		**EQ 100MG BASE**	**N62337 002** MAR 29, 1982
AB	WATSON LABS	**EQ 50MG BASE**	**N62031 002** OCT 13, 1982
AB		**EQ 100MG BASE**	**N62031 001**
AB	WEST WARD	**EQ 50MG BASE**	**N62396 002** NOV 07, 1984
AB		**EQ 100MG BASE**	**N62396 001** MAY 07, 1984

VIBRAMYCIN

AB	PFIZER	**EQ 50MG BASE**	**N50007 001**
AB +		**EQ 100MG BASE**	**N50007 002**

CAPSULE, COATED PELLETS; ORAL
DORYX

AB +	MAYNE PHARMA USA	**EQ 100MG BASE**	**N50582 001** JUL 22, 1985

DOXYCYCLINE HYCLATE

CAPSULE, COATED PELLETS; ORAL
DORYX

	MAYNE PHARMA USA	EQ 75MG BASE	N50582 002 AUG 13, 2001
AB	WARNER CHILCOTT	**EQ 100MG BASE**	**N62653 001** OCT 30, 1985

INJECTABLE; INJECTION
DOXY 100

+	AM PHARM PARTNERS	EQ 100MG BASE/VIAL	N62475 001 DEC 09, 1983

DOXY 200

+	AM PHARM PARTNERS	EQ 200MG BASE/VIAL	N62475 002 DEC 09, 1983

LIQUID, EXTENDED RELEASE; PERIODONTAL
ATRIDOX

+	ATRIX	EQ 10% W/W	N50751 001 SEP 03, 1998

TABLET; ORAL
DOXYCYCLINE HYCLATE

AB	AXIOM PHARM	**EQ 100MG BASE**	**N62269 002** NOV 08, 1982
AB	IVAX PHARMS	**EQ 100MG BASE**	**N62505 001** SEP 11, 1984
AB	MUTUAL PHARM	**EQ 100MG BASE**	**N62677 001** JUL 10, 1986
AB	MYLAN	**EQ 100MG BASE**	**N62432 001** FEB 15, 1983
AB	VINTAGE PHARMS	**EQ 100MG BASE**	**N62538 001** APR 07, 1986
AB	WATSON LABS	**EQ 100MG BASE**	**N62421 001** FEB 02, 1983
AB	WEST WARD	**EQ 100MG BASE**	**N65095 001** JUL 02, 2003

PERIOSTAT

+	COLLAGENEX PHARMS	20MG	N50783 001 FEB 02, 2001

VIBRA-TABS

AB +	PFIZER	**EQ 100MG BASE**	**N50533 001**

FDA data supplied by DrugPatentWatch.com

DRONABINOL

CAPSULE; ORAL
MARINOL
UNIMED 2.5MG N18651 001 MAY 31, 1985
5MG N18651 002 MAY 31, 1985
\+ 10MG N18651 003 MAY 31, 1985

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL
AP ABBOTT **2.5MG/ML** **N71981 001** FEB 29, 1988
AP **2.5MG/ML** **N72272 001** AUG 31, 1995
AP LUITPOLD **2.5MG/ML** **N72123 001** OCT 24, 1988
AP **2.5MG/ML** **N72335 001** OCT 24, 1988
AP MAYNE PHARMA USA **2.5MG/ML** **N71645 001** APR 07, 1988
INAPSINE
AP + AKORN **2.5MG/ML** **N16796 001**

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE AND DROPERIDOL
\+ ABBOTT 2.5MG/ML; EQ 0.05MG BASE/ML N71982 001 MAY 04, 1988

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL-28
YASMIN
\+ BERLEX LABS 3MG;0.03MG N21098 001 MAY 11, 2001

DUTASTERIDE

CAPSULE; ORAL
AVODART
\+ GLAXOSMITHKLINE 0.5MG N21319 001 NOV 20, 2001

DYPHYLLINE

TABLET; ORAL
DILOR
BP SAVAGE LABS 200MG N84514 001
DILOR-400
BP + SAVAGE LABS 400MG N84751 001
LUFYLLIN
BP MEDPOINTE PHARM HLC 200MG N84566 001
BP 400MG N84566 002

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC
PHOSPHOLINE IODIDE
\+ AYERST 0.125% N11963 001

ECONAZOLE NITRATE

CREAM; TOPICAL
ECONAZOLE NITRATE
AB ALTANA **1%** **N76075 001** NOV 26, 2002
AB TARO **1%** **N76005 001** NOV 26, 2002
SPECTAZOLE
AB + JOHNSON AND JOHNSON **1%** **N18751 001** DEC 23, 1982

EDETATE CALCIUM DISODIUM

INJECTABLE; INJECTION
CALCIUM DISODIUM VERSENATE
\+ 3M 200MG/ML N08922 001

FDA data supplied by DrugPatentWatch.com

EDETATE DISODIUM

INJECTABLE; INJECTION

	EDETATE DISODIUM			
AP	APOTEX	150MG/ML	N40376 001	NOV 04, 2002
AP	BIONICHE (CANADA)	150MG/ML	N40437 001	JUL 09, 2002
AP	STERIS	150MG/ML	N80391 001	
	ENDRATE			
AP +	ABBOTT	150MG/ML	N11355 001	

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

	EDROPHONIUM CHLORIDE			
AP	ABBOTT	10MG/ML	N40131 001	FEB 24, 1998
	ENLON			
AP	BAXTER HLTHCARE CORP	10MG/ML	N88873 001	AUG 06, 1985
	TENSILON			
AP +	VALEANT PHARM INTL	10MG/ML	N07959 001	
	TENSILON PRESERVATIVE FREE			
AP +	VALEANT PHARM INTL	10MG/ML	N07959 002	

EDROPHONIUM CHLORIDE; *MULTIPLE*
SEE ATROPINE SULFATE; EDROPHONIUM CHLORIDE

EFAVIRENZ

CAPSULE; ORAL

	SUSTIVA			
	BRISTOL MYERS SQUIBB	50MG	N20972 001	SEP 17, 1998
		100MG	N20972 002	SEP 17, 1998
+		200MG	N20972 003	SEP 17, 1998

TABLET; ORAL

	SUSTIVA			
	BRISTOL MYERS SQUIBB	300MG	N21360 001	FEB 01, 2002
+		600MG	N21360 002	FEB 01, 2002

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL

	VANIQA			
+	WOMEN FIRST HLTHCARE	13.9%	N21145 001	JUL 27, 2000

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

	RELPAX			
	PFIZER IRELAND	EQ 20MG BASE	N21016 001	DEC 26, 2002
+		EQ 40MG BASE	N21016 002	DEC 26, 2002

EMEDASTINE DIFUMARATE

SOLUTION/DROPS; OPHTHALMIC

	EMADINE			
+	ALCON	0.05%	N20706 001	DEC 29, 1997

EMTRICITABINE

CAPSULE; ORAL

	EMTRIVA			
+	GILEAD	200MG	N21500 001	JUL 02, 2003

ENALAPRIL MALEATE

TABLET; ORAL

	ENALAPRIL MALEATE			
AB	APOTHECON	2.5MG	N75583 001	AUG 22, 2000
AB		5MG	N75583 002	AUG 22, 2000
AB		10MG	N75583 003	AUG 22, 2000
AB		20MG	N75583 004	AUG 22, 2000
AB	EON	2.5MG	N75621 001	AUG 22, 2000

FDA data supplied by DrugPatentWatch.com

ENALAPRIL MALEATE

TABLET; ORAL

	ENALAPRIL MALEATE			
AB	EON	5MG	N75621 002 AUG 22, 2000	
AB		10MG	N75621 003 AUG 22, 2000	
AB		20MG	N75621 004 AUG 22, 2000	
AB	GENPHARM	2.5MG	N75472 001 AUG 22, 2000	
AB		5MG	N75472 002 AUG 22, 2000	
AB		10MG	N75472 003 AUG 22, 2000	
AB		20MG	N75472 004 AUG 22, 2000	
AB	IVAX PHARMS	2.5MG	N75482 001 AUG 22, 2000	
AB		5MG	N75482 002 AUG 22, 2000	
AB		10MG	N75482 003 AUG 22, 2000	
AB		20MG	N75482 004 AUG 22, 2000	
AB	KRKA DD NOVO MESTO	2.5MG	N75370 001 AUG 22, 2000	
AB		5MG	N75370 002 AUG 22, 2000	
AB		10MG	N75369 001 AUG 22, 2000	
AB		20MG	N75369 002 AUG 22, 2000	
AB	LEK PHARMS	2.5MG	N75496 001 AUG 22, 2000	
AB		5MG	N75496 002 AUG 22, 2000	
AB		10MG	N75459 001 AUG 22, 2000	
AB		20MG	N75459 002 AUG 22, 2000	
AB	MYLAN	2.5MG	N75480 001 AUG 22, 2000	
AB		5MG	N75480 002 AUG 22, 2000	
AB		10MG	N75480 003 AUG 22, 2000	

ENALAPRIL MALEATE

TABLET; ORAL

	ENALAPRIL MALEATE			
AB	MYLAN	20MG	N75480 004 AUG 22, 2000	
AB	RANBAXY	2.5MG	N75556 001 AUG 22, 2000	
AB		5MG	N75556 002 AUG 22, 2000	
AB		10MG	N75556 003 AUG 22, 2000	
AB		20MG	N75556 004 AUG 22, 2000	
AB	SANDOZ	2.5MG	N75048 001 AUG 22, 2000	
AB		5MG	N75048 002 AUG 22, 2000	
AB		10MG	N75048 003 AUG 22, 2000	
AB		20MG	N75048 004 AUG 22, 2000	
AB	TARO	2.5MG	N75657 001 JAN 23, 2001	
AB		5MG	N75657 002 JAN 23, 2001	
AB		10MG	N75657 003 JAN 23, 2001	
AB		20MG	N75657 004 JAN 23, 2001	
AB	TEVA	2.5MG	N75479 001 AUG 22, 2000	
AB		5MG	N75479 002 AUG 22, 2000	
AB		10MG	N75479 003 AUG 22, 2000	
AB		20MG	N75479 004 AUG 22, 2000	
AB	TORPHARM	2.5MG	N75178 002 MAR 23, 2001	
AB		5MG	N75178 001 MAR 23, 2001	
AB		10MG	N75178 003 MAR 23, 2001	
AB		20MG	N75178 004 MAR 23, 2001	
AB	WATSON LABS	2.5MG	N75501 001 AUG 22, 2000	

FDA data supplied by DrugPatentWatch.com

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

AB	WATSON LABS	5MG	N75501 002	AUG 22, 2000
AB		10MG	N75501 003	AUG 22, 2000
AB		20MG	N75501 004	AUG 22, 2000
AB	WOCKHARDT	2.5MG	N75483 001	AUG 22, 2000
AB		5MG	N75483 002	AUG 22, 2000
AB		10MG	N75483 003	AUG 22, 2000
AB		20MG	N75483 004	AUG 22, 2000

VASOTEC

AB	BIOVAIL	2.5MG	N18998 005	JUL 26, 1988
AB		5MG	N18998 001	DEC 24, 1985
AB		10MG	N18998 002	DEC 24, 1985
AB +		20MG	N18998 003	DEC 24, 1985

ENALAPRIL MALEATE; *MULTIPLE*

SEE DILTIAZEM MALATE; ENALAPRIL MALEATE

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

LEXXEL

+	ASTRAZENECA	5MG;2.5MG	N20668 002	OCT 28, 1998
+		5MG;5MG	N20668 001	DEC 27, 1996

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB	DR REDDYS LABS LTD	5MG;12.5MG	N75909 001	OCT 15, 2001

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB	DR REDDYS LABS LTD	10MG;25MG	N75909 002	OCT 15, 2001
AB	EON	5MG;12.5MG	N76116 001	SEP 19, 2001
AB		10MG;25MG	N76116 002	SEP 19, 2001
AB	IVAX PHARMS	5MG;12.5MG	N75736 001	MAR 25, 2003
AB		10MG;25MG	N75736 002	MAR 25, 2003
AB	MYLAN	5MG;12.5MG	N75624 001	SEP 18, 2001
AB		10MG;25MG	N75624 002	SEP 18, 2001
AB	TARO PHARM INDS	5MG;12.5MG	N75788 001	SEP 18, 2001
AB		10MG;25MG	N75788 002	SEP 18, 2001
AB	TEVA	5MG;12.5MG	N75727 001	SEP 18, 2001
AB		10MG;25MG	N75727 002	SEP 18, 2001

VASERETIC

AB	BIOVAIL	5MG;12.5MG	N19221 003	JUL 12, 1995
AB +		10MG;25MG	N19221 001	OCT 31, 1986

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP	ABBOTT	1.25MG/ML	N75456 001	AUG 22, 2000
AP		1.25MG/ML	N75458 001	AUG 22, 2000
AP	BEDFORD	1.25MG/ML	N75634 001	AUG 22, 2000
AP	GENSIA SICOR PHARMS	1.25MG/ML	N75578 001	AUG 22, 2000
AP	MAYNE PHARMA USA	1.25MG/ML	N75571 001	AUG 22, 2000

VASOTEC

AP +	BIOVAIL	1.25MG/ML	N19309 001	FEB 09, 1988

FDA data supplied by DrugPatentWatch.com

ENFLURANE

LIQUID; INHALATION

	ENFLURANE			
AN	MINRAD	**99.9%**	**N74396 001**	JUL 29, 1994
	ETHRANE			
AN	+ BAXTER HLTHCARE CORP	**99.9%**	**N17087 001**	

ENFUVIRTIDE

INJECTABLE; SUBCUTANEOUS

	FUZEON		
	+ ROCHE	90MG/VIAL	N21481 001 MAR 13, 2003

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

	LOVENOX		
	+ AVENTIS	30MG/0.3ML	N20164 001 MAR 29, 1993
	+	40MG/0.4ML	N20164 002 JAN 30, 1998
	+	60MG/0.6ML	N20164 003 MAR 27, 1998
	+	80MG/0.8ML	N20164 004 MAR 27, 1998
	+	100MG/ML	N20164 005 MAR 27, 1998
	+	300MG/3ML	N20164 009 JAN 23, 2003
	+	120MG/0.8ML	N20164 007 JUN 02, 2000
	+	150MG/ML	N20164 008 JUN 02, 2000

ENTACAPONE

TABLET; ORAL

	COMTAN		
	+ ORION	200MG	N20796 001 OCT 19, 1999

ENTACAPONE; *MULTIPLE*
SEE CARBIDOPA; ENTACAPONE; LEVODOPA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	ELESTAT		
	+ ALLERGAN	0.05%	N21565 001 OCT 16, 2003

EPINEPHRINE

INJECTABLE; IM-SC

	TWINJECT		
	+ HOLLISTER STIER LABS	EQ 0.3MG /DELIVERY	N20800 001 MAY 30, 2003

INJECTABLE; INTRAMUSCULAR

	EPIPEN		
	+ MERIDIAN MEDCL TECHN	0.3MG/DELIVERY	N19430 001 DEC 22, 1987
	EPIPEN JR.		
	+ MERIDIAN MEDCL TECHN	0.15MG/DELIVERY	N19430 002 DEC 22, 1987

EPINEPHRINE; *MULTIPLE*
SEE ARTICAINE HYDROCHLORIDE; EPINEPHRINE
SEE BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	LIDOCAINE HCL AND EPINEPHRINE			
AP	ABBOTT	**0.005MG/ML;0.5%**	**N89635 001**	JUN 21, 1988
AP		**0.005MG/ML;1%**	**N89649 001**	JUN 21, 1988
AP		**0.005MG/ML;1.5%**	**N88571 001**	SEP 13, 1985
AP		**0.005MG/ML;1.5%**	**N89645 001**	JUN 21, 1988
AP		**0.005MG/ML;1.5%**	**N89650 001**	JUN 21, 1988
AP		**0.005MG/ML;2%**	**N89651 001**	JUN 21, 1988
AP		**0.01MG/ML;1%**	**N89644 001**	JUN 21, 1988
AP		**0.01MG/ML;2%**	**N89646 001**	JUN 21, 1988

FDA data supplied by DrugPatentWatch.com

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION				
LIDOCAINE HCL AND EPINEPHRINE				
AP	EASTMAN KODAK	0.01MG/ML;2%	N40057 002	FEB 26, 1993
AP		0.02MG/ML;2%	N40057 001	FEB 26, 1993
AP	GRAHAM CHEM	0.01MG/ML;2%	N80504 004	OCT 19, 1983
AP		0.02MG/ML;2%	N80504 005	OCT 19, 1983
LIDOCAINE HCL W/ EPINEPHRINE				
AP	DELL LABS	0.01MG/ML;1%	N83389 001	
AP		0.01MG/ML;2%	N83390 001	
LIDOCATON				
AP	PHARMATON	0.01MG/ML;2%	N84729 001	AUG 17, 1983
OCTOCAINE				
AP	SEPTODONT	0.01MG/ML;2%	N84048 001	
AP +		0.02MG/ML;2%	N84048 002	
XYLOCAINE W/ EPINEPHRINE				
AP +	ASTRAZENECA	0.005MG/ML;0.5%	N06488 012	
AP +		0.005MG/ML;1%	N06488 018	NOV 13, 1986
AP +		0.005MG/ML;1.5%	N06488 017	
AP +		0.005MG/ML;2%	N06488 019	NOV 13, 1986
AP +		0.01MG/ML;1%	N06488 004	
+	DENTSPLY PHARM	0.01MG/ML;2%	N21381 001	
		0.02MG/ML;2%	N21381 002	
SOLUTION; IONTOPHORESIS				
IONTOCAINE				
+	IOMED	0.01MG/ML;2%	N20530 001	DEC 21, 1995

EPINEPHRINE BITARTRATE; *MULTIPLE*
SEE BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION			
LIGNOSPAN FORTE			
+	DEPROCO	EQ 0.02MG BASE/ML;2%	N88389 001 JAN 22, 1985
INJECTABLE; INJECTION			
LIGNOSPAN STANDARD			
+	DEPROCO	EQ 0.01MG BASE/ML;2%	N88390 001 JAN 22, 1985

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION			
CITANEST FORTE			
+	DENTSPLY PHARM	0.005MG/ML;4%	N21383 001

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION			
ELLENCE			
+	PHARMACIA AND UPJOHN	2MG/ML	N50778 001 SEP 15, 1999

EPLERENONE

TABLET; ORAL			
INSPRA			
	GD SEARLE LLC	25MG	N21437 001 SEP 27, 2002
		50MG	N21437 002 SEP 27, 2002
+		100MG	N21437 003 SEP 27, 2002

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION			
FLOLAN			
+	GLAXOSMITHKLINE	EQ 0.5MG BASE/VIAL	N20444 001 SEP 20, 1995
+		EQ 1.5MG BASE/VIAL	N20444 002 SEP 20, 1995

FDA data supplied by DrugPatentWatch.com

EPROSARTAN MESYLATE

TABLET; ORAL

	TEVETEN			
	BIOVAIL	EQ 300MG BASE	N20738 004	
			DEC 22, 1997	
		EQ 400MG BASE	N20738 005	
			DEC 22, 1997	
+		EQ 600MG BASE	N20738 006	
			MAY 27, 1999	

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	TEVETEN HCT			
	BIOVAIL	600MG;12.5MG	N21268 001	
			NOV 01, 2001	
+		600MG;25MG	N21268 002	
			NOV 01, 2001	

EPTIFIBATIDE

INJECTABLE; INJECTION

	INTEGRILIN			
+	MILLENNIUM PHARMS	75MG/100ML	N20718 002	
			MAY 18, 1998	
+		2MG/ML	N20718 001	
			MAY 18, 1998	

ERGOCALCIFEROL

CAPSULE; ORAL

	DRISDOL			
AA	+ SANOFI SYNTHELABO	**50,000 IU**	**N03444 001**	
	VITAMIN D			
AA	BANNER PHARMACAPS	**50,000 IU**	**N80704 001**	

ERGOCALCIFEROL; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

ERGOLOID MESYLATES

TABLET; ORAL

	ERGOLOID MESYLATES			
AB	MUTUAL PHARM	**1MG**	**N81113 001**	
			OCT 31, 1991	
	HYDERGINE			
AB	+ NOVARTIS	**1MG**	**N17993 001**	

TABLET; SUBLINGUAL

	ERGOLOID MESYLATES			
AA	WATSON LABS	**0.5MG**	**N87233 001**	
	GERIMAL			
AA	WATSON LABS	**0.5MG**	**N86189 001**	
AA		**1MG**	**N86188 001**	
	HYDERGINE			
AA	+ NOVARTIS	**0.5MG**	**N09087 002**	
AA	+	**1MG**	**N09087 001**	
	HYDROGENATED ERGOT ALKALOIDS			
AA	IVAX PHARMS	**1MG**	**N87185 001**	

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

	ERGOMAR			
+	HARVEST PHARMS	2MG	N87693 001	
			FEB 24, 1983	

ERGOTAMINE TARTRATE; *MULTIPLE*
SEE CAFFEINE; ERGOTAMINE TARTRATE

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, IV (INFUSION)

	INVANZ			
+	MERCK	EQ 1GM BASE/VIAL	N21337 001	
			NOV 21, 2001	

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

	ERYC			
AB	+ MAYNE PHARMA USA	**250MG**	**N50536 001**	
	ERYTHROMYCIN			
AB	ABBOTT	**250MG**	**N62746 001**	
			DEC 22, 1986	

FDA data supplied by DrugPatentWatch.com

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

	ERYTHROMYCIN		
AB	BARR	250MG	N63098 001 MAY 04, 1989

GEL; TOPICAL

	E-GLADES		
AT	GLADES PHARMS	2%	N65009 001 MAR 18, 2002
	ERYGEL		
AT	+ ALLERGAN HERBERT	2%	N50617 001 OCT 21, 1987
	ERYTHROMYCIN		
AT	ALTANA	2%	N64184 001 SEP 30, 1997
AT	STIEFEL	2%	N63211 001 JAN 29, 1993

LOTION; TOPICAL

	E-SOLVE 2		
	+ SYOSSET	2%	N62467 001 JUL 03, 1985

OINTMENT; OPHTHALMIC

	ERYTHROMYCIN		
AT	AKORN	0.5%	N64030 001 JUL 18, 1996
AT	BAUSCH AND LOMB	0.5%	N64067 001 JUL 29, 1994
AT	FOUGERA	0.5%	N62447 001 SEP 26, 1983
	ILOTYCIN		
AT	+ DISTA	0.5%	N50368 001

OINTMENT; TOPICAL

	AKNE-MYCIN		
	+ HEALTHPOINT	2%	N50584 001 JAN 10, 1985

SOLUTION; TOPICAL

	A/T/S		
AT	AVENTIS PHARMS	2%	N62405 001 NOV 18, 1982
	C-SOLVE-2		
AT	BIOGLAN PHARMA	2%	N62468 001 JUL 03, 1985
	ERYDERM		
AT	ABBOTT	2%	N62290 001

ERYTHROMYCIN

SOLUTION; TOPICAL

	ERYMAX		
AT	ALLERGAN HERBERT	2%	N62508 002 JUL 11, 1985
	ERYTHRA-DERM		
AT	PADDOCK	2%	N62687 001 FEB 05, 1988
	ERYTHRO-STATIN		
AT	HI TECH PHARMA	2%	N64101 001 OCT 22, 1996
	ERYTHROMYCIN		
AT	ALPHARMA	2%	N62326 001 APR 19, 1982
AT	ALTANA	2%	N64187 001 SEP 30, 1997
AT	BAUSCH AND LOMB	2%	N64039 001 JAN 27, 1994
AT	CLAY PARK	2%	N63038 001 JAN 11, 1991
AT	MORTON GROVE	2%	N62825 001 OCT 23, 1987
AT	STIEFEL	2%	N64127 001 FEB 14, 1997
	SANSAC		
AT	HEALTHPOINT	2%	N62522 001 JAN 24, 1985
	STATICIN		
	+ WESTWOOD SQUIBB	1.5%	N50526 001
	T-STAT		
AT	+ WESTWOOD SQUIBB	2%	N62436 001 MAR 09, 1983

SWAB; TOPICAL

	C-SOLVE-2		
AT	IVAX PHARMS	2%	N62751 001 JUL 30, 1993
	ERYCETTE		
AT	+ J AND J	2%	N50594 001 FEB 15, 1985
	ERYTHROMYCIN		
AT	STIEFEL	2%	N64126 001 JUL 03, 1996
AT		2%	N64128 001 JUL 03, 1996
	T-STAT		
AT	WESTWOOD SQUIBB	2%	N62748 001 JUL 23, 1987

FDA data supplied by DrugPatentWatch.com

ERYTHROMYCIN

TABLET; ORAL
ERYTHROMYCIN
ABBOTT 250MG N61621 001
\+ 500MG N61621 002

TABLET, COATED PARTICLES; ORAL
PCE
ABBOTT 333MG N50611 001
SEP 09, 1986
\+ 500MG N50611 002
AUG 22, 1990

TABLET, DELAYED RELEASE; ORAL
E-BASE
AB BARR **333MG** **N63086 001**
MAY 15, 1990
AB **500MG** **N62999 001**
NOV 25, 1988

E-MYCIN
AB ABBOTT **250MG** **N60272 001**
AB **333MG** **N60272 002**

ERY-TAB
AB \+ ABBOTT **250MG** **N62298 001**
AB \+ **333MG** **N62298 003**
MAR 29, 1982
AB \+ **500MG** **N62298 002**

ERYTHROMYCIN; *MULTIPLE*
SEE BENZOYL PEROXIDE; ERYTHROMYCIN

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL
ERYTHROMYCIN ESTOLATE
\+ BARR EQ 250MG BASE N62162 002

SUSPENSION; ORAL
ERYTHROMYCIN ESTOLATE
AB ALPHARMA **EQ 125MG BASE/5ML** **N62353 001**
NOV 18, 1982
AB **EQ 250MG BASE/5ML** **N62409 001**
DEC 16, 1982

ILOSONE
AB LILLY **EQ 125MG BASE/5ML** **N50010 001**
AB \+ **EQ 250MG BASE/5ML** **N50010 002**

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL
E.E.S.
AB ABBOTT **EQ 200MG BASE/5ML** **N50207 001**
ERYPED
AB ABBOTT **EQ 200MG BASE/5ML** **N50207 003**
MAR 30, 1987
\+ EQ 400MG BASE/5ML N50207 002
ERYTHROMYCIN ETHYLSUCCINATE
AB BARR **EQ 200MG BASE/5ML** **N62055 001**

SUSPENSION; ORAL
E.E.S. 200
AB ABBOTT **EQ 200MG BASE/5ML** **N61639 001**
E.E.S. 400
AB \+ ABBOTT **EQ 400MG BASE/5ML** **N61639 002**
ERYTHROMYCIN ETHYLSUCCINATE
AB ALPHARMA **EQ 200MG BASE/5ML** **N62200 001**
AB **EQ 400MG BASE/5ML** **N62200 002**
PEDIAMYCIN
AB ROSS LABS **EQ 200MG BASE/5ML** **N62304 001**
PEDIAMYCIN 400
AB ROSS LABS **EQ 400MG BASE/5ML** **N62304 002**

TABLET; ORAL
E.E.S. 400
AB \+ ABBOTT **EQ 400MG BASE** **N61905 002**
AUG 12, 1982
ERYTHROMYCIN ETHYLSUCCINATE
AB MYLAN **EQ 400MG BASE** **N62847 001**
SEP 14, 1988

TABLET, CHEWABLE; ORAL
E.E.S.
AB \+ ABBOTT **EQ 200MG BASE** **N50297 002**
ERYPED
AB ABBOTT **EQ 200MG BASE** **N50297 003**
JUL 05, 1988

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL
AB BARR **EQ 200MG BASE/5ML; EQ 600MG BASE/5ML** **N62759 001**
MAY 20, 1988

FDA data supplied by DrugPatentWatch.com

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

	ERYZOLE			
AB	ALRA	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	N62758 001 JUN 15, 1988	
	PEDIAZOLE			
AB	+ ROSS LABS	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	N50529 001	

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

	ERYTHROCIN			
AP	+ ABBOTT	EQ 500MG BASE/VIAL	N50182 002	
AP		EQ 500MG BASE/VIAL	N50609 001 SEP 24, 1986	
AP		EQ 500MG BASE/VIAL	N62638 001 OCT 31, 1986	
AP	+	EQ 1GM BASE/VIAL	N50182 003	
AP		EQ 1GM BASE/VIAL	N50609 002 SEP 24, 1986	
AP		EQ 1GM BASE/VIAL	N62638 002 OCT 31, 1986	
	ERYTHROMYCIN LACTOBIONATE			
AP	BAXTER HLTHCARE	EQ 500MG BASE/VIAL	N62993 001 MAY 09, 1989	
AP		EQ 1GM BASE/VIAL	N62993 002 MAY 09, 1989	
AP	GENSIA SICOR PHARMS	EQ 500MG BASE/VIAL	N63253 001 JUL 30, 1993	
AP		EQ 1GM BASE/VIAL	N63253 002 JUL 30, 1993	

ERYTHROMYCIN STEARATE

TABLET; ORAL

	ERYTHROCIN STEARATE			
AB	ABBOTT	EQ 250MG BASE	N60359 001	
AB	+	EQ 500MG BASE	N60359 003	
	ERYTHROMYCIN STEARATE			
AB	BARR	EQ 250MG BASE	N61591 001	
AB	MYLAN	EQ 250MG BASE	N61505 001	
AB		EQ 500MG BASE	N61505 002	

ESCITALOPRAM OXALATE

SOLUTION; ORAL

	LEXAPRO			
+	FOREST LABS	EQ 5MG BASE/5ML	N21365 001 NOV 27, 2002	

TABLET; ORAL

	LEXAPRO			
	FOREST LABS	10MG	N21323 002 AUG 14, 2002	
+		20MG	N21323 003 AUG 14, 2002	

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

	BREVIBLOC		
+	BAXTER HLTHCARE CORP	10MG/ML	N19386 006 FEB 25, 2003
+		20MG/ML	N19386 007 MAY 28, 2003
+		250MG/ML	N19386 002 DEC 31, 1986
	BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER		
+	BAXTER HLTHCARE CORP	2GM/100ML	N19386 005 JAN 27, 2003
	BREVIBLOC IN PLASTIC CONTAINER		
+	BAXTER HLTHCARE CORP	1GM/100ML	N19386 004 FEB 16, 2001

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

	NEXIUM		
+	ASTRAZENECA	EQ 20MG BASE	N21153 001 FEB 20, 2001
+		EQ 40MG BASE	N21153 002 FEB 20, 2001

ESTAZOLAM

TABLET; ORAL

	ESTAZOLAM		
AB	IVAX PHARMS	1MG	N74826 001 JUL 03, 1997

FDA data supplied by DrugPatentWatch.com

ESTAZOLAM

TABLET; ORAL

	ESTAZOLAM			
AB	IVAX PHARMS	2MG	**N74826 002** JUL 03, 1997	
AB	TEVA	1MG	**N74921 001** JUL 10, 1997	
AB		2MG	**N74921 002** JUL 10, 1997	
AB	WATSON LABS	1MG	**N74818 001** AUG 19, 1997	
AB		2MG	**N74818 002** AUG 19, 1997	
	PROSOM			
AB	ABBOTT	1MG	**N19080 001** DEC 26, 1990	
AB +		2MG	**N19080 002** DEC 26, 1990	

ESTRADIOL

CREAM; VAGINAL

	ESTRACE			
+	WARNER CHILCOTT	0.01%	N86069 001 JAN 31, 1984	

FILM, EXTENDED RELEASE; TRANSDERMAL

	ALORA			
BX	WATSON LABS	0.025MG/24HR	N20655 004 APR 05, 2002	
BX		0.05MG/24HR	N20655 001 DEC 20, 1996	
BX		0.075MG/24HR	N20655 002 DEC 20, 1996	
BX		0.1MG/24HR	N20655 003 DEC 20, 1996	
	CLIMARA			
AB2 +	BERLEX LABS	0.05MG/24HR	**N20375 001** DEC 22, 1994	
AB2 +		0.1MG/24HR	**N20375 002** DEC 22, 1994	
BX +		0.025MG/24HR	N20375 004 MAR 05, 1999	
BX +		0.0375MG/24HR	N20375 005 MAY 27, 2003	
BX +		0.075MG/24HR	N20375 003 MAR 23, 1998	

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

	CLIMARA			
+	BERLEX LABS	0.06MG/24HR	N20375 006 MAY 27, 2003	
	ESCLIM			
BX	WOMEN FIRST HLTHCARE	0.025MG/24HR	N20847 001 AUG 04, 1998	
BX		0.0375MG/24HR	N20847 002 AUG 04, 1998	
BX		0.05MG/24HR	N20847 003 AUG 04, 1998	
BX		0.075MG/24HR	N20847 004 AUG 04, 1998	
BX		0.1MG/24HR	N20847 005 AUG 04, 1998	
	ESTRADERM			
BX +	NOVARTIS	0.05MG/24HR	N19081 002 SEP 10, 1986	
BX +		0.1MG/24HR	N19081 003 SEP 10, 1986	
	ESTRADIOL			
AB2	MYLAN TECHNOLOGIES	0.05MG/24HR	**N75233 001** FEB 24, 2000	
AB2		0.1MG/24HR	**N75182 001** FEB 24, 2000	
	VIVELLE			
AB1 +	NOVARTIS	0.0375MG/24HR	**N20323 001** OCT 28, 1994	
AB1 +		0.05MG/24HR	**N20323 002** OCT 28, 1994	
AB1 +		0.075MG/24HR	**N20323 003** OCT 28, 1994	
AB1 +		0.1MG/24HR	**N20323 004** OCT 28, 1994	
+		0.025MG/24HR	N20323 005 AUG 16, 2000	
	VIVELLE-DOT			
AB1	NOVARTIS	0.0375MG/24HR	**N20538 005** JAN 08, 1999	
AB1		0.05MG/24HR	**N20538 006** JAN 08, 1999	
AB1		0.075MG/24HR	**N20538 007** JAN 08, 1999	
AB1		0.1MG/24HR	**N20538 008** JAN 08, 1999	

FDA data supplied by DrugPatentWatch.com

ESTRADIOL

INSERT, EXTENDED RELEASE; VAGINAL

	ESTRING			
+	PHARMACIA AND UPJOHN	0.0075MG/24HR	N20472 001	APR 26, 1996

TABLET; ORAL

	ESTRACE			
AB	BRISTOL MYERS SQUIBB	0.5MG	**N81295 001**	JUN 30, 1993
AB		1MG	**N84499 001**	
AB	+	2MG	**N84500 001**	
	ESTRADIOL			
AB	APPLIED ANAL	0.5MG	**N40138 001**	JAN 30, 1998
AB		1MG	**N40138 002**	JAN 30, 1998
AB		2MG	**N40138 003**	JAN 30, 1998
AB	BARR	0.5MG	**N40197 001**	OCT 22, 1997
AB		1MG	**N40197 002**	OCT 22, 1997
AB		2MG	**N40197 003**	OCT 22, 1997
AB	MYLAN	0.5MG	**N40326 001**	APR 21, 1999
AB		1MG	**N40326 002**	APR 21, 1999
AB		2MG	**N40326 003**	APR 21, 1999
AB	USL PHARMA	0.5MG	**N40297 001**	APR 17, 2002
AB		1MG	**N40297 002**	APR 17, 2002
AB		2MG	**N40297 003**	APR 17, 2002
AB	WATSON LABS	0.5MG	**N40114 003**	MAR 14, 1996
AB		1MG	**N40114 001**	MAR 14, 1996
AB		2MG	**N40114 002**	MAR 14, 1996
	GYNODIOL			
AB	DURAMED PHARMS BARR	0.5MG	**N40212 001**	DEC 29, 1997
AB		1MG	**N40212 002**	DEC 29, 1997

ESTRADIOL

TABLET; ORAL

	GYNODIOL			
AB	DURAMED PHARMS BARR	2MG	**N40212 004**	DEC 29, 1997
		1.5MG	N40212 003	DEC 29, 1997
	INNOFEM			
AB	NOVO NORDISK	0.5MG	**N40312 001**	NOV 19, 1999
AB		1MG	**N40312 002**	NOV 19, 1999
AB		2MG	**N40312 003**	NOV 19, 1999

TABLET; VAGINAL

	VAGIFEM			
+	NOVO NORDISK	25 UGM	N20908 001	MAR 26, 1999

ESTRADIOL; LEVONORGESTREL

FILM, EXTENDED RELEASE; TRANSDERMAL

	CLIMARA PRO			
+	BERLEX LABS	0.045MG/24HR;0.015MG/24HR	N21258 001	NOV 21, 2003

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE; TRANSDERMAL

	COMBIPATCH			
	NOVARTIS	0.05MG/24HR;0.14MG/24HR	N20870 001	AUG 07, 1998
+		0.05MG/24HR;0.25MG/24HR	N20870 002	AUG 07, 1998

TABLET; ORAL

	ACTIVELLA			
+	NOVO NORDISK	1MG;0.5MG	N20907 001	NOV 18, 1998

FDA data supplied by DrugPatentWatch.com

ESTRADIOL; NORGESTIMATE

TABLET; ORAL
PREFEST
+ KING PHARMS 1MG,1MG;0.09MG,N/A N21040 001 OCT 22, 1999

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL
FEMRING
GALEN LTD 0.05MG/24HR N21367 001 MAR 20, 2003
+ 0.1MG/24HR N21367 002 MAR 20, 2003

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION
DEPO-ESTRADIOL
AO + PHARMACIA AND UPJOHN **5MG/ML** **N85470 003**
ESTRADIOL CYPIONATE
AO STERIS **5MG/ML** **N85620 001**

ESTRADIOL HEMIHYDRATE

EMULSION; TOPICAL
ESTRASORB
+ NOVAVAX 0.25% N21371 001 OCT 09, 2003

ESTRADIOL VALERATE

INJECTABLE; INJECTION
DELESTROGEN
AO + KING PHARMS **20MG/ML** **N09402 004**
AO + **40MG/ML** **N09402 003**
+ 10MG/ML N09402 002
ESTRADIOL VALERATE
AO STERIS **20MG/ML** **N83547 001**
AO **40MG/ML** **N83714 001**

ESTRAMUSTINE PHOSPHATE SODIUM

CAPSULE; ORAL
EMCYT
+ PHARMACIA AND UPJOHN EQ 140MG PHOSPHATE N18045 001

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL
PREMARIN
+ WYETH PHARMS INC 0.625MG/GM N20216 001

INJECTABLE; INJECTION
PREMARIN
+ WYETH PHARMS INC 25MG/VIAL N10402 001

TABLET; ORAL
PREMARIN
WYETH PHARMS INC 0.3MG N04782 003
0.45MG N04782 006 JUL 16, 2003
+ 0.625MG N04782 004
0.9MG N04782 005 JAN 26, 1984
+ 1.25MG N04782 001
2.5MG N04782 002

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28
PREMPHASE 14/14
+ WYETH PHARMS INC 0.625MG,0.625MG;N/A,5MG N20527 002 NOV 17, 1995

PREMPRO
+ WYETH PHARMS INC 0.3MG;1.5MG N20527 005 JUN 04, 2003
+ 0.45MG;1.5MG N20527 004 MAR 12, 2003
+ 0.625MG,0.625MG;2.5MG, 2.5MG N20527 001 NOV 17, 1995
+ 0.625MG,0.625MG;5MG,5MG N20527 003 JAN 09, 1998

FDA data supplied by DrugPatentWatch.com

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

	CENESTIN			
	DURAMED	0.3MG	N20992 001	JUN 21, 2002
		0.625MG	N20992 002	MAR 24, 1999
		0.9MG	N20992 003	MAR 24, 1999
+		1.25MG	N20992 004	MAR 13, 2000

ESTROGENS, ESTERIFIED

TABLET; ORAL

	MENEST			
	MONARCH PHARMS	0.3MG	N84951 001	
		0.625MG	N84948 001	
		1.25MG	N84950 001	
+		2.5MG	N84949 001	

ESTRONE

INJECTABLE; INJECTION

	ESTRONE			
+	STERIS	5MG/ML	N85239 001	

ESTROPIPATE

CREAM; VAGINAL

	OGEN			
+	PHARMACIA AND UPJOHN	1.5MG/GM	N84710 001	

TABLET; ORAL

	ESTROPIPATE			
AB	BARR	**0.75MG**	**N40135 001**	NOV 27, 1996
AB		**1.5MG**	**N40135 002**	NOV 27, 1996
AB		**3MG**	**N40135 003**	NOV 27, 1996
AB	DURAMED PHARMS BARR	**0.75MG**	**N40296 001**	NOV 01, 1999
AB		**1.5MG**	**N40296 002**	NOV 01, 1999

ESTROPIPATE

TABLET; ORAL

	ESTROPIPATE				
AB	DURAMED PHARMS BARR	**3MG**	**N40296 003**	NOV 01, 1999
AB	MYLAN	**0.75MG**	**N40359 001**	AUG 26, 1999
AB		**1.5MG**	**N40359 002**	AUG 26, 1999
AB		**3MG**	**N40359 003**	AUG 26, 1999
AB	WATSON LABS	**0.75MG**	**N81213 001**	SEP 23, 1993
AB		**1.5MG**	**N81214 001**	SEP 23, 1993
AB		**3MG**	**N81215 001**	SEP 23, 1993
AB		**6MG**	**N81216 001**	SEP 23, 1993
	OGEN .625			
AB	PHARMACIA AND UPJOHN	**0.75MG**	**N83220 001**	
	OGEN 1.25			
AB	PHARMACIA AND UPJOHN	**1.5MG**	**N83220 002**	
	OGEN 2.5			
AB +	PHARMACIA AND UPJOHN	**3MG**	**N83220 003**	
	OGEN 5			
AB	PHARMACIA AND UPJOHN	**6MG**	**N83220 004**	
	ORTHO-EST			
AB	WOMEN FIRST HLTHCARE	**0.75MG**	**N89567 001**	FEB 27, 1991
AB		**1.5MG**	**N89582 001**	JUL 17, 1991

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

	EDECRIN			
+	MERCK	EQ 50MG BASE/VIAL	N16093 001	

ETHACRYNIC ACID

TABLET; ORAL

	EDECRIN			
+	MERCK	25MG	N16092 001	

FDA data supplied by DrugPatentWatch.com

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

	ETHAMBUTOL HCL			
AB	BARR	**400MG**	**N76057 001**	
			NOV 26, 2001	
AB	WEST WARD	**100MG**	**N75095 001**	
			NOV 30, 1999	
AB	+	**400MG**	**N75095 002**	
			NOV 30, 1999	

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

	ETHAMOLIN		
	+ QUESTCOR PHARMS	50MG/ML	N19357 001
			DEC 22, 1988

ETHINYL ESTRADIOL

TABLET; ORAL

	ESTINYL		
	SCHERING	0.02MG	N05292 001
		0.05MG	N05292 002
	+	0.5MG	N05292 003

ETHINYL ESTRADIOL; *MULTIPLE*

SEE DESOGESTREL; ETHINYL ESTRADIOL

SEE DROSPIRENONE; ETHINYL ESTRADIOL

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21

	DEMULEN 1/35-21			
AB	+ GD SEARLE LLC	**0.035MG;1MG**	**N18168 001**	
	DEMULEN 1/50-21			
AB	+ GD SEARLE LLC	**0.05MG;1MG**	**N16927 001**	
	ZOVIA 1/35E-21			
AB	WATSON LABS	**0.035MG;1MG**	**N72720 001**	
			DEC 30, 1991	
	ZOVIA 1/50E-21			
AB	WATSON LABS	**0.05MG;1MG**	**N72722 001**	
			DEC 30, 1991	

TABLET; ORAL-28

	DEMULEN 1/35-28		
AB	+ GD SEARLE LLC	**0.035MG;1MG**	**N18160 001**

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

	DEMULEN 1/50-28		
AB	GD SEARLE LLC	**0.05MG;1MG**	**N16936 001**
	ZOVIA 1/35E-28		
AB	WATSON LABS	**0.035MG;1MG**	**N72721 001**
			DEC 30, 1991
	ZOVIA 1/50E-28		
AB	WATSON LABS	**0.05MG;1MG**	**N72723 001**
			DEC 30, 1991

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL

	NUVARING		
	+ ORGANON USA INC	0.015MG;0.12MG	N21187 001
			OCT 03, 2001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

	PREVEN EMERGENCY CONTRACEPTIVE KIT		
	+ GYNETICS	0.05MG;0.25MG	N20946 001
			SEP 01, 1998
	SEASONALE		
	+ BARR	0.03MG;0.15MG	N21544 001
			SEP 05, 2003

TABLET; ORAL-21

	ALESSE		
AB1	+ WYETH PHARMS INC	**0.02MG;0.1MG**	**N20683 001**
			MAR 27, 1997
	AVIANE-21		
AB1	DURAMED PHARMS BARR	**0.02MG;0.1MG**	**N75796 002**
			APR 30, 2001
	ENPRESSE-21		
AB	DURAMED PHARMS BARR	**0.03MG,0.05MG,0.075MG;0.04MG,0.03MG,0.125MG**	**N75809 001**
			JUL 16, 2001
	LESSINA-21		
AB2	BARR	**0.02MG;0.1MG**	**N75803 001**
			MAR 20, 2002
	LEVLITE		
AB2	+ BERLEX LABS	**0.02MG;0.1MG**	**N20860 001**
			JUL 13, 1998

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

	LEVONORGESTREL AND ETHINYL ESTRADIOL			
AB1	BARR	0.02MG;0.1MG	N75862 001	APR 29, 2003
	LEVORA 0.15/30-21			
AB	WATSON LABS	0.03MG;0.15MG	N73592 001	DEC 13, 1993
	NORDETTE-21			
AB	+ MONARCH PHARMS	0.03MG;0.15MG	N18668 001	MAY 10, 1982
	PORTIA-21			
AB	BARR	0.03MG;0.15MG	N75866 001	MAY 23, 2002
	TRIPHASIL-21			
AB	+ WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG, 0.125MG	N19192 001	NOV 01, 1984
	TRIVORA-21			
AB	WATSON LABS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG, 0.125MG	N74538 001	DEC 18, 1997

TABLET; ORAL-28

	ALESSE			
AB1	WYETH PHARMS INC	0.02MG;0.1MG	N20683 002	MAR 27, 1997
	AVIANE-28			
AB1	DURAMED PHARMS BARR	0.02MG;0.1MG	N75796 001	APR 30, 2001
	ENPRESSE-28			
AB	DURAMED PHARMS BARR	0.03MG,0.03MG,0.075MG;0.04MG,0.05MG, 0.125MG	N75809 002	JUL 16, 2001
	LESSINA-28			
AB	BARR	0.02MG;0.1MG	N75803 002	MAR 20, 2002
	LEVLITE			
AB	BERLEX LABS	0.02MG;0.1MG	N20860 002	JUL 13, 1998
	LEVONORGESTREL AND ETHINYL ESTRADIOL			
AB1	BARR	0.02MG;0.1MG	N75862 002	APR 29, 2003
	LEVORA 0.15/30-28			
AB	WATSON LABS	0.03MG;0.15MG	N73594 001	DEC 13, 1993
	NORDETTE-28			
AB	MONARCH PHARMS	0.03MG;0.15MG	N18782 001	JUL 21, 1982

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

	PORTIA-28			
AB	BARR	0.03MG;0.15MG	N75866 002	MAY 23, 2002
	TRIPHASIL-28			
AB	WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG, 0.125MG	N19190 001	NOV 01, 1984
	TRIVORA-28			
AB	WATSON LABS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG, 0.125MG	N74538 002	DEC 18, 1997

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

	ORTHO EVRA			
+	ORTHO MCNEIL PHARM	0.02MG/24HR;0.15MG/24HR	N21180 001	NOV 20, 2001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	BREVICON 21-DAY			
AB	+ WATSON LABS	0.035MG;0.5MG	N17566 001	
	GENCEPT 10/11-21			
AB	BARR	0.035MG,0.035MG;0.5MG,1MG	N72694 001	FEB 28, 1992
	NORCEPT-E 1/35 21			
AB	GYNOPHARMA	0.035MG;1MG	N71545 001	FEB 09, 1989
	NORETHIN 1/35E-21			
AB	WATSON LABS	0.035MG;1MG	N71480 001	APR 12, 1988
	NORETHINDRONE AND ETHINYL ESTRADIOL			
AB	WATSON LABS	0.035MG;0.5MG	N70684 001	JAN 29, 1987
AB		0.035MG;1MG	N70685 001	JAN 29, 1987
	NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)			
AB	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71043 001	APR 01, 1988
	NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)			
AB	+ WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71041 001	SEP 24, 1991

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

	NORINYL 1+35 21-DAY		
AB	WATSON LABS	0.035MG;1MG	N17565 001
	NORTREL 0.5/35-21		
AB	BARR	0.035MG;0.5MG	N72692 001 FEB 28, 1992
	NORTREL 1/35-21		
AB	BARR	0.035MG;1MG	N72693 001 FEB 28, 1992
	NORTREL 7/7/7		
AB	BARR	0.035MG,0.035MG,0.035MG;0.5MG, 0.75MG,1MG	N75478 001 AUG 30, 2002
	OVCON-35		
+	WARNER CHILCOTT	0.035MG;0.4MG	N18127 001

TABLET; ORAL-28

	BREVICON 28-DAY		
AB	WATSON LABS	0.035MG;0.5MG	N17743 001
	GENCEPT 10/11-28		
AB	BARR	0.035MG,0.035MG;0.5MG,1MG	N72697 001 FEB 28, 1992
	MODICON 28		
AB	ORTHO MCNEIL PHARM	0.035MG;0.5MG	N17735 001
	NORCEPT-E 1/35 28		
AB	GYNOPHARMA	0.035MG;1MG	N71546 001 FEB 09, 1989
	NORETHIN 1/35E-28		
AB	WATSON LABS	0.035MG;1MG	N71481 001 APR 12, 1988
	NORETHINDRONE AND ETHINYL ESTRADIOL		
AB	WATSON LABS	0.035MG;0.5MG	N70686 001 JAN 29, 1987
AB		0.035MG;1MG	N70687 001 JAN 29, 1987
	NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)		
AB	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71044 001 APR 01, 1988
	NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)		
AB	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71042 001 SEP 24, 1991
	NORINYL 1+35 28-DAY		
AB	WATSON LABS	0.035MG;1MG	N17565 002
	NORTREL 0.5/35-28		
AB	BARR	0.035MG;0.5MG	N72695 001 FEB 28, 1992

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

	NORTREL 1/35-28		
AB	BARR	0.035MG;1MG	N72696 001 FEB 28, 1992
	NORTREL 7/7/7		
AB	BARR	0.035MG,0.035MG,0.035MG;0.05MG, 0.75MG,1MG	N75478 002 AUG 30, 2002
	ORTHO-NOVUM 1/35-28		
AB	ORTHO MCNEIL PHARM	0.035MG;1MG	N17919 002
	ORTHO-NOVUM 10/11-28 IN PLASTIC CONTAINER		
AB	ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N18354 002 JAN 11, 1982
	ORTHO-NOVUM 7/14-28		
AB +	ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG	N19004 002 APR 04, 1984
	ORTHO-NOVUM 7/7/7-28		
AB +	ORTHO MCNEIL PHARM	0.035MG,0.035MG,0.035MG;0.5MG, 0.75MG,1MG	N18985 002 APR 04, 1984
	OVCON-35		
+	WARNER CHILCOTT	0.035MG;0.4MG	N17716 001
	OVCON-50		
+	WARNER CHILCOTT	0.05MG;1MG	N17576 001
	TRI-NORINYL 28-DAY		
+	WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,1MG, 0.5MG	N18977 002 APR 13, 1984

TABLET, CHEWABLE; ORAL-28

	OVCON-35		
+	WARNER CHILCOTT	0.035MG;0.4MG	N21490 001 NOV 14, 2003

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

	FEMHRT		
+	GALEN CHEM	0.005MG;1MG	N21065 002 OCT 15, 1999

TABLET; ORAL-21

	JUNEL 1.5/30		
AB	BARR	0.03MG;1.5MG	N76381 001 MAY 30, 2003

FDA data supplied by DrugPatentWatch.com

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21

	JUNEL 1/20			
AB	BARR	0.02MG;1MG	N76380 001	MAY 30, 2003
	LOESTRIN 21 1.5/30			
AB	+ GALEN CHEM	0.03MG;1.5MG	N17875 001	
	LOESTRIN 21 1/20			
AB	+ GALEN CHEM	0.02MG;1MG	N17876 001	

TABLET; ORAL-28

	ESTROSTEP FE			
	+ GALEN CHEM	0.02MG,0.03MG,0.035MG;1MG,1MG, 1MG	N20130 002	OCT 09, 1996
	JUNEL FE 1.5/30			
AB	BARR	0.03MG;1.5MG	N76064 001	SEP 18, 2003
	JUNEL FE 1/20			
AB	BARR	0.02MG;1MG	N76081 001	SEP 18, 2003
	LOESTRIN FE 1.5/30			
AB	+ GALEN CHEM	0.03MG;1.5MG	N17355 001	
	LOESTRIN FE 1/20			
AB	+ GALEN CHEM	0.02MG;1MG	N17354 001	
	MICROGESTIN FE 1.5/30			
AB	WATSON LABS	0.03MG;1.5MG	N75548 001	FEB 05, 2001
	MICROGESTIN FE 1/20			
AB	WATSON LABS	0.02MG;1MG	N75647 001	FEB 05, 2001

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

	ORTHO CYCLEN-28			
AB	+ JOHNSON RW	0.035MG;0.25MG	N19653 002	DEC 29, 1989
	ORTHO TRI-CYCLEN			
AB	+ JOHNSON RW	0.035MG,0.035MG,0.035MG;0.18MG, 0.215MG,0.25MG	N19697 001	JUL 03, 1992
	ORTHO TRI-CYCLEN LO			
	+ JOHNSON AND JOHNSON	0.025MG,0.025MG,0.25MG;0.18MG, 0.215MG,0.25MG	N21241 001	AUG 22, 2002

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

	SPRINTEC			
AB	BARR	0.035MG;0.25MG	N75804 001	SEP 25, 2002
	TRI-SPRINTEC			
AB	BARR	0.035MG,0.035MG,0.035MG;0.18MG, 0.215MG,0.25MG	N75808 001	DEC 29, 2003

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

	CRYSELLE			
AB	DURAMED PHARMS BARR	0.03MG;0.3MG	N75840 001	NOV 30, 2001
	LO/OVRAL			
AB	+ WYETH PHARMS INC	0.03MG;0.3MG	N17612 001	
	LOW-OGESTREL-21			
AB	WATSON LABS	0.03MG;0.3MG	N75288 001	JUL 28, 1999
	OGESTREL 0.5/50-21			
AB	WATSON LABS	0.05MG;0.5MG	N75406 001	DEC 15, 1999
	OVRAL			
AB	+ WYETH PHARMS INC	0.05MG;0.5MG	N16672 001	

TABLET; ORAL-28

	CRYSELLE			
AB	DURAMED PHARMS BARR	0.03MG;0.3MG	N75840 002	NOV 30, 2001
	LO/OVRAL-28			
AB	WYETH PHARMS INC	0.03MG;0.3MG	N17802 001	
	LOW-OGESTREL-28			
AB	WATSON LABS	0.03MG;0.3MG	N75288 002	JUL 28, 1999
	OGESTREL 0.5/50-28			
AB	WATSON LABS	0.05MG;0.5MG	N75406 002	DEC 15, 1999
	OVRAL-28			
AB	WYETH PHARMS INC	0.05MG;0.5MG	N16806 001	

ETHIODIZED OIL

OIL; INTRALYMPHATIC, INTRAUTERINE

	ETHIODOL			
	SAVAGE LABS	99%	N09190 001	

FDA data supplied by DrugPatentWatch.com

ETHIONAMIDE

TABLET; ORAL
TRECATOR-SC
+ WYETH PHARMS INC 250MG N13026 002

ETHOSUXIMIDE

CAPSULE; ORAL
ETHOSUXIMIDE
AB BANNER PHARMACAPS **250MG** **N40430 001** OCT 28, 2002

ZARONTIN
AB + PARKE DAVIS **250MG** **N12380 001**

SYRUP; ORAL
ETHOSUXIMIDE
AA COPLEY PHARM **250MG/5ML** **N81306 001** JUL 30, 1993
AA MIKART **250MG/5ML** **N40506 001** DEC 22, 2003
AA PHARM ASSOC **250MG/5ML** **N40253 001** NOV 22, 2000

ZARONTIN
AA + PARKE DAVIS **250MG/5ML** **N80258 001**

ETHOTOIN

TABLET; ORAL
PEGANONE
+ OVATION PHARMS 250MG N10841 001

ETHYNODIOL DIACETATE; *MULTIPLE*
SEE ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

ETIDRONATE DISODIUM

INJECTABLE; INJECTION
DIDRONEL
+ MGI PHARMA INC 50MG/ML N19545 001 APR 20, 1987

TABLET; ORAL
DIDRONEL
AB PROCTER AND GAMBLE **200MG** **N17831 001**

ETIDRONATE DISODIUM

TABLET; ORAL
DIDRONEL
AB + PROCTER AND GAMBLE **400MG** **N17831 002**
ETIDRONATE DISODIUM
AB GENPHARM **200MG** **N75800 001** JAN 24, 2003
AB **400MG** **N75800 002** JAN 24, 2003

ETODOLAC

CAPSULE; ORAL
ETODOLAC
AB AAIPHARMA LLC **300MG** **N74929 001** JAN 30, 1998
AB ENDO PHARMS **200MG** **N74842 001** JUL 17, 1997
AB **300MG** **N74842 002** JUL 17, 1997
AB GENPHARM **200MG** **N75071 001** SEP 30, 1998
AB **300MG** **N75071 002** SEP 30, 1998
AB IVAX PHARMS **200MG** **N74899 001** JUL 08, 1997
AB **300MG** **N74899 002** JUL 08, 1997
AB MYLAN **200MG** **N74932 001** MAY 16, 1997
AB **300MG** **N74932 002** MAY 16, 1997
AB SANDOZ **200MG** **N74840 001** AUG 29, 1997
AB **200MG** **N74942 001** SEP 30, 1997
AB **300MG** **N74840 002** AUG 29, 1997
AB **300MG** **N74942 002** SEP 30, 1997
AB TARO **200MG** **N75078 001** APR 30, 1998
AB **300MG** **N75078 002** APR 30, 1998
AB TEVA **200MG** **N75126 001** SEP 16, 1999

tch.com

ETODOLAC

CAPSULE; ORAL

	ETODOLAC			
AB	TEVA	300MG	N75126 002	SEP 16, 1999
AB	TORPHARM	200MG	N75419 001	JUL 28, 2000
AB		300MG	N75419 002	JUL 28, 2000
AB	WATSON LABS	200MG	N74844 001	DEC 23, 1997
AB		300MG	N74844 002	DEC 23, 1997
	LODINE			
AB	WYETH PHARMS INC	200MG	N18922 002	JAN 31, 1991
AB +		300MG	N18922 003	JAN 31, 1991

TABLET; ORAL

	ETODOLAC			
AB	AAIPHARMA LLC	400MG	N74927 001	OCT 30, 1997
AB	APOTEX	400MG	N76004 001	DEC 03, 2002
AB		500MG	N76004 002	DEC 03, 2002
AB	ENDO PHARMS	400MG	N74841 001	JUN 27, 1997
AB	EON	400MG	N74903 001	APR 11, 1997
AB		500MG	N74903 002	APR 19, 1999
AB	GENPHARM	400MG	N75012 001	SEP 30, 1998
AB		500MG	N75012 002	SEP 30, 1998
AB	IVAX PHARMS	400MG	N74883 001	FEB 28, 1997
AB		500MG	N74883 002	NOV 20, 1998
AB	MYLAN	400MG	N75104 001	FEB 06, 1998
AB		500MG	N75104 002	NOV 20, 1998
AB	PUREPAC PHARM	400MG	N74819 001	FEB 28, 1997

ETODOLAC

TABLET; ORAL

	ETODOLAC			
AB	RANBAXY	400MG	N75226 001	NOV 24, 1998
AB		500MG	N75226 002	NOV 24, 1998
AB	SANDOZ	400MG	N74839 001	JUL 11, 1997
AB		400MG	N74846 001	FEB 28, 1997
AB	TARO PHARM INDS	400MG	N75074 001	MAR 11, 1998
AB		500MG	N75074 002	APR 25, 2000
AB	TEVA	400MG	N74847 001	APR 23, 1999
AB		400MG	N75009 001	NOV 26, 1997
AB		500MG	N74847 002	APR 23, 1999
AB		500MG	N75009 002	DEC 28, 1999
AB	WATSON LABS	400MG	N74892 001	APR 16, 1997
AB		400MG	N75069 001	APR 16, 1998
AB		500MG	N74892 002	OCT 29, 1998
	LODINE			
AB	WYETH PHARMS INC	400MG	N18922 004	JUL 29, 1993
AB +		500MG	N18922 005	JUN 28, 1996

TABLET, EXTENDED RELEASE; ORAL

	ETODOLAC			
AB	ANDRX PHARMS	400MG	N75829 001	NOV 30, 2001
AB		500MG	N75829 002	NOV 30, 2001
AB	EON	400MG	N75943 001	JUL 26, 2002
AB		500MG	N75943 002	JUL 26, 2002
AB		600MG	N75943 003	JUL 26, 2002

FDA data supplied by DrugPatentWatch.com

ETODOLAC

TABLET, EXTENDED RELEASE; ORAL

	ETODOLAC			
AB	POINT HOLDINGS	400MG	N75696 001	JUL 31, 2000
AB	TARO	400MG	N76174 001	MAR 13, 2003
AB		500MG	N76174 002	MAR 13, 2003
AB		600MG	N76174 003	MAR 13, 2003
AB	TEVA	400MG	N75665 003	FEB 05, 2001
AB		500MG	N75665 002	JUL 31, 2000
AB		600MG	N75665 001	JUL 31, 2000
	LODINE XL			
AB +	WYETH PHARMS INC	400MG	N20584 001	OCT 25, 1996
AB +		500MG	N20584 003	JAN 20, 1998
AB +		600MG	N20584 002	OCT 25, 1996

ETOMIDATE

INJECTABLE; INJECTION

	AMIDATE			
AP +	ABBOTT	2MG/ML	N18227 001	SEP 07, 1982
	ETOMIDATE			
AP	BEDFORD	2MG/ML	N74593 001	NOV 04, 1996

ETONOGESTREL; *MULTIPLE*
SEE ETHINYL ESTRADIOL; ETONOGESTREL

ETOPOSIDE

CAPSULE; ORAL

	ETOPOSIDE			
AB	GENPHARM	50MG	N75635 001	SEP 19, 2001

ETOPOSIDE

CAPSULE; ORAL

	VEPESID			
AB +	BRISTOL	50MG	N19557 001	DEC 30, 1986

INJECTABLE; INJECTION

	ETOPOSIDE			
AP	ABBOTT	20MG/ML	N74320 001	AUG 30, 1995
AP		20MG/ML	N74351 001	AUG 30, 1995
AP	AM PHARM PARTNERS	20MG/ML	N74983 001	SEP 30, 1998
AP	BEDFORD	20MG/ML	N74290 001	JUL 17, 1995
AP	MARSAM PHARMS LLC	20MG/ML	N74968 001	JAN 09, 1998
AP	PHARMACHEMIE	20MG/ML	N74227 001	FEB 22, 1996
AP	SICOR PHARMS	20MG/ML	N74284 001	FEB 10, 1994
AP		20MG/ML	N74529 001	JUL 24, 1996
AP	SUPERGEN	20MG/ML	N74513 001	MAR 14, 1996
	TOPOSAR			
AP	GENSIA SICOR PHARMS	20MG/ML	N74166 001	FEB 27, 1995
	VEPESID			
AP +	BRISTOL MYERS SQUIBB	20MG/ML	N18768 001	NOV 10, 1983

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

	ETOPOPHOS PRESERVATIVE FREE		
+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N20457 001 MAY 17, 1996

EXEMESTANE

TABLET; ORAL

	AROMASIN		
+	PHARMACIA AND UPJOHN	25MG	N20753 001 OCT 21, 1999

FDA data supplied by DrugPatentWatch.com

EZETIMIBE

TABLET; ORAL
ZETIA
+ MSP SINGAPORE 10MG N21445 001 OCT 25, 2002

FAMCICLOVIR

TABLET; ORAL
FAMVIR
NOVARTIS 125MG N20363 003 DEC 11, 1995
250MG N20363 001 APR 26, 1996
+ 500MG N20363 002 JUN 29, 1994

FAMOTIDINE

FOR SUSPENSION; ORAL
PEPCID
+ MERCK 40MG/5ML N19527 001 FEB 02, 1987

INJECTABLE; INJECTION
FAMOTIDINE

AP	ABBOTT	10MG/ML	**N75870 001** NOV 23, 2001
AP		10MG/ML	**N75905 001** NOV 23, 2001
AP	AM PHARM PARTNERS	10MG/ML	**N75709 001** APR 16, 2001
AP	APOTEX	10MG/ML	**N75942 001** AUG 02, 2002
AP	BAXTER HLTHCARE	10MG/ML	**N75488 001** APR 16, 2001
AP		10MG/ML	**N75799 001** APR 30, 2002
AP	BEDFORD	10MG/ML	**N75651 001** APR 16, 2001
AP		10MG/ML	**N75684 001** APR 16, 2001
AP	MAYNE PHARMA USA	10MG/ML	**N75705 001** APR 16, 2001

FAMOTIDINE PRESERVATIVE FREE

AP	AM PHARM PARTNERS	10MG/ML	**N75813 001** APR 16, 2001

FAMOTIDINE

INJECTABLE; INJECTION
FAMOTIDINE PRESERVATIVE FREE

AP	APOTEX	10MG/ML	**N76324 001** NOV 27, 2002
AP	BAXTER HLTHCARE	10MG/ML	**N75486 001** APR 16, 2001
AP		10MG/ML	**N75789 001** APR 30, 2002
AP	BEDFORD	10MG/ML	**N75622 001** APR 16, 2001
AP	BEN VENUE	10MG/ML	**N75825 001** APR 17, 2001
AP	MAYNE PHARMA USA	10MG/ML	**N75669 001** APR 16, 2001

FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

AP	APOTEX	10MG/ML	**N76322 001** NOV 27, 2002

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	0.4MG/ML	**N75591 001** MAY 10, 2001

PEPCID

AP	+ MERCK	10MG/ML	**N19510 001** NOV 04, 1986

PEPCID PRESERVATIVE FREE

AP	+ MERCK	10MG/ML	**N19510 004** NOV 04, 1986

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

AP	+ MERCK	0.4MG/ML	**N20249 001** FEB 18, 1994

TABLET; ORAL
FAMOTIDINE

AB	CARLSBAD	20MG	**N75805 001** APR 16, 2001
AB		40MG	**N75805 002** APR 16, 2001
AB	DR REDDYS LABS LTD	20MG	**N75718 001** APR 16, 2001
AB		40MG	**N75718 002** APR 16, 2001
AB	EON	20MG	**N75793 001** APR 16, 2001
AB		40MG	**N75793 002** APR 16, 2001
AB	GENPHARM	20MG	**N75457 001** APR 18, 2001

FDA data supplied by DrugPatentWatch.com

FAMOTIDINE

TABLET; ORAL
FAMOTIDINE

AB	GENPHARM	40MG	N75457 002 APR 18, 2001
AB	IVAX PHARMS	20MG	N75511 001 APR 16, 2001
AB		40MG	N75511 002 APR 16, 2001
AB	MUTUAL PHARM	20MG	N75639 002 DEC 12, 2001
AB		40MG	N75639 001 DEC 12, 2001
AB	MYLAN	20MG	N75704 001 APR 16, 2001
AB		40MG	N75704 002 APR 16, 2001
AB	PUREPAC PHARM	20MG	N75650 001 SEP 14, 2001
AB		40MG	N75650 002 SEP 14, 2001
AB	SANDOZ	20MG	N75302 001 APR 16, 2001
AB		20MG	N75607 001 MAY 10, 2001
AB		40MG	N75302 002 APR 16, 2001
AB		40MG	N75607 002 MAY 10, 2001
AB	TEVA	20MG	N75311 001 APR 16, 2001
AB		40MG	N75311 002 APR 16, 2001
AB	TORPHARM	20MG	N75611 001 JUL 23, 2001
AB		40MG	N75611 002 JUL 23, 2001
AB	WATSON LABS	20MG	N75062 002 APR 16, 2001
AB		40MG	N75062 001 APR 16, 2001
AB	WOCKHARDT	20MG	N75786 001 APR 16, 2001
AB		40MG	N75786 002 APR 16, 2001

PEPCID

AB	MERCK	20MG	N19462 001 OCT 15, 1986

FAMOTIDINE

TABLET; ORAL
PEPCID

AB	+ MERCK	40MG	N19462 002 OCT 15, 1986

FELBAMATE

SUSPENSION; ORAL
FELBATOL

+	MEDPOINTE	600MG/5ML	N20189 003 JUL 29, 1993

TABLET; ORAL
FELBATOL

	MEDPOINTE	400MG	N20189 001 JUL 29, 1993
+		600MG	N20189 002 JUL 29, 1993

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL
PLENDIL

	ASTRAZENECA	2.5MG	N19834 004 SEP 22, 1994
		5MG	N19834 001 JUL 25, 1991
+		10MG	N19834 002 JUL 25, 1991

FELODIPINE; *MULTIPLE*
SEE ENALAPRIL MALEATE; FELODIPINE

FENOFIBRATE

CAPSULE; ORAL
FENOFIBRATE (MICRONIZED)

AB	IMPAX LABS	67MG	N75868 001 OCT 27, 2003
AB		134MG	N75868 002 OCT 27, 2003
AB		200MG	N75868 003 OCT 27, 2003

FDA data supplied by DrugPatentWatch.com

FENOFIBRATE

CAPSULE; ORAL

	FENOFIBRATE (MICRONIZED)			
AB	TEVA	**67MG**	**N75753 001**	SEP 03, 2002
AB		**134MG**	**N75753 002**	APR 09, 2002
AB	+	**200MG**	**N75753 003**	APR 09, 2002

TABLET; ORAL

	TRICOR			
	ABBOTT	54MG	N21203 001	SEP 04, 2001
	+	160MG	N21203 003	SEP 04, 2001

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

	CORLOPAM			
AP	+ ABBOTT	**EQ 10MG BASE/ML**	**N19922 001**	SEP 23, 1997
	FENOLDOPAM MESYLATE			
AP	PHARMAFORCE	**EQ 10MG BASE/ML**	**N76656 001**	DEC 01, 2003

FENOPROFEN CALCIUM

CAPSULE; ORAL

	FENOPROFEN CALCIUM			
AB	PAR PHARM	**EQ 200MG BASE**	**N72437 001**	AUG 22, 1988
AB		**EQ 300MG BASE**	**N72438 001**	AUG 22, 1988
AB	SANDOZ	**EQ 200MG BASE**	**N72394 001**	OCT 17, 1988
AB		**EQ 300MG BASE**	**N72395 001**	OCT 17, 1988
	NALFON			
AB	+ RANBAXY	**EQ 300MG BASE**	**N17604 002**	
	NALFON 200			
AB	RANBAXY	**EQ 200MG BASE**	**N17604 003**	

TABLET; ORAL

	FENOPROFEN CALCIUM			
AB	CLONMEL HLTHCARE	**EQ 600MG BASE**	**N72326 001**	AUG 17, 1988

FENOPROFEN CALCIUM

TABLET; ORAL

	FENOPROFEN CALCIUM			
AB	IVAX PHARMS	**EQ 600MG BASE**	**N72557 001**	AUG 29, 1988
AB	MUTUAL PHARM	**EQ 600MG BASE**	**N72902 001**	DEC 21, 1990
AB	+ MYLAN	**EQ 600MG BASE**	**N72267 001**	AUG 17, 1988
AB	PAR PHARM	**EQ 600MG BASE**	**N72429 001**	AUG 17, 1988
AB	PUREPAC PHARM	**EQ 600MG BASE**	**N72274 001**	MAY 02, 1988
AB	SANDOZ	**EQ 600MG BASE**	**N72396 001**	OCT 17, 1988
AB	WATSON LABS	**EQ 600MG BASE**	**N72407 001**	AUG 17, 1988
AB		**EQ 600MG BASE**	**N72602 001**	OCT 11, 1988

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

	DURAGESIC			
AB	+ ALZA	**0.6MG/24HR**	**N19813 004**	AUG 07, 1990
AB		**1.2MG/24HR**	**N19813 003**	AUG 07, 1990
AB		**1.8MG/24HR**	**N19813 002**	AUG 07, 1990
AB		**2.4MG/24HR**	**N19813 001**	AUG 07, 1990
	FENTANYL			
AB	MYLAN TECHNOLOGIES	**0.6MG/24HR**	**N76258 001**	NOV 21, 2003
AB		**1.2MG/24HR**	**N76258 002**	NOV 21, 2003
AB		**1.8MG/24HR**	**N76258 003**	NOV 21, 2003
AB		**2.4MG/24HR**	**N76258 004**	NOV 21, 2003

FDA data supplied by DrugPatentWatch.com

FENTANYL CITRATE

INJECTABLE; INJECTION				
FENTANYL CITRATE				
AP	ABBOTT	**EQ 0.05MG BASE/ML**	**N19115 001** JAN 12, 1985	
FENTANYL CITRATE PRESERVATIVE FREE				
AP	ABBOTT	**EQ 0.05MG BASE/ML**	**N72786 001** SEP 24, 1991	
AP	+ BAXTER HLTHCARE	**EQ 0.05MG BASE/ML**	**N19101 001** JUL 11, 1984	
SUBLIMAZE PRESERVATIVE FREE				
AP	+ AKORN MFG	**EQ 0.05MG BASE/ML**	**N16619 001**	
TROCHE/LOZENGE; ORAL				
ACTIQ				
	ANESTA	EQ 0.2MG BASE	N20747 001 NOV 04, 1998	
		EQ 0.4MG BASE	N20747 002 NOV 04, 1998	
		EQ 0.6MG BASE	N20747 003 NOV 04, 1998	
		EQ 0.8MG BASE	N20747 004 NOV 04, 1998	
		EQ 1.2MG BASE	N20747 005 NOV 04, 1998	
	+	EQ 1.6MG BASE	N20747 006 NOV 04, 1998	

FENTANYL CITRATE; *MULTIPLE*
SEE DROPERIDOL; FENTANYL CITRATE

FERRIC HEXACYANOFERRATE(II)

CAPSULE; ORAL				
RADIOGARDASE (PRUSSIAN BLUE)				
	+ HEYL CHEMISCH	500MG	N21626 001 OCT 02, 2003	

FERUMOXIDES

INJECTABLE; INJECTION				
FERIDEX I.V.				
	+ ADV MAGNETICS	EQ 11.2MG IRON/ML	N20416 001 AUG 30, 1996	

FERUMOXSIL

SUSPENSION; ORAL				
GASTROMARK				
	+ ADV MAGNETICS	EQ 0.175MG IRON/ML	N20410 001 DEC 06, 1996	

FEXOFENADINE HYDROCHLORIDE

CAPSULE; ORAL				
ALLEGRA				
	+ AVENTIS PHARMS	60MG	N20625 001 JUL 25, 1996	
TABLET; ORAL				
ALLEGRA				
	AVENTIS PHARMS	30MG	N20872 001 FEB 25, 2000	
		60MG	N20872 002 FEB 25, 2000	
	+	180MG	N20872 004 FEB 25, 2000	

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL				
ALLEGRA-D				
	+ AVENTIS PHARMS	60MG;120MG	N20786 001 DEC 24, 1997	

FINASTERIDE

TABLET; ORAL				
PROPECIA				
	+ MERCK	1MG	N20788 001 DEC 19, 1997	
PROSCAR				
	+ MERCK	5MG	N20180 001 JUN 19, 1992	

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL				
FLAVOXATE HCL				
AB	IMPAX PHARMS	**100MG**	**N76234 001** AUG 28, 2003	

Supplied by DrugPatentWatch.com

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

	URISPAS			
AB	+ ORTHO MCNEIL PHARM	100MG	N16769 001	

FLECAINIDE ACETATE

TABLET; ORAL

	FLECAINIDE ACETATE			
AB	ALPHAPHARM	50MG	N75442 001	JUL 31, 2001
AB		100MG	N75442 002	JUL 31, 2001
AB		150MG	N75442 003	JUL 31, 2001
AB	BARR	50MG	N75882 001	OCT 28, 2002
AB		100MG	N75882 002	OCT 28, 2002
AB		150MG	N75882 003	OCT 28, 2002
AB	RANBAXY	50MG	N76421 001	MAR 28, 2003
AB		100MG	N76421 002	MAR 28, 2003
AB		150MG	N76421 003	MAR 28, 2003
AB	ROXANE	50MG	N76278 001	JAN 14, 2003
AB		100MG	N76278 002	JAN 14, 2003
AB		150MG	N76278 003	JAN 14, 2003
AB	SANDOZ	50MG	N76030 001	OCT 28, 2002
AB		100MG	N76030 002	OCT 28, 2002
AB		150MG	N76030 003	OCT 28, 2002
	TAMBOCOR			
AB	3M	50MG	N18830 004	AUG 23, 1988
AB		100MG	N18830 001	OCT 31, 1985
AB	+	150MG	N18830 003	JUN 03, 1988

FLOXURIDINE

INJECTABLE; INJECTION

	FLOXURIDINE			
AP	AM PHARM PARTNERS	500MG/VIAL	N75837 001	FEB 22, 2001
AP	BEDFORD	500MG/VIAL	N75387 001	APR 16, 2000
	FUDR			
AP	+ MAYNE PHARMA USA	500MG/VIAL	N16929 001	

FLUCONAZOLE

FOR SUSPENSION; ORAL

	DIFLUCAN			
	PFIZER	50MG/5ML	N20090 001	DEC 23, 1993
	+	200MG/5ML	N20090 002	DEC 23, 1993

INJECTABLE; INJECTION

	DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER			
	+ PFIZER	200MG/100ML	N19950 003	SEP 29, 1992
	DIFLUCAN IN SODIUM CHLORIDE 0.9%			
	+ PFIZER	200MG/100ML	N19950 001	JAN 29, 1990
	DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
	+ PFIZER	200MG/100ML	N19950 002	JAN 29, 1990

TABLET; ORAL

	DIFLUCAN			
	PFIZER	50MG	N19949 001	JAN 29, 1990
		100MG	N19949 002	JAN 29, 1990
		150MG	N19949 004	JUN 30, 1994
	+	200MG	N19949 003	JAN 29, 1990

FLUCYTOSINE

CAPSULE; ORAL

	ANCOBON			
	VALEANT PHARM INTL	250MG	N17001 001	

FDA data supplied by DrugPatentWatch.com

FLUCYTOSINE

CAPSULE; ORAL

	ANCOBON			
+	VALEANT PHARM INTL	500MG	N17001 002	

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

	FLUDARA			
AP +	BERLEX	**50MG/VIAL**	**N20038 001** APR 18, 1991	
	FLUDARABINE PHOSPHATE			
AP	GENSIA SICOR PHARMS	**50MG/VIAL**	**N76349 001** AUG 28, 2003	

FLUDEOXYGLUCOSE, F-18

INJECTABLE; INJECTION

	FLUDEOXYGLUCOSE F 18			
+	DOWNSTATE CLINCL	4-90mCi/ML	N20306 002 SEP 25, 2001	

FLUDROCORTISONE ACETATE

TABLET; ORAL

	FLORINEF			
AB +	KING PHARMS	**0.1MG**	**N10060 001**	
	FLUDROCORTISONE ACETATE			
AB	BARR	**0.1MG**	**N40425 001** JAN 21, 2003	
AB	IMPAX LABS	**0.1MG**	**N40431 001** MAR 18, 2002	

FLUMAZENIL

INJECTABLE; INJECTION

	ROMAZICON			
+	HLR	0.1MG/ML	N20073 001 DEC 20, 1991	

FLUNISOLIDE

AEROSOL, METERED; INHALATION

	AEROBID			
+	ROCHE PALO	0.25MG/INH		N18340 001 AUG 17, 1984

SPRAY, METERED; NASAL

	FLUNISOLIDE			
AB	BAUSCH AND LOMB	**0.025MG/SPRAY**		**N74805 001** FEB 20, 2002
	NASALIDE			
AB +	IVAX RES	**0.025MG/SPRAY**		**N18148 001**
	NASAREL			
+	IVAX RES	0.029MG/SPRAY		N20409 001 MAR 08, 1995

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

	FLUOCINOLONE ACETONIDE			
AT	FOUGERA	**0.01%**		**N88170 001** DEC 16, 1982
AT		**0.025%**		**N88169 001** DEC 16, 1982
AT	G AND W LABS	**0.01%**		**N89526 001** JUL 26, 1988
AT		**0.025%**		**N89525 001** JUL 26, 1988
AT	TARO	**0.01%**		**N40035 001** OCT 31, 1994
AT		**0.01%**		**N87102 001** APR 27, 1982
AT		**0.025%**		**N40042 001** OCT 31, 1994
AT		**0.025%**		**N87104 001** APR 27, 1982
	SYNALAR			
AT +	MEDICIS	**0.01%**		**N12787 004**
AT +		**0.025%**		**N12787 002**
AT +		**0.025%**		**N12787 005**

OIL; TOPICAL

	DERMA-SMOOTHE/FS			
+	HILL DERMAC	0.01%		N19452 001 FEB 03, 1988

FDA data supplied by DrugPatentWatch.com

FLUOCINOLONE ACETONIDE

OINTMENT; TOPICAL

	FLUOCINOLONE ACETONIDE			
AT	FOUGERA	**0.025%**	**N88168 001**	DEC 16, 1982
AT	G AND W LABS	**0.025%**	**N89524 001**	JUL 26, 1988
AT	TARO	**0.025%**	**N40041 001**	SEP 15, 1994
	SYNALAR			
AT	+ MEDICIS	**0.025%**	**N13960 001**	

SHAMPOO; TOPICAL

	FS SHAMPOO		
+	GALDERMA LABS LP	0.01%	N20001 001 AUG 27, 1990

SOLUTION; TOPICAL

	FLUOCINOLONE ACETONIDE		
AT	FOUGERA	**0.01%**	**N88167 001** DEC 16, 1982
AT	TARO	**0.01%**	**N89124 001** SEP 11, 1985
	SYNALAR		
AT +	MEDICIS	**0.01%**	**N15296 001**

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM; TOPICAL

	TRI-LUMA		
+	HILL DERMAC	0.01%;4%;0.05%	N21112 001 JAN 18, 2002

FLUOCINONIDE

CREAM; TOPICAL

	FLUOCINONIDE		
AB1	ALPHARMA US PHARM	**0.05%**	**N73085 001** FEB 14, 1992
AB1	FOUGERA	**0.05%**	**N73030 001** OCT 17, 1994
AB1	TARO	**0.05%**	**N19117 001** JUN 26, 1984
AB1		**0.05%**	**N71500 001** JUN 10, 1987

FLUOCINONIDE

CREAM; TOPICAL

	FLUOCINONIDE		
AB1	TEVA	**0.05%**	**N72488 001** FEB 06, 1989
	FLUOCINONIDE EMULSIFIED BASE		
AB2	ALPHARMA US PHARM	**0.05%**	**N74204 001** JUN 13, 1995
AB2	TARO	**0.05%**	**N72494 001** JAN 19, 1989
AB2	TEVA	**0.05%**	**N72490 001** FEB 07, 1989
	LIDEX		
AB1 +	MEDICIS	**0.05%**	**N16908 002**
	LIDEX-E		
AB2 +	MEDICIS	**0.05%**	**N16908 003**

GEL; TOPICAL

	FLUOCINONIDE		
AB	FOUGERA	**0.05%**	**N72933 001** DEC 30, 1994
AB	TARO	**0.05%**	**N74935 001** JUL 29, 1997
AB	TEVA	**0.05%**	**N72537 001** FEB 07, 1989
	LIDEX		
AB +	MEDICIS	**0.05%**	**N17373 001**

OINTMENT; TOPICAL

	FLUOCINONIDE		
AB	ALTANA	**0.05%**	**N74905 001** AUG 26, 1997
AB	TARO	**0.05%**	**N75008 001** JUN 30, 1999
AB	TEVA	**0.05%**	**N73481 001** DEC 27, 1991
	LIDEX		
AB +	MEDICIS	**0.05%**	**N16909 002**

SOLUTION; TOPICAL

	FLUOCINONIDE		
AT	ALPHARMA	**0.05%**	**N71535 001** DEC 02, 1988
AT	COPLEY PHARM	**0.05%**	**N72522 001** SEP 28, 1990
AT	FOUGERA	**0.05%**	**N72934 001** FEB 27, 1995

FDA data supplied by DrugPatentWatch.com

FLUOCINONIDE

SOLUTION; TOPICAL

	FLUOCINONIDE			
AT	TARO	**0.05%**	**N72857 001**	AUG 02, 1989
AT		**0.05%**	**N74799 001**	DEC 31, 1996
AT	TEVA	**0.05%**	**N72511 001**	FEB 07, 1989
	LIDEX			
AT	+ MEDICIS	**0.05%**	**N18849 001**	APR 06, 1984

FLUOROMETHOLONE

OINTMENT; OPHTHALMIC

	FML		
	+ ALLERGAN	0.1%	N17760 001 SEP 04, 1985

SUSPENSION; OPHTHALMIC

	FLUOR-OP		
AB	NOVARTIS	**0.1%**	**N70185 001** FEB 27, 1986

SUSPENSION/DROPS; OPHTHALMIC

	FML		
AB	+ ALLERGAN	**0.1%**	**N16851 002** JUL 28, 1982
	FML FORTE		
	ALLERGAN	0.25%	N19216 001 APR 23, 1986

FLUOROMETHOLONE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS; OPHTHALMIC

	FML-S		
	+ ALLERGAN	0.1%;10%	N19525 001 SEP 29, 1989

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

	FLAREX		
	+ ALCON	0.1%	N19079 001 FEB 11, 1986

FLUOROMETHOLONE ACETATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

	TOBRASONE		
	+ ALCON	0.1%;0.3%	N50628 001 JUL 21, 1989

FLUOROURACIL

CREAM; TOPICAL

	CARAC		
	+ DERMIK LABS	0.5%	N20985 001 OCT 27, 2000
	EFUDEX		
	+ VALEANT PHARM INTL	5%	N16831 003
	FLUOROPLEX		
	+ ALLERGAN HERBERT	1%	N16988 001

INJECTABLE; INJECTION

	ADRUCIL		
AP	GENSIA SICOR PHARMS	**50MG/ML**	**N40023 001** OCT 18, 1991
AP	+	**50MG/ML**	**N81225 001** AUG 28, 1991
	FLUOROURACIL		
AP	AM PHARM PARTNERS	**50MG/ML**	**N40278 001** SEP 30, 1998
AP		**50MG/ML**	**N40279 001** SEP 30, 1998
AP	BEDFORD	**50MG/ML**	**N89508 001** JAN 26, 1988
AP	BIGMAR	**50MG/ML**	**N40291 001** MAR 24, 1999
AP		**50MG/ML**	**N40379 001** NOV 15, 2000
AP	+ ICN PUERTO RICO	**50MG/ML**	**N12209 001**
AP	SICOR PHARMS	**50MG/ML**	**N40333 001** JAN 27, 2000
AP		**50MG/ML**	**N40334 001** FEB 25, 2000
AP	STERIS	**50MG/ML**	**N87792 001** OCT 13, 1982

SOLUTION; TOPICAL

	EFUDEX		
AT	+ VALEANT PHARM INTL	**2%**	**N16831 001**
AT	+	**5%**	**N16831 002**

FDA data supplied by DrugPatentWatch.com

FLUOROURACIL

SOLUTION; TOPICAL

FLUOROURACIL

AT	TARO	2%	
AT		5%	

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE

AB	ALPHAPHARM	EQ 10MG BASE	**N75577 001** JAN 29, 2002
AB		EQ 20MG BASE	**N75577 002** JAN 29, 2002
AB	BARR	EQ 10MG BASE	**N74803 002** JAN 30, 2002
AB		EQ 20MG BASE	**N74803 001** AUG 02, 2001
AB	CARLSBAD	EQ 10MG BASE	**N76022 001** JAN 30, 2002
AB		EQ 20MG BASE	**N76022 002** JAN 30, 2002
AB	DR REDDYS LABS INC	EQ 10MG BASE	**N75465 001** JAN 29, 2002
AB		EQ 20MG BASE	**N75465 002** JAN 29, 2002
AB		EQ 40MG BASE	**N75465 003** AUG 02, 2001
AB	EON	EQ 10MG BASE	**N75807 001** JAN 29, 2002
AB		EQ 20MG BASE	**N75807 002** JAN 29, 2002
AB	IVAX PHARMS	EQ 10MG BASE	**N75245 002** JAN 31, 2002
AB		EQ 20MG BASE	**N75245 001** JAN 31, 2002
AB	MALLINCKRODT	EQ 10MG BASE	**N75658 001** JAN 29, 2002
AB		EQ 20MG BASE	**N75658 002** JAN 29, 2002
AB	MUTUAL PHARMA	EQ 10MG BASE	**N75787 001** JAN 29, 2002
AB		EQ 20MG BASE	**N75787 002** JAN 29, 2002
AB		EQ 40MG BASE	**N76526 001** NOV 05, 2003
AB	MYLAN	EQ 10MG BASE	**N75207 001** JAN 30, 2002
AB		EQ 20MG BASE	**N75207 002** JAN 30, 2002
AB	PLIVA	EQ 10MG BASE	**N76001 001** JAN 29, 2002
AB		EQ 20MG BASE	**N76001 002** JAN 29, 2002
AB	RANBAXY	EQ 10MG BASE	**N76165 001** FEB 01, 2002
AB		EQ 20MG BASE	**N76165 002** FEB 01, 2002
AB	SANDOZ	EQ 10MG BASE	**N75049 001** AUG 02, 2001
AB	SIEGFRIED	EQ 10MG BASE	**N75464 001** JAN 30, 2002
AB		EQ 20MG BASE	**N75464 002** JAN 30, 2002
AB	TEVA	EQ 10MG BASE	**N75452 001** JAN 29, 2002
AB		EQ 20MG BASE	**N75452 002** JAN 29, 2002
AB		EQ 40MG BASE	**N75452 003** JAN 29, 2002
AB	WATSON LABS	EQ 10MG BASE	**N75662 001** JAN 29, 2002
AB		EQ 20MG BASE	**N75662 002** JAN 29, 2002

FLUOXETINE HCL

AB	SANDOZ	EQ 20MG BASE	**N75049 002** JAN 29, 2002
AB		EQ 40MG BASE	**N75049 003** JAN 29, 2002

PROZAC

AB	LILLY	EQ 10MG BASE	**N18936 006** DEC 23, 1992
AB		EQ 20MG BASE	**N18936 001** DEC 29, 1987
AB +		EQ 40MG BASE	**N18936 003** JUN 15, 1999
	SARAFEM LILLY	EQ 10MG BASE	N18936 007 JUL 06, 2000
	+	EQ 20MG BASE	N18936 008 JUL 06, 2000

FDA data supplied by DrugPatentWatch.com

FLUOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

	PROZAC WEEKLY			
	+ LILLY	EQ 90MG BASE	N21235 001	FEB 26, 2001

SOLUTION; ORAL

	FLUOXETINE			
AA	ALPHARMA	**EQ 20MG BASE/5ML**	**N75690 001**	JAN 31, 2002
AA	MALLINCKRODT	**EQ 20MG BASE/5ML**	**N75920 001**	JAN 29, 2002
AA	NOVEX	**EQ 20MG BASE/5ML**	**N75292 001**	FEB 07, 2002
AA	PHARM ASSOC	**EQ 20MG BASE/5ML**	**N76015 001**	JAN 30, 2002
AA	TEVA	**EQ 20MG BASE/5ML**	**N75506 001**	AUG 02, 2001
	FLUOXETINE HCL			
AA	HI TECH PHARMA	**EQ 20MG BASE/5ML**	**N75525 001**	JUN 27, 2002
AA	MORTON GROVE	**EQ 20MG BASE/5ML**	**N75514 001**	AUG 29, 2002
	PROZAC			
AA	+ LILLY	**EQ 20MG BASE/5ML**	**N20101 001**	APR 24, 1991

TABLET; ORAL

	FLUOXETINE HCL			
AB	ALPHAPHARM	**EQ 10MG BASE**	**N75755 001**	AUG 02, 2001
	+	EQ 20MG BASE	N75755 002	AUG 02, 2001
AB	BARR	**EQ 10MG BASE**	**N75810 001**	FEB 01, 2002
AB	DR REDDYS LABS INC	**EQ 10MG BASE**	**N76006 001**	JAN 30, 2002
AB	EON	**EQ 10MG BASE**	**N76024 001**	JAN 29, 2002
AB	TEVA	**EQ 10MG BASE**	**N75872 001**	JAN 29, 2002
AB	ZENITH GOLDLINE	**EQ 10MG BASE**	**N75865 001**	FEB 28, 2002
	PROZAC			
AB	+ LILLY	**EQ 10MG BASE**	**N20974 001**	MAR 09, 1999

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

SYMBYAX			
LILLY	EQ 25MG BASE;EQ 6MG BASE	N21520 002	DEC 24, 2003
	EQ 25MG BASE;EQ 12MG BASE	N21520 004	DEC 24, 2003
+	EQ 50MG BASE;EQ 6MG BASE	N21520 003	DEC 24, 2003
	EQ 50MG BASE;EQ 12MG BASE	N21520 005	DEC 24, 2003

FLUOXYMESTERONE

TABLET; ORAL

	FLUOXYMESTERONE			
BP	USL PHARMA	10MG	N88342 001	OCT 21, 1983
	HALOTESTIN			
BP	+ PHARMACIA AND UPJOHN	10MG	N10611 010	
		2MG	N10611 002	
		5MG	N10611 006	

FLUPHENAZINE DECANOATE

INJECTABLE; IM-SC

	FLUPHENAZINE DECANOATE			
AO	APOTEX	**25MG/ML**	**N75918 001**	AUG 17, 2001

INJECTABLE; INJECTION

	FLUPHENAZINE DECANOATE			
AO	AM PHARM PARTNERS	**25MG/ML**	**N71413 001**	JUL 14, 1987
AO	BEDFORD	**25MG/ML**	**N74531 001**	AUG 30, 1996
AO	GENSIA SICOR PHARMS	**25MG/ML**	**N74795 001**	SEP 10, 1996
	PROLIXIN DECANOATE			
AO	+ BRISTOL MYERS SQUIBB	**25MG/ML**	**N16727 001**	

FDA data supplied by DrugPatentWatch.com

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

	FLUPHENAZINE HCL			
AA	COPLEY PHARM	5MG/ML	N73058 001	AUG 30, 1991
AA	PHARM ASSOC	5MG/ML	N74725 001	SEP 16, 1996
	PERMITIL			
AA	+ SCHERING	5MG/ML	N16008 001	
	PROLIXIN			
AA	APOTHECON	5MG/ML	N70533 001	NOV 07, 1985

ELIXIR; ORAL

	FLUPHENAZINE HCL			
AA	COPLEY PHARM	2.5MG/5ML	N81310 001	APR 29, 1993
AA	PHARM ASSOC	2.5MG/5ML	N40146 001	AUG 21, 1996
	PROLIXIN			
AA	+ APOTHECON	2.5MG/5ML	N12145 003	

INJECTABLE; INJECTION

	FLUPHENAZINE HCL			
AP	AM PHARM PARTNERS	2.5MG/ML	N89556 001	APR 16, 1987
	PROLIXIN			
AP	+ APOTHECON	2.5MG/ML	N11751 005	

TABLET; ORAL

	FLUPHENAZINE HCL			
AB	MYLAN	1MG	N89801 001	AUG 12, 1988
AB		2.5MG	N89802 001	AUG 12, 1988
AB		5MG	N89803 001	AUG 12, 1988
AB		10MG	N89804 001	AUG 12, 1988
AB	PAR PHARM	1MG	N89740 001	AUG 25, 1988
AB		2.5MG	N89741 001	AUG 25, 1988
AB		5MG	N89742 001	AUG 25, 1988
AB		10MG	N89743 001	AUG 25, 1988

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

	FLUPHENAZINE HCL			
AB	SANDOZ	1MG	N89583 001	OCT 16, 1987
AB		2.5MG	N89584 001	OCT 16, 1987
AB		5MG	N89585 001	OCT 16, 1987
AB		10MG	N89586 001	OCT 16, 1987
	PROLIXIN			
AB	APOTHECON	1MG	N11751 004	
AB		2.5MG	N11751 001	
AB		5MG	N11751 003	
AB	+	10MG	N11751 002	

FLURANDRENOLIDE

CREAM; TOPICAL

	CORDRAN SP		
	+ OCLASSEN	0.025%	N12806 003
	+	0.05%	N12806 002

LOTION; TOPICAL

	CORDRAN		
	+ WATSON LABS	0.05%	N13790 001

OINTMENT; TOPICAL

	CORDRAN		
	+ OCLASSEN	0.025%	N12806 004
	+	0.05%	N12806 001

TAPE; TOPICAL

	CORDRAN		
	+ OCLASSEN	0.004MG/SQ CM	N16455 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

	DALMANE			
AB	VALEANT PHARM INTL	15MG	N16721 001	
AB	+	30MG	N16721 002	
	FLURAZEPAM HCL			
AB	MYLAN	15MG	N70344 001	NOV 27, 1985

FDA data supplied by DrugPatentWatch.com

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

	FLURAZEPAM HCL			
AB	MYLAN	30MG	N70345 001	NOV 27, 1985
AB	PAR PHARM	15MG	N70444 001	MAR 20, 1986
AB		30MG	N70445 001	MAR 20, 1986
AB	SANDOZ	15MG	N71716 001	JUL 31, 1991
AB		30MG	N71717 001	JUL 31, 1991
AB	WATSON LABS	15MG	N71205 001	NOV 25, 1986
AB		30MG	N71068 001	NOV 25, 1986
AB		30MG	N72369 001	MAR 30, 1989
AB	WEST WARD	15MG	N71107 001	DEC 08, 1986
AB		30MG	N71108 001	DEC 08, 1986

FLURBIPROFEN

TABLET; ORAL

	ANSAID			
AB	PHARMACIA AND UPJOHN	50MG	N18766 002	OCT 31, 1988
AB	+	100MG	N18766 003	OCT 31, 1988
	FLURBIPROFEN			
AB	CARACO	50MG	N75058 001	APR 27, 2001
AB		100MG	N75058 002	APR 27, 2001
AB	IVAX PHARMS	50MG	N74411 001	MAY 31, 1995
AB		100MG	N74411 002	MAY 31, 1995
AB	MYLAN	50MG	N74358 001	JUN 20, 1994
AB		100MG	N74358 002	JUN 20, 1994
AB	PLIVA	50MG	N74647 001	APR 01, 1997

FLURBIPROFEN

TABLET; ORAL

	FLURBIPROFEN			
AB	PLIVA	100MG	N74647 002	APR 01, 1997
AB	SANDOZ	50MG	N74448 001	JUL 28, 1995
AB		100MG	N74448 002	JUL 28, 1995
AB	TEVA	50MG	N74405 002	MAY 24, 1995
AB		100MG	N74405 001	MAY 24, 1995
AB		100MG	N74431 001	MAY 31, 1995
AB	WARNER CHILCOTT	100MG	N74560 002	MAY 16, 1997

FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

	FLURBIPROFEN SODIUM			
AT	AVENTIS BEHRING	0.03%	N74447 001	JAN 04, 1995
	OCUFEN			
AT	+ ALLERGAN	0.03%	N19404 001	DEC 31, 1986

FLUTAMIDE

CAPSULE; ORAL

	EULEXIN			
AB	+ SCHERING	125MG	N18554 001	JAN 27, 1989
	FLUTAMIDE			
AB	BARR	125MG	N75820 001	SEP 18, 2001
AB	EON	125MG	N75818 001	SEP 18, 2001
AB	GENPHARM	125MG	N76224 001	MAY 09, 2003
AB	IVAX PHARMS	125MG	N75780 001	SEP 19, 2001
AB	TEVA	125MG	N75298 001	SEP 18, 2001

FDA data supplied by DrugPatentWatch.com

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION
FLOVENT
GLAXOSMITHKLINE 0.044MG/INH N20548 001 MAR 27, 1996
0.11MG/INH N20548 002 MAR 27, 1996
\+ 0.22MG/INH N20548 003 MAR 27, 1996

CREAM; TOPICAL
CUTIVATE
\+ GLAXOSMITHKLINE 0.05% N19958 001 DEC 18, 1990

OINTMENT; TOPICAL
CUTIVATE
\+ GLAXOSMITHKLINE 0.005% N19957 001 DEC 14, 1990

POWDER; INHALATION
FLOVENT
\+ GLAXOSMITHKLINE 0.044MG/INH N20549 001 NOV 07, 1997
\+ 0.088MG/INH N20549 002 NOV 07, 1997
\+ 0.22MG/INH N20549 003 NOV 07, 1997

FLOVENT DISKUS 100
\+ GLAXOSMITHKLINE 0.1MG/INH N20833 002 SEP 29, 2000

FLOVENT DISKUS 250
\+ GLAXOSMITHKLINE 0.25MG/INH N20833 003 SEP 29, 2000

FLOVENT DISKUS 50
\+ GLAXOSMITHKLINE 0.05MG/INH N20833 001 SEP 29, 2000

SPRAY, METERED; NASAL
FLONASE
\+ GLAXOSMITHKLINE 0.05MG/SPRAY N20121 001 OCT 19, 1994

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION
ADVAIR DISKUS 100/50
\+ GLAXOSMITHKLINE 0.1MG/INH; EQ 0.05MG BASE/INH N21077 001 AUG 24, 2000

ADVAIR DISKUS 250/50
\+ GLAXOSMITHKLINE 0.25MG/INH; EQ 0.05MG BASE/INH N21077 002 AUG 24, 2000

ADVAIR DISKUS 500/50
\+ GLAXOSMITHKLINE 0.5MG/INH; EQ 0.05MG BASE/INH N21077 003 AUG 24, 2000

FLUVASTATIN SODIUM

CAPSULE; ORAL
LESCOL
NOVARTIS EQ 20MG BASE N20261 001 DEC 31, 1993
\+ EQ 40MG BASE N20261 002 DEC 31, 1993

TABLET, EXTENDED RELEASE; ORAL
LESCOL XL
\+ NOVARTIS 80MG N21192 001 OCT 06, 2000

FLUVOXAMINE MALEATE

TABLET; ORAL
FLUVOXAMINE MALEATE
AB BARR **25MG** **N75897 001** JAN 25, 2001
AB **50MG** **N75897 002** JAN 25, 2001
AB **100MG** **N75897 003** JAN 25, 2001
AB EON **25MG** **N75888 001** NOV 29, 2000
AB **50MG** **N75888 002** NOV 29, 2000
AB \+ **100MG** **N75888 003** NOV 29, 2000

FDA data supplied by DrugPatentWatch.com

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

AB	GENPHARM	50MG	N75950 001	OCT 15, 2001
AB		100MG	N75950 002	OCT 15, 2001
AB	IVAX PHARMS	25MG	N75898 001	MAR 12, 2001
AB		50MG	N75898 002	MAR 12, 2001
AB		100MG	N75898 003	MAR 12, 2001
AB	MUTUAL PHARM	25MG	N76125 001	APR 29, 2002
AB		50MG	N76125 002	APR 29, 2002
AB		100MG	N76125 003	APR 29, 2002
AB	MYLAN	25MG	N75889 001	NOV 29, 2000
AB		50MG	N75889 002	NOV 29, 2000
AB		100MG	N75889 003	NOV 29, 2000
AB	PUREPAC PHARM	25MG	N75901 001	DEC 28, 2000
AB		50MG	N75901 002	DEC 28, 2000
AB		100MG	N75901 003	DEC 28, 2000
AB	SANDOZ	25MG	N75887 001	JAN 05, 2001
AB		50MG	N75887 002	JAN 05, 2001
AB		100MG	N75887 003	JAN 05, 2001
AB	SYNTHON PHARMS	25MG	N75899 001	JAN 17, 2001
AB		50MG	N75899 002	JAN 17, 2001
AB		100MG	N75899 003	JAN 17, 2001
AB	TEVA	25MG	N75893 001	SEP 10, 2002
AB		50MG	N75893 002	SEP 10, 2002

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

AB	TEVA	100MG	N75893 003	SEP 10, 2002
AB	TORPHARM	25MG	N75902 001	MAY 07, 2001
AB		50MG	N75902 002	MAY 07, 2001
AB		100MG	N75902 003	MAY 07, 2001
AB	WATSON LABS	25MG	N75894 001	APR 18, 2001
AB		50MG	N75894 002	APR 18, 2001
AB		100MG	N75894 003	APR 18, 2001

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

AP	+ AM PHARM PARTNERS	5MG/ML	N89202 001	FEB 18, 1986
AP	LOCH	5MG/ML	N81066 001	DEC 29, 1993

TABLET; ORAL

FOLIC ACID

AA	MK LABS	1MG	N83526 001
AA	PVT FORM	1MG	N85061 001
AA	TABLICAPS	1MG	N83133 002
AA	+ WATSON LABS	1MG	N80680 001
AA	WEST WARD	1MG	N80600 001

FOLICET

AA	MISSION PHARMA	1MG	N87438 001

FOLIC ACID; *MULTIPLE*

SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

FDA data supplied by DrugPatentWatch.com

FOLIC ACID; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOLLITROPIN ALFA

INJECTABLE; INJECTION

GONAL-F			
+ SERONO	1,200 IU/VIAL		N20378 004 FEB 28, 2001

FOLLITROPIN ALFA/BETA

INJECTABLE; INJECTION

FOLLISTIM			
BX ORGANON USA INC	75 IU/VIAL		N20582 001 SEP 29, 1997
BX	150 IU/VIAL		N20582 002 SEP 29, 1997
GONAL-F			
BX SERONO	75 IU/VIAL		N20378 001 SEP 29, 1997
BX	150 IU/VIAL		N20378 002 SEP 29, 1997

FOMEPIZOLE

INJECTABLE; INJECTION

ANTIZOL			
+ ORPHAN MEDCL	1GM/ML		N20696 001 DEC 04, 1997

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION

VITRAVENE PRESERVATIVE FREE			
+ NOVARTIS	6.6MG/ML		N20961 001 AUG 26, 1998

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA			
+ FONDA BV	2.5MG/0.5ML		N21345 001 DEC 07, 2001

FORMOTEROL FUMARATE

CAPSULE; INHALATION

FORADIL			
+ NOVARTIS	0.012MG/INH		N20831 001 FEB 16, 2001

FOSAMPRENAVIR CALCIUM

TABLET; ORAL

LEXIVA			
+ GLAXOSMITHKLINE	EQ 700MG BASE		N21548 001 OCT 20, 2003

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCAVIR			
+ ASTRAZENECA	2.4GM/100ML		N20068 001 SEP 27, 1991

FOSFOMYCIN TROMETHAMINE

FOR SUSPENSION; ORAL

MONUROL			
+ ZAMBON	EQ 3GM BASE/PACKET		N50717 001 DEC 19, 1996

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM			
AB TEVA	**10MG**		**N76139 001** NOV 25, 2003
AB	**20MG**		**N76139 002** NOV 25, 2003

FDA data supplied by DrugPatentWatch.com

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

AB	TEVA	40MG	N76139 003	NOV 25, 2003

MONOPRIL

AB	BRISTOL MYERS SQUIBB	10MG	N19915 002	MAY 16, 1991
AB		20MG	N19915 003	MAY 16, 1991
AB	+	40MG	N19915 004	MAR 28, 1995

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

MONOPRIL-HCT

	BRISTOL MYERS SQUIBB	10MG;12.5MG	N20286 002	NOV 30, 1994
	+	20MG;12.5MG	N20286 001	NOV 30, 1994

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX

	+ PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N20450 001	AUG 05, 1996

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA

	+ ELAN PHARMS	EQ 2.5MG BASE	N21006 001	NOV 08, 2001

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FASLODEX

	+ ASTRAZENECA	50MG/ML	N21344 001	APR 25, 2002

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP	ABBOTT	10MG/ML	N18667 001	MAY 28, 1982
AP		10MG/ML	N70578 001	JUL 08, 1987
AP		10MG/ML	N72080 001	AUG 13, 1991
AP		10MG/ML	N74337 001	OCT 31, 1994
AP		10MG/ML	N75241 001	MAY 28, 1999
AP	AM PHARM PARTNERS	10MG/ML	N18902 001	MAY 22, 1984
AP	BAXTER HLTHCARE	10MG/ML	N71439 001	SEP 14, 1990
AP	INTL MEDICATION	10MG/ML	N18025 001	
AP	LUITPOLD	10MG/ML	N18579 001	NOV 30, 1983

LASIX

AP	+ AVENTIS PHARMS	10MG/ML	N16363 001	

SOLUTION; ORAL

FUROSEMIDE

AA	MORTON GROVE	10MG/ML	N70655 001	OCT 02, 1987
AA	ROXANE	10MG/ML	N70434 001	APR 22, 1987
		40MG/5ML	N70433 001	APR 22, 1987

LASIX

AA	+ AVENTIS PHARMS	10MG/ML	N17688 001	

TABLET; ORAL

FUROSEMIDE

AB	INTL MEDICATION	20MG	N18753 001	FEB 28, 1984
AB		40MG	N18753 002	FEB 28, 1984
AB	IVAX PHARMS	20MG	N18413 001	NOV 30, 1983
AB		40MG	N18413 002	NOV 30, 1983
AB	MYLAN	20MG	N18487 001	
AB		40MG	N18487 002	
AB		80MG	N70082 001	OCT 29, 1986

FDA data supplied by DrugPatentWatch.com

FUROSEMIDE

TABLET; ORAL

	FUROSEMIDE			
AB	ROXANE	20MG	N18823 001	NOV 10, 1983
AB		40MG	N18823 002	NOV 10, 1983
AB		80MG	N70086 001	JAN 24, 1986
AB	SANDOZ	20MG	N18569 002	
AB		40MG	N18569 001	
AB		80MG	N18569 005	AUG 14, 1984
AB	WATSON LABS	20MG	N70412 001	FEB 26, 1986
AB		20MG	N70449 001	NOV 22, 1985
AB		20MG	N71379 001	JAN 02, 1987
AB		40MG	N70413 001	FEB 26, 1986
AB		40MG	N70450 001	NOV 22, 1985
AB		80MG	N70528 001	JAN 07, 1986
AB		80MG	N71594 001	FEB 09, 1988
	LASIX			
AB	AVENTIS PHARMS	20MG	N16273 002	
AB		40MG	N16273 001	
AB	+	80MG	N16273 003	

GABAPENTIN

CAPSULE; ORAL

	GABAPENTIN			
AB	PUREPAC PHARM	100MG	N75350 001	SEP 12, 2003
AB		300MG	N75350 002	SEP 12, 2003
AB		400MG	N75350 003	SEP 12, 2003
	NEURONTIN			
AB	PFIZER PHARMS	100MG	N20235 001	DEC 30, 1993
AB		300MG	N20235 002	DEC 30, 1993

GABAPENTIN

CAPSULE; ORAL

	NEURONTIN			
AB	+ PFIZER PHARMS	400MG	N20235 003	DEC 30, 1993

SOLUTION; ORAL

	NEURONTIN			
	+ PARKE DAVIS	250MG/5ML	N21129 001	MAR 02, 2000

TABLET; ORAL

	NEURONTIN			
	PFIZER PHARMS	600MG	N20882 001	OCT 09, 1998
	+	800MG	N20882 002	OCT 09, 1998

GADODIAMIDE

INJECTABLE; INJECTION

	OMNISCAN			
	+ AMERSHAM HLTH	287MG/ML	N20123 001	JAN 08, 1993

GADOPENTETATE DIMEGLUMINE

INJECTABLE; INJECTION

	MAGNEVIST			
	+ BERLEX	469.01MG/ML	N19596 001	JUN 02, 1988
	+ BERLEX LABS	469.01MG/ML	N21037 001	MAR 10, 2000

GADOTERIDOL

INJECTABLE; INJECTION

	PROHANCE			
	+ BRACCO	279.3MG/ML	N20131 001	NOV 16, 1992
	PROHANCE MULTIPACK			
	+ BRACCO	279.3MG/ML	N21489 001	OCT 09, 2003

FDA data supplied by DrugPatentWatch.com

GADOVERSETAMIDE

INJECTABLE; INJECTION					
OPTIMARK					
+ MALLINCKRODT	330.9MG/ML	N20937 001 DEC 08, 1999			
+	330.9MG/ML	N20975 001 DEC 08, 1999			
OPTIMARK IN PLASTIC CONTAINER					
+ MALLINCKRODT	330.9MG/ML	N20976 001 DEC 08, 1999			

GALANTAMINE HYDROBROMIDE

SOLUTION; ORAL					
REMINYL					
+ JANSSEN PHARMA	4MG/ML	N21224 001 JUN 22, 2001			
TABLET; ORAL					
REMINYL					
+ JANSSEN PHARMA	EQ 4MG BASE	N21169 001 FEB 28, 2001			
	EQ 8MG BASE	N21169 002 FEB 28, 2001			
	EQ 12MG BASE	N21169 003 FEB 28, 2001			

GALLIUM CITRATE, GA-67

INJECTABLE; INJECTION					
GALLIUM CITRATE GA 67					
BS BRISTOL MYERS SQUIBB	2mCi/ML	N17478 001			
BS MALLINCKRODT	2mCi/ML	N18058 001			

GALLIUM NITRATE

INJECTABLE; INJECTION					
GANITE					
+ GENTA	25MG/ML	N19961 002 JAN 17, 1991			

GANCICLOVIR

CAPSULE; ORAL					
CYTOVENE					
AB ROCHE PALO	250MG	N20460 001 DEC 22, 1994			
AB +	500MG	N20460 002 DEC 12, 1997			
GANCICLOVIR					
AB RANBAXY	250MG	N76457 001 JUN 27, 2003			
AB	500MG	N76457 002 JUN 27, 2003			
IMPLANT; IMPLANTATION					
VITRASERT					
+ BAUSCH AND LOMB	4.5MG	N20569 001 MAR 04, 1996			

GANCICLOVIR SODIUM

INJECTABLE; INJECTION					
CYTOVENE IV					
AP + ROCHE PALO	EQ 500MG BASE/VIAL	N19661 001 JUN 23, 1989			
GANCICLOVIR SODIUM					
AP BEDFORD	EQ 500MG BASE/VIAL	N76222 001 JUL 16, 2003			

GANIRELIX ACETATE

INJECTABLE; INJECTION					
ANTAGON					
+ ORGANON USA INC	EQ 250 UGM BASE/0.5ML	N21057 001 JUL 29, 1999			

GATIFLOXACIN

INJECTABLE; INJECTION					
TEQUIN					
+ BRISTOL MYERS SQUIBB	EQ 2MG /ML(200MG/100ML)	N21062 001 DEC 17, 1999			
+	EQ 2MG /ML(400MG/200ML)	N21062 002 DEC 17, 1999			
+	EQ 10MG /ML(200MG)	N21062 003 DEC 17, 1999			

FDA data supplied by DrugPatentWatch.com

GATIFLOXACIN

INJECTABLE; INJECTION
TEQUIN
+ BRISTOL MYERS SQUIBB EQ 10MG /ML(400MG) N21062 004 DEC 17, 1999

SOLUTION/DROPS; OPHTHALMIC
ZYMAR
+ ALLERGAN 0.3% N21493 001 MAR 28, 2003

TABLET; ORAL
TEQUIN
BRISTOL MYERS SQUIBB 200MG N21061 001 DEC 17, 1999
+ 400MG N21061 002 DEC 17, 1999

GEFITINIB

TABLET; ORAL
IRESSA
+ ASTRAZENECA 250MG N21399 001 MAY 05, 2003

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION
GEMZAR
+ LILLY EQ 200MG BASE/VIAL N20509 001 MAY 15, 1996
+ EQ 1GM BASE/VIAL N20509 002 MAY 15, 1996

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL

AB	MYLAN	**600MG**	**N74452 001** FEB 16, 1995
AB	SANDOZ	**600MG**	**N74615 001** SEP 29, 1995
AB	TEVA	**600MG**	**N74256 001** OCT 31, 1993

GEMFIBROZIL

TABLET; ORAL
GEMFIBROZIL

AB	TORPHARM	**600MG**	**N75034 001** JUL 20, 1998
AB	WATSON LABS	**600MG**	**N74442 001** APR 28, 1995

LOPID

AB	+ PFIZER PHARMS	**600MG**	**N18422 003** NOV 20, 1986

GEMIFLOXACIN MESYLATE

TABLET; ORAL
FACTIVE
+ GENESOFT PHARMS EQ 320MG BASE N21158 001 APR 04, 2003

GEMTUZUMAB OZOGAMICIN

INJECTABLE; INJECTION
MYLOTARG
+ WYETH PHARMS INC 5MG/VIAL N21174 001 MAY 17, 2000

GENTAMICIN SULFATE

CREAM; TOPICAL
GENTAMICIN

AT	CLAY PARK	**EQ 0.1% BASE**	**N62307 001**

GENTAMICIN SULFATE

AT	+ FOUGERA	**EQ 0.1% BASE**	**N62531 001** JUL 05, 1984
AT	TARO	**EQ 0.1% BASE**	**N62427 001** MAY 26, 1983

INJECTABLE; INJECTION
GENTAMICIN SULFATE

AP	ABBOTT	**EQ 10MG BASE/ML**	**N62420 001** AUG 15, 1983
AP		**EQ 10MG BASE/ML**	**N62612 004** FEB 20, 1986
AP		**EQ 40MG BASE/ML**	**N62420 002** AUG 15, 1983

FDA data supplied by DrugPatentWatch.com

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

AP	+ AM PHARM PARTNERS	EQ 10MG BASE/ML	N62356 001	MAR 04, 1982
AP	+	EQ 40MG BASE/ML	N62356 002	MAR 04, 1982
AP		EQ 40MG BASE/ML	N62366 001	AUG 04, 1983
AP	PHARM SPEC	EQ 40MG BASE/ML	N62340 001	MAR 28, 1983

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	EQ 60MG BASE/100ML	N62414 006	AUG 15, 1983
AP		EQ 70MG BASE/100ML	N62414 007	AUG 15, 1983
AP		EQ 80MG BASE/100ML	N62414 008	AUG 15, 1983
AP		EQ 90MG BASE/100ML	N62414 009	AUG 15, 1983
AP		EQ 100MG BASE/100ML	N62414 010	AUG 15, 1983
AP		EQ 1.2MG BASE/ML	N62414 001	AUG 15, 1983
AP		EQ 1.4MG BASE/ML	N62414 002	AUG 15, 1983
AP		EQ 1.6MG BASE/ML	N62414 003	AUG 15, 1983
AP		EQ 1.8MG BASE/ML	N62414 004	AUG 15, 1983
AP		EQ 2MG BASE/ML	N62414 005	AUG 15, 1983
AP	B BRAUN	EQ 40MG BASE/100ML	N62814 008	AUG 28, 1987
AP		EQ 60MG BASE/100ML	N62814 009	AUG 28, 1987
AP		EQ 70MG BASE/100ML	N62814 010	AUG 28, 1987
AP		EQ 0.8MG BASE/ML	N62814 001	AUG 28, 1987
AP		EQ 80MG BASE/100ML	N62814 011	AUG 28, 1987
AP		EQ 90MG BASE/100ML	N62814 012	AUG 28, 1987
AP		EQ 100MG BASE/100ML	N62814 013	AUG 28, 1987

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	EQ 1.2MG BASE/ML	N62814 002	AUG 28, 1987
AP		EQ 120MG BASE/100ML	N62814 014	AUG 28, 1987
AP		EQ 1.4MG BASE/ML	N62814 003	AUG 28, 1987
AP		EQ 1.6MG BASE/ML	N62814 004	AUG 28, 1987
AP		EQ 1.8MG BASE/ML	N62814 005	AUG 28, 1987
AP		EQ 2MG BASE/ML	N62814 006	AUG 28, 1987
AP		EQ 2.4MG BASE/ML	N62814 007	AUG 28, 1987

ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	EQ 40MG BASE/100ML	N62373 003	SEP 07, 1982
AP		EQ 60MG BASE/100ML	N62373 004	SEP 07, 1982
AP		EQ 0.8MG BASE/ML	N62373 001	SEP 07, 1982
AP		EQ 80MG BASE/100ML	N62373 002	SEP 07, 1982
AP		EQ 100MG BASE/100ML	N62373 005	SEP 07, 1982
AP		EQ 120MG BASE/100ML	N62373 006	SEP 07, 1982
AP		EQ 1.2MG BASE/ML	N62373 007	SEP 07, 1982
AP		EQ 1.6MG BASE/ML	N62373 008	SEP 07, 1982
AP		EQ 2MG BASE/ML	N62373 009	SEP 07, 1982
AP		EQ 2.4MG BASE/ML	N62373 010	SEP 07, 1982

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

AB	+ AKORN	EQ 0.3% BASE	N64093 001	AUG 31, 1995

OINTMENT; TOPICAL

GENTAMICIN

AT	+ CLAY PARK	EQ 0.1% BASE	N62351 001	FEB 18, 1982

FDA data supplied by DrugPatentWatch.com

GENTAMICIN SULFATE

OINTMENT; TOPICAL

	GENTAMICIN SULFATE			
AT	FOUGERA	**EQ 0.1% BASE**	**N62533 001**	OCT 05, 1984
AT	TARO	**EQ 0.1% BASE**	**N62477 001**	DEC 23, 1983

SOLUTION; OPHTHALMIC

	GARAMYCIN			
AT	+ SCHERING	**EQ 0.3% BASE**	**N50039 002**	

SOLUTION/DROPS; OPHTHALMIC

	GENOPTIC			
AT	ALLERGAN	**EQ 0.3% BASE**	**N62452 001**	OCT 10, 1984
	GENTACIDIN			
AT	NOVARTIS	**EQ 0.3% BASE**	**N62480 001**	MAR 30, 1984
	GENTAK			
AT	AKORN	**EQ 0.3% BASE**	**N64163 001**	OCT 12, 2001
	GENTAMICIN SULFATE			
AT	AKORN	**EQ 0.3% BASE**	**N62635 001**	JAN 08, 1987
AT	BAUSCH AND LOMB	**EQ 0.3% BASE**	**N64048 001**	MAY 11, 1994
AT	FALCON PHARMS	**EQ 0.3% BASE**	**N62196 001**	

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT; OPHTHALMIC

	PRED-G			
	+ ALLERGAN	EQ 0.3% BASE;0.6%	N50612 001	DEC 01, 1989

SUSPENSION/DROPS; OPHTHALMIC

	PRED-G			
	+ ALLERGAN	EQ 0.3% BASE;1%	N50586 001	JUN 10, 1988

GLATIRAMER ACETATE

FOR SOLUTION; SUBCUTANEOUS

	COPAXONE			
	+ TEVA	20MG/VIAL	N20622 001	DEC 20, 1996

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS

	COPAXONE			
	+ TEVA	20MG/ML	N20622 002	FEB 12, 2002

GLIMEPIRIDE

TABLET; ORAL

	AMARYL			
	+ AVENTIS PHARMS	1MG	N20496 001	NOV 30, 1995
		2MG	N20496 002	NOV 30, 1995
		4MG	N20496 003	NOV 30, 1995

GLIPIZIDE

TABLET; ORAL

	GLIPIZIDE			
AB	ALPHAPHARM	**5MG**	**N74438 001**	JUN 20, 1995
AB		**10MG**	**N74438 002**	JUN 20, 1995
AB	DURAMED PHARMS BARR	**5MG**	**N74550 001**	SEP 11, 1997
AB		**10MG**	**N74550 002**	SEP 11, 1997
AB	ENDO PHARMS	**5MG**	**N74378 001**	NOV 28, 1994
AB		**10MG**	**N74378 002**	NOV 28, 1994
AB	IVAX PHARMS	**5MG**	**N74497 001**	AUG 31, 1995
AB		**10MG**	**N74497 002**	AUG 31, 1995
AB	MYLAN	**5MG**	**N74226 001**	MAY 10, 1994
AB		**10MG**	**N74226 002**	MAY 10, 1994
AB	PLIVA	**5MG**	**N74619 001**	APR 04, 1997
AB		**10MG**	**N74619 002**	APR 04, 1997

FDA data supplied by DrugPatentWatch.com

GLIPIZIDE

TABLET; ORAL

	GLIPIZIDE			
AB	SANDOZ	5MG	N74305 001	APR 07, 1995
AB		5MG	N74542 001	JUN 20, 1995
AB		10MG	N74305 002	APR 07, 1995
AB		10MG	N74542 002	JUN 20, 1995
AB	TEVA	5MG	N74387 001	MAR 04, 1996
AB		10MG	N74387 002	MAR 04, 1996
AB	TORPHARM	5MG	N75795 001	JUN 13, 2001
AB		10MG	N75795 002	JUN 13, 2001
AB	WATSON LABS	5MG	N74223 001	FEB 27, 1995
AB		5MG	N74370 001	NOV 22, 1994
AB		10MG	N74223 002	FEB 27, 1995
AB		10MG	N74370 002	NOV 22, 1994
	GLUCOTROL			
AB	PFIZER	5MG	N17783 001	MAY 08, 1984
AB +		10MG	N17783 002	MAY 08, 1984

TABLET, EXTENDED RELEASE; ORAL

	GLIPIZIDE			
AB	WATSON LABS	5MG	N76467 001	SEP 08, 2003
AB		10MG	N76467 002	NOV 07, 2003
	GLUCOTROL XL			
AB	PFIZER	5MG	N20329 001	APR 26, 1994
AB +		10MG	N20329 002	APR 26, 1994
		2.5MG	N20329 003	AUG 10, 1999

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

	METAGLIP			
	BRISTOL MYERS SQUIBB	2.5MG;250MG	N21460 001	OCT 21, 2002
		2.5MG;500MG	N21460 002	OCT 21, 2002
+		5MG;500MG	N21460 003	OCT 21, 2002

GLUCAGON HYDROCHLORIDE RECOMBINANT

INJECTABLE; INJECTION

	GLUCAGEN			
+	NOVO NORDISK	EQ 1MG BASE/VIAL	N20918 001	JUN 22, 1998

GLUCAGON RECOMBINANT

INJECTABLE; INJECTION

	GLUCAGON			
+	LILLY	1MG/VIAL	N20928 001	SEP 11, 1998

GLUCONOLACTONE; *MULTIPLE*

SEE CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

GLUTATHIONE DISULFIDE; *MULTIPLE*

SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

GLYBURIDE

TABLET; ORAL

	DIABETA			
BX	AVENTIS PHARMS	1.25MG	N17532 001	MAY 01, 1984
BX		2.5MG	N17532 002	MAY 01, 1984
BX		5MG	N17532 003	MAY 01, 1984

FDA data supplied by DrugPatentWatch.com

GLYBURIDE

TABLET; ORAL

	GLYBURIDE			
AB	AMIDE PHARM	1.5MG	**N75947 001**	NOV 14, 2002
AB		3MG	**N75947 002**	NOV 14, 2002
AB		6MG	**N75947 003**	NOV 14, 2002
AB	COREPHARMA	1.25MG	**N76257 001**	JUN 27, 2002
AB		2.5MG	**N76257 002**	JUN 27, 2002
AB		5MG	**N76257 003**	JUN 27, 2002
AB	TEVA	1.25MG	**N74388 001**	AUG 29, 1995
AB		2.5MG	**N74388 002**	AUG 29, 1995
AB		5MG	**N74388 003**	AUG 29, 1995
	GLYBURIDE (MICRONIZED)			
AB	CLONMEL HLTHCARE	1.5MG	**N74591 001**	DEC 22, 1997
AB		3MG	**N74591 002**	DEC 22, 1997
AB		4.5MG	**N74591 003**	DEC 22, 1997
AB		6MG	**N74591 004**	DEC 22, 1997
AB	HIKMA	1.5MG	**N75890 001**	JUL 31, 2003
AB		3MG	**N75890 002**	JUL 31, 2003
AB		6MG	**N75890 003**	JUL 31, 2003
AB	MYLAN	1.5MG	**N74792 001**	JUN 26, 1998
AB		3MG	**N74792 002**	JUN 26, 1998
AB		6MG	**N74792 003**	AUG 17, 1999
AB	SANDOZ	1.5MG	**N75174 001**	JUN 22, 1998
AB		3MG	**N75174 002**	JUN 22, 1998
AB	TEVA	1.5MG	**N74686 001**	APR 20, 1999

GLYBURIDE

TABLET; ORAL

	GLYBURIDE (MICRONIZED)			
AB	TEVA	3MG	**N74686 002**	APR 20, 1999
AB		4.5MG	**N74686 003**	APR 20, 1999
AB		6MG	**N74686 004**	APR 20, 1999
	GLYNASE			
AB	PHARMACIA AND UPJOHN	1.5MG	**N20051 001**	MAR 04, 1992
AB		3MG	**N20051 002**	MAR 04, 1992
AB +		6MG	**N20051 004**	SEP 24, 1993
	MICRONASE			
AB	PHARMACIA AND UPJOHN	1.25MG	**N17498 001**	MAY 01, 1984
AB		2.5MG	**N17498 002**	MAY 01, 1984
AB +		5MG	**N17498 003**	MAY 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

	GLUCOVANCE			
	BRISTOL MYERS SQUIBB	1.25MG;250MG	N21178 001	JUL 31, 2000
		2.5MG;500MG	N21178 002	JUL 31, 2000
+		5MG;500MG	N21178 003	JUL 31, 2000

GLYCERIN; *MULTIPLE*

SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

GLYCINE

SOLUTION; IRRIGATION

	AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER			
AT	BAXTER HLTHCARE	1.5GM/100ML	**N17865 001**	

FDA data supplied by DrugPatentWatch.com

GLYCINE

SOLUTION; IRRIGATION

	GLYCINE 1.5% IN PLASTIC CONTAINER			
AT	ABBOTT	**1.5GM/100ML**	**N17633 001**	
AT		**1.5GM/100ML**	**N18315 001**	
AT	B BRAUN	**1.5GM/100ML**	**N16784 001**	

GLYCOPYRROLATE

INJECTABLE; INJECTION

	GLYCOPYRROLATE			
AP	LUITPOLD	**0.2MG/ML**	**N89335 001**	JUL 23, 1986
	ROBINUL			
AP	+ BAXTER HLTHCARE CORP	**0.2MG/ML**	**N17558 001**	

TABLET; ORAL

	ROBINUL		
	+ FIRST HORIZON	1MG	N12827 001
	ROBINUL FORTE		
	+ FIRST HORIZON	2MG	N12827 002

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

	FACTREL			
	+ BAXTER HLTHCARE CORP	EQ 0.1MG BASE/VIAL	N18123 001	SEP 30, 1982

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

	CHORIONIC GONADOTROPIN			
AP	+ AM PHARM PARTNERS	**10,000 UNITS/VIAL**	**N17067 002**	
AP	+ STERIS	**10,000 UNITS/VIAL**	**N17016 007**	
	PREGNYL			
AP	+ ORGANON USA INC	**10,000 UNITS/VIAL**	**N17692 001**	

GOSERELIN ACETATE

IMPLANT; IMPLANTATION

	ZOLADEX			
	+ ASTRAZENECA	EQ 3.6MG BASE	N19726 001	DEC 29, 1989

GOSERELIN ACETATE

IMPLANT; IMPLANTATION

	ZOLADEX			
	+ ASTRAZENECA	EQ 10.8MG BASE	N20578 001	JAN 11, 1996

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

	NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN			
AT	+ BAUSCH AND LOMB	**0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML**	**N64047 001**	JAN 31, 1996
	NEOSPORIN			
AT	+ MONARCH PHARMS	**0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML**	**N60582 001**	

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

	KYTRIL			
	+ ROCHE	EQ 1MG BASE/ML	N20239 002	MAR 11, 1994

SOLUTION; ORAL

	KYTRIL			
	+ ROCHE	EQ 2MG BASE/10ML	N21238 001	JUN 27, 2001

TABLET; ORAL

	KYTRIL			
	+ ROCHE	EQ 1MG BASE	N20305 001	MAR 16, 1995

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

	GRIFULVIN V			
	+ J AND J	125MG/5ML	N62483 001	JAN 26, 1984

TABLET; ORAL

	FULVICIN-U/F			
AB	SCHERING	**250MG**	**N60569 002**	
AB	+	**500MG**	**N60569 001**	

FDA data supplied by DrugPatentWatch.com

GRISEOFULVIN, MICROCRYSTALLINE

TABLET; ORAL

	GRIFULVIN V			
AB	J AND J	250MG	N62279 002	
AB		500MG	N62279 003	
		125MG	N62279 001	

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

	FULVICIN P/G			
AB	SCHERING	125MG	N61996 001	
AB +		250MG	N61996 002	
	FULVICIN P/G 165			
AB	SCHERING	165MG	N61996 003	APR 06, 1982
	FULVICIN P/G 330			
AB +	SCHERING	330MG	N61996 004	APR 06, 1982
	GRIS-PEG			
AB	PEDINOL	125MG	N50475 001	
AB		250MG	N50475 002	

GUANABENZ ACETATE

TABLET; ORAL

	GUANABENZ ACETATE			
AB	COPLEY PHARM	EQ 4MG BASE	N74267 001	JUN 01, 1994
AB		EQ 8MG BASE	N74267 002	JUN 01, 1994
AB	EON	EQ 4MG BASE	N74517 001	SEP 30, 1998
AB		EQ 8MG BASE	N74517 002	SEP 30, 1998
AB	IVAX PHARMS	EQ 4MG BASE	N74149 001	APR 07, 1995
AB		EQ 8MG BASE	N74149 002	APR 07, 1995
AB	WATSON LABS	EQ 4MG BASE	N74025 001	FEB 28, 1994
AB +		EQ 8MG BASE	N74025 002	FEB 28, 1994

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

	GUANFACINE HCL			
AB	AMIDE PHARM	EQ 1MG BASE	N74673 001	FEB 28, 1997
AB		EQ 2MG BASE	N74673 002	FEB 28, 1997
AB	GENPHARM	EQ 1MG BASE	N75109 001	NOV 25, 1998
AB		EQ 2MG BASE	N75109 002	NOV 25, 1998
AB	MYLAN	EQ 1MG BASE	N74796 001	JAN 27, 1997
AB		EQ 2MG BASE	N74796 002	JAN 27, 1997
AB	WATSON LABS	EQ 1MG BASE	N74145 001	OCT 17, 1995
AB		EQ 1MG BASE	N74762 001	JUN 25, 1997
AB		EQ 2MG BASE	N74145 002	OCT 17, 1995
AB		EQ 2MG BASE	N74762 002	JUN 25, 1997
	TENEX			
AB	ESP PHARMA	EQ 1MG BASE	N19032 001	OCT 27, 1986
AB +		EQ 2MG BASE	N19032 002	NOV 07, 1988

GUANIDINE HYDROCHLORIDE

TABLET; ORAL

	GUANIDINE HCL		
	SCHERING	125MG	N01546 001

HALAZEPAM

TABLET; ORAL

	PAXIPAM		
	SCHERING	20MG	N17736 003
+		40MG	N17736 004

FDA data supplied by DrugPatentWatch.com

HALCINONIDE

CREAM; TOPICAL				
HALOG				
+ WESTWOOD SQUIBB	0.1%	N17556 001		
HALOG-E				
WESTWOOD SQUIBB	0.1%	N18234 001		
OINTMENT; TOPICAL				
HALOG				
+ WESTWOOD SQUIBB	0.1%	N17824 001		
SOLUTION; TOPICAL				
HALOG				
WESTWOOD SQUIBB	0.1%	N17823 001		

HALOBETASOL PROPIONATE

CREAM; TOPICAL				
ULTRAVATE				
+ WESTWOOD SQUIBB	0.05%	N19967 001 DEC 27, 1990		
OINTMENT; TOPICAL				
ULTRAVATE				
+ WESTWOOD SQUIBB	0.05%	N19968 001 DEC 17, 1990		

HALOPERIDOL

TABLET; ORAL					
HALOPERIDOL					
AB	MYLAN	**0.5MG**	**N70276 001** JUN 10, 1986		
AB		**1MG**	**N70277 001** JUN 10, 1986		
AB		**2MG**	**N70278 001** JUN 10, 1986		
AB		**5MG**	**N70279 001** JUN 10, 1986		
AB	PAR PHARM	**0.5MG**	**N71233 001** NOV 03, 1986		
AB		**1MG**	**N71234 001** NOV 03, 1986		
AB		**2MG**	**N71235 001** NOV 03, 1986		

HALOPERIDOL

TABLET; ORAL					
HALOPERIDOL					
AB	PAR PHARM	**5MG**	**N71236 001** NOV 03, 1986		
AB		**10MG**	**N71237 001** JUL 20, 1987		
AB	SANDOZ	**0.5MG**	**N71206 001** NOV 17, 1986		
AB		**1MG**	**N71207 001** NOV 17, 1986		
AB		**2MG**	**N71208 001** NOV 17, 1986		
AB		**5MG**	**N71209 001** NOV 17, 1986		
AB		**10MG**	**N71210 001** MAR 11, 1988		
	+	20MG	N71211 001 MAR 11, 1988		
AB	WATSON LABS	**0.5MG**	**N70981 001** MAR 06, 1987		
AB		**2MG**	**N70983 001** MAR 06, 1987		
AB		**5MG**	**N70984 001** MAR 06, 1987		

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION					
HALDOL					
AO	+ ORTHO MCNEIL	**EQ 50MG BASE/ML**	**N18701 001** JAN 14, 1986		
AO	+	**EQ 100MG BASE/ML**	**N18701 002** JAN 31, 1997		
HALOPERIDOL DECANOATE					
AO	AM PHARM PARTNERS	**EQ 50MG BASE/ML**	**N74893 001** DEC 19, 1997		
AO		**EQ 100MG BASE/ML**	**N74893 002** DEC 19, 1997		
AO	APOTEX	**EQ 50MG BASE/ML**	**N75440 001** FEB 28, 2000		
AO		**EQ 100MG BASE/ML**	**N75440 002** FEB 28, 2000		
AO	BEDFORD	**EQ 50MG BASE/ML**	**N74811 001** JAN 30, 1998		
AO		**EQ 100MG BASE/ML**	**N75305 001** SEP 28, 1998		

FDA data supplied by DrugPatentWatch.com

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

	HALOPERIDOL DECANOATE			
AO	GENSIA SICOR PHARMS	EQ 50MG BASE/ML	N75393 001	
			MAY 11, 1999	
AO		EQ 100MG BASE/ML	N75393 002	
			MAY 11, 1999	

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

	HALOPERIDOL			
AA	COPLEY PHARM	EQ 2MG BASE/ML	N71617 001	
			DEC 01, 1988	
AA	PHARM ASSOC	EQ 2MG BASE/ML	N73037 001	
			FEB 26, 1993	
AA	SILARX	EQ 2MG BASE/ML	N73364 001	
			SEP 28, 1993	
AA +	TEVA	EQ 2MG BASE/ML	N71015 001	
			AUG 25, 1987	

INJECTABLE; INJECTION

	HALDOL			
AP +	ORTHO MCNEIL	EQ 5MG BASE/ML	N15923 001	
	HALOPERIDOL			
AP	AM PHARM PARTNERS	EQ 5MG BASE/ML	N75689 001	
			MAR 09, 2001	
AP	BEDFORD	EQ 5MG BASE/ML	N75858 001	
			JUN 18, 2001	
AP	GENSIA SICOR PHARMS	EQ 5MG BASE/ML	N76035 001	
			AUG 29, 2001	
AP	STERIS	EQ 5MG BASE/ML	N70714 001	
			MAY 17, 1988	

SOLUTION; ORAL

	HALOPERIDOL LACTATE			
	UDL	EQ 1MG BASE/ML	N74536 001	
			NOV 02, 1995	

HALOTHANE

LIQUID; INHALATION

	HALOTHANE			
AN +	ABBOTT	99.99%	N83254 001	
AN	HALOCARBON	99.99%	N80810 001	

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEP-LOCK			
AP +	BAXTER HLTHCARE	10 UNITS/ML	N17037 007	
AP +		100 UNITS/ML	N17037 006	
	HEP-LOCK U/P			
AP	BAXTER HLTHCARE	10 UNITS/ML	N17037 010	
			JUN 10, 1983	
AP		100 UNITS/ML	N17037 011	
			JUN 10, 1983	
	HEPARIN LOCK FLUSH			
AP	ABBOTT	10 UNITS/ML	N05264 001	
AP		10 UNITS/ML	N40082 001	
			FEB 28, 1995	
AP		10 UNITS/ML	N88097 001	
			APR 28, 1983	
AP		10 UNITS/ML	N88346 001	
			MAY 18, 1983	
AP		100 UNITS/ML	N40082 002	
			FEB 28, 1995	
AP		100 UNITS/ML	N88098 001	
			APR 28, 1983	
AP		100 UNITS/ML	N88347 001	
			MAY 18, 1983	
AP	AM PHARM PARTNERS	10 UNITS/ML	N17029 007	
			MAY 06, 1982	
AP		100 UNITS/ML	N17029 006	
	HEPARIN LOCK FLUSH IN PLASTIC CONTAINER			
AP	ABBOTT	10 UNITS/ML	N05264 015	
			MAY 21, 1985	
AP		100 UNITS/ML	N05264 016	
			MAY 21, 1985	
	HEPARIN SODIUM			
AP +	ABBOTT	2,500 UNITS/ML	N88099 001	
			APR 28, 1983	
AP		5,000 UNITS/ML	N88100 001	
			APR 28, 1983	
AP	AM PHARM PARTNERS	1,000 UNITS/ML	N17029 001	
AP		1,000 UNITS/ML	N17979 001	
AP		5,000 UNITS/ML	N17651 006	
AP		10,000 UNITS/ML	N17029 003	
AP		10,000 UNITS/ML	N17979 002	
AP +		20,000 UNITS/ML	N17029 004	
AP	BAXTER HLTHCARE	1,000 UNITS/ML	N17037 001	
AP		5,000 UNITS/ML	N17037 002	
AP		10,000 UNITS/ML	N17037 003	
AP		5,000 UNITS/0.5ML	N17037 013	
			APR 07, 1986	

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM				
AP		LILLY	10,000 UNITS/ML	N05521 002
AP		MARSAM PHARMS LLC	1,000 UNITS/ML	N40007 001 JUN 07, 1996
AP			1,000 UNITS/ML	N40008 001 OCT 10, 1995
AP	+	PHARMACIA AND UPJOHN	1,000 UNITS/ML	N04570 001
AP	+		5,000 UNITS/ML	N04570 002
AP	+		10,000 UNITS/ML	N04570 003
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP		BAXTER HLTHCARE	200 UNITS/100ML	N18609 001 APR 28, 1982
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP		ABBOTT	200 UNITS/100ML	N18916 010 JUN 23, 1989
AP		B BRAUN	200 UNITS/100ML	N19953 001 JUL 20, 1992
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP		ABBOTT	10,000 UNITS/100ML	N19339 003 MAR 27, 1985
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
		ABBOTT	5,000 UNITS/100ML	N19339 001 MAR 27, 1985
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
		ABBOTT	5,000 UNITS/100ML	N18916 006 JAN 31, 1984
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP		BAXTER HLTHCARE	200 UNITS/100ML	N18609 002 APR 28, 1982
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP		ABBOTT	200 UNITS/100ML	N18916 011 JUN 23, 1989
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
AP		BAXTER HLTHCARE	4,000 UNITS/100ML	N18814 001 OCT 31, 1983
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP		ABBOTT	4,000 UNITS/100ML	N19805 001 JAN 25, 1989

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP		B BRAUN	4,000 UNITS/100ML	N19952 001 JUL 20, 1992
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
AP		BAXTER HLTHCARE	5,000 UNITS/100ML	N18814 003 JUL 09, 1985
AP			10,000 UNITS/100ML	N18814 004 JUL 02, 1987
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP		ABBOTT	5,000 UNITS/100ML	N19339 004 MAR 27, 1985
AP			5,000 UNITS/100ML	N19805 002 JAN 25, 1989
AP			10,000 UNITS/100ML	N19339 002 MAR 27, 1985
AP		B BRAUN	5,000 UNITS/100ML	N19952 004 JUL 20, 1992
AP			10,000 UNITS/100ML	N19952 005 JUL 20, 1992
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
		ABBOTT	5,000 UNITS/100ML	N18916 007 JAN 31, 1984
			10,000 UNITS/100ML	N18916 008 JAN 31, 1984
HEPARIN SODIUM IN PLASTIC CONTAINER				
AP		AM PHARM PARTNERS	1,000 UNITS/ML	N17029 013 DEC 05, 1985
AP			5,000 UNITS/ML	N17029 014 DEC 05, 1985
AP			10,000 UNITS/ML	N17029 015 DEC 05, 1985
AP			20,000 UNITS/ML	N17029 016 DEC 05, 1985
HEPARIN SODIUM PRESERVATIVE FREE				
AP	+	ABBOTT	2,500 UNITS/ML	N05264 014 APR 07, 1986
AP	+		10,000 UNITS/ML	N89522 001 MAY 04, 1987
	+		2,000 UNITS/ML	N05264 013 APR 07, 1986
AP	+	AM PHARM PARTNERS	1,000 UNITS/ML	N17029 010 APR 28, 1986

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM PRESERVATIVE FREE

AP	MARSAM PHARMS LLC	1,000 UNITS/ML	N89464 001	JUN 03, 1986

HEPFLUSH-10

AP	AM PHARM PARTNERS	10 UNITS/ML	N17651 009	JUN 26, 1984

HEXACHLOROPHENE

EMULSION; TOPICAL

PHISOHEX

+	SANOFI SYNTHELABO	3%	N06882 001	

SPONGE; TOPICAL

PRE-OP

AT	+ DAVIS AND GECK	480MG	N17433 001	

PRE-OP II

AT	DAVIS AND GECK	480MG	N17433 002	

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODAN

AA	+ ENDO PHARMS	1.5MG/5ML;5MG/5ML	N05213 002	JUL 26, 1988

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	AXIOM PHARM	1.5MG/5ML;5MG/5ML	N40285 001	JUL 19, 1999

HYDROCODONE COMPOUND

AA	ALPHARMA	1.5MG/5ML;5MG/5ML	N88017 001	JUL 05, 1983

MYCODONE

AA	MORTON GROVE	1.5MG/5ML;5MG/5ML	N88008 001	MAR 03, 1983

TABLET; ORAL

HOMATROPRINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AA	AMIDE PHARM	1.5MG;5MG	N40295 001	DEC 01, 2000

HYCODAN

AA	+ ENDO PHARMS	1.5MG;5MG	N05213 001	JUL 26, 1988

TUSSIGON

AA	JONES PHARMA	1.5MG;5MG	N88508 001	JUL 30, 1985

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HCL

AP	AM PHARM PARTNERS	20MG/ML	N40388 001	MAR 13, 2001
AP	GENSIA SICOR PHARMS	20MG/ML	N40373 001	FEB 23, 2000
AP	+ LUITPOLD	20MG/ML	N40136 001	JUN 30, 1997

TABLET; ORAL

APRESOLINE

AA	+ NOVARTIS	10MG	N08303 004	
AA	+	25MG	N08303 001	
AA	+	50MG	N08303 002	
AA	+	100MG	N08303 005	

HYDRALAZINE HCL

AA	ABC HOLDING	10MG	N88846 001	FEB 26, 1985
AA		25MG	N88847 001	FEB 26, 1985
AA		50MG	N88848 001	FEB 26, 1985
AA		100MG	N88849 001	FEB 26, 1985
AA	MUTUAL PHARM	10MG	N89359 001	JUL 25, 1986
AA		25MG	N89258 001	MAY 05, 1986
AA		50MG	N89259 001	MAY 05, 1986
AA	PAR PHARM	10MG	N87836 001	OCT 05, 1982
AA		25MG	N86961 002	
AA		50MG	N86962 001	
AA		100MG	N88391 001	SEP 27, 1983
AA	PLIVA	10MG	N89097 001	DEC 18, 1985
AA		25MG	N88467 001	MAY 01, 1984
AA		50MG	N88468 001	MAY 01, 1984
AA		100MG	N89098 001	DEC 18, 1985
AA	SANDOZ	10MG	N83241 001	
AA		25MG	N83560 001	
AA		50MG	N83561 001	

FDA data supplied by DrugPatentWatch.com

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

	HYDRALAZINE HCL			
AA	WATSON LABS	25MG	N84504 001	
AA		50MG	N84503 001	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

	APRESAZIDE			
AB	NOVARTIS	25MG;25MG	N84735 001	
AB		50MG;50MG	N84810 001	
	HYDRA-ZIDE			
AB	PAR PHARM	25MG;25MG	N88957 001	OCT 21, 1985
AB		50MG;50MG	N88946 001	OCT 21, 1985
+		100MG;50MG	N88961 001	OCT 21, 1985

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

	HYDROCHLOROTHIAZIDE			
AB	MYLAN	12.5MG	N75640 001	JAN 28, 2000
AB	VINTAGE PHARMS	12.5MG	N75907 001	SEP 17, 2002
	MICROZIDE			
AB +	WATSON LABS	12.5MG	N20504 001	DEC 27, 1996

SOLUTION; ORAL

	HYDROCHLOROTHIAZIDE			
+	ROXANE	50MG/5ML	N88587 001	JUL 02, 1984

TABLET; ORAL

	ESIDRIX			
AB	NOVARTIS	25MG	N11793 005	
AB		50MG	N11793 008	
	HYDROCHLOROTHIAZIDE			
AB	ABC HOLDING	25MG	N85683 001	
AB		50MG	N83965 001	
AB		50MG	N85672 001	
AB	CLONMEL HLTHCARE	25MG	N87059 001	

HYDROCHLOROTHIAZIDE

TABLET; ORAL

	HYDROCHLOROTHIAZIDE			
AB	CLONMEL HLTHCARE	50MG	N87068 001	
AB	EON	50MG	N85219 001	
AB	IVAX PHARMS	25MG	N83177 001	
AB		50MG	N83177 002	
AB +		100MG	N85022 001	
AB	PUREPAC PHARM	25MG	N85054 002	
AB		50MG	N85208 001	
AB	PVT FORM	25MG	N85181 001	
AB		50MG	N85182 001	
AB	SANDOZ	25MG	N87565 001	MAR 09, 1982
AB		50MG	N84912 001	
AB	VINTAGE PHARMS	25MG	N40412 001	MAR 29, 2002
AB		50MG	N40412 002	MAR 29, 2002
AB	WATSON LABS	25MG	N81189 001	JAN 24, 1992
	ORETIC			
AB	ABBOTT	50MG	N11971 002	

HYDROCHLOROTHIAZIDE; *MULTIPLE*

SEE AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE
SEE BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE
SEE BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE
SEE CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE
SEE CAPTOPRIL; HYDROCHLOROTHIAZIDE
SEE ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
SEE EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE
SEE FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE
SEE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

	AVALIDE			
	SANOFI SYNTHELABO	12.5MG;150MG	N20758 002	SEP 30, 1997
+		12.5MG;300MG	N20758 003	AUG 31, 1998

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB	EON	12.5MG;10MG	N76262 001 JUL 01, 2002
AB		12.5MG;20MG	N76262 002 JUL 01, 2002
AB		25MG;20MG	N76262 003 JUL 01, 2002
AB	IVAX PHARMS	12.5MG;10MG	N75776 001 JUL 01, 2002
AB		12.5MG;20MG	N75776 002 JUL 01, 2002
AB		25MG;20MG	N75776 003 JUL 01, 2002
AB	MYLAN	12.5MG;10MG	N76113 001 JUL 01, 2002
AB		12.5MG;20MG	N76113 002 JUL 01, 2002
AB		25MG;20MG	N76113 003 JUL 01, 2002
AB	PUREPAC PHARM	12.5MG;10MG	N76230 001 JUL 01, 2002
AB		12.5MG;20MG	N76230 002 JUL 01, 2002
AB		25MG;20MG	N76230 003 JUL 01, 2002
AB	RANBAXY	12.5MG;10MG	N76007 001 JUL 01, 2002
AB		12.5MG;20MG	N76007 002 JUL 01, 2002
AB		25MG;20MG	N76007 003 JUL 01, 2002
AB	SANDOZ	12.5MG;10MG	N75926 001 JUL 01, 2002
AB		12.5MG;20MG	N75926 002 JUL 01, 2002
AB		25MG;20MG	N75926 003 JUL 01, 2002
AB	TEVA	12.5MG;10MG	N75869 001 JUL 01, 2002
AB		12.5MG;20MG	N75869 002 JUL 01, 2002
AB		25MG;20MG	N75869 003 JUL 01, 2002
AB	WATSON LABS	12.5MG;10MG	N76194 003 JUL 01, 2002

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB	WATSON LABS	12.5MG;20MG	N76194 001 JUL 01, 2002
AB		25MG;20MG	N76194 002 JUL 01, 2002
AB	WEST WARD	12.5MG;10MG	N76265 001 JUL 08, 2002
AB		12.5MG;20MG	N76265 002 JUL 08, 2002
AB		25MG;20MG	N76265 003 JUL 08, 2002

PRINZIDE

AB	MERCK	12.5MG;10MG	N19778 003 NOV 18, 1993
AB		12.5MG;20MG	N19778 001 FEB 16, 1989
AB +		25MG;20MG	N19778 002 FEB 16, 1989

ZESTORETIC

AB	ASTRAZENECA	12.5MG;10MG	N19888 003 NOV 18, 1993
AB		12.5MG;20MG	N19888 001 SEP 20, 1990
AB		25MG;20MG	N19888 002 JUL 20, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

	MERCK	12.5MG;50MG	N20387 001 APR 28, 1995
+		25MG;100MG	N20387 002 NOV 10, 1998

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDORIL 15

AB	MERCK	15MG;250MG	N13402 001

ALDORIL 25

AB	MERCK	25MG;250MG	N13402 002

ALDORIL D30

AB	MERCK	30MG;500MG	N13402 003

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

	ALDORIL D50			
AB	+ MERCK	50MG;500MG	N13402 004	
	METHYLDOPA AND HYDROCHLOROTHIAZIDE			
AB	MYLAN	15MG;250MG	N70264 001	JAN 23, 1986
AB		25MG;250MG	N70265 001	JAN 23, 1986
AB	PAR PHARM	15MG;250MG	N70616 001	FEB 02, 1987
AB		25MG;250MG	N70612 001	FEB 02, 1987
AB		30MG;500MG	N70613 001	FEB 02, 1987
AB		50MG;500MG	N70614 001	FEB 02, 1987
AB	SANDOZ	15MG;250MG	N70182 001	JAN 15, 1986
AB		25MG;250MG	N70183 001	JAN 15, 1986
AB		30MG;500MG	N70543 001	JAN 15, 1986
AB		50MG;500MG	N70544 001	JAN 15, 1986
AB	WATSON LABS	15MG;250MG	N70958 001	FEB 06, 1989
AB		25MG;250MG	N70959 001	JAN 19, 1989
AB		30MG;500MG	N71069 001	JAN 19, 1989
AB		50MG;500MG	N70960 001	FEB 06, 1989

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

	LOPRESSOR HCT			
	NOVARTIS	25MG;50MG	N18303 001	DEC 31, 1984
		25MG;100MG	N18303 002	DEC 31, 1984
+		50MG;100MG	N18303 003	DEC 31, 1984

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

	UNIRETIC		
	SCHWARZ PHARMA	12.5MG;7.5MG	N20729 001 JUN 27, 1997
		12.5MG;15MG	N20729 003 FEB 14, 2002
+		25MG;15MG	N20729 002 JUN 27, 1997

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR HCT		
SANKYO	12.5MG;20MG	N21532 002 JUN 05, 2003
	12.5MG;40MG	N21532 003 JUN 05, 2003
+	25MG;40MG	N21532 005 JUN 05, 2003

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

	INDERIDE-40/25		
AB	WYETH PHARMS INC	25MG;40MG	**N18031 001**
	INDERIDE-80/25		
AB +	WYETH PHARMS INC	25MG;80MG	**N18031 002**
	PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE		
AB	BARR	25MG;40MG	**N70704 001** OCT 01, 1986
AB		25MG;80MG	**N70705 001** OCT 01, 1986
AB	MYLAN	25MG;40MG	**N70946 001** MAR 04, 1987
AB		25MG;80MG	**N70947 001** APR 01, 1987
AB	PLIVA	25MG;40MG	**N72042 001** MAR 14, 1988
AB		25MG;80MG	**N72043 001** MAR 14, 1988
AB	PUREPAC PHARM	25MG;40MG	**N70851 001** MAY 15, 1986
AB		25MG;80MG	**N70852 001** MAY 15, 1986

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE

AB	SANDOZ	25MG;40MG	**N71060 001**	AUG 26, 1987
AB		25MG;80MG	**N71061 001**	AUG 26, 1987
AB	WATSON LABS	25MG;40MG	**N70301 001**	APR 18, 1986
AB		25MG;80MG	**N70305 001**	APR 18, 1986

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC

	PFIZER PHARMS	12.5MG;EQ 10MG BASE	N20125 001	DEC 28, 1999
		12.5MG;EQ 20MG BASE	N20125 002	DEC 28, 1999
+		25MG;EQ 20MG BASE	N20125 003	DEC 28, 1999

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

ALDACTAZIDE

AB	GD SEARLE LLC	25MG;25MG	**N12616 004**	DEC 30, 1982
+		50MG;50MG	N12616 005	DEC 30, 1982

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB	HALSEY	25MG;25MG	**N87267 001**	
AB	MUTUAL PHARM	25MG;25MG	**N89534 001**	JUL 02, 1987
AB	MYLAN	25MG;25MG	**N86513 001**	
AB	SANDOZ	25MG;25MG	**N86881 001**	

SPIRONOLACTONE/HYDROCHLOROTHIAZIDE

AB	WATSON LABS	25MG;25MG	**N87398 001**	

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

	BOEHRINGER INGELHEIM	12.5MG;40MG	N21162 001	NOV 17, 2000

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

+	BOEHRINGER INGELHEIM	12.5MG;80MG	N21162 002	NOV 17, 2000

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL

TIMOLIDE 10-25

+	MERCK	25MG;10MG	N18061 001

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

AB	+	GLAXOSMITHKLINE	25MG;37.5MG	**N16042 003**	MAR 03, 1994

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		BARR	25MG;37.5MG	**N74970 001**	JAN 06, 1998
AB		DURAMED PHARMS BARR	25MG;37.5MG	**N75052 001**	JUN 18, 1999
AB		IVAX PHARMS	25MG;50MG	**N74259 001**	MAR 30, 1995
AB		MYLAN	25MG;37.5MG	**N74701 001**	JUN 07, 1996
AB		SANDOZ	25MG;37.5MG	**N74821 001**	JUN 05, 1997
AB	+		25MG;50MG	**N73191 001**	JUL 31, 1991

TABLET; ORAL

MAXZIDE

AB	+	MYLAN	50MG;75MG	**N19129 001**	OCT 22, 1984

MAXZIDE-25

AB		MYLAN	25MG;37.5MG	**N19129 003**	MAY 13, 1988

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		BARR	25MG;37.5MG	**N71251 002**	MAY 05, 1998
AB			50MG;75MG	**N71251 001**	APR 17, 1988
AB		PLIVA	25MG;37.5MG	**N74026 001**	APR 26, 1996

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

	TRIAMTERENE AND HYDROCHLOROTHIAZIDE			
AB	PLIVA	50MG;75MG	N73467 001 JAN 31, 1996	
AB	SANDOZ	25MG;37.5MG	N73281 001 APR 30, 1992	
AB		50MG;75MG	N72011 001 JUN 17, 1988	
AB	WATSON LABS	25MG;37.5MG	N73449 001 SEP 23, 1993	
AB		50MG;75MG	N71851 001 NOV 30, 1988	
AB		50MG;75MG	N71969 001 APR 17, 1988	

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

	DIOVAN HCT			
	NOVARTIS	12.5MG;80MG	N20818 001 MAR 06, 1998	
+		12.5MG;160MG	N20818 002 MAR 06, 1998	
		25MG;160MG	N20818 003 JAN 17, 2002	

HYDROCODONE BITARTRATE; *MULTIPLE*

SEE ACETAMINOPHEN; HYDROCODONE BITARTRATE

SEE ASPIRIN; HYDROCODONE BITARTRATE

SEE HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

	HYDROCODONE BITARTRATE AND IBUPROFEN			
AB	ANDRX PHARMS	7.5MG;200MG	N76604 001 DEC 31, 2003	
AB	TEVA	7.5MG;200MG	N76023 001 APR 11, 2003	
	VICOPROFEN			
AB	+ ABBOTT	7.5MG;200MG	N20716 001 SEP 23, 1997	

HYDROCODONE POLISTIREX; *MULTIPLE*

SEE CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

HYDROCORTISONE

CREAM; TOPICAL

	ALA-CORT			
AT	DEL RAY LABS	1%	N80706 006	
	ANUSOL HC			
AT	PARKEDALE	2.5%	N88250 001 JUN 06, 1984	
	HI-COR			
AT	C AND M PHARMA	2.5%	N80483 001	
	HYDROCORTISONE			
AT	ALPHARMA	2.5%	N89682 001 MAR 10, 1988	
AT	ALPHARMA US PHARM	1%	N87795 001 MAY 03, 1983	
AT	CLAY PARK	2.5%	N85025 001	
AT	EVERYLIFE	1%	N80452 002	
AT	FOUGERA	1%	N80693 003	
AT		2.5%	N89414 001 DEC 16, 1986	
AT	INGRAM PHARM	0.5%	N80456 002	
AT		1%	N80456 003	
AT	TARO	1%	N86155 001	
AT		2.5%	N88799 001 NOV 09, 1984	
	HYTONE			
AT	+ DERMIK LABS	1%	N80472 003	
AT	+	2.5%	N80472 004	
	PENECORT			
AT	ALLERGAN HERBERT	1%	N88216 001 JUN 06, 1984	
	SYNACORT			
AT	MEDICIS	1%	N87458 001	
AT		2.5%	N87457 001	

ENEMA; RECTAL

	COLOCORT			
AB	PADDOCK	100MG/60ML	N75172 001 DEC 03, 1999	
	CORTENEMA			
AB	+ SOLVAY	100MG/60ML	N16199 001	
	HYDROCORTISONE			
AB	COPLEY PHARM	100MG/60ML	N74171 001 MAY 27, 1994	

LOTION; TOPICAL

	ALA-CORT			
AT	DEL RAY LABS	1%	N83201 001	
	ALA-SCALP			
	DEL RAY LABS	2%	N83231 001	

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE

LOTION; TOPICAL

	CETACORT			
AT	HEALTHPOINT	0.5%	**N80426 002**	
AT		1%	**N80426 001**	
	HYDROCORTISONE			
AT	ALTANA	2.5%	**N40351 001**	JUL 25, 2000
AT	TARO	2.5%	**N40247 001**	JUL 23, 1999
AT	VINTAGE PHARMS	2.5%	**N40417 001**	JUL 30, 2003
	HYTONE			
AT +	DERMIK LABS	1%	**N80473 003**	
AT +		2.5%	**N80473 004**	NOV 30, 1982
	NUTRACORT			
AT	HEALTHPOINT	1%	**N80443 003**	
AT		2.5%	**N87644 001**	AUG 24, 1982
	STIE-CORT			
AT	STIEFEL	1%	**N89066 001**	NOV 25, 1985
AT		2.5%	**N89074 001**	NOV 26, 1985

OINTMENT; TOPICAL

	CORTRIL			
AT +	PFIPHARMECS	1%	**N09176 001**	
AT +		2.5%	**N09176 002**	
	HYDROCORTISONE			
AT	ALPHARMA US PHARM	1%	**N87796 001**	OCT 13, 1982
AT	ALTANA	1%	**N80692 001**	
AT	CLAY PARK	2.5%	**N85027 001**	
AT	FOUGERA	2.5%	**N81203 001**	MAY 28, 1993
AT	TARO	1%	**N86257 001**	
AT		2.5%	**N40310 001**	DEC 29, 2000
	HYDROCORTISONE IN ABSORBASE			
AT	CAROLINA MEDCL	1%	**N88138 001**	SEP 06, 1985

POWDER; FOR RX COMPOUNDING

	HYDROCORTISONE		
+	PHARMA TEK	100%	N85982 001

HYDROCORTISONE

SOLUTION; TOPICAL

	PENECORT			
AT	ALLERGAN HERBERT	1%	**N88214 001**	JUN 06, 1984
	TEXACORT			
AT +	SIRIUS LABS	1%	**N80425 001**	
+		2.5%	N81271 001	APR 17, 1992

TABLET; ORAL

	CORTEF			
BP	PHARMACIA AND UPJOHN	10MG	N08697 001	
BP +		20MG	N08697 002	
		5MG	N08697 003	
	HYDROCORTISONE			
BP	WEST WARD	20MG	N83365 001	
	HYDROCORTONE			
BP	MERCK	10MG	N08506 007	
BP +		20MG	N08506 011	

HYDROCORTISONE; *MULTIPLE*

SEE ACETIC ACID, GLACIAL; HYDROCORTISONE

SEE BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SEE CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

	CORTISPORIN			
AT +	MONARCH PHARMS	**1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N50479 001**	
	NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE			
AT	ALCON	**1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N62423 001**	AUG 25, 1983
AT	BAUSCH AND LOMB	**1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N64053 001**	DEC 29, 1995

SUSPENSION/DROPS; OPHTHALMIC

	CORTISPORIN		
+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N50169 001

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	ALCON UNIVERSAL	**1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N62874 001** MAY 11, 1988	

SUSPENSION/DROPS; OTIC

CORTISPORIN

AT	+ MONARCH PHARMS	**1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N60613 001**	

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	ALCON UNIVERSAL	**1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N62488 001** NOV 06, 1985	

OTICAIR

AT	BAUSCH AND LOMB	**1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N64065 001** AUG 28, 1996	

PEDIOTIC

AT	MONARCH PHARMS	**1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML**	**N62822 001** SEP 29, 1987	

HYDROCORTISONE ACETATE

AEROSOL, METERED; RECTAL

CORTIFOAM

+	SCHWARZ PHARMA	10%	N17351 001 FEB 10, 1982

CREAM; TOPICAL

HYDROCORTISONE ACETATE

+	FERNDALE LABS	2.5%	N40259 001 JUL 29, 1999

MICORT-HC

+	FERNDALE LABS	2%	N40398 001 MAR 29, 2002
		2.5%	N40396 001 FEB 27, 2001

LOTION; TOPICAL

DRICORT

+	INGRAM PHARM	0.5%	N86207 001

PASTE; TOPICAL

ORABASE HCA

	COLGATE	0.5%	N83205 001

HYDROCORTISONE ACETATE

POWDER; FOR RX COMPOUNDING

HYDROCORTISONE ACETATE

	PHARMA TEK	100%	N85981 001

HYDROCORTISONE ACETATE; *MULTIPLE*

SEE BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SEE COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

CORTISPORIN

+	MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM		N50218 001 AUG 09, 1985

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

TERRA-CORTRIL

+	PFIZER	1.5%;EQ 5MG BASE/ML		N61016 001

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

EPIFOAM

BX	SCHWARZ PHARMA	1%;1%		N86457 001

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%

BX	COPLEY PHARM	1%;1%		N89440 001 MAY 17, 1988

PROCTOFOAM HC

BX	SCHWARZ PHARMA	1%;1%		N86195 001

CREAM; TOPICAL

PRAMOSONE

FERNDALE LABS	0.5%;1%		N83778 001
	1%;1%		N85368 001

LOTION; TOPICAL

PRAMOSONE

FERNDALE LABS	1%;1%		N85980 001

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

LOTION; TOPICAL
PRAMOSONE
FERNDALE LABS 2.5%;1% N85979 001

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL
CARMOL HC
AT + KENWOOD LABS **1%;10%** **N80505 001**
U-CORT
AT TARO **1%;10%** **N89472 001**
JUN 13, 1988

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL
LOCOID
+ FERNDALE LABS 0.1% N18514 001
MAR 31, 1982
LOCOID LIPOCREAM
+ FERNDALE LABS 0.1% N20769 001
SEP 08, 1997

OINTMENT; TOPICAL
LOCOID
+ FERNDALE LABS 0.1% N18652 001
OCT 29, 1982

SOLUTION; TOPICAL
LOCOID
+ FERNDALE LABS 0.1% N19116 001
FEB 25, 1987

HYDROCORTISONE PROBUTATE

CREAM; TOPICAL
PANDEL
+ SAVAGE LABS 0.1% N20453 001
FEB 28, 1997

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-HYDROCORT
AP ABBOTT **EQ 1GM BASE/VIAL** **N85932 001**
AP **EQ 100MG BASE/VIAL** **N85929 001**
AP **EQ 250MG BASE/VIAL** **N85930 001**
AP **EQ 500MG BASE/VIAL** **N85931 001**
SOLU-CORTEF
AP + PHARMACIA AND UPJOHN **EQ 100MG BASE/VIAL** **N09866 001**
AP + **EQ 250MG BASE/VIAL** **N09866 002**
AP + **EQ 500MG BASE/VIAL** **N09866 003**
AP + **EQ 1GM BASE/VIAL** **N09866 004**

HYDROCORTISONE VALERATE

CREAM; TOPICAL
HYDROCORTISONE VALERATE
AB CLAY PARK **0.2%** **N75666 001**
MAY 24, 2000
AB COPLEY PHARM **0.2%** **N74489 001**
AUG 12, 1998
AB TARO **0.2%** **N75042 001**
AUG 25, 1998
WESTCORT
AB + WESTWOOD SQUIBB **0.2%** **N17950 001**

OINTMENT; TOPICAL
HYDROCORTISONE VALERATE
AB ALTANA **0.2%** **N75085 001**
JUL 31, 2001
AB TARO **0.2%** **N75043 001**
AUG 25, 1998
WESTCORT
AB + WESTWOOD SQUIBB **0.2%** **N18726 001**
AUG 08, 1983

HYDROFLUMETHIAZIDE

TABLET; ORAL
HYDROFLUMETHIAZIDE
AB PAR PHARM **50MG** **N88850 001**
MAY 31, 1985
SALURON
AB + SHIRE LABS **50MG** **N11949 001**

FDA data supplied by DrugPatentWatch.com

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

		DILAUDID-HP			
AP	+	ABBOTT	**10MG/ML**		**N19034 001** JAN 11, 1984
	+		250MG/VIAL		N19034 002 AUG 04, 1994
		HYDROMORPHONE HCL			
AP		ABBOTT	**10MG/ML**		**N74598 001** JUN 19, 1997
AP		MAYNE PHARMA USA	**10MG/ML**		**N76444 001** APR 25, 2003
AP		STERIS	**10MG/ML**		**N74317 001** AUG 23, 1995

SOLUTION; ORAL

		DILAUDID			
AA	+	ABBOTT	**5MG/5ML**		**N19891 001** DEC 07, 1992
		HYDROMORPHONE HCL			
AA		ROXANE	**5MG/5ML**		**N74653 001** JUL 29, 1998

TABLET; ORAL

		DILAUDID			
AB	+	ABBOTT	**8MG**		**N19892 001** DEC 07, 1992
		HYDROMORPHONE HCL			
AB		ROXANE	**8MG**		**N74597 001** JUL 29, 1998

HYDROQUINONE; *MULTIPLE*

SEE FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

		HYDROXOCOBALAMIN			
	+	STERIS	1MG/ML		N85998 001

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

		PAREMYD			
	+	AKORN	1%;0.25%		N19261 001 JAN 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

		HYDROXYCHLOROQUINE SULFATE			
AB		MYLAN	**200MG**		**N40274 001** MAY 29, 1998
		HYDROXYCHLOROQUINE SULFATE			
AB		COPLEY PHARM •	**200MG**		**N40081 001** SEP 30, 1994
AB		SANDOZ	**200MG**		**N40104 001** NOV 30, 1995
AB			**200MG**		**N40150 001** JAN 27, 1996
AB		WATSON LABS	**200MG**		**N40133 001** NOV 30, 1995
		PLAQUENIL			
AB	+	SANOFI SYNTHELABO	**200MG**		**N09768 001**

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

		LACRISERT			
	+	MERCK	5MG		N18771 001

HYDROXYUREA

CAPSULE; ORAL

		DROXIA			
		BRISTOL MYERS SQUIBB	200MG		N16295 002 FEB 25, 1998
			300MG		N16295 003 FEB 25, 1998
	+		400MG		N16295 004 FEB 25, 1998
		HYDREA			
AB	+	BRISTOL MYERS SQUIBB	**500MG**		**N16295 001**
		HYDROXYUREA			
AB		BARR	**250MG**		**N75143 002** SEP 21, 2000
AB			**500MG**		**N75143 001** OCT 16, 1998
AB	+	DURAMED PHARMS BARR	**250MG**		**N75020 002** JUN 26, 2000
AB			**500MG**		**N75020 001** JUL 30, 1998
AB		PAR PHARM	**500MG**		**N75340 001** FEB 24, 1999

FDA data supplied by DrugPatentWatch.com

HYDROXYUREA

CAPSULE; ORAL

	HYDROXYUREA			
AB	ROXANE	500MG	N74476 001	AUG 18, 1995

TABLET; ORAL

	HYDROXYUREA			
+	BARR	1GM	N75734 001	AUG 29, 2000

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDROXYZINE HCL			
AP	ABBOTT	25MG/ML	N87416 001	
AP		50MG/ML	N87546 001	
AP	AM PHARM PARTNERS	25MG/ML	N87329 001	
AP		50MG/ML	N87329 002	
AP	LUITPOLD	25MG/ML	N87408 001	
AP		50MG/ML	N87408 002	
AP	STERIS	50MG/ML	N85779 001	
	VISTARIL			
AP +	PFIZER	25MG/ML	N11111 001	
AP +		50MG/ML	N11111 002	

SYRUP; ORAL

	ATARAX			
AA +	ROERIG	10MG/5ML	N10485 001	
	HYDROXYZINE HCL			
AA	ALPHARMA	10MG/5ML	N86880 001	
AA	HI TECH PHARMA	10MG/5ML	N40010 001	OCT 28, 1994
AA	MORTON GROVE	10MG/5ML	N87294 001	APR 12, 1982
AA	VINTAGE PHARMS	10MG/5ML	N40391 001	APR 10, 2002

TABLET; ORAL

	HYDROXYZINE HCL			
AB	MUTUAL PHARM	10MG	N89381 001	MAY 19, 1986
AB		25MG	N89382 001	MAY 19, 1986
AB		50MG	N89383 001	MAY 19, 1986

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

	HYDROXYZINE HCL			
AB +	PLIVA	10MG	N88617 001	JAN 10, 1986
AB +		25MG	N88618 001	JAN 10, 1986
AB +		50MG	N88619 001	JAN 10, 1986
AB	SANDOZ	10MG	N87869 001	DEC 20, 1982
AB		25MG	N87870 001	DEC 20, 1982
AB		50MG	N87871 001	DEC 20, 1982
AB	WATSON LABS	10MG	N81149 001	MAR 18, 1994
AB		10MG	N88348 001	SEP 15, 1983
AB		25MG	N81150 001	MAR 18, 1994
AB		25MG	N88349 001	SEP 15, 1983
AB		50MG	N81151 001	MAR 18, 1994
AB		50MG	N88350 001	SEP 15, 1983

HYDROXYZINE PAMOATE

CAPSULE; ORAL

	HYDROXYZINE PAMOATE			
AB	BARR	EQ 25MG HCL	N88496 001	JUN 15, 1984
AB		EQ 50MG HCL	N88487 001	JUN 15, 1984
AB		EQ 100MG HCL	N88488 001	JUN 15, 1984
AB	EON	EQ 25MG HCL	N87479 001	
AB		EQ 50MG HCL	N86183 001	
AB	IVAX PHARMS	EQ 25MG HCL	N87761 001	MAR 05, 1982
AB		EQ 50MG HCL	N87760 001	MAR 05, 1982
AB	SANDOZ	EQ 25MG HCL	N81127 001	JUN 28, 1991

FDA data supplied by DrugPatentWatch.com

HYDROXYZINE PAMOATE

CAPSULE; ORAL

	HYDROXYZINE PAMOATE			
AB	WATSON LABS	**EQ 25MG HCL**	**N40156 001**	
			JUL 15, 1996	
AB		**EQ 25MG HCL**	**N81165 001**	
			JUL 31, 1991	
AB		**EQ 50MG HCL**	**N40156 002**	
			JUL 15, 1996	
	VISTARIL			
AB	PFIZER	**EQ 25MG HCL**	**N11459 002**	
AB	+	**EQ 50MG HCL**	**N11459 004**	
AB		**EQ 100MG HCL**	**N11459 006**	

SUSPENSION; ORAL

	VISTARIL		
	+ PFIZER	EQ 25MG HCL/5ML	N11795 001

IBUPROFEN

SUSPENSION; ORAL

	CHILDREN'S ADVIL		
BX	WYETH CONS	100MG/5ML	N19833 002
			SEP 19, 1989
	IBUPROFEN		
AB	ALPHARMA	**100MG/5ML**	**N74978 001**
			MAR 25, 1998
	MOTRIN		
AB	+ MCNEIL CONS SPECLT	**100MG/5ML**	**N19842 001**
			SEP 19, 1989

TABLET; ORAL

	IBU		
AB	BASF	**400MG**	**N18197 001**
AB		**400MG**	**N70083 001**
			FEB 22, 1985
AB		**600MG**	**N70099 001**
			MAR 29, 1985
AB		**800MG**	**N70745 001**
			JUL 23, 1986
		600MG	N70088 001
			FEB 08, 1985
	IBU-TAB		
AB	ALRA	**400MG**	**N71058 001**
			AUG 11, 1988
AB		**600MG**	**N71059 001**
			AUG 11, 1988

IBUPROFEN

TABLET; ORAL

	IBUPROFEN		
AB	BASF	**400MG**	**N75682 001**
			NOV 14, 2001
AB		**600MG**	**N75682 002**
			NOV 14, 2001
AB		**800MG**	**N75682 003**
			NOV 14, 2001
AB	DR REDDYS LABS INC	**400MG**	**N76112 001**
			OCT 31, 2001
AB		**600MG**	**N76112 002**
			OCT 31, 2001
AB		**800MG**	**N76112 003**
			OCT 31, 2001
AB	INTERPHARM	**400MG**	**N71334 001**
			NOV 25, 1986
AB		**600MG**	**N71335 001**
			NOV 25, 1986
AB		**800MG**	**N71935 001**
			OCT 13, 1987
AB	IVAX PHARMS	**400MG**	**N71145 001**
			SEP 23, 1986
AB		**600MG**	**N71146 001**
			SEP 23, 1986
AB		**800MG**	**N71769 001**
			MAY 08, 1987
AB	MUTUAL PHARM	**300MG**	**N71230 001**
			OCT 22, 1986
AB		**400MG**	**N71231 001**
			OCT 22, 1986
AB		**600MG**	**N71232 001**
			OCT 22, 1986
AB		**800MG**	**N72004 001**
			NOV 18, 1987
AB	MYLAN	**400MG**	**N70045 001**
			SEP 24, 1985
AB		**600MG**	**N70057 001**
			SEP 24, 1985
AB		**800MG**	**N71999 001**
			DEC 03, 1987
AB	OHM LABS	**400MG**	**N70818 001**
			DEC 26, 1985
AB	PAR PHARM	**400MG**	**N70329 001**
			AUG 06, 1985
AB		**600MG**	**N70330 001**
			AUG 06, 1985

FDA data supplied by DrugPatentWatch.com

IBUPROFEN

TABLET; ORAL

	IBUPROFEN			
AB	PAR PHARM	800MG	N70986 001	JUL 25, 1986
AB	PLIVA	400MG	N71666 001	JUN 18, 1987
AB		600MG	N71667 001	JUN 18, 1987
AB		800MG	N71668 001	JUN 18, 1987
AB	PVT FORM	300MG	N71266 001	OCT 15, 1986
AB		400MG	N71267 001	OCT 15, 1986
AB		600MG	N71268 001	OCT 15, 1986
AB		800MG	N72300 001	JUL 01, 1988
AB	SANDOZ	300MG	N70734 001	JUN 12, 1986
AB		400MG	N70735 001	JUN 12, 1986
AB		600MG	N70736 001	JUN 12, 1986
AB		800MG	N72169 001	DEC 11, 1987
AB	VINTAGE PHARMS	400MG	N71644 001	FEB 01, 1988
AB	WATSON LABS	400MG	N70436 001	AUG 21, 1985
AB		600MG	N70437 001	AUG 21, 1985
AB		800MG	N71547 001	JUL 02, 1987
	IBUPROHM			
AB	OHM LABS	400MG	N70469 001	AUG 29, 1985
	MOTRIN			
AB	MCNEIL CONS SPECLT	300MG	N17463 003	
AB		400MG	N17463 002	
AB		600MG	N17463 004	
AB +		800MG	N17463 005	MAY 22, 1985

IBUPROFEN; *MULTIPLE*
SEE HYDROCODONE BITARTRATE; IBUPROFEN

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

	CORVERT			
+	PHARMACIA AND UPJOHN	0.1MG/ML	N20491 001	DEC 28, 1995

ICODEXTRIN

SOLUTION; INTRAPERITONEAL

	EXTRANEAL			
+	BAXTER HLTHCARE	7.5GM/100ML	N21321 001	DEC 20, 2002

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

	IDAMYCIN PFS			
AP +	PHARMACIA AND UPJOHN	1MG/ML	N50734 001	FEB 17, 1997
	IDARUBICIN HCL			
AP	GENSIA SICOR PHARMS	5MG/VIAL	N65037 003	MAY 01, 2002
+		10MG/VIAL	N65037 002	MAY 01, 2002
+		20MG/VIAL	N65037 001	MAY 01, 2002
	IDARUBICIN HCL PFS			
AP	GENSIA SICOR PHARMS	1MG/ML	N65036 001	MAY 01, 2002

IDOXURIDINE

SOLUTION/DROPS; OPHTHALMIC

	DENDRID		
AT +	ALCON	0.1%	N14169 001
	HERPLEX		
AT +	ALLERGAN	0.1%	N13935 002

IFOSFAMIDE

INJECTABLE; INJECTION

	IFOSFAMIDE			
+	AM PHARM PARTNERS	1GM/VIAL	N76078 001	MAY 28, 2002

FDA data supplied by DrugPatentWatch.com

IFOSFAMIDE

INJECTABLE; INJECTION
IFOSFAMIDE

+	AM PHARM PARTNERS	3GM/VIAL	N76078 002 MAY 28, 2002	

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION
IFEX/MESNEX KIT

+	BRISTOL MYERS SQUIBB	1GM/VIAL;100MG/ML	N19763 003 OCT 10, 1992	
+		3GM/VIAL;100MG/ML	N19763 004 OCT 10, 1992	

INJECTABLE; INTRAVENOUS
IFOSFAMIDE/MESNA KIT

+	GENSIA SICOR PHARMS	EQ 1GM /20ML(50MG/ML); EQ 1GM /10ML(100MG/ML)	N75874 001 FEB 26, 2002	
+		EQ 3GM /60ML(50MG/ML); EQ 1GM /10ML(100MG/ML)	N75874 002 FEB 26, 2002	

IMATINIB MESYLATE

CAPSULE; ORAL
GLEEVEC

+	NOVARTIS	100MG	N21335 002 MAY 10, 2001	

TABLET; ORAL
GLEEVEC

	NOVARTIS	100MG	N21588 001 APR 18, 2003	
+		400MG	N21588 002 APR 18, 2003	

IMIGLUCERASE

INJECTABLE; INJECTION
CEREZYME

	GENZYME	200 UNITS/VIAL	N20367 001 MAY 23, 1994	

IMIGLUCERASE

INJECTABLE; INJECTION
CEREZYME

+	GENZYME	400 UNITS/VIAL	N20367 002 SEP 22, 1999	

IMIPENEM; *MULTIPLE*
SEE CILASTATIN SODIUM; IMIPENEM

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL
IMIPRAMINE HCL

AB		MUTUAL PHARM	10MG	**N81048 001** JUN 05, 1990
AB			25MG	**N81049 001** JUN 05, 1990
AB			50MG	**N81050 001** JUN 05, 1990
AB		PAR PHARM	10MG	**N88292 001** OCT 21, 1983
AB			10MG	**N89422 001** JUL 14, 1987
AB			25MG	**N88262 001** OCT 21, 1983
AB			25MG	**N89497 001** JUL 14, 1987
AB			50MG	**N88276 001** OCT 21, 1983
AB		SANDOZ	10MG	**N84936 002**
AB			25MG	**N83745 001**
AB			50MG	**N84937 001**
AB		TEVA	10MG	**N83729 001**
AB			25MG	**N83729 004**
AB			50MG	**N83729 003**

TOFRANIL

AB		TYCO HLTHCARE	10MG	**N87844 001** MAY 22, 1984
AB			25MG	**N87845 001** MAY 22, 1984
AB	+		50MG	**N87846 001** MAY 22, 1984

FDA data supplied by DrugPatentWatch.com

IMIPRAMINE PAMOATE

CAPSULE; ORAL

	TOFRANIL-PM			
	TYCO HLTHCARE	EQ 75MG HCL	N17090 001	
		EQ 100MG HCL	N17090 004	
		EQ 125MG HCL	N17090 003	
+		EQ 150MG HCL	N17090 002	

IMIQUIMOD

CREAM; TOPICAL

	ALDARA			
+	3M	5%	N20723 001	FEB 27, 1997

INAMRINONE LACTATE

INJECTABLE; INJECTION

	AMRINONE			
AP	+ ABBOTT	**EQ 5MG BASE/ML**	**N74616 001**	AUG 03, 1998
AP	BEDFORD	**EQ 5MG BASE/ML**	**N75513 001**	MAY 09, 2000
	AMRINONE LACTATE			
AP	BAXTER HLTHCARE CORP	**EQ 5MG BASE/ML**	**N75542 001**	MAY 10, 2000

INDAPAMIDE

TABLET; ORAL

	INDAPAMIDE			
AB	ALPHAPHARM	**1.25MG**	**N75105 001**	JUL 23, 1998
AB		**2.5MG**	**N75105 002**	JUL 23, 1998
AB	IVAX PHARMS	**1.25MG**	**N74299 002**	APR 29, 1996
AB		**2.5MG**	**N74299 001**	JUL 27, 1995
AB	MYLAN	**1.25MG**	**N74461 002**	MAR 26, 1997
AB		**2.5MG**	**N74461 001**	MAR 27, 1996
AB	PUREPAC PHARM	**1.25MG**	**N74722 001**	JUN 17, 1996

INDAPAMIDE

TABLET; ORAL

	INDAPAMIDE			
AB	PUREPAC PHARM	**2.5MG**	**N74722 002**	JUN 17, 1996
AB	SANDOZ	**1.25MG**	**N74594 001**	MAY 23, 1996
AB		**2.5MG**	**N74594 002**	MAY 23, 1996
AB	TEVA	**1.25MG**	**N74498 002**	FEB 12, 1998
AB		**2.5MG**	**N74498 001**	OCT 31, 1996
AB	TRIGEN	**1.25MG**	**N75201 001**	DEC 04, 1998
AB		**2.5MG**	**N75201 002**	DEC 04, 1998
AB	WATSON LABS	**1.25MG**	**N74585 001**	SEP 26, 1996
AB		**2.5MG**	**N74585 002**	SEP 26, 1996
	LOZOL			
AB	AVENTIS	**1.25MG**	**N18538 002**	APR 29, 1993
AB	+	**2.5MG**	**N18538 001**	JUL 06, 1983

INDINAVIR SULFATE

CAPSULE; ORAL

	CRIXIVAN			
	MERCK	EQ 100MG BASE	N20685 006	APR 19, 2000
		EQ 200MG BASE	N20685 003	MAR 13, 1996
		EQ 333MG BASE	N20685 005	DEC 17, 1998
+		EQ 400MG BASE	N20685 001	MAR 13, 1996

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION

	INDIUM IN-111 OXYQUINOLINE			
	AMERSHAM HLTH	1mCi/ML	N19044 001	DEC 24, 1985

FDA data supplied by DrugPatentWatch.com

INDIUM IN-111 PENTETATE DISODIUM

INJECTABLE; INTRATHECAL

	MPI INDIUM DTPA IN 111			
	AMERSHAM HLTH	1mCi/ML	N17707 001	FEB 18, 1982

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

	OCTREOSCAN			
	MALLINCKRODT	3mCi/ML	N20314 001	JUN 02, 1994

INDOCYANINE GREEN

INJECTABLE; INJECTION

	CARDIO-GREEN			
	+ AKORN	25MG/VIAL	N11525 001	

INDOMETHACIN

CAPSULE; ORAL

	INDO-LEMMON			
AB	TEVA	25MG	**N70266 001**	NOV 07, 1985
AB		50MG	**N70267 001**	NOV 07, 1985
	INDOCIN			
AB	MERCK	25MG	**N16059 001**	
AB	+	50MG	**N16059 002**	
	INDOMETHACIN			
AB	ABLE	25MG	**N76666 001**	DEC 17, 2003
AB		50MG	**N76666 002**	DEC 17, 2003
AB	CLONMEL HLTHCARE	25MG	**N18851 001**	MAY 18, 1984
AB		50MG	**N18851 002**	MAY 18, 1984
AB	IVAX PHARMS	25MG	**N70719 001**	FEB 12, 1986
AB		50MG	**N70756 001**	FEB 12, 1986
AB	MUTUAL PHARM	25MG	**N70899 001**	FEB 09, 1987

INDOMETHACIN

CAPSULE; ORAL

	INDOMETHACIN			
AB	MUTUAL PHARM	50MG	**N70900 001**	FEB 09, 1987
AB	MYLAN	25MG	**N18858 001**	APR 20, 1984
AB		50MG	**N18858 002**	APR 20, 1984
AB		50MG	**N70624 001**	SEP 04, 1985
AB	PAR PHARM	25MG	**N18829 002**	AUG 06, 1984
AB		50MG	**N18829 001**	AUG 06, 1984
AB		50MG	**N70651 001**	MAR 05, 1986
AB	PLIVA	25MG	**N71148 001**	MAR 18, 1987
AB		50MG	**N71149 001**	MAR 18, 1987
AB	SANDOZ	25MG	**N70673 001**	APR 29, 1987
AB		50MG	**N70674 001**	APR 29, 1987
AB	TEVA	25MG	**N71342 001**	APR 18, 1988
AB		50MG	**N71343 001**	APR 18, 1988

CAPSULE, EXTENDED RELEASE; ORAL

	INDOCIN SR			
AB	+ EON	75MG	**N74464 001**	MAY 28, 1998
	INDOMETHACIN			
AB	ABLE	75MG	**N76114 001**	FEB 06, 2002
AB	INWOOD LABS	75MG	**N72410 001**	MAR 15, 1989

SUPPOSITORY; RECTAL

	INDOMETHEGAN			
	+ G AND W LABS	50MG	N73314 001	AUG 31, 1992

SUSPENSION; ORAL

	INDOCIN			
	+ MERCK	25MG/5ML	N18332 001	OCT 10, 1985

FDA data supplied by DrugPatentWatch.com

INDOMETHACIN SODIUM

INJECTABLE; INJECTION			
INDOCIN I.V.			
+ MERCK	EQ 1MG BASE/VIAL	N18878 001	JAN 30, 1985

INSULIN ASPART

INJECTABLE; SUBCUTANEOUS			
NOVOLOG			
+ NOVO NORDISK	100 UNITS/ML	N20986 001	JUN 07, 2000

INSULIN ASPART; INSULIN ASPART PROTAMINE

INJECTABLE; SUBCUTANEOUS			
NOVOLOG MIX 70/30			
+ NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N21172 001	NOV 01, 2001

INSULIN ASPART PROTAMINE; *MULTIPLE*
SEE INSULIN ASPART; INSULIN ASPART PROTAMINE

INSULIN GLARGINE

INJECTABLE; INJECTION			
LANTUS			
+ AVENTIS PHARMS	100 UNITS/ML	N21081 001	APR 20, 2000

INSULIN LISPRO

INJECTABLE; INJECTION			
HUMALOG			
+ LILLY	100 UNITS/ML	N20563 001	JUN 14, 1996
HUMALOG PEN			
+ LILLY	100 UNITS/ML	N20563 002	AUG 06, 1998

INSULIN LISPRO; INSULIN LISPRO PROTAMINE

INJECTABLE; INJECTION			
HUMALOG MIX 50/50			
+ LILLY	50 UNITS/ML;50 UNITS/ML	N21018 001	DEC 22, 1999
HUMALOG MIX 75/25			
+ LILLY	25 UNITS/ML;75 UNITS/ML	N21017 001	DEC 22, 1999

INSULIN LISPRO PROTAMINE; *MULTIPLE*
SEE INSULIN LISPRO; INSULIN LISPRO PROTAMINE

INSULIN PURIFIED PORK

INJECTABLE; INJECTION			
ILETIN II			
+ LILLY	500 UNITS/ML	N18344 002	

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION			
HUMULIN R			
+ LILLY	500 UNITS/ML	N18780 004	MAR 31, 1994

INTRINSIC FACTOR; *MULTIPLE*
SEE COBALT CHLORIDE, CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR

IOBENGUANE SULFATE I 131

INJECTABLE; INJECTION			
IOBENGUANE SULFATE I 131			
CIS	2.3mCi/ML	N20084 001	MAR 25, 1994

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION			
CHOLOGRAFIN MEGLUMINE			
+ BRACCO	52%	N09321 003	

FDA data supplied by DrugPatentWatch.com

IODIPAMIDE MEGLUMINE; *MULTIPLE*
SEE DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

IODIXANOL

INJECTABLE; INJECTION

VISIPAQUE 270			
+ AMERSHAM HLTH	55%	N20351 001	MAR 22, 1996
VISIPAQUE 320			
+ AMERSHAM HLTH	65.2%	N20351 002	MAR 22, 1996

IOHEXOL

INJECTABLE; INJECTION

OMNIPAQUE 140			
+ AMERSHAM HLTH	30.2%	N18956 005	NOV 30, 1988

SOLUTION; INJECTION, ORAL

OMNIPAQUE 350			
+ AMERSHAM HLTH	75.5%	N18956 004	DEC 26, 1985
	75.5%	N20608 003	OCT 24, 1995

SOLUTION; INJECTION, ORAL, RECTAL

OMNIPAQUE 180			
+ AMERSHAM HLTH	38.8%	N18956 001	DEC 26, 1985
OMNIPAQUE 240			
+ AMERSHAM HLTH	51.8%	N18956 002	DEC 26, 1985
	51.8%	N20608 001	OCT 24, 1995
OMNIPAQUE 300			
+ AMERSHAM HLTH	64.7%	N18956 003	DEC 26, 1985
	64.7%	N20608 002	OCT 24, 1995

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200				
AP	ABBOTT	41%	**N74898 001**	DEC 30, 1997
AP	COOK IMAGING	41%	**N74881 001**	JUL 28, 2000
IOPAMIDOL-200 IN PLASTIC CONTAINER				
AP	ABBOTT	41%	**N74636 001**	DEC 30, 1997
IOPAMIDOL-250				
AP	ABBOTT	51%	**N74898 002**	DEC 30, 1997
AP		51%	**N75005 001**	FEB 24, 1998
AP	AM PHARM PARTNERS	51%	**N74679 001**	APR 02, 1997
AP	COOK IMAGING	51%	**N74881 002**	JUL 28, 2000
IOPAMIDOL-250 IN PLASTIC CONTAINER				
AP	ABBOTT	51%	**N74636 002**	DEC 30, 1997
IOPAMIDOL-300				
AP	ABBOTT	61%	**N74898 003**	DEC 30, 1997
AP		61%	**N75005 002**	FEB 24, 1998
AP	AM PHARM PARTNERS	61%	**N74679 002**	APR 02, 1997
AP	COOK IMAGING	61%	**N74881 003**	JUL 28, 2000
IOPAMIDOL-300 IN PLASTIC CONTAINER				
AP	ABBOTT	61%	**N74636 003**	DEC 30, 1997
AP		61%	**N74637 001**	APR 03, 1997
IOPAMIDOL-370				
AP	ABBOTT	76%	**N74898 004**	DEC 30, 1997
AP		76%	**N75005 003**	FEB 24, 1998
AP	AM PHARM PARTNERS	76%	**N74679 003**	APR 02, 1997
AP	COOK IMAGING	76%	**N74881 004**	JUL 28, 2000
IOPAMIDOL-370 IN PLASTIC CONTAINER				
AP	ABBOTT	76%	**N74636 004**	DEC 30, 1997

FDA data supplied by DrugPatentWatch.com

IOPAMIDOL

INJECTABLE; INJECTION

	ISOVUE-200			
AP	+ BRACCO	41%	N18735 006	
			JUL 07, 1987	
	ISOVUE-250			
AP	+ BRACCO	51%	N18735 007	
			JUL 06, 1992	
AP	+	51%	N20327 002	
			OCT 12, 1994	
	ISOVUE-300			
AP	+ BRACCO	61%	N18735 002	
			DEC 31, 1985	
AP	+	61%	N20327 003	
			OCT 12, 1994	
	ISOVUE-370			
AP	+ BRACCO	76%	N18735 003	
			DEC 31, 1985	
AP	+	76%	N20327 004	
			OCT 12, 1994	
	ISOVUE-M 200			
	+ BRACCO	41%	N18735 001	
			DEC 31, 1985	
	ISOVUE-M 300			
	+ BRACCO	61%	N18735 004	
			DEC 31, 1985	

IOPANOIC ACID

TABLET; ORAL

	TELEPAQUE		
	+ AMERSHAM HLTH	500MG	N08032 001

IOPROMIDE

INJECTABLE; INJECTION

	ULTRAVIST (PHARMACY BULK)		
	+ BERLEX LABS	300MG/ML	N21425 001
			SEP 20, 2002
	+	370MG/ML	N21425 002
			SEP 20, 2002
	ULTRAVIST 150		
	+ BERLEX LABS	31.2%	N20220 004
			MAY 10, 1995
	ULTRAVIST 240		
	+ BERLEX LABS	49.9%	N20220 003
			MAY 10, 1995

IOPROMIDE

INJECTABLE; INJECTION

	ULTRAVIST 300		
	+ BERLEX LABS	62.3%	N20220 002
			MAY 10, 1995
	ULTRAVIST 370		
	+ BERLEX LABS	76.9%	N20220 001
			MAY 10, 1995

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION

CONRAY		
+ MALLINCKRODT	60%	N13295 001
CONRAY 30		
+ MALLINCKRODT	30%	N16983 001
CONRAY 43		
+ MALLINCKRODT	43%	N13295 002

SOLUTION; INTRAVESICAL

CYSTO-CONRAY II		
MALLINCKRODT	17.2%	N17057 002

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION

VASCORAY		
+ MALLINCKRODT	52%;26%	N16783 001

IOTHALAMATE SODIUM

INJECTABLE; INJECTION

CONRAY 400		
+ MALLINCKRODT	66.8%	N14295 001

IOTHALAMATE SODIUM; *MULTIPLE*
SEE IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

IOTHALAMATE SODIUM, I-125

INJECTABLE; INJECTION

GLOFIL-125		
QUESTCOR PHARMS	250-300 uCi/ML	N17279 001

FDA data supplied by DrugPatentWatch.com

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 160			
+ MALLINCKRODT	34%	N19710 003	DEC 30, 1988
OPTIRAY 240			
+ MALLINCKRODT	51%	N19710 002	DEC 30, 1988
OPTIRAY 300			
+ MALLINCKRODT	64%	N19710 004	JAN 22, 1992
+	64%	N20923 004	MAY 13, 1999
OPTIRAY 320			
+ MALLINCKRODT	68%	N19710 001	DEC 30, 1988
OPTIRAY 350			
+ MALLINCKRODT	74%	N19710 005	JAN 22, 1992
+	74%	N20923 003	MAY 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE; INJECTION

HEXABRIX			
+ MALLINCKRODT	39.3%;19.6%	N18905 002	JUL 26, 1985

IOXAGLATE SODIUM; *MULTIPLE*
SEE IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

IOXILAN

INJECTABLE; INJECTION

OXILAN-300			
GUERBET	62%	N20316 001	DEC 21, 1995
OXILAN-350			
GUERBET	73%	N20316 002	DEC 21, 1995

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

	ATROVENT			
	+ BOEHRINGER INGELHEIM	0.018MG/INH		N19085 001 DEC 29, 1986

SOLUTION; INHALATION

	ATROVENT			
AN	+ BOEHRINGER INGELHEIM	**0.02%**		**N20228 001** SEP 29, 1993
	IPATROPIUM BROMIDE			
AN	ROXANE	**0.02%**		**N75867 001** JUL 22, 2002
	IPRATROPIUM BROMIDE			
AN	ALPHARMA	**0.02%**		**N75111 001** APR 22, 1999
AN	ASLUNG PHARM	**0.02%**		**N75693 001** JAN 26, 2001
AN	BAUSCH AND LOMB	**0.02%**		**N75835 001** OCT 15, 2001
AN	DEY	**0.02%**		**N74755 001** JAN 10, 1997
AN	IVAX PHARMS	**0.02%**		**N75313 001** FEB 07, 2000
AN	NEPHRON	**0.02%**		**N75562 001** SEP 27, 2001
AN	NOVEX	**0.02%**		**N75441 001** MAR 28, 2001
AN	WARRICK PHARMS	**0.02%**		**N75507 001** JAN 19, 2001

SPRAY, METERED; NASAL

	ATROVENT			
AB	+ BOEHRINGER INGELHEIM	**0.021MG/SPRAY**		**N20393 001** OCT 20, 1995
AB	+	**0.042MG/SPRAY**		**N20394 001** OCT 20, 1995
	IPRATROPIUM BROMIDE			
AB	BAUSCH AND LOMB	**0.021MG/SPRAY**		**N76025 001** MAR 31, 2003
AB		**0.042MG/SPRAY**		**N76103 001** MAR 31, 2003
AB	DEY	**0.021MG/SPRAY**		**N75552 001** MAR 31, 2003
AB		**0.042MG/SPRAY**		**N75553 001** MAR 31, 2003
AB	NOVEX	**0.021MG/SPRAY**		**N76156 001** APR 18, 2003

FDA data supplied by DrugPatentWatch.com

IPRATROPIUM BROMIDE

SPRAY, METERED; NASAL

	IPRATROPIUM BROMIDE			
AB	NOVEX	**0.042MG/SPRAY**	**N76155 001** APR 18, 2003	
AB	ROXANE	**0.021MG/SPRAY**	**N76664 001** NOV 05, 2003	
AB		**0.042MG/SPRAY**	**N76598 001** NOV 05, 2003	

IPRATROPIUM BROMIDE; *MULTIPLE*
SEE ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

IRBESARTAN

TABLET; ORAL

	AVAPRO		
	SANOFI SYNTHELABO	75MG	N20757 001 SEP 30, 1997
		150MG	N20757 002 SEP 30, 1997
+		300MG	N20757 003 SEP 30, 1997

IRBESARTAN; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; IRBESARTAN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

	CAMPTOSAR		
+	PHARMACIA AND UPJOHN	20MG/ML	N20571 001 JUN 14, 1996

IRON DEXTRAN

INJECTABLE; INJECTION

	DEXFERRUM		
BP	LUITPOLD	EQ 50MG IRON/ML	N40024 001 FEB 23, 1996
	INFED		
BP +	SCHEIN	EQ 50MG IRON/ML	N17441 001
	PROFERDEX		
BP	NEW RIVER	EQ 50MG IRON/ML	N17807 001

IRON SUCROSE

INJECTABLE; INTRAVENOUS

	VENOFER		
+	LUITPOLD	EQ 20MG BASE/ML	N21135 001 NOV 06, 2000

ISOCARBOXAZID

TABLET; ORAL

	MARPLAN		
+	OXFORD PHARM	10MG	N11961 001

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

	BETA-2		
AN	NEPHRON	**1%**	**N86711 001**
	ISOETHARINE HCL		
AN +	ROXANE	**1%**	**N86899 001**

ISOFLURANE

LIQUID; INHALATION

	FORANE		
AN +	BAXTER HLTHCARE CORP	**99.9%**	**N17624 001**
	ISOFLURANE		
AN	ABBOTT	**99.9%**	**N74097 001** JAN 25, 1993
AN	HALOCARBON PRODS	**99.9%**	**N75225 001** OCT 20, 1999
AN	MARSAM PHARMS LLC	**99.9%**	**N74393 001** MAY 12, 1995
AN	MINRAD	**99.9%**	**N74416 001** SEP 30, 1994
AN	RHODIA	**99.9%**	**N74502 001** JUN 27, 1995

ISONIAZID

INJECTABLE; INJECTION

	NYDRAZID		
+	APOTHECON	100MG/ML	N08662 001

FDA data supplied by DrugPatentWatch.com

ISONIAZID

SYRUP; ORAL

	ISONIAZID			
	+ CAROLINA MEDCL	50MG/5ML	N88235 001	NOV 10, 1983

TABLET; ORAL

	ISONIAZID			
AA	AXIOM PHARM	**300MG**	**N83633 001**	
AA	BARR	**100MG**	**N80936 001**	
AA		**300MG**	**N80937 002**	
AA	DURAMED PHARMS BARR	**300MG**	**N88119 001**	MAR 17, 1983
AA +	EON	**100MG**	**N08678 002**	
AA +		**300MG**	**N08678 003**	
AA	MIKART	**100MG**	**N40090 001**	JUN 26, 1997
AA		**300MG**	**N40090 002**	JUN 26, 1997
AA	WATSON LABS	**300MG**	**N80521 001**	
AA	WEST WARD	**100MG**	**N80212 001**	
AA		**300MG**	**N87425 001**	
	LANIAZID			
AA	LANNETT	**100MG**	**N80140 002**	
AA		**300MG**	**N89776 001**	JUN 13, 1988
		50MG	N80140 001	

ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET; ORAL

RIFATER			
+ AVENTIS PHARMS	50MG;300MG;120MG	N50705 001	MAY 31, 1994

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMATE			
+ AVENTIS PHARMS	150MG;300MG	N61884 001	

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

	ISOPROTERENOL HCL			
AP	ABBOTT	**0.2MG/ML**	**N83346 001**	

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

	ISOPROTERENOL HCL			
	ABBOTT	0.02MG/ML	N83283 001	
AP	INTL MEDICATION	**0.2MG/ML**	**N83724 001**	
	ISUPREL			
AP +	ABBOTT	**0.2MG/ML**	**N10515 001**	

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

	DILATRATE-SR			
	+ SCHWARZ PHARMA	40MG	N19790 001	SEP 02, 1988

TABLET; ORAL

	ISORDIL			
AB	BIOVAIL	**5MG**	**N12093 007**	JUL 29, 1988
AB		**10MG**	**N12093 002**	JUL 29, 1988
AB		**20MG**	**N12093 006**	JUL 29, 1988
AB +		**30MG**	**N12093 005**	JUL 29, 1988
+		40MG	N12093 001	JUL 29, 1988
	ISOSORBIDE DINITRATE			
AB	PAR PHARM	**5MG**	**N86923 001**	MAR 12, 1987
AB		**10MG**	**N86925 001**	MAR 12, 1987
AB		**20MG**	**N87537 001**	OCT 02, 1987
AB		**30MG**	**N87946 001**	JAN 12, 1988
AB	SANDOZ	**5MG**	**N86221 001**	JAN 07, 1988
AB		**10MG**	**N86223 001**	JAN 07, 1988
AB		**20MG**	**N89367 001**	APR 07, 1988
AB	WATSON LABS	**5MG**	**N86034 001**	JAN 06, 1988
AB		**10MG**	**N86032 001**	JAN 07, 1988

FDA data supplied by DrugPatentWatch.com

ISOSORBIDE DINITRATE

TABLET; ORAL

	ISOSORBIDE DINITRATE			
AB	WEST WARD	5MG	N86067 001	
			OCT 29, 1987	
AB		10MG	N86066 001	
			OCT 29, 1987	
AB		20MG	N88088 001	
			NOV 02, 1987	

TABLET; SUBLINGUAL

	ISORDIL			
AB	BIOVAIL	2.5MG	N12940 004	
			JUL 29, 1988	
AB		5MG	N12940 003	
			JUL 29, 1988	
	+	10MG	N12940 005	
			JUL 29, 1988	
	ISOSORBIDE DINITRATE			
AB	SANDOZ	2.5MG	N86225 001	
			FEB 19, 1988	
AB		5MG	N86222 001	
			FEB 19, 1988	
AB	WATSON LABS	2.5MG	N86033 001	
			FEB 26, 1988	
AB		5MG	N86031 001	
			SEP 29, 1987	
AB	WEST WARD	2.5MG	N86054 001	
			OCT 29, 1987	
AB		5MG	N86055 001	
			NOV 02, 1987	

TABLET, EXTENDED RELEASE; ORAL

	ISOSORBIDE DINITRATE		
+	INWOOD LABS	40MG	N40009 001
			DEC 30, 1998

ISOSORBIDE MONONITRATE

TABLET; ORAL

	ISMO			
AB	ESP PHARMA	20MG	N19091 001	
			DEC 30, 1991	
	ISOSORBIDE MONONITRATE			
AB	PUREPAC PHARM	10MG	N75037 002	
			OCT 30, 1998	

TABLET; ORAL

	ISOSORBIDE MONONITRATE			
AB	PUREPAC PHARM	20MG	N75037 001	
			OCT 30, 1998	
AB	TEVA	20MG	N75147 001	
			NOV 27, 1998	
AB	WEST WARD	20MG	N75361 001	
			OCT 05, 2000	
	MONOKET			
AB	SCHWARZ	10MG	N20215 002	
			JUN 30, 1993	
AB	+	20MG	N20215 001	
			JUN 30, 1993	

TABLET, EXTENDED RELEASE; ORAL

	IMDUR			
AB	+ SCHERING PLOUGH	30MG	N20225 001	
			AUG 12, 1993	
AB	+	60MG	N20225 002	
			AUG 12, 1993	
AB	+	120MG	N20225 003	
			MAR 30, 1995	
	ISOSORBIDE MONONITRATE			
AB	BRIGHTSTONE	60MG	N75166 001	
			OCT 07, 1999	
AB	DEXCEL LTD	60MG	N75522 001	
			APR 17, 2000	
AB	ELAN PHARM	60MG	N75041 001	
			SEP 22, 1998	
AB	IVAX PHARMS	30MG	N75448 002	
			AUG 07, 2001	
AB		60MG	N75448 001	
			JUN 19, 2000	
AB		120MG	N75448 003	
			AUG 07, 2001	
AB	KREMERS URBAN	30MG	N75155 002	
			JAN 13, 2000	
AB		60MG	N75155 001	
			OCT 30, 1998	
AB		120MG	N75155 003	
			AUG 04, 2000	
AB	KV PHARM	30MG	N75395 001	
			MAR 16, 2000	
AB		60MG	N75395 002	
			MAR 16, 2000	
AB		120MG	N75395 003	
			MAR 16, 2000	

FDA data supplied by DrugPatentWatch.com

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

	ISOSORBIDE MONONITRATE			
AB	PUREPAC PHARM	30MG	N75306 001 DEC 31, 1998	
AB		60MG	N75306 002 DEC 31, 1998	

ISOSULFAN BLUE

INJECTABLE; INJECTION

	LYMPHAZURIN			
+	US SURGCL	1%	N18310 001	

ISOTRETINOIN

CAPSULE; ORAL

	ACCUTANE			
AB	HLR	10MG	N18662 002 MAY 07, 1982	
AB	+	20MG	N18662 004 MAR 28, 1983	
AB	+	40MG	N18662 003 MAY 07, 1982	
	AMNESTEEM			
AB	GENPHARM	10MG	N75945 001 NOV 08, 2002	
AB		20MG	N75945 002 NOV 08, 2002	
AB		40MG	N75945 003 NOV 08, 2002	
	CLARAVIS			
AB	BARR	10MG	N76356 001 APR 11, 2003	
AB		20MG	N76135 002 APR 11, 2003	
AB		40MG	N76135 001 APR 11, 2003	
	ISOTRETINOIN			
AB	RANBAXY	10MG	N76041 001 DEC 24, 2002	
AB		20MG	N76041 002 DEC 24, 2002	
AB		40MG	N76041 003 DEC 24, 2002	

ISOTRETINOIN

CAPSULE; ORAL

	SOTRET			
	RANBAXY	30MG		N76503 001 JUN 20, 2003

ISRADIPINE

CAPSULE; ORAL

	DYNACIRC			
	RELIANT PHARMS	2.5MG		N19546 001 DEC 20, 1990
+		5MG		N19546 002 DEC 20, 1990

TABLET, EXTENDED RELEASE; ORAL

	DYNACIRC CR			
+	RELIANT PHARMS	5MG		N20336 001 JUN 01, 1994
+		10MG		N20336 002 JUN 01, 1994

ITRACONAZOLE

CAPSULE; ORAL

	SPORANOX			
+	JANSSEN PHARMA	100MG		N20083 001 SEP 11, 1992

INJECTABLE; INJECTION

	SPORANOX			
+	JANSSEN PHARMA	10MG/ML		N20966 001 MAR 30, 1999

SOLUTION; ORAL

	SPORANOX			
+	JANSSEN PHARMA	10MG/ML		N20657 001 FEB 21, 1997

IVERMECTIN

TABLET; ORAL

	STROMECTOL			
	MERCK	3MG		N50742 002 OCT 08, 1998

FDA data supplied by DrugPatentWatch.com

IVERMECTIN

TABLET; ORAL
STROMECTOL
+ MERCK — 6MG — N50742 001 NOV 22, 1996

KANAMYCIN SULFATE

CAPSULE; ORAL
KANTREX
+ APOTHECON — EQ 500MG BASE — N62726 001 MAR 06, 1987

INJECTABLE; INJECTION
KANAMYCIN

AP	AM PHARM PARTNERS	**EQ 500MG BASE/2ML**	**N65111 001**	DEC 17, 2002
AP		**EQ 1GM BASE/3ML**	**N65111 002**	DEC 17, 2002

KANTREX

AP	+ APOTHECON	**EQ 500MG BASE/2ML**	**N61901 001**	
AP	+	**EQ 1GM BASE/3ML**	**N61901 002**	
	+	EQ 75MG BASE/2ML	N61901 003	

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
KETALAR

AP	+ PARKEDALE	**EQ 50MG BASE/ML**	**N16812 002**	
AP	+	**EQ 100MG BASE/ML**	**N16812 003**	
	+	EQ 10MG BASE/ML	N16812 001	

KETAMINE HCL

AP	ABBOTT	**EQ 50MG BASE/ML**	**N74549 001**	JUN 27, 1996
AP		**EQ 100MG BASE/ML**	**N74549 002**	JUN 27, 1996
AP	BEDFORD	**EQ 50MG BASE/ML**	**N74524 001**	MAR 22, 1996
AP		**EQ 100MG BASE/ML**	**N74524 002**	MAR 22, 1996
AP	BIONICHE (CANADA)	**EQ 50MG BASE/ML**	**N76092 002**	DEC 28, 2001
AP		**EQ 100MG BASE/ML**	**N76092 003**	OCT 25, 2002

KETOCONAZOLE

CREAM; TOPICAL
KETOCONAZOLE

AB	TEVA	**2%**	**N75581 001**	APR 25, 2000

KETOZOLE

AB	TARO	**2%**	**N75638 001**	DEC 18, 2002

NIZORAL

AB	+ JANSSEN PHARMA	**2%**	**N19084 001**	DEC 31, 1985

SHAMPOO; TOPICAL
NIZORAL
+ MCNEIL CONS SPECLT — 2% — N19927 001 AUG 31, 1990

TABLET; ORAL
KETOCONAZOLE

AB	AAIPHARMA LLC	**200MG**	**N75341 001**	JUL 27, 1999
AB	MUTUAL PHARMA	**200MG**	**N75314 001**	JUN 15, 1999
AB	MYLAN	**200MG**	**N75597 001**	DEC 23, 1999
AB	PLIVA	**200MG**	**N75362 001**	JUN 15, 1999
AB	TARO	**200MG**	**N75319 001**	JUN 15, 1999
AB	TEVA	**200MG**	**N74971 001**	JUN 15, 1999
AB		**200MG**	**N75273 001**	JUN 15, 1999
AB	TORPHARM	**200MG**	**N75912 001**	JAN 10, 2002

NIZORAL

AB	+ JANSSEN	**200MG**	**N18533 001**	

KETOPROFEN

CAPSULE; ORAL
KETOPROFEN

AB	CLONMEL HLTHCARE	**25MG**	**N74014 001**	JAN 29, 1993
AB		**50MG**	**N74014 002**	JAN 29, 1993

FDA data supplied by DrugPatentWatch.com

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

AB	CLONMEL HLTHCARE	75MG	N74014 003	JAN 29, 1993
AB	MYLAN	50MG	N74035 002	DEC 31, 1996
AB		75MG	N74035 003	DEC 31, 1996
AB	SANDOZ	50MG	N74024 001	DEC 29, 1995
AB		75MG	N74024 002	DEC 29, 1995
AB	TEVA	25MG	N73515 001	DEC 22, 1992
AB		50MG	N73516 001	DEC 22, 1992
AB +		75MG	N73517 001	DEC 22, 1992

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

AB	ANDRX PHARMS	100MG	N75270 002	MAR 24, 1999
AB		150MG	N75270 003	MAR 24, 1999
AB		200MG	N75270 001	MAR 24, 1999
AB	ELAN PHARM	200MG	N74879 001	DEC 10, 1997
AB	MYLAN	100MG	N75679 003	FEB 20, 2002
AB		150MG	N75679 002	FEB 20, 2002
AB		200MG	N75679 001	FEB 20, 2002

ORUVAIL

AB	WYETH PHARMS INC	100MG	N19816 003	FEB 08, 1995
AB		150MG	N19816 002	FEB 08, 1995
AB +		200MG	N19816 001	SEP 24, 1993

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	ABBOTT	15MG/ML	N74802 001	JUN 05, 1997
AP		15MG/ML	N74993 001	JAN 27, 1999
AP		30MG/ML	N74802 002	JUN 05, 1997
AP		30MG/ML	N74993 002	JAN 27, 1999
AP	AM PHARM PARTNERS	15MG/ML	N75784 001	JAN 11, 2002
AP		30MG/ML	N75784 002	JAN 11, 2002
AP	APOTEX	15MG/ML	N75631 002	JUN 29, 2001
AP		30MG/ML	N75626 001	JUL 24, 2001
AP		30MG/ML	N75631 001	JUN 29, 2001
AP	BAXTER HLTHCARE CORP	15MG/ML	N75299 001	NOV 03, 1999
AP		30MG/ML	N75299 002	NOV 03, 1999
AP	BEDFORD	15MG/ML	N75222 001	APR 26, 1999
AP		30MG/ML	N75222 002	APR 26, 1999
AP +		30MG/ML	N75228 001	APR 26, 1999

TORADOL

AP +	ROCHE PALO	15MG/ML	N19698 001	NOV 30, 1989
AP +		30MG/ML	N19698 002	NOV 30, 1989

SOLUTION/DROPS; OPHTHALMIC

ACULAR

+	ALLERGAN	0.5%	N19700 001	NOV 09, 1992

ACULAR LS

+	ALLERGAN	0.4%	N21528 001	MAY 30, 2003

ACULAR PRESERVATIVE FREE

+	ALLERGAN	0.5%	N20811 001	NOV 03, 1997

FDA data supplied by DrugPatentWatch.com

KETOROLAC TROMETHAMINE

TABLET; ORAL

	KETOROLAC TROMETHAMINE			
AB	MYLAN	10MG	N74761 001	MAY 16, 1997
AB	PLIVA	10MG	N75284 001	JUN 23, 1999
AB	TEVA	10MG	N74754 001	MAY 16, 1997
AB	WATSON LABS	10MG	N74955 001	SEP 19, 1997
	TORADOL			
AB	+ ROCHE PALO	10MG	N19645 001	DEC 20, 1991

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

	ZADITOR			
	+ NOVARTIS	EQ 0.025% BASE	N21066 001	JUL 02, 1999

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

	LABETALOL HCL			
AP	ABBOTT	5MG/ML	N75239 001	NOV 29, 1999
AP		5MG/ML	N75240 001	NOV 29, 1999
AP	APOTEX	5MG/ML	N76051 001	JUL 05, 2002
AP	BEDFORD	5MG/ML	N75303 001	MAY 28, 1999
AP	MAYNE PHARMA USA	5MG/ML	N75242 001	SEP 30, 1999
AP	TAYLOR	5MG/ML	N75431 001	NOV 29, 1999
AP		5MG/ML	N75524 001	NOV 29, 1999
	NORMODYNE			
AP	+ SCHERING	5MG/ML	N18686 001	AUG 01, 1984
	TRANDATE			
AP	+ PROMETHEUS LABS	5MG/ML	N19425 001	DEC 31, 1985

LABETALOL HYDROCHLORIDE

TABLET; ORAL

	LABETALOL HCL			
AB	EON	100MG	N75113 001	AUG 04, 1998
AB		200MG	N75113 002	AUG 04, 1998
AB		300MG	N75113 003	AUG 04, 1998
AB	IVAX PHARMS	100MG	N74787 001	AUG 03, 1998
AB		200MG	N74787 002	AUG 03, 1998
AB		300MG	N74787 003	AUG 03, 1998
AB	MUTUAL PHARM	100MG	N75215 001	JUL 29, 1999
AB		200MG	N75215 002	JUL 29, 1999
AB		300MG	N75215 003	JUL 29, 1999
AB	TEVA	100MG	N74989 001	SEP 30, 1998
AB		200MG	N74989 002	SEP 30, 1998
AB		300MG	N74989 003	SEP 30, 1998
AB	WATSON LABS	100MG	N75133 001	AUG 03, 1998
AB		200MG	N75133 002	AUG 03, 1998
AB		300MG	N75133 003	AUG 03, 1998
	NORMODYNE			
AB	SCHERING	100MG	N18687 001	AUG 31, 1987
AB		200MG	N18687 002	AUG 01, 1984
AB	+	300MG	N18687 003	AUG 01, 1984
	TRANDATE			
AB	PROMETHEUS LABS	100MG	N18716 001	MAY 24, 1985
AB		200MG	N18716 002	AUG 01, 1984
AB		300MG	N18716 003	AUG 01, 1984

FDA data supplied by DrugPatentWatch.com

LACTULOSE

FOR SOLUTION; ORAL

	LACTULOSE			
	+ INALCO	10GM/PACKET	N74712 001	DEC 10, 1997
	+	20GM/PACKET	N74712 002	DEC 10, 1997

SOLUTION; ORAL

	CONSTILAC			
AA	ALRA	**10GM/15ML**	**N71054 001**	JUL 26, 1988
	CONSTULOSE			
AA	+ ALPHARMA	**10GM/15ML**	**N70288 001**	AUG 15, 1988
	EVALOSE			
AA	COPLEY PHARM	**10GM/15ML**	**N73497 001**	MAY 28, 1993
	LACTULOSE			
AA	HI TECH PHARMA	**10GM/15ML**	**N74076 001**	JUL 03, 1995
AA	MORTON GROVE	**10GM/15ML**	**N74602 001**	NOV 14, 1996
AA	NOVEX	**10GM/15ML**	**N75911 001**	FEB 21, 2002
AA	PHARM ASSOC	**10GM/15ML**	**N74623 001**	JUL 30, 1996
AA	ROXANE	**10GM/15ML**	**N73591 001**	MAY 29, 1992
AA	VINTAGE PHARMS	**10GM/15ML**	**N75993 001**	JUL 26, 2001
AA	VISTAPHARM	**10GM/15ML**	**N74138 001**	SEP 30, 1992
	LAXILOSE			
AA	TECHNILAB	**10GM/15ML**	**N73686 001**	MAY 28, 1993

SOLUTION; ORAL, RECTAL

	ACILAC			
AA	TECHNILAB	**10GM/15ML**	**N73685 001**	MAY 28, 1993
	CHOLAC			
AA	ALRA	**10GM/15ML**	**N71331 001**	JUL 26, 1988
	ENULOSE			
AA	+ ALPHARMA	**10GM/15ML**	**N71548 001**	AUG 15, 1988

LACTULOSE

SOLUTION; ORAL, RECTAL

	GENERLAC			
AA	MORTON GROVE	**10GM/15ML**	**N74603 001**	OCT 31, 1996
	HEPTALAC			
AA	COPLEY PHARM	**10GM/15ML**	**N73504 001**	MAY 28, 1993
	LACTULOSE			
AA	HI TECH PHARMA	**10GM/15ML**	**N74077 001**	JUL 03, 1995
AA	NOVEX	**10GM/15ML**	**N76645 001**	JUL 28, 2003

LAMIVUDINE

SOLUTION; ORAL

	EPIVIR		
+	GLAXOSMITHKLINE	10MG/ML	N20596 001 NOV 17, 1995
	EPIVIR-HBV		
+	GLAXOSMITHKLINE	5MG/ML	N21004 001 DEC 08, 1998

TABLET; ORAL

	EPIVIR		
+	GLAXOSMITHKLINE	150MG	N20564 001 NOV 17, 1995
		300MG	N20564 003 JUN 24, 2002
	EPIVIR-HBV		
+	GLAXOSMITHKLINE	100MG	N21003 001 DEC 08, 1998

LAMIVUDINE; *MULTIPLE*

SEE ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

	COMBIVIR		
+	GLAXOSMITHKLINE	150MG;300MG	N20857 001 SEP 26, 1997

FDA data supplied by DrugPatentWatch.com

LAMOTRIGINE

TABLET; ORAL
LAMICTAL
GLAXOSMITHKLINE 25MG N20241 005 DEC 27, 1994
100MG N20241 001 DEC 27, 1994
150MG N20241 002 DEC 27, 1994
\+ 200MG N20241 003 DEC 27, 1994

TABLET, CHEWABLE; ORAL
LAMICTAL CD
GLAXOSMITHKLINE 2MG N20764 004 SEP 08, 2000
5MG N20764 001 AUG 24, 1998
\+ 25MG N20764 002 AUG 24, 1998

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
PREVACID
TAP PHARM 15MG N20406 001 MAY 10, 1995
\+ 30MG N20406 002 MAY 10, 1995

FOR SUSPENSION, EXTENDED RELEASE; ORAL
PREVACID
TAP PHARM 15MG/PACKET N21281 001 MAY 03, 2001
\+ 30MG/PACKET N21281 002 MAY 03, 2001

TABLET, ORALLY DISINTEGRATING; ORAL
PREVACID
TAP PHARM 15MG N21428 001 AUG 30, 2002
\+ 30MG N21428 002 AUG 30, 2002

LANSOPRAZOLE; *MULTIPLE*
SEE AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET; ORAL
NAPRAPAC 250 (COPACKAGED)
TAP PHARM 15MG,N/A;N/A,250MG N21507 002 NOV 14, 2003
NAPRAPAC 375 (COPACKAGED)
TAP PHARM 15MG,N/A;N/A,375MG N21507 003 NOV 14, 2003
NAPRAPAC 500 (COPACKAGED)
\+ TAP PHARM 15MG,N/A;N/A,500MG N21507 004 NOV 14, 2003

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC
XALATAN
\+ PHARMACIA AND UPJOHN 0.005% N20597 001 JUN 05, 1996

LEFLUNOMIDE

TABLET; ORAL
ARAVA
AVENTIS PHARMS 10MG N20905 001 SEP 10, 1998
\+ 20MG N20905 002 SEP 10, 1998

LEPIRUDIN

INJECTABLE; INJECTION
REFLUDAN
\+ BERLEX LABS 50MG/VIAL N20807 001 MAR 06, 1998

LETROZOLE

TABLET; ORAL
FEMARA
\+ NOVARTIS 2.5MG N20726 001 JUL 25, 1997

FDA data supplied by DrugPatentWatch.com

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM					
AP		BEDFORD	EQ 50MG BASE/VIAL	N89384 001	SEP 14, 1987
AP			EQ 100MG BASE/VIAL	N89717 001	MAR 28, 1988
AP		GENSIA SICOR PHARMS	EQ 50MG BASE/VIAL	N81278 001	SEP 28, 1993
AP			EQ 100MG BASE/VIAL	N81277 001	SEP 28, 1993
AP			EQ 350MG BASE/VIAL	N40174 001	JUN 12, 1997
AP	+	MAYNE PHARMA USA	EQ 50MG BASE/VIAL	N08107 002	
AP	+		EQ 100MG BASE/VIAL	N08107 004	MAY 23, 1988
AP	+		EQ 350MG BASE/VIAL	N08107 005	APR 05, 1989
AP		PHARMACHEMIE	EQ 350MG BASE/VIAL	N40262 001	DEC 15, 1999
AP		PHARMACHEMIE USA	EQ 50MG BASE/VIAL	N89628 001	APR 17, 1997
AP			EQ 100MG BASE/VIAL	N89915 001	APR 17, 1997
LEUCOVORIN CALCIUM PRESERVATIVE FREE					
AP	+	ABBOTT	EQ 10MG BASE/ML	N40147 001	JUN 25, 1997
AP		BEDFORD	EQ 10MG BASE/ML	N40347 001	APR 25, 2000
AP	+		EQ 200MG BASE/VIAL	N40056 001	MAY 23, 1995
AP			EQ 350MG BASE/VIAL	N40335 001	APR 20, 2000
AP		BIGMAR	EQ 200MG BASE/VIAL	N40258 001	FEB 26, 1999
	+		EQ 500MG BASE/VIAL	N40286 001	FEB 26, 1999
AP		GENSIA SICOR PHARMS	EQ 10MG BASE/ML	N40332 001	JUN 28, 1999
AP		LUITPOLD	EQ 50MG BASE/VIAL	N40338 001	JAN 31, 2001

TABLET; ORAL

LEUCOVORIN CALCIUM					
AB		BARR	EQ 5MG BASE	N71198 001	SEP 24, 1987
AB			EQ 25MG BASE	N71199 001	SEP 24, 1987
AB		PAR PHARM	EQ 5MG BASE	N74544 001	AUG 28, 1997
AB			EQ 25MG BASE	N74544 002	AUG 28, 1997
AB		PHARMACHEMIE	EQ 5MG BASE	N73099 001	MAR 28, 1997
AB			EQ 25MG BASE	N73101 001	MAR 28, 1997
AB		ROXANE	EQ 5MG BASE	N72733 001	FEB 22, 1993
AB			EQ 10MG BASE	N72734 001	FEB 22, 1993
AB			EQ 15MG BASE	N72735 001	FEB 22, 1993
AB	+		EQ 25MG BASE	N72736 001	FEB 22, 1993
AB		SANDOZ	EQ 15MG BASE	N75327 001	MAR 24, 1999
AB		XANODYNE PHARM	EQ 10MG BASE	N71962 001	NOV 19, 1987
AB			EQ 15MG BASE	N71104 001	MAR 04, 1987
BX			EQ 5MG BASE	N18459 001	JAN 30, 1986

LEUPROLIDE ACETATE

IMPLANT; IMPLANTATION

VIADUR					
	+	ALZA	EQ 65MG BASE	N21088 001	MAR 03, 2000

INJECTABLE; INJECTION

LEUPROLIDE ACETATE					
AP		BEDFORD LABS	1MG/0.2ML	N74728 001	AUG 04, 1998
AP		GENSIA SICOR PHARMS	1MG/0.2ML	N75471 001	OCT 25, 2000
AP		GENZYME	1MG/0.2ML	N75721 001	NOV 29, 2001
LUPRON					
AP	+	TAP PHARM	1MG/0.2ML	N19010 001	APR 09, 1985

FDA data supplied by DrugPatentWatch.com

LEUPROLIDE ACETATE

INJECTABLE; INJECTION				
LUPRON DEPOT				
+ TAP PHARM	3.75MG/VIAL	N20011 001 OCT 22, 1990		
+	7.5MG/VIAL	N19732 001 JAN 26, 1989		
+	22.5MG/VIAL	N20517 001 DEC 22, 1995		
LUPRON DEPOT-3				
+ TAP PHARM	11.25MG/VIAL	N20708 001 MAR 07, 1997		
LUPRON DEPOT-4				
+ TAP PHARM	30MG/VIAL	N20517 002 MAY 30, 1997		
LUPRON DEPOT-PED				
+ TAP PHARM	7.5MG/VIAL	N20263 002 APR 16, 1993		
+	11.25MG/VIAL	N20263 005 JAN 21, 1994		
+	15MG/VIAL	N20263 006 JAN 21, 1994		
INJECTABLE; SUBCUTANEOUS				
ELIGARD				
+ ATRIX	7.5MG/VIAL	N21343 001 JAN 23, 2002		
+	22.5MG/VIAL	N21379 001 JUL 24, 2002		
+	30MG/VIAL	N21488 001 FEB 13, 2003		

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION		
XOPENEX		
+ SEPRACOR	EQ 0.0103% BASE	N20837 003 JAN 30, 2002
+	EQ 0.021% BASE	N20837 001 MAR 25, 1999
+	EQ 0.042% BASE	N20837 002 MAR 25, 1999
+	EQ 0.25% BASE	N20837 004 JUL 18, 2003

LEVETIRACETAM

SOLUTION; ORAL		
KEPPRA		
+ UCB	100MG/ML	N21505 001 JUL 15, 2003
TABLET; ORAL		
KEPPRA		
UCB	250MG	N21035 001 NOV 30, 1999
	500MG	N21035 002 NOV 30, 1999
+	750MG	N21035 003 NOV 30, 1999

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC				
AKBETA				
AT	AKORN	**0.25%**	**N74779 001**	OCT 29, 1996
AT		**0.5%**	**N74780 001**	OCT 29, 1996
BETAGAN				
AT	+ ALLERGAN	**0.25%**	**N19814 001**	JUN 28, 1989
AT	+	**0.5%**	**N19219 002**	DEC 19, 1985
LEVOBUNOLOL HCL				
AT	BAUSCH AND LOMB	**0.25%**	**N74307 001**	MAR 04, 1994
AT		**0.5%**	**N74326 001**	MAR 04, 1994
AT	FALCON PHARMS	**0.25%**	**N74851 001**	OCT 28, 1996
AT		**0.5%**	**N74850 001**	OCT 28, 1996
AT	NOVEX	**0.25%**	**N75473 001**	AUG 03, 2000
AT		**0.5%**	**N75475 001**	AUG 03, 2000

FDA data supplied by DrugPatentWatch.com

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHIROCAINE
PURDUE PHARMA LP — EQ 2.5MG BASE/ML — N20997 001 AUG 05, 1999
EQ 5MG BASE/ML — N20997 002 AUG 05, 1999
+ EQ 7.5MG BASE/ML — N20997 003 AUG 05, 1999

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
LIVOSTIN
+ NOVARTIS — EQ 0.05% BASE — N20219 001 NOV 10, 1993

LEVOCARNITINE

INJECTABLE; INJECTION
CARNITOR
AP + SIGMA TAU — **200MG/ML** — **N20182 001** DEC 16, 1992

LEVOCARNITINE
AP BEDFORD — **200MG/ML** — **N75567 001** MAR 29, 2001
AP GENSIA SICOR PHARMS — **200MG/ML** — **N75881 001** MAR 29, 2001
AP LUITPOLD — **200MG/ML** — **N75861 001** JUN 22, 2001

SOLUTION; ORAL
CARNITOR
+ SIGMA TAU — 1GM/10ML — N19257 001 APR 10, 1986

TABLET; ORAL
CARNITOR
+ SIGMA TAU — 330MG — N18948 001 DEC 27, 1985

LEVODOPA; *MULTIPLE*
SEE CARBIDOPA; ENTACAPONE; LEVODOPA
SEE CARBIDOPA; LEVODOPA

LEVOFLOXACIN

INJECTABLE; INJECTION
LEVAQUIN
+ ORTHO MCNEIL PHARM — EQ 500MG /20ML(25MG/ML) — N20635 001 DEC 20, 1996
+ EQ 750MG /30ML(25MG/ML) — N20635 004 DEC 20, 1996

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER
+ ORTHO MCNEIL PHARM — EQ 250MG /50ML(5MG/ML) — N20635 002 DEC 20, 1996
+ EQ 500MG /100ML(5MG/ML) — N20635 003 DEC 20, 1996
+ EQ 750MG /150ML(5MG/ML) — N20635 005 DEC 20, 1996

SOLUTION/DROPS; OPHTHALMIC
QUIXIN
+ SANTEN — 0.5% — N21199 001 AUG 18, 2000

TABLET; ORAL
LEVAQUIN
ORTHO MCNEIL PHARM — 250MG — N20634 001 DEC 20, 1996
500MG — N20634 002 DEC 20, 1996
+ 750MG — N20634 003 SEP 08, 2000

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL
ORLAAM
+ ROXANE — 10MG/ML — N20315 001 JUL 09, 1993

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CARBOCAINE W/ NEO-COBEFRIN
AP + EASTMAN KODAK — **0.05MG/ML;2%** — **N12125 002**
ISOCAINE HCL W/ LEVONORDEFRIN
AP NOVOCOL — **0.05MG/ML;2%** — **N84697 001**
MEPIVACAINE HCL W/ LEVONORDEFRIN
AP GRAHAM CHEM — **0.05MG/ML;2%** — **N84850 002** OCT 21, 1983

FDA data supplied by DrugPatentWatch.com

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

POLOCAINE W/ LEVONORDEFRIN

AP	DENTSPLY PHARM	**0.05MG/ML;2%**	**N89517 001** APR 14, 1988	

SCANDONEST L

AP	DEPROCO	**0.05MG/ML;2%**	**N88388 001** OCT 10, 1984	

LEVONORGESTREL

IMPLANT; IMPLANTATION

NORPLANT II

BX	+ POPULATION COUNCIL	75MG/IMPLANT	N20544 001 NOV 01, 1996	

INTRAUTERINE DEVICE; INTRAUTERINE

MIRENA

	+ BERLEX LABS	52MG	N21225 001 DEC 06, 2000	

TABLET; ORAL

PLAN B

	+ WOMENS CAPITAL	0.75MG	N21045 001 JUL 28, 1999	

LEVONORGESTREL; *MULTIPLE*

SEE ESTRADIOL; LEVONORGESTREL

SEE ETHINYL ESTRADIOL; LEVONORGESTREL

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION

LEVO-DROMORAN

	+ VALEANT PHARM INTL	2MG/ML	N08719 001 DEC 19, 1991	

TABLET; ORAL

LEVORPHANOL TARTRATE

	+ ROXANE	2MG	N74278 001 MAR 31, 2000	

LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVO-T

BX	ALARA PHARM	0.025MG		N21342 001 MAR 01, 2002
BX		0.05MG		N21342 002 MAR 01, 2002
BX		0.075MG		N21342 003 MAR 01, 2002
BX		0.088MG		N21342 004 MAR 01, 2002
BX		0.1MG		N21342 005 MAR 01, 2002
BX		0.112MG		N21342 006 MAR 01, 2002
BX		0.125MG		N21342 007 MAR 01, 2002
BX		0.137MG		N21342 012 DEC 08, 2003
BX		0.15MG		N21342 008 MAR 01, 2002
BX		0.175MG		N21342 009 MAR 01, 2002
BX		0.2MG		N21342 010 MAR 01, 2002
BX	+	0.3MG		N21342 011 MAR 01, 2002

LEVOLET

BX	VINTAGE PHARMS	0.025MG		N21137 001 JUN 06, 2003
BX		0.05MG		N21137 002 JUN 06, 2003
BX		0.075MG		N21137 003 JUN 06, 2003
BX		0.088MG		N21137 004 JUN 06, 2003
BX		0.1MG		N21137 005 JUN 06, 2003
BX		0.112MG		N21137 006 JUN 06, 2003
BX		0.125MG		N21137 007 JUN 06, 2003
BX		0.137MG		N21137 008 JUN 06, 2003
BX		0.15MG		N21137 009 JUN 06, 2003
BX		0.175MG		N21137 010 JUN 06, 2003

FDA data supplied by DrugPatentWatch.com

LEVOTHYROXINE SODIUM

TABLET; ORAL

	LEVOLET		
BX	VINTAGE PHARMS	0.2MG	N21137 011 JUN 06, 2003
BX		0.3MG	N21137 012 JUN 06, 2003
	LEVOTHYROXINE SODIUM		
AB	MYLAN	**0.025MG**	**N76187 001** JUN 05, 2002
AB		**0.05MG**	**N76187 002** JUN 05, 2002
AB		**0.075MG**	**N76187 003** JUN 05, 2002
AB		**0.088MG**	**N76187 004** JUN 05, 2002
AB		**0.1MG**	**N76187 005** JUN 05, 2002
AB		**0.112MG**	**N76187 006** JUN 05, 2002
AB		**0.125MG**	**N76187 007** JUN 05, 2002
AB		**0.15MG**	**N76187 008** JUN 05, 2002
AB		**0.175MG**	**N76187 009** JUN 05, 2002
AB		**0.2MG**	**N76187 010** JUN 05, 2002
AB		**0.3MG**	**N76187 011** JUN 05, 2002
	LEVOXYL		
BX	JONES PHARMA	0.025MG	N21301 001 MAY 25, 2001
BX		0.05MG	N21301 002 MAY 25, 2001
BX		0.075MG	N21301 003 MAY 25, 2001
BX		0.088MG	N21301 004 MAY 25, 2001
BX		0.1MG	N21301 005 MAY 25, 2001
BX		0.112MG	N21301 006 MAY 25, 2001
BX		0.125MG	N21301 007 MAY 25, 2001
BX		0.137MG	N21301 008 MAY 25, 2001

LEVOTHYROXINE SODIUM

TABLET; ORAL

	LEVOXYL		
BX	JONES PHARMA	0.15MG	N21301 009 MAY 25, 2001
BX		0.175MG	N21301 010 MAY 25, 2001
BX		0.2MG	N21301 011 MAY 25, 2001
BX +		0.3MG	N21301 012 MAY 25, 2001
	NOVOTHYROX		
BX	GENPHARM	0.025MG	N21292 001 MAY 31, 2002
BX		0.05MG	N21292 002 MAY 31, 2002
BX		0.075MG	N21292 003 MAY 31, 2002
BX		0.088MG	N21292 004 MAY 31, 2002
BX		0.1MG	N21292 005 MAY 31, 2002
BX		0.112MG	N21292 006 MAY 31, 2002
BX		0.125MG	N21292 007 MAY 31, 2002
BX		0.137MG	N21292 008 MAY 31, 2002
BX		0.15MG	N21292 009 MAY 31, 2002
BX		0.175MG	N21292 010 MAY 31, 2002
BX		0.2MG	N21292 011 MAY 31, 2002
BX +		0.3MG	N21292 012 MAY 31, 2002
	SYNTHROID		
BX	ABBOTT	0.025MG	N21402 001 JUL 24, 2002
BX		0.05MG	N21402 002 JUL 24, 2002
BX		0.075MG	N21402 003 JUL 24, 2002
BX		0.088MG	N21402 004 JUL 24, 2002
BX		0.1MG	N21402 005 JUL 24, 2002

FDA data supplied by DrugPatentWatch.com

LEVOTHYROXINE SODIUM

TABLET; ORAL

	SYNTHROID				
BX	ABBOTT	0.112MG	N21402 006	JUL 24, 2002	
BX		0.125MG	N21402 007	JUL 24, 2002	
BX		0.137MG	N21402 008	JUL 24, 2002	
BX		0.15MG	N21402 009	JUL 24, 2002	
BX		0.175MG	N21402 010	JUL 24, 2002	
BX		0.2MG	N21402 012	JUL 24, 2002	
BX +		0.3MG	N21402 011	JUL 24, 2002	
	THYRO-TABS				
BX	LLOYD	0.025MG	N21116 001	OCT 24, 2002	
BX		0.05MG	N21116 002	OCT 24, 2002	
BX		0.075MG	N21116 003	OCT 24, 2002	
BX		0.088MG	N21116 010	OCT 24, 2002	
BX		0.1MG	N21116 004	OCT 24, 2002	
BX		0.112MG	N21116 011	OCT 24, 2002	
BX		0.125MG	N21116 005	OCT 24, 2002	
BX		0.15MG	N21116 006	OCT 24, 2002	
BX		0.175MG	N21116 007	OCT 24, 2002	
BX		0.2MG	N21116 008	OCT 24, 2002	
BX +		0.3MG	N21116 009	OCT 24, 2002	
	UNITHROID				
AB	STEVENS J	**0.025MG**	**N21210 001**	AUG 21, 2000	
AB		**0.05MG**	**N21210 002**	AUG 21, 2000	
AB		**0.075MG**	**N21210 003**	AUG 21, 2000	

LEVOTHYROXINE SODIUM

TABLET; ORAL

	UNITHROID				
AB	STEVENS J	**0.088MG**	**N21210 004**	AUG 21, 2000	
AB		**0.1MG**	**N21210 005**	AUG 21, 2000	
AB		**0.112MG**	**N21210 006**	AUG 21, 2000	
AB		**0.125MG**	**N21210 007**	AUG 21, 2000	
AB		**0.15MG**	**N21210 008**	AUG 21, 2000	
AB		**0.175MG**	**N21210 009**	AUG 21, 2000	
AB		**0.2MG**	**N21210 010**	AUG 21, 2000	
AB +		**0.3MG**	**N21210 011**	AUG 21, 2000	

LIDOCAINE

FILM, EXTENDED RELEASE; BUCCAL

	LIDOCAINE			
+	NOVEN	46.1MG/PATCH	N20575 002	MAY 21, 1996

FILM, EXTENDED RELEASE; TOPICAL

	LIDODERM			
+	TEIKOKU PHARMA USA	700MG/12HR	N20612 001	MAR 19, 1999

OINTMENT; TOPICAL

	LIDOCAINE			
AT +	FOUGERA	**5%**	**N80198 001**	
AT	GRAHAM CHEM	**5%**	**N80210 001**	
AT	TARO	**5%**	**N86724 001**	

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

	EMLA			
AB +	ASTRAZENECA	**2.5%;2.5%**	**N19941 001**	DEC 30, 1992
	LIDOCAINE AND PRILOCAINE			
AB	ALTANA	**2.5%;2.5%**	**N76453 001**	AUG 18, 2003

FDA data supplied by DrugPatentWatch.com

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

AB	ATRIX	2.5%;2.5%	N76320 001	AUG 27, 2003
AB	HI TECH PHARMA	2.5%;2.5%	N76290 001	SEP 25, 2003

DISC; TOPICAL

EMLA

+	ASTRAZENECA	2.5%;2.5%	N20962 001	FEB 04, 1998

GEL; PERIODONTAL

ORAQIX

+	DENTSPLY PHARM	2.5%;2.5%	N21451 001	DEC 19, 2003

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL

AP	ABBOTT	0.5%	N88328 001	MAY 17, 1984
AP		1%	N40013 001	JUN 23, 1995
AP		1%	N83158 001	
AP		1%	N88329 001	MAY 17, 1984
AP		2%	N40078 001	JUN 23, 1995
AP		2%	N83158 002	
AP		2%	N88294 001	MAY 17, 1984
AP		2%	N88331 001	MAY 17, 1984
AP		20%	N83158 003	
AP	GRAHAM CHEM	2%	N80504 001	
AP	INTL MEDICATION	1%	N83173 001	
AP		2%	N83173 002	
AP	LUITPOLD	1%	N80850 001	
AP		2%	N83198 001	

LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	200MG/100ML	N18967 001	MAR 30, 1984
AP		200MG/100ML	N19830 002	APR 08, 1992

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	200MG/100ML	N18461 002	

LIDOCAINE HCL 0.2% IN DEXTROSE 5%

AP	ABBOTT	200MG/100ML	N83158 005	

LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	200MG/100ML	N18388 001	

LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	400MG/100ML	N18967 002	MAR 30, 1984
AP		400MG/100ML	N19830 003	APR 08, 1992
AP	BAXTER HLTHCARE	400MG/100ML	N18461 003	

LIDOCAINE HCL 0.4% IN DEXTROSE 5%

AP	ABBOTT	400MG/100ML	N83158 006	

LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	400MG/100ML	N18388 002	

LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	800MG/100ML	N18967 003	MAR 30, 1984
AP		800MG/100ML	N19830 004	APR 08, 1992
AP	BAXTER HLTHCARE	800MG/100ML	N18461 004	FEB 22, 1982

LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	800MG/100ML	N18388 003	NOV 05, 1982

LIDOCAINE HCL IN PLASTIC CONTAINER

AP	ABBOTT	0.5%	N88325 001	JUL 31, 1984
AP		1%	N88299 001	JUL 31, 1984
AP		1.5%	N88326 001	JUL 31, 1984
AP		2%	N88327 001	JUL 31, 1984
AP		10%	N88367 001	JUL 31, 1984
AP		20%	N88368 001	JUL 31, 1984
AP	AM PHARM PARTNERS	1%	N88586 001	JUL 24, 1985

LIDOCAINE HCL PRESERVATIVE FREE

AP	ABBOTT	1%	N80408 001	
AP		1.5%	N80408 002	
AP		4%	N88295 001	MAY 17, 1984

FDA data supplied by DrugPatentWatch.com

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	LIDOCAINE HCL PRESERVATIVE FREE				
AP	AM PHARM PARTNERS	1%		N80404 002	
AP		2%		N17584 001	
AP		2%		N80404 003	
AP		4%		N17584 002	
AP	INTL MEDICATION	20%		N17702 001	
	LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER				
AP	ABBOTT	1%		N40302 001	SEP 28, 1998
AP		2%		N40302 002	SEP 28, 1998
	LIDOPEN				
AP	MERIDIAN MEDCL TECHN	10%		N17549 001	
	XYLOCAINE				
AP	+ ASTRAZENECA	0.5%		N06488 008	
AP	+	1%		N06488 007	
AP	+	1.5%		N06488 010	
AP	+ DENTSPLY PHARM	2%		N21380 001	
	XYLOCAINE 4% PRESERVATIVE FREE				
AP	+ ASTRAZENECA	4%		N10417 001	
	XYLOCAINE PRESERVATIVE FREE				
AP	ASTRAZENECA	1%		N16801 005	JAN 19, 1988
AP		2%		N16801 001	
AP		4%		N16801 002	
AP	+	10%		N16801 003	
AP	+	20%		N16801 004	

INJECTABLE; SPINAL

	LIDOCAINE HCL 5% AND DEXTROSE 7.5%			
	+ ABBOTT	5%		N83914 001
	XYLOCAINE 1.5% W/ DEXTROSE 7.5%			
	+ ASTRAZENECA	1.5%		N16297 001

JELLY; TOPICAL

	LIDOCAINE HCL			
AT	AKORN	2%		N40433 001 FEB 12, 2003
AT	COPLEY PHARM	2%		N81318 001 APR 29, 1993
AT	INTL MEDICATION	2%		N86283 001
	XYLOCAINE			
AT	+ ASTRAZENECA	2%		N08816 001

SOLUTION; ORAL

	LIDOCAINE HCL			
AT	HI TECH PHARMA	2%		N40014 001 JUL 10, 1995

LIDOCAINE HYDROCHLORIDE

SOLUTION; ORAL

	LIDOCAINE HCL			
AT	MORTON GROVE	2%		N87872 001 NOV 18, 1982
	LIDOCAINE HCL VISCOUS			
AT	ALPHARMA	2%		N86578 001
	LIDOCAINE VISCOUS			
AT	ROXANE	2%		N88802 001 APR 26, 1985
	XYLOCAINE VISCOUS			
AT	+ ASTRAZENECA	2%		N09470 001

SOLUTION; TOPICAL

	ANESTACON			
AT	+ POLYMEDICA	2%		N80429 001
	LARYNG-O-JET KIT			
AT	INTL MEDICATION	4%		N86364 001
	LIDOCAINE HCL			
AT	MORTON GROVE	4%		N87881 001 NOV 18, 1982
AT	ROXANE	4%		N88803 001 APR 03, 1985
	LTA II KIT			
AT	ABBOTT	4%		N80409 001
AT		4%		N88542 001 JUL 31, 1984
	PEDIATRIC LTA KIT			
AT	ABBOTT	2%		N85995 001
	XYLOCAINE 4% PRESERVATIVE FREE			
AT	+ ASTRAZENECA	4%		N10417 002

LIDOCAINE HYDROCHLORIDE; *MULTIPLE*

SEE BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE
SEE EPINEPHRINE; LIDOCAINE HYDROCHLORIDE
SEE EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE; INJECTION

TERRAMYCIN			
PFIZER	2%;50MG/ML		N60567 001
	2%;125MG/ML		N60567 002

FDA data supplied by DrugPatentWatch.com

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
LINCOCIN
+ PHARMACIA AND UPJOHN EQ 300MG BASE/ML N50317 001

LINDANE

LOTION; TOPICAL
LINDANE
AT + ALPHARMA **1%** **N87313 001**
AT MORTON GROVE **1%** **N88190 001**
AUG 16, 1984

SHAMPOO; TOPICAL
LINDANE
AT + ALPHARMA **1%** **N87266 001**
AT MORTON GROVE **1%** **N88191 001**
SEP 18, 1984

LINEZOLID

FOR SUSPENSION; ORAL
ZYVOX
+ PHARMACIA AND UPJOHN 100MG/5ML N21132 001
APR 18, 2000

INJECTABLE; INJECTION
ZYVOX
+ PHARMACIA AND UPJOHN 200MG/100ML N21131 001
APR 18, 2000

TABLET; ORAL
ZYVOX
+ PHARMACIA AND UPJOHN 600MG N21130 002
APR 18, 2000

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION
TRIOSTAT
+ JONES PHARMA EQ 0.01MG BASE/ML N20105 001
DEC 31, 1991

TABLET; ORAL
CYTOMEL
JONES PHARMA EQ 0.005MG BASE N10379 001

LIOTHYRONINE SODIUM

TABLET; ORAL
CYTOMEL
JONES PHARMA EQ 0.025MG BASE N10379 002
+ EQ 0.05MG BASE N10379 003

LIOTRIX (T4;T3)

TABLET; ORAL
THYROLAR-0.25
FORREST LABS 0.0125MG;0.0031MG N16807 001
THYROLAR-0.5
FORREST LABS 0.025MG;0.00625MG N16807 005
THYROLAR-1
FORREST LABS 0.05MG;0.0125MG N16807 004
THYROLAR-2
FORREST LABS 0.1MG;0.025MG N16807 002
THYROLAR-3
+ FORREST LABS 0.15MG;0.0375MG N16807 003

LISINOPRIL

TABLET; ORAL
LISINOPRIL

AB	APOTEX	**2.5MG**	**N76102 001** SEP 30, 2002
AB		**5MG**	**N76102 002** SEP 30, 2002
AB		**10MG**	**N76102 003** SEP 30, 2002
AB		**20MG**	**N76102 004** SEP 30, 2002
AB		**30MG**	**N76102 005** SEP 30, 2002
AB		**40MG**	**N76102 006** SEP 30, 2002
AB	EON	**2.5MG**	**N75994 001** JUL 01, 2002
AB		**5MG**	**N75994 002** JUL 01, 2002
AB		**10MG**	**N75994 003** JUL 01, 2002
AB		**20MG**	**N75994 004** JUL 01, 2002
AB		**30MG**	**N75994 005** JUL 01, 2002

FDA data supplied by DrugPatentWatch.com

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB	EON	40MG	N75994 006 JUL 01, 2002
AB	IVAX PHARMS	2.5MG	N75752 001 JUL 01, 2002
AB		5MG	N75752 002 JUL 01, 2002
AB		10MG	N75752 003 JUL 01, 2002
AB		20MG	N75752 004 JUL 01, 2002
AB		30MG	N75752 005 JUL 01, 2002
AB		40MG	N75752 006 JUL 01, 2002
AB	LEK PHARMS	2.5MG	N75999 001 JUL 01, 2002
AB		5MG	N75999 002 JUL 01, 2002
AB		10MG	N75999 003 JUL 01, 2002
AB		20MG	N75999 004 JUL 01, 2002
AB		30MG	N75999 005 JUL 01, 2002
AB		40MG	N75999 006 JUL 01, 2002
AB	MYLAN	2.5MG	N76071 001 JUL 01, 2002
AB		5MG	N76071 002 JUL 01, 2002
AB		10MG	N76071 003 JUL 01, 2002
AB		20MG	N76071 004 JUL 01, 2002
AB		30MG	N76071 005 JUL 01, 2002
AB		40MG	N76071 006 JUL 01, 2002
AB	PAR PHARM	2.5MG	N75743 001 JUL 01, 2002
AB		5MG	N75743 002 JUL 01, 2002
AB		10MG	N75743 003 JUL 01, 2002

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB	PAR PHARM	20MG	N75743 004 JUL 01, 2002
AB		30MG	N75743 005 JUL 01, 2002
AB		40MG	N75743 006 JUL 01, 2002
AB	PUREPAC PHARM	2.5MG	N76180 001 JUL 01, 2002
AB		5MG	N76180 002 JUL 01, 2002
AB		10MG	N76180 003 JUL 01, 2002
AB		20MG	N76164 001 JUL 01, 2002
AB		30MG	N76164 002 JUL 01, 2002
AB		40MG	N76164 003 JUL 01, 2002
AB	RANBAXY	2.5MG	N75944 001 JUL 01, 2002
AB		5MG	N75944 002 JUL 01, 2002
AB		10MG	N75944 003 JUL 01, 2002
AB		20MG	N75944 004 JUL 01, 2002
AB		30MG	N75944 006 FEB 11, 2003
AB		40MG	N75944 005 JUL 01, 2002
AB	SANDOZ	2.5MG	N75903 001 JUL 01, 2002
AB		5MG	N75903 002 JUL 01, 2002
AB		10MG	N75903 003 JUL 01, 2002
AB		20MG	N75903 004 JUL 01, 2002
AB		30MG	N75903 005 JUL 01, 2002
AB		40MG	N75903 006 JUL 01, 2002
AB	TEVA	2.5MG	N75783 001 JUL 01, 2002

FDA data supplied by DrugPatentWatch.com

LISINOPRIL

TABLET; ORAL

	LISINOPRIL			
AB	TEVA	5MG	**N75783 002**	JUL 01, 2002
AB		10MG	**N75783 003**	JUL 01, 2002
AB		20MG	**N75783 004**	JUL 01, 2002
AB		30MG	**N75783 005**	JUL 01, 2002
AB		40MG	**N75783 006**	JUL 01, 2002
AB	WATSON LABS	2.5MG	**N76059 001**	JUL 01, 2002
AB		5MG	**N76059 002**	JUL 01, 2002
AB		10MG	**N76059 003**	JUL 01, 2002
AB		20MG	**N76059 004**	JUL 01, 2002
AB		30MG	**N76059 005**	JUL 01, 2002
AB		40MG	**N76059 006**	JUL 01, 2002
AB	WEST WARD	2.5MG	**N76063 001**	JUL 01, 2002
AB		5MG	**N76063 002**	JUL 01, 2002
AB		10MG	**N76063 003**	JUL 01, 2002
AB		20MG	**N76063 004**	JUL 01, 2002
AB		30MG	**N76063 006**	JUN 27, 2003
AB		40MG	**N76063 005**	JUL 01, 2002
	PRINIVIL			
AB	MERCK	2.5MG	**N19558 006**	JAN 28, 1994
AB		5MG	**N19558 001**	DEC 29, 1987
AB		10MG	**N19558 002**	DEC 29, 1987
AB		20MG	**N19558 003**	DEC 29, 1987
AB		40MG	**N19558 004**	OCT 25, 1988

LISINOPRIL

TABLET; ORAL

	ZESTRIL			
AB	ASTRAZENECA	2.5MG	**N19777 005**	APR 29, 1993
AB		5MG	**N19777 001**	MAY 19, 1988
AB		10MG	**N19777 002**	MAY 19, 1988
AB		20MG	**N19777 003**	MAY 19, 1988
AB		30MG	**N19777 006**	JAN 20, 1999
AB +		40MG	**N19777 004**	MAY 19, 1988

LISINOPRIL; *MULTIPLE*

SEE HYDROCHLOROTHIAZIDE; LISINOPRIL

LITHIUM CARBONATE

CAPSULE; ORAL

	ESKALITH			
AB	GLAXOSMITHKLINE	300MG	**N16860 001**	
	LITHIUM CARBONATE			
AB	ABLE	300MG	**N76121 001**	SEP 27, 2001
AB	ROXANE	150MG	**N17812 002**	JAN 28, 1987
AB		300MG	**N17812 001**	
+		600MG	N17812 003	JAN 28, 1987
AB	WEST WARD	150MG	**N76243 002**	FEB 24, 2003
AB		300MG	**N76243 001**	JUN 27, 2002

TABLET; ORAL

	LITHIUM CARBONATE			
AB +	PFIZER	300MG	**N16834 001**	
AB	ROXANE	300MG	**N18558 001**	JAN 29, 1982

TABLET, EXTENDED RELEASE; ORAL

	ESKALITH CR			
AB +	GLAXOSMITHKLINE	450MG	**N18152 001**	MAR 29, 1982

FDA data supplied by DrugPatentWatch.com

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

	LITHIUM CARBONATE			
AB	ABLE	**300MG**	**N76382 001**	APR 21, 2003
AB	BARR	**300MG**	**N76170 001**	JUN 10, 2002
AB		**450MG**	**N76366 001**	AUG 21, 2003
AB	WEST WARD	**450MG**	**N76490 001**	JUN 17, 2003
	LITHOBID			
AB	+ SOLVAY	**300MG**	**N18027 001**	

LITHIUM CITRATE

SYRUP; ORAL

	LITHIUM CITRATE			
AA	MORTON GROVE	**EQ 300MG CARBONATE/5ML**	**N70755 001**	MAY 21, 1986
AA	+ ROXANE	**EQ 300MG CARBONATE/5ML**	**N18421 001**	

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC

	ALOMIDE			
	+ ALCON	EQ 0.1% BASE	N20191 001	SEP 23, 1993

LOMEFLOXACIN HYDROCHLORIDE

TABLET; ORAL

	MAXAQUIN			
	+ PHARMACIA	EQ 400MG BASE	N20013 001	FEB 21, 1992

LOMUSTINE

CAPSULE; ORAL

	CEENU			
	BRISTOL MYERS SQUIBB	10MG	N17588 001	
		40MG	N17588 002	
	+	100MG	N17588 003	

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

	IMODIUM			
AB	+ MCNEIL CONS SPECLT	**2MG**	**N17694 001**	
	LOPERAMIDE HCL			
AB	MYLAN	**2MG**	**N72741 001**	SEP 18, 1991
AB	SANDOZ	**2MG**	**N72993 001**	AUG 28, 1992
AB	TEVA	**2MG**	**N73122 001**	AUG 30, 1991
AB		**2MG**	**N73192 001**	APR 30, 1992

LOPINAVIR; RITONAVIR

CAPSULE; ORAL

	KALETRA			
	+ ABBOTT	133.3MG;33.3MG	N21226 001	SEP 15, 2000

SOLUTION; ORAL

	KALETRA			
	+ ABBOTT	80MG/ML;20MG/ML	N21251 001	SEP 15, 2000

LORACARBEF

CAPSULE; ORAL

	LORABID			
	KING PHARMS	200MG	N50668 001	DEC 31, 1991
	+	400MG	N50668 002	APR 05, 1996

FOR SUSPENSION; ORAL

	LORABID			
	KING PHARMS	100MG/5ML	N50667 001	DEC 31, 1991
	+	200MG/5ML	N50667 002	DEC 31, 1991

FDA data supplied by DrugPatentWatch.com

LORAZEPAM

CONCENTRATE; ORAL

	LORAZEPAM INTENSOL			
	+ ROXANE	2MG/ML		N72755 001 JUN 28, 1991

INJECTABLE; INJECTION

	ATIVAN			
AP	+ BAXTER HLTHCARE CORP	**2MG/ML**		**N18140 001**
AP	+	**4MG/ML**		**N18140 002**
	LORAZEPAM			
AP	ABBOTT	**2MG/ML**		**N74243 001** APR 12, 1994
AP		**2MG/ML**		**N74280 001** MAY 27, 1994
AP		**2MG/ML**		**N74282 001** MAY 27, 1994
AP		**2MG/ML**		**N74300 001** APR 12, 1994
AP		**4MG/ML**		**N74243 002** APR 12, 1994
AP		**4MG/ML**		**N74280 002** MAY 27, 1994
AP		**4MG/ML**		**N74282 002** MAY 27, 1994
AP		**4MG/ML**		**N74300 003** MAR 19, 1997
AP	AKORN	**2MG/ML**		**N74974 001** JUL 23, 1998
AP	CLONMEL HLTHCARE	**2MG/ML**		**N74793 001** MAR 16, 2000
AP		**4MG/ML**		**N74793 002** MAR 16, 2000
AP	ELKINS SINN	**2MG/ML**		**N74496 001** SEP 28, 1998
AP		**4MG/ML**		**N74496 002** SEP 28, 1998
AP	MARSAM PHARMS LLC	**2MG/ML**		**N74535 001** SEP 12, 1996
AP		**2MG/ML**		**N74551 001** SEP 12, 1996
AP		**1MG/0.5ML**		**N74551 003** SEP 12, 1996
AP		**4MG/ML**		**N74535 002** SEP 12, 1996
AP		**4MG/ML**		**N74551 002** SEP 12, 1996

LORAZEPAM

INJECTABLE; INJECTION

	LORAZEPAM			
AP	STERIS	**2MG/ML**		**N74276 001** APR 15, 1994
AP		**4MG/ML**		**N74276 002** APR 15, 1994
AP	TAYLOR	**2MG/ML**		**N75025 001** JUL 23, 1998

SOLUTION; ORAL

	LORAZEPAM			
	+ ROXANE	0.5MG/5ML		N74648 001 MAR 18, 1997

TABLET; ORAL

	ATIVAN			
AB	BIOVAIL	**0.5MG**		**N17794 001**
AB		**1MG**		**N17794 002**
AB	+	**2MG**		**N17794 003**
	LORAZEPAM			
AB	MUTUAL PHARM	**0.5MG**		**N72553 001** MAR 29, 1991
AB		**1MG**		**N72554 001** MAR 29, 1991
AB		**2MG**		**N72555 001** MAR 29, 1991
AB	MYLAN	**0.5MG**		**N71589 001** OCT 13, 1987
AB		**1MG**		**N71590 001** OCT 13, 1987
AB		**2MG**		**N71591 001** OCT 13, 1987
AB	PUREPAC PHARM	**0.5MG**		**N71403 001** APR 21, 1987
AB		**1MG**		**N71404 001** APR 21, 1987
AB		**2MG**		**N71141 001** APR 21, 1987
AB	RANBAXY	**0.5MG**		**N76045 001** AUG 29, 2001
AB		**1MG**		**N76045 002** AUG 29, 2001
AB		**2MG**		**N76045 003** AUG 29, 2001
AB	SANDOZ	**0.5MG**		**N71193 001** APR 15, 1988

FDA data supplied by DrugPatentWatch.com

LORAZEPAM

TABLET; ORAL
LORAZEPAM

AB	SANDOZ	1MG	N71194 001	APR 15, 1988
AB		2MG	N71195 001	APR 15, 1988
AB	WATSON LABS	0.5MG	N71117 001	JUL 24, 1986
AB		0.5MG	N72926 001	OCT 31, 1991
AB		1MG	N71087 001	MAR 23, 1987
AB		1MG	N71118 001	JUL 24, 1986
AB		1MG	N72927 001	OCT 31, 1991
AB		2MG	N71088 001	MAR 23, 1987
AB		2MG	N71110 001	JUL 24, 1986
AB		2MG	N72928 001	OCT 31, 1991

LOSARTAN POTASSIUM

TABLET; ORAL
COZAAR

	MERCK	25MG	N20386 001	APR 14, 1995
		50MG	N20386 002	APR 14, 1995
+		100MG	N20386 003	OCT 13, 1998

LOSARTAN POTASSIUM; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC
ALREX

+	BAUSCH AND LOMB	0.2%	N20803 001	MAR 09, 1998

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC
LOTEMAX

+	BAUSCH AND LOMB	0.5%	N20583 001	MAR 09, 1998

LOVASTATIN

TABLET; ORAL
LOVASTATIN

AB	CARLSBAD	10MG	N75991 001	JUN 05, 2002
AB		20MG	N75991 002	JUN 05, 2002
AB		40MG	N75991 003	JUN 05, 2002
AB	EON	10MG	N75636 001	DEC 17, 2001
AB		20MG	N75636 002	DEC 17, 2001
AB		40MG	N75636 003	DEC 17, 2001
AB	GENPHARM	10MG	N75935 001	DEC 17, 2001
AB		20MG	N75935 002	DEC 17, 2001
AB		40MG	N75935 003	DEC 17, 2001
AB	MYLAN	10MG	N75451 001	DEC 17, 2001
AB		20MG	N75451 002	DEC 17, 2001
AB		40MG	N75451 003	DEC 17, 2001
AB	PUREPAC PHARM	10MG	N75828 001	DEC 17, 2001
AB		20MG	N75828 002	DEC 17, 2001
AB		40MG	N75828 003	DEC 17, 2001
AB	SANDOZ	10MG	N75300 001	DEC 17, 2001
AB		20MG	N75300 002	DEC 17, 2001
AB		40MG	N75300 003	DEC 17, 2001

FDA data supplied by DrugPatentWatch.com

LOVASTATIN

TABLET; ORAL

	LOVASTATIN			
AB	TEVA	**10MG**	**N75551 003**	DEC 17, 2001
AB		**20MG**	**N75551 002**	DEC 17, 2001
AB		**40MG**	**N75551 001**	DEC 17, 2001
	MEVACOR			
AB	MERCK	**10MG**	**N19643 002**	MAR 28, 1991
AB		**20MG**	**N19643 003**	AUG 31, 1987
AB	+	**40MG**	**N19643 004**	DEC 14, 1988

TABLET, EXTENDED RELEASE; ORAL

	ALTOCOR			
	ANDRX	10MG	N21316 001	JUN 26, 2002
		20MG	N21316 002	JUN 26, 2002
		40MG	N21316 003	JUN 26, 2002
	+	60MG	N21316 004	JUN 26, 2002

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL

	ADVICOR			
	KOS	20MG;500MG	N21249 001	DEC 17, 2001
		20MG;750MG	N21249 002	DEC 17, 2001
	+	20MG;1GM	N21249 003	DEC 17, 2001

LOXAPINE SUCCINATE

CAPSULE; ORAL

	LOXAPINE SUCCINATE			
AB	WATSON LABS	**EQ 5MG BASE**	**N72204 001**	JUN 15, 1988

LOXAPINE SUCCINATE

CAPSULE; ORAL

	LOXAPINE SUCCINATE			
AB	WATSON LABS	**EQ 10MG BASE**	**N72205 001**	JUN 15, 1988
AB		**EQ 25MG BASE**	**N72206 001**	JUN 15, 1988
AB		**EQ 50MG BASE**	**N72062 001**	JUN 15, 1988
	LOXITANE			
AB	WATSON LABS	**EQ 5MG BASE**	**N17525 001**	
AB		**EQ 10MG BASE**	**N17525 002**	
AB	+	**EQ 25MG BASE**	**N17525 003**	
AB		**EQ 50MG BASE**	**N17525 004**	

MAFENIDE ACETATE

CREAM; TOPICAL

	SULFAMYLON		
+	BERTEK PHARMS	EQ 85MG BASE/GM	N16763 001

FOR SOLUTION; TOPICAL

	SULFAMYLON		
+	MYLAN	5%	N19832 003 JUN 05, 1998

MAGNESIUM ACETATE; *MULTIPLE*

SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

MAGNESIUM ACETATE TETRAHYDRATE; *MULTIPLE*

SEE DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
PLASMA-LYTE 56 IN PLASTIC CONTAINER
BAXTER HLTHCARE 32MG/100ML;128MG/100ML; 234MG/100ML N19047 001 JUN 15, 1984

MAGNESIUM CARBONATE; *MULTIPLE*
SEE CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

MAGNESIUM CHLORIDE; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

MAGNESIUM CHLORIDE; *MULTIPLE*
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER
B BRAUN 30MG/100ML;37MG/100ML;0.82MG/100ML; 370MG/100ML;530MG/100ML;500MG/100ML; 12MG/100ML N19696 001 SEP 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN PLASTIC CONTAINER
AP B BRAUN **30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML N18252 001**
AP **30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML N19711 001** SEP 29, 1989

NORMOSOL-R IN PLASTIC CONTAINER
ABBOTT 30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML N17586 001

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML N17378 001**

FDA data supplied by DrugPatentWatch.com

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

PLASMA-LYTE A IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**30MG/100ML;37MG/100ML;368MG/100ML; 526MG/100ML;502MG/100ML**	**N17378 002** NOV 22, 1982	

SOLUTION; IRRIGATION

PHYSIOLYTE IN PLASTIC CONTAINER

B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML; 530MG/100ML;500MG/100ML	N19024 001 JUN 08, 1984	

PHYSIOSOL IN PLASTIC CONTAINER

ABBOTT	30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML	N17637 002 JUL 08, 1982	

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

ABBOTT	30MG/100ML;37MG/100ML;222MG/100ML; 526MG/100ML;502MG/100ML	N18406 002 JUL 08, 1982	

MAGNESIUM OXIDE; *MULTIPLE*

SEE CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE

AP	ABBOTT	**500MG/ML**	**N75151 001** APR 25, 2000	
AP	+ AM PHARM PARTNERS	**500MG/ML**	**N19316 001** SEP 08, 1986	

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+	ABBOTT	1GM/100ML	N20488 001 JUL 11, 1995	
+		2GM/100ML	N20488 002 JUL 11, 1995	

MAGNESIUM SULFATE IN PLASTIC CONTAINER

+	ABBOTT	4GM/100ML	N20309 001 JUN 24, 1994	
+		80MG/ML	N20309 002 JUN 24, 1994	

MAGNESIUM SULFATE; *MULTIPLE*

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

TIS-U-SOL

AT	BAXTER HLTHCARE	**20MG/100ML;40MG/100ML;6.25MG/100ML; 800MG/100ML;8.75MG/100ML**	**N18508 001** FEB 19, 1982	

TIS-U-SOL IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	**20MG/100ML;40MG/100ML;6.25MG/100ML; 800MG/100ML;8.75MG/100ML**	**N18336 001**	

MALATHION

LOTION; TOPICAL

OVIDE

+	MEDICIS	0.5%	N18613 001 AUG 02, 1982	

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION

TESLASCAN

+	AMERSHAM HLTH	37.9MG/ML	N20652 001 NOV 26, 1997	

MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

ABBOTT	EQ 0.1MG MANGANESE/ML	N18962 001 JUN 26, 1986	

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

AP	B BRAUN	**10GM/100ML**	**N16080 002**	

FDA data supplied by DrugPatentWatch.com

MANNITOL

INJECTABLE; INJECTION

	MANNITOL 10% IN PLASTIC CONTAINER			
AP	ABBOTT	10GM/100ML	N19603 002	JAN 08, 1987
AP	B BRAUN	10GM/100ML	N20006 002	JUL 26, 1993
	MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER			
AP	B BRAUN	10GM/100ML	N16080 006	
	MANNITOL 15%			
AP	B BRAUN	15GM/100ML	N16080 003	
	MANNITOL 15% IN PLASTIC CONTAINER			
AP	ABBOTT	15GM/100ML	N19603 003	JAN 08, 1990
AP	B BRAUN	15GM/100ML	N20006 003	JUL 26, 1993
	MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%			
AP	B BRAUN	15GM/100ML	N16080 005	
	MANNITOL 20%			
AP	B BRAUN	20GM/100ML	N14738 001	
AP		20GM/100ML	N16080 004	
	MANNITOL 20% IN PLASTIC CONTAINER			
AP	ABBOTT	20GM/100ML	N19603 004	JAN 08, 1990
AP	B BRAUN	20GM/100ML	N20006 004	JUL 26, 1993
	MANNITOL 25%			
AP	ABBOTT	12.5GM/50ML	N16269 006	AUG 25, 1994
AP	AM PHARM PARTNERS	12.5GM/50ML	N80677 001	
AP	INTL MEDICATION	12.5GM/50ML	N83051 001	
AP	LUITPOLD	12.5GM/50ML	N87409 001	JAN 21, 1982
	MANNITOL 5%			
AP	B BRAUN	5GM/100ML	N16080 001	
	MANNITOL 5% IN PLASTIC CONTAINER			
AP	ABBOTT	5GM/100ML	N19603 001	JAN 08, 1987
AP	B BRAUN	5GM/100ML	N20006 001	JUL 26, 1993
	MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%			
AP	B BRAUN	5GM/100ML	N16080 007	
	OSMITROL 10% IN WATER			
AP	BAXTER HLTHCARE	10GM/100ML	N13684 002	
	OSMITROL 10% IN WATER IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	10GM/100ML	N13684 006	
	OSMITROL 15% IN WATER			
AP	BAXTER HLTHCARE	15GM/100ML	N13684 004	

MANNITOL

INJECTABLE; INJECTION

	OSMITROL 15% IN WATER IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	15GM/100ML	N13684 008	
	OSMITROL 20% IN WATER			
AP	BAXTER HLTHCARE	20GM/100ML	N13684 003	
	OSMITROL 20% IN WATER IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	20GM/100ML	N13684 007	
	OSMITROL 5% IN WATER			
AP	BAXTER HLTHCARE	5GM/100ML	N13684 001	
	OSMITROL 5% IN WATER IN PLASTIC CONTAINER			
AP	BAXTER HLTHCARE	5GM/100ML	N13684 005	

SOLUTION; IRRIGATION

	RESECTISOL IN PLASTIC CONTAINER		
	B BRAUN	5GM/100ML	N16772 002

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

	SORBITOL-MANNITOL IN PLASTIC CONTAINER			
AT	ABBOTT	540MG/100ML;2.7GM/100ML	N17636 001	
AT		540MG/100ML;2.7GM/100ML	N18316 001	

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

	LUDIOMIL			
AB	NOVARTIS	25MG	N17543 001	
AB	+	50MG	N17543 002	
AB		75MG	N17543 003	SEP 30, 1982
	MAPROTILINE HCL			
AB	MYLAN	25MG	N72284 001	OCT 03, 1988
AB		50MG	N72285 001	OCT 03, 1988
AB		75MG	N72286 001	OCT 03, 1988
AB	WATSON LABS	25MG	N72162 001	JUN 01, 1988
AB		50MG	N72163 001	JUN 01, 1988
AB		75MG	N72164 001	JUN 01, 1988

FDA data supplied by DrugPatentWatch.com

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

	MEBENDAZOLE			
AB	COPLEY PHARM	100MG	N73580 001	
			JAN 04, 1995	
	VERMOX			
AB	+ MCNEIL CONS SPECLT	100MG	N17481 001	

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

	INVERSINE			
	+ TARGACEPT	2.5MG	N10251 001	

MECHLORETHAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	MUSTARGEN			
	+ MERCK	10MG/VIAL	N06695 001	

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

	ANTIVERT			
AA	+ PFIZER	12.5MG	N10721 006	
AA	+	25MG	N10721 004	
AA	+	50MG	N10721 001	
			JAN 20, 1982	
	MECLIZINE HCL			
AA	ABC HOLDING	12.5MG	N85253 001	
AA		25MG	N85252 001	
AA	BUNDY	12.5MG	N84382 001	
AA		25MG	N84872 001	
AA	IVAX PHARMS	12.5MG	N84975 001	
AA		25MG	N84657 001	
AA	PAR PHARM	12.5MG	N87127 001	
AA		25MG	N87128 001	
AA		50MG	N89674 001	
			MAR 31, 1988	
AA	PLIVA	12.5MG	N88732 001	
			DEC 11, 1985	
AA		25MG	N88734 001	
			DEC 11, 1985	
AA	SANDOZ	12.5MG	N84843 002	
			MAY 22, 1989	

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

	MECLIZINE HCL			
AA	SANDOZ	25MG	N84092 003	
			MAY 22, 1989	
AA	VINTAGE PHARMS	12.5MG	N40179 001	
			JAN 30, 1997	
AA		25MG	N40179 002	
			JAN 30, 1997	
AA	WATSON LABS	25MG	N85740 001	

TABLET, CHEWABLE; ORAL

	ANTIVERT			
AA	+ PFIZER	25MG	N10721 005	
	MECLIZINE HCL			
AA	PLIVA	25MG	N88733 001	
			DEC 11, 1985	

MECLOFENAMATE SODIUM

CAPSULE; ORAL

	MECLOFENAMATE SODIUM			
AB	MYLAN	EQ 50MG BASE	N71080 001	
			SEP 03, 1986	
AB	+	EQ 100MG BASE	N71081 001	
			SEP 03, 1986	
AB	SANDOZ	EQ 50MG BASE	N72262 001	
			NOV 29, 1988	
AB		EQ 100MG BASE	N72263 001	
			NOV 29, 1988	
AB	WATSON LABS	EQ 50MG BASE	N71468 001	
			APR 15, 1987	
AB		EQ 100MG BASE	N71469 001	
			APR 15, 1987	

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

	DEPO-PROVERA			
	+ PHARMACIA AND UPJOHN	150MG/ML	N20246 001	
			OCT 29, 1992	
	+	400MG/ML	N12541 003	

TABLET; ORAL

	MEDROXYPROGESTERONE ACETATE			
AB	BARR	2.5MG	N40159 001	
			AUG 09, 1996	

FDA data supplied by DrugPatentWatch.com

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

	MEDROXYPROGESTERONE ACETATE			
AB	BARR	5MG	**N40159 002**	AUG 09, 1996
AB		10MG	**N40159 003**	AUG 09, 1996
AB	DURAMED PHARMS BARR	2.5MG	**N40311 001**	DEC 01, 1999
AB		5MG	**N40311 002**	DEC 01, 1999
AB		10MG	**N40311 003**	DEC 01, 1999
BP	USL PHARMA	10MG	N88484 001	JUL 26, 1984
	PROVERA			
AB	PHARMACIA AND UPJOHN	2.5MG	**N11839 001**	
AB		5MG	**N11839 003**	
AB +		10MG	**N11839 004**	

MEDROXYPROGESTERONE ACETATE; *MULTIPLE*
SEE ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

MEDRYSONE

SUSPENSION; OPHTHALMIC

	HMS		
+	ALLERGAN	1%	N16624 003

MEFENAMIC ACID

CAPSULE; ORAL

	PONSTEL		
+	FIRST HORIZON	250MG	N15034 003

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

	LARIAM			
AB +	ROCHE	250MG	**N19591 001**	MAY 02, 1989
	MEFLOQUINE			
AB	BARR	250MG	**N76392 001**	DEC 29, 2003

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

	MEFLOQUINE HCL			
AB	SANDOZ	250MG	**N76175 001**	FEB 20, 2002

MEGESTROL ACETATE

SUSPENSION; ORAL

	MEGACE			
AB +	BRISTOL MYERS SQUIBB	40MG/ML	**N20264 001**	SEP 10, 1993
	MEGESTROL ACETATE			
AB	COPLEY PHARM	40MG/ML	**N75681 001**	MAY 05, 2003
AB	PAR PHARM	40MG/ML	**N75671 001**	JUL 25, 2001
AB	ROXANE	40MG/ML	**N75997 001**	FEB 15, 2002

TABLET; ORAL

	MEGACE			
AB	BRISTOL MYERS SQUIBB	20MG	**N16979 001**	
AB +		40MG	**N16979 002**	
	MEGESTROL ACETATE			
AB	BARR	20MG	**N74621 002**	AUG 16, 1996
AB		40MG	**N74621 001**	NOV 30, 1995
AB	PAR PHARM	20MG	**N72422 001**	AUG 08, 1988
AB		40MG	**N72423 001**	AUG 08, 1988
AB	ROXANE	20MG	**N74458 001**	SEP 29, 1995
AB		40MG	**N74458 002**	SEP 29, 1995
AB	TEVA	40MG	**N74745 001**	FEB 27, 1998

MELOXICAM

TABLET; ORAL

	MOBIC			
	BOEHRINGER INGELHEIM	7.5MG	N20938 001	APR 13, 2000

FDA data supplied by DrugPatentWatch.com

MELOXICAM

TABLET; ORAL
MOBIC
+ BOEHRINGER INGELHEIM 15MG — N20938 002 — AUG 23, 2000

MELPHALAN

TABLET; ORAL
ALKERAN
+ GLAXOSMITHKLINE 2MG — N14691 002

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION
ALKERAN
+ GLAXOSMITHKLINE EQ 50MG BASE/VIAL — N20207 001 — NOV 18, 1992

MEMANTINE HYDROCHLORIDE

TABLET; ORAL
NAMENDA
FOREST LABS 5MG — N21487 001 — OCT 16, 2003
+ 10MG — N21487 002 — OCT 16, 2003

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION
PERGONAL
BX + SERONO 75 IU/AMP;75 IU/AMP — N17646 001
REPRONEX
BX + FERRING 75 IU/VIAL;75 IU/VIAL — N21047 001 — AUG 27, 1999

MEPENZOLATE BROMIDE

TABLET; ORAL
CANTIL
+ AVENTIS PHARMS 25MG — N10679 003

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DEMEROL
AP + ABBOTT 25MG/ML — N21171 001
AP + 50MG/ML — N21171 002
AP + 75MG/ML — N21171 003
AP + 100MG/ML — N21171 004
MEPERIDINE HCL
AP BAXTER HLTHCARE CORP 25MG/ML — N80455 007
AP 50MG/ML — N80455 008
AP 75MG/ML — N80455 009
AP 100MG/ML — N80455 010
AP ELKINS SINN 25MG/ML — N80445 001
AP 50MG/ML — N80445 002
AP 75MG/ML — N80445 003
AP 100MG/ML — N80445 004
AP STERIS 50MG/ML — N73444 001 — MAR 17, 1992
AP 100MG/ML — N73445 001 — MAR 17, 1992
MEPERIDINE HCL PRESERVATIVE FREE
AP + ABBOTT 10MG/ML — N88432 001 — AUG 16, 1984
AP ASTRAZENECA 10MG/ML — N81002 001 — JUL 30, 1993
AP INTL MEDICATION 10MG/ML — N81309 001 — AUG 30, 1993
AP MALLINCKRODT 10MG/ML — N40163 001 — MAY 12, 1997
AP MAYNE PHARMA USA 10MG/ML — N40305 001 — MAR 10, 1999
AP STERIS 10MG/ML — N73443 001 — MAR 17, 1992

SYRUP; ORAL
DEMEROL
AA + SANOFI SYNTHELABO 50MG/5ML — N05010 005
MEPERIDINE HCL
AA ROXANE 50MG/5ML — N88744 001 — JAN 30, 1985

TABLET; ORAL
DEMEROL
AA + SANOFI SYNTHELABO 50MG — N05010 001
AA + 100MG — N05010 004
MEPERIDINE HCL
AA AMIDE PHARM 50MG — N40331 001 — MAY 28, 1999

FDA data supplied by DrugPatentWatch.com

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

	MEPERIDINE HCL			
AA	AMIDE PHARM	100MG	N40331 002	
			MAY 28, 1999	
AA	AXIOM PHARM	50MG	N80448 001	
AA		100MG	N80448 002	
AA	BARR	50MG	N88639 001	
			JUL 02, 1984	
AA		100MG	N88640 001	
			SEP 19, 1984	
AA	CARACO	50MG	N40446 001	
			AUG 08, 2002	
AA		100MG	N40446 002	
			AUG 08, 2002	
AA	DURAMED PHARMS BARR	50MG	N40318 001	
			OCT 05, 1999	
AA		100MG	N40318 002	
			OCT 05, 1999	
AA	MALLINCKRODT	50MG	N40352 001	
			JUN 13, 2000	
AA		100MG	N40352 002	
			JUN 13, 2000	
AA	ROXANE	50MG	N40110 001	
			MAR 12, 1997	
AA		100MG	N40110 002	
			MAR 12, 1997	
AA	VINTAGE PHARMS	50MG	N40191 001	
			DEC 17, 1998	
AA		100MG	N40191 002	
			DEC 17, 1998	
AA	WATSON LABS	50MG	N40186 001	
			JUN 30, 1997	
AA		100MG	N40186 002	
			JUN 30, 1997	

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	CARBOCAINE			
AP	+ EASTMAN KODAK	3%	N12125 003	
AP	+ STERLING WINTHROP	1%	N12250 001	
AP	+	1.5%	N12250 005	
AP	+	2%	N12250 002	
	ISOCAINE HCL			
AP	NOVOCOL	3%	N80925 001	
	MEPIVACAINE HCL			
AP	GRAHAM CHEM	3%	N83559 001	

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	MEPIVACAINE HCL			
AP	STERIS	1%	N88769 001	
			NOV 20, 1984	
AP		2%	N88770 001	
			NOV 20, 1984	
	POLOCAINE			
AP	ASTRAZENECA	1%	N89407 001	
			DEC 01, 1986	
AP		2%	N89410 001	
			DEC 01, 1986	
AP	DENTSPLY PHARM	3%	N88653 001	
			AUG 21, 1984	
	POLOCAINE-MPF			
AP	ASTRAZENECA	1%	N89406 001	
			DEC 01, 1986	
AP		1.5%	N89408 001	
			DEC 01, 1986	
AP		2%	N89409 001	
			DEC 01, 1986	
	SCANDONEST PLAIN			
AP	DEPROCO	3%	N88387 001	
			OCT 10, 1984	

MEPIVACAINE HYDROCHLORIDE; *MULTIPLE*
SEE LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

MEPROBAMATE

TABLET; ORAL

	MEPROBAMATE		
AA	EON	200MG	N14547 002
AA		400MG	N14547 001
	+ ROXANE	600MG	N84332 001
AA	SANDOZ	400MG	N80655 001
AA	SCHERER LABS	400MG	N83343 001
AA	TABLICAPS	400MG	N83494 001
AA	WATSON LABS	200MG	N83304 001
AA		200MG	N85720 001
AA		400MG	N83308 001
AA		400MG	N85721 001
	MILTOWN		
AA	+ MEDPOINTE PHARM HLC	200MG	N09698 004
AA	+	400MG	N09698 002
	TRANMEP		
AA	SOLVAY	400MG	N16249 001

FDA data supplied by DrugPatentWatch.com

MEPROBAMATE; *MULTIPLE*
SEE ASPIRIN; MEPROBAMATE

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL
SOLAGE
+ GALDERMA LABS 2%;0.01% N20922 001 DEC 10, 1999

MERCAPTOPURINE

TABLET; ORAL
PURINETHOL
+ TEVA 50MG N09053 002

MEROPENEM

INJECTABLE; INJECTION
MERREM I.V.
+ ASTRAZENECA 500MG/VIAL N50706 003 JUN 21, 1996
+ 1GM/VIAL N50706 001 JUN 21, 1996

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL
PENTASA
+ SHIRE LABS 250MG N20049 001 MAY 10, 1993

ENEMA; RECTAL
ROWASA
+ SOLVAY 4GM/60ML N19618 001 DEC 24, 1987

SUPPOSITORY; RECTAL
CANASA
+ AXCAN SCANDIPHARM 500MG N21252 001 JAN 05, 2001

TABLET, DELAYED RELEASE; ORAL
ASACOL
+ PROCTER AND GAMBLE 400MG N19651 001 JAN 31, 1992

MESNA

INJECTABLE; INTRAVENOUS
MESNA
AP AM PHARM PARTNERS **100MG/ML** **N75811 001** APR 26, 2001
AP GENSIA SICOR PHARMS **100MG/ML** **N75764 001** APR 27, 2001
MESNEX
AP + BAXTER HLTHCARE **100MG/ML** **N19884 001** DEC 30, 1988

TABLET; ORAL
MESNEX
+ BAXTER HLTHCARE 400MG N20855 001 MAR 21, 2002

MESNA; *MULTIPLE*
SEE IFOSFAMIDE; MESNA

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL
SERENTIL
+ NOVARTIS EQ 25MG BASE/ML N16997 001

TABLET; ORAL
SERENTIL
NOVARTIS EQ 25MG BASE N16774 002
+ EQ 100MG BASE N16774 004

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21
NORETHIN 1/50M-21
AB WATSON LABS **0.05MG;1MG** **N71539 001** APR 12, 1988
NORETHINDRONE AND MESTRANOL
AB WATSON LABS **0.05MG;1MG** **N70758 001** JUL 01, 1988
NORINYL 1+50 21-DAY
AB + WATSON LABS **0.05MG;1MG** **N13625 002**

TABLET; ORAL-28
NORETHIN 1/50M-28
AB WATSON LABS **0.05MG;1MG** **N71540 001** APR 12, 1988

FDA data supplied by DrugPatentWatch.com

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28

	NORETHINDRONE AND MESTRANOL			
AB	WATSON LABS	0.05MG;1MG	N70759 001	JUL 01, 1988
	NORINYL 1+50 28-DAY			
AB	WATSON LABS	0.05MG;1MG	N16659 001	
	ORTHO-NOVUM 1/50 28			
AB	ORTHO MCNEIL PHARM	0.05MG;1MG	N16709 001	

METAPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

	ALUPENT			
+	BOEHRINGER INGELHEIM	0.65MG/INH	N16402 001	

SOLUTION; INHALATION

	ALUPENT			
AN +	BOEHRINGER INGELHEIM	0.4%	N18761 002	OCT 10, 1986
AN +		0.6%	N18761 001	JUN 30, 1983
	METAPROTERENOL SULFATE			
AN	DEY	0.4%	N71786 001	AUG 05, 1988
AN		0.6%	N70804 001	AUG 17, 1987
AN	MORTON GROVE	0.4%	N75586 001	MAY 30, 2002
AN		0.6%	N75586 002	MAY 30, 2002
AN	NEPHRON	0.4%	N71855 001	JUL 14, 1988
AN		0.6%	N71726 001	JUL 14, 1988
AN	NOVEX	0.4%	N75402 001	FEB 28, 2001
AN		0.6%	N75403 001	FEB 28, 2001

SYRUP; ORAL

	METAPROTERENOL SULFATE			
AA +	MORTON GROVE	10MG/5ML	N74702 001	MAR 24, 1997
AA	NOVEX	10MG/5ML	N75235 001	JAN 27, 2000

METAPROTERENOL SULFATE

SYRUP; ORAL

	METAPROTERENOL SULFATE			
AA	SILARX	10MG/5ML	N73632 001	JUL 22, 1992

TABLET; ORAL

	METAPROTERENOL SULFATE			
AB	PAR PHARM	10MG	N72024 001	JUN 28, 1988
AB +		20MG	N72025 001	JUN 28, 1988
AB	TEVA	10MG	N72519 001	MAR 30, 1990
AB		20MG	N72520 001	MAR 30, 1990
AB	WATSON LABS	10MG	N73013 001	JAN 31, 1991
AB		20MG	N72795 001	JAN 31, 1991

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

	ARAMINE			
AP +	MERCK	EQ 10MG BASE/ML	N09509 002	DEC 22, 1987
	METARAMINOL BITARTRATE			
AP	AM PHARM PARTNERS	EQ 10MG BASE/ML	N80722 001	

METAXALONE

TABLET; ORAL

	SKELAXIN			
	JONES PHARMA INC	400MG	N13217 001	
+		800MG	N13217 003	AUG 30, 2002

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL

	RIOMET			
+	RANBAXY	500MG/5ML	N21591 001	SEP 11, 2003

FDA data supplied by DrugPatentWatch.com

METFORMIN HYDROCHLORIDE

TABLET; ORAL

	GLUCOPHAGE			
AB	BRISTOL MYERS SQUIBB	500MG	N20357 001	MAR 03, 1995
AB		850MG	N20357 002	MAR 03, 1995
AB	+	1GM	N20357 005	NOV 05, 1998
	METFORMIN HCL			
AB	ALPHAPHARM	500MG	N75969 001	JAN 29, 2002
AB		850MG	N75969 002	JAN 29, 2002
AB		1GM	N75969 003	JAN 29, 2002
AB	ANDRX PHARMS	500MG	N75961 001	JAN 25, 2002
AB		850MG	N75961 002	JAN 25, 2002
AB		1GM	N75961 003	JAN 25, 2002
AB	BARR	500MG	N75971 001	JAN 25, 2002
AB		850MG	N75971 002	JAN 25, 2002
AB		1GM	N75971 003	JAN 25, 2002
AB	CARACO	500MG	N75967 001	JAN 29, 2002
AB		850MG	N75967 002	JAN 29, 2002
AB		1GM	N75967 003	JAN 29, 2002
AB	EON	500MG	N75965 001	JAN 25, 2002
AB		850MG	N75965 002	JAN 25, 2002
AB		1GM	N75965 003	JAN 25, 2002
AB	GENPHARM	500MG	N75973 001	JAN 25, 2002
AB		850MG	N75973 002	JAN 25, 2002
AB		1GM	N75973 003	JAN 25, 2002
AB	GOLDLINE	500MG	N75972 001	JAN 24, 2002

METFORMIN HYDROCHLORIDE

TABLET; ORAL

	METFORMIN HCL			
AB	GOLDLINE	625MG	N75972 005	JAN 24, 2002
AB		750MG	N75972 004	JAN 24, 2002
AB		850MG	N75972 002	JAN 24, 2002
AB		1GM	N75972 003	JAN 24, 2002
AB	MUTUAL PHARMA	500MG	N76038 001	FEB 21, 2002
AB		850MG	N76038 002	FEB 21, 2002
AB		1GM	N76038 003	FEB 21, 2002
AB	MYLAN	500MG	N75976 001	JAN 24, 2002
AB		850MG	N75976 002	JAN 24, 2002
AB		1GM	N75976 003	JAN 24, 2002
AB	PUREPAC PHARM	500MG	N76033 001	JAN 24, 2002
AB		850MG	N76033 002	JAN 24, 2002
AB		1GM	N76033 003	JAN 24, 2002
AB	SANDOZ	500MG	N75985 001	JAN 25, 2002
AB		850MG	N75985 002	JAN 25, 2002
AB		1GM	N75985 003	JAN 25, 2002
AB	TEVA	500MG	N75978 001	JAN 25, 2002
AB		500MG	N76328 001	DEC 16, 2002
AB		850MG	N75978 002	JAN 25, 2002
AB		850MG	N76328 002	DEC 16, 2002
AB		1GM	N75978 003	NOV 05, 2002
AB		1GM	N76328 003	DEC 16, 2002

FDA data supplied by DrugPatentWatch.com

METFORMIN HYDROCHLORIDE

TABLET; ORAL
METFORMIN HCL

AB	TORPHARM	500MG	N75984 001	APR 23, 2002
AB		850MG	N75984 002	APR 23, 2002
AB		1GM	N75984 003	APR 23, 2002
AB	WATSON LABS	500MG	N75979 001	JAN 24, 2002
AB		850MG	N75979 002	JAN 24, 2002
AB		1GM	N75979 003	JAN 24, 2002
AB	ZENITH GOLDLINE	500MG	N75975 001	JAN 24, 2002
AB		625MG	N75975 004	JAN 24, 2002
AB		750MG	N75975 005	JAN 24, 2002
AB		850MG	N75975 002	JAN 24, 2002
AB		1GM	N75975 003	JAN 24, 2002

TABLET, EXTENDED RELEASE; ORAL
GLUCOPHAGE XR

AB	BRISTOL MYERS SQUIBB	500MG	N21202 001	OCT 13, 2000
+		750MG	N21202 004	APR 11, 2003

METFORMIN HYDROCHLORIDE; *MULTIPLE*
SEE GLIPIZIDE; METFORMIN HYDROCHLORIDE
SEE GLYBURIDE; METFORMIN HYDROCHLORIDE

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL
AVANDAMET

SB PHARMCO	500MG;EQ 1MG BASE	N21410 001	OCT 10, 2002
	500MG;EQ 2MG BASE	N21410 002	OCT 10, 2002

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL
AVANDAMET

SB PHARMCO	500MG;EQ 4MG BASE	N21410 003	OCT 10, 2002
	1GM;EQ 2MG BASE	N21410 004	AUG 25, 2003
+	1GM;EQ 4MG BASE	N21410 005	AUG 25, 2003

METHACHOLINE CHLORIDE

FOR SOLUTION; INHALATION
PROVOCHOLINE

+ METHAPHARM	100MG/VIAL	N19193 001	OCT 31, 1986

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL
METHADONE HCL

AA	ROXANE	10MG/ML	N40180 001	APR 30, 1998
AA	UDL	10MG/ML	N40088 001	NOV 30, 1994

METHADONE HCL INTENSOL

AA	ROXANE	10MG/ML	N89897 001	SEP 06, 1988

METHADOSE

AA	+ MALLINCKRODT	10MG/ML	N17116 002	

INJECTABLE; INJECTION
DOLOPHINE HCL

+ AAIPHARMA LLC	10MG/ML	N21624 001	

POWDER; FOR RX COMPOUNDING
METHADONE HCL

MALLINCKRODT	50GM/BOT	N06383 002	
	100GM/BOT	N06383 003	
	500GM/BOT	N06383 004	

SOLUTION; ORAL
METHADONE HCL

+ ROXANE	5MG/5ML	N87393 001	
+	10MG/5ML	N87997 001	AUG 30, 1982

FDA data supplied by DrugPatentWatch.com

METHADONE HYDROCHLORIDE

TABLET; ORAL

		DOLOPHINE HCL			
AA	+	ROXANE	5MG	**N06134 002**	
AA	+		10MG	**N06134 010**	
		METHADONE HCL			
AA		EON	5MG	**N40241 001**	MAY 29, 1998
AA			10MG	**N40241 002**	MAY 29, 1998
AA			40MG	**N75082 001**	MAR 25, 1998
AA		ROXANE	5MG	**N88108 001**	MAR 08, 1983
AA			10MG	**N88109 001**	MAR 08, 1983
AA	+		40MG	**N17058 001**	
AA			40MG	**N74081 001**	APR 28, 1995
		METHADOSE			
AA		MALLINCKRODT	5MG	**N40050 001**	APR 15, 1993
AA			10MG	**N40050 002**	APR 15, 1993
AA			40MG	**N74184 001**	APR 29, 1993

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

	DESOXYN			
+	OVATION PHARMS	5MG	N05378 002	

METHAZOLAMIDE

TABLET; ORAL

		METHAZOLAMIDE			
AB		COPLEY PHARM	25MG	**N40001 001**	JUN 30, 1993
AB			50MG	**N40001 002**	JUN 30, 1993
AB		MIKART	25MG	**N40062 001**	JAN 27, 1994
AB	+		50MG	**N40062 002**	JAN 27, 1994

METHAZOLAMIDE

TABLET; ORAL

		METHAZOLAMIDE			
AB		SANDOZ	25MG	**N40036 001**	JUN 30, 1993
AB			25MG	**N40102 001**	AUG 28, 1996
AB			50MG	**N40036 002**	JUN 30, 1993
AB			50MG	**N40102 002**	AUG 28, 1996

METHENAMINE HIPPURATE

TABLET; ORAL

		HIPREX			
AB	+	AVENTIS PHARMS	1GM	**N17681 001**	
		METHENAMINE HIPPURATE			
AB		COREPHARMA	1GM	**N76411 001**	JUN 20, 2003
		UREX			
AB		3M	1GM	**N16151 001**	

METHIMAZOLE

TABLET; ORAL

		METHIMAZOLE			
AB		EON	5MG	**N40411 001**	MAR 27, 2001
AB			10MG	**N40411 002**	MAR 27, 2001
AB		GENPHARM	5MG	**N40350 001**	MAR 29, 2000
AB			10MG	**N40350 002**	MAR 29, 2000
	+		20MG	N40350 003	JUN 07, 2001
AB		JONES PHARMA	5MG	**N40320 001**	MAR 31, 2000
AB			10MG	**N40320 002**	MAR 31, 2000
		TAPAZOLE			
AB		LILLY	5MG	**N07517 002**	
AB			10MG	**N07517 004**	

FDA data supplied by DrugPatentWatch.com

METHOCARBAMOL

INJECTABLE; INJECTION

	METHOCARBAMOL			
AP	STERIS	100MG/ML	N86459 001	
	ROBAXIN			
AP	+ BAXTER HLTHCARE CORP	100MG/ML	N11790 001	

TABLET; ORAL

	METHOCARBAMOL			
AA	ABLE	500MG	N40413 001	MAR 17, 2003
AA		750MG	N40413 002	MAR 17, 2003
AA	EON	500MG	N87283 001	
AA		750MG	N87282 001	
AA	IMPAX LABS	500MG	N84927 001	
AA		750MG	N84928 001	
AA	LANNETT	500MG	N84756 002	MAR 31, 2003
AA		750MG	N84756 001	
AA	PAR PHARM	500MG	N86989 001	
AA		750MG	N86988 001	
AA	SANDOZ	500MG	N84616 001	
AA		750MG	N84615 001	
AA	TABLICAPS	500MG	N84846 001	
AA	VINTAGE PHARMS	500MG	N40489 001	JAN 29, 2003
AA		750MG	N40489 002	JAN 29, 2003
AA	WATSON LABS	500MG	N84277 001	
AA		500MG	N85180 001	
AA		750MG	N84276 002	
AA		750MG	N85192 001	
AA	WEST WARD	500MG	N85159 001	
AA		750MG	N85123 001	
	ROBAXIN			
AA	+ SCHWARZ PHARMA	500MG	N11011 004	
	ROBAXIN-750			
AA	+ SCHWARZ PHARMA	750MG	N11011 006	

METHOCARBAMOL; *MULTIPLE*
SEE ASPIRIN; METHOCARBAMOL

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

	BREVITAL SODIUM		
+	KING PHARMS	500MG/VIAL	N11559 001
+		2.5GM/VIAL	N11559 002
+		5GM/VIAL	N11559 003

METHOTREXATE SODIUM

INJECTABLE; INJECTION

	METHOTREXATE			
AP	BIGMAR	EQ 25MG BASE/ML	N40263 001	FEB 26, 1999
	METHOTREXATE LPF			
AP	+ MAYNE PHARMA USA	EQ 25MG BASE/ML	N11719 007	MAR 31, 1982
	METHOTREXATE PRESERVATIVE FREE			
AP	BIGMAR	EQ 1GM BASE/VIAL	N40266 001	FEB 26, 1999
AP		EQ 25MG BASE/ML	N40265 001	FEB 26, 1999
	METHOTREXATE SODIUM			
AP	BEDFORD	EQ 25MG BASE/ML	N89340 001	SEP 16, 1986
AP		EQ 25MG BASE/ML	N89341 001	SEP 16, 1986
AP		EQ 25MG BASE/ML	N89342 001	SEP 16, 1986
AP		EQ 25MG BASE/ML	N89343 001	SEP 16, 1986
AP	+ MAYNE PHARMA USA	EQ 25MG BASE/ML	N11719 005	
+		EQ 20MG BASE/VIAL	N11719 001	
AP	NORBROOK	EQ 25MG BASE/ML	N88648 001	MAY 09, 1986
AP	PHARMACHEMIE USA	EQ 25MG BASE/ML	N89158 001	JUL 08, 1988
	METHOTREXATE SODIUM PRESERVATIVE FREE			
AP	+ MAYNE PHARMA USA	EQ 1GM BASE/VIAL	N11719 009	APR 07, 1988
	MEXATE-AQ			
AP	BRISTOL MYERS	EQ 25MG BASE/ML	N88760 001	FEB 14, 1985

TABLET; ORAL

	METHOTREXATE SODIUM			
AB	BARR	EQ 2.5MG BASE	N81099 001	OCT 15, 1990

FDA data supplied by DrugPatentWatch.com

METHOTREXATE SODIUM

TABLET; ORAL

		METHOTREXATE SODIUM		
AB	+ CLONMEL HLTHCARE	EQ 2.5MG BASE	N08085 002	
AB	DURAMED PHARMS BARR	EQ 2.5MG BASE	N40233 001	JUN 17, 1999
AB	MYLAN	EQ 2.5MG BASE	N81235 001	MAY 15, 1992
AB	ROXANE	EQ 2.5MG BASE	N40054 001	AUG 01, 1994
	TREXALL			
	BARR	EQ 5MG BASE	N40385 001	MAR 21, 2001
		EQ 7.5MG BASE	N40385 002	MAR 21, 2001
		EQ 10MG BASE	N40385 003	MAR 21, 2001
	+	EQ 15MG BASE	N40385 004	MAR 21, 2001

METHOXSALEN

CAPSULE; ORAL

	8-MOP		
	+ VALEANT PHARM INTL	10MG	N09048 001
	OXSORALEN-ULTRA		
	+ VALEANT PHARM INTL	10MG	N19600 001 OCT 30, 1986

INJECTABLE; INJECTION

	UVADEX		
	+ THERAKOS	0.02MG/ML	N20969 001 FEB 25, 1999

LOTION; TOPICAL

	OXSORALEN		
	+ VALEANT PHARM INTL	1%	N09048 002

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

	PAMINE		
	+ BRADLEY PHARMS	2.5MG	N08848 001
	PAMINE FORTE		
	+ BRADLEY PHARMS	5MG	N08848 002 MAR 25, 2003

METHSUXIMIDE

CAPSULE; ORAL

	CELONTIN		
	PARKE DAVIS	150MG	N10596 007
	+	300MG	N10596 008

METHYCLOTHIAZIDE

TABLET; ORAL

		ENDURON		
AB	ABBOTT	2.5MG	N12524 001	
AB	+	5MG	N12524 004	
		METHYCLOTHIAZIDE		
AB	IVAX PHARMS	2.5MG	N87913 001	JUN 03, 1982
AB	MYLAN	5MG	N87672 001	AUG 17, 1982
AB	SANDOZ	2.5MG	N89835 001	AUG 18, 1988
AB		5MG	N89837 001	AUG 18, 1988
AB	WATSON LABS	5MG	N88724 001	SEP 06, 1984

METHYCLOTHIAZIDE; *MULTIPLE*
SEE DESERPIDINE; METHYCLOTHIAZIDE

METHYLDOPA

TABLET; ORAL

		ALDOMET		
AB	+ MERCK	500MG	N13400 002	
		METHYLDOPA		
AB	CLONMEL HLTHCARE	250MG	N70084 001	OCT 15, 1985
AB		500MG	N70085 001	OCT 15, 1985
AB	IVAX PHARMS	250MG	N70098 001	FEB 20, 1986
AB		500MG	N70343 001	FEB 20, 1986
AB	MYLAN	250MG	N70075 001	APR 18, 1985
AB		500MG	N70076 001	APR 18, 1985

FDA data supplied by DrugPatentWatch.com

METHYLDOPA

TABLET; ORAL

	METHYLDOPA			
AB	PAR PHARM	125MG	**N70535 001**	
			JAN 02, 1987	
AB		250MG	**N70536 001**	
			JAN 02, 1987	
AB		500MG	**N70537 001**	
			JAN 02, 1987	
AB	PLIVA	125MG	**N72126 001**	
			JUL 07, 1988	
AB		250MG	**N72127 001**	
			JUL 07, 1988	
AB		500MG	**N72128 001**	
			JUL 07, 1988	
AB	SANDOZ	125MG	**N71700 001**	
			MAR 02, 1988	
AB		250MG	**N18934 001**	
			JUN 29, 1984	
AB		500MG	**N18934 002**	
			JUN 29, 1984	
AB	WATSON LABS	250MG	**N70703 001**	
			JUN 06, 1986	
AB		500MG	**N70625 001**	
			JUN 06, 1986	

METHYLDOPA; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; METHYLDOPA

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

	ALDOMET			
AP	+ MERCK	50MG/ML	**N13401 001**	
	METHYLDOPATE HCL			
AP	ABBOTT	50MG/ML	**N70698 001**	
			JUN 15, 1987	
AP		50MG/ML	**N70699 001**	
			JUN 15, 1987	
AP	GENSIA SICOR PHARMS	50MG/ML	**N72974 001**	
			NOV 22, 1991	
AP	LUITPOLD	50MG/ML	**N71279 001**	
			OCT 02, 1987	

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

	METHERGINE			
	+ NOVARTIS	0.2MG/ML	N06035 004	

TABLET; ORAL

METHERGINE			
NOVARTIS	0.2MG	N06035 003	

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	METADATE CD			
BX	CELLTECH PHARMS	20MG	N21259 001	
			APR 03, 2001	
BX	+	30MG	N21259 002	
			JUN 19, 2003	
		10MG	N21259 003	
			MAY 27, 2003	
	RITALIN LA			
BX	NOVARTIS	20MG	N21284 001	
			JUN 05, 2002	
BX		30MG	N21284 002	
			JUN 05, 2002	
	+	40MG	N21284 003	
			JUN 05, 2002	

SOLUTION; ORAL

METHYLIN			
+ MALLINCKRODT BAKER	5MG/5ML	N21419 001	
		DEC 19, 2002	
+	10MG/5ML	N21419 002	
		DEC 19, 2002	

TABLET; ORAL

	METHYLPHENIDATE HCL			
AB	ABLE	5MG	**N40404 001**	
			MAR 29, 2001	
AB		10MG	**N40404 002**	
			MAR 29, 2001	
AB		20MG	**N40404 003**	
			MAR 29, 2001	
AB	CELLTECH MFG	5MG	**N86429 001**	
AB		10MG	**N85799 001**	
AB		20MG	**N86428 001**	
AB	*MALLINCKRODT*	5MG	***N40300 001***	
			NOV 27, 1998	

FDA data supplied by DrugPatentWatch.com

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

	METHYLPHENIDATE HCL			
AB	MALLINCKRODT	10MG	**N40300 002**	NOV 27, 1998
AB		20MG	**N40300 003**	NOV 27, 1998
AB	PUREPAC PHARM	5MG	**N40321 001**	FEB 05, 2002
AB		10MG	**N40321 002**	FEB 05, 2002
AB		20MG	**N40321 003**	FEB 05, 2002
AB	WATSON LABS	5MG	**N40220 001**	AUG 29, 1997
AB		10MG	**N40220 002**	AUG 29, 1997
AB		20MG	**N40220 003**	AUG 29, 1997
	RITALIN			
AB	NOVARTIS	5MG	**N10187 003**	
AB		10MG	**N10187 006**	
AB	+	20MG	**N10187 010**	

TABLET, CHEWABLE; ORAL

	METHYLIN			
	MALLINCKRODT	2.5MG	N21475 001	APR 15, 2003
		5MG	N21475 002	APR 15, 2003
	+	10MG	N21475 003	APR 15, 2003

TABLET, EXTENDED RELEASE; ORAL

	CONCERTA			
	ALZA	18MG	N21121 001	AUG 01, 2000
		27MG	N21121 004	APR 01, 2002
		36MG	N21121 002	AUG 01, 2000
	+	54MG	N21121 003	DEC 08, 2000
	METADATE ER			
AB	+ CELLTECH MFG	20MG	**N89601 001**	JUN 01, 1988
AB	CELLTECH PHARMS	10MG	**N40306 001**	OCT 20, 1999

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	METHYLIN ER			
AB	MALLINCKRODT	10MG	**N75629 001**	MAY 09, 2000
AB		20MG	**N75629 002**	MAY 09, 2000
	METHYLPHENIDATE HCL			
AB	ABLE	20MG	**N76032 001**	MAY 09, 2001
AB	PUREPAC PHARM	20MG	**N75450 001**	DEC 21, 2001
AB	WATSON LABS	20MG	**N40410 001**	FEB 09, 2001
	RITALIN-SR			
AB	NOVARTIS	20MG	**N18029 001**	MAR 30, 1982

METHYLPREDNISOLONE

TABLET; ORAL

	MEDROL			
AB	PHARMACIA AND UPJOHN	4MG	**N11153 001**	
AB		8MG	**N11153 004**	
AB		16MG	**N11153 003**	
AB		24MG	**N11153 005**	
AB	+	32MG	**N11153 006**	
	METHYLPREDNISOLONE			
AB	DURAMED PHARMS BARR	4MG	**N88497 001**	FEB 21, 1984
AB	PAR PHARM	16MG	**N89207 001**	APR 25, 1988
AB		24MG	**N89208 001**	APR 25, 1988
AB		32MG	**N89209 001**	APR 25, 1988
AB	SANDOZ	4MG	**N40194 001**	OCT 31, 1997
AB	TRIGEN	4MG	**N40189 001**	OCT 31, 1997
AB		8MG	**N40189 002**	OCT 31, 1997
AB	VINTAGE PHARMS	4MG	**N40183 001**	DEC 22, 1998
AB	WATSON LABS	4MG	**N40232 001**	OCT 16, 1997

FDA data supplied by DrugPatentWatch.com

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

DEPO-MEDROL

+	PHARMACIA AND UPJOHN	20MG/ML		N11757 002
+		40MG/ML		N11757 001
+		80MG/ML		N11757 004

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

AP	ABBOTT	**EQ 1GM BASE/VIAL**		**N85852 001**
AP		**EQ 1GM BASE/VIAL**		**N89174 001** AUG 18, 1987
AP		**EQ 40MG BASE/VIAL**		**N85853 001**
AP		**EQ 125MG BASE/VIAL**		**N85855 001**
AP		**EQ 500MG BASE/VIAL**		**N85854 001**
AP		**EQ 500MG BASE/VIAL**		**N89173 001** AUG 18, 1987

METHYLPREDNISOLONE SODIUM SUCCINATE

AP	GENSIA SICOR PHARMS	**EQ 125MG BASE/VIAL**		**N81266 001** NOV 30, 1992

SOLU-MEDROL

AP	+ PHARMACIA AND UPJOHN	**EQ 40MG BASE/VIAL**		**N11856 003**
AP	+	**EQ 125MG BASE/VIAL**		**N11856 004**
AP	+	**EQ 500MG BASE/VIAL**		**N11856 005**
AP	+	**EQ 1GM BASE/VIAL**		**N11856 006**
	+	EQ 2GM BASE/VIAL		N11856 007 FEB 27, 1985

METHYLTESTOSTERONE

CAPSULE; ORAL

TESTRED

BP	+ VALEANT PHARM INTL	10MG		N83976 001

VIRILON

BP	STAR PHARMS FL	10MG		N87750 001 NOV 24, 1982

TABLET; ORAL

ANDROID 10

AB	VALEANT PHARM INTL	**10MG**		**N86450 001**

ANDROID 25

AB	+ VALEANT PHARM INTL	**25MG**		**N87147 001**

METHYLTESTOSTERONE

BP	IMPAX LABS	10MG		N80767 002

METHYLTESTOSTERONE

TABLET; ORAL

METHYLTESTOSTERONE

BP	IMPAX LABS	25MG		N84310 001

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

METIPRANOLOL

AT	FALCON PHARMS	**0.3%**		**N75720 001** AUG 06, 2001

OPTIPRANOLOL

AT	+ BAUSCH AND LOMB	**0.3%**		**N19907 001** DEC 29, 1989

METOCLOPRAMIDE HYDROCHLORIDE

CONCENTRATE; ORAL

METOCLOPRAMIDE INTENSOL

	ROXANE	EQ 10MG BASE/ML		N72995 001 JAN 30, 1992

INJECTABLE; INJECTION

METOCLOPRAMIDE HCL

AP	ABBOTT	**EQ 5MG BASE/ML**		**N70505 001** JUN 23, 1989
AP		**EQ 5MG BASE/ML**		**N73117 001** JAN 17, 1991
AP		**EQ 5MG BASE/ML**		**N73118 001** JAN 17, 1991
AP		**EQ 5MG BASE/ML**		**N74147 001** AUG 02, 1996
AP	GENSIA SICOR PHARMS	**EQ 5MG BASE/ML**		**N73135 001** NOV 27, 1991
AP	MAYNE PHARMA USA	**EQ 5MG BASE/ML**		**N70847 001** NOV 07, 1988
AP		**EQ 5MG BASE/ML**		**N71291 001** MAR 03, 1989

REGLAN

AP	+ BAXTER HLTHCARE CORP	**EQ 5MG BASE/ML**		**N17862 001**

SOLUTION; ORAL

METOCLOPRAMIDE

AA	JVL	**EQ 5MG BASE/5ML**		**N74703 001** OCT 31, 1997

FDA data supplied by DrugPatentWatch.com

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL

		METOCLOPRAMIDE			
AA		VISTAPHARM	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001
		METOCLOPRAMIDE HCL			
AA		ALPHARMA	EQ 5MG BASE/5ML	N71340 001	AUG 18, 1988
AA		PHARM ASSOC	EQ 5MG BASE/5ML	N72744 001	MAY 28, 1991
AA		PHARM VENTURES	EQ 5MG BASE/5ML	N71402 001	JUN 25, 1993
AA		ROXANE	EQ 5MG BASE/5ML	N72038 001	DEC 05, 1988
AA		SILARX	EQ 5MG BASE/5ML	N73680 001	OCT 27, 1992
AA	+	TEVA	EQ 5MG BASE/5ML	N70819 001	JUL 10, 1987
AA			EQ 5MG BASE/5ML	N71315 001	JUN 30, 1993

TABLET; ORAL

		METOCLOPRAMIDE HCL			
AB		PLIVA	EQ 5MG BASE	N72750 001	DEC 28, 1995
AB			EQ 10MG BASE	N71250 001	FEB 03, 1988
AB		PUREPAC PHARM	EQ 10MG BASE	N70581 001	OCT 17, 1985
AB		SANDOZ	EQ 5MG BASE	N74478 001	OCT 05, 1995
AB			EQ 10MG BASE	N72215 001	JAN 30, 1990
AB			EQ 10MG BASE	N74478 002	OCT 05, 1995
AB		TEVA	EQ 5MG BASE	N72801 001	JUN 15, 1993
AB			EQ 10MG BASE	N70184 001	JUL 29, 1985
AB		WATSON LABS	EQ 10MG BASE	N70511 001	JAN 22, 1986
		REGLAN			
AB		SCHWARZ PHARMA	EQ 5MG BASE	N17854 002	MAY 05, 1987
AB	+		EQ 10MG BASE	N17854 001	

METOLAZONE

TABLET; ORAL

		METOLAZONE			
AB		EON	2.5MG	N76732 001	DEC 19, 2003
AB			5MG	N76466 001	DEC 19, 2003
AB			10MG	N76466 002	DEC 19, 2003
AB		MYLAN	2.5MG	N76698 001	DEC 23, 2003
AB		TEVA	10MG	N75543 003	DEC 24, 2003
		MYKROX			
	+	CELLTECH PHARMS	0.5MG	N19532 001	OCT 30, 1987
		ZAROXOLYN			
AB		CELLTECH PHARMS	2.5MG	N17386 001	
AB	+		5MG	N17386 002	
AB	+		10MG	N17386 003	

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

	TOPROL-XL			
	ASTRAZENECA	EQ 25MG TARTRATE	N19962 004	FEB 05, 2001
+		EQ 50MG TARTRATE	N19962 001	JAN 10, 1992
		EQ 100MG TARTRATE	N19962 002	JAN 10, 1992
+		EQ 200MG TARTRATE	N19962 003	JAN 10, 1992

METOPROLOL TARTRATE

INJECTABLE; INJECTION

		LOPRESSOR			
AP	+	NOVARTIS	1MG/ML	N18704 001	MAR 30, 1984
		METOPROLOL TARTRATE			
AP		ABBOTT	1MG/ML	N74133 001	DEC 21, 1993
AP			1MG/ML	N75160 001	JUL 06, 1998

FDA data supplied by DrugPatentWatch.com

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

AP	BEDFORD LABS	**1MG/ML**	**N76495 001** JUL 07, 2003
AP	STERIS	**1MG/ML**	**N74032 001** DEC 21, 1993

TABLET; ORAL

LOPRESSOR

AB	NOVARTIS	**50MG**	**N17963 001**
AB	+	**100MG**	**N17963 002**

METOPROLOL TARTRATE

AB	APOTHECON	**50MG**	**N74258 001** JAN 27, 1994
AB		**100MG**	**N74258 002** JAN 27, 1994
AB	CARACO	**50MG**	**N74644 001** DEC 10, 1996
AB		**100MG**	**N74644 002** DEC 10, 1996
AB	COPLEY PHARM	**50MG**	**N74333 001** JAN 27, 1994
AB		**100MG**	**N74333 002** JAN 27, 1994
AB	MUTUAL PHARM	**50MG**	**N73653 001** DEC 21, 1993
AB		**100MG**	**N73654 001** DEC 21, 1993
AB	MYLAN	**50MG**	**N73666 001** DEC 21, 1993
AB		**100MG**	**N73666 002** DEC 21, 1993
AB	PAR PHARM	**50MG**	**N74453 001** APR 27, 1995
AB		**100MG**	**N74453 002** APR 27, 1995
AB	SANDOZ	**50MG**	**N73288 001** MAR 25, 1994
AB		**100MG**	**N73289 001** MAR 25, 1994
AB	TEVA	**50MG**	**N74141 001** JAN 31, 1995
AB		**50MG**	**N74143 001** SEP 30, 1994
AB		**100MG**	**N74141 002** JAN 31, 1995

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

AB	TEVA	**100MG**	**N74143 002** SEP 30, 1994
AB	WATSON LABS	**50MG**	**N74217 001** MAY 27, 1994
AB		**100MG**	**N74217 002** MAY 27, 1994

METOPROLOL TARTRATE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

METRONIDAZOLE

CAPSULE; ORAL

FLAGYL

AB	+ GD SEARLE LLC	**375MG**	**N20334 001** MAY 03, 1995

METRONIDAZOLE

AB	ABLE	**375MG**	**N76505 001** NOV 13, 2003

CREAM; TOPICAL

METROCREAM

+	GALDERMA LABS LP	0.75%	N20531 001 SEP 20, 1995

NORITATE

+	DERMIK LABS	1%	N20743 001 SEP 26, 1997

GEL; TOPICAL

METROGEL

+	GALDERMA LABS LP	0.75%	N19737 001 NOV 22, 1988

GEL; VAGINAL

METROGEL-VAGINAL

+	3M	0.75%	N20208 001 AUG 17, 1992

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

AP	+ BAXTER HLTHCARE	**500MG/100ML**	**N18657 001**
AP	+ GD SEARLE LLC	**500MG/100ML**	**N18353 002**

FDA data supplied by DrugPatentWatch.com

METRONIDAZOLE

INJECTABLE; INJECTION

	METRO I.V. IN PLASTIC CONTAINER			
AP	+ B BRAUN	500MG/100ML	**N18900 001**	SEP 29, 1983
	METRONIDAZOLE IN PLASTIC CONTAINER			
AP	+ ABBOTT	500MG/100ML	**N18890 002**	NOV 18, 1983

LOTION; TOPICAL

	METROLOTION			
	+ GALDERMA LABS LP	0.75%	N20901 001	NOV 24, 1998

TABLET; ORAL

	FLAGYL			
AB	GD SEARLE LLC	250MG	**N12623 001**	
AB	+	500MG	**N12623 003**	
	METROMIDOL			
AB	LABS AF	250MG	**N74523 001**	OCT 24, 1996
AB		500MG	**N74523 002**	OCT 24, 1996
	METRONIDAZOLE			
AB	ABLE	250MG	**N76519 001**	JUN 27, 2003
AB		500MG	**N76519 002**	JUN 27, 2003
AB	EON	250MG	**N18620 001**	MAR 04, 1982
AB		500MG	**N18620 002**	JUN 02, 1983
AB	IVAX PHARMS	250MG	**N18517 001**	
AB		500MG	**N18517 002**	MAY 05, 1982
AB	LNK	250MG	**N19029 001**	APR 10, 1984
AB	MUTUAL PHARM	250MG	**N70772 001**	JUL 16, 1986
AB		500MG	**N70773 001**	JUL 16, 1986
AB	PAR PHARM	250MG	**N18845 001**	AUG 18, 1983
AB		250MG	**N70040 001**	JAN 29, 1985
AB		500MG	**N18930 001**	AUG 18, 1983

METRONIDAZOLE

TABLET; ORAL

	METRONIDAZOLE			
AB	PAR PHARM	500MG	**N70039 001**	JAN 29, 1985
AB	PLIVA	250MG	**N70027 001**	NOV 06, 1984
AB		500MG	**N70033 001**	DEC 06, 1984
AB	SANDOZ	250MG	**N18740 001**	OCT 22, 1982
AB		500MG	**N18740 002**	OCT 22, 1982
AB	TEVA	250MG	**N70035 001**	DEC 20, 1984
AB		500MG	**N70044 001**	FEB 08, 1985
AB	WATSON LABS	250MG	**N18764 001**	SEP 17, 1982
AB		500MG	**N18764 002**	DEC 20, 1982

TABLET, EXTENDED RELEASE; ORAL

	FLAGYL ER			
AB	+ GD SEARLE LLC	750MG	**N20868 001**	NOV 26, 1997
	METRONIDAZOLE			
AB	ABLE	750MG	**N76462 001**	JUN 25, 2003

METRONIDAZOLE; *MULTIPLE*
SEE BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

	FLAGYL I.V.		
	+ GD SEARLE LLC	EQ 500MG BASE/VIAL	N18353 001

METYRAPONE

CAPSULE; ORAL

	METOPIRONE		
	+ NOVARTIS	250MG	N12911 002 AUG 09, 1996

FDA data supplied by DrugPatentWatch.com

METYROSINE

CAPSULE; ORAL
DEMSER
+ MERCK 250MG N17871 001

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	SANDOZ	150MG	N74450 001	MAY 16, 1996
AB		200MG	N74450 002	MAY 16, 1996
AB		250MG	N74450 003	MAY 16, 1996
AB	TEVA	150MG	N74377 001	MAY 16, 1995
AB		200MG	N74377 002	MAY 16, 1995
AB		250MG	N74377 003	MAY 16, 1995
AB	WATSON LABS	150MG	N74711 001	FEB 26, 1997
AB		150MG	N74865 001	APR 13, 1998
AB		200MG	N74711 002	FEB 26, 1997
AB		200MG	N74865 002	APR 13, 1998
AB		250MG	N74711 003	FEB 26, 1997
AB		250MG	N74865 003	APR 13, 1998

MEXITIL

AB	BOEHRINGER INGELHEIM	150MG	N18873 002	DEC 30, 1985
AB		200MG	N18873 003	DEC 30, 1985
AB +		250MG	N18873 004	DEC 30, 1985

MICONAZOLE NITRATE

CREAM; TOPICAL
MONISTAT-DERM
+ JOHNSON AND JOHNSON 2% N17494 001

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

AB	ALPHARMA US PHARM	200MG	N73508 001	NOV 19, 1993

MONISTAT 3

AB +	ORTHO MCNEIL PHARM	200MG	N18888 001	AUG 15, 1984

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HCL

AP +	ABBOTT	EQ 1MG BASE/ML	N75293 001	JUN 20, 2000
AP		EQ 1MG BASE/ML	N75409 002	JUN 20, 2000
AP		EQ 1MG BASE/ML	N75857 001	JUL 22, 2002
AP +		EQ 5MG BASE/ML	N75293 002	JUN 20, 2000
AP		EQ 5MG BASE/ML	N75409 001	JUN 20, 2000
AP		EQ 5MG BASE/ML	N75857 002	JUL 22, 2002
AP	AM PHARM PARTNERS	EQ 1MG BASE/ML	N75154 002	JUN 20, 2000
AP		EQ 5MG BASE/ML	N75154 001	JUN 20, 2000
AP	APOTEX	EQ 1MG BASE/ML	N75637 001	OCT 31, 2000
AP		EQ 5MG BASE/ML	N75637 002	OCT 31, 2000
AP	BAXTER HLTHCARE	EQ 1MG BASE/ML	N75243 001	JUN 20, 2000
AP		EQ 5MG BASE/ML	N75243 002	JUN 20, 2000
AP	BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	N75324 001	JUN 20, 2000
AP		EQ 5MG BASE/ML	N75324 002	JUN 20, 2000
AP	BEDFORD	EQ 1MG BASE/ML	N75247 002	JUN 23, 2000
AP		EQ 5MG BASE/ML	N75247 001	JUN 23, 2000
AP	BEN VENUE	EQ 1MG BASE/ML	N75421 002	JUN 20, 2000

FDA data supplied by DrugPatentWatch.com

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HCL

AP	BEN VENUE	**EQ 5MG BASE/ML**	**N75421 001** JUN 20, 2000	
AP	MAYNE PHARMA USA	**EQ 1MG BASE/ML**	**N75396 001** JUN 20, 2000	
AP		**EQ 5MG BASE/ML**	**N75396 002** JUN 20, 2000	
AP		**EQ 5MG BASE/ML**	**N75484 001** JUN 20, 2000	
AP	ROSS LABS	**EQ 1MG BASE/ML**	**N75856 001** JUN 13, 2002	
AP		**EQ 5MG BASE/ML**	**N75856 002** JUN 13, 2002	
AP	TAYLOR	**EQ 5MG BASE/ML**	**N75481 001** JUN 30, 2000	
AP	TAYLOR PHARMA	**EQ 1MG BASE/ML**	**N75494 001** JUN 30, 2000	
AP		**EQ 5MG BASE/ML**	**N75494 002** JUN 30, 2000	

SYRUP; ORAL
MIDAZOLAM HCL

AA	HI TECH PHARMA	**EQ 2MG BASE/ML**	**N75958 001** SEP 04, 2003	
AA	RANBAXY	**EQ 2MG BASE/ML**	**N76058 001** MAR 15, 2002	
AA	+ ROXANE	**EQ 2MG BASE/ML**	**N75873 001** APR 30, 2002	

MIDODRINE HYDROCHLORIDE

TABLET; ORAL
MIDODRINE HCL

AB	EON	**2.5MG**	**N76514 001** SEP 11, 2003	
AB		**5MG**	**N76514 002** SEP 11, 2003	
AB	MYLAN	**2.5MG**	**N76577 001** SEP 10, 2003	
AB		**5MG**	**N76577 002** SEP 10, 2003	
AB		**10MG**	**N76577 003** SEP 10, 2003	

PROAMATINE

AB	SHIRE PHARM	**2.5MG**	**N19815 001** SEP 06, 1996	

MIDODRINE HYDROCHLORIDE

TABLET; ORAL
PROAMATINE

AB	+ SHIRE PHARM	**5MG**	**N19815 002** SEP 06, 1996	
AB		**10MG**	**N19815 003** MAR 20, 2002	

MIFEPRISTONE

TABLET; ORAL
MIFEPREX

	+ DANCO LABS LLC	200MG	N20687 001 SEP 28, 2000	

MIGLITOL

TABLET; ORAL
GLYSET

	PHARMACIA AND UPJOHN	25MG	N20682 001 DEC 18, 1996	
		50MG	N20682 002 DEC 18, 1996	
	+	100MG	N20682 003 DEC 18, 1996	

MIGLUSTAT

CAPSULE; ORAL
ZAVESCA

	+ ACTELION PHARMS	100MG	N21348 001 JUL 31, 2003	

MILRINONE LACTATE

INJECTABLE; INJECTION
MILRINONE LACTATE

AP	ABBOTT	**EQ 1MG BASE/ML**	**N75884 001** MAY 28, 2002	
AP	AM PHARM PARTNERS	**EQ 1MG BASE/ML**	**N75936 001** MAY 28, 2002	
AP	BAXTER HLTHCARE	**EQ 1MG BASE/ML**	**N75530 001** MAY 28, 2002	

FDA data supplied by DrugPatentWatch.com

MILRINONE LACTATE

INJECTABLE; INJECTION

	MILRINONE LACTATE			
AP	BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	N75852 001	MAY 28, 2002
AP	BEDFORD	EQ 10MG /10ML(10MG/ML)	N75660 001	MAY 28, 2002
AP	BIONICHE (CANADA)	EQ 1MG BASE/ML	N76428 001	JUN 16, 2003
AP	INTL MEDICATED	EQ 1MG BASE/ML	N76013 001	AUG 02, 2002
AP	MAYNE PHARMA USA	EQ 1MG BASE/ML	N75830 001	MAY 28, 2002
	MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	ABBOTT	EQ 20MG BASE/100ML	N75885 001	MAY 28, 2002
AP	BAXTER HLTHCARE	EQ 20MG BASE/100ML	N75510 001	MAY 28, 2002
AP		EQ 20MG BASE/100ML	N75834 001	MAY 28, 2002
	MILRINONE LACTOSE IN 5% DEXTROSE			
AP	BAXTER HLTHCARE	EQ 20MG BASE/100ML	N76259 001	AUG 08, 2002
	PRIMACOR			
AP +	SANOFI SYNTHELABO	EQ 1MG BASE/ML	N19436 001	DEC 31, 1987
	PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP +	SANOFI SYNTHELABO	EQ 20MG BASE/100ML	N20343 003	AUG 09, 1994

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	MINOCIN			
AB	WYETH PHARMS INC	EQ 50MG BASE	N50649 001	MAY 31, 1990
AB		EQ 75MG BASE	N50649 003	FEB 12, 2001
AB +		EQ 100MG BASE	N50649 002	MAY 31, 1990
	MINOCYCLINE HCL			
AB	IMPAX LABS	EQ 50MG BASE	N65005 001	MAR 23, 1999
AB		EQ 75MG BASE	N65005 003	APR 18, 2001
AB		EQ 100MG BASE	N65005 002	MAR 23, 1999

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	MINOCYCLINE HCL			
AB	RANBAXY	EQ 50MG BASE	N65062 001	NOV 30, 2000
AB		EQ 75MG BASE	N65062 002	NOV 30, 2000
AB		EQ 100MG BASE	N65062 003	NOV 30, 2000
AB	TEVA	EQ 50MG BASE	N63011 001	MAR 02, 1992
AB		EQ 75MG BASE	N63009 002	AUG 12, 2003
AB		EQ 100MG BASE	N63009 001	MAR 02, 1992
AB	WATSON LABS	EQ 50MG BASE	N63181 001	DEC 30, 1991
AB		EQ 75MG BASE	N63065 002	JUN 10, 1999
AB		EQ 100MG BASE	N63065 001	DEC 30, 1991
	VECTRIN			
AB	MEDICIS	EQ 50MG BASE	N63066 001	AUG 14, 1990
AB		EQ 75MG BASE	N63067 002	SEP 15, 1999
AB		EQ 100MG BASE	N63067 001	JUL 31, 1990

INJECTABLE; INJECTION

MINOCIN			
+ WYETH PHARMS INC	EQ 100MG BASE/VIAL	N50444 001	

POWDER, EXTENDED RELEASE; DENTAL

ARESTIN			
+ ORAPHARMA	EQ 1MG BASE	N50781 001	FEB 16, 2001

TABLET; ORAL

MINOCYCLINE HCL			
MEDICIS	EQ 50MG BASE	N65131 001	APR 16, 2003
	EQ 75MG BASE	N65131 002	APR 16, 2003
+	EQ 100MG BASE	N65131 003	APR 16, 2003

FDA data supplied by DrugPatentWatch.com

MINOXIDIL

TABLET; ORAL

	LONITEN			
AB	PHARMACIA AND UPJOHN	2.5MG	N18154 001	
AB	+	10MG	N18154 003	
	MINOXIDIL			
AB	MUTUAL PHARM	2.5MG	N72708 001	DEC 14, 1995
AB		10MG	N72709 001	DEC 14, 1995
AB	PAR PHARM	2.5MG	N71826 001	NOV 14, 1988
AB		10MG	N71839 001	NOV 14, 1988
AB	WATSON LABS	2.5MG	N71344 001	MAR 03, 1987
AB		10MG	N71345 001	MAR 03, 1987

MIRTAZAPINE

TABLET; ORAL

	MIRTAZAPINE			
AB	ALPHAPHARM	15MG	N76176 001	JUN 19, 2003
AB		30MG	N76176 002	JUN 19, 2003
AB		45MG	N76176 003	JUN 19, 2003
AB	AMIDE PHARM	15MG	N76241 001	JUN 25, 2003
AB		30MG	N76241 002	JUN 25, 2003
AB		45MG	N76241 003	JUN 25, 2003
AB	ANDRX PHARMS	15MG	N76336 001	JUN 20, 2003
AB		30MG	N76336 002	JUN 20, 2003
AB		45MG	N76336 003	JUN 20, 2003
AB	EON	15MG	N76219 001	JUN 19, 2003
AB		30MG	N76219 002	JUN 19, 2003
AB		45MG	N76219 003	JUN 19, 2003

MIRTAZAPINE

TABLET; ORAL

	MIRTAZAPINE			
AB	IVAX PHARMS	15MG	N76244 001	DEC 22, 2003
AB		30MG	N76244 002	DEC 22, 2003
AB		45MG	N76244 003	DEC 22, 2003
AB	MYLAN	15MG	N76122 001	JUN 19, 2003
AB		30MG	N76122 002	JUN 19, 2003
AB		45MG	N76122 003	JUN 19, 2003
AB	PUREPAC PHARM	15MG	N76308 001	JUN 20, 2003
AB		30MG	N76308 002	JUN 20, 2003
AB		45MG	N76308 003	JUN 20, 2003
AB	ROXANE	15MG	N76270 001	JUN 19, 2003
AB		30MG	N76270 002	JUN 19, 2003
AB		45MG	N76270 003	JUN 19, 2003
AB	SANDOZ	15MG	N76189 001	JUN 19, 2003
AB		30MG	N76189 002	JUN 19, 2003
AB		45MG	N76189 003	JUN 19, 2003
AB	TEVA	15MG	N76119 001	JAN 24, 2003
AB		30MG	N76119 002	JAN 24, 2003
AB		45MG	N76119 003	JUN 19, 2003
AB	WATSON LABS	15MG	N76312 001	JUN 19, 2003
AB		30MG	N76312 002	JUN 19, 2003
AB		45MG	N76312 003	JUN 19, 2003
	REMERON			
AB	+ ORGANON USA INC	15MG	N20415 001	JUN 14, 1996

FDA data supplied by DrugPatentWatch.com

MIRTAZAPINE

TABLET; ORAL

	REMERON			
AB	ORGANON USA INC	30MG	N20415 002	JUN 14, 1996
AB		45MG	N20415 003	MAR 17, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

	MIRTAZAPINE			
AB	BARR	15MG	N76307 001	DEC 17, 2003
AB		30MG	N76307 002	DEC 17, 2003
	REMERON SOLTAB			
AB	+ ORGANON USA INC	15MG	N21208 001	JAN 12, 2001
AB		30MG	N21208 002	JAN 12, 2001
		45MG	N21208 003	JAN 12, 2001

MISOPROSTOL

TABLET; ORAL

	CYTOTEC			
AB	GD SEARLE LLC	0.1MG	N19268 003	SEP 21, 1990
AB	+	0.2MG	N19268 001	DEC 27, 1988
	MISOPROSTOL			
AB	IVAX PHARMS	0.1MG	N76095 001	JUL 10, 2002
AB		0.2MG	N76095 002	JUL 10, 2002

MISOPROSTOL; *MULTIPLE*
SEE DICLOFENAC SODIUM; MISOPROSTOL

MITOMYCIN

INJECTABLE; INJECTION

	MITOMYCIN			
AP	BAXTER HLTHCARE	5MG/VIAL	N64180 001	DEC 23, 1999

MITOMYCIN

INJECTABLE; INJECTION

	MITOMYCIN			
AP	BAXTER HLTHCARE	20MG/VIAL	N64180 002	DEC 23, 1999
AP	BEDFORD	5MG/VIAL	N64117 001	APR 19, 1995
AP		20MG/VIAL	N64117 002	APR 19, 1995
AP	MAYNE PHARMA USA	20MG/VIAL	N64106 001	NOV 29, 1995
AP	SUPERGEN	5MG/VIAL	N64144 001	APR 30, 1998
AP		20MG/VIAL	N64144 002	APR 30, 1998
	MUTAMYCIN			
AP	+ BRISTOL MYERS	5MG/VIAL	N62336 001	
AP	+	20MG/VIAL	N62336 002	
	+	40MG/VIAL	N62336 003	MAR 10, 1988
	MYTOZYTREX			
	+ SUPERGEN	5MG/VIAL	N50763 001	NOV 14, 2002

MITOTANE

TABLET; ORAL

	LYSODREN		
	+ BRISTOL	500MG	N16885 001

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

	NOVANTRONE		
	+ SERONO INC	EQ 2MG BASE/ML	N19297 001 DEC 23, 1987

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

	MIVACRON		
	+ ABBOTT	EQ 2MG BASE/ML	N20098 001 JAN 22, 1992
	MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER		
	+ ABBOTT	EQ 50MG BASE/100ML	N20098 003 JAN 22, 1992

FDA data supplied by DrugPatentWatch.com

MODAFINIL

	TABLET; ORAL			
	PROVIGIL			
	CEPHALON	100MG	N20717 001	DEC 24, 1998
+		200MG	N20717 002	DEC 24, 1998

MOEXIPRIL HYDROCHLORIDE

	TABLET; ORAL			
	MOEXIPRIL HCL			
AB	TEVA	**7.5MG**	**N76204 001**	MAY 08, 2003
AB		**15MG**	**N76204 002**	MAY 08, 2003
	UNIVASC			
AB	SCHWARZ PHARMA	**7.5MG**	**N20312 001**	APR 19, 1995
AB +		**15MG**	**N20312 002**	APR 19, 1995

MOEXIPRIL HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

MOLINDONE HYDROCHLORIDE

	CONCENTRATE; ORAL		
	MOBAN		
+	ENDO PHARMS	20MG/ML	N17938 001
	TABLET; ORAL		
	MOBAN		
	ENDO PHARMS	5MG	N17111 004
		10MG	N17111 005
+		25MG	N17111 006
		50MG	N17111 007
+		100MG	N17111 008

MOMETASONE FUROATE

	CREAM; TOPICAL			
	ELOCON			
+	SCHERING	0.1%	N19625 001	MAY 06, 1987

MOMETASONE FUROATE

	LOTION; TOPICAL			
	ELOCON			
+	SCHERING	0.1%	N19796 001	MAR 30, 1989
	OINTMENT; TOPICAL			
	ELOCON			
AB +	SCHERING	**0.1%**	**N19543 001**	APR 30, 1987
	MOMETASONE FUROATE			
AB	ATRIX	**0.1%**	**N76481 001**	NOV 14, 2003
AB	CLAY PARK	**0.1%**	**N76067 001**	MAR 18, 2002

MOMETASONE FUROATE MONOHYDRATE

	SPRAY, METERED; NASAL			
	NASONEX			
+	SCHERING PLOUGH	EQ 0.05MG BASE/SPRAY	N20762 001	OCT 01, 1997

MONOBENZONE

	CREAM; TOPICAL			
	BENOQUIN			
+	VALEANT PHARM INTL	20%	N08173 003	

MONTELUKAST SODIUM

	GRANULE; ORAL			
	SINGULAIR			
+	MERCK	EQ 4MG BASE/PACKET	N21409 001	JUL 26, 2002
	TABLET; ORAL			
	SINGULAIR			
+	MERCK	EQ 10MG BASE	N20829 002	FEB 20, 1998
	TABLET, CHEWABLE; ORAL			
	SINGULAIR			
	MERCK	EQ 4MG BASE	N20830 002	MAR 03, 2000

FDA data supplied by DrugPatentWatch.com

MONTELUKAST SODIUM

TABLET, CHEWABLE; ORAL

	SINGULAIR			
+	MERCK	EQ 5MG BASE	N20830 001	FEB 20, 1998

MORICIZINE HYDROCHLORIDE

TABLET; ORAL

	ETHMOZINE			
	SHIRE LABS	200MG	N19753 001	JUN 19, 1990
		250MG	N19753 002	JUN 19, 1990
+		300MG	N19753 003	JUN 19, 1990

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

		AVINZA			
BX	+	LIGAND	30MG	N21260 001	MAR 20, 2002
BX	+		60MG	N21260 002	MAR 20, 2002
	+		90MG	N21260 003	MAR 20, 2002
	+		120MG	N21260 004	MAR 20, 2002
		KADIAN			
BX	+	ALPHARMA	30MG	N20616 004	MAR 09, 2001
BX	+		60MG	N20616 005	MAR 09, 2001
	+		20MG	N20616 001	JUL 03, 1996
	+		50MG	N20616 002	JUL 03, 1996
	+		100MG	N20616 003	JUL 03, 1996

INJECTABLE; INJECTION

		ASTRAMORPH PF			
AP		ASTRAZENECA	**0.5MG/ML**	**N71050 001**	OCT 07, 1986

MORPHINE SULFATE

INJECTABLE; INJECTION

		ASTRAMORPH PF			
AP		ASTRAZENECA	**0.5MG/ML**	**N71051 001**	OCT 07, 1986
AP			**1MG/ML**	**N71052 001**	OCT 07, 1986
AP			**1MG/ML**	**N71053 001**	OCT 07, 1986
		DURAMORPH PF			
AP	+	BAXTER HLTHCARE	**0.5MG/ML**	**N18565 001**	SEP 18, 1984
AP	+		**1MG/ML**	**N18565 002**	SEP 18, 1984
		INFUMORPH			
	+	BAXTER HLTHCARE	10MG/ML	N18565 003	JUL 19, 1991
	+		25MG/ML	N18565 004	JUL 19, 1991
		MORPHINE SULFATE			
AP	+	ABBOTT	**0.5MG/ML**	**N19917 001**	OCT 30, 1992
AP			**0.5MG/ML**	**N71849 001**	MAY 11, 1988
AP			**0.5MG/ML**	**N73509 001**	SEP 30, 1992
AP	+		**1MG/ML**	**N19916 001**	OCT 30, 1992
AP			**1MG/ML**	**N71850 001**	MAY 11, 1988
AP			**1MG/ML**	**N73510 001**	SEP 30, 1992
AP		MALLINCKRODT	**1MG/ML**	**N20631 001**	JUL 03, 1996
	+		2MG/ML	N20631 002	JUL 03, 1996
	+	MERIDIAN MEDCL TECHN	15MG/ML	N19999 001	JUL 12, 1990
AP		STERIS	**0.5MG/ML**	**N73373 001**	SEP 30, 1991
AP			**0.5MG/ML**	**N73375 001**	SEP 30, 1991
AP			**1MG/ML**	**N73374 001**	SEP 30, 1991
AP			**1MG/ML**	**N73376 001**	SEP 30, 1991

FDA data supplied by DrugPatentWatch.com

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

	MORPHINE SULFATE				
AB	AB GENERICS	**15MG**	**N74862 001**	JUL 07, 1998	
AB		**30MG**	**N74862 002**	JUL 07, 1998	
AB		**60MG**	**N74862 003**	JUL 07, 1998	
AB		**100MG**	**N74769 001**	JUL 02, 1998	
AB		**200MG**	**N74769 002**	JUL 02, 1998	
AB	ENDO PHARMS	**15MG**	**N75295 001**	OCT 28, 1998	
AB		**30MG**	**N75295 002**	OCT 28, 1998	
AB		**60MG**	**N75295 003**	OCT 28, 1998	
AB		**100MG**	**N75295 004**	SEP 15, 2000	
AB		**200MG**	**N75295 005**	SEP 15, 2000	
AB	MALLINCKRODT	**15MG**	**N76412 001**	JUL 31, 2003	
AB		**30MG**	**N76412 002**	JUL 31, 2003	
AB		**60MG**	**N76412 003**	JUL 31, 2003	
AB		**100MG**	**N76438 001**	JUL 03, 2003	
AB		**200MG**	**N76438 002**	JUL 03, 2003	
AB	WATSON LABS	**100MG**	**N75656 001**	JAN 30, 2001	
	MS CONTIN				
AB	PURDUE FREDERICK	**15MG**	**N19516 003**	SEP 12, 1989	
AB		**30MG**	**N19516 001**	MAY 29, 1987	
AB +		**60MG**	**N19516 002**	APR 08, 1988	
AB		**100MG**	**N19516 004**	JAN 16, 1990	
AB		**200MG**	**N19516 005**	NOV 08, 1993	
	ORAMORPH SR				
BC	AAIPHARMA	15MG	N19977 004	NOV 23, 1994	

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

	ORAMORPH SR				
BC	AAIPHARMA	30MG	N19977 001	AUG 15, 1991	
BC		60MG	N19977 002	AUG 15, 1991	
BC		100MG	N19977 003	AUG 15, 1991	

MOXIFLOXACIN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

	AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER			
+	BAYER PHARMS	160MG/100ML	N21277 001	NOV 30, 2001

SOLUTION/DROPS; OPHTHALMIC

	VIGAMOX			
+	ALCON	0.5%	N21598 001	APR 15, 2003

TABLET; ORAL

	AVELOX			
+	BAYER PHARMS	EQ 400MG BASE	N21085 001	DEC 10, 1999

MUPIROCIN

OINTMENT; TOPICAL

	BACTROBAN			
AB +	GLAXOSMITHKLINE	**2%**	**N50591 001**	DEC 31, 1987
	CENTANY			
BX	JOHNSON AND JOHNSON	2%	N50788 001	DEC 04, 2002
	MUPIROCIN			
AB	CLAY PARK	**2%**	**N65123 001**	NOV 07, 2003
AB	TEVA	**2%**	**N65085 001**	NOV 07, 2003

FDA data supplied by DrugPatentWatch.com

MUPIROCIN CALCIUM

CREAM, AUGMENTED; TOPICAL

BACTROBAN				
+ GLAXOSMITHKLINE	2%	N50746 001 DEC 11, 1997		

OINTMENT; NASAL

BACTROBAN				
+ GLAXOSMITHKLINE	EQ 2% BASE	N50703 001 SEP 18, 1995		

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

CELLCEPT				
+ ROCHE PALO	250MG	N50722 001 MAY 03, 1995		

SUSPENSION; ORAL

CELLCEPT				
+ ROCHE PALO	200MG/ML	N50759 001 OCT 01, 1998		

TABLET; ORAL

CELLCEPT				
+ ROCHE PALO	500MG	N50723 001 JUN 19, 1997		

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

CELLCEPT				
+ ROCHE PALO	500MG/VIAL	N50758 001 AUG 12, 1998		

NABUMETONE

TABLET; ORAL

NABUMETONE					
AB	COPLEY PHARM	**750MG**	**N75179 001** JUN 06, 2000		
AB	EON	**500MG**	**N75280 001** FEB 25, 2002		
AB		**750MG**	**N75280 002** FEB 25, 2002		

NABUMETONE

TABLET; ORAL

NABUMETONE					
AB	IVAX PHARMS	**500MG**	**N76009 001** JAN 24, 2003		
AB		**750MG**	**N76009 002** JAN 24, 2003		
AB	SANDOZ	**500MG**	**N75590 001** FEB 25, 2002		
AB		**750MG**	**N75590 002** FEB 25, 2002		
AB	TEVA	**500MG**	**N75189 001** MAY 26, 2000		
AB		**750MG**	**N75189 002** SEP 24, 2001		
RELAFEN					
AB	GLAXOSMITHKLINE	**500MG**	**N19583 001** DEC 24, 1991		
AB	+	**750MG**	**N19583 002** DEC 24, 1991		

NADOLOL

TABLET; ORAL

CORGARD					
AB	APOTHECON	**20MG**	**N18063 005** OCT 28, 1986		
AB		**40MG**	**N18063 001**		
AB		**80MG**	**N18063 002**		
AB		**120MG**	**N18063 003**		
AB	+	**160MG**	**N18063 004**		
NADOLOL					
AB	COPLEY PHARM	**80MG**	**N74368 001** AUG 31, 1994		
AB		**120MG**	**N74368 002** AUG 31, 1994		
AB		**160MG**	**N74368 003** AUG 31, 1994		
AB	IVAX PHARMS	**20MG**	**N74229 001** AUG 30, 1996		
AB		**40MG**	**N74229 002** AUG 30, 1996		
AB		**80MG**	**N74255 001** JAN 24, 1996		
AB		**120MG**	**N74255 002** JAN 24, 1996		

FDA data supplied by DrugPatentWatch.com

NADOLOL

TABLET; ORAL
NADOLOL

AB	IVAX PHARMS	**160MG**	**N74255 003** JAN 24, 1996
AB	MYLAN	**20MG**	**N74172 001** OCT 31, 1993
AB		**40MG**	**N74172 002** OCT 31, 1993
AB		**80MG**	**N74172 003** OCT 31, 1993
AB	SANDOZ	**20MG**	**N74501 001** NOV 09, 1995
AB		**40MG**	**N74501 002** NOV 09, 1995
AB		**80MG**	**N74501 003** NOV 09, 1995

NADOLOL; *MULTIPLE*
SEE BENDROFLUMETHIAZIDE; NADOLOL

NAFARELIN ACETATE

SPRAY, METERED; NASAL
SYNAREL

+	GD SEARLE LLC	EQ 0.2MG BASE/SPRAY	N19886 001 FEB 13, 1990

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCILLIN SODIUM

AP	APOTHECON	**EQ 1GM BASE/VIAL**	**N62527 002** AUG 02, 1984
AP		**EQ 1GM BASE/VIAL**	**N62732 001** DEC 23, 1986
AP		**EQ 2GM BASE/VIAL**	**N62527 003** AUG 02, 1984
AP		**EQ 2GM BASE/VIAL**	**N62732 002** DEC 23, 1986
AP		**EQ 10GM BASE/VIAL**	**N62527 004** AUG 02, 1984
+		EQ 500MG BASE/VIAL	N62527 001 AUG 02, 1984

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NALLPEN IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	EQ 20MG BASE/ML	N50655 001 OCT 31, 1989
+		EQ 2GM BASE/100ML	N50655 002 OCT 31, 1989

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL
NAFTIN

ALLERGAN HERBERT	1%	N19599 001 FEB 29, 1988

GEL; TOPICAL
NAFTIN

+	ALLERGAN HERBERT	1%	N19356 001 JUN 18, 1990

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HCL

AP	ABBOTT	**10MG/ML**	**N70914 001** FEB 03, 1989
AP		**10MG/ML**	**N70915 001** FEB 03, 1989
AP		**20MG/ML**	**N70916 001** FEB 03, 1989
AP		**20MG/ML**	**N70918 001** FEB 03, 1989

NUBAIN

AP	+ ENDO PHARMS	**10MG/ML**	**N18024 001**
AP	+	**20MG/ML**	**N18024 002** MAY 27, 1982

NALIDIXIC ACID

TABLET; ORAL
NALIDIXIC ACID

AB	WATSON LABS	**1GM**	**N71919 001** JUN 29, 1988
AB		**250MG**	**N71936 001** JUN 29, 1988

FDA data supplied by DrugPatentWatch.com

NALIDIXIC ACID

TABLET; ORAL

NALIDIXIC ACID

AB	WATSON LABS	500MG	N72061 001	JUN 29, 1988

NEGGRAM

AB	SANOFI SYNTHELABO	250MG	N14214 002	
AB		500MG	N14214 004	
AB	+	1GM	N14214 005	

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION

REVEX

+	BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML	N20459 001	APR 17, 1995
+		EQ 1MG BASE/ML	N20459 002	APR 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HCL

AP	ABBOTT	0.02MG/ML	N70171 001	SEP 24, 1986
AP		0.02MG/ML	N70252 001	JAN 16, 1987
AP		0.02MG/ML	N70253 001	JAN 16, 1987
AP		0.4MG/ML	N70254 001	JAN 07, 1987
AP		0.4MG/ML	N70255 001	JAN 07, 1987
AP		0.4MG/ML	N70256 001	JAN 07, 1987
AP		0.4MG/ML	N70257 001	JAN 07, 1987
AP	INTL MEDICATION	0.4MG/ML	N70639 001	SEP 24, 1986
AP		1MG/ML	N72076 001	MAR 24, 1988

NARCAN

AP	+ ENDO PHARMS	0.02MG/ML	N16636 002	
AP	+	0.4MG/ML	N16636 001	
AP	+	1MG/ML	N16636 003	JUN 14, 1982

NALOXONE HYDROCHLORIDE; *MULTIPLE*

SEE BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

NALOXONE HCL AND PENTAZOCAINE

AB	AMIDE PHARM	EQ 0.5MG BASE; EQ 50MG BASE	N75735 001	JUL 11, 2001

PENTAZOCINE AND NALOXONE HYDROCHLORIDES

AB	RANBAXY	EQ 0.5MG BASE; EQ 50MG BASE	N75523 001	MAR 17, 2000
AB	WATSON LABS	EQ 0.5MG BASE; EQ 50MG BASE	N74736 001	JAN 21, 1997

TALWIN NX

AB	+ SANOFI SYNTHELABO	EQ 0.5MG BASE; EQ 50MG BASE	N18733 001	DEC 16, 1982

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HCL

AB	AMIDE PHARM	50MG	N75274 001	MAY 26, 1999
AB	BARR	50MG	N74918 001	MAY 08, 1998
AB	EON	50MG	N75434 001	MAR 08, 2000
AB	MALLINCKRODT	50MG	N76264 002	MAR 22, 2002
		25MG	N76264 001	MAR 22, 2002
	+	100MG	N76264 003	MAR 22, 2002

REVIA

AB	+ BARR PHARMS	50MG	N18932 001	NOV 20, 1984

FDA data supplied by DrugPatentWatch.com

NANDROLONE DECANOATE

INJECTABLE; INJECTION

	NANDROLONE DECANOATE			
+	STERIS	50MG/ML	N86385 001	JAN 13, 1984
+		100MG/ML	N86598 001	JAN 13, 1984
+		200MG/ML	N88128 001	DEC 05, 1983

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	ALBALON			
AT	+ ALLERGAN	**0.1%**	**N80248 001**	
	NAFAZAIR			
AT	BAUSCH AND LOMB	**0.1%**	**N40073 001**	MAY 25, 1994
	NAPHAZOLINE HCL			
AT	TAYLOR	**0.1%**	**N83590 001**	
	VASOCON			
AT	NOVARTIS	**0.1%**	**N80235 002**	MAR 24, 1983

NAPROXEN

SUSPENSION; ORAL

	NAPROSYN			
AB	+ ROCHE PALO	**25MG/ML**	**N18965 001**	MAR 23, 1987
	NAPROXEN			
AB	ROXANE	**25MG/ML**	**N74190 001**	MAR 30, 1994

TABLET; ORAL

	NAPROSYN			
AB	ROCHE PALO	**250MG**	**N17581 002**	
AB		**375MG**	**N17581 003**	
AB	+	**500MG**	**N17581 004**	APR 15, 1982
	NAPROXEN			
AB	CLONMEL HLTHCARE	**250MG**	**N74410 001**	APR 28, 1995
AB		**375MG**	**N74410 002**	APR 28, 1995

NAPROXEN

TABLET; ORAL

	NAPROXEN			
AB	CLONMEL HLTHCARE	**500MG**	**N74410 003**	APR 28, 1995
AB	COPLEY PHARM	**250MG**	**N74207 001**	DEC 21, 1993
AB		**375MG**	**N74207 002**	DEC 21, 1993
AB		**500MG**	**N74207 003**	DEC 21, 1993
AB	INTERPHARM	**250MG**	**N75927 001**	DEC 18, 2001
AB		**375MG**	**N75927 002**	DEC 18, 2001
AB		**500MG**	**N75927 003**	DEC 18, 2001
AB	IVAX PHARMS	**250MG**	**N74111 001**	FEB 28, 1995
AB		**375MG**	**N74111 002**	FEB 28, 1995
AB		**500MG**	**N74111 003**	FEB 28, 1995
AB	LEDERLE	**250MG**	**N74105 001**	DEC 21, 1993
AB		**375MG**	**N74105 002**	DEC 21, 1993
AB		**500MG**	**N74105 003**	DEC 21, 1993
AB	MYLAN	**250MG**	**N74121 001**	DEC 21, 1993
AB		**375MG**	**N74121 002**	DEC 21, 1993
AB		**500MG**	**N74121 003**	DEC 21, 1993
AB	PLIVA	**250MG**	**N74182 001**	JUN 27, 1996
AB		**375MG**	**N74182 002**	JUN 27, 1996
AB		**500MG**	**N74182 003**	JUN 27, 1996
AB	SANDOZ	**250MG**	**N74140 001**	DEC 21, 1993
AB		**375MG**	**N74140 002**	DEC 21, 1993
AB		**500MG**	**N74140 003**	DEC 21, 1993

FDA data supplied by DrugPatentWatch.com

NAPROXEN

TABLET; ORAL

NAPROXEN

AB	TEVA	250MG	N74129 001	DEC 21, 1993
AB		250MG	N74201 001	DEC 21, 1993
AB		250MG	N74216 001	APR 11, 1996
AB		375MG	N74129 002	DEC 21, 1993
AB		375MG	N74201 002	DEC 21, 1993
AB		375MG	N74216 002	APR 11, 1996
AB		500MG	N74129 003	DEC 21, 1993
AB		500MG	N74201 003	DEC 21, 1993
AB		500MG	N74216 003	APR 11, 1996
AB	WATSON LABS	250MG	N74163 001	FEB 10, 1995
AB		250MG	N74457 001	MAY 31, 1995
AB		375MG	N74163 002	FEB 10, 1995
AB		375MG	N74457 002	MAY 31, 1995
AB		500MG	N74163 003	FEB 10, 1995
AB		500MG	N74457 003	MAY 31, 1995

TABLET, DELAYED RELEASE; ORAL

EC-NAPROSYN

AB	+ ROCHE PALO	375MG	N20067 002	OCT 14, 1994
AB	+	500MG	N20067 003	OCT 14, 1994

NAPROXEN

AB	PLIVA	375MG	N75337 001	MAY 26, 1999
AB		500MG	N75337 002	MAY 26, 1999
AB	PUREPAC PHARM	375MG	N74936 001	FEB 24, 1998

NAPROXEN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

AB	PUREPAC PHARM	500MG	N74936 002	FEB 24, 1998
AB	SANDOZ	375MG	N75061 001	FEB 18, 1998
AB		500MG	N75061 002	FEB 18, 1998
AB	TEVA	375MG	N75227 001	JUN 30, 1998
AB		500MG	N75227 002	JUN 30, 1998

TABLET, EXTENDED RELEASE; ORAL

NAPROXEN

AB	+ ALPHAPHARM	375MG	N75390 001	APR 19, 2001
AB	+	500MG	N75390 002	APR 19, 2001

NAPROXEN; *MULTIPLE*
SEE LANSOPRAZOLE; NAPROXEN

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

AB	ROCHE PALO	EQ 250MG BASE	N18164 001	

ANAPROX DS

AB	+ ROCHE PALO	EQ 500MG BASE	N18164 003	SEP 30, 1987

NAPROXEN SODIUM

AB	ABLE	EQ 250MG BASE	N76544 001	AUG 22, 2003
AB		EQ 500MG BASE	N76544 002	AUG 22, 2003
AB	COPLEY PHARM	EQ 250MG BASE	N74289 001	JAN 27, 1994
AB		EQ 500MG BASE	N74289 002	JAN 27, 1994
AB	HIKMA	EQ 250MG BASE	N74480 002	FEB 18, 1998
AB		EQ 500MG BASE	N74480 001	MAY 14, 1996

FDA data supplied by DrugPatentWatch.com

NAPROXEN SODIUM

TABLET; ORAL

	NAPROXEN SODIUM			
AB	IVAX PHARMS	**EQ 250MG BASE**	**N74230 001**	MAR 14, 1995
AB		**EQ 500MG BASE**	**N74230 002**	MAR 14, 1995
AB	MYLAN	**EQ 250MG BASE**	**N74367 001**	AUG 31, 1994
AB		**EQ 500MG BASE**	**N74367 002**	AUG 31, 1994
AB	PLIVA	**EQ 250MG BASE**	**N74242 001**	JUN 20, 1996
AB		**EQ 500MG BASE**	**N74242 002**	JUN 20, 1996
AB	SANDOZ	**EQ 250MG BASE**	**N74162 001**	DEC 21, 1993
AB		**EQ 250MG BASE**	**N74495 001**	DEC 05, 1994
AB		**EQ 500MG BASE**	**N74162 002**	DEC 21, 1993
AB		**EQ 500MG BASE**	**N74495 002**	DEC 05, 1994
AB	TEVA	**EQ 250MG BASE**	**N74142 001**	DEC 21, 1993
AB		**EQ 250MG BASE**	**N74198 001**	DEC 21, 1993
AB		**EQ 500MG BASE**	**N74142 002**	DEC 21, 1993
AB		**EQ 500MG BASE**	**N74198 002**	DEC 21, 1993
AB	WATSON LABS	**EQ 250MG BASE**	**N74195 001**	DEC 21, 1993
AB		**EQ 250MG BASE**	**N74455 001**	MAY 31, 1995
AB		**EQ 500MG BASE**	**N74195 002**	DEC 21, 1993
AB		**EQ 500MG BASE**	**N74455 002**	MAY 31, 1995

TABLET, EXTENDED RELEASE; ORAL

	NAPRELAN			
AB	+ ELAN PHARMA	**EQ 375MG BASE**	**N20353 001**	JAN 05, 1996
AB	+	**EQ 500MG BASE**	**N20353 002**	JAN 05, 1996
	NAPROXEN SODIUM			
AB	ANDRX PHARMS	**EQ 375MG BASE**	**N75416 002**	APR 23, 2003

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL

	NAPROXEN SODIUM			
AB	ANDRX PHARMS	**EQ 500MG BASE**	**N75416 001**	AUG 27, 2002

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

	AMERGE			
	GLAXOSMITHKLINE	EQ 1MG BASE	N20763 002	FEB 10, 1998
	+	EQ 2.5MG BASE	N20763 001	FEB 10, 1998

NATAMYCIN

SUSPENSION; OPHTHALMIC

NATACYN			
+ ALCON	5%	N50514 001	

NATEGLINIDE

TABLET; ORAL

STARLIX			
NOVARTIS	60MG	N21204 001	DEC 22, 2000
+	120MG	N21204 002	DEC 22, 2000

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

TILADE			
+ AVENTIS	1.75MG/INH	N19660 001	DEC 30, 1992

SOLUTION/DROPS; OPHTHALMIC

ALOCRIL			
+ ALLERGAN	2%	N21009 001	DEC 08, 1999

FDA data supplied by DrugPatentWatch.com

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HCL

AB	DR REDDYS LABS INC	50MG	**N76309 001** SEP 16, 2003
AB		100MG	**N76309 002** SEP 16, 2003
AB		150MG	**N76309 003** SEP 16, 2003
AB		200MG	**N76309 004** SEP 16, 2003
AB		250MG	**N76309 005** SEP 16, 2003
AB	EON	50MG	**N76302 001** SEP 16, 2003
AB		100MG	**N76302 002** SEP 16, 2003
AB		150MG	**N76302 003** SEP 16, 2003
AB		200MG	**N76302 004** SEP 16, 2003
AB		250MG	**N76302 005** SEP 16, 2003
AB	IVAX PHARMS	50MG	**N75763 001** SEP 16, 2003
AB		100MG	**N75763 002** SEP 16, 2003
AB		150MG	**N75763 003** SEP 16, 2003
AB		200MG	**N75763 004** SEP 16, 2003
AB		250MG	**N75763 005** SEP 16, 2003
AB	MYLAN	100MG	**N76129 002** SEP 16, 2003
AB		150MG	**N76129 003** SEP 16, 2003
AB		200MG	**N76129 004** SEP 16, 2003
AB		250MG	**N76129 005** SEP 16, 2003
AB	RANBAXY	50MG	**N76409 001** SEP 16, 2003
AB		100MG	**N76409 002** SEP 16, 2003
AB		150MG	**N76409 003** SEP 16, 2003

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HCL

AB	RANBAXY	200MG	**N76409 004** SEP 16, 2003
AB		250MG	**N76409 005** SEP 16, 2003
AB	ROXANE	50MG	**N76196 001** SEP 16, 2003
AB		100MG	**N76196 002** SEP 16, 2003
AB		150MG	**N76196 003** SEP 16, 2003
AB		200MG	**N76196 004** SEP 16, 2003
AB		250MG	**N76196 005** SEP 16, 2003
AB	SANDOZ	50MG	**N76072 001** SEP 16, 2003
AB		100MG	**N76072 002** SEP 16, 2003
AB		150MG	**N76072 003** SEP 16, 2003
AB		200MG	**N76072 004** SEP 16, 2003
AB		250MG	**N76072 005** SEP 16, 2003
AB	TEVA	50MG	**N76037 001** SEP 16, 2003
AB		100MG	**N76037 002** SEP 16, 2003
AB		150MG	**N76037 003** SEP 16, 2003
AB		200MG	**N76037 004** SEP 16, 2003
AB		250MG	**N76037 005** SEP 16, 2003
AB	WATSON LABS	100MG	**N76073 002** SEP 16, 2003
AB		150MG	**N76073 003** SEP 16, 2003
AB		200MG	**N76073 004** SEP 16, 2003
AB		250MG	**N76073 005** SEP 16, 2003

SERZONE

AB	BRISTOL MYERS SQUIBB	50MG	**N20152 001** DEC 22, 1994

FDA data supplied by DrugPatentWatch.com

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL
SERZONE

AB		BRISTOL MYERS SQUIBB	**100MG**	**N20152 002** DEC 22, 1994
AB			**150MG**	**N20152 003** DEC 22, 1994
AB			**200MG**	**N20152 004** DEC 22, 1994
AB	+		**250MG**	**N20152 005** DEC 22, 1994

NELFINAVIR MESYLATE

FOR SUSPENSION; ORAL
VIRACEPT

+	AGOURON	EQ 50MG BASE/SCOOPFUL	N20778 001 MAR 14, 1997

TABLET; ORAL
VIRACEPT

+	AGOURON	EQ 250MG BASE	N20779 001 MAR 14, 1997
+		EQ 625MG BASE	N21503 001 APR 30, 2003

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING
NEO-RX

AA	PHARMA TEK	**100%**	**N61579 001**

SOLUTION; ORAL
NEO-FRADIN

+	PHARMATEK	EQ 87.5MG BASE/5ML	N65010 001 MAY 23, 2002

TABLET; ORAL
NEOMYCIN SULFATE

+	TEVA	EQ 350MG BASE	N60304 001

NEOMYCIN SULFATE; *MULTIPLE*
SEE BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

NEOMYCIN SULFATE; *MULTIPLE*
SEE COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE
SEE DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SEE HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION
NEOSPORIN G.U. IRRIGANT

+	MONARCH PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML	N60707 001

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC
POLY-PRED

+	ALLERGAN	EQ 0.35% BASE;10,000 UNITS/ML; 0.5%	N50081 002

NESIRITIDE

FOR SOLUTION; INTRAVENOUS
NATRECOR

+	SCIOS	1.5MG/VIAL	N20920 001 AUG 10, 2001

NEVIRAPINE

SUSPENSION; ORAL
VIRAMUNE

+	BOEHRINGER INGELHEIM	50MG/5ML	N20933 001 SEP 11, 1998

TABLET; ORAL
VIRAMUNE

+	BOEHRINGER INGELHEIM	200MG	N20636 001 JUN 21, 1996

FDA data supplied by DrugPatentWatch.com

NIACIN

TABLET; ORAL

NIACIN			
AA	MK LABS	500MG	N83525 001
AA	TABLICAPS	500MG	N84237 001
AA	WOCKHARDT	500MG	N81134 001 APR 28, 1992
NIACOR			
AA	UPSHER SMITH	500MG	N40378 001 MAY 03, 2000

TABLET, EXTENDED RELEASE; ORAL

NIASPAN			
+	KOS	500MG	N20381 002 JUL 28, 1997
+		750MG	N20381 003 JUL 28, 1997
+		1GM	N20381 004 JUL 28, 1997

NIACIN; *MULTIPLE*
SEE LOVASTATIN; NIACIN

NIACINAMIDE; *MULTIPLE*
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K
SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

CARDENE			
AB	ROCHE PALO	20MG	N19488 001 DEC 21, 1988
AB	+	30MG	N19488 002 DEC 21, 1988
NICARDIPINE HCL			
AB	GENPHARM	20MG	N74928 001 MAR 19, 1998
AB		30MG	N74928 002 MAR 19, 1998
AB	IVAX PHARMS	20MG	N74439 001 DEC 10, 1996
AB		30MG	N74439 002 DEC 10, 1996
AB	MYLAN	20MG	N74642 001 JUL 18, 1996
AB		30MG	N74642 002 JUL 18, 1996
AB	TEVA	20MG	N74540 001 OCT 28, 1996
AB		30MG	N74540 002 OCT 28, 1996
AB	WATSON LABS	20MG	N74670 001 OCT 28, 1996
AB		30MG	N74670 002 OCT 28, 1996

CAPSULE, EXTENDED RELEASE; ORAL

CARDENE SR			
+	ROCHE PALO	30MG	N20005 001 FEB 21, 1992
+		45MG	N20005 002 FEB 21, 1992
+		60MG	N20005 003 FEB 21, 1992

INJECTABLE; INJECTION

CARDENE			
+	ROCHE PALO	2.5MG/ML	N19734 001 JAN 30, 1992

FDA data supplied by DrugPatentWatch.com

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

	NICOTINE			
	SANO	7MG/24HR	N74645 001	OCT 20, 1997
		14MG/24HR	N74611 001	OCT 20, 1997
		21MG/24HR	N74612 001	OCT 20, 1997

INHALANT; ORAL

	NICOTROL			
+	PHARMACIA AND UPJOHN	4MG/CARTRIDGE	N20714 001	MAY 02, 1997

SPRAY, METERED; NASAL

	NICOTROL			
+	PHARMACIA AND UPJOHN	0.5MG/SPRAY	N20385 001	MAR 22, 1996

NIFEDIPINE

CAPSULE; ORAL

	NIFEDIPINE			
AB	FLEMINGTON PHARM	**10MG**	**N72781 001**	JUL 30, 1993
AB	PUREPAC PHARM	**10MG**	**N72579 001**	JAN 08, 1991
AB		**20MG**	**N72556 001**	SEP 20, 1990
AB	SCHERER RP	**10MG**	**N73250 001**	OCT 08, 1991
AB		**20MG**	**N74045 001**	APR 30, 1992
AB	TEVA	**10MG**	**N72651 001**	FEB 19, 1992
	PROCARDIA			
AB	PFIZER	**10MG**	**N18482 001**	
AB +		**20MG**	**N18482 002**	JUL 24, 1986

TABLET, EXTENDED RELEASE; ORAL

	ADALAT CC			
AB1	BAYER PHARMS	**30MG**	**N20198 001**	APR 21, 1993
AB1 +		**60MG**	**N20198 002**	APR 21, 1993

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

	ADALAT CC			
AB1 +	BAYER PHARMS	**90MG**	**N20198 003**	APR 21, 1993
	NIFEDIPINE			
AB1	BIOVAIL	**30MG**	**N75269 001**	DEC 04, 2000
AB2		**30MG**	**N75289 002**	FEB 06, 2001
AB1		**60MG**	**N75269 002**	DEC 04, 2000
AB2		**60MG**	**N75289 001**	SEP 27, 2000
AB1		**90MG**	**N76070 001**	AUG 16, 2002
AB1	ELAN PHARM	**30MG**	**N75128 001**	MAR 10, 2000
AB1		**60MG**	**N75659 001**	OCT 26, 2001
	PROCARDIA XL			
AB2	PFIZER	**30MG**	**N19684 001**	SEP 06, 1989
AB2		**60MG**	**N19684 002**	SEP 06, 1989
BC +		90MG	N19684 003	SEP 06, 1989

NILUTAMIDE

TABLET; ORAL

	NILANDRON			
+	AVENTIS PHARMS	150MG	N20169 002	APR 30, 1999

NIMODIPINE

CAPSULE; ORAL

	NIMOTOP			
+	BAYER PHARMS	30MG	N18869 001	DEC 28, 1988

FDA data supplied by DrugPatentWatch.com

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

	SULAR			
+	FIRST HORIZON	10MG	N20356 001	FEB 02, 1995
		20MG	N20356 002	FEB 02, 1995
+		30MG	N20356 003	FEB 02, 1995
+		40MG	N20356 004	FEB 02, 1995

NITAZOXANIDE

FOR SUSPENSION; ORAL

	ALINIA			
+	ROMARK	100MG/5ML	N21498 001	NOV 22, 2002

NITISINONE

CAPSULE; ORAL

	ORFADIN			
	SWEDISH ORPHAN	2MG	N21232 001	JAN 18, 2002
		5MG	N21232 002	JAN 18, 2002
+		10MG	N21232 003	JAN 18, 2002

NITRIC OXIDE

GAS; INHALATION

	INOMAX			
	INO	100PPM	N20845 002	DEC 23, 1999
+		800PPM	N20845 003	DEC 23, 1999

NITROFURANTOIN

SUSPENSION; ORAL

	FURADANTIN			
+	FIRST HORIZON	25MG/5ML	N09175 001	

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

	MACROBID			
+	PROCTER AND GAMBLE	75MG;25MG	N20064 001	DEC 24, 1991

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

	MACRODANTIN			
AB	PROCTER AND GAMBLE	**25MG**	**N16620 003**	
AB		**50MG**	**N16620 001**	
AB	+	**100MG**	**N16620 002**	
	NITROFURANTION			
AB	MYLAN	**100MG**	**N74967 002**	JUL 09, 1997
	NITROFURANTOIN			
AB	IVAX PHARMS	**50MG**	**N73671 001**	JAN 28, 1993
AB		**100MG**	**N73652 001**	JAN 28, 1993
AB	MYLAN	**50MG**	**N74967 001**	JUL 09, 1997
AB	SANDOZ	**25MG**	**N74336 001**	JAN 25, 1995
AB		**50MG**	**N74336 002**	JAN 25, 1995
AB		**100MG**	**N74336 003**	JAN 25, 1995
AB	WATSON LABS	**25MG**	**N73696 001**	DEC 31, 1992
AB		**50MG**	**N73696 002**	DEC 31, 1992
AB		**100MG**	**N73696 003**	DEC 31, 1992

NITROFURANTOIN, MACROCRYSTALLINE; *MULTIPLE*
SEE NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

NITROFURAZONE

OINTMENT; TOPICAL

	NITROFURAZONE			
AT	TARO	**0.2%**	**N86156 001**	
AT	WENDT	**0.2%**	**N86766 001**	

FDA data supplied by DrugPatentWatch.com

NITROFURAZONE

SOLUTION; TOPICAL
NITROFURAZONE
+ WENDT 0.2% N87081 001

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL
MINITRAN
AB1 3M 0.1MG/HR N89771 001 AUG 30, 1996
AB1 0.2MG/HR N89772 001 AUG 30, 1996
AB1 0.4MG/HR N89773 001 AUG 30, 1996
AB1 0.6MG/HR N89774 001 AUG 30, 1996

NITRO-DUR
AB1 + KEY PHARMS 0.1MG/HR N20145 001 APR 04, 1995
AB1 + 0.2MG/HR N20145 002 APR 04, 1995
AB1 + 0.4MG/HR N20145 004 APR 04, 1995
AB1 + 0.6MG/HR N20145 005 APR 04, 1995
BX + 0.8MG/HR N20145 006 APR 04, 1995
+ 0.3MG/HR N20145 003 APR 04, 1995

NITROGLYCERIN
AB2 HERCON LABS 0.2MG/HR N89884 001 OCT 30, 1998
AB2 0.4MG/HR N89885 001 OCT 30, 1998
AB2 0.6MG/HR N89886 001 OCT 30, 1998
AB2 + MYLAN TECHNOLOGIES 0.1MG/HR N75033 001 FEB 06, 1998
AB1 0.1MG/HR N75076 001 NOV 12, 1999
AB2 + 0.2MG/HR N74609 001 AUG 30, 1996
AB1 0.2MG/HR N75073 001 NOV 12, 1999
AB2 + 0.4MG/HR N74607 001 AUG 30, 1996

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL
NITROGLYCERIN
AB1 MYLAN TECHNOLOGIES 0.4MG/HR N75075 001 NOV 12, 1999
AB2 + 0.6MG/HR N74559 001 AUG 30, 1996
AB1 0.6MG/HR N74992 001 NOV 12, 1999

INJECTABLE; INJECTION
NITROGLYCERIN
AP + ABBOTT 5MG/ML N18531 001 MAY 24, 1988
+ LUITPOLD 5MG/ML N72034 001

NITROGLYCERIN IN DEXTROSE 5%
AP ABBOTT 10MG/100ML N71846 001 AUG 31, 1990
AP 0.1MG/ML N74083 001 OCT 26, 1994
AP 20MG/100ML N71847 001 AUG 31, 1990
AP 40MG/100ML N71848 001 AUG 31, 1990
AP + BAXTER HLTHCARE 10MG/100ML N19970 001 DEC 29, 1989
AP + 20MG/100ML N19970 002 DEC 29, 1989
AP + 40MG/100ML N19970 003 DEC 29, 1989

OINTMENT; TRANSDERMAL
NITROGLYCERIN
+ FOUGERA 2% N87355 001 JUL 08, 1988

SPRAY, METERED; SUBLINGUAL
NITROLINGUAL PUMPSPRAY
+ POHL BOSKAMP 0.4MG/SPRAY N18705 002 JAN 10, 1997

TABLET; SUBLINGUAL
NITROSTAT
PFIZER PHARMS 0.3MG N21134 001 MAY 01, 2000
0.4MG N21134 002 MAY 01, 2000

FDA data supplied by DrugPatentWatch.com

NITROGLYCERIN

TABLET; SUBLINGUAL

	NITROSTAT			
	+ PFIZER PHARMS	0.6MG	N21134 003	MAY 01, 2000

NIZATIDINE

CAPSULE; ORAL

	AXID			
AB	RELIANT PHARMS	**150MG**	**N19508 001**	APR 12, 1988
AB	+	**300MG**	**N19508 002**	APR 12, 1988
	NIZATIDINE			
AB	EON	**150MG**	**N76178 001**	JUL 05, 2002
AB		**300MG**	**N76178 002**	JUL 05, 2002
AB	GENPHARM	**150MG**	**N75934 001**	JUL 09, 2002
AB		**300MG**	**N75934 002**	JUL 09, 2002
AB	MYLAN	**150MG**	**N75806 001**	JUL 05, 2002
AB		**300MG**	**N75806 002**	JUL 05, 2002
AB	TEVA	**150MG**	**N75668 001**	SEP 12, 2002
AB		**300MG**	**N75668 002**	SEP 12, 2002
AB	TORPHARM	**150MG**	**N76383 001**	JAN 23, 2003
AB		**300MG**	**N76383 002**	JAN 23, 2003
AB	WATSON LABS	**150MG**	**N75616 001**	JUL 09, 2002
AB		**300MG**	**N75616 002**	JUL 09, 2002
AB	ZENITH GOLDLINE	**150MG**	**N75461 001**	JUL 08, 2002
AB		**300MG**	**N75461 002**	JUL 08, 2002

NORELGESTROMIN; *MULTIPLE*
SEE ETHINYL ESTRADIOL; NORELGESTROMIN

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

	LEVOPHED			
AP	+ ABBOTT	**EQ 1MG BASE/ML**	**N07513 001**	
	NOREPINEPHRINE BITARTRATE			
AP	BEDFORD	**EQ 1MG BASE/ML**	**N40462 001**	OCT 31, 2003
AP	GENSIA SICOR PHARMS	**EQ 1MG BASE/ML**	**N40455 001**	MAR 03, 2003

NORETHINDRONE

TABLET; ORAL-28

	CAMILA			
AB1	BARR	**0.35MG**	**N76177 001**	OCT 21, 2002
	ERRIN			
AB2	BARR	**0.35MG**	**N76225 001**	OCT 21, 2002
	MICRONOR			
AB2	+ ORTHO MCNEIL PHARM	**0.35MG**	**N16954 001**	
	NOR-QD			
AB1	+ WATSON LABS (UTAH)	**0.35MG**	**N17060 001**	

NORETHINDRONE; *MULTIPLE*
SEE ETHINYL ESTRADIOL; NORETHINDRONE
SEE MESTRANOL; NORETHINDRONE

NORETHINDRONE ACETATE

TABLET; ORAL

	AYGESTIN			
AB	+ DURAMED PHARMS BARR	**5MG**	**N18405 001**	APR 21, 1982
	NORETHINDRONE ACETATE			
AB	BARR	**5MG**	**N75951 001**	MAY 25, 2001

NORETHINDRONE ACETATE; *MULTIPLE*
SEE ESTRADIOL; NORETHINDRONE ACETATE
SEE ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

FDA data supplied by DrugPatentWatch.com

NORFLOXACIN

TABLET; ORAL
NOROXIN
+ MERCK 400MG N19384 002 OCT 31, 1986

NORGESTIMATE; *MULTIPLE*
SEE ESTRADIOL; NORGESTIMATE
SEE ETHINYL ESTRADIOL; NORGESTIMATE

NORGESTREL

TABLET; ORAL
OVRETTE
+ WYETH PHARMS INC 0.075MG N17031 001

NORGESTREL; *MULTIPLE*
SEE ETHINYL ESTRADIOL; NORGESTREL

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
AVENTYL HCL

BD	LILLY	EQ 10MG BASE	N14684 001
BD		EQ 25MG BASE	N14684 002
	NORTRIPTYLINE HCL		
AB	MYLAN	**EQ 10MG BASE**	**N74234 001** JUL 26, 1993
AB		**EQ 25MG BASE**	**N74234 002** JUL 26, 1993
AB		**EQ 50MG BASE**	**N74234 003** JUL 26, 1993
AB		**EQ 75MG BASE**	**N74234 004** JUL 26, 1993
AB	SANDOZ	**EQ 10MG BASE**	**N74054 001** DEC 31, 1992
AB		**EQ 10MG BASE**	**N74835 001** JUN 30, 1997
AB		**EQ 25MG BASE**	**N74054 002** DEC 31, 1992
AB		**EQ 25MG BASE**	**N74835 002** JUN 30, 1997
AB		**EQ 50MG BASE**	**N74054 003** DEC 31, 1992

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HCL

AB	SANDOZ	**EQ 50MG BASE**	**N74835 003** JUN 30, 1997
AB		**EQ 75MG BASE**	**N74054 004** DEC 31, 1992
AB		**EQ 75MG BASE**	**N74835 004** JUN 30, 1997
AB	TARO	**EQ 10MG BASE**	**N75520 004** MAY 08, 2000
AB		**EQ 25MG BASE**	**N75520 003** MAY 08, 2000
AB		**EQ 50MG BASE**	**N75520 001** MAY 08, 2000
AB		**EQ 75MG BASE**	**N75520 002** MAY 08, 2000
AB	TEVA	**EQ 10MG BASE**	**N73667 001** APR 11, 1996
AB		**EQ 10MG BASE**	**N74132 001** MAR 27, 1995
AB		**EQ 25MG BASE**	**N73667 002** APR 11, 1996
AB		**EQ 25MG BASE**	**N74132 002** MAR 27, 1995
AB		**EQ 50MG BASE**	**N73667 003** APR 11, 1996
AB		**EQ 50MG BASE**	**N74132 003** MAR 27, 1995
AB		**EQ 75MG BASE**	**N73667 004** APR 11, 1996
AB		**EQ 75MG BASE**	**N74132 004** MAR 27, 1995
AB	WATSON LABS	**EQ 10MG BASE**	**N73553 001** MAR 30, 1992
AB		**EQ 25MG BASE**	**N73554 001** MAR 30, 1992
AB		**EQ 50MG BASE**	**N73555 001** MAR 30, 1992
AB		**EQ 75MG BASE**	**N73556 001** MAR 30, 1992
	PAMELOR		
AB	TYCO HLTHCARE	**EQ 10MG BASE**	**N18013 001**
AB		**EQ 25MG BASE**	**N18013 002**
AB		**EQ 50MG BASE**	**N18013 004**
AB	+	**EQ 75MG BASE**	**N18013 003**

SOLUTION; ORAL
AVENTYL HCL

AA	+ RANBAXY	**EQ 10MG BASE/5ML**	**N14685 001**

FDA data supplied by DrugPatentWatch.com

NORTRIPTYLINE HYDROCHLORIDE

SOLUTION; ORAL

	NORTRIPTYLINE HCL			
AA	PHARM ASSOC	EQ 10MG BASE/5ML	**N75606 001** AUG 28, 2000	
	PAMELOR			
AA	TYCO HLTHCARE	EQ 10MG BASE/5ML	**N18012 001**	

NYSTATIN

CREAM; TOPICAL

	MYCOSTATIN			
AT	+ WESTWOOD SQUIBB	100,000 UNITS/GM	**N60575 001**	
	NYSTATIN			
AT	ALPHARMA	100,000 UNITS/GM	**N62949 001** JUN 13, 1988	
AT	ALTANA	100,000 UNITS/GM	**N62129 001**	
AT	CLAY PARK	100,000 UNITS/GM	**N62225 001**	
AT	TARO	100,000 UNITS/GM	**N62457 001** JUL 28, 1983	
AT		100,000 UNITS/GM	**N64022 001** JAN 29, 1993	

OINTMENT; TOPICAL

	NYSTATIN			
AT	ALPHARMA	100,000 UNITS/GM	**N62840 001** NOV 13, 1987	
AT	+ ALTANA	100,000 UNITS/GM	**N62124 002** SEP 23, 1982	
AT	CLAY PARK	100,000 UNITS/GM	**N62472 001** FEB 13, 1984	

PASTILLE; ORAL

	MYCOSTATIN			
	+ BRISTOL MYERS SQUIBB	200,000 UNITS	N50619 001 APR 09, 1987	

POWDER; ORAL

	NYSTATIN			
	+ PADDOCK	100%	N62613 001 NOV 26, 1985	

POWDER; TOPICAL

	MYCOSTATIN			
AT	+ WESTWOOD SQUIBB	100,000 UNITS/GM	**N60578 001**	
	NYSTOP			
AT	PADDOCK	100,000 UNITS/GM	**N64118 001** AUG 16, 1996	

NYSTATIN

SUSPENSION; ORAL

	MYCOSTATIN			
AA	+ APOTHECON	100,000 UNITS/ML	**N61533 001**	
	NILSTAT			
AA	+ CLONMEL HLTHCARE	100,000 UNITS/ML	**N50299 001**	
	NYSTATIN			
AA	ALPHARMA	100,000 UNITS/ML	**N62349 001** JUL 14, 1982	
AA	BAUSCH AND LOMB	100,000 UNITS/ML	**N64042 001** FEB 28, 1994	
AA	FOUGERA	100,000 UNITS/ML	**N62517 001** JUN 07, 1984	
AA	MORTON GROVE	100,000 UNITS/ML	**N62512 001** OCT 29, 1984	
AA	UDL	100,000 UNITS/ML	**N64142 001** JUN 25, 1998	
	NYSTEX			
AA	SAVAGE LABS	100,000 UNITS/ML	**N62519 001** JUL 06, 1984	

TABLET; ORAL

	MYCOSTATIN			
AA	+ APOTHECON	500,000 UNITS	**N60574 001**	
	NYSTATIN			
AA	MUTUAL PHARM	500,000 UNITS	**N62838 001** DEC 22, 1988	
AA	PAR PHARM	500,000 UNITS	**N62474 001** DEC 22, 1983	
AA	TEVA	500,000 UNITS	**N62506 001** JAN 16, 1984	

TABLET; VAGINAL

	NYSTATIN			
	+ ODYSSEY PHARMS	100,000 UNITS	N62615 001 OCT 17, 1985	

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

	MYCO-TRIACET II			
AT	TEVA	100,000 UNITS/GM;0.1%	**N61954 002** SEP 20, 1985	
	MYCOLOG-II			
AT	+ APOTHECON	100,000 UNITS/GM;0.1%	**N62606 001** MAY 15, 1985	

FDA data supplied by DrugPatentWatch.com

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

	MYKACET			
AT	ALPHARMA US PHARM	**100,000 UNITS/GM;0.1%**	**N62367 001**	MAY 28, 1985
	MYTREX F			
AT	SAVAGE LABS	**100,000 UNITS/GM;0.1%**	**N62597 001**	OCT 08, 1985
	NYSTATIN AND TRIAMCINOLONE ACETONIDE			
AT	TARO	**100,000 UNITS/GM;0.1%**	**N62347 001**	MAR 30, 1987
AT		**100,000 UNITS/GM;0.1%**	**N62364 001**	DEC 22, 1987
	NYSTATIN-TRIAMCINOLONE ACETONIDE			
AT	FOUGERA	**100,000 UNITS/GM;0.1%**	**N62599 001**	OCT 08, 1985

OINTMENT; TOPICAL

	MYCOLOG-II			
AT	+ APOTHECON	**100,000 UNITS/GM;0.1%**	**N60572 001**	JUN 28, 1985
	MYKACET			
AT	ALPHARMA US PHARM	**100,000 UNITS/GM;0.1%**	**N62733 001**	MAR 09, 1987
	MYTREX F			
AT	SAVAGE LABS	**100,000 UNITS/GM;0.1%**	**N62601 001**	OCT 09, 1985
	NYSTATIN AND TRIAMCINOLONE ACETONIDE			
AT	TARO	**100,000 UNITS/GM;0.1%**	**N63305 001**	MAR 29, 1993
	NYSTATIN-TRIAMCINOLONE ACETONIDE			
AT	FOUGERA	**100,000 UNITS/GM;0.1%**	**N62602 001**	OCT 09, 1985

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

	SANDOSTATIN			
+	NOVARTIS	EQ 0.05MG BASE/ML	N19667 001	OCT 21, 1988
+		EQ 0.1MG BASE/ML	N19667 002	OCT 21, 1988
+		EQ 0.2MG BASE/ML	N19667 004	JUN 12, 1991
+		EQ 0.5MG BASE/ML	N19667 003	OCT 21, 1988

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

	SANDOSTATIN			
+	NOVARTIS	EQ 1MG BASE/ML	N19667 005	JUN 12, 1991
	SANDOSTATIN LAR			
	NOVARTIS	EQ 10MG BASE/VIAL	N21008 001	NOV 25, 1998
		EQ 20MG BASE/VIAL	N21008 002	NOV 25, 1998
+		EQ 30MG BASE/VIAL	N21008 003	NOV 25, 1998

OFLOXACIN

INJECTABLE; INJECTION

	OFLOXACIN			
+	BEDFORD	40MG/ML	N75762 001	JAN 16, 2002

SOLUTION/DROPS; OPHTHALMIC

	OCUFLOX			
+	ALLERGAN	0.3%	N19921 001	JUL 30, 1993

SOLUTION/DROPS; OTIC

	FLOXIN			
+	DAIICHI	0.3%	N20799 001	DEC 16, 1997

TABLET; ORAL

	FLOXIN			
AB	ORTHO MCNEIL PHARM	**200MG**	**N19735 001**	DEC 28, 1990
AB		**300MG**	**N19735 002**	DEC 28, 1990
AB	+	**400MG**	**N19735 003**	DEC 28, 1990
	OFLOXACIN			
AB	PAR PHARM	**200MG**	**N76093 001**	SEP 02, 2003
AB		**300MG**	**N76093 002**	SEP 02, 2003
AB		**400MG**	**N76093 003**	SEP 02, 2003
AB	RANBAXY	**200MG**	**N76220 001**	SEP 02, 2003

FDA data supplied by DrugPatentWatch.com

OFLOXACIN

TABLET; ORAL
OFLOXACIN

AB	RANBAXY	300MG	N76220 002 SEP 02, 2003
AB		400MG	N76220 003 SEP 02, 2003
AB	TEVA	200MG	N76182 001 SEP 02, 2003
AB		300MG	N76182 002 SEP 02, 2003
AB		400MG	N76182 003 SEP 02, 2003

OLANZAPINE

TABLET; ORAL
ZYPREXA

	LILLY	2.5MG	N20592 001 SEP 30, 1996
+		5MG	N20592 002 SEP 30, 1996
		7.5MG	N20592 003 SEP 30, 1996
		10MG	N20592 004 SEP 30, 1996
		15MG	N20592 005 SEP 09, 1997
		20MG	N20592 006 SEP 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL
ZYPREXA ZYDIS

+	LILLY	5MG	N21086 001 APR 06, 2000
		10MG	N21086 002 APR 06, 2000
		15MG	N21086 003 APR 06, 2000
		20MG	N21086 004 APR 06, 2000

OLANZAPINE; *MULTIPLE*
SEE FLUOXETINE HYDROCHLORIDE; OLANZAPINE

OLMESARTAN MEDOXOMIL

TABLET; ORAL
BENICAR

	SANKYO	5MG	N21286 001 APR 25, 2002
		20MG	N21286 003 APR 25, 2002
+		40MG	N21286 004 APR 25, 2002

OLMESARTAN MEDOXOMIL; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
PATANOL

+	ALCON	EQ 0.1% BASE	N20688 001 DEC 18, 1996

OLSALAZINE SODIUM

CAPSULE; ORAL
DIPENTUM

+	PHARMACIA AND UPJOHN	250MG	N19715 001 JUL 31, 1990

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
OMEPRAZOLE

AB	ANDRX PHARMS	10MG	N75347 001 NOV 16, 2001
AB		20MG	N75347 002 NOV 16, 2001
AB		40MG	N75347 003 NOV 16, 2001
AB	EON	10MG	N75791 001 DEC 23, 2002
AB		20MG	N75791 002 DEC 23, 2002
AB	IMPAX LABS	10MG	N75785 001 NOV 08, 2002

FDA data supplied by DrugPatentWatch.com

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

		OMEPRAZOLE		
AB		IMPAX LABS	20MG	**N75785 002** NOV 08, 2002
AB		KREMERS URBAN DEV	10MG	**N75410 001** NOV 01, 2002
AB			20MG	**N75410 002** NOV 01, 2002
AB		LEK PHARMS	10MG	**N75757 001** JAN 28, 2003
AB			20MG	**N75757 002** JAN 28, 2003
AB		MYLAN	10MG	**N75876 001** MAY 29, 2003
AB			20MG	**N75876 002** MAY 29, 2003
AB		TORPHARM	10MG	**N76048 001** OCT 06, 2003
AB			20MG	**N76048 002** OCT 06, 2003
		PRILOSEC		
AB		ASTRAZENECA	10MG	**N19810 003** OCT 05, 1995
AB	+		20MG	**N19810 001** SEP 14, 1989
AB	+		40MG	**N19810 002** JAN 15, 1998

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

		ZOFRAN ODT		
		GLAXOSMITHKLINE	EQ 4MG BASE	N20781 001 JAN 27, 1999
	+		EQ 8MG BASE	N20781 002 JAN 27, 1999

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

		ZOFRAN		
	+	GLAXOSMITHKLINE	EQ 2MG BASE/ML	N20007 001 JAN 04, 1991
		ZOFRAN IN PLASTIC CONTAINER		
	+	GLAXOSMITHKLINE	EQ 0.64MG BASE/ML	N20403 001 JAN 31, 1995

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

		ZOFRAN PRESERVATIVE FREE		
	+	GLAXOSMITHKLINE	EQ 2MG BASE/ML	N20007 003 DEC 10, 1993

SOLUTION; ORAL

		ZOFRAN		
	+	GLAXOSMITHKLINE	EQ 4MG BASE/5ML	N20605 001 JAN 24, 1997

TABLET; ORAL

		ZOFRAN		
		GLAXOSMITHKLINE	EQ 4MG BASE	N20103 001 DEC 31, 1992
			EQ 8MG BASE	N20103 002 DEC 31, 1992
	+		EQ 24MG BASE	N20103 003 AUG 27, 1999

ORLISTAT

CAPSULE; ORAL

		XENICAL		
	+	HLR	120MG	N20766 001 APR 23, 1999

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

		NORFLEX		
AP	+	3M	30MG/ML	**N13055 001**
		ORPHENADRINE CITRATE		
AP		BEDFORD LABS	30MG/ML	**N40463 001** MAR 04, 2003
AP		STERIS	30MG/ML	**N84779 001** MAR 15, 1982
AP			30MG/ML	**N87062 001**

TABLET, EXTENDED RELEASE; ORAL

		NORFLEX		
AB	+	3M	100MG	**N12157 001**
		ORPHENADRINE CITRATE		
AB		EON	100MG	**N40327 001** FEB 15, 2000

FDA data supplied by DrugPatentWatch.com

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

	ORPHENADRINE CITRATE			
AB	IMPAX PHARMS	100MG	**N40368 001**	JUN 23, 2000
AB	KIEL	100MG	**N40249 001**	JAN 29, 1999
AB	SANDOZ	100MG	**N40284 001**	JUN 19, 1998

ORPHENADRINE CITRATE; *MULTIPLE*
SEE ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

	TAMIFLU			
+	ROCHE	EQ 75MG BASE	N21087 001	OCT 27, 1999

FOR SUSPENSION; ORAL

	TAMIFLU			
+	ROCHE	EQ 12MG BASE/ML	N21246 001	DEC 14, 2000

OXACILLIN SODIUM

CAPSULE; ORAL

	BACTOCILL			
AB	GLAXOSMITHKLINE	**EQ 250MG BASE**	**N61336 001**	
AB	+	**EQ 500MG BASE**	**N61336 002**	
	OXACILLIN SODIUM			
AB	TEVA	**EQ 250MG BASE**	**N62222 001**	
AB		**EQ 500MG BASE**	**N62222 002**	

FOR SOLUTION; ORAL

	BACTOCILL			
AA	GLAXOSMITHKLINE	**EQ 250MG BASE/5ML**	**N62321 001**	
	OXACILLIN SODIUM			
AA	TEVA	**EQ 250MG BASE/5ML**	**N62252 001**	

INJECTABLE; INJECTION

	BACTOCILL IN PLASTIC CONTAINER			
+	BAXTER HLTHCARE	EQ 20MG BASE/ML	N50640 001	OCT 26, 1989

OXACILLIN SODIUM

INJECTABLE; INJECTION

	BACTOCILL IN PLASTIC CONTAINER			
+	BAXTER HLTHCARE	EQ 40MG BASE/ML	N50640 002	OCT 26, 1989
	OXACILLIN SODIUM			
AP	APOTHECON	**EQ 250MG BASE/VIAL**	**N61490 001**	
AP	+	**EQ 500MG BASE/VIAL**	**N61490 002**	
AP	+	**EQ 1GM BASE/VIAL**	**N61490 003**	
AP		**EQ 1GM BASE/VIAL**	**N62737 001**	DEC 23, 1986
AP	+	**EQ 2GM BASE/VIAL**	**N62737 002**	DEC 23, 1986
AP	+	**EQ 10GM BASE/VIAL**	**N61490 006**	MAY 09, 1991
AP	MARSAM PHARMS LLC	**EQ 250MG BASE/VIAL**	**N62856 001**	OCT 26, 1988
AP		**EQ 500MG BASE/VIAL**	**N62856 002**	OCT 26, 1988
AP		**EQ 1GM BASE/VIAL**	**N62856 003**	OCT 26, 1988
AP		**EQ 2GM BASE/VIAL**	**N62856 004**	OCT 26, 1988
AP		**EQ 10GM BASE/VIAL**	**N62984 001**	SEP 29, 1988
		EQ 4GM BASE/VIAL	N62856 005	OCT 26, 1988

OXALIPLATIN

INJECTABLE; IV (INFUSION)

	ELOXATIN			
	SANOFI	50MG/VIAL	N21492 001	AUG 09, 2002
+		100MG/VIAL	N21492 002	AUG 09, 2002

OXAMNIQUINE

CAPSULE; ORAL

	VANSIL			
+	PFIZER	250MG	N18069 001	

FDA data supplied by DrugPatentWatch.com

OXANDROLONE

TABLET; ORAL
OXANDRIN
SAVIENT PHARMS 2.5MG N13718 001
\+ 10MG N13718 002
NOV 05, 2001

OXAPROZIN

TABLET; ORAL
DAYPRO
AB + GD SEARLE LLC **600MG** **N18841 004**
OCT 29, 1992

OXAPROZIN
AB CARACO **600MG** **N75844 001**
JAN 03, 2002
AB DR REDDYS LABS LTD **600MG** **N75855 001**
JAN 31, 2001
AB EON **600MG** **N75845 001**
JAN 31, 2001
AB GENPHARM **600MG** **N75847 001**
FEB 28, 2001
AB IVAX PHARMS **600MG** **N75846 001**
MAY 13, 2002
AB MYLAN **600MG** **N75851 001**
AUG 17, 2001
AB PUREPAC PHARM **600MG** **N75843 001**
OCT 03, 2001
AB SANDOZ **600MG** **N75842 001**
APR 12, 2001
AB **600MG** **N75850 001**
APR 27, 2001
AB TEVA **600MG** **N75849 001**
JUL 03, 2002
AB WATSON LABS **600MG** **N75848 001**
FEB 09, 2001

OXAPROZIN POTASSIUM

TABLET; ORAL
DAYPRO ALTA
\+ PHARMACIA 600MG N20776 001
OCT 17, 2002

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM
AB IVAX PHARMS **10MG** **N70943 001**
AUG 03, 1987
AB **15MG** **N70944 001**
AUG 03, 1987
AB **30MG** **N70945 001**
AUG 03, 1987
AB PUREPAC PHARM **10MG** **N72251 001**
APR 14, 1988
AB **15MG** **N72252 001**
APR 14, 1988
AB **30MG** **N72253 001**
APR 14, 1988
AB SANDOZ **10MG** **N71813 001**
APR 19, 1988
AB **15MG** **N71756 001**
APR 19, 1988
AB **30MG** **N71814 001**
APR 19, 1988
AB WATSON LABS **10MG** **N72952 001**
SEP 28, 1990
AB **15MG** **N72953 001**
SEP 28, 1990
AB **30MG** **N72954 001**
SEP 28, 1990

SERAX
AB ALPHARMA **10MG** **N15539 002**
AB **15MG** **N15539 004**
AB + **30MG** **N15539 006**

TABLET; ORAL
SERAX
\+ ALPHARMA 15MG N15539 008

OXCARBAZEPINE

SUSPENSION; ORAL
TRILEPTAL
\+ NOVARTIS 300MG/5ML N21285 001
MAY 25, 2001

TABLET; ORAL
TRILEPTAL
NOVARTIS 150MG N21014 001
JAN 14, 2000

FDA data supplied by DrugPatentWatch.com

OXCARBAZEPINE

TABLET; ORAL

TRILEPTAL				
NOVARTIS	300MG	N21014 002		
		JAN 14, 2000		
+	600MG	N21014 003		
		JAN 14, 2000		

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT				
+ GLAXOSMITHKLINE	EQ 1% BASE	N19828 001		
		DEC 30, 1988		

LOTION; TOPICAL

OXISTAT				
+ GLAXOSMITHKLINE	EQ 1% BASE	N20209 001		
		SEP 30, 1992		

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA				
+ PARKE DAVIS	400MG	N87863 001		
		MAY 24, 1983		
+ WARNER CHILCOTT	600MG	N86742 001		

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

OXYTROL				
+ WATSON LABS (UTAH)	3.9MG/24HR	N21351 002		
		FEB 26, 2003		

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

DITROPAN				
AA + ALZA	**5MG/5ML**	**N18211 001**		
OXYBUTYNIN CHLORIDE				
AA MIKART	**5MG/5ML**	**N75039 001**		
		JAN 29, 1999		

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

OXYBUTYNIN CHLORIDE				
AA MORTON GROVE	**5MG/5ML**	**N74868 001**		
		FEB 12, 1997		
AA NOVEX	**5MG/5ML**	**N74997 001**		
		OCT 15, 1997		
AA PHARM ASSOC	**5MG/5ML**	**N75137 001**		
		DEC 18, 1998		
AA SILARX	**5MG/5ML**	**N74520 001**		
		MAR 29, 1996		

TABLET; ORAL

DITROPAN				
AB + ALZA	**5MG**	**N17577 001**		
OXYBUTYNIN CHLORIDE				
AB PLIVA	**5MG**	**N71655 001**		
		NOV 14, 1988		
AB USL PHARMA	**5MG**	**N74625 001**		
		JUL 31, 1996		
AB VINTAGE PHARMS	**5MG**	**N75079 001**		
		OCT 31, 1997		

TABLET, EXTENDED RELEASE; ORAL

DITROPAN XL				
ALZA	5MG	N20897 001		
		DEC 16, 1998		
	10MG	N20897 002		
		DEC 16, 1998		
+	15MG	N20897 003		
		JUN 22, 1999		

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

ROXICODONE				
+ AAIPHARMA	15MG	N21011 001		
		AUG 31, 2000		
	30MG	N21011 002		
		AUG 31, 2000		

TABLET, EXTENDED RELEASE; ORAL

OXYCONTIN				
PURDUE PHARMA LP	10MG	N20553 001		
		DEC 12, 1995		
	20MG	N20553 002		
		DEC 12, 1995		

FDA data supplied by DrugPatentWatch.com

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN
+ PURDUE PHARMA LP 40MG N20553 003 DEC 12, 1995
+ 80MG N20553 004 JAN 06, 1997

OXYCODONE HYDROCHLORIDE; *MULTIPLE*
SEE ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
SEE ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

OXYCODONE TEREPHTHALATE; *MULTIPLE*
SEE ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

OXYMETHOLONE

TABLET; ORAL
ANADROL-50
+ UNIMED PHARMS 50MG N16848 001

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
NUMORPHAN
+ ENDO PHARMS 1MG/ML N11707 002
+ 1.5MG/ML N11707 001

SUPPOSITORY; RECTAL
NUMORPHAN
+ ENDO PHARMS 5MG N11738 004

OXYTETRACYCLINE; *MULTIPLE*
SEE LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TERRAMYCIN
+ PFIZER EQ 250MG BASE N50286 002

OXYTETRACYCLINE HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
TERRAMYCIN W/ POLYMYXIN B SULFATE
+ PFIZER EQ 5MG BASE/GM; 10,000 UNITS/GM N61015 001

OXYTOCIN

INJECTABLE; INJECTION
OXYTOCIN
AP AM PHARM PARTNERS **10 USP UNITS/ML** **N18248 001**
PITOCIN
AP + PARKEDALE **10 USP UNITS/ML** **N18261 001**
SYNTOCINON
AP NOVARTIS **10 USP UNITS/ML** **N18245 001**

PACLITAXEL

INJECTABLE; INJECTION
PACLITAXEL
AP BAKER NORTON **6MG/ML** **N75184 001** JAN 25, 2002
AP BEDFORD **6MG/ML** **N75190 001** JAN 28, 2002
AP IVAX PHARMS **6MG/ML** **N75297 001** JAN 25, 2002
AP MAYNE PHARMA USA **6MG/ML** **N76131 001** MAY 08, 2002
AP **6MG/ML** **N76233 001** AUG 01, 2002
AP MYLAN **6MG/ML** **N75278 001** JAN 25, 2002
TAXOL
AP + BRISTOL MYERS SQUIBB **6MG/ML** **N20262 001** DEC 29, 1992

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS
ALOXI
+ HELSINN HLTHCARE EQ 0.25MG BASE/5ML N21372 001 JUL 25, 2003

FDA data supplied by DrugPatentWatch.com

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

		AREDIA			
AP	+	NOVARTIS	**30MG/VIAL**	**N20036 001**	OCT 31, 1991
AP	+		**90MG/VIAL**	**N20036 004**	MAY 06, 1993
	+		60MG/VIAL	N20036 003	MAY 06, 1993
		PAMIDRONATE DISODIUM			
AP		AESGEN	**30MG/VIAL**	**N75594 001**	MAY 06, 2002
AP			**90MG/VIAL**	**N75594 002**	MAY 06, 2002
AP		AM PHARM PARTNERS	**30MG/VIAL**	**N75773 001**	MAY 06, 2002
AP			**30MG /10ML(3MG/ML)**	**N76207 001**	MAY 17, 2002
AP			**90MG/VIAL**	**N75773 002**	MAY 06, 2002
AP			**90MG /10ML(9MG/ML)**	**N76207 002**	MAY 17, 2002
AP		BEDFORD	**30 MG /10ML(3MG/ML)**	**N21113 001**	MAR 04, 2002
AP			**30MG/VIAL**	**N75290 001**	APR 30, 2001
AP	+		**90MG /10ML(9MG/ML)**	**N21113 002**	MAR 04, 2002
AP			**90MG/VIAL**	**N75290 003**	APR 30, 2001
AP		GENSIA SICOR PHARMS	**30MG /10ML(3MG/ML)**	**N76153 001**	MAR 27, 2002
AP			**90MG /10ML(9MG/ML)**	**N76153 002**	MAR 27, 2002
AP		MAYNE PHARMA USA	**EQ 30MG /10ML(3MG/ML)**	**N75841 001**	JUN 27, 2002
AP			**EQ 60MG /10ML(6MG/ML)**	**N75841 002**	JUN 27, 2002
AP			**EQ 90MG /10ML(9MG/ML)**	**N75841 003**	JUN 27, 2002

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

		PANCURONIUM			
AP		ELKINS SINN	**1MG/ML**	**N72058 001**	MAR 23, 1988

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

		PANCURONIUM			
AP		ELKINS SINN	**2MG/ML**	**N72059 001**	MAR 23, 1988
AP			**2MG/ML**	**N72060 001**	MAR 23, 1988
		PANCURONIUM BROMIDE			
AP		ABBOTT	**1MG/ML**	**N72320 001**	JAN 19, 1989
AP			**2MG/ML**	**N72321 001**	JAN 19, 1989
AP	+	GENSIA SICOR PHARMS	**1MG/ML**	**N72759 001**	JUL 31, 1990
AP	+		**2MG/ML**	**N72760 001**	JUL 31, 1990

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)

		PROTONIX IV		
	+	WYETH PHARMS INC	EQ 40MG BASE/VIAL	N20988 001 MAR 22, 2001

TABLET, DELAYED RELEASE; ORAL

		PROTONIX		
		WYETH PHARMS INC	EQ 20MG BASE	N20987 002 JUN 12, 2001
	+		EQ 40MG BASE	N20987 001 FEB 02, 2000

PARICALCITOL

INJECTABLE; INJECTION

		ZEMPLAR		
	+	ABBOTT	0.005MG/ML	N20819 001 APR 17, 1998

PAROMOMYCIN SULFATE

CAPSULE; ORAL

		HUMATIN		
AA	+	KING PHARMS	**EQ 250MG BASE**	**N62310 001**
		PAROMOMYCIN SULFATE		
AA		CARACO	**EQ 250MG BASE**	**N64171 001** JUN 30, 1997

FDA data supplied by DrugPatentWatch.com

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL
PAXIL
+ GLAXOSMITHKLINE — EQ 10MG BASE/5ML — N20710 001 JUN 25, 1997

TABLET; ORAL
PAROXETINE HCL
AB TORPHARM — **EQ 10MG BASE** — **N75356 001** JUL 30, 2003
AB — **EQ 20MG BASE** — **N75356 002** JUL 30, 2003
AB — **EQ 30MG BASE** — **N75356 003** JUL 30, 2003
AB — **EQ 40MG BASE** — **N75356 004** JUL 30, 2003

PAXIL
AB GLAXOSMITHKLINE — **EQ 10MG BASE** — **N20031 001** DEC 29, 1992
AB — **EQ 20MG BASE** — **N20031 002** DEC 29, 1992
AB — **EQ 30MG BASE** — **N20031 003** DEC 29, 1992
AB + — **EQ 40MG BASE** — **N20031 005** DEC 29, 1992

TABLET, EXTENDED RELEASE; ORAL
PAXIL CR
GLAXOSMITHKLINE — EQ 12.5MG BASE — N20936 001 FEB 16, 1999
EQ 25MG BASE — N20936 002 FEB 16, 1999
+ EQ 37.5MG BASE — N20936 003 DEC 06, 2000

PAROXETINE MESYLATE

TABLET; ORAL
PAROXETINE MESYLATE
SYNTHON PHARMS — EQ 10MG BASE — N21299 001 JUL 03, 2003
EQ 20MG BASE — N21299 002 JUL 03, 2003
EQ 30MG BASE — N21299 003 JUL 03, 2003
+ EQ 40MG BASE — N21299 004 JUL 03, 2003

PEGADEMASE BOVINE

INJECTABLE; INJECTION
ADAGEN
+ ENZON — 250 UNITS/ML — N19818 001 MAR 21, 1990

PEGVISOMANT

INJECTABLE; SUBCUTANEOUS
SOMAVERT
+ PHARMACIA AND UPJOHN — 10MG/VIAL — N21106 001 MAR 25, 2003
+ — 15MG/VIAL — N21106 002 MAR 25, 2003
+ — 20MG/VIAL — N21106 003 MAR 25, 2003

PEMIROLAST POTASSIUM

SOLUTION/DROPS; OPHTHALMIC
ALAMAST
+ SANTEN — 0.1% — N21079 001 SEP 24, 1999

PEMOLINE

TABLET; ORAL
CYLERT
AB + ABBOTT — **18.75MG** — **N16832 001**
AB — **37.5MG** — **N16832 002**
AB + — **75MG** — **N16832 003**

PEMOLINE
AB AMIDE PHARM — **18.75MG** — **N75595 001** FEB 28, 2000
AB — **37.5MG** — **N75595 002** FEB 28, 2000
AB — **75MG** — **N75595 003** FEB 28, 2000
AB COPLEY PHARM — **18.75MG** — **N75030 003** FEB 22, 2000
AB — **37.5MG** — **N75030 001** JAN 29, 1999
AB — **75MG** — **N75030 002** JAN 29, 1999

FDA data supplied by DrugPatentWatch.com

PEMOLINE

TABLET; ORAL

	PEMOLINE			
AB	MALLINCKRODT	18.75MG	N75726 003 MAR 30, 2001	
AB		37.5MG	N75726 002 MAR 30, 2001	
AB		75MG	N75726 001 MAR 30, 2001	
AB	SANDOZ	18.75MG	N75286 001 DEC 27, 1999	
AB		37.5MG	N75286 002 JUN 30, 1999	
AB		75MG	N75286 003 JUN 30, 1999	
AB	VINTAGE PHARMS	18.75MG	N75328 001 APR 19, 2000	
AB		37.5MG	N75328 002 APR 19, 2000	
AB		75MG	N75328 003 APR 19, 2000	
AB	WATSON LABS	18.75MG	N75287 001 JUN 13, 2001	
AB		37.5MG	N75287 002 SEP 18, 2000	
AB		75MG	N75287 003 SEP 18, 2000	

TABLET, CHEWABLE; ORAL

	CYLERT			
AB	+ ABBOTT	37.5MG	N17703 001	
	PEMOLINE			
AB	AMIDE PHARM	37.5MG	N75678 001 JUL 26, 2000	
AB	COPLEY PHARM	37.5MG	N75555 001 FEB 18, 2000	

PENBUTOLOL SULFATE

TABLET; ORAL

	LEVATOL			
+	SCHWARZ PHARMA	20MG	N18976 004 JAN 05, 1989	

PENCICLOVIR SODIUM

CREAM; TOPICAL

	DENAVIR			
+	NOVARTIS	1%		N20629 001 SEP 24, 1996

PENICILLAMINE

CAPSULE; ORAL

	CUPRIMINE			
	MERCK	125MG		N19853 002
+		250MG		N19853 001

TABLET; ORAL

	DEPEN			
+	MEDPOINTE PHARM HLC	250MG		N19854 001

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

	BICILLIN L-A			
BC	+ KING PHARMS	600,000 UNITS/ML		N50141 001
+		300,000 UNITS/ML		N50141 003
	PERMAPEN			
BC	PFIZER	600,000 UNITS/ML		N60014 001

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION

	BICILLIN C-R			
+	KING PHARMS	150,000 UNITS/ML; 150,000 UNITS/ML		N50138 002
+		300,000 UNITS/ML; 300,000 UNITS/ML		N50138 001
	BICILLIN C-R 900/300			
+	KING PHARMS	900,000 UNITS/2ML; 300,000 UNITS/2ML		N50138 003

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

	PENICILLIN G POTASSIUM			
AP	PFIZER	20,000,000 UNITS/VIAL		N60074 003

FDA data supplied by DrugPatentWatch.com

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

	PENICILLIN G POTASSIUM			
AP	SANDOZ	**1,000,000 UNITS/VIAL**	**N65079 001** AUG 30, 2002	
AP		**5,000,000 UNITS/VIAL**	**N65079 002** AUG 30, 2002	
AP		**20,000,000 UNITS/VIAL**	**N65079 003** AUG 30, 2002	
	PENICILLIN G POTASSIUM IN PLASTIC CONTAINER			
	+ BAXTER HLTHCARE	20,000 UNITS/ML	N50638 001 JUN 25, 1990	
	+	40,000 UNITS/ML	N50638 002 JUN 25, 1990	
	+	60,000 UNITS/ML	N50638 003 JUN 25, 1990	
	PFIZERPEN			
AP	+ PFIZER	**1,000,000 UNITS/VIAL**	**N60657 001**	
AP	+	**5,000,000 UNITS/VIAL**	**N60657 002**	
AP	+	**20,000,000 UNITS/VIAL**	**N60657 003**	

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

	WYCILLIN		
	+ KING PHARMS	300,000 UNITS/ML	N60101 002
	+	600,000 UNITS/ML	N60101 001

PENICILLIN G PROCAINE; *MULTIPLE*
SEE PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

PENICILLIN G SODIUM

INJECTABLE; IM-IV

	PENICILLIN G SODIUM		
	+ BIOCHEMIE	5,000,000 UNITS/VIAL	N65068 001 FEB 26, 2001

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

	PENICILLIN V POTASSIUM		
AA	CLONMEL	**EQ 125MG BASE/5ML**	**N62981 001** FEB 10, 1989

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

	PENICILLIN V POTASSIUM		
AA	CLONMEL	**EQ 250MG BASE/5ML**	**N62981 002** FEB 10, 1989
AA	CONSOLIDATED PHARM	**EQ 125MG BASE/5ML**	**N61529 001**
AA		**EQ 250MG BASE/5ML**	**N61529 002**
	PENICILLIN-VK		
AA	TEVA	**EQ 125MG BASE/5ML**	**N60456 001**
AA		**EQ 250MG BASE/5ML**	**N60456 002**
	VEETIDS		
AA	APOTHECON	**EQ 125MG BASE/5ML**	**N61410 001**
AA		**EQ 250MG BASE/5ML**	**N61410 002**

TABLET; ORAL

	PENICILLIN V POTASSIUM		
AB	BIOCHEMIE	**EQ 250MG BASE**	**N64071 001** NOV 30, 1995
AB	+	**EQ 500MG BASE**	**N64071 002** NOV 30, 1995
AB	CLONMEL	**EQ 250MG BASE**	**N62936 001** NOV 25, 1988
AB		**EQ 500MG BASE**	**N62935 001** NOV 23, 1988
	PENICILLIN-VK		
AB	TEVA	**EQ 250MG BASE**	**N60711 002**
AB		**EQ 500MG BASE**	**N60711 003**
	VEETIDS		
AB	APOTHECON	**EQ 250MG BASE**	**N61411 001**
AB		**EQ 500MG BASE**	**N61411 002**

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

	NEBUPENT		
	+ AM PHARM PARTNERS	300MG/VIAL	N19887 001 JUN 15, 1989
		600MG/VIAL	N19887 002 MAR 22, 1996

INJECTABLE; INJECTION

	PENTAM		
AP	+ AM PHARM PARTNERS	**300MG/VIAL**	**N19264 001** OCT 16, 1984
	PENTAMIDINE ISETHIONATE		
AP	ABBOTT	**300MG/VIAL**	**N73479 001** JUN 30, 1992

FDA data supplied by DrugPatentWatch.com

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

	PENTAMIDINE ISETHIONATE			
AP	STERIS	**300MG/VIAL**	**N74303 001**	AUG 17, 1995

PENTAZOCINE HYDROCHLORIDE; *MULTIPLE*

SEE ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

SEE NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

PENTAZOCINE LACTATE

INJECTABLE; INJECTION

	TALWIN		
	+ ABBOTT	EQ 30MG BASE/ML	N16194 001

PENTOBARBITAL SODIUM

CAPSULE; ORAL

	NEMBUTAL SODIUM			
AA	+ OVATION PHARMS	**100MG**	**N83245 001**	
	+	30MG	N84095 001	
	SODIUM PENTOBARBITAL			
AA	VALEANT PHARM INTL	**100MG**	**N83264 001**	

INJECTABLE; INJECTION

	NEMBUTAL SODIUM		
	+ OVATION PHARMS	50MG/ML	N83246 001

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

	ELMIRON		
	+ JOHNSON AND JOHNSON	100MG	N20193 001 SEP 26, 1996

PENTOSTATIN

INJECTABLE; INJECTION

	NIPENT		
	+ SUPERGEN	10MG/VIAL	N20122 001 OCT 11, 1991

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

	PENTOXIFYLLINE		
AB	BIOVAIL	**400MG**	**N75028 001** JUL 20, 1998
AB	CLONMEL HLTHCARE	**400MG**	**N74877 001** JUL 08, 1997
AB	IMPAX LABS	**400MG**	**N75093 001** AUG 10, 1999
AB	MYLAN	**400MG**	**N74425 001** JUL 08, 1997
AB	PLIVA	**400MG**	**N74874 001** MAY 25, 1999
AB	PUREPAC PHARM	**400MG**	**N74878 001** JUL 09, 1997
AB	TEVA	**400MG**	**N75199 001** SEP 03, 1999
AB	TORPHARM	**400MG**	**N75191 001** JUN 09, 1999
AB	WATSON LABS	**400MG**	**N75107 001** SEP 04, 1998
	PENTOXIL		
AB	UPSHER SMITH	**400MG**	**N74962 001** MAR 31, 1999
	TRENTAL		
AB	+ AVENTIS PHARMS	**400MG**	**N18631 001** AUG 30, 1984

PERFLEXANE; *MULTIPLE*

SEE DIMYRISTOYL LECITHIN; PERFLEXANE

PERFLUTREN

INJECTABLE; INTRAVENOUS

	DEFINITY		
	+ BRISTOL MYERS SQUIBB	6.52MG/ML	N21064 001 JUL 31, 2001

PERGOLIDE MESYLATE

TABLET; ORAL

	PERGOLIDE MESYLATE		
AB	IVAX PHARMS	**EQ 0.05MG BASE**	**N76094 001** SEP 04, 2003

FDA data supplied by DrugPatentWatch.com

PERGOLIDE MESYLATE

TABLET; ORAL

	PERGOLIDE MESYLATE			
AB	IVAX PHARMS	**EQ 0.25MG BASE**	**N76094 002**	SEP 04, 2003
AB		**EQ 1MG BASE**	**N76094 003**	SEP 04, 2003
AB	TEVA	**EQ 0.05MG BASE**	**N76061 001**	NOV 27, 2002
AB		**EQ 0.25MG BASE**	**N76061 002**	NOV 27, 2002
AB		**EQ 1MG BASE**	**N76061 003**	NOV 27, 2002
	PERMAX			
AB	+ LILLY	**EQ 0.05MG BASE**	**N19385 001**	DEC 30, 1988
AB		**EQ 0.25MG BASE**	**N19385 002**	DEC 30, 1988
AB		**EQ 1MG BASE**	**N19385 003**	DEC 30, 1988

PERINDOPRIL ERBUMINE

TABLET; ORAL

	ACEON			
	SOLVAY PHARMA	2MG	N20184 001	DEC 30, 1993
		4MG	N20184 002	DEC 30, 1993
	+	8MG	N20184 003	DEC 30, 1993

PERMETHRIN

CREAM; TOPICAL

	ELIMITE			
AB	+ ALLERGAN	**5%**	**N19855 001**	AUG 25, 1989
	PERMETHRIN			
AB	ALPHARMA	**5%**	**N74806 001**	JAN 23, 1998
AB	CLAY PARK	**5%**	**N76369 001**	APR 21, 2003

PERPHENAZINE

CONCENTRATE; ORAL

	PERPHENAZINE			
	+ PHARM ASSOC	16MG/5ML	N40360 001	MAY 25, 2001

INJECTABLE; INJECTION

	TRILAFON			
	+ SCHERING	5MG/ML	N11213 002	

TABLET; ORAL

	PERPHENAZINE			
AB	IVAX PHARMS	**2MG**	**N89707 001**	SEP 10, 1987
AB		**4MG**	**N89708 001**	SEP 10, 1987
AB		**8MG**	**N89456 001**	SEP 10, 1987
AB	+	**16MG**	**N89457 001**	SEP 10, 1987
AB	SANDOZ	**2MG**	**N89683 001**	DEC 08, 1988
AB		**4MG**	**N89684 001**	DEC 08, 1988
AB		**8MG**	**N89685 001**	DEC 08, 1988
AB		**16MG**	**N89686 001**	DEC 08, 1988
AB	VINTAGE PHARMS	**2MG**	**N40226 001**	DEC 31, 1998
AB		**4MG**	**N40226 002**	DEC 31, 1998
AB		**8MG**	**N40226 003**	DEC 31, 1998
AB		**16MG**	**N40226 004**	DEC 31, 1998

PERPHENAZINE; *MULTIPLE*
SEE AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

	PHENDIMETRAZINE TARTRATE			
AA	+ EON	**35MG**	**N85695 001**	

FDA data supplied by DrugPatentWatch.com

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

	X-TROZINE			
AA	SHIRE RICHWOOD	**35MG**	**N87394 001**	
			SEP 22, 1982	

CAPSULE, EXTENDED RELEASE; ORAL

	BONTRIL			
BC	MALLINCKRODT	105MG	N88021 001	
			SEP 21, 1982	
	PHENDIMETRAZINE TARTRATE			
BC	+ EON	105MG	N18074 001	
	X-TROZINE L.A.			
BC	SHIRE RICHWOOD	105MG	N87371 001	
			AUG 24, 1982	

TABLET; ORAL

	BONTRIL PDM			
AA	AMARIN PHARMS	**35MG**	**N85272 001**	
	CAM-METRAZINE			
AA	+ ABC HOLDING	**35MG**	**N83922 001**	
AA		**35MG**	**N85318 001**	
AA		**35MG**	**N85320 001**	
AA		**35MG**	**N85321 001**	
AA		**35MG**	**N85511 001**	
AA	CAMALL	**35MG**	**N85756 001**	
	PHENDIMETRAZINE TARTRATE			
AA	ABC HOLDING	**35MG**	**N85761 001**	
AA		**35MG**	**N85941 001**	
			JUN 27, 1983	
AA	EON	**35MG**	**N85588 001**	
AA		**35MG**	**N85830 001**	
AA	MIKART	**35MG**	**N89452 001**	
			OCT 30, 1991	
	X-TROZINE			
AA	SHIRE RICHWOOD	**35MG**	**N86553 001**	
AA		**35MG**	**N86554 001**	

PHENELZINE SULFATE

TABLET; ORAL

	NARDIL		
	+ PARKE DAVIS	EQ 15MG BASE	N11909 002

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

	DIBENZYLINE		
	+ WELLSPRING PHARM	10MG	N08708 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

	ADIPEX-P		
AA	+ TEVA	**37.5MG**	**N88023 001**
			AUG 02, 1983
	ONA-MAST		
AA	MAST MM	**30MG**	**N86511 001**
AA		**30MG**	**N86516 001**
	PHENTERMINE HCL		
AA	ABC HOLDING	**30MG**	**N85417 001**
AA		**30MG**	**N86732 002**
AA		**30MG**	**N87215 001**
AA		**37.5MG**	**N87915 001**
			DEC 22, 1983
AA		**37.5MG**	**N87918 001**
			DEC 22, 1983
AA		**37.5MG**	**N87930 001**
			OCT 14, 1983
AA		**37.5MG**	**N88610 001**
			JUN 04, 1984
AA		**37.5MG**	**N88611 001**
			JUN 04, 1984
AA		**37.5MG**	**N88625 001**
			AUG 23, 1984
		18.75MG	N88576 001
			MAY 23, 1984
AA	ABLE	**15MG**	**N40497 001**
			MAR 13, 2003
AA		**30MG**	**N40403 001**
			AUG 30, 2001
AA		**30MG**	**N40427 001**
			AUG 30, 2001
AA	AMBI PHARMS	**30MG**	**N40083 001**
			MAR 07, 1997
AA	AMIDE PHARM	**15MG**	**N40460 001**
			JAN 14, 2003
AA		**30MG**	**N40227 001**
			JUN 18, 1997
AA		**30MG**	**N40448 001**
			JAN 22, 2003

FDA data supplied by DrugPatentWatch.com

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

		PHENTERMINE HCL			
AA		AMIDE PHARM	37.5MG	N40228 001	
				JUN 19, 1997	
AA		CAMALL	15MG	N86735 001	
AA			30MG	N87226 001	
AA	+	EON	15MG	N87301 001	
AA	+		30MG	N86945 001	
				JUL 20, 1983	
AA			30MG	N87190 001	
AA			30MG	N87208 001	
AA			30MG	N87223 001	
AA		MUTUAL PHARM	30MG	N40525 001	
				OCT 23, 2003	
AA			37.5MG	N40527 001	
				OCT 23, 2003	
AA		VINTAGE PHARMS	37.5MG	N40377 001	
				JAN 04, 2002	

TABLET; ORAL

		ADIPEX-P			
AA	+	TEVA	37.5MG	N85128 001	
		ONA MAST			
AA		MAST MM	8MG	N86260 001	
		PHENTERMINE HCL			
AA	+	ABC HOLDING	8MG	N83923 001	
AA			8MG	N85319 001	
AA			37.5MG	N87805 001	
				DEC 06, 1982	
AA			37.5MG	N88596 001	
				APR 04, 1984	
AA		ABLE	37.5MG	N40402 001	
				AUG 30, 2001	
AA		AMIDE PHARM	37.5MG	N40190 001	
				MAY 30, 1997	
AA	+	EON	30MG	N88605 001	
				SEP 28, 1987	
AA		MUTUAL PHARM	37.5MG	N40526 001	
				OCT 23, 2003	
AA		PUREPAC PHARM	37.5MG	N40276 001	
				NOV 25, 1998	

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

	IONAMIN			
+	CELLTECH PHARMS	EQ 15MG BASE		N11613 004

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

	IONAMIN			
+	CELLTECH PHARMS	EQ 30MG BASE		N11613 002

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

	PHENTOLAMINE MESYLATE			
AP	BEDFORD	5MG/VIAL		N40235 001
				MAR 11, 1998
	REGITINE			
AP	+ NOVARTIS	5MG/VIAL		N08278 003

PHENYLEPHRINE HYDROCHLORIDE; *MULTIPLE*

SEE CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SEE CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

		PROMETH VC PLAIN			
AA	+	ALPHARMA	5MG/5ML;6.25MG/5ML		N88761 001
					NOV 08, 1984
		PROMETHAZINE VC PLAIN			
AA		MORTON GROVE	5MG/5ML;6.25MG/5ML		N88897 001
					JAN 04, 1985

PHENYTOIN

SUSPENSION; ORAL

		DILANTIN-125			
AB	+	PARKE DAVIS	125MG/5ML		N08762 001
		PHENTYTOIN			
AB		MORTON GROVE	125MG/5ML		N40420 001
					APR 19, 2002
		PHENYTOIN			
AB		ALPHARMA	125MG/5ML		N89892 001
					SEP 25, 1992
AB		VISTAPHARM	125MG/5ML		N40342 001
					JAN 31, 2001

TABLET, CHEWABLE; ORAL

	DILANTIN			
+	PFIZER PHARMS	50MG		N84427 001

FDA data supplied by DrugPatentWatch.com

PHENYTOIN SODIUM

INJECTABLE; INJECTION
PHENYTOIN
+ ELKINS SINN 50MG/ML N84307 001

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL
DILANTIN
AB + PARKE DAVIS **100MG** **N84349 002**
+ 30MG N84349 001
EXTENDED PHENYTOIN SODIUM
AB BARR **100MG** **N40435 001**
JUN 20, 2003
AB MYLAN **100MG** **N40298 001**
DEC 28, 1998
PHENYTEK
+ MYLAN 200MG N40298 002
DEC 06, 2001
+ 300MG N40298 003
DEC 06, 2001

PHENYTOIN SODIUM, PROMPT

CAPSULE; ORAL
PROMPT PHENYTOIN SODIUM
+ IVAX PHARMS 100MG N80259 001

PHOSPHORIC ACID; *MULTIPLE*
SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

PHYTONADIONE

INJECTABLE; INJECTION
AQUAMEPHYTON
BP + MERCK 1MG/0.5ML N12223 002

PHYTONADIONE

INJECTABLE; INJECTION
AQUAMEPHYTON
BP + MERCK 10MG/ML N12223 001
PHYTONADIONE
BP INTL MEDICATION 1MG/0.5ML N83722 001
VITAMIN K1
BP ABBOTT 1MG/0.5ML N87954 001
JUL 25, 1983
BP 10MG/ML N87955 001
JUL 25, 1983

TABLET; ORAL
MEPHYTON
+ MERCK 5MG N10104 003

PHYTONADIONE; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

PILOCARPINE HYDROCHLORIDE

GEL; OPHTHALMIC
PILOPINE HS
+ ALCON 4% N18796 001
OCT 01, 1984

TABLET; ORAL
SALAGEN
MGI PHARMA INC 5MG N20237 001
MAR 22, 1994
+ 7.5MG N20237 002
APR 18, 2003

PIMECROLIMUS

CREAM; TOPICAL
ELIDEL
+ NOVARTIS 1% N21302 001
DEC 13, 2001

FDA data supplied by DrugPatentWatch.com

PIMOZIDE

TABLET; ORAL				
ORAP				
	TEVA	1MG	N17473 003	AUG 27, 1997
+		2MG	N17473 001	JUL 31, 1984

PINDOLOL

TABLET; ORAL				
PINDOLOL				
AB	GENPHARM	**5MG**	**N74013 001**	SEP 24, 1992
AB		**10MG**	**N74018 001**	SEP 24, 1992
AB	IVAX PHARMS	**5MG**	**N73687 001**	FEB 26, 1993
AB		**10MG**	**N73687 002**	FEB 26, 1993
AB	MARTEC	**5MG**	**N74474 001**	OCT 28, 1996
AB		**10MG**	**N74474 002**	OCT 28, 1996
AB	MUTUAL PHARM	**5MG**	**N74063 001**	JAN 27, 1994
AB		**10MG**	**N74063 002**	JAN 27, 1994
AB	MYLAN	**5MG**	**N74019 001**	SEP 03, 1992
AB		**10MG**	**N74019 002**	SEP 03, 1992
AB	SANDOZ	**5MG**	**N73608 001**	MAR 29, 1993
AB		**10MG**	**N73609 001**	MAR 29, 1993
AB	TEVA	**5MG**	**N73661 001**	OCT 31, 1993
AB		**5MG**	**N74123 001**	APR 17, 1997
AB		**10MG**	**N73661 002**	OCT 31, 1993
AB		**10MG**	**N74123 002**	APR 17, 1997
AB	WATSON LABS	**5MG**	**N74437 001**	FEB 27, 1995

PINDOLOL

TABLET; ORAL				
PINDOLOL				
AB	WATSON LABS	**10MG**	**N74437 002**	FEB 27, 1995
VISKEN				
AB	NOVARTIS	**5MG**	**N18285 001**	SEP 03, 1982
AB	+	**10MG**	**N18285 002**	SEP 03, 1982

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL			
ACTOS			
	TAKEDA PHARMS NA	EQ 15MG BASE	N21073 001 JUL 15, 1999
		EQ 30MG BASE	N21073 002 JUL 15, 1999
+		EQ 45MG BASE	N21073 003 JUL 15, 1999

PIPERACILLIN SODIUM

INJECTABLE; INJECTION			
PIPERACILLIN			
+	AM PHARM	EQ 2GM BASE/VIAL	N65114 001 NOV 14, 2003
+		EQ 3GM BASE/VIAL	N65114 002 NOV 14, 2003
+		EQ 4GM BASE/VIAL	N65114 003 NOV 14, 2003

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION			
ZOSYN			
+	WYETH PHARMS INC	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	N50684 001 OCT 22, 1993
+		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	N50684 002 OCT 22, 1993

FDA data supplied by DrugPatentWatch.com

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

ZOSYN

+	WYETH PHARMS INC	EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	N50684 003	OCT 22, 1993
+		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	N50684 004	OCT 22, 1993

ZOSYN IN PLASTIC CONTAINER

+	WYETH PHARMS INC	EQ 40MG BASE/ML; EQ 5MG BASE/ML	N50750 001	FEB 24, 1998
+		EQ 4GM BASE/100ML; EQ 500MG BASE/100ML	N50750 003	FEB 24, 1998
+		EQ 60MG BASE/ML; EQ 7.5MG BASE/ML	N50750 002	FEB 24, 1998

PIPERAZINE CITRATE

SYRUP; ORAL

MULTIFUGE

+	BLULINE	EQ 500MG BASE/5ML	N09452 001

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

+	3M	EQ 0.2MG BASE/INH	N20014 001	NOV 30, 1992

PIROXICAM

CAPSULE; ORAL

FELDENE

AB	PFIZER	10MG	**N18147 002**	APR 06, 1982
AB	+	20MG	**N18147 003**	APR 06, 1982

PIROXICAM

AB	COPLEY PHARM	10MG	**N74103 001**	AUG 28, 1992

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB	COPLEY PHARM	20MG	**N74103 002**	AUG 28, 1992
AB	EGIS	10MG	**N74808 001**	JUL 08, 1997
AB		20MG	**N74808 002**	JUL 08, 1997
AB	GENPHARM	10MG	**N74043 001**	SEP 22, 1992
AB		20MG	**N74043 002**	SEP 22, 1992
AB	IVAX PHARMS	10MG	**N74148 001**	JUN 03, 1996
AB		20MG	**N74148 002**	JUN 03, 1996
AB	MEPHA	10MG	**N74116 001**	JUN 15, 1993
AB		20MG	**N74118 001**	JUN 15, 1993
AB	MUTUAL PHARM	10MG	**N73535 001**	MAR 12, 1993
AB		20MG	**N73536 001**	MAR 12, 1993
AB	MYLAN	10MG	**N74102 001**	JUL 31, 1992
AB		20MG	**N74102 002**	JUL 31, 1992
AB	TEVA	10MG	**N73637 001**	JAN 28, 1994
AB		10MG	**N74131 001**	DEC 11, 1992
AB		20MG	**N73638 001**	JAN 28, 1994
AB		20MG	**N74131 002**	DEC 11, 1992
AB	WATSON LABS	10MG	**N74287 001**	MAY 16, 1996
AB		10MG	**N74460 001**	SEP 29, 1995
AB		20MG	**N74287 002**	MAY 16, 1996
AB		20MG	**N74460 002**	SEP 29, 1995

FDA data supplied by DrugPatentWatch.com

PLICAMYCIN

INJECTABLE; INJECTION
MITHRACIN
+ PFIZER 2.5MG/VIAL N50109 001

PODOFILOX

GEL; TOPICAL
CONDYLOX
+ OCLASSEN 0.5% N20529 001 MAR 13, 1997

SOLUTION; TOPICAL
CONDYLOX
AT + PADDOCK **0.5%** **N19795 001** DEC 13, 1990

PODOFILOX
AT PADDOCK **0.5%** **N75600 001** JAN 29, 2002

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL
MIRALAX
+ BRAINTREE 17GM/SCOOPFUL N20698 001 FEB 18, 1999

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL
NULYTELY
+ BRAINTREE 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT N19797 001 APR 22, 1991

NULYTELY-FLAVORED
+ BRAINTREE 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT N19797 002 NOV 18, 1994

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL
OCL
+ ABBOTT 6GM/100ML;75MG/100ML;168MG/100ML;146MG/100ML;1.29GM/100ML N19284 001 APR 30, 1986

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

FOR SOLUTION; ORAL
COLYTE
AA + SCHWARZ PHARMA **227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT** **N18983 010** JAN 31, 1989
AA + **240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT** **N18983 007** JUN 12, 1987

COLYTE WITH FLAVOR PACKS
AA + SCHWARZ PHARMA **240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT** **N18983 012** OCT 08, 1998

COLYTE-FLAVORED
AA + SCHWARZ PHARMA **227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT** **N18983 008** NOV 14, 1991
AA + **240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT** **N18983 009** NOV 14, 1991

GOLYTELY
AA + BRAINTREE **227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET** **N19011 002** JUN 02, 1992
AA + **236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT** **N19011 001** JUL 13, 1984

FOR SUSPENSION; ORAL
CO-LAV
AA COPLEY PHARM **240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT** **N73428 001** JAN 28, 1992

FDA data supplied by DrugPatentWatch.com

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

FOR SUSPENSION; ORAL

	GO-EVAC			
AA	COPLEY PHARM	**236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT**	**N73433 001** APR 28, 1992	

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

	POLYMYXIN B SULFATE			
AP	+ BEDFORD	**EQ 500,000 U BASE/VIAL**	**N60716 001**	
AP	PHARMA TEK	**EQ 500,000 U BASE/VIAL**	**N63000 001** SEP 30, 1994	

POWDER; FOR RX COMPOUNDING

	POLY-RX		
+	PHARMA TEK	100,000,000 UNITS/BOT	N61578 001

POLYMYXIN B SULFATE; *MULTIPLE*

SEE BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SEE BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SEE BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SEE BACITRACIN ZINC; POLYMYXIN B SULFATE

SEE DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SEE GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SEE HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SEE HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SEE NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SEE NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SEE OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

POLYMYXIN B SULFATE; TRIMETHOPRIM

SOLUTION/DROPS; OPHTHALMIC

	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE			
AT	TAYLOR PHARMA	**10,000 UNITS/ML; EQ 1MG BASE/ML**	**N65006 001** DEC 17, 1998	

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

	POLYTRIM			
AT	+ ALLERGAN	**10,000 UNITS/ML; EQ 1MG BASE/ML**	**N50567 001** OCT 20, 1988	
	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE			
AT	BAUSCH AND LOMB	**10,000 UNITS/ML; EQ 1MG BASE/ML**	**N64120 001** FEB 14, 1997	
AT	FALCON PHARMS	**10,000 UNITS/ML; EQ 1MG BASE/ML**	**N64211 001** APR 13, 1998	

POLYTHIAZIDE

TABLET; ORAL

	RENESE		
	PFIZER	1MG	N12845 001
		2MG	N12845 002
+		4MG	N12845 003

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

	MINIZIDE		
	PFIZER	0.5MG;EQ 1MG BASE	N17986 001
		0.5MG;EQ 2MG BASE	N17986 002
+		0.5MG;EQ 5MG BASE	N17986 003

POLYTHIAZIDE; RESERPINE

TABLET; ORAL

	RENESE-R		
+	PFIZER	2MG;0.25MG	N13636 001

PORACTANT ALFA

SUSPENSION; INTRATRACHEAL

	CUROSURF		
+	DEY	80MG/ML	N20744 001 NOV 18, 1999

FDA data supplied by DrugPatentWatch.com

PORFIMER SODIUM

INJECTABLE; INJECTION
PHOTOFRIN
+ AXCAN SCANDIPHARM 75MG/VIAL N20451 001 DEC 27, 1995

POTASSIUM ACETATE

INJECTABLE; INJECTION
POTASSIUM ACETATE IN PLASTIC CONTAINER
+ ABBOTT 2MEQ/ML N18896 001 JUL 20, 1984

POTASSIUM ACETATE; *MULTIPLE*
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE
SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

POTASSIUM AMINOSALICYLATE

CAPSULE; ORAL
PASKALIUM
+ GLENWOOD 500MG N09395 004

TABLET; ORAL
PASKALIUM
+ GLENWOOD 1GM N09395 003

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
MICRO-K
AB KV PHARM **8MEQ** **N18238 001**
MICRO-K 10
AB + KV PHARM **10MEQ** **N18238 002** MAY 14, 1984

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE
AB KV PHARM **10MEQ** **N70980 001** FEB 17, 1987
AB TEVA **8MEQ** **N73531 001** APR 26, 1996
AB **10MEQ** **N73532 001** APR 26, 1996

INJECTABLE; INJECTION
POTASSIUM CHLORIDE
AP + ABBOTT **2MEQ/ML** **N80205 001**
AP **2MEQ/ML** **N83345 002**
+ 1.5MEQ/ML N83345 001
AP AM PHARM PARTNERS **2MEQ/ML** **N80225 001**
+ 3MEQ/ML N80225 003
AP B BRAUN **2MEQ/ML** **N85870 001**
AP BAXTER HLTHCARE **2MEQ/ML** **N85499 001**
AP INTL MEDICATION **2MEQ/ML** **N83163 001**
AP LUITPOLD **2MEQ/ML** **N87584 001**
AP **2MEQ/ML** **N87585 001**

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 746MG/100ML N19904 005 DEC 17, 1990
+ 14.9MG/ML N19904 001 DEC 26, 1989

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER
AP + ABBOTT **29.8MG/ML** **N20161 006** AUG 11, 1998
AP + BAXTER HLTHCARE **29.8MG/ML** **N19904 002** DEC 26, 1989
+ 1.49GM/100ML N19904 006 DEC 17, 1990

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER
AP + ABBOTT **2.24GM/100ML** **N20161 003** AUG 11, 1998
AP + BAXTER HLTHCARE **2.24GM/100ML** **N19904 003** DEC 26, 1989

POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER
AP + ABBOTT **2.98GM/100ML** **N20161 004** AUG 11, 1998
AP + BAXTER HLTHCARE **2.98GM/100ML** **N19904 004** DEC 26, 1989

POTASSIUM CHLORIDE IN PLASTIC CONTAINER
AP AM PHARM PARTNERS **2MEQ/ML** **N88901 001** JAN 25, 1985

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

	POTASSIUM CHLORIDE IN PLASTIC CONTAINER			
AP	AM PHARM PARTNERS	**2MEQ/ML**	**N88908 001**	JAN 25, 1985

TABLET, EXTENDED RELEASE; ORAL

	K+10			
BC	ALRA	10MEQ	N70999 001	OCT 22, 1987
	K+8			
AB	ALRA	**8MEQ**	**N70998 001**	JAN 25, 1993
	K-DUR 10			
AB	KEY PHARMS	**10MEQ**	**N19439 002**	JUN 13, 1986
	K-DUR 20			
AB	+ KEY PHARMS	**20MEQ**	**N19439 001**	JUN 13, 1986
	K-TAB			
BC	ABBOTT	10MEQ	N18279 001	
	KLOR-CON			
AB	UPSHER SMITH	**8MEQ**	**N19123 001**	APR 17, 1986
BC		10MEQ	N19123 002	APR 17, 1986
	KLOR-CON M10			
AB	UPSHER SMITH	**10MEQ**	**N74726 002**	AUG 09, 2000
	KLOR-CON M15			
	UPSHER SMITH	15MEQ	N74726 003	JUN 06, 2003
	KLOR-CON M20			
AB	UPSHER SMITH	**20MEQ**	**N74726 001**	NOV 20, 1998
	KLOTRIX			
BC	APOTHECON	10MEQ	N17850 001	
	POTASSIUM CHLORIDE			
BC	ABBOTT	8MEQ	N18279 002	AUG 01, 1988
AB	ANDRX PHARMS	**10MEQ**	**N75604 001**	APR 10, 2002
AB		**20MEQ**	**N75604 002**	APR 10, 2002
AB	COPLEY PHARM	**8MEQ**	**N70618 001**	SEP 09, 1987
AB	KV PHARM	**20MEQ**	**N76044 001**	APR 05, 2002

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	SLOW-K			
AB	+ NOVARTIS	**8MEQ**	**N17476 002**	

POTASSIUM CHLORIDE; *MULTIPLE*

SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE; *MULTIPLE*

SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SEE DEXTROSE; POTASSIUM CHLORIDE

SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

SEE DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SEE MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	**150MG/100ML;900MG/100ML**	**N19708 004**	SEP 29, 1989

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	**149MG/100ML;900MG/100ML**	**N19686 001**	OCT 17, 1988

POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	**298MG/100ML;900MG/100ML**	**N19686 002**	OCT 17, 1988

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**150MG/100ML;900MG/100ML**	**N17648 001**	

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.224%

	BAXTER HLTHCARE	224MG/100ML;900MG/100ML	N17648 003	

SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	**300MG/100ML;900MG/100ML**	**N17648 002**	

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE

	MISSION PHARMA	5MEQ	N19071 001	AUG 30, 1985
+		10MEQ	N19071 002	AUG 31, 1992

POTASSIUM LACTATE; *MULTIPLE*

SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

POTASSIUM PERCHLORATE

CAPSULE; ORAL

PERCHLORACAP

+	MALLINCKRODT	200MG	N17551 001	

POTASSIUM PHOSPHATE, DIBASIC; *MULTIPLE*

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

POTASSIUM PHOSPHATE, DIBASIC; *MULTIPLE*
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

POTASSIUM PHOSPHATE, MONOBASIC; *MULTIPLE*
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

POVIDONE-IODINE

SOLUTION/DROPS; OPHTHALMIC
BETADINE
\+ ALCON 5% N18634 001 DEC 17, 1986

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION
PRALIDOXIME CHLORIDE
\+ MERIDIAN MEDCL TECHN 300MG/ML N18986 001 APR 26, 1983

PROTOPAM CHLORIDE
\+ BAXTER HLTHCARE CORP 1GM/VIAL N14134 001

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL
MIRAPEX
BOEHRINGER INGELHEIM
0.125MG N20667 001 JUL 01, 1997
\+ 0.25MG N20667 002 JUL 01, 1997
0.5MG N20667 006 FEB 12, 1998
1MG N20667 003 JUL 01, 1997
1.5MG N20667 005 JUL 01, 1997

PRAMOXINE HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

PRAVASTATIN SODIUM

TABLET; ORAL
PRAVACHOL
BRISTOL MYERS SQUIBB
10MG N19898 002 OCT 31, 1991
20MG N19898 003 OCT 31, 1991
40MG N19898 004 MAR 22, 1993
\+ 80MG N19898 008 DEC 18, 2001

PRAVASTATIN SODIUM; *MULTIPLE*
SEE ASPIRIN; PRAVASTATIN SODIUM

PRAZIQUANTEL

TABLET; ORAL
BILTRICIDE
\+ BAYER PHARMS 600MG N18714 001 DEC 29, 1982

FDA data supplied by DrugPatentWatch.com

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

	MINIPRESS			
AB	PFIZER	EQ 1MG BASE	N17442 002	
AB +		EQ 2MG BASE	N17442 003	
AB		EQ 5MG BASE	N17442 001	
	PRAZOSIN HCL			
AB	CLONMEL HLTHCARE	EQ 1MG BASE	N72705 001	MAY 16, 1989
AB		EQ 5MG BASE	N72707 001	MAY 16, 1989
AB	IVAX PHARMS	EQ 1MG BASE	N71994 001	SEP 12, 1988
AB		EQ 2MG BASE	N71995 001	SEP 12, 1988
AB		EQ 5MG BASE	N71745 001	SEP 12, 1988
AB	MYLAN	EQ 1MG BASE	N72573 001	MAY 16, 1989
AB		EQ 2MG BASE	N72574 001	MAY 16, 1989
AB		EQ 5MG BASE	N72575 001	MAY 16, 1989
AB	SANDOZ	EQ 1MG BASE	N72576 001	MAY 16, 1989
AB		EQ 2MG BASE	N72577 001	MAY 16, 1989
AB		EQ 5MG BASE	N72578 001	MAY 16, 1989
AB	WATSON LABS	EQ 1MG BASE	N72352 001	MAY 16, 1989
AB		EQ 2MG BASE	N72333 001	MAY 16, 1989
AB		EQ 5MG BASE	N72609 001	MAY 16, 1989

TABLET, EXTENDED RELEASE; ORAL

	MINIPRESS XL			
+	PFIZER	2.5MG	N19775 001	JAN 29, 1992
+		5MG	N19775 002	JAN 29, 1992

PRAZOSIN HYDROCHLORIDE; *MULTIPLE*
SEE POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

PREDNICARBATE

CREAM; TOPICAL

	DERMATOP E EMOLLIENT			
+	DERMIK LABS	0.1%	N20279 001	OCT 29, 1993

OINTMENT; TOPICAL

	DERMATOP			
+	DERMIK LABS	0.1%	N19568 001	SEP 23, 1991

PREDNISOLONE

SYRUP; ORAL

	PREDNISOLONE			
AA	AXIOM PHARM	15MG/5ML	N40287 001	MAY 28, 1999
AA	COPLEY PHARM	15MG/5ML	N40322 001	JAN 19, 2000
AA	HI TECH PHARMA	15MG/5ML	N40401 001	FEB 27, 2003
AA +	KV PHARM	15MG/5ML	N40364 001	APR 10, 2002
+		5MG/5ML	N40423 001	OCT 22, 2001
AA	MORTON GROVE	15MG/5ML	N40313 001	SEP 10, 2003
AA	PHARM ASSOC	15MG/5ML	N40399 001	MAR 05, 2003
AA	UDL	15MG/5ML	N40323 001	MAY 13, 1999
AA	WE PHARMS	15MG/5ML	N40192 001	MAY 28, 1998
	PRELONE			
AA	TEVA	15MG/5ML	N89081 001	FEB 04, 1986

TABLET; ORAL

	PREDNISOLONE		
BX	EVERYLIFE	2.5MG	N84439 002
BX		5MG	N84439 003
BX	LANNETT	5MG	N80531 002
BX	SPERTI	2.5MG	N80358 002
BX		5MG	N80358 003
		1MG	N80358 001
BX +	WATSON LABS	5MG	N80354 001

FDA data supplied by DrugPatentWatch.com

PREDNISOLONE ACETATE

INJECTABLE; INJECTION
PREDNISOLONE ACETATE

+	STERIS	25MG/ML	N83398 001	
+		50MG/ML	N83764 001	

SUSPENSION/DROPS; OPHTHALMIC
ECONOPRED PLUS

AB	FALCON PHARMS	**1%**	**N17469 001**	

PRED FORTE

AB	+ ALLERGAN	**1%**	**N17011 001**	

PRED MILD

+	ALLERGAN	0.12%	N17100 001	

PREDNISOLONE ACETATE; *MULTIPLE*
SEE GENTAMICIN SULFATE; PREDNISOLONE ACETATE
SEE NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC
BLEPHAMIDE S.O.P.

+	ALLERGAN	0.2%;10%	N87748 001 DEC 03, 1986	

SUSPENSION; OPHTHALMIC
BLEPHAMIDE

+	ALLERGAN	0.2%;10%	N12813 002	

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL
ORAPRED

AA	+ ASCENT PEDS	**EQ 15MG BASE/5ML**	**N75117 001** DEC 14, 2000	

PEDIAPRED

AA	+ CELLTECH PHARMS	**EQ 5MG BASE/5ML**	**N19157 001** MAY 28, 1986	

PREDNISOLONE SODIUM PHOSPHATE

AA	HI TECH PHARMA	**EQ 5MG BASE/5ML**	**N75183 001** MAR 26, 2003	
AA	MORTON GROVE	**EQ 5MG BASE/5ML**	**N75099 001** JUN 28, 2002	

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL
PREDNISOLONE SODIUM PHOSPHATE

AA	PHARM ASSOC	**EQ 5MG BASE/5ML**	**N76123 001** DEC 23, 2002	
AA	WE PHARMS	**EQ 5MG BASE/5ML**	**N75181 001** DEC 23, 2002	
AA		**EQ 15MG BASE/5ML**	**N75250 001** JUL 12, 2002	

SOLUTION/DROPS; OPHTHALMIC
INFLAMASE FORTE

AT	+ NOVARTIS	**EQ 0.9% PHOSPHATE**	**N80751 002**	

INFLAMASE MILD

AT	+ NOVARTIS	**EQ 0.11% PHOSPHATE**	**N80751 001**	

PREDNISOLONE SODIUM PHOSPHATE

AT	BAUSCH AND LOMB	**EQ 0.11% PHOSPHATE**	**N40065 001** JUL 29, 1994	
AT		**EQ 0.9% PHOSPHATE**	**N40070 001** JUL 29, 1994	

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	ALCON	**EQ 0.23% PHOSPHATE;10%**	**N73630 001** MAY 27, 1993	
AT	BAUSCH AND LOMB	**EQ 0.23% PHOSPHATE;10%**	**N74449 001** DEC 29, 1995	

VASOCIDIN

AT	+ NOVARTIS	**EQ 0.23% PHOSPHATE;10%**	**N18988 001** AUG 26, 1988	

PREDNISONE

SOLUTION; ORAL
PREDNISONE

+	ROXANE	5MG/5ML	N88703 001 NOV 08, 1984	

PREDNISONE INTENSOL

+	ROXANE	5MG/ML	N88810 001 FEB 20, 1985	

TABLET; ORAL
DELTASONE

AB	+ PHARMACIA AND UPJOHN	**2.5MG**	**N09986 005**	

FDA data supplied by DrugPatentWatch.com

PREDNISONE

TABLET; ORAL

DELTASONE

AB	+ PHARMACIA AND UPJOHN	5MG	N09986 002	
AB	+	10MG	N09986 006	
AB	+	20MG	N09986 007	
AB	+	50MG	N09986 008	

PREDNISONE

AB	MUTUAL PHARM	5MG	N89245 001 DEC 04, 1985
AB		10MG	N89246 001 DEC 04, 1985
AB		20MG	N89247 001 DEC 04, 1985
AB	PVT FORM	5MG	N80209 001
AB	+ ROXANE	1MG	N87800 001 APR 22, 1982
AB		2.5MG	N87801 001 APR 22, 1982
AB		5MG	N80352 001
AB		10MG	N84122 001
AB		20MG	N87342 001
AB		50MG	N84283 001
AB	SANDOZ	10MG	N89983 001 JAN 12, 1989
AB		20MG	N85813 001
AB		50MG	N89984 001 JAN 12, 1989
AB	TRIGEN	5MG	N40362 002 AUG 29, 2001
AB		10MG	N40362 001 AUG 29, 2001
AB	VINTAGE PHARMS	5MG	N40256 001 JUL 12, 2002
AB		10MG	N40256 002 JUL 12, 2002
AB		20MG	N40392 001 FEB 12, 2003
AB	WATSON LABS	5MG	N80356 001
AB		10MG	N85162 001
AB		10MG	N87773 001 JUL 13, 1982
AB		20MG	N85161 001
AB		20MG	N86813 001
AB		50MG	N87772 001 JUL 13, 1982
AB	WEST WARD	5MG	N80292 001

PREDNISONE

TABLET; ORAL

PREDNISONE

AB	WEST WARD	10MG	N88832 001 DEC 04, 1985
AB		20MG	N83677 001

PRILOCAINE; *MULTIPLE*

SEE LIDOCAINE; PRILOCAINE

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST PLAIN

+	DENTSPLY PHARM	4%	N21382 001

PRILOCAINE HYDROCHLORIDE; *MULTIPLE*

SEE EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

PRIMAQUINE PHOSPHATE

TABLET; ORAL

PRIMAQUINE

+	SANOFI SYNTHELABO	EQ 15MG BASE	N08316 001

PRIMIDONE

TABLET; ORAL

MYSOLINE

AB	+ XCEL PHARMS	50MG	N09170 003
AB		250MG	N09170 002

PRIMIDONE

AB	LANNETT	50MG	N84903 002 MAY 24, 2001
AB		250MG	N84903 001
AB	WATSON LABS	250MG	N83551 001

PROBENECID

TABLET; ORAL

PROBALAN

AB	LANNETT	500MG	N80966 001

FDA data supplied by DrugPatentWatch.com

PROBENECID

TABLET; ORAL
PROBENECID

AB		IVAX PHARMS	500MG	N83740 001
				MAY 09, 1984
AB	+	MYLAN	500MG	N84211 002
AB		WATSON LABS	500MG	N84442 004
				MAR 29, 1983

PROBENECID; *MULTIPLE*
SEE COLCHICINE; PROBENECID

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL
PROCAINAMIDE HCL

AB		IVAX PHARMS	250MG	N84604 001
AB			375MG	N84595 001
AB			500MG	N84606 001
AB		LANNETT	250MG	N83693 001
AB		SANDOZ	250MG	N89219 001
				JUL 01, 1986
AB			375MG	N89220 001
				JUL 01, 1986
AB			500MG	N89221 001
				JUL 01, 1986
AB		WATSON LABS	250MG	N83287 001
AB			375MG	N84403 001
AB			500MG	N84280 001

PRONESTYL

AB		*APOTHECON*	250MG	N07335 001
AB			375MG	N07335 004
AB	+		500MG	N07335 003

INJECTABLE; INJECTION
PROCAINAMIDE HCL

AP		ABBOTT	100MG/ML	N89069 001
				FEB 12, 1986
AP			500MG/ML	N89070 001
				FEB 12, 1986
AP			500MG/ML	N89537 001
				AUG 25, 1987
AP		INTL MEDICATION	100MG/ML	N88636 001
				JUL 31, 1984
AP			500MG/ML	N88637 001
				JUL 31, 1984

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
PRONESTYL

AP	+	APOTHECON	100MG/ML	N07335 002
AP	+		500MG/ML	N07335 005

TABLET; ORAL
PRONESTYL

	APOTHECON	250MG	N17371 001
		375MG	N17371 002
+		500MG	N17371 003

TABLET, EXTENDED RELEASE; ORAL
PROCAINAMIDE HCL

AB		COPLEY PHARM	1GM	N40111 001
				DEC 13, 1996
AB			500MG	N88974 001
				JUL 22, 1985
AB			750MG	N89438 001
				MAR 23, 1987
AB		PLIVA	500MG	N88959 001
				DEC 02, 1985
AB		SANDOZ	250MG	N89369 001
				AUG 14, 1987
AB			500MG	N89370 001
				JAN 09, 1987
AB			750MG	N89371 001
				AUG 14, 1987
AB		WATSON LABS	250MG	N89026 001
				OCT 22, 1985
AB			500MG	N89027 001
				OCT 22, 1985
AB			750MG	N89042 001
				OCT 22, 1985

PROCANBID

+	KING PHARMS	500MG	N20545 001
			JAN 31, 1996
+		1GM	N20545 002
			JAN 31, 1996

PRONESTYL-SR

BC	*APOTHECON*	500MG	N87361 001

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
NOVOCAIN

AP	+	ABBOTT	1%	N85362 003

FDA data supplied by DrugPatentWatch.com

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	NOVOCAIN			
AP	+ ABBOTT	2%	N85362 004	
	+	10%	N86797 001	
	PROCAINE HCL			
AP	ABBOTT	1%	N80416 001	
AP		2%	N80416 002	
AP	STERIS	1%	N80658 001	

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL

	MATULANE		
	+ SIGMA TAU	EQ 50MG BASE	N16785 001

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

	COMPAZINE			
AB	GLAXOSMITHKLINE	2.5MG	N11127 003	
AB		5MG	N11127 001	
AB	+	25MG	N11127 002	
	COMPRO			
AB	PADDOCK	25MG	N40246 001	JUN 28, 2000
	PROCHLORPERAZINE			
AB	ABLE	2.5MG	N40407 001	JUL 11, 2001
AB		5MG	N40407 002	JUL 11, 2001
AB		25MG	N40407 003	JUL 11, 2001
AB	G AND W LABS	25MG	N40058 001	NOV 24, 1993

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

	COMPAZINE			
AP	+ GLAXOSMITHKLINE	EQ 5MG BASE/ML	N10742 002	
	PROCHLORPERAZINE			
AP	BAXTER HLTHCARE	EQ 5MG BASE/ML	N87759 001	OCT 01, 1982

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

	PROCHLORPERAZINE EDISYLATE			
AP	ABBOTT	EQ 5MG BASE/ML	N89703 001	APR 07, 1988
AP	ELKINS SINN	EQ 5MG BASE/ML	N89903 001	AUG 29, 1989
AP	GENSIA SICOR PHARMS	EQ 5MG BASE/ML	N40505 001	MAY 30, 2003
AP	STERIS	EQ 5MG BASE/ML	N89530 001	JUL 08, 1987

SYRUP; ORAL

	COMPAZINE		
	GLAXOSMITHKLINE	EQ 5MG BASE/5ML	N11188 001

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

	COMPAZINE			
	+ GLAXOSMITHKLINE	EQ 10MG BASE	N21019 001	OCT 06, 1999
	+	EQ 15MG BASE	N21019 002	OCT 06, 1999

TABLET; ORAL

	COMPAZINE			
AB	GLAXOSMITHKLINE	EQ 5MG BASE	N10571 001	
AB		EQ 10MG BASE	N10571 002	
AB	+	EQ 25MG BASE	N10571 003	
	PROCHLORPERAZINE MALEATE			
AB	COPLEY PHARM	EQ 5MG BASE	N40120 001	JUL 11, 1996
AB		EQ 10MG BASE	N40120 002	JUL 11, 1996
AB	DURAMED PHARMS BARR	EQ 5MG BASE	N40207 001	MAY 01, 1997
AB		EQ 10MG BASE	N40207 002	MAY 01, 1997
AB	IVAX PHARMS	EQ 5MG BASE	N40162 001	JAN 20, 1998
AB		EQ 10MG BASE	N40162 002	JAN 20, 1998
AB	MYLAN	EQ 5MG BASE	N40185 002	OCT 28, 1996
AB		EQ 10MG BASE	N40185 001	OCT 28, 1996

FDA data supplied by DrugPatentWatch.com

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

AB	SANDOZ	EQ 5MG BASE	N40101 001	JUL 19, 1996
AB		EQ 10MG BASE	N40101 002	JUL 19, 1996
AB		EQ 25MG BASE	N40101 003	JUL 19, 1996
AB	TRIGEN	EQ 5MG BASE	N40268 001	FEB 27, 1998
AB		EQ 10MG BASE	N40268 002	FEB 27, 1998

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL

KEMADRIN

+	MONARCH PHARMS	5MG	N09818 003

PROGESTERONE

CAPSULE; ORAL

PROMETRIUM

	UNIMED PHARMS	100MG	N19781 001 MAY 14, 1998
+		200MG	N19781 002 OCT 15, 1999

GEL; VAGINAL

CRINONE

	COLUMBIA RES LABS	4%	N20701 001 JUL 31, 1997
+		8%	N20701 002 JUL 31, 1997

INJECTABLE; INJECTION

PROGESTERONE

AO	AM PHARM PARTNERS	50MG/ML	N75906 001	APR 25, 2001
AO	+ SCHEIN	50MG/ML	N17362 002	

PROGUANIL HYDROCHLORIDE; *MULTIPLE*
SEE ATOVAQUONE; PROGUANIL HYDROCHLORIDE

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HCL

AP	ABBOTT	25MG/ML	N40372 001	JUN 08, 2000
AP		50MG/ML	N40372 002	JUN 08, 2000
AP		50MG/ML	N83838 002	
AP	BAXTER HLTHCARE	25MG/ML	N83312 001	
AP		50MG/ML	N83312 002	
AP	+ GENSIA SICOR PHARMS	25MG/ML	N40454 001	AUG 22, 2002
AP	+	50MG/ML	N40454 002	AUG 22, 2002
AP	PHARMAFORCE	25MG/ML	N40471 001	NOV 21, 2002
AP		25MG/ML	N40515 001	MAR 19, 2003
AP	STERIS	25MG/ML	N84591 001	
AP		50MG/ML	N80629 002	

SUPPOSITORY; RECTAL

PHENERGAN

AB	WYETH PHARMS INC	12.5MG	N10926 002	
AB	+	25MG	N10926 001	
AB	+	50MG	N11689 001	

PROMETHACON

BR	POLYMEDICA	25MG	N84901 001	

PROMETHAZINE HCL

AB	ABLE	12.5MG	N40504 001	APR 11, 2003
AB		25MG	N40504 002	APR 11, 2003
AB		50MG	N40449 001	FEB 27, 2003
AB	CLAY PARK	12.5MG	N40500 001	JUN 30, 2003
AB		25MG	N40500 002	JUN 30, 2003
AB	G AND W LABS	12.5MG	N40428 002	MAR 31, 2003
AB		25MG	N40428 001	FEB 05, 2002
AB	PADDOCK	12.5MG	N40479 001	JUN 24, 2003
AB		25MG	N40479 002	JUN 24, 2003

FDA data supplied by DrugPatentWatch.com

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL

	PROMETHEGAN			
BR	G AND W LABS	50MG	N87165 001	AUG 14, 1987

SYRUP; ORAL

	PROMETH PLAIN			
AA	+ ALPHARMA	**6.25MG/5ML**	**N85953 001**	
	PROMETHAZINE HCL			
AA	HI TECH PHARMA	**6.25MG**	**N40026 001**	SEP 25, 1998
	PROMETHAZINE PLAIN			
AA	MORTON GROVE	**6.25MG/5ML**	**N87953 001**	NOV 15, 1982

TABLET; ORAL

	PHENERGAN			
BP	WYETH PHARMS INC	25MG	N07935 003	
BP	+	50MG	N07935 004	
		12.5MG	N07935 002	
	PROMETHAZINE HCL			
BP	SANDOZ	25MG	N84234 001	
BP		50MG	N84176 001	
BP	WATSON LABS	25MG	N83426 001	
BP		50MG	N83711 001	

PROMETHAZINE HYDROCHLORIDE; *MULTIPLE*
SEE CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
SEE CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE
SEE DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE
SEE PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	RYTHMOL SR			
	RELIANT PHARMS	225MG	N21416 001	SEP 04, 2003
		325MG	N21416 002	SEP 04, 2003
	+	425MG	N21416 003	SEP 04, 2003

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

	PROPAFENONE HCL			
AB	KV PHARM	**150MG**	**N76193 001**	FEB 07, 2002
AB		**225MG**	**N76193 002**	FEB 07, 2002
AB		**300MG**	**N76193 003**	FEB 07, 2002
AB	MUTUAL PHARM	**150MG**	**N75998 001**	NOV 29, 2001
AB		**225MG**	**N75998 002**	NOV 29, 2001
AB		**300MG**	**N75998 003**	NOV 29, 2001
AB	VINTAGE PHARMS	**150MG**	**N75938 001**	OCT 17, 2002
AB		**225MG**	**N75938 002**	OCT 17, 2002
AB		**300MG**	**N75938 003**	OCT 17, 2002
AB	WATSON LABS	**150MG**	**N75203 001**	OCT 24, 2000
AB		**225MG**	**N75203 002**	OCT 24, 2000
	RYTHMOL			
AB	RELIANT PHARMS	**150MG**	**N19151 001**	NOV 27, 1989
AB		**225MG**	**N19151 003**	NOV 20, 1992
AB	+	**300MG**	**N19151 002**	NOV 27, 1989

PROPANTHELINE BROMIDE

TABLET; ORAL

	PRO-BANTHINE			
BP	+ SHIRE LABS	7.5MG	N08732 003	
BP	+	15MG	N08732 002	
	PROPANTHELINE BROMIDE			
BP	ROXANE	7.5MG	N80927 001	
BP		15MG	N80927 002	

FDA data supplied by DrugPatentWatch.com

PROPARACAINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

	PROPARACAINE HCL			
AT	TAYLOR PHARMA	0.5%	**N40277 001**	
			MAR 16, 2000	

SOLUTION/DROPS; OPHTHALMIC

	ALCAINE			
AT	ALCON	0.5%	**N80027 001**	
	OPHTHAINE			
AT	+ APOTHECON	0.5%	**N08883 001**	
	OPHTHETIC			
AT	+ ALLERGAN	0.5%	**N12583 001**	
	PARACAINE			
AT	OPTOPICS	0.5%	**N87681 001**	
			AUG 05, 1982	
	PROPARACAINE HCL			
AT	BAUSCH AND LOMB	0.5%	**N40074 001**	
			SEP 29, 1995	

PROPOFOL

INJECTABLE; INJECTION

	DIPRIVAN			
AB	+ ASTRAZENECA	10MG/ML	**N19627 002**	
			JUN 11, 1996	
	PROPOFOL			
AB	GENSIA SICOR PHARMS	10MG/ML	**N75102 001**	
			JAN 04, 1999	
AB		10MG/ML	**N75392 001**	
			SEP 19, 2000	

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

	DARVON			
AA	+ AAIPHARMA LLC	65MG	**N10997 003**	
	+	32MG	N10997 001	
	KESSO-GESIC			
AA	MK LABS	65MG	**N83544 001**	
	PROPOXYPHENE HCL			
AA	IVAX PHARMS	65MG	**N80269 001**	
AA	TEVA	65MG	**N88615 001**	
			OCT 22, 1984	
AA	WEST WARD	65MG	**N83501 001**	

PROPOXYPHENE HYDROCHLORIDE; *MULTIPLE*
SEE ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE
SEE ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVON-N			
+ AAIPHARMA LLC	100MG		N16862 002

PROPOXYPHENE NAPSYLATE; *MULTIPLE*
SEE ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERAL LA			
BX WYETH PHARMS INC	80MG		N18553 002
			APR 19, 1983
BX	120MG		N18553 003
			APR 19, 1983
	60MG		N18553 004
			MAR 18, 1987
+	160MG		N18553 001
			APR 19, 1983
INNOPRAN XL			
BX RELIANT PHARMS	80MG		N21438 001
			MAR 12, 2003
BX	120MG		N21438 002
			MAR 12, 2003

CONCENTRATE; ORAL

PROPRANOLOL HCL INTENSOL			
+ ROXANE	80MG/ML		N71388 001
			MAY 15, 1987

INJECTABLE; INJECTION

	PROPRANOLOL HCL			
AP	+ BAXTER HLTHCARE CORP	1MG/ML		**N16419 001**
AP	BEDFORD	1MG/ML		**N75792 001**
				AUG 29, 2000
AP	SABEX 2002	1MG/ML		**N76400 001**
				FEB 26, 2003

SOLUTION; ORAL

PROPRANOLOL HCL			
+ ROXANE	20MG/5ML		N70979 001
			MAY 15, 1987

FDA data supplied by DrugPatentWatch.com

PROPRANOLOL HYDROCHLORIDE

SOLUTION; ORAL
PROPRANOLOL HCL

+	ROXANE	40MG/5ML	N70690 001	MAY 15, 1987

TABLET; ORAL
INDERAL

AB	+ WYETH PHARMS INC	10MG	**N16418 001**	
AB		20MG	**N16418 003**	
AB		40MG	**N16418 002**	
AB		60MG	**N16418 009**	OCT 18, 1982
AB	+	80MG	**N16418 004**	

PROPRANOLOL HCL

AB	MYLAN	10MG	**N70211 001**	NOV 19, 1985
AB		20MG	**N70212 001**	NOV 19, 1985
AB		40MG	**N70213 001**	NOV 19, 1985
AB		80MG	**N70214 001**	NOV 19, 1985
AB	PAR PHARM	10MG	**N70217 001**	AUG 01, 1986
AB		20MG	**N70218 001**	AUG 01, 1986
AB		40MG	**N70219 001**	AUG 01, 1986
AB		60MG	**N70220 001**	SEP 24, 1986
AB		80MG	**N70221 001**	APR 14, 1986
AB		90MG	**N71288 001**	OCT 22, 1986
AB	PLIVA	10MG	**N71972 001**	APR 06, 1988
AB		20MG	**N71973 001**	APR 06, 1988
AB		40MG	**N71974 001**	APR 06, 1988
AB		60MG	**N71975 001**	APR 06, 1988
AB		80MG	**N71976 001**	APR 06, 1988
AB		90MG	**N71977 001**	APR 06, 1988

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	SANDOZ	10MG	**N70663 001**	JUN 13, 1986
AB		20MG	**N70664 001**	JUN 13, 1986
AB		40MG	**N70665 001**	JUN 13, 1986
AB		60MG	**N70666 001**	OCT 10, 1986
AB		80MG	**N70667 001**	JUN 13, 1986
AB	TEVA	40MG	**N70234 001**	JUN 23, 1986
AB	WATSON LABS	10MG	**N70175 001**	MAY 13, 1986
AB		10MG	**N70548 001**	JUL 10, 1986
AB		20MG	**N70176 001**	MAY 13, 1986
AB		40MG	**N70177 001**	MAY 13, 1986
AB		40MG	**N70550 001**	APR 11, 1986
AB		60MG	**N71791 001**	JUL 15, 1987
AB		80MG	**N70178 001**	MAY 13, 1986
AB		80MG	**N70551 001**	JUL 10, 1986
AB		90MG	**N71792 001**	JUL 15, 1987

PROPRANOLOL HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

PROPYLTHIOURACIL

TABLET; ORAL
PROPYLTHIOURACIL

BD	+ CLONMEL HLTHCARE	50MG	N06188 001	
BD	IMPAX LABS	50MG	N80159 001	
BD	PUREPAC PHARM	50MG	N80172 001	
BD	WEST WARD	50MG	N80154 001	

FDA data supplied by DrugPatentWatch.com

PROTAMINE SULFATE

INJECTABLE; INJECTION
PROTAMINE SULFATE

AP	AM PHARM PARTNERS	**10MG/ML**	**N89454 001** APR 07, 1987
AP +	LILLY	**10MG/ML**	**N06460 002**

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
VIVACTIL

AB	ODYSSEY PHARMS	**5MG**	**N73644 001** AUG 24, 1995
AB +		**10MG**	**N73645 001** AUG 24, 1995

PSEUDOEPHEDRINE HYDROCHLORIDE; *MULTIPLE*
SEE ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
SEE CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
SEE FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL
CORPHED

AA	SANDOZ	**60MG;2.5MG**	**N88602 001** APR 11, 1985

PSEUDOEPHEDRINE HCL AND TRIPROLIDINE HCL

AA +	EON	**60MG;2.5MG**	**N88193 001** MAY 17, 1983

PSEUDOEPHEDRINE SULFATE; *MULTIPLE*
SEE AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

PYRAZINAMIDE

TABLET; ORAL
PYRAZINAMIDE

AB +	CLONMEL HLTHCARE	**500MG**	**N80157 001**

PYRAZINAMIDE

TABLET; ORAL
PYRAZINAMIDE

AB	MIKART	**500MG**	**N81319 001** JUN 30, 1992

PYRAZINAMIDE; *MULTIPLE*
SEE ISONIAZID; PYRAZINAMIDE; RIFAMPIN

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION
MESTINON

AP +	VALEANT PHARM INTL	**5MG/ML**	**N09830 001**

REGONOL

AP	SABEX 2002	**5MG/ML**	**N17398 001**

SYRUP; ORAL
MESTINON

+	VALEANT PHARM INTL	60MG/5ML	N15193 001

TABLET; ORAL
MESTINON

AB +	VALEANT PHARM INTL	**60MG**	**N09829 002**

PYRIDOSTIGMINE BROMIDE

AB	BARR	**60MG**	**N40512 001** OCT 08, 2003
AB	COREPHARMA	**60MG**	**N40457 001** DEC 26, 2002
AB	IMPAX LABS	**60MG**	**N40502 001** APR 24, 2003

TABLET, EXTENDED RELEASE; ORAL
MESTINON

+	VALEANT PHARM INTL	180MG	N11665 001

PYRIDOXINE; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

FDA data supplied by DrugPatentWatch.com

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION
PYRIDOXINE HCL

AP	AM PHARM PARTNERS	**100MG/ML**	**N80618 001**	
AP	+ STERIS	**100MG/ML**	**N80572 001**	

PYRIDOXINE HYDROCHLORIDE; *MULTIPLE*
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

PYRIMETHAMINE

TABLET; ORAL
DARAPRIM

+	GLAXOSMITHKLINE	25MG	N08578 001

PYRIMETHAMINE; SULFADOXINE

TABLET; ORAL
FANSIDAR

+	ROCHE	25MG;500MG	N18557 001

QUAZEPAM

TABLET; ORAL
DORAL

	MEDPOINTE PHARM HLC	7.5MG	N18708 003 FEB 26, 1987
+		15MG	N18708 001 DEC 27, 1985

QUETIAPINE FUMARATE

TABLET; ORAL
SEROQUEL

+	ASTRAZENECA	EQ 25MG BASE	N20639 001 SEP 26, 1997
		EQ 100MG BASE	N20639 002 SEP 26, 1997
		EQ 150MG BASE	N20639 004 DEC 20, 1998
		EQ 200MG BASE	N20639 003 SEP 26, 1997
+		EQ 300MG BASE	N20639 005 JUL 26, 2000

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
ACCUPRIL

AB	PFIZER PHARMS	**EQ 5MG BASE**	**N19885 001**	NOV 19, 1991
AB		**EQ 10MG BASE**	**N19885 002**	NOV 19, 1991
AB		**EQ 20MG BASE**	**N19885 003**	NOV 19, 1991
AB	+	**EQ 40MG BASE**	**N19885 004**	NOV 19, 1991

QUINAPRIL HCL

AB	TEVA	**EQ 5MG BASE**	**N75504 001**	MAY 30, 2003
AB		**EQ 10MG BASE**	**N75504 002**	MAY 30, 2003
AB		**EQ 20MG BASE**	**N75504 003**	MAY 30, 2003
AB		**EQ 40MG BASE**	**N75504 004**	NOV 20, 1998

QUINAPRIL HYDROCHLORIDE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

QUINIDINE GLUCONATE

INJECTABLE; INJECTION
QUINIDINE GLUCONATE

+	LILLY	80MG/ML	N07529 002 FEB 10, 1989

FDA data supplied by DrugPatentWatch.com

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL
QUINIDINE GLUCONATE

+	MUTUAL PHARM	324MG	N89338 001	FEB 11, 1987

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

AB	CLONMEL HLTHCARE	**200MG**	**N87011 001**	
AB	EON	**200MG**	**N84631 001**	
AB		**300MG**	**N88072 001**	SEP 26, 1983
AB	LANNETT	**200MG**	**N83743 001**	
AB	MUTUAL PHARM	**100MG**	**N81029 001**	APR 14, 1989
AB		**200MG**	**N81030 001**	APR 14, 1989
AB	PVT FORM	**200MG**	**N83808 001**	
AB	SANDOZ	**200MG**	**N84914 001**	
AB		**300MG**	**N89839 001**	SEP 29, 1988
AB	WATSON LABS	**200MG**	**N83288 001**	
AB		**200MG**	**N85140 002**	
AB		**300MG**	**N85583 001**	

TABLET, EXTENDED RELEASE; ORAL
QUINIDINE SULFATE

+	COPLEY PHARM	300MG	N40045 001	JUN 30, 1994

QUINUPRISTIN; *MULTIPLE*
SEE DALFOPRISTIN; QUINUPRISTIN

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL
ACIPHEX

+	EISAI MEDCL RES	20MG	N20973 002	AUG 19, 1999

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL
EVISTA

+	LILLY	60MG	N20815 001	DEC 09, 1997

RAMIPRIL

CAPSULE; ORAL
ALTACE

	KING PHARMS	1.25MG	N19901 001	JAN 28, 1991
		2.5MG	N19901 002	JAN 28, 1991
		5MG	N19901 003	JAN 28, 1991
+		10MG	N19901 004	JAN 28, 1991

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL
RANITIDINE HCL

AB	DR REDDYS LABS LTD	**EQ 150MG BASE**	**N75742 001**	NOV 29, 2000
AB		**EQ 300MG BASE**	**N75742 002**	NOV 29, 2000
AB	GENPHARM	**EQ 150MG BASE**	**N75564 001**	OCT 27, 2000
AB		**EQ 300MG BASE**	**N75564 002**	OCT 27, 2000
AB	SANDOZ	**EQ 150MG BASE**	**N74655 001**	OCT 22, 1997
AB +		**EQ 300MG BASE**	**N74655 002**	OCT 22, 1997
AB	TEVA	**EQ 150MG BASE**	**N75557 001**	OCT 31, 2003
AB		**EQ 300MG BASE**	**N75557 002**	OCT 31, 2003

GRANULE, EFFERVESCENT; ORAL
ZANTAC 150

+	GLAXOSMITHKLINE	EQ 150MG BASE/PACKET	N20251 002	MAR 31, 1994

FDA data supplied by DrugPatentWatch.com

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
ZANTAC
\+ GLAXOSMITHKLINE EQ 25MG BASE/ML N19090 001 OCT 19, 1984

ZANTAC IN PLASTIC CONTAINER
\+ GLAXOSMITHKLINE EQ 1MG BASE/ML N19593 002 SEP 27, 1991

SYRUP; ORAL
ZANTAC
\+ GLAXOSMITHKLINE EQ 15MG BASE/ML N19675 001 DEC 30, 1988

TABLET; ORAL
RANITIDINE

AB	RANBAXY	**EQ 150MG BASE**	**N75439 001** APR 19, 2000
AB		**EQ 300MG BASE**	**N75439 002** APR 19, 2000

RANITIDINE HCL

AB	GENPHARM	**EQ 150MG BASE**	**N74023 001** AUG 22, 1997
AB		**EQ 300MG BASE**	**N74023 002** AUG 22, 1997
AB	IVAX PHARMS	**EQ 150MG BASE**	**N75165 001** SEP 30, 1998
AB		**EQ 300MG BASE**	**N75165 002** SEP 30, 1998
AB	MYLAN	**EQ 150MG BASE**	**N74552 001** JUL 30, 1998
AB		**EQ 300MG BASE**	**N74552 002** JUL 30, 1998
AB	PAR PHARM	**EQ 150MG BASE**	**N75180 001** JAN 28, 1999
AB		**EQ 300MG BASE**	**N75180 002** JAN 28, 1999
AB	SANDOZ	**EQ 150MG BASE**	**N74467 001** AUG 29, 1997
AB		**EQ 300MG BASE**	**N74467 002** AUG 29, 1997
AB	TEVA	**EQ 150MG BASE**	**N74488 001** JUL 31, 1997
AB		**EQ 300MG BASE**	**N74488 002** JUL 31, 1997
AB	TORPHARM	**EQ 150MG BASE**	**N74680 001** SEP 12, 1997

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE HCL

AB	TORPHARM	**EQ 300MG BASE**	**N74680 002** SEP 12, 1997
AB	WATSON LABS	**EQ 150MG BASE**	**N74864 001** OCT 20, 1997
AB		**EQ 300MG BASE**	**N74864 002** OCT 20, 1997
AB	WOCKHARDT	**EQ 150MG BASE**	**N75208 001** DEC 17, 1998
AB		**EQ 300MG BASE**	**N75208 002** DEC 17, 1998

ZANTAC 150

AB	GLAXOSMITHKLINE	**EQ 150MG BASE**	**N18703 001** JUN 09, 1983

ZANTAC 300

AB	\+ GLAXOSMITHKLINE	**EQ 300MG BASE**	**N18703 002** DEC 09, 1985

TABLET, EFFERVESCENT; ORAL
ZANTAC 150
\+ GLAXOSMITHKLINE EQ 150MG BASE N20251 001 MAR 31, 1994

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION
ULTIVA

ABBOTT	EQ 1MG BASE/VIAL	N20630 001 JUL 12, 1996
	EQ 2MG BASE/VIAL	N20630 002 JUL 12, 1996
\+	EQ 5MG BASE/VIAL	N20630 003 JUL 12, 1996

REPAGLINIDE

TABLET; ORAL
PRANDIN

NOVO NORDISK	0.5MG	N20741 001 DEC 22, 1997
	1MG	N20741 002 DEC 22, 1997
\+	2MG	N20741 003 DEC 22, 1997

FDA data supplied by DrugPatentWatch.com

RESCINNAMINE

TABLET; ORAL
MODERIL
PFIZER 0.25MG N10686 003
\+ 0.5MG N10686 006

RESERPINE

TABLET; ORAL
RESERPINE
BP EON 0.1MG N09838 001
BP + 0.25MG N09838 002
SERPALAN
BP LANNETT 0.1MG N10124 001
BP 0.25MG N10124 002

RESERPINE; *MULTIPLE*
SEE CHLOROTHIAZIDE; RESERPINE
SEE POLYTHIAZIDE; RESERPINE

RIBAVIRIN

CAPSULE; ORAL
REBETOL
\+ SCHERING PLOUGH RES 200MG N20903 001 JUN 03, 1998
\+ 200MG N20903 002 JUL 25, 2001

FOR SOLUTION; INHALATION
VIRAZOLE
\+ VALEANT PHARM INTL 6GM/VIAL N18859 001 DEC 31, 1985

SOLUTION; ORAL
REBETOL
\+ SCHERING 40MG/ML N21546 001 JUL 29, 2003

TABLET; ORAL
COPEGUS
\+ ROCHE 200MG N21511 001 DEC 03, 2002

RIBOFLAVIN; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

RIBOFLAVIN PHOSPHATE SODIUM; *MULTIPLE*
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

RIFABUTIN

CAPSULE; ORAL
MYCOBUTIN
\+ PHARMACIA AND UPJOHN 150MG N50689 001 DEC 23, 1992

RIFAMPIN

CAPSULE; ORAL
RIFADIN
AB AVENTIS PHARMS **150MG** **N62303 001**
AB + **300MG** **N50420 001**
RIFAMPIN
AB EON **150MG** **N64150 002** JAN 02, 1998
AB **300MG** **N64150 001** MAY 28, 1997
AB VERSAPHARM **150MG** **N65028 001** MAR 14, 2001
AB **300MG** **N65028 002** MAR 14, 2001
RIMACTANE
AB SANDOZ **300MG** **N50429 001**

FDA data supplied by DrugPatentWatch.com

RIFAMPIN

INJECTABLE; INJECTION

	RIFADIN			
AP	+ AVENTIS PHARMS	**600MG/VIAL**	**N50627 001**	MAY 25, 1989
	RIFAMPIN			
AP	BEDFORD	**600MG/VIAL**	**N64217 001**	OCT 29, 1999

RIFAMPIN; *MULTIPLE*
SEE ISONIAZID; PYRAZINAMIDE; RIFAMPIN
SEE ISONIAZID; RIFAMPIN

RIFAPENTINE

TABLET; ORAL

	PRIFTIN		
	+ AVENTIS PHARMS	150MG	N21024 001 JUN 22, 1998

RILUZOLE

TABLET; ORAL

	RILUTEK		
AB	+ AVENTIS	**50MG**	**N20599 001** DEC 12, 1995
	RILUZOLE		
AB	IMPAX LABS	**50MG**	**N76173 001** JAN 29, 2003

RIMANTADINE HYDROCHLORIDE

SYRUP; ORAL

	FLUMADINE		
	+ FOREST LABS	50MG/5ML	N19650 001 SEP 17, 1993

TABLET; ORAL

	FLUMADINE		
AB	+ FOREST LABS	**100MG**	**N19649 001** SEP 17, 1993
	RIMANTADINE HCL		
AB	AMIDE PHARM	**100MG**	**N76375 001** JAN 14, 2003

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

	RIMANTADINE HCL		
AB	COREPHARMA	**100MG**	**N75916 001** NOV 02, 2001
AB	IMPAX LABS	**100MG**	**N76132 001** AUG 30, 2002

RIMEXOLONE

SUSPENSION/DROPS; OPHTHALMIC

	VEXOL		
	+ ALCON	1%	N20474 001 DEC 30, 1994

RISEDRONATE SODIUM

TABLET; ORAL

	ACTONEL		
	PROCTER AND GAMBLE	5MG	N20835 002 APR 14, 2000
		30MG	N20835 001 MAR 27, 1998
	+	35MG	N20835 003 MAY 25, 2002

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

	RISPERDAL CONSTA		
	JOHNSON AND JOHNSON	25MG/VIAL	N21346 001 OCT 29, 2003
		37.5MG/VIAL	N21346 002 OCT 29, 2003
	+	50MG/VIAL	N21346 003 OCT 29, 2003

SOLUTION; ORAL

	RISPERDAL		
	+ JANSSEN PHARMA	1MG/ML	N20588 001 JUN 10, 1996

TABLET; ORAL

	RISPERDAL		
	JANSSEN PHARMA	0.25MG	N20272 008 MAY 10, 1999

FDA data supplied by DrugPatentWatch.com

RISPERIDONE

TABLET; ORAL
RISPERDAL
JANSSEN PHARMA 0.5MG N20272 007 JAN 27, 1999
\+ 1MG N20272 001 DEC 29, 1993
2MG N20272 002 DEC 29, 1993
3MG N20272 003 DEC 29, 1993
4MG N20272 004 DEC 29, 1993

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERDAL
JOHNSON AND JOHNSON 0.5MG N21444 001 APR 02, 2003
\+ 1MG N21444 002 APR 02, 2003
2MG N21444 003 APR 02, 2003

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION
RITODRINE HCL
\+ ABBOTT 10MG/ML N71618 001 FEB 28, 1991
\+ 15MG/ML N71619 001 FEB 28, 1991

RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER
\+ ABBOTT 30MG/100ML N71438 001 JAN 22, 1991

RITONAVIR

CAPSULE; ORAL
NORVIR
\+ ABBOTT 100MG N20945 001 JUN 29, 1999

SOLUTION; ORAL
NORVIR
\+ ABBOTT 80MG/ML N20659 001 MAR 01, 1996

RITONAVIR; *MULTIPLE*
SEE LOPINAVIR; RITONAVIR

RIVASTIGMINE TARTRATE

CAPSULE; ORAL
EXELON
NOVARTIS EQ 1.5MG BASE N20823 003 APR 21, 2000
EQ 3MG BASE N20823 004 APR 21, 2000
EQ 4.5MG BASE N20823 005 APR 21, 2000
\+ EQ 6MG BASE N20823 006 APR 21, 2000

SOLUTION; ORAL
EXELON
\+ NOVARTIS EQ 2MG BASE/ML N21025 001 APR 21, 2000

RIZATRIPTAN BENZOATE

TABLET; ORAL
MAXALT
MERCK EQ 5MG BASE N20864 001 JUN 29, 1998
\+ EQ 10MG BASE N20864 002 JUN 29, 1998

TABLET, ORALLY DISINTEGRATING; ORAL
MAXALT-MLT
MERCK EQ 5MG BASE N20865 001 JUN 29, 1998
\+ EQ 10MG BASE N20865 002 JUN 29, 1998

ROCURONIUM BROMIDE

INJECTABLE; INJECTION
ZEMURON (P/F)
\+ ORGANON USA INC 10MG/ML N20214 001 MAR 17, 1994

FDA data supplied by DrugPatentWatch.com

ROFECOXIB

SUSPENSION; ORAL			
VIOXX			
MERCK	12.5MG/5ML	N21052 001	MAY 20, 1999
+	25MG/5ML	N21052 002	MAY 20, 1999
TABLET; ORAL			
VIOXX			
MERCK	12.5MG	N21042 001	MAY 20, 1999
	25MG	N21042 002	MAY 20, 1999
+	50MG	N21042 003	FEB 25, 2000

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL			
REQUIP			
+ GLAXOSMITHKLINE	EQ 0.25MG BASE	N20658 001	SEP 19, 1997
	EQ 0.5MG BASE	N20658 002	SEP 19, 1997
	EQ 1MG BASE	N20658 003	SEP 19, 1997
	EQ 2MG BASE	N20658 004	SEP 19, 1997
	EQ 3MG BASE	N20658 006	JAN 27, 1999
	EQ 4MG BASE	N20658 007	JAN 27, 1999
+	EQ 5MG BASE	N20658 005	SEP 19, 1997

ROPIVACAINE HYDROCHLORIDE MONOHYDRATE

INJECTABLE; INJECTION			
NAROPIN			
ASTRAZENECA	2MG/ML	N20533 001	SEP 24, 1996
	5MG/ML	N20533 003	SEP 24, 1996
	7.5MG/ML	N20533 004	SEP 24, 1996

ROPIVACAINE HYDROCHLORIDE MONOHYDRATE

INJECTABLE; INJECTION			
NAROPIN			
+ ASTRAZENECA	10MG/ML	N20533 005	SEP 24, 1996

ROSIGLITAZONE MALEATE

TABLET; ORAL			
AVANDIA			
SB PHARMCO	EQ 2MG BASE	N21071 002	MAY 25, 1999
	EQ 4MG BASE	N21071 003	MAY 25, 1999
+	EQ 8MG BASE	N21071 004	MAY 25, 1999

ROSIGLITAZONE MALEATE; *MULTIPLE*
SEE METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

ROSUVASTATIN CALCIUM

TABLET; ORAL			
CRESTOR			
ASTRAZENECA	5MG	N21366 002	AUG 12, 2003
	10MG	N21366 003	AUG 12, 2003
	20MG	N21366 004	AUG 12, 2003
+	40MG	N21366 005	AUG 12, 2003

RUBIDIUM CHLORIDE RB-82

INJECTABLE; INJECTION			
CARDIOGEN-82			
BRACCO	N/A	N19414 001	DEC 29, 1989

FDA data supplied by DrugPatentWatch.com

SACROSIDASE

SOLUTION; ORAL
SUCRAID
+ QOL MEDCL — 8,500 IU/ML — N20772 001 APR 09, 1998

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION
LIPOSYN II 10%
+ ABBOTT — 5%;5% (5GM/100ML); 5%;5% (5GM/100ML) — N18997 001 AUG 27, 1984

LIPOSYN II 20%
+ ABBOTT — 10% (10GM/100ML); 10%;10% (10GM/100ML) — N18991 001 AUG 27, 1984

SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION
SEREVENT
+ GLAXOSMITHKLINE — EQ 0.021MG BASE/INH — N20236 001 FEB 04, 1994

POWDER; INHALATION
SEREVENT
+ GLAXOSMITHKLINE — EQ 0.046MG BASE/INH — N20692 001 SEP 19, 1997

SALMETEROL XINAFOATE; *MULTIPLE*
SEE FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

SAMARIUM SM 153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION
QUADRAMET
+ CYTOGEN — 50mCi/ML — N20570 001 MAR 28, 1997

SAQUINAVIR

CAPSULE; ORAL
FORTOVASE
+ HLR — 200MG — N20828 001 NOV 07, 1997

SAQUINAVIR MESYLATE

CAPSULE; ORAL
INVIRASE
+ HLR — EQ 200MG BASE — N20628 001 DEC 06, 1995

SCOPOLAMINE

FILM, EXTENDED RELEASE; TRANSDERMAL
TRANSDERM SCOP
+ NOVARTIS — 1MG/72HR — N17874 001

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECOBARBITAL SODIUM
AA EVERYLIFE — **100MG** — **N85895 001**
SECONAL SODIUM
AA + RANBAXY — **100MG** — **N86101 002** OCT 03, 1983
\+ — 50MG — N86101 001 OCT 03, 1983

SECRETIN

FOR SOLUTION; INTRAVENOUS
SECREFLO
+ CHIRHOCLIN — 16 UGM/VIAL — N21136 001 APR 04, 2002

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL
ELDEPRYL
AB + SOMERSET — **5MG** — **N20647 001** MAY 15, 1996

FDA data supplied by DrugPatentWatch.com

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

		SELEGELINE HCL		
AB		AAIPHARMA LLC	5MG	**N75145 001** SEP 15, 2003
		SELEGILINE HCL		
AB		CLONMEL HLTHCARE	5MG	**N75352 001** NOV 30, 1998
AB		TORPHARM	5MG	**N75321 001** DEC 04, 1998

TABLET; ORAL

		SELEGILINE HCL		
AB		ALPHAPHARM	5MG	**N74866 001** NOV 26, 1997
AB		APOTEX	5MG	**N74871 001** JUN 06, 1997
AB		CLONMEL HLTHCARE	5MG	**N74641 001** AUG 02, 1996
AB		ENDO PHARMS	5MG	**N74565 001** AUG 02, 1996
AB		IVAX PHARMS	5MG	**N74756 001** NOV 25, 1998
AB		SIEGFRIED	5MG	**N74672 001** APR 01, 1997
AB	+	SOMERSET	5MG	**N19334 001** JUN 05, 1989
AB		STASON	5MG	**N74912 001** APR 30, 1998
AB		TEVA	5MG	**N74537 001** AUG 02, 1996
AB			5MG	**N74744 001** JAN 27, 1997

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

		SELENIUM SULFIDE		
AT		ALPHARMA	2.5%	**N84394 001**
AT		CLAY PARK	2.5%	**N89996 001** JAN 10, 1991
AT		MORTON GROVE	2.5%	**N88228 001** SEP 01, 1983
		SELSUN		
AT	+	CHATTEM	2.5%	**N07936 001**

SERMORELIN ACETATE

INJECTABLE; INJECTION

		GEREF		
	+	SERONO	EQ 0.05MG BASE/AMP	N19863 001 DEC 28, 1990

SERTACONAZOLE NITRATE

CREAM; TOPICAL

		ERTACZO		
	+	JOHNSON AND JOHNSON	2%	N21385 001 DEC 10, 2003

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

		ZOLOFT		
	+	PFIZER	EQ 20MG BASE/ML	N20990 001 DEC 07, 1999

TABLET; ORAL

		ZOLOFT		
		PFIZER	EQ 25MG BASE	N19839 005 MAR 06, 1996
			EQ 50MG BASE	N19839 001 DEC 30, 1991
	+		EQ 100MG BASE	N19839 002 DEC 30, 1991

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL

		RENAGEL		
	+	GENZYME	403MG	N20926 001 OCT 30, 1998

TABLET; ORAL

		RENAGEL		
		GENZYME	400MG	N21179 001 JUL 12, 2000
	+		800MG	N21179 002 JUL 12, 2000

FDA data supplied by DrugPatentWatch.com

SEVOFLURANE

LIQUID; INHALATION

	SEVOFLURANE			
AN	BAXTER HLTHCARE	**100%**	**N75895 001**	
			JUL 02, 2002	
	ULTANE			
AN	+ ABBOTT	**100%**	**N20478 001**	
			JUN 07, 1995	

SIBUTRAMINE HYDROCHLORIDE

CAPSULE; ORAL

	MERIDIA		
	ABBOTT	5MG	N20632 001
			NOV 22, 1997
		10MG	N20632 002
			NOV 22, 1997
	+	15MG	N20632 003
			NOV 22, 1997

SILDENAFIL CITRATE

TABLET; ORAL

	VIAGRA		
	PFIZER IRELAND	25MG	N20895 001
			MAR 27, 1998
		50MG	N20895 002
			MAR 27, 1998
	+	100MG	N20895 003
			MAR 27, 1998

SILVER SULFADIAZINE

CREAM; TOPICAL

	SILVADENE			
AB	+ KING PHARMS	**1%**	**N17381 001**	
	SSD			
AB	BASF	**1%**	**N18578 001**	
			FEB 25, 1982	
	SSD AF			
BX	BASF	1%	N18578 003	
			JUL 11, 1990	
	THERMAZENE			
AB	KENDALL LP	**1%**	**N18810 001**	
			DEC 23, 1985	

SIMVASTATIN

TABLET; ORAL

	ZOCOR		
	MERCK	5MG	N19766 001
			DEC 23, 1991
		10MG	N19766 002
			DEC 23, 1991
		20MG	N19766 003
			DEC 23, 1991
		40MG	N19766 004
			DEC 23, 1991
	+	80MG	N19766 005
			JUL 10, 1998

SINCALIDE

INJECTABLE; INJECTION

	KINEVAC		
	+ BRACCO	0.005MG/VIAL	N17697 001

SIROLIMUS

SOLUTION; ORAL

	RAPAMUNE		
	+ WYETH PHARMS INC	1MG/ML	N21083 001
			SEP 15, 1999

TABLET; ORAL

	RAPAMUNE		
	WYETH PHARMS INC	1MG	N21110 001
			AUG 25, 2000
	+	2MG	N21110 002
			AUG 22, 2002

SODIUM ACETATE; *MULTIPLE*

SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

SODIUM ACETATE; *MULTIPLE*
SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SODIUM ACETATE, ANHYDROUS

INJECTABLE; INJECTION
SODIUM ACETATE IN PLASTIC CONTAINER

+	ABBOTT	2MEQ/ML	N18893 001	MAY 04, 1983

SODIUM BICARBONATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SODIUM BICARBONATE; *MULTIPLE*
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL
BAROS

	LAFAYETTE PHARMS	460MG/GM;420MG/GM	N18509 001	AUG 07, 1985

SODIUM CARBONATE; *MULTIPLE*
SEE CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+ ABBOTT	**9MG/ML**	**N18800 001**	OCT 29, 1982
AP	AM PHARM PARTNERS	**9MG/ML**	**N88911 001**	FEB 07, 1985

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	ABBOTT	**450MG/100ML**	**N18090 001**	
AP		**450MG/100ML**	**N19759 001**	JUN 08, 1988
AP	B BRAUN	**450MG/100ML**	**N19635 001**	MAR 09, 1988
AP	BAXTER HLTHCARE	**450MG/100ML**	**N18016 001**	

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ABBOTT	**900MG/100ML**	**N16366 001**	
AP		**9MG/ML**	**N18803 001**	OCT 29, 1982
AP		**9MG/ML**	**N19217 001**	JUL 13, 1984
AP		**900MG/100ML**	**N19465 001**	JUL 15, 1985
AP		**9MG/ML**	**N19465 002**	JUL 15, 1985
AP		**900MG/100ML**	**N19480 001**	SEP 17, 1985
AP	AM PHARM PARTNERS	**9MG/ML**	**N88912 001**	JAN 10, 1985
AP	B BRAUN	**900MG/100ML**	**N17464 001**	

FDA data supplied by DrugPatentWatch.com

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		B BRAUN	**900MG/100ML**	**N19635 002**
				MAR 09, 1988
AP		BAXTER HLTHCARE	**900MG/100ML**	**N16677 001**
AP	+		**9MG/ML**	**N16677 004**
				OCT 30, 1985
AP			**900MG/100ML**	**N20178 001**
				DEC 07, 1992
AP			**9MG/ML**	**N20178 002**
				DEC 07, 1992

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	3GM/100ML	N19022 001
			NOV 01, 1983

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5GM/100ML	N19022 002
			NOV 01, 1983

SODIUM CHLORIDE IN PLASTIC CONTAINER

	ABBOTT	2.5MEQ/ML	N18897 001
			JUL 20, 1984

SOLUTION FOR SLUSH; IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

	BAXTER HLTHCARE	900MG/100ML	N19319 002
			MAY 17, 1985

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AT	ABBOTT	**450MG/100ML**	**N17670 001**
AT	BAXTER HLTHCARE	**450MG/100ML**	**N17864 001**

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AT	ABBOTT	**900MG/100ML**	**N17514 001**
AT		**900MG/100ML**	**N18314 001**
AT	B BRAUN	**900MG/100ML**	**N16733 001**
AT	BAXTER HLTHCARE	**900MG/100ML**	**N17427 001**
AT		**900MG/100ML**	**N17867 001**

SODIUM CHLORIDE; *MULTIPLE*

SEE AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SODIUM CHLORIDE; *MULTIPLE*

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

SEE AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SEE DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

SODIUM CHLORIDE; *MULTIPLE*
SEE DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE
SEE DEXTROSE; SODIUM CHLORIDE
SEE MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
SEE MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS
SEE POTASSIUM CHLORIDE; SODIUM CHLORIDE

SODIUM CHROMATE, CR-51

INJECTABLE; INJECTION

CHROMITOPE SODIUM		
BRACCO	200 uCi/ML	N13993 001
SODIUM CHROMATE CR 51		
MALLINCKRODT	100 uCi/ML	N16708 001

SODIUM CITRATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SODIUM CITRATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT			
+	R AND D LABS	62.5MG/5ML	N20955 001 FEB 18, 1999

SODIUM GLUCONATE; *MULTIPLE*
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SODIUM IODIDE, I-123

CAPSULE; ORAL

SODIUM IODIDE I 123			
AA	AMERSHAM HLTH	**100 uCi**	**N17630 001**
AA	MALLINCKRODT	**100 uCi**	**N71909 001** FEB 28, 1989
AA		**200 uCi**	**N71910 001** FEB 28, 1989
AA	SYNCOR PHARMS	**100 uCi**	**N18671 001** MAY 27, 1982
AA		**200 uCi**	**N18671 002** MAY 27, 1982

SOLUTION; ORAL

SODIUM IODIDE I 123		
AMERSHAM HLTH	2mCi/ML	N17630 002

SODIUM IODIDE, I-131

CAPSULE; ORAL

IODOTOPE			
+	BRACCO	1-130mCi	N10929 001
SODIUM IODIDE I 131			
+	MALLINCKRODT	15-100 uCi	N16517 002

FDA data supplied by DrugPatentWatch.com

SODIUM IODIDE, I-131

CAPSULE; ORAL
SODIUM IODIDE I 131
+ MALLINCKRODT 0.8-100mCi N16517 001

SOLUTION; ORAL
SODIUM IODIDE I 131
+ CIS 50mCi/ML N17315 001
+ MALLINCKRODT 3.5-150mCi/VIAL N16515 001
SODIUM IODIDE I 131, KIT
+ DRAXIMAGE 1-500mCi/0.5ML N21305 003 JAN 24, 2003
+ 1-250mCi/0.25ML N21305 002 JAN 24, 2003

SODIUM LACTATE

INJECTABLE; INJECTION
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER
AP ABBOTT **1.87GM/100ML** **N18249 001**
AP BAXTER HLTHCARE **1.87GM/100ML** **N16692 001**
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER
AP B BRAUN **1.87GM/100ML** **N20004 001** APR 21, 1992

SODIUM LACTATE IN PLASTIC CONTAINER
ABBOTT 5MEQ/ML N18947 001 SEP 05, 1984

SODIUM LACTATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE
SEE CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

SODIUM LACTATE; *MULTIPLE*
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NITROPRESS
AP + ABBOTT **25MG/ML** **N71961 001** AUG 01, 1988
+ 50MG/VIAL N70566 001 JUN 09, 1986
SODIUM NITROPRUSSIDE
AP GENSIA SICOR PHARMS **25MG/ML** **N73465 001** MAR 30, 1992

SODIUM OXYBATE

SOLUTION; ORAL
XYREM
+ ORPHAN MEDCL 500MG/ML N21196 001 JUL 17, 2002

SODIUM PHENYLBUTYRATE

POWDER; ORAL
BUPHENYL
+ MEDICIS 3GM/TEASPOONFUL N20573 001 APR 30, 1996

TABLET; ORAL
BUPHENYL
+ MEDICIS 500MG N20572 001 MAY 13, 1996

SODIUM PHOSPHATE; *MULTIPLE*
SEE CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
SEE MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

FDA data supplied by DrugPatentWatch.com

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL
VISICOL
+ INKINE 0.398GM;1.102GM N21097 001
SEP 21, 2000

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; *MULTIPLE*
SEE AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SEE MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION
SODIUM PHOSPHATES IN PLASTIC CONTAINER
ABBOTT 142MG/ML;276MG/ML N18892 001
MAY 10, 1983

SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS; *MULTIPLE*
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
SEE SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE; *MULTIPLE*
SEE SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

SODIUM PHOSPHATE, P-32

SOLUTION; INJECTION, ORAL
SODIUM PHOSPHATE P 32
MALLINCKRODT 0.67mCi/ML N11777 001

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
KAYEXALATE
AA + SANOFI SYNTHELABO **453.6GM/BOT** **N11287 001**
KIONEX
AA PADDOCK **454GM/BOT** **N40029 001**
FEB 06, 1998
SODIUM POLYSTYRENE SULFONATE
AA CAROLINA MEDCL **454GM/BOT** **N89910 001**
JAN 19, 1989

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
AA ROXANE **15GM/60ML** **N89049 001**
NOV 17, 1986
SPS
AA + CAROLINA MEDCL **15GM/60ML** **N87859 001**
DEC 08, 1982

SODIUM SULFATE; *MULTIPLE*
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SODIUM SULFATE, ANHYDROUS; *MULTIPLE*
SEE POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

SOMATREM

INJECTABLE; INJECTION
PROTROPIN
+ GENENTECH 5MG/VIAL N19107 001
OCT 17, 1985
+ 10MG/VIAL N19107 002
OCT 24, 1989

FDA data supplied by DrugPatentWatch.com

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

	GENOTROPIN			
	+ PHARMACIA AND UPJOHN	5.8MG/VIAL	N20280 006	AUG 24, 1995
	+	13.8MG/VIAL	N20280 007	OCT 23, 1996
	GENOTROPIN PRESERVATIVE FREE			
	PHARMACIA AND UPJOHN	0.2MG/VIAL	N20280 001	JAN 27, 1998
		0.4MG/VIAL	N20280 002	JAN 27, 1998
		0.6MG/VIAL	N20280 003	JAN 27, 1998
		0.8MG/VIAL	N20280 005	JAN 27, 1998
		1MG/VIAL	N20280 008	JAN 27, 1998
		1.2MG/VIAL	N20280 009	JAN 27, 1998
		1.4MG/VIAL	N20280 010	JAN 27, 1998
		1.5MG/VIAL	N20280 004	AUG 24, 1995
		1.6MG/VIAL	N20280 011	JAN 27, 1998
		1.8MG/VIAL	N20280 012	JAN 27, 1998
	+	2MG/VIAL	N20280 013	JAN 27, 1998
	HUMATROPE			
BX	+ LILLY	5MG/VIAL	N19640 004	MAR 08, 1987
BX		6MG/VIAL	N19640 005	FEB 04, 1999
	+	12MG/VIAL	N19640 006	FEB 04, 1999
	+	24MG/VIAL	N19640 007	FEB 04, 1999
	NORDITROPIN			
BX	NOVO NORDISK	4MG/VIAL	N19721 001	MAY 08, 1995
		5MG/1.5ML	N21148 001	JUN 20, 2000
		10MG/1.5ML	N21148 002	JUN 20, 2000
		8MG/VIAL	N19721 002	MAY 08, 1995

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

	NORDITROPIN			
	+ NOVO NORDISK	15MG/1.5ML	N21148 003	JUN 20, 2000
	NUTROPIN			
BX	GENENTECH	5MG/VIAL	N20168 001	NOV 17, 1993
	+	10MG/VIAL	N20168 002	NOV 17, 1993
	NUTROPIN AQ			
	+ GENENTECH	5MG/ML	N20522 001	DEC 29, 1995
	NUTROPIN AQ PEN			
BX	+ GENENTECH	5MG/ML	N20522 002	APR 22, 2002
	NUTROPIN DEPOT			
	+ GENENTECH	13.5MG/VIAL	N21075 001	DEC 22, 1999
	+	18MG/VIAL	N21075 002	DEC 22, 1999
	+	22.5MG/VIAL	N21075 003	DEC 22, 1999
	SAIZEN			
BX	SERONO	5MG/VIAL	N19764 002	OCT 08, 1996
BX		6MG/VIAL	N19764 001	OCT 08, 1996
	+	8.8MG/VIAL	N19764 003	AUG 29, 2000
	SEROSTIM			
BX	SERONO	5MG/VIAL	N20604 002	AUG 23, 1996
BX		6MG/VIAL	N20604 001	AUG 23, 1996
		4MG/VIAL	N20604 003	JUL 25, 1997
	+	8.8MG/VIAL	N20604 004	SEP 06, 2001
	TEV-TROPIN			
BX	+ SAVIENT PHARMS	5MG/ML	N19774 002	JAN 04, 2002
	ZORBTIVE			
BX	SERONO INC	4MG/VIAL	N21597 001	DEC 01, 2003
BX		5MG/VIAL	N21597 002	DEC 01, 2003

FDA data supplied by DrugPatentWatch.com

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

	ZORBTIVE			
BX	SERONO INC	6MG/VIAL	N21597 003	DEC 01, 2003
+		8.8MG/VIAL	N21597 004	DEC 01, 2003

SORBITOL

SOLUTION; IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	3GM/100ML	N17863 001
SORBITOL 3.3% IN PLASTIC CONTAINER		
B BRAUN	3.3GM/100ML	N16741 001

SORBITOL; *MULTIPLE*
SEE MANNITOL; SORBITOL

SOTALOL HYDROCHLORIDE

TABLET; ORAL

	BETAPACE			
AB1	BERLEX LABS	**80MG**	**N19865 001**	OCT 30, 1992
AB1		**120MG**	**N19865 005**	APR 20, 1994
AB1 +		**160MG**	**N19865 002**	OCT 30, 1992
AB1		**240MG**	**N19865 003**	OCT 30, 1992
	BETAPACE AF			
AB2	BERLEX LABS	**80MG**	**N21151 001**	FEB 22, 2000
AB2		**120MG**	**N21151 002**	FEB 22, 2000
AB2 +		**160MG**	**N21151 003**	FEB 22, 2000
	SORINE			
AB1	UPSHER SMITH	**80MG**	**N75500 001**	APR 27, 2001
AB1		**120MG**	**N75500 004**	APR 27, 2001
AB1		**160MG**	**N75500 002**	APR 27, 2001

SOTALOL HYDROCHLORIDE

TABLET; ORAL

	SORINE			
AB1	UPSHER SMITH	**240MG**	**N75500 003**	APR 27, 2001
	SOTALOL HCL			
AB1	APOTEX	**80MG**	**N76140 001**	SEP 26, 2002
AB1		**120MG**	**N76140 002**	SEP 26, 2002
AB1		**160MG**	**N76140 003**	SEP 26, 2002
AB1		**240MG**	**N76140 004**	SEP 26, 2002
AB1	EON	**80MG**	**N75366 001**	MAY 01, 2000
AB1		**120MG**	**N75366 002**	MAY 01, 2000
AB1		**160MG**	**N75366 003**	MAY 01, 2000
AB1		**240MG**	**N75366 004**	MAY 01, 2000
AB1	GENPHARM	**80MG**	**N75237 001**	MAY 01, 2000
AB1		**120MG**	**N75237 002**	MAY 01, 2000
AB1		**160MG**	**N75237 003**	MAY 01, 2000
AB1		**240MG**	**N75237 004**	MAY 01, 2000
AB1	IMPAX PHARMS	**80MG**	**N75663 001**	NOV 07, 2000
AB1		**120MG**	**N75663 002**	NOV 07, 2000
AB1		**160MG**	**N75663 003**	NOV 07, 2000
AB1		**240MG**	**N75663 004**	NOV 07, 2000
AB1	MUTUAL PHARM	**80MG**	**N75515 001**	OCT 15, 2001
AB1		**120MG**	**N75515 004**	OCT 15, 2001
AB1		**160MG**	**N75515 002**	OCT 15, 2001
AB1		**240MG**	**N75515 003**	OCT 15, 2001
AB1	MYLAN	**80MG**	**N75725 001**	DEC 19, 2000

FDA data supplied by DrugPatentWatch.com

SOTALOL HYDROCHLORIDE

TABLET; ORAL

	SOTALOL HCL			
AB1	MYLAN	**120MG**	**N75725 002**	DEC 19, 2000
AB1		**160MG**	**N75725 003**	DEC 19, 2000
AB1		**240MG**	**N75725 004**	DEC 19, 2000
AB1	TEVA	**80MG**	**N75429 001**	MAY 01, 2000
AB1		**120MG**	**N75429 002**	MAY 01, 2000
AB1		**160MG**	**N75429 003**	MAY 01, 2000
AB1		**240MG**	**N75429 004**	MAY 01, 2000
AB2	TORPHARM	**80MG**	**N76214 001**	AUG 27, 2003
AB2		**120MG**	**N76214 002**	AUG 27, 2003
AB2		**160MG**	**N76214 003**	AUG 27, 2003
AB1	VINTAGE PHARMS	**80MG**	**N75563 001**	NOV 07, 2003
AB1		**120MG**	**N75563 002**	NOV 07, 2003
AB1		**160MG**	**N75563 003**	NOV 07, 2003
AB1		**240MG**	**N75563 004**	NOV 07, 2003
AB1	WATSON LABS	**80MG**	**N75238 001**	JUL 13, 2000
AB1		**120MG**	**N75238 002**	JUL 13, 2000
AB1		**160MG**	**N75238 003**	JUL 13, 2000
AB1		**240MG**	**N75238 004**	JUL 13, 2000

SOYBEAN OIL

INJECTABLE; INJECTION

	INTRALIPID 10%			
AP	+ FRESENIUS KABI	**10%**	**N17643 001**	
	INTRALIPID 20%			
AP	+ FRESENIUS KABI	**20%**	**N18449 001**	

SOYBEAN OIL

INJECTABLE; INJECTION

	INTRALIPID 20%			
AP	+ FRESENIUS KABI	**20%**	**N20248 001**	AUG 07, 1996
	INTRALIPID 30%			
AP	+ FRESENIUS KABI	**30%**	**N19942 001**	DEC 30, 1993
	LIPOSYN III 10%			
AP	+ ABBOTT	**10%**	**N18969 001**	SEP 24, 1984
	LIPOSYN III 20%			
AP	+ ABBOTT	**20%**	**N18970 001**	SEP 25, 1984
	LIPOSYN III 30%			
AP	+ ABBOTT	**30%**	**N20181 001**	JAN 13, 1998
	NUTRILIPID 10%			
AP	+ B BRAUN	**10%**	**N19531 001**	MAY 28, 1993
	NUTRILIPID 20%			
AP	+ B BRAUN	**20%**	**N19531 002**	MAY 28, 1993
	SOYACAL 10%			
AP	+ ALPHA THERA	**10%**	**N18465 001**	JUN 29, 1983
	SOYACAL 20%			
AP	+ ALPHA THERA	**20%**	**N18786 001**	JUN 29, 1983

SOYBEAN OIL; *MULTIPLE*
SEE SAFFLOWER OIL; SOYBEAN OIL

SPARFLOXACIN

TABLET; ORAL

	ZAGAM		
	+ MYLAN	200MG	N20677 001 DEC 19, 1996

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

	TROBICIN	
	+ PHARMACIA AND UPJOHN EQ 2GM BASE/VIAL	N50347 001

FDA data supplied by DrugPatentWatch.com

SPIRONOLACTONE

TABLET; ORAL

	ALDACTONE				
AB	GD SEARLE LLC	25MG	N12151 009	DEC 30, 1983	
AB		50MG	N12151 008	DEC 30, 1982	
AB	+	100MG	N12151 010	DEC 30, 1983	
	SPIRONOLACTONE				
AB	HALSEY	25MG	N87265 001		
AB	MUTUAL PHARM	25MG	N89424 001	JUL 23, 1986	
AB		50MG	N89424 002	AUG 11, 1999	
AB		100MG	N89424 003	AUG 11, 1999	
AB	MYLAN	25MG	N40424 001	AUG 20, 2001	
AB		25MG	N87086 001		
AB		50MG	N40424 002	AUG 20, 2001	
AB		100MG	N40424 003	AUG 20, 2001	
AB	PUREPAC PHARM	50MG	N40353 001	JUL 29, 1999	
AB		100MG	N40353 002	JUL 29, 1999	
AB	SANDOZ	25MG	N86809 001		

SPIRONOLACTONE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

STAVUDINE

CAPSULE; ORAL

	ZERIT			
	BRISTOL MYERS SQUIBB	15MG	N20412 002	JUN 24, 1994
		20MG	N20412 003	JUN 24, 1994
		30MG	N20412 004	JUN 24, 1994
+		40MG	N20412 005	JUN 24, 1994

STAVUDINE

CAPSULE, EXTENDED RELEASE; ORAL

	ZERIT XR			
	BRISTOL MYERS SQUIBB	37.5MG	N21453 001	DEC 31, 2002
		50MG	N21453 002	DEC 31, 2002
		75MG	N21453 003	DEC 31, 2002
+		100MG	N21453 004	DEC 31, 2002

FOR SOLUTION; ORAL

	ZERIT			
+	BRISTOL MYERS SQUIBB	1MG/ML	N20413 001	SEP 06, 1996

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

	STREPTOMYCIN SULFATE			
+	PFIZER	EQ 1GM BASE/2.5ML	N60111 001	
+	PHARMA TEK	EQ 1GM BASE/VIAL	N64210 001	JUN 30, 1998

STREPTOZOCIN

INJECTABLE; INJECTION

	ZANOSAR			
+	GENSIA SICOR PHARMS	1GM/VIAL	N50577 001	MAY 07, 1982

STRONTIUM CHLORIDE, SR-89

INJECTABLE; INJECTION

	METASTRON			
AP	+ AMERSHAM HLTH	1mCi/ML	N20134 001	JUN 18, 1993
	STRONTIUM CHLORIDE SR-89			
AP	BIO NUCLEONICS	1mCi/ML	N75941 001	JAN 06, 2003

FDA data supplied by DrugPatentWatch.com

SUCCIMER

CAPSULE; ORAL
CHEMET
+ OVATION PHARMS 100MG N19998 002 JAN 30, 1991

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
ANECTINE
AP + GLAXOSMITHKLINE **20MG/ML** **N08453 002**
+ 500MG/VIAL N08453 001
+ 1GM/VIAL N08453 004
QUELICIN
AP + ABBOTT **20MG/ML** **N08845 006**
QUELICIN PRESERVATIVE FREE
AP + ABBOTT **20MG/ML** **N08845 001**
+ 100MG/ML N08845 004
SUCCINYLCHOLINE CHLORIDE
AP ORGANON USA INC **20MG/ML** **N80997 001**

SUCRALFATE

SUSPENSION; ORAL
CARAFATE
+ AXCAN SCANDIPHARM 1GM/10ML N19183 001 DEC 16, 1993

TABLET; ORAL
CARAFATE
AB + BLUE RIDGE **1GM** **N18333 001**
SUCRALFATE
AB RATIOPHARM **1GM** **N74415 001** JUN 08, 1998
AB TEVA **1GM** **N70848 001** MAR 29, 1996

SUFENTANIL CITRATE

INJECTABLE; INJECTION
SUFENTA
AP + AKORN **EQ 0.05MG BASE/ML** **N19050 001** MAY 04, 1984
SUFENTANIL CITRATE
AP ELKINS SINN **EQ 0.05MG BASE/ML** **N74413 001** DEC 15, 1995

SUFENTANIL CITRATE

INJECTABLE; INJECTION
SULFENTANIL CITRATE
AP ABBOTT **EQ 0.05MG BASE/ML** **N74534 001** DEC 11, 1996

SULBACTAM SODIUM; *MULTIPLE*
SEE AMPICILLIN SODIUM; SULBACTAM SODIUM

SULCONAZOLE NITRATE

CREAM; TOPICAL
EXELDERM
+ WESTWOOD SQUIBB 1% N18737 001 FEB 28, 1989

SULFACETAMIDE SODIUM

LOTION; TOPICAL
KLARON
+ DERMIK LABS 10% N19931 001 DEC 23, 1996

OINTMENT; OPHTHALMIC
CETAMIDE
AT + ALCON **10%** **N80021 001**
SULFACETAMIDE SODIUM
AT ALTANA **10%** **N80029 001**

SOLUTION/DROPS; OPHTHALMIC
BLEPH-10
AT + ALLERGAN **10%** **N80028 001**
BLEPH-30
AT + ALLERGAN **30%** **N80028 002**
ISOPTO CETAMIDE
AT + ALCON **15%** **N80020 002**
OCUSULF-10
AT MIZA PHARMS USA **10%** **N80660 001**
SULFACEL-15
AT OPTOPICS **15%** **N80024 001**
SULFACETAMIDE SODIUM
AT AKORN **10%** **N40215 001** MAY 25, 1999
AT **30%** **N40216 001** MAY 25, 1999

FDA data supplied by DrugPatentWatch.com

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

	SULFACETAMIDE SODIUM			
AT	ALCON UNIVERSAL	10%	**N89560 001** OCT 18, 1988	
AT	BAUSCH AND LOMB	10%	**N40066 001** DEC 28, 1994	
AT	STERIS	30%	**N89068 001** MAY 05, 1987	

SULFACETAMIDE SODIUM; *MULTIPLE*

SEE FLUOROMETHOLONE; SULFACETAMIDE SODIUM

SEE PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

SEE PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SULFACYTINE

TABLET; ORAL

	RENOQUID		
+	GLENWOOD	250MG	N17569 001

SULFADIAZINE

TABLET; ORAL

	SULFADIAZINE		
+	EON	500MG	N40091 001 JUL 29, 1994

SULFADOXINE; *MULTIPLE*

SEE PYRIMETHAMINE; SULFADOXINE

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

	BACTRIM			
AP	+ WOMEN FIRST HLTHCARE	80MG/ML;16MG/ML	**N18374 001**	
	SULFAMETHOXAZOLE AND TRIMETHOPRIM			
AP	ABBOTT	80MG/ML;16MG/ML	**N73199 001** SEP 11, 1992	
AP	ELKINS SINN	80MG/ML;16MG/ML	**N70627 001** DEC 29, 1987	
AP		80MG/ML;16MG/ML	**N70628 001** DEC 29, 1987	

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

	SULFAMETHOXAZOLE AND TRIMETHOPRIM		
AP	GENSIA SICOR PHARMS	80MG/ML;16MG/ML	**N73303 001** OCT 31, 1991

SUSPENSION; ORAL

	SEPTRA		
AB	+ MONARCH PHARMS	200MG/5ML;40MG/5ML	**N17598 001**
	SEPTRA GRAPE		
AB	MONARCH PHARMS	200MG/5ML;40MG/5ML	**N17598 002** FEB 12, 1986
	SULFAMETHOXAZOLE AND TRIMETHOPRIM		
AB	HI TECH PHARMA	200MG/5ML;40MG/5ML	**N74650 001** DEC 29, 1997
AB	TEVA	200MG/5ML;40MG/5ML	**N18812 001** JAN 28, 1983
AB		200MG/5ML;40MG/5ML	**N18812 002** JUN 10, 1983
AB		200MG/5ML;40MG/5ML	**N70028 001** JUN 02, 1987
	SULFATRIM		
AB	ALPHARMA	200MG/5ML;40MG/5ML	**N18615 002** JAN 07, 1983
	SULFATRIM PEDIATRIC		
AB	ALPHARMA	200MG/5ML;40MG/5ML	**N18615 001** JAN 07, 1983

TABLET; ORAL

	BACTRIM		
AB	WOMEN FIRST HLTHCARE	400MG;80MG	**N17377 001**
	BACTRIM DS		
AB	+ WOMEN FIRST HLTHCARE	800MG;160MG	**N17377 002**
	COTRIM		
AB	TEVA	400MG;80MG	**N70034 001** MAY 16, 1985
	COTRIM D.S.		
AB	TEVA	800MG;160MG	**N70048 001** MAR 18, 1985
	SEPTRA		
AB	MONARCH PHARMS	400MG;80MG	**N17376 001**
	SEPTRA DS		
AB	MONARCH PHARMS	800MG;160MG	**N17376 002**
	SULFAMETHOPRIM		
AB	PAR PHARM	400MG;80MG	**N70022 001** FEB 15, 1985
	SULFAMETHOPRIM-DS		
AB	PAR PHARM	800MG;160MG	**N70032 001** FEB 15, 1985

FDA data supplied by DrugPatentWatch.com

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

	SULFAMETHOXAZOLE AND TRIMETHOPRIM			
AB	MUTUAL PHARM	400MG;80MG	N71016 001	AUG 25, 1986
AB		800MG;160MG	N71017 001	AUG 25, 1986
AB	PLIVA	400MG;80MG	N70215 001	SEP 10, 1985
AB		800MG;160MG	N70216 001	SEP 10, 1985
AB	SANDOZ	400MG;80MG	N70889 001	NOV 13, 1986
AB		800MG;160MG	N70890 001	NOV 13, 1986
AB	WATSON LABS	400MG;80MG	N18852 001	MAY 09, 1983
	SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH			
AB	EON	800MG;160MG	N18598 004	MAY 19, 1982
AB	TEVA	800MG;160MG	N70037 001	JUN 02, 1987
AB	WATSON LABS	800MG;160MG	N18854 001	MAY 09, 1983
	SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH			
AB	PLANTEX	400MG;80MG	N70030 001	JUN 02, 1987

SULFANILAMIDE

CREAM; VAGINAL

	AVC			
AT	+ NOVAVAX	15%	N06530 003	JAN 27, 1987
	SULFANILAMIDE			
AT	TEVA	15%	N88718 001	SEP 19, 1985

SULFASALAZINE

SUSPENSION; ORAL

	AZULFIDINE			
	+ PHARMACIA AND UPJOHN	250MG/5ML	N86983 001	

TABLET; ORAL

	AZULFIDINE			
AB	+ PHARMACIA AND UPJOHN	500MG	N07073 001	

SULFASALAZINE

TABLET; ORAL

	SULFASALAZINE			
AB	MUTUAL PHARM	500MG	N89590 001	OCT 19, 1987
AB	VINTAGE PHARMS	500MG	N40349 001	JAN 11, 2002
AB	WATSON LABS	500MG	N85828 001	
AB		500MG	N87197 001	

TABLET, DELAYED RELEASE; ORAL

	AZULFIDINE EN-TABS			
AB	+ PHARMACIA AND UPJOHN	500MG	N07073 002	APR 06, 1983
	SULFASALAZINE			
AB	VINTAGE PHARMS	500MG	N75339 001	JAN 11, 2002

SULFINPYRAZONE

CAPSULE; ORAL

	ANTURANE			
AB	+ NOVARTIS	200MG	N11556 004	
	SULFINPYRAZONE			
AB	BARR	200MG	N87666 001	SEP 17, 1982
AB	IVAX PHARMS	200MG	N87770 001	NOV 19, 1982
AB	PAR PHARM	200MG	N88934 001	SEP 06, 1985

TABLET; ORAL

	ANTURANE			
AB	+ NOVARTIS	100MG	N11556 003	
	SULFINPYRAZONE			
AB	BARR	100MG	N87665 001	SEP 17, 1982
AB	PAR PHARM	100MG	N88933 001	SEP 06, 1985

SULFISOXAZOLE

TABLET; ORAL

	SOSOL			
AB	MK LABS	500MG	N80036 001	
	SULFISOXAZOLE			
AB	+ IVAX PHARMS	500MG	N80142 001	

FDA data supplied by DrugPatentWatch.com

SULFISOXAZOLE ACETYL

SUSPENSION; ORAL
GANTRISIN PEDIATRIC
+ ROCHE — EQ 500MG BASE/5ML — N09182 004

SULFISOXAZOLE ACETYL; *MULTIPLE*
SEE ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

SULINDAC

TABLET; ORAL

	CLINORIL			
AB	MERCK	**150MG**	**N17911 001**	
AB	+	**200MG**	**N17911 002**	
	SULINDAC			
AB	MUTUAL PHARM	**150MG**	**N72050 001**	APR 17, 1991
AB		**200MG**	**N72051 001**	APR 17, 1991
AB	MYLAN	**150MG**	**N73038 001**	JUN 22, 1993
AB		**200MG**	**N73039 001**	JUN 22, 1993
AB	SANDOZ	**150MG**	**N72712 001**	AUG 30, 1991
AB		**200MG**	**N72713 001**	AUG 30, 1991
AB	TEVA	**150MG**	**N72972 001**	FEB 28, 1992
AB		**200MG**	**N72973 001**	FEB 28, 1992
AB	WARNER CHILCOTT	**150MG**	**N72710 001**	MAR 25, 1991
AB		**200MG**	**N72711 001**	MAR 25, 1991
AB	WATSON LABS	**150MG**	**N71891 001**	APR 03, 1990
AB		**200MG**	**N71795 001**	APR 03, 1990

SUMATRIPTAN

SPRAY; NASAL
IMITREX
+ GLAXOSMITHKLINE — 5MG/SPRAY — N20626 001 AUG 26, 1997

SUMATRIPTAN

SPRAY; NASAL
IMITREX

+	GLAXOSMITHKLINE	10MG/SPRAY	N20626 002 AUG 26, 1997
+		20MG/SPRAY	N20626 003 AUG 26, 1997

SUMATRIPTAN SUCCINATE

INJECTABLE; INJECTION
IMITREX
+ GLAXOSMITHKLINE — EQ 6MG BASE/0.5ML — N20080 001 DEC 28, 1992

TABLET; ORAL
IMITREX

GLAXOSMITHKLINE	EQ 25MG BASE	N20132 002 JUN 01, 1995
	EQ 50MG BASE	N20132 003 JUN 01, 1995
+	EQ 100MG BASE	N20132 001 JUN 01, 1995

TACRINE HYDROCHLORIDE

CAPSULE; ORAL
COGNEX

FIRST HORIZON	EQ 10MG BASE	N20070 001 SEP 09, 1993
	EQ 20MG BASE	N20070 002 SEP 09, 1993
	EQ 30MG BASE	N20070 003 SEP 09, 1993
+	EQ 40MG BASE	N20070 004 SEP 09, 1993

TACROLIMUS

CAPSULE; ORAL
PROGRAF

FUJISAWA HLTHCARE	EQ 0.5MG BASE	N50708 003 AUG 24, 1998
	EQ 1MG BASE	N50708 001 APR 08, 1994

FDA data supplied by DrugPatentWatch.com

TACROLIMUS

CAPSULE; ORAL
PROGRAF
+ FUJISAWA HLTHCARE — EQ 5MG BASE — N50708 002 APR 08, 1994

INJECTABLE; INJECTION
PROGRAF
+ FUJISAWA HLTHCARE — EQ 5MG BASE/ML — N50709 001 APR 08, 1994

OINTMENT; TOPICAL
PROTOPIC
FUJISAWA HLTHCARE — 0.03% — N50777 001 DEC 08, 2000
+ — 0.1% — N50777 002 DEC 08, 2000

TADALAFIL

TABLET; ORAL
CIALIS
LILLY ICOS — 5MG — N21368 001 NOV 21, 2003
— 10MG — N21368 002 NOV 21, 2003
+ — 20MG — N21368 003 NOV 21, 2003

TALC

AEROSOL, METERED; INTRAPLEURAL
SCLEROSOL
+ BRYAN — 400MG/SPRAY — N20587 001 DEC 24, 1997

POWDER; INTRAPLEURAL
TALC
+ BRYAN — 5GM/BOT — N21388 001 DEC 15, 2003

TAMOXIFEN CITRATE

TABLET; ORAL
NOLVADEX
AB ASTRAZENECA — **EQ 10MG BASE** — **N17970 001**

TAMOXIFEN CITRATE

TABLET; ORAL
NOLVADEX
AB + ASTRAZENECA — **EQ 20MG BASE** — **N17970 002** MAR 21, 1994

TAMOXIFEN CITRATE
AB AEGIS PHARMS — **EQ 10MG BASE** — **N76398 001** MAR 31, 2003
AB — **EQ 20MG BASE** — **N76398 002** MAR 31, 2003
AB ANDRX PHARMS — **EQ 10MG BASE** — **N76179 001** FEB 20, 2003
AB — **EQ 20MG BASE** — **N76179 002** FEB 20, 2003
AB BARR — **EQ 10MG BASE** — **N70929 001** FEB 20, 2003
AB — **EQ 20MG BASE** — **N70929 002** FEB 20, 2003
AB IVAX PHARMS — **EQ 10MG BASE** — **N75740 001** FEB 20, 2003
AB — **EQ 20MG BASE** — **N75740 002** FEB 20, 2003
AB MYLAN — **EQ 10MG BASE** — **N74732 002** FEB 20, 2003
AB — **EQ 20MG BASE** — **N74732 001** FEB 20, 2003
AB PHARMACHEMIE — **EQ 10MG BASE** — **N74539 001** MAR 31, 2003
AB — **EQ 20MG BASE** — **N74858 001** FEB 20, 2003
AB ROXANE — **EQ 10MG BASE** — **N76027 001** FEB 20, 2003
AB — **EQ 20MG BASE** — **N76027 002** FEB 20, 2003
AB TEVA — **EQ 10MG BASE** — **N74504 001** APR 28, 2003
AB — **EQ 10MG BASE** — **N75797 001** FEB 20, 2003
AB — **EQ 20MG BASE** — **N74504 002** APR 28, 2003

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL
FLOMAX
+ BOEHRINGER INGELHEIM — 0.4MG — N20579 001 APR 15, 1997

FDA data supplied by DrugPatentWatch.com

TARTARIC ACID; *MULTIPLE*
SEE SODIUM BICARBONATE; TARTARIC ACID

TAZAROTENE

CREAM; TOPICAL
AVAGE
+ ALLERGAN 0.1% N21184 003 SEP 30, 2002

TAZORAC
+ ALLERGAN 0.05% N21184 001 SEP 29, 2000
+ 0.1% N21184 002 SEP 29, 2000

GEL; TOPICAL
TAZORAC
+ ALLERGAN 0.05% N20600 001 JUN 13, 1997
+ 0.1% N20600 002 JUN 13, 1997

TAZOBACTAM SODIUM; *MULTIPLE*
SEE PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
MACROTEC
BS BRACCO N/A N17833 001
PULMOLITE
BS CIS N/A N17776 001
TECHNESCAN MAA
BS MALLINCKRODT N/A N17842 001
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT
BS DRAXIMAGE N/A N17881 001 DEC 30, 1987

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION
ACUTECT
DIATIDE RES LABS N/A N20887 001 SEP 14, 1998

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE; INJECTION
NEUROLITE
BRISTOL MYERS SQUIBB N/A N20256 001 NOV 23, 1994

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION
NEO TECT KIT
+ DIATIDE RES LABS N/A N21012 001 AUG 03, 1999

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION
HEPATOLITE
CIS N/A N18467 001 MAR 16, 1982

TECHNETIUM TC-99M EXAMETAZIME KIT

INJECTABLE; INJECTION
CERETEC
AMERSHAM HLTH N/A N19829 001 DEC 30, 1988

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION
TECHNESCAN GLUCEPTATE
DRAXIMAGE N/A N18272 001 JAN 27, 1982

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE; INJECTION
CHOLETEC
BRACCO N/A N18963 001 JAN 21, 1987

FDA data supplied by DrugPatentWatch.com

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

	CIS-MDP			
AP	CIS		**N/A**	**N18124 001**
	MDP-BRACCO			
AP	BRACCO		**N/A**	**N18107 001**
	OSTEOLITE			
AP	CIS		**N/A**	**N17972 001**
	TECHNESCAN MDP KIT			
AP	+ DRAXIMAGE		**N/A**	**N18035 001**
	TECHNETIUM TC 99M MPI MDP			
AP	AMERSHAM HLTH		**N/A**	**N18141 001**

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE; INJECTION

TECHNESCAN MAG3			
MALLINCKRODT	N/A		N19882 001 JUN 15, 1990

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION

TECHNESCAN HDP			
MALLINCKRODT	N/A		N18321 001

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

	AN-DTPA			
AP	CIS		**N/A**	**N17714 001**
	DTPA			
AP	DRAXIMAGE		**N/A**	**N18511 001** DEC 29, 1989
	TECHNETIUM TC-99M PENTETATE KIT			
AP	AMERSHAM HLTH		**N/A**	**N17264 002**

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

	CIS-PYRO			
AP	CIS		**N/A**	**N19039 001** JUN 30, 1987
	PHOSPHOTEC			
AP	BRACCO		**N/A**	**N17680 001**

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

	TECHNESCAN PYP KIT			
AP	MALLINCKRODT		**N/A**	**N17538 001**

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

ULTRATAG			
MALLINCKRODT	N/A		N19981 001 JUN 10, 1991

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

CARDIOLITE			
BRISTOL MYERS SQUIBB	N/A		N19785 001 DEC 21, 1990
MIRALUMA			
BRISTOL MYERS SQUIBB	N/A		N19785 003 MAY 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL

TECHNELITE			
BRISTOL MYERS SQUIBB	0.0083-2.7 CI/GENERATOR		N17771 001
ULTRA-TECHNEKOW FM			
MALLINCKRODT	0.25-3 CI/GENERATOR		N17243 002

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE; INJECTION

MPI DMSA KIDNEY REAGENT			
AMERSHAM HLTH	N/A		N17944 001 MAY 18, 1982

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

	AN-SULFUR COLLOID			
AP	CIS		**N/A**	**N17858 001**
	TECHNECOLL			
AP	MALLINCKRODT		**N/A**	**N17059 001**

FDA data supplied by DrugPatentWatch.com

TECHNETIUM TC-99M TEBOROXIME KIT

INJECTABLE; INJECTION
CARDIOTEC
BRACCO N/A N19928 001 DEC 19, 1990

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION
MYOVIEW
AMERSHAM HLTH N/A N20372 001 FEB 09, 1996

TEGASEROD MALEATE

TABLET; ORAL
ZELNORM
NOVARTIS EQ 2MG BASE N21200 001 JUL 24, 2002
\+ EQ 6MG BASE N21200 002 JUL 24, 2002

TELMISARTAN

TABLET; ORAL
MICARDIS
BOEHRINGER INGELHEIM 20MG N20850 003 APR 04, 2000
40MG N20850 001 NOV 10, 1998
\+ 80MG N20850 002 NOV 10, 1998

TELMISARTAN; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; TELMISARTAN

TEMAZEPAM

CAPSULE; ORAL
RESTORIL
AB TYCO HLTHCARE **15MG** **N18163 001**
AB \+ **30MG** **N18163 002**

TEMAZEPAM

CAPSULE; ORAL
RESTORIL
TYCO HLTHCARE 7.5MG N18163 003 OCT 25, 1991

TEMAZEPAM
AB MYLAN **15MG** **N70919 001** JUL 07, 1986
AB **30MG** **N70920 001** JUL 10, 1986
AB PAR PHARM **15MG** **N71456 001** APR 21, 1987
AB **30MG** **N71457 001** APR 21, 1987
AB PUREPAC PHARM **15MG** **N71638 001** AUG 07, 1987
AB **30MG** **N71620 001** AUG 07, 1987
AB SANDOZ **15MG** **N71427 001** JAN 12, 1988
AB **30MG** **N71428 001** JAN 12, 1988
AB WATSON LABS **15MG** **N71446 001** MAY 21, 1993
AB **30MG** **N71447 001** MAY 21, 1993

TEMOZOLOMIDE

CAPSULE; ORAL
TEMODAR
SCHERING 5MG N21029 001 AUG 11, 1999
20MG N21029 002 AUG 11, 1999
100MG N21029 003 AUG 11, 1999
\+ 250MG N21029 004 AUG 11, 1999

TENIPOSIDE

INJECTABLE; INJECTION
VUMON
\+ BRISTOL MYERS SQUIBB 10MG/ML N20119 001 JUL 14, 1992

FDA data supplied by DrugPatentWatch.com

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

	VIREAD			
	+ GILEAD	300MG	N21356 001 OCT 26, 2001	

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

	HYTRIN			
AB	ABBOTT	**EQ 1MG BASE**	**N20347 001** DEC 14, 1994	
AB	+	**EQ 2MG BASE**	**N20347 002** DEC 14, 1994	
AB		**EQ 5MG BASE**	**N20347 003** DEC 14, 1994	
AB		**EQ 10MG BASE**	**N20347 004** DEC 14, 1994	
	TERAZOSIN HCL			
AB	IVAX PHARMS	**EQ 1MG BASE**	**N75614 002** JAN 30, 2001	
AB		**EQ 2MG BASE**	**N75614 001** JAN 30, 2001	
AB		**EQ 5MG BASE**	**N75614 003** JAN 30, 2001	
AB		**EQ 10MG BASE**	**N75614 004** JAN 30, 2001	
AB	MYLAN	**EQ 1MG BASE**	**N75140 002** FEB 11, 2000	
AB		**EQ 2MG BASE**	**N75140 003** FEB 11, 2000	
AB		**EQ 5MG BASE**	**N75140 001** FEB 11, 2000	
AB		**EQ 10MG BASE**	**N75140 004** FEB 11, 2000	
AB	MYLAN TECHNOLOGIES	**EQ 1MG BASE**	**N75384 001** DEC 01, 2000	
AB		**EQ 2MG BASE**	**N75384 002** DEC 01, 2000	
AB		**EQ 5MG BASE**	**N75384 003** DEC 01, 2000	
AB		**EQ 10MG BASE**	**N75384 004** DEC 01, 2000	
AB	RANBAXY	**EQ 1MG BASE**	**N76021 001** AUG 22, 2002	
AB		**EQ 2MG BASE**	**N76021 002** AUG 22, 2002	

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

	TERAZOSIN HCL			
AB	RANBAXY	**EQ 5MG BASE**	**N76021 003** AUG 22, 2002	
AB		**EQ 10MG BASE**	**N76021 004** AUG 22, 2002	
AB	SANDOZ	**EQ 1MG BASE**	**N74823 001** MAR 30, 1998	
AB		**EQ 1MG BASE**	**N75667 001** JUL 28, 2000	
AB		**EQ 2MG BASE**	**N74823 002** MAR 30, 1998	
AB		**EQ 2MG BASE**	**N75667 002** JUL 28, 2000	
AB		**EQ 5MG BASE**	**N74823 003** MAR 30, 1998	
AB		**EQ 5MG BASE**	**N75667 003** JUL 28, 2000	
AB		**EQ 10MG BASE**	**N74823 004** MAR 30, 1998	
AB		**EQ 10MG BASE**	**N75667 004** JUL 28, 2000	
AB	TORPHARM	**EQ 1MG BASE**	**N75498 001** APR 12, 2001	
AB		**EQ 2MG BASE**	**N75498 002** APR 12, 2001	
AB		**EQ 5MG BASE**	**N75498 003** APR 12, 2001	
AB		**EQ 10MG BASE**	**N75498 004** APR 12, 2001	

TABLET; ORAL

	HYTRIN			
AB	ABBOTT	**EQ 1MG BASE**	**N19057 001** AUG 07, 1987	
AB	+	**EQ 2MG BASE**	**N19057 002** AUG 07, 1987	
AB		**EQ 5MG BASE**	**N19057 003** AUG 07, 1987	
AB		**EQ 10MG BASE**	**N19057 004** AUG 07, 1987	
	TERAZOSIN HCL			
AB	IVAX PHARMS	**EQ 1MG BASE**	**N74530 001** APR 21, 2000	
AB		**EQ 2MG BASE**	**N74530 002** APR 21, 2000	

FDA data supplied by DrugPatentWatch.com

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL

	TERAZOSIN HCL		
AB	IVAX PHARMS	**EQ 5MG BASE**	**N74530 003** APR 21, 2000
AB		**EQ 10MG BASE**	**N74530 004** APR 21, 2000
AB	SANDOZ	**EQ 1MG BASE**	**N74315 001** DEC 31, 1998
AB		**EQ 1MG BASE**	**N74657 001** APR 28, 2000
AB		**EQ 2MG BASE**	**N74315 002** DEC 31, 1998
AB		**EQ 2MG BASE**	**N74657 002** APR 28, 2000
AB		**EQ 5MG BASE**	**N74315 003** DEC 31, 1998
AB		**EQ 5MG BASE**	**N74657 003** APR 28, 2000
AB		**EQ 10MG BASE**	**N74315 004** DEC 31, 1998
AB		**EQ 10MG BASE**	**N74657 004** APR 28, 2000
AB	TEVA	**EQ 1MG BASE**	**N74446 001** MAY 18, 2000
AB		**EQ 2MG BASE**	**N74446 002** MAY 18, 2000
AB		**EQ 5MG BASE**	**N74446 003** MAY 18, 2000
AB		**EQ 10MG BASE**	**N74446 004** MAY 18, 2000

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

	LAMISIL		
+	NOVARTIS	1%	N20192 001 DEC 30, 1992

SOLUTION; TOPICAL

	LAMISIL		
+	NOVARTIS	1%	N20749 001 OCT 17, 1997

TABLET; ORAL

	LAMISIL		
+	NOVARTIS	EQ 250MG BASE	N20539 001 MAY 10, 1996

TERBUTALINE SULFATE

INJECTABLE; INJECTION

	BRETHINE		
+	AAIPHARMA LLC	1MG/ML	N18571 001

TABLET; ORAL

	BRETHINE		
AB	AAIPHARMA LLC	**2.5MG**	**N17849 001**
AB	+	**5MG**	**N17849 002**
	TERBUTALINE SULFATE		
AB	IMPAX LABS	**2.5MG**	**N75877 001** JUN 26, 2001
AB		**5MG**	**N75877 002** JUN 26, 2001

TERCONAZOLE

CREAM; VAGINAL

	TERAZOL 3		
+	ORTHO MCNEIL PHARM	0.8%	N19964 001 FEB 21, 1991
	TERAZOL 7		
+	ORTHO MCNEIL PHARM	0.4%	N19579 001 DEC 31, 1987

SUPPOSITORY; VAGINAL

	TERAZOL 3		
+	ORTHO MCNEIL PHARM	80MG	N19641 001 MAY 24, 1988

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

	FORTEO		
+	LILLY	EQ 0.75MG 3ML(0.25MG/ML)	N21318 001 NOV 26, 2002

TESTOLACTONE

TABLET; ORAL

	TESLAC		
+	BRISTOL MYERS SQUIBB	50MG	N16118 001

FDA data supplied by DrugPatentWatch.com

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

	ANDRODERM				
BX	+ WATSON LABS	5MG/24HR	N20489 002		
			MAY 02, 1997		
	+	2.5MG/24HR	N20489 001		
			SEP 29, 1995		
	TESTODERM				
	+ ALZA	4MG/24HR	N19762 001		
			OCT 12, 1993		
	+	6MG/24HR	N19762 002		
			OCT 12, 1993		
	TESTODERM TTS				
BX	+ ALZA	5MG/24HR	N20791 001		
			DEC 18, 1997		

GEL; TOPICAL

	ANDROGEL		
BX	+ UNIMED PHARMS	1%	N21015 001
			FEB 28, 2000
	TESTIM		
BX	+ AUXILIUM A2	1%	N21454 001
			OCT 31, 2002

INJECTABLE; INJECTION

	TESTOSTERONE		
	+ STERIS	100MG/ML	N86417 001
			JUL 07, 1983

PELLET; IMPLANTATION

	TESTOSTERONE		
	BARTOR	75MG	N80911 001

TABLET, EXTENDED RELEASE; BUCCAL

	STRIANT		
	+ COLUMBIA LABS	30MG	N21543 001
			JUN 19, 2003

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

	DEPO-TESTOSTERONE			
AO	+ PHARMACIA AND UPJOHN	**100MG/ML**	**N85635 002**	
AO	+	**200MG/ML**	**N85635 003**	
	TESTOSTERONE CYPIONATE			
AO	STERIS	**100MG/ML**	**N86029 001**	
AO		**200MG/ML**	**N86030 001**	

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

	DELATESTRYL			
AO	+ SAVIENT PHARMS	**200MG/ML**	**N09165 003**	
	TESTOSTERONE ENANTHATE			
AO	STERIS	**200MG/ML**	**N85598 001**	

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION

	TESTOSTERONE PROPIONATE		
	+ STERIS	25MG/ML	N80188 001
		50MG/ML	N80188 002
	+	100MG/ML	N80188 003

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	BRISTACYCLINE			
AB	BRISTOL	**250MG**	**N61658 001**	
AB		**250MG**	**N61888 001**	
AB		**500MG**	**N61658 002**	
AB		**500MG**	**N61888 002**	
	SUMYCIN			
AB	APOTHECON	**250MG**	**N60429 001**	
AB	+	**500MG**	**N60429 003**	
	TETRACYCLINE HCL			
AB	AXIOM PHARM	**250MG**	**N60736 001**	
AB		**500MG**	**N60736 002**	
AB	BARR	**250MG**	**N61837 001**	
AB		**500MG**	**N61837 002**	
AB	IMPAX LABS	**250MG**	**N60469 001**	
AB		**500MG**	**N60469 003**	
		100MG	N60469 002	
AB	IVAX PHARMS	**250MG**	**N60704 001**	
AB		**500MG**	**N60704 002**	
AB	LABS ATRAL	**250MG**	**N62752 001**	
			AUG 12, 1988	
AB		**500MG**	**N62752 002**	
			AUG 12, 1988	
AB	MAST MM	**250MG**	**N62085 001**	
AB	MYLAN	**250MG**	**N60783 001**	
AB		**500MG**	**N60783 002**	

SUSPENSION; ORAL

	SUMYCIN		
	+ APOTHECON	125MG/5ML	N60400 001

FDA data supplied by DrugPatentWatch.com

TETRACYCLINE HYDROCHLORIDE

TABLET; ORAL
SUMYCIN
PAR PHARM 250MG N61147 001
\+ 500MG N61147 004

TETRACYCLINE HYDROCHLORIDE; *MULTIPLE*
SEE BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE; ORAL
TETREX
BRISTOL EQ 100MG HCL N61653 001
EQ 250MG HCL N61653 002
EQ 250MG HCL N61889 002
\+ EQ 500MG HCL N61653 003
EQ 500MG HCL N61889 001

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL
TYZINE
\+ KENWOOD LABS 0.05% N86576 002
0.1% N86576 001

SPRAY; NASAL
TYZINE
\+ KENWOOD LABS 0.1% N86576 003

THALIDOMIDE

CAPSULE; ORAL
THALOMID
CELGENE 50MG N20785 001
JUL 16, 1998
100MG N20785 002
JAN 17, 2003
\+ 200MG N20785 003
JAN 17, 2003

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION
THALLOUS CHLORIDE TL 201
AP \+ AMERSHAM HLTH **1mCi/ML** **N18110 002**
FEB 27, 1996
AP \+ BRISTOL MYERS SQUIBB **1mCi/ML** **N17806 001**
AP \+ MALLINCKRODT **1mCi/ML** **N18150 001**
AP MOUNT SINAI MEDCTR **1mCi/ML** **N75569 001**
NOV 21, 2001

INJECTABLE; INTRAVENOUS
THALLOUS CHLORIDE TL 201
\+ BRISTOL MYERS SQUIBB 2mCi/ML N17806 002
OCT 09, 1998

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
AEROLATE III
\+ FLEMING PHARMS 65MG N85075 003
NOV 24, 1986

AEROLATE JR
BC FLEMING PHARMS 130MG N85075 002
NOV 24, 1986

AEROLATE SR
BC FLEMING PHARMS 260MG N85075 001
NOV 24, 1986

THEO-24
BC UCB 100MG N87942 001
AUG 22, 1983
BC 200MG N87943 001
AUG 22, 1983
BC 300MG N87944 001
AUG 22, 1983
400MG N81034 001
FEB 28, 1992

THEOPHYLLINE
AB INWOOD LABS **100MG** **N40052 001**
FEB 14, 1994
AB **125MG** **N40052 002**
FEB 14, 1994
AB **200MG** **N40052 003**
FEB 14, 1994
AB **300MG** **N40052 004**
FEB 14, 1994

ELIXIR; ORAL
ELIXOPHYLLIN
AA FORREST LABS **80MG/15ML** **N85186 001**

FDA data supplied by DrugPatentWatch.com

THEOPHYLLINE

ELIXIR; ORAL

	THEOPHYLLINE			
AA	ALPHARMA	80MG/15ML	N85863 001	
AA	MORTON GROVE	80MG/15ML	N86748 001	
AA	PHARM ASSOC	80MG/15ML	N86720 001	
AA	TARO	80MG/15ML	N89626 001	
			OCT 28, 1988	

INJECTABLE; INJECTION

	THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ B BRAUN	40MG/100ML	N19826 001	
			AUG 14, 1992	
	THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ B BRAUN	80MG/100ML	N19826 002	
			AUG 14, 1992	
	THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ B BRAUN	160MG/100ML	N19826 003	
			AUG 14, 1992	
	THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ B BRAUN	320MG/100ML	N19826 006	
			AUG 14, 1992	
	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ BAXTER HLTHCARE	40MG/100ML	N18649 001	
			JUL 26, 1982	
AP	+	80MG/100ML	N18649 002	
			JUL 26, 1982	
AP	+	160MG/100ML	N18649 003	
			JUL 26, 1982	
AP	+	200MG/100ML	N18649 004	
			JUL 26, 1982	
AP	+	320MG/100ML	N18649 006	
			NOV 13, 1985	
AP	+	400MG/100ML	N18649 005	
			JUL 26, 1982	
AP	+	4MG/ML	N18649 007	
			JUL 26, 1982	
	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ ABBOTT	40MG/100ML	N19211 001	
			DEC 14, 1984	
AP	+	80MG/100ML	N19211 002	
			DEC 14, 1984	
AP	+	160MG/100ML	N19211 003	
			DEC 14, 1984	
AP	+	200MG/100ML	N19211 004	
			DEC 14, 1984	
AP	+	320MG/100ML	N19211 006	
			JAN 20, 1988	

THEOPHYLLINE

INJECTABLE; INJECTION

	THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ ABBOTT	400MG/100ML	N19211 005	
			DEC 14, 1984	
AP	+	4MG/ML	N19211 007	
			DEC 14, 1984	

SOLUTION; ORAL

	AEROLATE			
	+ FLEMING PHARMS	150MG/15ML	N89141 001	
			DEC 03, 1986	
	THEOLAIR			
AA	+ 3M	80MG/15ML	N86107 001	
	THEOPHYLLINE			
AA	ROXANE	80MG/15ML	N87449 001	
			SEP 15, 1983	

TABLET; ORAL

	QUIBRON-T			
	+ MONARCH PHARMS	300MG	N88656 001	
			AUG 22, 1985	
	THEOLAIR			
	+ 3M	125MG	N86399 001	
	+	250MG	N86399 002	

TABLET, EXTENDED RELEASE; ORAL

	QUIBRON-T/SR			
BC	MONARCH PHARMS	300MG	N87563 001	
			JUN 21, 1983	
	T-PHYL			
BC	PURDUE FREDERICK	200MG	N88253 001	
			AUG 17, 1983	
	THEOCHRON			
AB	INWOOD LABS	100MG	N88320 001	
			FEB 21, 1985	
AB		200MG	N88321 001	
			FEB 21, 1985	
AB		300MG	N87400 002	
			JAN 11, 1983	
	THEOLAIR-SR			
BC	3M	200MG	N88369 001	
			JUL 16, 1987	
BC		300MG	N88364 001	
			JUL 16, 1987	
		250MG	N86363 002	
			JUL 16, 1987	

FDA data supplied by DrugPatentWatch.com

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

	THEOLAIR-SR			
	+ 3M	500MG	N89132 001	JUL 16, 1987
	THEOPHYLLINE			
AB	INWOOD LABS	**450MG**	**N40034 001**	APR 28, 1995
AB	+ PLIVA	**100MG**	**N89807 001**	APR 30, 1990
AB	+	**200MG**	**N89808 001**	APR 30, 1990
AB		**300MG**	**N89763 001**	APR 30, 1990
AB	+	**450MG**	**N81236 001**	NOV 09, 1992
	UNIPHYL			
	+ PURDUE FREDERICK	400MG	N87571 001	SEP 01, 1982
	+	600MG	N40086 001	APR 15, 1996

THIABENDAZOLE

SUSPENSION; ORAL

MINTEZOL			
+ MERCK	500MG/5ML	N16097 001	

TABLET, CHEWABLE; ORAL

MINTEZOL		
+ MERCK	500MG	N16096 001

THIAMINE; *MULTIPLE*

SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	THIAMINE HCL			
AP	ABBOTT	**100MG/ML**	**N40079 001**	MAY 03, 1996
AP	+ AM PHARM PARTNERS	**100MG/ML**	**N80556 001**	

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

	THIAMINE HCL			
AP	ELKINS SINN	**100MG/ML**	**N80575 001**	
AP	STERIS	**100MG/ML**	**N80571 001**	
	+	200MG/ML	N80571 002	

THIAMINE HYDROCHLORIDE; *MULTIPLE*

SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

THIETHYLPERAZINE MALEATE

TABLET; ORAL

TORECAN			
+ NOVARTIS	10MG	N12753 001	

THIOGUANINE

TABLET; ORAL

THIOGUANINE			
+ GLAXOSMITHKLINE	40MG	N12429 001	

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

	THIORIDAZINE HCL			
AA	ALPHARMA	**100MG/ML**	**N88229 001**	AUG 23, 1983
AA	+ COPLEY PHARM	**30MG/ML**	**N89602 001**	NOV 09, 1987
AA	+	**100MG/ML**	**N89603 001**	NOV 09, 1987

FDA data supplied by DrugPatentWatch.com

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

	THIORIDAZINE HCL			
AA	HI TECH PHARMA	30MG/ML	N40125 001	AUG 16, 1996
AA		100MG/ML	N40126 001	AUG 16, 1996
AA	PHARM ASSOC	30MG/ML	N40187 001	AUG 28, 1997
AA		100MG/ML	N40213 001	MAY 29, 1998
	THIORIDAZINE HCL INTENSOL			
AA	ROXANE	30MG/ML	N88941 001	DEC 16, 1985
AA		100MG/ML	N88942 001	DEC 16, 1985

TABLET; ORAL

	THIORIDAZINE HCL			
AB	HALSEY	50MG	N88370 001	NOV 18, 1983
AB	IVAX PHARMS	10MG	N88270 001	APR 14, 1983
AB		15MG	N88271 001	APR 14, 1983
AB		25MG	N88272 001	APR 14, 1983
AB	MUTUAL PHARM	10MG	N89431 001	AUG 01, 1986
AB		25MG	N89432 001	AUG 01, 1986
AB		50MG	N89433 001	AUG 01, 1986
AB		100MG	N89953 001	OCT 07, 1988
AB	MYLAN	10MG	N88001 001	MAR 15, 1983
AB		25MG	N88002 001	MAR 15, 1983
AB		50MG	N88003 001	MAR 15, 1983
AB		100MG	N88004 001	NOV 18, 1983
AB	SANDOZ	10MG	N88131 001	AUG 30, 1983
AB		15MG	N88132 001	AUG 30, 1983

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

	THIORIDAZINE HCL			
AB +	SANDOZ	25MG	N88133 001	AUG 30, 1983
AB		50MG	N88134 001	AUG 30, 1983
AB +		100MG	N88135 001	NOV 20, 1984
AB		150MG	N88136 001	SEP 17, 1986
AB +		200MG	N88137 001	SEP 17, 1986
AB	TEVA	100MG	N88456 001	MAY 17, 1985
AB	WATSON LABS	10MG	N88476 001	NOV 08, 1983
AB		15MG	N88477 001	NOV 08, 1983
AB		25MG	N88478 001	NOV 08, 1983
AB		25MG	N88567 001	MAY 11, 1984
AB		50MG	N88479 001	NOV 08, 1983
AB		50MG	N88563 001	MAY 11, 1984
AB		100MG	N88564 001	MAY 11, 1984
AB		100MG	N88736 001	JUL 24, 1984
AB		150MG	N88869 001	JUN 28, 1985
AB		200MG	N88872 001	APR 26, 1985

THIOTEPA

INJECTABLE; INJECTION

	THIOTEPA			
AP	AM PHARM PARTNERS	15MG/VIAL	N75698 001	SEP 20, 2001
AP	BEDFORD	15MG/VIAL	N75547 001	APR 02, 2001
AP +	GENSIA SICOR PHARMS	15MG/VIAL	N75730 001	APR 20, 2001

FDA data supplied by DrugPatentWatch.com

THIOTEPA

INJECTABLE; INJECTION

	THIOTEPA			
	+ GENSIA SICOR PHARMS	30MG/VIAL	N75730 002	APR 20, 2001

THIOTHIXENE

CAPSULE; ORAL

	NAVANE			
AB	PFIZER	**1MG**	**N16584 001**	
AB		**2MG**	**N16584 002**	
AB	+	**5MG**	**N16584 003**	
AB		**10MG**	**N16584 004**	
		20MG	N16584 005	
	THIOTHIXENE			
AB	MYLAN	**1MG**	**N71090 001**	JUN 23, 1987
AB		**2MG**	**N71091 001**	JUN 23, 1987
AB		**5MG**	**N71092 001**	JUN 23, 1987
AB		**10MG**	**N71093 001**	JUN 23, 1987
AB	SANDOZ	**1MG**	**N71610 001**	JUN 24, 1987
AB		**2MG**	**N71570 001**	JUN 24, 1987
AB		**5MG**	**N71529 001**	JUN 24, 1987
AB		**10MG**	**N71530 001**	JUN 24, 1987
AB	WATSON LABS	**1MG**	**N70600 001**	JUN 05, 1987
AB		**2MG**	**N70601 001**	JUN 05, 1987
AB		**5MG**	**N70602 001**	JUN 05, 1987
AB		**10MG**	**N70603 001**	JUN 05, 1987

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

	NAVANE			
AA	+ PFIZER	**EQ 5MG BASE/ML**	**N16758 001**	

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

	THIOTHIXENE HCL			
AA	COPLEY PHARM	**EQ 5MG BASE/ML**	**N71554 001**	OCT 16, 1987

INJECTABLE; INJECTION

	NAVANE		
	+ PFIZER	EQ 10MG BASE/VIAL	N16904 002

THONZONIUM BROMIDE; *MULTIPLE*

SEE COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

THYROTROPIN ALFA

INJECTABLE; INJECTION

	THYROGEN		
	+ GENZYME	1.1MG/VIAL	N20898 001 NOV 30, 1998

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

	GABITRIL		
	+ CEPHALON	2MG	N20646 005 APR 16, 1999
		4MG	N20646 001 SEP 30, 1997
		12MG	N20646 002 SEP 30, 1997
	+	16MG	N20646 003 SEP 30, 1997

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

	TICAR		
	+ GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N50497 001
	+	EQ 3GM BASE/VIAL	N50497 002
	+	EQ 20GM BASE/VIAL	N50497 004
	+	EQ 30GM BASE/VIAL	N50497 005 APR 04, 1984

FDA data supplied by DrugPatentWatch.com

TICARCILLIN DISODIUM; *MULTIPLE*
SEE CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

	TICLID			
AB	+ ROCHE PALO	250MG	N19979 002 OCT 31, 1991	
	TICLOPIDINE HCL			
AB	CARACO	250MG	N75526 001 SEP 26, 2002	
AB	EON	250MG	N75326 001 AUG 20, 1999	
AB	GENPHARM	250MG	N75161 001 SEP 13, 1999	
AB	MYLAN	250MG	N75316 001 NOV 02, 1999	
AB	PUREPAC PHARM	250MG	N75253 001 AUG 20, 1999	
AB	SANDOZ	250MG	N75318 001 AUG 20, 1999	
AB	TEVA	250MG	N75149 001 AUG 20, 1999	
AB	TORPHARM	250MG	N75089 001 JUL 01, 1999	
AB	WATSON LABS	250MG	N75309 001 APR 26, 2000	

TILUDRONATE DISODIUM

TABLET; ORAL

	SKELID			
+	SANOFI SYNTHELABO	EQ 200MG BASE	N20707 001 MAR 07, 1997	

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

	BETIMOL			
+	SANTEN OY	EQ 0.25% BASE	N20439 001 MAR 31, 1995	
+		EQ 0.5% BASE	N20439 002 MAR 31, 1995	

TIMOLOL MALEATE

SOLUTION; OPHTHALMIC

	TIMOLOL MALEATE			
AT	HI TECH PHARMA	EQ 0.5% BASE	N75163 001 SEP 10, 2002	

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

	TIMOLOL MALEATE			
AB	FALCON PHARMS	EQ 0.25% BASE	N20963 001 OCT 21, 1998	
AB		EQ 0.5% BASE	N20963 002 OCT 21, 1998	
	TIMOPTIC-XE			
AB	+ MERCK	EQ 0.25% BASE	N20330 001 NOV 04, 1993	
AB	+	EQ 0.5% BASE	N20330 002 NOV 04, 1993	

SOLUTION/DROPS; OPHTHALMIC

	TIMOLOL MALEATE			
AT	AKORN	EQ 0.25% BASE	N74465 001 MAR 25, 1997	
AT		EQ 0.25% BASE	N74515 001 MAR 25, 1997	
AT		EQ 0.5% BASE	N74466 001 MAR 25, 1997	
AT		EQ 0.5% BASE	N74516 001 MAR 25, 1997	
AT	BAUSCH AND LOMB	EQ 0.25% BASE	N74778 001 MAR 25, 1997	
AT		EQ 0.5% BASE	N74776 001 MAR 25, 1997	
AT	FALCON PHARMS	EQ 0.25% BASE	N74261 001 APR 28, 1995	
AT		EQ 0.5% BASE	N74262 001 APR 28, 1995	
AT	FOUGERA	EQ 0.25% BASE	N74667 001 MAR 25, 1997	
AT		EQ 0.5% BASE	N74668 001 MAR 25, 1997	
AT	NOVEX	EQ 0.25% BASE	N75411 001 SEP 08, 2000	
AT		EQ 0.5% BASE	N75412 001 SEP 08, 2000	
AT	PACIFIC PHARMA	EQ 0.25% BASE	N74746 001 MAR 25, 1997	
AT		EQ 0.5% BASE	N74747 001 MAR 25, 1997	

FDA data supplied by DrugPatentWatch.com

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

	TIMOPTIC			
AT	+ MERCK	**EQ 0.25% BASE**	**N18086 001**	
AT	+	**EQ 0.5% BASE**	**N18086 002**	
	TIMOPTIC IN OCUDOSE			
	+ MERCK	EQ 0.25% BASE	N19463 001	NOV 05, 1986
	+	EQ 0.5% BASE	N19463 002	NOV 05, 1986

TABLET; ORAL

	BLOCADREN			
AB	MERCK	**5MG**	**N18017 001**	
AB		**10MG**	**N18017 002**	
AB	+	**20MG**	**N18017 004**	
	TIMOLOL MALEATE			
AB	MYLAN	**5MG**	**N72666 001**	JUN 08, 1990
AB		**10MG**	**N72667 001**	JUN 08, 1990
AB		**20MG**	**N72668 001**	JUN 08, 1990
AB	SANDOZ	**5MG**	**N72550 001**	APR 13, 1989
AB		**10MG**	**N72551 001**	APR 13, 1989
AB		**20MG**	**N72552 001**	APR 13, 1989
AB	WATSON LABS	**5MG**	**N72917 001**	JUL 31, 1991
AB		**10MG**	**N72918 001**	JUL 31, 1991
AB		**20MG**	**N72919 001**	JUL 31, 1991

TIMOLOL MALEATE; *MULTIPLE*
SEE DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE
SEE HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TINZAPARIN SODIUM

INJECTABLE; INJECTION

	INNOHEP			
	+ PHARMION	20,000 IU/ML	N20484 001	JUL 14, 2000

TIOPRONIN

TABLET; ORAL

	TIOPRONIN			
	+ MISSION PHARMA	100MG	N19569 001	AUG 11, 1988

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

	AGGRASTAT			
	+ GUILFORD PHARMS	EQ 0.05MG BASE/ML	N20913 001	MAY 14, 1998
	+	EQ 0.25MG BASE/ML	N20912 001	MAY 14, 1998

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

	ZANAFLEX			
	ELAN PHARMS	EQ 2MG BASE	N21447 001	AUG 29, 2002
		EQ 4MG BASE	N21447 002	AUG 29, 2002
	+	EQ 6MG BASE	N21447 003	AUG 29, 2002

TABLET; ORAL

	TIZANIDINE HCL			
AB	ALPHAPHARM	**EQ 2MG BASE**	**N76282 001**	DEC 16, 2003
AB		**EQ 4MG BASE**	**N76282 002**	DEC 16, 2003
AB	AMIDE PHARM	**EQ 2MG BASE**	**N76281 001**	OCT 20, 2003
AB		**EQ 4MG BASE**	**N76281 002**	OCT 20, 2003
AB	BARR	**EQ 2MG BASE**	**N76371 001**	APR 09, 2003
AB		**EQ 4MG BASE**	**N76371 002**	APR 09, 2003
AB	CARACO	**EQ 2MG BASE**	**N76416 001**	SEP 29, 2003
AB		**EQ 4MG BASE**	**N76416 002**	SEP 29, 2003
AB	COREPHARMA	**EQ 2MG BASE**	**N76347 001**	OCT 11, 2002

FDA data supplied by DrugPatentWatch.com

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

	TIZANIDINE HCL			
AB	COREPHARMA	EQ 4MG BASE	N76347 002	
			OCT 11, 2002	
AB	DR REDDYS LABS INC	EQ 2MG BASE	N76286 001	
			JUL 03, 2002	
AB		EQ 4MG BASE	N76286 002	
			JUL 03, 2002	
AB	EON	EQ 2MG BASE	N76399 001	
			NOV 26, 2002	
AB		EQ 4MG BASE	N76280 002	
			JUN 27, 2002	
AB	MYLAN	EQ 2MG BASE	N76354 001	
			MAR 28, 2003	
AB		EQ 4MG BASE	N76354 002	
			MAR 28, 2003	
AB	PUREPAC PHARM	EQ 2MG BASE	N76283 001	
			JUL 12, 2002	
AB		EQ 4MG BASE	N76283 002	
			JUL 12, 2002	
AB	TEVA	EQ 2MG BASE	N76284 001	
			JUL 03, 2002	
AB		EQ 4MG BASE	N76284 002	
			JUL 03, 2002	
	ZANAFLEX			
AB	ELAN PHARMS	EQ 2MG BASE	N20397 002	
			FEB 04, 2000	
AB +		EQ 4MG BASE	N20397 001	
			NOV 27, 1996	

TOBRAMYCIN

OINTMENT; OPHTHALMIC

	TOBREX		
+	ALCON	0.3%	N50555 001

SOLUTION; INHALATION

	TOBI		
+	CHIRON	300MG/5ML	N50753 001
			DEC 22, 1997

SOLUTION/DROPS; OPHTHALMIC

	AKTOB		
AT	AKORN	0.3%	N64096 001
			JAN 31, 1996

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

	TOBRAMYCIN		
AT	ALTANA	0.3%	N65026 001
			SEP 11, 2001
AT	BAUSCH AND LOMB	0.3%	N64052 001
			NOV 29, 1993
AT	NOVEX	0.3%	N65087 001
			FEB 25, 2002
	TOBREX		
AT	ALCON	0.3%	N62535 001
			DEC 13, 1984
AT +	FALCON PHARMS	0.3%	N50541 001

TOBRAMYCIN; *MULTIPLE*
SEE DEXAMETHASONE; TOBRAMYCIN
SEE FLUOROMETHOLONE ACETATE; TOBRAMYCIN

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

	NEBCIN			
AP	+ LILLY	EQ 1.2GM BASE/VIAL	N50519 001	
AP	+	EQ 10MG BASE/ML	N50477 005	
AP		EQ 10MG BASE/ML	N62008 004	
AP		EQ 10MG BASE/ML	N62707 001	
			APR 29, 1987	
AP	+	EQ 40MG BASE/ML	N62008 001	
	TOBRAMYCIN			
AP	AM PHARM PARTNERS	EQ 10MG BASE/ML	N65122 001	
			NOV 29, 2002	
AP		EQ 40MG BASE/ML	N65122 002	
			NOV 29, 2002	
AP	PHARMA TEK	EQ 1.2GM BASE/VIAL	N65013 001	
			AUG 17, 2001	
	TOBRAMYCIN (PHARMACY BULK)			
AP	AM PHARM PARTNERS	EQ 40MG BASE/ML	N65120 001	
			NOV 29, 2002	
	TOBRAMYCIN SULFATE			
AP	ABBOTT	EQ 10MG BASE/ML	N63080 001	
			APR 30, 1991	
AP		EQ 10MG BASE/ML	N63112 001	
			APR 30, 1991	
AP		EQ 40MG BASE/ML	N63111 001	
			APR 30, 1991	

FDA data supplied by DrugPatentWatch.com

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
TOBRAMYCIN SULFATE

AP	+ ABBOTT	EQ 40MG BASE/ML	N63116 001 MAY 18, 1992	
AP		EQ 40MG BASE/ML	N63161 001 MAY 29, 1991	
AP	APOTHECON	EQ 10MG BASE/ML	N64021 001 MAY 31, 1994	
AP		EQ 40MG BASE/ML	N64021 002 MAY 31, 1994	
AP	BAXTER HLTHCARE	EQ 40MG BASE/ML	N63117 001 APR 26, 1991	
AP		EQ 40MG BASE/ML	N63118 001 JUL 29, 1991	
AP	GENSIA SICOR PHARMS	EQ 40MG BASE/ML	N63100 001 JAN 30, 1992	
AP	MARSAM PHARMS LLC	EQ 10MG BASE/ML	N62945 001 AUG 09, 1989	
AP		EQ 40MG BASE/ML	N62945 002 AUG 09, 1989	

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	ABBOTT	EQ 80MG BASE/100ML	N63081 001 JUL 31, 1990
+		EQ 1.2MG BASE/ML	N63081 003 JUL 31, 1990
+		EQ 1.6MG BASE/ML	N63081 006 JUN 02, 1993

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL
TONOCARD

	ASTRAZENECA	400MG	N18257 001 NOV 09, 1984
+		600MG	N18257 002 NOV 09, 1984

TOCOPHEROL ACETATE; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

AB	IVAX PHARMS	100MG	N18894 001 NOV 02, 1984	
AB		250MG	N18894 002 NOV 02, 1984	
AB		500MG	N18894 003 NOV 02, 1984	
AB	MUTUAL PHARM	100MG	N71357 001 JUL 16, 1987	
AB		250MG	N71358 001 JUL 16, 1987	
AB		500MG	N71359 001 JUL 16, 1987	
AB	MYLAN	250MG	N70259 001 JAN 02, 1986	
AB		500MG	N70913 001 MAR 17, 1986	
AB	PAR PHARM	100MG	N70159 001 JAN 06, 1986	
AB		250MG	N70160 001 JAN 06, 1986	
AB		500MG	N70161 001 JAN 06, 1986	
AB	SANDOZ	100MG	N71633 001 DEC 09, 1987	
AB		250MG	N70289 001 MAR 13, 1986	
AB		500MG	N70290 001 MAR 13, 1986	
AB	WATSON LABS	100MG	N70513 001 JAN 09, 1986	
AB		250MG	N70514 001 JAN 09, 1986	
AB		500MG	N70515 001 JAN 09, 1986	

TOLINASE

AB	PHARMACIA AND UPJOHN	100MG	N15500 002
AB		250MG	N15500 004
AB	+	500MG	N15500 005

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE

AB	IVAX PHARMS	500MG	N87093 001

FDA data supplied by DrugPatentWatch.com

TOLBUTAMIDE

TABLET; ORAL

	TOLBUTAMIDE			
AB	MYLAN	**500MG**	**N86445 001**	
AB	SANDOZ	**500MG**	**N86574 001**	
AB +	WATSON LABS	**500MG**	**N86109 001**	
AB		**500MG**	**N87318 001**	

TOLCAPONE

TABLET; ORAL

	TASMAR			
	ROCHE	100MG	N20697 001	JAN 29, 1998
+		200MG	N20697 002	JAN 29, 1998

TOLMETIN SODIUM

CAPSULE; ORAL

	TOLECTIN DS			
AB +	ORTHO MCNEIL PHARM	**EQ 400MG BASE**	**N18084 001**	
	TOLMETIN SODIUM			
AB	IVAX PHARMS	**EQ 400MG BASE**	**N73392 001**	JAN 24, 1992
AB	MUTUAL PHARM	**EQ 400MG BASE**	**N73311 001**	NOV 27, 1991
AB	MYLAN	**EQ 400MG BASE**	**N73393 001**	MAY 27, 1993
AB	PUREPAC PHARM	**EQ 400MG BASE**	**N73308 001**	JAN 24, 1992
AB	TEVA	**EQ 400MG BASE**	**N73290 001**	NOV 27, 1991
AB		**EQ 400MG BASE**	**N73519 001**	MAY 29, 1992

TABLET; ORAL

	TOLECTIN			
AB	ORTHO MCNEIL PHARM	**EQ 200MG BASE**	**N17628 001**	
	TOLECTIN 600			
AB +	ORTHO MCNEIL PHARM	**EQ 600MG BASE**	**N17628 002**	MAR 08, 1989
	TOLMETIN SODIUM			
AB	IVAX PHARMS	**EQ 600MG BASE**	**N74399 001**	MAR 28, 1996

TOLMETIN SODIUM

TABLET; ORAL

	TOLMETIN SODIUM			
AB	MUTUAL PHARM	**EQ 200MG BASE**	**N73310 001**	NOV 27, 1991
AB	MYLAN	**EQ 600MG BASE**	**N74473 001**	AUG 30, 1994
AB	PUREPAC PHARM	**EQ 600MG BASE**	**N73527 001**	JUN 30, 1992
AB	SANDOZ	**EQ 200MG BASE**	**N73588 001**	JUL 31, 1992
AB		**EQ 600MG BASE**	**N74002 001**	SEP 27, 1993

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

	DETROL LA			
+	PHARMACIA AND UPJOHN	2MG	N21228 001	DEC 22, 2000
+		4MG	N21228 002	DEC 22, 2000

TABLET; ORAL

	DETROL			
	PHARMACIA AND UPJOHN	1MG	N20771 001	MAR 25, 1998
+		2MG	N20771 002	MAR 25, 1998

TOPIRAMATE

CAPSULE; ORAL

	TOPAMAX SPRINKLE			
	ORTHO MCNEIL	15MG	N20844 001	OCT 26, 1998
+		25MG	N20844 002	OCT 26, 1998

TABLET; ORAL

	TOPAMAX			
+	ORTHO MCNEIL PHARM	25MG	N20505 004	DEC 24, 1996
		100MG	N20505 001	DEC 24, 1996

FDA data supplied by DrugPatentWatch.com

TOPIRAMATE

TABLET; ORAL

TOPAMAX				
ORTHO MCNEIL PHARM	200MG	N20505 002 DEC 24, 1996		

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

HYCAMTIN				
+ GLAXOSMITHKLINE	EQ 4MG BASE/VIAL	N20671 001 MAY 28, 1996		

TOREMIFENE CITRATE

TABLET; ORAL

FARESTON				
+ ORION	EQ 60MG BASE	N20497 001 MAY 29, 1997		

TORSEMIDE

INJECTABLE; INJECTION

DEMADEX				
+ ROCHE	10MG/ML	N20137 002 AUG 23, 1993		

TABLET; ORAL

DEMADEX				
AB ROCHE	5MG	**N20136 001** AUG 23, 1993		
AB	10MG	**N20136 002** AUG 23, 1993		
AB +	20MG	**N20136 003** AUG 23, 1993		
AB	100MG	**N20136 004** AUG 23, 1993		
TORSEMIDE				
AB PAR PHARM	5MG	**N76226 001** MAY 27, 2003		
AB	10MG	**N76226 002** MAY 27, 2003		
AB	20MG	**N76226 003** MAY 27, 2003		

TORSEMIDE

TABLET; ORAL

TORSEMIDE				
AB PAR PHARM	100MG	**N76226 004** MAY 27, 2003		
AB PLIVA PHARM IND	5MG	**N76346 001** MAY 30, 2003		
AB	10MG	**N76346 002** MAY 30, 2003		
AB	20MG	**N76346 003** MAY 30, 2003		
AB TEVA	5MG	**N76110 001** MAY 14, 2002		
AB	10MG	**N76110 002** MAY 14, 2002		
AB	20MG	**N76110 003** MAY 14, 2002		
AB	100MG	**N76110 004** MAY 14, 2002		

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HCL				
AB ALPHAPHARM	50MG	**N75980 001** NOV 21, 2002		
AB CARACO	50MG	**N75964 001** JUN 19, 2002		
AB COREPHARMA	50MG	**N76003 001** JUN 20, 2002		
AB EON	50MG	**N75968 001** JUN 25, 2002		
AB IVAX PHARMS	50MG	**N75963 001** JUL 03, 2002		
AB MALLINCKRODT	50MG	**N75983 001** JUN 25, 2002		
AB MUTUAL PHARM	50MG	**N76100 001** JUN 20, 2002		
AB MYLAN	50MG	**N75986 001** JUN 21, 2002		
AB PLIVA	50MG	**N75982 001** JUL 01, 2002		
AB PUREPAC PHARM	50MG	**N75960 001** JUN 19, 2002		
AB TEVA	50MG	**N75977 001** JUN 19, 2002		

FDA data supplied by DrugPatentWatch.com

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

	TRAMADOL HCL			
AB	TORPHARM	50MG	**N75981 001**	JUL 10, 2002
AB	WATSON LABS	50MG	**N75962 001**	JUN 24, 2002
	ULTRAM			
AB +	ORTHO MCNEIL PHARM	50MG	**N20281 002**	MAR 03, 1995

TRAMADOL HYDROCHLORIDE; *MULTIPLE*
SEE ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TRANDOLAPRIL

TABLET; ORAL

	MAVIK			
	ABBOTT	1MG	N20528 001	APR 26, 1996
		2MG	N20528 002	APR 26, 1996
+		4MG	N20528 003	APR 26, 1996

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	TARKA			
+	ABBOTT	1MG;240MG	N20591 003	OCT 22, 1996
+		2MG;180MG	N20591 001	OCT 22, 1996
+		2MG;240MG	N20591 004	OCT 22, 1996
+		4MG;240MG	N20591 002	OCT 22, 1996

TRANEXAMIC ACID

INJECTABLE; INJECTION

	CYKLOKAPRON			
+	PHARMACIA AND UPJOHN	100MG/ML	N19281 001	DEC 30, 1986

TRANYLCYPROMINE SULFATE

TABLET; ORAL

	PARNATE			
+	GLAXOSMITHKLINE	EQ 10MG BASE	N12342 003	AUG 16, 1985

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

	TRAVATAN			
+	ALCON UNIVERSAL	0.004%	N21257 001	MAR 16, 2001

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

	DESYREL			
AB	APOTHECON	50MG	**N18207 001**	
AB		100MG	**N18207 002**	
AB		150MG	**N18207 003**	MAR 25, 1985
AB +		300MG	**N18207 004**	NOV 07, 1988
	TRAZODONE HCL			
AB	BARR	50MG	**N71258 001**	MAR 25, 1987
AB		100MG	**N71196 001**	MAR 25, 1987
AB		150MG	**N71196 002**	APR 26, 1999
AB		300MG	**N71196 003**	APR 26, 1999
AB	MUTUAL PHARM	50MG	**N73136 001**	MAR 24, 1993
AB		100MG	**N73137 001**	MAR 24, 1993
AB		150MG	**N73138 001**	DEC 22, 1995
AB	MYLAN	50MG	**N71405 001**	FEB 27, 1991
AB		100MG	**N71406 001**	FEB 27, 1991
AB	PLIVA	50MG	**N71523 001**	DEC 11, 1987
AB		100MG	**N71524 001**	DEC 11, 1987

FDA data supplied by DrugPatentWatch.com

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

	TRAZODONE HCL			
AB	PLIVA	**150MG**	**N71525 001**	
			MAR 09, 1988	
AB	PUREPAC PHARM	**50MG**	**N71636 001**	
			APR 18, 1988	
AB		**100MG**	**N71514 001**	
			APR 18, 1988	
AB	SANDOZ	**50MG**	**N72484 001**	
			APR 30, 1990	
AB		**100MG**	**N72483 001**	
			APR 30, 1990	
AB	TEVA	**50MG**	**N72192 001**	
			FEB 02, 1989	
AB		**100MG**	**N72193 001**	
			FEB 02, 1989	
AB		**150MG**	**N74357 001**	
			APR 30, 1997	
AB	WATSON LABS	**50MG**	**N70857 001**	
			OCT 10, 1986	
AB		**100MG**	**N70858 001**	
			OCT 10, 1986	

TREPROSTINIL SODIUM

INJECTABLE; SUBCUTANEOUS

	REMODULIN			
	UNITED THERAP	1MG/ML	N21272 001	
			MAY 21, 2002	
		2.5MG/ML	N21272 002	
			MAY 21, 2002	
		5MG/ML	N21272 003	
			MAY 21, 2002	
+		10MG/ML	N21272 004	
			MAY 21, 2002	

TRETINOIN

CAPSULE; ORAL

	VESANOID			
+	ROCHE	10MG	N20438 001	
			NOV 22, 1995	

CREAM; TOPICAL

	AVITA			
AB	BERTEK PHARMS	**0.025%**	**N20404 003**	
			JAN 14, 1997	

TRETINOIN

CREAM; TOPICAL

	RENOVA			
+	JOHNSON AND JOHNSON	0.02%	N21108 001	
			AUG 31, 2000	
	RETIN-A			
AB +	JOHNSON AND JOHNSON	**0.025%**	**N19049 001**	
			SEP 16, 1988	
AB +		**0.05%**	**N17522 001**	
AB +		**0.1%**	**N17340 001**	
	TRETINOIN			
AB	SPEAR PHARMS	**0.025%**	**N75264 001**	
			DEC 24, 1998	
AB		**0.05%**	**N75265 001**	
			DEC 24, 1998	
AB		**0.1%**	**N75213 001**	
			DEC 24, 1998	

CREAM, AUGMENTED; TOPICAL

	RENOVA			
+	JOHNSON AND JOHNSON	0.05%	N19963 001	
			DEC 29, 1995	

GEL; TOPICAL

	AVITA			
BT	BERTEK PHARMS	0.025%	N20400 001	
			JAN 29, 1998	
	RETIN-A			
AB +	JOHNSON AND JOHNSON	**0.01%**	**N17955 001**	
AB +		**0.025%**	**N17579 002**	
	RETIN-A MICRO			
+	JOHNSON AND JOHNSON	0.04%	N20475 002	
			MAY 10, 2002	
+		0.1%	N20475 001	
			FEB 07, 1997	
	TRETINOIN			
AB	SPEAR PHARMS	**0.01%**	**N75589 001**	
			JUN 11, 2002	
AB		**0.025%**	**N75529 001**	
			FEB 22, 2000	

SOLUTION; TOPICAL

	RETIN-A			
AT +	JOHNSON AND JOHNSON	**0.05%**	**N16921 001**	
	TRETINOIN			
AT	COPLEY PHARM	**0.05%**	**N74873 001**	
			JUN 19, 1998	

FDA data supplied by DrugPatentWatch.com

TRETINOIN

SOLUTION; TOPICAL

	TRETINOIN			
AT	MORTON GROVE	0.05%	N75260 001	JAN 25, 1999

TRETINOIN; *MULTIPLE*

SEE FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

SEE MEQUINOL; TRETINOIN

TRIAMCINOLONE

TABLET; ORAL

	ARISTOCORT		
BP	FUJISAWA HLTHCARE	4MG	N11161 007
	KENACORT		
BP	BRISTOL MYERS SQUIBB	4MG	N11283 006
+		8MG	N11283 010
	TRIAMCINOLONE		
BP	WATSON LABS	4MG	N84270 001

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

	AZMACORT		
+	AVENTIS	0.1MG/INH	N18117 001 APR 23, 1982

CREAM; TOPICAL

	ARISTOCORT		
AT	FUJISAWA HLTHCARE	0.025%	**N83017 003**
AT		0.1%	**N83016 004**
AT		0.5%	**N83015 002**
	ARISTOCORT A		
AT	FUJISAWA HLTHCARE	0.025%	**N83017 004**
AT		0.025%	**N88818 001** OCT 16, 1984
AT		0.1%	**N83016 005**
AT		0.1%	**N88819 001** OCT 16, 1984
AT		0.5%	**N83015 003**
AT		0.5%	**N88820 001** OCT 16, 1984
	KENALOG		
AT +	APOTHECON	0.025%	**N11601 003**

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

	KENALOG		
AT +	APOTHECON	0.1%	**N11601 006**
AT +		0.5%	**N83943 001**
	TRIACET		
AT	TEVA	0.025%	**N84908 001**
AT		0.1%	**N84908 002**
AT		0.5%	**N84908 003**
	TRIAMCINOLONE ACETONIDE		
AT	ALPHARMA US PHARM	0.1%	**N87798 001** JUN 04, 1982
AT	ALTANA	0.025%	**N85692 001**
AT		0.1%	**N85692 003**
AT		0.5%	**N85692 002**
AT	AMBIX	0.025%	**N87932 001** MAY 09, 1983
AT	CLAY PARK	0.025%	**N86415 001**
AT		0.1%	**N86414 001**
AT		0.5%	**N86413 001**
AT	G AND W LABS	0.025%	**N89797 001** MAY 31, 1991
AT		0.1%	**N89798 001** MAY 31, 1991
AT	TARO	0.025%	**N86277 001**
AT		0.1%	**N40039 001** NOV 26, 1997
AT		0.1%	**N86276 001**
AT		0.5%	**N86275 001**
	TRIDERM		
AT	DEL RAY LABS	0.1%	**N88042 001** MAR 19, 1984

INJECTABLE; INJECTION

KENALOG-10		
APOTHECON	10MG/ML	N12041 001
KENALOG-40		
+ APOTHECON	40MG/ML	N14901 001

LOTION; TOPICAL

	KENALOG		
AT	APOTHECON	0.025%	**N84343 001**
AT +		0.1%	**N84343 002**
	TRIAMCINOLONE ACETONIDE		
AT	ALTANA	0.025%	**N40467 001** APR 21, 2003
AT		0.1%	**N40467 002** APR 21, 2003

FDA data supplied by DrugPatentWatch.com

TRIAMCINOLONE ACETONIDE

LOTION; TOPICAL

	TRIAMCINOLONE ACETONIDE			
AT	MORTON GROVE	0.025%	N88450 001	
			APR 01, 1985	
AT		0.1%	N88451 001	
			APR 03, 1985	
AT	TARO	0.1%	N89129 001	
			AUG 14, 1986	

OINTMENT; TOPICAL

	ARISTOCORT			
AT	FUJISAWA HLTHCARE	0.1%	N80750 004	
	ARISTOCORT A			
AT	FUJISAWA HLTHCARE	0.1%	N80750 003	
AT		0.1%	N88780 001	
			OCT 01, 1984	
	KENALOG			
AT	APOTHECON	0.025%	N11600 003	
AT		0.1%	N11600 001	
	TRIAMCINOLONE ACETONIDE			
AT	ALPHARMA US PHARM	0.1%	N87799 001	
			JUN 07, 1982	
AT	ALTANA	0.025%	N85691 001	
AT		0.1%	N85691 003	
AT		0.5%	N85691 002	
AT +	CLAY PARK	0.025%	N87356 001	
AT +		0.1%	N87357 001	
AT +		0.5%	N87385 001	
AT	TARO	0.025%	N40040 001	
			SEP 30, 1994	
AT		0.025%	N40374 001	
			JUN 05, 2001	
AT		0.1%	N40037 001	
			SEP 30, 1994	
AT		0.1%	N87902 001	
			DEC 27, 1982	
AT		0.5%	N40386 001	
			JUN 05, 2001	
	TRIAMCINOLONE ACETONIDE IN ABSORBASE			
+	CAROLINA MEDCL	0.05%	N89595 001	
			MAR 23, 1995	

PASTE; DENTAL

	KENALOG IN ORABASE			
AT +	APOTHECON	0.1%	N12097 001	
	ORACORT			
AT	TARO	0.1%	N70730 001	
			OCT 01, 1986	

TRIAMCINOLONE ACETONIDE

PASTE; DENTAL

	ORALONE			
AT	TARO	0.1%	N71383 001	
			JUL 06, 1987	

SPRAY; TOPICAL

	KENALOG		
+	APOTHECON	0.147MG/GM	N12104 001

SPRAY, METERED; NASAL

	NASACORT AQ		
+	AVENTIS	0.055MG/SPRAY	N20468 001
			MAY 20, 1996

TRIAMCINOLONE ACETONIDE; *MULTIPLE*
SEE NYSTATIN; TRIAMCINOLONE ACETONIDE

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

	ARISTOCORT		
+	SABEX 2002	25MG/ML	N11685 003
+		40MG/ML	N12802 001

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

	ARISTOSPAN		
+	SABEX 2002	5MG/ML	N16466 001
+		20MG/ML	N16466 002

TRIAMTERENE

CAPSULE; ORAL

	DYRENIUM		
	WELLSPRING PHARM	50MG	N13174 001
+		100MG	N13174 002

TRIAMTERENE; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; TRIAMTERENE

FDA data supplied by DrugPatentWatch.com

TRIAZOLAM

TABLET; ORAL

	HALCION			
AB	PHARMACIA AND UPJOHN	**0.125MG**	**N17892 003**	APR 26, 1985
AB	+	**0.25MG**	**N17892 001**	NOV 15, 1982
	TRIAZOLAM			
AB	ALPHAPHARM	**0.125MG**	**N74031 001**	MAR 25, 1994
AB		**0.25MG**	**N74031 002**	MAR 25, 1994
AB	ROXANE	**0.125MG**	**N74224 001**	JUN 01, 1994
AB		**0.25MG**	**N74224 002**	JUN 01, 1994
AB	WATSON LABS	**0.125MG**	**N74445 001**	OCT 20, 1995
AB		**0.25MG**	**N74445 002**	OCT 20, 1995

TRICHLORMETHIAZIDE

TABLET; ORAL

	NAQUA		
BP	+ SCHERING	4MG	N12265 002
	TRICHLORMETHIAZIDE		
BP	ABC HOLDING	4MG	N85568 001
BP	PAR PHARM	2MG	N87007 001
BP		4MG	N87005 001

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

	SYPRINE		
	+ MERCK	250MG	N19194 001 NOV 08, 1985

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

	STELAZINE		
AA	+ GLAXOSMITHKLINE	**EQ 10MG BASE/ML**	**N11552 006**

INJECTABLE; INJECTION

STELAZINE		
+ GLAXOSMITHKLINE	EQ 2MG BASE/ML	N11552 005

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

	STELAZINE			
AB	GLAXOSMITHKLINE	**EQ 1MG BASE**	**N11552 001**	
AB		**EQ 2MG BASE**	**N11552 002**	
AB		**EQ 5MG BASE**	**N11552 003**	
AB	+	**EQ 10MG BASE**	**N11552 004**	
	TRIFLUOPERAZINE HCL			
AB	MYLAN	**EQ 1MG BASE**	**N40209 001**	JUL 07, 1997
AB		**EQ 2MG BASE**	**N40209 002**	JUL 07, 1997
AB		**EQ 5MG BASE**	**N40209 003**	JUL 07, 1997
AB		**EQ 10MG BASE**	**N40209 004**	JUL 07, 1997
AB	SANDOZ	**EQ 1MG BASE**	**N40153 001**	OCT 25, 1996
AB		**EQ 1MG BASE**	**N85785 001**	
AB		**EQ 2MG BASE**	**N40153 002**	OCT 25, 1996
AB		**EQ 2MG BASE**	**N85786 001**	
AB		**EQ 5MG BASE**	**N40153 003**	OCT 25, 1996
AB		**EQ 5MG BASE**	**N85789 001**	
AB		**EQ 10MG BASE**	**N40153 004**	OCT 25, 1996
AB		**EQ 10MG BASE**	**N85788 001**	

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

	TRIFLURIDINE		
AT	ALCON	**1%**	**N74311 001** OCT 06, 1995
	VIROPTIC		
AT	+ MONARCH PHARMS	**1%**	**N18299 001**

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

	TRIHEXYPHENIDYL HCL			
AA	MIKART	**2MG/5ML**	**N40251 001**	SEP 27, 1999
AA	PHARM ASSOC	**2MG/5ML**	**N40177 001**	APR 17, 1997

FDA data supplied by DrugPatentWatch.com

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

		TRIHEXYPHENIDYL HCL		
AA	+	PHARM VENTURES	**2MG/5ML**	**N89514 001** APR 07, 1989

TABLET; ORAL

		TRIHEXYPHENIDYL HCL		
AA		VINTAGE PHARMS	**2MG**	**N40254 001** DEC 24, 1998
AA			**5MG**	**N40254 002** DEC 24, 1998
AA		WATSON LABS	**2MG**	**N40184 001** FEB 06, 1998
AA	+		**2MG**	**N84363 001**
AA			**5MG**	**N40184 002** FEB 06, 1998
AA	+		**5MG**	**N84364 001**
AA		WEST WARD	**2MG**	**N40337 002** FEB 16, 2000
AA			**5MG**	**N40337 001** FEB 16, 2000

TRIMETHADIONE

TABLET; ORAL

		TRIDIONE		
	+	ABBOTT	150MG	N05856 009

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

		TIGAN		
AB	+	KING PHARMS	**300MG**	**N17531 006** DEC 13, 2001
		TRIMETHOBENZAMIDE HCL		
AB		AMIDE PHARM	**300MG**	**N76546 001** AUG 20, 2003
AB		MUTUAL PHARMA	**300MG**	**N76570 001** AUG 28, 2003

INJECTABLE; INJECTION

		TIGAN		
AP	+	KING PHARMS	**100MG/ML**	**N17530 001**
		TRIMETHOBENZAMIDE HCL		
AP		ABBOTT	**100MG/ML**	**N88804 001** APR 03, 1987

TRIMETHOPRIM

TABLET; ORAL

		PROLOPRIM		
AB		MONARCH PHARMS	**100MG**	**N17943 001**
		TRIMETHOPRIM		
AB		TEVA	**100MG**	**N18679 001** JUL 30, 1982
	+		200MG	N71259 001 JUN 18, 1987
AB		WATSON LABS	**100MG**	**N70049 001** JUN 06, 1985

TRIMETHOPRIM; *MULTIPLE*
SEE POLYMYXIN B SULFATE; TRIMETHOPRIM
SEE SULFAMETHOXAZOLE; TRIMETHOPRIM

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

		PRIMSOL		
	+	ASCENT PEDS	EQ 50MG BASE/5ML	N74973 001 JAN 24, 2000

TRIMETHOPRIM SULFATE; *MULTIPLE*
SEE POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION

		NEUTREXIN		
	+	MEDIMMUNE ONCOLOGY	EQ 25MG BASE/VIAL	N20326 001 DEC 17, 1993
	+		EQ 200MG BASE/VIAL	N20326 002 JUL 31, 1998

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

		SURMONTIL		
		PLIVA	EQ 25MG BASE	N16792 001
			EQ 50MG BASE	N16792 002
	+		EQ 100MG BASE	N16792 003 SEP 15, 1982

FDA data supplied by DrugPatentWatch.com

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL
PBZ
AA + NOVARTIS 50MG N05914 002

TRIPROLIDINE HYDROCHLORIDE; *MULTIPLE*
SEE CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
SEE PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR
TRELSTAR
+ PHARMACIA AND UPJOHN 11.25MG/VIAL N21288 001 JUN 29, 2001

TRELSTAR DEPOT
+ PHARMACIA AND UPJOHN EQ 3.75MG BASE/VIAL N20715 001 JUN 15, 2000

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS; OTIC
CERUMENEX
+ PURDUE FREDERICK 10% N11340 002

TROLEANDOMYCIN

CAPSULE; ORAL
TAO
+ PFIZER EQ 250MG BASE N50336 002

TROMETHAMINE

INJECTABLE; INJECTION
THAM
+ ABBOTT 3.6GM/100ML N13025 002

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
MYDRIACYL
AT + ALCON 0.5% N84305 001

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
MYDRIACYL
AT + ALCON 1% N84306 001

TROPICACYL
AT AKORN 0.5% N40314 001 SEP 29, 2000
AT 1% N40315 001 SEP 29, 2000

TROPICAMIDE
AT ALCON UNIVERSAL 1% N89172 001 DEC 28, 1990
AT BAUSCH AND LOMB 0.5% N40067 001 JUL 27, 1994
AT 1% N40064 001 JUL 27, 1994
AT MIZA PHARMS USA 0.5% N87636 001 JUL 30, 1982
AT 1% N87637 001 AUG 09, 1982

TROPICAMIDE; *MULTIPLE*
SEE HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

TROVAFLOXACIN MESYLATE

TABLET; ORAL
TROVAN
PFIZER EQ 100MG BASE N20759 001 DEC 18, 1997
+ EQ 200MG BASE N20759 002 DEC 18, 1997

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE
AP + ABBOTT 3MG/ML N06095 001
AP + BRISTOL MYERS SQUIBB 3MG/ML N05657 001

TYLOXAPOL; *MULTIPLE*
SEE CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

FDA data supplied by DrugPatentWatch.com

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC
RESCULA
+ NOVARTIS 0.15% N21214 001 AUG 03, 2000

UREA

INJECTABLE; INJECTION
UREAPHIL
+ ABBOTT 40GM/VIAL N12154 001

UREA; *MULTIPLE*
SEE HYDROCORTISONE ACETATE; UREA

UREA, C-13

FOR SOLUTION; ORAL
BREATHTEK UBT FOR H-PYLORI
+ MERETEK EQ 75MG /POUCHE N20586 002 MAY 10, 2001

UREA, C-14

CAPSULE; ORAL
PYTEST
+ BALLARD MEDCL 1 uCi N20617 001 MAY 09, 1997

PYTEST KIT
+ BALLARD MEDCL 1 uCi N20617 002 MAY 09, 1997

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
BRAVELLE
BX + FERRING 75 IU/VIAL N21289 001 MAY 06, 2002

INJECTABLE; SUBCUTANEOUS
FERTINEX
BX + SERONO 75 IU/AMP N19415 005 AUG 23, 1996

URSODIOL

CAPSULE; ORAL
ACTIGALL
AB + WATSON PHARMS **300MG** **N19594 002** DEC 31, 1987

URSODIOL
AB AMIDE PHARM **300MG** **N75517 001** MAR 14, 2000
AB COPLEY PHARM **300MG** **N75592 001** MAY 25, 2000

TABLET; ORAL
URSO
+ AXCAN SCANDIPHARM 250MG N20675 001 DEC 10, 1997

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL
VALTREX
GLAXOSMITHKLINE EQ 500MG BASE N20487 001 JUN 23, 1995
EQ 1GM BASE N20487 002 JUN 23, 1995

VALDECOXIB

TABLET; ORAL
BEXTRA
GD SEARLE LLC 10MG N21341 002 NOV 16, 2001
+ 20MG N21341 003 NOV 16, 2001

VALGANCICLOVIR HYDROCHLORIDE

TABLET; ORAL
VALCYTE
+ ROCHE PALO EQ 450MG BASE N21304 001 MAR 29, 2001

FDA data supplied by DrugPatentWatch.com

VALPROATE SODIUM

INJECTABLE; INJECTION

	DEPACON			
AP	+ ABBOTT	EQ 100MG BASE/ML	**N20593 001**	DEC 30, 1996
	VALPROATE SODIUM			
AP	AM PHARM	EQ 100MG BASE/ML	**N76539 001**	JUN 26, 2003
AP	BEDFORD	EQ 100MG BASE/ML	**N76295 001**	NOV 14, 2002

VALPROIC ACID

CAPSULE; ORAL

	DEPAKENE			
AB	+ ABBOTT	250MG	**N18081 001**	
	VALPROIC ACID			
AB	BANNER PHARMACAPS	250MG	**N73484 001**	JUN 29, 1993
AB	SCHERER RP	250MG	**N73229 001**	OCT 29, 1991
AB	USL PHARMA	250MG	**N70631 001**	JUN 11, 1987

SYRUP; ORAL

	DEPAKENE			
AA	+ ABBOTT	250MG/5ML	**N18082 001**	
	MYPROIC ACID			
AA	MORTON GROVE	250MG/5ML	**N70868 001**	JUL 01, 1986
	VALPROIC ACID			
AA	COPLEY PHARM	250MG/5ML	**N73178 001**	AUG 25, 1992
AA	HIGH TECH PHARMA	250MG/5ML	**N74060 001**	JAN 13, 1995
AA	PHARM ASSOC	250MG/5ML	**N75379 001**	DEC 15, 2000
AA	UDL	250MG/5ML	**N75782 001**	DEC 22, 2000

VALRUBICIN

SOLUTION; INTRAVESICAL

	VALSTAR PRESERVATIVE FREE			
+	ANTHRA	40MG/ML	N20892 001	SEP 25, 1998

VALSARTAN

TABLET; ORAL

	DIOVAN			
	NOVARTIS	40MG	N21283 004	AUG 14, 2002
		80MG	N21283 001	JUL 18, 2001
		160MG	N21283 002	JUL 18, 2001
+		320MG	N21283 003	JUL 18, 2001

VALSARTAN; *MULTIPLE*
SEE HYDROCHLOROTHIAZIDE; VALSARTAN

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HCL			
LILLY	EQ 125MG BASE	N50606 001	APR 15, 1986
+	EQ 250MG BASE	N50606 002	APR 15, 1986

FOR SOLUTION; ORAL

VANCOCIN HCL			
+ LILLY	EQ 250MG BASE/5ML	N61667 002	JUL 13, 1983
+	EQ 500MG BASE/6ML	N61667 001	

INJECTABLE; INJECTION

	VANCOCIN HCL			
AP	+ LILLY	EQ 500MG BASE/VIAL	**N60180 001**	
AP		EQ 500MG BASE/VIAL	**N62476 001**	MAR 15, 1984
AP		EQ 500MG BASE/VIAL	**N62716 001**	MAR 13, 1987
AP		EQ 500MG BASE/VIAL	**N62812 001**	NOV 17, 1987
AP	+	EQ 1GM BASE/VIAL	**N60180 002**	MAR 21, 1986
AP		EQ 1GM BASE/VIAL	**N62476 002**	MAR 21, 1986
AP		EQ 1GM BASE/VIAL	**N62716 002**	MAR 13, 1987

FDA data supplied by DrugPatentWatch.com

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

	VANCOCIN HCL			
AP	LILLY	**EQ 1GM BASE/VIAL**	**N62812 002** NOV 17, 1987	
AP	+	**EQ 10GM BASE/VIAL**	**N62812 003** NOV 17, 1987	
	VANCOCIN HCL IN PLASTIC CONTAINER			
	+ BAXTER HLTHCARE	EQ 500MG BASE/100ML	N50671 001 APR 29, 1993	
	VANCOLED			
AP	+ BAXTER HLTHCARE	**EQ 500MG BASE/VIAL**	**N62682 001** JUL 22, 1986	
AP	+	**EQ 1GM BASE/VIAL**	**N62682 002** MAR 30, 1988	
AP	+	**EQ 5GM BASE/VIAL**	**N62682 004** MAY 11, 1988	
AP	+	**EQ 10GM BASE/VIAL**	**N62682 005** MAY 11, 1988	
	+	EQ 2GM BASE/VIAL	N62682 003 MAY 11, 1988	
	VANCOMYCIN HCL			
AP	ABBOTT	**EQ 1GM BASE/VIAL**	**N62912 001** AUG 04, 1988	
AP		**EQ 1GM BASE/VIAL**	**N62933 001** OCT 29, 1992	
AP		**EQ 5GM BASE/VIAL**	**N63076 001** DEC 21, 1990	
AP		**EQ 500MG BASE/VIAL**	**N62911 001** AUG 04, 1988	
AP		**EQ 500MG BASE/VIAL**	**N62931 001** OCT 29, 1992	
AP	AM PHARM PARTNERS	**EQ 500MG BASE/VIAL**	**N62663 001** MAR 17, 1987	
AP		**EQ 1GM BASE/VIAL**	**N62663 002** JUL 31, 1987	
AP		**EQ 5GM BASE/VIAL**	**N62663 003** JUN 03, 1988	
AP		**EQ 10GM BASE/VIAL**	**N62663 004** NOV 28, 1997	

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

	LEVITRA		
	BAYER PHARMS	2.5MG	N21400 003 AUG 19, 2003

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

	LEVITRA		
	BAYER PHARMS	5MG	N21400 001 AUG 19, 2003
		10MG	N21400 002 AUG 19, 2003
	+	20MG	N21400 004 AUG 19, 2003

VECURONIUM BROMIDE

INJECTABLE; INJECTION

	VECURONIUM BROMIDE			
AP	ABBOTT	**10MG/VIAL**	**N75164 001** OCT 21, 1999	
AP		**20MG/VIAL**	**N75164 002** OCT 21, 1999	
	+	4MG/VIAL	N75558 001 SEP 11, 2001	
AP	BAXTER HLTHCARE	**10MG/VIAL**	**N75218 001** AUG 23, 1999	
AP		**20MG/VIAL**	**N75218 002** AUG 23, 1999	
AP	+ BEDFORD	**10MG/VIAL**	**N75549 001** JUN 13, 2000	
AP		**20MG/VIAL**	**N75549 002** JUN 13, 2000	
AP	GENSIA	**10MG/VIAL**	**N74688 001** AUG 25, 1999	
AP		**20MG/VIAL**	**N74688 002** AUG 25, 1999	
AP	STERIS	**10MG/VIAL**	**N74334 001** AUG 31, 1995	
AP		**20MG/VIAL**	**N74334 002** AUG 31, 1995	

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	EFFEXOR XR		
	WYETH PHARMS INC	EQ 37.5MG BASE	N20699 001 OCT 20, 1997
		EQ 75MG BASE	N20699 002 OCT 20, 1997

FDA data supplied by DrugPatentWatch.com

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	EFFEXOR XR			
+	WYETH PHARMS INC	EQ 150MG BASE	N20699 004	OCT 20, 1997

TABLET; ORAL

	EFFEXOR			
	WYETH PHARMS INC	EQ 25MG BASE	N20151 002	DEC 28, 1993
		EQ 37.5MG BASE	N20151 006	DEC 28, 1993
+		EQ 50MG BASE	N20151 003	DEC 28, 1993
		EQ 75MG BASE	N20151 004	DEC 28, 1993
		EQ 100MG BASE	N20151 005	DEC 28, 1993

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	VERAPAMIL HCL				
AB	MYLAN	**120MG**	**N75138 001**	APR 20, 1999	
AB		**180MG**	**N75138 002**	APR 20, 1999	
AB		**240MG**	**N75138 003**	APR 20, 1999	
	VERELAN				
AB	+ ELAN DRUG	**120MG**	**N19614 001**	MAY 29, 1990	
AB	+	**180MG**	**N19614 003**	JAN 09, 1992	
AB	+	**240MG**	**N19614 002**	MAY 29, 1990	
	+	360MG	N19614 004	MAY 10, 1996	
	VERELAN PM				
	+ ELAN PHARM	100MG	N20943 001	NOV 25, 1998	
	+	200MG	N20943 002	NOV 25, 1998	
	+	300MG	N20943 003	NOV 25, 1998	

INJECTABLE; INJECTION

	ISOPTIN				
AP	+ ABBOTT	**2.5MG/ML**	**N18485 001**		

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

	VERAPAMIL HCL				
AP	ABBOTT	**2.5MG/ML**	**N70577 001**	FEB 02, 1987	
AP		**2.5MG/ML**	**N70737 001**	MAY 06, 1987	
AP		**2.5MG/ML**	**N70738 001**	MAY 06, 1987	
AP		**2.5MG/ML**	**N70739 001**	MAY 06, 1987	
AP		**2.5MG/ML**	**N70740 001**	MAY 06, 1987	
AP		**2.5MG/ML**	**N75136 001**	OCT 20, 1998	
AP	BEDFORD	**2.5MG/ML**	**N72888 001**	JUL 28, 1995	
AP	INTL MEDICATION	**2.5MG/ML**	**N70451 001**	DEC 16, 1985	
AP	LUITPOLD	**2.5MG/ML**	**N70225 001**	NOV 12, 1985	
AP		**2.5MG/ML**	**N70617 001**	NOV 12, 1985	

TABLET; ORAL

	CALAN				
AB	GD SEARLE LLC	**40MG**	**N18817 003**	FEB 23, 1988	
AB		**80MG**	**N18817 001**	SEP 10, 1984	
AB		**120MG**	**N18817 002**	SEP 10, 1984	
	ISOPTIN				
AB	ABBOTT	**40MG**	**N18593 003**	NOV 23, 1987	
AB		**80MG**	**N18593 001**	MAR 08, 1982	
AB	+	**120MG**	**N18593 002**	MAR 08, 1982	
	VERAPAMIL HCL				
AB	MUTUAL PHARM	**80MG**	**N71488 001**	JAN 13, 1988	
AB		**120MG**	**N71489 001**	JAN 13, 1988	
AB	MYLAN	**80MG**	**N71482 001**	FEB 15, 1989	
AB		**120MG**	**N71483 001**	FEB 15, 1989	

FDA data supplied by DrugPatentWatch.com

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

	VERAPAMIL HCL			
AB	PLIVA	**40MG**	**N72751 001**	FEB 23, 1996
AB		**80MG**	**N72124 001**	JAN 26, 1989
AB		**120MG**	**N72125 001**	JAN 26, 1989
AB	PUREPAC PHARM	**80MG**	**N71019 001**	SEP 24, 1986
AB		**120MG**	**N70468 001**	SEP 24, 1986
AB	SANDOZ	**40MG**	**N73168 001**	JUL 31, 1992
AB		**80MG**	**N71423 001**	MAY 24, 1988
AB		**120MG**	**N71424 001**	MAY 25, 1988
AB	WATSON LABS	**40MG**	**N72923 001**	JUN 29, 1993
AB		**40MG**	**N72924 001**	JUN 29, 1993
AB		**80MG**	**N70855 001**	SEP 24, 1986
AB		**80MG**	**N70995 001**	OCT 01, 1986
AB		**80MG**	**N71366 001**	OCT 01, 1986
AB		**120MG**	**N70856 001**	SEP 24, 1986
AB		**120MG**	**N70994 001**	OCT 01, 1986
AB		**120MG**	**N71367 001**	OCT 01, 1986

TABLET, EXTENDED RELEASE; ORAL

	COVERA-HS			
BC	+ GD SEARLE LLC	180MG	N20552 001	FEB 26, 1996
BC	+	240MG	N20552 002	FEB 26, 1996
	ISOPTIN SR			
AB	+ ABBOTT	**120MG**	**N19152 003**	MAR 06, 1991
AB	+	**180MG**	**N19152 002**	DEC 15, 1989

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	ISOPTIN SR			
AB	+ ABBOTT	**240MG**	**N19152 001**	DEC 16, 1986
	VERAPAMIL HCL			
AB	IVAX PHARMS	**120MG**	**N73568 002**	OCT 10, 1997
AB		**180MG**	**N74330 001**	JAN 31, 1994
AB		**240MG**	**N73568 001**	JUL 31, 1992
AB	MYLAN	**120MG**	**N74587 002**	FEB 21, 1997
AB		**180MG**	**N74587 003**	SEP 09, 1997
AB		**240MG**	**N74587 001**	MAR 23, 1996
AB	PLIVA	**240MG**	**N72922 001**	MAR 01, 1996

VERAPAMIL HYDROCHLORIDE; *MULTIPLE*
SEE TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

VERTEPORFIN

INJECTABLE; INJECTION

	VISUDYNE		
	+ QLT	15MG/VIAL	N21119 001 APR 12, 2000

VINBLASTINE SULFATE

INJECTABLE; INJECTION

	VINBLASTINE SULFATE			
	+ AM PHARM PARTNERS	1MG/ML	N89515 001	APR 29, 1987
AP	+ BEDFORD	**10MG/VIAL**	**N89395 001**	APR 09, 1987
AP	MAYNE PHARMA USA	**10MG/VIAL**	**N89565 001**	AUG 18, 1987

FDA data supplied by DrugPatentWatch.com

VINCRISTINE SULFATE

INJECTABLE; INJECTION

		ONCOVIN			
AP	+	LILLY	**1MG/ML**	**N14103 003**	MAR 07, 1984
		VINCASAR PFS			
AP		GENSIA SICOR PHARMS	**1MG/ML**	**N71426 001**	JUL 17, 1987
		VINCRISTINE SULFATE			
AP		AM PHARM	**1MG/ML**	**N76401 001**	OCT 28, 2003
AP	+	AM PHARM PARTNERS	**1MG/ML**	**N76296 001**	DEC 20, 2002
		VINCRISTINE SULFATE PFS			
AP		MAYNE PHARMA USA	**1MG/ML**	**N71484 001**	APR 19, 1988
AP		SICOR PHARMS	**1MG/ML**	**N75493 001**	SEP 01, 1999

VINORELBINE TARTRATE

INJECTABLE; INJECTION

		NAVELBINE			
AP	+	GLAXOSMITHKLINE	**EQ 10MG BASE/ML**	**N20388 001**	DEC 23, 1994
		VINORELBINE TARTRATE			
AP		BEDFORD	**EQ 10MG BASE/ML**	**N76461 001**	DEC 11, 2003
AP		ESI LEDERLE	**EQ 10MG BASE/ML**	**N75992 001**	JUN 10, 2003
AP		GENSIA SICOR PHARMS	**EQ 10MG BASE/ML**	**N76028 001**	FEB 03, 2003

VITAMIN A; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

VITAMIN A PALMITATE

CAPSULE; ORAL

	VITAMIN A			
AA	MK LABS	**EQ 50,000 UNITS BASE**	**N83457 001**	
		EQ 25,000 UNITS BASE	N83457 002	
	VITAMIN A PALMITATE			
AA	ARCUM	**EQ 50,000 UNITS BASE**	**N83311 001**	
AA		**EQ 50,000 UNITS BASE**	**N83321 001**	

INJECTABLE; INJECTION

	AQUASOL A		
+	AAIPHARMA LLC	EQ 50,000 UNITS BASE/ML	N06823 001

VITAMIN A PALMITATE; *MULTIPLE*
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

VITAMIN E; *MULTIPLE*
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E
SEE ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

VITAMIN K; *MULTIPLE*
SEE ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K
SEE ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

FDA data supplied by DrugPatentWatch.com

VORICONAZOLE

FOR SUSPENSION; ORAL					
VFEND					
+ PFIZER	200MG/5ML	N21630 001 DEC 19, 2003			
INJECTABLE; IV (INFUSION)					
VFEND					
+ PFIZER	200MG/VIAL	N21267 001 MAY 24, 2002			
TABLET; ORAL					
VFEND					
PFIZER	50MG	N21266 001 MAY 24, 2002			
+	200MG	N21266 002 MAY 24, 2002			

WARFARIN SODIUM

INJECTABLE; INJECTION					
COUMADIN					
+ BRISTOL MYERS SQUIBB	5MG/VIAL	N09218 024 FEB 07, 1995			
TABLET; ORAL					
COUMADIN					
AB BRISTOL MYERS SQUIBB	**1MG**	**N09218 022** MAR 01, 1990			
AB	**2MG**	**N09218 013**			
AB	**2.5MG**	**N09218 018**			
AB	**3MG**	**N09218 025** NOV 18, 1996			
AB	**4MG**	**N09218 023** AUG 24, 1993			
AB	**5MG**	**N09218 007**			
AB	**6MG**	**N09218 026** NOV 18, 1996			
AB	**7.5MG**	**N09218 016**			
AB +	**10MG**	**N09218 005**			
JANTOVEN					
AB USL PHARMA	**1MG**	**N40416 001** OCT 02, 2003			
AB	**2MG**	**N40416 002** OCT 02, 2003			
AB	**2.5MG**	**N40416 003** OCT 02, 2003			

WARFARIN SODIUM

TABLET; ORAL					
JANTOVEN					
AB USL PHARMA	**3MG**	**N40416 004** OCT 02, 2003			
AB	**4MG**	**N40416 005** OCT 02, 2003			
AB	**5MG**	**N40416 006** OCT 02, 2003			
AB	**6MG**	**N40416 007** OCT 02, 2003			
AB	**7.5MG**	**N40416 008** OCT 02, 2003			
AB	**10MG**	**N40416 009** OCT 02, 2003			
WARFARIN SODIUM					
AB BARR	**1MG**	**N40145 001** MAR 26, 1997			
AB	**2MG**	**N40145 002** MAR 26, 1997			
AB	**2.5MG**	**N40145 003** MAR 26, 1997			
AB	**3MG**	**N40145 008** NOV 05, 1998			
AB	**4MG**	**N40145 004** MAR 26, 1997			
AB	**5MG**	**N40145 005** MAR 26, 1997			
AB	**6MG**	**N40145 009** NOV 05, 1998			
AB	**7.5MG**	**N40145 006** MAR 26, 1997			
AB	**10MG**	**N40145 007** MAR 26, 1997			
AB SANDOZ	**1MG**	**N40196 001** SEP 30, 1997			
AB	**2MG**	**N40196 002** SEP 30, 1997			
AB	**2.5MG**	**N40196 003** SEP 30, 1997			
AB	**3MG**	**N40196 008** JUL 26, 2000			
AB	**4MG**	**N40196 004** SEP 30, 1997			
AB	**5MG**	**N40196 005** SEP 30, 1997			
AB	**6MG**	**N40196 009** JUL 26, 2000			

FDA data supplied by DrugPatentWatch.com

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

AB	SANDOZ	7.5MG	N40196 006 SEP 30, 1997
AB		10MG	N40196 007 SEP 30, 1997
AB	TARO	1MG	N40301 002 JUL 15, 1999
AB		2MG	N40301 003 JUL 15, 1999
AB		2.5MG	N40301 004 JUL 15, 1999
AB		3MG	N40301 005 JUL 15, 1999
AB		4MG	N40301 006 JUL 15, 1999
AB		5MG	N40301 007 JUL 15, 1999
AB		6MG	N40301 008 JUL 15, 1999
AB		7.5MG	N40301 009 JUL 15, 1999
AB		10MG	N40301 001 JUL 15, 1999

WATER FOR INJECTION, STERILE

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

AP	ABBOTT	100%	N18802 001 OCT 27, 1982

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP	ABBOTT	100%	N18233 001
AP		100%	N18801 001 OCT 27, 1982
AP		100%	N19869 001 DEC 26, 1989
AP	AM PHARM PARTNERS	100%	N88400 001 JAN 16, 1984
AP	B BRAUN	100%	N19077 001 MAR 02, 1984
AP		100%	N19633 001 FEB 29, 1988
AP	BAXTER HLTHCARE	100%	N18632 001 JUN 30, 1982

WATER FOR INJECTION, STERILE

LIQUID; N/A

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	100%	N18632 002 APR 19, 1988

WATER FOR IRRIGATION, STERILE

LIQUID; IRRIGATION

STERILE WATER

AT	BAXTER HLTHCARE	100%	N17428 001

STERILE WATER IN PLASTIC CONTAINER

AT	ABBOTT	100%	N17513 001
AT		100%	N18313 001
AT	B BRAUN	100%	N16734 001
AT	BAXTER HLTHCARE	100%	N17866 001

XENON, XE-133

GAS; INHALATION

XENON XE 133

AA	BRISTOL MYERS SQUIBB	10mCi/VIAL	N17284 001
AA		20mCi/VIAL	N17284 002
	GEN ELECTRIC	0.25-5 CI/AMP	N17550 003
		5-100 CI/CYLINDER	N17550 001
AA	MALLINCKRODT	10mCi/VIAL	N18327 001 MAR 09, 1982
AA		20mCi/VIAL	N18327 002 MAR 09, 1982

ZAFIRLUKAST

TABLET; ORAL

ACCOLATE

	ASTRAZENECA	10MG	N20547 003 SEP 17, 1999
+		20MG	N20547 001 SEP 26, 1996

ZALCITABINE

TABLET; ORAL

HIVID

	ROCHE	0.375MG	N20199 001 JUN 19, 1992

FDA data supplied by DrugPatentWatch.com

ZALCITABINE

TABLET; ORAL
HIVID
+ ROCHE 0.75MG N20199 002 JUN 19, 1992

ZALEPLON

CAPSULE; ORAL
SONATA
JONES PHARMA 5MG N20859 001 AUG 13, 1999
+ 10MG N20859 002 AUG 13, 1999

ZANAMIVIR

CAPSULE; INHALATION
RELENZA
+ GLAXOSMITHKLINE 5MG N21036 001 JUL 26, 1999

ZIDOVUDINE

CAPSULE; ORAL
RETROVIR
+ GLAXOSMITHKLINE 100MG N19655 001 MAR 19, 1987

INJECTABLE; INJECTION
RETROVIR
+ GLAXOSMITHKLINE 10MG/ML N19951 001 FEB 02, 1990

SYRUP; ORAL
RETROVIR
GLAXOSMITHKLINE 50MG/5ML N19910 001 SEP 28, 1989

TABLET; ORAL
RETROVIR
+ GLAXOSMITHKLINE 300MG N20518 002 OCT 04, 1996

ZIDOVUDINE; *MULTIPLE*
SEE ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

ZIDOVUDINE; *MULTIPLE*
SEE LAMIVUDINE; ZIDOVUDINE

ZILEUTON

TABLET; ORAL
ZYFLO
+ ABBOTT 600MG N20471 003 DEC 09, 1996

ZINC ACETATE

CAPSULE; ORAL
GALZIN
TEVA EQ 25MG ZINC N20458 001 JAN 28, 1997
+ EQ 50MG ZINC N20458 002 JAN 28, 1997

ZINC CHLORIDE

INJECTABLE; INJECTION
ZINC CHLORIDE IN PLASTIC CONTAINER
+ ABBOTT EQ 1MG ZINC/ML N18959 001 JUN 26, 1986

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL
GEODON
PFIZER 20MG N20825 001 FEB 05, 2001
40MG N20825 002 FEB 05, 2001
60MG N20825 003 FEB 05, 2001
+ 80MG N20825 004 FEB 05, 2001

ZIPRASIDONE MESYLATE

INJECTABLE; INTRAMUSCULAR
GEODON
+ PFIZER EQ 20MG BASE/ML N20919 001 JUN 21, 2002

FDA data supplied by DrugPatentWatch.com

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOMETA			
+ NOVARTIS	EQ 4MG BASE/5ML	N21223 002	MAR 07, 2003
+	EQ 4MG BASE/VIAL	N21223 001	AUG 20, 2001

ZOLMITRIPTAN

SPRAY; NASAL

ZOMIG			
+ ASTRAZENECA	5MG/SPRAY	N21450 004	SEP 30, 2003

TABLET; ORAL

ZOMIG			
IPR	2.5MG	N20768 001	NOV 25, 1997
+	5MG	N20768 002	NOV 25, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

ZOMIG-ZMT			
ASTRAZENECA	2.5MG	N21231 001	FEB 13, 2001
+	5MG	N21231 002	SEP 17, 2001

ZOLPIDEM TARTRATE

TABLET; ORAL

AMBIEN			
LOREX	5MG	N19908 001	DEC 16, 1992
+	10MG	N19908 002	DEC 16, 1992

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN			
DAINIPPON	25MG	N20789 003	AUG 22, 2003

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN			
DAINIPPON	50MG	N20789 002	AUG 22, 2003
+	100MG	N20789 001	MAR 27, 2000

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACEPHEN			
G AND W LABS	120MG	N18060 001	
	120MG	N72218 001	MAR 27, 1992
	325MG	N18060 003	DEC 18, 1986
	325MG	N72344 001	MAR 27, 1992
	650MG	N18060 002	
	650MG	N72237 001	MAR 27, 1992
ACETAMINOPHEN			
ALPHARMA US PHARM	120MG	N18337 003	SEP 12, 1983
	325MG	N18337 002	
+	650MG	N18337 001	
SUPPOSITORIA	120MG	N70607 001	APR 06, 1987
	650MG	N70608 001	DEC 01, 1986
INFANTS' FEVERALL			
ALPHARMA US PHARM	80MG	N18337 004	AUG 26, 1992
NEOPAP			
POLYMEDICA	120MG	N16401 001	

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN			
COREPHARMA	650MG	N76200 001	MAR 19, 2002
PERRIGO	650MG	N75077 001	FEB 25, 2000
TYLENOL (CAPLET)			
+ MCNEIL CONS SPECLT	650MG	N19872 001	JUN 08, 1994
TYLENOL (GELTAB)			
+ MCNEIL CONS SPECLT	650MG	N19872 002	JAN 11, 2001

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE			
PERRIGO	250MG;250MG;65MG	N75794 001	NOV 26, 2001

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

EXCEDRIN (MIGRAINE)			
+ BRISTOL MYERS	250MG;250MG;65MG	N20802 001	JAN 14, 1998

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

TAVIST ALLERGY/SINUS/HEADACHE			
+ NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N21082 001	MAR 01, 2001

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DRIXORAL PLUS			
+ SCHERING PLOUGH	500MG;3MG;60MG	N19453 001	MAY 22, 1987

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

AVAGARD			
+ 3M	61%;1%	N21074 001	JUN 07, 2001

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

FOAMCOAT			
GUARDIAN DRUG	80MG;20MG	N71793 001	SEP 04, 1987
GAVISCON			
AVENTIS PHARMS	80MG;20MG	N18685 001	DEC 09, 1983
+	160MG;40MG	N18685 002	DEC 09, 1983

FDA data supplied by DrugPatentWatch.com

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
VASOCON-A
+ NOVARTIS 0.5%;0.05% N18746 002 JUL 11, 1994

ASPIRIN

TABLET; ORAL
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN
+ BAYER 500MG N21317 001 OCT 18, 2001

ASPIRIN; *MULTIPLE*
SEE ACETAMINOPHEN; ASPIRIN; CAFFEINE

AVOBENZONE; OCTYL METHOXYCINNAMATE; OXYBENZONE

LOTION; TOPICAL
SHADE UVAGUARD
+ SCHERING PLOUGH 3%;7.5%;3% N20045 001 DEC 07, 1992

BENTOQUATAM

LOTION; TOPICAL
IVY BLOCK
+ ENVIRODERM 5% N20532 001 AUG 26, 1996

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
EFIDAC 24 PSEUDOEPHEDRINE HCL/BROMPHENIRAMINE MALEATE
+ ALZA 16MG;240MG N19672 001 MAR 29, 1996

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL
LOTRIMIN ULTRA
+ SCHERING PLOUGH 1% N21307 001 DEC 07, 2001

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
FEMSTAT 3
+ ROCHE PALO 2% N20421 001 DEC 21, 1995

CAFFEINE; *MULTIPLE*
SEE ACETAMINOPHEN; ASPIRIN; CAFFEINE

CALCIUM CARBONATE, PRECIPITATED; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL
PEPCID COMPLETE
+ MERCK 800MG;10MG;165MG N20958 001 OCT 16, 2000

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED; TOPICAL
EXIDINE
+ XTTRIUM 4% N19127 001 DEC 24, 1984

SOLUTION; TOPICAL
BRIAN CARE
SOAPCO 4% N71419 001 DEC 17, 1987

CHG SCRUB
ECOLAB 4% N19258 002 JUL 22, 1986

CHLORAPREP ONE-STEP SEPP
+ BECKLOFF 2% N21555 001 OCT 07, 2002

CIDA-STAT
ECOLAB 2% N19258 001 JUL 22, 1986

DYNA-HEX
XTTRIUM 0.75% N20111 001 SEP 11, 1997

EXIDINE
+ XTTRIUM 2% N19422 001 DEC 17, 1985
4% N19125 001 DEC 24, 1984

HIBICLENS
+ SSL INTL 4% N17768 001

FDA data supplied by DrugPatentWatch.com

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

HIBISTAT			
+ SSL INTL	0.5%	N18300 001	
MICRODERM			
J AND J	4%	N72255 001	APR 15, 1991
PREVACARE R			
J AND J	0.5%	N72292 001	JAN 28, 1992
STERI-STAT			
MATRIX MEDCL	4%	N70104 001	JUL 24, 1986

SPONGE; TOPICAL

BIOSCRUB			
GRIFFEN	4%	N19822 001	MAR 31, 1989
CHLORHEXIDINE GLUCONATE			
DESERET	4%	N72525 001	OCT 24, 1989
KENDALL IL	4%	N19490 001	MAR 27, 1987
HIBICLENS			
+ SSL INTL	4%	N18423 001	
MICRODERM			
J AND J	4%	N72295 001	FEB 28, 1991
PHARMASEAL SCRUB CARE			
PHARMASEAL	4%	N19793 001	DEC 02, 1988

CHLORHEXIDINE GLUCONATE; *MULTIPLE*
SEE ALCOHOL; CHLORHEXIDINE GLUCONATE

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP			
+ MEDI FLEX HOSP	2%;70%	N20832 001	JUL 14, 2000

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE			
+ SANDOZ	12MG	N70797 001	AUG 12, 1988

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON			
+ SCHERING PLOUGH	8MG	N07638 001	
+	12MG	N07638 002	
EFIDAC 24 CHLORPHENIRAMINE MALEATE			
ALZA	16MG	N19746 002	NOV 18, 1994

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL ALLERGY SINUS			
+ WYETH CONS	2MG;200MG;30MG	N21441 001	DEC 19, 2002

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON			
+ SCHERING PLOUGH	8MG;120MG	N18397 001	

CIMETIDINE

TABLET; ORAL

CIMETIDINE			
IVAX PHARMS	200MG	N75345 001	JUN 16, 1999
LEINER	200MG	N74961 001	JUN 19, 1998
LEK PHARMS	200MG	N75122 002	JUN 19, 1998
PERRIGO	200MG	N75285 001	OCT 29, 1998
PHARM FORM	200MG	N74963 001	JUN 19, 1998
TORPHARM	100MG	N74948 001	JUN 19, 1998

FDA data supplied by DrugPatentWatch.com

CIMETIDINE

TABLET; ORAL		
CIMETIDINE		
TORPHARM	200MG	N74948 002 JUL 26, 2002
WATSON LABS	200MG	N75425 001 JUL 29, 1999
TAGAMET HB		
+ GLAXOSMITHKLINE	200MG	N20238 002 AUG 21, 1996

CLEMASTINE FUMARATE

TABLET; ORAL		
CLEMASTINE FUMARATE		
PERRIGO	1.34MG	N74512 001 NOV 22, 1995
SANDOZ	1.34MG	N73458 001 OCT 31, 1993
TEVA	1.34MG	N73282 002 DEC 03, 1992
TAVIST-1		
+ NOVARTIS	1.34MG	N20925 001 AUG 21, 1992

CLEMASTINE FUMARATE; *MULTIPLE*
SEE ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CLOTRIMAZOLE

CREAM; VAGINAL		
CLOTRIMAZOLE		
ALPHARMA US PHARM	1%	N74165 001 JUL 16, 1993
TARO	1%	N72641 001 DEC 04, 1995
GYNE-LOTRIMIN		
+ SCHERING PLOUGH	1%	N18052 002 NOV 30, 1990
GYNE-LOTRIMIN 3		
+ SCHERING PLOUGH	2%	N20574 001 NOV 24, 1998
MYCELEX-7		
BAYER PHARMS	1%	N18230 002 DEC 26, 1991

CLOTRIMAZOLE

CREAM; VAGINAL		
TRIVAGIZOLE 3		
TARO	2%	N21143 001 APR 12, 2000
CREAM, TABLET; TOPICAL, VAGINAL		
GYNE-LOTRIMIN 3 COMBINATION PACK		
+ SCHERING PLOUGH	1%,200MG	N20526 002 JUL 29, 1996
GYNE-LOTRIMIN COMBINATION PACK		
+ SCHERING PLOUGH	1%,100MG	N20289 002 APR 26, 1993
MYCELEX-7 COMBINATION PACK		
BAYER PHARMS	1%,100MG	N20389 002 JUN 23, 1994
TABLET; VAGINAL		
GYNE-LOTRIMIN		
+ SCHERING PLOUGH	100MG	N17717 002 NOV 30, 1990
GYNE-LOTRIMIN 3		
+ SCHERING PLOUGH	200MG	N20525 001 JUL 29, 1996
GYNIX		
COPLEY PHARM	100MG	N73249 001 FEB 13, 1998
MYCELEX-7		
BAYER PHARMS	100MG	N18182 002 DEC 26, 1991

CROMOLYN SODIUM

SPRAY, METERED; NASAL		
CROMOLYN SODIUM		
ALPHARMA	5.2MG/INH	N74800 001 JUL 26, 2001
BAUSCH AND LOMB	5.2MG/SPRAY	N75702 001 JUL 03, 2001
PERRIGO	5.2MG/SPRAY	N75427 001 DEC 12, 2001
NASALCROM		
+ PHARMACIA UPJOHN	5.2MG/SPRAY	N20463 001 JAN 03, 1997

DEXBROMPHENIRAMINE MALEATE; *MULTIPLE*
SEE ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

FDA data supplied by DrugPatentWatch.com

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DISOPHROL			
SCHERING PLOUGH	6MG;120MG	N13483 004	SEP 13, 1982
DRIXORAL			
+ SCHERING PLOUGH	6MG;120MG	N13483 003	SEP 13, 1982

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DELSYM			
+ CELLTECH PHARMS	EQ 30MG HBR/5ML	N18658 001	OCT 08, 1982

DOCOSANOL

CREAM; TOPICAL

ABREVA			
+ GLAXOSMITHKLINE	10%	N20941 001	JUL 25, 2000

DOXYLAMINE SUCCINATE

TABLET; ORAL

DOXYLAMINE SUCCINATE			
COPLEY PHARM	25MG	N88900 002	FEB 12, 1988
PERRIGO	25MG	N40167 001	SEP 18, 1996
UNISOM			
+ PFIZER	25MG	N18066 001	

EPINEPHRINE

AEROSOL, METERED; INHALATION

EPINEPHRINE			
ALPHARMA	0.2MG/INH	N87907 001	MAY 23, 1984
PRIMATENE MIST			
+ WHITEHALL ROBINS	0.2MG/INH	N16126 001	

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

BRONITIN MIST			
WHITEHALL ROBINS	0.3MG/INH	N16126 002	

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE			
DR REDDYS LABS LTD	10MG	N75758 001	AUG 17, 2001
EON	10MG	N76101 001	OCT 21, 2002
GENPHARM	10MG	N75674 001	DEC 21, 2001
IVAX PHARMS	10MG	N75512 001	JUL 26, 2001
TEVA	10MG	N75312 001	MAY 31, 2001
TORPHARM	10MG	N75610 001	MAR 12, 2002
WATSON LABS	10MG	N75404 001	NOV 28, 2001
PEPCID AC			
MERCK	10MG	N20325 001	APR 28, 1995
+	20MG	N20325 002	SEP 23, 2003
PEPCID AC (GELTAB)			
MERCK	10MG	N20902 001	AUG 05, 1999

TABLET, CHEWABLE; ORAL

FAMOTIDINE			
PERRIGO	10MG	N75715 001	AUG 22, 2003
PEPCID AC			
+ MERCK	10MG	N20801 001	SEP 24, 1998

FAMOTIDINE; *MULTIPLE*

SEE CALCIUM CARBONATE, PRECIPITATED; FAMOTIDINE; MAGNESIUM HYDROXIDE

FDA data supplied by DrugPatentWatch.com

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX			
ADAMS LABS	600MG	N21282 001	JUL 12, 2002
+	1.2GM	N21282 002	DEC 18, 2002

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN			
BANNER PHARMACAPS	200MG	N21472 001	OCT 18, 2002
+ PHARM FORM	200MG	N74782 001	JUL 06, 1998

SUSPENSION; ORAL

CHILDREN'S ADVIL			
WYETH CONS	100MG/5ML	N20589 001	JUN 27, 1996
CHILDREN'S ADVIL-FLAVORED			
WYETH CONS	100MG/5ML	N20589 002	NOV 07, 1997
CHILDREN'S IBUPROFEN			
PERRIGO	100MG/5ML	N74937 001	DEC 22, 1998
CHILDREN'S MOTRIN			
+ MCNEIL	100MG/5ML	N20516 001	JUN 16, 1995
IBUPROFEN			
ALPHARMA	100MG/5ML	N74916 001	APR 30, 1999

SUSPENSION/DROPS; ORAL

CHILDREN'S MOTRIN			
+ MCNEIL	40MG/ML	N20603 001	JUN 10, 1996
IBUPROFEN			
PERRIGO	40MG/ML	N75217 001	DEC 16, 1998
PEDIATRIC ADVIL			
+ WYETH CONS	100MG/2.5ML	N20812 001	JAN 30, 1998

TABLET; ORAL

ADVIL			
WYETH CONS	200MG	N18989 001	MAY 18, 1984

IBUPROFEN

TABLET; ORAL

CAP-PROFEN			
PERRIGO	200MG	N72097 001	DEC 08, 1987
IBU-TAB 200			
ALRA	200MG	N71057 001	AUG 11, 1988
IBUPROFEN			
BASF	200MG	N75661 001	DEC 12, 2001
DR REDDYS LABS INC	100MG	N76117 001	NOV 20, 2001
INTERPHARM	200MG	N71333 001	FEB 17, 1987
	200MG	N72199 001	MAY 23, 1988
IVAX PHARMS	200MG	N71144 001	JAN 20, 1987
	200MG	N72901 001	DEC 19, 1991
	200MG	N72903 001	DEC 19, 1991
LEINER	200MG	N74931 001	JUL 20, 1998
LNK	200MG	N75010 001	MAR 01, 1999
	200MG	N75139 001	MAR 01, 1999
MCNEIL	200MG	N73019 001	MAR 30, 1994
MUTUAL PHARM	200MG	N71229 001	APR 01, 1987
	200MG	N72249 001	JAN 10, 1989
MYLAN	200MG	N71870 001	MAY 05, 1988
NEIL	200MG	N76460 001	NOV 26, 2003
OHM	200MG	N71163 001	JUL 15, 1986
PAR PHARM	200MG	N70481 001	SEP 24, 1986
	200MG	N70985 001	OCT 02, 1987
	200MG	N71575 001	MAY 08, 1987

FDA data supplied by DrugPatentWatch.com

IBUPROFEN

TABLET; ORAL

IBUPROFEN		
PERRIGO	200MG	N72096 001 DEC 08, 1987
	200MG	N72098 001 DEC 08, 1987
	200MG	N75995 001 MAR 14, 2002
PVT FORM	200MG	N71732 001 SEP 10, 1987
	200MG	N71735 001 SEP 10, 1987
	200MG	N72299 001 JUL 01, 1988
	200MG	N73691 001 FEB 25, 1994
SANDOZ	200MG	N70733 001 SEP 19, 1986
	200MG	N71807 001 FEB 25, 1988
	200MG	N74525 001 DEC 15, 1995
	200MG	N74533 001 DEC 15, 1995
VINTAGE PHARMS	200MG	N71639 001 FEB 02, 1988
WATSON LABS	200MG	N70435 001 MAR 05, 1986
IBUPROHM		
OHM LABS	200MG	N71214 001 DEC 01, 1986
JUNIOR STRENGTH ADVIL		
WYETH CONS	100MG	N20267 002 DEC 13, 1996
JUNIOR STRENGTH IBUPROFEN		
PERRIGO	100MG	N75367 001 APR 22, 1999
JUNIOR STRENGTH MOTRIN		
MCNEIL	100MG	N20602 001 JUN 10, 1996
MEDIPREN		
MCNEIL	200MG	N70475 001 FEB 06, 1986
	200MG	N71215 001 JUN 26, 1986
MOTRIN IB		
+ MCNEIL	200MG	N19012 003 DEC 17, 1990

IBUPROFEN

TABLET; ORAL

MOTRIN MIGRAINE PAIN		
+ MCNEIL	200MG	N19012 004 FEB 25, 2000
PROFEN		
PVT FORM	200MG	N71265 001 OCT 15, 1986
TAB-PROFEN		
PERRIGO	200MG	N72095 001 DEC 08, 1987

TABLET, CHEWABLE; ORAL

CHILDREN'S ADVIL		
WYETH CONS	50MG	N20944 001 DEC 18, 1998
CHILDREN'S MOTRIN		
MCNEIL	50MG	N20601 001 NOV 15, 1996
JUNIOR STRENGTH ADVIL		
WYETH CONS	100MG	N20944 002 DEC 18, 1998
JUNIOR STRENGTH MOTRIN		
+ MCNEIL	100MG	N20601 003 NOV 15, 1996

IBUPROFEN; *MULTIPLE*

SEE CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

ADVIL COLD AND SINUS		
WYETH CONS	200MG;30MG	N21374 001 MAY 30, 2002

SUSPENSION; ORAL

CHILDREN'S ADVIL COLD		
WYETH CONS	100MG/5ML;15MG/5ML	N21373 001 APR 18, 2002
CHILDREN'S MOTRIN COLD		
+ MCNEIL CONS SPECLT	100MG/5ML;15MG/5ML	N21128 001 AUG 01, 2000
IBUPROFEN AND PSEUDOEPHEDRINE HCL		
PERRIGO	100MG/5ML;15MG/5ML	N76478 001 NOV 05, 2003

FDA data supplied by DrugPatentWatch.com

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL COLD AND SINUS			
+ WYETH CONS	200MG;30MG	N19771 001	SEP 19, 1989
IBUPROFEN AND PSEUDOEPHEDRINE HCL			
PHARM FORM	200MG;30MG	N75588 001	APR 08, 2002
IBUPROHM COLD AND SINUS			
OHM LABS	200MG;30MG	N74567 001	APR 17, 2001
SINE-AID IB			
MCNEIL CONS SPECLT	200MG;30MG	N19899 001	DEC 31, 1992

IBUPROFEN POTASSIUM

CAPSULE; ORAL

ADVIL LIQUI-GELS			
+ WYETH CONS	200MG	N20402 001	APR 20, 1995
ADVIL MIGRAINE LIQUI-GELS			
+ WYETH CONS	200MG	N20402 002	MAR 16, 2000

INSULIN PURIFIED PORK

INJECTABLE; INJECTION

REGULAR ILETIN II (PORK)			
+ LILLY	100 UNITS/ML	N18344 001	

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN R			
+ LILLY	100 UNITS/ML	N18780 001	OCT 28, 1982
HUMULIN R PEN			
+ LILLY	100 UNITS/ML	N18780 005	AUG 06, 1998
NOVOLIN R			
+ NOVO NORDISK	100 UNITS/ML	N19938 001	JUN 25, 1991
VELOSULIN BR			
+ NOVO NORDISK	100 UNITS/ML	N21028 001	JUL 19, 1999

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 50/50			
+ LILLY	50 UNITS/ML;50 UNITS/ML	N20100 001	APR 29, 1992
HUMULIN 70/30			
+ LILLY	30 UNITS/ML;70 UNITS/ML	N19717 001	APR 25, 1989
HUMULIN 70/30 PEN			
+ LILLY	30 UNITS/ML;70 UNITS/ML	N19717 002	AUG 06, 1998
NOVOLIN 70/30			
+ NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N19991 001	JUN 25, 1991

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE; INJECTION

NPH ILETIN I (BEEF-PORK)			
+ LILLY	100 UNITS/ML	N17936 002	

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

NPH ILETIN II (PORK)			
+ LILLY	100 UNITS/ML	N18345 001	

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN N			
+ LILLY	100 UNITS/ML	N18781 001	OCT 28, 1982
NOVOLIN N			
NOVO NORDISK	100 UNITS/ML	N19959 001	JUL 01, 1991

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN; *MULTIPLE*

SEE INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

FDA data supplied by DrugPatentWatch.com

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

INJECTABLE; INJECTION		
HUMULIN U		
+ LILLY	100 UNITS/ML	N19571 002 JUN 10, 1987

INSULIN ZINC SUSP PURIFIED PORK

INJECTABLE; INJECTION		
LENTE ILETIN II (PORK)		
+ LILLY	100 UNITS/ML	N18347 001

INSULIN ZINC SUSP RECOMBINANT HUMAN

INJECTABLE; INJECTION		
HUMULIN L		
+ LILLY	100 UNITS/ML	N19377 002 SEP 30, 1985
NOVOLIN L		
NOVO NORDISK	100 UNITS/ML	N19965 001 JUN 25, 1991

ISOPROPYL ALCOHOL; *MULTIPLE*

SEE CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

KETOCONAZOLE

SHAMPOO; TOPICAL		
NIZORAL A-D		
+ MCNEIL CONS SPECLT	1%	N20310 001 OCT 10, 1997

KETOPROFEN

TABLET; ORAL		
ACTRON		
BAYER	12.5MG	N20499 001 OCT 06, 1995
ORUDIS KT		
+ WYETH CONS	12.5MG	N20429 001 OCT 06, 1995

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL		
IMODIUM A-D		
+ MCNEIL	1MG/5ML	N19487 001 MAR 01, 1988
LOPERAMIDE HCL		
DURAMED PHARMS BARR	1MG/5ML	N74991 001 DEC 29, 1997
HI TECH PHARMA	1MG/5ML	N74352 001 NOV 17, 1995
MORTON GROVE	1MG/5ML	N74730 001 AUG 28, 1997
PERRIGO	1MG/5ML	N73243 001 JAN 21, 1992
ROXANE	1MG/5ML	N73079 001 APR 30, 1992
TEVA	1MG/5ML	N73478 001 JUN 23, 1995
TABLET; ORAL		
IMODIUM A-D		
+ MCNEIL	2MG	N19860 001 NOV 22, 1989
LOPERAMIDE HCL		
LEINER	2MG	N73254 001 JUL 30, 1993
LNK	2MG	N76497 001 JUN 10, 2003
OHM LABS	2MG	N74091 001 DEC 10, 1992
PERRIGO	2MG	N75232 001 JAN 06, 2000
TABLET, CHEWABLE; ORAL		
IMODIUM A-D		
+ MCNEIL	2MG	N20448 001 JUL 24, 1997

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL		
IMODIUM ADVANCED		
+ MCNEIL CONS SPECLT	2MG;125MG	N21140 001 NOV 30, 2000
TABLET, CHEWABLE; ORAL		
IMODIUM ADVANCED		
+ MCNEIL	2MG;125MG	N20606 001 JUN 26, 1996

FDA data supplied by DrugPatentWatch.com

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE; ORAL
LOPERAMIDE HCL AND SIMETHICONE
PERRIGO 2MG;125MG N76029 001 AUG 30, 2002

LORATADINE

SYRUP; ORAL
CLARITIN
+ SCHERING 1MG/ML N20641 002 NOV 27, 2002

CLARITIN HIVES RELIEF
+ SCHERING 1MG/ML N20641 003 NOV 19, 2003

LORATADINE
TEVA 1MG/ML N75505 001 NOV 07, 2003

TABLET; ORAL
CLARITIN
+ SCHERING 10MG N19658 002 NOV 27, 2002

CLARITIN HIVES RELIEF
+ SCHERING 10MG N19658 003 NOV 19, 2003

LORATADINE
GENPHARM 10MG N76154 001 AUG 20, 2003

RANBAXY 10MG N76134 001 AUG 18, 2003

SANDOZ 10MG N75209 001 JAN 21, 2003

TABLET, ORALLY DISINTEGRATING; ORAL
ALAVERT
WYETH CONS 10MG N21375 001 DEC 19, 2002

CLARITIN HIVES RELIEF REDITAB
+ SCHERING 10MG N20704 003 NOV 19, 2003

CLARITIN REDITABS
+ SCHERING 10MG N20704 002 NOV 27, 2002

LORATADINE
ANDRX PHARMS 10MG N75990 001 NOV 03, 2003

LORATADINE

TABLET, ORALLY DISINTEGRATING; ORAL
LORATADINE
IMPAX LABS 10MG N76011 001 SEP 29, 2003

WYETH CONS 10MG N75822 001 FEB 10, 2003

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
CLARITIN-D
+ SCHERING 5MG;120MG N19670 002 NOV 27, 2002

CLARITIN-D 24 HOUR
+ SCHERING 10MG;240MG N20470 002 NOV 27, 2002

LORATADINE AND PSEUDOEPHEDRINE SULFATE
ANDRX PHARMS 10MG;240MG N75706 001 FEB 21, 2003

IMPAX LABS 5MG;120MG N76050 001 JAN 30, 2003

MAGNESIUM HYDROXIDE; *MULTIPLE*
SEE CALCIUM CARBONATE, PRECIPITATED; FAMOTIDINE; MAGNESIUM HYDROXIDE

MAGNESIUM TRISILICATE; *MULTIPLE*
SEE ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

MICONAZOLE NITRATE

CREAM; TOPICAL, VAGINAL
MONISTAT 3 COMBINATION PACK
+ PERSONAL PRODS 2%,4% N21261 003 JUN 17, 2003

MONISTAT 3 COMBINATION PACK (PREFILLED)
+ PERSONAL PRODS 2%,4% N21261 001 FEB 02, 2001

CREAM; VAGINAL
MICONAZOLE 7
ALPHARMA US PHARM 2% N74164 001 MAR 29, 1996

FDA data supplied by DrugPatentWatch.com

MICONAZOLE NITRATE

CREAM; VAGINAL
MICONAZOLE NITRATE

COPLEY PHARM	2%	N74030 001 OCT 30, 1992
G AND W LABS	2%	N74366 001 FEB 22, 1996
PERRIGO	2%	N74760 001 MAY 15, 1997
TARO	2%	N74444 001 JAN 13, 1997
TEVA	2%	N74136 001 JAN 04, 1995

MONISTAT 3

+ ADVANCED CARE PRODS	4%	N20827 001 MAR 30, 1998

MONISTAT 7

+ ADV CARE	2%	N17450 002 FEB 15, 1991

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
M-ZOLE 3 COMBINATION PACK

ALPHARMA US PHARM	2%,200MG	N74926 001 APR 16, 1999

M-ZOLE 7 DUAL PACK

ALPHARMA	2%,100MG	N74586 001 JUL 17, 1997

MICONAZOLE NITRATE COMBINATION PACK

PERRIGO	2%,200MG	N75329 001 APR 20, 1999

MONISTAT 1 COMBINATION PACK

+ PERSONAL PRODS	1.2GM,2%	N21308 001 JUN 29, 2001

MONISTAT 7 COMBINATION PACK

+ ADV CARE	2%,100MG	N20288 002 APR 26, 1993

MONISTAT-3 COMBINATION PACK

+ ADV CARE	2%,200MG	N20670 002 APR 16, 1996

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

ALPHARMA US PHARM	100MG	N73507 001 NOV 19, 1993
G AND W LABS	100MG	N74414 001 APR 30, 1997
+ PERRIGO	100MG	N74395 001 MAR 20, 1997

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL
MONISTAT 7

+ ADVANCED CARE PRODS	100MG	N18520 002 FEB 15, 1991

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)

ALPHARMA	2%	N74588 001 APR 05, 1996
BAUSCH AND LOMB	2%	N74643 001 APR 09, 1996
COPLEY PHARM	2%	N74500 001 MAY 23, 1996
HI TECH PHARMA	2%	N74731 001 DEC 24, 1996
MORTON GROVE	2%	N74767 001 FEB 28, 1997
NOVEX	2%	N74924 001 APR 29, 1998
PERRIGO	2%	N75357 001 JUL 30, 1999
SIGHT PHARMS	2%	N74743 002 OCT 18, 1996
TEVA	2%	N74589 001 APR 05, 1996

MINOXIDIL (FOR WOMEN)

NOVEX	2%	N74924 002 APR 29, 1998
PERRIGO	2%	N75357 002 JUL 30, 1999
SIGHT PHARMS	2%	N74743 001 OCT 18, 1996

MINOXIDIL EXTRA STRENGTH (FOR MEN)

ALPHARMA	5%	N75518 001 NOV 17, 2000
CLAY PARK	5%	N75737 001 MAR 15, 2002
MORTON GROVE	5%	N75438 001 FEB 27, 2003
NOVEX	5%	N75839 001 OCT 01, 2001
PERRIGO	5%	N75598 001 JUN 13, 2001

FDA data supplied by DrugPatentWatch.com

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)		
TEVA	5%	N75619 001 NOV 17, 2000
ROGAINE (FOR MEN)		
+ PHARMACIA AND UPJOHN	2%	N19501 002 FEB 09, 1996
ROGAINE (FOR WOMEN)		
+ PHARMACIA AND UPJOHN	2%	N19501 003 FEB 09, 1996
ROGAINE EXTRA STRENGTH (FOR MEN)		
+ PHARMACIA AND UPJOHN	5%	N20834 001 NOV 14, 1997

NAPHAZOLINE HYDROCHLORIDE; *MULTIPLE*
SEE ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

NAPHCON-A		
+ ALCON	0.025%;0.3%	N20226 001 JUN 08, 1994
OPCON-A		
+ BAUSCH AND LOMB	0.02675%;0.315%	N20065 001 JUN 08, 1994
VISINE-A		
PFIZER	0.025%;0.3%	N20485 001 JAN 31, 1996

NAPROXEN SODIUM

TABLET; ORAL

ALEVE		
+ BAYER	EQ 200MG BASE	N20204 002 JAN 11, 1994
NAPROXEN SODIUM		
DR REDDYS LABS INC	EQ 200MG BASE	N75168 001 JUL 28, 1998
LEINER	EQ 200MG BASE	N74635 001 JAN 13, 1997
PERRIGO	EQ 200MG BASE	N74661 001 JAN 13, 1997

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM		
PVT FORM	EQ 200MG BASE	N74789 001 FEB 27, 1997
SANDOZ	EQ 200MG BASE	N74646 001 JAN 13, 1997

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALEVE COLD AND SINUS		
+ BAYER	EQ 200MG BASE;120MG	N21076 001 NOV 29, 1999

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

HABITROL		
+ NOVARTIS	7MG/24HR	N20076 004 NOV 12, 1999
+	14MG/24HR	N20076 005 NOV 12, 1999
+	21MG/24HR	N20076 006 NOV 12, 1999
NICODERM CQ		
+ AVENTIS PHARMS	7MG/24HR	N20165 006 AUG 02, 1996
+	14MG/24HR	N20165 005 AUG 02, 1996
+	21MG/24HR	N20165 004 AUG 02, 1996
NICOTROL		
+ PHARMACIA AND UPJOHN	15MG/16HR	N20536 001 JUL 03, 1996
PROSTEP		
+ AVEVA	11MG/24HR	N19983 003 DEC 23, 1998
+	22MG/24HR	N19983 004 DEC 23, 1998

FDA data supplied by DrugPatentWatch.com

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL
NICORETTE
+ GLAXOSMITHKLINE EQ 2MG BASE N18612 002 FEB 09, 1996
+ EQ 4MG BASE N20066 002 FEB 09, 1996

NICORETTE (ORANGE)
+ GLAXOSMITHKLINE EQ 4MG BASE N20066 004 SEP 25, 2000

NICORETTE (MINT)
+ GLAXOSMITHKLINE EQ 2MG BASE N18612 003 DEC 23, 1998
+ EQ 4MG BASE N20066 003 DEC 23, 1998

NICORETTE (ORANGE)
+ GLAXOSMITHKLINE EQ 2MG BASE N18612 004 SEP 25, 2000

NICOTINE POLACRILEX
WATSON LABS EQ 2MG BASE N74507 001 MAR 15, 1999
EQ 4MG BASE N74707 001 MAR 19, 1999

TROCHE/LOZENGE; ORAL
COMMIT
GLAXOSMITHKLINE CONS EQ 2MG BASE N21330 001 OCT 31, 2002
+ EQ 4MG BASE N21330 002 OCT 31, 2002

NIZATIDINE

TABLET; ORAL
AXID AR
+ WYETH CONS 75MG N20555 001 MAY 09, 1996

OCTYL METHOXYCINNAMATE; *MULTIPLE*
SEE AVOBENZONE; OCTYL METHOXYCINNAMATE; OXYBENZONE

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE; ORAL
PRILOSEC OTC
+ ASTRAZENECA EQ 20MG BASE N21229 001 JUN 20, 2003

OXYBENZONE; *MULTIPLE*
SEE AVOBENZONE; OCTYL METHOXYCINNAMATE; OXYBENZONE

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OCUCLEAR
SCHERING PLOUGH 0.025% N18471 001 MAY 30, 1986

VISINE L.R.
+ PFIZER 0.025% N19407 001 MAR 31, 1989

PERMETHRIN

LOTION; TOPICAL
NIX
+ INSIGHT PHARMS 1% N19918 001 MAY 02, 1990

PERMETHRIN
ALPHARMA 1% N75014 001 MAR 28, 2000

CLAY PARK 1% N76090 001 DEC 20, 2001

PHENIRAMINE MALEATE; *MULTIPLE*
SEE NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL
RID MOUSSE
+ PFIZER 4%;EQ 0.33% BASE N21043 001 MAR 07, 2000

FDA data supplied by DrugPatentWatch.com

POTASSIUM IODIDE

TABLET; ORAL

IOSAT		
ANBEX	130MG	N18664 001 OCT 14, 1982
THYRO-BLOCK		
+ MEDPOINTE PHARM HLC	130MG	N18307 001
THYROSAFE		
+ R R REGISTRATIONS	65MG	N76350 001 SEP 10, 2002

POVIDONE-IODINE

SOLUTION; TOPICAL

E-Z PREP		
+ BECTON DICKINSON	10%	N19382 001 JUL 25, 1989
POVIDONE IODINE		
+ ALLEGIANCE HLTHCARE	1%	N19522 001 MAR 31, 1989

SPONGE; TOPICAL

E-Z PREP		
+ BECTON DICKINSON	5%	N19382 002 JUL 25, 1989
E-Z PREP 220		
+ BECTON DICKINSON	5%	N19382 003 JUL 25, 1989
E-Z SCRUB 201		
+ BECTON DICKINSON	20%	N19240 001 NOV 29, 1985
E-Z SCRUB 241		
+ BECTON DICKINSON	10%	N19476 001 JAN 07, 1987

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EFIDAC 24 PSEUDOEPHEDRINE HCL		
+ ALZA	240MG	N20021 002 DEC 15, 1992
PSEUDOEPHEDRINE HCL		
PERRIGO	120MG	N75153 001 FEB 26, 1999
SUDAFED 12 HOUR		
+ WARNER LAMBERT	120MG	N73585 001 OCT 31, 1991

PSEUDOEPHEDRINE HYDROCHLORIDE; *MULTIPLE*

SEE ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SEE BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SEE CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SEE IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SEE NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

AFRINOL		
+ SCHERING PLOUGH	120MG	N18191 001

PSEUDOEPHEDRINE SULFATE; *MULTIPLE*

SEE ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

SEE CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

SEE DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

SEE LORATADINE; PSEUDOEPHEDRINE SULFATE

PYRETHRINS; *MULTIPLE*

SEE PIPERONYL BUTOXIDE; PYRETHRINS

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE		
DR REDDYS LABS LTD	EQ 75MG BASE	N75294 001 MAR 28, 2000
GENPHARM	EQ 75MG BASE	N75497 001 JAN 14, 2000
IVAX PHARMS	EQ 75MG BASE	N75296 001 JAN 14, 2000
LEINER	EQ 75MG BASE	N75094 001 JUN 21, 1999
PERRIGO	EQ 75MG BASE	N76195 001 AUG 30, 2002
RANBAXY	EQ 75MG BASE	N75132 001 JAN 14, 2000
SANDOZ	EQ 75MG BASE	N75519 001 SEP 26, 2002
TORPHARM	EQ 75MG BASE	N75167 001 MAY 04, 2000

FDA data supplied by DrugPatentWatch.com

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE
WATSON LABS EQ 75MG BASE N75212 001 JAN 14, 2000

ZANTAC 75
+ WARNER LAMBERT EQ 75MG BASE N20520 001 DEC 19, 1995

SIMETHICONE; *MULTIPLE*
SEE LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

SODIUM CHLORIDE

AEROSOL, METERED; INHALATION
BRONCHO SALINE
+ BLAIREX 0.9% N19912 001 SEP 03, 1992

SODIUM FLUORIDE; TRICLOSAN

PASTE; DENTAL
COLGATE TOTAL
+ COLGATE PALMOLIVE 0.24%;0.3% N20231 001 JUL 11, 1997

SODIUM MONOFLUOROPHOSPHATE

GEL; DENTAL
EXTRA-STRENGTH AIM
+ CHESEBROUGH PONDS 1.2% N19518 002 AUG 06, 1986

PASTE; DENTAL
EXTRA-STRENGTH AIM
+ CHESEBROUGH PONDS 1.2% N19518 001 JUN 03, 1987

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL
LAMISIL
+ NOVARTIS 1% N20980 001 MAR 09, 1999

TERBINAFINE HYDROCHLORIDE

SOLUTION; TOPICAL
LAMISIL AT
+ NOVARTIS 1% N21124 001 MAR 17, 2000

TIOCONAZOLE

OINTMENT; VAGINAL
TIOCONAZOLE
PERRIGO 6.5% N75915 001 NOV 21, 2001

VAGISTAT-1
+ BRISTOL MYERS SQUIBB 6.5% N20676 001 FEB 11, 1997

TRICLOSAN; *MULTIPLE*
SEE SODIUM FLUORIDE; TRICLOSAN

TRICLOSAN; *MULTIPLE*
SEE SODIUM FLUORIDE; TRICLOSAN

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION
ACD-A SOLUTION — ANDA
GAMBRO BCT, INC — N010228
FEB 25, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION
ADSOL WITH ACD-A
BAXTER HEALTHCARE CORP - FENWAL DIVISION
N000922
AUG 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION
ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A — ANDA
HAEMONETICS CORP — N980728
FEB 6, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION ACD

INJECTABLE; INJECTION
AS3 SOLUTION/ACD-A
GAMBRO BCT, INC
N001214
MAY 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION ACD

INJECTABLE; INJECTION
NONE
CYTOSOL LABORATORIES, INC
N020037
AUG 26, 2003

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
MEDSEP CORPORATION — N710497
(ANDA)

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
FRESENIUS USA, INC
N110912
SEP 02, 1959

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION — N100855
JUN 03, 1959

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION — N160918
MAR 17, 1978

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

INJECTABLE; INJECTION
AS3 NUTRICEL ADDITIVE SYSTEM ADDITIVE SOLUTION FORMULA 3
GAMBRO BCT, INC
N012142
MAY 29, 2002

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

INJECTABLE; INJECTION
CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3
HAEMONETICS CORP — N000127
JAN 18, 2002

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION
NONE
FRESENIUS USA, INC — N780519
APR 23, 1980

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION
NONE
TERUMO MEDICAL CORP — N820528
NOV 03, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION
BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER
BAXTER HEALTHCARE CORP - FENWAL DIVISION — N940404
JUL 28, 1994

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION
NONE
MEDSEP CORPORATION — N800077
NOV 06, 1980

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
MILES, INC — N160527
JUN 22, 1970

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
MEDSEP CORPORATION — N800222
AUG 23, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
FRESENIUS USA, INC — N160907
MAY 16, 1973

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
TERUMO MEDICAL CORP — N781211
JUN 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION — N170401
DEC 06, 1977

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION — N811012
JUN 28, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION
ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION
BAXTER HLTHCARE FENWAL DIV — 2.2GM/100ML;0.9GM/100ML; 0.75GM/100ML;0.027GM/100ML — N811104
MAY 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION
OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION
TERUMO MEDICAL CORP — 0.9GM/100ML;0.877GM/100ML; 0.525GM/100ML;0.03GM/100ML — N880217
OCT 07, 1988

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION
AS-2 NUTRICEL ADDITIVE SYSTEM
MEDSEP CORP — 0.042GM/100ML;0.285GM/100ML; 0.718GM/100ML;0.017GM/100ML; 0.396GM/100ML;0.588GM/100ML — N820915
SEP 22, 1983

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION
AS-3 NUTRICEL ADDITIVE SYSTEM
MEDSEP CORP 0.042GM/100ML;0.276GM/100ML; 0.410GM/100ML;0.30GM/100ML; 1.10GM/100ML;0.588GM/100ML N820915 OCT 19, 1984

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION
CDP BLOOD BAG UNIT IN PLASTIC CONTAINER N900224
BAXTER HLTHCARE - FENWAL DIVISION DEC 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION
ADSOL IN PLASTIC CONTAINER
BAXTER HLTH CARE - FENWAL DIVISION N900223 DEC 27, 1991

ANTICOAGULANT HEPARIN SOLUTION USP

INJECTABLE; INJECTION
NONE
FRESENIUS USA, INC N770822 MAY 17, 1978

ANTICOAGULANT SODIUM CITRATE SOLUTION

INJECTABLE; INJECTION
TRICITRASOL
CYTOSOL LABORATORIES, INC N010409 JUL 10, 2003

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION N770923 JAN 20, 1978

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION
NONE
MEDSEP CORPORATION N760305 JUN 30, 1978

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION
NONE
HAEMONETICS CORPORATION N980123 MAR 3, 2000

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION
NONE
FRESENIUS USA, INC N160702 DEC 28, 1970

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION
NONE
TERUMO MEDICAL CORP N781214 FEB 08, 1980

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION
NONE
BAXTER HEALTHCARE CORP - FENWAL DIVISION N770923 JAN 20, 1978

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION
PROMIT
PHARMALINK BASLAKEMEDEL AB N830715 OCT 30, 1984

DEXTRAN 40, 10% W/V DEXTRAN 40 IN 0.8% NACL 500 ML PVC BAGS

INJECTABLE, INJECTION
RHEOMACRODEX
PHARMALINK BASLAKEMEDEL AB N830527 MAR 27, 1985

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

DEXTRAN 40, 10% W/V DEXTRAN 40 IN 5% DEXTROSE 500 ML PVC BAGS

INJECTABLE, INJECTION
RHEOMACRODEX
PHARMALINK BASLAKEMEDEL AB — N830627 — MAR 27, 1985

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
GENTRAN 40
BAXTER HLTHCARE IV SYSTEMS — 10GM/100ML;5GM/100ML — N840619 — FEB 22, 1985

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
LMD IN PLASTIC CONTAINER
ABBOTT LABS — 10GM/100ML;5GM/100ML — ANDA N720563 — OCT 30, 1992

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
NONE
ABBOTT LABS — 10GM/100ML;5GM/100ML — N160375 — JUL 25, 1967

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
NONE
MCGAW, INC — 10GM/100ML;5GM/100ML — N160767 — APR 6, 1970

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
NONE
MILES, INC — 10GM/100ML;5GM/100ML — N160653 — SEP 23, 1969

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION
RHEOMACRODEX
PHARMALINK BASLAKEMEDEL AB — 10GM/100ML;5GM/100ML — N140716 — JAN 18, 1967

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
GENTRAN 40
BAXTER HLTHCARE IV SYSTEMS — 10GM/100ML;0.9GM/100ML — N840620 — FEB 22, 1985

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
LMD IN PLASTIC CONTAINER
ABBOTT LABS — 10GM/100ML;0.9GM/100ML — ANDA N720562 — OCT 30, 1992

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
RHEOMACRODEX
PHARMALINK BASLAKEMEDEL AB — 10GM/100ML;0.9GM/100ML — N140716 — JAN 18, 1967

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
ABBOTT LABS — 10GM/100ML;0.9GM/100ML — N160375 — JUL 25, 1967

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
MILES, INC — 10GM/100ML;0.9GM/100ML — N160653 — SEP 23, 1969

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
PHARMACHEM — 10GM/100ML;0.9GM/100ML — N160836 — NOV 14, 1972

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
MCGAW, INC 10GM/100ML;0.9GM/100ML N160767
APR 6, 1970

DEXTRAN 70, 6% W/V DEXTRAN 70 IN 0.9% NACL IN 500 ML PVC BAGS

INJECTABLE; INJECTION
MACRODEX
PHARMALINK BASLAKEMEDEL AB N830613
MAR 27, 1985

DEXTRAN 70, 6% W/V DEXTRAN 70 IN 5% DEXTROSE

INJECTABLE; INJECTION
MACRODEX
PHARMALINK BASLAKEMEDEL AB N830629
MAR 27, 1985

DEXTRAN 70, 6% IN DEXTROSE 5%

INJECTABLE; INJECTION
MACRODEX
PHARMALINK BASLAKEMEDEL AB 6GM/100ML;5GM/100ML N060826
JUN 8, 1954

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
MACRODEX
PHARMALINK BASLAKEMEDEL AB 6GM/100ML;5GM/100ML N060826
JUN 8, 1954

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
MCGAW, INC 6GM/100ML;0.9 GM/100ML N090024
AUG 18, 1969

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
MILES, INC 6GM/100ML;0.9 GM/100ML N080716
MAR 13, 1953

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
GENTRAIN 70
BAXTER HLTHCARE IV SYSTEMS 6GM/100ML;0.9 GM/100ML N160607
JAN 26, 1970

DEXTRAN 70, 6% IN DEXTROSE 5%

INJECTABLE; INJECTION
NONE
ABBOTT LABS 6GM/100ML;5GM/100ML N080819
MAR 31, 1953

DEXTRAN 75, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
PHARMACHEM 6GM/100ML;0.9GM/100ML N080564
SEP 19, 1952

DEXTRAN 75, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
NONE
PHARMACHEM 6GM/100ML;0.9GM/100ML N160759
AUG 19, 1970

HETASTARCH 6% IN SODIUM CHLORIDE 0.9% NACL 500 ML GLASS BOTTLES

INJECTABLE; INJECTION
NONE
ABBOTT LABORATORIES - HOSPITAL PRODUCTS DIV ANDA N720746
FEB 07, 1996

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
HESPAN
MCGAW, INC 6GM/100ML;0.9GM/100ML N160889
JUL 17, 1972

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
HESPAN IN PLASTIC CONTAINER
MCGAW, INC 6GM/100ML;0.9GM/100ML N890105
APR 04, 1991

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT	6GM/100ML;0.9GM/100ML	ANDA N740193 JAN 30, 1995

HETASTARCH 6% IN 0.9% NACL

INJECTABLE; INJECTION
NONE

GENSIA LABS, INC	6GM/100ML;0.9GM/100ML	ANDA N740592 NOV 12, 1998

HETASTARCH 6% IN 0.9% NACL

INJECTABLE; INJECTION
NONE

MCGAW, INC	6GM/100ML;0.9GM/100ML	ANDA N740283 OCT 21, 1998

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION
HEXTEND

BIOTIME, INC	6GM/100ML	N200952 MAR 31, 1999

INDIUM IN^{111} CHLORIDE

SOLUTION; INJECTION
INDICLOR

MEDI-PHYSICS	N/A	N19862 DEC 29, 1992

INDIUM IN^{111} CHLORIDE STERILE SOLUTION

INJECTABLE; INJECTION ULTRAPURE
ULTRAPURE

MALLINCKRODT	N/A	N19841 SEP 27, 1994

PENTASTARCH 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
PENTASPAN

MCGAW, INC	10GM/100ML;0.9GM/100ML	N841207 MAY 19, 1987

PENTASTARCH 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION
PENTASPAN IN PLASTIC CONTAINER

MCGAW, INC	10GM/100ML;0.9GM/100ML	N890104 APR 04, 1991

PERFLUORODECALIN; PERFLUOROTRI-N-PROPYLAMINE

INJECTABLE; INJECTION
FLUOSOL

ALPHA THERPTC	17.5GM/100ML;7.5GM/100ML	N860909 DEC 26, 1989

RED BLOOD CELL PROCESSING SOLUTION

INJECATABLE; INJECTION
REJUVESOL

CYTOSOL LABS, INC	N/A	N950522 FEB 26, 1997

UROKINASE

INJECTABLE; INJECTION
ABBOKINASE OPEN-CATHETER

ABBOTT LABS	5,000 IU/VIAL	N761021 DEC 15, 1983

UROKINASE

INJECTABLE; INJECTION
ABBOKINASE

ABBOTT LABS	9,000 IU/VIAL	N761021

UROKINASE

INJECTABLE; INJECTION
ABBOKINASE

ABBOTT LABS	250,000 IU/VIAL	N761021

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN		
INJECTABLE		
INJECTAPAP	100MG/ML	N17785
SUPPOSITORY		
ACETAMINOPHEN	120MG	N73106
ACETAMINOPHEN	325MG	N73107
ACETAMINOPHEN	650MG	N73108
ACETAMINOPHEN	120MG	N71010
ACETAMINOPHEN	650MG	N71011
TYLENOL	120MG	N17756
TYLENOL	650MG	N17756
ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE		
CAPSULE		
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE	150MG;180MG;15MG	N81095
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE	150MG;180MG;60MG	N81097
CODEINE, ASPIRIN, APAP FORMULA NO. 2	150MG;180MG;15MG	N85640
CODEINE, ASPIRIN, APAP FORMULA NO. 3	150MG;180MG;30MG	N85639
CODEINE, ASPIRIN, APAP FORMULA NO. 4	150MG;180MG;60MG	N85638
ACETAMINOPHEN; BUTALBITAL		
CAPSULE		
BANCAP	325MG;50MG	N88889
TRIAPRIN	325MG;50MG	N89268
TABLET		
BUTALBITAL AND ACETAMINOPHEN	325MG;50MG	N89568
BUTALBITAL AND ACETAMINOPHEN	325MG;50MG	N87550
ACETAMINOPHEN; BUTALBITAL; CAFFEINE		
CAPSULE		
ACETAMINOPHEN, BUTALBITAL AND CAFFEINE	325MG;50MG;40MG	N88825
ANOQUAN	325MG;50MG;40MG	N87628
BUTALBITAL, ACETAMINOPHEN, CAFFEINE	325MG;50MG;40MG	N88743
BUTALBITAL, ACETAMINOPHEN, CAFFEINE	325MG;50MG;40MG	N88765
BUTALBITAL, ACETAMINOPHEN, CAFFEINE	325MG;50MG;40MG	N89067
BUTALBITAL, ACETAMINOPHEN, CAFFEINE	325MG;50MG;40MG	N88758
FEMCET	325MG;50MG;40MG	N89102
MEDIGESIC PLUS	325MG;50MG;40MG	N89115
TRIAD	325MG;50MG;40MG	N89023
TABLET		
ACETAMINOPHEN, BUTALBITAL AND CAFFEINE	325MG;50MG;40MG	N87629
ESGIC	325MG;50MG;40MG	N89660
ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE		
CAPSULE		
DHC PLUS	356.4MG;30MG;16MG	N88584
SYNALGOS-DC-A	356.4MG;30MG;16MG	N89166

ACETAMINOPHEN; CODEINE PHOSPHATE		
CAPSULE		
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;30MG	N88324
ACETAMINOPHEN W/ CODEINE #2	300MG;15MG	N88537
ACETAMINOPHEN W/ CODEINE #4	300MG;60MG	N88599
PHENAPHEN W/ CODEINE NO. 2	325MG;15MG	N84444
PHENAPHEN W/ CODEINE NO. 3	325MG;30MG	N84445
PHENAPHEN W/ CODEINE NO. 4	325MG;60MG	N84446
PROVAL #3	325MG;30MG	N85685
TYLENOL W/ CODEINE NO. 3	300MG;30MG	N87422
TYLENOL W/ CODEINE NO. 4	300MG;60MG	N87421
SOLUTION		
TYLENOL W/ CODEINE	120MG/5ML;12MG/5ML	N85057
TABLET		
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;15MG	N88353
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;30MG	N88354
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;60MG	N88355
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;15MG	N87433
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;30MG	N85917
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;60MG	N87423
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;15MG	N85795
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;30MG	N85794
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;60MG	N86549
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;30MG	N85288
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;60MG	N85365
ACETAMINOPHEN AND CODEINE PHOSPHATE	325MG;15MG	N85364
ACETAMINOPHEN AND CODEINE PHOSPHATE	325MG;45MG	*N85363
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;60MG	N89244
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;30MG	N86681
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;60MG	N86683
ACETAMINOPHEN AND CODEINE PHOSPHATE	500MG;15MG	*N89511
ACETAMINOPHEN AND CODEINE PHOSPHATE	500MG;30MG	*N89512
ACETAMINOPHEN AND CODEINE PHOSPHATE	500MG;60MG	*N89513
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;30MG	N85291
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;60MG	N85964
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;15MG	N85992
ACETAMINOPHEN AND CODEINE PHOSPHATE	300MG;30MG	N85218
ACETAMINOPHEN AND CODEINE PHOSPHATE #2	300MG;15MG	N89183
ACETAMINOPHEN AND CODEINE PHOSPHATE #3	300MG;30MG	N89080
ACETAMINOPHEN AND CODEINE PHOSPHATE #3	300MG;30MG	N89184
ACETAMINOPHEN AND CODEINE PHOSPHATE #3	300MG;30MG	N89253
ACETAMINOPHEN AND CODEINE PHOSPHATE #4	300MG;60MG	N89185
ACETAMINOPHEN AND CODEINE PHOSPHATE #4	300MG;60MG	N89254
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 2	300MG;15MG	N89478
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 2	300MG;15MG	N89481
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 3	300MG;30MG	N89479
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 3	300MG;30MG	N89482

FDA data supplied by DrugPatentWatch.com

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET

ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4	300MG;60MG	N89480
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4	300MG;60MG	N89483
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4	300MG;60MG	N84667
ACETAMINOPHEN W/ CODEINE	300MG;60MG	N87653
ACETAMINOPHEN W/ CODEINE	300MG;30MG	N87141
ACETAMINOPHEN W/ CODEINE NO. 2	300MG;15MG	N84659
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;15MG	N83871
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;30MG	N83872
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;30MG	N87919
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;60MG	N87920
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;30MG	N85676
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;60MG	N87306
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;15MG	N87277
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;30MG	N87276
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;60MG	N87275
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;30MG	N84360
ACETAMINOPHEN W/ CODEINE PHOSPHATE	300MG;60MG	N85607
APAP W/ CODEINE PHOSPHATE	325MG;30MG	N85217
CAPITAL WITH CODEINE	325MG;30MG	N83643
CODEINE PHOSPHATE AND ACETAMINOPHEN	300MG;30MG	N85896
EMPRACET W/ CODEINE PHOSPHATE #3	300MG;30MG	N83951
EMPRACET W/ CODEINE PHOSPHATE #4	300MG;60MG	N83951
PAPA-DEINE #3	300MG;30MG	N88037
PAPA-DEINE #4	300MG;60MG	N88715
PHENAPHEN-650 W/ CODEINE	650MG;30MG	N85856
TYLENOL W/ CODEINE	325MG;15MG	N85056
TYLENOL W/ CODEINE	325MG;30MG	N85056
TYLENOL W/ CODEINE	325MG;60MG	N85056
TYLENOL W/ CODEINE	325MG;7.5MG	N85056
TYLENOL W/ CODEINE NO. 1	300MG;7.5MG	N85055
TYLENOL W/ CODEINE NO. 2	300MG;15MG	N85055
TYLENOL W/ CODEINE NO. 4	300MG;60MG	N85055

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE

BANCAP HC	500MG;5MG	N87961
CO-GESIC	500MG;5MG	N89360

TABLET

DURADYNE DHC	500MG;5MG	N87809
HYDROCODONE BITARTRATE AND ACETAMINOPHEN	500MG;5MG	N88577
HYDROCODONE BITARTRATE AND ACETAMINOPHEN	500MG;5MG	N89554
HYDROCODONE BITARTRATE AND ACETAMINOPHEN	500MG;5MG	N89290

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET

HYDROCODONE BITARTRATE AND ACETAMINOPHEN	500MG;5MG	N89291
HYDROCODONE BITARTRATE AND ACETAMINOPHEN	325MG;7.5MG	N40248
NORCET	500MG;5MG	N88871
TYCOLET	500MG;5MG	N89385
VICODIN	500MG;5MG	N85667

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE

OXYCODONE AND ACETAMINOPHEN	500MG;5MG	N89994
TYLOX-325	325MG;5MG	N88246

TABLET

OXYCODONE 2.5/APAP 500	500MG;2.5MG	N85910
OXYCODONE 5/APAP 500	500MG;5MG	N85911

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

CAPSULE

TYLOX	500MG;4.5MG;0.38MG	N85375

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET

DARVOCET	325MG;32.5MG	N16844
DOLENE AP-65	650MG;65MG	N85100
PROPOXYPHENE HCL AND ACETAMINOPHEN	325MG;32MG	N83689

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET

PROPACET 100	650MG;100MG	N70107
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN	325MG;50MG	N70115
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN	325MG;50MG	N72105
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN	650MG;100MG	N70116
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN	650MG;100MG	N72106
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN	650MG;100MG	N71319
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN	650MG;100MG	N70732
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN	325MG;50MG	N70398
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN	650MG;100MG	N70399

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE

DIAMOX	500MG	N12945

FDA data supplied by DrugPatentWatch.com

ACETAZOLAMIDE		
TABLET		
ACETAZOLAMIDE	250MG	N83320
ACETAZOLAMIDE	250MG	N87686
ACETAZOLAMIDE	250MG	N87654
ACETAZOLAMIDE	250MG	N84498
ACETIC ACID, GLACIAL		
SOLUTION/DROPS		
ACETIC ACID	2%	N85493
ORLEX	2%	N86845
ACETIC ACID, GLACIAL; ALUMINUM ACETATE		
SOLUTION/DROPS		
BOROFAIR	2%;0.79%	N88606
DOMEBORO	2%;0.79%	N84476
ACETIC ACID, GLACIAL; DESONIDE		
SOLUTION/DROPS		
TRIDESILON	2%;0.05%	N17914
ACETIC ACID, GLACIAL; HYDROCORTISONE		
SOLUTION/DROPS		
ACETIC ACID W/ HYDROCORTISONE	2%;1%	N85492
HYDROCORTISONE AND ACETIC ACID	2%;1%	N40097
ORLEX HC	2%;1%	N86844
ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE		
SUSPENSION/DROPS		
NEO-CORT-DOME	2%;1%;EQ 0.35% BASE	N50238
ACETOHEXAMIDE		
TABLET		
ACETOHEXAMIDE	250MG	N70753
ACETOHEXAMIDE	500MG	N70754
DYMELOR	250MG	N13378
DYMELOR	500MG	N13378
ACETOPHENAZINE MALEATE		
TABLET		
TINDAL	20MG	N12254
ACETRIZOATE SODIUM		
SOLUTION		
SALPIX	53%	N09008
ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE		
SOLUTION		
MUCOMYST W/ ISOPROTERENOL	10%;0.05%	N17366
ACETYLDIGITOXIN		
TABLET		
ACYLANID	0.1MG	N09436

ACRISORCIN		
CREAM		
AKRINOL	2MG/GM	N12470
ACYCLOVIR		
CAPSULE		
ACYCLOVIR	200MG	N74750
ACYCLOVIR	200MG	N74570
TABLET		
ACYCLOVIR	400MG	N74834
ACYCLOVIR	800MG	N74834
ACYCLOVIR	400MG	N74658
ACYCLOVIR	800MG	N74658
ACYCLOVIR	200MG	*N74556
ACYCLOVIR SODIUM		
INJECTABLE		
ACYCLOVIR SODIUM	EQ 1GM BASE/VIAL	N74897
ACYCLOVIR SODIUM	EQ 500MG BASE/VIAL	N74897
ZOVIRAX	EQ 250MG BASE/VIAL	N18603
ALBUMIN CHROMATED CR-51 SERUM		
INJECTABLE		
CHROMALBIN	100uCi/VIAL	N17835
CHROMALBIN	250uCi/VIAL	N17835
CHROMALBIN	500uCi/VIAL	N17835
ALBUMIN IODINATED I-125 SERUM		
INJECTABLE		
ALBUMOTOPE 125 I	5-50uCi/AMP	N17836
RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN)	2.5uCi/AMP	N17846
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125	100uCi/ML	N17844
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125	6.67uCi/ML	N17844
ALBUMIN IODINATED I-131 SERUM		
INJECTABLE		
MEGATOPE	20uCi/AMP	N17837
MEGATOPE	2mCi/VIAL	N17837
MEGATOPE	5uCi/AMP	N17837
ALBUTEROL SULFATE		
CAPSULE		
VENTOLIN ROTACAPS	EQ 0.2MG BASE	N19489
SOLUTION		
ALBUTEROL SULFATE	EQ 0.083% BASE	N73495
ALBUTEROL SULFATE	EQ 0.5% BASE	N73307
VENTOLIN	EQ 0.083% BASE	N19773
VENTOLIN	EQ 0.5% BASE	*N19269

FDA data supplied by DrugPatentWatch.com

ALBUTEROL SULFATE		
SYRUP		
ALBUTEROL SULFATE	EQ 2MG BASE/5ML	N74302
ALBUTEROL SULFATE	EQ 2MG BASE/5ML	N73165
PROVENTIL	EQ 2MG BASE/5ML	N18062
VENTOLIN	EQ 2MG BASE/5ML	N19621
TABLET		
ALBUTEROL SULFATE	EQ 2MG BASE	N72449
ALBUTEROL SULFATE	EQ 4MG BASE	N72450
ALBUTEROL SULFATE	EQ 2MG BASE	N73120
ALBUTEROL SULFATE	EQ 4MG BASE	N73121
ALBUTEROL SULFATE	EQ 2MG BASE	N72859
ALBUTEROL SULFATE	EQ 4MG BASE	N72860
ALBUTEROL SULFATE	EQ 2MG BASE	N72966
ALBUTEROL SULFATE	EQ 4MG BASE	N72967
ALBUTEROL SULFATE	EQ 2MG BASE	N72817
ALBUTEROL SULFATE	EQ 4MG BASE	N72818
PROVENTIL	EQ 2MG BASE	N17853
PROVENTIL	EQ 4MG BASE	N17853
VENTOLIN	EQ 2MG BASE	N19112
VENTOLIN	EQ 4MG BASE	N19112
TABLET, EXTENDED RELEASE		
PROVENTIL	EQ 4MG BASE	N19383
ALCOHOL		
INJECTABLE		
ALCOHOL 5% IN DEXTROSE 5%	5ML/100ML	N83483
ALCOHOL; DEXTROSE		
INJECTABLE		
ALCOHOL 5% IN DEXTROSE 5% IN WATER	5ML/100ML;5GM/100ML	N83256
ALGLUCERASE		
INJECTABLE		
CEREDASE	10 UNITS/ML	N20057
ALKAVERVIR		
TABLET		
VERILOID	2MG	N07336
VERILOID	3MG	N07336
ALLOPURINOL		
TABLET		
ALLOPURINOL	100MG	N70466
ALLOPURINOL	300MG	N70467
ALLOPURINOL	100MG	N70579
ALLOPURINOL	300MG	N70580
ALLOPURINOL	100MG	N70950
ALLOPURINOL	300MG	N70951

ALLOPURINOL		
TABLET		
ALLOPURINOL	100MG	N18241
ALLOPURINOL	100MG	N18785
ALLOPURINOL	300MG	N18241
ALLOPURINOL	300MG	N18785
LOPURIN	100MG	N18297
LOPURIN	300MG	N18297
ALPHA-TOCOPHEROL; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A		
INJECTABLE		
CERNEVIT-12	11.2 IU/VIAL;125MG/VIAL;60UG M/VIAL;200 IU/VIAL;5.5MG/VIAL;414UG M/VIAL;46MG/VIAL;17.25M G/VIAL;4.53MG/VIAL;4.14M G/VIAL;3.51MG/VIAL;3,500 IU/VIAL	N20924
ALPRAZOLAM		
SOLUTION		
ALPRAZOLAM	0.5MG/5ML	N74314
TABLET		
ALPRAZOLAM	0.25MG	N74174
ALPRAZOLAM	0.5MG	N74174
ALPRAZOLAM	1MG	N74174
ALPRAZOLAM	2MG	N74174
ALPRAZOLAM	0.25MG	N74199
ALPRAZOLAM	0.5MG	N74199
ALPRAZOLAM	1MG	N74199
ALPROSTADIL		
INJECTABLE		
CAVERJECT	0.005MG/ML	N20755
CAVERJECT	0.01MG/ML	N20755
CAVERJECT	0.02MG/ML	N20755
EDEX	0.005MG/VIAL	N20649
ALSEROXYLON		
TABLET		
RAUTENSIN	2MG	N09215
RAUWILOID	2MG	N08867
ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE		
TABLET, CHEWABLE		
ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE	80MG;20MG	N89449
FOAMICON	80MG;20MG	N72687

FDA data supplied by DrugPatentWatch.com

AMANTADINE HYDROCHLORIDE

CAPSULE

AMANTADINE HCL	100MG	N71382
SYMADINE	100MG	N71000
SYMMETREL	100MG	N16020

AMCINONIDE

CREAM

CYCLOCORT	0.025%	N18116

AMDINOCILLIN

INJECTABLE

COACTIN	1GM/VIAL	N50565
COACTIN	250MG/VIAL	N50565
COACTIN	500MG/VIAL	N50565

AMIFOSTINE

INJECTABLE

ETHYOL	375MG/VIAL	N20221

AMIKACIN SULFATE

INJECTABLE

AMIKACIN SULFATE	EQ 250MG BASE/ML	N63265
AMIKACIN SULFATE	EQ 250MG BASE/ML	N63266
AMIKACIN SULFATE	EQ 250MG BASE/ML	N64099
AMIKACIN SULFATE	EQ 250MG BASE/ML	N63169
AMIKACIN SULFATE	EQ 50MG BASE/ML	N63167
AMIKACIN SULFATE	EQ 250MG BASE/ML	N63275
AMIKACIN SULFATE	EQ 50MG BASE/ML	N63274
AMIKIN	EQ 250MG BASE/ML	N50495
AMIKIN	EQ 250MG BASE/ML	N62562
AMIKIN	EQ 50MG BASE/ML	N50495
AMIKIN	EQ 50MG BASE/ML	N62562
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 10MG BASE/ML	N50618
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 5MG BASE/ML	N50618

AMINO ACIDS

INJECTABLE

AMINOSYN 3.5% IN PLASTIC CONTAINER	3.5% (3.5GM/100ML)	N18804
AMINOSYN 3.5% IN PLASTIC CONTAINER	3.5% (3.5GM/100ML)	N18875
AMINOSYN 7%	7% (7GM/100ML)	N17673
AMINOSYN 8.5%	8.5% (8.5GM/100ML)	N17673
AMINOSYN II 3.5%	3.5% (3.5GM/100ML)	N19438
AMINOSYN II 3.5% IN PLASTIC CONTAINER	3.5% (3.5GM/100ML)	N19491
AMINOSYN II 5%	5% (5GM/100ML)	N19438
AMINOSYN-HBC 7% IN PLASTIC CONTAINER	7% (7GM/100ML)	N19400
BRANCHAMIN 4%	4% (4GM/100ML)	N18678
FREAMINE 8.5%	8.5% (8.5GM/100ML)	N16822
FREAMINE II 8.5%	8.5% (8.5GM/100ML)	N16822

AMINO ACIDS

INJECTABLE

NEOPHAM 6.4%	6.4% (6.4GM/100ML)	N18792
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER	15% (15GM/100ML)	N20107
NOVAMINE 8.5%	8.5% (8.5GM/100ML)	N17957

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19714
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER	4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19714
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19714
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19714

AMINO ACIDS; DEXTROSE

INJECTABLE

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER	3.5%;25GM/100ML	N19118
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER	3.5%;5GM/100ML	N19120
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER	4.25%;25GM/100ML	N19119
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER	3.5%;25GM/100ML	N19505
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER	3.5%;25GM/100ML	N19713
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER	3.5%;5GM/100ML	N19506
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER	3.5%;5GM/100ML	N19713
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER	4.25%;10GM/100ML	N19713
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER	4.25%;20GM/100ML	N19713
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER	4.25%;25GM/100ML	N19504

FDA data supplied by DrugPatentWatch.com

AMINO ACIDS; DEXTROSE

INJECTABLE

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER	4.25%;25GM/100ML	N19713
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER	5%;25GM/100ML	N19565
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER	5%;25GM/100ML	N19713

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N19682
AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER	4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N19712

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER	3.5%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19564
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER	4.25%;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19564

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N19564
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N19712
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER	4.25%;10GM/100ML;30MG/100ML;97MG/100ML;120MG/100ML;49.3MG/100ML	N19564

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE

AMINOSYN 3.5% M IN PLASTIC CONTAINER	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N18804
AMINOSYN 3.5% M IN PLASTIC CONTAINER	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N18875

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE

AMINOSYN 3.5% M	3.5%;21MG/100ML;128MG/100ML;234MG/100ML	N17789

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE

AMINOSYN II 3.5% M IN PLASTIC CONTAINER	3.5%;32MG/100ML;128MG/100ML;222MG/100ML;49MG/100ML	N19493

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE

VEINAMINE 8%	8%;61MG/100ML;211MG/100ML;56MG/100ML;388MG/100ML	N17957

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE

AMINOSYN II 7% W/ ELECTROLYTES	7%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N19437

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE

AMINOSYN II 3.5% M	3.5%;30MG/100ML;97MG/100ML;120MG/100ML;49MG/100ML	N19437

AMINOCAPROIC ACID

INJECTABLE

AMINOCAPROIC ACID	250MG/ML	N70522
AMINOCAPROIC ACID	250MG/ML	N18590

AMINOPHYLLINE

ENEMA

SOMOPHYLLIN	300MG/5ML	N18232

INJECTABLE

AMINOPHYLLIN	25MG/ML	N87243
AMINOPHYLLIN	25MG/ML	N87621
AMINOPHYLLINE	25MG/ML	N84568
AMINOPHYLLINE	25MG/ML	N87200
AMINOPHYLLINE	25MG/ML	N87250
AMINOPHYLLINE	25MG/ML	N87431
AMINOPHYLLINE	25MG/ML	N87886
AMINOPHYLLINE	25MG/ML	N88407
AMINOPHYLLINE	25MG/ML	N87239
AMINOPHYLLINE	25MG/ML	N87867
AMINOPHYLLINE	25MG/ML	N87868

FDA data supplied by DrugPatentWatch.com

AMINOPHYLLINE		
INJECTABLE		
AMINOPHYLLINE	25MG/ML	N86606
AMINOPHYLLINE	25MG/ML	N87387
AMINOPHYLLINE	25MG/ML	N88429
AMINOPHYLLINE	25MG/ML	N88749
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	100MG/100ML	N18924
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	200MG/100ML	N18924
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	400MG/100ML	N18924
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	500MG/100ML	N18924
SOLUTION		
AMINOPHYLLINE	105MG/5ML	N88156
SOMOPHYLLIN	105MG/5ML	N86466
SOMOPHYLLIN-DF	105MG/5ML	N87045
TABLET		
AMINOPHYLLIN	100MG	N02386
AMINOPHYLLIN	200MG	N02386
AMINOPHYLLINE	100MG	N87522
AMINOPHYLLINE	200MG	N87523
AMINOPHYLLINE	100MG	N88297
AMINOPHYLLINE	200MG	N88298
AMINOPHYLLINE	100MG	N88182
AMINOPHYLLINE	200MG	N88183
AMINOPHYLLINE	100MG	N84674
AMINOPHYLLINE	100MG	N84574
AMINOPHYLLINE	200MG	N84576
AMINOPHYLLINE	100MG	N85284
AMINOPHYLLINE	200MG	N85289
AMINOPHYLLINE	100MG	N84588
AMINOPHYLLINE	200MG	N84588
AMINOPHYLLINE	100MG	N84533
AMINOPHYLLINE	100MG	N84552
AMINOPHYLLINE	200MG	N84552
AMINOPHYLLINE	100MG	N84699
AMINOPHYLLINE	200MG	N85333
AMINOPHYLLINE	100MG	N85261
AMINOPHYLLINE	100MG	N85262
AMINOPHYLLINE	200MG	N85261
AMINOPHYLLINE	200MG	N84563
AMINOPHYLLINE	100MG	N88314
AMINOPHYLLINE	200MG	N88319
AMINOPHYLLINE	100MG	N85409
AMINOPHYLLINE	200MG	N85410
AMINOPHYLLINE	100MG	N85567

AMINOPHYLLINE		
TABLET		
AMINOPHYLLINE	200MG	N85564
TABLET, DELAYED RELEASE		
AMINOPHYLLINE	100MG	N84577
AMINOPHYLLINE	200MG	N84575
AMINOPHYLLINE	100MG	N84632
AMINOPHYLLINE	100MG	N84531
AMINOPHYLLINE	200MG	N84530
TABLET, EXTENDED RELEASE		
PHYLLOCONTIN	225MG	N86760
AMINOSALICYLATE SODIUM		
POWDER		
P.A.S. SODIUM	4GM/PACKET	N80947
SODIUM AMINOSALICYLATE	100%	N80097
TABLET		
PARASAL SODIUM	1GM	N06811
PARASAL SODIUM	500MG	N06811
TEEBACIN	500MG	N07320
AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID		
TABLET		
NEOPASALATE	846MG;112MG	N80059
AMINOSALICYLIC ACID		
TABLET		
PARASAL	1GM	N06811
PARASAL	500MG	N06811
AMINOSALICYLIC ACID RESIN COMPLEX		
POWDER		
REZIPAS	EQ 500MG BASE/GM	N09052
AMITRIPTYLINE HYDROCHLORIDE		
CONCENTRATE		
ENDEP	40MG/ML	N85749
INJECTABLE		
AMITRIPTYLINE HCL	10MG/ML	N85594
TABLET		
AMITID	100MG	N86454
AMITID	10MG	N86454
AMITID	25MG	N86454
AMITID	50MG	N86454
AMITID	75MG	N86454
AMITRIL	100MG	N85093
AMITRIL	10MG	N83939
AMITRIL	150MG	N86295

FDA data supplied by DrugPatentWatch.com

AMITRIPTYLINE HYDROCHLORIDE

TABLET

AMITRIL	25MG	N83937
AMITRIL	50MG	N83938
AMITRIL	75MG	N84957
AMITRIPTYLINE HCL	100MG	N88675
AMITRIPTYLINE HCL	25MG	N88672
AMITRIPTYLINE HCL	50MG	N88673
AMITRIPTYLINE HCL	75MG	N88674
AMITRIPTYLINE HCL	100MG	N86336
AMITRIPTYLINE HCL	10MG	N85864
AMITRIPTYLINE HCL	150MG	N86335
AMITRIPTYLINE HCL	25MG	N85935
AMITRIPTYLINE HCL	50MG	N85936
AMITRIPTYLINE HCL	75MG	N86337
AMITRIPTYLINE HCL	100MG	N88425
AMITRIPTYLINE HCL	10MG	N88421
AMITRIPTYLINE HCL	150MG	N88426
AMITRIPTYLINE HCL	25MG	N88422
AMITRIPTYLINE HCL	50MG	N88423
AMITRIPTYLINE HCL	75MG	N88424
AMITRIPTYLINE HCL	100MG	N85742
AMITRIPTYLINE HCL	100MG	N85927
AMITRIPTYLINE HCL	10MG	N85744
AMITRIPTYLINE HCL	10MG	N85923
AMITRIPTYLINE HCL	150MG	N89423
AMITRIPTYLINE HCL	25MG	N85627
AMITRIPTYLINE HCL	25MG	N85922
AMITRIPTYLINE HCL	50MG	N85745
AMITRIPTYLINE HCL	50MG	N85925
AMITRIPTYLINE HCL	50MG	N87557
AMITRIPTYLINE HCL	75MG	N85743
AMITRIPTYLINE HCL	75MG	N85926
AMITRIPTYLINE HCL	100MG	N86747
AMITRIPTYLINE HCL	100MG	N87368
AMITRIPTYLINE HCL	10MG	N86744
AMITRIPTYLINE HCL	10MG	N87366
AMITRIPTYLINE HCL	150MG	N87370
AMITRIPTYLINE HCL	25MG	N86746
AMITRIPTYLINE HCL	25MG	N87367
AMITRIPTYLINE HCL	50MG	N86743
AMITRIPTYLINE HCL	50MG	N87181
AMITRIPTYLINE HCL	75MG	N86745
AMITRIPTYLINE HCL	75MG	N87369
AMITRIPTYLINE HCL	100MG	N88701
AMITRIPTYLINE HCL	10MG	N88697
AMITRIPTYLINE HCL	150MG	N88702

AMITRIPTYLINE HYDROCHLORIDE

TABLET

AMITRIPTYLINE HCL	25MG	N88698
AMITRIPTYLINE HCL	50MG	N88699
AMITRIPTYLINE HCL	75MG	N88700
AMITRIPTYLINE HCL	100MG	N88079
AMITRIPTYLINE HCL	100MG	N88107
AMITRIPTYLINE HCL	10MG	N88075
AMITRIPTYLINE HCL	10MG	N88084
AMITRIPTYLINE HCL	25MG	N88076
AMITRIPTYLINE HCL	25MG	N88085
AMITRIPTYLINE HCL	50MG	N88077
AMITRIPTYLINE HCL	50MG	N88105
AMITRIPTYLINE HCL	75MG	N88078
AMITRIPTYLINE HCL	75MG	N88106
AMITRIPTYLINE HCL	100MG	N86003
AMITRIPTYLINE HCL	100MG	N86146
AMITRIPTYLINE HCL	10MG	N86002
AMITRIPTYLINE HCL	10MG	N86144
AMITRIPTYLINE HCL	150MG	N86090
AMITRIPTYLINE HCL	150MG	N86148
AMITRIPTYLINE HCL	25MG	N85944
AMITRIPTYLINE HCL	25MG	N86145
AMITRIPTYLINE HCL	50MG	N85945
AMITRIPTYLINE HCL	50MG	N86143
AMITRIPTYLINE HCL	75MG	N86004
AMITRIPTYLINE HCL	75MG	N86147
AMITRIPTYLINE HCL	100MG	N88857
AMITRIPTYLINE HCL	10MG	N88853
AMITRIPTYLINE HCL	25MG	N88854
AMITRIPTYLINE HCL	50MG	N88855
AMITRIPTYLINE HCL	75MG	N88856
AMITRIPTYLINE HCL	100MG	N86854
AMITRIPTYLINE HCL	10MG	N86610
AMITRIPTYLINE HCL	150MG	N86853
AMITRIPTYLINE HCL	25MG	N86859
AMITRIPTYLINE HCL	50MG	N86857
AMITRIPTYLINE HCL	75MG	N85030
AMITRIPTYLINE HCL	75MG	N86860
AMITRIPTYLINE HCL	25MG	N87775
AMITRIPTYLINE HCL	100MG	N87639
AMITRIPTYLINE HCL	10MG	N87632
AMITRIPTYLINE HCL	50MG	N87616
AMITRIPTYLINE HCL	75MG	N87617
AMITRIPTYLINE HCL	100MG	N85820
AMITRIPTYLINE HCL	100MG	N88634
AMITRIPTYLINE HCL	10MG	N85816

FDA data supplied by DrugPatentWatch.com

AMITRIPTYLINE HYDROCHLORIDE

TABLET

AMITRIPTYLINE HCL	10MG	N88620
AMITRIPTYLINE HCL	150MG	N85821
AMITRIPTYLINE HCL	150MG	N88635
AMITRIPTYLINE HCL	25MG	N85817
AMITRIPTYLINE HCL	25MG	N88621
AMITRIPTYLINE HCL	50MG	N85815
AMITRIPTYLINE HCL	50MG	N88622
AMITRIPTYLINE HCL	75MG	N85819
AMITRIPTYLINE HCL	75MG	N88633
AMITRIPTYLINE HCL	10MG	N87647
AMITRIPTYLINE HCL	25MG	N87278
ENDEP	100MG	N83639
ENDEP	10MG	N83639
ENDEP	150MG	N85303
ENDEP	25MG	N83639
ENDEP	50MG	N83639
ENDEP	75MG	N83639

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL	EQ 12.5MG BASE;5MG	N70765
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL	EQ 25MG BASE;10MG	N70766
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL	EQ 12.5MG BASE;5MG	N70477
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL	EQ 25MG BASE;10MG	N70478

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET

ETRAFON 2-10	10MG;2MG	N14713
ETRAFON 2-25	25MG;2MG	N14713
ETRAFON-A	10MG;4MG	N14713
ETRAFON-FORTE	25MG;4MG	N14713
PERPHENAZINE AND AMITRIPTYLINE HCL	10MG;2MG	N71077
PERPHENAZINE AND AMITRIPTYLINE HCL	10MG;4MG	N71078
PERPHENAZINE AND AMITRIPTYLINE HCL	25MG;2MG	N70297
PERPHENAZINE AND AMITRIPTYLINE HCL	25MG;4MG	N71079
PERPHENAZINE AND AMITRIPTYLINE HCL	10MG;2MG	N70935
PERPHENAZINE AND AMITRIPTYLINE HCL	10MG;4MG	N70937
PERPHENAZINE AND AMITRIPTYLINE HCL	25MG;2MG	N70936
PERPHENAZINE AND AMITRIPTYLINE HCL	25MG;4MG	N70938
PERPHENAZINE AND AMITRIPTYLINE HCL	50MG;4MG	N70939
PERPHENAZINE AND AMITRIPTYLINE HCL	10MG;2MG	N70565
PERPHENAZINE AND AMITRIPTYLINE HCL	10MG;4MG	N70620
PERPHENAZINE AND AMITRIPTYLINE HCL	25MG;2MG	N70621
PERPHENAZINE AND AMITRIPTYLINE HCL	25MG;4MG	N70595
PERPHENAZINE AND AMITRIPTYLINE HCL	50MG;4MG	N70574
PERPHENAZINE AND AMITRIPTYLINE HCL	10MG;2MG	N70373

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET

PERPHENAZINE AND AMITRIPTYLINE HCL	10MG;2MG	N72539
PERPHENAZINE AND AMITRIPTYLINE HCL	10MG;4MG	N70375
PERPHENAZINE AND AMITRIPTYLINE HCL	10MG;4MG	N72540
PERPHENAZINE AND AMITRIPTYLINE HCL	25MG;2MG	N70374
PERPHENAZINE AND AMITRIPTYLINE HCL	25MG;2MG	N72541
PERPHENAZINE AND AMITRIPTYLINE HCL	25MG;4MG	N70376
PERPHENAZINE AND AMITRIPTYLINE HCL	25MG;4MG	N72134
PERPHENAZINE AND AMITRIPTYLINE HCL	50MG;4MG	N70377
PERPHENAZINE AND AMITRIPTYLINE HCL	50MG;4MG	N71558
PERPHENAZINE AND AMITRIPTYLINE HCL	50MG;4MG	N72135
TRIAVIL 2-10	10MG;2MG	N14715
TRIAVIL 2-25	25MG;2MG	N14715
TRIAVIL 4-10	10MG;4MG	N14715
TRIAVIL 4-25	25MG;4MG	N14715
TRIAVIL 4-50	50MG;4MG	N14715

AMMONIUM CHLORIDE

INJECTABLE

AMMONIUM CHLORIDE	5MEQ/ML	N83130
AMMONIUM CHLORIDE	3MEQ/ML	N86205
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE	900MG/100ML	N06580
AMMONIUM CHLORIDE 2.14%	40MEQ/100ML	N85734

AMODIAQUINE HYDROCHLORIDE

TABLET

CAMOQUIN HCL	EQ 200MG BASE	N06441

AMOXAPINE

TABLET

ASENDIN	100MG	N18021
ASENDIN	150MG	N18021
ASENDIN	25MG	N18021
ASENDIN	50MG	N18021

AMOXICILLIN

CAPSULE

AMOXICILLIN	250MG	N62528
AMOXICILLIN	500MG	N62528
AMOXICILLIN	250MG	N62067
AMOXICILLIN	500MG	N62067
AMOXICILLIN	250MG	N63030
AMOXICILLIN	500MG	N63031
AMOXIL	250MG	N50459
AMOXIL	250MG	N62216
AMOXIL	500MG	N50459
TRIMOX	250MG	N62098
TRIMOX	250MG	N62152

AMOXICILLIN

CAPSULE

TRIMOX	250MG	N63099
TRIMOX	500MG	N62098
TRIMOX	500MG	N62152
TRIMOX	500MG	N63099
UTIMOX	250MG	N62107
UTIMOX	500MG	N62107
WYMOX	250MG	N62120
WYMOX	500MG	N62120

FOR SUSPENSION

AMOXICILLIN	125MG/5ML	N62090
AMOXICILLIN	250MG/5ML	N62090
AMOXIL	125MG/5ML	N50460
AMOXIL	250MG/5ML	N50460
AMOXIL	50MG/ML	N50460
LAROTID	50MG/ML	N50460
POLYMOX	125MG/5ML	N61851
POLYMOX	125MG/5ML	N62323
POLYMOX	250MG/5ML	N61851
POLYMOX	250MG/5ML	N62323
TRIMOX	125MG/5ML	N61886
TRIMOX	125MG/5ML	N62099
TRIMOX	125MG/5ML	N62154
TRIMOX	250MG/5ML	N61886
TRIMOX	250MG/5ML	N62099
TRIMOX	250MG/5ML	N62154
TRIMOX	50MG/ML	N61886
UTIMOX	125MG/5ML	N62127
UTIMOX	250MG/5ML	N62127
WYMOX	125MG/5ML	N62131
WYMOX	250MG/5ML	N62131

TABLET, CHEWABLE

AMOXICILLIN	125MG	N64131
AMOXICILLIN	250MG	N64131

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

CAPSULE

DELCOBESE	1.25MG;1.25MG;1.25MG;1.25MG	* N83564
DELCOBESE	2.5MG;2.5MG;2.5MG;2.5MG	* N83564
DELCOBESE	3.75MG;3.75MG;3.75MG;3.75MG	* N83564
DELCOBESE	5MG;5MG;5MG;5MG	* N83564

TABLET

DELCOBESE	1.25MG;1.25MG;1.25MG;1.25MG	* N83563
DELCOBESE	2.5MG;2.5MG;2.5MG;2.5MG	* N83563
DELCOBESE	3.75MG;3.75MG;3.75MG;3.75MG	* N83563
DELCOBESE	5MG;5MG;5MG;5MG	* N83563

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE

BIPHETAMINE 12.5	EQ 6.25MG BASE;EQ 6.25MG BASE	N10093
BIPHETAMINE 20	EQ 10MG BASE;EQ 10MG BASE	N10093
BIPHETAMINE 7.5	EQ 3.75MG BASE;EQ 3.75MG BASE	N10093

AMPHETAMINE SULFATE

TABLET

AMPHETAMINE SULFATE	10MG	N83901
AMPHETAMINE SULFATE	5MG	N83901

AMPHOTERICIN B

INJECTABLE

AMPHOTERICIN B	50MG/VIAL	N64141
AMPHOTERICIN B	50MG/VIAL	N62728

OINTMENT

FUNGIZONE	3%	N50313

SUSPENSION

FUNGIZONE	100MG/ML	N50341

AMPICILLIN SODIUM

INJECTABLE

AMPICILLIN SODIUM	EQ 125MG BASE/VIAL	N62860
AMPICILLIN SODIUM	EQ 1GM BASE/VIAL	N62860
AMPICILLIN SODIUM	EQ 250MG BASE/VIAL	N62860
AMPICILLIN SODIUM	EQ 2GM BASE/VIAL	N62860
AMPICILLIN SODIUM	EQ 500MG BASE/VIAL	N62860
AMPICILLIN SODIUM	EQ 10GM BASE/VIAL	N62692
AMPICILLIN SODIUM	EQ 125MG BASE/VIAL	N62692
AMPICILLIN SODIUM	EQ 1GM BASE/VIAL	N62692
AMPICILLIN SODIUM	EQ 250MG BASE/VIAL	N62692
AMPICILLIN SODIUM	EQ 2GM BASE/VIAL	N62692
AMPICILLIN SODIUM	EQ 500MG BASE/VIAL	N62692
AMPICILLIN SODIUM	EQ 125MG BASE/VIAL	N61936
AMPICILLIN SODIUM	EQ 1GM BASE/VIAL	N61936
AMPICILLIN SODIUM	EQ 250MG BASE/VIAL	N61936
AMPICILLIN SODIUM	EQ 2GM BASE/VIAL	N61936
AMPICILLIN SODIUM	EQ 500MG BASE/VIAL	N61936
AMPICILLIN SODIUM	EQ 10GM BASE/VIAL	N63142

FDA data supplied by DrugPatentWatch.com

AMPICILLIN SODIUM
INJECTABLE

AMPICILLIN SODIUM	EQ 125MG BASE/VIAL	N63143
AMPICILLIN SODIUM	EQ 1GM BASE/VIAL	N62772
AMPICILLIN SODIUM	EQ 1GM BASE/VIAL	N63139
AMPICILLIN SODIUM	EQ 250MG BASE/VIAL	N63145
AMPICILLIN SODIUM	EQ 2GM BASE/VIAL	N63140
AMPICILLIN SODIUM	EQ 2GM BASE/VIAL	N63141
AMPICILLIN SODIUM	EQ 500MG BASE/VIAL	N63146
AMPICILLIN SODIUM	EQ 500MG BASE/VIAL	N63147
AMPICILLIN SODIUM	EQ 125MG BASE/VIAL	N62797
AMPICILLIN SODIUM	EQ 2GM BASE/VIAL	N62797
AMPICILLIN SODIUM	EQ 1GM BASE/VIAL	N62634
AMPICILLIN SODIUM	EQ 2GM BASE/VIAL	N62634
AMPICILLIN SODIUM	EQ 1GM BASE/VIAL	N62565
AMPICILLIN SODIUM	EQ 2GM BASE/VIAL	N62565
AMPICILLIN SODIUM	EQ 500MG BASE/VIAL	N62565
AMPICILLIN SODIUM	EQ 10GM BASE/VIAL	N62994
AMPICILLIN SODIUM	EQ 125MG BASE/VIAL	N62816
AMPICILLIN SODIUM	EQ 1GM BASE/VIAL	N62816
AMPICILLIN SODIUM	EQ 250MG BASE/VIAL	N62816
AMPICILLIN SODIUM	EQ 2GM BASE/VIAL	N62816
AMPICILLIN SODIUM	EQ 500MG BASE/VIAL	N62816
OMNIPEN-N	EQ 125MG BASE/VIAL	N60626
OMNIPEN-N	EQ 125MG BASE/VIAL	N62718
OMNIPEN-N	EQ 1GM BASE/VIAL	N60626
OMNIPEN-N	EQ 1GM BASE/VIAL	N62718
OMNIPEN-N	EQ 250MG BASE/VIAL	N60626
OMNIPEN-N	EQ 250MG BASE/VIAL	N62718
OMNIPEN-N	EQ 2GM BASE/VIAL	N60626
OMNIPEN-N	EQ 2GM BASE/VIAL	N62718
OMNIPEN-N	EQ 500MG BASE/VIAL	N60626
OMNIPEN-N	EQ 500MG BASE/VIAL	N62718
PENBRITIN-S	EQ 125MG BASE/VIAL	N50072
PENBRITIN-S	EQ 1GM BASE/VIAL	N50072
PENBRITIN-S	EQ 250MG BASE/VIAL	N50072
PENBRITIN-S	EQ 2GM BASE/VIAL	N50072
PENBRITIN-S	EQ 4GM BASE/VIAL	N50072
PENBRITIN-S	EQ 500MG BASE/VIAL	N50072
POLYCILLIN-N	EQ 125MG BASE/VIAL	N50309
POLYCILLIN-N	EQ 1GM BASE/VIAL	N50309
POLYCILLIN-N	EQ 250MG BASE/VIAL	N50309
POLYCILLIN-N	EQ 2GM BASE/VIAL	N50309
POLYCILLIN-N	EQ 500MG BASE/VIAL	N50309
TOTACILLIN-N	EQ 10GM BASE/VIAL	N60677
TOTACILLIN-N	EQ 125MG BASE/VIAL	N60677
TOTACILLIN-N	EQ 1GM BASE/VIAL	N60677

AMPICILLIN SODIUM
INJECTABLE

TOTACILLIN-N	EQ 1GM BASE/VIAL	N62727
TOTACILLIN-N	EQ 250MG BASE/VIAL	N60677
TOTACILLIN-N	EQ 2GM BASE/VIAL	N60677
TOTACILLIN-N	EQ 2GM BASE/VIAL	N62727
TOTACILLIN-N	EQ 500MG BASE/VIAL	N60677

AMPICILLIN SODIUM; SULBACTAM SODIUM
INJECTABLE

UNASYN	EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL	N50608

AMPICILLIN/AMPICILLIN TRIHYDRATE
CAPSULE

AMCILL	EQ 250MG BASE	N62041
AMCILL	EQ 500MG BASE	N62041
AMPICILLIN	EQ 250MG BASE	N62208
AMPICILLIN	EQ 500MG BASE	N62208
AMPICILLIN	EQ 250MG BASE	N61387
AMPICILLIN	EQ 500MG BASE	N61387
AMPICILLIN TRIHYDRATE	EQ 250MG BASE	N64082
AMPICILLIN TRIHYDRATE	EQ 500MG BASE	N64082
AMPICILLIN TRIHYDRATE	EQ 250MG BASE	N60765
AMPICILLIN TRIHYDRATE	EQ 500MG BASE	N60765
AMPICILLIN TRIHYDRATE	EQ 250MG BASE	N61755
AMPICILLIN TRIHYDRATE	EQ 500MG BASE	N61755
AMPICILLIN TRIHYDRATE	EQ 250MG BASE	N61853
AMPICILLIN TRIHYDRATE	EQ 500MG BASE	N61853
OMNIPEN (AMPICILLIN)	250MG	N60624
OMNIPEN (AMPICILLIN)	500MG	N60624
PENBRITIN	EQ 250MG BASE	N60908
PENBRITIN	EQ 500MG BASE	N60908
PFIZERPEN-A	EQ 250MG BASE	N62050
PFIZERPEN-A	EQ 500MG BASE	N62050
POLYCILLIN	EQ 250MG BASE	N50310
POLYCILLIN	EQ 500MG BASE	N50310
PRINCIPEN '250'	EQ 250MG BASE	N50056
PRINCIPEN '250'	EQ 250MG BASE	N62157
PRINCIPEN '500'	EQ 500MG BASE	N50056
PRINCIPEN '500'	EQ 500MG BASE	N62157
TOTACILLIN	EQ 250MG BASE	N60060
TOTACILLIN	EQ 500MG BASE	N60060

FOR SUSPENSION

AMCILL	EQ 125MG BASE/5ML	N62030
AMCILL	EQ 250MG BASE/5ML	N62030
AMPICILLIN TRIHYDRATE	EQ 125MG BASE/5ML	N61829
AMPICILLIN TRIHYDRATE	EQ 250MG BASE/5ML	N61829

FDA data supplied by DrugPatentWatch.com

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION

AMPICILLIN TRIHYDRATE	EQ 125MG BASE/5ML	N61980
OMNIPEN (AMPICILLIN)	100MG/ML	N60625
OMNIPEN (AMPICILLIN)	125MG/5ML	N60625
OMNIPEN (AMPICILLIN)	250MG/5ML	N60625
OMNIPEN (AMPICILLIN)	500MG/5ML	N60625
PENBRITIN	EQ 100MG BASE/ML	N50019
PENBRITIN	EQ 125MG BASE/5ML	N50019
PENBRITIN	EQ 250MG BASE/5ML	N50019
PFIZERPEN-A	EQ 125MG BASE/5ML	N62049
PFIZERPEN-A	EQ 250MG BASE/5ML	N62049
POLYCILLIN	EQ 125MG BASE/5ML	N62297
POLYCILLIN	EQ 250MG BASE/5ML	N62297
POLYCILLIN	EQ 100MG BASE/ML	N50308
POLYCILLIN	EQ 125MG BASE/5ML	N50308
POLYCILLIN	EQ 250MG BASE/5ML	N50308
POLYCILLIN	EQ 500MG BASE/5ML	N50308
PRINCIPEN '125'	EQ 125MG BASE/5ML	N60127
PRINCIPEN '125'	EQ 125MG BASE/5ML	N62151
PRINCIPEN '250'	EQ 250MG BASE/5ML	N60127
PRINCIPEN '250'	EQ 250MG BASE/5ML	N62151
TOTACILLIN	EQ 125MG BASE/5ML	N60666
TOTACILLIN	EQ 125MG BASE/5ML	N62223
TOTACILLIN	EQ 250MG BASE/5ML	N60666
TOTACILLIN	EQ 250MG BASE/5ML	N62223

TABLET, CHEWABLE

POLYCILLIN	EQ 125MG BASE	N50093

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE

PRINCIPEN W/ PROBENECID	EQ 389MG BASE;111MG	N50488
PRINCIPEN W/ PROBENECID	EQ 389MG BASE;111MG	N62150

FOR SUSPENSION

POLYCILLIN-PRB	EQ 3.5GM BASE/BOT;1GM/BOT	N61898
POLYCILLIN-PRB	EQ 3.5GM BASE/BOT;1GM/BOT	N50457
PROBAMPACIN	EQ 3.5GM BASE/BOT;1GM/BOT	N61741

ANILERIDINE HYDROCHLORIDE

TABLET

LERITINE	EQ 25MG BASE	N10585

ANILERIDINE PHOSPHATE

INJECTABLE

LERITINE	25MG/ML	N10520

ANISOTROPINE METHYLBROMIDE

TABLET

ANISOTROPINE METHYLBROMIDE	50MG	N86046
VALPIN 50	50MG	N13428

ARBUTAMINE HYDROCHLORIDE

INJECTABLE

GENESA	0.05MG/ML	N20420

ARDEPARIN SODIUM

INJECTABLE

NORMIFLO	*10,000 UNITS/0.5ML*	**N20227*
NORMIFLO	5,000 UNITS/0.5ML	*N20227

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE

BEROCCA PN	50MG/ML;0.03MG/ML;0.0025MG/ML;7.5MG/ML;100 IU/ML;0.2MG/ML;20MG/ML;2MG/ML;1.8MG/ML;1.5MG/ML;1,650 IU/ML;5 IU/ML	N06071

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE

M.V.C. 9+3	*10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML*	N18440
MVC PLUS	10MG/ML;0.006MG/ML;0.5UGM/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ML;0.3MG/ML;330 UNITS/ML;1 IU/ML	N18439

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE

M.V.I.-12 LYOPHILIZED	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5UGM/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N18933

FDA data supplied by DrugPatentWatch.com

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E		
INJECTABLE		
VITAPED	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;400 IU/10ML;0.14MG/VIAL;17MG/VIAL;5MG/VIAL;0.2MG/10ML;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML;7 IU/10ML	N20176
ASPIRIN		
TABLET, EXTENDED RELEASE		
8-HOUR BAYER	650MG	N16030
MEASURIN	650MG	N16030
ASPIRIN; BUTALBITAL		
TABLET		
AXOTAL	650MG;50MG	N88305
ASPIRIN; BUTALBITAL; CAFFEINE		
CAPSULE		
BUTALBITAL, ASPIRIN AND CAFFEINE	325MG;50MG;40MG	N86231
TABLET		
BUTALBITAL ASPIRIN AND CAFFEINE	325MG;50MG;40MG	N88972
BUTALBITAL COMPOUND	325MG;50MG;40MG	N85441
BUTALBITAL, ASPIRIN & CAFFEINE	325MG;50MG;40MG	N89448
BUTALBITAL, ASPIRIN AND CAFFEINE	325MG;50MG;40MG	N86237
LANORINAL	325MG;50MG;40MG	N86986
ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE		
CAPSULE		
COMPOUND 65	389MG;32.4MG;65MG	N84553
PROPOXYPHENE COMPOUND 65	389MG;32.4MG;65MG	N80044
PROPOXYPHENE COMPOUND 65	389MG;32.4MG;65MG	N83077
PROPOXYPHENE COMPOUND-65	389MG;32.4MG;65MG	N83101
PROPOXYPHENE HCL W/ ASPIRIN AND CAFFEINE	389MG;32.4MG;65MG	N85732
ASPIRIN; CARISOPRODOL		
TABLET		
CARISOPRODOL COMPOUND	325MG;200MG	N88809
ASPIRIN; HYDROCODONE BITARTRATE		
TABLET		
VICOPRIN	500MG;5MG	N86333
ASPIRIN; MEPROBAMATE		
TABLET		
MEPRO-ASPIRIN	325MG;200MG	N89127
MEPROBAMATE AND ASPIRIN	325MG;200MG	N89126
MICRAININ	325MG;200MG	N84978
ASPIRIN; MEPROBAMATE		
TABLET		
Q-GESIC	325MG;200MG	N88740
ASPIRIN; METHOCARBAMOL		
TABLET		
METHOCARBAMOL AND ASPIRIN	325MG;400MG	N89193
ROBAXISAL	325MG;400MG	N12281
ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE		
TABLET		
CODOXY	325MG;4.5MG;0.38MG	N87464
OXYCODONE AND ASPIRIN (HALF-STRENGTH)	325MG;2.25MG;0.19MG	N87742
ROXIPRIN	325MG;4.5MG;0.38MG	N87743
ASPIRIN; PENTAZOCINE HYDROCHLORIDE		
TABLET		
TALWIN COMPOUND	325MG;EQ 12.5MG BASE	N16891
ASPIRIN; PROPOXYPHENE HYDROCHLORIDE		
CAPSULE		
DARVON W/ ASA	325MG;65MG	N10996
ASPIRIN; PROPOXYPHENE NAPSYLATE		
CAPSULE		
DARVON-N W/ ASA	325MG;100MG	N16829
TABLET		
DARVON-N W/ ASA	325MG;100MG	N16863
ATENOLOL		
TABLET		
ATENOLOL	100MG	N73318
ATENOLOL	50MG	N73317
ATENOLOL	100MG	N74126
ATENOLOL	25MG	N74126
ATENOLOL	50MG	N74126
ATOMOXETINE HYDROCHLORIDE		
CAPSULE		
STRATTERA	5MG	N21411
ATROPINE		
INJECTABLE		
ATROPINE	EQ 2MG SULFATE/0.7ML	N71295
ATROPINE SULFATE		
AEROSOL, METERED		
ATROPINE SULFATE	EQ 0.36MG BASE/INH	N20056
ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE		
TABLET		
MOTOFEN HALF-STRENGTH	0.025MG;0.5MG	N17744

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION		
COLONAID	0.025MG/5ML;2.5MG/5ML	N85735
LOMANATE	0.025MG/5ML;2.5MG/5ML	N85746
TABLET		
COLONAID	0.025MG;2.5MG	N85737
DI-ATRO	0.025MG;2.5MG	N85266
DIPHENOXYLATE HCL AND ATROPINE SULFATE	0.025MG;2.5MG	N87934
DIPHENOXYLATE HCL AND ATROPINE SULFATE	0.025MG;2.5MG	N85506
DIPHENOXYLATE HCL AND ATROPINE SULFATE	0.025MG;2.5MG	N86798
DIPHENOXYLATE HCL AND ATROPINE SULFATE	0.025MG;2.5MG	N85509
DIPHENOXYLATE HCL AND ATROPINE SULFATE	0.025MG;2.5MG	N86950
DIPHENOXYLATE HCL AND ATROPINE SULFATE	0.025MG;2.5MG	N87131
DIPHENOXYLATE HCL AND ATROPINE SULFATE	0.025MG;2.5MG	N85035
DIPHENOXYLATE HCL AND ATROPINE SULFATE	0.025MG;2.5MG	N86057
DIPHENOXYLATE HCL AND ATROPINE SULFATE	0.025MG;2.5MG	N85876
DIPHENOXYLATE HCL AND ATROPINE SULFATE	0.025MG;2.5MG	N87765
DIPHENOXYLATE HCL W/ ATROPINE SULFATE	0.025MG;2.5MG	N85659
DIPHENOXYLATE HCL W/ ATROPINE SULFATE	0.025MG;2.5MG	N85766
DIPHENOXYLATE HCL W/ ATROPINE SULFATE	0.025MG;2.5MG	N87842
DIPHENOXYLATE HCL W/ ATROPINE SULFATE	0.025MG;2.5MG	N87195
LOGEN	0.025MG;2.5MG	N88962
LO-TROL	0.025MG;2.5MG	N88009
LOW-QUEL	0.025MG;2.5MG	N85211

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE		
ATROPINE AND DEMEROL	0.4MG/ML;100MG/ML	N87848
ATROPINE AND DEMEROL	0.4MG/ML;50MG/ML	N87853
ATROPINE AND DEMEROL	0.4MG/ML;75MG/ML	N87847
MEPERIDINE AND ATROPINE SULFATE	0.4MG/ML;100MG/ML	N85121
MEPERIDINE AND ATROPINE SULFATE	0.4MG/ML;50MG/ML	N85121
MEPERIDINE AND ATROPINE SULFATE	0.4MG/ML;75MG/ML	N85121

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE		
ATNAA	2.1MG/0.7ML;600MG/2ML	N21175

AZATHIOPRINE

TABLET		
IMURAN	25MG	* N16324

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

FOR SUSPENSION, TABLET		
TROVAN/ZITHROMAX COMPLIANCE PAK	EQ 1GM BASE;EQ 100MG BASE	N50762

AZLOCILLIN SODIUM

INJECTABLE		
AZLIN	EQ 2GM BASE/VIAL	N50562
AZLIN	EQ 2GM BASE/VIAL	N62388
AZLIN	EQ 2GM BASE/VIAL	N62417
AZLIN	EQ 3GM BASE/VIAL	N50562
AZLIN	EQ 3GM BASE/VIAL	N62388
AZLIN	EQ 3GM BASE/VIAL	N62417
AZLIN	EQ 4GM BASE/VIAL	N50562
AZLIN	EQ 4GM BASE/VIAL	N62388
AZLIN	EQ 4GM BASE/VIAL	N62417

AZTREONAM

INJECTABLE		
AZACTAM	1GM/VIAL	N50580
AZACTAM	2GM/VIAL	N50580
AZACTAM	500MG/VIAL	N50580
AZACTAM IN PLASTIC CONTAINER	10MG/ML	N50632

BACAMPICILLIN HYDROCHLORIDE

TABLET		
SPECTROBID	800MG	N50520

BACITRACIN

INJECTABLE		
BACITRACIN	50,000 UNITS/VIAL	N60282
OINTMENT		
BACIGUENT	500 UNITS/GM	N60734
BACITRACIN	500 UNITS/GM	N62799
BACITRACIN	500 UNITS/GM	N60687
BACITRACIN	500 UNITS/GM	N62857
BACITRACIN	500 UNITS/GM	N62158
BACITRACIN	500 UNITS/GM	N62453
POWDER		
BACITRACIN	5,000,000 UNITS/BOT	N62456

BACITRACIN ZINC

POWDER		
ZIBA-RX	500,000 UNITS/BOT	N61737

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT		
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N62381
ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62389

FDA data supplied by DrugPatentWatch.com

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT

LANABIOTIC	400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM;5,000 UNITS/GM	N62499

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N62833
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62386
BACITRACIN-NEOMYCIN-POLYMYXIN	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N62167
NEO-POLYCIN	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N60647

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL

POLYSPORIN	10,000 UNITS/GM;2,000,000 UNITS/GM	N50167

OINTMENT

BACITRACIN ZINC-POLYMYXIN B SULFATE	500 UNITS/GM;10,000 UNITS/GM	N62849
OCUMYCIN	500 UNITS/GM;10,000 UNITS/GM	N62430

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N60731

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT

MYCITRACIN	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N61048

BACITRACIN; POLYMYXIN B SULFATE

DISC

LANABIOTIC	500 UNITS/GM;5,000 UNITS/GM	N50598

BACLOFEN

TABLET

BACLOFEN	10MG	N73043
BACLOFEN	20MG	N73044
BACLOFEN	10MG	N71260
BACLOFEN	20MG	N71261

BACLOFEN

TABLET

BACLOFEN	10MG	N74698
BACLOFEN	20MG	N73093
BACLOFEN	20MG	N74698
LIORESAL	10MG	* N17851
LIORESAL	20MG	* N17851

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED

BECLOVENT	0.042MG/INH	N18153
BECONASE	0.042MG/INH	N18584
VANCENASE	0.042MG/INH	N18521

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED

VANCENASE AQ	EQ 0.084MG DIPROP/SPRAY	N20469

BENDROFLUMETHIAZIDE

TABLET

NATURETIN-10	10MG	N12164
NATURETIN-2.5	2.5MG	N12164

BENOXINATE HYDROCHLORIDE

SOLUTION/DROPS

BENOXINATE HCL	0.4%	N84149

BENTIROMIDE

SOLUTION

CHYMEX	500MG/7.5ML	N18366

BENZPHETAMINE HYDROCHLORIDE

TABLET

DIDREX	25MG	N12427

BENZQUINAMIDE HYDROCHLORIDE

SUPPOSITORY

EMETE-CON	EQ 100MG BASE	N16818

BENZTHIAZIDE

TABLET

AQUATAG	25MG	N16001
AQUATAG	50MG	N16001
BENZTHIAZIDE	50MG	N83206
EXNA	50MG	N12489
FOVANE	50MG	N12128
URESE	25MG	N12128

BENZTROPINE MESYLATE

TABLET

BENZTROPINE MESYLATE	0.5MG	N88514
BENZTROPINE MESYLATE	1MG	N88510

BENZTROPINE MESYLATE		
TABLET		
BENZTROPINE MESYLATE	2MG	N88511
BENZTROPINE MESYLATE	0.5MG	N89211
BENZTROPINE MESYLATE	1MG	N89212
BENZTROPINE MESYLATE	2MG	N89213
COGENTIN	0.5MG	* N09193
COGENTIN	1MG	* N09193
COGENTIN	2MG	* N09193
BENZYL BENZOATE		
EMULSION		
BENZYL BENZOATE	50%	N84535
BEPRIDIL HYDROCHLORIDE		
TABLET		
BEPADIN	200MG	N19001
BEPADIN	300MG	N19001
BEPADIN	400MG	N19001
VASCOR	300MG	N19002
VASCOR	400MG	N19002
BETA-CAROTENE		
CAPSULE		
SOLATENE	30MG	N17589
BETAMETHASONE		
CREAM		
CELESTONE	0.2%	N14762
TABLET		
CELESTONE	0.6MG	N12657
BETAMETHASONE BENZOATE		
CREAM		
UTICORT	0.025%	N16998
GEL		
UTICORT	0.025%	N17244
LOTION		
UTICORT	0.025%	N17528
OINTMENT		
UTICORT	0.025%	N18089
BETAMETHASONE DIPROPIONATE		
CREAM		
BETAMETHASONE DIPROPIONATE	EQ 0.05% BASE	N72536
BETAMETHASONE DIPROPIONATE	EQ 0.05% BASE	N74579
BETAMETHASONE DIPROPIONATE	EQ 0.05% BASE	N19136
DIPROSONE	EQ 0.05% BASE	N17536
CREAM, AUGMENTED		
DIPROLENE	EQ 0.05% BASE	N19408

BETAMETHASONE DIPROPIONATE		
DISC		
DIPROSONE	EQ 0.1% BASE	N17829
LOTION		
BETAMETHASONE DIPROPIONATE	EQ 0.05% BASE	N71085
BETAMETHASONE DIPROPIONATE	EQ 0.05% BASE	N70274
OINTMENT		
BETAMETHASONE DIPROPIONATE	EQ 0.05% BASE	N72526
BETAMETHASONE DIPROPIONATE	EQ 0.05% BASE	N19140
DIPROSONE	EQ 0.05% BASE	N17691
BETAMETHASONE VALERATE		
CREAM		
BETAMETHASONE VALERATE	EQ 0.1% BASE	N70053
BETAMETHASONE VALERATE	EQ 0.1% BASE	N18860
BETAMETHASONE VALERATE	EQ 0.1% BASE	N70485
VALISONE	EQ 0.01% BASE	N16322
VALISONE	EQ 0.1% BASE	N16322
LOTION		
BETAMETHASONE VALERATE	EQ 0.1% BASE	N18870
BETAMETHASONE VALERATE	EQ 0.1% BASE	N70484
VALISONE	EQ 0.1% BASE	N16932
OINTMENT		
BETAMETHASONE VALERATE	EQ 0.1% BASE	N71478
BETAMETHASONE VALERATE	EQ 0.1% BASE	N18864
BETAMETHASONE VALERATE	EQ 0.1% BASE	N70486
VALISONE	EQ 0.1% BASE	N16740
BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE		
TABLET		
KERLEDEX	10MG;12.5MG	N19807
KERLEDEX	5MG;12.5MG	N19807
BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE		
SUSPENSION/DROPS		
BETOPTIC PILO	EQ 0.25% BASE;1.75%	N20619
BETAZOLE HYDROCHLORIDE		
INJECTABLE		
HISTALOG	50MG/ML	N09344
BETHANECHOL CHLORIDE		
INJECTABLE		
URECHOLINE	5MG/ML	* N06536
TABLET		
BETHANECHOL CHLORIDE	10MG	N88288
BETHANECHOL CHLORIDE	25MG	N88289
BETHANECHOL CHLORIDE	10MG	N84378
BETHANECHOL CHLORIDE	10MG	N84379
BETHANECHOL CHLORIDE	25MG	N84383

FDA data supplied by DrugPatentWatch.com

BETHANECHOL CHLORIDE

TABLET

BETHANECHOL CHLORIDE	25MG	N84384
BETHANECHOL CHLORIDE	5MG	N84353
BETHANECHOL CHLORIDE	25MG	N84689
BETHANECHOL CHLORIDE	10MG	N84712
BETHANECHOL CHLORIDE	25MG	N84074
BETHANECHOL CHLORIDE	5MG	N84702
BETHANECHOL CHLORIDE	10MG	N84408
BETHANECHOL CHLORIDE	10MG	N85228
BETHANECHOL CHLORIDE	10MG	N85842
BETHANECHOL CHLORIDE	25MG	N84441
BETHANECHOL CHLORIDE	25MG	N85229
BETHANECHOL CHLORIDE	25MG	N85839
BETHANECHOL CHLORIDE	50MG	N87397
BETHANECHOL CHLORIDE	50MG	N87444
BETHANECHOL CHLORIDE	5MG	N84402
BETHANECHOL CHLORIDE	5MG	N85230
BETHANECHOL CHLORIDE	5MG	N85841
DUVOID	10MG	N86262
DUVOID	25MG	N86263
DUVOID	50MG	N85882
MYOTONACHOL	10MG	N84188
MYOTONACHOL	25MG	N84188
MYOTONACHOL	5MG	N84188
URECHOLINE	10MG	* N06536
URECHOLINE	25MG	* N06536
URECHOLINE	50MG	* N06536
URECHOLINE	5MG	* N06536

BETHANIDINE SULFATE

TABLET

TENATHAN	10MG	N17675
TENATHAN	25MG	N17675

BIPERIDEN LACTATE

INJECTABLE

AKINETON	5MG/ML	N12418

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	10MG;6.25MG	N75642
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	2.5MG;6.25MG	N75642
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	5MG;6.25MG	N75642

BITOLTEROL MESYLATE

AEROSOL, METERED

TORNALATE	0.37MG/INH	N18770

SOLUTION

TORNALATE	0.2%	N19548

BRETYLIUM TOSYLATE

INJECTABLE

BRETYLIUM TOSYLATE	100MG/ML	N71298
BRETYLIUM TOSYLATE	50MG/ML	N70134
BRETYLIUM TOSYLATE	50MG/ML	N71151
BRETYLIUM TOSYLATE	50MG/ML	N71152
BRETYLIUM TOSYLATE	50MG/ML	N71153
BRETYLIUM TOSYLATE	50MG/ML	N70545
BRETYLIUM TOSYLATE	50MG/ML	N70546
BRETYLIUM TOSYLATE IN DEXTROSE 5%	200MG/100ML	N19005
BRETYLIUM TOSYLATE IN DEXTROSE 5%	400MG/100ML	N19005
BRETYLIUM TOSYLATE IN DEXTROSE 5%	800MG/100ML	N19005
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER	800MG/100ML	N19008
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER	200MG/100ML	N19837
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER	400MG/100ML	N19837
BRETYLOL	50MG/ML	N17954

BRIMONIDINE TARTRATE

SOLUTION/DROPS

ALPHAGAN	0.2%	* N20613
ALPHAGAN	0.5%	N20490

BROMOCRIPTINE MESYLATE

CAPSULE

BROMOCRIPTINE MESYLATE	EQ 5MG BASE	N75100

BROMODIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE

AMBODRYL	25MG	N07984

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP

BROMANYL	12.5MG/5ML;10MG/5ML	N88343

BROMPHENIRAMINE MALEATE

ELIXIR

BROMPHENIRAMINE MALEATE	2MG/5ML	N86936
BROMPHENIRAMINE MALEATE	2MG/5ML	N87517
BROMPHENIRAMINE MALEATE	2MG/5ML	N87964

INJECTABLE

BROMPHENIRAMINE MALEATE	100MG/ML	N83820
DIMETANE-TEN	10MG/ML	N11418

FDA data supplied by DrugPatentWatch.com

BROMPHENIRAMINE MALEATE

TABLET		
BROMPHENIRAMINE MALEATE	4MG	N86187
BROMPHENIRAMINE MALEATE	4MG	N84468
BROMPHENIRAMINE MALEATE	4MG	N84351
BROMPHENIRAMINE MALEATE	4MG	N86987
BROMPHENIRAMINE MALEATE	4MG	N87009
BROMPHENIRAMINE MALEATE	4MG	N88604
BROMPHENIRAMINE MALEATE	4MG	N83215
BROMPHENIRAMINE MALEATE	4MG	N85850
BROMPHENIRAMINE MALEATE	4MG	N83123
BROMPHENIRAMINE MALEATE	4MG	N85769
DIMETANE	4MG	N10799
TABLET, EXTENDED RELEASE		
DIMETANE	12MG	N10799
DIMETANE	8MG	N10799

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP		
BROMANATE DC	2MG/5ML;10MG/5ML;12.5MG/5ML	N88723
DIMETANE-DC	2MG/5ML;10MG/5ML;12.5MG/5ML	N11694
MYPHETANE DC	2MG/5ML;10MG/5ML;12.5MG/5ML	N88904

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP		
BROMANATE DM	2MG/5ML;10MG/5ML;30MG/5ML	N88722
DIMETANE-DX	2MG/5ML;10MG/5ML;30MG/5ML	N19279

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR		
BIPHETAP	4MG/5ML;25MG/5ML	N88687
BROMANATE	4MG/5ML;25MG/5ML	N88688
DIMETAPP	2MG/5ML;12.5MG/5ML	N13087
TABLET, EXTENDED RELEASE		
BROMATAPP	12MG;75MG	N71099
DIMETAPP	12MG;75MG	N12436

BUCLIZINE HYDROCHLORIDE

TABLET		
BUCLADIN-S	50MG	N10911

BUDESONIDE

AEROSOL, METERED		
RHINOCORT	0.032MG/INH	N20233
POWDER, METERED		
PULMICORT	0.32MG/INH	N20441
SUSPENSION		
PULMICORT RESPULES	1MG/2ML	N20929

BUPIVACAINE HYDROCHLORIDE

INJECTABLE		
BUPIVACAINE HCL KIT	0.075%	N19978
BUPIVACAINE HCL KIT	0.114%	N19978
BUPIVACAINE HCL KIT	0.23%	N19978

BUPROPION HYDROCHLORIDE

TABLET		
WELLBUTRIN	50MG	N18644
TABLET, EXTENDED RELEASE		
ZYBAN	100MG	N20711

BUSPIRONE HYDROCHLORIDE

CAPSULE		
BUSPAR	10MG	N21190
BUSPAR	15MG	N21190
BUSPAR	5MG	N21190
BUSPAR	7.5MG	N21190

BUTABARBITAL SODIUM

CAPSULE		
BUTICAPS	100MG	N85381
BUTICAPS	15MG	N85381
BUTICAPS	30MG	N85381
BUTICAPS	50MG	N85381
ELIXIR		
BUTABARB	30MG/5ML	N85873
BUTABARBITAL SODIUM	30MG/5ML	N85383
BUTALAN	33.3MG/5ML	N85880
SARISOL	30MG/5ML	N84723
TABLET		
BUTABARBITAL SODIUM	15MG	N85938
BUTABARBITAL SODIUM	30MG	N85934
BUTABARBITAL SODIUM	15MG	N84292
BUTABARBITAL SODIUM	30MG	N84272
BUTABARBITAL SODIUM	16.2MG	N83606
BUTABARBITAL SODIUM	32.4MG	N83898
BUTABARBITAL SODIUM	48.6MG	N83897
BUTABARBITAL SODIUM	97.2MG	N83896
BUTABARBITAL SODIUM	15MG	N88632

FDA data supplied by DrugPatentWatch.com

BUTABARBITAL SODIUM

TABLET

BUTABARBITAL SODIUM	30MG	N88631
BUTABARBITAL SODIUM	15MG	N85764
BUTABARBITAL SODIUM	30MG	N85772
BUTABARBITAL SODIUM	15MG	N83325
BUTABARBITAL SODIUM	30MG	N83337
BUTISOL SODIUM	100MG	N00793
BUTISOL SODIUM	15MG	N00793
SARISOL NO. 1	15MG	N84719
SARISOL NO. 2	30MG	N84719
SODIUM BUTABARBITAL	15MG	N83484
SODIUM BUTABARBITAL	30MG	N84040
SODIUM BUTABARBITAL	100MG	N85881
SODIUM BUTABARBITAL	15MG	N85849
SODIUM BUTABARBITAL	30MG	N85866
SODIUM BUTABARBITAL	15MG	N85418
SODIUM BUTABARBITAL	30MG	N85432

BUTOCONAZOLE NITRATE

CREAM

FEMSTAT	2%	N19215

SUPPOSITORY

FEMSTAT	100MG	N19359

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY

MIGERGOT	100MG;2MG	N86557

TABLET

CAFERGOT	100MG;1MG	N06620
WIGRAINE	100MG;1MG	N86562

CALCIFEDIOL

CAPSULE

CALDEROL	0.02MG	N18312
CALDEROL	0.05MG	N18312

CALCITONIN HUMAN

INJECTABLE

CIBACALCIN	0.5MG/VIAL	N18470

CALCITONIN, SALMON

INJECTABLE

CALCIMAR	400 IU/VIAL	N17497
CALCITONIN-SALMON	200 IU/ML	N73690
MIACALCIN	100 IU/ML	N17808

CALCIUM ACETATE

CAPSULE

PHOSLO	EQ 169MG CALCIUM	N21160
PHOSLO	EQ 84.5MG CALCIUM	N21160

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE

ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER	37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML	N18271

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE

ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER	35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N18269

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER	29MG/100ML;2.5GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N18460
DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER	29MG/100ML;1.5GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N18460
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER	29MG/100ML;4.25GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML	N18460

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER	26MG/100ML;1.5GM/100ML;15MG/100ML;560MG/100ML;390MG/100ML	N18460
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER	26MG/100ML;5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML	N18460
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER	26MG/100ML;4.25GM/100ML;15MG/100ML;560MG/100ML;390MG/100ML	N18460

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER	4MG/100ML;4GM/100ML;6MG/100ML;120MG/100ML;62MG/100ML	N19634
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N17510
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N18499
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N19685

FDA data supplied by DrugPatentWatch.com

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N19685
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N19685
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N19685
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N19685

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION

INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER	25.7MG/100ML;1.5GM/100ML;538MG/100ML;448MG/100ML	N19395
INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER	25.7MG/100ML;2.5GM/100ML;538MG/100ML;448MG/100ML	N19395
INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER	25.7MG/100ML;4.25GM/100ML;538MG/100ML;448MG/100ML	N19395

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE

TPN ELECTROLYTES IN PLASTIC CONTAINER	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;16.1MG/ML	N19399

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE

ISOLYTE E IN PLASTIC CONTAINER	35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N18899

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE

ACETATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;30MG/100ML;380MG/100ML;600MG/100ML	N18725

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION

RINGER'S IN PLASTIC CONTAINER	33MG/100ML;30MG/100ML;860MG/100ML	N18462

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE

LACTATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N19485
LACTATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N18023
LACTATED RINGER'S IN PLASTIC CONTAINER	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N18417

CALCIUM GLUCEPTATE

INJECTABLE

CALCIUM GLUCEPTATE	EQ 90MG CALCIUM/5ML	N80001
CALCIUM GLUCEPTATE	EQ 90MG CALCIUM/5ML	N83159
CALCIUM GLUCEPTATE	EQ 90MG CALCIUM/5ML	N89373
CALCIUM GLUCEPTATE	EQ 90MG CALCIUM/5ML	N06470

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE

ISOPAQUE 440	0.78MG/ML;75.9MG/ML;0.15MG/ML;16.6MG/ML	N16847

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE

ISOPAQUE 280	0.35MG/ML;140.1MG/ML;46 1.8MG/ML	N17506

CANDICIDIN

OINTMENT

VANOBID	0.6MG/GM	N61596

TABLET

VANOBID	3MG	N61613

CAPTOPRIL

TABLET

CAPOTEN	150MG	N18343
CAPOTEN	37.5MG	N18343
CAPOTEN	75MG	N18343
CAPTOPRIL	100MG	N74640
CAPTOPRIL	12.5MG	N74640
CAPTOPRIL	25MG	N74640
CAPTOPRIL	50MG	N74640

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET

CAPTOPRIL AND HYDROCHLOROTHIAZIDE	50MG;25MG	N74832

CARBACHOL

SOLUTION

CARBACHOL	0.01%	N70292

FDA data supplied by DrugPatentWatch.com

CARBAMAZEPINE			
TABLET			
CARBAMAZEPINE	200MG	N70300	
CARBAMAZEPINE	200MG	N70429	
CARBENICILLIN DISODIUM			
INJECTABLE			
GEOPEN	EQ 10GM BASE/VIAL	N50306	
GEOPEN	EQ 1GM BASE/VIAL	N50306	
GEOPEN	EQ 2GM BASE/VIAL	N50306	
GEOPEN	EQ 30GM BASE/VIAL	N50306	
GEOPEN	EQ 5GM BASE/VIAL	N50306	
PYOPEN	EQ 10GM BASE/VIAL	N50298	
PYOPEN	EQ 1GM BASE/VIAL	N50298	
PYOPEN	EQ 20GM BASE/VIAL	N50298	
PYOPEN	EQ 2GM BASE/VIAL	N50298	
PYOPEN	EQ 5GM BASE/VIAL	N50298	
CARBIDOPA; LEVODOPA			
TABLET			
CARBIDOPA AND LEVODOPA	10MG;100MG	N74080	
CARBIDOPA AND LEVODOPA	25MG;100MG	N74080	
CARBIDOPA AND LEVODOPA	25MG;250MG	N74080	
CARBIDOPA AND LEVODOPA	10MG;100MG	N73381	
CARBIDOPA AND LEVODOPA	25MG;100MG	N73382	
CARBIDOPA AND LEVODOPA	25MG;250MG	N73383	
CARBINOXAMINE MALEATE			
ELIXIR			
CLISTIN	4MG/5ML	* N08955	
TABLET			
CLISTIN	4MG	* N08915	
CARISOPRODOL			
CAPSULE			
SOMA	250MG	N11792	
TABLET			
CARISOPRODOL	350MG	N89566	
CARISOPRODOL	350MG	N89390	
CARISOPRODOL	350MG	N85433	
RELA	350MG	N12155	
CARPHENAZINE MALEATE			
CONCENTRATE			
PROKETAZINE	50MG/ML	N14173	
TABLET			
PROKETAZINE	12.5MG	N12768	
PROKETAZINE	25MG	N12768	
PROKETAZINE	50MG	N12768	
CARPROFEN			
TABLET			
RIMADYL	100MG	N18550	
RIMADYL	150MG	N18550	
CARTEOLOL HYDROCHLORIDE			
TABLET			
CARTROL	10MG	N19204	
CEFACLOR			
CAPSULE			
CEFACLOR	EQ 250MG BASE	N64107	
CEFACLOR	EQ 500MG BASE	N64107	
CEFACLOR	EQ 250MG BASE	N64081	
CEFACLOR	EQ 500MG BASE	N64081	
FOR SUSPENSION			
CEFACLOR	EQ 125MG BASE/5ML	N64114	
CEFACLOR	EQ 187MG BASE/5ML	N64115	
CEFACLOR	EQ 250MG BASE/5ML	N64116	
CEFACLOR	EQ 375MG BASE/5ML	N64110	
CEFACLOR	EQ 125MG BASE/5ML	N64087	
CEFACLOR	EQ 187MG BASE/5ML	N64086	
CEFACLOR	EQ 250MG BASE/5ML	N64085	
TABLET, EXTENDED RELEASE			
CECLOR CD	EQ 375MG BASE	N50673	
CEFADROXIL/CEFADROXIL HEMIHYDRATE			
CAPSULE			
CEFADROXIL	EQ 500MG BASE	N63017	
CEFADROXIL	EQ 500MG BASE	N62695	
DURICEF	EQ 250MG BASE	N50512	
ULTRACEF	EQ 500MG BASE	N62378	
FOR SUSPENSION			
CEFADROXIL	EQ 125MG BASE/5ML	N62334	
CEFADROXIL	EQ 250MG BASE/5ML	N62334	
CEFADROXIL	EQ 500MG BASE/5ML	N62334	
CEFADROXIL	EQ 125MG BASE/5ML	N62698	
CEFADROXIL	EQ 250MG BASE/5ML	N62698	
CEFADROXIL	EQ 500MG BASE/5ML	N62698	
ULTRACEF	EQ 125MG BASE/5ML	N62376	
ULTRACEF	EQ 250MG BASE/5ML	N62376	
ULTRACEF	EQ 500MG BASE/5ML	N62376	
TABLET			
CEFADROXIL	EQ 1GM BASE	N62774	
ULTRACEF	EQ 1GM BASE	N62390	
ULTRACEF	EQ 1GM BASE	N62408	

FDA data supplied by DrugPatentWatch.com

CEFAMANDOLE NAFATE

INJECTABLE

MANDOL	EQ 10GM BASE/VIAL	N50504
MANDOL	EQ 1GM BASE/VIAL	N62560
MANDOL	EQ 2GM BASE/VIAL	N62560
MANDOL	EQ 500MG BASE/VIAL	N50504

CEFAZOLIN SODIUM

INJECTABLE

ANCEF	EQ 250MG BASE/VIAL	N50461
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 10MG BASE/ML	N50566
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N50566
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 10MG BASE/ML	N50566
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N50566
CEFAZOLIN SODIUM	EQ 10GM BASE/VIAL	N62688
CEFAZOLIN SODIUM	EQ 1GM BASE/VIAL	N62688
CEFAZOLIN SODIUM	EQ 20GM BASE/VIAL	N62688
CEFAZOLIN SODIUM	EQ 500MG BASE/VIAL	N62688
CEFAZOLIN SODIUM	EQ 10GM BASE/VIAL	N62894
CEFAZOLIN SODIUM	EQ 1GM BASE/VIAL	N62894
CEFAZOLIN SODIUM	EQ 250MG BASE/VIAL	N62894
CEFAZOLIN SODIUM	EQ 500MG BASE/VIAL	N62894
CEFAZOLIN SODIUM	EQ 5GM BASE/VIAL	N62894
CEFAZOLIN SODIUM	EQ 10GM BASE/VIAL	N62807
CEFAZOLIN SODIUM	EQ 1GM BASE/VIAL	N62807
CEFAZOLIN SODIUM	EQ 20GM BASE/VIAL	N62807
CEFAZOLIN SODIUM	EQ 250MG BASE/VIAL	N62807
CEFAZOLIN SODIUM	EQ 500MG BASE/VIAL	N62807
CEFAZOLIN SODIUM	EQ 5GM BASE/VIAL	N62807
CEFAZOLIN SODIUM	EQ 10GM BASE/VIAL	N63018
CEFAZOLIN SODIUM	EQ 1GM BASE/VIAL	N63016
CEFAZOLIN SODIUM	EQ 250MG BASE/VIAL	N63016
CEFAZOLIN SODIUM	EQ 500MG BASE/VIAL	N63016
CEFAZOLIN SODIUM	EQ 5GM BASE/VIAL	N63018
KEFZOL	EQ 1GM BASE/VIAL	N62557
KEFZOL	EQ 500MG BASE/VIAL	N62557

CEFIXIME

FOR SUSPENSION

SUPRAX	100MG/5ML	N50622

TABLET

SUPRAX	200MG	N50621
SUPRAX	400MG	N50621

CEFMENOXIME HYDROCHLORIDE

INJECTABLE

CEFMAX	EQ 1GM BASE/VIAL	N50571
CEFMAX	EQ 2GM BASE/VIAL	N50571
CEFMAX	EQ 500MG BASE/VIAL	N50571

CEFMETAZOLE SODIUM

INJECTABLE

ZEFAZONE	EQ 1GM BASE/VIAL	N50637
ZEFAZONE	EQ 2GM BASE/VIAL	N50637
ZEFAZONE IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N50683
ZEFAZONE IN PLASTIC CONTAINER	EQ 40MG BASE/ML	N50683

CEFONICID SODIUM

INJECTABLE

MONOCID	EQ 10GM BASE/VIAL	N50579
MONOCID	EQ 1GM BASE/VIAL	N50579
MONOCID	EQ 1GM BASE/VIAL	N63295
MONOCID	EQ 2GM BASE/VIAL	N50579
MONOCID	EQ 500MG BASE/VIAL	N50579

CEFOPERAZONE SODIUM

INJECTABLE

CEFOBID	EQ 1GM BASE/VIAL	N63333
CEFOBID	EQ 2GM BASE/VIAL	N63333

CEFORANIDE

INJECTABLE

PRECEF	10GM/VIAL	N62579
PRECEF	1GM/VIAL	N62579
PRECEF	20GM/VIAL	N62579
PRECEF	2GM/VIAL	N62579
PRECEF	500MG/VIAL	N62579
PRECEF	10GM/VIAL	N50554
PRECEF	1GM/VIAL	N50554
PRECEF	20GM/VIAL	N50554
PRECEF	2GM/VIAL	N50554
PRECEF	500MG/VIAL	N50554

CEFOTAXIME SODIUM

INJECTABLE

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N50596
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 40MG BASE/ML	N50596

CEFOTIAM HYDROCHLORIDE

INJECTABLE

CERADON	EQ 1GM BASE/VIAL	N50601

CEFOXITIN SODIUM

INJECTABLE

MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N50581

FDA data supplied by DrugPatentWatch.com

CEFOXITIN SODIUM
INJECTABLE

MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 40MG BASE/ML	N50581
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N50581
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 40MG BASE/ML	N50581

CEFPIRAMIDE SODIUM
INJECTABLE

CEFPIRAMIDE SODIUM	EQ 10GM BASE/VIAL	N50633
CEFPIRAMIDE SODIUM	EQ 1GM BASE/VIAL	N50633
CEFPIRAMIDE SODIUM	EQ 2GM BASE/VIAL	N50633

CEFPODOXIME PROXETIL
FOR SUSPENSION

BANAN	EQ 100MG BASE/5ML	N50688
BANAN	EQ 50MG BASE/5ML	N50688

TABLET

BANAN	EQ 100MG BASE	N50687
BANAN	EQ 200MG BASE	N50687

CEFTAZIDIME
INJECTABLE

TAZIDIME IN PLASTIC CONTAINER	1GM/VIAL	N62739
TAZIDIME IN PLASTIC CONTAINER	2GM/VIAL	N62739

CEFTAZIDIME (ARGININE FORMULATION)
INJECTABLE

CEPTAZ	500MG/VIAL	N50646
PENTACEF	10GM/VIAL	N64008
PENTACEF	1GM/VIAL	N63322
PENTACEF	1GM/VIAL	N64006
PENTACEF	2GM/VIAL	N63322
PENTACEF	2GM/VIAL	N64006
PENTACEF	6GM/VIAL	N64008

CEFTAZIDIME SODIUM
INJECTABLE

FORTAZ IN PLASTIC CONTAINER	EQ 10MG BASE/ML	N50634

CEFTIZOXIME SODIUM
INJECTABLE

CEFIZOX	EQ 500MG BASE/VIAL	N50560
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N50589
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 40MG BASE/ML	N50589

CEFTRIAXONE SODIUM
INJECTABLE

ROCEPHIN	EQ 500MG BASE/VIAL	N62654
ROCEPHIN	EQ 1GM BASE/VIAL	N62510
ROCEPHIN	EQ 250MG BASE/VIAL	N62510

CEFTRIAXONE SODIUM
INJECTABLE

ROCEPHIN	EQ 500MG BASE/VIAL	N62510
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER	EQ 10MG BASE/ML	N50624

CEFTRIAXONE SODIUM; LIDOCAINE
INJECTABLE

ROCEPHIN KIT	EQ 1GM BASE/VIAL;1%	N50585
ROCEPHIN KIT	EQ 500MG BASE/VIAL;1%	N50585

CEFUROXIME SODIUM
INJECTABLE

KEFUROX IN PLASTIC CONTAINER	EQ 1.5GM BASE/VIAL	N62590
KEFUROX IN PLASTIC CONTAINER	EQ 750MG BASE/VIAL	N62590

CELLULOSE SODIUM PHOSPHATE
POWDER

CALCIBIND	2.5GM/PACKET	N18757

CEPHALEXIN
CAPSULE

CEPHALEXIN	EQ 250MG BASE	N62973
CEPHALEXIN	EQ 500MG BASE	N62974
CEPHALEXIN	EQ 250MG BASE	N62809
CEPHALEXIN	EQ 500MG BASE	N62809
CEPHALEXIN	EQ 500MG BASE	N62869
CEPHALEXIN	EQ 250MG BASE	N62821
CEPHALEXIN	EQ 500MG BASE	N62823
CEPHALEXIN	EQ 250MG BASE	N62872
CEPHALEXIN	EQ 500MG BASE	N62871

FOR SUSPENSION

CEPHALEXIN	EQ 125MG BASE/5ML	N62986
CEPHALEXIN	EQ 250MG BASE/5ML	N62987
CEPHALEXIN	EQ 125MG BASE/5ML	N62778
CEPHALEXIN	EQ 125MG BASE/5ML	N62873
CEPHALEXIN	EQ 250MG BASE/5ML	N62867
CEPHALEXIN	EQ 125MG BASE/5ML	N62779
CEPHALEXIN	EQ 250MG BASE/5ML	N62781
KEFLEX	EQ 100MG BASE/ML	N50406
KEFLEX	EQ 125MG BASE/5ML	N50406
KEFLEX	EQ 250MG BASE/5ML	N50406

TABLET

CEPHALEXIN	EQ 250MG BASE	N62826
CEPHALEXIN	EQ 500MG BASE	N62827
CEPHALEXIN	EQ 1GM BASE	N62863
CEPHALEXIN	EQ 250MG BASE	N62863
CEPHALEXIN	EQ 500MG BASE	N62863
KEFLET	EQ 1GM BASE	N50440
KEFLET	EQ 250MG BASE	N62745

FDA data supplied by DrugPatentWatch.com

CEPHALEXIN		
TABLET		
KEFLET	EQ 500MG BASE	N50440
KEFLET	EQ 500MG BASE	N62745
CEPHALEXIN HYDROCHLORIDE		
TABLET		
KEFTAB	EQ 250MG BASE	N50614
KEFTAB	EQ 333MG BASE	N50614
CEPHALOGLYCIN		
CAPSULE		
KAFOCIN	250MG	N50219
CEPHALOTHIN SODIUM		
INJECTABLE		
CEPHALOTHIN	EQ 1GM BASE/VIAL	N62426
CEPHALOTHIN	EQ 2GM BASE/VIAL	N62426
CEPHALOTHIN	EQ 4GM BASE/VIAL	N62426
CEPHALOTHIN	EQ 500MG BASE/VIAL	N62426
CEPHALOTHIN SODIUM	EQ 1GM BASE/VIAL	N62547
CEPHALOTHIN SODIUM	EQ 1GM BASE/VIAL	N62548
CEPHALOTHIN SODIUM	EQ 2GM BASE/VIAL	N62547
CEPHALOTHIN SODIUM	EQ 2GM BASE/VIAL	N62548
CEPHALOTHIN SODIUM	EQ 1GM BASE/VIAL	N62666
CEPHALOTHIN SODIUM	EQ 2GM BASE/VIAL	N62666
CEPHALOTHIN SODIUM	EQ 1GM BASE/VIAL	N62464
CEPHALOTHIN SODIUM	EQ 2GM BASE/VIAL	N62464
CEPHALOTHIN SODIUM	EQ 4GM BASE/VIAL	N62464
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N62422
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N62422
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N62730
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER	EQ 40MG BASE/ML	N62422
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER	EQ 40MG BASE/ML	N62422
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER	EQ 40MG BASE/ML	N62730
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER	EQ 20MG BASE/ML	N62422
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER	EQ 40MG BASE/ML	N62422
KEFLIN	EQ 1GM BASE/VIAL	N50482
KEFLIN	EQ 20GM BASE/VIAL	N50482
KEFLIN	EQ 2GM BASE/VIAL	N50482
KEFLIN	EQ 4GM BASE/VIAL	N50482
KEFLIN IN PLASTIC CONTAINER	EQ 1GM BASE/VIAL	N62549
KEFLIN IN PLASTIC CONTAINER	EQ 2GM BASE/VIAL	N62549
CEPHALOTHIN SODIUM		
INJECTABLE		
SEFFIN	EQ 10GM BASE/VIAL	N62435
SEFFIN	EQ 1GM BASE/VIAL	N62435
SEFFIN	EQ 2GM BASE/VIAL	N62435
CEPHAPIRIN SODIUM		
INJECTABLE		
CEFADYL	EQ 1GM BASE/VIAL	N50446
CEFADYL	EQ 1GM BASE/VIAL	N61769
CEFADYL	EQ 1GM BASE/VIAL	N62724
CEFADYL	EQ 1GM BASE/VIAL	N62961
CEFADYL	EQ 20GM BASE/VIAL	N50446
CEFADYL	EQ 2GM BASE/VIAL	N50446
CEFADYL	EQ 2GM BASE/VIAL	N61769
CEFADYL	EQ 2GM BASE/VIAL	N62724
CEFADYL	EQ 2GM BASE/VIAL	N62961
CEFADYL	EQ 4GM BASE/VIAL	N50446
CEFADYL	EQ 4GM BASE/VIAL	N61769
CEFADYL	EQ 4GM BASE/VIAL	N62961
CEFADYL	EQ 500MG BASE/VIAL	N50446
CEFADYL	EQ 500MG BASE/VIAL	N62961
CEPHAPIRIN SODIUM	EQ 1GM BASE/VIAL	N62723
CEPHAPIRIN SODIUM	EQ 20GM BASE/VIAL	N62723
CEPHAPIRIN SODIUM	EQ 2GM BASE/VIAL	N62723
CEPHAPIRIN SODIUM	EQ 4GM BASE/VIAL	N62723
CEPHAPIRIN SODIUM	EQ 500MG BASE/VIAL	N62723
CEPHAPIRIN SODIUM	EQ 1GM BASE/VIAL	N62720
CEPHAPIRIN SODIUM	EQ 20GM BASE/VIAL	N62720
CEPHAPIRIN SODIUM	EQ 2GM BASE/VIAL	N62720
CEPHAPIRIN SODIUM	EQ 500MG BASE/VIAL	N62720
CEPHRADINE		
CAPSULE		
CEPHRADINE	250MG	N62850
CEPHRADINE	500MG	N62851
CEPHRADINE	250MG	N62762
CEPHRADINE	500MG	N62762
CEPHRADINE	250MG	N62813
CEPHRADINE	500MG	N62813
VELOSEF '250'	250MG	N50548
VELOSEF '500'	500MG	N50548
FOR SUSPENSION		
CEPHRADINE	125MG/5ML	N62858
CEPHRADINE	250MG/5ML	N62859
INJECTABLE		
VELOSEF	1GM/VIAL	N61976
VELOSEF	250MG/VIAL	N61976

FDA data supplied by DrugPatentWatch.com

CEPHRADINE		
INJECTABLE		
VELOSEF	2GM/VIAL	N61976
VELOSEF	4GM/VIAL	N61976
VELOSEF	500MG/VIAL	N61976
TABLET		
VELOSEF	1GM	N50530
CERIVASTATIN SODIUM		
TABLET		
BAYCOL	0.05MG	N20740
BAYCOL	0.1MG	N20740
BAYCOL	0.2MG	N20740
BAYCOL	0.3MG	N20740
BAYCOL	0.4MG	N20740
BAYCOL	0.8MG	N20740
CERULETIDE DIETHYLAMINE		
INJECTABLE		
TYMTRAN	0.02MG/ML	N18296
CHENODIOL		
TABLET		
CHENIX	250MG	N18513
CHLOPHEDIANOL HYDROCHLORIDE		
SYRUP		
ULO	25MG/5ML	N12126
CHLORAMPHENICOL		
CAPSULE		
AMPHICOL	100MG	N60058
AMPHICOL	250MG	N60058
CHLORAMPHENICOL	250MG	N62247
CHLOROMYCETIN	100MG	N60591
CHLOROMYCETIN	250MG	N60591
CHLOROMYCETIN	50MG	N60591
MYCHEL	250MG	N60851
CREAM		
CHLOROMYCETIN	1%	N50183
FOR SOLUTION		
CHLOROMYCETIN	25MG/VIAL	N50143
INJECTABLE		
CHLOROMYCETIN	250MG/ML	N50153
OINTMENT		
CHLOROFAIR	1%	N62439
CHLOROMYCETIN	1%	N50156
CHLOROPTIC S.O.P.	1%	N61187
ECONOCHLOR	1%	N61648

CHLORAMPHENICOL		
SOLUTION/DROPS		
CHLORAMPHENICOL	0.5%	N62042
CHLORAMPHENICOL	0.5%	N62628
CHLOROFAIR	0.5%	N62437
CHLOROMYCETIN	0.5%	N50205
CHLOROPTIC	0.5%	N50091
ECONOCHLOR	0.5%	N61645
OPHTHOCHLOR	0.5%	N61220
OPTOMYCIN	0.5%	N62171
CHLORAMPHENICOL PALMITATE		
SUSPENSION		
CHLOROMYCETIN PALMITATE	EQ 150MG BASE/5ML	N50152
CHLOROMYCETIN PALMITATE	EQ 150MG BASE/5ML	N62301
CHLORAMPHENICOL SODIUM SUCCINATE		
INJECTABLE		
CHLORAMPHENICOL	EQ 1GM BASE/VIAL	N62406
CHLORAMPHENICOL SODIUM SUCCINATE	EQ 1GM BASE/VIAL	N62278
MYCHEL-S	EQ 1GM BASE/VIAL	N60132
CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN		
OINTMENT		
ELASE-CHLOROMYCETIN	10MG/GM;666 UNITS/GM;1 UNITS/GM	N50294
CHLORAMPHENICOL; HYDROCORTISONE ACETATE		
FOR SUSPENSION		
CHLOROMYCETIN HYDROCORTISONE	12.5MG/VIAL;25MG/VIAL	N50202
CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE		
OINTMENT		
OPHTHOCORT	10MG/GM;5MG/GM;10,000 UNITS/GM	N50201
CHLORAMPHENICOL; POLYMYXIN B SULFATE		
OINTMENT		
CHLOROMYXIN	1%;10,000 UNITS/GM	N50203
CHLORAMPHENICOL; PREDNISOLONE		
OINTMENT		
CHLOROPTIC-P S.O.P.	1%;0.5%	N61188
CHLORDIAZEPOXIDE		
CAPSULE, EXTENDED RELEASE		
LIBRELEASE	30MG	N17813
TABLET		
LIBRITABS	10MG	N85481
LIBRITABS	25MG	N85488
LIBRITABS	5MG	N85482

FDA data supplied by DrugPatentWatch.com

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE

A-POXIDE	10MG	N85447
A-POXIDE	10MG	N85518
A-POXIDE	25MG	N85447
A-POXIDE	25MG	N85513
A-POXIDE	5MG	N85447
A-POXIDE	5MG	N85517
CHLORDIAZACHEL	10MG	N84639
CHLORDIAZACHEL	25MG	N85087
CHLORDIAZACHEL	5MG	N85086
CHLORDIAZEPOXIDE HCL	10MG	N87524
CHLORDIAZEPOXIDE HCL	25MG	N87512
CHLORDIAZEPOXIDE HCL	5MG	N87525
CHLORDIAZEPOXIDE HCL	10MG	N84920
CHLORDIAZEPOXIDE HCL	25MG	N84823
CHLORDIAZEPOXIDE HCL	5MG	N84919
CHLORDIAZEPOXIDE HCL	10MG	N85119
CHLORDIAZEPOXIDE HCL	25MG	N85120
CHLORDIAZEPOXIDE HCL	5MG	N85118
CHLORDIAZEPOXIDE HCL	10MG	N85339
CHLORDIAZEPOXIDE HCL	25MG	N84685
CHLORDIAZEPOXIDE HCL	5MG	N85340
CHLORDIAZEPOXIDE HCL	10MG	N85113
CHLORDIAZEPOXIDE HCL	25MG	N86212
CHLORDIAZEPOXIDE HCL	5MG	N86213
CHLORDIAZEPOXIDE HCL	10MG	N83742
CHLORDIAZEPOXIDE HCL	25MG	N83570
CHLORDIAZEPOXIDE HCL	5MG	N83741
CHLORDIAZEPOXIDE HCL	10MG	N86876
CHLORDIAZEPOXIDE HCL	10MG	N87037
CHLORDIAZEPOXIDE HCL	25MG	N86893
CHLORDIAZEPOXIDE HCL	25MG	N87231
CHLORDIAZEPOXIDE HCL	5MG	N86892
CHLORDIAZEPOXIDE HCL	5MG	N87234
CHLORDIAZEPOXIDE HCL	10MG	N86217
CHLORDIAZEPOXIDE HCL	10MG	N84601
CHLORDIAZEPOXIDE HCL	25MG	N84887
CHLORDIAZEPOXIDE HCL	5MG	N84886
CHLORDIAZEPOXIDE HCL	10MG	N84598
CHLORDIAZEPOXIDE HCL	25MG	N85164
CHLORDIAZEPOXIDE HCL	5MG	N85163
CHLORDIAZEPOXIDE HCL	10MG	N89533
CHLORDIAZEPOXIDE HCL	25MG	N89558
CHLORDIAZEPOXIDE HCL	10MG	N84939
CHLORDIAZEPOXIDE HCL	25MG	N85144
CHLORDIAZEPOXIDE HCL	5MG	N85155

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE

CHLORDIAZEPOXIDE HCL	10MG	N84700
CHLORDIAZEPOXIDE HCL	25MG	N84705
CHLORDIAZEPOXIDE HCL	5MG	N84706
CHLORDIAZEPOXIDE HCL	10MG	N84041
CHLORDIAZEPOXIDE HCL	25MG	N84679
CHLORDIAZEPOXIDE HCL	5MG	N84678
CHLORDIAZEPOXIDE HCL	10MG	N88986
CHLORDIAZEPOXIDE HCL	25MG	N88988
CHLORDIAZEPOXIDE HCL	5MG	N88987
CHLORDIAZEPOXIDE HCL	10MG	N88706
CHLORDIAZEPOXIDE HCL	25MG	N86494
CHLORDIAZEPOXIDE HCL	25MG	N88707
CHLORDIAZEPOXIDE HCL	5MG	N88705
CHLORDIAZEPOXIDE HCL	25MG	N84645
CHLORDIAZEPOXIDE HCL	5MG	N84644
CHLORDIAZEPOXIDE HCL	10MG	N88010
CHLORDIAZEPOXIDE HCL	25MG	N88130
CHLORDIAZEPOXIDE HCL	5MG	N88129
CHLORDIAZEPOXIDE HCL	10MG	N85000
CHLORDIAZEPOXIDE HCL	25MG	N85294
CHLORDIAZEPOXIDE HCL	5MG	N85014
LIBRIUM	10MG	N12249
LIBRIUM	25MG	N12249
LIBRIUM	5MG	N12249
LYGEN	10MG	N85009
LYGEN	25MG	N85108
LYGEN	5MG	N85107

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET

MENRIUM 10-4	10MG;0.4MG	N14740
MENRIUM 5-2	5MG;0.2MG	N14740
MENRIUM 5-4	5MG;0.4MG	N14740

CHLORHEXIDINE GLUCONATE

SOLUTION

EXIDINE	2.5%	N19421

SPONGE

E-Z SCRUB	4%	N73416

CHLORMERODRIN, HG-197

INJECTABLE

CHLORMERODRIN HG 197	0.6-1.4mCi/ML	N17269

CHLORMEZANONE

TABLET

TRANCOPAL	100MG	N11467

FDA data supplied by DrugPatentWatch.com

CHLORMEZANONE		
TABLET		
TRANCOPAL	200MG	N11467
CHLOROPROCAINE HYDROCHLORIDE		
INJECTABLE		
NESACAINE-MPF	2%	N09435
NESACAINE-MPF	3%	N09435
CHLOROQUINE HYDROCHLORIDE		
INJECTABLE		
ARALEN HCL	EQ 40MG BASE/ML	N06002
CHLOROQUINE PHOSPHATE		
TABLET		
CHLOROQUINE PHOSPHATE	EQ 150MG BASE	N87228
CHLOROQUINE PHOSPHATE	EQ 150MG BASE	N80886
CHLOROQUINE PHOSPHATE	EQ 150MG BASE	N87504
CHLOROQUINE PHOSPHATE	EQ 150MG BASE	N87979
CHLOROQUINE PHOSPHATE	EQ 300MG BASE	N88030
CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE		
TABLET		
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE	EQ 300MG BASE;EQ 45MG BASE	N14860
CHLOROTHIAZIDE		
TABLET		
CHLOROTHIAZIDE	250MG	N85569
CHLOROTHIAZIDE	250MG	N85485
CHLOROTHIAZIDE	250MG	N86940
CHLOROTHIAZIDE	500MG	N86938
CHLOROTHIAZIDE	250MG	N85165
CHLOROTHIAZIDE	250MG	N85173
CHLOROTHIAZIDE	250MG	N86795
CHLOROTHIAZIDE	500MG	N84026
CHLOROTHIAZIDE	500MG	N86796
CHLOROTHIAZIDE; METHYLDOPA		
TABLET		
ALDOCLOR-150	150MG;250MG	N16016
ALDOCLOR-250	250MG;250MG	N16016
METHYLDOPA AND CHLOROTHIAZIDE	150MG;250MG	N70783
METHYLDOPA AND CHLOROTHIAZIDE	250MG;250MG	N70654
CHLOROTHIAZIDE; RESERPINE		
TABLET		
CHLOROTHIAZIDE AND RESERPINE	250MG;0.125MG	N88557
CHLOROTHIAZIDE AND RESERPINE	500MG;0.125MG	N88365
CHLOROTHIAZIDE W/ RESERPINE	250MG;0.125MG	N84853
CHLOROTHIAZIDE W/ RESERPINE	500MG;0.125MG	N88151
CHLOROTHIAZIDE-RESERPINE	250MG;0.125MG	N87744
CHLOROTHIAZIDE; RESERPINE		
TABLET		
CHLOROTHIAZIDE-RESERPINE	500MG;0.125MG	N87745
CHLOROTRIANISENE		
CAPSULE		
CHLOROTRIANISENE	12MG	N84652
TACE	12MG	N08102
TACE	25MG	N11444
TACE	72MG	N16235
CHLORPHENESIN CARBAMATE		
TABLET		
MAOLATE	400MG	N14217
CHLORPHENIRAMINE MALEATE		
CAPSULE, EXTENDED RELEASE		
TELDRIN	12MG	N17369
TELDRIN	8MG	N17369
INJECTABLE		
CHLORPHENIRAMINE MALEATE	10MG/ML	N80821
CHLORPHENIRAMINE MALEATE	10MG/ML	N80797
CHLORPHENIRAMINE MALEATE	100MG/ML	N86095
CHLORPHENIRAMINE MALEATE	10MG/ML	N83593
CHLORPHENIRAMINE MALEATE	10MG/ML	N86096
CHLOR-TRIMETON	100MG/ML	N08794
CHLOR-TRIMETON	10MG/ML	N08826
PYRIDAMAL 100	100MG/ML	N83733
SYRUP		
CHLORPHENIRAMINE MALEATE	2MG/5ML	N87520
CHLOR-TRIMETON	2MG/5ML	N06921
TABLET		
ANTAGONATE	4MG	N83381
CHLORPHENIRAMINE MALEATE	4MG	N83078
CHLORPHENIRAMINE MALEATE	4MG	N83062
CHLORPHENIRAMINE MALEATE	4MG	N80938
CHLORPHENIRAMINE MALEATE	4MG	N80700
CHLORPHENIRAMINE MALEATE	4MG	N80809
CHLORPHENIRAMINE MALEATE	4MG	N80779
CHLORPHENIRAMINE MALEATE	4MG	N87164
CHLORPHENIRAMINE MALEATE	4MG	N86941
CHLORPHENIRAMINE MALEATE	4MG	N86519
CHLORPHENIRAMINE MALEATE	4MG	N83243
CHLORPHENIRAMINE MALEATE	4MG	N85104
CHLORPHENIRAMINE MALEATE	4MG	N83753
CHLORPHENIRAMINE MALEATE	4MG	N85522
CHLORPHENIRAMINE MALEATE	4MG	N88556
CHLORPHENIRAMINE MALEATE	4MG	N86306

CHLORPHENIRAMINE MALEATE

TABLET

CHLORPHENIRAMINE MALEATE	4MG	N80786
CHLORPHENIRAMINE MALEATE	4MG	N80626
CHLORPHENIRAMINE MALEATE	4MG	N80961
CHLORPHENIRAMINE MALEATE	4MG	N87747
CHLORPHENIRAMINE MALEATE	4MG	N80598
CHLORPHENIRAMINE MALEATE	4MG	N85837
CHLORPHENIRAMINE MALEATE	4MG	N80696
CHLORPHENIRAMINE MALEATE	4MG	N80791
CHLORPHENIRAMINE MALEATE	4MG	N85139
CHLORPHENIRAMINE MALEATE	4MG	N83787
CHLOR-TRIMETON	4MG	N06921
KLOROMIN	4MG	N83629
PHENETRON	4MG	N80846

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE

CHLOROHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL	12MG;75MG	N88681
CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL	12MG;75MG	N88940
COLD CAPSULE IV	12MG;75MG	N18793
COLD CAPSULE V	8MG;75MG	N18794
CONTAC 12 HOUR	8MG;75MG	N18099
DRIZE	12MG;75MG	N88359
ORNADE	12MG;75MG	N12152
PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE	8MG;75MG	N18809

TABLET, EXTENDED RELEASE

CONTAC	12MG;75MG	N19613
DEMAZIN	4MG;25MG	N18556
TRIAMINIC-12	12MG;75MG	N18115

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE

CODIMAL-L.A. 12	12MG;120MG	N18935
ISOCLOR	8MG;120MG	N18747
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE	8MG;120MG	N19428
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE	12MG;120MG	N71455
PSEUDOEPHEDRINE HCL/CHLORPHENIRAMINE MALEATE	12MG;120MG	N18843
PSEUDOEPHEDRINE HCL/CHLORPHENIRAMINE MALEATE	8MG;120MG	N18844

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE

PENNTUSS	EQ 4MG MALEATE/5ML;EQ 10MG BASE/5ML	N18928

CHLORPHENIRAMINE POLISTIREX; PHENYLPROPANOLAMINE POLISTIREX

SUSPENSION, EXTENDED RELEASE

CORSYM	EQ 4MG MALEATE/5ML;EQ 37.5MG HCL/5ML	N18050

CHLORPHENTERMINE HYDROCHLORIDE

TABLET

PRE-SATE	EQ 65MG BASE	N14696

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE

THORAZINE	150MG	N11120
THORAZINE	30MG	N11120
THORAZINE	75MG	N11120

CONCENTRATE

CHLORPROMAZINE HCL	100MG/ML	N87053
CHLORPROMAZINE HCL	30MG/ML	N87032

INJECTABLE

CHLORPROMAZINE HCL	25MG/ML	N84911
CHLORPROMAZINE HCL	25MG/ML	N89563
CHLORPROMAZINE HCL	25MG/ML	N80365
CHLORPROMAZINE HCL	25MG/ML	N85591
CHLORPROMAZINE HCL	25MG/ML	N80370

SYRUP

CHLORPROMAZINE HCL	10MG/5ML	N86712

TABLET

CHLORPROMAZINE HCL	100MG	N84412
CHLORPROMAZINE HCL	10MG	N84414
CHLORPROMAZINE HCL	200MG	N84413
CHLORPROMAZINE HCL	25MG	N84415
CHLORPROMAZINE HCL	50MG	N84411
CHLORPROMAZINE HCL	100MG	N83574
CHLORPROMAZINE HCL	10MG	N83549
CHLORPROMAZINE HCL	200MG	N83575
CHLORPROMAZINE HCL	25MG	N83549
CHLORPROMAZINE HCL	50MG	N83549
CHLORPROMAZINE HCL	100MG	N85752
CHLORPROMAZINE HCL	10MG	N85750
CHLORPROMAZINE HCL	200MG	N85748
CHLORPROMAZINE HCL	25MG	N85751

FDA data supplied by DrugPatentWatch.com

CHLORPROMAZINE HYDROCHLORIDE
TABLET

CHLORPROMAZINE HCL	50MG	N85484
CHLORPROMAZINE HCL	100MG	N84789
CHLORPROMAZINE HCL	10MG	N84803
CHLORPROMAZINE HCL	200MG	N84802
CHLORPROMAZINE HCL	25MG	N84801
CHLORPROMAZINE HCL	50MG	N84800
CHLORPROMAZINE HCL	100MG	N80403
CHLORPROMAZINE HCL	10MG	N80403
CHLORPROMAZINE HCL	200MG	N80403
CHLORPROMAZINE HCL	25MG	N80403
CHLORPROMAZINE HCL	50MG	N80403
CHLORPROMAZINE HCL	200MG	N80340
CHLORPROMAZINE HCL	25MG	N80340
CHLORPROMAZINE HCL	50MG	N80340
CHLORPROMAZINE HCL	100MG	N85331
CHLORPROMAZINE HCL	10MG	N85331
CHLORPROMAZINE HCL	200MG	N85331
CHLORPROMAZINE HCL	25MG	N85331
CHLORPROMAZINE HCL	50MG	N85331
CHLORPROMAZINE HCL	10MG	N88038
CHLORPROMAZINE HCL	25MG	N87645
CHLORPROMAZINE HCL	50MG	N87646
CHLORPROMAZINE HCL	100MG	N85957
CHLORPROMAZINE HCL	10MG	N85959
CHLORPROMAZINE HCL	200MG	N85958
CHLORPROMAZINE HCL	25MG	N85956
CHLORPROMAZINE HCL	50MG	N85960
CHLORPROMAZINE HCL	100MG	N87884
CHLORPROMAZINE HCL	10MG	N87783
CHLORPROMAZINE HCL	200MG	N87880
CHLORPROMAZINE HCL	25MG	N87865
CHLORPROMAZINE HCL	50MG	N87878
PROMAPAR	100MG	N86888
PROMAPAR	10MG	N86886
PROMAPAR	200MG	N86885
PROMAPAR	25MG	N84423
PROMAPAR	50MG	N86887

CHLORPROPAMIDE
TABLET

CHLORPROPAMIDE	100MG	N88812
CHLORPROPAMIDE	100MG	N89446
CHLORPROPAMIDE	250MG	N88813
CHLORPROPAMIDE	250MG	N89447
CHLORPROPAMIDE	100MG	N89561

CHLORPROPAMIDE
TABLET

CHLORPROPAMIDE	250MG	N89562
CHLORPROPAMIDE	100MG	N88918
CHLORPROPAMIDE	250MG	N88919
CHLORPROPAMIDE	250MG	N84669
CHLORPROPAMIDE	100MG	N89321
CHLORPROPAMIDE	250MG	N88662
CHLORPROPAMIDE	100MG	N88840
CHLORPROPAMIDE	250MG	N87353
CHLORPROPAMIDE	100MG	N88694
CHLORPROPAMIDE	250MG	N88695
CHLORPROPAMIDE	100MG	N88768
CHLORPROPAMIDE	100MG	N88708
CHLORPROPAMIDE	250MG	N88709
CHLORPROPAMIDE	100MG	N86865
CHLORPROPAMIDE	100MG	N88608
CHLORPROPAMIDE	250MG	N86866
CHLORPROPAMIDE	250MG	N88568
GLUCAMIDE	250MG	N88641

CHLORPROTHIXENE
CONCENTRATE

TARACTAN	100MG/5ML	N16149

INJECTABLE

TARACTAN	12.5MG/ML	N12487

TABLET

TARACTAN	100MG	N12486
TARACTAN	10MG	N12486
TARACTAN	25MG	N12486
TARACTAN	50MG	N12486

CHLORTETRACYCLINE HYDROCHLORIDE
OINTMENT

AUREOMYCIN	1%	N50404

CHLORTHALIDONE
TABLET

CHLORTHALIDONE	25MG	N87364
CHLORTHALIDONE	50MG	N87384
CHLORTHALIDONE	25MG	N87698
CHLORTHALIDONE	50MG	N87699
CHLORTHALIDONE	25MG	N87451
CHLORTHALIDONE	50MG	N87450
CHLORTHALIDONE	50MG	N87118
CHLORTHALIDONE	25MG	N87292
CHLORTHALIDONE	50MG	N87293
CHLORTHALIDONE	25MG	N87555
CHLORTHALIDONE	25MG	N88164

FDA data supplied by DrugPatentWatch.com

CHLORTHALIDONE
TABLET

CHLORTHALIDONE	50MG	N87176
CHLORTHALIDONE	50MG	N87947
CHLORTHALIDONE	25MG	N87311
CHLORTHALIDONE	50MG	N87312
CHLORTHALIDONE	25MG	N89285
CHLORTHALIDONE	25MG	N89738
CHLORTHALIDONE	50MG	N89286
CHLORTHALIDONE	50MG	N89739
CHLORTHALIDONE	50MG	N89591
CHLORTHALIDONE	25MG	N88139
CHLORTHALIDONE	50MG	N88140
CHLORTHALIDONE	25MG	N87380
CHLORTHALIDONE	50MG	N87381
CHLORTHALIDONE	25MG	N87473
CHLORTHALIDONE	50MG	N87247
CHLORTHALIDONE	50MG	N88651
CHLORTHALIDONE	25MG	N89051
CHLORTHALIDONE	50MG	N89052
CHLORTHALIDONE	25MG	N88012
CHLORTHALIDONE	50MG	N88073
CHLORTHALIDONE	25MG	N87515
CHLORTHALIDONE	50MG	N87516
CHLORTHALIDONE	25MG	N87050
CHLORTHALIDONE	25MG	N87100
CHLORTHALIDONE	25MG	N87296
CHLORTHALIDONE	25MG	N87706
CHLORTHALIDONE	50MG	N87029
CHLORTHALIDONE	50MG	N87082
CHLORTHALIDONE	50MG	N87521
CHLORTHALIDONE	50MG	N87689
HYGROTON	25MG	N12283
HYGROTON	50MG	N12283
THALITONE	25MG	N19574
THALITONE	25MG	N88051

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE
TABLET

CLONIDINE HCL AND CHLORTHALIDONE	15MG;0.1MG	N71179
CLONIDINE HCL AND CHLORTHALIDONE	15MG;0.2MG	N71178
CLONIDINE HCL AND CHLORTHALIDONE	15MG;0.3MG	N71142
COMBIPRES	15MG;0.1MG	N17503
COMBIPRES	15MG;0.2MG	N17503
COMBIPRES	15MG;0.3MG	N17503

CHLORTHALIDONE; METOPROLOL TARTRATE
CAPSULE

LOPRESSIDONE	25MG;100MG	N19451
LOPRESSIDONE	25MG;200MG	N19451

CHLORTHALIDONE; RESERPINE
TABLET

DEMI-REGROTON	25MG;0.125MG	N15103
REGROTON	50MG;0.25MG	N15103

CHLORZOXAZONE
TABLET

CHLORZOXAZONE	250MG	N89592
CHLORZOXAZONE	500MG	N89948
CHLORZOXAZONE	250MG	N86901
CHLORZOXAZONE	250MG	N86948
CHLORZOXAZONE	500MG	N81019
PARAFLEX	250MG	N11300

CHOLESTYRAMINE
BAR, CHEWABLE

CHOLYBAR	EQ 4GM RESIN/BAR	N71621
CHOLYBAR	EQ 4GM RESIN/BAR	N71739

TABLET

QUESTRAN	EQ 1GM RESIN	N73403
QUESTRAN	EQ 800MG RESIN	N73403

CHROMIC CHLORIDE
INJECTABLE

CHROMIC CHLORIDE	EQ 0.004MG CHROMIUM/ML	N19271

CHYMOPAPAIN
INJECTABLE

CHYMODIACTIN	10,000 UNITS/VIAL	* N18663
CHYMODIACTIN	4,000 UNITS/VIAL	N18663
DISCASE	12,500 UNITS/VIAL	N18625

CHYMOTRYPSIN
FOR SOLUTION

ALPHA CHYMAR	750 UNITS/VIAL	N11837
CATARASE	300 UNITS/VIAL	N16938
CATARASE	150 UNITS/VIAL	N18121
ZOLYSE	750 UNITS/VIAL	N11903

CIMETIDINE
SUSPENSION

TAGAMET HB 200	200MG/20ML	N20951

TABLET

CIMETIDINE	100MG	N75122
CIMETIDINE	200MG	N74250
CIMETIDINE	100MG	N74972

FDA data supplied by DrugPatentWatch.com

CIMETIDINE		
TABLET		
CIMETIDINE	300MG	N74361
CIMETIDINE	400MG	N74361
CIMETIDINE	800MG	N74371
TAGAMET HB	100MG	* N20238
CIMETIDINE HYDROCHLORIDE		
SOLUTION		
TAGAMET	EQ 300MG BASE/5ML	N17924
CINOXACIN		
CAPSULE		
CINOBAC	250MG	N18067
CINOBAC	500MG	N18067
CINOXACIN	250MG	N73005
CINOXACIN	500MG	N73006
CIPROFLOXACIN		
INJECTABLE		
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	200MG/100ML	N19858
CISAPRIDE MONOHYDRATE		
SUSPENSION		
PROPULSID	EQ 1MG BASE/ML	N20398
TABLET		
PROPULSID	EQ 10MG BASE	N20210
PROPULSID	EQ 20MG BASE	N20210
TABLET, ORALLY DISINTEGRATING		
PROPULSID QUICKSOLV	EQ 20MG BASE	N20767
CISPLATIN		
INJECTABLE		
PLATINOL-AQ	0.5MG/ML	N18057
CITALOPRAM HYDROBROMIDE		
TABLET		
CELEXA	EQ 60MG BASE	N20822
CITRIC ACID; UREA, C-13		
FOR SOLUTION; TABLET, FOR SOLUTION		
IDKIT:HP	4GM;75MG	N21314
CLARITHROMYCIN		
FOR SUSPENSION		
BIAXIN	187MG/5ML	N50698

CLEMASTINE FUMARATE		
SYRUP		
TAVIST	EQ 0.5MG BASE/5ML	N18675
TABLET		
CLEMASTINE FUMARATE	1.34MG	N73282
TAVIST-1	1.34MG	N17661
TAVIST-1	1.34MG	N17661
CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE		
TABLET, EXTENDED RELEASE		
TAVIST D	EQ 1MG BASE;75MG	N18298
TAVIST-D	1.34MG;75MG	N18298
TAVIST-D	1.34MG;75MG	N20640
CLIDINIUM BROMIDE		
CAPSULE		
QUARZAN	2.5MG	N10355
QUARZAN	5MG	N10355
CLINDAMYCIN HYDROCHLORIDE		
CAPSULE		
CLEOCIN	EQ 150MG BASE	N61809
CLEOCIN	EQ 75MG BASE	N61809
CLINDAMYCIN HCL	EQ 75MG BASE	N63082
CLINDAMYCIN PALMITATE HYDROCHLORIDE		
FOR SOLUTION		
CLEOCIN	EQ 75MG BASE/5ML	N61827
CLINDAMYCIN PHOSPHATE		
CREAM		
CLEOCIN	EQ 2% BASE	N50680
INJECTABLE		
CLEOCIN PHOSPHATE	EQ 150MG BASE/ML	N61839
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62943
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62747
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62928
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62806
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N63068
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N63163
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62908
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62953
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N63041
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N63282
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62905
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62913
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62819
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62852
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N62900

FDA data supplied by DrugPatentWatch.com

CLINDAMYCIN PHOSPHATE		
INJECTABLE		
CLINDAMYCIN PHOSPHATE	EQ 150MG BASE/ML	N63079
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%	EQ 12MG BASE/ML	N50636
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 12MG BASE/ML	N65027
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 18MG BASE/ML	N65027
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 6MG BASE/ML	N65027
SOLUTION		
CLEOCIN T	EQ 1% BASE	N62363
CLINDAMYCIN PHOSPHATE	EQ 1% BASE	N62944
CLINDAMYCIN PHOSPHATE	EQ 1% BASE	N62930
CLIOQUINOL; NYSTATIN		
OINTMENT		
NYSTAFORM	10MG/GM;100,000 UNITS/GM	N50235
CLOFAZIMINE		
CAPSULE		
LAMPRENE	100MG	N19500
CLOFIBRATE		
CAPSULE		
ATROMID-S	500MG	N16099
CLOFIBRATE	500MG	N72191
CLOFIBRATE	500MG	N71603
CLONAZEPAM		
TABLET		
KLONOPIN	0.125MG	N17533
KLONOPIN	0.25MG	N17533
CLONIDINE HYDROCHLORIDE		
TABLET		
CLONIDINE HCL	0.1MG	N70881
CLONIDINE HCL	0.2MG	N70882
CLONIDINE HCL	0.3MG	N70883
CLONIDINE HCL	0.1MG	N71103
CLONIDINE HCL	0.2MG	N71102
CLONIDINE HCL	0.3MG	N71101
CLONIDINE HCL	0.2MG	N70924
CLONIDINE HCL	0.3MG	N70923
CLONIDINE HCL	0.1MG	N71252
CLONIDINE HCL	0.2MG	N71253
CLONIDINE HCL	0.3MG	N71254
CLONIDINE HCL	0.1MG	N70461
CLONIDINE HCL	0.2MG	N70460
CLONIDINE HCL	0.3MG	N70459

CLONIDINE HYDROCHLORIDE		
TABLET		
CLONIDINE HCL	0.1MG	N70747
CLONIDINE HCL	0.2MG	N70702
CLONIDINE HCL	0.3MG	N70659
CLONIDINE HCL	0.1MG	N72138
CLONIDINE HCL	0.2MG	N72139
CLONIDINE HCL	0.3MG	N72140
CLONIDINE HCL	0.1MG	N70395
CLONIDINE HCL	0.2MG	N70396
CLONIDINE HCL	0.3MG	N70397
CLORAZEPATE DIPOTASSIUM		
CAPSULE		
CLORAZEPATE DIPOTASSIUM	15MG	N71779
CLORAZEPATE DIPOTASSIUM	3.75MG	N71777
CLORAZEPATE DIPOTASSIUM	7.5MG	N71778
CLORAZEPATE DIPOTASSIUM	15MG	N71431
CLORAZEPATE DIPOTASSIUM	3.75MG	N71429
CLORAZEPATE DIPOTASSIUM	7.5MG	N71430
CLORAZEPATE DIPOTASSIUM	15MG	N71744
CLORAZEPATE DIPOTASSIUM	3.75MG	N71742
CLORAZEPATE DIPOTASSIUM	7.5MG	N71743
CLORAZEPATE DIPOTASSIUM	15MG	N71729
CLORAZEPATE DIPOTASSIUM	3.75MG	N71727
CLORAZEPATE DIPOTASSIUM	7.5MG	N71728
CLORAZEPATE DIPOTASSIUM	15MG	N71926
CLORAZEPATE DIPOTASSIUM	3.75MG	N71924
CLORAZEPATE DIPOTASSIUM	7.5MG	N71925
CLORAZEPATE DIPOTASSIUM	15MG	N71522
CLORAZEPATE DIPOTASSIUM	3.75MG	N71549
CLORAZEPATE DIPOTASSIUM	7.5MG	N71550
CLORAZEPATE DIPOTASSIUM	15MG	N71244
CLORAZEPATE DIPOTASSIUM	3.75MG	N71242
CLORAZEPATE DIPOTASSIUM	7.5MG	N71243
CLORAZEPATE DIPOTASSIUM	15MG	N71776
CLORAZEPATE DIPOTASSIUM	3.75MG	N71774
CLORAZEPATE DIPOTASSIUM	7.5MG	N71775
CLORAZEPATE DIPOTASSIUM	15MG	N71860
CLORAZEPATE DIPOTASSIUM	3.75MG	N71878
CLORAZEPATE DIPOTASSIUM	7.5MG	N71879
TRANXENE	15MG	N17105
TRANXENE	3.75MG	N17105
TRANXENE	7.5MG	N17105
TABLET		
CLORAZEPATE DIPOTASSIUM	15MG	N71749
CLORAZEPATE DIPOTASSIUM	3.75MG	N71747

FDA data supplied by DrugPatentWatch.com

CLORAZEPATE DIPOTASSIUM
TABLET

CLORAZEPATE DIPOTASSIUM	7.5MG	N71748
CLORAZEPATE DIPOTASSIUM	15MG	N72015
CLORAZEPATE DIPOTASSIUM	3.75MG	N72013
CLORAZEPATE DIPOTASSIUM	7.5MG	N72014
CLORAZEPATE DIPOTASSIUM	15MG	N72332
CLORAZEPATE DIPOTASSIUM	3.75MG	N72330
CLORAZEPATE DIPOTASSIUM	7.5MG	N72331
CLORAZEPATE DIPOTASSIUM	15MG	N71702
CLORAZEPATE DIPOTASSIUM	3.75MG	N71730
CLORAZEPATE DIPOTASSIUM	7.5MG	N71731
CLORAZEPATE DIPOTASSIUM	3.75MG	N72512
CLORAZEPATE DIPOTASSIUM	15MG	N71830
CLORAZEPATE DIPOTASSIUM	3.75MG	N71828
CLORAZEPATE DIPOTASSIUM	7.5MG	N71829

CLOTRIMAZOLE
TABLET

MYCELEX-G	500MG	N19069

CLOXACILLIN SODIUM
CAPSULE

CLOXACILLIN SODIUM	EQ 250MG BASE	N61452
CLOXACILLIN SODIUM	EQ 500MG BASE	N61452
CLOXAPEN	EQ 250MG BASE	N62233
CLOXAPEN	EQ 500MG BASE	N62233

FOR SOLUTION

CLOXACILLIN SODIUM	EQ 125MG BASE/5ML	N62978
TEGOPEN	EQ 125MG BASE/5ML	N50192
TEGOPEN	EQ 125MG BASE/5ML	N61453

CLOZAPINE
TABLET

CLOZAPINE	100MG	N74546
CLOZAPINE	25MG	N74546

COBALT CHLORIDE, CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN, CO-60; INTRINSIC FACTOR
N/A

RUBRATOPE-60 KIT	N/A	N16090

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE
SYRUP

PHENERGAN VC W/ CODEINE	10MG/5ML;5MG/5ML;6.25MG/5ML	N08306
PHERAZINE VC W/ CODEINE	10MG/5ML;5MG/5ML;6.25MG/5ML	N88870
PROMETHAZINE VC W/ CODEINE	10MG/5ML;5MG/5ML;6.25MG/5ML	N88816

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE
SYRUP

PHENERGAN W/ CODEINE	10MG/5ML;6.25MG/5ML	N08306
PHERAZINE W/ CODEINE	10MG/5ML;6.25MG/5ML	N88739
PROMETHAZINE W/ CODEINE	10MG/5ML;6.25MG/5ML	N88814

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
SYRUP

ACTIFED W/ CODEINE	10MG/5ML;30MG/5ML;1.25 MG/5ML	N12575
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE	10MG/5ML;30MG/5ML;1.25 MG/5ML	N89018

COLCHICINE; PROBENECID
TABLET

COLBENEMID	0.5MG;500MG	*N12383
PROBEN-C	0.5MG;500MG	N85552
PROBENECID AND COLCHICINE	0.5MG;500MG	N84321
PROBENECID AND COLCHICINE	0.5MG;500MG	N86130
PROBENECID AND COLCHICINE	0.5MG;500MG	N83720
PROBENECID W/ COLCHICINE	0.5MG;500MG	N86954
PROBENECID W/ COLCHICINE	0.5MG;500MG	N83221

COLESEVELAM HYDROCHLORIDE
CAPSULE

WELCHOL	375MG	N21141

COLISTIN SULFATE
SUSPENSION

COLY-MYCIN S	EQ 25MG BASE/5ML	N50355

COPPER
INTRAUTERINE DEVICE

CU-7	89MG	N17408
TATUM-T	120MG	N18205

CORTICOTROPIN
INJECTABLE

ACTH	25 UNITS/VIAL	N08317
ACTH	40 UNITS/VIAL	N08317
ACTHAR	25 UNITS/VIAL	N07504
ACTHAR	40 UNITS/VIAL	N07504
CORTICOTROPIN	40 UNITS/ML	N10831
CORTICOTROPIN	80 UNITS/ML	N10831
CORTICOTROPIN	40 UNITS/VIAL	N88772
H.P. ACTHAR GEL	40 UNITS/ML	N08372
PURIFIED CORTROPHIN GEL	40 UNITS/ML	N08975
PURIFIED CORTROPHIN GEL	80 UNITS/ML	N08975

FDA data supplied by DrugPatentWatch.com

CORTICOTROPIN-ZINC HYDROXIDE		
INJECTABLE		
CORTROPHIN-ZINC	40 UNITS/ML	N09854
CORTISONE ACETATE		
INJECTABLE		
CORTISONE ACETATE	25MG/ML	N08126
CORTISONE ACETATE	25MG/ML	N83147
CORTISONE ACETATE	25MG/ML	N85677
CORTISONE ACETATE	50MG/ML	N83147
CORTISONE ACETATE	50MG/ML	N85677
CORTONE	25MG/ML	N07110
CORTONE	50MG/ML	N07110
TABLET		
CORTISONE ACETATE	25MG	N83471
CORTISONE ACETATE	25MG	N80836
CORTISONE ACETATE	25MG	N84246
CORTISONE ACETATE	25MG	N85736
CORTISONE ACETATE	25MG	N09458
CORTISONE ACETATE	25MG	N80731
CORTISONE ACETATE	25MG	N80630
CORTISONE ACETATE	25MG	N83536
CORTISONE ACETATE	25MG	N80694
CORTISONE ACETATE	25MG	N08284
CORTISONE ACETATE	5MG	N08284
CORTISONE ACETATE	25MG	N80493
CORTISONE ACETATE	25MG	N80333
CORTISONE ACETATE	25MG	N85884
CORTISONE ACETATE	25MG	N80341
CORTONE	25MG	N07750
CROMOLYN SODIUM		
CAPSULE		
GASTROCROM	100MG	N19188
INTAL	20MG	N16990
SOLUTION/DROPS		
CROMOPTIC	4%	N75088
CRYPTENAMINE ACETATES		
INJECTABLE		
UNITENSEN	260CSR UNIT/ML	N08814
CRYPTENAMINE TANNATES		
TABLET		
UNITENSEN	260CSR UNIT	N09217
CUPRIC SULFATE		
INJECTABLE		
CUPRIC SULFATE	EQ 0.4MG COPPER/ML	N19350

CYANOCOBALAMIN		
INJECTABLE		
BERUBIGEN	1MG/ML	N06798
BETALIN 12	0.1MG/ML	N80855
BETALIN 12	1MG/ML	N80855
COBAVITE	0.1MG/ML	N83013
COBAVITE	1MG/ML	N83064
CYANOCOBALAMIN	1MG/ML	N87969
CYANOCOBALAMIN	0.03MG/ML	N80510
CYANOCOBALAMIN	0.1MG/ML	N80510
CYANOCOBALAMIN	1MG/ML	N80510
CYANOCOBALAMIN	1MG/ML	N83075
CYANOCOBALAMIN	1MG/ML	N80564
CYANOCOBALAMIN	1MG/ML	N80515
CYANOCOBALAMIN	0.03MG/ML	N80689
CYANOCOBALAMIN	0.1MG/ML	N80689
CYANOCOBALAMIN	1MG/ML	N80689
CYANOCOBALAMIN	0.03MG/ML	N80668
CYANOCOBALAMIN	1MG/ML	N87551
CYANOCOBALAMIN	0.1MG/ML	N83120
CYANOCOBALAMIN	1MG/ML	N83120
CYANOCOBALAMIN	1MG/ML	N07085
CYANOCOBALAMIN	0.1MG/ML	N80554
CYANOCOBALAMIN	1MG/ML	N80554
REDISOL	1MG/ML	N06668
RUBIVITE	0.03MG/ML	N10791
RUBIVITE	0.05MG/ML	N10791
RUBIVITE	0.12MG/ML	N10791
RUBIVITE	0.1MG/ML	N10791
RUBIVITE	1MG/ML	N10791
RUBRAMIN PC	0.1MG/ML	N06799
RUBRAMIN PC	1MG/ML	* N06799
RUVITE	1MG/ML	N80570
VI-TWEL	1MG/ML	N07012
TABLET		
CYANOCOBALAMIN	1MG	N84264
CYANOCOBALAMIN, CO-60		
CAPSULE		
RUBRATOPE-60	0.5-1uCi	N16090
CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; CYANOCOBALAMIN, CO-58		
N/A		
DICOPAC KIT	N/A;N/A;N/A	N17406
CYANOCOBALAMIN; CYANOCOBALAMIN, CO-57; INTRINSIC FACTOR		
N/A		
CYANOCOBALAMIN CO 57 SCHILLING TEST KIT	0.1MG;0.5uCi;60MG	N16635

FDA data supplied by DrugPatentWatch.com

CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE		
INJECTABLE		
DEPINAR	0.5MG/ML;2.3MG/ML;1MG/ML	N11208
CYCLACILLIN		
FOR SUSPENSION		
CYCLAPEN-W	125MG/5ML	N50508
CYCLAPEN-W	250MG/5ML	N50508
CYCLAPEN-W	500MG/5ML	N50508
TABLET		
CYCLACILLIN	250MG	N62895
CYCLACILLIN	500MG	N62895
CYCLAPEN-W	250MG	N50509
CYCLAPEN-W	500MG	N50509
CYCLIZINE LACTATE		
INJECTABLE		
MAREZINE	50MG/ML	N09495
CYCLOPENTOLATE HYDROCHLORIDE		
SOLUTION/DROPS		
AK-PENTOLATE	1%	N85555
CYCLOPENTOLATE HCL	1%	N84150
CYCLOPENTOLATE HCL	1%	N84863
PENTOLAIR	0.5%	N88643
PENTOLAIR	1%	N88150
CYCLOPHOSPHAMIDE		
INJECTABLE		
CYTOXAN	100MG/VIAL	N12142
CYTOXAN	1GM/VIAL	N12142
CYTOXAN	200MG/VIAL	N12142
CYTOXAN	2GM/VIAL	N12142
CYTOXAN	500MG/VIAL	N12142
NEOSAR	100MG/VIAL	N40015
NEOSAR	1GM/VIAL	N40015
NEOSAR	200MG/VIAL	N40015
NEOSAR	2GM/VIAL	N40015
NEOSAR	500MG/VIAL	N40015
CYCLOSPORINE		
CAPSULE		
NEORAL	50MG	*N50715
CYCLOTHIAZIDE		
TABLET		
ANHYDRON	2MG	N13157
FLUIDIL	2MG	N18173
CYCRIMINE HYDROCHLORIDE		
TABLET		
PAGITANE	1.25MG	N08951
PAGITANE	2.5MG	N08951
CYPROHEPTADINE HYDROCHLORIDE		
SYRUP		
CYPROHEPTADINE HCL	2MG/5ML	N89199
CYPROHEPTADINE HCL	2MG/5ML	N87001
CYPROHEPTADINE HCL	2MG/5ML	N89021
TABLET		
CYPROHEPTADINE HCL	4MG	N88798
CYPROHEPTADINE HCL	4MG	N87685
CYPROHEPTADINE HCL	4MG	N88232
CYPROHEPTADINE HCL	4MG	N89057
CYPROHEPTADINE HCL	4MG	N86737
CYPROHEPTADINE HCL	4MG	N87566
CYPROHEPTADINE HCL	4MG	N86678
CYPROHEPTADINE HCL	4MG	N87839
CYPROHEPTADINE HCL	4MG	N86808
CYPROHEPTADINE HCL	4MG	N87405
CYPROHEPTADINE HCL	4MG	N87284
CYPROHEPTADINE HCL	4MG	N85245
CYPROHEPTADINE HCL	4MG	N86165
CYPROHEPTADINE HCL	4MG	N86580
PERIACTIN	4MG	*N12649
CYSTEINE HYDROCHLORIDE		
INJECTABLE		
CYSTEINE HCL	7.25%	N19523
CYTARABINE		
INJECTABLE		
CYTARABINE	100MG/VIAL	N16793
CYTARABINE	1GM/VIAL	N16793
CYTARABINE	2GM/VIAL	N16793
CYTARABINE	500MG/VIAL	N16793
DACARBAZINE		
INJECTABLE		
DACARBAZINE	100MG/VIAL	N70962
DACARBAZINE	200MG/VIAL	N70990
DALFOPRISTIN; QUINUPRISTIN		
INJECTABLE		
SYNERCID	420MG/VIAL;180MG/VIAL	N50748
DANAPAROID SODIUM		
INJECTABLE		
ORGARAN	750 UNITS/0.6ML	N20430

FDA data supplied by DrugPatentWatch.com

DANAZOL		
CAPSULE		
DANAZOL	200MG	N71569
DAUNORUBICIN HYDROCHLORIDE		
INJECTABLE		
CERUBIDINE	EQ 20MG BASE/VIAL	N61876
CERUBIDINE	EQ 20MG BASE/VIAL	N50484
DECAMETHONIUM BROMIDE		
INJECTABLE		
SYNCURINE	1MG/ML	N06931
DEMECARIUM BROMIDE		
SOLUTION/DROPS		
HUMORSOL	0.125%	N11860
HUMORSOL	0.25%	N11860
DEMECLOCYCLINE HYDROCHLORIDE		
CAPSULE		
DECLOMYCIN	150MG	N50262
SYRUP		
DECLOMYCIN	75MG/5ML	N50257
TABLET		
DECLOMYCIN	75MG	N50261
DESERPIDINE		
TABLET		
HARMONYL	0.1MG	N10796
HARMONYL	0.25MG	N10796
DESERPIDINE; HYDROCHLOROTHIAZIDE		
TABLET		
ORETICYL 25	0.125MG;25MG	N12148
ORETICYL 50	0.125MG;50MG	N12148
ORETICYL FORTE	0.25MG;25MG	N12148
DESERPIDINE; METHYCLOTHIAZIDE		
TABLET		
METHYCLOTHIAZIDE AND DESERPIDINE	0.25MG;5MG	N88486
METHYCLOTHIAZIDE AND DESERPIDINE	0.5MG;5MG	N88452
DESIPRAMINE HYDROCHLORIDE		
CAPSULE		
PERTOFRANE	25MG	N13621
PERTOFRANE	50MG	N13621
TABLET		
DESIPRAMINE HCL	100MG	N71867
DESIPRAMINE HCL	25MG	N71864
DESIPRAMINE HCL	50MG	N71865
DESIPRAMINE HCL	75MG	N71866
DESLANOSIDE		
INJECTABLE		
CEDILANID-D	0.2MG/ML	N09282
DESMOPRESSIN ACETATE		
SOLUTION		
CONCENTRAID	0.01%	N19776
SPRAY, METERED		
DDAVP	0.01MG/SPRAY	N17922
DESOGESTREL; ETHINYL ESTRADIOL		
TABLET		
DESOGEN	0.15MG;0.03MG	N20071
ORTHO-CEPT	0.15MG;0.03MG	N20301
DESOXIMETASONE		
OINTMENT		
DESOXIMETASONE	0.25%	N73440
TOPICORT	0.05%	N18594
DESOXYCORTICOSTERONE ACETATE		
INJECTABLE		
DOCA	5MG/ML	N01104
PELLET		
PERCORTEN	125MG	N05151
DESOXYCORTICOSTERONE PIVALATE		
INJECTABLE		
PERCORTEN	25MG/ML	N08822
DEXAMETHASONE		
AEROSOL		
AEROSEB-DEX	0.01%	N83296
DECASPRAY	0.04%	N12731
ELIXIR		
DECADRON	0.5MG/5ML	N12376
DEXAMETHASONE	0.5MG/5ML	N88997
GEL		
DECADERM	0.1%	N13538
SUSPENSION/DROPS		
DEXAMETHASONE	0.1%	N89170
TABLET		
DEXAMETHASONE	0.25MG	N84013
DEXAMETHASONE	0.25MG	N84764
DEXAMETHASONE	0.5MG	N84084
DEXAMETHASONE	0.5MG	N84766
DEXAMETHASONE	0.75MG	N84081
DEXAMETHASONE	0.75MG	N84765
DEXAMETHASONE	1.5MG	N84086
DEXAMETHASONE	1.5MG	N84763
DEXAMETHASONE	0.75MG	N85376

FDA data supplied by DrugPatentWatch.com

DEXAMETHASONE

TABLET

DEXAMETHASONE	0.75MG	N83806
DEXAMETHASONE	0.75MG	N83420
DEXAMETHASONE	0.25MG	N84614
DEXAMETHASONE	0.75MG	N80399
DEXAMETHASONE	0.75MG	N87534
DEXAMETHASONE	1.5MG	N87533
DEXAMETHASONE	0.25MG	N85455
DEXAMETHASONE	0.5MG	N85458
DEXAMETHASONE	0.75MG	N80968
DEXAMETHASONE	0.75MG	N84457
DEXAMETHASONE	0.75MG	N85818
DEXAMETHASONE	1.5MG	N85456
DEXAMETHASONE	1.5MG	N85840
DEXAMETHASONE	0.75MG	N84327
DEXONE 0.5	0.5MG	N84991
DEXONE 0.75	0.75MG	N84993
DEXONE 1.5	1.5MG	N84990
DEXONE 4	4MG	N84992
HEXADROL	0.5MG	N12675
HEXADROL	0.75MG	N12675
HEXADROL	1.5MG	N12675

DEXAMETHASONE ACETATE

INJECTABLE

DECADRON-LA	EQ 8MG BASE/ML	N16675
DEXAMETHASONE ACETATE	EQ 16MG BASE/ML	N87711
DEXAMETHASONE ACETATE	EQ 8MG BASE/ML	N84315

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL

DEXACORT	EQ 0.1MG PHOSPHATE/INH	N14242

AEROSOL, METERED

DEXACORT	EQ 0.1MG PHOSPHATE/INH	N13413

CREAM

DECADRON	EQ 0.1% PHOSPHATE	N11983

INJECTABLE

DECADRON	EQ 24MG PHOSPHATE/ML	*N12071
DECADRON	EQ 4MG PHOSPHATE/ML	*N12071
DEXACEN-4	EQ 4MG PHOSPHATE/ML	N84342
DEXAMETHASONE	EQ 10MG PHOSPHATE/ML	N88469
DEXAMETHASONE	EQ 4MG PHOSPHATE/ML	N88448
DEXAMETHASONE SODIUM PHOSPHATE	EQ 4MG PHOSPHATE/ML	N84493
DEXAMETHASONE SODIUM PHOSPHATE	EQ 4MG PHOSPHATE/ML	N87065
DEXAMETHASONE SODIUM PHOSPHATE	EQ 4MG PHOSPHATE/ML	N84752

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE

DEXAMETHASONE SODIUM PHOSPHATE	EQ 4MG PHOSPHATE/ML	N83161
DEXAMETHASONE SODIUM PHOSPHATE	EQ 4MG PHOSPHATE/ML	N81125
DEXAMETHASONE SODIUM PHOSPHATE	EQ 20MG PHOSPHATE/ML	N88522
DEXAMETHASONE SODIUM PHOSPHATE	EQ 10MG PHOSPHATE/ML	N87668
DEXAMETHASONE SODIUM PHOSPHATE	EQ 24MG PHOSPHATE/ML	N85606
DEXAMETHASONE SODIUM PHOSPHATE	EQ 4MG PHOSPHATE/ML	N83702
DEXAMETHASONE SODIUM PHOSPHATE	EQ 4MG PHOSPHATE/ML	N84355
DEXAMETHASONE SODIUM PHOSPHATE	EQ 4MG PHOSPHATE/ML	N89169
DEXAMETHASONE SODIUM PHOSPHATE	EQ 4MG PHOSPHATE/ML	N85641
HEXADROL	EQ 10MG PHOSPHATE/ML	*N14694
HEXADROL	EQ 20MG PHOSPHATE/ML	N14694
HEXADROL	EQ 4MG PHOSPHATE/ML	*N14694

OINTMENT

DECADRON	EQ 0.05% PHOSPHATE	N11977
DEXAIR	EQ 0.05% PHOSPHATE	N88071
MAXIDEX	EQ 0.05% PHOSPHATE	N83342

SOLUTION/DROPS

DEXAIR	EQ 0.1% PHOSPHATE	N88433
DEXAMETHASONE SODIUM PHOSPHATE	EQ 0.1% PHOSPHATE	N84855
DEXAMETHASONE SODIUM PHOSPHATE	EQ 0.1% PHOSPHATE	N84170
DEXAMETHASONE SODIUM PHOSPHATE	EQ 0.1% PHOSPHATE	N84173

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE

DECADRON W/ XYLOCAINE	EQ 4MG PHOSPHATE/ML;10MG/ML	N13334

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

OINTMENT

NEODECADRON	EQ 0.05% PHOSPHATE;EQ 3.5MG BASE/GM	N50324

SOLUTION/DROPS

NEODECADRON	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N50322
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N64055
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N62714
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N62539

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT

DEXACIDIN	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62566

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT		
DEXASPORIN	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62411
SUSPENSION/DROPS		
DEXASPORIN	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62428

DEXBROMPHENIRAMINE MALEATE

SYRUP		
DISOMER	2MG/5ML	N11814
TABLET		
DISOMER	2MG	N11814

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET		
DISOPHROL	2MG;60MG	N12394
TABLET, EXTENDED RELEASE		
BROMPHERIL	6MG;120MG	N89116
DISOBROM	6MG;120MG	N70770
RESPORAL	6MG;120MG	N89139

DEXCHLORPHENIRAMINE MALEATE

SYRUP		
POLARAMINE	2MG/5ML	N86837
TABLET		
POLARAMINE	2MG	N86835

DEXTROAMPHETAMINE SULFATE

CAPSULE		
DEXAMPEX	15MG	N85355
ELIXIR		
DEXEDRINE	5MG/5ML	N83902
TABLET		
DEXAMPEX	10MG	N83735
DEXAMPEX	5MG	N83735
DEXTROAMPHETAMINE SULFATE	10MG	N83930
DEXTROAMPHETAMINE SULFATE	10MG	N83903
DEXTROAMPHETAMINE SULFATE	15MG	*N85652
DEXTROAMPHETAMINE SULFATE	5MG	N83903
DEXTROAMPHETAMINE SULFATE	5MG	N86521
DEXTROAMPHETAMINE SULFATE	5MG	N84125
DEXTROAMPHETAMINE SULFATE	10MG	N85371
DEXTROAMPHETAMINE SULFATE	5MG	N85370
DEXTROAMPHETAMINE SULFATE	10MG	N85892
DEXTROAMPHETAMINE SULFATE	5MG	N84986
FERNDEX	5MG	N84001

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP		
PHENERGAN W/ DEXTROMETHORPHAN	15MG/5ML;6.25MG/5ML	N11265
PHERAZINE DM	15MG/5ML;6.25MG/5ML	N88913

DEXTROSE

INJECTABLE		
DEXTROSE 10% IN PLASTIC CONTAINER	10GM/100ML	N18504
DEXTROSE 2.5% IN PLASTIC CONTAINER	2.5GM/100ML	N19626
DEXTROSE 38.5% IN PLASTIC CONTAINER	38.5GM/100ML	N18923
DEXTROSE 50% IN PLASTIC CONTAINER	500MG/ML	N19445
DEXTROSE 60%	60GM/100ML	N17995
DEXTROSE 60% IN PLASTIC CONTAINER	60GM/100ML	N17995
DEXTROSE 60% IN PLASTIC CONTAINER	60GM/100ML	N20047
DEXTROSE 7.7% IN PLASTIC CONTAINER	7.7GM/100ML	N19626

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE		
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER	5GM/100ML;37MG/100ML	N19699
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER	5GM/100ML;75MG/100ML	N19699
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER	5GM/100ML;110MG/100ML	N19699
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER	5GM/100ML;220MG/100ML	N19699

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE		
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%	5GM/100ML;75MG/100ML;200MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER	5GM/100ML;150MG/100ML;200MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER	5GM/100ML;220MG/100ML;200MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	5GM/100ML;300MG/100ML;200MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER	5GM/100ML;75MG/100ML;330MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER	5GM/100ML;150MG/100ML;330MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER	5GM/100ML;220MG/100ML;330MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER	5GM/100ML;300MG/100ML;330MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%	5GM/100ML;75MG/100ML;450MG/100ML	N18268

FDA data supplied by DrugPatentWatch.com

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER	5GM/100ML;150MG/100ML; 450MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER	5GM/100ML;220MG/100ML; 450MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	5GM/100ML;300MG/100ML; 450MG/100ML	N18268
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER	5GM/100ML;224MG/100ML; 450MG/100ML	N18008
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER	5GM/100ML;300MG/100ML; 450MG/100ML	N18008
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER	5GM/100ML;75MG/100ML;450MG/100ML	N18008

DEXTROSE; SODIUM CHLORIDE

INJECTABLE

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	10GM/100ML;200MG/100ML	N18386
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	10GM/100ML;450MG/100ML	N18229
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	10GM/100ML;900MG/100ML	N18047
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	2.5GM/100ML;450MG/100ML	N18030
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	2.5GM/100ML;900MG/100ML	N18376
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	3.3GM/100ML;300MG/100ML	N18055
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER	5GM/100ML;110MG/100ML	N18030
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	5GM/100ML;200MG/100ML	N18030
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	5GM/100ML;200MG/100ML	N18399
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER	5GM/100ML;225MG/100ML	N19482
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	5GM/100ML;300MG/100ML	N19486
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	5GM/100ML;300MG/100ML	N18501
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER	5GM/100ML;330MG/100ML	N18030
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	5GM/100ML;450MG/100ML	N19484
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	5GM/100ML;450MG/100ML	N18030

DEXTROSE; SODIUM CHLORIDE

INJECTABLE

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	5GM/100ML;450MG/100ML	N18400
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	5GM/100ML;900MG/100ML	N19483
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	5GM/100ML;900MG/100ML	N18026
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	5GM/100ML;900MG/100ML	N18500

DEXTROTHYROXINE SODIUM

TABLET

CHOLOXIN	1MG	N12302
CHOLOXIN	2MG	N12302
CHOLOXIN	4MG	N12302
CHOLOXIN	6MG	N12302

DEZOCINE

INJECTABLE

DALGAN	10MG/ML	N19082
DALGAN	15MG/ML	N19082
DALGAN	5MG/ML	N19082

DIATRIZOATE MEGLUMINE

INJECTABLE

ANGIOVIST 282	60%	N87726
CARDIOGRAFIN	85%	N11620
DIATRIZOATE MEGLUMINE	76%	N10040
UROVIST MEGLUMINE DIU/CT	30%	N87739

SOLUTION

UROVIST CYSTO	30%	N87729
UROVIST CYSTO PEDIATRIC	30%	N87731

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE

ANGIOVIST 292	52%;8%	N87724
ANGIOVIST 370	66%;10%	N87723
DIATRIZOATE-60	52%;8%	N88166
HYPAQUE-M,75%	50%;25%	N10220
HYPAQUE-M,90%	60%;30%	N10220
MD-60	52%;8%	N87074
MD-76	66%;10%	N87073
RENOVIST	34.3%;35%	N10040
RENOVIST II	28.5%;29.1%	N10040

SOLUTION

GASTROVIST	66%;10%	N87728

DIATRIZOATE SODIUM

INJECTABLE

HYPAQUE	25%	N09561

FDA data supplied by DrugPatentWatch.com

DIATRIZOATE SODIUM		
INJECTABLE		
MD-50	50%	N87075
UROVIST SODIUM 300	50%	N87725
SOLUTION		
HYPAQUE	40%	N11386
HYPAQUE SODIUM 20%	20%	N09561
DIAZEPAM		
CAPSULE, EXTENDED RELEASE		
VALRELEASE	15MG	N18179
INJECTABLE		
DIAZEPAM	5MG/ML	N70662
DIAZEPAM	5MG/ML	N71308
DIAZEPAM	5MG/ML	N70311
DIAZEPAM	5MG/ML	N70312
DIAZEPAM	5MG/ML	N70313
DIAZEPAM	5MG/ML	N72371
DIAZEPAM	5MG/ML	N70911
DIAZEPAM	5MG/ML	N70912
DIAZEPAM	5MG/ML	N70930
DIAZEPAM	5MG/ML	* N20124
DIAZEPAM	5MG/ML	N71613
DIAZEPAM	5MG/ML	N71614
DIZAC	5MG/ML	N19287
VALIUM	5MG/ML	N16087
TABLET		
DIAZEPAM	10MG	N70228
DIAZEPAM	5MG	N70227
DIAZEPAM	10MG	N70896
DIAZEPAM	2MG	N70894
DIAZEPAM	5MG	N70895
DIAZEPAM	10MG	N70905
DIAZEPAM	2MG	N70903
DIAZEPAM	5MG	N70904
DIAZEPAM	10MG	N70956
DIAZEPAM	2MG	N70987
DIAZEPAM	5MG	N70996
DIAZEPAM	10MG	N70362
DIAZEPAM	2MG	N70360
DIAZEPAM	5MG	N70361
DIAZEPAM	10MG	N72402
DIAZEPAM	10MG	N70776
DIAZEPAM	2MG	N70787
DIAZEPAM	5MG	N70788
DIAZEPAM	10MG	N70358
DIAZEPAM		
TABLET		
DIAZEPAM	2MG	N70356
DIAZEPAM	5MG	N70357
DIAZEPAM	10MG	N70222
DIAZEPAM	2MG	N70209
DIAZEPAM	5MG	N70210
DIAZEPAM	10MG	N70458
DIAZEPAM	2MG	N70456
DIAZEPAM	5MG	N70457
Q-PAM	10MG	N70425
Q-PAM	10MG	N72433
Q-PAM	2MG	N70423
Q-PAM	2MG	N72431
Q-PAM	5MG	N70424
Q-PAM	5MG	N72432
DIAZOXIDE		
CAPSULE		
PROGLYCEM	100MG	N17425
PROGLYCEM	50MG	N17425
INJECTABLE		
DIAZOXIDE	15MG/ML	N71519
DIBUCAINE HYDROCHLORIDE		
INJECTABLE		
HEAVY SOLUTION NUPERCAINE	2.5MG/ML	N06203
DICHLORPHENAMIDE		
TABLET		
DARANIDE	50MG	N11366
DICLOFENAC POTASSIUM		
TABLET		
CATAFLAM	25MG	* N20142
DICLOFENAC SODIUM		
SOLUTION/DROPS		
DICLOFENAC SODIUM	0.1%	N20809
DICLOXACILLIN SODIUM		
CAPSULE		
DYCILL	EQ 250MG BASE	N60254
DYCILL	EQ 250MG BASE	N62238
DYCILL	EQ 500MG BASE	N60254
DYCILL	EQ 500MG BASE	N62238
PATHOCIL	EQ 250MG BASE	N50011
PATHOCIL	EQ 500MG BASE	N50011
FOR SUSPENSION		
DYNAPEN	EQ 62.5MG BASE/5ML	N50337
PATHOCIL	EQ 62.5MG BASE/5ML	N50092

FDA data supplied by DrugPatentWatch.com

DICUMAROL		
CAPSULE		
DICUMAROL	25MG	N05509
DICUMAROL	50MG	N05509
TABLET		
DICUMAROL	100MG	N05545
DICUMAROL	25MG	N05545
DICUMAROL	50MG	N05545
DICYCLOMINE HYDROCHLORIDE		
CAPSULE		
DICYCLOMINE HCL	10MG	N84505
DICYCLOMINE HCL	10MG	N89361
DICYCLOMINE HCL	10MG	N83179
INJECTABLE		
DICYCLOMINE HCL	10MG/ML	N80614
SYRUP		
DICYCLOMINE HCL	10MG/5ML	N84479
TABLET		
DICYCLOMINE HCL	20MG	N84600
DICYCLOMINE HCL	20MG	N88585
DICYCLOMINE HCL	20MG	N84361
DIDANOSINE		
FOR SOLUTION		
VIDEX	375MG/PACKET	N20155
DIENESTROL		
CREAM		
DIENESTROL	0.01%	N06110
DV	0.01%	N83518
ESTRAGUARD	0.01%	N84436
SUPPOSITORY		
DV	0.7MG	N83517
DIETHYLCARBAMAZINE CITRATE		
TABLET		
HETRAZAN	50MG	N06459
DIETHYLPROPION HYDROCHLORIDE		
TABLET		
DIETHYLPROPION HCL	25MG	N85544
DIETHYLPROPION HCL	25MG	N85916
DIETHYLPROPION HCL	25MG	N88642
DIETHYLPROPION HCL	25MG	N85741
TENUATE	25MG	N17668
TEPANIL	25MG	N11673
TABLET, EXTENDED RELEASE		
TENUATE	75MG	N17669
DIETHYLPROPION HYDROCHLORIDE		
TABLET, EXTENDED RELEASE		
TEPANIL TEN-TAB	75MG	N17956
DIETHYLSTILBESTROL		
INJECTABLE		
STILBESTROL	0.2MG/ML	N04056
STILBESTROL	0.5MG/ML	N04056
STILBESTROL	1MG/ML	N04056
STILBESTROL	5MG/ML	N04056
SUPPOSITORY		
DIETHYLSTILBESTROL	0.1MG	N04040
DIETHYLSTILBESTROL	0.5MG	N04040
STILBESTROL	0.1MG	N04056
STILBESTROL	0.5MG	N04056
TABLET		
DIETHYLSTILBESTROL	0.1MG	N04041
DIETHYLSTILBESTROL	0.5MG	N04041
DIETHYLSTILBESTROL	1MG	N04041
DIETHYLSTILBESTROL	5MG	N04041
STILBESTROL	0.5MG	N83004
STILBESTROL	1MG	N83002
STILBESTROL	5MG	N83006
STILBETIN	0.1MG	N04056
STILBETIN	0.25MG	N04056
STILBETIN	0.5MG	N04056
STILBETIN	1MG	N04056
STILBETIN	5MG	N04056
TABLET, DELAYED RELEASE		
DIETHYLSTILBESTROL	0.1MG	N04039
DIETHYLSTILBESTROL	0.25MG	N04039
DIETHYLSTILBESTROL	0.5MG	N04039
DIETHYLSTILBESTROL	1MG	N04039
DIETHYLSTILBESTROL	5MG	N04039
STILBESTROL	0.5MG	N83003
STILBESTROL	1MG	N83005
STILBESTROL	5MG	N83007
STILBETIN	0.1MG	N04056
STILBETIN	0.5MG	N04056
STILBETIN	1MG	N04056
STILBETIN	5MG	N04056
DIETHYLSTILBESTROL DIPHOSPHATE		
INJECTABLE		
STILPHOSTROL	250MG/5ML	N10010

FDA data supplied by DrugPatentWatch.com

DIETHYLSTILBESTROL DIPHOSPHATE		
TABLET		
STILPHOSTROL	50MG	N10010
DIFLUNISAL		
TABLET		
DIFLUNISAL	250MG	N74285
DIFLUNISAL	500MG	N74285
DIGITOXIN		
INJECTABLE		
CRYSTODIGIN	0.2MG/ML	N84100
DIGOXIN		
CAPSULE		
LANOXICAPS	0.15MG	N18118
INJECTABLE		
DIGOXIN	0.25MG/ML	N83217
DIGOXIN	0.25MG/ML	N84386
TABLET		
LANOXIN	0.0625MG	N20405
LANOXIN	0.1875MG	N20405
LANOXIN	0.375MG	N20405
LANOXIN	0.5MG	N20405
DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE		
INJECTABLE		
EMBOLEX	0.5MG/0.5ML;2,500 UNITS/0.5ML;5.33MG/0.5ML	N18885
EMBOLEX	0.5MG/0.7ML;5,000 UNITS/0.7ML;7.46MG/0.7ML	N18885
DILTIAZEM HYDROCHLORIDE		
CAPSULE, EXTENDED RELEASE		
CARDIZEM SR	180MG	N19471
TABLET		
DILTIAZEM HCL	120MG	N74051
DILTIAZEM HCL	30MG	N74051
DILTIAZEM HCL	60MG	N74051
DILTIAZEM HCL	90MG	N74051
DILTIAZEM HCL	30MG	N74084
DILTIAZEM HCL	60MG	N74084
DILTIAZEM MALATE		
TABLET, EXTENDED RELEASE		
TIAMATE	EQ 120MG HCL	N20506
TIAMATE	EQ 180MG HCL	N20506
TIAMATE	EQ 240MG HCL	N20506

DIMENHYDRINATE		
INJECTABLE		
DIMENHYDRINATE	50MG/ML	N84767
DIMENHYDRINATE	50MG/ML	N83531
DIMENHYDRINATE	50MG/ML	N84316
LIQUID		
DIMENHYDRINATE	12.5MG/4ML	N80715
TABLET		
DIMENHYDRINATE	50MG	N85985
DIMENHYDRINATE	50MG	N80841
DIMENHYDRINATE	50MG	N85166
DINOPROST TROMETHAMINE		
INJECTABLE		
PROSTIN F2 ALPHA	EQ 5MG BASE/ML	N17434
DIPHEMANIL METHYLSULFATE		
TABLET		
PRANTAL	100MG	N08114
DIPHENHYDRAMINE HYDROCHLORIDE		
CAPSULE		
BENADRYL	25MG	N05845
BENADRYL	50MG	N05845
DIPHENHYDRAMINE HCL	25MG	N80519
DIPHENHYDRAMINE HCL	50MG	N80519
DIPHENHYDRAMINE HCL	25MG	N83634
DIPHENHYDRAMINE HCL	50MG	N83275
DIPHENHYDRAMINE HCL	25MG	N85701
DIPHENHYDRAMINE HCL	50MG	N85701
DIPHENHYDRAMINE HCL	25MG	N80845
DIPHENHYDRAMINE HCL	50MG	N80845
DIPHENHYDRAMINE HCL	50MG	N87914
DIPHENHYDRAMINE HCL	25MG	N84524
DIPHENHYDRAMINE HCL	50MG	N83953
DIPHENHYDRAMINE HCL	25MG	N80807
DIPHENHYDRAMINE HCL	50MG	N80807
DIPHENHYDRAMINE HCL	25MG	N80762
DIPHENHYDRAMINE HCL	50MG	N80762
DIPHENHYDRAMINE HCL	25MG	N80868
DIPHENHYDRAMINE HCL	50MG	N80868
DIPHENHYDRAMINE HCL	25MG	N86874
DIPHENHYDRAMINE HCL	50MG	N86875
DIPHENHYDRAMINE HCL	25MG	N86543
DIPHENHYDRAMINE HCL	50MG	N86544
DIPHENHYDRAMINE HCL	25MG	N83061
DIPHENHYDRAMINE HCL	50MG	N83061
DIPHENHYDRAMINE HCL	25MG	N89101
DIPHENHYDRAMINE HCL	50MG	N88880

FDA data supplied by DrugPatentWatch.com

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE

DIPHENHYDRAMINE HCL	25MG	N85156
DIPHENHYDRAMINE HCL	50MG	N85150
DIPHENHYDRAMINE HCL	25MG	N83027
DIPHENHYDRAMINE HCL	50MG	N83027
DIPHENHYDRAMINE HCL	50MG	N80635
DIPHENHYDRAMINE HCL	25MG	N89040
DIPHENHYDRAMINE HCL	50MG	N89041
DIPHENHYDRAMINE HCL	25MG	N85874
DIPHENHYDRAMINE HCL	50MG	N85874
DIPHENHYDRAMINE HCL	25MG	N80596
DIPHENHYDRAMINE HCL	25MG	N88034
DIPHENHYDRAMINE HCL	50MG	N87630
DIPHENHYDRAMINE HCL	25MG	N83797
DIPHENHYDRAMINE HCL	25MG	N85138
DIPHENHYDRAMINE HCL	50MG	N83797
DIPHENHYDRAMINE HCL	50MG	N85083
DIPHENHYDRAMINE HCL	50MG	N83567
DIPHENHYDRAMINE HCL	25MG	N83441
DIPHENHYDRAMINE HCL	50MG	N80800

ELIXIR

BELIX	12.5MG/5ML	N86586
BENADRYL	12.5MG/5ML	N05845
DIBENIL	12.5MG/5ML	N88304
DIPHEN	12.5MG/5ML	N84640
DIPHENHYDRAMINE HCL	12.5MG/5ML	N83674
DIPHENHYDRAMINE HCL	12.5MG/5ML	N87941
DIPHENHYDRAMINE HCL	12.5MG/5ML	N85621
DIPHENHYDRAMINE HCL	12.5MG/5ML	N80939
DIPHENHYDRAMINE HCL	12.5MG/5ML	N86937
DIPHENHYDRAMINE HCL	12.5MG/5ML	N88680
DIPHENHYDRAMINE HCL	12.5MG/5ML	N83063
DIPHENHYDRAMINE HCL	12.5MG/5ML	N83237
DIPHENHYDRAMINE HCL	12.5MG/5ML	N85287
HYDRAMINE	12.5MG/5ML	N80763

INJECTABLE

BENADRYL	10MG/ML	N06146
DIPHENHYDRAMINE HCL	10MG/ML	N87066
DIPHENHYDRAMINE HCL	50MG/ML	N83183
DIPHENHYDRAMINE HCL	10MG/ML	N80822
DIPHENHYDRAMINE HCL	10MG/ML	N83533
DIPHENHYDRAMINE HCL	50MG/ML	N80577
DIPHENHYDRAMINE HCL PRESERVATIVE FREE	50MG/ML	N80586

SYRUP

ANTITUSSIVE	12.5MG/5ML	N71292
BELDIN	12.5MG/5ML	N89179

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP

BENYLIN	12.5MG/5ML	N06514
DIPHEN	12.5MG/5ML	N70118
DIPHENHYDRAMINE HCL	12.5MG/5ML	N70497
DIPHENHYDRAMINE HCL	12.5MG/5ML	N73611
DIPHENHYDRAMINE HCL	12.5MG/5ML	N72416
HYDRAMINE	12.5MG/5ML	N70205
SILPHEN	12.5MG/5ML	N72646
VICKS FORMULA 44	12.5MG/5ML	N70524

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION

BENYLIN	12.5MG/5ML;30MG/5ML	N19014

DIPHENIDOL HYDROCHLORIDE

TABLET

VONTROL	EQ 25MG BASE	N16033

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE

HISPRIL	5MG	N11945

DIPYRIDAMOLE

INJECTABLE

IV PERSANTINE	5MG/ML	N19817

TABLET

DIPYRIDAMOLE	25MG	N88999
DIPYRIDAMOLE	75MG	N89001
DIPYRIDAMOLE	50MG	N89426
DIPYRIDAMOLE	75MG	N89427

DISOPYRAMIDE PHOSPHATE

CAPSULE

DISOPYRAMIDE PHOSPHATE	EQ 100MG BASE	N70351
DISOPYRAMIDE PHOSPHATE	EQ 150MG BASE	N70352
DISOPYRAMIDE PHOSPHATE	EQ 100MG BASE	N71190
DISOPYRAMIDE PHOSPHATE	EQ 150MG BASE	N71191
DISOPYRAMIDE PHOSPHATE	EQ 100MG BASE	N70138
DISOPYRAMIDE PHOSPHATE	EQ 150MG BASE	N70139
DISOPYRAMIDE PHOSPHATE	EQ 100MG BASE	N70940
DISOPYRAMIDE PHOSPHATE	EQ 150MG BASE	N70941
DISOPYRAMIDE PHOSPHATE	EQ 100MG BASE	N70240
DISOPYRAMIDE PHOSPHATE	EQ 150MG BASE	N70241

DISULFIRAM

TABLET

ANTABUSE	500MG	N88483
ANTABUSE	250MG	* N07883

FDA data supplied by DrugPatentWatch.com

DISULFIRAM		
TABLET		
ANTABUSE	500MG	* N07883
DISULFIRAM	250MG	N88792
DISULFIRAM	500MG	N88793
DISULFIRAM	250MG	N86889
DISULFIRAM	250MG	N87973
DISULFIRAM	500MG	N86890
DISULFIRAM	500MG	N87974
DIVALPROEX SODIUM		
TABLET, DELAYED RELEASE		
DEPAKOTE CP	EQ 250MG BASE	N19794
DEPAKOTE CP	EQ 500MG BASE	N19794
DOBUTAMINE HYDROCHLORIDE		
INJECTABLE		
DOBUTAMINE HCL	EQ 12.5MG BASE/ML	N74098
DOBUTAMINE HCL	EQ 12.5MG BASE/ML	N74381
DOPAMINE HYDROCHLORIDE		
INJECTABLE		
DOPAMINE HCL	40MG/ML	N70656
DOPAMINE HCL	80MG/ML	N70657
DOPAMINE HCL	160MG/ML	N70364
DOPAMINE HCL	40MG/ML	N18549
DOPAMINE HCL	40MG/ML	N70012
DOPAMINE HCL	40MG/ML	N70058
DOPAMINE HCL	80MG/ML	N70013
DOPAMINE HCL	80MG/ML	N70059
DOPAMINE HCL	160MG/ML	N70092
DOPAMINE HCL	160MG/ML	N70093
DOPAMINE HCL	160MG/ML	N70094
DOPAMINE HCL	40MG/ML	N18656
DOPAMINE HCL	40MG/ML	N70087
DOPAMINE HCL	80MG/ML	N70089
DOPAMINE HCL	80MG/ML	N70090
DOPAMINE HCL	80MG/ML	N70091
DOPAMINE HCL	40MG/ML	N18398
DOPAMINE HCL	80MG/ML	N18398
DOPAMINE HCL	40MG/ML	N70011
DOPAMINE HCL	40MG/ML	N70046
DOPAMINE HCL	80MG/ML	N70047
DOPAMINE HCL	40MG/ML	N18138
DOPAMINE HCL	40MG/ML	N70558
DOPAMINE HCL	80MG/ML	N70559

DOXEPIN HYDROCHLORIDE		
CAPSULE		
DOXEPIN HCL	EQ 100MG BASE	N71675
DOXEPIN HCL	EQ 10MG BASE	N71685
DOXEPIN HCL	EQ 150MG BASE	N71676
DOXEPIN HCL	EQ 25MG BASE	N71686
DOXEPIN HCL	EQ 50MG BASE	N71673
DOXEPIN HCL	EQ 75MG BASE	N71674
DOXEPIN HCL	EQ 100MG BASE	N71521
DOXEPIN HCL	EQ 25MG BASE	N71502
DOXEPIN HCL	EQ 50MG BASE	N71653
DOXEPIN HCL	EQ 75MG BASE	N71654
DOXEPIN HCL	EQ 100MG BASE	N16987
DOXEPIN HCL	EQ 10MG BASE	N16987
DOXEPIN HCL	EQ 150MG BASE	N16987
DOXEPIN HCL	EQ 25MG BASE	N16987
DOXEPIN HCL	EQ 50MG BASE	N16987
DOXEPIN HCL	EQ 75MG BASE	N16987
DOXEPIN HCL	EQ 100MG BASE	N72110
DOXEPIN HCL	EQ 10MG BASE	N73054
DOXEPIN HCL	EQ 150MG BASE	N72387
DOXEPIN HCL	EQ 25MG BASE	N72109
DOXEPIN HCL	EQ 50MG BASE	N73055
DOXEPIN HCL	EQ 75MG BASE	N72386
DOXEPIN HCL	EQ 100MG BASE	N72375
DOXEPIN HCL	EQ 10MG BASE	N70972
DOXEPIN HCL	EQ 150MG BASE	N72376
DOXEPIN HCL	EQ 25MG BASE	N70973
DOXEPIN HCL	EQ 50MG BASE	N70931
DOXEPIN HCL	EQ 75MG BASE	N70932
DOXEPIN HCL	EQ 100MG BASE	N70955
DOXEPIN HCL	EQ 10MG BASE	N70952
DOXEPIN HCL	EQ 150MG BASE	N71764
DOXEPIN HCL	EQ 25MG BASE	N70953
DOXEPIN HCL	EQ 50MG BASE	N70954
DOXEPIN HCL	EQ 75MG BASE	N71763
DOXORUBICIN HYDROCHLORIDE		
INJECTABLE		
ADRIAMYCIN RDF	150MG/VIAL	N50467
DOXYCYCLINE		
FOR SUSPENSION		
DOXYCHEL	EQ 25MG BASE/5ML	N61720
DOXYCYCLINE HYCLATE		
CAPSULE		
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62119
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62418

FDA data supplied by DrugPatentWatch.com

DOXYCYCLINE HYCLATE

CAPSULE		
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62119
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62418
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62463
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62463
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62763
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62763
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62442
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62434
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62631
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62631
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62479
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62479
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62469
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62469
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62594
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62594
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62142
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62142
DOXY-LEMMON	EQ 100MG BASE	N62497
DOXY-LEMMON	EQ 50MG BASE	N62497
PERIOSTAT	EQ 20MG BASE	N50744
CAPSULE, COATED PELLETS		
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N63187
INJECTABLE		
DOXYCHEL HYCLATE	EQ 100MG BASE/VIAL	N61953
DOXYCYCLINE	EQ 100MG BASE/VIAL	N62450
DOXYCYCLINE	EQ 200MG BASE/VIAL	N62450
DOXYCYCLINE	EQ 100MG BASE/VIAL	N62569
DOXYCYCLINE	EQ 200MG BASE/VIAL	N62569
DOXYCYCLINE HYCLATE	EQ 100MG BASE/VIAL	N62992
DOXYCYCLINE HYCLATE	EQ 200MG BASE/VIAL	N62992
VIBRAMYCIN	EQ 100MG BASE/VIAL	N50442
VIBRAMYCIN	EQ 200MG BASE/VIAL	N50442
TABLET		
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62391
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62462
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62764
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62494
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62593
DOXYCYCLINE HYCLATE	EQ 100MG BASE	N62392
DOXYCYCLINE HYCLATE	EQ 50MG BASE	N62392
DOXYCYCLINE HYLATE	EQ 50MG BASE	N62269
DOXY-LEMMON	EQ 100MG BASE	N62581

DOXYLAMINE SUCCINATE

CAPSULE		
UNISOM	25MG	N19440
TABLET		
DECAPRYN	12.5MG	N06412
DECAPRYN	25MG	N06412
DOXYLAMINE SUCCINATE	25MG	N88603
DOXY-SLEEP-AID	25MG	N70156

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE		
BENDECTIN	10MG;10MG	*N10598

DROMOSTANOLONE PROPIONATE

INJECTABLE		
DROLBAN	50MG/ML	N12936

DROPERIDOL

INJECTABLE		
DROPERIDOL	2.5MG/ML	N70992
DROPERIDOL	2.5MG/ML	N70993
DROPERIDOL	2.5MG/ML	N72018
DROPERIDOL	2.5MG/ML	N72019
DROPERIDOL	2.5MG/ML	N72020
DROPERIDOL	2.5MG/ML	N72021
DROPERIDOL	2.5MG/ML	N71750
DROPERIDOL	2.5MG/ML	N71754
DROPERIDOL	2.5MG/ML	N71755
DROPERIDOL	2.5MG/ML	N73520
DROPERIDOL	2.5MG/ML	N73521
DROPERIDOL	2.5MG/ML	N73523

DROPERIDOL; FENTANYL CITRATE

INJECTABLE		
FENTANYL CITRATE AND DROPERIDOL	2.5MG/ML;EQ 0.05MG BASE/ML	N72026
FENTANYL CITRATE AND DROPERIDOL	2.5MG/ML;EQ 0.05MG BASE/ML	N72027
FENTANYL CITRATE AND DROPERIDOL	2.5MG/ML;EQ 0.05MG BASE/ML	N72028
INNOVAR	2.5MG/ML;EQ 0.05MG BASE/ML	N16049

DYCLONINE HYDROCHLORIDE

SOLUTION		
DYCLONE	0.5%	N09925
DYCLONE	1%	N09925

DYDROGESTERONE

TABLET		
GYNOREST	10MG	N17388

FDA data supplied by DrugPatentWatch.com

DYDROGESTERONE		
TABLET		
GYNOREST	5MG	N17388
DYPHYLLINE		
ELIXIR		
NEOTHYLLINE	160MG/15ML	N07794
INJECTABLE		
NEOTHYLLINE	250MG/ML	N09088
TABLET		
NEOTHYLLINE	200MG	N07794
NEOTHYLLINE	400MG	N07794
ECHOTHIOPHATE IODIDE		
FOR SOLUTION		
PHOSPHOLINE IODIDE	0.03%	N11963
PHOSPHOLINE IODIDE	0.06%	N11963
PHOSPHOLINE IODIDE	0.25%	N11963
EDETATE CALCIUM DISODIUM		
TABLET		
CALCIUM DISODIUM VERSENATE	500MG	N08922
EDETATE DISODIUM		
INJECTABLE		
DISODIUM EDETATE	150MG/ML	N84356
SODIUM VERSENATE	200MG/ML	N10573
EDROPHONIUM CHLORIDE		
INJECTABLE		
EDROPHONIUM CHLORIDE	10MG/ML	N40044
EDROPHONIUM CHLORIDE PRESERVATIVE FREE	10MG/ML	N40043
REVERSOL	10MG/ML	N89624
EFLORNITHINE HYDROCHLORIDE		
INJECTABLE		
ORNIDYL	200MG/ML	N19879
ENFLURANE		
LIQUID		
ENFLURANE	99.9%	N70803
ENOXACIN		
TABLET		
PENETREX	200MG	N19616
PENETREX	400MG	N19616
ENOXAPARIN SODIUM		
INJECTABLE		
LOVENOX	90MG/0.6ML	N20164

EPINEPHRINE		
AEROSOL, METERED		
BRONKAID MIST	0.25MG/INH	N16803
INJECTABLE		
EPI E Z PEN JR	0.15MG/DELIVERY	N19430
EPIPEN E Z PEN	0.3MG/DELIVERY	N19430
SUS-PHRINE SULFITE-FREE	1.5MG/AMP	N07942
SUS-PHRINE SULFITE-FREE	5MG/ML	N07942
EPINEPHRINE BITARTRATE		
AEROSOL, METERED		
MEDIHALER-EPI	0.3MG/INH	N10374
EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE		
INJECTABLE		
DURANEST	0.005MG/ML;1%	N17751
DURANEST	0.005MG/ML;1.5%	N17751
DURANEST	0.005MG/ML;1.5%	N21384
EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE		
INJECTABLE		
CITANEST FORTE	0.005MG/ML;4%	N14763
EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE		
INJECTABLE		
DURANEST	0.005MG/ML;0.5%	N17751
EPINEPHRINE; LIDOCAINE HYDROCHLORIDE		
INJECTABLE		
ALPHACAINE HCL W/ EPINEPHRINE	0.01MG/ML;2%	N84720
ALPHACAINE HCL W/ EPINEPHRINE	0.02MG/ML;2%	N84732
LIDOCAINE HCL AND EPINEPHRINE	0.01MG/ML;1%	N80406
LIDOCAINE HCL AND EPINEPHRINE	0.01MG/ML;2%	N80406
LIDOCAINE HCL W/ EPINEPHRINE	0.01MG/ML;1%	N83154
LIDOCAINE HCL W/ EPINEPHRINE	0.01MG/ML;1%	N80820
LIDOCAINE HCL W/ EPINEPHRINE	0.01MG/ML;2%	N80757
LIDOCAINE HCL W/ EPINEPHRINE	0.01MG/ML;1%	N86402
LIDOCAINE HCL W/ EPINEPHRINE	0.01MG/ML;1%	N80377
LIDOCAINE HCL W/ EPINEPHRINE	0.01MG/ML;1%	N85463
LIDOCAINE HCL W/ EPINEPHRINE	0.01MG/ML;2%	N80377
LIDOCATON	0.02MG/ML;2%	N84728
XYLOCAINE W/ EPINEPHRINE	0.005MG/ML;1%	N10418
XYLOCAINE W/ EPINEPHRINE	0.005MG/ML;1.5%	N10418
XYLOCAINE W/ EPINEPHRINE	0.005MG/ML;2%	N10418
XYLOCAINE W/ EPINEPHRINE	0.01MG/ML;2%	N06488
XYLOCAINE W/ EPINEPHRINE	0.02MG/ML;2%	N06488
EPINEPHRINE; PROCAINE HYDROCHLORIDE		
INJECTABLE		
PROCAINE HCL W/ EPINEPHRINE	0.02MG/ML;1%	N80758
PROCAINE HCL W/ EPINEPHRINE	0.02MG/ML;2%	N80759

FDA data supplied by DrugPatentWatch.com

ERGOCALCIFEROL		
CAPSULE		
DELTALIN	50,000 IU	N80884
VITAMIN D	50,000 IU	N80747
VITAMIN D	50,000 IU	N80956
VITAMIN D	50,000 IU	N80951
VITAMIN D	50,000 IU	N80825
VITAMIN D	50,000 IU	N84053
VITAMIN D	50,000 IU	N83102
ERGOLOID MESYLATES		
CAPSULE		
HYDERGINE LC	1MG	N18706
SOLUTION		
HYDERGINE	1MG/ML	N18418
TABLET		
ALKERGOT	0.5MG	N85153
ALKERGOT	1MG	N87417
CIRCANOL	0.5MG	N84868
CIRCANOL	1MG	N85809
DEAPRIL-ST	1MG	N85020
ERGOLOID MESYLATES	0.5MG	N87407
ERGOLOID MESYLATES	1MG	N87552
ERGOLOID MESYLATES	1MG	N88891
ERGOLOID MESYLATES	0.5MG	N85899
ERGOLOID MESYLATES	0.5MG	N86265
ERGOLOID MESYLATES	1MG	N85900
ERGOLOID MESYLATES	1MG	N86264
ERGOLOID MESYLATES	0.5MG	N86984
ERGOLOID MESYLATES	1MG	N86985
ERGOLOID MESYLATES	0.5MG	N89233
ERGOLOID MESYLATES	1MG	N89234
ERGOLOID MESYLATES	0.5MG	N88013
ERGOLOID MESYLATES	1MG	N88014
ERGOLOID MESYLATES	0.5MG	N84930
ERGOLOID MESYLATES	1MG	N85177
ERGOLOID MESYLATES	1MG	N86433
ERGOLOID MESYLATES	1MG	N87183
ERGOLOID MESYLATES	1MG	N87244
GERIMAL	1MG	N88207
HYDERGINE	0.5MG	N17993
HYDROGENATED ERGOT ALKALOIDS	0.5MG	N87186
ERGOTAMINE TARTRATE		
AEROSOL, METERED		
MEDIHALER ERGOTAMINE	0.36MG/INH	N12102
TABLET		
ERGOSTAT	2MG	N88337
ERGOTAMINE TARTRATE		
TABLET		
WIGRETTES	2MG	N86750
ERYTHROMYCIN		
CAPSULE, DELAYED REL PELLETS		
ERYC	250MG	N62546
ERYC	250MG	N62618
ERYC	250MG	N62338
ERYC 125	125MG	N62648
ERYC SPRINKLES	125MG	N50593
GEL		
EMGEL	2%	N63107
OINTMENT		
ERYTHROMYCIN	5MG/GM	N62446
ERYTHROMYCIN	5MG/GM	N62481
POWDER		
ERYTHROMYCIN	100%	N50610
SOLUTION		
ERYTHROMYCIN	1.5%	N62328
ERYTHROMYCIN	2%	N62327
ERYTHROMYCIN	2%	N62342
ERYTHROMYCIN	2%	N62957
ERYTHROMYCIN	2%	N50532
ERYTHROMYCIN	1.5%	N62485
ERYTHROMYCIN	2%	N62616
TABLET, DELAYED RELEASE		
E-BASE	333MG	N63028
ILOTYCIN	250MG	N61910
ROBIMYCIN	250MG	N61633
R-P MYCIN	250MG	N61659
ERYTHROMYCIN ESTOLATE		
CAPSULE		
ERYTHROMYCIN ESTOLATE	EQ 125MG BASE	N62162
ERYTHROMYCIN ESTOLATE	EQ 250MG BASE	N62237
ERYTHROMYCIN ESTOLATE	EQ 250MG BASE	N62087
ILOSONE	EQ 125MG BASE	N61897
ILOSONE	EQ 250MG BASE	N61897
FOR SUSPENSION		
ILOSONE	EQ 125MG BASE/5ML	N61893
SUSPENSION		
ERYTHROMYCIN ESTOLATE	EQ 125MG BASE/5ML	N62169
ERYTHROMYCIN ESTOLATE	EQ 250MG BASE/5ML	N62169
ERYTHROMYCIN ESTOLATE	EQ 250MG BASE/5ML	N62362
ILOSONE	EQ 125MG BASE/5ML	N61894

ERYTHROMYCIN ESTOLATE

SUSPENSION		
ILOSONE	EQ 250MG BASE/5ML	N61894
SUSPENSION/DROPS		
ILOSONE	EQ 100MG BASE/ML	N61894
TABLET		
ILOSONE	EQ 500MG BASE	N61896
TABLET, CHEWABLE		
ILOSONE	EQ 125MG BASE	N61895
ILOSONE	EQ 250MG BASE	N61895

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION		
ILOSONE SULFA	EQ 125MG BASE/5ML;EQ 600MG BASE/5ML	N50599

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE		
PEDIAMYCIN	EQ 200MG BASE/5ML	N62305
SUSPENSION		
E-MYCIN E	EQ 200MG BASE/5ML	N62198
E-MYCIN E	EQ 400MG BASE/5ML	N62198
ERYTHROMYCIN ETHYLSUCCINATE	EQ 200MG BASE/5ML	N62177
ERYTHROMYCIN ETHYLSUCCINATE	EQ 400MG BASE/5ML	N62177
ERYTHROMYCIN ETHYLSUCCINATE	EQ 400MG BASE/5ML	N62674
ERYTHROMYCIN ETHYLSUCCINATE	EQ 200MG BASE/5ML	N62231
ERYTHROMYCIN ETHYLSUCCINATE	EQ 400MG BASE/5ML	N62231
ERYTHROMYCIN ETHYLSUCCINATE	EQ 200MG BASE/5ML	N62559
ERYTHROMYCIN ETHYLSUCCINATE	EQ 400MG BASE/5ML	N62558
WYAMYCIN E	EQ 200MG BASE/5ML	N62123
WYAMYCIN E	EQ 400MG BASE/5ML	N62123
SUSPENSION/DROPS		
PEDIAMYCIN	EQ 100MG BASE/2.5ML	N62305
TABLET		
E.E.S. 400	EQ 400MG BASE	N61905
ERYTHROMYCIN ETHYLSUCCINATE	EQ 400MG BASE	N62256
TABLET, CHEWABLE		
PEDIAMYCIN	EQ 200MG BASE	N62306

ERYTHROMYCIN GLUCEPTATE

INJECTABLE		
ILOTYCIN GLUCEPTATE	EQ 1GM BASE/VIAL	N50370
ILOTYCIN GLUCEPTATE	EQ 250MG BASE/VIAL	N50370
ILOTYCIN GLUCEPTATE	EQ 500MG BASE/VIAL	N50370

ERYTHROMYCIN LACTOBIONATE

INJECTABLE		
ERYTHROCIN	EQ 1GM BASE/VIAL	N62586
ERYTHROCIN	EQ 500MG BASE/VIAL	N62586

ERYTHROMYCIN LACTOBIONATE

INJECTABLE		
ERYTHROMYCIN	EQ 1GM BASE/VIAL	N62563
ERYTHROMYCIN	EQ 500MG BASE/VIAL	N62563
ERYTHROMYCIN LACTOBIONATE	EQ 1GM BASE/VIAL	N62604
ERYTHROMYCIN LACTOBIONATE	EQ 500MG BASE/VIAL	N62604

ERYTHROMYCIN STEARATE

TABLET		
BRISTAMYCIN	EQ 250MG BASE	N61304
BRISTAMYCIN	EQ 250MG BASE	N61887
ERYPAR	EQ 250MG BASE	N62032
ERYPAR	EQ 500MG BASE	N62032
ERYPAR	EQ 250MG BASE	N62322
ERYTHROCIN STEARATE	EQ 125MG BASE	N60359
ERYTHROMYCIN STEARATE	EQ 500MG BASE	N63179
ERYTHROMYCIN STEARATE	EQ 250MG BASE	N61461
ERYTHROMYCIN STEARATE	EQ 500MG BASE	N61461
ERYTHROMYCIN STEARATE	EQ 250MG BASE	N62089
ERYTHROMYCIN STEARATE	EQ 500MG BASE	N62089
ERYTHROMYCIN STEARATE	EQ 250MG BASE	N61743
ERYTHROMYCIN STEARATE	EQ 250MG BASE	N62121
ERYTHROMYCIN STEARATE	EQ 500MG BASE	N62121
ETHRIL 250	EQ 250MG BASE	N61605
ETHRIL 500	EQ 500MG BASE	N61605
PFIZER-E	EQ 250MG BASE	N61791
PFIZER-E	EQ 500MG BASE	N61791
WYAMYCIN S	EQ 250MG BASE	N61675
WYAMYCIN S	EQ 500MG BASE	N61675

ESCITALOPRAM OXALATE

TABLET		
LEXAPRO	5MG	N21323

ESMOLOL HYDROCHLORIDE

INJECTABLE		
BREVIBLOC	100MG/ML	N19386

ESTRADIOL

FILM, EXTENDED RELEASE		
ESTRADIOL	0.05MG/24HR	N21048
ESTRADIOL	0.075MG/24HR	N21048
ESTRADIOL	0.1MG/24HR	N21048
FEMPATCH	0.025MG/24HR	N20417
TABLET		
ESTRADIOL	0.5MG	N40275
ESTRADIOL	1MG	N40275
ESTRADIOL	2MG	N40275

FDA data supplied by DrugPatentWatch.com

ESTRADIOL CYPIONATE
INJECTABLE

DEPO-ESTRADIOL	1MG/ML	N85470
DEPO-ESTRADIOL	3MG/ML	N85470

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE
INJECTABLE

LUNELLE	5MG/0.5ML;25MG/0.5ML	N20874

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE
INJECTABLE

DEPO-TESTADIOL	2MG/ML;50MG/ML	N17968
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE	2MG/ML;50MG/ML	N85603

ESTRADIOL VALERATE
INJECTABLE

ESTRADIOL VALERATE	10MG/ML	N83546

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE
INJECTABLE

DITATE-DS	8MG/ML;180MG/ML	N86423
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE	4MG/ML;90MG/ML	N85865
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE	8MG/ML;180MG/ML	N85860

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
TABLET

PREMPHASE (PREMARIN;CYCRIN 14/14)	0.625MG;0.625MG;5MG	N20303
PREMPRO (PREMARIN;CYCRIN)	0.625MG;0.625MG;2.5MG;2.5MG	N20303

ESTROGENS, CONJUGATED; MEPROBAMATE
TABLET

MILPREM-200	0.45MG;200MG	N11045
MILPREM-400	0.45MG;400MG	N11045
PMB 200	0.45MG;200MG	N10971
PMB 400	0.45MG;400MG	N10971

ESTROGENS, ESTERIFIED
TABLET

AMNESTROGEN	0.3MG	N83266
AMNESTROGEN	0.625MG	N83266
AMNESTROGEN	1.25MG	N83266
AMNESTROGEN	2.5MG	N83266
ESTERIFIED ESTROGENS	0.625MG	N83414
ESTERIFIED ESTROGENS	1.25MG	N83765
ESTERIFIED ESTROGENS	2.5MG	N85907
ESTERIFIED ESTROGENS	1.25MG	N85302
ESTRATAB	0.3MG	N86715
ESTRATAB	0.625MG	N83209

ESTROGENS, ESTERIFIED
TABLET

ESTRATAB	1.25MG	N83856
ESTRATAB	2.5MG	N83857
EVEX	0.625MG	N84215
EVEX	1.25MG	N83376
FEMOGEN	0.625MG	N85076
FEMOGEN	1.25MG	N85008
FEMOGEN	2.5MG	N85007

ESTRONE
INJECTABLE

ESTROGENIC SUBSTANCE	2MG/ML	N83488
ESTRONE	2MG/ML	N83397
NATURAL ESTROGENIC SUBSTANCE-ESTRONE	2MG/ML	N85237
THEELIN	1MG/ML	N03977
THEELIN	2MG/ML	N03977
THEELIN	5MG/ML	N03977

ETHACRYNIC ACID
TABLET

EDECRIN	50MG	N16092

ETHAMBUTOL HYDROCHLORIDE
TABLET

MYAMBUTOL	100MG	N16320
MYAMBUTOL	200MG	N16320
MYAMBUTOL	400MG	N16320
MYAMBUTOL	500MG	N16320

ETHCHLORVYNOL
CAPSULE

ETHCHLORVYNOL	100MG	N84463
ETHCHLORVYNOL	200MG	N84463
ETHCHLORVYNOL	500MG	N84463
ETHCHLORVYNOL	750MG	N84463
PLACIDYL	100MG	N10021
PLACIDYL	200MG	N10021
PLACIDYL	500MG	N10021
PLACIDYL	750MG	N10021

ETHINAMATE
CAPSULE

VALMID	500MG	N09750

ETHINYL ESTRADIOL
TABLET

FEMINONE	0.05MG	N16649
LYNORAL	0.01MG	N05490
LYNORAL	0.05MG	N05490

FLUOCINOLONE ACETONIDE		
OINTMENT		
FLUOCINOLONE ACETONIDE	0.025%	N88046
FLUOCINOLONE ACETONIDE	0.025%	N88507
FLUOCINOLONE ACETONIDE	0.025%	N88742
FLUONID	0.025%	N87157
FLUOTREX	0.025%	N88172
SOLUTION		
FLUOCINOLONE ACETONIDE	0.01%	N87159
FLUOCINOLONE ACETONIDE	0.01%	N40059
FLUOCINOLONE ACETONIDE	0.01%	N88312
FLUOCINOLONE ACETONIDE	0.01%	N88048
FLUOCINOLONE ACETONIDE	0.01%	N88449
FLUONID	0.01%	N87158
FLUOTREX	0.01%	N88171
FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE		
CREAM		
NEO-SYNALAR	0.025%;EQ 3.5MG BASE/GM	N60700
FLUOCINONIDE		
CREAM		
FLUOCINONIDE	0.05%	N71790
FLUORESCEIN SODIUM		
INJECTABLE		
FUNDUSCEIN-25	25%	N17869
FLUOROMETHOLONE		
CREAM		
OXYLONE	0.025%	N11748
FLUOROURACIL		
INJECTABLE		
ADRUCIL	50MG/ML	N17959
ADRUCIL	50MG/ML	N81222
FLUOROURACIL	50MG/ML	N88929
FLUOROURACIL	50MG/ML	N89152
FLUOROURACIL	50MG/ML	N89428
FLUOROURACIL	50MG/ML	N89519
FLUOROURACIL	50MG/ML	N87791
FLUOROURACIL	50MG/ML	N88766
FLUOROURACIL	50MG/ML	N88767
FLUOROURACIL	50MG/ML	N89434
SOLUTION		
FLUOROPLEX	1%	N16765
FLUOXETINE HYDROCHLORIDE		
CAPSULE		
PROZAC	EQ 60MG BASE	N18936
FLUOXETINE HYDROCHLORIDE		
TABLET		
PROZAC	EQ 20MG BASE	N20974
FLUOXYMESTERONE		
TABLET		
ANDROID-F	10MG	N87196
FLUOXYMESTERONE	10MG	N88221
FLUOXYMESTERONE	10MG	N88309
FLUOXYMESTERONE	2MG	N88260
FLUOXYMESTERONE	5MG	N88265
ORA-TESTRYL	2MG	N11359
ORA-TESTRYL	5MG	N11359
FLUPHENAZINE DECANOATE		
INJECTABLE		
FLUPHENAZINE DECANOATE	25MG/ML	N74966
FLUPHENAZINE ENANTHATE		
INJECTABLE		
PROLIXIN ENANTHATE	25MG/ML	N16110
FLUPHENAZINE HYDROCHLORIDE		
TABLET		
FLUPHENAZINE HCL	10MG	N88550
FLUPHENAZINE HCL	1MG	N88555
FLUPHENAZINE HCL	2.5MG	N88544
FLUPHENAZINE HCL	5MG	N88527
PERMITIL	0.25MG	N12034
PERMITIL	10MG	N12034
PERMITIL	2.5MG	N12034
PERMITIL	5MG	N12034
TABLET, EXTENDED RELEASE		
PERMITIL	1MG	N12419
FLUPREDNISOLONE		
TABLET		
ALPHADROL	1.5MG	N12259
FLURANDRENOLIDE		
LOTION		
FLURANDRENOLIDE	0.05%	N87203
FLURANDRENOLIDE; NEOMYCIN SULFATE		
CREAM		
CORDRAN-N	0.05%;EQ 3.5MG BASE/GM	N50346
OINTMENT		
CORDRAN-N	0.05%;EQ 3.5MG BASE/GM	N50345

FDA data supplied by DrugPatentWatch.com

FLURAZEPAM HYDROCHLORIDE		
CAPSULE		
FLURAZEPAM HCL	15MG	N70454
FLURAZEPAM HCL	15MG	N71808
FLURAZEPAM HCL	30MG	N70455
FLURAZEPAM HCL	30MG	N71809
FLURAZEPAM HCL	15MG	N71927
FLURAZEPAM HCL	30MG	N71551
FLURAZEPAM HCL	15MG	N71659
FLURAZEPAM HCL	30MG	N71660
FLURAZEPAM HCL	15MG	N70562
FLURAZEPAM HCL	30MG	N70563
FLURAZEPAM HCL	15MG	N71767
FLURAZEPAM HCL	30MG	N71768
FLURAZEPAM HCL	15MG	N72368
FLUVOXAMINE MALEATE		
TABLET		
LUVOX	100MG	N20243
LUVOX	150MG	N20243
LUVOX	25MG	N20243
LUVOX	50MG	N20243
FOLIC ACID		
INJECTABLE		
FOLVITE	5MG/ML	N05897
TABLET		
FOLIC ACID	1MG	N84915
FOLIC ACID	1MG	N89177
FOLIC ACID	1MG	N84472
FOLIC ACID	1MG	N80755
FOLIC ACID	1MG	N83598
FOLIC ACID	1MG	N80686
FOLIC ACID	1MG	N83000
FOLIC ACID	1MG	N80816
FOLIC ACID	1MG	N06135
FOLIC ACID	1MG	N84158
FOLIC ACID	1MG	N88949
FOLIC ACID	1MG	N80784
FOLIC ACID	1MG	N88199
FOLIC ACID	1MG	N87828
FOLIC ACID	1MG	N80903
FOLIC ACID	1MG	N88730
FOLIC ACID	1MG	N86296
FOLIC ACID	1MG	N83141
FOLIC ACID	1MG	N85141
FOLIC ACID	1MG	N80691
FOLVITE	1MG	N05897

FOLLITROPIN ALFA/BETA		
INJECTABLE		
GONAL-F	37.5 IU/VIAL	N20378
FURAZOLIDONE		
SUSPENSION		
FUROXONE	50MG/15ML	N11323
TABLET		
FUROXONE	100MG	N11270
FUROSEMIDE		
INJECTABLE		
FUROSEMIDE	10MG/ML	N18507
FUROSEMIDE	10MG/ML	N19036
FUROSEMIDE	10MG/ML	N70014
FUROSEMIDE	10MG/ML	N70095
FUROSEMIDE	10MG/ML	N70096
FUROSEMIDE	10MG/ML	N18267
FUROSEMIDE	10MG/ML	N74017
FUROSEMIDE	10MG/ML	N70017
FUROSEMIDE	10MG/ML	N70023
FUROSEMIDE	10MG/ML	N70078
FUROSEMIDE	10MG/ML	N70019
FUROSEMIDE	10MG/ML	N70604
FUROSEMIDE	10MG/ML	N18420
FUROSEMIDE	10MG/ML	N18670
TABLET		
FUROSEMIDE	20MG	N18415
FUROSEMIDE	40MG	N18415
FUROSEMIDE	80MG	N18415
FUROSEMIDE	40MG	N18750
FUROSEMIDE	20MG	N70043
FUROSEMIDE	40MG	N18790
FUROSEMIDE	80MG	N70100
FUROSEMIDE	20MG	N18868
FUROSEMIDE	40MG	N18868
FUROSEMIDE	20MG	N18370
FUROSEMIDE	40MG	N18370
FUROSEMIDE	20MG	N18419
FUROSEMIDE	40MG	N18419
FUROSEMIDE	80MG	N18419
FUROSEMIDE	20MG	N18369
FUROSEMIDE	40MG	N18369
GALLAMINE TRIETHIODIDE		
INJECTABLE		
FLAXEDIL	100MG/ML	N07842
FLAXEDIL	20MG/ML	N07842

FDA data supplied by DrugPatentWatch.com

GALLIUM CITRATE, GA-67		
INJECTABLE		
GALLIUM CITRATE GA 67	1mCi/ML	N17700
NEOSCAN	2mCi/ML	N17655
GEMFIBROZIL		
CAPSULE		
GEMFIBROZIL	300MG	N73466
GEMFIBROZIL	300MG	N72929
LOPID	200MG	N18422
LOPID	300MG	N18422
TABLET		
GEMFIBROZIL	600MG	N74270
GEMFIBROZIL	600MG	N74360
GEMFIBROZIL	600MG	N74156
GENTAMICIN SULFATE		
CREAM		
GARAMYCIN	EQ 0.1% BASE	N60462
GENTAFAIR	EQ 0.1% BASE	N62458
GENTAMICIN SULFATE	EQ 0.1% BASE	N62471
GENTAMICIN SULFATE	EQ 0.1% BASE	N64056
GENTAMICIN SULFATE	EQ 1MG BASE/GM	N62530
INJECTABLE		
APOGEN	EQ 10MG BASE/ML	N62289
APOGEN	EQ 40MG BASE/ML	N62289
BRISTAGEN	EQ 40MG BASE/ML	N62288
GARAMYCIN	EQ 10MG BASE/ML	N61739
GARAMYCIN	EQ 1MG BASE/ML	N61716
GARAMYCIN	EQ 2MG BASE/ML	N50505
GARAMYCIN	EQ 40MG BASE/ML	N61716
GENTAFAIR	EQ 40MG BASE/ML	N62493
GENTAMICIN	EQ 100MG BASE/100ML	N62325
GENTAMICIN	EQ 1MG BASE/ML	N62325
GENTAMICIN	EQ 40MG BASE/ML	N62325
GENTAMICIN SULFATE	EQ 1.2MG BASE/ML	N62413
GENTAMICIN SULFATE	EQ 1.4MG BASE/ML	N62413
GENTAMICIN SULFATE	EQ 1.6MG BASE/ML	N62413
GENTAMICIN SULFATE	EQ 1.8MG BASE/ML	N62413
GENTAMICIN SULFATE	EQ 100MG BASE/100ML	N62413
GENTAMICIN SULFATE	EQ 2MG BASE/ML	N62413
GENTAMICIN SULFATE	EQ 60MG BASE/100ML	N62413
GENTAMICIN SULFATE	EQ 70MG BASE/100ML	N62413
GENTAMICIN SULFATE	EQ 80MG BASE/100ML	N62413
GENTAMICIN SULFATE	EQ 90MG BASE/100ML	N62413
GENTAMICIN SULFATE	EQ 10MG BASE/ML	N62251
GENTAMICIN SULFATE	EQ 40MG BASE/ML	N62251
GENTAMICIN SULFATE	EQ 10MG BASE/ML	N63149

GENTAMICIN SULFATE		
INJECTABLE		
GENTAMICIN SULFATE	EQ 40MG BASE/ML	N63106
GENTAMICIN SULFATE	EQ 40MG BASE/ML	N62354
GENTAMICIN SULFATE	EQ 10MG BASE/ML	N62507
GENTAMICIN SULFATE	EQ 40MG BASE/ML	N62507
GENTAMICIN SULFATE	EQ 10MG BASE/ML	N62318
GENTAMICIN SULFATE	EQ 40MG BASE/ML	N62318
GENTAMICIN SULFATE	EQ 10MG BASE/ML	N62264
GENTAMICIN SULFATE	EQ 40MG BASE/ML	N62264
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 1.2MG BASE/ML	N62588
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 1.4MG BASE/ML	N62588
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 1.6MG BASE/ML	N62588
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 1.8MG BASE/ML	N62588
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 100MG BASE/100ML	N62588
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 2MG BASE/ML	N62588
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 60MG BASE/100ML	N62588
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 70MG BASE/100ML	N62588
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 80MG BASE/100ML	N62588
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	EQ 90MG BASE/100ML	N62588
U-GENCIN	EQ 10MG BASE/ML	N62248
U-GENCIN	EQ 40MG BASE/ML	N62248
OINTMENT		
GARAMYCIN	EQ 0.1% BASE	N60463
GARAMYCIN	EQ 0.3% BASE	N50425
GENTACIDIN	EQ 0.3% BASE	N62501
GENTAFAIR	EQ 0.1% BASE	N62444
GENTAFAIR	EQ 3MG BASE/GM	N62443
GENTAMICIN SULFATE	EQ 0.1% BASE	N62496
GENTAMICIN SULFATE	EQ 0.1% BASE	N64054
GENTAMICIN SULFATE	EQ 0.1% BASE	N62534
SOLUTION/DROPS		
GENTAFAIR	EQ 0.3% BASE	N62440
GENTAMICIN SULFATE	EQ 0.3% BASE	N62523
GENTAMICIN SULFATE	EQ 3MG BASE/ML	N62932
GENTIAN VIOLET		
SUPPOSITORY		
GVS	0.4%	N83513

FDA data supplied by DrugPatentWatch.com

GENTIAN VIOLET		
TAMPON		
GENAPAX	5MG	N85017
GLIPIZIDE		
TABLET		
GLUCOTROL	2.5MG	N17783
GLUCAGON HYDROCHLORIDE		
INJECTABLE		
GLUCAGON	EQ 10MG BASE/VIAL	N12122
GLUCAGON	EQ 1MG BASE/VIAL	N12122
GLUTETHIMIDE		
CAPSULE		
DORIDEN	500MG	N09519
TABLET		
DORIDEN	250MG	N09519
DORIDEN	500MG	N09519
GLUTETHIMIDE	500MG	N85171
GLUTETHIMIDE	250MG	N89458
GLUTETHIMIDE	500MG	N89459
GLUTETHIMIDE	250MG	N83475
GLUTETHIMIDE	500MG	N85571
GLUTETHIMIDE	500MG	N83234
GLUTETHIMIDE	500MG	N87297
GLUTETHIMIDE	500MG	N84362
GLUTETHIMIDE	500MG	N85763
GLYBURIDE		
TABLET		
GLYBURIDE (MICRONIZED)	1.5MG	N20055
GLYBURIDE (MICRONIZED)	3MG	N20055
GLYBURIDE (MICRONIZED)	6MG	N20055
GLYNASE	4.5MG	* N20051
GLYCINE		
SOLUTION		
GLYCINE 1.5% IN PLASTIC CONTAINER	1.5GM/100ML	N18522
GLYCOPYRROLATE		
INJECTABLE		
GLYCOPYRROLATE	0.2MG/ML	N89393
GLYCOPYRROLATE	0.2MG/ML	N88475
GLYCOPYRROLATE	0.2MG/ML	N81169
GLYCOPYRROLATE	0.2MG/ML	N86947
ROBINUL	0.2MG/ML	N14764
TABLET		
GLYCOPYRROLATE	1MG	N85562
GLYCOPYRROLATE	1MG	N86902
GLYCOPYRROLATE	2MG	N85563

GLYCOPYRROLATE		
TABLET		
GLYCOPYRROLATE	2MG	N86178
GLYCOPYRROLATE	2MG	N86900
GONADORELIN ACETATE		
INJECTABLE		
LUTREPULSE KIT	0.8MG/VIAL	N19687
LUTREPULSE KIT	3.2MG/VIAL	N19687
GONADORELIN HYDROCHLORIDE		
INJECTABLE		
FACTREL	EQ 0.2MG BASE/VIAL	N18123
FACTREL	EQ 0.5MG BASE/VIAL	N18123
GONADOTROPIN, CHORIONIC		
INJECTABLE		
A.P.L.	10,000 UNITS/VIAL	N17055
A.P.L.	20,000 UNITS/VIAL	N17055
A.P.L.	5,000 UNITS/VIAL	N17055
CHORIONIC GONADOTROPIN	15,000 UNITS/VIAL	N17067
CHORIONIC GONADOTROPIN	20,000 UNITS/VIAL	N17067
CHORIONIC GONADOTROPIN	5,000 UNITS/VIAL	N17067
CHORIONIC GONADOTROPIN	10,000 UNITS/VIAL	N17054
CHORIONIC GONADOTROPIN	5,000 UNITS/VIAL	N17054
CHORIONIC GONADOTROPIN	15,000 UNITS/VIAL	N17016
CHORIONIC GONADOTROPIN	2,000 UNITS/VIAL	N17016
CHORIONIC GONADOTROPIN	2,000 UNITS/VIAL	N17016
CHORIONIC GONADOTROPIN	20,000 UNITS/VIAL	N17016
CHORIONIC GONADOTROPIN	5,000 UNITS/VIAL	N17016
FOLLUTEIN	10,000 UNITS/VIAL	N17056
GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE		
SOLUTION/DROPS		
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	N62818
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	N62788
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	N62383
NEO-POLYCIN	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	N60427
GRANISETRON HYDROCHLORIDE		
INJECTABLE		
KYTRIL	EQ 3MG BASE/ML	N20239
TABLET		
KYTRIL	EQ 2MG BASE	N20305
GREPAFLOXACIN HYDROCHLORIDE		
TABLET		
RAXAR	EQ 200MG BASE	N20695

FDA data supplied by DrugPatentWatch.com

GREPAFLOXACIN HYDROCHLORIDE		
TABLET		
RAXAR	EQ 400MG BASE	N20695
RAXAR	EQ 600MG BASE	N20695
GRISEOFULVIN, MICROCRYSTALLINE		
CAPSULE		
GRISACTIN	125MG	N50051
GRISACTIN	250MG	N50051
SUSPENSION		
GRIFULVIN V	125MG/5ML	N50448
TABLET		
GRIFULVIN V	125MG	N60618
GRIFULVIN V	250MG	N60618
GRIFULVIN V	500MG	N60618
GRISACTIN	500MG	N60212
GRISEOFULVIN, ULTRAMICROCRYSTALLINE		
TABLET		
GRISACTIN ULTRA	125MG	N62178
GRISACTIN ULTRA	165MG	N62438
GRISACTIN ULTRA	250MG	N62178
GRISACTIN ULTRA	330MG	N62438
ULTRAGRIS-165	165MG	N62645
ULTRAGRIS-330	330MG	N62646
GUANABENZ ACETATE		
TABLET		
WYTENSIN	EQ 16MG BASE	N18587
WYTENSIN	EQ 4MG BASE	N18587
WYTENSIN	EQ 8MG BASE	N18587
GUANADREL SULFATE		
TABLET		
HYLOREL	10MG	N18104
HYLOREL	25MG	N18104
GUANETHIDINE MONOSULFATE		
TABLET		
GUANETHIDINE MONOSULFATE	EQ 10MG SULFATE	N86113
GUANETHIDINE MONOSULFATE	EQ 25MG SULFATE	N86114
ISMELIN	EQ 10MG SULFATE	N12329
ISMELIN	EQ 25MG SULFATE	N12329
GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE		
TABLET		
ESIMIL	10MG;25MG	N13553
GUANFACINE HYDROCHLORIDE		
TABLET		
TENEX	EQ 3MG BASE	N19032

HALCINONIDE		
CREAM		
HALOG	0.025%	N17818
OINTMENT		
HALOG	0.025%	N18125
HALOFANTRINE HYDROCHLORIDE		
TABLET		
HALFAN	250MG	N20250
HALOPERIDOL		
TABLET		
HALDOL	0.5MG	* N15921
HALDOL	10MG	* N15921
HALDOL	1MG	* N15921
HALDOL	20MG	* N15921
HALDOL	2MG	* N15921
HALDOL	5MG	* N15921
HALDOL SOLUTAB	1MG	N17079
HALOPERIDOL	0.5MG	N71216
HALOPERIDOL	10MG	N71220
HALOPERIDOL	1MG	N71217
HALOPERIDOL	20MG	N71221
HALOPERIDOL	2MG	N71218
HALOPERIDOL	5MG	N71219
HALOPERIDOL	0.5MG	N71156
HALOPERIDOL	10MG	N71173
HALOPERIDOL	1MG	N71157
HALOPERIDOL	20MG	N71177
HALOPERIDOL	2MG	N71172
HALOPERIDOL	5MG	N71212
HALOPERIDOL	0.5MG	N72727
HALOPERIDOL	10MG	N72731
HALOPERIDOL	1MG	N72728
HALOPERIDOL	20MG	N72732
HALOPERIDOL	2MG	N72729
HALOPERIDOL	5MG	N72730
HALOPERIDOL	20MG	N71328
HALOPERIDOL	0.5MG	N71071
HALOPERIDOL	10MG	N71075
HALOPERIDOL	1MG	N71072
HALOPERIDOL	20MG	N71076
HALOPERIDOL	2MG	N71073
HALOPERIDOL	5MG	N71074
HALOPERIDOL	0.5MG	N71255
HALOPERIDOL	1MG	N71269
HALOPERIDOL	2MG	N71256
HALOPERIDOL	5MG	N71257

FDA data supplied by DrugPatentWatch.com

HALOPERIDOL		
TABLET		
HALOPERIDOL	0.5MG	N71128
HALOPERIDOL	10MG	N71132
HALOPERIDOL	1MG	N71129
HALOPERIDOL	20MG	N71133
HALOPERIDOL	2MG	N71130
HALOPERIDOL	5MG	N71131
HALOPERIDOL	0.5MG	N71722
HALOPERIDOL	10MG	N72121
HALOPERIDOL	1MG	N71723
HALOPERIDOL	20MG	N72122
HALOPERIDOL	2MG	N71724
HALOPERIDOL	5MG	N71725
HALOPERIDOL	0.5MG	N70720
HALOPERIDOL	10MG	N70724
HALOPERIDOL	1MG	N70721
HALOPERIDOL	20MG	N70725
HALOPERIDOL	2MG	N70722
HALOPERIDOL	5MG	N70723
HALOPERIDOL	0.5MG	N71571
HALOPERIDOL	10MG	N71375
HALOPERIDOL	10MG	N72113
HALOPERIDOL	1MG	N70982
HALOPERIDOL	1MG	N71572
HALOPERIDOL	20MG	N71376
HALOPERIDOL	20MG	N72353
HALOPERIDOL	2MG	N71573
HALOPERIDOL	5MG	N71374
HALOPERIDOL DECANOATE		
INJECTABLE		
HALOPERIDOL DECANOATE	EQ 100MG BASE/ML	N75176
HALOPERIDOL DECANOATE	EQ 50MG BASE/ML	N75176
HALOPERIDOL LACTATE		
CONCENTRATE		
HALDOL	EQ 2MG BASE/ML	N15922
HALOPERIDOL	EQ 2MG BASE/ML	N70318
HALOPERIDOL	EQ 2MG BASE/ML	N70710
HALOPERIDOL	EQ 2MG BASE/ML	N70726
HALOPERIDOL INTENSOL	EQ 2MG BASE/ML	N72045
INJECTABLE		
HALOPERIDOL	EQ 5MG BASE/ML	N71187
HALOPERIDOL	EQ 5MG BASE/ML	N72516
HALOPERIDOL	EQ 5MG BASE/ML	N72517
HALOPERIDOL	EQ 5MG BASE/ML	N70802
HALOPERIDOL	EQ 5MG BASE/ML	N70800

HALOPERIDOL LACTATE		
INJECTABLE		
HALOPERIDOL	EQ 5MG BASE/ML	N70801
HALOPERIDOL	EQ 5MG BASE/ML	N70864
HALOPERIDOL	EQ 5MG BASE/ML	N70713
HALOPERIDOL	EQ 5MG BASE/ML	N70744
HALOPROGIN		
CREAM		
HALOTEX	1%	N16942
SOLUTION		
HALOTEX	1%	N16943
HALOTHANE		
LIQUID		
FLUOTHANE	99.99%	N11338
HALOTHANE	99.99%	N84977
HEPARIN CALCIUM		
INJECTABLE		
CALCIPARINE	25,000 UNITS/ML	N18237
HEPARIN SODIUM		
INJECTABLE		
HEP FLUSH KIT IN PLASTIC CONTAINER	10 UNITS/ML	N17029
HEP FLUSH KIT IN PLASTIC CONTAINER	100 UNITS/ML	N17029
HEPARIN LOCK FLUSH	100 UNITS/ML	N05264
HEPARIN LOCK FLUSH	100 UNITS/ML	N17651
HEPARIN LOCK FLUSH	10 UNITS/ML	N17007
HEPARIN LOCK FLUSH	100 UNITS/ML	N17007
HEPARIN LOCK FLUSH	10 UNITS/ML	N86357
HEPARIN LOCK FLUSH	500 UNITS/ML	N86357
HEPARIN LOCK FLUSH	10 UNITS/ML	N89063
HEPARIN LOCK FLUSH	100 UNITS/ML	N89064
HEPARIN LOCK FLUSH	10 UNITS/ML	N17346
HEPARIN LOCK FLUSH	10 UNITS/ML	N87904
HEPARIN LOCK FLUSH	10 UNITS/ML	N87958
HEPARIN LOCK FLUSH	10 UNITS/ML	N88458
HEPARIN LOCK FLUSH	10 UNITS/ML	N88580
HEPARIN LOCK FLUSH	100 UNITS/ML	N87906
HEPARIN LOCK FLUSH	100 UNITS/ML	N87959
HEPARIN LOCK FLUSH	100 UNITS/ML	N88460
HEPARIN LOCK FLUSH	100 UNITS/ML	N88581
HEPARIN LOCK FLUSH	10 UNITS/ML	N87903
HEPARIN LOCK FLUSH	10 UNITS/ML	N88457
HEPARIN LOCK FLUSH	100 UNITS/ML	N87905
HEPARIN LOCK FLUSH	100 UNITS/ML	N88459
HEPARIN LOCK FLUSH	100 UNITS/ML	N17064
HEPARIN LOCK FLUSH PRESERVATIVE FREE	10 UNITS/ML	N17029

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM

INJECTABLE

HEPARIN LOCK FLUSH PRESERVATIVE FREE	100 UNITS/ML	N17029
HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER	10 UNITS/ML	N17029
HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER	100 UNITS/ML	N17029
HEPARIN SODIUM	10,000 UNITS/ML	N40095
HEPARIN SODIUM	1,000 UNITS/ML	N17486
HEPARIN SODIUM	10,000 UNITS/ML	N17486
HEPARIN SODIUM	20,000 UNITS/ML	N17486
HEPARIN SODIUM	40,000 UNITS/ML	N17486
HEPARIN SODIUM	5,000 UNITS/ML	N17486
HEPARIN SODIUM	1,000 UNITS/ML	N17033
HEPARIN SODIUM	1,000 UNITS/ML	N17651
HEPARIN SODIUM	10,000 UNITS/ML	N17651
HEPARIN SODIUM	20,000 UNITS/ML	N17651
HEPARIN SODIUM	5,000 UNITS/ML	N17029
HEPARIN SODIUM	5,000 UNITS/ML	N17979
HEPARIN SODIUM	1,000 UNITS/ML	N17007
HEPARIN SODIUM	10,000 UNITS/ML	N17007
HEPARIN SODIUM	15,000 UNITS/ML	N17007
HEPARIN SODIUM	2,500 UNITS/ML	N17007
HEPARIN SODIUM	20,000 UNITS/ML	N17007
HEPARIN SODIUM	5,000 UNITS/0.5ML	N17007
HEPARIN SODIUM	5,000 UNITS/ML	N17007
HEPARIN SODIUM	7,500 UNITS/ML	N17007
HEPARIN SODIUM	1,000 UNITS/ML	N17130
HEPARIN SODIUM	10,000 UNITS/ML	N17130
HEPARIN SODIUM	20,000 UNITS/ML	N17130
HEPARIN SODIUM	5,000 UNITS/ML	N17130
HEPARIN SODIUM	1,000 UNITS/ML	N17540
HEPARIN SODIUM	10,000 UNITS/ML	N17540
HEPARIN SODIUM	20,000 UNITS/ML	N17540
HEPARIN SODIUM	40,000 UNITS/ML	N17540
HEPARIN SODIUM	5,000 UNITS/ML	N17540
HEPARIN SODIUM	1,000 UNITS/ML	N05521
HEPARIN SODIUM	20,000 UNITS/ML	N05521
HEPARIN SODIUM	1,000 UNITS/ML	N87452
HEPARIN SODIUM	1,000 UNITS/ML	N00552
HEPARIN SODIUM	10,000 UNITS/ML	N00552
HEPARIN SODIUM	5,000 UNITS/ML	N00552
HEPARIN SODIUM	1,000 UNITS/ML	N17346
HEPARIN SODIUM	10,000 UNITS/ML	N17346
HEPARIN SODIUM	20,000 UNITS/ML	N17346
HEPARIN SODIUM	5,000 UNITS/ML	N17346
HEPARIN SODIUM	7,500 UNITS/ML	N17346

HEPARIN SODIUM

INJECTABLE

HEPARIN SODIUM	1,000 UNITS/ML	N17780
HEPARIN SODIUM	10,000 UNITS/ML	N17780
HEPARIN SODIUM	20,000 UNITS/ML	N17780
HEPARIN SODIUM	40,000 UNITS/ML	N17780
HEPARIN SODIUM	5,000 UNITS/ML	N17780
HEPARIN SODIUM	1,000 UNITS/ML	N88239
HEPARIN SODIUM	1,000 UNITS/ML	N87043
HEPARIN SODIUM	10,000 UNITS/0.5ML	N87363
HEPARIN SODIUM	10,000 UNITS/ML	N87107
HEPARIN SODIUM	5,000 UNITS/0.5ML	N87395
HEPARIN SODIUM	5,000 UNITS/ML	N87077
HEPARIN SODIUM	1,000 UNITS/ML	N17064
HEPARIN SODIUM	10,000 UNITS/ML	N17064
HEPARIN SODIUM	2,500 UNITS/ML	N17064
HEPARIN SODIUM	20,000 UNITS/ML	N17064
HEPARIN SODIUM	3,000 UNITS/ML	N17064
HEPARIN SODIUM	4,000 UNITS/ML	N17064
HEPARIN SODIUM	40,000 UNITS/ML	N17064
HEPARIN SODIUM	5,000 UNITS/ML	N17064
HEPARIN SODIUM	6,000 UNITS/ML	N17064
HEPARIN SODIUM	7,500 UNITS/ML	N17064
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER	200 UNITS/100ML	N19130
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	200 UNITS/100ML	N19042
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%	10,000 UNITS/100ML	N18911
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER	2,000 UNITS/100ML	N18814
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%	10,000 UNITS/100ML	N18911
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%	10,000 UNITS/100ML	N18916
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%	10,000 UNITS/100ML	N18911
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%	10,000 UNITS/100ML	N18916
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%	5,000 UNITS/100ML	N18911
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	5,000 UNITS/100ML	N19802
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%	5,000 UNITS/100ML	N18911
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%	5,000 UNITS/100ML	N18916
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER	200 UNITS/100ML	N19130
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	200 UNITS/100ML	N19042
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%	10,000 UNITS/100ML	N18911

FDA data supplied by DrugPatentWatch.com

HEPARIN SODIUM

INJECTABLE

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%	5,000 UNITS/100ML	N18911
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER	5,000 UNITS/100ML	N19134
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	10,000 UNITS/100ML	N19802
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	5,000 UNITS/100ML	N19802
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%	5,000 UNITS/100ML	N18911
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	5,000 UNITS/100ML	N18916
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	5,000 UNITS/100ML	N19135
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	5,000 UNITS/100ML	N19802
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	500 UNITS/100ML	N18609
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER	1,000 UNITS/100ML	N19130
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%	100 UNITS/ML	N18911
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%	100 UNITS/ML	N18916
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%	1,000 UNITS/100ML	N18916
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	1,000 UNITS/100ML	N19042
HEPARIN SODIUM PRESERVATIVE FREE	1,000 UNITS/ML	N86129
LIPO-HEPIN	1,000 UNITS/0.5ML	N17027
LIPO-HEPIN	1,000 UNITS/ML	N17027
LIPO-HEPIN	10,000 UNITS/0.5ML	N17027
LIPO-HEPIN	10,000 UNITS/ML	N17027
LIPO-HEPIN	15,000 UNITS/0.5ML	N17027
LIPO-HEPIN	20,000 UNITS/0.5ML	N17027
LIPO-HEPIN	20,000 UNITS/ML	N17027
LIPO-HEPIN	40,000 UNITS/ML	N17027
LIPO-HEPIN	5,000 UNITS/0.5ML	N17027
LIPO-HEPIN	5,000 UNITS/ML	N17027
LIPO-HEPIN	7,500 UNITS/0.5ML	N17027
LIQUAEMIN LOCK FLUSH	100 UNITS/ML	N00552
LIQUAEMIN SODIUM	1,000 UNITS/ML	N00552
LIQUAEMIN SODIUM	10,000 UNITS/ML	N00552
LIQUAEMIN SODIUM	20,000 UNITS/ML	N00552
LIQUAEMIN SODIUM	40,000 UNITS/ML	N00552
LIQUAEMIN SODIUM	5,000 UNITS/ML	N00552
LIQUAEMIN SODIUM PRESERVATIVE FREE	1,000 UNITS/ML	N00552
LIQUAEMIN SODIUM PRESERVATIVE FREE	10,000 UNITS/ML	N00552
LIQUAEMIN SODIUM PRESERVATIVE FREE	5,000 UNITS/ML	N00552

HEPARIN SODIUM

INJECTABLE

PANHEPRIN	1,000 UNITS/ML	N05264
PANHEPRIN	10,000 UNITS/ML	N05264
PANHEPRIN	20,000 UNITS/ML	N05264
PANHEPRIN	40,000 UNITS/ML	N05264
PANHEPRIN	5,000 UNITS/ML	N05264
SODIUM HEPARIN	10,000 UNITS/ML	N17033
SODIUM HEPARIN	20,000 UNITS/ML	N17033
SODIUM HEPARIN	5,000 UNITS/ML	N17033
SODIUM HEPARIN	1,000 UNITS/ML	N17036

HETACILLIN

FOR SUSPENSION

VERSAPEN	EQ 112.5MG AMPICIL/5ML	N50060
VERSAPEN	EQ 112.5MG AMPICIL/ML	N50060
VERSAPEN	EQ 112.5MG AMPICIL/ML	N61398
VERSAPEN	EQ 225MG AMPICIL/5ML	N61398

HETACILLIN POTASSIUM

CAPSULE

VERSAPEN-K	EQ 225MG AMPICIL	N61396
VERSAPEN-K	EQ 450MG AMPICIL	N61396

HEXACHLOROPHENE

AEROSOL

SEPTISOL	0.23%	N17424
TURGEX	3%	N18375

EMULSION

HEXA-GERM	3%	N17411
PHISOHEX	3%	N08402
SOY-DOME	3%	N17405
TURGEX	3%	N19055

SOAP

GAMOPHEN	2%	N06270

SOLUTION

DIAL	0.25%	N17421
GERMA-MEDICA	1%	N17412
GERMA-MEDICA "MG"	0.25%	N17412
SEPTI-SOFT	0.25%	N17460
SEPTISOL	0.25%	N17423

SPONGE

E-Z SCRUB	450MG	N17452
HEXASCRUB	3%	N18363
PHISO-SCRUB	3%	N17446
SCRUBTEAM SURGICAL SPONGEBRUSH	330MG	N17413

FDA data supplied by DrugPatentWatch.com

HEXAFLUORENIUM BROMIDE		
INJECTABLE		
MYLAXEN	20MG/ML	N09789
HEXOCYCLIUM METHYLSULFATE		
TABLET		
TRAL	25MG	N10599
HEXYLCAINE HYDROCHLORIDE		
SOLUTION		
CYCLAINE	5%	N08472
HISTAMINE PHOSPHATE		
INJECTABLE		
HISTAMINE PHOSPHATE	EQ 0.1MG BASE/ML	N00734
HISTAMINE PHOSPHATE	EQ 0.2MG BASE/ML	N00734
HISTAMINE PHOSPHATE	EQ 1MG BASE/ML	N00734
HISTRELIN ACETATE		
INJECTABLE		
SUPPRELIN	EQ 0.2MG BASE/ML	N19836
SUPPRELIN	EQ 0.5MG BASE/ML	N19836
SUPPRELIN	EQ 1MG BASE/ML	N19836
HOMATROPINE METHYLBROMIDE		
TABLET		
HOMAPIN-10	10MG	N86308
HOMAPIN-5	5MG	N86309
TABLET, CHEWABLE		
EQUIPIN	3MG	N86310
HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE		
SYRUP		
HYDROPANE	1.5MG/5ML;5MG/5ML	N88066
HYALURONIDASE		
INJECTABLE		
WYDASE	1,500 UNITS/VIAL	* N06343
WYDASE	150 UNITS/ML	* N06343
WYDASE	150 UNITS/VIAL	* N06343
HYDRALAZINE HYDROCHLORIDE		
INJECTABLE		
APRESOLINE	20MG/ML	N08303
HYDRALAZINE HCL	20MG/ML	N89532
HYDRALAZINE HCL	20MG/ML	N88518
HYDRALAZINE HCL	20MG/ML	N88517
TABLET		
DRALZINE	25MG	N84301
HYDRALAZINE HCL	25MG	N88560
HYDRALAZINE HCL	50MG	N88649
HYDRALAZINE HCL	25MG	N88310

HYDRALAZINE HYDROCHLORIDE		
TABLET		
HYDRALAZINE HCL	50MG	N88311
HYDRALAZINE HCL	25MG	N86243
HYDRALAZINE HCL	50MG	N86242
HYDRALAZINE HCL	50MG	N85088
HYDRALAZINE HCL	100MG	N88729
HYDRALAZINE HCL	100MG	N89178
HYDRALAZINE HCL	10MG	N88728
HYDRALAZINE HCL	10MG	N89218
HYDRALAZINE HCL	25MG	N84106
HYDRALAZINE HCL	25MG	N89130
HYDRALAZINE HCL	50MG	N84107
HYDRALAZINE HCL	50MG	N89222
HYDRALAZINE HCL	25MG	N84922
HYDRALAZINE HCL	50MG	N84923
HYDRALAZINE HCL	100MG	N84581
HYDRALAZINE HCL	10MG	N84443
HYDRALAZINE HCL	25MG	N84437
HYDRALAZINE HCL	50MG	N84469
HYDRALAZINE HCL	25MG	N88177
HYDRALAZINE HCL	50MG	N88178
HYDRALAZINE HCL	100MG	N88686
HYDRALAZINE HCL	10MG	N88671
HYDRALAZINE HCL	25MG	N88657
HYDRALAZINE HCL	50MG	N88652
HYDRALAZINE HCL	10MG	N88787
HYDRALAZINE HCL	25MG	N88788
HYDRALAZINE HCL	50MG	N88789
HYDRALAZINE HCL	25MG	N87780
HYDRALAZINE HCL	50MG	N87751
HYDRALAZINE HCL	25MG	N87712
HYDRALAZINE HCL	50MG	N87908
HYDRALAZINE HCL	25MG	N86088
HYDRALAZINE HCL	25MG	N85532
HYDRALAZINE HCL	50MG	N85533
HYDRALAZINE HCL	25MG	N88240
HYDRALAZINE HCL	50MG	N88241
HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE		
CAPSULE		
APRESAZIDE	100MG;50MG	N84811
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	100MG;50MG	N87609
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	25MG;25MG	N87608
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	50MG;50MG	N87213
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	25MG;25MG	N89200
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	50MG;50MG	N89201

FDA data supplied by DrugPatentWatch.com

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE

HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	100MG;50MG	N85440
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	25MG;25MG	N85457
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	50MG;50MG	N85446
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 100/50	100MG;50MG	N88358
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 25/25	25MG;25MG	N88356
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 50/50	50MG;50MG	N88357

TABLET

APRESOLINE-ESIDRIX	25MG;15MG	N12026
HYDRALAZINE AND HYDROCHLORTHIAZIDE	25MG;15MG	N85827
HYDROCHLOROTHIAZIDE W/ HYDRALAZINE	25MG;15MG	N85373

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET

CAM-AP-ES	25MG;15MG;0.1MG	N84897
HYDRALAZINE HCL, HYDROCHLOROTHIAZIDE AND RESERPINE	25MG;15MG;0.1MG	N84291
HYDRALAZINE HCL-HYDROCHLOROTHIAZIDE-RESERPINE	25MG;15MG;0.1MG	N87085
HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE	25MG;15MG;0.1MG	N85771
HYDRAP-ES	25MG;15MG;0.1MG	N84876
HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE	25MG;15MG;0.1MG	N83770
HYDROSERPINE PLUS (R-H-H)	25MG;15MG;0.1MG	N83877
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	25MG;15MG;0.1MG	N88570
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	25MG;15MG;0.1MG	N88376
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	25MG;15MG;0.1MG	N85549
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE	25MG;15MG;0.1MG	N87556
RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HCL	25MG;15MG;0.1MG	N87709
SER-A-GEN	25MG;15MG;0.1MG	N87210
SER-AP-ES	25MG;15MG;0.1MG	N12193
UNIPRES	25MG;15MG;0.1MG	N85893
UNIPRES	25MG;15MG;0.1MG	N86298

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET

DRALSERP	25MG;0.1MG	N84617
SERPASIL-APRESOLINE	25MG;0.1MG	N09296
SERPASIL-APRESOLINE	50MG;0.2MG	N09296

HYDROCHLOROTHIAZIDE

SOLUTION

HYDROCHLOROTHIAZIDE	50MG/5ML	N89661
HYDROCHLOROTHIAZIDE INTENSOL	100MG/ML	N88588

TABLET

ESIDRIX	100MG	N11793
HYDROCHLOROTHIAZIDE	25MG	N86369
HYDROCHLOROTHIAZIDE	50MG	N83554
HYDROCHLOROTHIAZIDE	25MG	N87539
HYDROCHLOROTHIAZIDE	50MG	N87540
HYDROCHLOROTHIAZIDE	50MG	N84771
HYDROCHLOROTHIAZIDE	100MG	N87060
HYDROCHLOROTHIAZIDE	50MG	N85152
HYDROCHLOROTHIAZIDE	25MG	N83899
HYDROCHLOROTHIAZIDE	100MG	N83972
HYDROCHLOROTHIAZIDE	25MG	N83972
HYDROCHLOROTHIAZIDE	50MG	N83972
HYDROCHLOROTHIAZIDE	50MG	N84135
HYDROCHLOROTHIAZIDE	100MG	N85098
HYDROCHLOROTHIAZIDE	25MG	N84029
HYDROCHLOROTHIAZIDE	50MG	N83607
HYDROCHLOROTHIAZIDE	25MG	N84776
HYDROCHLOROTHIAZIDE	25MG	N85067
HYDROCHLOROTHIAZIDE	50MG	N84776
HYDROCHLOROTHIAZIDE	50MG	N84658
HYDROCHLOROTHIAZIDE	25MG	N86192
HYDROCHLOROTHIAZIDE	50MG	N86192
HYDROCHLOROTHIAZIDE	25MG	N84880
HYDROCHLOROTHIAZIDE	50MG	N85112
HYDROCHLOROTHIAZIDE	25MG	N84325
HYDROCHLOROTHIAZIDE	50MG	N84324
HYDROCHLOROTHIAZIDE	50MG	N86597
HYDROCHLOROTHIAZIDE	25MG	N85004
HYDROCHLOROTHIAZIDE	50MG	N84536
HYDROCHLOROTHIAZIDE	50MG	N85005
HYDROCHLOROTHIAZIDE	25MG	N85323
HYDROCHLOROTHIAZIDE	100MG	N88829
HYDROCHLOROTHIAZIDE	25MG	N88827
HYDROCHLOROTHIAZIDE	50MG	N88828
HYDROCHLOROTHIAZIDE	25MG	N88924
HYDROCHLOROTHIAZIDE	50MG	N88923
HYDROCHLOROTHIAZIDE	25MG	N87827
HYDROCHLOROTHIAZIDE	50MG	N87752
HYDROCHLOROTHIAZIDE	25MG	N87638
HYDROCHLOROTHIAZIDE	50MG	N87610
HYDROCHLOROTHIAZIDE	25MG	N87586
HYDROCHLOROTHIAZIDE	50MG	N87587

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE

TABLET

HYDROCHLOROTHIAZIDE	100MG	N81190
HYDROCHLOROTHIAZIDE	100MG	N85099
HYDROCHLOROTHIAZIDE	100MG	N87002
HYDROCHLOROTHIAZIDE	25MG	N83458
HYDROCHLOROTHIAZIDE	25MG	N85232
HYDROCHLOROTHIAZIDE	50MG	N83232
HYDROCHLOROTHIAZIDE	50MG	N83456
HYDROCHLOROTHIAZIDE	50MG	N85233
HYDROCHLOROTHIAZIDE	50MG	N86087
HYDROCHLOROTHIAZIDE	50MG	N86594
HYDROCHLOROTHIAZIDE	25MG	N84899
HYDROCHLOROTHIAZIDE	50MG	N84878
HYDROCHLOROTHIAZIDE	100MG	N85347
HYDROCHLOROTHIAZIDE	25MG	N83809
HYDROCHLOROTHIAZIDE	50MG	N83809
HYDRO-D	25MG	N86504
HYDRO-D	50MG	N83891
HYDRODIURIL	100MG	*N11835
HYDRODIURIL	25MG	*N11835
HYDRODIURIL	50MG	*N11835
ORETIC	25MG	N11971
ZIDE	50MG	N83925

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET

AVALIDE	12.5MG;75MG	N20758

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET

NORMOZIDE	25MG;100MG	N19046
NORMOZIDE	25MG;200MG	N19046
NORMOZIDE	25MG;300MG	N19046
NORMOZIDE	25MG;400MG	N19046
TRANDATE HCT	25MG;100MG	N19174
TRANDATE HCT	25MG;200MG	N19174
TRANDATE HCT	25MG;300MG	N19174
TRANDATE HCT	25MG;400MG	N19174

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET

METHYLDOPA AND HYDROCHLOROTHIAZIDE	15MG;250MG	N72507
METHYLDOPA AND HYDROCHLOROTHIAZIDE	25MG;250MG	N72508
METHYLDOPA AND HYDROCHLOROTHIAZIDE	30MG;500MG	N72509
METHYLDOPA AND HYDROCHLOROTHIAZIDE	50MG;500MG	N72510
METHYLDOPA AND HYDROCHLOROTHIAZIDE	15MG;250MG	N71458
METHYLDOPA AND HYDROCHLOROTHIAZIDE	25MG;250MG	N71459
METHYLDOPA AND HYDROCHLOROTHIAZIDE	30MG;500MG	N71460

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET

METHYLDOPA AND HYDROCHLOROTHIAZIDE	50MG;500MG	N71461
METHYLDOPA AND HYDROCHLOROTHIAZIDE	15MG;250MG	N71897
METHYLDOPA AND HYDROCHLOROTHIAZIDE	25MG;250MG	N71898
METHYLDOPA AND HYDROCHLOROTHIAZIDE	30MG;500MG	N71899
METHYLDOPA AND HYDROCHLOROTHIAZIDE	50MG;500MG	N71900
METHYLDOPA AND HYDROCHLOROTHIAZIDE	15MG;250MG	N70853
METHYLDOPA AND HYDROCHLOROTHIAZIDE	25MG;250MG	N70688
METHYLDOPA AND HYDROCHLOROTHIAZIDE	30MG;500MG	N70854
METHYLDOPA AND HYDROCHLOROTHIAZIDE	50MG;500MG	N70689
METHYLDOPA AND HYDROCHLOROTHIAZIDE	15MG;250MG	N70829
METHYLDOPA AND HYDROCHLOROTHIAZIDE	25MG;250MG	N70830
METHYLDOPA AND HYDROCHLOROTHIAZIDE	15MG;250MG	N71819
METHYLDOPA AND HYDROCHLOROTHIAZIDE	25MG;250MG	N71820
METHYLDOPA AND HYDROCHLOROTHIAZIDE	30MG;500MG	N71821
METHYLDOPA AND HYDROCHLOROTHIAZIDE	50MG;500MG	N71822
METHYLDOPA AND HYDROCHLOROTHIAZIDE	15MG;250MG	N70365
METHYLDOPA AND HYDROCHLOROTHIAZIDE	15MG;250MG	N71920
METHYLDOPA AND HYDROCHLOROTHIAZIDE	25MG;250MG	N70366
METHYLDOPA AND HYDROCHLOROTHIAZIDE	25MG;250MG	N71921
METHYLDOPA AND HYDROCHLOROTHIAZIDE	30MG;500MG	N70367
METHYLDOPA AND HYDROCHLOROTHIAZIDE	30MG;500MG	N71922
METHYLDOPA AND HYDROCHLOROTHIAZIDE	50MG;500MG	N70368
METHYLDOPA AND HYDROCHLOROTHIAZIDE	50MG;500MG	N71923

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET

VISKAZIDE	25MG;10MG	N18872
VISKAZIDE	25MG;5MG	N18872

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE

INDERIDE LA 120/50	50MG;120MG	N19059
INDERIDE LA 160/50	50MG;160MG	N19059
INDERIDE LA 80/50	50MG;80MG	N19059

TABLET

PROPRANOLOL HCL & HYDROCHLOROTHIAZIDE	25MG;40MG	N71126
PROPRANOLOL HCL & HYDROCHLOROTHIAZIDE	25MG;80MG	N71127
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE	25MG;40MG	N71552
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE	25MG;80MG	N71553
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE	25MG;40MG	N71771
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE	25MG;80MG	N71772
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE	25MG;40MG	N71498
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE	25MG;80MG	N71501

FDA data supplied by DrugPatentWatch.com

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET

H.R.-50	50MG;0.125MG	N85338
HYDROCHLOROTHIAZIDE W/ RESERPINE	25MG;0.125MG	N83571
HYDROCHLOROTHIAZIDE W/ RESERPINE	25MG;0.1MG	N83572
HYDROCHLOROTHIAZIDE W/ RESERPINE	50MG;0.125MG	N83573
HYDROCHLOROTHIAZIDE W/ RESERPINE	50MG;0.1MG	N83568
HYDROCHLOROTHIAZIDE W/ RESERPINE	25MG;0.125MG	N85421
HYDROCHLOROTHIAZIDE W/ RESERPINE	50MG;0.125MG	N85420
HYDROCHLOROTHIAZIDE W/ RESERPINE	50MG;0.125MG	N84603
HYDROCHLOROTHIAZIDE W/ RESERPINE	25MG;0.125MG	N84466
HYDROCHLOROTHIAZIDE W/ RESERPINE	25MG;0.125MG	N85317
HYDROCHLOROTHIAZIDE W/ RESERPINE	25MG;0.125MG	N86330
HYDROCHLOROTHIAZIDE W/ RESERPINE	50MG;0.125MG	N83666
HYDROCHLOROTHIAZIDE W/ RESERPINE	50MG;0.125MG	N84467
HYDROCHLOROTHIAZIDE W/ RESERPINE	50MG;0.125MG	N86331
HYDROPRES 25	25MG;0.125MG	N11958
HYDROPRES 50	50MG;0.125MG	N11958
HYDRO-RESERP	50MG;0.125MG	N84714
HYDRO-SERP "25"	25MG;0.125MG	N84827
HYDRO-SERP "50"	50MG;0.125MG	N85213
RESERPINE AND HYDROCHLOROTHIAZIDE	25MG;0.125MG	N84580
RESERPINE AND HYDROCHLOROTHIAZIDE	50MG;0.125MG	N84579
RESERPINE AND HYDROCHLOROTHIAZIDE	50MG;0.125MG	N88200
RESERPINE AND HYDROCHLOROTHIAZIDE-50	50MG;0.125MG	N88189
SERPASIL-ESIDRIX #1	25MG;0.1MG	N11878
SERPASIL-ESIDRIX #2	50MG;0.1MG	N11878

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET

SPIRONOLACTONE + HYDROCHLOROTHIAZIDE	25MG;25MG	N88025
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE	25MG;25MG	N87999
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE	25MG;25MG	N89137
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE	25MG;25MG	N87004
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE	25MG;25MG	N87511
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE	25MG;25MG	N87948
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE	25MG;25MG	N88054
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE	25MG;25MG	N87553
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE	25MG;25MG	N87651
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE	25MG;25MG	N87655
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE	25MG;25MG	N85974
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE	25MG;25MG	N86026

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE

DYAZIDE	25MG;50MG	N16042
TRIAMTERENE AND HYDROCHLOROTHIAZIDE	25MG;37.5MG	N74857
TRIAMTERENE AND HYDROCHLOROTHIAZIDE	25MG;50MG	N71737

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET

TRIAMTERENE AND HYDROCHLOROTHIAZIDE	50MG;75MG	N72022
TRIAMTERENE AND HYDROCHLOROTHIAZIDE	50MG;75MG	N71980

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP

CODAMINE	5MG/5ML;25MG/5ML	N75103
HYCOMINE	5MG/5ML;25MG/5ML	N19410
HYCOMINE PEDIATRIC	2.5MG/5ML;12.5MG/5ML	N19411

HYDROCORTAMATE HYDROCHLORIDE

OINTMENT

MAGNACORT	0.5%	N10554

HYDROCORTISONE

AEROSOL

AEROSEB-HC	0.5%	N85805

CREAM

CORT-DOME	0.5%	N09585
CORT-DOME	1%	N09585
DERMACORT	1%	N83011
ELDECORT	1%	N80459
ELDECORT	2.5%	N84055
FLEXICORT	0.5%	N87136
FLEXICORT	1%	N87136
FLEXICORT	2.5%	N87136
HC #1	0.5%	N80438
HC #4	1%	N80438
HC (HYDROCORTISONE)	0.5%	N80482
HC (HYDROCORTISONE)	1%	N80482
H-CORT	0.5%	N86823
HYDROCORTISONE	2.5%	N89754
HYDROCORTISONE	0.5%	N80848
HYDROCORTISONE	1%	N80848
HYDROCORTISONE	1%	N86080
HYDROCORTISONE	2.5%	N86271
HYDROCORTISONE	0.5%	N84970
HYDROCORTISONE	1%	N85026
HYDROCORTISONE	0.5%	N80452
HYDROCORTISONE	1%	N84059
HYDROCORTISONE	1%	N85733
HYDROCORTISONE	1%	N89706
HYDROCORTISONE	1%	N88845
HYDROCORTISONE	2.5%	N89413
HYDROCORTISONE	1%	N87838
HYDROCORTISONE	1%	N86170
HYDROCORTISONE	0.5%	N85527
HYDROCORTISONE	0.5%	N86154

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE

CREAM

HYDROCORTISONE	0.5%	N80400
HYDROCORTISONE	1%	N80400
HYDROCORTISONE	1%	N85191
HYDROCORTISONE	2.5%	N80400
HYDROCORTISONE	1%	N89273
HYDROCORTISONE	1%	N88027
HYDROCORTISONE	2.5%	N88029
HYDROCORTISONE	1%	N80496
NOGENIC HC	1%	N87427
NUTRACORT	0.5%	N80442
NUTRACORT	1%	N80442
PROCTOCORT	1%	N83011
SYNACORT	0.5%	N87459

GEL

NUTRACORT	1%	N84698
PENECORT	1%	N88215

INJECTABLE

CORTEF	50MG/ML	N09864

LOTION

ACTICORT	1%	N86535
BALNEOL-HC	1%	N88041
BETA-HC	1%	N89495
CORT-DOME	0.5%	N09895
CORT-DOME	1%	N09895
DERMACORT	0.5%	N84573
DERMACORT	1%	N86462
EPICORT	0.5%	N83219
GLYCORT	1%	N87489
H-CORT	0.5%	N86824
HYDROCORTISONE	0.5%	N87317
HYDROCORTISONE	1%	N87315
HYDROCORTISONE	0.5%	N85662
HYDROCORTISONE	1%	N85663
HYDROCORTISONE	0.5%	N85282
HYDROCORTISONE	1%	N85282
HYDROCORTISONE	1%	N89705
HYDROCORTISONE	1%	N89024
NUTRACORT	0.5%	N80443

OINTMENT

HC (HYDROCORTISONE)	0.5%	N80481
HC (HYDROCORTISONE)	1%	N80481
HYDROCORTISONE	0.5%	N80489
HYDROCORTISONE	1%	N80489
HYDROCORTISONE	1%	N86079
HYDROCORTISONE	2.5%	N86272

HYDROCORTISONE

OINTMENT

HYDROCORTISONE	0.5%	N84969
HYDROCORTISONE	1%	N85028
HYDROCORTISONE	1%	N89704
HYDROCORTISONE	1%	N88842
HYDROCORTISONE	0.5%	N86256
HYDROCORTISONE	1%	N88061
HYDROCORTISONE	2.5%	N88039
HYTONE	1%	N80474
HYTONE	2.5%	N80474
PENECORT	2.5%	N88217

POWDER

H-CORT	100%	N87834
HYDROCORTISONE	100%	N88082

TABLET

CORTRIL	10MG	N09796
CORTRIL	10MG	N09127
CORTRIL	20MG	N09127
HYDROCORTISONE	20MG	N83140
HYDROCORTISONE	20MG	N83999
HYDROCORTISONE	20MG	N80624
HYDROCORTISONE	20MG	N80642
HYDROCORTISONE	10MG	N80568
HYDROCORTISONE	20MG	N80568
HYDROCORTISONE	20MG	N80781
HYDROCORTISONE	20MG	N80732
HYDROCORTISONE	20MG	N85070
HYDROCORTISONE	10MG	N09659
HYDROCORTISONE	20MG	N09659
HYDROCORTISONE	20MG	N84243
HYDROCORTISONE	10MG	N84247
HYDROCORTISONE	20MG	N80395
HYDROCORTISONE	20MG	N84247
HYDROCORTISONE	10MG	N88539
HYDROCORTISONE	20MG	N80355
HYDROCORTISONE	10MG	N80344
HYDROCORTISONE	20MG	N80344

HYDROCORTISONE ACETATE

CREAM

HEMSOL-HC	1%	N81274
HYDROCORTISONE ACETATE	1%	N80419
HYDROCORTISONE ACETATE	1%	N89914
HYDROCORTISONE ACETATE	0.5%	N86050
HYDROCORTISONE ACETATE	1%	N86052

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE ACETATE		
INJECTABLE		
CORTEF ACETATE	50MG/ML	N09378
CORTRIL	25MG/ML	N09164
HYDROCORTISONE ACETATE	25MG/ML	N09637
HYDROCORTISONE ACETATE	50MG/ML	N09637
HYDROCORTISONE ACETATE	25MG/ML	N83739
HYDROCORTISONE ACETATE	50MG/ML	N83739
HYDROCORTISONE ACETATE	25MG/ML	N83128
HYDROCORTISONE ACETATE	25MG/ML	N83759
HYDROCORTISONE ACETATE	50MG/ML	N83759
HYDROCORTISONE ACETATE	50MG/ML	N85214
HYDROCORTONE	25MG/ML	N08228
HYDROCORTONE	50MG/ML	N08228
OINTMENT		
CORTEF ACETATE	1%	N08917
CORTEF ACETATE	2.5%	* N08917
HYDROCORTISONE ACETATE	0.5%	N80828
HYDROCORTONE	1.5%	N09018
HYDROCORTISONE ACETATE; NEOMYCIN SULFATE		
CREAM		
NEO-CORTEF	1%;EQ 3.5MG BASE/GM	N61049
NEO-CORTEF	2.5%;EQ 3.5MG BASE/GM	N61049
OINTMENT		
NEO-CORTEF	0.5%;EQ 3.5MG BASE/GM	N60610
NEO-CORTEF	0.5%;EQ 3.5MG BASE/GM	N60751
NEO-CORTEF	1%;EQ 3.5MG BASE/GM	N60751
NEO-CORTEF	1.5%;EQ 3.5MG BASE/GM	N60610
NEO-CORTEF	2.5%;EQ 3.5MG BASE/GM	N60751
SUSPENSION/DROPS		
COR-OTICIN	1.5%;EQ 3.5MG BASE/ML	N60188
NEO-CORTEF	0.5%;EQ 3.5MG BASE/ML	N60612
NEO-CORTEF	1.5%;EQ 3.5MG BASE/ML	N60612
HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE		
LOTION		
PRAMOSONE	0.5%;1%	N83213
HYDROCORTISONE BUTYRATE		
CREAM		
LOCOID	0.1%	N18795
OINTMENT		
LOCOID	0.1%	N19106
SOLUTION		
LOCOID	0.1%	N19819

HYDROCORTISONE CYPIONATE		
SUSPENSION		
CORTEF	EQ 10MG BASE/5ML	N09900
HYDROCORTISONE SODIUM PHOSPHATE		
INJECTABLE		
HYDROCORTONE	EQ 50MG BASE/ML	N12052
HYDROCORTISONE SODIUM SUCCINATE		
INJECTABLE		
A-HYDROCORT	EQ 100MG BASE/VIAL	N85928
A-HYDROCORT	EQ 100MG BASE/VIAL	N89577
A-HYDROCORT	EQ 1GM BASE/VIAL	N89580
A-HYDROCORT	EQ 250MG BASE/VIAL	N89578
A-HYDROCORT	EQ 500MG BASE/VIAL	N89579
HYDROCORTISONE SODIUM SUCCINATE	EQ 100MG BASE/VIAL	N88667
HYDROCORTISONE SODIUM SUCCINATE	EQ 100MG BASE/VIAL	N88712
HYDROCORTISONE SODIUM SUCCINATE	EQ 1GM BASE/VIAL	N88670
HYDROCORTISONE SODIUM SUCCINATE	EQ 250MG BASE/VIAL	N88668
HYDROCORTISONE SODIUM SUCCINATE	EQ 500MG BASE/VIAL	N88669
HYDROCORTISONE SODIUM SUCCINATE	EQ 100MG BASE/VIAL	N86619
HYDROCORTISONE SODIUM SUCCINATE	EQ 1GM BASE/VIAL	N87569
HYDROCORTISONE SODIUM SUCCINATE	EQ 250MG BASE/VIAL	N87567
HYDROCORTISONE SODIUM SUCCINATE	EQ 500MG BASE/VIAL	N87568
HYDROCORTISONE SODIUM SUCCINATE	EQ 100MG BASE/VIAL	N87532
HYDROCORTISONE SODIUM SUCCINATE	EQ 100MG BASE/VIAL	N84737
HYDROCORTISONE SODIUM SUCCINATE	EQ 100MG BASE/VIAL	N84738
HYDROCORTISONE SODIUM SUCCINATE	EQ 1GM BASE/VIAL	N84748
HYDROCORTISONE SODIUM SUCCINATE	EQ 250MG BASE/VIAL	N84737
HYDROCORTISONE SODIUM SUCCINATE	EQ 500MG BASE/VIAL	N84747
HYDROCORTISONE; NEOMYCIN SULFATE		
CREAM		
NEO-CORT-DOME	0.5%;EQ 3.5MG BASE/GM	N50237
NEO-CORT-DOME	1%;EQ 3.5MG BASE/GM	N50237
HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE		
SOLUTION/DROPS		
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62394
OTOCORT	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N60730
SUSPENSION/DROPS		
NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62617
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62623
OTICAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62399
OTOBIONE	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N61816

FDA data supplied by DrugPatentWatch.com

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS

OTOCORT	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62521

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS

OTOBIOTIC	5MG/ML;EQ 10,000 UNITS BASE/ML	N62302
PYOCIDIN	5MG/ML;EQ 10,000 UNITS BASE/ML	N61606

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

OINTMENT

ACHROMYCIN	1.5%;1%	N50272

HYDROCORTISONE; UREA

CREAM

ALPHADERM	1%;10%	N86008
CALMURID HC	1%;10%	N83947

HYDROFLUMETHIAZIDE

TABLET

DIUCARDIN	50MG	N83383
HYDROFLUMETHIAZIDE	50MG	N88031
HYDROFLUMETHIAZIDE	50MG	N88528

HYDROFLUMETHIAZIDE; RESERPINE

TABLET

HYDROFLUMETHIAZIDE AND RESERPINE	50MG;0.125MG	N88195
HYDROFLUMETHIAZIDE AND RESERPINE	25MG;0.125MG	N88127
HYDROFLUMETHIAZIDE AND RESERPINE	50MG;0.125MG	N88110
RESERPINE AND HYDROFLUMETHIAZIDE	50MG;0.125MG	N88932
RESERPINE AND HYDROFLUMETHIAZIDE	50MG;0.125MG	N88907
SALUTENSIN	50MG;0.125MG	N12359
SALUTENSIN-DEMI	25MG;0.125MG	N12359

HYDROXOCOBALAMIN

INJECTABLE

ALPHAREDISOL	1MG/ML	N80778
HYDROXOCOBALAMIN	1MG/ML	N84921
HYDROXOCOBALAMIN	1MG/ML	N85528
HYDROXOMIN	1MG/ML	N84629

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS

PAREDRINE	1%	N00004

HYDROXYPROGESTERONE CAPROATE

INJECTABLE

DELALUTIN	125MG/ML	N10347
DELALUTIN	125MG/ML	N16911
DELALUTIN	250MG/ML	N10347

HYDROXYPROGESTERONE CAPROATE

INJECTABLE

DELALUTIN	250MG/ML	N16911
HYDROXYPROGESTERONE CAPROATE	125MG/ML	N18004
HYDROXYPROGESTERONE CAPROATE	125MG/ML	N17439
HYDROXYPROGESTERONE CAPROATE	250MG/ML	N17439

HYDROXYSTILBAMIDINE ISETHIONATE

INJECTABLE

HYDROXYSTILBAMIDINE ISETHIONATE	225MG/AMP	N09166

HYDROXYZINE HYDROCHLORIDE

INJECTABLE

HYDROXYZINE	50MG/ML	N85551
HYDROXYZINE HCL	50MG/ML	N86821
HYDROXYZINE HCL	25MG/ML	N87273
HYDROXYZINE HCL	50MG/ML	N87273
HYDROXYZINE HCL	25MG/ML	N88184
HYDROXYZINE HCL	50MG/ML	N88185
HYDROXYZINE HCL	25MG/ML	N85551
HYDROXYZINE HCL	25MG/ML	N88862
HYDROXYZINE HCL	25MG/ML	N89106
HYDROXYZINE HCL	50MG/ML	N88881
HYDROXYZINE HCL	50MG/ML	N89107
HYDROXYZINE HCL	25MG/ML	N87592
HYDROXYZINE HCL	25MG/ML	N86822
HYDROXYZINE HCL	25MG/ML	N87591
HYDROXYZINE HCL	50MG/ML	N87310
HYDROXYZINE HCL	50MG/ML	N87593
HYDROXYZINE HCL	50MG/ML	N87595
HYDROXYZINE HCL	50MG/ML	N87596
HYDROXYZINE HCL	25MG/ML	N85778
HYDROXYZINE HCL	25MG/ML	N87274
HYDROXYZINE HCL	50MG/ML	N87274
HYDROXYZINE HCL	25MG/ML	N86258
HYDROXYZINE HCL	50MG/ML	N86258
ORGATRAX	25MG/ML	N87014
ORGATRAX	50MG/ML	N87014

SYRUP

HYDROXYZINE HCL	10MG/5ML	N88785
HYDROXYZINE HCL	10MG/5ML	N87730

TABLET

ATARAX	100MG	N10392
ATARAX	10MG	N10392
ATARAX	25MG	N10392
ATARAX	50MG	N10392
HYDROXYZINE HCL	10MG	N89071
HYDROXYZINE HCL	25MG	N89072

PDA data supplied by DrugPatentWatch.com

HYDROXYZINE HYDROCHLORIDE
TABLET

HYDROXYZINE HCL	50MG	N89073
HYDROXYZINE HCL	10MG	N87246
HYDROXYZINE HCL	25MG	N85247
HYDROXYZINE HCL	50MG	N87245
HYDROXYZINE HCL	100MG	N87862
HYDROXYZINE HCL	10MG	N88409
HYDROXYZINE HCL	10MG	N89366
HYDROXYZINE HCL	25MG	N87857
HYDROXYZINE HCL	25MG	N89117
HYDROXYZINE HCL	50MG	N87860
HYDROXYZINE HCL	50MG	N89396
HYDROXYZINE HCL	10MG	N87216
HYDROXYZINE HCL	25MG	N87410
HYDROXYZINE HCL	50MG	N87411
HYDROXYZINE HCL	100MG	N87822
HYDROXYZINE HCL	10MG	N87819
HYDROXYZINE HCL	25MG	N87820
HYDROXYZINE HCL	50MG	N87821
HYDROXYZINE HCL	10MG	N87602
HYDROXYZINE HCL	25MG	N87603
HYDROXYZINE HCL	50MG	N87604
HYDROXYZINE HCL	100MG	N81054
HYDROXYZINE HCL	10MG	N88120
HYDROXYZINE HCL	25MG	N88121
HYDROXYZINE HCL	50MG	N88122
HYDROXYZINE HCL	10MG	N88540
HYDROXYZINE HCL	25MG	N88551
HYDROXYZINE HCL	50MG	N88529
HYDROXYZINE HCL	10MG	N88794
HYDROXYZINE HCL	25MG	N88795
HYDROXYZINE HCL	50MG	N88796
HYDROXYZINE HCL	10MG	N89121
HYDROXYZINE HCL	25MG	N89122
HYDROXYZINE HCL	50MG	N89123
HYDROXYZINE HCL	10MG	N86827
HYDROXYZINE HCL	25MG	N86829
HYDROXYZINE HCL	50MG	N86836

HYDROXYZINE PAMOATE
CAPSULE

HYDROXYZINE PAMOATE	EQ 100MG HCL	N88595
HYDROXYZINE PAMOATE	EQ 25MG HCL	N88593
HYDROXYZINE PAMOATE	EQ 50MG HCL	N88594
HYDROXYZINE PAMOATE	EQ 100MG HCL	N87658
HYDROXYZINE PAMOATE	EQ 25MG HCL	N87656

HYDROXYZINE PAMOATE
CAPSULE

HYDROXYZINE PAMOATE	EQ 25MG HCL	N89145
HYDROXYZINE PAMOATE	EQ 50MG HCL	N87657
HYDROXYZINE PAMOATE	EQ 50MG HCL	N89146
HYDROXYZINE PAMOATE	EQ 100MG HCL	N81129
HYDROXYZINE PAMOATE	EQ 50MG HCL	N81128
HYDROXYZINE PAMOATE	EQ 100MG HCL	N89033
HYDROXYZINE PAMOATE	EQ 25MG HCL	N89031
HYDROXYZINE PAMOATE	EQ 50MG HCL	N89032
HYDROXYZINE PAMOATE	EQ 25MG HCL	N88392
HYDROXYZINE PAMOATE	EQ 50MG HCL	N88393
HYDROXYZINE PAMOATE	EQ 100MG HCL	N86697
HYDROXYZINE PAMOATE	EQ 100MG HCL	N86728
HYDROXYZINE PAMOATE	EQ 100MG HCL	N87790
HYDROXYZINE PAMOATE	EQ 25MG HCL	N86698
HYDROXYZINE PAMOATE	EQ 25MG HCL	N86840
HYDROXYZINE PAMOATE	EQ 50MG HCL	N86695
HYDROXYZINE PAMOATE	EQ 50MG HCL	N86705
HYDROXYZINE PAMOATE	EQ 50MG HCL	N87767
HY-PAM "25"	EQ 25MG HCL	N88713

IBANDRONATE SODIUM
TABLET

BONIVA	EQ 2.5MG BASE	N21455

IBUPROFEN
CAPSULE

MIDOL	200MG	* N70626
MIDOL	200MG	* N71002

SUSPENSION

IBU	100MG/5ML	N19784

SUSPENSION/DROPS

MOTRIN	40MG/ML	N20476

TABLET

ACHES-N-PAIN	200MG	N71065
IBUPRIN	200MG	N71773
IBUPROFEN	600MG	N70556
IBUPROFEN	800MG	N71264
IBUPROFEN	200MG	N70493
IBUPROFEN	200MG	N70908
IBUPROFEN	200MG	N71462
IBUPROFEN	400MG	N70079
IBUPROFEN	600MG	N70080
IBUPROFEN	800MG	N71448
IBUPROFEN	200MG	N71027
IBUPROFEN	300MG	N71028
IBUPROFEN	400MG	N71029

FDA data supplied by DrugPatentWatch.com

DISCONTINUED DRUG PRODUCT LIST

IBUPROFEN		
TABLET		
IBUPROFEN	600MG	N71030
IBUPROFEN	800MG	N72137
IBUPROFEN	200MG	N71154
IBUPROFEN	200MG	N72040
IBUPROFEN	400MG	N70629
IBUPROFEN	600MG	N70630
IBUPROFEN	400MG	N70081
IBUPROFEN	600MG	N70476
IBUPROFEN	300MG	N70328
IBUPROFEN	200MG	N71122
IBUPROFEN	200MG	N71664
IBUPROFEN	300MG	N71123
IBUPROFEN	400MG	N71124
IBUPROFEN	600MG	N71125
IBUPROFEN	800MG	N71964
IBUPROFEN	400MG	N72064
IBUPROFEN	600MG	N72065
IBUPROFEN	800MG	N71938
IBUPROFEN	600MG	N70709
IBUPROFEN	200MG	N73141
IBUPROFEN	400MG	N73343
IBUPROFEN	600MG	N73344
IBUPROFEN	800MG	N73345
IBUPROFEN	200MG	N71765
IBUPROFEN	200MG	N71905
IBUPROFEN	300MG	N71338
IBUPROFEN	400MG	N70038
IBUPROFEN	600MG	N70041
IBUPROFEN	800MG	N71911
IBU-TAB	800MG	N71965
MIDOL	200MG	N70591
MIDOL	200MG	N71001
MOTRIN	100MG	N20418
NUPRIN	200MG	N72035
NUPRIN	200MG	N72036
NUPRIN	200MG	N19012
NUPRIN	200MG	N19012
RUFEN	600MG	N18197
TABLET, CHEWABLE		
MOTRIN	100MG	N20135
MOTRIN	50MG	N20135
IDARUBICIN HYDROCHLORIDE		
INJECTABLE		
IDAMYCIN	10MG/VIAL	N50661

IDARUBICIN HYDROCHLORIDE		
INJECTABLE		
IDAMYCIN	20MG/VIAL	N50661
IDAMYCIN	5MG/VIAL	N50661
IDOXURIDINE		
OINTMENT		
STOXIL	0.5%	N15868
SOLUTION/DROPS		
STOXIL	0.1%	N13934
IFOSFAMIDE		
INJECTABLE		
IFEX	1GM/VIAL	*N19763
IFEX	3GM/VIAL	*N19763
IMATINIB MESYLATE		
CAPSULE		
GLEEVEC	50MG	N21335
IMIPRAMINE HYDROCHLORIDE		
CONCENTRATE		
IMIPRAMINE HCL	25MG/ML	N86765
INJECTABLE		
TOFRANIL	12.5MG/ML	N11838
TABLET		
IMIPRAMINE HCL	10MG	N85200
IMIPRAMINE HCL	25MG	N84869
IMIPRAMINE HCL	50MG	N85133
IMIPRAMINE HCL	10MG	N86269
IMIPRAMINE HCL	25MG	N86267
IMIPRAMINE HCL	50MG	N86268
IMIPRAMINE HCL	10MG	N83799
IMIPRAMINE HCL	25MG	N83799
IMIPRAMINE HCL	50MG	N83799
IMIPRAMINE HCL	25MG	N87776
IMIPRAMINE HCL	10MG	N88036
IMIPRAMINE HCL	25MG	N87619
IMIPRAMINE HCL	50MG	N87631
IMIPRAMINE HCL	10MG	N85220
IMIPRAMINE HCL	10MG	N85875
IMIPRAMINE HCL	25MG	N84252
IMIPRAMINE HCL	25MG	N85878
IMIPRAMINE HCL	50MG	N85221
IMIPRAMINE HCL	50MG	N85877
IMIPRAMINE HCL	25MG	N88222
IMIPRAMINE HCL	50MG	N88223
JANIMINE	10MG	N17895
JANIMINE	25MG	N17895

FDA data supplied by DrugPatentWatch.com

IMIPRAMINE HYDROCHLORIDE		
TABLET		
JANIMINE	50MG	N17895
PRAMINE	10MG	N83827
PRAMINE	25MG	N83827
PRAMINE	50MG	N83827
PRESAMINE	10MG	N11836
PRESAMINE	25MG	N11836
PRESAMINE	50MG	N11836
INAMRINONE LACTATE		
INJECTABLE		
INOCOR	EQ 5MG BASE/ML	N18700
INDAPAMIDE		
TABLET		
INDAPAMIDE	1.25MG	N74665
INDAPAMIDE	2.5MG	N74665
INDECAINIDE HYDROCHLORIDE		
TABLET, EXTENDED RELEASE		
DECABID	EQ 100MG BASE	N19693
DECABID	EQ 50MG BASE	N19693
DECABID	EQ 75MG BASE	N19693
INDOCYANINE GREEN		
INJECTABLE		
CARDIO-GREEN	10MG/VIAL	N11525
CARDIO-GREEN	40MG/VIAL	N11525
CARDIO-GREEN	50MG/VIAL	N11525
INDOMETHACIN		
CAPSULE		
INDOMETHACIN	25MG	N70326
INDOMETHACIN	50MG	N70327
INDOMETHACIN	25MG	N70067
INDOMETHACIN	25MG	N70782
INDOMETHACIN	50MG	N70068
INDOMETHACIN	50MG	N70635
INDOMETHACIN	25MG	N18730
INDOMETHACIN	50MG	N18730
INDOMETHACIN	25MG	N18806
INDOMETHACIN	50MG	N18806
INDOMETHACIN	25MG	N70813
INDOMETHACIN	50MG	N70592
INDOMETHACIN	25MG	N70353
INDOMETHACIN	50MG	N70354
INDOMETHACIN	25MG	N70487
INDOMETHACIN	50MG	N70488

INDOMETHACIN		
CAPSULE		
INDOMETHACIN	25MG	N18690
INDOMETHACIN	25MG	N70529
INDOMETHACIN	25MG	N70784
INDOMETHACIN	25MG	N72996
INDOMETHACIN	50MG	N18690
INDOMETHACIN	50MG	N70530
INDOMETHACIN	50MG	N70785
INDOMETHACIN	50MG	N71635
INDOMETHACIN	50MG	N72997
CAPSULE, EXTENDED RELEASE		
INDOCIN SR	75MG	N18185
SUPPOSITORY		
INDOCIN	50MG	* N17814
SUSPENSION		
INDOMETHACIN	25MG/5ML	N71412
INSULIN PORK		
INJECTABLE		
ILETIN I	500 UNITS/ML	N17931
INSULIN	40 UNITS/ML	N17926
REGULAR INSULIN	100 UNITS/ML	N17926
INSULIN PURIFIED BEEF		
INJECTABLE		
REGULAR ILETIN II	100 UNITS/ML	N18478
INSULIN PURIFIED PORK		
INJECTABLE		
REGULAR PURIFIED PORK INSULIN	100 UNITS/ML	N18381
VELOSULIN	100 UNITS/ML	N18193
INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK		
INJECTABLE		
INSULIN NORDISK MIXTARD (PORK)	30 UNITS/ML;70 UNITS/ML	N18195
INSULIN RECOMBINANT HUMAN		
INJECTABLE		
HUMULIN BR	100 UNITS/ML	N19529
INSULIN RECOMBINANT PURIFIED HUMAN		
INJECTABLE		
NOVOLIN R	100 UNITS/ML	N18778
VELOSULIN BR HUMAN	100 UNITS/ML	N19450
INSULIN RECOMBINANT PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN		
INJECTABLE		
MIXTARD HUMAN 70/30	30 UNITS/ML;70 UNITS/ML	N19585
NOVOLIN 70/30	30 UNITS/ML;70 UNITS/ML	N19441

FDA data supplied by DrugPatentWatch.com

INSULIN SUSP ISOPHANE BEEF
INJECTABLE

NPH INSULIN	100 UNITS/ML	N17929
NPH INSULIN	40 UNITS/ML	N17929

INSULIN SUSP ISOPHANE BEEF/PORK
INJECTABLE

NPH ILETIN I (BEEF-PORK)	40 UNITS/ML	N17936

INSULIN SUSP ISOPHANE PURIFIED BEEF
INJECTABLE

NPH ILETIN II	100 UNITS/ML	N18479

INSULIN SUSP ISOPHANE PURIFIED PORK
INJECTABLE

INSULIN INSULATARD NPH NORDISK	100 UNITS/ML	N18194
NPH PURIFIED PORK ISOPHANE INSULIN	100 UNITS/ML	N18623

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN
INJECTABLE

INSULATARD NPH HUMAN	100 UNITS/ML	N19449
NOVOLIN N	100 UNITS/ML	N19065

INSULIN SUSP PROTAMINE ZINC BEEF/PORK
INJECTABLE

PROTAMINE, ZINC & ILETIN I (BEEF-PORK)	100 UNITS/ML	N17932
PROTAMINE, ZINC & ILETIN I (BEEF-PORK)	40 UNITS/ML	N17932

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF
INJECTABLE

PROTAMINE ZINC AND ILETIN II	100 UNITS/ML	N18476
PROTAMINE ZINC INSULIN	100 UNITS/ML	N17928
PROTAMINE ZINC INSULIN	40 UNITS/ML	N17928

INSULIN SUSP PROTAMINE ZINC PURIFIED PORK
INJECTABLE

PROTAMINE ZINC AND ILETIN II (PORK)	100 UNITS/ML	N18346

INSULIN ZINC SUSP BEEF
INJECTABLE

LENTE INSULIN	100 UNITS/ML	N17998
LENTE INSULIN	40 UNITS/ML	N17998

INSULIN ZINC SUSP EXTENDED BEEF
INJECTABLE

ULTRALENTE INSULIN	100 UNITS/ML	N17997

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF
INJECTABLE

ULTRALENTE	100 UNITS/ML	N18385

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN
INJECTABLE

HUMULIN U	40 UNITS/ML	N19571

INSULIN ZINC SUSP PROMPT BEEF
INJECTABLE

SEMILENTE INSULIN	100 UNITS/ML	N17996

INSULIN ZINC SUSP PROMPT PURIFIED PORK
INJECTABLE

SEMILENTE	100 UNITS/ML	N18382

INSULIN ZINC SUSP PURIFIED BEEF
INJECTABLE

LENTE ILETIN II	100 UNITS/ML	N18477

INSULIN ZINC SUSP PURIFIED BEEF/PORK
INJECTABLE

LENTARD	100 UNITS/ML	N18384

INSULIN ZINC SUSP PURIFIED PORK
INJECTABLE

LENTE	100 UNITS/ML	N18383

INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN
INJECTABLE

NOVOLIN L	100 UNITS/ML	N18777

INULIN
INJECTABLE

INULIN AND SODIUM CHLORIDE	100MG/ML	N02282

INVERT SUGAR
INJECTABLE

TRAVERT 10% IN PLASTIC CONTAINER	10GM/100ML	N16717

IOCETAMIC ACID
TABLET

CHOLEBRINE	750MG	N17129

IODAMIDE MEGLUMINE
INJECTABLE

RENOVUE-65	65%	N17902
RENOVUE-DIP	24%	N17903

IODIPAMIDE MEGLUMINE
INJECTABLE

CHOLOGRAFIN MEGLUMINE	10.3%	N09321

IODIPAMIDE SODIUM
INJECTABLE

CHOLOGRAFIN SODIUM	20%	N09321

IODIXANOL
INJECTABLE

VISIPAQUE 270	55%	N20808
VISIPAQUE 320	65.2%	N20808

FDA data supplied by DrugPatentWatch.com

IODOHIPPURATE SODIUM, I-123		
INJECTABLE		
NEPHROFLOW	1mCi/ML	N18289
IODOHIPPURATE SODIUM, I-131		
INJECTABLE		
HIPPURAN I 131	0.25mCi/ML	N16666
HIPPUTOPE	1-2mCi/VIAL	N15419
IODOHIPPURATE SODIUM I 131	0.2mCi/ML	N17313
IODOXAMATE MEGLUMINE		
INJECTABLE		
CHOLOVUE	40.3%	N18076
CHOLOVUE	9.9%	N18077
IOFETAMINE HYDROCHLORIDE I-123		
INJECTABLE		
SPECTAMINE	1mCi/ML	N19432
IOHEXOL		
INJECTABLE		
OMNIPAQUE 210	45.3%	N18956
SOLUTION		
OMNIPAQUE 70	15.1%	N18956
IOPAMIDOL		
INJECTABLE		
IOPAMIDOL	41%	N74629
IOPAMIDOL	51%	N74629
IOPAMIDOL	61%	N74629
IOPAMIDOL	76%	N74629
IOPAMIDOL	61%	N74734
IOPAMIDOL	76%	N74734
IOPAMIDOL-300	61%	N74638
ISOVUE-128	26%	N18735
ISOVUE-200	41%	N20327
IOPHENDYLATE		
INJECTABLE		
PANTOPAQUE	100%	N05319
IOTHALAMATE SODIUM		
INJECTABLE		
ANGIO-CONRAY	80%	N13319
CONRAY 325	54.3%	N17685
IOTROLAN		
INJECTABLE		
OSMOVIST 190	40.6%	N19580
OSMOVIST 240	51.3%	N19580
IOVERSOL		
INJECTABLE		
OPTIRAY 240	51%	N20923
OPTIRAY 320	68%	N20923
IPODATE CALCIUM		
GRANULE		
ORAGRAFIN CALCIUM	3GM/PACKET	N12968
IPODATE SODIUM		
CAPSULE		
BILIVIST	500MG	N87768
ORAGRAFIN SODIUM	500MG	N12967
IRON DEXTRAN		
INJECTABLE		
IRON DEXTRAN	EQ 50MG IRON/ML	N10787
ISOETHARINE HYDROCHLORIDE		
SOLUTION		
BRONKOSOL	0.25%	N12339
BRONKOSOL	1%	N12339
ISOETHARINE HCL	1%	N87101
ISOETHARINE HCL	0.062%	N87937
ISOETHARINE HCL	0.062%	N89614
ISOETHARINE HCL	0.125%	N87938
ISOETHARINE HCL	0.125%	N89615
ISOETHARINE HCL	0.167%	N88470
ISOETHARINE HCL	0.167%	N89616
ISOETHARINE HCL	0.2%	N88471
ISOETHARINE HCL	0.2%	N89617
ISOETHARINE HCL	0.25%	N88472
ISOETHARINE HCL	0.25%	N89618
ISOETHARINE HCL	0.08%	N88144
ISOETHARINE HCL	0.14%	N88145
ISOETHARINE HCL	0.25%	N88146
ISOETHARINE HCL	0.08%	N88187
ISOETHARINE HCL	0.1%	N87389
ISOETHARINE HCL	0.17%	N87390
ISOETHARINE HCL	0.25%	N88188
ISOETHARINE HCL	1%	N86763
ISOETHARINE HCL	0.077%	N86651
ISOETHARINE HCL	0.08%	N86651
ISOETHARINE HCL	0.1%	N86651
ISOETHARINE HCL	0.143%	N86651
ISOETHARINE HCL	0.167%	N86651
ISOETHARINE HCL	0.2%	N86651
ISOETHARINE HCL	0.25%	N86651
ISOETHARINE HCL	1%	N86651

FDA data supplied by DrugPatentWatch.com

ISOETHARINE HYDROCHLORIDE			
SOLUTION			
ISOETHARINE HCL	0.5%	N85997	
ISOETHARINE HCL	1%	N85889	
ISOETHARINE HCL	0.1%	N87396	
ISOETHARINE HCL	0.125%	N87025	
ISOETHARINE HCL	0.167%	N88226	
ISOETHARINE HCL	0.2%	N87324	
ISOETHARINE HCL	0.25%	N88275	
ISOETHARINE HCL S/F	0.08%	N89817	
ISOETHARINE HCL S/F	0.1%	N89818	
ISOETHARINE HCL S/F	0.17%	N89819	
ISOETHARINE HCL S/F	0.25%	N89820	
ISOETHARINE HCL S/F	1%	N89252	
ISOETHARINE MESYLATE			
AEROSOL, METERED			
BRONKOMETER	0.34MG/INH	N12339	
ISOETHARINE MESYLATE	0.34MG/INH	N87858	
ISOFLUROPHATE			
OINTMENT			
FLOROPRYL	0.025%	N10656	
ISONIAZID			
INJECTABLE			
RIMIFON	100MG/ML	N08420	
RIMIFON	25MG/ML	N08420	
SYRUP			
ISONIAZID	50MG/5ML	N81118	
LANIAZID	50MG/5ML	N89243	
RIMIFON	50MG/5ML	N08420	
TABLET			
DOW-ISONIAZID	300MG	N80330	
HYZYD	100MG	N80134	
HYZYD	300MG	N80134	
INH	300MG	N80935	
ISONIAZID	100MG	N84050	
ISONIAZID	100MG	N80136	
ISONIAZID	100MG	N88231	
ISONIAZID	50MG	N83632	
ISONIAZID	100MG	N80153	
ISONIAZID	100MG	N80270	
ISONIAZID	300MG	N83610	
ISONIAZID	100MG	N08499	
ISONIAZID	300MG	N08499	
ISONIAZID	100MG	N80941	
ISONIAZID	100MG	N08428	
ISONIAZID	300MG	N08428	
ISONIAZID			
TABLET			
ISONIAZID	50MG	N08428	
ISONIAZID	100MG	N83060	
ISONIAZID	100MG	N85091	
ISONIAZID	100MG	N80368	
ISONIAZID	50MG	N80368	
ISONIAZID	100MG	N80132	
ISONIAZID	50MG	N80132	
ISONIAZID	100MG	N80401	
ISONIAZID	100MG	N80523	
ISONIAZID	100MG	N85790	
ISONIAZID	300MG	N83178	
ISONIAZID	300MG	N85784	
ISONIAZID	50MG	N80522	
ISONIAZID	100MG	N80120	
NYDRAZID	100MG	N08392	
STANOZIDE	100MG	N80126	
STANOZIDE	300MG	N80126	
ISOPROPAMIDE IODIDE			
TABLET			
DARBID	EQ 5MG BASE	N10744	
ISOPROTERENOL HYDROCHLORIDE			
AEROSOL, METERED			
ISOPROTERENOL HCL	0.12MG/INH	N10375	
ISOPROTERENOL HCL	0.12MG/INH	N85904	
ISUPREL	0.103MG/INH	N11178	
DISC			
NORISODRINE AEROTROL	0.25%	N16814	
INJECTABLE			
ISOPROTERENOL HCL	0.2MG/ML	N83431	
ISOPROTERENOL HCL	0.2MG/ML	N83486	
SOLUTION			
AEROLONE	0.25%	N07245	
ISOPROTERENOL HCL	0.031%	N87935	
ISOPROTERENOL HCL	0.062%	N87936	
ISOPROTERENOL HCL	0.5%	N86764	
ISOPROTERENOL HCL	0.25%	N85994	
ISOPROTERENOL HCL	0.5%	N85540	
ISUPREL	0.5%	N06327	
ISUPREL	1%	N06327	
VAPO-ISO	0.5%	N16813	
TABLET			
ISUPREL	10MG	N06328	
ISUPREL	15MG	N06328	

FDA data supplied by DrugPatentWatch.com

ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE		
AEROSOL, METERED		
DUO-MEDIHALER	0.16MG/INH;0.24MG/INH	N13296
ISOPROTERENOL SULFATE		
AEROSOL, METERED		
MEDIHALER-ISO	0.08MG/INH	N10375
POWDER		
NORISODRINE	10%	N06905
NORISODRINE	25%	N06905
ISOSORBIDE		
SOLUTION		
ISMOTIC	100GM/220ML	N17063
ISOSORBIDE DINITRATE		
CAPSULE, EXTENDED RELEASE		
ISORDIL	40MG	N12882
TABLET		
ISOSORBIDE DINITRATE	10MG	N86169
ISOSORBIDE DINITRATE	10MG	N87545
ISOSORBIDE DINITRATE	2.5MG	N84204
ISOSORBIDE DINITRATE	20MG	N86167
ISOSORBIDE DINITRATE	30MG	N87564
ISOSORBIDE DINITRATE	5MG	N86166
ISOSORBIDE DINITRATE	5MG	N86168
ISOSORBIDE DINITRATE	10MG	N89191
ISOSORBIDE DINITRATE	20MG	N89192
ISOSORBIDE DINITRATE	5MG	N89190
SORBITRATE	10MG	N16192
SORBITRATE	2.5MG	N16191
SORBITRATE	20MG	N86405
SORBITRATE	30MG	N88124
SORBITRATE	40MG	N88125
SORBITRATE	5MG	N16191
SORBITRATE	5MG	N16192
TABLET, CHEWABLE		
SORBITRATE	10MG	N16776
SORBITRATE	5MG	N16776
TABLET, EXTENDED RELEASE		
ISORDIL	40MG	N12882
KANAMYCIN SULFATE		
CAPSULE		
KANTREX	EQ 500MG BASE	N60516
KANTREX	EQ 500MG BASE	N61911
INJECTABLE		
KANAMYCIN	EQ 1GM BASE/3ML	N62324

KANAMYCIN SULFATE		
INJECTABLE		
KANAMYCIN	EQ 500MG BASE/2ML	N62324
KANAMYCIN	EQ 75MG BASE/2ML	N62324
KANAMYCIN SULFATE	EQ 1GM BASE/3ML	N62504
KANAMYCIN SULFATE	EQ 500MG BASE/2ML	N62504
KANAMYCIN SULFATE	EQ 75MG BASE/2ML	N62504
KANAMYCIN SULFATE	EQ 1GM BASE/3ML	N62466
KANAMYCIN SULFATE	EQ 500MG BASE/2ML	N62466
KANAMYCIN SULFATE	EQ 1GM BASE/3ML	N63025
KANAMYCIN SULFATE	EQ 500MG BASE/2ML	N63022
KANAMYCIN SULFATE	EQ 75MG BASE/2ML	N63021
KANAMYCIN SULFATE	EQ 1GM BASE/3ML	N62669
KANAMYCIN SULFATE	EQ 500MG BASE/2ML	N62672
KANAMYCIN SULFATE	EQ 75MG BASE/2ML	N62668
KANAMYCIN SULFATE	EQ 1GM BASE/3ML	N62605
KANAMYCIN SULFATE	EQ 500MG BASE/2ML	N62605
KANAMYCIN SULFATE	EQ 75MG BASE/2ML	N62605
KANAMYCIN SULFATE	EQ 1GM BASE/3ML	N62520
KANAMYCIN SULFATE	EQ 1GM BASE/3ML	N63092
KANTREX	EQ 1GM BASE/3ML	N61655
KANTREX	EQ 1GM BASE/3ML	N62564
KANTREX	EQ 500MG BASE/2ML	N61655
KANTREX	EQ 500MG BASE/2ML	N62564
KANTREX	EQ 75MG BASE/2ML	N61655
KANTREX	EQ 75MG BASE/2ML	N62564
KLEBCIL	EQ 1GM BASE/3ML	N62170
KLEBCIL	EQ 500MG BASE/2ML	N62170
KLEBCIL	EQ 75MG BASE/2ML	N62170
KETOCONAZOLE		
SUSPENSION		
NIZORAL	100MG/5ML	N70767
KETOPROFEN		
CAPSULE		
ORUDIS	25MG	N18754
ORUDIS	50MG	N18754
ORUDIS	75MG	N18754
TABLET		
KETOPROFEN	12.5MG	N75364
KETOROLAC TROMETHAMINE		
INJECTABLE		
KETOROLAC TROMETHAMINE	15MG/ML	N74801
KETOROLAC TROMETHAMINE	30MG/ML	N74801
KETOROLAC TROMETHAMINE	15MG/ML	N75348
KETOROLAC TROMETHAMINE	30MG/ML	N75348
KETOROLAC TROMETHAMINE	15MG/ML	N75230

FDA data supplied by DrugPatentWatch.com

KETOROLAC TROMETHAMINE		
INJECTABLE		
KETOROLAC TROMETHAMINE	30MG/ML	N75230
TABLET		
KETOROLAC TROMETHAMINE	10MG	N74790
KRYPTON, KR-81M		
GAS		
MPI KRYPTON 81M GAS GENERATOR	N/A	N18088
LABETALOL HYDROCHLORIDE		
INJECTABLE		
LABETALOL HCL	5MG/ML	N75355
TABLET		
LABETALOL HCL	100MG	N75223
LABETALOL HCL	200MG	N75223
LABETALOL HCL	300MG	N75223
NORMODYNE	400MG	N18687
TRANDATE	400MG	N18716
LACTULOSE		
SOLUTION		
CEPHULAC	10GM/15ML	* N17657
CHRONULAC	10GM/15ML	N17884
DUPHALAC	10GM/15ML	N72372
GENERLAC	10GM/15ML	N71842
LACTULOSE	10GM/15ML	N71841
LACTULOSE	10GM/15ML	N72029
LACTULOSE	10GM/15ML	N73160
LACTULOSE	10GM/15ML	N73590
LACTULOSE	10GM/15ML	N17906
PORTALAC	10GM/15ML	N72374
LAMOTRIGINE		
TABLET		
LAMICTAL	250MG	N20241
LAMICTAL	50MG	N20241
TABLET, CHEWABLE		
LAMICTAL CD	100MG	N20764
LEFLUNOMIDE		
TABLET		
ARAVA	100MG	N20905
LEUCOVORIN CALCIUM		
FOR SOLUTION		
LEUCOVORIN CALCIUM	EQ 60MG BASE/VIAL	N08107
INJECTABLE		
LEUCOVORIN CALCIUM	EQ 3MG BASE/ML	N89352
LEUCOVORIN CALCIUM	EQ 50MG BASE/VIAL	N89353
LEUCOVORIN CALCIUM	EQ 50MG BASE/VIAL	N88939

LEUCOVORIN CALCIUM		
INJECTABLE		
LEUCOVORIN CALCIUM	EQ 100MG BASE/VIAL	N81224
LEUCOVORIN CALCIUM	EQ 50MG BASE/VIAL	N70480
LEUCOVORIN CALCIUM	EQ 3MG BASE/ML	N08107
WELLCOVORIN	EQ 100MG BASE/VIAL	N89834
WELLCOVORIN	EQ 25MG BASE/VIAL	N89833
WELLCOVORIN	EQ 50MG BASE/VIAL	N89465
WELLCOVORIN	EQ 5MG BASE/ML	N87439
TABLET		
LEUCOVORIN CALCIUM	EQ 25MG BASE	N71598
LEUCOVORIN CALCIUM	EQ 5MG BASE	N71600
WELLCOVORIN	EQ 25MG BASE	N18342
WELLCOVORIN	EQ 5MG BASE	N18342
LEUPROLIDE ACETATE		
INJECTABLE		
LUPRON DEPOT-PED	3.75MG/VIAL;7.5MG/VIAL	N20263
LUPRON DEPOT-PED	7.5MG/VIAL;7.5MG/VIAL	N20263
LEVALLORPHAN TARTRATE		
INJECTABLE		
LORFAN	1MG/ML	N10423
LEVAMISOLE HYDROCHLORIDE		
TABLET		
ERGAMISOL	EQ 50MG BASE	N20035
LEVOBETAXOLOL HYDROCHLORIDE		
SUSPENSION/DROPS		
BETAXON	EQ 0.5% BASE	N21114
LEVOCARNITINE		
SOLUTION		
CARNITOR	1GM/10ML	N18948
LEVODOPA		
CAPSULE		
BENDOPA	100MG	N16948
BENDOPA	250MG	N16948
BENDOPA	500MG	N16948
DOPAR	100MG	N16913
DOPAR	250MG	N16913
DOPAR	500MG	N16913
LARODOPA	100MG	N16912
LARODOPA	250MG	N16912
LARODOPA	500MG	N16912
TABLET		
DOPAR	250MG	N16913
DOPAR	500MG	N16913
LARODOPA	100MG	N16912

FDA data supplied by DrugPatentWatch.com

LEVODOPA		
TABLET		
LARODOPA	250MG	N16912
LARODOPA	500MG	N16912
LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE		
INJECTABLE		
ARESTOCAINE HCL W/ LEVONORDEFRIN	0.05MG/ML;2%	N85010
LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE		
INJECTABLE		
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN	0.05MG/ML;2%;0.4%	N08592
LEVONORGESTREL		
IMPLANT		
LEVONORGESTREL	75MG/IMPLANT	N20627
NORPLANT	36MG/IMPLANT	N19897
NORPLANT SYSTEM IN PLASTIC CONTAINER	36MG/IMPLANT	N20088
LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS		
CAPSULE		
NOVRAD	EQ 100MG BASE	N12928
NOVRAD	EQ 50MG BASE	N12928
SUSPENSION		
NOVRAD	EQ 50MG BASE/5ML	N12928
LEVORPHANOL TARTRATE		
TABLET		
LEVO-DROMORAN	2MG	N08720
LIDOCAINE		
AEROSOL		
XYLOCAINE	10%	N14394
FILM, EXTENDED RELEASE		
LIDOCAINE	23MG/PATCH	N20575
OINTMENT		
ALPHACAINE	5%	N84944
ALPHACAINE	5%	N84946
ALPHACAINE	5%	N84947
XYLOCAINE	5%	N08048
SOLUTION		
XYLOCAINE	5%	N14127
SUPPOSITORY		
XYLOCAINE	100MG	N13077
LIDOCAINE HYDROCHLORIDE		
INJECTABLE		
ALPHACAINE HCL	2%	N84721
LIDOCAINE HCL	1.5%	N88330
LIDOCAINE HCL	10%	N87980
LIDOCAINE HYDROCHLORIDE		
INJECTABLE		
LIDOCAINE HCL	20%	N89362
LIDOCAINE HCL	1%	N85037
LIDOCAINE HCL	2%	N85037
LIDOCAINE HCL	1%	N80390
LIDOCAINE HCL	1%	N80420
LIDOCAINE HCL	1%	N86761
LIDOCAINE HCL	1.5%	N80420
LIDOCAINE HCL	2%	N17508
LIDOCAINE HCL	2%	N80390
LIDOCAINE HCL	2%	N80420
LIDOCAINE HCL	2%	N80420
LIDOCAINE HCL	2%	N86761
LIDOCAINE HCL	20%	N17508
LIDOCAINE HCL	4%	N17508
LIDOCAINE HCL	1%	N80710
LIDOCAINE HCL	2%	N80760
LIDOCAINE HCL	1%	N83387
LIDOCAINE HCL	2%	N83388
LIDOCAINE HCL	0.5%	N85131
LIDOCAINE HCL	1%	N80407
LIDOCAINE HCL	2%	N80407
LIDOCAINE HCL	4%	N84626
LIDOCAINE HCL	1%	N83135
LIDOCAINE HCL	2%	N83135
LIDOCAINE HCL	1%	N17701
LIDOCAINE HCL	1GM/VIAL	N18543
LIDOCAINE HCL	2%	N17701
LIDOCAINE HCL	2GM/VIAL	N18543
LIDOCAINE HCL	1%	N80414
LIDOCAINE HCL	2%	N80414
LIDOCAINE HCL	1%	N80377
LIDOCAINE HCL	1%	N83627
LIDOCAINE HCL	2%	N80377
LIDOCAINE HCL	2%	N83627
LIDOCAINE HCL	1%	N83083
LIDOCAINE HCL	2%	N83083
LIDOCAINE HCL 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER	100MG/100ML	N18461
LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER	200MG/100ML	N18954
LIDOCAINE HCL PRESERVATIVE FREE	1%	N84625
LIDOCAINE HCL PRESERVATIVE FREE	2%	N84625
LIDOCAINE HCL PRESERVATIVE FREE	4%	N17702
LIDOCATON	2%	N84727
XYLOCAINE	1%	N10416

FDA data supplied by DrugPatentWatch.com

LIDOCAINE HYDROCHLORIDE		
INJECTABLE		
XYLOCAINE	1.5%	N10418
XYLOCAINE	2%	N06488
XYLOCAINE	2%	N10418
XYLOCAINE 5% W/ GLUCOSE 7.5%	5%	N10496
SOLUTION		
LARYNGOTRACHEAL ANESTHESIA KIT	4%	N87931
LIDOCAINE HCL	4%	N89688
LIDOCAINE HCL VISCOUS	2%	N86389
PEDIATRIC LTA KIT	2%	N88572
LINCOMYCIN HYDROCHLORIDE		
CAPSULE		
LINCOCIN	EQ 250MG BASE	N50316
LINCOCIN	EQ 500MG BASE	N50316
INJECTABLE		
LINCOMYCIN HCL	EQ 300MG BASE/ML	N63180
LINDANE		
CREAM		
KWELL	1%	N06309
KWELL	1%	N84218
LOTION		
GAMENE	1%	N84989
KWELL	1%	N06309
KWELL	1%	N84218
SCABENE	1%	N86769
SHAMPOO		
GAMENE	1%	N84988
KWELL	1%	N10718
KWELL	1%	N84219
SCABENE	1%	N87940
LINEZOLID		
TABLET		
ZYVOX	400MG	N21130
LIOTHYRONINE SODIUM		
TABLET		
LIOTHYRONINE SODIUM	EQ 0.025MG BASE	N85755
LIOTHYRONINE SODIUM	EQ 0.05MG BASE	N85753
LIOTRIX (T4;T3)		
TABLET		
EUTHROID-0.5	0.03MG;0.0075MG	N16680
EUTHROID-1	0.06MG;0.015MG	N16680
EUTHROID-2	0.12MG;0.03MG	N16680
EUTHROID-3	0.18MG;0.045MG	N16680
THYROLAR-5	0.25MG;0.0625MG	N16807

LITHIUM CARBONATE		
CAPSULE		
LITHIUM CARBONATE	300MG	N72542
LITHIUM CARBONATE	300MG	N70407
LITHONATE	300MG	N16782
TABLET		
ESKALITH	300MG	N17971
LITHANE	300MG	N18833
LITHOTABS	300MG	N16980
LITHIUM CITRATE		
SYRUP		
LITHONATE	EQ 300MG CARBONATE/5ML	N17672
LOPERAMIDE HYDROCHLORIDE		
CAPSULE		
IMODIUM	2MG	N17690
LOPERAMIDE HCL	2MG	N73080
SOLUTION		
IMODIUM	1MG/5ML	N19037
LOPERAMIDE HCL	1MG/5ML	N73187
LOPERAMIDE HCL	1MG/5ML	N73062
TABLET		
LOPERAMIDE HCL	2MG	N73528
LOPERAMIDE HCL	2MG	N74194
LORAZEPAM		
TABLET		
LORAZ	0.5MG	N70200
LORAZ	1MG	N70201
LORAZ	2MG	N70202
LORAZEPAM	0.5MG	N70727
LORAZEPAM	1MG	N70728
LORAZEPAM	2MG	N70729
LORAZEPAM	0.5MG	N70472
LORAZEPAM	0.5MG	N71434
LORAZEPAM	1MG	N70473
LORAZEPAM	1MG	N71435
LORAZEPAM	2MG	N70474
LORAZEPAM	2MG	N71436
LORAZEPAM	0.5MG	N70675
LORAZEPAM	1MG	N70676
LORAZEPAM	2MG	N70677
LORAZEPAM	0.5MG	N71245
LORAZEPAM	1MG	N71246
LORAZEPAM	2MG	N71247
LORAZEPAM	1MG	N70539
LORAZEPAM	2MG	N70540

FDA data supplied by DrugPatentWatch.com

LORAZEPAM		
TABLET		
LORAZEPAM	1MG	N71038
LORAZEPAM	2MG	N71039
LORAZEPAM	0.5MG	N71086
LOTEPREDNOL ETABONATE		
SUSPENSION/DROPS		
LOTEMAX	0.5%	N20841
LOXAPINE HYDROCHLORIDE		
CONCENTRATE		
LOXITANE C	EQ 25MG BASE/ML	N17658
INJECTABLE		
LOXITANE IM	EQ 50MG BASE/ML	N18039
LOXAPINE SUCCINATE		
TABLET		
LOXITANE	EQ 10MG BASE	N17525
LOXITANE	EQ 25MG BASE	N17525
LOXITANE	EQ 50MG BASE	N17525
LYPRESSIN		
SOLUTION		
DIAPID	0.185MG/ML	N16755
MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE		
INJECTABLE		
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER	30MG/100ML;37MG/100ML; 0.82MG/100ML;370MG/100 ML;530MG/100ML;500MG/1 00ML;12MG/100ML	N19006
MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE		
SOLUTION		
PHYSIOSOL IN PLASTIC CONTAINER	14MG/100ML;37MG/100ML; 222MG/100ML;526MG/100M L;502MG/100ML	N18406
SYNOVALYTE IN PLASTIC CONTAINER	30MG/100ML;37MG/100ML; 368MG/100ML;526MG/100M L;502MG/100ML	N19326
MANGANESE CHLORIDE TETRAHYDRATE		
FOR SOLUTION		
LUMENHANCE	3.49MG/GM	N20686
MANGANESE SULFATE		
INJECTABLE		
MANGANESE SULFATE	EQ 0.1MG MANGANESE/ML	N19228

MANNITOL		
INJECTABLE		
MANNITOL 10%	10GM/100ML	N16269
MANNITOL 10%	10GM/100ML	N16472
MANNITOL 15%	15GM/100ML	N16269
MANNITOL 15%	15GM/100ML	N16472
MANNITOL 20%	20GM/100ML	N16269
MANNITOL 20%	20GM/100ML	N16472
MANNITOL 25%	12.5GM/50ML	N16269
MANNITOL 25%	12.5GM/50ML	N86754
MANNITOL 25%	12.5GM/50ML	N89239
MANNITOL 25%	12.5GM/50ML	N89240
MANNITOL 25%	12.5GM/50ML	N05620
MANNITOL 25%	12.5GM/50ML	N87460
MANNITOL 5%	5GM/100ML	N16269
SOLUTION		
RESECTISOL	5GM/100ML	N16704
MANNITOL; SORBITOL		
SOLUTION		
SORBITOL-MANNITOL	540MG/100ML;2.7GM/100ML	N80224
MAPROTILINE HYDROCHLORIDE		
TABLET		
MAPROTILINE HCL	25MG	N72129
MAPROTILINE HCL	50MG	N72130
MAPROTILINE HCL	75MG	N72131
MAPROTILINE HCL	25MG	N71943
MAPROTILINE HCL	50MG	N71944
MAPROTILINE HCL	75MG	N71945
MASOPROCOL		
CREAM		
ACTINEX	10%	N19940
MAZINDOL		
TABLET		
MAZANOR	1MG	N17980
MAZANOR	2MG	N17980
SANOREX	1MG	N17247
SANOREX	2MG	N17247
MEBUTAMATE		
TABLET		
DORMATE	600MG	N17374
MECLIZINE HYDROCHLORIDE		
TABLET		
MECLIZINE HCL	25MG	N85891
MECLIZINE HCL	12.5MG	N83784

FDA data supplied by DrugPatentWatch.com

MECLIZINE HYDROCHLORIDE		
TABLET		
MECLIZINE HCL	12.5MG	N85524
MECLIZINE HCL	25MG	N85523
MECLIZINE HCL	12.5MG	N89113
MECLIZINE HCL	25MG	N89114
MECLIZINE HCL	12.5MG	N88256
MECLIZINE HCL	25MG	N88257
MECLIZINE HCL	12.5MG	N87877
MECLIZINE HCL	25MG	N87620
MECLIZINE HCL	12.5MG	N85195
MECLIZINE HCL	12.5MG	N85269
TABLET, CHEWABLE		
MECLIZINE HCL	25MG	N86392
MECLIZINE HCL	25MG	N84976
MECLOCYCLINE SULFOSALICYLATE		
CREAM		
MECLAN	1%	N50518
MECLOFENAMATE SODIUM		
CAPSULE		
MECLODIUM	EQ 100MG BASE	N71381
MECLODIUM	EQ 50MG BASE	N71380
MECLOFENAMATE SODIUM	EQ 100MG BASE	N71363
MECLOFENAMATE SODIUM	EQ 50MG BASE	N71362
MECLOFENAMATE SODIUM	EQ 100MG BASE	N72809
MECLOFENAMATE SODIUM	EQ 50MG BASE	N72848
MECLOFENAMATE SODIUM	EQ 100MG BASE	N72078
MECLOFENAMATE SODIUM	EQ 50MG BASE	N72077
MECLOFENAMATE SODIUM	EQ 100MG BASE	N71008
MECLOFENAMATE SODIUM	EQ 50MG BASE	N71007
MECLOFENAMATE SODIUM	EQ 100MG BASE	N71684
MECLOFENAMATE SODIUM	EQ 50MG BASE	N71710
MECLOFENAMATE SODIUM	EQ 100MG BASE	N70401
MECLOFENAMATE SODIUM	EQ 100MG BASE	N71641
MECLOFENAMATE SODIUM	EQ 50MG BASE	N70400
MECLOFENAMATE SODIUM	EQ 50MG BASE	N71640
MECLOMEN	EQ 100MG BASE	N18006
MECLOMEN	EQ 50MG BASE	N18006
MEDROXYPROGESTERONE ACETATE		
INJECTABLE		
DEPO-PROVERA	100MG/ML	* N12541
TABLET		
AMEN	10MG	N83242
CURRETAB	10MG	N85686
CYCRIN	10MG	N89386
CYCRIN	2.5MG	N81239
MEDROXYPROGESTERONE ACETATE		
TABLET		
CYCRIN	5MG	N81240
MEFLOQUINE HYDROCHLORIDE		
TABLET		
MEFLOQUINE HCL	250MG	N19578
MEGESTROL ACETATE		
TABLET		
MEGESTROL ACETATE	20MG	N70646
MEGESTROL ACETATE	40MG	N70647
MEMANTINE HYDROCHLORIDE		
TABLET		
NAMENDA	15MG	N21487
NAMENDA	20MG	N21487
MENADIOL SODIUM DIPHOSPHATE		
INJECTABLE		
KAPPADIONE	10MG/ML	N05725
SYNKAYVITE	10MG/ML	N03718
SYNKAYVITE	37.5MG/ML	N03718
SYNKAYVITE	5MG/ML	N03718
TABLET		
SYNKAYVITE	5MG	N03718
MENADIONE		
TABLET		
MENADIONE	5MG	N02139
MENOTROPINS (FSH;LH)		
INJECTABLE		
HUMEGON	150 IU/VIAL;150 IU/VIAL	N20328
HUMEGON	75 IU/VIAL;75 IU/VIAL	N20328
MENOTROPINS	150 IU/VIAL;150 IU/VIAL	N73599
MENOTROPINS	75 IU/VIAL;75 IU/VIAL	N73598
PERGONAL	150 IU/AMP;150 IU/AMP	N17646
REPRONEX	150 IU/VIAL;150 IU/VIAL	N21047
MEPENZOLATE BROMIDE		
SOLUTION		
CANTIL	25MG/5ML	N10679
MEPERIDINE HYDROCHLORIDE		
INJECTABLE		
DEMEROL	100MG/ML	N05010
DEMEROL	25MG/ML	N05010
DEMEROL	50MG/ML	N05010
DEMEROL	75MG/ML	N05010
MEPERIDINE HCL	100MG/ML	N80386
MEPERIDINE HCL	25MG/ML	N80388

FDA data supplied by DrugPatentWatch.com

MEPERIDINE HYDROCHLORIDE

INJECTABLE

MEPERIDINE HCL	50MG/ML	N80385
MEPERIDINE HCL	50MG/ML	N80387
MEPERIDINE HCL	75MG/ML	N80389
MEPERIDINE HCL	100MG/ML	N89786
MEPERIDINE HCL	100MG/ML	N89787
MEPERIDINE HCL	100MG/ML	N89788
MEPERIDINE HCL	25MG/ML	N89781
MEPERIDINE HCL	50MG/ML	N89782
MEPERIDINE HCL	50MG/ML	N89783
MEPERIDINE HCL	50MG/ML	N89784
MEPERIDINE HCL	75MG/ML	N89785
MEPERIDINE HCL	100MG/ML	N88282
MEPERIDINE HCL	25MG/ML	N88279
MEPERIDINE HCL	50MG/ML	N88280
MEPERIDINE HCL	75MG/ML	N88281
MEPERIDINE HCL	10MG/ML	N86332
MEPERIDINE HCL	100MG/ML	N80364
MEPERIDINE HCL	50MG/ML	N80364
MEPERIDINE HCL	75MG/ML	N80364

TABLET

MEPERIDINE HCL	50MG	N80454

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE

MEPERGAN	25MG/ML;25MG/ML	N11730

MEPHENTERMINE SULFATE

INJECTABLE

WYAMINE SULFATE	EQ 15MG BASE/ML	N08248
WYAMINE SULFATE	EQ 30MG BASE/ML	N08248

MEPHENYTOIN

TABLET

MESANTOIN	100MG	N06008

MEPIVACAINE HYDROCHLORIDE

INJECTABLE

ARESTOCAINE HCL	3%	N84777
MEPIVACAINE HCL	1%	N87509

MEPREDNISONE

TABLET

BETAPAR	4MG	N16053

MEPROBAMATE

CAPSULE

EQUANIL	400MG	N12455

MEPROBAMATE

CAPSULE, EXTENDED RELEASE

MEPROSPAN	200MG	N11284
MEPROSPAN	400MG	N11284

TABLET

AMOSENE	400MG	N84030
BAMATE	200MG	N80380
BAMATE	400MG	N80380
EQUANIL	200MG	N10028
EQUANIL	400MG	N10028
MEPRIAM	400MG	N16069
MEPROBAMATE	200MG	N84220
MEPROBAMATE	400MG	N84589
MEPROBAMATE	600MG	N84230
MEPROBAMATE	200MG	N15426
MEPROBAMATE	400MG	N15426
MEPROBAMATE	200MG	N80699
MEPROBAMATE	400MG	N80699
MEPROBAMATE	400MG	N16928
MEPROBAMATE	600MG	N84329
MEPROBAMATE	200MG	N14322
MEPROBAMATE	400MG	N14322
MEPROBAMATE	200MG	N15438
MEPROBAMATE	400MG	N15438
MEPROBAMATE	600MG	N84181
MEPROBAMATE	200MG	N14882
MEPROBAMATE	400MG	N14882
MEPROBAMATE	400MG	N86299
MEPROBAMATE	400MG	N89538
MEPROBAMATE	400MG	N15072
MEPROBAMATE	200MG	N14368
MEPROBAMATE	400MG	N14368
MEPROBAMATE	400MG	N83618
MEPROBAMATE	200MG	N84744
MEPROBAMATE	400MG	N84744
MEPROBAMATE	200MG	N84546
MEPROBAMATE	400MG	N84547
MEPROBAMATE	400MG	N84438
MEPROBAMATE	400MG	N84153
MEPROBAMATE	200MG	N84804
MEPROBAMATE	400MG	N84804
MEPROBAMATE	400MG	N14601
MEPROBAMATE	200MG	N84435
MEPROBAMATE	200MG	N14474
MEPROBAMATE	400MG	N14474
MEPROBAMATE	200MG	N87825

FDA data supplied by DrugPatentWatch.com

MEPROBAMATE

TABLET

MEPROBAMATE	400MG	N87826
MEPROBAMATE	200MG	N15139
MEPROBAMATE	400MG	N15139
MEPROBAMATE	400MG	N88011
MEPROBAMATE	600MG	N84274
MEPROBAMATE	600MG	N85719
MEPROBAMATE	200MG	N15417
MEPROBAMATE	400MG	N15417
MEPROBAMATE	200MG	N83830
MEPROBAMATE	400MG	N83442
MILTOWN	600MG	N83919
NEURAMATE	200MG	N14359
NEURAMATE	400MG	N14359
TRANMEP	400MG	N84369

MERSALYL SODIUM; THEOPHYLLINE

INJECTABLE

MERSALYL-THEOPHYLLINE	100MG/ML;50MG/ML	N84875

MESALAMINE

SUPPOSITORY

ROWASA	500MG	*N19919

MESORIDAZINE BESYLATE

INJECTABLE

SERENTIL	EQ 25MG BASE/ML	N16775

TABLET

SERENTIL	EQ 10MG BASE	N16774
SERENTIL	EQ 50MG BASE	N16774

MESTRANOL; NORETHINDRONE

TABLET

NORINYL	0.1MG;2MG	N13625
NORINYL 1+80 21-DAY	0.08MG;1MG	N16724
NORINYL 1+80 28-DAY	0.08MG;1MG	N16725
ORTHO-N0VUM 1/80 28	0.08MG;1MG	N16715
ORTHO-NOVUM 1/50 21	0.05MG;1MG	N12728
ORTHO-NOVUM 1/80 21	0.08MG;1MG	N16715
ORTHO-NOVUM 10-21	0.06MG;10MG	N12728
ORTHO-NOVUM 2-21	0.1MG;2MG	N12728

MESTRANOL; NORETHYNODREL

TABLET

ENOVID	0.075MG;5MG	N10976
ENOVID	0.075MG;5MG	N10976
ENOVID	0.15MG;9.85MG	N10976
ENOVID-E	0.1MG;2.5MG	N10976
ENOVID-E 21	0.1MG;2.5MG	N10976

METAPROTERENOL SULFATE

SOLUTION

ALUPENT	5%	N17659
METAPROTERENOL SULFATE	0.4%	N71275
METAPROTERENOL SULFATE	0.6%	N71018
METAPROTERENOL SULFATE	0.33%	N71806
METAPROTERENOL SULFATE	0.5%	N71805
METAPROTERENOL SULFATE	5%	N70805
METAPROTERENOL SULFATE	5%	N72190
PROMETA	5%	N73340

SYRUP

ALUPENT	10MG/5ML	N17571
METAPROTERENOL SULFATE	10MG/5ML	N73034
METAPROTERENOL SULFATE	10MG/5ML	N71656
METAPROTERENOL SULFATE	10MG/5ML	N72761
PROMETA	10MG/5ML	N72023

TABLET

ALUPENT	10MG	N15874
ALUPENT	20MG	N15874
METAPROTERENOL SULFATE	10MG	N72054
METAPROTERENOL SULFATE	20MG	N72055
METAPROTERENOL SULFATE	10MG	N71013
METAPROTERENOL SULFATE	20MG	N71014

METARAMINOL BITARTRATE

INJECTABLE

METARAMINOL BITARTRATE	EQ 10MG BASE/ML	N80431
METARAMINOL BITARTRATE	EQ 10MG BASE/ML	N83363
METARAMINOL BITARTRATE	EQ 10MG BASE/ML	N86418
METARAMINOL BITARTRATE	EQ 20MG BASE/ML	N86418

METFORMIN HYDROCHLORIDE

TABLET

GLUCOPHAGE	625MG	*N20357
GLUCOPHAGE	750MG	*N20357

METHACYCLINE HYDROCHLORIDE

CAPSULE

RONDOMYCIN	EQ 140MG BASE	N60641
RONDOMYCIN	EQ 280MG BASE	N60641

SYRUP

RONDOMYCIN	EQ 70MG BASE/5ML	N60641

METHADONE HYDROCHLORIDE

SYRUP

DOLOPHINE HCL	10MG/30ML	N06134

TABLET, DISPERSIBLE

WESTADONE	2.5MG	N17108

FDA data supplied by DrugPatentWatch.com

METHADONE HYDROCHLORIDE		
TABLET, EFFERVESCENT		
WESTADONE	10MG	N17108
WESTADONE	40MG	N17108
WESTADONE	5MG	N17108
METHAMPHETAMINE HYDROCHLORIDE		
TABLET		
METHAMPEX	10MG	N83889
METHAMPHETAMINE HCL	10MG	N84931
METHAMPHETAMINE HCL	5MG	N84931
METHAMPHETAMINE HCL	5MG	N86359
TABLET, EXTENDED RELEASE		
DESOXYN	10MG	N05378
DESOXYN	15MG	N05378
DESOXYN	5MG	N05378
METHANTHELINE BROMIDE		
TABLET		
BANTHINE	50MG	N07390
METHARBITAL		
TABLET		
GEMONIL	100MG	N08322
METHAZOLAMIDE		
TABLET		
METHAZOLAMIDE	25MG	N40011
METHAZOLAMIDE	50MG	N40011
NEPTAZANE	25MG	N11721
NEPTAZANE	50MG	N11721
METHDILAZINE		
TABLET, CHEWABLE		
TACARYL	3.6MG	N11950
METHDILAZINE HYDROCHLORIDE		
SYRUP		
METHDILAZINE HCL	4MG/5ML	N87122
TACARYL	4MG/5ML	N11950
TABLET		
TACARYL	8MG	N11950
METHICILLIN SODIUM		
INJECTABLE		
STAPHCILLIN	EQ 3.6GM BASE/VIAL	N50117
STAPHCILLIN	EQ 3.6GM BASE/VIAL	N61449
STAPHCILLIN	EQ 5.4GM BASE/VIAL	N50117
STAPHCILLIN	EQ 5.4GM BASE/VIAL	N61449
STAPHCILLIN	EQ 900MG BASE/VIAL	N50117
METHICILLIN SODIUM		
INJECTABLE		
STAPHCILLIN	EQ 900MG BASE/VIAL	N61449
METHIXENE HYDROCHLORIDE		
TABLET		
TREST	1MG	N13420
METHOCARBAMOL		
INJECTABLE		
METHOCARBAMOL	100MG/ML	N89849
TABLET		
DELAXIN	500MG	N85454
FORBAXIN	750MG	N85136
METHOCARBAMOL	500MG	N89417
METHOCARBAMOL	750MG	N89418
METHOCARBAMOL	500MG	N87660
METHOCARBAMOL	750MG	N87661
METHOCARBAMOL	500MG	N85961
METHOCARBAMOL	750MG	N85963
METHOCARBAMOL	500MG	N84488
METHOCARBAMOL	750MG	N84486
METHOCARBAMOL	500MG	N84675
METHOCARBAMOL	750MG	N84924
METHOCARBAMOL	500MG	N85137
METHOCARBAMOL	500MG	N84648
METHOCARBAMOL	750MG	N84649
METHOCARBAMOL	500MG	N85660
METHOCARBAMOL	750MG	N85658
METHOCARBAMOL	500MG	N84259
METHOCARBAMOL	750MG	N84323
METHOCARBAMOL	750MG	N85033
METHOCARBAMOL	500MG	N84231
METHOCARBAMOL	750MG	N84471
METHOCARBAMOL	500MG	N88731
METHOCARBAMOL	750MG	N89082
METHOCARBAMOL	500MG	N85718
METHOCARBAMOL	750MG	N85718
METHOCARBAMOL	500MG	N88646
METHOCARBAMOL	750MG	N88647
METHOCARBAMOL	500MG	N84448
METHOCARBAMOL	750MG	N84449
METHOCARBAMOL	500MG	N87589
METHOCARBAMOL	750MG	N87590
METHOCARBAMOL	500MG	N87453
METHOCARBAMOL	750MG	N87454
METHOCARBAMOL	500MG	N83605
METHOCARBAMOL	750MG	N83605

FDA data supplied by DrugPatentWatch.com

METHOTREXATE SODIUM			
INJECTABLE			
ABITREXATE	EQ 100MG BASE/VIAL	N89355	
ABITREXATE	EQ 250MG BASE/VIAL	N89356	
ABITREXATE	EQ 25MG BASE/ML	N89161	
ABITREXATE	EQ 50MG BASE/VIAL	N89354	
FOLEX	EQ 100MG BASE/VIAL	N87695	
FOLEX	EQ 250MG BASE/VIAL	N88954	
FOLEX	EQ 25MG BASE/VIAL	N87695	
FOLEX	EQ 50MG BASE/VIAL	N87695	
FOLEX PFS	EQ 25MG BASE/ML	N81242	
FOLEX PFS	EQ 25MG BASE/ML	N89180	
METHOTREXATE SODIUM	EQ 100MG BASE/VIAL	N88937	
METHOTREXATE SODIUM	EQ 2.5MG BASE/ML	N89323	
METHOTREXATE SODIUM	EQ 20MG BASE/VIAL	N88935	
METHOTREXATE SODIUM	EQ 25MG BASE/ML	N89263	
METHOTREXATE SODIUM	EQ 25MG BASE/ML	N89322	
METHOTREXATE SODIUM	EQ 50MG BASE/VIAL	N88936	
METHOTREXATE SODIUM	EQ 100MG BASE/VIAL	N11719	
METHOTREXATE SODIUM	EQ 2.5MG BASE/ML	N11719	
METHOTREXATE SODIUM	EQ 50MG BASE/VIAL	N11719	
MEXATE	EQ 100MG BASE/VIAL	N86358	
MEXATE	EQ 20MG BASE/VIAL	N86358	
MEXATE	EQ 250MG BASE/VIAL	N86358	
MEXATE	EQ 50MG BASE/VIAL	N86358	
MEXATE-AQ PRESERVED	EQ 25MG BASE/ML	N89887	
METHOTRIMEPRAZINE			
INJECTABLE			
LEVOPROME	20MG/ML	N15865	
METHOXAMINE HYDROCHLORIDE			
INJECTABLE			
VASOXYL	10MG/ML	N06772	
VASOXYL	20MG/ML	N06772	
METHOXSALEN			
CAPSULE			
METHOXSALEN	10MG	N87781	
METHOXYFLURANE			
LIQUID			
PENTHRANE	99.9%	N13056	
METHSCOPOLAMINE BROMIDE			
TABLET			
METHSCOPOLAMINE BROMIDE	2.5MG	N80970	
METHYCLOTHIAZIDE			
TABLET			
AQUATENSEN	5MG	N17364	
METHYCLOTHIAZIDE			
TABLET			
METHYCLOTHIAZIDE	5MG	N87786	
METHYCLOTHIAZIDE	2.5MG	N87671	
METHYCLOTHIAZIDE	2.5MG	N89135	
METHYCLOTHIAZIDE	5MG	N89136	
METHYCLOTHIAZIDE	5MG	N88745	
METHYCLOTHIAZIDE	2.5MG	N85487	
METHYCLOTHIAZIDE	2.5MG	N88750	
METHYCLOTHIAZIDE	5MG	N85476	
METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE			
TABLET			
EUTRON	5MG;25MG	N16047	
METHYCLOTHIAZIDE; RESERPINE			
TABLET			
DIUTENSEN-R	2.5MG;0.1MG	N12708	
METHYLDOPA			
SUSPENSION			
ALDOMET	250MG/5ML	N18389	
TABLET			
ALDOMET	125MG	N13400	
ALDOMET	250MG	N13400	
METHYLDOPA	125MG	N70070	
METHYLDOPA	250MG	N71006	
METHYLDOPA	500MG	N71009	
METHYLDOPA	125MG	N70073	
METHYLDOPA	125MG	N71751	
METHYLDOPA	250MG	N70060	
METHYLDOPA	250MG	N71752	
METHYLDOPA	500MG	N70074	
METHYLDOPA	500MG	N71753	
METHYLDOPA	125MG	N70331	
METHYLDOPA	250MG	N70332	
METHYLDOPA	500MG	N70333	
METHYLDOPA	125MG	N70749	
METHYLDOPA	250MG	N70750	
METHYLDOPA	500MG	N70452	
METHYLDOPA	125MG	N70192	
METHYLDOPA	250MG	N70193	
METHYLDOPA	500MG	N70194	
METHYLDOPA	250MG	N70669	
METHYLDOPA	500MG	N70670	
METHYLDOPA	125MG	N71105	
METHYLDOPA	250MG	N71106	
METHYLDOPA	500MG	N71067	
METHYLDOPA	125MG	N70245	

FDA data supplied by DrugPatentWatch.com

METHYLDOPA
TABLET

METHYLDOPA	125MG	N70260
METHYLDOPA	250MG	N70246
METHYLDOPA	250MG	N70261
METHYLDOPA	500MG	N70247
METHYLDOPA	500MG	N70262

METHYLDOPATE HYDROCHLORIDE
INJECTABLE

METHYLDOPATE HCL	50MG/ML	N70652
METHYLDOPATE HCL	50MG/ML	N70291
METHYLDOPATE HCL	50MG/ML	N71812
METHYLDOPATE HCL	50MG/ML	N70691
METHYLDOPATE HCL	50MG/ML	N70849
METHYLDOPATE HCL	50MG/ML	N70841

METHYLPREDNISOLONE
TABLET

MEDROL	2MG	N11153
METHYLPREDNISOLONE	4MG	N87341
METHYLPREDNISOLONE	4MG	N85650
METHYLPREDNISOLONE	16MG	N86159
METHYLPREDNISOLONE	4MG	N86161

METHYLPREDNISOLONE ACETATE
ENEMA

MEDROL	40MG/BOT	N18102

INJECTABLE

METHYLPREDNISOLONE ACETATE	40MG/ML	N86903
METHYLPREDNISOLONE ACETATE	80MG/ML	N86903
METHYLPREDNISOLONE ACETATE	20MG/ML	N85597
METHYLPREDNISOLONE ACETATE	20MG/ML	N87248
METHYLPREDNISOLONE ACETATE	40MG/ML	N85374
METHYLPREDNISOLONE ACETATE	40MG/ML	N85600
METHYLPREDNISOLONE ACETATE	80MG/ML	N85595
METHYLPREDNISOLONE ACETATE	80MG/ML	N86507
M-PREDROL	40MG/ML	N86666
M-PREDROL	80MG/ML	N87135

OINTMENT

MEDROL ACETATE	0.25%	N12421
MEDROL ACETATE	1%	N12421

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE
CREAM

NEO-MEDROL ACETATE	0.25%;EQ 3.5MG BASE/GM	N60611
NEO-MEDROL ACETATE	1%;EQ 3.5MG BASE/GM	N60611

METHYLPREDNISOLONE SODIUM SUCCINATE
INJECTABLE

A-METHAPRED	EQ 125MG BASE/VIAL	N89574
A-METHAPRED	EQ 1GM BASE/VIAL	N89576
A-METHAPRED	EQ 40MG BASE/VIAL	N89573
A-METHAPRED	EQ 500MG BASE/VIAL	N89575
METHYLPREDNISOLONE	EQ 125MG BASE/VIAL	N86906
METHYLPREDNISOLONE	EQ 1GM BASE/VIAL	N86906
METHYLPREDNISOLONE	EQ 500MG BASE/VIAL	N86906
METHYLPREDNISOLONE	EQ 1GM BASE/VIAL	N87535
METHYLPREDNISOLONE	EQ 500MG BASE/VIAL	N87535
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 125MG BASE/VIAL	N88677
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 125MG BASE/VIAL	N89144
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 1GM BASE/VIAL	N88679
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 1GM BASE/VIAL	N89188
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 1GM BASE/VIAL	N89189
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 40MG BASE/VIAL	N88676
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 40MG BASE/VIAL	N89143
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 500MG BASE/VIAL	N88678
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 500MG BASE/VIAL	N89186
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 500MG BASE/VIAL	N89187
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 40MG BASE/VIAL	N86906
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 1GM BASE/VIAL	N81268
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 500MG BASE/VIAL	N81267
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 125MG BASE/VIAL	N87813
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 1GM BASE/VIAL	N87852
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 40MG BASE/VIAL	N87812
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 500MG BASE/VIAL	N87851
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 125MG BASE/VIAL	N87030
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 1GM BASE/VIAL	N88524
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 40MG BASE/VIAL	N86953
METHYLPREDNISOLONE SODIUM SUCCINATE	EQ 500MG BASE/VIAL	N88523

METHYLPREDNISOLONE; NEOMYCIN SULFATE
OINTMENT

NEO-MEDROL	0.1%;EQ 3.5MG BASE/GM	N60645

METHYLTESTOSTERONE
CAPSULE

METHYLTESTOSTERONE	10MG	N84967

TABLET

ANDROID 5	5MG	N87222
METANDREN	10MG	N03240
METANDREN	10MG	N03240
METANDREN	25MG	N03240
METANDREN	5MG	N03240
METHYLTESTOSTERONE	10MG	N84287
METHYLTESTOSTERONE	10MG	N80839

FDA data supplied by DrugPatentWatch.com

METHYLTESTOSTERONE
TABLET

METHYLTESTOSTERONE	25MG	N80973
METHYLTESTOSTERONE	10MG	N84312
METHYLTESTOSTERONE	10MG	N87092
METHYLTESTOSTERONE	25MG	N87111
METHYLTESTOSTERONE	10MG	N80256
METHYLTESTOSTERONE	25MG	N80256
METHYLTESTOSTERONE	10MG	N84244
METHYLTESTOSTERONE	25MG	N84241
METHYLTESTOSTERONE	10MG	N80308
METHYLTESTOSTERONE	10MG	N80309
METHYLTESTOSTERONE	10MG	N80475
METHYLTESTOSTERONE	10MG	N80475
METHYLTESTOSTERONE	25MG	N80310
METHYLTESTOSTERONE	25MG	N80475
METHYLTESTOSTERONE	10MG	N80214
METHYLTESTOSTERONE	25MG	N80214
METHYLTESTOSTERONE	5MG	N80214
METHYLTESTOSTERONE	5MG	N83836
METHYLTESTOSTERONE	10MG	N80313
METHYLTESTOSTERONE	10MG	N85125
METHYLTESTOSTERONE	25MG	N85270
METHYLTESTOSTERONE	10MG	N80271
METHYLTESTOSTERONE	10MG	N80933
METHYLTESTOSTERONE	25MG	N80931
METHYLTESTOSTERONE	10MG	N84331
METHYLTESTOSTERONE	25MG	N84331
METHYLTESTOSTERONE	25MG	N84642
ORETON	10MG	N80281
ORETON METHYL	10MG	N03158
ORETON METHYL	25MG	N03158

METHYPRYLON
CAPSULE

NOLUDAR	300MG	N09660

ELIXIR

NOLUDAR	50MG/5ML	N09660

TABLET

NOLUDAR	200MG	N09660
NOLUDAR	50MG	N09660

METHYSERGIDE MALEATE
TABLET

SANSERT	2MG	N12516

METOCLOPRAMIDE HYDROCHLORIDE
INJECTABLE

METOCLOPRAMIDE HCL	EQ 5MG BASE/ML	N70506

METOCLOPRAMIDE HYDROCHLORIDE
INJECTABLE

METOCLOPRAMIDE HCL	EQ 10MG BASE/2ML	N70293
METOCLOPRAMIDE HCL	EQ 5MG BASE/ML	N72155
METOCLOPRAMIDE HCL	EQ 5MG BASE/ML	N72244
METOCLOPRAMIDE HCL	EQ 5MG BASE/ML	N72247
METOCLOPRAMIDE HCL	EQ 5MG BASE/ML	N71990
METOCLOPRAMIDE HCL	EQ 10MG BASE/2ML	N70892
METOCLOPRAMIDE HCL	EQ 10MG BASE/2ML	N70622
METOCLOPRAMIDE HCL	EQ 5MG BASE/ML	N70623
REGLAN	EQ 10MG BASE/ML	N17862

SOLUTION

METOCLOPRAMIDE HCL	EQ 5MG BASE/5ML	N70949
METOCLOPRAMIDE HCL	EQ 5MG BASE/5ML	N71665
REGLAN	EQ 5MG BASE/5ML	N18821

TABLET

CLOPRA	EQ 10MG BASE	N70294
CLOPRA	EQ 5MG BASE	N72384
CLOPRA-"YELLOW"	EQ 10MG BASE	N70632
MAXOLON	EQ 10MG BASE	N70106
METOCLOPRAMIDE HCL	EQ 10MG BASE	N72639
METOCLOPRAMIDE HCL	EQ 10MG BASE	N70660
METOCLOPRAMIDE HCL	EQ 10MG BASE	N70906
METOCLOPRAMIDE HCL	EQ 10MG BASE	N71213
METOCLOPRAMIDE HCL	EQ 10MG BASE	N71536
METOCLOPRAMIDE HCL	EQ 5MG BASE	N71536
METOCLOPRAMIDE HCL	EQ 10MG BASE	N70342
METOCLOPRAMIDE HCL	EQ 10MG BASE	N70850
METOCLOPRAMIDE HCL	EQ 5MG BASE	N72436
METOCLOPRAMIDE HCL	EQ 10MG BASE	N70598
METOCLOPRAMIDE HCL	EQ 10MG BASE	N70926
METOCLOPRAMIDE HCL	EQ 10MG BASE	N70339
METOCLOPRAMIDE HCL	EQ 10MG BASE	N70363
METOCLOPRAMIDE HCL	EQ 10MG BASE	N70453
METOCLOPRAMIDE HCL	EQ 10MG BASE	N70645

METOCURINE IODIDE
INJECTABLE

METUBINE IODIDE	2MG/ML	N06632

METOLAZONE
TABLET

DIULO	10MG	N18535
DIULO	2.5MG	N18535
DIULO	5MG	N18535

FDA data supplied by DrugPatentWatch.com

METOPROLOL FUMARATE		
TABLET, EXTENDED RELEASE		
LOPRESSOR	EQ 100MG TARTRATE	N19786
LOPRESSOR	EQ 200MG TARTRATE	N19786
LOPRESSOR	EQ 300MG TARTRATE	N19786
LOPRESSOR	EQ 400MG TARTRATE	N19786
METOPROLOL TARTRATE		
TABLET		
METOPROLOL TARTRATE	100MG	N74380
METOPROLOL TARTRATE	50MG	N74380
METRIZAMIDE		
INJECTABLE		
AMIPAQUE	13.5GM/VIAL	N17982
AMIPAQUE	2.5GM/VIAL	N17982
AMIPAQUE	3.75GM/VIAL	N17982
AMIPAQUE	6.75GM/VIAL	N17982
METRONIDAZOLE		
INJECTABLE		
METRO I.V.	500MG/100ML	N18674
METRONIDAZOLE	500MG/100ML	N18889
METRONIDAZOLE	500MG/100ML	N70071
METRONIDAZOLE	500MG/100ML	N18907
METRONIDAZOLE	500MG/100ML	N70004
METRONIDAZOLE	500MG/100ML	N70042
METRONIDAZOLE	500MG/100ML	N70170
TABLET		
METRONIDAZOLE	250MG	N18818
METRONIDAZOLE	250MG	N70021
METRONIDAZOLE	500MG	N18818
METRONIDAZOLE	500MG	N70593
METRONIDAZOLE	250MG	N70008
METRONIDAZOLE	500MG	N70009
METRONIDAZOLE	250MG	N18599
METRONIDAZOLE	500MG	N18599
PROTOSTAT	250MG	N18871
PROTOSTAT	500MG	N18871
SATRIC	250MG	N70029
SATRIC	500MG	N70731
METRONIDAZOLE HYDROCHLORIDE		
INJECTABLE		
METRONIDAZOLE HCL	EQ 500MG BASE/VIAL	N70295
METYRAPONE		
TABLET		
METOPIRONE	250MG	N12911
MEZLOCILLIN SODIUM MONOHYDRATE		
INJECTABLE		
MEZLIN	EQ 1GM BASE/VIAL	N50549
MEZLIN	EQ 1GM BASE/VIAL	N62333
MEZLIN	EQ 1GM BASE/VIAL	N62372
MEZLIN	EQ 20GM BASE/VIAL	N50549
MEZLIN	EQ 20GM BASE/VIAL	N62372
MEZLIN	EQ 2GM BASE/VIAL	N50549
MEZLIN	EQ 2GM BASE/VIAL	N62333
MEZLIN	EQ 2GM BASE/VIAL	N62372
MEZLIN	EQ 3GM BASE/VIAL	N50549
MEZLIN	EQ 3GM BASE/VIAL	N62333
MEZLIN	EQ 3GM BASE/VIAL	N62372
MEZLIN	EQ 3GM BASE/VIAL	N62697
MEZLIN	EQ 4GM BASE/VIAL	N50549
MEZLIN	EQ 4GM BASE/VIAL	N62333
MEZLIN	EQ 4GM BASE/VIAL	N62372
MEZLIN	EQ 4GM BASE/VIAL	N62697
MICONAZOLE		
INJECTABLE		
MONISTAT	10MG/ML	N18040
MICONAZOLE NITRATE		
CREAM, INSERT		
MONISTAT DUAL- PAK	1.2GM;2%	N20968
LOTION		
MONISTAT-DERM	2%	N17739
TAMPON		
MONISTAT 5	100MG	N18592
MIDAZOLAM HYDROCHLORIDE		
INJECTABLE		
MIDAZOLAM HCL	EQ 1MG BASE/ML	N75620
MIDAZOLAM HCL	EQ 5MG BASE/ML	N75620
MIDAZOLAM HCL	EQ 5MG BASE/ML	N75641
MIDAZOLAM HCL	EQ 5MG BASE/ML	N75263
MIDAZOLAM HCL	EQ 5MG BASE/ML	N75249
MIDAZOLAM HCL	EQ 5MG BASE/ML	N75455
VERSED	EQ 1MG BASE/ML	* N18654
VERSED	EQ 5MG BASE/ML	* N18654
SYRUP		
VERSED	EQ 2MG BASE/ML	* N20942
MILRINONE LACTATE		
INJECTABLE		
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 10MG BASE/100ML	N20343
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 15MG BASE/100ML	N20343

FDA data supplied by DrugPatentWatch.com

MINOCYCLINE HYDROCHLORIDE		
CAPSULE		
MINOCIN	EQ 100MG BASE	N50315
MINOCIN	EQ 50MG BASE	N50315
INJECTABLE		
MINOCIN	EQ 100MG BASE/VIAL	N62139
SUSPENSION		
MINOCIN	EQ 50MG BASE/5ML	N50445
TABLET		
MINOCYCLINE HCL	EQ 100MG BASE	* N50451
MINOCYCLINE HCL	EQ 50MG BASE	* N50451
MINOXIDIL		
TABLET		
MINODYL	10MG	N71534
MINODYL	2.5MG	N72153
MINOXIDIL	10MG	N71796
MINOXIDIL	2.5MG	N71799
MINOXIDIL	2.5MG	N71537
MITOMYCIN		
INJECTABLE		
MUTAMYCIN	20MG/VIAL	N50450
MUTAMYCIN	5MG/VIAL	N50450
MIVACURIUM CHLORIDE		
INJECTABLE		
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER	EQ 0.5MG BASE/ML	N20098
MOLINDONE HYDROCHLORIDE		
CAPSULE		
MOBAN	10MG	N17111
MOBAN	25MG	N17111
MOBAN	5MG	N17111
MONOCTANOIN		
LIQUID		
MOCTANIN	100%	N19368
MORPHINE SULFATE		
TABLET, EXTENDED RELEASE		
MORPHINE SULFATE	15MG	N75407
MOXALACTAM DISODIUM		
INJECTABLE		
MOXAM	EQ 10GM BASE/VIAL	N50550
MOXAM	EQ 1GM BASE/VIAL	N50550
MOXAM	EQ 250MG BASE/VIAL	N50550
MOXAM	EQ 2GM BASE/VIAL	N50550
MOXAM	EQ 500MG BASE/VIAL	N50550
NABILONE		
CAPSULE		
CESAMET	1MG	N18677
NAFCILLIN SODIUM		
CAPSULE		
UNIPEN	EQ 250MG BASE	N50111
FOR SOLUTION		
UNIPEN	EQ 250MG BASE/5ML	N50199
INJECTABLE		
NAFCILLIN SODIUM	EQ 1GM BASE/VIAL	N61984
NAFCILLIN SODIUM	EQ 2GM BASE/VIAL	N61984
NAFCILLIN SODIUM	EQ 4GM BASE/VIAL	N61984
NAFCILLIN SODIUM	EQ 500MG BASE/VIAL	N61984
NAFCILLIN SODIUM	EQ 1.5GM BASE/VIAL	N62844
NAFCILLIN SODIUM	EQ 10GM BASE/VIAL	N63008
NAFCILLIN SODIUM	EQ 1GM BASE/VIAL	N62844
NAFCILLIN SODIUM	EQ 2GM BASE/VIAL	N62844
NAFCILLIN SODIUM	EQ 4GM BASE/VIAL	N62844
NAFCILLIN SODIUM	EQ 500MG BASE/VIAL	N62844
NALLPEN	EQ 10GM BASE/VIAL	N61999
NALLPEN	EQ 1GM BASE/VIAL	N61999
NALLPEN	EQ 1GM BASE/VIAL	N62755
NALLPEN	EQ 2GM BASE/VIAL	N61999
NALLPEN	EQ 2GM BASE/VIAL	N62755
NALLPEN	EQ 500MG BASE/VIAL	N61999
UNIPEN	EQ 10GM BASE/VIAL	N50320
UNIPEN	EQ 1GM BASE/VIAL	N62717
UNIPEN	EQ 20GM BASE/VIAL	N50320
UNIPEN	EQ 2GM BASE/VIAL	N50320
UNIPEN	EQ 2GM BASE/VIAL	N62717
UNIPEN	EQ 4GM BASE/VIAL	N50320
UNIPEN	EQ 500MG BASE/VIAL	N50320
UNIPEN	EQ 500MG BASE/VIAL	N62717
UNIPEN IN PLASTIC CONTAINER	EQ 1GM BASE/VIAL	N50320
TABLET		
UNIPEN	EQ 500MG BASE	N50462
NALBUPHINE HYDROCHLORIDE		
INJECTABLE		
NALBUPHINE	10MG/ML	N70751
NALBUPHINE	20MG/ML	N70752
NALBUPHINE HCL	1.5MG/ML	N20200
NALBUPHINE HCL	20MG/ML	N70917
NALBUPHINE HCL	10MG/ML	N72070
NALBUPHINE HCL	10MG/ML	N72071
NALBUPHINE HCL	10MG/ML	N72072
NALBUPHINE HCL	20MG/ML	N72073

FDA data supplied by DrugPatentWatch.com

DISCONTINUED DRUG PRODUCT LIST

NALBUPHINE HYDROCHLORIDE		
INJECTABLE		
NALBUPHINE HCL	20MG/ML	N72074
NALBUPHINE HCL	20MG/ML	N72075
NALBUPHINE HCL	10MG/ML	N74471
NALBUPHINE HCL	20MG/ML	N74471
NALIDIXIC ACID		
SUSPENSION		
NEGGRAM	250MG/5ML	N17430
TABLET		
NALIDIXIC ACID	1GM	N70272
NALIDIXIC ACID	250MG	N70270
NALIDIXIC ACID	500MG	N70271
NALOXONE HYDROCHLORIDE		
INJECTABLE		
NALOXONE	0.4MG/ML	N70496
NALOXONE	0.4MG/ML	N70299
NALOXONE	0.4MG/ML	N70298
NALOXONE	0.02MG/ML	N70188
NALOXONE	0.02MG/ML	N70189
NALOXONE	0.4MG/ML	N70190
NALOXONE	0.4MG/ML	N70191
NALOXONE HCL	0.4MG/ML	N70172
NALOXONE HCL	0.02MG/ML	N70648
NALOXONE HCL	0.02MG/ML	N70661
NALOXONE HCL	0.4MG/ML	N70649
NALOXONE HCL	1MG/ML	N71604
NALOXONE HCL	0.02MG/ML	N72081
NALOXONE HCL	0.02MG/ML	N72082
NALOXONE HCL	0.02MG/ML	N72083
NALOXONE HCL	0.02MG/ML	N72084
NALOXONE HCL	0.02MG/ML	N72085
NALOXONE HCL	0.4MG/ML	N72086
NALOXONE HCL	0.4MG/ML	N72087
NALOXONE HCL	0.4MG/ML	N72088
NALOXONE HCL	0.4MG/ML	N72089
NALOXONE HCL	0.4MG/ML	N72090
NALOXONE HCL	1MG/ML	N72091
NALOXONE HCL	1MG/ML	N72092
NALOXONE HCL	1MG/ML	N72093
NALOXONE HCL	0.02MG/ML	N71272
NALOXONE HCL	1MG/ML	N71273
NALOXONE HCL	1MG/ML	N71274
NALOXONE HCL	1MG/ML	N71287
NALOXONE HCL	0.4MG/ML	N70417
NALOXONE HCL	1MG/ML	N72115

NALOXONE HYDROCHLORIDE		
INJECTABLE		
NALOXONE HCL	0.4MG/ML	N71611
NALOXONE HCL	0.02MG/ML	N71671
NALOXONE HCL	0.4MG/ML	N71681
NALOXONE HCL	0.4MG/ML	N71682
NALOXONE HCL	0.02MG/ML	N71672
NALOXONE HCL	0.4MG/ML	N71683
NALOXONE HCL	0.4MG/ML	N71339
NARCAN	0.4MG/ML	N71083
NARCAN	1MG/ML	N71084
NARCAN	1MG/ML	N71311
NANDROLONE DECANOATE		
INJECTABLE		
DECA-DURABOLIN	100MG/ML	N13132
DECA-DURABOLIN	200MG/ML	N13132
DECA-DURABOLIN	50MG/ML	N13132
NANDROLONE DECANOATE	100MG/ML	N87519
NANDROLONE DECANOATE	100MG/ML	N88290
NANDROLONE DECANOATE	200MG/ML	N88317
NANDROLONE DECANOATE	100MG/ML	N87599
NANDROLONE DECANOATE	50MG/ML	N87598
NANDROLONE DECANOATE	50MG/ML	N88554
NANDROLONE PHENPROPIONATE		
INJECTABLE		
DURABOLIN	25MG/ML	N11891
DURABOLIN	50MG/ML	N11891
NANDROLONE PHENPROPIONATE	25MG/ML	N86386
NANDROLONE PHENPROPIONATE	50MG/ML	N87488
NAPHAZOLINE HYDROCHLORIDE		
SOLUTION/DROPS		
NAFAZAIR	0.1%	N88101
NAPHCON FORTE	0.1%	N80229
OPCON	0.1%	N87506
NAPROXEN		
TABLET		
NAPROXEN	250MG	N74110
NAPROXEN	375MG	N74110
NAPROXEN	500MG	N74110
NAPROXEN	250MG	N74263
NAPROXEN	375MG	N74263
NAPROXEN	500MG	N74263
NAPROXEN	250MG	N74211
NAPROXEN	375MG	N74211
NAPROXEN	500MG	N74211

FDA data supplied by DrugPatentWatch.com

NAPROXEN SODIUM		
TABLET		
NAPROXEN SODIUM	EQ 250MG BASE	N74106
NAPROXEN SODIUM	EQ 500MG BASE	N74106
NAPROXEN SODIUM	EQ 250MG BASE	N74319
NAPROXEN SODIUM	EQ 500MG BASE	N74319
NAPROXEN SODIUM	EQ 250MG BASE	N74257
NAPROXEN SODIUM	EQ 500MG BASE	N74257
TABLET, EXTENDED RELEASE		
NAPRELAN	EQ 750MG BASE	N20353
NEDOCROMIL SODIUM		
SOLUTION		
TILADE	0.5%	N20750
NEFAZODONE HYDROCHLORIDE		
TABLET		
SERZONE	300MG	N20152
NEOMYCIN SULFATE		
SOLUTION		
MYCIFRADIN	EQ 87.5MG BASE/5ML	N50285
TABLET		
MYCIFRADIN	EQ 350MG BASE	N60520
NEOBIOTIC	EQ 350MG BASE	N60475
NEOMYCIN SULFATE	EQ 350MG BASE	N60365
NEOMYCIN SULFATE	EQ 350MG BASE	N61586
NEOMYCIN SULFATE	EQ 350MG BASE	N60607
NEOMYCIN SULFATE	EQ 350MG BASE	N60385
NEOMYCIN SULFATE	EQ 350MG BASE	N62173
NEOMYCIN SULFATE; POLYMYXIN B SULFATE		
CREAM		
NEOSPORIN	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N50176
OINTMENT		
STATROL	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N50344
SOLUTION		
NEOMYCIN AND POLYMYXIN B SULFATES	EQ 40MG BASE/ML;200,000 UNITS/ML	N62664
SOLUTION/DROPS		
STATROL	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N50456
STATROL	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N62339
NEOMYCIN SULFATE; PREDNISOLONE ACETATE		
OINTMENT		
NEO-DELTA-CORTEF	EQ 3.5MG BASE/GM;0.25%	N61039
NEO-DELTA-CORTEF	EQ 3.5MG BASE/GM;0.5%	N61039
SUSPENSION/DROPS		
NEO-DELTA-CORTEF	EQ 3.5MG BASE/ML;0.25%	N61037
NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE		
OINTMENT		
NEO-HYDELTRASOL	EQ 3.5MG BASE/GM;EQ 0.25% PHOSPHATE	N50378
NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE		
CREAM		
MYTREX A	EQ 3.5MG BASE/GM;0.1%	N62598
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE	EQ 3.5MG BASE/GM;0.1%	N62600
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE	EQ 3.5MG BASE/GM;0.1%	N62595
OINTMENT		
MYTREX A	EQ 3.5MG BASE/GM;0.1%	N62609
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE	EQ 3.5MG BASE/GM;0.1%	N62608
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE	EQ 3.5MG BASE/GM;0.1%	N62607
NETILMICIN SULFATE		
INJECTABLE		
NETROMYCIN	EQ 100MG BASE/ML	N50544
NETROMYCIN	EQ 10MG BASE/ML	N50544
NETROMYCIN	EQ 25MG BASE/ML	N50544
NIACIN		
CAPSULE		
WAMPOCAP	500MG	N11073
TABLET		
NIACIN	500MG	N83203
NIACIN	500MG	N83453
NIACIN	500MG	N83115
NIACIN	500MG	N83180
NIACIN	500MG	N83271
NIACIN	500MG	N83306
NIACIN	500MG	N83136
NIACIN	500MG	N83305
NIACIN	500MG	N85172
NIACIN	500MG	N83718
NICOLAR	500MG	N83823
TABLET, EXTENDED RELEASE		
NIASPAN	375MG	N20381
NIASPAN TITRATION STARTER PACK	375MG;500MG;750MG	N20381

FDA data supplied by DrugPatentWatch.com

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE		
SUSPENSION		
TPN SUSPENSION	15MG/5ML;3.75MG/5ML;600 MG/5ML	N08378
NICLOSAMIDE		
TABLET, CHEWABLE		
NICLOCIDE	500MG	N18669
NIFEDIPINE		
CAPSULE		
ADALAT	10MG	N19478
ADALAT	20MG	N19478
NIFEDIPINE	10MG	N72409
NIFEDIPINE	20MG	N73421
TABLET, EXTENDED RELEASE		
NIFEDIPINE	30MG	N75108
NILUTAMIDE		
TABLET		
NILANDRON	50MG	N20169
NITROFURANTOIN		
CAPSULE		
NITROFURANTOIN	100MG	N84326
NITROFURANTOIN	50MG	N84326
TABLET		
FURADANTIN	100MG	N08693
FURADANTIN	50MG	N08693
FURALAN	100MG	N80017
FURALAN	50MG	N80017
NITROFURANTOIN	100MG	N80003
NITROFURANTOIN	50MG	N80003
NITROFURANTOIN	100MG	N80043
NITROFURANTOIN	50MG	N80043
NITROFURANTOIN	100MG	N80078
NITROFURANTOIN	50MG	N80078
NITROFURANTOIN	100MG	N80447
NITROFURANTOIN	100MG	N85796
NITROFURANTOIN	50MG	N80447
NITROFURANTOIN	50MG	N85797
NITROFURANTOIN	100MG	N84085
NITROFURANTOIN SODIUM		
INJECTABLE		
IVADANTIN	EQ 180MG BASE/VIAL	N12402
NITROFURANTOIN, MACROCRYSTALLINE		
CAPSULE		
NITROFURANTOIN MACROCRYSTALLINE	100MG	N70249
NITROFURANTOIN, MACROCRYSTALLINE		
CAPSULE		
NITROFURANTOIN MACROCRYSTALLINE	50MG	N70248
NITROFURAZONE		
CREAM		
FURACIN	0.2%	N83789
DRESSING		
ACTIN-N	0.2%	N17343
OINTMENT		
FURACIN	0.2%	N05795
NITROFURAZONE	0.2%	N86077
NITROFURAZONE	0.2%	N84968
NITROFURAZONE	0.2%	N84393
POWDER		
FURACIN	0.2%	N83791
SOLUTION		
NITROFURAZONE	0.2%	N85130
NITROGLYCERIN		
AEROSOL		
NITROLINGUAL	0.4MG/SPRAY	N18705
FILM, EXTENDED RELEASE		
TRANSDERM-NITRO	0.1MG/HR	N20144
TRANSDERM-NITRO	0.2MG/HR	N20144
TRANSDERM-NITRO	0.4MG/HR	N20144
TRANSDERM-NITRO	0.6MG/HR	N20144
TRANSDERM-NITRO	0.8MG/HR	N20144
INJECTABLE		
NITRO IV	5MG/ML	N18672
NITRO-BID	10MG/ML	N71159
NITRO-BID	5MG/ML	N18621
NITROGLYCERIN	5MG/ML	N70077
NITROGLYCERIN	5MG/ML	N71203
NITROGLYCERIN	5MG/ML	N70026
NITROGLYCERIN	5MG/ML	N71492
NITROGLYCERIN	5MG/ML	N70633
NITROGLYCERIN	5MG/ML	N70634
NITROL	0.8MG/ML	N18774
NITRONAL	1MG/ML	N18672
NITROSTAT	0.8MG/ML	N18588
NITROSTAT	10MG/ML	N70871
NITROSTAT	10MG/ML	N70872
NITROSTAT	5MG/ML	N18588
NITROSTAT	5MG/ML	N70863
TRIDIL	0.5MG/ML	N18537
TRIDIL	5MG/ML	N18537

FDA data supplied by DrugPatentWatch.com

NONOXYNOL-9		
AEROSOL		
DELFEN	12.5%	N14349
SPONGE		
TODAY	1GM	N18683
NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE		
INJECTABLE		
RAVOCAINE AND NOVOCAIN W/ LEVOPHED	EQ 0.033MG BASE/ML;2%;0.4%	N08592
NORETHINDRONE		
TABLET		
NORLUTIN	5MG	N10895
NORETHINDRONE ACETATE		
TABLET		
NORLUTATE	5MG	N12184
NORFLOXACIN		
SOLUTION/DROPS		
CHIBROXIN	0.3%	N19757
NOVOBIOCIN SODIUM		
CAPSULE		
ALBAMYCIN	EQ 250MG BASE	N50339
NYSTATIN		
CREAM		
CANDEX	100,000 UNITS/GM	N61810
MYKINAC	100,000 UNITS/GM	N62387
NILSTAT	100,000 UNITS/GM	N61445
NYSTATIN	100,000 UNITS/GM	N61966
LOTION		
CANDEX	100,000 UNITS/ML	N50233
OINTMENT		
MYCOSTATIN	100,000 UNITS/GM	N60571
MYKINAC	100,000 UNITS/GM	N62731
NILSTAT	100,000 UNITS/GM	N61444
POWDER		
BARSTATIN 100	100%	N62489
NILSTAT	100%	N50576
SUPPOSITORY		
NYSERT	100,000 UNITS	N50478
SUSPENSION		
NYSTATIN	100,000 UNITS/ML	N62571
NYSTATIN	100,000 UNITS/ML	N62835
NYSTATIN	100,000 UNITS/ML	N62518
NYSTATIN	100,000 UNITS/ML	N62541
NYSTATIN	100,000 UNITS/ML	N62832
NYSTATIN		
SUSPENSION		
NYSTATIN	100,000 UNITS/ML	N62876
NYSTATIN	100,000 UNITS/ML	N62670
NYSTATIN	100,000 UNITS/ML	N62776
TABLET		
KOROSTATIN	100,000 UNITS	N61718
MYCOSTATIN	100,000 UNITS	N60577
NILSTAT	100,000 UNITS	N61325
NILSTAT	500,000 UNITS	N61151
NYSTATIN	100,000 UNITS	N61965
NYSTATIN	500,000 UNITS	N62065
NYSTATIN	100,000 UNITS	N62459
NYSTATIN	100,000 UNITS	N62460
NYSTATIN	100,000 UNITS	N62509
NYSTATIN	500,000 UNITS	N62525
NYSTATIN	100,000 UNITS	N62502
NYSTATIN	500,000 UNITS	N62524
NYSTATIN	100,000 UNITS	N62176
NYSTATIN	500,000 UNITS	N62402
NYSTATIN; TRIAMCINOLONE ACETONIDE		
CREAM		
MYCOLOG-II	100,000 UNITS/GM;0.1%	N60576
NYSTATIN AND TRIAMCINOLONE ACETONIDE	100,000 UNITS/GM;0.1%	N63010
NYSTATIN AND TRIAMCINOLONE ACETONIDE	100,000 UNITS/GM;0.1%	N62186
NYSTATIN AND TRIAMCINOLONE ACETONIDE	100,000 UNITS/GM;0.1%	N62657
NYSTATIN-TRIAMCINOLONE ACETONIDE	100,000 UNITS/GM;0.1%	N62596
OINTMENT		
MYCO-TRIACET II	100,000 UNITS/GM;0.1%	N62045
NYSTATIN AND TRIAMCINOLONE ACETONIDE	100,000 UNITS/GM;0.1%	N62280
NYSTATIN AND TRIAMCINOLONE ACETONIDE	100,000 UNITS/GM;0.1%	N62656
NYSTATIN-TRIAMCINOLONE ACETONIDE	100,000 UNITS/GM;0.1%	N62603
OFLOXACIN		
INJECTABLE		
FLOXIN	20MG/ML	N20087
FLOXIN	40MG/ML	N20087
FLOXIN IN DEXTROSE 5%	400MG/100ML	N20087
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER	400MG/100ML	N20087
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER	4MG/ML	N20087
ORPHENADRINE CITRATE		
TABLET, EXTENDED RELEASE		
ORPHENADRINE CITRATE	100MG	N88067
ORPHENADRINE CITRATE	100MG	N85046
ORPHENADRINE CITRATE	100MG	N84303

FDA data supplied by DrugPatentWatch.com

ORPHENADRINE HYDROCHLORIDE		
TABLET		
DISIPAL	50MG	N10653
OXACILLIN SODIUM		
CAPSULE		
BACTOCILL	EQ 250MG BASE	N62241
BACTOCILL	EQ 500MG BASE	N62241
OXACILLIN SODIUM	EQ 250MG BASE	N61450
OXACILLIN SODIUM	EQ 500MG BASE	N61450
PROSTAPHLIN	EQ 500MG BASE	N50118
FOR SOLUTION		
OXACILLIN SODIUM	EQ 250MG BASE/5ML	N61457
PROSTAPHLIN	EQ 250MG BASE/5ML	N50194
INJECTABLE		
BACTOCILL	EQ 10GM BASE/VIAL	N61334
BACTOCILL	EQ 1GM BASE/VIAL	N61334
BACTOCILL	EQ 1GM BASE/VIAL	N62736
BACTOCILL	EQ 2GM BASE/VIAL	N61334
BACTOCILL	EQ 2GM BASE/VIAL	N62736
BACTOCILL	EQ 4GM BASE/VIAL	N61334
BACTOCILL	EQ 500MG BASE/VIAL	N61334
OXACILLIN SODIUM	EQ 1GM BASE/VIAL	N50195
OXACILLIN SODIUM	EQ 250MG BASE/VIAL	N50195
OXACILLIN SODIUM	EQ 2GM BASE/VIAL	N50195
OXACILLIN SODIUM	EQ 4GM BASE/VIAL	N50195
OXACILLIN SODIUM	EQ 500MG BASE/VIAL	N50195
OXACILLIN SODIUM	EQ 10GM BASE/VIAL	N62711
OXACILLIN SODIUM	EQ 1GM BASE/VIAL	N62711
OXACILLIN SODIUM	EQ 250MG BASE/VIAL	N62711
OXACILLIN SODIUM	EQ 2GM BASE/VIAL	N62711
OXACILLIN SODIUM	EQ 4GM BASE/VIAL	N62711
OXACILLIN SODIUM	EQ 500MG BASE/VIAL	N62711
OXACILLIN SODIUM	EQ 125MG BASE/VIAL	N62798
OXACILLIN SODIUM	EQ 1GM BASE/VIAL	N62798
OXACILLIN SODIUM	EQ 250MG BASE/VIAL	N62798
OXACILLIN SODIUM	EQ 2GM BASE/VIAL	N62798
OXACILLIN SODIUM	EQ 500MG BASE/VIAL	N62798
OXAZEPAM		
CAPSULE		
OXAZEPAM	10MG	N71955
OXAZEPAM	15MG	N71956
OXAZEPAM	30MG	N71957
OXAZEPAM	10MG	N70957
OXAZEPAM	15MG	N71025
OXAZEPAM	30MG	N71026
OXAZEPAM	10MG	N71713
OXAZEPAM		
CAPSULE		
OXAZEPAM	15MG	N71714
OXAZEPAM	30MG	N71715
ZAXOPAM	10MG	N70650
ZAXOPAM	15MG	N70640
ZAXOPAM	30MG	N70641
TABLET		
OXAZEPAM	15MG	N70683
OXAZEPAM	15MG	N71508
OXAZEPAM	15MG	N71494
OXPRENOLOL HYDROCHLORIDE		
CAPSULE		
TRASICOR	160MG	N18166
TRASICOR	20MG	N18166
TRASICOR	40MG	N18166
TRASICOR	80MG	N18166
OXTRIPHYLLINE		
SOLUTION		
CHOLEDYL	100MG/5ML	N09268
OXTRIPHYLLINE	100MG/5ML	N88243
SYRUP		
CHOLEDYL	50MG/5ML	N09268
OXTRIPHYLLINE PEDIATRIC	50MG/5ML	N88242
TABLET, DELAYED RELEASE		
CHOLEDYL	100MG	N09268
CHOLEDYL	200MG	N09268
OXTRIPHYLLINE	100MG	N87866
OXTRIPHYLLINE	200MG	N87835
OXYBUTYNIN CHLORIDE		
TABLET		
OXYBUTYNIN CHLORIDE	5MG	N72296
OXYBUTYNIN CHLORIDE	5MG	N70746
OXYBUTYNIN CHLORIDE	5MG	N72485
OXYCODONE HYDROCHLORIDE		
TABLET, EXTENDED RELEASE		
OXYCONTIN	160MG	N20553
ROXICODONE	10MG	N20932
ROXICODONE	30MG	N20932
OXYPHENBUTAZONE		
TABLET		
OXYPHENBUTAZONE	100MG	N88399
TANDEARIL	100MG	N12542

FDA data supplied by DrugPatentWatch.com

OXYPHENCYCLIMINE HYDROCHLORIDE		
TABLET		
DARICON	10MG	N11612
OXYPHENONIUM BROMIDE		
TABLET		
ANTRENYL	5MG	N08492
OXYTETRACYCLINE		
TABLET		
TERRAMYCIN	250MG	N50287
OXYTETRACYCLINE CALCIUM		
SYRUP		
TERRAMYCIN	EQ 125MG BASE/5ML	N60595
OXYTETRACYCLINE HYDROCHLORIDE		
CAPSULE		
OXY-KESSO-TETRA	EQ 250MG BASE	N60179
OXYTETRACYCLINE HCL	EQ 250MG BASE	N60760
OXYTETRACYCLINE HCL	EQ 250MG BASE	N60869
OXYTETRACYCLINE HCL	EQ 250MG BASE	N60634
OXYTETRACYCLINE HCL	EQ 250MG BASE	N60770
TERRAMYCIN	EQ 125MG BASE	N50286
INJECTABLE		
TERRAMYCIN	EQ 250MG BASE/VIAL	N60586
TERRAMYCIN	EQ 500MG BASE/VIAL	N60586
OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE		
OINTMENT		
TERRAMYCIN W/ POLYMYXIN	EQ 5MG BASE/GM;10,000 UNITS/GM	N61841
TABLET		
TERRAMYCIN-POLYMYXIN	EQ 100MG BASE;100,000 UNITS	N61009
OXYTOCIN		
INJECTABLE		
OXYTOCIN	10USP UNITS/ML	N18243
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%	1USP UNITS/100ML	N19185
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%	2USP UNITS/100ML	N19185
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%	2USP UNITS/100ML	N19185
OXYTOCIN 5 USP UNITS IN DEXTROSE 5%	1USP UNITS/100ML	N19185
SOLUTION		
SYNTOCINON	40USP UNITS/ML	N12285
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)		
CAPSULE		
COTAZYM	30,000USP UNITS;8,000USP UNITS;30,000USP UNITS	N20580

PANCURONIUM BROMIDE		
INJECTABLE		
PANCURONIUM BROMIDE	1MG/ML	N72210
PANCURONIUM BROMIDE	2MG/ML	N72211
PANCURONIUM BROMIDE	2MG/ML	N72212
PANCURONIUM BROMIDE	2MG/ML	N72213
PAVULON	1MG/ML	N17015
PAVULON	2MG/ML	N17015
PARAMETHADIONE		
CAPSULE		
PARADIONE	150MG	N06800
PARADIONE	300MG	N06800
SOLUTION		
PARADIONE	300MG/ML	N06800
PARAMETHASONE ACETATE		
TABLET		
HALDRONE	1MG	N12772
HALDRONE	2MG	N12772
PARGYLINE HYDROCHLORIDE		
TABLET		
EUTONYL	10MG	N13448
EUTONYL	25MG	N13448
EUTONYL	50MG	N13448
PAROMOMYCIN SULFATE		
CAPSULE		
HUMATIN	EQ 250MG BASE	N60521
SYRUP		
HUMATIN	EQ 125MG BASE/5ML	N60522
PAROXETINE HYDROCHLORIDE		
CAPSULE		
PAXIL	EQ 10MG BASE	*N20885
PAXIL	EQ 20MG BASE	*N20885
PAXIL	EQ 30MG BASE	*N20885
PAXIL	EQ 40MG BASE	*N20885
TABLET		
PAXIL	EQ 50MG BASE	N20031
PENBUTOLOL SULFATE		
TABLET		
LEVATOL	10MG	N18976
PENICILLIN G BENZATHINE		
INJECTABLE		
BICILLIN L-A	300,000 UNITS/ML	N50131
SUSPENSION		
BICILLIN	300,000 UNITS/5ML	N50126

FDA data supplied by DrugPatentWatch.com

DISCONTINUED DRUG PRODUCT LIST

PENICILLIN G BENZATHINE

TABLET

BICILLIN	200,000 UNITS	N50128

PENICILLIN G POTASSIUM

FOR SOLUTION

PENICILLIN	200,000 UNITS/5ML	N60307
PENICILLIN	400,000 UNITS/5ML	N60307
PENICILLIN G POTASSIUM	200,000 UNITS/5ML	N60752
PENICILLIN G POTASSIUM	250,000 UNITS/5ML	N60752
PENICILLIN G POTASSIUM	400,000 UNITS/5ML	N60752
PENICILLIN G POTASSIUM	250,000 UNITS/5ML	N61740
PENICILLIN G POTASSIUM	400,000 UNITS/5ML	N61740
PENICILLIN-2	250,000 UNITS/5ML	N60307
PENTIDS '200'	200,000 UNITS/5ML	N62149
PENTIDS '400'	400,000 UNITS/5ML	N62149
PFIZERPEN G	400,000 UNITS/5ML	N60587

INJECTABLE

PENICILLIN G POTASSIUM	1,000,000 UNITS/VIAL	N60362
PENICILLIN G POTASSIUM	10,000,000 UNITS/VIAL	N60362
PENICILLIN G POTASSIUM	20,000,000 UNITS/VIAL	N60362
PENICILLIN G POTASSIUM	5,000,000 UNITS/VIAL	N60362
PENICILLIN G POTASSIUM	1,000,000 UNITS/VIAL	N60806
PENICILLIN G POTASSIUM	10,000,000 UNITS/VIAL	N60806
PENICILLIN G POTASSIUM	5,000,000 UNITS/VIAL	N60806
PENICILLIN G POTASSIUM	500,000 UNITS/VIAL	N60806
PENICILLIN G POTASSIUM	1,000,000 UNITS/VIAL	N60384
PENICILLIN G POTASSIUM	20,000,000 UNITS/VIAL	N60384
PENICILLIN G POTASSIUM	20,000,000 UNITS/VIAL	N60601
PENICILLIN G POTASSIUM	200,000 UNITS/VIAL	N60384
PENICILLIN G POTASSIUM	5,000,000 UNITS/VIAL	N60384
PENICILLIN G POTASSIUM	500,000 UNITS/VIAL	N60384
PENICILLIN G POTASSIUM	1,000,000 UNITS/VIAL	N62991
PENICILLIN G POTASSIUM	10,000,000 UNITS/VIAL	N62991
PENICILLIN G POTASSIUM	20,000,000 UNITS/VIAL	N62991
PENICILLIN G POTASSIUM	5,000,000 UNITS/VIAL	N62991
PENICILLIN G POTASSIUM	1,000,000 UNITS/VIAL	N62003
PENICILLIN G POTASSIUM	5,000,000 UNITS/VIAL	N62003

TABLET

PENICILLIN G POTASSIUM	250,000 UNITS	N60392
PENICILLIN G POTASSIUM	400,000 UNITS	N60073
PENICILLIN G POTASSIUM	250,000 UNITS	N60403
PENICILLIN G POTASSIUM	200,000 UNITS	N60781
PENICILLIN G POTASSIUM	250,000 UNITS	N60781
PENICILLIN G POTASSIUM	400,000 UNITS	N60781
PENICILLIN G POTASSIUM	500,000 UNITS	N60781
PENICILLIN G POTASSIUM	800,000 UNITS	N60781

PENICILLIN G POTASSIUM

TABLET

PENICILLIN G POTASSIUM	200,000 UNITS	N61588
PENICILLIN G POTASSIUM	250,000 UNITS	N61588
PENICILLIN G POTASSIUM	400,000 UNITS	N61588
PENICILLIN G POTASSIUM	200,000 UNITS	N60306
PENICILLIN G POTASSIUM	250,000 UNITS	N60306
PENICILLIN G POTASSIUM	400,000 UNITS	N60306
PENICILLIN G POTASSIUM	500,000 UNITS	N60306
PENICILLIN G POTASSIUM	200,000 UNITS	N60413
PENICILLIN G POTASSIUM	250,000 UNITS	N60413
PENICILLIN G POTASSIUM	400,000 UNITS	N60413
PENTIDS '200'	200,000 UNITS	N62155
PENTIDS '250'	250,000 UNITS	N62155
PENTIDS '400'	400,000 UNITS	N60392
PENTIDS '400'	400,000 UNITS	N62155
PENTIDS '800'	800,000 UNITS	N60392
PENTIDS '800'	800,000 UNITS	N62155
PFIZERPEN G	100,000 UNITS	N60075
PFIZERPEN G	200,000 UNITS	N60075
PFIZERPEN G	250,000 UNITS	N60075
PFIZERPEN G	400,000 UNITS	N60075
PFIZERPEN G	50,000 UNITS	N60075
PFIZERPEN G	800,000 UNITS	N60075

PENICILLIN G PROCAINE

INJECTABLE

DURACILLIN A.S.	300,000 UNITS/ML	N60093
PENICILLIN G PROCAINE	300,000 UNITS/ML	N60800
PENICILLIN G PROCAINE	600,000 UNITS/1.2ML	N60800
PENICILLIN G PROCAINE	300,000 UNITS/ML	N62029
PENICILLIN G PROCAINE	1,500,000 UNITS/VIAL	N60099
PENICILLIN G PROCAINE	300,000 UNITS/VIAL	N60099
PFIZERPEN-AS	300,000 UNITS/ML	N60286
PFIZERPEN-AS	600,000 UNITS/ML	N60286

PENICILLIN G SODIUM

INJECTABLE

PENICILLIN G SODIUM	5,000,000 UNITS/VIAL	N61935
PENICILLIN G SODIUM	5,000,000 UNITS/VIAL	N61051
PENICILLIN G SODIUM	5,000,000 UNITS/VIAL	N63014
PENICILLIN G SODIUM	1,000,000 UNITS/VIAL	N61046

PENICILLIN V

FOR SUSPENSION

V-CILLIN	125MG/0.6ML	N60002

FDA data supplied by DrugPatentWatch.com

PENICILLIN V POTASSIUM
FOR SOLUTION

BEEPEN-VK	EQ 125MG BASE/5ML	N62270
BEEPEN-VK	EQ 250MG BASE/5ML	N62270
BETAPEN-VK	EQ 125MG BASE/5ML	N61149
BETAPEN-VK	EQ 250MG BASE/5ML	N61149
LEDERCILLIN VK	EQ 125MG BASE/5ML	N60136
LEDERCILLIN VK	EQ 250MG BASE/5ML	N60136
PENAPAR-VK	EQ 125MG BASE/5ML	N62002
PENAPAR-VK	EQ 250MG BASE/5ML	N62002
PENICILLIN V POTASSIUM	EQ 125MG BASE/5ML	N61624
PENICILLIN V POTASSIUM	EQ 250MG BASE/5ML	N61624
PENICILLIN V POTASSIUM	EQ 125MG BASE/5ML	N61758
PENICILLIN V POTASSIUM	EQ 250MG BASE/5ML	N61758
PEN-VEE K	EQ 125MG BASE/5ML	N60007
PEN-VEE K	EQ 250MG BASE/5ML	N60007
PFIZERPEN VK	EQ 125MG BASE/5ML	N61815
PFIZERPEN VK	EQ 250MG BASE/5ML	N61815
V-CILLIN K	EQ 125MG BASE/5ML	N60004
V-CILLIN K	EQ 250MG BASE/5ML	N60004
VEETIDS '125'	EQ 125MG BASE/5ML	N61206
VEETIDS '125'	EQ 125MG BASE/5ML	N62153
VEETIDS '250'	EQ 250MG BASE/5ML	N61206
VEETIDS '250'	EQ 250MG BASE/5ML	N62153

TABLET

BEEPEN-VK	EQ 250MG BASE	N62273
BEEPEN-VK	EQ 500MG BASE	N62273
BETAPEN-VK	EQ 250MG BASE	N61150
BETAPEN-VK	EQ 500MG BASE	N61150
LEDERCILLIN VK	EQ 250MG BASE	N60134
LEDERCILLIN VK	EQ 500MG BASE	N60134
PENAPAR-VK	EQ 250MG BASE	N62001
PENAPAR-VK	EQ 500MG BASE	N62001
PENICILLIN V POTASSIUM	EQ 250MG BASE	N61528
PENICILLIN V POTASSIUM	EQ 500MG BASE	N61528
PENICILLIN V POTASSIUM	EQ 125MG BASE	N60518
PENICILLIN V POTASSIUM	EQ 250MG BASE	N60518
PENICILLIN V POTASSIUM	EQ 500MG BASE	N60518
PENICILLIN V POTASSIUM	EQ 250MG BASE	N61530
PENICILLIN V POTASSIUM	EQ 500MG BASE	N61530
PENICILLIN V POTASSIUM	EQ 125MG BASE	N61571
PENICILLIN V POTASSIUM	EQ 250MG BASE	N61571
PENICILLIN V POTASSIUM	EQ 500MG BASE	N61571
PEN-VEE K	EQ 125MG BASE	N60006
PEN-VEE K	EQ 250MG BASE	N60006
PEN-VEE K	EQ 500MG BASE	N60006
PFIZERPEN VK	EQ 250MG BASE	N61836

PENICILLIN V POTASSIUM
TABLET

PFIZERPEN VK	EQ 500MG BASE	N61836
UTICILLIN VK	EQ 250MG BASE	N61651
UTICILLIN VK	EQ 500MG BASE	N61651
V-CILLIN K	EQ 125MG BASE	N60003
V-CILLIN K	EQ 250MG BASE	N60003
V-CILLIN K	EQ 500MG BASE	N60003
VEETIDS '250'	EQ 250MG BASE	N61164
VEETIDS '250'	EQ 250MG BASE	N62156
VEETIDS '500'	EQ 500MG BASE	N61164
VEETIDS '500'	EQ 500MG BASE	N62156

PENTAGASTRIN
INJECTABLE

PEPTAVLON	0.25MG/ML	N17048

PENTAMIDINE ISETHIONATE
INJECTABLE

PENTACARINAT	300MG/VIAL	N73447
PENTAMIDINE ISETHIONATE	300MG/VIAL	N73617

PENTAZOCINE HYDROCHLORIDE
TABLET

TALWIN 50	EQ 50MG BASE	N16732

PENTETATE CALCIUM TRISODIUM YB-169
INJECTABLE

YTTERBIUM YB 169 DTPA	2mCi/ML	N17518

PENTOBARBITAL
ELIXIR

NEMBUTAL	18.2MG/5ML	N83244

PENTOBARBITAL SODIUM
CAPSULE

NEMBUTAL SODIUM	50MG	N84093
PENTOBARBITAL SODIUM	100MG	N85915
PENTOBARBITAL SODIUM	50MG	N85937
PENTOBARBITAL SODIUM	100MG	N83284
PENTOBARBITAL SODIUM	100MG	N83338
SODIUM PENTOBARBITAL	100MG	N84590
SODIUM PENTOBARBITAL	100MG	N83368
SODIUM PENTOBARBITAL	100MG	N83259
SODIUM PENTOBARBITAL	100MG	N84677
SODIUM PENTOBARBITAL	100MG	N83461
SODIUM PENTOBARBITAL	50MG	N83461
SODIUM PENTOBARBITAL	100MG	N84156
SODIUM PENTOBARBITAL	100MG	N84560
SODIUM PENTOBARBITAL	100MG	N83301
SODIUM PENTOBARBITAL	100MG	N85791

FDA data supplied by DrugPatentWatch.com

PENTOBARBITAL SODIUM		
CAPSULE		
SODIUM PENTOBARBITAL	100MG	N83239
INJECTABLE		
PENTOBARBITAL SODIUM	50MG/ML	N83270
SODIUM PENTOBARBITAL	50MG/ML	N83261
SUPPOSITORY		
NEMBUTAL	120MG	N83247
NEMBUTAL	200MG	N83247
NEMBUTAL	60MG	N83247
TABLET		
PENTOBARBITAL SODIUM	100MG	N83285
SODIUM PENTOBARBITAL	100MG	N84238
PENTOLINIUM TARTRATE		
INJECTABLE		
ANSOLYSEN	10MG/ML	N09372
PERFLUBRON		
LIQUID		
IMAGENT	100%	N20091
PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE		
PASTE		
SKIN EXPOSURE RED	50%;50%	N21084
PERMETHRIN		
LOTION		
NIX	1%	N19435
PERPHENAZINE		
CONCENTRATE		
TRILAFON	16MG/5ML	N11557
SYRUP		
TRILAFON	2MG/5ML	N11294
TABLET		
TRILAFON	16MG	* N10775
TRILAFON	2MG	* N10775
TRILAFON	4MG	* N10775
TRILAFON	8MG	* N10775
TABLET, EXTENDED RELEASE		
TRILAFON	8MG	N11361
PHENACEMIDE		
TABLET		
PHENURONE	500MG	N07707

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE		
TABLET		
AZO GANTANOL	100MG;500MG	N13294
PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM		
TABLET		
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL	200MG;800MG;160MG	N21105
PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE		
TABLET		
AZO GANTRISIN	50MG;500MG	N19358
PHENDIMETRAZINE TARTRATE		
CAPSULE		
PHENAZINE	35MG	N86523
PHENAZINE	35MG	N86524
PHENAZINE	35MG	N86525
PHENDIMETRAZINE TARTRATE	35MG	N85633
PHENDIMETRAZINE TARTRATE	35MG	N85694
PHENDIMETRAZINE TARTRATE	35MG	N85702
PHENDIMETRAZINE TARTRATE	35MG	N85634
PHENDIMETRAZINE TARTRATE	35MG	N85645
PHENDIMETRAZINE TARTRATE	35MG	N85670
PHENDIMETRAZINE TARTRATE	35MG	N86403
PHENDIMETRAZINE TARTRATE	35MG	N86408
PHENDIMETRAZINE TARTRATE	35MG	N86410
PHENDIMETRAZINE TARTRATE	35MG	N87424
SPRX-3	35MG	N85897
STATOBEX	35MG	N85507
CAPSULE, EXTENDED RELEASE		
MELFIAT-105	105MG	N87487
PHENDIMETRAZINE TARTRATE	105MG	N87214
PHENDIMETRAZINE TARTRATE	105MG	N88020
PHENDIMETRAZINE TARTRATE	105MG	N88028
PHENDIMETRAZINE TARTRATE	105MG	N88062
PHENDIMETRAZINE TARTRATE	105MG	N88063
PHENDIMETRAZINE TARTRATE	105MG	N88111
PHENDIMETRAZINE TARTRATE	105MG	N87378
SPRX-105	105MG	N88024
TABLET		
ADPHEN	35MG	N83655
ALPHAZINE	35MG	N85034
DI-METREX	35MG	N85698
MELFIAT	35MG	N83790
METRA	35MG	N83754
PHENAZINE	35MG	N87305

FDA data supplied by DrugPatentWatch.com

PHENDIMETRAZINE TARTRATE

TABLET

PHENAZINE-35	35MG	N85512
PHENDIMETRAZINE TARTRATE	35MG	N86020
PHENDIMETRAZINE TARTRATE	35MG	N83644
PHENDIMETRAZINE TARTRATE	35MG	N83684
PHENDIMETRAZINE TARTRATE	35MG	N83686
PHENDIMETRAZINE TARTRATE	35MG	N83687
PHENDIMETRAZINE TARTRATE	35MG	N84831
PHENDIMETRAZINE TARTRATE	35MG	N84834
PHENDIMETRAZINE TARTRATE	35MG	N84835
PHENDIMETRAZINE TARTRATE	35MG	N85402
PHENDIMETRAZINE TARTRATE	35MG	N85497
PHENDIMETRAZINE TARTRATE	35MG	N86834
PHENDIMETRAZINE TARTRATE	35MG	N84740
PHENDIMETRAZINE TARTRATE	35MG	N84741
PHENDIMETRAZINE TARTRATE	35MG	N84742
PHENDIMETRAZINE TARTRATE	35MG	N84743
PHENDIMETRAZINE TARTRATE	35MG	N83682
PHENDIMETRAZINE TARTRATE	35MG	N85611
PHENDIMETRAZINE TARTRATE	35MG	N85612
PHENDIMETRAZINE TARTRATE	35MG	N84138
PHENDIMETRAZINE TARTRATE	35MG	N84141
PHENDIMETRAZINE TARTRATE	35MG	N85525
PHENDIMETRAZINE TARTRATE	35MG	N85914
PHENDIMETRAZINE TARTRATE	35MG	N83790
PHENDIMETRAZINE TARTRATE	35MG	N85199
PHENDIMETRAZINE TARTRATE	35MG	N85697
PHENDIMETRAZINE TARTRATE	35MG	N86365
PHENDIMETRAZINE TARTRATE	35MG	N86370
PHENDIMETRAZINE TARTRATE	35MG	N83993
PHENDIMETRAZINE TARTRATE	35MG	N83805
PHENDIMETRAZINE TARTRATE	35MG	N84398
PHENDIMETRAZINE TARTRATE	35MG	N84399
PHENDIMETRAZINE TARTRATE	35MG	N85519
PHENDIMETRAZINE TARTRATE	35MG	N86005
PHENDIMETRAZINE TARTRATE	35MG	N86106
PHENDIMETRAZINE TARTRATE	35MG	N85767
PHENDIMETRAZINE TARTRATE	35MG	N85768
PHENDIMETRAZINE TARTRATE	35MG	N85770
PHENDIMETRAZINE TARTRATE	35MG	N85773
PLEGINE	35MG	N12248
STATOBEX	35MG	N86013
STATOBEX-G	35MG	N85095
X-TROZINE	35MG	N86550
X-TROZINE	35MG	N86551
X-TROZINE	35MG	N86552

PHENINDIONE

TABLET

HEDULIN	50MG	N08767

PHENMETRAZINE HYDROCHLORIDE

TABLET

PRELUDIN	25MG	N10460

TABLET, EXTENDED RELEASE

PRELUDIN	50MG	N11752
PRELUDIN	75MG	N11752

PHENPROCOUMON

TABLET

LIQUAMAR	3MG	N11228

PHENSUXIMIDE

CAPSULE

MILONTIN	500MG	N08855

PHENTERMINE HYDROCHLORIDE

CAPSULE

FASTIN	30MG	N17352
OBESTIN-30	30MG	N87144
OBY-TRIM	30MG	N87764
PHENTERMINE HCL	30MG	N85411
PHENTERMINE HCL	30MG	N88948
PHENTERMINE HCL	37.5MG	N88414
PHENTERMINE HCL	30MG	N86329
PHENTERMINE HCL	30MG	N87022
PHENTERMINE HCL	30MG	N86911
PHENTERMINE HCL	30MG	N87126
PHENTERMINE HCL	30MG	N87777
PHENTERMINE HCL	30MG	N88612
PHENTERMINE HCL	30MG	N88613
PHENTERMINE HCL	30MG	N88614
PHENTERMINE HCL	30MG	N84487
PHENTERMINE HCL	30MG	N88430
PHENTERMINE HCL	30MG	N88797
PHENTERMINE HCL	30MG	N87202
PHENTERMINE HCL	30MG	N87235
PHENTERMINE HCL	30MG	N86740

TABLET

PHENTERMINE HCL	8MG	N85671
PHENTERMINE HCL	8MG	N85689
PHENTERMINE HCL	8MG	N85553
PHENTERMINE HCL	37.5MG	N88910
PHENTERMINE HCL	37.5MG	N88917
PHENTERMINE HCL	8MG	N83804
PHENTERMINE HCL	8MG	N86453

FDA data supplied by DrugPatentWatch.com

PHENTERMINE HYDROCHLORIDE		
TABLET		
PHENTERMINE HCL	8MG	N86456
PHENTERMINE HCL	8MG	N85739
TORA	8MG	N84035
PHENTERMINE RESIN COMPLEX		
CAPSULE, EXTENDED RELEASE		
PHENTERMINE RESIN 30	EQ 30MG BASE	N89120
PHENYL AMINOSALICYLATE		
POWDER		
PHENY-PAS-TEBAMIN	50%	N11695
TABLET		
PHENY-PAS-TEBAMIN	500MG	N11695
PHENYLBUTAZONE		
CAPSULE		
AZOLID	100MG	N87260
BUTAZOLIDIN	100MG	N08319
PHENYLBUTAZONE	100MG	N88994
PHENYLBUTAZONE	100MG	N88218
PHENYLBUTAZONE	100MG	N87774
PHENYLBUTAZONE	100MG	N87756
TABLET		
AZOLID	100MG	N87091
BUTAZOLIDIN	100MG	N08319
PHENYLBUTAZONE	100MG	N88863
PHENYLBUTAZONE	100MG	N84339
PHENYLBUTAZONE	100MG	N86151
PHENYLBUTAZONE	100MG	N87674
PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE		
SYRUP		
PHENERGAN VC	5MG/5ML;6.25MG/5ML	N08604
PHERAZINE VC	5MG/5ML;6.25MG/5ML	N88868
PROMETHAZINE VC PLAIN	5MG/5ML;6.25MG/5ML	N88815
PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE		
SOLUTION/DROPS		
PREFRIN-A	0.12%;0.1%	N07953
PHENYTOIN		
SUSPENSION		
DILANTIN-30	30MG/5ML	N08762
PHENYTOIN SODIUM		
INJECTABLE		
DILANTIN	50MG/ML	N10151
PHENYTOIN SODIUM	50MG/ML	N89521
PHENYTOIN SODIUM	50MG/ML	N89744
PHENYTOIN SODIUM		
INJECTABLE		
PHENYTOIN SODIUM	50MG/ML	N89003
PHENYTOIN SODIUM	50MG/ML	N89501
PHENYTOIN SODIUM	50MG/ML	N89779
PHENYTOIN SODIUM	50MG/ML	N88519
PHENYTOIN SODIUM	50MG/ML	N88521
PHENYTOIN SODIUM	50MG/ML	N88520
PHENYTOIN SODIUM	50MG/ML	N85434
PHENYTOIN SODIUM	50MG/ML	N89900
PHENYTOIN SODIUM, EXTENDED		
CAPSULE		
EXTENDED PHENYTOIN SODIUM	100MG	N89441
PHENYTEX	100MG	N88711
PHENYTOIN SODIUM, PROMPT		
CAPSULE		
DIPHENYLAN SODIUM	100MG	N80857
DIPHENYLAN SODIUM	30MG	N80857
PHENYTOIN SODIUM	100MG	N85435
PHENYTOIN SODIUM	100MG	N85894
PROMPT PHENYTOIN SODIUM	100MG	N80905
PHYTONADIONE		
INJECTABLE		
KONAKION	10MG/ML	N11745
KONAKION	1MG/0.5ML	N11745
PHYTONADIONE	10MG/ML	N84060
PHYTONADIONE	1MG/0.5ML	N84060
VITAMIN K1	10MG/ML	N87956
PILOCARPINE		
DRUG DELIVERY SYSTEM		
OCUSERT PILO-40	11MG	N17548
INSERT, EXTENDED RELEASE		
OCUSERT PILO-20	5MG	N17431
PINACIDIL		
CAPSULE, EXTENDED RELEASE		
PINDAC	12.5MG	N19456
PINDAC	25MG	N19456
PINDOLOL		
TABLET		
PINDOLOL	10MG	N74125
PINDOLOL	5MG	N74125

FDA data supplied by DrugPatentWatch.com

PIPECURONIUM BROMIDE		
INJECTABLE		
ARDUAN	10MG/VIAL	N19638
PIPERACETAZINE		
TABLET		
QUIDE	10MG	N13615
QUIDE	25MG	N13615
PIPERACILLIN SODIUM		
INJECTABLE		
PIPRACIL	EQ 2GM BASE/VIAL	*N50545
PIPRACIL	EQ 2GM BASE/VIAL	N62750
PIPRACIL	EQ 3GM BASE/VIAL	*N50545
PIPRACIL	EQ 3GM BASE/VIAL	N62750
PIPRACIL	EQ 40GM BASE/VIAL	*N50545
PIPRACIL	EQ 4GM BASE/VIAL	*N50545
PIPRACIL	EQ 4GM BASE/VIAL	N62750
PIPERAZINE CITRATE		
SYRUP		
ANTEPAR	EQ 500MG BASE/5ML	N09102
BRYREL	EQ 500MG BASE/5ML	N17796
PIPERAZINE CITRATE	EQ 500MG BASE/5ML	N80774
PIPERAZINE CITRATE	EQ 500MG BASE/5ML	N80963
PIPERAZINE CITRATE	EQ 500MG BASE/5ML	N80671
VERMIDOL	EQ 500MG BASE/5ML	N80992
TABLET		
ANTEPAR	EQ 500MG BASE	N09102
PIPERAZINE CITRATE	EQ 250MG BASE	N80874
PIPOBROMAN		
TABLET		
VERCYTE	10MG	N16245
VERCYTE	25MG	N16245
PIRBUTEROL ACETATE		
AEROSOL, METERED		
MAXAIR	EQ 0.2MG BASE/INH	N19009
PIROXICAM		
CAPSULE		
PIROXICAM	10MG	N73651
PIROXICAM	20MG	N73651
PIROXICAM	10MG	N74036
PIROXICAM	20MG	N74036
POLYESTRADIOL PHOSPHATE		
INJECTABLE		
ESTRADURIN	40MG/AMP	N10753

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS		
FOR SOLUTION		
COLYTE	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N18983
COLYTE	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N18983
COLYTE	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N18983
FOR SUSPENSION		
COLOVAGE	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N71320
E-Z-EM PREP LYTE	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	N71278
GLYCOPREP	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	N72319
PEG-LYTE	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	N73098
POLYMYXIN B SULFATE		
INJECTABLE		
AEROSPORIN	EQ 500,000 U BASE/VIAL	N62036
POWDER		
POLYMYXIN B SULFATE	100,000,000 UNITS/BOT	N62455
POTASSIUM AMINOSALICYLATE		
POWDER		
POTASSIUM AMINOSALICYLATE	100%	N80098
POTASSIUM CHLORIDE		
CAPSULE, EXTENDED RELEASE		
K-LEASE	10MEQ	N72427
K-LEASE	8MEQ	N73398
FOR SUSPENSION, EXTENDED RELEASE		
MICRO-K LS	20MEQ/PACKET	N19561
INJECTABLE		
POTASSIUM CHLORIDE	1MEQ/ML	N80205
POTASSIUM CHLORIDE	1MEQ/ML	N83345
POTASSIUM CHLORIDE	2.4MEQ/ML	N80205
POTASSIUM CHLORIDE	3.2MEQ/ML	N80205

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE

INJECTABLE		
POTASSIUM CHLORIDE	2MEQ/ML	N88286
POTASSIUM CHLORIDE	2MEQ/ML	N80204
POTASSIUM CHLORIDE	2MEQ/ML	N84290
POTASSIUM CHLORIDE	2MEQ/ML	N86713
POTASSIUM CHLORIDE	2MEQ/ML	N86714
POTASSIUM CHLORIDE	2MEQ/ML	N87787
POTASSIUM CHLORIDE	2MEQ/ML	N87817
POTASSIUM CHLORIDE	2MEQ/ML	N87885
POTASSIUM CHLORIDE	2MEQ/ML	N80203
POTASSIUM CHLORIDE	1MEQ/ML	N86219
POTASSIUM CHLORIDE	2MEQ/ML	N86219
POTASSIUM CHLORIDE	2MEQ/ML	N86220
POTASSIUM CHLORIDE	3MEQ/ML	N86219
POTASSIUM CHLORIDE	3MEQ/ML	N86220
POTASSIUM CHLORIDE	4MEQ/ML	N86219
POTASSIUM CHLORIDE	2MEQ/ML	N07865
POTASSIUM CHLORIDE	2MEQ/ML	N80221
POTASSIUM CHLORIDE	2MEQ/ML	N80736
POTASSIUM CHLORIDE	1MEQ/ML	N80195
POTASSIUM CHLORIDE	2MEQ/ML	N80195
POTASSIUM CHLORIDE	3MEQ/ML	N80195
POTASSIUM CHLORIDE	4MEQ/ML	N80195
POTASSIUM CHLORIDE	2MEQ/ML	N86297
POTASSIUM CHLORIDE	2MEQ/ML	N87362
POTASSIUM CHLORIDE	2MEQ/ML	N86208
POTASSIUM CHLORIDE	2MEQ/ML	N89163
POTASSIUM CHLORIDE	2MEQ/ML	N89421
POTASSIUM CHLORIDE	3MEQ/ML	N86210
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER	14.9MG/ML	N20161
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER	745MG/100ML	N20161
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER	1.49GM/100ML	N20161
TABLET, EXTENDED RELEASE		
KAON CL	6.7MEQ	N17046
KAON CL-10	10MEQ	N17046
TEN-K	10MEQ	N19381

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE		
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	37MG/100ML;900MG/100ML	N19708
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	75MG/100ML;900MG/100ML	N19708

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE		
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	110MG/100ML;900MG/100ML	N19708
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	220MG/100ML;900MG/100ML	N19708
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	300MG/100ML;900MG/100ML	N19708
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER	75MG/100ML;900MG/100ML	N18722
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER	75MG/100ML;900MG/100ML	N17648
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER	150MG/100ML;900MG/100ML	N18722
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER	220MG/100ML;900MG/100ML	N18722
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	300MG/100ML;900MG/100ML	N18722

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE		
THAM-E	370MG/VIAL;1.75GM/VIAL;36GM/VIAL	N13025

POTASSIUM CITRATE

FOR SOLUTION		
POTASSIUM CITRATE	10MEQ/PACKET	N19647
POTASSIUM CITRATE	20MEQ/PACKET	N19647

POTASSIUM IODIDE

SOLUTION		
POTASSIUM IODIDE	1GM/ML	N18551

PRALIDOXIME CHLORIDE

INJECTABLE		
PRALIDOXIME CHLORIDE	300MG/ML	N18799
TABLET		
PROTOPAM CHLORIDE	500MG	N14122

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET		
MIRAPEX	1.25MG	N20667

PRAZEPAM

CAPSULE		
CENTRAX	10MG	N18144
CENTRAX	20MG	N18144
CENTRAX	5MG	N18144
PRAZEPAM	10MG	N70428
PRAZEPAM	5MG	N70427
TABLET		
CENTRAX	10MG	N17415

FDA data supplied by DrugPatentWatch.com

PRAZOSIN HYDROCHLORIDE		
CAPSULE		
PRAZOSIN HCL	EQ 1MG BASE	N72782
PRAZOSIN HCL	EQ 2MG BASE	N72783
PRAZOSIN HCL	EQ 5MG BASE	N72784
PRAZOSIN HCL	EQ 2MG BASE	N72706
PRAZOSIN HCL	EQ 1MG BASE	N72991
PRAZOSIN HCL	EQ 2MG BASE	N72921
PRAZOSIN HCL	EQ 5MG BASE	N72992
PREDNISOLONE		
CREAM		
METI-DERM	0.5%	N10209
SYRUP		
PRELONE	5MG/5ML	N89654
TABLET		
CORTALONE	1MG	N80304
CORTALONE	2.5MG	N80304
CORTALONE	5MG	N80304
DELTA-CORTEF	5MG	N09987
FERNISOLONE-P	5MG	N83941
PREDNISOLONE	5MG	N84426
PREDNISOLONE	5MG	N83675
PREDNISOLONE	5MG	N80625
PREDNISOLONE	5MG	N84773
PREDNISOLONE	1MG	N84439
PREDNISOLONE	2.5MG	N80562
PREDNISOLONE	5MG	N80562
PREDNISOLONE	5MG	N80326
PREDNISOLONE	5MG	N80780
PREDNISOLONE	5MG	N80748
PREDNISOLONE	5MG	N80378
PREDNISOLONE	5MG	N80307
PREDNISOLONE	1MG	N80351
PREDNISOLONE	5MG	N80351
PREDNISOLONE	5MG	N84542
PREDNISOLONE	5MG	N80322
PREDNISOLONE	5MG	N80325
PREDNISOLONE	5MG	N80211
PREDNISOLONE	5MG	N80327
PREDNISOLONE	5MG	N80339
PREDNISOLONE	5MG	N88892
PREDNISOLONE	5MG	N85170
PREDNISOLONE	5MG	N80398
PREDNISOLONE	5MG	N87987
PREDNISOLONE	5MG	N80236
PREDNISOLONE	5MG	N80534

PREDNISOLONE		
TABLET		
PREDNISOLONE	5MG	N85085
PREDNISOLONE	5MG	N85415
PREDNISOLONE	5MG	N85416
PREDNISOLONE	5MG	N80324
PREDNISOLONE	5MG	N80342
STERANE	5MG	N09996
PREDNISOLONE ACETATE		
INJECTABLE		
METICORTELONE	25MG/ML	N10255
PREDNISOLONE ACETATE	25MG/ML	N83032
PREDNISOLONE ACETATE	50MG/ML	N84492
PREDNISOLONE ACETATE	25MG/ML	N83738
PREDNISOLONE ACETATE	50MG/ML	N83738
PREDNISOLONE ACETATE	25MG/ML	N84717
PREDNISOLONE ACETATE	50MG/ML	N84717
PREDNISOLONE ACETATE	25MG/ML	N83654
PREDNISOLONE ACETATE	40MG/ML	N83767
PREDNISOLONE ACETATE	50MG/ML	N85781
STERANE	25MG/ML	N11446
SUSPENSION/DROPS		
ECONOPRED	0.125%	N17468
PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM		
OINTMENT		
CETAPRED	0.25%;10%	N87771
METIMYD	0.5%;10%	N10210
PREDSULFAIR	0.5%;10%	N88032
SUSPENSION		
ISOPTO CETAPRED	0.25%;10%	N87547
SUSPENSION/DROPS		
METIMYD	0.5%;10%	N10210
PREDAMIDE	0.5%;10%	N88059
PREDSULFAIR	0.5%;10%	N88007
PREDSULFAIR II	0.2%;10%	N88837
SULPHRIN	0.5%;10%	N88089
PREDNISOLONE SODIUM PHOSPHATE		
INJECTABLE		
HYDELTRASOL	EQ 20MG PHOSPHATE/ML	N11583
PREDNISOLONE SODIUM PHOSPHATE	EQ 20MG PHOSPHATE/ML	N80517
OINTMENT		
HYDELTRASOL	EQ 0.25% PHOSPHATE	N11028
SOLUTION/DROPS		
METRETON	EQ 0.5% PHOSPHATE	N83834
PREDAIR	EQ 0.11% PHOSPHATE	N88415
PREDAIR FORTE	EQ 0.9% PHOSPHATE	N88165

FDA data supplied by DrugPatentWatch.com

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS

PREDNISOLONE SODIUM PHOSPHATE	EQ 0.11% PHOSPHATE	N83358
PREDNISOLONE SODIUM PHOSPHATE	EQ 0.9% PHOSPHATE	N83358
PREDNISOLONE SODIUM PHOSPHATE	EQ 0.11% PHOSPHATE	N81043
PREDNISOLONE SODIUM PHOSPHATE	EQ 0.9% PHOSPHATE	N81044
PREDNISOLONE SODIUM PHOSPHATE	EQ 0.11% PHOSPHATE	N84171
PREDNISOLONE SODIUM PHOSPHATE	EQ 0.9% PHOSPHATE	N84168
PREDNISOLONE SODIUM PHOSPHATE	EQ 0.9% PHOSPHATE	N84169
PREDNISOLONE SODIUM PHOSPHATE	EQ 0.9% PHOSPHATE	N84172

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS

SULSTER	EQ 0.23% PHOSPHATE;10%	N74511

PREDNISOLONE TEBUTATE

INJECTABLE

HYDELTRA-TBA	20MG/ML	N10562
PREDNISOLONE TEBUTATE	20MG/ML	N83362

PREDNISONE

SOLUTION

PREDNISONE	5MG/5ML	N89726

SYRUP

LIQUID PRED	5MG/5ML	N87611

TABLET

CORTAN	20MG	N87480
DELTA-DOME	5MG	N80293
FERNISONE	5MG	N83364
METICORTEN	1MG	N09766
METICORTEN	5MG	N09766
ORASONE	10MG	N83009
ORASONE	1MG	N83009
ORASONE	20MG	N83009
ORASONE	50MG	N85999
ORASONE	5MG	N83009
PARACORT	5MG	N10962
PREDNICEN-M	5MG	N84655
PREDNISONE	10MG	N89388
PREDNISONE	20MG	N89389
PREDNISONE	5MG	N89387
PREDNISONE	5MG	N83676
PREDNISONE	10MG	N88395
PREDNISONE	20MG	N88396
PREDNISONE	5MG	N88394
PREDNISONE	20MG	N85811
PREDNISONE	5MG	N80491
PREDNISONE	5MG	N84774

PREDNISONE

TABLET

PREDNISONE	1MG	N84440
PREDNISONE	2.5MG	N84440
PREDNISONE	5MG	N84440
PREDNISONE	2.5MG	N80563
PREDNISONE	5MG	N80563
PREDNISONE	10MG	N86595
PREDNISONE	20MG	N84634
PREDNISONE	50MG	N86596
PREDNISONE	5MG	N80300
PREDNISONE	5MG	N80701
PREDNISONE	10MG	N84341
PREDNISONE	20MG	N84417
PREDNISONE	20MG	N85543
PREDNISONE	50MG	N86946
PREDNISONE	5MG	N80320
PREDNISONE	5MG	N80782
PREDNISONE	10MG	N89598
PREDNISONE	20MG	N89599
PREDNISONE	5MG	N89597
PREDNISONE	1MG	N80328
PREDNISONE	2.5MG	N80306
PREDNISONE	5MG	N80279
PREDNISONE	10MG	N84133
PREDNISONE	20MG	N84134
PREDNISONE	5MG	N80283
PREDNISONE	5MG	N84236
PREDNISONE	20MG	N84275
PREDNISONE	5MG	N80514
PREDNISONE	5MG	N86968
PREDNISONE	5MG	N80301
PREDNISONE	5MG	N85115
PREDNISONE	1MG	N80350
PREDNISONE	2.5MG	N80350
PREDNISONE	5MG	N80350
PREDNISONE	5MG	N83059
PREDNISONE	5MG	N84662
PREDNISONE	20MG	N83807
PREDNISONE	5MG	N80321
PREDNISONE	10MG	N86062
PREDNISONE	20MG	N86061
PREDNISONE	5MG	N80353
PREDNISONE	20MG	N85151
PREDNISONE	5MG	N80232
PREDNISONE	20MG	N17109
PREDNISONE	25MG	N87833

FDA data supplied by DrugPatentWatch.com

DISCONTINUED DRUG PRODUCT LIST

PREDNISONE

TABLET

PREDNISONE	5MG	N80336
PREDNISONE	5MG	N80371
PREDNISONE	1MG	N80359
PREDNISONE	2.5MG	N80359
PREDNISONE	5MG	N80359
PREDNISONE	10MG	N88866
PREDNISONE	20MG	N88867
PREDNISONE	5MG	N88865
PREDNISONE	5MG	N80397
PREDNISONE	10MG	N87985
PREDNISONE	20MG	N87986
PREDNISONE	5MG	N87984
PREDNISONE	20MG	N87470
PREDNISONE	5MG	N87471
PREDNISONE	5MG	N80237
PREDNISONE	20MG	N87701
PREDNISONE	5MG	N87682
PREDNISONE	5MG	N80334
PREDNISONE	5MG	N80506
PREDNISONE	50MG	N86867
PREDNISONE	5MG	N85084
PREDNISONE	50MG	N88465
PREDNISONE	10MG	N89028
PREDNISONE	2.5MG	N84913
PREDNISONE	20MG	N84913
PREDNISONE	5MG	N80343
SERVISONE	5MG	N80223

PRILOCAINE HYDROCHLORIDE

INJECTABLE

CITANEST	1%	N14763
CITANEST	2%	N14763
CITANEST	3%	N14763
CITANEST PLAIN	4%	N14763

PRIMIDONE

SUSPENSION

MYSOLINE	250MG/5ML	N10401

TABLET

PRIMIDONE	250MG	N85052

PROBENECID

TABLET

BENEMID	500MG	N07898
PROBENECID	500MG	N86917
PROBENECID	500MG	N86150

PROBUCOL

TABLET

LORELCO	250MG	N17535
LORELCO	500MG	N17535

PROCAINAMIDE HYDROCHLORIDE

CAPSULE

PROCAINAMIDE HCL	250MG	N87542
PROCAINAMIDE HCL	375MG	N87697
PROCAINAMIDE HCL	500MG	N87543
PROCAINAMIDE HCL	500MG	N84696
PROCAINAMIDE HCL	250MG	N86942
PROCAINAMIDE HCL	375MG	N86952
PROCAINAMIDE HCL	500MG	N86943
PROCAINAMIDE HCL	250MG	N88989
PROCAINAMIDE HCL	500MG	N88990
PROCAINAMIDE HCL	250MG	N87643
PROCAINAMIDE HCL	500MG	N87875
PROCAINAMIDE HCL	250MG	N83795
PROCAINAMIDE HCL	250MG	N85167
PROCAINAMIDE HCL	375MG	N87020
PROCAINAMIDE HCL	500MG	N84357
PROCAINAMIDE HCL	500MG	N87021
PROCAN	250MG	N85804
PROCAN	375MG	N87502
PROCAN	500MG	N85079
PROCAPAN	250MG	N83553

INJECTABLE

PROCAINAMIDE HCL	100MG/ML	N89415
PROCAINAMIDE HCL	500MG/ML	N89416
PROCAINAMIDE HCL	100MG/ML	N89029
PROCAINAMIDE HCL	500MG/ML	N89030
PROCAINAMIDE HCL	100MG/ML	N88824
PROCAINAMIDE HCL	500MG/ML	N88830
PROCAINAMIDE HCL	100MG/ML	N88530
PROCAINAMIDE HCL	500MG/ML	N88531
PROCAINAMIDE HCL	500MG/ML	N88532
PROCAINAMIDE HCL	100MG/ML	N87079
PROCAINAMIDE HCL	500MG/ML	N87080
PROCAINAMIDE HCL	100MG/ML	N89528
PROCAINAMIDE HCL	500MG/ML	N89529

TABLET, EXTENDED RELEASE

PROCAINAMIDE HCL	500MG	N89840
PROCAINAMIDE HCL	250MG	N88958
PROCAINAMIDE HCL	500MG	N89284
PROCAINAMIDE HCL	1GM	N89520

FDA data supplied by DrugPatentWatch.com

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE

PROCAINAMIDE HCL	250MG	N88533
PROCAINAMIDE HCL	500MG	N88534
PROCAINAMIDE HCL	750MG	N88535
PROCAN SR	250MG	N86468
PROCAN SR	1GM	N88489
PROCAN SR	500MG	N86065
PROCAN SR	750MG	N87510

PROCAINE HYDROCHLORIDE

INJECTABLE

PROCAINE HCL	1%	N80384
PROCAINE HCL	1%	N80421
PROCAINE HCL	2%	N80384
PROCAINE HCL	2%	N80421
PROCAINE HCL	1%	N80711
PROCAINE HCL	2%	N80756
PROCAINE HCL	1%	N83315
PROCAINE HCL	2%	N83315
PROCAINE HCL	1%	N86202
PROCAINE HCL	2%	N86202
PROCAINE HCL	1%	N80415
PROCAINE HCL	2%	N80415
PROCAINE HCL	1%	N83535
PROCAINE HCL	2%	N80658
PROCAINE HCL	2%	N83535

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE

ACHROMYCIN	40MG/VIAL;100MG/VIAL	N50276
ACHROMYCIN	40MG/VIAL;250MG/VIAL	N50276
TETRACYN	40MG/VIAL;100MG/VIAL	N60285
TETRACYN	40MG/VIAL;250MG/VIAL	N60285

PROCAINE MERETHOXYLLINE; THEOPHYLLINE

INJECTABLE

DICURIN PROCAINE	100MG/ML;50MG/ML	N08869

PROCHLORPERAZINE EDISYLATE

CONCENTRATE

COMPAZINE	EQ 10MG BASE/ML	N11276
PROCHLORPERAZINE	EQ 10MG BASE/ML	N87153
PROCHLORPERAZINE EDISYLATE	EQ 10MG BASE/ML	N88598

INJECTABLE

PROCHLORPERAZINE EDISYLATE	EQ 5MG BASE/ML	N89523
PROCHLORPERAZINE EDISYLATE	EQ 5MG BASE/ML	N89675
PROCHLORPERAZINE EDISYLATE	EQ 5MG BASE/ML	N89251
PROCHLORPERAZINE EDISYLATE	EQ 5MG BASE/ML	N89605

PROCHLORPERAZINE EDISYLATE

INJECTABLE

PROCHLORPERAZINE EDISYLATE	EQ 5MG BASE/ML	N89606
PROCHLORPERAZINE EDISYLATE	EQ 5MG BASE/ML	N86348

SYRUP

PROCHLORPERAZINE EDISYLATE	EQ 5MG BASE/5ML	N87154
PROCHLORPERAZINE EDISYLATE	EQ 5MG BASE/5ML	N88597

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE

COMPAZINE	EQ 10MG BASE	N11000
COMPAZINE	EQ 15MG BASE	N11000
COMPAZINE	EQ 30MG BASE	N11000
COMPAZINE	EQ 75MG BASE	N11000

TABLET

PROCHLORPERAZINE	EQ 10MG BASE	N85178
PROCHLORPERAZINE	EQ 25MG BASE	N85579
PROCHLORPERAZINE	EQ 5MG BASE	N85580
PROCHLORPERAZINE MALEATE	EQ 10MG BASE	N89485
PROCHLORPERAZINE MALEATE	EQ 25MG BASE	N89486
PROCHLORPERAZINE MALEATE	EQ 5MG BASE	N89484

PROCYCLIDINE HYDROCHLORIDE

TABLET

KEMADRIN	2MG	N09818

PROGESTERONE

CAPSULE

PROMETRIUM	300MG	N19781

INJECTABLE

PROGESTERONE	25MG/ML	N09238
PROGESTERONE	50MG/ML	N09238

INSERT, EXTENDED RELEASE

PROGESTASERT	38MG	N17553

PROMAZINE HYDROCHLORIDE

CONCENTRATE

SPARINE	100MG/ML	N10942
SPARINE	30MG/ML	N10942

INJECTABLE

PROMAZINE HCL	25MG/ML	N84510
PROMAZINE HCL	50MG/ML	N84517
SPARINE	25MG/ML	N10349
SPARINE	50MG/ML	N10349

SYRUP

SPARINE	10MG/5ML	N10942

FDA data supplied by DrugPatentWatch.com

PROMAZINE HYDROCHLORIDE		
TABLET		
SPARINE	100MG	N10348
SPARINE	10MG	N10348
SPARINE	200MG	N10348
SPARINE	25MG	N10348
SPARINE	50MG	N10348
PROMETHAZINE HYDROCHLORIDE		
INJECTABLE		
PHENERGAN	25MG/ML	* N08857
PHENERGAN	50MG/ML	N08857
PROMETHAZINE HCL	25MG/ML	N84223
PROMETHAZINE HCL	50MG/ML	N84222
PROMETHAZINE HCL	25MG/ML	N83955
PROMETHAZINE HCL	50MG/ML	N83955
PROMETHAZINE HCL	25MG/ML	N89463
PROMETHAZINE HCL	50MG/ML	N89477
PROMETHAZINE HCL	25MG/ML	N83532
PROMETHAZINE HCL	50MG/ML	N83532
ZIPAN-25	25MG/ML	N83997
ZIPAN-50	50MG/ML	N83997
SUPPOSITORY		
PROMETHACON	50MG	N84902
SYRUP		
MYMETHAZINE FORTIS	25MG/5ML	N87996
PHENERGAN FORTIS	25MG/5ML	N08381
PHENERGAN PLAIN	6.25MG/5ML	N08381
PROMETH FORTIS	25MG/5ML	N84772
PROMETHAZINE	6.25MG/5ML	N89013
PROMETHAZINE HCL	25MG/5ML	N85385
PROMETHAZINE HCL	6.25MG/5ML	N85388
PROMETHAZINE HCL	6.25MG/5ML	N87518
PROMETHAZINE HCL	6.25MG/5ML	N86395
TABLET		
PROMETHAZINE HCL	12.5MG	N84160
PROMETHAZINE HCL	25MG	N84166
PROMETHAZINE HCL	50MG	N84539
PROMETHAZINE HCL	25MG	N85146
PROMETHAZINE HCL	50MG	N85146
PROMETHAZINE HCL	12.5MG	N84555
PROMETHAZINE HCL	25MG	N84554
PROMETHAZINE HCL	50MG	N84557
PROMETHAZINE HCL	25MG	N84214
PROMETHAZINE HCL	12.5MG	N83604
PROMETHAZINE HCL	25MG	N83603
PROMETHAZINE HCL	50MG	N83613

PROMETHAZINE HYDROCHLORIDE		
TABLET		
PROMETHAZINE HCL	12.5MG	N80949
PROMETHAZINE HCL	25MG	N80949
PROMETHAZINE HCL	50MG	N80949
PROMETHAZINE HCL	12.5MG	N83214
PROMETHAZINE HCL	25MG	N83658
PROMETHAZINE HCL	12.5MG	N84233
PROMETHAZINE HCL	12.5MG	N84080
PROMETHAZINE HCL	25MG	N84027
PROMETHAZINE HCL	25MG	N89109
PROMETHAZINE HCL	12.5MG	N83401
PROMETHAZINE HCL	12.5MG	N83712
PROMETHAZINE HCL	12.5MG	N85986
PROMETHAZINE HCL	25MG	N83204
PROMETHAZINE HCL	25MG	N85684
PROMETHAZINE HCL	50MG	N83403
PROMETHAZINE HCL	50MG	N85664
REMSED	25MG	N83176
REMSED	50MG	N83176
PROPANTHELINE BROMIDE		
INJECTABLE		
PRO-BANTHINE	30MG/VIAL	N08843
TABLET		
PROPANTHELINE BROMIDE	15MG	N87663
PROPANTHELINE BROMIDE	15MG	N85780
PROPANTHELINE BROMIDE	15MG	N84541
PROPANTHELINE BROMIDE	15MG	N83706
PROPANTHELINE BROMIDE	15MG	N88377
PROPANTHELINE BROMIDE	15MG	N80977
PROPANTHELINE BROMIDE	15MG	N80928
PROPANTHELINE BROMIDE	15MG	N84428
PROPANTHELINE BROMIDE	15MG	N83029
PROPANTHELINE BROMIDE	15MG	N83151
PROPARACAINE HYDROCHLORIDE		
SOLUTION/DROPS		
KAINAIR	0.5%	N88087
PROPARACAINE HCL	0.5%	N84144
PROPARACAINE HCL	0.5%	N84151
PROPIOLACTONE		
SOLUTION		
BETAPRONE	N/A	N11657
PROPIOMAZINE HYDROCHLORIDE		
INJECTABLE		
LARGON	20MG/ML	N12382

FDA data supplied by DrugPatentWatch.com

PROPOFOL		
INJECTABLE		
DIPRIVAN	10MG/ML	N19627
PROPOXYPHENE HYDROCHLORIDE		
CAPSULE		
DOLENE	65MG	N80530
PROPHENE 65	65MG	N83538
PROPOXYPHENE HCL	65MG	N83184
PROPOXYPHENE HCL	65MG	N83185
PROPOXYPHENE HCL	32MG	N84014
PROPOXYPHENE HCL	65MG	N83688
PROPOXYPHENE HCL	65MG	N83870
PROPOXYPHENE HCL	65MG	N86495
PROPOXYPHENE HCL	65MG	N83186
PROPOXYPHENE HCL	65MG	N83317
PROPOXYPHENE HCL	32MG	N83597
PROPOXYPHENE HCL	32MG	N83528
PROPOXYPHENE HCL	65MG	N83299
PROPOXYPHENE HCL	65MG	N83278
PROPOXYPHENE HCL	32MG	N83464
PROPOXYPHENE HCL	65MG	N83113
PROPOXYPHENE HCL	32MG	N83089
PROPOXYPHENE HCL	65MG	N83089
PROPOXYPHENE HCL	65MG	N83125
PROPOXYPHENE HCL	65MG	N80783
PROPOXYPHENE HCL	65MG	N80908
PROPOXYPHENE HCL	65MG	N85190
PROPOXYPHENE HCL	65MG	N84551
PROPOXYPHENE HCL 65	65MG	N83786
PROPOXYPHENE NAPSYLATE		
SUSPENSION		
DARVON-N	50MG/5ML	N16861
PROPRANOLOL HYDROCHLORIDE		
CAPSULE, EXTENDED RELEASE		
PROPRANOLOL HCL	120MG	N72501
PROPRANOLOL HCL	160MG	N72502
PROPRANOLOL HCL	60MG	N72499
PROPRANOLOL HCL	80MG	N72500
INJECTABLE		
PROPRANOLOL HCL	1MG/ML	N70135
PROPRANOLOL HCL	1MG/ML	N70137
PROPRANOLOL HCL	1MG/ML	N70136
SOLUTION		
PROPRANOLOL HCL	20MG/5ML	N71984
PROPRANOLOL HCL	40MG/5ML	N71985

PROPRANOLOL HYDROCHLORIDE		
SUSPENSION		
INDERAL	10MG/ML	N19536
TABLET		
INDERAL	90MG	N16418
PROPRANOLOL HCL	10MG	N70125
PROPRANOLOL HCL	20MG	N70126
PROPRANOLOL HCL	40MG	N70127
PROPRANOLOL HCL	60MG	N71495
PROPRANOLOL HCL	80MG	N70128
PROPRANOLOL HCL	90MG	N71496
PROPRANOLOL HCL	10MG	N70306
PROPRANOLOL HCL	20MG	N70307
PROPRANOLOL HCL	40MG	N70308
PROPRANOLOL HCL	60MG	N70309
PROPRANOLOL HCL	80MG	N70310
PROPRANOLOL HCL	90MG	N71327
PROPRANOLOL HCL	10MG	N70319
PROPRANOLOL HCL	20MG	N70320
PROPRANOLOL HCL	40MG	N70103
PROPRANOLOL HCL	60MG	N70321
PROPRANOLOL HCL	80MG	N70322
PROPRANOLOL HCL	10MG	N71368
PROPRANOLOL HCL	20MG	N71369
PROPRANOLOL HCL	40MG	N71370
PROPRANOLOL HCL	80MG	N71371
PROPRANOLOL HCL	10MG	N72063
PROPRANOLOL HCL	20MG	N72066
PROPRANOLOL HCL	40MG	N72067
PROPRANOLOL HCL	60MG	N72068
PROPRANOLOL HCL	80MG	N72069
PROPRANOLOL HCL	10MG	N72117
PROPRANOLOL HCL	20MG	N72118
PROPRANOLOL HCL	40MG	N72119
PROPRANOLOL HCL	80MG	N72120
PROPRANOLOL HCL	60MG	N72275
PROPRANOLOL HCL	10MG	N70814
PROPRANOLOL HCL	20MG	N70815
PROPRANOLOL HCL	40MG	N70816
PROPRANOLOL HCL	60MG	N70817
PROPRANOLOL HCL	80MG	N70757
PROPRANOLOL HCL	10MG	N70516
PROPRANOLOL HCL	20MG	N70517
PROPRANOLOL HCL	40MG	N70518
PROPRANOLOL HCL	60MG	N70519
PROPRANOLOL HCL	80MG	N70520
PROPRANOLOL HCL	90MG	N70521

FDA data supplied by DrugPatentWatch.com

PROPRANOLOL HYDROCHLORIDE
TABLET

PROPRANOLOL HCL	10MG	N71658
PROPRANOLOL HCL	20MG	N71687
PROPRANOLOL HCL	40MG	N71688
PROPRANOLOL HCL	60MG	N72197
PROPRANOLOL HCL	80MG	N71689
PROPRANOLOL HCL	90MG	N72198
PROPRANOLOL HCL	10MG	N70120
PROPRANOLOL HCL	20MG	N70121
PROPRANOLOL HCL	40MG	N70122
PROPRANOLOL HCL	60MG	N70123
PROPRANOLOL HCL	80MG	N70124
PROPRANOLOL HCL	10MG	N71515
PROPRANOLOL HCL	20MG	N71516
PROPRANOLOL HCL	40MG	N71517
PROPRANOLOL HCL	80MG	N71518
PROPRANOLOL HCL	10MG	N70232
PROPRANOLOL HCL	20MG	N70233
PROPRANOLOL HCL	10MG	N70438
PROPRANOLOL HCL	20MG	N70439
PROPRANOLOL HCL	40MG	N70440
PROPRANOLOL HCL	60MG	N70441
PROPRANOLOL HCL	80MG	N70442
PROPRANOLOL HCL	10MG	N70140
PROPRANOLOL HCL	10MG	N70378
PROPRANOLOL HCL	20MG	N70141
PROPRANOLOL HCL	20MG	N70379
PROPRANOLOL HCL	20MG	N70549
PROPRANOLOL HCL	40MG	N70142
PROPRANOLOL HCL	40MG	N70380
PROPRANOLOL HCL	60MG	N70143
PROPRANOLOL HCL	60MG	N70381
PROPRANOLOL HCL	60MG	N71098
PROPRANOLOL HCL	80MG	N70144
PROPRANOLOL HCL	80MG	N70382
PROPRANOLOL HCL	90MG	N71183

PROPYLIODONE
SUSPENSION

DIONOSIL AQUEOUS	50%	N09309
DIONOSIL OILY	60%	N09309

PROPYLTHIOURACIL
TABLET

PROPYLTHIOURACIL	50MG	N84075
PROPYLTHIOURACIL	50MG	N80285
PROPYLTHIOURACIL	50MG	N80015

PROPYLTHIOURACIL
TABLET

PROPYLTHIOURACIL	50MG	N83982
PROPYLTHIOURACIL	50MG	N80215
PROPYLTHIOURACIL	50MG	N80016
PROPYLTHIOURACIL	50MG	N06213
PROPYLTHIOURACIL	50MG	N84543
PROPYLTHIOURACIL	50MG	N80840
PROPYLTHIOURACIL	50MG	N80932
PROPYLTHIOURACIL	50MG	N85201

PROTAMINE SULFATE
INJECTABLE

PROTAMINE SULFATE	10MG/ML	N89474
PROTAMINE SULFATE	10MG/ML	N89475
PROTAMINE SULFATE	250MG/VIAL	N07413
PROTAMINE SULFATE	50MG/VIAL	N07413

PROTEIN HYDROLYSATE
INJECTABLE

AMINOSOL 5%	5%	N05932
HYPROTIGEN 5%	5%	N06170

PROTIRELIN
INJECTABLE

THYPINONE	0.5MG/ML	N17638
THYREL TRH	0.5MG/ML	N18087

PROTOKYLOL HYDROCHLORIDE
TABLET

VENTAIRE	2MG	N83459

PROTRIPTYLINE HYDROCHLORIDE
TABLET

VIVACTIL	10MG	N16012
VIVACTIL	5MG	N16012

PSEUDOEPHEDRINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE

NOVAFED	120MG	N17603
SUDAFED 12 HOUR	120MG	* N17941

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE

ACTIFED	120MG;5MG	N18996
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES	120MG;5MG	N71798

SYRUP

ACTAHIST	30MG/5ML;1.25MG/5ML	N88344
HISTAFED	30MG/5ML;1.25MG/5ML	N88283

FDA data supplied by DrugPatentWatch.com

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE		
SYRUP		
MYFED	30MG/5ML;1.25MG/5ML	N88116
TRILITRON	30MG/5ML;1.25MG/5ML	N88474
TABLET		
ALLERFED	60MG;2.5MG	N88860
TRILITRON	60MG;2.5MG	N88515
TRIPHED	60MG;2.5MG	N88630
TRIPROLIDINE AND PSEUDOEPHEDRINE	60MG;2.5MG	N88318
TRIPROLIDINE AND PSEUDOEPHEDRINE	60MG;2.5MG	N88117
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL	60MG;2.5MG	N85273
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL	60MG;2.5MG	N88578
TABLET, EXTENDED RELEASE		
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES	120MG;5MG	N72758
PSEUDOEPHEDRINE POLISTIREX		
SUSPENSION, EXTENDED RELEASE		
PSEUDO-12	EQ 60MG HCL/5ML	N19401
PYRIDOSTIGMINE BROMIDE		
TABLET		
PYRIDOSTIGMINE BROMIDE	30MG	N89572
PYRIDOSTIGMINE BROMIDE	30MG	N20414
PYRIDOXINE HYDROCHLORIDE		
INJECTABLE		
HEXA-BETALIN	100MG/ML	N80854
PYRIDOXINE HCL	100MG/ML	N87967
PYRIDOXINE HCL	100MG/ML	N80761
PYRIDOXINE HCL	100MG/ML	N83772
PYRIDOXINE HCL	50MG/ML	N83771
PYRIDOXINE HCL	100MG/ML	N80581
PYRIDOXINE HCL	100MG/ML	N80669
PYRIDOXINE HCL	100MG/ML	N83760
PYRILAMINE MALEATE		
TABLET		
PYRILAMINE MALEATE	25MG	N80808
PYRILAMINE MALEATE	25MG	N85231
PYRITHIONE ZINC		
LOTION		
HEAD & SHOULDERS CONDITIONER	0.3%	N19412
PYRVINIUM PAMOATE		
SUSPENSION		
POVAN	EQ 50MG BASE/5ML	N11964
PYRVINIUM PAMOATE		
TABLET		
POVAN	EQ 50MG BASE	N12485
QUINESTROL		
TABLET		
ESTROVIS	0.1MG	N16768
ESTROVIS	0.2MG	N16768
QUINETHAZONE		
TABLET		
HYDROMOX	50MG	N13264
QUINETHAZONE; RESERPINE		
TABLET		
HYDROMOX R	50MG;0.125MG	N13927
QUINIDINE GLUCONATE		
TABLET		
QUINACT	266MG	N85978
QUINACT	400MG	N86099
TABLET, EXTENDED RELEASE		
DURAQUIN	330MG	N17917
QUINAGLUTE	324MG	N16647
QUINALAN	324MG	N88081
QUINATIME	324MG	N87448
QUINIDINE GLUCONATE	324MG	N88582
QUINIDINE GLUCONATE	324MG	N89476
QUINIDINE GLUCONATE	324MG	N88431
QUINIDINE GLUCONATE	324MG	N89894
QUINIDINE GLUCONATE	324MG	N89164
QUINIDINE GLUCONATE	324MG	N87785
QUINIDINE GLUCONATE	324MG	N87810
QUINIDINE POLYGALACTURONATE		
TABLET		
CARDIOQUIN	275MG	N11642
QUINIDINE SULFATE		
CAPSULE		
CIN-QUIN	200MG	N85296
CIN-QUIN	300MG	N85297
QUINIDINE SULFATE	200MG	N85103
TABLET		
CIN-QUIN	100MG	N85299
CIN-QUIN	200MG	N84932
CIN-QUIN	300MG	N85298
QUINIDINE SULFATE	200MG	N84177
QUINIDINE SULFATE	200MG	N83622
QUINIDINE SULFATE	200MG	N83439

FDA data supplied by DrugPatentWatch.com

QUINIDINE SULFATE		
TABLET		
QUINIDINE SULFATE	200MG	N83583
QUINIDINE SULFATE	200MG	N83347
QUINIDINE SULFATE	200MG	N84549
QUINIDINE SULFATE	200MG	N85175
QUINIDINE SULFATE	200MG	N85276
QUINIDINE SULFATE	200MG	N86176
QUINIDINE SULFATE	200MG	N85038
QUINIDINE SULFATE	300MG	N81031
QUINIDINE SULFATE	200MG	N85322
QUINIDINE SULFATE	200MG	N84627
QUINIDINE SULFATE	200MG	N84003
QUINIDINE SULFATE	200MG	N83640
QUINIDINE SULFATE	300MG	N85632
QUINIDINE SULFATE	200MG	N85068
QUINIDINE SULFATE	200MG	N88973
QUINIDINE SULFATE	200MG	N87837
QUINIDINE SULFATE	200MG	N83393
QUINIDINE SULFATE	200MG	N87909
QUINIDINE SULFATE	200MG	N83963
QUINIDINE SULFATE	200MG	N83879
QUINIDINE SULFATE	100MG	N85584
QUINIDINE SULFATE	200MG	N83862
QUINIDINE SULFATE	200MG	N85444
QUINORA	200MG	N83576
QUINORA	300MG	N85222
TABLET, EXTENDED RELEASE		
QUINIDEX	300MG	N12796
RABEPRAZOLE SODIUM		
TABLET, DELAYED RELEASE		
ACIPHEX	10MG	N20973
RANITIDINE BISMUTH CITRATE		
TABLET		
TRITEC	400MG	N20559
RANITIDINE HYDROCHLORIDE		
CAPSULE		
ZANTAC 150	EQ 150MG BASE	*N20095
ZANTAC 300	EQ 300MG BASE	*N20095
INJECTABLE		
ZANTAC IN PLASTIC CONTAINER	EQ 50MG BASE/100ML	N19593
TABLET		
RANITIDINE	EQ 75MG BASE	N75254
RANITIDINE HCL	EQ 150MG BASE	N74662

RANITIDINE HYDROCHLORIDE		
TABLET		
RANITIDINE HCL	EQ 300MG BASE	N74662
RANITIDINE HCL	EQ 150MG BASE	N75000
RANITIDINE HCL	EQ 300MG BASE	N75000
TABLET, EFFERVESCENT		
ZANTAC 75	EQ 75MG BASE	*N20745
RAPACURONIUM BROMIDE		
INJECTABLE		
RAPLON	100MG/VIAL	N20984
RAPLON	200MG/VIAL	N20984
RAUWOLFIA SERPENTINA		
TABLET		
HIWOLFIA	100MG	N09276
HIWOLFIA	50MG	N09276
HIWOLFIA	50MG	N09276
HYSERPIN	50MG	N10581
KOGLUCOID	100MG	N09278
KOGLUCOID	50MG	N09278
RAUDIXIN	100MG	N08842
RAUDIXIN	50MG	N08842
RAUSERPIN	100MG	N09926
RAUSERPIN	50MG	N09926
RAUVAL	100MG	N09108
RAUVAL	50MG	N09108
RAUWOLFIA SERPENTINA	100MG	N09477
RAUWOLFIA SERPENTINA	50MG	N09477
RAUWOLFIA SERPENTINA	100MG	N80498
RAUWOLFIA SERPENTINA	50MG	N80498
RAUWOLFIA SERPENTINA	100MG	N09273
RAUWOLFIA SERPENTINA	50MG	N09273
RAUWOLFIA SERPENTINA	100MG	N11521
RAUWOLFIA SERPENTINA	50MG	N11521
RAUWOLFIA SERPENTINA	100MG	N80842
RAUWOLFIA SERPENTINA	50MG	N80842
RAUWOLFIA SERPENTINA	100MG	N80583
RAUWOLFIA SERPENTINA	50MG	N80583
RAUWOLFIA SERPENTINA	100MG	N80500
RAUWOLFIA SERPENTINA	50MG	N80500
RAUWOLFIA SERPENTINA	100MG	N83444
RAUWOLFIA SERPENTINA	50MG	N83867
RAUWOLFIA SERPENTINA	100MG	N09668
RAUWOLFIA SERPENTINA	50MG	N09668
RAUWOLFIA SERPENTINA	100MG	N80914
RAUWOLFIA SERPENTINA	50MG	N80907

FDA data supplied by DrugPatentWatch.com

RAUWOLFIA SERPENTINA		
TABLET		
WOLFINA	100MG	N09255
WOLFINA	50MG	N09255
RESCINNAMINE		
CAPSULE		
CINNASIL	0.5MG	N84736
RESERPINE		
ELIXIR		
SERPASIL	0.2MG/4ML	N09115
INJECTABLE		
SANDRIL	2.5MG/ML	N10012
SERPASIL	2.5MG/ML	N09434
TABLET		
HISERPIA	0.1MG	N09631
HISERPIA	0.25MG	N09631
RAU-SED	0.1MG	N09357
RAU-SED	0.25MG	N09357
RAU-SED	0.5MG	N09357
RAU-SED	1MG	N09357
RESERPINE	0.25MG	N80721
RESERPINE	0.1MG	N83058
RESERPINE	0.25MG	N83058
RESERPINE	0.1MG	N09663
RESERPINE	0.25MG	N09663
RESERPINE	0.1MG	N83145
RESERPINE	0.25MG	N83145
RESERPINE	0.1MG	N10441
RESERPINE	0.25MG	N10441
RESERPINE	0.5MG	N10441
RESERPINE	1MG	N10441
RESERPINE	0.1MG	N80457
RESERPINE	0.25MG	N80457
RESERPINE	1MG	N80457
RESERPINE	0.1MG	N09627
RESERPINE	0.25MG	N09627
RESERPINE	0.1MG	N11185
RESERPINE	0.25MG	N11185
RESERPINE	0.1MG	N80492
RESERPINE	0.25MG	N80492
RESERPINE	0.1MG	N80525
RESERPINE	0.25MG	N80525
RESERPINE	1MG	N84974
RESERPINE	0.25MG	N84663
RESERPINE	0.1MG	N80753
RESERPINE	0.25MG	N80753
RESERPINE		
TABLET		
RESERPINE	0.1MG	N86117
RESERPINE	0.25MG	N80582
RESERPINE	0.25MG	N85775
RESERPINE	1MG	N80582
RESERPINE	0.25MG	N80637
RESERPINE	0.1MG	N09859
RESERPINE	0.25MG	N09859
RESERPINE	0.25MG	N80446
RESERPINE	0.25MG	N85207
RESERPINE	0.1MG	N89020
RESERPINE	0.25MG	N89019
RESERPINE	0.1MG	N09667
RESERPINE	0.25MG	N09667
RESERPINE	0.1MG	N80679
RESERPINE	0.25MG	N80393
RESERPINE	0.25MG	N85401
RESERPINE	1MG	N80749
RESERPINE	0.1MG	N80975
RESERPINE	0.25MG	N80975
RESERPINE	1MG	N80975
RESERPINE	0.1MG	N80723
RESERPINE	0.25MG	N80723
RESERPINE	1MG	N80723
SANDRIL	0.1MG	N09376
SANDRIL	0.25MG	N09376
SERPANRAY	0.1MG	N09391
SERPANRAY	0.25MG	N09391
SERPANRAY	1MG	N09391
SERPASIL	0.1MG	N09115
SERPASIL	0.25MG	N09115
SERPASIL	1MG	N09115
SERPATE	0.1MG	N09453
SERPATE	0.25MG	N09453
SERPIVITE	0.25MG	N09645
RESERPINE; TRICHLORMETHIAZIDE		
TABLET		
METATENSIN #2	0.1MG;2MG	N12972
METATENSIN #4	0.1MG;4MG	N12972
NAQUIVAL	0.1MG;4MG	N12265
TRICHLORMETHIAZIDE W/ RESERPINE	0.1MG;4MG	N85248
RISPERIDONE		
TABLET		
RISPERDAL	5MG	N20272

FDA data supplied by DrugPatentWatch.com

RITODRINE HYDROCHLORIDE		
INJECTABLE		
RITODRINE HCL	10MG/ML	N71188
RITODRINE HCL	15MG/ML	N71189
YUTOPAR	10MG/ML	N18580
YUTOPAR	15MG/ML	N18580
TABLET		
YUTOPAR	10MG	N18555
RITONAVIR		
CAPSULE		
NORVIR	100MG	N20680
ROCURONIUM BROMIDE		
INJECTABLE		
ZEMURON	10MG/ML	N20214
ROSE BENGAL SODIUM, I-131		
INJECTABLE		
ROBENGATOPE	0.5mCi/VIAL	N16224
ROBENGATOPE	1mCi/VIAL	N16224
ROBENGATOPE	2mCi/VIAL	N16224
SODIUM ROSE BENGAL I 131	0.5mCi/ML	N17318
SAFFLOWER OIL		
INJECTABLE		
LIPOSYN 10%	10% (10GM/100ML)	N18203
LIPOSYN 20%	20% (20GM/100ML)	N18614
SARALASIN ACETATE		
INJECTABLE		
SARENIN	EQ 0.6MG BASE/ML	N18009
SECOBARBITAL SODIUM		
CAPSULE		
SECOBARBITAL SODIUM	100MG	N85869
SECOBARBITAL SODIUM	100MG	N85903
SECOBARBITAL SODIUM	50MG	N85909
SECOBARBITAL SODIUM	100MG	N84762
SECOBARBITAL SODIUM	100MG	N85867
SECOBARBITAL SODIUM	100MG	N85477
SECOBARBITAL SODIUM	100MG	N85898
SECOBARBITAL SODIUM	100MG	N86273
SECOBARBITAL SODIUM	100MG	N85798
SECOBARBITAL SODIUM	100MG	N86390
SODIUM SECOBARBITAL	100MG	N84422
SODIUM SECOBARBITAL	100MG	N84225
SODIUM SECOBARBITAL	100MG	N84676
SODIUM SECOBARBITAL	100MG	N85285
SODIUM SECOBARBITAL	100MG	N84561
SODIUM SECOBARBITAL	100MG	N85792
SECOBARBITAL SODIUM		
CAPSULE		
SODIUM SECOBARBITAL	100MG	N84926
INJECTABLE		
SECOBARBITAL SODIUM	100MG/VIAL	N83281
SECONAL SODIUM	50MG/ML	N07392
SODIUM SECOBARBITAL	50MG/ML	N83262
SUPPOSITORY		
SECONAL SODIUM	120MG	N86530
SECONAL SODIUM	200MG	N86530
SECONAL SODIUM	30MG	N86530
SECONAL SODIUM	60MG	N86530
SECRETIN		
INJECTABLE		
SECRETIN-FERRING	75CU/VIAL	N18290
SELENIUM SULFIDE		
LOTION/SHAMPOO		
EXSEL	2.5%	N83892
SELENIUM SULFIDE	2.5%	N85777
SELENIUM SULFIDE	2.5%	N86209
SELENOMETHIONINE, SE-75		
INJECTABLE		
SELENOMETHIONINE SE 75	250uCi/ML	N17257
SELENOMETHIONINE SE 75	500uCi/ML	N17322
SELENOMETHIONINE SE 75	100uCi/ML	N17098
SETHOTOPE	85-550uCi/ML	N17047
SERACTIDE ACETATE		
INJECTABLE		
ACTHAR GEL-SYNTHETIC	40 UNITS/ML	N17861
ACTHAR GEL-SYNTHETIC	80 UNITS/ML	N17861
SERMORELIN ACETATE		
INJECTABLE		
GEREF	EQ 0.5MG BASE/VIAL	N20443
GEREF	EQ 1MG BASE/VIAL	N20443
SERTRALINE HYDROCHLORIDE		
TABLET		
ZOLOFT	EQ 150MG BASE	N19839
ZOLOFT	EQ 200MG BASE	N19839
SILVER SULFADIAZINE		
DRESSING		
SILDAFLO	1%	N19608
SIMETHICONE-CELLULOSE		
SUSPENSION		
SONORX	7.5MG/ML	N20773

FDA data supplied by DrugPatentWatch.com

SODIUM BENZOATE; SODIUM PHENYLACETATE		
SOLUTION		
UCEPHAN	100MG/ML;100MG/ML	N19530
SODIUM BICARBONATE		
INJECTABLE		
SODIUM BICARBONATE IN PLASTIC CONTAINER	0.9MEQ/ML	N19443
SODIUM BICARBONATE IN PLASTIC CONTAINER	1MEQ/ML	N19443
SODIUM CHLORIDE		
INJECTABLE		
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	9MG/ML	N88909
SODIUM CHLORIDE	20GM/100ML	N17013
SODIUM CHLORIDE	20GM/100ML	N17038
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	450MG/100ML	N18184
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	450MG/100ML	N18503
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	9MG/ML	N19218
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	900MG/100ML	N18502
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER	234MG/ML	N19329
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER	3GM/100ML	N19635
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER	5GM/100ML	N19635
SOLUTION		
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	450MG/100ML	N18380
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	450MG/100ML	N18497
SODIUM CHLORIDE IN PLASTIC CONTAINER	900MG/100ML	N18247
SODIUM CHROMATE, CR-51		
INJECTABLE		
CHROMITOPE SODIUM	2mCi/VIAL	N13993
SODIUM FLUORIDE, F-18		
INJECTABLE		
FLUORINE F-18	2mCi/ML	N17042
SODIUM IODIDE, I-123		
CAPSULE		
SODIUM IODIDE I 123	400uCi	N18671
SODIUM IODIDE, I-131		
CAPSULE		
IODOTOPE	1-150mCi	N10929
SODIUM IODIDE I 131	100uCi	N17316
SODIUM IODIDE I 131	50uCi	N17316
SODIUM IODIDE I 131	0.8-100mCi	N16515
SOLUTION		
IODOTOPE	7-106mCi/BOT	N10929
SODIUM LACTATE		
INJECTABLE		
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER	1.87GM/100ML	N18186
SODIUM NITROPRUSSIDE		
INJECTABLE		
NIPRIDE	50MG/VIAL	N17546
NITROPRESS	50MG/VIAL	N18450
NITROPRESS	50MG/VIAL	N71555
SODIUM NITROPRUSSIDE	50MG/VIAL	N70031
SODIUM NITROPRUSSIDE	50MG/VIAL	N18581
SODIUM PHOSPHATE, P-32		
SOLUTION		
PHOSPHOTOPE	1-8mCi/VIAL	N10927
SODIUM PHOSPHATE P 32	1.5mCi/VIAL	N11777
SODIUM POLYSTYRENE SULFONATE		
POWDER		
SODIUM POLYSTYRENE SULFONATE	453.6GM/BOT	N88786
SUSPENSION		
SODIUM POLYSTYRENE SULFONATE	15GM/60ML	N88717
SODIUM POLYSTYRENE SULFONATE	15GM/60ML	N88453
SODIUM SUCCINATE		
INJECTABLE		
SODIUM SUCCINATE	30%	N80516
SODIUM TETRADECYL SULFATE		
INJECTABLE		
SOTRADECOL	1%	* N05970
SOTRADECOL	3%	* N05970
SODIUM THIOSULFATE		
INJECTABLE		
SODIUM THIOSULFATE	250MG/ML	N20166
SOMATROPIN		
INJECTABLE		
ASELLACRIN 10	10 IU/VIAL	N17726
ASELLACRIN 2	2 IU/VIAL	N17726
CRESCORMON	4 IU/VIAL	N17992
SOMATROPIN RECOMBINANT		
INJECTABLE		
BIO-TROPIN	4.8MG/VIAL	N19774
HUMATROPE	2MG/VIAL	N19640
SORBITOL		
SOLUTION		
SORBITOL 3% IN PLASTIC CONTAINER	3GM/100ML	N18512
SOTALOL HYDROCHLORIDE		
TABLET		
BETAPACE	320MG	N19865
BETAPACE AF	100MG	N21151
BETAPACE AF	40MG	N21151

FDA data supplied by DrugPatentWatch.com

SOTALOL HYDROCHLORIDE
TABLET
BETAPACE AF 60MG N21151

SOYBEAN OIL
INJECTABLE
TRAVAMULSION 10% 10% N18660
TRAVAMULSION 20% 20% N18758

SPECTINOMYCIN HYDROCHLORIDE
INJECTABLE
TROBICIN EQ 4GM BASE/VIAL N50347

SPIRAPRIL HYDROCHLORIDE
TABLET
RENORMAX 12MG N20240
RENORMAX 24MG N20240
RENORMAX 3MG N20240
RENORMAX 6MG N20240

SPIRONOLACTONE
TABLET
SPIRONOLACTONE 25MG N87687
SPIRONOLACTONE 25MG N87108
SPIRONOLACTONE 25MG N87634
SPIRONOLACTONE 25MG N87998
SPIRONOLACTONE 25MG N88053
SPIRONOLACTONE 25MG N89364
SPIRONOLACTONE 25MG N87554
SPIRONOLACTONE 25MG N87648
SPIRONOLACTONE 25MG N87952
SPIRONOLACTONE 25MG N86898
SPIRONOLACTONE 25MG N87078

STANOZOLOL
TABLET
WINSTROL 2MG N12885

STAVUDINE
CAPSULE
ZERIT 5MG N20412

STREPTOMYCIN SULFATE
INJECTABLE
STREPTOMYCIN SULFATE EQ 500MG BASE/ML N60684
STREPTOMYCIN SULFATE EQ 1GM BASE/2ML N60404
STREPTOMYCIN SULFATE EQ 1GM BASE/VIAL N60107
STREPTOMYCIN SULFATE EQ 5GM BASE/VIAL N60107
STREPTOMYCIN SULFATE EQ 1GM BASE/VIAL N60076
STREPTOMYCIN SULFATE EQ 5GM BASE/VIAL N60076

SUCCINYLCHOLINE CHLORIDE
INJECTABLE
ANECTINE 50MG/ML N08453
QUELICIN PRESERVATIVE FREE 50MG/ML N08845
SUCCINYLCHOLINE CHLORIDE 100MG/VIAL N85400
SUCOSTRIN 100MG/ML N08847
SUCOSTRIN 20MG/ML N08847

SUFENTANIL CITRATE
INJECTABLE
SUFENTANIL CITRATE EQ 0.05MG BASE/ML N74406

SULCONAZOLE NITRATE
SOLUTION
EXELDERM 1% N18738

SULFACETAMIDE SODIUM
OINTMENT
BLEPH-10 10% N84015
SODIUM SULAMYD 10% N05963
SULFAIR 10 10% N88000
SOLUTION/DROPS
OCUSULF-30 30% N80660
SODIUM SULAMYD 10% N05963
SODIUM SULAMYD 30% N05963
SODIUM SULFACETAMIDE 10% N83021
SODIUM SULFACETAMIDE 15% N83021
SODIUM SULFACETAMIDE 30% N83021
SODIUM SULFACETAMIDE 10% N84143
SODIUM SULFACETAMIDE 10% N84145
SODIUM SULFACETAMIDE 30% N84146
SODIUM SULFACETAMIDE 30% N84147
SULF-10 10% N80025
SULF-15 15% N89047
SULFACETAMIDE SODIUM 10% N88947
SULFAIR 10 10% N87949
SULFAIR FORTE 30% N88385
SULFAIR-15 15% N88186
SULTEN-10 10% N87818

SULFADIAZINE
TABLET
SULFADIAZINE 300MG N04125
SULFADIAZINE 500MG N80088
SULFADIAZINE 500MG N80081
SULFADIAZINE 500MG N80084
SULFADIAZINE 500MG N04054
SULFADIAZINE 500MG N04122

FDA data supplied by DrugPatentWatch.com

SULFADIAZINE SODIUM		
INJECTABLE		
SULFADIAZINE SODIUM	250MG/ML	N04054
SULFADIAZINE; SULFAMERAZINE		
SUSPENSION		
SULFONAMIDES DUPLEX	250MG/5ML;250MG/5ML	N06317
SULFAMETER		
TABLET		
SULLA	500MG	N16000
SULFAMETHIZOLE		
TABLET		
MICROSUL	1GM	N86012
PROKLAR	500MG	N80273
THIOSULFIL	250MG	N08565
THIOSULFIL	500MG	N08565
SULFAMETHOXAZOLE		
SUSPENSION		
GANTANOL	500MG/5ML	N13664
TABLET		
GANTANOL	500MG	N12715
GANTANOL-DS	1GM	N12715
SULFAMETHOXAZOLE	500MG	N87662
SULFAMETHOXAZOLE	500MG	N87189
SULFAMETHOXAZOLE	500MG	N86163
SULFAMETHOXAZOLE	500MG	N85844
SULFAMETHOXAZOLE	1GM	N86000
SULFAMETHOXAZOLE	500MG	N85053
UROBAK	500MG	N87307
SULFAMETHOXAZOLE; TRIMETHOPRIM		
INJECTABLE		
SEPTRA	80MG/ML;16MG/ML	N18452
SULFAMETHOXAZOLE AND TRIMETHOPRIM	80MG/ML;16MG/ML	N70223
SULFAMETHOXAZOLE AND TRIMETHOPRIM	80MG/ML;16MG/ML	N72383
SULFAMETHOXAZOLE AND TRIMETHOPRIM	80MG/ML;16MG/ML	N71556
SUSPENSION		
BACTRIM	200MG/5ML;40MG/5ML	N17560
BACTRIM PEDIATRIC	200MG/5ML;40MG/5ML	N17560
SULMEPRIM	200MG/5ML;40MG/5ML	N70063
SULMEPRIM PEDIATRIC	200MG/5ML;40MG/5ML	N70064
TRIMETH/SULFA	200MG/5ML;40MG/5ML	N72289
TRIMETH/SULFA	200MG/5ML;40MG/5ML	N72398
TRIMETH/SULFA	200MG/5ML;40MG/5ML	N72399
TABLET		
SULFAMETHOXAZOLE & TRIMETHOPRIM	400MG;80MG	N18946
SULFAMETHOXAZOLE & TRIMETHOPRIM	800MG;160MG	N18946
SULFAMETHOXAZOLE; TRIMETHOPRIM		
TABLET		
SULFAMETHOXAZOLE AND TRIMETHOPRIM	400MG;80MG	N18598
SULFAMETHOXAZOLE AND TRIMETHOPRIM	400MG;80MG	N70006
SULFAMETHOXAZOLE AND TRIMETHOPRIM	400MG;80MG	N71299
SULFAMETHOXAZOLE AND TRIMETHOPRIM	800MG;160MG	N71300
SULFAMETHOXAZOLE AND TRIMETHOPRIM	400MG;80MG	N72408
SULFAMETHOXAZOLE AND TRIMETHOPRIM	400MG;80MG	N72768
SULFAMETHOXAZOLE AND TRIMETHOPRIM	400MG;80MG	N18242
SULFAMETHOXAZOLE AND TRIMETHOPRIM	800MG;160MG	N18242
SULFAMETHOXAZOLE AND TRIMETHOPRIM	400MG;80MG	N70203
SULFAMETHOXAZOLE AND TRIMETHOPRIM	800MG;160MG	N70204
SULFAMETHOXAZOLE AND TRIMETHOPRIM	400MG;80MG	N70002
SULFAMETHOXAZOLE AND TRIMETHOPRIM	800MG;160MG	N70000
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH	800MG;160MG	N70007
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH	800MG;160MG	N72417
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH	800MG;160MG	N72769
SULFATRIM-DS	800MG;160MG	N70066
SULFATRIM-SS	400MG;80MG	N70065
UROPLUS DS	800MG;160MG	N71816
UROPLUS SS	400MG;80MG	N71815
SULFANILAMIDE		
SUPPOSITORY		
AVC	1.05GM	N06530
SULFAPHENAZOLE		
SUSPENSION		
SULFABID	500MG/5ML	N13093
TABLET		
SULFABID	500MG	N13092
SULFAPYRIDINE		
TABLET		
SULFAPYRIDINE	500MG	N00159
SULFASALAZINE		
SUSPENSION		
AZULFIDINE	250MG/5ML	N18605
TABLET		
S.A.S.-500	500MG	N83450
SULFASALAZINE	500MG	N80197
SULFASALAZINE	500MG	N86184
SULFASALAZINE	500MG	N89339
SULFASALAZINE	500MG	N84964

FDA data supplied by DrugPatentWatch.com

SULFASALAZINE		
TABLET, DELAYED RELEASE		
SULFASALAZINE	500MG	N88052
SULFINPYRAZONE		
CAPSULE		
SULFINPYRAZONE	200MG	N88666
TABLET		
SULFINPYRAZONE	100MG	N87769
SULFINPYRAZONE	100MG	N87667
SULFISOXAZOLE		
TABLET		
GANTRISIN	500MG	N06525
SOXAZOLE	500MG	N80366
SULFALAR	500MG	N84955
SULFISOXAZOLE	500MG	N84031
SULFISOXAZOLE	500MG	N80189
SULFISOXAZOLE	500MG	N80109
SULFISOXAZOLE	500MG	N80085
SULFISOXAZOLE	500MG	N87649
SULFISOXAZOLE	500MG	N84385
SULFISOXAZOLE	500MG	N80087
SULFISOXAZOLE	500MG	N80082
SULFISOXAZOLE	500MG	N85628
SULFISOXAZOLE	500MG	N80268
SULFISOXAZOLE	500MG	N87332
SULFISOXAZOLE	500MG	N85534
SULFISOXAZOLE	500MG	N80379
SULSOXIN	500MG	N80040
SULFISOXAZOLE ACETYL		
EMULSION		
LIPO GANTRISIN	EQ 1GM BASE/5ML	N09182
SYRUP		
GANTRISIN	EQ 500MG BASE/5ML	N09182
SULFISOXAZOLE DIOLAMINE		
INJECTABLE		
GANTRISIN	EQ 400MG BASE/ML	N06917
OINTMENT		
GANTRISIN	EQ 4% BASE	N08414
SOLUTION/DROPS		
GANTRISIN	EQ 4% BASE	N07757
SULFISOXAZOLE DIOLAMINE	EQ 4% BASE	N84148

SULFOXONE SODIUM		
TABLET, DELAYED RELEASE		
DIASONE SODIUM	165MG	N06044
SULFUR		
POWDER		
BENSULFOID	33.32%	N02918
SULINDAC		
TABLET		
SULINDAC	150MG	N73261
SULINDAC	200MG	N73262
SUPROFEN		
SOLUTION/DROPS		
PROFENAL	1%	N19387
SUTILAINS		
OINTMENT		
TRAVASE	82,000 UNITS/GM	*N12828
TALBUTAL		
TABLET		
LOTUSATE	120MG	N09410
TECHNETIUM TC-99M ALBUMIN AGGREGATED		
INJECTABLE		
TC 99M-LUNGAGGREGATE	5mCi/ML	N17848
TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT		
INJECTABLE		
A-N STANNOUS AGGREGATED ALBUMIN	N/A	N17916
AN-MAA	N/A	N17792
LUNGAGGREGATE REAGENT	N/A	N17838
TECHNETIUM TC 99M MAA	N/A	N17773
TECHNETIUM TC-99M ALBUMIN COLLOID KIT		
INJECTABLE		
MICROLITE	N/A	N18263
TECHNETIUM TC-99M ALBUMIN KIT		
INJECTABLE		
TECHNETIUM TC 99M HSA	N/A	N17775
TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT		
INJECTABLE		
INSTANT MICROSPHERES	N/A	N17832
TECHNETIUM TC-99M ETIDRONATE KIT		
INJECTABLE		
CINTICHEM TECHNETIUM 99M HEDSPA	N/A	N17653
MPI STANNOUS DIPHOSPHONATE	N/A	N17667
OSTEOSCAN	N/A	N17454

FDA data supplied by DrugPatentWatch.com

TECHNETIUM TC-99M ETIDRONATE KIT		
INJECTABLE		
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT	N/A	N17562
TECHNETIUM TC-99M FERPENTETATE KIT		
INJECTABLE		
RENOTEC	N/A	N17045
TECHNETIUM TC-99M GLUCEPTATE KIT		
INJECTABLE		
GLUCOSCAN	N/A	N17907
TECHNETIUM TC-99M LIDOFENIN KIT		
INJECTABLE		
TECHNESCAN HIDA	N/A	N18489
TECHNETIUM TC-99M MEDRONATE KIT		
INJECTABLE		
AMERSCAN MDP KIT	N/A	N18335
TECHNETIUM TC-99M PENTETATE KIT		
INJECTABLE		
MPI DTPA KIT - CHELATE	N/A	N17255
TECHNETIUM TC-99M POLYPHOSPHATE KIT		
INJECTABLE		
SODIUM POLYPHOSPHATE-TIN KIT	N/A	N17664
TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT		
INJECTABLE		
PYROLITE	N/A	N17684
TECHNETIUM TC-99M RED BLOOD CELL KIT		
INJECTABLE		
RBC-SCAN	N/A	N20063
TECHNETIUM TC-99M SODIUM PERTECHNETATE		
SOLUTION		
SODIUM PERTECHNETATE TC 99M	2-100mCi/ML	N17471
SODIUM PERTECHNETATE TC 99M	12mCi/ML	N17321
SODIUM PERTECHNETATE TC 99M	24mCi/ML	N17321
SODIUM PERTECHNETATE TC 99M	48mCi/ML	N17321
SODIUM PERTECHNETATE TC 99M	10-60mCi/ML	N17725
TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR		
SOLUTION		
MINITEC	0.22-2.22 CI/GENERATOR	N17339
TECHNETIUM TC 99M GENERATOR	830-16600mCi/GENERATOR	N17693
TECHNETIUM TC-99M SULFUR COLLOID		
SOLUTION		
TECHNETIUM TC 99M SULFUR COLLOID	4mCi/ML	N17456
TECHNETIUM TC 99M SULFUR COLLOID	3mCi/ML	N17724

TECHNETIUM TC-99M SULFUR COLLOID KIT		
SOLUTION		
TECHNETIUM TC 99M TSC	N/A	N17784
TESULOID	N/A	N16923
TEMAZEPAM		
CAPSULE		
TEMAZ	15MG	N70564
TEMAZ	30MG	N70547
TEMAZEPAM	15MG	N71708
TEMAZEPAM	30MG	N71709
TEMAZEPAM	15MG	N71174
TEMAZEPAM	30MG	N71175
TEMAZEPAM	15MG	N70489
TEMAZEPAM	30MG	N70490
TEMAZEPAM	15MG	N70383
TEMAZEPAM	30MG	N70384
TERBINAFINE		
GEL		
LAMISIL	1%	N20846
TERBUTALINE SULFATE		
AEROSOL, METERED		
BRETHAIRE	0.2MG/INH	N18762
BRICANYL	0.2MG/INH	N18000
INJECTABLE		
BRICANYL	1MG/ML	N17466
TABLET		
BRICANYL	2.5MG	N17618
BRICANYL	5MG	N17618
TERIPARATIDE ACETATE		
INJECTABLE		
PARATHAR	200 UNITS/VIAL	N19498
TESTOLACTONE		
INJECTABLE		
TESLAC	100MG/ML	N16119
TABLET		
TESLAC	250MG	N16118
TESTOSTERONE		
INJECTABLE		
TESTOSTERONE	25MG/ML	N86420
TESTOSTERONE	50MG/ML	N86419
TESTOSTERONE CYPIONATE		
INJECTABLE		
DEPO-TESTOSTERONE	50MG/ML	N85635
TESTOSTERONE CYPIONATE	100MG/ML	N84401

FDA data supplied by DrugPatentWatch.com

TESTOSTERONE CYPIONATE		
INJECTABLE		
TESTOSTERONE CYPIONATE	200MG/ML	N84401
TESTOSTERONE ENANTHATE		
INJECTABLE		
DELATESTRYL	200MG/ML	N09165
TESTOSTERONE ENANTHATE	100MG/ML	N83667
TESTOSTERONE ENANTHATE	100MG/ML	N85599
TESTOSTERONE ENANTHATE	200MG/ML	N83667
TESTOSTERONE PROPIONATE		
INJECTABLE		
TESTOSTERONE PROPIONATE	100MG/ML	N80743
TESTOSTERONE PROPIONATE	25MG/ML	N80741
TESTOSTERONE PROPIONATE	50MG/ML	N80742
TESTOSTERONE PROPIONATE	25MG/ML	N80276
TESTOSTERONE PROPIONATE	50MG/ML	N80254
TESTOSTERONE PROPIONATE	100MG/ML	N83595
TESTOSTERONE PROPIONATE	25MG/ML	N85490
TESTOSTERONE PROPIONATE	50MG/ML	N85490
TETRACYCLINE HYDROCHLORIDE		
CAPSULE		
ACHROMYCIN V	250MG	N50278
ACHROMYCIN V	500MG	N50278
CYCLOPAR	250MG	N61725
CYCLOPAR	250MG	N62175
CYCLOPAR	250MG	N62332
CYCLOPAR	500MG	N61725
CYCLOPAR	500MG	N62332
PANMYCIN	250MG	N60347
RETET	250MG	N61443
RETET	500MG	N61443
ROBITET	250MG	N61734
ROBITET	500MG	N61734
SUMYCIN	100MG	N60429
SUMYCIN	125MG	N60429
TETRACHEL	250MG	N60343
TETRACHEL	500MG	N60343
TETRACYCLINE HCL	250MG	N61802
TETRACYCLINE HCL	500MG	N61802
TETRACYCLINE HCL	250MG	N60059
TETRACYCLINE HCL	250MG	N61471
TETRACYCLINE HCL	125MG	N60173
TETRACYCLINE HCL	250MG	N60173
TETRACYCLINE HCL	250MG	N61148
TETRACYCLINE HCL	500MG	N61148
TETRACYCLINE HCL	250MG	N60290

TETRACYCLINE HYDROCHLORIDE		
CAPSULE		
TETRACYCLINE HCL	500MG	N60290
TETRACYCLINE HCL	250MG	N62686
TETRACYCLINE HCL	500MG	N62686
TETRACYCLINE HCL	500MG	N61214
TETRACYCLINE HCL	250MG	N62540
TETRACYCLINE HCL	500MG	N62540
TETRACYCLINE HCL	250MG	N60471
TETRACYCLINE HCL	500MG	N60471
TETRACYCLINE HCL	250MG	N62300
TETRACYCLINE HCL	500MG	N62300
TETRACYCLINE HCL	250MG	N62103
TETRACYCLINE HCL	250MG	N62343
TETRACYCLINE HCL	500MG	N62103
TETRACYCLINE HCL	500MG	N62343
TETRACYCLINE HCL	250MG	N60768
TETRACYCLINE HCL	500MG	N60768
TETRACYCLINE HCL	250MG	N61685
TETRACYCLINE HCL	500MG	N61685
TETRACYN	250MG	N60082
TETRACYN	500MG	N60082
FIBER, EXTENDED RELEASE		
ACTISITE	12.7MG/FIBER	N50653
FOR SOLUTION		
TOPICYCLINE	2.2MG/ML	N50493
INJECTABLE		
ACHROMYCIN	250MG/VIAL	N50273
ACHROMYCIN	500MG/VIAL	N50273
TETRACYN	250MG/VIAL	N60096
TETRACYN	500MG/VIAL	N60096
OINTMENT		
ACHROMYCIN	10MG/GM	N50266
SUSPENSION		
ACHROMYCIN V	125MG/5ML	N50263
TETRACYCLINE HCL	125MG/5ML	N60633
TETRACYCLINE HCL	125MG/5ML	N60174
TETRACYCLINE HCL	125MG/5ML	N60446
TETRACYCLINE HCL	125MG/5ML	N60291
TETRACYN	125MG/5ML	N60095
TETRAMED	125MG/5ML	N61468
SUSPENSION/DROPS		
ACHROMYCIN	1%	N50268
TABLET		
PANMYCIN	250MG	N61705
PANMYCIN	500MG	N61705

FDA data supplied by DrugPatentWatch.com

TETRACYCLINE HYDROCHLORIDE		
TABLET		
SUMYCIN	100MG	N61147
SUMYCIN	50MG	N61147
TETRACYCLINE PHOSPHATE COMPLEX		
CAPSULE		
TETREX	EQ 250MG HCL	N50212
TETREX	EQ 500MG HCL	N50212
THALLOUS CHLORIDE, TL-201		
INJECTABLE		
THALLOUS CHLORIDE TL 201	1mCi/ML	N18548
THEOPHYLLINE		
CAPSULE		
BRONKODYL	100MG	N85264
BRONKODYL	200MG	N85264
ELIXOPHYLLIN	100MG	N85545
ELIXOPHYLLIN	200MG	N83921
SOMOPHYLLIN-T	100MG	N87155
SOMOPHYLLIN-T	200MG	N87155
SOMOPHYLLIN-T	250MG	N87155
THEOPHYLLINE	100MG	N85263
THEOPHYLLINE	200MG	N85263
THEOPHYLLINE	100MG	N84731
THEOPHYLLINE	200MG	N84731
THEOPHYLLINE	250MG	N84731
CAPSULE, EXTENDED RELEASE		
ELIXOPHYLLIN SR	125MG	N86826
ELIXOPHYLLIN SR	250MG	N86826
SLO-BID	100MG	N87892
SLO-BID	125MG	N89540
SLO-BID	200MG	N87893
SLO-BID	300MG	N87894
SLO-BID	50MG	N88269
SLO-BID	75MG	N89539
SLO-PHYLLIN	125MG	N85203
SLO-PHYLLIN	250MG	N85205
SLO-PHYLLIN	60MG	N85206
SOMOPHYLLIN-CRT	100MG	N87194
SOMOPHYLLIN-CRT	200MG	N88382
SOMOPHYLLIN-CRT	250MG	N87193
SOMOPHYLLIN-CRT	300MG	N88383
SOMOPHYLLIN-CRT	50MG	N87763
THEOBID	260MG	N85983
THEOBID JR.	130MG	N87854
THEOCLEAR L.A.-130	130MG	N86569
THEOPHYLLINE		
CAPSULE, EXTENDED RELEASE		
THEOCLEAR L.A.-260	260MG	N86569
THEO-DUR	125MG	N88016
THEO-DUR	200MG	N87995
THEO-DUR	50MG	N88022
THEO-DUR	75MG	N88015
THEOPHYLLINE	125MG	N88654
THEOPHYLLINE	250MG	N88689
THEOPHYLLINE	260MG	N87462
THEOPHYLLINE	100MG	N89976
THEOPHYLLINE	200MG	N89977
THEOPHYLLINE	300MG	N89932
THEOPHYLLINE-SR	300MG	N88255
THEOPHYL-SR	125MG	N86480
THEOPHYL-SR	250MG	N86471
THEOVENT	125MG	N87010
THEOVENT	250MG	N87910
ELIXIR		
ELIXOMIN	80MG/15ML	N88303
LANOPHYLLIN	80MG/15ML	N84578
THEOLIXIR	80MG/15ML	N84559
THEOPHYL-225	112.5MG/15ML	N86485
THEOPHYLLINE	80MG/15ML	N89223
THEOPHYLLINE	80MG/15ML	N87679
THEOPHYLLINE	80MG/15ML	N85169
THEOPHYLLINE	80MG/15ML	N85952
THEOPHYLLINE	80MG/15ML	N84739
INJECTABLE		
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER	40MG/100ML	N19083
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER	80MG/100ML	N19083
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER	160MG/100ML	N19083
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER	200MG/100ML	N19212
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER	200MG/100ML	N19826
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER	400MG/100ML	N19212
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER	400MG/100ML	N19826
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER	4MG/ML	N19212
SUSPENSION		
ELIXICON	100MG/5ML	N85502

FDA data supplied by DrugPatentWatch.com

THEOPHYLLINE		
SYRUP		
ACCURBRON	150MG/15ML	N88746
AQUAPHYLLIN	80MG/15ML	N87917
SLO-PHYLLIN	80MG/15ML	N85187
THEOCLEAR-80	80MG/15ML	N87095
THEOPHYLLINE	150MG/15ML	N86545
THEOPHYLLINE	80MG/15ML	N86001
TABLET		
SLO-PHYLLIN	100MG	N85202
SLO-PHYLLIN	200MG	N85204
THEOCLEAR-100	100MG	N85353
THEOCLEAR-200	200MG	N85353
THEOPHYL-225	225MG	N84726
TABLET, CHEWABLE		
THEOPHYL	100MG	N86506
TABLET, EXTENDED RELEASE		
DURAPHYL	100MG	N88503
DURAPHYL	200MG	N88504
DURAPHYL	300MG	N88505
LABID	250MG	N87225
SUSTAIRE	100MG	N85665
SUSTAIRE	300MG	N85665
THEO-DUR	100MG	N85328
THEO-DUR	200MG	N86998
THEO-DUR	300MG	N85328
THEO-DUR	450MG	N89131
UNI-DUR	400MG	N89822
UNI-DUR	600MG	N89823
THEOPHYLLINE SODIUM GLYCINATE		
ELIXIR		
SYNOPHYLATE	EQ 165MG BASE/15ML	N06333
TABLET		
ASBRON	EQ 150MG BASE	N85148
THIAMINE HYDROCHLORIDE		
INJECTABLE		
BETALIN S	100MG/ML	N80853
THIAMINE HCL	100MG/ML	N87968
THIAMINE HCL	100MG/ML	N80509
THIAMINE HCL	100MG/ML	N80718
THIAMINE HCL	200MG/ML	N80712
THIAMINE HCL	100MG/ML	N83775
THIAMINE HCL	100MG/ML	N80667
THIAMINE HCL	100MG/ML	N80770
THIAMINE HCL	100MG/ML	N83534
THIAMINE HYDROCHLORIDE		
INJECTABLE		
THIAMINE HCL	200MG/ML	N83534
THIAMINE HCL	100MG/ML	N80553
THIAMYLAL SODIUM		
INJECTABLE		
SURITAL	10GM/VIAL	N07600
SURITAL	1GM/VIAL	N07600
SURITAL	5GM/VIAL	N07600
THIETHYLPERAZINE MALATE		
INJECTABLE		
TORECAN	5MG/ML	N12754
THIETHYLPERAZINE MALEATE		
SUPPOSITORY		
TORECAN	10MG	N13247
THIOPENTAL SODIUM		
SUSPENSION		
PENTOTHAL	400MG/GM	N11679
THIORIDAZINE		
SUSPENSION		
MELLARIL-S	EQ 100MG HCL/5ML	N17923
MELLARIL-S	EQ 25MG HCL/5ML	N17923
THIORIDAZINE HYDROCHLORIDE		
CONCENTRATE		
MELLARIL	100MG/ML	N11808
MELLARIL	30MG/ML	N11808
THIORIDAZINE HCL	30MG/ML	N87766
THIORIDAZINE HCL	100MG/ML	N88227
THIORIDAZINE HCL	30MG/ML	N88258
THIORIDAZINE HCL	100MG/ML	N88308
THIORIDAZINE HCL	30MG/ML	N88307
TABLET		
MELLARIL	100MG	N11808
MELLARIL	10MG	N11808
MELLARIL	150MG	N11808
MELLARIL	15MG	N11808
MELLARIL	200MG	N11808
MELLARIL	25MG	N11808
MELLARIL	50MG	N11808
THIORIDAZINE HCL	100MG	N88379
THIORIDAZINE HCL	10MG	N88375
THIORIDAZINE HCL	150MG	N88737
THIORIDAZINE HCL	15MG	N88461
THIORIDAZINE HCL	200MG	N88738
THIORIDAZINE HCL	25MG	N87264

FDA data supplied by DrugPatentWatch.com

THIORIDAZINE HYDROCHLORIDE
TABLET

THIORIDAZINE HCL	100MG	N88273
THIORIDAZINE HCL	50MG	N88194
THIORIDAZINE HCL	100MG	N88335
THIORIDAZINE HCL	10MG	N88332
THIORIDAZINE HCL	25MG	N88333
THIORIDAZINE HCL	50MG	N88334
THIORIDAZINE HCL	100MG	N88480
THIORIDAZINE HCL	10MG	N88351
THIORIDAZINE HCL	150MG	N89764
THIORIDAZINE HCL	15MG	N88352
THIORIDAZINE HCL	200MG	N89765
THIORIDAZINE HCL	25MG	N88336
THIORIDAZINE HCL	50MG	N88322
THIORIDAZINE HCL	100MG	N89048
THIORIDAZINE HCL	10MG	N88663
THIORIDAZINE HCL	25MG	N88664
THIORIDAZINE HCL	50MG	N88665
THIORIDAZINE HCL	10MG	N89103
THIORIDAZINE HCL	25MG	N89104
THIORIDAZINE HCL	50MG	N89105
THIORIDAZINE HCL	10MG	N88493
THIORIDAZINE HCL	100MG	N88284
THIORIDAZINE HCL	10MG	N88412
THIORIDAZINE HCL	10MG	N88561
THIORIDAZINE HCL	150MG	N88410
THIORIDAZINE HCL	15MG	N88345
THIORIDAZINE HCL	15MG	N88562
THIORIDAZINE HCL	200MG	N88381
THIORIDAZINE HCL	25MG	N88296
THIORIDAZINE HCL	25MG	N88755
THIORIDAZINE HCL	50MG	N88323
THIORIDAZINE HCL	10MG	N88658
THIORIDAZINE HCL	15MG	N88659
THIORIDAZINE HCL	25MG	N88660
THIORIDAZINE HCL	50MG	N88661

THIOTEPA
INJECTABLE

THIOPLEX	15MG/VIAL	N20058
THIOTEPA	15MG/VIAL	N11683

THIOTHIXENE
CAPSULE

THIOTHIXENE	10MG	N71887
THIOTHIXENE	1MG	N71884
THIOTHIXENE	20MG	N72200

THIOTHIXENE
CAPSULE

THIOTHIXENE	2MG	N71885
THIOTHIXENE	5MG	N71886
THIOTHIXENE	10MG	N71628
THIOTHIXENE	2MG	N71626
THIOTHIXENE	5MG	N71627

THIOTHIXENE HYDROCHLORIDE
CONCENTRATE

THIOTHIXENE HCL	EQ 5MG BASE/ML	N70969
THIOTHIXENE HCL	EQ 1MG BASE/ML	N71917
THIOTHIXENE HCL	EQ 5MG BASE/ML	N71939
THIOTHIXENE HCL	EQ 5MG BASE/ML	N71184
THIOTHIXENE HCL INTENSOL	EQ 5MG BASE/ML	N73494

INJECTABLE

NAVANE	EQ 2MG BASE/ML	N16904

THYROGLOBULIN
TABLET

PROLOID	100MG	N02245
PROLOID	130MG	N02245
PROLOID	16MG	N02245
PROLOID	200MG	N02245
PROLOID	325MG	N02245
PROLOID	32MG	N02245
PROLOID	65MG	N02245
THYROGLOBULIN	64.8MG	N80151

THYROTROPIN
INJECTABLE

THYTROPAR	10 IU/VIAL	N08682

TIAGABINE HYDROCHLORIDE
TABLET

GABITRIL	20MG	N20646

TICARCILLIN DISODIUM
INJECTABLE

TICAR	EQ 3GM BASE/VIAL	N62690
TICAR	EQ 6GM BASE/VIAL	N50497

TICLOPIDINE HYDROCHLORIDE
TABLET

TICLID	125MG	N19979

TIMOLOL MALEATE
TABLET

TIMOLOL MALEATE	10MG	N72467
TIMOLOL MALEATE	20MG	N72468
TIMOLOL MALEATE	5MG	N72466

FDA data supplied by DrugPatentWatch.com

TIMOLOL MALEATE		
TABLET		
TIMOLOL MALEATE	10MG	N72649
TIMOLOL MALEATE	20MG	N72650
TIMOLOL MALEATE	5MG	N72648
TIMOLOL MALEATE	10MG	N72002
TIMOLOL MALEATE	20MG	N72003
TIMOLOL MALEATE	5MG	N72001
TIMOLOL MALEATE	10MG	N72270
TIMOLOL MALEATE	20MG	N72271
TIMOLOL MALEATE	5MG	N72269
TIOCONAZOLE		
CREAM		
TZ-3	1%	N18682
TOBRAMYCIN		
SOLUTION/DROPS		
TOBRAMYCIN	0.3%	N63176
TOBRAMYCIN SULFATE		
INJECTABLE		
TOBRAMYCIN SULFATE	EQ 40MG BASE/ML	N64026
TOBRAMYCIN SULFATE	EQ 10MG BASE/ML	N63119
TOBRAMYCIN SULFATE	EQ 40MG BASE/ML	N63120
TOBRAMYCIN SULFATE	EQ 40MG BASE/ML	N63121
TOBRAMYCIN SULFATE	EQ 40MG BASE/ML	N63122
TOBRAMYCIN SULFATE	EQ 10MG BASE/ML	N63113
TOBRAMYCIN SULFATE	EQ 10MG BASE/ML	N63128
TOBRAMYCIN SULFATE	EQ 40MG BASE/ML	N63127
TOLAZAMIDE		
TABLET		
TOLAZAMIDE	100MG	N70162
TOLAZAMIDE	250MG	N70163
TOLAZAMIDE	500MG	N70164
TOLAZAMIDE	100MG	N70165
TOLAZAMIDE	250MG	N70166
TOLAZAMIDE	500MG	N70167
TOLAZAMIDE	250MG	N71270
TOLAZAMIDE	500MG	N71271
TOLAZAMIDE	250MG	N70763
TOLAZAMIDE	500MG	N70764
TOLAZAMIDE	100MG	N71355
TOLAZAMIDE	250MG	N70168
TOLAZAMIDE	500MG	N70169
TOLAZAMIDE	100MG	N70242
TOLAZAMIDE	250MG	N70243
TOLAZAMIDE	500MG	N70244

TOLAZOLINE HYDROCHLORIDE		
INJECTABLE		
PRISCOLINE	25MG/ML	N06403
TOLBUTAMIDE		
TABLET		
ORINASE	250MG	N10670
ORINASE	500MG	N10670
TOLBUTAMIDE	500MG	N86141
TOLBUTAMIDE	500MG	N87541
TOLBUTAMIDE	500MG	N87121
TOLBUTAMIDE	500MG	N86926
TOLBUTAMIDE	500MG	N12678
TOLBUTAMIDE	500MG	N86047
TOLBUTAMIDE	500MG	N88950
TOLBUTAMIDE	500MG	N88893
TOLBUTAMIDE	500MG	N87876
TOLBUTAMIDE	250MG	N89110
TOLBUTAMIDE	500MG	N89111
TOLBUTAMIDE SODIUM		
INJECTABLE		
ORINASE DIAGNOSTIC	EQ 1GM BASE/VIAL	N12095
TOLMETIN SODIUM		
CAPSULE		
TOLMETIN SODIUM	EQ 400MG BASE	N73462
TABLET		
TOLMETIN SODIUM	EQ 600MG BASE	N74729
TOPIRAMATE		
CAPSULE		
TOPAMAX SPRINKLE	50MG	N20844
TABLET		
TOPAMAX	300MG	N20505
TOPAMAX	400MG	N20505
TOPAMAX	50MG	N20505
TRAMADOL HYDROCHLORIDE		
TABLET		
TRAMADOL HCL	50MG	N75974
ULTRAM	100MG	N20281
TRANEXAMIC ACID		
TABLET		
CYKLOKAPRON	500MG	N19280
TRAZODONE HYDROCHLORIDE		
TABLET		
TRAZODONE HCL	100MG	N71140
TRAZODONE HCL	50MG	N71139

FDA data supplied by DrugPatentWatch.com

TRAZODONE HYDROCHLORIDE		
TABLET		
TRAZODONE HCL	100MG	N70921
TRAZODONE HCL	100MG	N70492
TRAZODONE HCL	50MG	N70491
TRAZODONE HCL	100MG	N71113
TRAZODONE HCL	50MG	N71112
TRIALODINE	50MG	N70942
TRETINOIN		
SWAB		
RETIN-A	0.05%	N16921
TRIAMCINOLONE		
TABLET		
ARISTOCORT	16MG	N11161
ARISTOCORT	1MG	N11161
ARISTOCORT	2MG	N11161
ARISTOCORT	8MG	N11161
KENACORT	1MG	N11283
KENACORT	2MG	N11283
TRIAMCINOLONE	2MG	N84286
TRIAMCINOLONE	2MG	N84318
TRIAMCINOLONE	4MG	N84267
TRIAMCINOLONE	4MG	N84319
TRIAMCINOLONE	8MG	N84268
TRIAMCINOLONE	8MG	N84320
TRIAMCINOLONE	4MG	N84340
TRIAMCINOLONE	4MG	N83750
TRIAMCINOLONE	2MG	N84406
TRIAMCINOLONE	2MG	N84020
TRIAMCINOLONE	4MG	N84020
TRIAMCINOLONE	2MG	N84708
TRIAMCINOLONE	4MG	N84709
TRIAMCINOLONE	8MG	N84707
TRIAMCINOLONE	4MG	N85601
TRIAMCINOLONE	4MG	N84775
TRIAMCINOLONE	4MG	N85834
TRIAMCINOLONE ACETONIDE		
AEROSOL, METERED		
NASACORT	0.055MG/INH	N19798
CREAM		
FLUTEX	0.025%	N85539
FLUTEX	0.1%	N85539
FLUTEX	0.5%	N85539
KENALOG-H	0.1%	N86240
TRIACORT	0.1%	N87113
TRIAMCINOLONE ACETONIDE	0.025%	N87797

TRIAMCINOLONE ACETONIDE		
CREAM		
TRIAMCINOLONE ACETONIDE	0.025%	N88094
TRIAMCINOLONE ACETONIDE	0.1%	N88095
TRIAMCINOLONE ACETONIDE	0.5%	N88096
TRIAMCINOLONE ACETONIDE	0.025%	N87990
TRIAMCINOLONE ACETONIDE	0.1%	N87991
TRIAMCINOLONE ACETONIDE	0.5%	N87992
TRIAMCINOLONE ACETONIDE	0.025%	N87921
TRIAMCINOLONE ACETONIDE	0.1%	N87912
TRIAMCINOLONE ACETONIDE	0.5%	N87922
TRIAMCINOLONE ACETONIDE	0.025%	N40038
TRIAMCINOLONE ACETONIDE	0.025%	N89274
TRIAMCINOLONE ACETONIDE	0.1%	N89275
TRIAMCINOLONE ACETONIDE	0.5%	N89276
TRIATEX	0.025%	N87430
TRIATEX	0.1%	N87429
TRIATEX	0.5%	N87428
TRYMEX	0.025%	N88196
TRYMEX	0.1%	N88197
TRYMEX	0.5%	N88198
GEL		
ARISTOGEL	0.1%	N83380
INJECTABLE		
TRIAMCINOLONE ACETONIDE	3MG/ML	N19503
TRIAMCINOLONE ACETONIDE	40MG/ML	N85825
LOTION		
KENALOG	0.025%	N11602
KENALOG	0.1%	N11602
TRIAMCINOLONE ACETONIDE	0.025%	N87191
TRIAMCINOLONE ACETONIDE	0.1%	N87192
OINTMENT		
ARISTOCORT	0.5%	N80745
ARISTOCORT A	0.5%	N80745
ARISTOCORT A	0.5%	N88781
FLUTEX	0.025%	N87375
FLUTEX	0.1%	N87377
FLUTEX	0.5%	N87376
KENALOG	0.5%	N83944
TRIAMCINOLONE ACETONIDE	0.5%	N89913
TRIAMCINOLONE ACETONIDE	0.025%	N89795
TRIAMCINOLONE ACETONIDE	0.1%	N89796
TRIAMCINOLONE ACETONIDE	0.025%	N88090
TRIAMCINOLONE ACETONIDE	0.1%	N88091
TRIAMCINOLONE ACETONIDE	0.5%	N88092
TRIAMCINOLONE ACETONIDE	0.025%	N88692
TRIAMCINOLONE ACETONIDE	0.1%	N88690

FDA data supplied by DrugPatentWatch.com

TRIAMCINOLONE ACETONIDE		
OINTMENT		
TRYMEX	0.025%	N88693
TRYMEX	0.1%	N88691
SPRAY, METERED		
TRI-NASAL	0.05MG/SPRAY	N20120
TRIAMCINOLONE DIACETATE		
INJECTABLE		
TRIAMCINOLONE DIACETATE	25MG/ML	N85122
TRIAMCINOLONE DIACETATE	40MG/ML	N86394
TRIAMCINOLONE DIACETATE	40MG/ML	N84072
TRIAMCINOLONE DIACETATE	40MG/ML	N85529
SYRUP		
ARISTOCORT	2MG/5ML	N11960
KENACORT	EQ 4MG BASE/5ML	N12515
TRIAZOLAM		
TABLET		
HALCION	0.5MG	N17892
TRICHLORMETHIAZIDE		
TABLET		
METAHYDRIN	2MG	N12594
METAHYDRIN	4MG	N12594
NAQUA	2MG	N12265
TRICHLOREX	4MG	N83436
TRICHLOREX	4MG	N85630
TRICHLORMAS	4MG	N86259
TRICHLORMETHIAZIDE	4MG	N86171
TRICHLORMETHIAZIDE	4MG	N83967
TRICHLORMETHIAZIDE	2MG	N83847
TRICHLORMETHIAZIDE	2MG	N86458
TRICHLORMETHIAZIDE	4MG	N83462
TRICHLORMETHIAZIDE	4MG	N83855
TRICHLORMETHIAZIDE	4MG	N85962
TRICLOFOS SODIUM		
SOLUTION		
TRICLOS	1.5GM/15ML	N16830
TABLET		
TRICLOS	750MG	N16809
TRIDIHEXETHYL CHLORIDE		
INJECTABLE		
PATHILON	10MG/ML	N09729
TABLET		
PATHILON	25MG	N09489

TRIFLUOPERAZINE HYDROCHLORIDE		
CONCENTRATE		
TRIFLUOPERAZINE HCL	EQ 10MG BASE/ML	N88143
TRIFLUOPERAZINE HCL	EQ 10MG BASE/ML	N85787
TABLET		
TRIFLUOPERAZINE HCL	EQ 10MG BASE	N88970
TRIFLUOPERAZINE HCL	EQ 1MG BASE	N88967
TRIFLUOPERAZINE HCL	EQ 2MG BASE	N88968
TRIFLUOPERAZINE HCL	EQ 5MG BASE	N88969
TRIFLUOPERAZINE HCL	EQ 10MG BASE	N87614
TRIFLUOPERAZINE HCL	EQ 1MG BASE	N87612
TRIFLUOPERAZINE HCL	EQ 2MG BASE	N87613
TRIFLUOPERAZINE HCL	EQ 5MG BASE	N87328
TRIFLUOPERAZINE HCL	EQ 10MG BASE	N88710
TRIFLUOPERAZINE HCL	EQ 1MG BASE	N85975
TRIFLUOPERAZINE HCL	EQ 2MG BASE	N85976
TRIFLUOPERAZINE HCL	EQ 5MG BASE	N85973
TRIFLUPROMAZINE		
SUSPENSION		
VESPRIN	EQ 50MG HCL/5ML	N11491
TRIFLUPROMAZINE HYDROCHLORIDE		
INJECTABLE		
VESPRIN	10MG/ML	N11325
VESPRIN	20MG/ML	N11325
VESPRIN	3MG/ML	N11325
TABLET		
VESPRIN	10MG	N11123
VESPRIN	25MG	N11123
VESPRIN	50MG	N11123
TRIHEXYPHENIDYL HYDROCHLORIDE		
CAPSULE, EXTENDED RELEASE		
ARTANE	5MG	N06773
ARTANE	5MG	N12947
ELIXIR		
ARTANE	2MG/5ML	N06773
TABLET		
ARTANE	2MG	N06773
ARTANE	5MG	N06773
TREMIN	2MG	N80381
TREMIN	5MG	N80381
TRIHEXYPHENIDYL HCL	5MG	N85622
TRIHEXYPHENIDYL HCL	2MG	N88035
TRIHEXYPHENIDYL HCL	2MG	N85117
TRIHEXYPHENIDYL HCL	5MG	N85105

FDA data supplied by DrugPatentWatch.com

TRILOSTANE		
CAPSULE		
MODRASTANE	30MG	N18719
MODRASTANE	60MG	N18719
TRIMEPRAZINE TARTRATE		
CAPSULE, EXTENDED RELEASE		
TEMARIL	EQ 5MG BASE	N11316
SYRUP		
TEMARIL	EQ 2.5MG BASE/5ML	N11316
TRIMEPRAZINE TARTRATE	EQ 2.5MG BASE/5ML	N85015
TRIMEPRAZINE TARTRATE	EQ 2.5MG BASE/5ML	N88285
TABLET		
TEMARIL	EQ 2.5MG BASE	N11316
TRIMETHADIONE		
CAPSULE		
TRIDIONE	300MG	N05856
SOLUTION		
TRIDIONE	200MG/5ML	N05856
TRIMETHAPHAN CAMSYLATE		
INJECTABLE		
ARFONAD	50MG/ML	N08983
TRIMETHOBENZAMIDE HYDROCHLORIDE		
INJECTABLE		
TRIMETHOBENZAMIDE HCL	100MG/ML	N88960
TRIMETHOBENZAMIDE HCL	100MG/ML	N89043
TRIMETHOBENZAMIDE HCL	100MG/ML	N89094
TRIMETHOBENZAMIDE HCL	100MG/ML	N86577
TRIMETHOBENZAMIDE HCL	100MG/ML	N87939
TRIMETHOPRIM		
TABLET		
PROLOPRIM	200MG	N17943
TRIMETHOPRIM	100MG	N70494
TRIMETHOPRIM	200MG	N70495
TRIMPEX	100MG	N17952
TRIMPEX 200	200MG	N17952
TRIMETHOPRIM HYDROCHLORIDE		
SOLUTION		
PRIMSOL	EQ 25MG BASE/5ML	N74374
TRIMIPRAMINE MALEATE		
CAPSULE		
TRIMIPRAMINE MALEATE	EQ 100MG BASE	N71285
TRIMIPRAMINE MALEATE	EQ 25MG BASE	N71283
TRIMIPRAMINE MALEATE	EQ 50MG BASE	N71284
TRIOXSALEN		
TABLET		
TRISORALEN	5MG	N12697
TRIPELENNAMINE CITRATE		
ELIXIR		
PBZ	EQ 25MG HCL/5ML	N05914
TRIPELENNAMINE HYDROCHLORIDE		
TABLET		
PBZ	25MG	N83149
TRIPELENNAMINE HCL	50MG	N83037
TRIPELENNAMINE HCL	50MG	N80744
TRIPELENNAMINE HCL	50MG	N83989
TRIPELENNAMINE HCL	50MG	N80785
TRIPELENNAMINE HCL	50MG	N83557
TRIPELENNAMINE HCL	50MG	N85412
TRIPELENNAMINE HCL	25MG	N83625
TRIPELENNAMINE HCL	50MG	N83626
TRIPELENNAMINE HCL	50MG	N80713
TRIPELENNAMINE HCL	50MG	N80790
TRIPELENNAMINE HCL	50MG	N85188
TABLET, EXTENDED RELEASE		
PBZ-SR	100MG	N10533
PBZ-SR	50MG	N10533
TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)		
CREAM		
GYNE-SULF	3.7%;2.86%;3.42%	N88607
SULTRIN	3.7%;2.86%;3.42%	N05794
TRIPLE SULFA	3.7%;2.86%;3.42%	N87864
TRIPLE SULFA	3.7%;2.86%;3.42%	N87285
TRIPLE SULFA	3.7%;2.86%;3.42%	N86424
TRYSUL	3.7%;2.86%;3.42%	N87887
VAGILIA	3.7%;2.86%;3.42%	N88821
TABLET		
SULTRIN	184MG;143.75MG;172.5MG	N05794
TRIPLE SULFA	184MG;143.75MG;172.5MG	N88463
TRIPLE SULFA	184MG;143.75MG;172.5MG	N88462
TRIPROLIDINE HYDROCHLORIDE		
SYRUP		
ACTIDIL	1.25MG/5ML	N11496
MYIDYL	1.25MG/5ML	N87963
TRIPROLIDINE HCL	1.25MG/5ML	N85940
TRIPROLIDINE HCL	1.25MG/5ML	N88735
TRIPROLIDINE HCL	1.25MG/5ML	N87514

FDA data supplied by DrugPatentWatch.com

TRIPROLIDINE HYDROCHLORIDE		
TABLET		
ACTIDIL	2.5MG	N11110
TRIPROLIDINE HCL	2.5MG	N85610
TRIPROLIDINE HCL	2.5MG	N85094
TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)		
SUSPENSION		
LANTRISUL	167MG/5ML;167MG/5ML;167MG/5ML	N80123
NEOTRIZINE	167MG/5ML;167MG/5ML;167MG/5ML	N06317
SULFALOID	167MG/5ML;167MG/5ML;167MG/5ML	N80100
SULFOSE	167MG/5ML;167MG/5ML;167MG/5ML	N80013
TERFONYL	167MG/5ML;167MG/5ML;167MG/5ML	N06904
TRIPLE SULFA	167MG/5ML;167MG/5ML;167MG/5ML	N80280
TRIPLE SULFAS	167MG/5ML;167MG/5ML;167MG/5ML	N06920
TABLET		
NEOTRIZINE	167MG;167MG;167MG	N06317
SULFALOID	167MG;167MG;167MG	N80099
SULFA-TRIPLE #2	167MG;167MG;167MG	N80079
SULFOSE	167MG;167MG;167MG	N80013
TERFONYL	167MG;167MG;167MG	N06904
TRIPLE SULFA	167MG;167MG;167MG	N80086
TRIPLE SULFAS	167MG;167MG;167MG	N06920
TRIPLE SULFOID	167MG;167MG;167MG	N80094
TROGLITAZONE		
TABLET		
PRELAY	200MG	N20719
PRELAY	300MG	N20719
PRELAY	400MG	N20719
REZULIN	200MG	N20720
REZULIN	300MG	N20720
REZULIN	400MG	N20720
TROLEANDOMYCIN		
SUSPENSION		
TAO	EQ 125MG BASE/5ML	N50332
TROPICAMIDE		
SOLUTION/DROPS		
MYDRIACYL	0.5%	N12111
MYDRIACYL	1%	N12111
MYDRIAFAIR	0.5%	N88274
MYDRIAFAIR	1%	N88230
TROPICAMIDE		
SOLUTION/DROPS		
TROPICAMIDE	1%	N88447
TROPICAMIDE	0.5%	N89171
TUBOCURARINE CHLORIDE		
INJECTABLE		
TUBOCURARINE CHLORIDE	3MG/ML	N06325
TYROPANOATE SODIUM		
CAPSULE		
BILOPAQUE	750MG	N13731
UNDECOYLIUM CHLORIDE; UNDECOYLIUM CHLORIDE IODINE COMPLEX		
SOLUTION		
VIRAC REX	0.5%;1.8%	N11914
URACIL MUSTARD		
CAPSULE		
URACIL MUSTARD	1MG	N12892
UREA		
INJECTABLE		
STERILE UREA	40GM/VIAL	N17698
UREA, C-13		
FOR SOLUTION		
HELICOSOL	125MG/VIAL	N21092
MERETEK UBT KIT (W/ PRANACTIN)	125MG/VIAL	N20586
PYLORI-CHEK BREATH TEST	100MG/VIAL	N20900
UROFOLLITROPIN		
INJECTABLE		
FERTINEX	150 IU/AMP	N19415
METRODIN	150 IU/AMP	N19415
METRODIN	75 IU/AMP	N19415
URSODIOL		
CAPSULE		
ACTIGALL	150MG	N19594
VALPROIC ACID		
CAPSULE		
VALPROIC ACID	250MG	N70431
VALPROIC ACID	250MG	N70195
VALSARTAN		
CAPSULE		
DIOVAN	160MG	N20665
DIOVAN	80MG	N20665
VANCOMYCIN HYDROCHLORIDE		
FOR SOLUTION		
VANCOLED	EQ 250MG BASE/5ML	N63321

FDA data supplied by DrugPatentWatch.com

VANCOMYCIN HYDROCHLORIDE		
FOR SOLUTION		
VANCOLED	EQ 500MG BASE/6ML	N63321
INJECTABLE		
VANCOMYCIN HCL	EQ 1GM BASE/VIAL	N62879
VANCOMYCIN HCL	EQ 500MG BASE/VIAL	N62879
VANCOR	EQ 1GM BASE/VIAL	N62956
VANCOR	EQ 500MG BASE/VIAL	N62956
VASOPRESSIN TANNATE		
INJECTABLE		
PITRESSIN TANNATE	5PRESSOR UNITS/ML	N03402
VECURONIUM BROMIDE		
INJECTABLE		
NORCURON	10MG/VIAL	N18776
NORCURON	20MG/VIAL	N18776
VENLAFAXINE HYDROCHLORIDE		
CAPSULE, EXTENDED RELEASE		
EFFEXOR XR	EQ 100MG BASE	N20699
TABLET		
EFFEXOR	EQ 12.5MG BASE	N20151
VERAPAMIL HYDROCHLORIDE		
INJECTABLE		
CALAN	2.5MG/ML	N18925
CALAN	2.5MG/ML	N19038
VERAPAMIL HCL	2.5MG/ML	N70348
VERAPAMIL HCL	2.5MG/ML	N72233
VERAPAMIL HCL	2.5MG/ML	N73485
VERAPAMIL HCL	2.5MG/ML	N70696
VERAPAMIL HCL	2.5MG/ML	N70697
VERAPAMIL HCL	2.5MG/ML	N70695
TABLET		
CALAN	160MG	N18817
VERAPAMIL HCL	120MG	N71881
VERAPAMIL HCL	80MG	N71880
VERAPAMIL HCL	120MG	N70483
VERAPAMIL HCL	80MG	N70482
VERAPAMIL HCL	120MG	N70341
VERAPAMIL HCL	80MG	N70340
VERAPAMIL HCL	40MG	N72799
TABLET, EXTENDED RELEASE		
VERAPAMIL HCL	120MG	N75072
VERAPAMIL HCL	240MG	N75072
VERATRUM VIRIDE		
TABLET		
VERTAVIS	130CSR UNIT	N05691
VIDARABINE		
INJECTABLE		
VIRA-A	EQ 187.4MG BASE/ML	N50523
OINTMENT		
VIRA-A	3%	N50486
VINBLASTINE SULFATE		
INJECTABLE		
VELBAN	10MG/VIAL	N12665
VINBLASTINE SULFATE	10MG/VIAL	N89011
VINCRISTINE SULFATE		
INJECTABLE		
ONCOVIN	1MG/VIAL	N14103
ONCOVIN	5MG/VIAL	N14103
VINCREX	5MG/VIAL	N70867
VINCRISTINE SULFATE	1MG/ML	N70873
VINCRISTINE SULFATE	1MG/ML	N70411
VINCRISTINE SULFATE	1MG/VIAL	N71559
VINCRISTINE SULFATE	2MG/VIAL	N71560
VINCRISTINE SULFATE	5MG/VIAL	N71561
VIOMYCIN SULFATE		
INJECTABLE		
VIOCIN SULFATE	EQ 1GM BASE/VIAL	N61086
VIOCIN SULFATE	EQ 5GM BASE/VIAL	N61086
VITAMIN A		
CAPSULE		
AQUASOL A	25,000USP UNITS	N83080
AQUASOL A	50,000USP UNITS	N83080
VITAMIN A	50,000USP UNITS	N83973
VITAMIN A	50,000 IU	N83351
VITAMIN A	50,000 IU	N83134
VITAMIN A	50,000USP UNITS	N80952
VITAMIN A	50,000USP UNITS	N80985
VITAMIN A PALMITATE		
CAPSULE		
AFAXIN	EQ 50,000 UNITS BASE	N83187
ALPHALIN	EQ 50,000 UNITS BASE	N80883
DEL-VI-A	EQ 50,000 UNITS BASE	N80830
VI-DOM-A	EQ 50,000 UNITS BASE	N80972
VITAMIN A	EQ 50,000 UNITS BASE	N80702
VITAMIN A	EQ 50,000 UNITS BASE	N80860
VITAMIN A	EQ 50,000 UNITS BASE	N80746
VITAMIN A	EQ 50,000 UNITS BASE	N83207

FDA data supplied by DrugPatentWatch.com

VITAMIN A PALMITATE			
CAPSULE			
VITAMIN A	EQ 50,000 UNITS BASE	N85479	
VITAMIN A	EQ 50,000 UNITS BASE	N80943	
VITAMIN A	EQ 50,000 UNITS BASE	N83114	
VITAMIN A	EQ 50,000 UNITS BASE	N80953	
VITAMIN A	EQ 50,000 UNITS BASE	N80955	
VITAMIN A	EQ 50,000 UNITS BASE	N83035	
VITAMIN A	EQ 50,000 UNITS BASE	N83190	
VITAMIN A	EQ 50,000 UNITS BASE	N80967	
VITAMIN A	EQ 50,000 UNITS BASE	N83665	
VITAMIN A PALMITATE	EQ 50,000 UNITS BASE	N83948	
VITAMIN A PALMITATE	EQ 50,000 UNITS BASE	N83981	
VITAMIN A SOLUBILIZED	EQ 50,000 UNITS BASE	N80921	
INJECTABLE			
VITAMIN A PALMITATE	EQ 50,000 UNITS BASE/ML	N80819	
WARFARIN POTASSIUM			
TABLET			
ATHROMBIN-K	10MG	N11771	
ATHROMBIN-K	25MG	N11771	
ATHROMBIN-K	2MG	N11771	
ATHROMBIN-K	5MG	N11771	
WARFARIN SODIUM			
INJECTABLE			
COUMADIN	50MG/VIAL	N09218	
COUMADIN	75MG/VIAL	N09218	
TABLET			
ATHROMBIN	10MG	N11771	
ATHROMBIN	25MG	N11771	
ATHROMBIN	5MG	N11771	
PANWARFIN	10MG	N17020	
PANWARFIN	2.5MG	N17020	
PANWARFIN	2MG	N17020	
PANWARFIN	5MG	N17020	
PANWARFIN	7.5MG	N17020	
WARFARIN SODIUM	2.5MG	N88720	
WARFARIN SODIUM	2MG	N88719	
WARFARIN SODIUM	5MG	N88721	
WARFARIN SODIUM	10MG	N86122	
WARFARIN SODIUM	2.5MG	N86120	
WARFARIN SODIUM	2MG	N86123	
WARFARIN SODIUM	5MG	N86119	
WARFARIN SODIUM	7.5MG	N86118	
WATER FOR INJECTION, STERILE			
LIQUID			
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER	100%	N89099	
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER	100%	N89100	
WATER FOR IRRIGATION, STERILE			
LIQUID			
STERILE WATER IN PLASTIC CONTAINER	100%	N18246	
XENON, XE-127			
GAS			
XENON XE 127	10mCi/VIAL	N18536	
XENON XE 127	5mCi/VIAL	N18536	
XENON, XE-133			
GAS			
XENON XE 133	1 CI/AMP	N17256	
XENON XE 133	10mCi/VIAL	N17687	
XENON XE 133	20mCi/VIAL	N17687	
XENON XE 133-V.S.S.	10mCi/VIAL	N17687	
INJECTABLE			
XENON XE 133	1.3-1.7 CI/AMP	N17256	
XENON XE 133	6.3mCi/ML	N17283	
SOLUTION			
XENEISOL	18-25mCi/AMP	N17262	
XYLOSE			
POWDER			
XYLO-PFAN	25GM/BOT	N17605	
XYLOSE	25GM/BOT	N18856	
ZIDOVUDINE			
TABLET			
RETROVIR	200MG	N20518	
ZILEUTON			
TABLET			
ZYFLO	300MG	N20471	
ZINC SULFATE			
INJECTABLE			
ZINC SULFATE	EQ 1MG ZINC/ML	N19229	

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS
Through December 31, 2003

The List is provided by the Office of Orphan Products Development and is not edited prior to publication.

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved= MA*	*Indication Designation*	*Sponsor and Address*
(+/-)-7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid	DD: 3/31/2003	Prevention of serious adverse events associated with vascular leak syndrome caused by Interleukin-2 therapy	BioMedicines, Inc. 2000 Powell Street
	MA:		Suite 1640 Emeryville CA 94608
(4S)-4-ethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1-H-pyrano[3?,4?:6,7]-indolizino-[1,2-b]-quinoline-11-carbaldehyde O-(tert-butyl)-(E)-oxime *Gimatecan*	DD: MA: MA:	Treatment malignant glioma	Sigma-Tau Research, Inc. 800 South Frederick Avenue Suite 103 Gaithersburg MD 20877-4150
(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide	DD: 10/3/2001 MA:	Treatment of circadian rhythm sleep disorders in blind people with no light perception	Phase 2 Discovery, Inc. 3130 Highland Avenue, Third Floor Cincinnati OH 45219-2374
(R)-N-[2-(6-Chloro-methoxy-1H-indol-3yl)propyl]acetamide	DD: 7/3/2003 MA:	Treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients	Phase 2 Discovery, Inc. 3130 Highland Ave. Third Floor Cincinnati OH 45219
1,1'-[1,4-phenylenebis(methylene)-bis-1,4,8,11-tetraazacyclotetradecan	DD: 7/10/2003 MA:	For combination use with filgrastim to improve the yield of progentor cells in the apheresis product for subsequest stem cell transplantation following myelosuppressive or myeloablative chemotherapy	AnorMED Inc. 200-20353 64th Avenue Langley, BC, V2Y IN5
1,5-(Butylimino)-1,5 dideoxy,D-glucitol	DD: 5/12/1998 MA:	Treatment of Fabry's disease.	Oxford GlycoSciences 10, The Quadrant Abington Science Park, Abington
1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine hydrogen methanesulfonate	DD: 1/18/2000 MA:	Treatment of hormone refractory prostate carcinoma.	Cell Therapeutics, Inc. 201 Elliott Avenue West Suite 400 Seattle WA 98119
111Indium pentetreotide *SomatoTher*	DD: 6/10/1999 MA:	Treatment of somatostatin receptor positive neuroendocrine tumors.	Louisiana State University Medical Center Foundation 1600 Canal St. 10th Floor New Orleans LA 70112

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
166Ho-DOTMP	DD: 2/10/1999 MA:	Treatment of multiple myeloma.	NeoRx Corporation 410 W. Harrison Street Seattle WA 98119-4007
2',3',5'-tri-o-acetyluridine	DD: 1/13/2003 MA:	Treatment of mitochondrial disease	Repligen Corporation 41 Seyon Street Building 1, Suite 100 Waltham MA 02453
2'-3'-dideoxyadenosine	DD: 7/21/1987 MA:	Treatment of aquired immunodeficiency syndrome.	National Cancer Institute, Dct NIH, Exec. Plaza N., Room 7-18 Bethesda MD 20892
2'-deoxycytidine	DD: 9/9/1996 MA:	As a host-protective agent in the treatment of acute myelogenous leukemia.	Grant, Steven M.D. Massey Cancer Center, VCU P.O. Box 980230 Richmond VA 23298-0230
2-(3-diethylaminopropyl)-8,8-dipropyl-2-azaspiro [4,5] decan dimaleate *Atiprimod*	DD: 12/2/2003 MA: MA:	Treatment of mulitple myeloma and associated bone resorption	Callisto Pharmaceuticals, Inc. 2 Executive Drive Suite 450 Somerset NJ 08873
2-0-Butyryl-1-0-octyl-myo-inositol 3,4,5,6-tetrakisphosphate	DD: 8/15/2003 MA:	Treatment of cystic fibrosis	Inologic, Inc. 101 Elliott Ave., West Seattle WA 98119
2-0-desulfated heparin *Aeropin*	DD: 9/17/1993 MA:	Treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s University of Utah Health Sciences Center 50 North Medical Drive, Room 4R240 Salt Lake City UT 84132
2-chloroethyl-3-sarcosinamide-1-nitrosourea *Sarmustine*	DD: MA: MA:	Treatment for malignant glioma	Pangene Corporation 5500 Stewart Avenue Fremont CA 94538
2-chloroethyl-3-sarcosinamide-1-nitrosourea	DD: 8/3/2001 MA:	Treatment for malignant gliomas	Lawrence Panasci, MD Professor of Medicine, McGill University 3755 Cote Ste Catherine
2-methoxyestradiol *Panzem*	DD: 7/10/2001 MA:	Treatment of multiple myeloma	EntreMed, Inc. 9640 Medical Center Drive Rockville MD 20850
24,25 dihydroxycholecalciferol	DD: 2/27/1987 MA:	Treatment of uremic osteodystrophy.	Lemmon Company 1510 Delp Drive Kulpsville PA 19443

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
3'-azido-2',3'dideoxyuridine *AZDU*	DD: MA:	Treatment of acquired immunodeficiency syndrome.	Berlex Laboratories, Inc. 1401 Harbor Bay Parkway 1401 Harbor Bay Parkway Alameda CA 94501
3,4-diaminopyridine	DD: MA:	Treatment of Lambert-Eaton myasthenic syndrome.	Jacobus Pharmaceutical Company 37 Cleveland Avenue P.O. Box 5290 Princeton NJ 08540
3,5,3'-triiodothyroacetate	DD: 9/20/2000 MA: MA:	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid gland.	Elliot Danforth, Jr., M.D. University of Vermont 84 Beartown Road Underhill VT 05489
3-(3,5-dimethyl-1H-2ylmethylene)-1, 3-dihydro-indol-2-one	DD: 9/11/1998 MA:	Treatment of Kaposi's sarcoma.	Sugen, Inc. 230 East Grand Ave. South San Francisco CA 94080-4811
3-(3,5-Dimethyl-1H-2ylmethylene)-1, 3-dihydro-indol-2-one	DD: 3/23/2000 MA:	Treatment of von Hippel-Lindau disease.	Sugen, Inc. 230 East Grand Ave. South San Francisco CA 94080
3-(4'aminoisoindoline-1'-one)-1-piperidine-2,6-dione *Revimid (proposed)*	DD: 9/20/2001 MA: MA:	Treatment for multiple myeloma	Celegene Corporation 7 Powder Horn Drive Warren NJ 07059
4,5-dibromorhodamine 123 *Theralux Irradiation Device*	DD: 4/10/2003 MA:	Treatment of chronic myelogenous leukemia	Celmed BioSciences Inc. 2310 boul Alfred-Nobel Saint-Laurent, Quebec
4-aminosalicylic acid *Pamisyl (P-D), Rezipas (Squibb)*	DD: MA:	Treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.	Beeken, Warren M.D. University Of Vermont University Of Vermont Given C-317 Burlington VT 05405
40SD02	DD: MA: MA:	Treatment of chronic iron overload resulting from conventional transfusional treatment of anemia. beta-thalassemia major and sickle cell	Biomedical Frontiers, Inc. 1095 10th Ave., S.E. Minneapolis MN 55414
5,5',5"-[Phosphinothioylidyne-tris(Imino-2,1-ethanediyl)]tris[5-methylchelidoninium]trihydroide hexahydrochloride	DD: 8/20/2003 MA:	Treatment of pancreatic cancer	Now Pharm AG 241, route d'Arlon L-1150
5,6-dihydro-5-azacytidine	DD: 5/11/1992 MA:	Treatment of malignant mesothelioma.	ILEX Oncology, Inc. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
5-aza-2'-deoxycytidine	DD: 8/3/1987 MA:	Treatment of acute leukemia.	SuperGen, Inc. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
506U78	DD: 9/2/1999 MA:	Treatment of chronic lymphocytic leukemia.	GlaxoSmithKline Five Moore Dr. P.O. Box 13398 Research Triangle Park NC 27709-3398
5a8, monoclonal antibody to CD4	DD: MA: MA:	For use in post-exposure prophylaxis for occupational exposure to human immunodeficiency virus.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
6-hydroxymethylacylfulvene	DD: 4/6/1999 MA:	Treatment of histologically confirmed advanced or metastatic pancreatic cancer.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington MN 55438-2318
8 Cyclopentyl 1,3-dipropylxanthine	DD: 3/24/1997 MA:	Treatment of cystic fibrosis.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Boulevard San Mateo CA 94404-1593
8-methoxsalen *Uvadex*	DD: 6/22/1993 MA: MA:	For use in conjunction with the UVAR photopheresis to treat diffuse systemic sclerosis.	Therakos, Inc. Oaklands Corporate Center Oaklands Corporate Center 437 Creamery Way Exton PA 19341
8-methoxsalen *Uvadex*	DD: 5/12/1994 MA:	For the prevention of acute rejection of cardiac allografts.	Therakos, Inc. Oaklands Corporate Center Oaklands Corporate Center 437 Creamery Way Exton PA 19341
9-cis retinoic acid *Panretin*	DD: 4/10/1992 MA:	Treatment of acute promyelocytic leukemia.	Ligand Pharmaceuticals, Inc. 10275 Science Center Dr. San Diego CA 92121-1117
9-cis-retinoic acid	DD: 1/2/1997 MA:	Prevention of retinal detachment due to proliferative vitreoretinopathy.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine CA 92623-9534
9-nitro-20-(S)-camptothecin	DD: 9/16/1996 MA:	Treatment of pancreatic cancer.	SuperGen, Inc. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
9-nitro-20-(S)-camptothecin *Camvirex*	DD: 5/15/2001 MA:	Treatment of pediatric HIV infection/AIDS	NovoMed Pharmaceuticals, Inc. P.O. Box 900 Germantown MD 20875-0900

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
a-(3-aminophthalimido) *Actimid*	DD: 1/15/2003 MA: MA:	Treatment of multiple myeloma	Celgene Corporation 7 Powder Horn Drive Warren NJ 07059
a-Galactosidase A *Plant-Produced Human a-Glactosidase*	DD: 1/21/2003 MA:	Treatment of Fabry's disease	Large Scale Biology Corporation 3333 Vacaville Parkway Suite 1000 Vacaville CA 95688
Abetimus	DD: 7/28/2000 MA:	Treatment of lupus nephritis.	La Jolla Pharmaceutical Co. 6455 Nancy Ridge Dr. San Diego CA 92121
ACA125	DD: MA:	Treatment of epithelial ovarian cancer	CellControl Biomedical Laboratories AG Am Klopferspitz 19 D-82152
Acetylcysteine *Mucomyst/Mucomyst 10 IV*	DD: 8/13/1987 MA: MA:	Intravenous treatment of patients presenting with moderate to severe acetaminophen overdose.	Bristol-Myers Squibb Company P.O. Box 4500 P.O. Box 4500 Princeton NJ 08543-4500
acetylcysteine *Acetadote*	DD: MA:	For the intravenous treatment of moderate to severe acetaminophen overdose	Ligand 209 10th Street South 209 10th Street South Suite 332 Nashville TN 37203
Acid sphingomyelinase	DD: 8/3/2000 MA:	Treatment of Niemann-Pick disease type B.	Genzyme Corporation One Kendall Square Cambridge MA 02139
Aconiazide	DD: 6/20/1988 MA:	Treatment of tuberculosis.	Lincoln Diagnostics P.O. Box 1128 Decatur IL 62525
Adeno-associated viral vector containing the gene for human coagulation factor IX *Coagulin-B*	DD: 6/13/2001 MA: MA:	Intrahepatic treatment of patients with moderate to severe hemophilia	Avigen, Inc. 1301 Harbor Bay Parkway Alameda CA 94502
Adeno-associated viral vector containing the gene for human coagulation factor IX *Coagulin-B*	DD: 6/13/2001 MA: MA:	Intramuscular treatment of patients with moderate to severe hemophilia	Avigen, Inc. 1301 Harbor Bay Parkway Alameda CA 94502
Adeno-associated viral-based vector cystic fibrosis gene therapy	DD: 2/15/1995 MA:	Treatment of cystic fibrosis.	Targeted Genetics Corporation 1100 Olive Way, Suite 100 Seattle WA 98101

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Adenosine	DD: 8/1/1989 MA:	For use in conjunction with BCNU in the treatment of brain tumors.	Medco Research, Inc. 8455 Beverly Boulevard Suite 308 Los Angeles CA 90048
Adenovirus-based vector Factor VIII complementary DNA to somatic *MiniAdFVIII*	DD: MA: MA:	Treatment of hemophilia A.	GenStar Therapeutics Corporation 10835 Altman Row Suite 150 San Diego CA 92121
adenovirus-mediated herpes simplex virus-thymidine kinase	DD: 7/31/2001 MA:	Use with gancyclovir in the treatment of malignant glioma	Ark Therapeutics Ltd 6 Warren Mews
Aerosolized pooled immune	DD: 1/3/1989 MA:	Treatment of respiratory syncytial virus lower respiratory tract disease.	Pediatric Pharmaceuticals, Inc. 718 Bradford Avenue Westfield NJ 07090
AI-RSA	DD: 10/8/1992 MA:	Treatment of autoimmune uveitis.	AutoImmune, Inc. 128 Spring Street Lexington MA 02173
Albendazole *Albenza*	DD: 1/18/1996 MA: 6/11/1996 MA: 6/11/1996	Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis.	SmithKline Beecham Pharmaceuticals One Franklin Plaza One Franklin Plaza P.O. Box 7929 Philadelphia PA 19101
Albendazole *Albenza*	DD: 1/17/1996 MA: 6/11/1996 MA: 6/11/1996	Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).	SmithKline Beecham Pharmaceuticals One Franklin Plaza One Franklin Plaza P.O. Box 7929 Philadelphia PA 19101
albuterol	DD: 3/12/2002 MA:	Prevention of paralysis due to spinal cord injury	MotoGen, Inc. 3 Pine View Road Mount Kisco NY 10549
Aldesleukin *Proleukin*	DD: 9/14/1988 MA: 5/5/1992	Treatment of metastatic renal cell carcinoma.	Chiron Corporation 4560 Horton Street 4560 Horton Street Emeryville CA 94608-2916
Aldesleukin *Proleukin*	DD: 3/22/1989 MA:	Treatment of primary immunodeficiency disease associated with T-cell defects.	Chiron Corporation 4560 Horton Street 4560 Horton Street Emeryville CA 94608-2916
Aldesleukin *Proleukin*	DD: MA:	For the treatment non-Hodgkin's lymphoma.	Chiron Corporation 4560 Horton St. Emeryville CA 94608-2916

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Aldesleukin *Proleukin*	DD: 7/31/1998 MA:	Treatment of acute myelogenous leukemia.	Chiron Corporation 4560 Horton St. Emeryville CA 94608-2916
Aldesleukin *Proleukin*	DD: 9/10/1996 MA: 1/9/1998	Treatment of metastatic melanoma.	Chiron Corporation 4560 Horton Street Emeryville CA 94608-2916
alemtuzumab *Campath*	DD: MA: 5/7/2001	Treatment of chronic lymphocytic leukemia.	Millennium and ILEX Partners, LP 75 Sidney Street Cambridge MA 02138
alendronate *Fosamax*	DD: 3/31/2003 MA:	Treatment of osteogenesis imperfecta in pediatric patients 4 years of age and older	Merck & Co., Inc. 126 East Lincoln Ave. 126 East Lincoln Ave. Rahway NJ 07065-0900
Alendronate disodium *Fosamax*	DD: 2/13/2001 MA:	Treatment of the bone manifestations of Gaucher disease	Richard J. Wenstrup, M.D. Division of Human Genetics Division of Human Genetics Children's Hospital Research Foundation Cincinnati OH 45229-3039
Alglucerase injection *Ceredase*	DD: 7/21/1995 MA:	Replacement therapy in patients with Type II and III Gaucher's disease.	Genzyme Corporation One Kendall Square One Kendall Square Cambridge MA 02139-1562
Alglucerase injection *Ceredase*	DD: 3/11/1985 MA: 4/5/1991	For replacement therapy in patients with Gaucher's disease type I.	Genzyme Corporation One Kendall Square One Kendall Square Cambridge MA 02139-1562
Alitretinoin *Panretin*	DD: 3/24/1998 MA: 2/2/1999	Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive 10275 Science Center Drive San Diego CA 92121-1117
allantoin *Alwextin*	DD: MA: MA:	Treatment of skin blistering and erosions associated with inherited epidermolysis bullosa	Alwyn Company, Inc. 2301 Highway 60 East 2301 Highway 60 East Lake Crystal MN 56055
Allogeneic human retinal pigment epithelial cells on gelatin microcarriers *Spheramine*	DD: 7/18/1997 MA: MA:	Treatment of Hoehn and Yahr stage 3 and 4 Parkinson's disease.	Titan Pharmaceuticals, Inc. Post Office Plaza 50 Division Street, Suite 503 Somerville NJ 08876
Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture *CYTOIMPLANT*	DD: 6/13/1997 MA: MA:	Treatment of pancreatic cancer.	Applied Immunotherapeutics, LLC 14132 E. Firestone Boulevard Santa Fe Springs CA 90670

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Allopurinol riboside	DD: 12/4/1985 MA:	Treatment of Chagas' disease.	Burroughs Wellcome Company 3030 Cornwallis Road P.O. Box 12700 Research Triangle Park NC 27709
Allopurinol riboside	DD: 12/4/1985 MA:	Treatment of cutaneous and visceral leishmaniasis.	Burroughs Wellcome Company 3030 Cornwallis Road P.O. Box 12700 Research Triangle Park NC 27709
Allopurinol sodium *Aloprim for Injection*	DD: MA: 5/17/1996 MA: 5/17/1996	Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral	Catalytica Pharmaceuticals, Inc PO Box 1887 PO Box 1887 Greenville NC 27835-1887
Allopurinol sodium	DD: 11/9/1987 MA:	Ex-vivo preservation of cadaveric kidneys for transplantation	Burroughs Wellcome Company 3030 Cornwallis Road Research Triangle Pk NC 27709
Alpha-1-antitrypsin (recombinant DNA Origin)	DD: 1/1/1984 MA:	As supplementation therapy for alpha-1-antitrypsin deficiency in the ZZ phenotype population.	Chiron Corporation 4560 Horton Street Emeryville CA 94608-2916
Alpha-galactosidase A *CC-galactosidase*	DD: 6/17/1991 MA:	Treatment of alpha-galactosidase A deficiency (Fabry's disease).	Orphan Medical, Inc. 13911 Ridgedale Drive 13911 Ridgedale Drive Suite 475 Minnetonka MN 55305
Alpha-galactosidase A *Replagal*	DD: 6/22/1998 MA:	Long-term enzyme replacement therapy for the treatment of Fabry disease.	Transkaryotic Therapies Inc. 195 Albany St. 195 Albany St. Cambridge MA 02139
Alpha-galactosidase A *Fabrase*	DD: 7/20/1990 MA:	Treatment of Fabry's disease.	Desnick, Robert J. M.D. The Mount Sinai School Of Medicine Fifth Avenue at 100th Street, Box New York NY 10029
Alpha-melanocyte stimulating hormone	DD: 8/19/1997 MA:	Prevention and treatment of intrinsic acute renal failure due to ischemia.	National Institute of Diabetes, and Digestive and Kidney Diseases National Institutes of Health, 31 Center Drive MSC Building 31, Room 9N-222 Bethesda MD 20892-2560
Alpha1-proteinase inhibitor	DD: MA:	For slowing the progression of emphysema in alpha1-antitrypsin deficient patients.	Aventis Behring L.L.C. 1020 First Ave. PO Box 61501 King of Prussia PA 19406-0901
Alpha1-proteinase inhibitor *Prolastin*	DD: 12/7/1984 MA: 12/2/1987 MA: 12/2/1987	For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.	Bayer Corporation Pharmaceutical Division, Biological Pharmaceutical Division, Biological Products 400 Morgan Lane New Haven CT 06516

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Alprostadil	DD: MA: MA:	Treatment of severe peripheral arterial occlusive disease (critical limb ischemia) in angioplasty, are not indicated. patients where other procedures, grafts or	Schwarz Pharma, Inc. P.O. Box 2038 Milwaukee WI 53201
alteplase *Activase*	DD: 1/27/2003 MA:	Treatment of intraventricular hemmorage associated with intracerebral hemmorrhage	Daniel F. Hanley, MD Johns Hopkins University Johns Hopkins University 600 N. Wolfe St., Jefferson 1-109 Baltimore MD 21287
Altretamine *Hexalen*	DD: 2/9/1984 MA:	Treatment of advanced adenocarcinoma of the ovary.	Medimmune Oncology, Inc. One Tower Bridge One Tower Bridge 100 Front Street, Suite 400 Conshohocken PA 19428
AMG 531	DD: 3/27/2003 MA:	Treatment of immune thrombocytopenic purpura.	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799
Amifostine *Ethyol*	DD: MA: MA:	For the reduction of the incidence and severity of toxicities associated with cisplatin administration.	Medimmune Oncology, Inc. 35 West Watkins Mill Rd. 35 West Watkins Mill Rd. Gaithersburg MD 20878
Amifostine *Ethyol*	DD: 5/30/1990 MA: MA:	For use as a chemoprotective agent for cyclophosphamide in the treatment of advanced ovarian carcinoma.	Medimmune Oncology, Inc. 35 West Watkins Mill Rd. 35 West Watkins Mill Rd. Gaithersburg MD 20878
Amifostine *Ethyol*	DD: 5/12/1998 MA: 6/24/1999 MA: 6/24/1999	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	Medimmune Oncology, Inc. One Tower Bridge One Tower Bridge 100 Front Street, Suite 400 Conshohocken PA 19428
Amifostine *Ethyol*	DD: 10/4/1999 MA:	Treatment of myelodysplastic syndromes.	Medimmune Oncology, Inc. 35 West Watkins Mill Rd. Gaithersburg MD 20878
Amifostine *Ethyol*	DD: 5/30/1990 MA: MA:	For use as a chemoprotective agent for cisplatin in the treatment of metastatic melanoma.	Medimmune Oncology, Inc. 35 West Watkins Mills Rd. 35 West Watkins Mills Rd. Gaithersburg MD 20878
Amifostine *Ethyol*	DD: 5/30/1990 MA: 12/8/1995 MA: 12/8/1995	For use as a chemoprotective agent for cisplatin in the treatment of advanced ovarian carcinoma.	Medimmune Oncology, Inc. One Tower Bridge One Tower Bridge 100 Front Street, Suite 400 West Conshohocken PA 19428
Amiloride HCl solution for	DD: 7/18/1990 MA:	Treatment of cystic fibrosis.	Glaxo Wellcome Research and Development 5 Moore Drive PO Box 13398 Research Triangle Park NC 27709

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Aminocaproic acid *Caprogel*	DD: 1/6/1995 MA:	For the topical treatment of traumatic hyphema of the eye.	Eastern Virginia Medical School Department of Ophthalomology Department of Ophthalomology 880 Kempsville Road, Suite 2500 Norfolk VA 23502-3990
Aminosalicylate sodium	DD: 4/6/1993 MA:	Treatment of Crohn's disease.	Syncom Pharmaceuticals, Inc. 66 Hanover Road Florham Park NJ 07932
Aminosalicylic acid *Paser Granules*	DD: 2/19/1992 MA: 6/30/1994	Treatment of tuberculosis infections.	Jacobus Pharmaceutical Company 37 Cleveland Lane P.O. Box 5290 Princeton NJ 08540
Aminosidine *Gabbromicina*	DD: 5/14/1993 MA:	Treatment of tuberculosis.	Kanyok, Thomas P. Pharm.D. University Of Illinois At Chicago College of Pharm 833 South Wood Street (m/c886) Rm. 176 Chicago IL 60612
Aminosidine *Paromomycin*	DD: 9/9/1994 MA:	Treatment of visceral leishmaniasis (kala-azar).	Kanyok, Thomas P. Pharm.D. University of Illinois at Chicago University of Illinois at Chicago College of Pharm 833 South Wood Street (m/c886) Rm. 176 Chicago IL 60612
Aminosidine *Gabbromicina*	DD: MA:	Treatment of Mycobacterium avium complex.	Kanyok, Thomas P. Pharm.D. University of Illinois at Chicago University of Illinois at Chicago College of Pharm 833 South Wood Street (m/c886) Rm. 176 Chicago IL 60612
Amiodarone *Amio-Aqueous*	DD: 8/17/1993 MA:	Treatment of incessant ventricular tachycardia.	Academic Pharmaceuticals, Inc. 21 N. Skokie Valley Highway 21 N. Skokie Valley Highway Suite G3 Lake Bluff IL 60044
Amiodarone HCl *Cordarone*	DD: 3/16/1994 MA: 8/3/1995 MA: 8/3/1995	For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.	Wyeth-Ayerst Laboratories P.O. Box 8299 P.O. Box 8299 Philadelphia PA 19101
Ammonium tetrathiomolybdate	DD: 1/31/1994 MA:	Treatment of Wilson's disease.	Brewer, George J. M.D. University Of Michigan Medical 4708 Medical Science Building II 0618 Ann Arbor MI 48109
Amphotericin B lipid complex *Abelcet*	DD: 5/6/1996 MA:	Treatment of invasive zygomycosis.	The Liposome Company, Inc. One Research Way Princeton NJ 08540

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Amphotericin B lipid complex *Abelcet*	DD: 6/27/1996 MA:	Treatment of invasive candidiasis.	The Liposome Company, Inc. One Research Way Princeton NJ 08540
Amphotericin B lipid complex *Abelcet*	DD: 9/23/1996 MA:	Treatment of invasive sporotrichosis.	The Liposome Company, Inc. One Research Way Princeton NJ 08540
Amphotericin B lipid complex *Abelcet*	DD: 5/6/1996 MA:	Treatment of invasive coccidioidomycosis.	The Liposome Company, Inc. One Research Way Princeton NJ 08540
Amphotericin B lipid complex *Abelcet*	DD: 8/21/1996 MA:	Treatment of invasive protothecosis.	The Liposome Company, Inc. One Research Way Princeton NJ 08540
Amphotericin B lipid complex *Abelcet*	DD: 12/5/1991 MA:	Treatment of invasive fungal infections.	Liposome Company, Inc. One Research Way Princeton NJ 08540
Amsacrine *Amsidyl*	DD: 12/7/1984 MA:	Treatment of acute adult leukemia.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor MI 48106
Anagrelide *Agrylin*	DD: 6/11/1985 MA:	Treatment of polycythemia vera.	Roberts Pharmaceutical Corp. Meridian Center II 4 Industrial Way West Eatontown NJ 07724-2274
Anagrelide *Agrylin*	DD: 7/14/1986 MA:	Treatment of thrombocytosis in chronic myelogenous leukemia.	Roberts Pharmaceutical Corp. Meridian Center II Meridian Center II 4 Industrial Way West Eatontown NJ 07724-2274
Anagrelide *Agrylin*	DD: 1/27/1988 MA: 3/14/1997	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp. Meridian Center III 6 Industrial Way West Eatontown NJ 07724
Ananain, comosain *Vianain*	DD: 1/21/1992 MA:	For the enzymatic debridement of severe burns.	Genzyme Corporation One Kendall Square One Kendall Square Cambridge MA 02139
Anaritide acetate *Auriculin*	DD: 4/10/1992 MA:	Improvement of early renal allograft function following renal transplantation.	Scios, Inc. 2450 Bayshore Parkway 2450 Bayshore Parkway Mountain View CA 94043

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Anaritide acetate *Auriculin*	DD: 8/27/1992 MA:	Treatment of patients with acute renal failure.	Scios, Inc. 2450 Bayshore Parkway 2450 Bayshore Parkway Mountain View CA 94043
Ancestim *Stemgen*	DD: 7/5/1995 MA: MA:	For use in combination with filgrastim to decrease the number of phereses required to collect peripheral blood progenitor cells capable of providing rapid multi-lineage hematopoietic reconstitution following myelosuppressive or myeloablative therapy.	Amgen, Inc. One Amgen Center Drive One Amgen Center Drive Thousand Oaks CA 91320-1799
Ancrod *Viprinex*	DD: MA: MA:	To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.	Knoll Pharmaceutical Company 3000 Continental Dr., North 3000 Continental Dr., North Mt. Olive NJ 07828
Angiotensin 1-7	DD: 2/16/2000 MA:	Treatment of neutropenia associated with autologous bone marrow transplantation.	Maret Pharmaceuticals 4041 MacArthur Blvd. Suite 375 Newport Beach CA 92660
Angiotensin 1-7 *MARstem*	DD: 8/3/2001 MA:	Treatment of myelodysplastic syndrome	Maret Pharmaceutical Corporation 4041 MacArthur Boulevard, Suite 375 Newport Beach CA 92660
Anti pan T lymphocyte monoclonal antibody *Anti-t Lymphocyte Immunotoxin*	DD: 1/29/1986 MA: MA:	For in-vivo treatment of bone marrow recipients to prevent graft rejection and graft versus host disease.	Xoma Corporation 2910 Seventh Street Berkeley CA 94710
Anti pan T lymphocyte monoclonal antibody *Anti-t Lymphocyte Immunotoxin*	DD: 1/29/1986 MA: MA:	For ex-vivo treatment to eliminate mature T cells from potential bone marrow grafts.	Xoma Corporation 2910 Seventh Street Berkeley CA 94710
anti-CD23 IgG1, kappa monoclonal antibody	DD: 2/12/2003 MA:	Treatment of chronic lymphocytic leukemia	IDEC Pharmaceuticals, Inc. 3030 Callan Road San Diego CA 92121
Anti-CD45 monoclonal antibodies	DD: 9/10/1990 MA:	Prevention of acute graft rejection of human organ transplants.	Baxter Healthcare Corporation 1620 Waukegan Road Mcgaw Park IL 60085
Anti-CEA Sheep-human chimeric monoclonal antibody labeled w/iodine-131 (KAb201)	DD: 5/21/2003 MA:	Treatment of pancreatic cancer	KS Biomedix Ltd Ground Floor, 1 Occam Court Surrey Research Park
Anti-cytomegalovirus monoclonal antibodies	DD: 5/3/1990 MA:	Prevention of human cytomegalovirus infection in patients diagnosed with AIDS.	Biomedical Research Institute 345 North Smith Avenue St. Paul MN 55102

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Anti-cytomegalovirus monoclonal antibodies	DD: 5/2/1990 MA:	Treatment of human cytomegalovirus infection in bone marrow and organ transplant patients.	Biomedical Research Institute 345 North Smith Avenue St. Paul MN 55102
Anti-cytomegalovirus monoclonal antibodies	DD: 5/2/1990 MA:	Prevention of human cytomegalovirus infection in bone marrow and organ transplant patients.	Biomedical Research Institute 345 North Smith Avenue St. Paul MN 55102
Anti-cytomegalovirus monoclonal antibodies	DD: 5/3/1990 MA:	Treatment of human cytomegalovirus infection in patients diagnosed with AIDS.	Biomedical Research Institute 345 North Smith Avenue St. Paul MN 55102
anti-interferon-gamma Fab from goats	DD: MA:	For the treatment of immunologic corneal allograft rejection	Advanced Biotherapy, Inc. 6355 Topanga Canyon Blvd. Suite 510 Woodland Hills CA 91367
Anti-tap-72 immunotoxin *Xomazyme-791*	DD: 3/6/1987 MA:	Treatment of metastatic colorectal adenocarcinoma.	Xoma Corporation 2910 Seventh Street 2910 Seventh Street Berkeley CA 94710
Anti-thymocyte Globulin (Rabbitt) *Thymoglobulin*	DD: 9/6/2000 MA:	Treatment of myelodysplastic syndrome (MDS)	SangStat Medical Corporation 6300 Dumbarton Circle 6300 Dumbarton Circle Freemont CA 94555
Anti-thymocyte serum *Nashville Rabbit Anti-thymocyte Serum*	DD: 6/2/1993 MA: MA:	Treatment of allograft rejection, including solid organ (kidney, liver, heart, lung, and pancreas) and bone marrow transplantation.	Applied Medical Research 1600 Hayes Street 1600 Hayes Street Nashville TN 37203
antiangiogenic components extracted from marine cartilage *Neovastat (AE-941)*	DD: MA:	Treatment of renal cell carcinoma	AEterna Laboratories, Inc. Dr. Claude Hariton, Chief Medical Officer, VP, Cli 1405 boul. Du Parc - Technologique
Antiepilepsirine	DD: 3/23/1989 MA:	Treatment of drug resistant generalized tonic-clonic epilepsy in children and adults.	Children's Hospital 700 Children's Drive Columbus OH 43205
Antihemophilic factor (human) *Alphanate*	DD: 1/5/1996 MA:	Treatment of von Willebrand's disease.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles CA 90032-3520
Antihemophilic factor *ReFacto*	DD: 2/8/1996 MA: MA:	For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).	Genetics Institute, Inc. 87 CambridgePark Drive 87 CambridgePark Drive Cambridge MA 02140

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Antihemophilic factor *Kogenate*	DD: 9/25/1989 MA: 2/25/1993 MA: 2/25/1993	Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.	Bayer Corporation 1884 Miles Avenue 1884 Miles Avenue Elkhart IN 46515
Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized *Humate-P*	DD: MA: 4/1/1999	Treatment and prevention of bleeding in hemophilia A (classical hemophilia) in adult patients; and treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease, and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate in adult and pediatric patients.	Aventis Behring L.L.C. 1020 First Avenue PO Box 61501 King Of Prussia PA 19406-0901
Antimelanoma Antibody XMMME-001-DTPA 111 Indium *Antimelanoma Antibody*	DD: MA: MA:	Diagnostic use in imaging systemic and nodal melanoma metastasis.	Xoma Corporation 2910 Seventh Street Berkeley CA 94710
Antimelanoma Antibody XMMME-001-RTA *Antimelanoma Antibody*	DD: MA: MA:	Treatment of stage III melanoma not amenable to surgical resection.	Xoma Corporation 2910 Seventh Street Berkeley CA 94710
Antipyrine Test	DD: 2/21/1985 MA:	For use as an index of hepatic drug-metabolizing capacity.	Upsher-Smith Laboratories, Inc 4905 23rd Avenue North Minneapolis MN 55447
antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA] *GTI-2040*	DD: 3/12/2003 MA: MA:	Treatment for renal cell carcinoma	Lorus Therapeutics, Inc 2 Meridan Road Toronto, Ontario
Antithrombin III (human) *Thrombate III*	DD: MA: MA:	For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.	Bayer Corporation Pharmaceutical Division, Biological Pharmaceutical Division, Biological Products 400 Morgan Lane New Haven CT 06516
Antithrombin III (human) *ATnativ*	DD: 2/8/1985 MA: MA:	For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.	Pharmacia & Upjohn AB Lindhagensgatan 133 Lindhagensgatan 133 SE-112 87 Stockholm
Antithrombin III (human) concentrate IV *Kybernin P*	DD: 7/2/1985 MA: MA:	For prophylaxis and treatment of thromboembolic episodes in patients with genetic AT-III deficiency.	Aventis Behring L.L.C. 1020 First Ave. PO Box 61501 King of Prussia PA 19406-0901
Antithrombin III human *Antithrombin III human*	DD: 1/2/1986 MA: MA:	Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or	American National Red Cross 9312 Old Georgetown Road 9312 Old Georgetown Road Bethesda MD 20814

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
		who are about to undergo surgery or	
Antivenin, crotalidae polyvalent immune Fab (ovine) *CroFab*	DD: 1/12/1994 MA: 10/2/2000 MA: 10/2/2000	Treatment of envenomations inflicted by North American crotalid snakes.	Protherics, Inc. 1207 17th Ave. S., Suite 103 Nashville TN 37212
Antivenom (crotalidae) purified (avian)	DD: 2/12/1991 MA:	Treatment of envenomation by poisonous snakes belonging to the Crotalidae family.	Ophidian Pharmaceuticals, Inc. 5445 East Cheryl Parkway Madison WI 53711
AP1903	DD: MA: MA:	Treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.	Ariad Gene Therapeutics, Inc. 26 Landsdowne St. Cambridge MA 02139-4234
APL 400-020 V-Beta DNA vaccine	DD: 3/8/1995 MA:	Treatment of cutaneous T cell lymphoma.	Wyeth-Lederle Vaccines and Pediatrics 211 Bailey Rd. West Henrietta NY 14586-9728
Apomorphine	DD: MA: MA:	For use as rescue treatment for early morning motor dysfunction in late-stage Parkinson's disease.	Scherer DDS Frankland Road Swindon SN5 8RU
Apomorphine	DD: 7/17/1995 MA: MA:	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Pentech Pharmaceuticals, Inc. 1110 Lake Cook Rd. Suite 257 Buffalo Grove IL 60089
Apomorphine HCl *Apokyn*	DD: 4/22/1993 MA: MA:	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Mylan Pharmaceuticals, Inc. 781 Chestnut Ridge Rd. 781 Chestnut Ridge Rd. PO Box 4310 Morgantown WV 26505-4310
Aprotinin *Trasylol*	DD: MA: MA:	For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary coronary artery bypass graft surgery where the risk of bleeding is especially high (impaired hemostasis) or where transfusion is unavailable or	Bayer Corporation Pharmaceutical Division Pharmaceutical Division 400 Morgan Lane West Haven CT 06516
Arcitumomab *99m Tc-labeled CEA-Scan*	DD: 5/10/1996 MA: MA:	Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma.	Immunomedics, Inc. 300 American Road 300 American Road Morris Plains NJ 07950
Arginine butyrate	DD: 4/7/1992 MA:	Treatment of beta-hemoglobinopathies and beta-thalassemia.	Perrine, Susan P., M.D. Boston University Cancer Research Center Boston MA 02118

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Arginine butyrate	DD: 5/25/1994 MA:	Treatment of sickle cell disease and beta thalassemia.	Vertex Pharmaceuticals Inc. 130 Waverly Street Cambridge MA 02139-4242
arsenic *Trisenox*	DD: 11/2/2001 MA:	Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7	Cell Therapeutics, Inc. 501 Elliott Avenue West 501 Elliott Avenue West Suite 400 Seattle WA 98119
arsenic trioxide *Trisenox*	DD: 6/13/2003 MA:	Treatment of liver cancer	Cell Therapeutics, Inc. 501 Elliott Avenue West Suite 400 Seattle WA 98119
arsenic trioxide *Trisenox*	DD: 7/17/2000 MA:	Treatment of myelodysplastic syndrome.	Cell Therapeutics, Inc. 201 Elliott Avenue West Suite 400 Seattle WA 98119
arsenic trioxide *Trisenox*	DD: MA:	Treatment of chronic myeloid leukemia	Cell Therapeutics, Inc. 501 Elliott Avenue West Suite 400 Seattle WA 98119
Arsenic trioxide *Trisenox*	DD: 3/3/1998 MA: 9/25/2000	Treatment of acute promyelocytic leukemia.	Cell Therapeutics, Inc. 201 Elliott Ave. West Suite 400 Seattle WA 98119
Arsenic trioxide *Trisenox*	DD: 4/28/2000 MA:	Treatment of multiple myeloma.	Cell Therapeutics, Inc. 201 Elliott Ave. West, Suite 400 Seattle WA 98119
arsenic trioxide *Trisenox*	DD: 5/13/2003 MA:	Treatment of chronic lymphocytic leukemia	Cell Therapeutics, Inc. 501 Elliott avenue West Suite 400 Seattle WA 98119
Artesunate	DD: 7/19/1999 MA:	Treatment of malaria.	World Health Organisation Special Programme for Research and Training in Tro Via Appia , Geneva 27
As-101	DD: 11/9/1987 MA:	Treatment of acquired immunodeficiency syndrome.	NPDC-AS101, Inc. 783 Jersey Avenue New Brunswick NJ 08901
Atomoxetine hydrochloride *STRATTERA*	DD: 8/26/2003 MA:	Treatment of Tourette's Syndrome	ELI LILLY & Company Lilly Corporate Center Indianapolis IN 46285

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Atovaquone *Mepron*	DD: 9/10/1990 MA:	Treatment of AIDS associated Pneumocystis Carinii Pneumonia.	Glaxo Wellcome Inc. 5 Moore Drive 5 Moore Drive Research Triangle Park NC 27709
Atovaquone *Mepron*	DD: 8/14/1991 MA: 1/5/1999 MA: 1/5/1999	Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3.	Glaxo Wellcome Research and Development 5 Moore Drive 5 Moore Drive PO Box 13398 Research Triangle Park NC 27709
Atovaquone *Mepron*	DD: 3/16/1993 MA: MA:	Primary prophylaxis of HIV-infected persons at high risk for developing Toxoplasma gondii encephalitis.	Glaxo Wellcome Inc. 5 Moore Drive 5 Moore Drive PO Box 13398 Research Triangle Park NC 27709
Atovaquone *Mepron*	DD: 3/16/1993 MA:	Treatment and suppression of Toxoplasma gondii encephalitis.	Glaxo Wellcome Inc. 5 Moore Drive 5 Moore Drive PO Box 13398 Research Triangle Park NC 27709-3398
augmerosen *Genasense*	DD: 8/28/2001 MA:	Treatment of chronic lymphocytic leukemia	Genta Incorporated Two Oak Way Berkeley Heights NJ 07922
augmerosen *Genasense*	DD: 8/28/2001 MA:	Treatment of acute myelocytic leukemia	Genta Incorporated Two Oak Way Berkeley Heights NJ 07922
augmerosen *Genasense*	DD: 8/28/2001 MA:	Treatment of multiple myeloma	Genta Incorporated Two Oak Way Berkeley Heights NJ 07922
autologous antigen presenting cells pulsed with autologous tumor Ig idiotype *Mylovenge*	DD: 4/18/2002 MA: MA:	Treatment of multiple myeloma	Dendreon Corporation 3005 First Avenue Seattle WA 98121
Autologous dendritic cells pulsed with autologous glioblastoma multiforme acid-eluted tumor antigens *DCVax-Brain*	DD: MA: MA:	Treatment of glioblastoma multiforme	Northwest Biotherapeutics, Inc. 22322 20th Avenue SE Suite 150 Bothell WA 98021
Autologous DNP-conjugated tumor vaccine *M-Vax*	DD: 2/23/1999 MA:	For adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (Stage III and limited Stage IV disease).	Avax Technologies, Inc. 9200 Indian Creek Parkway Building 9, Suite 200 Overland Park KS 66210

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
autologous tumor-derived gp96 heat shock protein-peptide *Oncophage*	DD: 7/11/2002 MA: MA:	Treatment of metastatic melanoma	Antigenics, Inc. 34 Commerce Way Woburn MA 01702
autologous tumor-derived gp96 heat shock protein-peptide *Oncophage*	DD: 5/10/2002 MA: MA:	Treatment of renal cell carcinoma	Antigenics, Inc. 34 Commerce Way Woburn MA 01702
Autolymphocyte therapy	DD: 7/12/1994 MA:	Treatment of renal cell carcinoma.	Cytogen Corporation 600 College Road East CN 5308 Princeton NJ 08540-5308
azacitidine	DD: 12/3/2001 MA:	Treatament of myelodysplastic syndromes	Pharmion Corporation 4865 Riverbend Road Boulder CO 80301
Azathioprine *Imuran*	DD: 9/14/1999 MA:	Treatment of oral manifestations of graft-versus-host disease.	Oral Solutions, Inc. 787 Seventh Ave., 48th Floor 787 Seventh Ave., 48th Floor New York NY 10019
aztreonam	DD: 3/12/2002 MA: MA:	Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis	Corus Pharma 2025 First Ave., Suite 800 Seattle WA 98121
B Lymphocyte Stimulator *BLyS*	DD: 2/21/2001 MA:	Treatment of common variable immunodeficiency (CVID)	Human Genome Sciences, Inc. 9410 Key West Avenue 9410 Key West Avenue Rockville MD 20850
Bacitracin *Altracin*	DD: 3/13/1984 MA: MA:	Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.	A. L. Laboratories, Inc. One Executive Drive One Executive Drive P.O. Box 1399 Fort Lee NJ 07024
Baclofen *Lioresal Intrathecal*	DD: MA: 6/25/1992 MA: 6/25/1992	Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative	Medtronic, Inc. 800 53rd Avenue N.E. 800 53rd Avenue N.E. Minneapolis MN 55432
baclofen	DD: 12/2/2003 MA:	Treatment of dystonia	Medtronic Neurological 710 Medtronic Parkway NE Minneapolis MN 55432-5604
Baclofen	DD: MA:	Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.	Infusaid, Inc. 1400 Providence Highway Norwood MA 02062

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Baclofen *Lioresal Intrathecal*	DD: 9/26/1994 MA:	Treatment of spasticity associated with cerebral palsy.	Medtronic, Inc. 800 53rd Avenue N.E. 800 53rd Avenue N.E. P.O. 1250 Minneapolis MN 55440-9087
Basiliximab *Simulect*	DD: MA: 5/12/1998	Prophylaxis of solid organ rejection.	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080
beclomethasone	DD: 8/28/2001 MA:	Prevention of gastrointestinal graft-versus-host disease	Enteron Pharmaceuticals, Inc. 1680 Michigan Ave. Suite 700 Miami FL 33139
Beclomethasone dipropionate	DD: 3/27/1998 MA:	For oral administration in the treatment of intestinal graft-versus-host disease.	George B. McDonald, M.D. Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North (SC-113); PO Box 19024 Seattle WA 98109
Benzoate and phenylacetate *Ucephan*	DD: 1/21/1986 MA: MA:	For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency.	Immunex Immunex 2525 McGaw Avenue 2525 McGaw Avenue P.O. Box 19791 Irvine CA 92623
benzoate/phenylacetate *Ammonul*	DD: MA: MA:	For the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	Medicis Pharmaceutical Corp. 8125 N. Hayden Road 8125 N. Hayden Road Scottsdale AZ 85258
Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide *Total Block VL SPF 75*	DD: 8/13/2001 MA: MA:	For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy	Fallien Cosmeceuticals Ltd. 677 W. Dekalb Pike King of Prussia PA 19406
Benzydamine hydrochloride *Tantum*	DD: 5/18/1998 MA: MA:	Prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue 70 Grand Avenue River Edge NJ 07661
Benzylpenicillin, benzylpenicilloic, benzylpenilloic *Pre-Pen/MDM*	DD: 9/29/1987 MA:	Assessing the risk of administrating penicillin when it is the preferred drug of choice in adult patients who have previously received penicillin and have a history of clinical sensitivity.	Hollister-Stier Laboratories LLC PO Box 3145 Spokane WA 99220-3145
Beractant *Survanta intratracheal suspension*	DD: 2/5/1986 MA: 7/1/1991	Treatment of neonatal respiratory distress syndrome.	Ross Laboratories 625 Cleveland Avenue 625 Cleveland Avenue Columbus OH 43215

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Beractant *Survanta Intratracheal Suspension*	DD: MA: MA:	Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.	Ross Laboratories 625 Cleveland Avenue 625 Cleveland Avenue Columbus OH 43215
Beractant *Survanta intratracheal suspension*	DD: 2/5/1986 MA: 7/1/1991	Prevention of neonatal respiratory distress syndrome.	Ross Laboratories 625 Cleveland Avenue 625 Cleveland Avenue Columbus OH 43215
Beraprost	DD: 4/29/1999 MA:	Treatment of pulmonary arterial hypertension associated with any New York Heart Association classification (Class I, II, III, or IV).	United Therapeutics Corporation 68 T.W. Alexander Drive, PO Box 14186 Research Triangle Park NC 27709
Beta alethine *Betathine*	DD: 3/24/1997 MA:	Treatment of multiple myeloma.	Dovetail Technologies, Inc. Bldg. 337, Paint Branch Drive College Park MD 20742
Beta alethine *Betathine*	DD: 3/24/1997 MA:	Treatment of metastatic melanoma.	Dovetail Technologies, Inc. Bldg. 337, Paint Branch Drive College Park MD 20742
Betaine *Cystadane*	DD: 5/16/1994 MA:	Treatment of homocystinuria.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 475 Minnetonka MN 55305
Bethanidine sulfate	DD: MA:	Prevention of recurrence of primary ventricular fibrillation.	Medco Research, Inc. 8455 Beverly Blvd. Suite 308 Los Angeles CA 90048
Bethanidine sulfate	DD: 9/20/1988 MA:	Treatment of primary ventricular fibrillation.	Medco Research, Inc. 8455 Beverly Blvd. Suite 308 Los Angeles CA 90048
Bexarotene *Targretin*	DD: 6/18/1999 MA: MA:	Treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.	Ligand Pharmaceuticals, Inc. 10275 Science Center Dr. 10275 Science Center Dr. San Diego CA 92121
bifidobacterium longum infantis 35624	DD: 1/16/2003 MA:	Treatment of pediatric Crohn's disease	Alimentary Health Limited Guardwell, Kinsale
Bindarit	DD: 2/3/1998 MA:	Treatment of lupus nephritis.	Angelini Pharmaceuticals, Inc. 70 Grand Avenue River Edge NJ 07661

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL)	DD: 2/11/2002 MA:	Treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond Parson's grade 2	Excorp Medical, Inc. Suite 235 7200 Hudson Blvd. Oakdale MN 55128
Bis(4-fluorophenyl)phenylacetamid	DD: 3/2/2000 MA:	Treatment of sickle cell disease.	ICAgen Inc. Ion Channel Advances PO Box 14487 Durham NC 27709
Bispecific antibody 520c9x22	DD: 10/5/1993 MA:	For in vivo serotherapy of patients with ovarian cancer.	Medarex, Inc. 67 Beaver Avenue Annandale NJ 08801-0953
Bleomycin *Blenoxane*	DD: 2/9/1999 MA:	Treatment of pancreatic cancer.	Genetronics, Inc. 11199 Sorrento Valley Rd. San Diego CA 92121-1334
Bleomycin sulfate *Blenoxane*	DD: 9/17/1993 MA: 2/20/1996	Treatment of malignant pleural effusion.	Bristol-Myers Squibb Pharmaceutical Research Institute P.O. Box 4000 Princeton NJ 08543
BMY-45622	DD: MA:	Treatment of ovarian cancer.	Bristol-Myers Squibb 5 Research Parkway Wallingford CT 06492
bortezomib *VELCADE*	DD: 1/15/2003 MA: 5/13/2003	To treat multiple myeloma	Millennium Pharmaceuticals, Inc. 75 Sidney Street Cambridge MA 02139
Bosentan *Tracleer*	DD: 10/6/2000 MA:	Treatment of pulmonary arterial hypertension.	Actelion Life Sciences Ltd. 1840 Gateway Dr. 1840 Gateway Dr. 2nd Floor San Mateo CA 94404
Botulinum toxin type A *Dysport*	DD: 8/12/1998 MA:	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Limited 1 Bath Road 1 Bath Road Maidenhead, Berkshire
Botulinum toxin type A *Botox*	DD: 8/20/1986 MA:	Treatment of cervical dystonia.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine CA 92623-9534
Botulinum toxin type A *Botox*	DD: 12/6/1991 MA:	Treatment of dynamic muscle contracture in pediatric cerebral palsy patients.	Allergan, Inc. 2525 Dupont Drive 2525 Dupont Drive P.O. Box 19534 Irvine CA 92623-9534

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Botulinum toxin type A *Botox*	DD: 3/22/1984 MA: MA:	Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above).	Allergan, Inc. 2525 Dupont Drive 2525 Dupont Drive P.O. Box 19534 Irvine CA 92713
Botulinum toxin type A *Botox*	DD: 3/22/1984 MA: MA:	Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above).	Allergan, Inc. 2525 Dupont Drive 2525 Dupont Drive P.O. Box 19534 Irvine CA 92713
Botulinum toxin type A *Dysport*	DD: 3/23/1989 MA:	Treatment of essential blepharospasm.	Porton International, Inc. 1155 15th Street, N.W., #315 Washington DC 20005
Botulinum toxin type A	DD: 9/15/1992 MA:	Treatment of synkinetic closure of the eyelid associated with VII cranial nerve aberrant regeneration.	Botulinum Toxin Research Associates, Inc. 1261 Furnace Brook Parkway Quincy MA 02169
Botulinum toxin type A *Dysport*	DD: MA:	Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.	Ipsen Limited 1 Bath Rd., Maidenhead 1 Bath Rd., Maidenhead Berkshire SL6 4UH
Botulinum toxin type B *NeuroBloc*	DD: 1/16/1992 MA: 12/8/2000	Treatment of cervical dystonia.	Elan Pharmaceuticals, Inc. 800 Gateway Blvd. South San Francisco CA 94080
Botulinum toxin type F	DD: 12/5/1991 MA:	Treatment of essential blepharospasm.	Ipsen Limited (name changed from Porton International Inc) Milford MA
Botulinum toxin type F	DD: MA:	Treatment of spasmodic torticollis (cervical dystonia).	Ipsen Limited (name changed from Porton International Inc.) Milford MA
Botulism immune globulin *BabyBIG*	DD: 1/31/1989 MA:	Treatment of infant botulism.	California Department of Health Services 2151 Berkeley Way Berkeley CA 94704-1011
Bovine colostrum	DD: MA:	Treatment of AIDS-related diarrhea.	Hastings, Donald DVM 1030 North Parkview Drive Bismarck ND 58501
Bovine immunoglobulin concentrate, Cryptosporidium parvum *Sporidin-G*	DD: 3/1/1994 MA: MA:	Treatment and symptomatic relief of Cryptosporidium parvum infection of the gastrointestinal tract in immunocompromised patients.	GalaGen, Inc. 4001 Lexington Avenue North Arden Hills MN 55126

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Bovine whey protein concentrate	DD: 9/30/1993	Treatment of cryptosporidiosis caused by the presence of Cryptosporidium parvum in the gastrointestinal tract of patients who are immunodeficient/immunocompromised or immunocompetent.	Biomune Systems, Inc. 540 Arapeen Drive, Suite 202
Immuno-C	MA:		540 Arapeen Drive, Suite 202
	MA:		Salt Lake City UT 84108
Branched chain amino acids	DD:	Treatment of amyotrophic lateral sclerosis.	Mount Sinai Medical Center One Gustave L. Levy Place
	MA:		New York NY 10029
Brimonidine	DD: 2/7/2000	Treatment of anterior ischemic optic neuropathy.	Allergan, Inc. 2525 Dupont Dr.
Alphagan	MA:		2525 Dupont Dr. P.O. Box 19534 Irvine CA 92623-9534
Bromhexine	DD: 5/15/1989	Treatment of mild to moderate keratoconjunctivitis sicca in patients with Sjogren's syndrome.	Boehringer Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road, Box 368
Bisolvon	MA:		900 Ridgebury Road, Box 368 Ridgefield CT 06877-0368
Broxuridine	DD: 9/18/1995	Radiation sensitizer in the treatment of primary brain tumors.	NeoPharm, Inc. 225 East Deerpath, Suite 250
Broxine/Neomark	MA:		225 East Deerpath, Suite 250 Lake Forest IL 60045
bryostatin-1	DD: 12/3/2001	For use in combination with paclitaxel in the treatment of esophageal cancer	GPC Biotech, Inc. 610 Lincoln Street
	MA:		Waltham MA 02451
Buffered intrathecal electrolyte/dextrose injection	DD: 8/24/1994	For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment meningeal leukemia and lymphocytic lymphoma.	Orphan Medical, Inc. 13911 Ridgedale Drive
Elliotts B Solution	MA: 9/27/1996		Suite 475 Minnetonka MN 55305
Buprenorphine hydrochloride	DD: 6/15/1994	Treatment of opiate addiction in opiate users.	Reckitt Benckiser Pharmaceuticals, Inc. 1901 Huguenot Road
Subutex	MA: 10/8/2002		Richmond VA 23235
Buprenorphine in combination with naloxone	DD:	Treatment of opiate addiction in opiate users.	Reckitt Benckiser Pharmaceuticals, Inc. 1901 Huguenot Road
Suboxone	MA: 10/8/2002		Richmond VA 23235
busulfan	DD:	Preparative therapy for pediatric patients undergoing bone marrow transplantation	SuperGen, Inc. 4140 Dublin Blvd
Partaject	MA:		4140 Dublin Blvd Suite 200 Dublin CA 94568
Busulfan	DD: 3/5/2001	Intrathecal therapy for neoplastic meningitis	SuperGen, Inc. 4140 Dublin Boulevard
Spartajet-Busulfan	MA:		Dublin CA 94568

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Busulfan *Spartaject*	DD: 7/7/1997 MA:	Treatment of primary brain malignancies.	SuperGen, Inc. Two Annabel Lane, Suite 220 San Ramon CA 94583
Busulfan *Spartaject*	DD: 4/21/1994 MA: MA:	For use as preparative therapy for malignancies treated with bone marrow transplantation.	Sparta Pharmaceuticals, Inc. 111 Rock Road 111 Rock Road Horsham PA 19044-2310
Busulfan *Busulfex*	DD: 7/28/1994 MA: 2/4/1999 MA: 2/4/1999	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Orphan Medical, Inc. 13911 Ridgedale Drive 13911 Ridgedale Drive Suite 250 Minnetonka MN 55305
Butyrylcholinesterase	DD: 9/30/1992 MA:	Treatment of post-surgical apnea.	Shire Laboratories Inc. 1550 East Gude Drive Rockville MD 20850
Butyrylcholinesterase	DD: 3/25/1992 MA: MA:	For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.	Shire Laboratories Inc. 1550 East Gude Drive Rockville MD 20850
BW 12C	DD: MA:	Treatment of sickle cell disease.	Burroughs Wellcome Company 3030 Cornwallis Road P.O. Box 12700 Research Triangle Pk NC 27709
C1 esterase inhibitor (human)	DD: 8/21/1996 MA:	Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles CA 90032
C1-esterase-inhibitor, human, pasteurized *Berinert P*	DD: MA: MA:	Prevention and/or treatment of acute attacks of hereditary angioedema.	Aventis Behring L.L.C. 1020 First Ave. PO Box 61501 King of Prussia PA 19406-0901
C1-inhibitor *C1-inhibitor (human) vapor heated,*	DD: 8/30/1990 MA:	Treatment of acute attacks of angioedema.	Baxter Healthcare Corp. Hyland Division (Baxter Hyland) 550 North Brand Blvd. Glendale CA 91203
C1-inhibitor *C1-inhibitor (human) vapor heated,*	DD: 8/30/1990 MA: MA:	Prevention of acute attacks of angioedema, including short-term prophylaxis for patients requiring dental or other surgical procedures.	Baxter Healthcare Corp. Hyland Division (Baxter Hyland) Hyland Division (Baxter Hyland) 550 North Brand Blvd. Glendale CA 91203
Caffeine *Cafcit*	DD: 9/20/1988 MA: 9/21/1999	Treatment of apnea of prematurity.	O.P.R. Development, L.P. 1501 Wakarusa Drive Lawrence KS 66047
Calcitonin salmon nasal spray *Miacalcin Nasal Spray*	DD: MA:	Treatment of symptomatic Paget's disease (osteitis deformans).	Sandoz Pharmaceuticals Corp. 59 Route 10 59 Route 10 East Hanover NJ 07936

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Calcitonin-human for injection Corporation *Cibacalcin*	DD: 1/20/1987 MA:	Treatment of symptomatic Paget's disease (osteitis deformans).	Novartis Pharmaceutical 59 Route 10 59 Route 10 East Hanover NJ 07936
Calcium acetate	DD: 6/27/1989 MA:	Treatment of hyperphosphatemia in end stage renal disease.	Pharmedic Company 28101 Ballard Road, Suite F Lake Forest IL 60045
Calcium acetate *Phos-Lo*	DD: MA:	Treatment of hyperphosphatemia in end stage renal failure.	Braintree Laboratories 60 Columbian Street 60 Columbian Street P.O. Box 361 Braintree MA 02184
Calcium carbonate *R & D calcium carbonate/600*	DD: 6/6/1990 MA:	Treatment of hyperphosphatemia in patients with end stage renal disease.	R & D Laboratories, Inc. 4204 Glencoe Avenue 4204 Glencoe Avenue Marina Del Rey CA 90292
Calcium gluconate *Calgonate*	DD: MA:	For use as a wash for hydrofluoric acid spills on human skin.	Calgonate Corp. 190 Commerce Drive 190 Commerce Drive Warwick RI 02886
Calcium gluconate gel *H-F Gel*	DD: 5/21/1991 MA: MA:	For use in the emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	LTR Pharmaceuticals, Inc. 145 Sakonnet Blvd. 145 Sakonnet Blvd. Narragansett RI 02882
Calcium gluconate gel 2.5%	DD: 9/10/1990 MA:	Emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.	Paddock Laboratories, Inc. 3940 Quebec Avenue North Minneapolis MN 55427
Calfactant *Infasurf*	DD: 9/5/2000 MA:	Acute respiratory distress syndrome (ARDS)	ONY, Inc. Baird Research Park 1576 Sweet Home Road Amherst NY 14228
Capsaicin	DD: 5/2/2003 MA:	Treatment of painful HIV-associated neuropathy	NeurogesX, Inc. San Carlos Business Park 981F Industrial Road San Carols CA 94070-4117
capsaicin	DD: MA:	Treatment of erythromelalgia	NeurogesX, Inc. 981F Industrial Road San Carlos CA 94070
carbamic acid, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl] methoxy]-phenyl]iminomethyl]-,eth	DD: 1/15/2002 MA:	Management of cystic fibrosis	Boehringer Ingelheim Pharmaceuticals, Inc 900 Ridgebury Road P.O. Box 368 Ridgefield CT 06877

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Carbamylglutamic acid	DD: 1/20/1998 MA:	Treatment of N-acetylglutamate synthetase deficiency.	Orphan Europe Immeuble "Le Guillaumet" 60, avenue du General de Gaulle - Cedex 70
Carbovir	DD: MA: MA:	Treatment of persons with AIDS and in patients with symptomatic HIV infection and a CD4 count less than 200/mm3.	Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park NC 27709
Carboxypeptidase G2	DD: 8/19/2003 MA:	Treatment of patients at risk of methotrexate toxicity	Protherics, Inc. 5214 Maryland Way, Suite 405 Brentwood TN 37027
Carmustine	DD: 7/3/2000 MA:	Treatment of intracranial malignancies.	Direct Therapeutics, Inc. 460 Seaport Court Suite 220 Redwood CA 94063
Cascara sagrada fluid extract	DD: 3/21/1989 MA:	Treatment of oral drug overdosage to speed lower bowel evacuation.	Intramed Corporation 102 Tremont Way Augusta GA 30907
CD4 human truncated 369 AA polypeptide *Soluble T4*	DD: MA:	Treatment of acquired immunodeficiency syndrome.	SmithKline Beecham Route 23 & Woodmont Ave., P.O. Box 1510 King Of Prussia PA 19406
CD5-T lymphocyte immunotoxin *Xomazyme-H65*	DD: 8/27/1987 MA: MA:	Treatment of graft versus host disease and/or rejection in patients who have received bone marrow transplants.	Xoma Corporation 2910 Seventh Street 2910 Seventh Street Berkeley CA 94710
CDP571	DD: MA:	Treatment of Crohn's disease.	Celltech Chiroscience Limited 216 Bath Road Slough SL1 4EN
cells produced using the AastromReplicelle System and SC-I Therapy Kit	DD: 7/10/2002 MA:	For use in patients receiving high dose chemotherapy who are unable to generate an acceptable dose of peripheral blood stem cells and who have a sufficient bone marrow aspirate without morphological evidence of tumor	Aastrom Biosciences Incorporated P.O. Box 376 Ann Arbor MI 48106
Centruroides immune F(ab)2 *Alacramyn*	DD: 6/12/2000 MA:	Treatment of scorpion envenomations requiring medical attention.	Silanes Laboratories S.A. de C.V. Amores #1034 Col Del Valle Amores #1034 Col Del Valle C.P. 03100 Mexico D.F.
Ceramide trihexosidase/alpha-galactosidase *Fabrazyme*	DD: 1/19/1988 MA: 4/24/2003 MA: 4/24/2003	Treatment of Fabry's disease.	Genzyme Corporation One Kendall Square Cambridge MA 02139-1562

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Cetiedil citrate injection	DD: MA:	Treatment of sickle cell disease crisis.	Baker Cummins Pharmaceuticals,
Cetuximab	DD: 7/3/2000 MA: MA:	Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor.	ImClone Systems Incorporated Branchburg Corporate Center 22 Chubb Way Somerville NJ 08876
Chenodiol *Chenix*	DD: 9/21/1984 MA: 7/28/1983 MA: 7/28/1983	For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age.	Solvay 901 Sawyer Road 901 Sawyer Road Marietta GA 30062
Chimeric (human-murine) G250 IgG monoclonal antibody	DD: 7/24/2000 MA:	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH Grillparzerstrasse 10B 81675 Munich
Chimeric M-T412 (human-murine) IgG monoclonal anti-CD4	DD: 6/5/1991 MA:	Treatment of multiple sclerosis.	Centocor, Inc. 244 Great Valley Parkway Malvern PA 19355
Chimeric, humanized monoclonal antibody to staphylococcus	DD: 8/3/2000 MA:	Prophylaxis of Staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants.	Biosynexus, Inc. 9610 Medical Center Drive Suite 100 Rockville MD 20850
Chlorhexidine gluconate *Peridex*	DD: 8/18/1986 MA: MA:	For use in the amelioration of oral mucositis associated with cytoreductive therapy used in conditioning patients for bone marrow transplantation therapy.	Procter & Gamble Company Sharon Wood Technical Center Sharon Wood Technical Center 11370 Reed Hartman Highway Cincinnati OH 45241
cholic acid (3 alpha, 7 alpha, 12 alpha trihydroxy 5-beta cholanolic acid) *Falkochol*	DD: 7/18/2003 MA: MA:	Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism	Dr. Falk Pharma GmbH Leinenweberstrasse 5 Postfach 6529
Choline chloride *Intrachol*	DD: 2/10/1994 MA: MA:	Treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition.	Orphan Medical, Inc. 13911 Ridgedale Drive 13911 Ridgedale Drive Suite 250 Minnetonka MN 55305
Chondrocyte-alginate gel suspension	DD: 12/1/1997 MA:	For use in correcting vesicoureteral reflux in the pediatric population.	Curis, Inc. 61 Moulton Street Cambridge MA 02138
Chondroitinase	DD: 2/9/1995 MA:	Treatment of patients undergoing vitrectomy.	Bausch & Lomb Pharmaceuticals, 8500 Hidden River Pkwy. Tampa FL 33637

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Ciliary neurotrophic factor	DD: 1/30/1992 MA:	Treatment of amyotrophic lateral sclerosis.	Regeneron Pharmaceuticals Inc 777 Old Saw Mill River Road Tarrytown NY 10591
Ciliary neurotrophic factor, recombinant human	DD: 5/8/1992 MA:	Treatment of motor neuron disease (including amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and primary lateral sclerosis).	Syntex-Synergen Neuroscience 3200 Walnut Street Boulder CO 80301
Ciliary neurotrophic factor, recombinant human	DD: 4/2/1992 MA:	Treatment of spinal muscular atrophies.	Syntex-Synergen Neuroscience 3200 Walnut Street Boulder CO 80301
cinacalcet	DD: 5/12/2003 MA:	Treatment of hypercalcemia in patients with parathyroid carcinoma	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799
Cisplatin/epinephrine *IntraDose*	DD: 4/3/2000 MA:	Treatment of squamous cell carcinoma of the head and neck.	Matrix Pharmaceutical, Inc. 34700 Campus Drive 34700 Campus Drive Fremont CA 94555-3612
Cisplatin/epinephrine *IntraDose*	DD: 9/7/2000 MA:	Treatment of metastatic malignant melanoma.	Matrix Pharmaceutical, Inc. 34700 Campus Drive 34700 Campus Drive Fremont CA 94555-3612
Citric acid, glucono-delta-lactone and magnesium carbonate *Renacidin Irrigation*	DD: 8/28/1989 MA: 10/2/1990 MA: 10/2/1990	Treatment of renal and bladder calculi of the apatite or struvite variety.	United-Guardian, Inc. P.O. Box 2500 Smithtown NY 11787
civamide *Zucapsaicin*	DD: 12/9/2002 MA:	Treatment of postherpetic neuralgia of the trigeminal nerve	Winston Laboratories, Inc. 100 Fairway Drive, Suite 134 100 Fairway Drive, Suite 134 Vernon Hills IL 60061
Cladribine *Leustatin Injection*	DD: MA:	Treatment of chronic lymphocytic leukemia.	R. W. Johnson Pharmaceutical Research Institute Route 202, P.O. Box 300 Raritan NJ 08869-0602
Cladribine *Leustatin*	DD: 7/20/1990 MA:	Treatment of acute myeloid leukemia.	Johnson & Johnson Pharmaceutical Research & Dev., LLC 920 US Highway 202 P.O. Box 300 Raritan NJ 08869
Cladribine *Mylinax*	DD: 4/19/1994 MA:	Treatment of the chronic progressive form of multiple sclerosis.	R. W. Johnson Pharmaceutical Research Institute Route 202 PO Box 300 Raritan NJ 08869-0602

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Cladribine *Leustatin Injection*	DD: 4/19/1993 MA:	Treatment of non-Hodgkin's lymphoma.	R. W. Johnson Pharmaceutical Research Institute Route 202 South, P.O. Box 300 Raritan NJ 08869-0602
Cladribine *Leustatin Injection*	DD: MA: 2/26/1993	Treatment of hairy cell leukemia.	R. W. Johnson Pharmaceutical Research Institute Route 202, P.O. Box 300 Raritan NJ 08869
Clindamycin *Cleocin*	DD: MA:	Treatment of Pneumocystis carinii pneumonia associated with AIDS patients.	Pharmacia & Upjohn 7000 Portage Road 7000 Portage Road Unit 0633-298-113 Kalamazoo MI 49001-0199
Clindamycin *Cleocin*	DD: MA:	Prevention of Pneumocystis carinii pneumonia in AIDS patients.	Pfizer Inc. 235 East 42nd Street 235 East 42nd Street 150-3-46 New York NY 10017
clofarabine *Clofarex*	DD: 2/7/2002 MA:	Treatment of acute lymphoblastic leukemia	Ilex Products, Inc. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263
clofarabine *Clofarex*	DD: 3/14/2002 MA:	Treatment of acute myelogenous leukemia	Ilex Products, Inc. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263
Clofazimine *Lamprene*	DD: 6/11/1984 MA: MA:	Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.	Novartis Pharmaceutical Corporation 59 Route 10 59 Route 10 East Hanover NJ 07936
Clonazepam *Klonopin*	DD: 8/4/1994 MA:	Treatment of hyperekplexia (startle disease).	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110
Clonidine *Duraclon*	DD: 1/24/1989 MA: 10/2/1996 MA: 10/2/1996	For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates.	Roxane Laboratories, Inc. PO Box 16532 PO Box 16532 Columbus OH 43216-6532
Clostridial collagenase	DD: 5/23/1996 MA:	Treatment of advanced (involutional or residual stage) Dupuytren's disease.	Hurst, L. M.D. & Badalamente, M. Ph.D. State University of New York at Stony Brook School of Medicine, Health Sciences Center T18-020 Stony Brook NY 11794-8181
Clotrimazole	DD: 4/24/1995 MA:	Treatment of sickle cell disease.	Brugnara, Carlo M.D. The Children's Hospital 300 Longwood Avenue, Bader 760 Boston MA 02115

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Coagulation factor IX	DD: 6/27/1989	Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.	Armour Pharmaceutical Company 500 Arcola Road, P.O. Box 1200
Mononine	MA: 8/20/1992 MA: 8/20/1992		500 Arcola Road, P.O. Box 1200 Collegeville PA 19426
Coagulation Factor IX (human)	DD: 7/5/1990	For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis.	Alpha Therapeutic Corporation 5555 Valley Boulevard
AlphaNine	MA: MA:		5555 Valley Boulevard Los Angeles CA 90032
Coagulation Factor IX *BeneFix*	DD: 10/3/1994 MA: 2/11/1997	Treatment of hemophilia B.	Genetics Institute, Inc. 87 Cambridge Park Drive Cambridge MA 02140
Coagulation factor VIIa (recombinant)	DD: 6/6/1988	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Novo Nordisk Pharmaceuticals, Inc. 100 Overlook Center
NovoSeven	MA: 3/25/1999 MA: 3/25/1999		Suite 200 Princeton NJ 08540-7810
Coenzyme Q10	DD: 3/5/2001 MA:	For the treatment of Huntington's disease	Vitaline Corporation 385 Williamson Way Ashland OR 97520
Colchicine	DD: 12/9/1985 MA: MA:	For arresting the progression of neurologic disability caused by chronic progressive multiple sclerosis.	Pharmacontrol Corporation 661 Palisade Ave., P.O. Box 931 Englewood Cliffs NJ 07632
Colfosceril palmitate, cetyl alcohol, tyloxapol *Exosurf Neonatal for Intratracheal*	DD: MA: 8/2/1990 MA: 8/2/1990	Treatment of established hyaline membrane disease at all gestational ages.	Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park NC 27709
Colfosceril palmitate, cetyl alcohol, tyloxapol *Exosurf*	DD: 1/11/1993 MA: MA:	Treatment of adult respiratory distress syndrome.	GlaxoSmithKline 5 Moore Drive P.O. Box 13398 Research Triangle Park NC 27709
Colfosceril palmitate, cetyl alcohol, tyloxapol *Exosurf Neonatal for Intratracheal*	DD: MA: 8/2/1990	Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less.	Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park NC 27709
Collagenase (lyophilized) for injection *Plaquase*	DD: 3/12/1996 MA: MA:	Treatment of Peyronie's disease.	Advance Biofactures Corporation 35 Wilbur Street Lynbrook NY 11563-2358
Combretastatin A4 Phosphate	DD: 7/23/2003 MA: MA:	Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage IV papillary or follicular thyroid cancer	OXiGENE, Inc 321 Arsenal Street Watertown MA 02472

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
conjugate of human transferrin and a mutant diphtheria toxin *TransMID*	DD: 12/3/2001 MA: MA:	Treatment of malignant tumors of the central nervous system	INTELLIgene Expressions Inc. 1938-94 St.
conjugated bile acids *COBARTin*	DD: 7/18/2003 MA:	Treatment of steatorrhea in patients with short bowel syndrome	Jarrow Formulas, Inc. 1824 S. Robertson Blvd. 1824 S. Robertson Blvd. Los Angeles CA 90035-4317
Corticorelin ovine triflutate *Acthrel*	DD: MA: 5/23/1996 MA: 5/23/1996	For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.	Ferring Laboratories, Inc. 400 Rella Boulevard, Suite 201 400 Rella Boulevard, Suite 201 Suffern NY 10901
Corticotropin-releasing factor, human *Xerecept*	DD: 4/6/1998 MA: MA:	Treatment of peritumoral brain edema.	Neurobiological Technologies, Inc. 1387 Marina Way South Richmond CA 94804
Coumarin *Onkolox*	DD: MA:	Treatment of renal cell carcinoma.	Drossapharm LTD 4002 Basel
creatine *Creapure*	DD: 2/12/2002 MA:	Treatment of amyotrophic lateral sclerosis	Avicena Group, Inc. 580 California St. Suite 1600 San Francisco CA 94104
Cromolyn sodium *Gastrocrom*	DD: 3/8/1984 MA:	Treatment of mastocytosis.	Fisons Corporation 755 Jefferson Rd P.O. Box 1710 Rochester NY 14603
Cromolyn sodium 4% ophthalmic solution *Opticrom 4% ophthalmic solution*	DD: 7/24/1985 MA: 10/3/1984 MA: 10/3/1984	Treatment of vernal keratoconjunctivitis.	Fisons Corporation 755 Jefferson Rd. P.O. Box 1710 Rochester NY 14603
Cryptosporidium hyperimmune bovine colostrum IgG concentrate	DD: MA:	Treatment of diarrhea in AIDS patients caused by infection with Cryptosporidium parvum.	ImmuCell Corporation 56 Evergreen Drive Portland ME 04103
CT-2584 Mesylate	DD: 4/16/1999 MA:	Treatment of adult soft tissue sarcoma.	Cell Therapeutics, Inc. 501 Elliott Ave. West Suite 400 Seattle WA 98119
CT-2584 mesylate	DD: 4/16/1999 MA:	Treatment of malignant mesothelioma.	Cell Therapeutics, Inc. 501 Elliott Avenue West, #400 Seattle WA 98119

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
cultured, partially T-Cell depleted, allogenic thymic tissue for transplantation	DD: 8/15/2003 MA:	As a therapy for primary immune deficiency resulting from athymia associated with complete DiGeorge Syndrome	Duke University Medical Center Division of Pediatric Allergy & Immunology Erwin Road Durham NC 27710
CY-1503 *Cylexin*	DD: MA: MA:	Treatment of post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension.	Cytel Corporation 3525 John Hopkins Court 3525 John Hopkins Court San Diego CA 92121
CY-1503 *Cylexin*	DD: 7/18/1997 MA: MA:	Treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.	Cytel Corporation 3525 John Hopkins Court 3525 John Hopkins Court San Diego CA 92121
CY-1899	DD: 3/16/1994 MA:	Treatment of chronic active hepatitis B infection in HLA-A2 positive patients.	Cytel Corporation 3525 John Hopkins Court San Diego CA 92121
cyclosporin	DD: MA:	Prophylaxis of acute rejection in patients requiring allogenic lung transplant	Chiron Corporation 4560 Horton Street Emeryville CA 94608
cyclosporine	DD: MA: MA:	For the treatment of refractory acute rejection in patients requiring allogenic lung transplants.	Chiron Corporation 4560 Horton Street Emeryville CA 94608
Cyclosporine 2% ophthalmic ointment	DD: 8/1/1991 MA:	For use in corneal melting syndromes of known or presumed immunologic etiopathogenesis, including Mooren's ulcer.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine CA 92623-9534
Cyclosporine 2% ophthalmic ointment	DD: 8/1/1991 MA:	Treatment of patients at high risk of graft rejection following penetrating keratoplasty.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine CA 92623-9534
Cyclosporine in combination with omega-3 polyunsaturated fatty	DD: 12/6/2000 MA:	Prevention of solid organ graft rejection.	RTP Pharma Corporation 200 Westpark Corporate Center 4364 South Alston Avenue Durham NC 27713-2280
Cyclosporine ophthalmic *Optimmune*	DD: 11/9/1988 MA:	Treatment of severe keratoconjunctivitis sicca associated with Sjogren's syndrome.	University Of Georgia College Of Veterinary Medicine College Of Veterinary Medicine Department of Small Animal Medicine Athens GA 30602
Cyproterone acetate *Androcur*	DD: MA:	Treatment of severe hirsutism.	Berlex Laboratories, Inc. 300 Fairfield Road Wayne NJ 07470

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Cysteamine *Cystagon*	DD: 1/25/1991 MA: 8/15/1994	Treatment of nephropathic cystinosis.	Mylan Laboratories, Inc. 781 Chestnut Ridge Road P.O. Box 4310 Morgantown WV 26504
Cysteamine	DD: 5/1/1986 MA:	Treatment of nephropathic cystinosis.	Thoene, Jess G., M.D. University of Michigan Medical 300 NIB, 1192 SE Ann Arbor MI 48109-0408
Cysteamine hydrochloride	DD: 8/19/1997 MA:	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue Gaithersburg MD 20877
Cystic fibrosis gene therapy	DD: 6/30/1992 MA:	Treatment of cystic fibrosis.	Genzyme Corporation One Mountain Rd. P.O. Box 9322 Framingham MA 01701-9322
Cystic fibrosis Tr gene therapy (recombinant adenovirus) *AdGVCFTR.10*	DD: 3/9/1995 MA: MA:	Treatment of cystic fibrosis.	GenVec, Inc. 12111 Parklawn Drive Rockville MD 20852
Cystic fibrosis transmembrane conductance regulator	DD: 1/14/1992 MA:	For cystic fibrosis transmembrane conductance regulator protein replacement therapy in cystic fibrosis patients.	Genzyme Corporation One Mountain Road P.O. Box 9322 Framingham MA 01701-9322
Cystic fibrosis transmembrane conductance regulator gene	DD: 1/8/1993 MA:	Treatment of cystic fibrosis.	Genetic Therapy, Inc. 938 Clopper Road Gaithersburg MD 20878
Cytarabine liposomal *DepoCyt*	DD: 6/2/1993 MA: 4/1/1999	Treatment of neoplastic meningitis.	DepoTech Corporation 10450 Science Center Drive San Diego CA 92121
Cytomegalovirus immune globulin (human) *CytoGam*	DD: 8/3/1987 MA: 12/4/1998 MA: 12/4/1998	Prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.	Massachussetts Public Health Biologic Laboratories 305 South Street 305 South Street Boston MA 02130-3597
Cytomegalovirus immune globulin intravenous (human)	DD: 1/28/1991 MA:	For use in conjunction with ganciclovir sodium for the treatment of cytomegalovirus pneumonia in bone marrow transplant patients.	Bayer Corporation Pharmaceutical Division, Biological Products 400 Morgan Lane New Haven CT 06516
D-peptide of the sequence AKRHHGYKRKFH - NH2 *PulmaDex*	DD: MA: MA:	Treatment of cystic fibrosis	Demegen, Inc. 100 Technology Drive Suite 440 B Pittsburgh PA 15219

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Daclizumab *Zenapax*	DD: 3/5/1993 MA:	Prevention of acute renal allograft rejection.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110
Dantrolene sodium *Dantrium*	DD: MA:	Treatment of the neuroleptic malignant syndrome.	Norwich Eaton Pharmaceuticals P.O. Box 191 P.O. Box 191 Norwich NY 13815
Dapsone	DD: 11/7/1994 MA:	Prophylaxis of toxoplasmosis in severely immunocompromised patients with CD4 counts below 100.	Jacobus Pharmaceutical Company, Inc. 37 Cleveland Lane P.O. Box 5290 Princeton NJ 08540
Dapsone USP *Dapsone*	DD: MA:	Prophylaxis for Pneumocystis carinii pneumonia.	Jacobus Pharmaceutical Company 37 Cleveland Lane 37 Cleveland Lane P.O. Box 5290 Princeton NJ 08540
Dapsone USP *Dapsone*	DD: 1/8/1992 MA: MA:	For the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim.	Jacobus Pharmaceutical Company 37 Cleveland Lane 37 Cleveland Lane P.O. Box 5290 Princeton NJ 08540
Daunorubicin citrate liposome injection *DaunoXome*	DD: 5/14/1993 MA: 4/8/1996 MA: 4/8/1996	Treatment of patients with advanced HIV-associated Kaposi's sarcoma.	NeXstar Pharmaceuticals, Inc. 650 Cliffside Drive San Dimas CA 91773
debrase *Debridase*	DD: 8/20/2003 MA:	Debridement of acute, deep dermal burns in hospitalized patients	MediWound, Ltd. 3, Azrieli Center 3, Azrieli Center Triangular Tower 45th Floor
Decitabine	DD: 3/8/1999 MA:	Treatment of chronic myelogenous leukemia.	SuperGen, Inc. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
Decitabine	DD: 3/8/1999 MA:	Treatment of myelodysplastic syndromes.	SuperGen, Inc. 4140 Dublin Blvd. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
decitabine	DD: 9/9/2002 MA:	Treatment of sickle cell anemia	SuperGen, Inc. 4140 Dublin Blvd., Suite 200 Dublin CA 94568
Deferasirox	DD: MA:	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
deferiprone *Ferriprox*	DD: MA: MA:	Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy	Apotex Research Inc. 150 Signet Drive 150 Signet Drive
Defibrotide	DD: 5/21/2003 MA:	For the treatment of hepatic veno-occlusive disease	Gentium SpA Piazza XX Settembre, 2 22079 Villa Guardia (CO)
Defibrotide	DD: 7/5/1985 MA:	Treatment of thrombotic thrombocytopenic purpura.	Crinos International Via Belvedere 1 Villa Guardia, Italy IT 22079
Dehydroepiandrosterone	DD: 7/13/1994 MA: MA:	Treatment of systemic lupus erythematosus (SLE) and the reduction in the use of steroids in steroid-dependent SLE patients.	Genelabs Technologies, Inc. 505 Penobscot Drive Redwood City CA 94063
Dehydroepiandrosterone (DHEA) *Fidelin*	DD: 8/19/2003 MA:	Replacement therapy in individuals with adrenal insufficiency	Paladin Labs, Inc. 6111 Royalmount Avenue Suite 6111 Royalmount Avenue Suite Montreal, Quebec
Dehydroepiandrosterone sulfate sodium	DD: 1/28/1997 MA:	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City UT 84109-1405
Dehydroepiandrosterone sulfate sodium	DD: 1/29/1997 MA:	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City UT 84109-1405
Denileukin diftitox *Ontak*	DD: 8/21/1996 MA: 2/5/1999 MA: 2/5/1999	Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.	Ligand Pharmaceuticals Inc. 10275 Science Center Drive 10275 Science Center Drive San Diego CA 92121
Deoxyribose, phosphorothioate	DD: 7/31/2000 MA:	Treatment of advanced malignant melanoma (Stages II,III, IV).	Genta, Inc. 99 Hayden Ave., Suite 200 Lexington MA 02421-7966
Deslorelin *Somagard*	DD: 11/5/1987 MA:		Roberts Pharmaceutical Corp. Meridian Center II Four Industrial Way West Eatontown NJ 07724-2274
Desmopressin acetate	DD: 1/22/1991 MA: 3/7/1994	Treatment of mild hemophilia A and von Willebrand's disease.	Aventis Behring L.L.C. 1020 First Avenue PO Box 61501 King of Prussia PA 19406-0901

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Dexamethasone	DD: 9/11/1998 MA: MA:	For use in posterior segment drug delivery system in the treatment of idiopathic intermediate uveitis.	Oculex Pharmaceuticals, Inc. 639 N. Pastoria Avenue Sunnyvale CA 94086-2917
Dexrazoxane *Zinecard*	DD: MA: 5/26/1995	For the prevention of cardiomyopathy associated with doxorubicin administration.	Pharmacia & Upjohn 7000 Portage Road 7000 Portage Road Kalamazoo MI 49001-0199
dextran 1	DD: 3/21/2003 MA:	Treatment of cystic fibrosis	BCY LifeSciences Inc. 160 Eglinton Ave. East Suite 600
Dextran 70 *Dehydrex*	DD: 3/5/1990 MA:	Treatment of recurrent corneal erosion unresponsive to conventional therapy.	Holles Laboratories, Inc. 30 Forest Notch 30 Forest Notch Cohasset MA 02025
Dextran and deferoxamine *Bio-Rescue*	DD: 3/8/1991 MA:	Treatment of acute iron poisoning.	Biomedical Frontiers, Inc. 1095 10th Avenue S.E. Minneapolis MN 55414
Dextran sulfate (inhaled, aerosolized) *Uendex*	DD: 10/5/1990 MA: MA:	For use as an adjunct to the treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s University Of Utah Medical Center 50 North Medical Drive, Room 4R240 Salt Lake City UT 84132
Dextran sulfate sodium	DD: MA:	Treatment of aquired immunodeficiency syndrome.	Ueno Fine Chemicals Industry, Ltd. 2-31 Koraibashi, Higashi-ku
DHA-paclitaxel *Taxoprexin*	DD: 5/1/2003 MA:	Treatment of adenocarcinoma of the stomach or lower esophagus	Protarga, Inc. 2200 Renaissance Boulevard 2200 Renaissance Boulevard Suite 450 King of Prussia PA 19406
DHA-paclitaxel *Taxoprexin*	DD: MA:	Treatment of metastatic malignant melanoma	Protarga, Inc. 2200 Renaissance Boulevard 2200 Renaissance Boulevard Suite 450 King of Prussia PA 19406
DHA-paclitaxel *Taxoprexin*	DD: 9/25/2001 MA:	Treatment of pancreatic cancer	Protarga, Inc. 2200 Renaissance Blvd. Suite 450 King of Prussia PA 19406
Dianeal peritoneal dialysis solution with 1.1% amino acids *Nutrineal (Peritoneal Dialysis Solution*	DD: 6/11/1992 MA:	For use as a nutritional supplement for the treatment of malnourishment in patients undergoing continuous ambulatory peritoneal dialysis.	Baxter Healthcare Corporation 1620 Waukegan Road McGaw Park IL 60085

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Diazepam viscous solution for rectal administration	DD: 2/25/1992 MA: 7/29/1997	For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity.	Xcel Pharmaceuticals, Inc. 6363 Greenwich Drive Suite 100 San Diego CA 92122
Diaziquone	DD: MA:	Treatment of primary brain malignancies (grade III and IV astrocytomas).	Warner-Lambert Company 2800 Plymouth Rd., P.O. Box 1047 Ann Arbor MI 48106
Dideoxyinosine	DD: 6/22/1988 MA:	Treatment of acquired immunodeficiency syndrome.	Bristol-Myers Squibb
Diethyldithiocarbamate *Imuthiol*	DD: 4/3/1986 MA:	Treatment of AIDS.	Connaught Laboratories Route 611, P.O. Box 187 Swiftwater PA 18370
diferuloylmethane	DD: 6/13/2003 MA:	Treatment of cystic fibrosis	Seer Pharmarceuticals, LLC P. O. Box 138 Southport CT 06890
digitoxin	DD: 11/2/2001 MA:	Treatment of ovarian cancer	PrimeCyte, Inc. 130 Fifth Ave., N. Seattle WA 98109-4933
digitoxin	DD: MA:	Treatment of soft tissue sarcomas	PrimeCyte, Inc. 130 Fifth Ave., N. Seattle WA 98109-4933
Digoxin immune FAB (Ovine) *Digibind*	DD: 11/1/1984 MA: 4/22/1986 MA: 4/22/1986	Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.	Glaxo Wellcome Inc. 5 Moore Drive 5 Moore Drive Research Triangle Park NC 27709
Digoxin immune fab(ovine) *Digidote*	DD: 3/11/1985 MA: MA:	Treatment of life-threatening acute cardiac glycoside intoxication manifested by conduction disorders, ectopic ventricular activity and (in some cases) hyperkalemia.	Boehringer Mannheim Corp. 1301 Piccard Drive 1301 Piccard Drive Rockville MD 20850
Dihydrotestosterone *Androgel -DHT*	DD: 2/5/1996 MA:	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Unimed Pharmaceuticals, Inc. Four Parkway North Four Parkway North Deerfield IL 60015-2544
Dimethyl sulfoxide	DD: MA: MA:	Treatment of increased intracranial pressure in patients with severe, closed-head injury, whom no other effective treatment is also known as traumatic brain coma, for available.	Pharma 21 c/o Univ. of Calif., San Diego 9500 Gilman Dr. La Jolla CA 92093-0624
Dimethyl sulfoxide	DD: 6/6/1986 MA:	Treatment of cutaneous manifestations of scleroderma.	Research Industries Corp.

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Dimethylsulfoxide	DD: 4/15/1997 MA: MA:	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson AZ 85710
Dimethylsulfoxide	DD: 4/6/1998 MA:	Treatment of palmar-plantar erythrodysethesia syndrome.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson AZ 85710
Dipalmitoylphosphatidylcholine /phosphatidylglycerol *ALEC*	DD: 7/28/1988 MA: MA:	Prevention and treatment of neonatal respiratory distress syndrome.	Forum Products, Inc. 33 Flying Point Road Southampton NY 11968
diphenylcyclopenone	DD: 6/13/2003 MA: MA:	Treatment of chronic severe forms of alopecia areata (Alopecia Totalis [AT]/Alopecia Universalis [AU])	Lloyd E. King, Jr. 1900 Patterson Street Suite 104 Nashville TN 37203
Disaccharide tripeptide glycerol dipalmitoyl *Immther*	DD: 3/1/1990 MA: MA:	Treatment of pulmonary and hepatic metastases in patients with colorectal adenocarcinoma.	ImmunoTherapeutics, Inc. 3505 Riverview Circle Moorhead MN 56560
Disodium clodronate	DD: 6/16/1993 MA:	Treatment of hypercalcemia of malignancy.	Discovery Experimental & Development, Inc. 29949 S.R. 54 West Wesley Chapel FL 33543
Disodium clodronate tetrahydrate *Bonefos*	DD: 3/5/1990 MA:	Treatment of increased bone resorption due to malignancy.	Anthra Pharmaceuticals, Inc. 103 Carnegie Center, Suite 102 103 Carnegie Center, Suite 102 Princeton NJ 08540
Disodium silibinin *Legalon*	DD: 7/10/1986 MA:	Treatment of hepatic intoxication by Amanita phalloides (mushroom poisoning).	Pharmaquest Corporation 4470 Redwood Highway 4470 Redwood Highway San Rafael CA 94903
DMP 777	DD: 6/4/1996 MA:	Therapeutic management of patients with lung disease attributable to cystic fibrosis.	DuPont Pharmaceuticals Company Chestnut Run, Maple Run Centre Rd. Wilmington DE 19805
DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2 *Leuvectin*	DD: 4/28/2000 MA: MA:	Treatment of renal cell carcinoma.	Vical Incorporated 9373 Towne Center Dr. Suite 100 San Diego CA 92121-3088
DNP-Modified autologous tumor vaccine *O-Vax*	DD: 9/21/2000 MA: MA:	Adjuvant therapy for the treatment of ovarian cancer	AVAX Technologies, Inc. 9200 Indian Creek Parkway Building 9, Suite 200 Overland Park KS 66210

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
docosahexanoic acid-paclitaxel *Taxoprexin*	DD: 3/5/2001 MA:	Treatment of hormone-refractory prostate cancer.	Protarga, Inc. 1100 East Hector Street 1100 East Hector Street Suite 450 Conshohocken PA 19428-2377
Dornase alfa *Pulmozyme*	DD: 1/16/1991 MA: MA:	To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.	Genentech, Inc. 460 Point San Bruno Boulevard 460 Point San Bruno Boulevard South San Francisco CA 94080
Doxorubicin liposome *Doxil*	DD: 11/4/1998 MA: 6/28/1999	Treatment of ovarian cancer.	Alza Corporation 1550 Plymouth St. PO Box 7210 Mountain View CA 94039-7210
Dronabinol *Marinol*	DD: 1/15/1991 MA: MA:	For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.	Unimed Pharmaceuticals, Inc. 2150 East Lake Cook Road, Suite 2150 East Lake Cook Road, Suite Buffalo Grove IL 60089-1862
Duramycin	DD: MA:	Treatment of cystic fibrosis.	MoliChem Medicines Inc. 207 South Elliott Road PMB#231 Chapel Hill NC 27514
Dynamine	DD: MA: MA:	Treatment of hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth disease).	Mayo Foundation 200 First Street Southwest Rochester MN 55905
Dynamine	DD: 2/5/1990 MA:	Treatment of Lambert Eaton myasthenic syndrome.	Mayo Foundation 200 First Street Southwest Rochester MN 55905
eculizumab	DD: 8/20/2003 MA:	Treatment of paroxysmal nocturnal hemoglobinuria	Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410
eculizumab	DD: 3/5/2001 MA:	Idiopathic membranous glomerular nephropathy	Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410
Eflornithine HCl *Ornidyl*	DD: 4/18/1986 MA:	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Marion Merrell Dow, Inc. P.O. Box 9627 P.O. Box 9627 Kansas City MO 64134
Eflornithine HCl *Ornidyl*	DD: 4/23/1986 MA:	Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).	Hoechst Marion Roussel P.O. Box 9627 P.O. Box 9627 Kansas City MO 64134
Elcatonin	DD: 9/25/1995 MA:	Intrathecal treatment of intractable pain.	Innapharma, Inc. 10 Mountainview Road Upper Saddle River NJ 07458

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Enadoline hydrochloride	DD: 1/28/1997 MA:	Treatment of severe head injury.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor MI 48105
Encapsulated porcine islet preparation *BetaRx*	DD: 7/5/1995 MA: MA:	Treatment of type I diabetic patients who are already on immunosuppression.	VivoRx 2825 Santa Monica Blvd. 2nd Floor Santa Monica CA 90404-2429
Enisoprost	DD: MA: MA:	For use in organ transplant patients to diminish the nephrotoxicity induced by cyclosporine.	G.D. Searle & Company 4901 Searle Parkway Skokie IL 60077
Enisoprost	DD: MA: MA:	For use with cyclosporine in organ transplant recipients to reduce acute transplant rejection.	G.D. Searle & Company 4901 Searle Parkway Skokie IL 60077
Epidermal growth factor (human)	DD: 3/6/1985 MA:	For promotion of cutaneous wound healing in extreme burn treatment protocols.	Ethicon, Inc. P.O. Box 151 Somerville NJ 08876
Epidermal growth factor (human)	DD: 10/5/1987 MA: MA:	For acceleration of corneal epithelial regeneration and the healing of stromal defects. tissue in the condition of non-healing corneal	Chiron Vision 500 Iolab Drive Claremont CA 91711
Epirubicin *Ellence*	DD: 9/14/1999 MA: 9/15/1999	Treatment of breast cancer.	Pharmacia & Upjohn Company 0634-298-113 7000 Portage Rd. Kalamazoo MI 49001-0199
Epoetin alfa	DD: MA:	Treatment of myelodysplastic syndrome.	Johnson & Johnson Pharmaceutical Research & Dev., 920 U.S. Highway Route 202, P.O. Box 300 Raritan NJ 08869-0602
Epoetin alfa *Epogen*	DD: 7/1/1991 MA:	Treatment of anemia associated with HIV infection or HIV treatment.	Amgen, Inc. 1840 Dehavilland Drive 1840 Dehavilland Drive Thousand Oaks CA 91320
Epoetin alfa *Epogen*	DD: 4/10/1986 MA: 6/1/1989	Treatment of anemia associated with end stage renal disease.	Amgen, Inc. 1840 Dehavilland Drive 1840 Dehavilland Drive Thousand Oaks CA 91320
Epoetin alpha *Procrit*	DD: 3/7/1989 MA:	Treatment of HIV associated anemia related to HIV infection or HIV treatment.	R. W. Johnson Pharmaceutical Research Institute Route 202, P.O. Box 300 Raritan NJ 08869

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Epoetin alpha *Procrit*	DD: 7/21/1988 MA:	Treatment of anemia of prematurity in preterm infants.	R. W. Johnson Pharmaceutical Research Institute Route 202, P.O. Box 300 Raritan NJ 08869-0602
Epoetin alpha *Procrit*	DD: 8/27/1987 MA:	Treatment of anemia associated with end stage renal disease.	R. W. Johnson Pharmaceutical Research Institute Route 202 South P.O. Box 300 Raritan NJ 08869
Epoetin beta *Marogen*	DD: MA:	Treatment of anemia associated with end stage renal disease.	Chugai-USA, Inc. 3780 Hawthorn Court 3780 Hawthorn Court Waukegan IL 60087
Epoprostenol *Flolan*	DD: 3/29/1984 MA: MA:	Replacement of heparin in patients requiring hemodialysis and who are at increased risk of hemorrhage.	Glaxo Wellcome Inc. 5 Moore Drive 5 Moore Drive Research Triangle Park NC 27709
Epoprostenol *Flolan*	DD: 9/25/1985 MA: 9/20/1995	Treatment of primary pulmonary hypertension.	Glaxo Wellcome Inc. 5 Moore Drive 5 Moore Drive Research Triangle Park NC 27709
Epoprostenol *Cycloprostin*	DD: MA: MA:	Replacement of heparin in patients requiring hemodialysis and who are at increased risk of hemorrhage.	Upjohn Company 301 Henrietta Street 301 Henrietta Street Kalamazoo MI 49001
Epoprostenol *Flolan*	DD: 3/22/1999 MA: 4/14/2000 MA: 4/14/2000	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	GlaxoSmithKline Five Moore Dr. Five Moore Dr. PO Box 13398 Research Triangle Park NC 27709-3398
epratuzumab *LymphoCIDE*	DD: 7/13/1998 MA:	Treatment of non-Hodgkin's lymphoma.	Amgen One Amgen Center Drive Thousand Oaks CA 20857
Erlotinib Hydrochloride *Tarceva*	DD: 7/18/2003 MA:	Treatment of malignant gliomas	Genentech, Inc 1 DNA Way South San Francisco CA 94080-4990
Erwinia L-asparaginase	DD: 1/25/1985 MA:	For use as an alternative to E. coli asparaginase in those situations where repeat courses of asparaginase therapy for acute lymphoblastic leukemia are required or where allergic reactions force the discontinuance of the E. coli preparation.	Lyphomed, Inc.
Erwinia L-asparaginase *Erwinase*	DD: 7/30/1986 MA:	Treatment of acute lymphocytic leukemia.	Porton International, Inc. 7114 Springbrook Terrace, #200 Spotsylvania VA 22553

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Erythropoietin (human,	DD: MA:	Treatment of anemia associated with end stage renal disease.	Organon Teknika Corporation
Erythropoietin (recombinant	DD: 8/19/1987 MA:	Treatment of anemia associated with end stage renal disease.	McDonnell Douglas Corp P.O. Box 516, 107/2 MS10 St. Louis MO 63166
Etanercept *Enbrel*	DD: MA: 5/27/1999 MA: 5/27/1999	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	Immunex Corporation 51 University St. 51 University St. Seattle WA 98101-2936
Etanercept *Enbrel*	DD: 4/6/1999 MA:	Treatment of Wegener's granulomatosis.	Immunex Corporation 51 University Street Seattle WA 98101-2936
Ethanolamine oleate *Ethamolin*	DD: 3/22/1984 MA: MA:	Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding.	Block Drug Company, Inc. 257 Cornelison Avenue 257 Cornelison Avenue Jersey City NJ 07302
Ethinyl Estradiol, USP	DD: 6/22/1988 MA:	Treatment of Turner's syndrome.	Bio-Technology General Corp. 70 Wood Avenue, South Iselin NJ 08830
Ethiofos	DD: 8/1/1989 MA:	Use as a chemoprotective agent for cisplatin and cyclophosphamide in the treatment of ovarian cancer.	U.S. Bioscience
Ethyl eicosapentaenoate	DD: 4/6/2000 MA:	Treatment of Huntington's disease.	Laxdale Ltd. Kings Park House, Laurelhill Business Park Polmaise Road, Stirling FK7 9JQ
Etidronate disodium *Didronel IV infusion*	DD: 5/2/1991 MA: MA:	Prevention of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. 6300 West Old Shakoppe Rd. Suite 110 Bloomington MN 55438-2318
Etidronate disodium *Didronel IV Infusion*	DD: 5/2/1991 MA: MA:	Treatment of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. 6300 West Old Shakoppe Rd. Suite 110 Bloomington MN 55438-2318
Etidronate disodium *Didronel*	DD: 3/21/1986 MA: 4/21/1987 MA: 4/21/1987	Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. 6300 West Old Shakoppe Rd. Suite 110 Bloomington MN 55438-2318

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Etiocholanedione	DD: 5/7/1996 MA:	Treatment of Prader-Willi syndrome.	SuperGen, Inc. Two Annabel Lane, Suite 220 San Ramon CA 94583
Etiocholanedione	DD: 11/3/1995 MA:	Treatment of aplastic anemia.	SuperGen, Inc. Two Annabel Lane, Suite 220 Suite 10 San Ramon CA 94583
Exemestane *Aromasin*	DD: 9/19/1991 MA: MA:	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Pharmacia & Upjohn 7000 Portage Road 7000 Portage Road Mail Stop: 0636-298-113 Kalamazoo MI 49001-0199
Exisulind	DD: 2/14/1994 MA: MA:	For the suppression and control of colonic adenomatous polyps in the inherited disease adenomatous polyposis coli.	Cell Pathways, Inc. 702 Electronic Drive Horsham PA 19044
Factor XIII [A2] homodimer, recombinant DNA origin	DD: 5/21/2003 MA:	Treatment of congenital FXIII deficiency	ZymoGenetics, Inc. 1201 Eastlake Avenue East Seattle WA 98102
Factor XIII [A2} homodimer, recombinant DNA origin	DD: 11/6/2003 MA:	For the prophylaxis of bleeding associated with congential FXIII deficiency	ZymoGenetics, Inc. 1201 Eastlake Avenue East Seattle WA 98102
factor XIII concentrate (human), pasteurized *Fibrogammin P*	DD: 1/16/1985 MA: MA:	Treatment of congenital factor XIII deficiency.	Aventis Behring L.L.C. 1020 First Ave. PO Box 61501 King of Prussia PA 19406-0901
Factor XIII, recombinant	DD: 4/22/1993 MA:	Treatment of congenital factor XIII deficiency.	Zymogenetics, Inc. 4225 Roosevelt Way Seattle WA 98105
Fampridine *Neurelan*	DD: 6/2/1987 MA:	Relief of symptoms of multiple sclerosis.	Acorda Therapeutics 15 Skyline Dr. Hawthorne NY 10532
Fampridine *Neurelan*	DD: 6/2/1997 MA:	Treatment of chronic, incomplete spinal cord injury.	Acorda Therapeutics, Inc. 15 Skyline Dr. 15 Skyline Dr. Hawthorne NY 10532
Felbamate *Felbatol*	DD: 1/24/1989 MA: 7/29/1993	Treatment of Lennox-Gastaut syndrome.	Wallace Laboratories 301B College Road East Princeton NJ 08540

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
ferric hexacyanoferrate (II) "Prussian Blue"	DD: 6/26/2003 MA:	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Degussa AG Weissfrauenstr.9 D-60287 Frankfurt
FIAU	DD: 7/24/1992 MA:	Adjunctive treatment of chronic active hepatitis B.	Oclassen Pharmaceuticals, Inc. 100 Pelican Way San Rafael CA 94901
Fibrinogen (human)	DD: 8/23/1995 MA:	For the control of bleeding and prophylactic treatment of patients deficient in fibrinogen.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles CA 90032
Fibronectin (human plasma	DD: 9/5/1988 MA: MA:	Treatment of non-healing corneal ulcers or epithelial defects which have been the underlying cause has been eliminated. unresponsive to conventional therapy and	Melville Biologics, Inc. 310 East 67th Street New York NY 10021
Fibronectin (plasma derived)	DD: 12/5/1988 MA: MA:	Treatment of non-healing corneal ulcers or epithelial defects which are unresponsive to infectious cause of the defect has been conventional therapy and for which any eliminated.	Chiron Vision 9342 Jeronimo Road Irvine CA 92718
Filgrastim *Neupogen*	DD: 11/7/1990 MA: MA:	Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).	Amgen, Inc. 1840 Dehavilland Drive 1840 Dehavilland Drive Thousand Oaks CA 91320
Filgrastim *Neupogen*	DD: 8/30/1990 MA:	Treatment of myelodysplastic syndrome.	Amgen, Inc. 1840 Dehavilland Drive Thousand Oaks CA 91320
Filgrastim *Neupogen*	DD: 10/1/1990 MA: 6/15/1994	Treatment of neutropenia associated with bone marrow transplants.	Amgen, Inc. 1840 Dehavilland Drive 1840 Dehavilland Drive Thousand Oaks CA 91320
Filgrastim *Neupogen*	DD: 7/17/1995 MA: MA:	For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.	Amgen, Inc. 1840 Dehavilland Drive 1840 Dehavilland Drive Thousand Oaks CA 91320
Filgrastim *Neupogen*	DD: 9/3/1991 MA: MA:	Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir.	Amgen, Inc. One Amgen Center Dr. One Amgen Center Dr. Thousand Oaks CA 91320-1799
Filgrastim *Neupogen*	DD: 11/7/1996 MA: 4/2/1998 MA: 4/2/1998	Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.	Amgen, Inc. One Amgen Center Dr. One Amgen Center Dr. Thousand Oaks CA 91320-1799

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Flucinolone	DD: 7/31/2000 MA:	Treatment uveitis involving the posterior segment of the eye.	Bausch & Lomb Pharmaceuticals, 8500 Hidden River Parkway Tampa FL 33637
Fludarabine phosphate *Fludara*	DD: 4/18/1989 MA:	Treatment and management of patients with non-Hodgkins lymphoma.	Berlex Laboratories, Inc. 15049 San Pablo Avenue 15049 San Pablo Avenue P.O. Box 4099 Richmond CA 94804-0099
Fludarabine phosphate *Fludara*	DD: 4/18/1989 MA: 4/18/1991	Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL.	Berlex Laboratories, Inc. 15049 San Pablo Avenue, P.O. Box 15049 San Pablo Avenue, P.O. Box 4099 Richmond CA 94804
Flumecinol *Zixoryn*	DD: 1/15/1985 MA:	Treatment of hyperbilirubinemia in newborn infants unresponsive to phototherapy.	Farmacon, Inc. Post House, Suite 213 Post House, Suite 213 1720 Post Road East Westport CT 06880-5643
Flunarizine *Sibelium*	DD: 1/6/1986 MA: MA:	Treatment of alternating hemiplegia.	Janssen Research Foundation P.O. Box 200 Titusville NJ 08560
Fluorouracil *Adrucil*	DD: 2/6/1989 MA: MA:	For use in combination with leucovorin for therapy of metastatic adenocarcinoma of the colon and rectum.	Lederle Laboratories Division of American Cyanamid Division of American Cyanamid Company 401 N. Middletown Road Pearl River NY 10965
Fluorouracil	DD: MA: MA:	For use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110-1199
Fluorouracil	DD: 4/18/1990 MA: MA:	For use in combination with interferon alpha-2a, recombinant, for the treatment of advanced colorectal carcinoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110-1199
Fluorouracil	DD: 6/29/2000 MA:	Treatment of glioblastoma multiforme.	Ethypharm SA 194 Bureaux de la Colline - Batiment 92213 Saint-Cloud Cedex
Fluoxetine *Prozac*	DD: 4/30/1999 MA:	Treatment of autism.	Hollander, MD, Eric Mt. Sinai School of Medicine, Dept. of Psychiatry Box 1230, One Gustave L. Levy New York NY 10029-6574

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Follitropin alfa, recombinant *Gonal-F*	DD: MA: 5/24/2000 MA: 5/24/2000	For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism. AMENDED indication 6/27/00: For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.	Serono Laboratories, Inc. 100 Longwater Circle 100 Longwater Circle Norwell MA 02061
Fomepizole *Antizole*	DD: MA: 12/4/1997	Treatment of methanol or ethylene glycol poisoning.	Orphan Medical, Inc. 13911 Ridgedale Drive 13911 Ridgedale Drive Suite 250 Minnetonka MN 55305
Fomepizole *Antizole*	DD: MA: 12/8/2000	Treatment of methanol or ethylene glycol poisoning.	Orphan Medical, Inc. 13911 Ridgedale Drive 13911 Ridgedale Drive Suite 250 Minnetonka MN 55305
Fosphenytoin *Cerebyx*	DD: 6/4/1991 MA: 8/5/1996	For the acute treatment of patients with status epilepticus of the grand mal type.	Warner-Lambert Company 2800 Plymouth Road 2800 Plymouth Road Ann Arbor MI 48106
Fructose-1,6-diphosphate *Cordox*	DD: 5/29/1998 MA:	Treatment of painful vaso-occlusive episodes associated with sickle cell disease.	Questcor Pharmaceuticals, Inc. 3260 Whipple Road 3260 Whipple Road Union City CA 94587-1217
G17DT Immunogen	DD: 7/18/2002 MA:	Treatment of gastric cancer	Aphton Corporation 26 Harter Avenue Suite 14 Woodland CA 95776
G17DT Immunogen	DD: 7/10/2002 MA:	Treatment of adenocarcinoma of the pancreas	Aphton Corporation 26 Harter Avenue Suite 14 Woodland CA 95776
Gabapentin *Neurontin*	DD: 7/5/1995 MA:	Treatment of amyotrophic lateral sclerosis.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor MI 48105
Gallium nitrate injection *Ganite*	DD: 12/5/1988 MA: 1/17/1991	Treatment of hypercalcemia of malignancy.	Solopak Pharmaceutical Co. 1845 Tonne Road Elk Grove Village IL 60007
Gamma hydroxybutyrate	DD: 12/3/1987 MA: MA:	Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, behavior. hypnagogic hallucinations and automatic	Biocraft Laboratories, Inc. 18-01 River Road Fair Lawn NJ 07410
Gamma-hydroxybutyric acid	DD: 1/22/1985 MA:	Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations, and automatic behavior.	Sigma Chemical Company

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Gammalinolenic acid	DD: 7/27/1994 MA:	Treatment of juvenile rheumatoid arthritis.	Zurier, Robert B. M.D. University of Massachusetts Medical Center 55 Lake Avenue Worcester MA 01655
Ganaxolone	DD: 5/25/1994 MA:	Treatment of infantile spasms.	Purdue Pharma L.P. Purdue Pharma L.P. One Stamford Forum Stamford CT 06901-3431
Ganciclovir intravitreal implant *Vitrasert Implant*	DD: 6/7/1995 MA: 3/4/1996	Treatment of cytomegalovirus retinitis.	Bausch & Lomb Surgical, Chiron Vision Products 9342 Jeronimo Road Irvine CA 92718-1903
Ganciclovir sodium *Cytovene*	DD: MA: 6/23/1989	Treatment of cytomegalovirus retinitis in immunocompromised patients with AIDS.	Syntex (USA), Inc. 3401 Hillview Avenue 3401 Hillview Avenue Palo Alto CA 94304
Gancyclovir	DD: 6/7/1985 MA: MA:	Treatment of severe human cytomegalovirus infections in specific immunosuppressed patient populations.	Burroughs Wellcome Company 3030 Cornwallis Road
Gangliosides as sodium salts *Cronassial*	DD: MA:	Treatment of retinitis pigmentosa.	Fidia Pharmaceutical Corp. 1401 Eye Street, N.W. Suite 900 Washington DC 20005
Gavilimomab	DD: MA:	Acute graft-versus-host disease (aGVHD)	Abgenix, Inc. 7601 Dumbarton Circle Fremont CA 94555
Gemtuzumab zogamicin *Mylotarg*	DD: MA: 5/17/2000	Treatment of CD33-positive acute myeloid leukemia.	Wyeth-Ayerst Laboratories PO Box 8299 PO Box 8299 Philadelphia PA 19101-8299
Gene plasmid hVEGF165 driven by human cytomegalovirus, and [2,3-bis(oleoyl)propyl]trimethyl ammonium and dioleoyl phosphatidyl ethanolamine *Trinam*	DD: MA: MA:	Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.	Ark Therapeutics Ltd. 1 Fitzroy Mews
genetically engineered herpes simplex virus (G207)	DD: 4/29/2002 MA:	Tretament of malignant glioma	MediGene, Inc. 9880 Campus Point Drive, Suite A San Diego CA 92121

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Gentamicin impregnated PMMA beads on surgical wire *Septopal*	DD: 1/31/1991 MA: MA:	Treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin.	Lipha Pharmaceuticals, Inc. 9 West 57th Street Suite 3825 New York NY 10019-2701
Gentamicin liposome injection *Maitec*	DD: 7/10/1990 MA:	Treatment of disseminated Mycobacterium avium-intracellulare infection.	Liposome Company, Inc. One Research Way One Research Way Princeton NJ 08540
Glatiramer acetate *Copaxone*	DD: 11/9/1987 MA:	Treatment of multiple sclerosis.	Teva Pharmaceuticals USA 1510 Delp Drive Kulpsville PA 19443
Glatiramer acetate for injection *Copaxone*	DD: 6/5/2001 MA:	Treatment of primary-progressive multiple sclerosis	TEVA Pharmaceuticals, USA 1090 Horsham Road 1090 Horsham Road North Wales PA 19454
Glutamine	DD: 3/6/1995 MA: MA:	For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).	Nutritional Restart Pharmaceutical, L.P. 4364 South Alston Avenue Durham NC 27713
Glyceol	DD: 2/22/1990 MA:	To decrease intracranial hypertension and/or alleviate cerebral edema in patients who may benefit from osmotherapy.	Chugai Pharmaceutical Co., Ltd.
Glyceryl trioleate and glyceryl trierucate	DD: 2/14/1995 MA:	Treatment of adrenoleukodystrophy.	Moser, Hugo W. M.D. Johns Hopkins University Kennedy Krieger Institute, 707 North Broadway Baltimore MD 21205
Gonadorelin acetate *Lutrepulse*	DD: 4/22/1987 MA: MA:	For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.	Ferring Laboratories, Inc. 400 Rella Boulevard, Suite 201 400 Rella Boulevard, Suite 201 Suffern NY 10901
Gossypol	DD: MA:	Treatment of cancer of the adrenal cortex.	Reidenberg, Marcus M. M.D. The New York Hospital - Cornell Medical Center 525 East 68th Street, Box 70 New York NY 10021
Gp100 adenoviral gene therapy	DD: 3/25/1997 MA:	Treatment of metastatic melanoma.	Genzyme Corporation One Mountain Rd. P.O. Box 9322 Framingham MA 01701-9322
Granulocyte macrophage-colony stimulating factor *Leucomax*	DD: 5/4/1990 MA: MA:	Treatment of chronic lymphocytic leukemia to increase granulocyte count.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Granulocyte macrophage-colony stimulating factor *Leucomax*	DD: MA: MA:	Treatment of neutropenia associated with bone marrow transplants.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033
Granulocyte macrophage-colony stimulating factor *Leucomax*	DD: 5/3/1990 MA: MA:	Treatment of neutropenia due to hairy cell leukemia.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033
Granulocyte macrophage-colony stimulating factor *Leucomax*	DD: 8/7/1989 MA: MA:	Treatment of myelodysplastic syndrome.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033
Granulocyte macrophage-colony stimulating factor *Leucomax*	DD: 6/6/1989 MA: MA:	Treatment of severe thermal injuries in patients with greater than 40% full or partial thickness burns.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033
Group B streptococcus immune globulin	DD: 5/8/1990 MA:	Treatment of neonates for disseminated group B streptococcal infection.	North American Biologicals, Inc. 12280 Wilkins Avenue Rockville MD 20852
Growth hormone releasing factor	DD: 8/7/1989 MA: MA:	For the long-term treatment of children who have growth failure due to a lack of secretion. adequate endogenous growth hormone	Valeant Pharmaceuticals International 3300 Hyland Avenue Costa Mesa CA 92626
Guanethidine monosulfate *Ismelin*	DD: 1/6/1986 MA:	Treatment of moderate to severe reflex sympathetic dystrophy and causalgia.	Novartis Pharmaceuticals 59 Route 10 59 Route 10 East Hanover NJ 07936-1080
Guanfacine *Tenex*	DD: 8/5/1999 MA:	Treatment of fragile X syndrome.	Watson Laboratories, Inc. 311 Bonnie Circle PO Box 1900 Corona CA 91718-1900
Gusperimus *Spanidin*	DD: 6/27/1996 MA:	Treatment of acute renal graft rejection episodes.	Bristol-Myers Squibb Pharmaceutical Research Institute 5 Research Parkway P.O. Box 5100 Wallingford CT 06492-7660
h5G1.1-mAb	DD: 9/21/2000 MA:	Treatment of dermatomyositis	Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc. 352 Knotter Drive 25 Science Park Cheshire CT 06410

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Halofantrine Pharmaceuticals *Halfan*	DD: 11/4/1991 MA: 7/24/1992 MA: 7/24/1992	Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.	SmithKline Beecham One Franklin Plaza One Franklin Plaza P.O. Box 7929 Philadelphia PA 19101
Halofuginone *Stenorol*	DD: 2/7/2000 MA:	Treatment of systemic sclerosis.	Collgard Biopharmaceuticals Ltd. Textile House, 2 Koifman St. Tel-Aviv 68012
heat killed mycobacterium with immunomodulator *CADI Mw*	DD: MA: MA:	Adjuvant to multi-drug therapy in the management of multibacillary leprosy	CPL, Inc. 16020 Swingley Ridge Road Suite 145 Chesterfield MO 63017
Heme arginate *Normosang*	DD: 3/1/1994 MA:	Treatment of myelodysplastic syndromes.	Berlex Laboratories, Inc. 15049 San Pablo Avenue Richmond CA 94804-0099
Heme arginate *Normosang*	DD: 3/10/1988 MA:	Treatment of symptomatic stage of acute porphyria.	Berlex Laboratories, Inc. 15049 San Pablo Avenue 15049 San Pablo Avenue Richmond CA 94804-0099
Hemin *Panhematin*	DD: 3/16/1984 MA: 7/20/1983 MA: 7/20/1983	Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.	Abbott Laboratories Diagnostics Division Diagnostics Division Abbott Park IL 60064
Hemin and zinc mesoporphyrin *Hemex*	DD: MA:	Treatment of acute porphyric syndromes.	Bonkovsky, Herbert L. M.D. University Of Massachusetts Medical Center 55 Lake Avenue North Worcester MA 01655
Hepatitis B immune globulin intravenous (human) *Nabi-HB*	DD: 3/8/1995 MA: MA:	Prophylaxis against hepatitis B virus reinfection in liver transplant patients.	NABI 12280 Wilkins Avenue Rockville MD 20852
Hepatitis C virus immune globulin (human)	DD: MA:	Prophylaxis of hepatitis C infection in liver transplant recipients.	NABI 5800 Park of Commerce Blvd., N.W. Boca Raton FL 33487
HepeX-B	DD: 7/15/2003 MA: MA:	For the prevention of hepatitis B virus (HBV) reinfection in patients who have received a liver transplantation	XTL Biopharmaceuticals, Ltd. Kiryat Weizmann Science Park Bldg 3
Herpes simplex virus gene	DD: MA:	Treatment of primary and metastatic brain tumors.	Genetic Therapy, Inc. 938 Clopper Road Gaithersburg MD 20878

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Histamine *Maxamine*	DD: MA:	Adjunct to cytokine therapy in the treatment of acute myeloid leukemia.	Maxim Pharmaceuticals, Inc. 8899 University Center Lane 8899 University Center Lane Suite 400 San Diego CA 92122
Histamine *Maxamine*	DD: 2/1/2000 MA:	For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.	Maxim Pharmaceuticals, Inc. 8899 University Center Lane 8899 University Center Lane Suite 400 San Diego CA 92122
Histrelin	DD: 5/3/1991 MA:	Treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria.	Anderson, Karl E., M.D. University of Texas Medical Branch at Galveston Route J-09, 700 The Strand Galveston TX 77550
Histrelin acetate *Supprelin Injection*	DD: 8/10/1988 MA:	Treatment of central precocious puberty.	Roberts Pharmaceutical Corp. Meridian Center III 6 Industrial Way West Eatontown NJ 07724
HIV neutralizing antibodies *Immupath*	DD: 3/24/1992 MA:	Treatment of acquired immunodeficiency syndrome.	Hemacare Corporation 4954 Van Nuys Boulevard 4954 Van Nuys Boulevard Sherman Oaks CA 91403
HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex *Allovectin-7*	DD: 9/30/1999 MA: MA:	Treatment of invasive and metastatic melanoma (Stages II, III, and IV).	Vical Incorporated 9373 Towne Centre Dr., Suite 100 San Diego CA 92121
homoharringtonine	DD: 2/8/2002 MA:	Treatment for chronic myelogenous leukemia	American BioScience, Inc. 2730 Wilshire Blvd. #110 Santa Monica CA 90403
HPA-23	DD: 7/17/1985 MA:	Treatment of acquired immunodeficiency syndrome.	Rhone-Poulenc Rorer Pharm. 500 Arcola Road Collegeville PA 19426
Hsp E7	DD: 3/19/2001 MA:	Treatment of recurrent respiratory papillomatosis (RRP)	StressGen Biotechnologies, Inc. 409 2nd Avenue Suite 201 Collegeville PA 19426-2655
Hu1D10, humanized monoclonal antibody *Remitogen*	DD: MA: MA:	For use in the treatment of 1D10+ B cell non-Hodgkin?s lymphoma	Protein Design Labs, Inc. 34801 Campus Drive Fremont CA 94555
Human acid precursor alpha-glucosidase, recombinant	DD: 9/10/1996 MA:	Treatment of glycogen storage disease type II.	Pharming/Genzyme LLC c/o Genzyme Corporation 1 Mountain Rd. Framingham MA 01701-9322

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
human anti-transforming growth factor beta 1 monoclonal antibody	DD: 1/11/2002 MA:	Treatment of systemic sclerosis	Genzyme Corporation One Kendall Square Cambridge MA 02139
Human Anti-tumor Necrosis factor alpha monoclonal antibody	DD: 1/16/2003 MA:	Treatment of uveitis of the posterior segment of non-infectious etiology, and uveitis of the anterior segment of non-infectious etiology and refractory to conventional therapy	Centocor, Inc. 200 Great Valley Parkway Malvern PA 19355-1307
human gammaglobulin	DD: MA:	Treatment of idiopathic inflammatory myopathies	Protein Therapeutics, Inc. 2761 N. Country Club Road Suite 202 Tucson AZ 85716
human gammaglobulin	DD: 5/25/2001 MA:	Treatment for juvenile rheumatoid arthritis	Protein Therapeutics, Inc 2761 N. Country Club Rd. Suite 202 Tucson AZ 85716
human gammaglobulin	DD: 9/16/2002 MA: MA:	Treatment of gastrointestinal disturbances (to include constipation, diarrhea, and regression-onset autism in pediatric patients. abdominal pain) associated with	Protein Therapeutics, Inc. 2761 N. Country Club Rd. Suite 202 Tucson AZ 85716
Human IgM monoclonal antibody (C-58) To CMV *Centovir*	DD: 8/7/1989 MA: MA:	Treatment of cytomegalovirus infections in allogenic bone marrow transplant patients.	Centocor, Inc. 244 Great Valley Parkway Malvern PA 19355
Human IgM monoclonal antibody (C-58) To CMV *Centovir*	DD: 8/7/1989 MA: MA:	Prophylaxis of cytomegalovirus infections in bone marrow transplant patients.	Centocor, Inc. 244 Great Valley Parkway Malvern PA 19355
Human immunodeficiency virus immune globulin *Hivig*	DD: 1/4/1995 MA: MA:	Treatment of HIV-infected pediatric patients.	NABI 5800 Park of Commerce Blvd., NW Boca Raton FL 33487
Human immunodeficiency virus immune globulin	DD: 3/25/1992 MA:	Treatment of HIV-infected pregnant women and infants of HIV-infected mothers.	NABI 5800 Park of Commerce Blvd., N.W. Boca Raton FL 33487
Human immunodeficiency virus immune globulin	DD: MA:	Treatment of AIDS.	NABI 5800 Park of Commerce Blvd., NW Boca Raton FL 33487

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Human T-lymphotropic virus type III Gp160 antigens *Vaxsyn HIV-1*	DD: MA: MA:	Treatment of AIDS.	MicroGeneSys, Inc. 1000 Research Parkway Meriden CT 06450
Humanized anti-CD2 monoclonal antibody	DD: MA:	Treatment of graft-versus-host disease.	MedImmune, Inc. 35 West Watkins Mill Rd. Gaithersburg MD 20878
Humanized anti-human CD2 MAb *MEDI-507*	DD: 9/17/1998 MA: MA:	For the induction of donor-specific immunologic unresponsiveness resulting in prophylaxis of organ rejection without the need for chronic immunosuppressive therapy, in patients receiving allogeneic renal transplants.	Biotransplant, Inc. Building 75, 3rd. Ave. Building 75, 3rd. Ave. Charlestown Navy Yard Charlestown MA 02129
Humanized anti-tac *Zenapax*	DD: 3/5/1993 MA:	Prevention of acute graft-vs-host disease following bone marrow transplantation.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110-1199
Humanized MAb (IDEC-131) to CD40L	DD: 2/9/1999 MA:	Treatment of systemic lupus erythematosus.	Idec Pharmaceuticals Corporation 3030 Callan Rd. San Diego CA 92121
humanized monoclonal antibody against Shiga-like toxin II	DD: 9/12/2001 MA:	To prevent the development of or to decrease the incidence and severity of hemolytic uremic syndrome and associated sequelae of Shiga-like toxin-producing E. coli.	Teijin America, Inc. 600 Alexander Park Suite 304 Princeton NJ 08540
hyaluronic acid	DD: 3/19/2002 MA:	Treatment of emphysema in patients due to alpha-1 antitrypsin deficiency	Exhale Therapeutics, Inc. 1301 Shoreway Road Suite 320 Belmont CA 94002
hydroxocobalamin *Cyanokit*	DD: MA:	Treatment of acute cyanide poisoning	EMD Pharmaceuticals, Inc. P. O. Box 13319 2311 Shannon Road, Suite 500 Durham NC 27707
Hydroxocobalamin *CYANOKIT*	DD: 9/22/2000 MA:	Treatment of acute cyanide poisoning	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 250 Minnetonka MN 55305
Hydroxycobalamin/sodium thiosulfate	DD: 10/4/1985 MA:	Treatment of severe acute cyanide poisoning.	Hall, Alan H., M.D. Mile 5.0 Pass Creek Road PO Box 24 Elk Mountain WY 82324
Hydroxyurea *Droxia*	DD: 10/1/1990 MA: 2/25/1998	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Bristol-Myers Squibb Pharmaceutical Research Institute P.O. Box 4000 Princeton NJ 08543

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Hypericin	DD: 8/3/2000 MA:	Treatment of glioblastoma multiforme.	Nexell Therapeutics 2751 Centerville Rd., Suite 210 Wilmington DE 19808
Hypericin	DD: 2/7/2000 MA:	Treatment of cutaneous T-cell lymphoma.	Nexell Therapeutics, Inc. 2751 Centerville Rd., Suite 210 Wilmington DE 19808
I(131)-TM-601 (chlorotoxin)	DD: 2/14/2002 MA:	treatment of malignant glioma	TransMolecular, Inc. 3800 Colonnade Parkway Suite 240 Birmingham AL 35243
ibritumomab tiuxetan *Zevalin*	DD: 9/6/1994 MA: 2/19/2002	Treatment of B-cell non-Hodgkin's lymphoma.	IDEC Pharmaceuticals Corporation 3030 Callan Road 3030 Callan Road San Diego CA 92121
Ibuprofen i.v. solution	DD: MA:	Treatment of patent ductus arteriosus.	Farmacon-IL-LLC 1720 Post Road East Suite 213 Westport CT 06880-5643
Ibuprofen i.v. solution *Salprofen*	DD: MA:	Prevention of patent ductus arteriosus.	Farmacon-IL, LLC 1720 Post Road East Suite 213 Westport CT 06880-5643
Icatbant	DD: MA:	Treatment of angioedema	Jerini AG Invalidenstr. 130 10115 Berlin
Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution *Extraneal (with 7.5% Icodextrin)*	DD: 7/18/1997 MA: MA:	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Baxter Healthcare Corporation Renal Division 1620 Waukegan Road McGaw Park IL 60085
Idarubicin *Idamycin*	DD: 12/2/1992 MA:	Treatment of chronic myelogenous leukemia.	Pharmacia & Upjohn 7000 Portage Road Unit 0633-298-113 Kalamazoo MI 49001-0199
Idarubicin *Idamycin*	DD: 12/1/1992 MA:	Treatment of myelodysplastic syndromes.	Pharmacia & Upjohn 7000 Portage Road Unit 0633-298-113 Kalamazoo MI 49001-0199
Idarubicin HCl for injection *Idamycin*	DD: 2/12/1991 MA:	Treatment of acute lymphoblastic leukemia in pediatric patients.	Pharmacia & Upjohn 7000 Portage Road 7000 Portage Road Unit 0633-298-113 Kalamazoo MI 49001-0199
Idarubicin HCl for injection *Idamycin*	DD: 7/25/1988 MA: 9/27/1990 MA: 9/27/1990	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Adria Laboratories, Inc. P.O. Box 16529 P.O. Box 16529 Columbus OH 43216

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
IDN 6556	DD: 8/19/2003 MA:	Treatment of patients undergoing solid organ transplantation.	Idun Pharmaceuticals, Inc. 9380 Judicial drive San Diego CA 92121
Idoxuridine	DD: 4/8/1996 MA:	Treatment of nonparenchymatous sarcomas.	NeoPharm, Inc. 225 East Deerpath, Suite 250 Lake Forest IL 60045
iduronate-2-sulfatase	DD: MA:	Long term enzyme replacement therapy for patients with MPS II (Hunter Syndrome)	Transkaryotic Therapies Inc. 195 Albany Street Cambridge MA 02139
Ifosfamide *Ifex*	DD: 1/20/1987 MA:	Treatment of testicular cancer.	Bristol-Myers Squibb Pharmaceutical Research Institute 5 Research Parkway, P.O. Box 5100 Wallingford CT 06492
Ifosfamide *Ifex*	DD: 8/7/1985 MA:	Treatment of soft tissue sarcomas.	Bristol-Myers Squibb Pharmaceutical Research Institute P.O. Box 4000 Princeton NJ 08543
Ifosfamide *Ifex*	DD: 8/7/1985 MA:	Treatment of bone sarcomas.	Bristol-Myers Squibb Pharmaceutical Research Institute P.O. Box 4000 Princeton NJ 08543-4000
IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL)	DD: 4/6/2000 MA:	Treatment of astrocytic glioma.	Neurocrine Biosciences, Inc. 10555 Science Center Dr. San Diego CA 92121
IL13-PE38QQR	DD: 11/2/2001 MA:	Treatment of malignant glioma	NeoPharm, Inc. 150 Field Drive Suite 195 Lake Forest IL 60045
Iloprost solution for infusion	DD: 5/14/1990 MA:	Treatment of heparin-associated thrombocytopenia.	Berlex Laboratories, Inc. 300 Fairfield Road Wayne NJ 07470
Iloprost solution for infusion	DD: 9/21/1989 MA:	Treatment of Raynaud's phenomenon secondary to systemic sclerosis.	Berlex Laboratories, Inc. 300 Fairfield Road Wayne NJ 07470
Imatinib *Gleevec*	DD: 1/31/2001 MA: 5/10/2001	Treatment of chronic myelogenous leukemia	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
imatinib mesylate *Gleevec*	DD: 11/1/2001 MA: 2/1/2002	Treatment of gastrointestinal stromal tumors	Novartis Pharmaceuticals Corp. One Health Plaza East Hanover NJ 07936-1080
Imciromab pentetate *Myoscint*	DD: 1/25/1989 MA:	Detecting early necrosis as an indication of rejection of orthotopic cardiac transplants.	Centocor, Inc. 244 Great Valley Parkway 244 Great Valley Parkway Malvern PA 19355
imexon	DD: 11/1/2003 MA:	Treatment of pancreatic adenocarcinoma	AmpliMed, CorporationAmpliMed, Corporation 2321 Camino La Zorrela Tucson AZ 85718
Imexon *n/a*	DD: 8/3/2001 MA:	Treatment of metastatic malignant melanoma	AmpliMed Corporation 2321 Camino La Zorrela 2321 Camino La Zorrela Tucson AZ 85718
Imexon	DD: 11/8/1996 MA:	Treatment of multiple myeloma.	AmpliMed Corporation 2321 Camino La Zorrela Tucson AZ 85718
Imiglucerase *Cerezyme*	DD: 11/5/1991 MA: 5/23/1994	Replacement therapy in patients with types I, II, and III Gaucher's disease.	Genzyme Corporation One Kendall Square One Kendall Square Cambridge MA 02139-1562
Immune globulin intravenous (human) *Iveegam, Immuno*	DD: MA: MA:	Treatment of juvenile rheumatoid arthritis.	Immuno Clinical Research Corp. 750 Lexington Avenue, 19th Floor New York NY 10022
Immune globulin intravenous (human) *Iveegam, Immuno*	DD: MA: MA:	Treatment of polymyositis/dermatomyositis.	Immuno Clinical Research Corp. 155 East 56th Street New York NY 10022
Immune globulin intravenous (human) *Immune Globulin Intravenous (human)*	DD: MA: MA:	Treatment of patients with acute myocarditis.	Immuno Clinical Research Corp. 750 Lexington Avenue New York NY 10022
Immune globulin intravenous, human *Gamimune N*	DD: 2/18/1993 MA:	Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus.	Bayer Corporation Pharmaceutical Division, Biological Products Products 400 Morgan Lane New Haven CT 06516
Imported fire ant venom, allergenic extract	DD: 5/12/1992 MA:	For skin testing of victims of fire ant stings to confirm fire ant sensitivity and if positive, for use as immunotherapy for the prevention of IgE-mediated anaphylactic reactions.	ALK Laboratories, Inc. Research Center 27 Village Lane Wallingford CT 06492

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Indium In 111 murine monoclonal antibody FAB to myosin *Myoscint*	DD: 8/7/1989 MA: MA:	To aid in the diagnosis of myocarditis.	Centocor, Inc. 244 Great Valley Parkway Malvern PA 19355
Indium In-111 altumomab pentetate *Hybri-ceaker*	DD: 2/6/1990 MA: MA:	Detection of suspected and previously unidentified tumor foci of recurrent colorectal carcinoma.	Hybritech, Inc. 11095 Torreyanna Road 11095 Torreyanna Road San Diego CA 92196
infliximab *Remicade*	DD: 5/6/2003 MA:	Treatment of giant cell arteritis	Centocor, Inc. 200 Great Valley Parkway Malvern PA 19355-1307
Infliximab *Remicade*	DD: MA: 8/24/1998 MA: 8/24/1998	Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapy; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).	Centocor, Inc. 200 Great Valley Parkway 200 Great Valley Parkway Malvern PA 19355-1307
infliximab *REMICADE*	DD: MA:	Treatment of pediatric (0 to 16 years of age) Crohn's Disease	Centocor, Inc. 200 Great Valley Parkway 200 Great Valley Parkway Malvern PA 19355-1307
infliximab *REMICADE*	DD: MA:	Treatment of pediatric (0 to 16 years of age) ulcerative colitis	Centocor, Inc. 200 Great Valley Parkway 200 Great Valley Parkway Malvern PA 19355-1307
infliximab *Remicade*	DD: 5/21/2003 MA:	Treatment of chronic sarcoidosis	Centocor, Inc. 200 Great Valley Parkway Malvern PA 19355-1307
infliximab *Remicade*	DD: MA: MA:	Treatment of juvenile rheumatoid arthritis	Centocor, Inc. 200 Great Valley Parkway Malvern PA 19355-1307
INGN 201 *ADVEXIN*	DD: 1/27/2003 MA: MA:	Treatment of head and neck cancer	Introgen Therapeutics, Inc. 2250 Holcombe Blvd Houston TX 77030
INH-A00021 *Veronate*	DD: 6/13/2001 MA: MA:	Reduction (prevention) of nosocomial bacteremia caused by staphylococci in very low birth weight infants.	Inhibitex, Inc. 8995 Westside Parkway 8995 Westside Parkway Suite 150 Alpharetta GA 30004
inolimomab *Leukotac*	DD: MA:	Treatment of graft versus host disease	Opi 6, Chemin de l'industrie 69570 DARDILLY - France

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Inosine pranobex *Isoprinosine*	DD: 9/20/1988 MA:	Treatment of subacute sclerosing panencephalitis.	Newport Pharmaceuticals 897 West Sixteenth Street 897 West Sixteenth Street Newport Beach CA 92663
Interferon alfa-2a *Roferon A*	DD: 6/6/1989 MA:	Treatment of chronic myelogenous leukemia.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110
Interferon alfa-2a (recombinant) *Roferon-A*	DD: 5/11/1990 MA:	For the treatment of metastatic malignant melanoma in combination with Teceleukin.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110
Interferon alfa-2a (recombinant) *Roferon-A*	DD: 5/14/1990 MA: MA:	For the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110-1199
Interferon alfa-2a (recombinant) *Roferon-A*	DD: MA:	Treatment of AIDS related Kaposi's sarcoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110
Interferon alfa-2a (recombinant) *Roferon-A*	DD: 4/18/1988 MA:	Treatment of renal cell carcinoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110-1199
Interferon alfa-2a (recombinant) *Roferon-A*	DD: MA:	For use in combination with fluorouracil for the treatment of esophageal carcinoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110-1199
Interferon alfa-2a (recombinant) *Roferon-A*	DD: 5/2/1990 MA: MA:	For the concomitant administration with Teceleukin for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07119
Interferon alfa-2b (recombinant) *Intron A*	DD: MA:	Treatment of acute hepatitis B.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033
Interferon alfa-2b (recombinant) *Intron A*	DD: 6/22/1987 MA:	Treatment of metastatic renal cell carcinoma.	Schering Corporation 2000 Galloping Hill Road 2000 Galloping Hill Road Kenilworth NJ 07033
Interferon alfa-2b (recombinant) *Intron A*	DD: 5/4/1990 MA:	Treatment of chronic delta hepatitis.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033
Interferon alfa-2b (recombinant) *Intron A*	DD: 8/17/1988 MA:	Treatment of laryngeal (respiratory) papillomatosis.	Schering Corporation 2000 Galloping Hill Road 2000 Galloping Hill Road Kenilworth NJ 07033

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Interferon alfa-2b (recombinant) *Intron A*	DD: 6/22/1987 MA:	Treatment of chronic myelogenous leukemia.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033
Interferon alfa-2b (recombinant) *Intron A*	DD: 8/3/1987 MA:	Treatment of ovarian carcinoma.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033
Interferon alfa-2b (recombinant) *Intron A*	DD: 8/10/1988 MA:	Treatment of carcinoma in situ of the urinary bladder.	Schering Corporation 2000 Galloping Hill Road 2000 Galloping Hill Road Kenilworth NJ 07033
Interferon alfa-2b (recombinant) *Intron A*	DD: 5/13/1988 MA:	Treatment of primary malignant brain tumors.	Schering Corporation 2000 Galloping Hill Road 2000 Galloping Hill Road Kenilworth NJ 07033
Interferon alfa-2b (recombinant) *Intron A*	DD: 6/24/1987 MA:	Treatment of AIDS-related Kaposi's sarcoma.	Schering Corporation 2000 Galloping Hill Road 2000 Galloping Hill Road Kenilworth NJ 07033
Interferon alfa-2b (recombinant) *Intron A*	DD: 4/18/1988 MA:	Treatment of invasive carcinoma of the cervix.	Schering Corporation 2000 Galloping Hill Road 2000 Galloping Hill Road Kenilworth NJ 07033
Interferon alfa-nl *Wellferon*	DD: 8/25/1986 MA:	Treatment of AIDS related Kaposi's sarcoma.	Burroughs Wellcome Company 3030 Cornwallis Road 3030 Cornwallis Road Research Triangle Pk NC 27709
Interferon alfa-nl *Wellferon*	DD: MA: MA:	Treatment of human papillomavirus in patients with severe resistant/recurrent respiratory (laryngeal) papillomatosis.	Glaxo Wellcome Inc. 5 Moore Drive 5 Moore Drive Research Triangle Park NC 27709
Interferon beta (recombinant *Avonex*	DD: 1/13/1993 MA:	Treatment of primary brain tumors.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
Interferon beta (recombinant) *r-HuIFN-beta*	DD: 5/9/1991 MA:	For the intralesional and/or systemic treatment of AIDS-related Kaposi's sarcoma.	Biogen, Inc. 14 Cambridge Center 14 Cambridge Center Cambridge MA 02142
Interferon beta (recombinant) *R-IFN-beta*	DD: 2/12/1991 MA:	For the systemic treatment of metastatic renal cell carcinoma.	Biogen, Inc. 14 Cambridge Center 14 Cambridge Center Cambridge MA 02142
Interferon beta (recombinant) *r-HuIFN-beta*	DD: 4/18/1991 MA:	For the systemic treatment of cutaneous T-cell lymphoma.	Biogen, Inc. 14 Cambridge Center 14 Cambridge Center Cambridge MA 02142

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Interferon beta, recombinant *Betaseron*	DD: MA:	Treatment of acquired immunodeficiency syndrome.	Berlex Laboratories, Inc. 15049 San Pablo Avenue, P.O. Box 15049 San Pablo Avenue, P.O. Box 4099 Richmond CA 94804
Interferon beta-1a *Avonex*	DD: MA: 5/17/1996	Treatment of multiple sclerosis.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
Interferon beta-1a *Rebif*	DD: 3/11/1996 MA:	Treatment of patients with secondary progressive multiple sclerosis.	Serono Laboratories, Inc. 100 Longwater Circle 100 Longwater Circle Norwell MA 02061
Interferon Beta-1a *Avonex*	DD: MA:	Treatment of juvenile rheumatoid arthritis.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
Interferon beta-1a (recombinant human) *Avonex*	DD: 1/7/1999 MA: MA:	Treatment of pulmonary fibrosis.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
Interferon beta-1a (recombinant human)	DD: 7/24/1992 MA:	Treatment of acute non-A, non-B hepatitis.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
Interferon beta-1a (recombinant) *Rebif*	DD: 12/2/1992 MA: MA:	Treatment of symptomatic patients with AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	Serono Laboratories, Inc. 100 Longwater Circle 100 Longwater Circle Norwell MA 02061
Interferon beta-1a (recombinant) *r-HuIFN-beta*	DD: 4/3/1991 MA:	For the systemic treatment of cutaneous malignant melanoma.	Biogen, Inc. 14 Cambridge Center 14 Cambridge Center Cambridge MA 02142
Interferon beta-1b *Betaseron*	DD: MA: 7/23/1993	Treatment of multiple sclerosis.	Chiron Corp. & Berlex Laboratories 4560 Horton Street Emeryville CA 94608
Interferon gamma 1-b *Actimmune*	DD: 9/30/1988 MA:	Treatment of chronic granulomatous disease.	InterMune, Inc. 3280 Bayshore Blvd Brisbane CA 94005
Interferon gamma-1b *Actimmune*	DD: 12/4/1995 MA:	Treatment of renal cell carcinoma.	Genentech, Inc. 1 DNA Way South San Francisco CA 94080-4990

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
interferon gamma-1b *Actimmune*	DD: 9/12/2002 MA:	Treatment of idiopathic pulmonary fibrosis	InterMune, Inc. 3280 Bayshore Boulevard Brisbane CA 94005
Interferon gamma-1b *Actimmune*	DD: 9/30/1996 MA: 2/10/2000 MA: 2/10/2000	Delaying time to disease progression in patients with severe, malignant osteopetrosis.	InterMune , Inc. 3280 Bayshore Boulevard 3280 Bayshore Boulevard Brisbane CA 94005
Interferon-alfa-1b	DD: 4/17/2001 MA:	Treatment of multiple myeloma	Ernest C.Borden Center for Cancer Drud Discovery and Development 9500 Euclid Avenue Clevland OH 44195
Interleukin-1 alpha, human recombinant	DD: 6/17/1991 MA:	For hematopoietic potentiation in aplastic anemia.	Immunex Corporation 51 University Street Seattle WA 98101
Interleukin-1 alpha, human recombinant	DD: 6/17/1991 MA:	For the promotion of early engraftment in bone marrow transplantation.	Immunex Corporation 51 University Street Seattle WA 98101
Interleukin-1 receptor antagonist, human recombinant *Antril*	DD: MA: MA:	Prevention and treatment of graft versus host disease in transplant recipients.	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799
Interleukin-1 receptor antagonist, human recombinant *Antril*	DD: 9/23/1991 MA: MA:	Treatment of juvenile rheumatoid arthritis.	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799
Interleukin-2 *Teceleukin*	DD: 5/3/1990 MA:	In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110
Interleukin-2 *Teleleukin*	DD: 2/6/1990 MA:	Treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110
Interleukin-2 *Teceleukin*	DD: 2/5/1990 MA:	Treatment of metastatic renal cell carcinoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110
Interleukin-2 *Teceleukin*	DD: 5/11/1990 MA: MA:	In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Interleukin-3 human (recombinant)	DD: 5/20/1991 MA: MA:	Promotion of erythropoiesis in Diamond-Blackfan anemia (congenital pure red cell aplasia).	Immunex Corporation 51 University Street Seattle WA 98101
Interleukin-3, human, recombinant	DD: 9/30/1993 MA: MA:	For sequential administration with sargramostim to accelerate neutrophil and autologous bone marrow transplantation for platelet recovery in patients undergoing the treatment of Hodgkin's disease or non-Hodgkin's lymphoma.	Sandoz Pharmaceuticals Corp. 59 Route 10 East Hanover NJ 07936
Intraoral fluoride releasing system *IFRS*	DD: 7/31/2001 MA: MA:	Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer	Digestive Care, Inc. 1120 Win Drive 1120 Win Drive Bethlehem PA 18017
Iobenguane Sulfate I 131	DD: MA: 3/21/1990	For use as a diagnostic adjunct in patients with pheochromocytoma.	University of Michigan UH B1 H410/0028 1500 E. Medical Center Drive Ann Arbor MI 48109-0028
Iodine 131 6B-iodomethyl-19-norcholesterol	DD: 8/1/1984 MA:	For use in adrenal cortical imaging.	David E. Kuhl, M.D. University of Michigan Medical Center/1500 E. Med. B1G412 /0028 University Hospital Ann Arbor MI 48109-0028
Iodine I 123 murine monoclonal antibody to alpha-fetoprotein	DD: 9/30/1988 MA:	Detection of alpha-fetoprotein producing germ cell tumors.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950
Iodine I 123 murine monoclonal antibody to alpha-fetoprotein	DD: 9/30/1988 MA:	Detection of hepatocellular carcinoma and hepatoblastoma.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950
Iodine I 123 murine monoclonal antibody to hCG	DD: 11/7/1988 MA:	Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950
Iodine I 131 bis(indium-diethylenetriaminepent aacetic acid)tyrosyllysine/hMN-14 x m734 F(ab')2 bispecific monoclonal antibody *Pentacea*	DD: 2/22/2000 MA: MA:	Treatment of small-cell lung cancer.	IBC Pharmaceuticals, L.L.C. 300 American Rd. Morris Plains NJ 07950
Iodine I 131 Lym-1 Monoclonal Antibody	DD: 11/2/1987 MA:	Treatment of B-cell lymphoma.	Lederle Laboratories Division American Cyanamide Company Pearl River NY 10965

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Iodine I 131 murine monoclonal antibody IgG2a to B cell *Immurait, LI-2-I-131*	DD: 9/18/1989 MA: MA:	Treatment of B-cell leukemia and B-cell lymphoma.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950
Iodine I 131 murine monoclonal antibody to alpha-fetoprotein	DD: 9/30/1988 MA:	Treatment of hepatocellular carcinoma and hepatoblastoma.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950
Iodine I 131 murine monoclonal antibody to alpha-fetoprotein	DD: 9/30/1988 MA:	Treatment of alpha-fetoprotein producing germ cell tumors.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950
Iodine I 131 murine monoclonal antibody to hCG	DD: 11/7/1988 MA:	Treatment of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950
Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B) *131IchTNT-1*	DD: 2/12/1999 MA: MA:	Treatment of glioblastoma multiforme and anaplastic astrocytoma.	Peregrine Pharmaceuticals, Inc. 14282 Franklin Ave. Tustin CA 92780-7017
irofulven	DD: 7/6/1999 MA:	Treatment of ovarian cancer.	MGI Pharma, Inc. 5775 West Old Shakoppe Rd. Suite 100 Bloomington MN 55437-3107
irofulven	DD: 7/27/1999 MA:	Treatment of renal cell carcinoma.	MGI Pharma, Inc. 6300 West Old Shakoppe Rd. Suite 110 Bloomington MN 55438-2318
iron(III)-hexacyanoferrate(II) *Radiogardase*	DD: 5/1/2003 MA: 10/2/2003 MA: 10/2/2003	Treatment of patients with known or susupected internal contamination with radioactive or non-radioactive cesium or thallium	Heyl Chemisch-Pharmzeutische Fabrik GMBH & Co, KG Goerzallee 253 Goerzallee 253 D-14167 Berlin, Federal Republic of Germany
Isobutyramide	DD: 5/25/1994 MA:	Treatment of sickle cell disease and beta thalassemia.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles CA 90032
Isobutyramide *Isobutyramide oral solution*	DD: MA:	Treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.	Perrine, Susan P., M.D. Boston University Boston University Cancer Research Center Boston MA 02118

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Japanese encephalitis vaccine (live, attenuated)	DD: 5/19/1999 MA:	Prevention of Japanese encephalitis.	Boran Pharmaceuticals 3F, Koryo Academytel, 437-3 Ahyun-Dong, Mapo-Gu, Seoul
Ketoconazole *Nizoral*	DD: 3/27/1991 MA: MA:	For use with cyclosporine A to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.	Pharmedic Company 28101 Ballard Road 28101 Ballard Road Lake Forest IL 60045
L-2-oxothiazolidine-4-carboxylic *Procysteine*	DD: 7/30/1996 MA:	Treatment of amyotrophic lateral sclerosis.	Transcend Therapeutics, Inc. 640 Memorial Drive, 3rd Floor West Cambridge MA 02139
L-2-oxothiazolidine-4-carboxylic *Procysteine*	DD: 6/14/1994 MA:	Treatment of adult respiratory distress syndrome.	Transcend Therapeutics, Inc. 640 Memorial Drive, 3rd Floor West 640 Memorial Drive, 3rd Floor West Cambridge MA 02139
L-5-hydroxytryptophan	DD: 1/20/1999 MA:	Treatment of tetrahydrobiopterin deficiency.	Watson Laboratories, Inc. 311 Bonnie Circle P.O. Box 1900 Corona CA 91718-1900
L-baclofen	DD: 7/13/1990 MA:	Treatment of trigeminal neuralgia.	Fromm, Gerhard M.D. University Of Pittsburgh School of Medicine Pittsburgh PA 15261
L-baclofen *Neuralgon*	DD: MA: MA:	Treatment of intractable spasticity associated with spinal cord injury or multiple sclerosis.	Pharmascience Inc. 6111 Royalmount, Suite 100 6111 Royalmount, Suite 100 Montreal, Quebec H4P 2T4
L-Baclofen *Neuralgon*	DD: 1/30/1992 MA:	Treatment of intractable spasticity in children with cerebral palsy.	Pharmascience Inc. 6111 Royalmount, Suite 100 6111 Royalmount, Suite 100 Montreal, Quebec H4P 2T4
L-Baclofen	DD: 1/6/1998 MA:	Treatment of trigeminal neuralgia.	Pharmascience Inc. 6111 Royalmount, #100 Montreal, Quebec H4P 2T4
L-cycloserine	DD: 8/1/1989 MA:	Treatment of Gaucher's disease.	Lev, Meir M.D. The City College, City University Of NY Medical Sc Convent Avenue at 138 Street New York NY 10031
L-cysteine	DD: 5/16/1994 MA:	For the prevention and lessening of photosensitivity in erythropoietic protoporphyria.	Orphan Pharmaceuticals, U.S.A., Inc. 1101 Kermit Dr. 1101 Kermit Dr. Suite 608 Nashville TN 37217

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
L-glutamine	DD: 8/1/2001 MA:	Treatment of sickle cell disease	Orphan Drugs International, LLC (d.b.a. Hope Therapeutics) PO Box 0401 Montrose CA 91021-0401
L-glutamyl-L-tryptophan	DD: MA:	Treatment of AIDS-related Kaposi's sarcoma.	Cytran Incorporated 10230 N.E. Points Dr. Suite 530 Kirkland WA 98033-7869
L-leucovorin *Isovorin*	DD: MA: MA:	For use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum.	Lederle Laboratories Division of American Cyanamid Division of American Cyanamid Company 401 N. Middletown Road Pearl River NY 10965
L-leucovorin *Isovorin*	DD: 8/1/1991 MA: MA:	For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.	Lederle Laboratories Division of American Cyanamid Division of American Cyanamid Company 401 N. Middletown Road Pearl River NY 10965
L-threonine *Threostat*	DD: 2/6/1989 MA:	Treatment of amyotrophic lateral sclerosis.	Tyson And Associates 12832 Chadron Avenue Hawthorne CA 90250
L-threonine	DD: 7/24/1992 MA:	Treatment of spasticity associated with familial spastic paraparesis.	Interneuron Pharmaceuticals, Inc. 99 Hayden Ave., Suite 200 Lexington MA 02421-7966
Lactic acid *Aphthaid*	DD: 6/29/1999 MA: MA:	Treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.	Frontier Pharmaceutical, Inc. SUNY Farmingdale SUNY Farmingdale Conklin Hall Farmingdale NY 11735
lactic acid bacteria (Lactobacilli, Bifidobacteria, and Steptococci)	DD: 1/15/2002 MA:	Treatment of active chronic pouchitis	VSL Pharmaceuticals, Inc. 800 S. Frederick Avenue Gaithersburg MD 20877
lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)	DD: 1/15/2002 MA:	Prevention of disease relapse in patients with chronic pouchitis	VSL Pharmaceuticals, Inc. 800 S. Frederick Ave. Gaithersburg MD 20877
Lactobin *Lactobin*	DD: 9/12/1990 MA:	Treatment of AIDS-associated diarrhea unresponsive to initial antidiarrheal therapy.	Roxane Laboratories, Inc. P.O. Box 16532 P.O. Box 16532 Columbus OH 43216-6532
Lactoferrin alpha	DD: 8/20/2003 MA:	For the treatment of graft versus host disease	Agennix, Inc. Greenway Plaza Suite 910 Houston TX 77046

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Lactoferrin alpha	DD: 8/20/2003 MA:	For the prevention of graft-versus-host disease	Agennix, Inc. 8 Greenway Plaza Suite 910 Houston TX 77046
Lamotrigine *Lamictal*	DD: 8/23/1995 MA: 8/24/1998	Treatment of Lennox-Gastaut syndrome.	Glaxo Wellcome Research and Development 5 Moore Drive P.O. Box 13398 Research Triangle Park NC 27709
Lanreotide, Somatostatin *Ipstyl*	DD: 9/11/2000 MA:	Treatment for acromegly	IPSEN, Inc. 27 Maple Street Milford MA 01757
laronidase *Aldurazyme*	DD: 9/24/1997 MA: 4/30/2003	Treatment of patients with mucopolysaccharidosis-I.	BioMarin Pharmaceutical, Inc. 371 Bel Marin Keys Boulevard, Suite 371 Bel Marin Keys Boulevard, Suite 210 Novato CA 94949-5608
Latrodectus immune F(ab)2 *Aracmyn*	DD: 6/18/2001 MA:	Treatment of black widow spider envenomations	Rare Disease Therapeutics, Inc. 1101 Kermit Drive, Suite 608 1101 Kermit Drive, Suite 608 Nashville TN 37217
Leflunomide	DD: MA:	Prevention of acute and chronic rejection in patients who have received solid organ transplants.	Williams, MD, James W. Rush-Presbyterian-St. Luke's Medical Ctr., Dept. o 1653 West Congress Parkway Chicago IL 60612-3833
Lepirudin *Refluden*	DD: 2/13/1997 MA: 3/6/1998	Treatment of heparin-associated thrombocytopenia type II.	Hoechst Marion Roussel Frankfurt am Main Frankfurt am Main
Leucovorin *Leucovorin calcium*	DD: 8/17/1988 MA: 8/31/1988	For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma.	Immunex Corporation 51 University Street 51 University Street Seattle WA 98101
Leucovorin *Leucovorin calcium*	DD: 12/8/1986 MA: MA:	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	Immunex Corporation 51 University Street 51 University Street Seattle WA 98101
Leucovorin calcium *Wellcovorin*	DD: 6/23/1988 MA:	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	Glaxo Wellcome Research and Development 5 Moore Drive 5 Moore Drive PO Box 13398 Research Triangle Park NC 27709
Leupeptin	DD: 9/18/1990 MA:	For use as an adjunct to microsurgical peripheral nerve repair.	Neuromuscular Adjuncts, Inc. S.U.N.Y. at Stony Brook H.S.C. T18-020 Stony Brook NY 11794-8181

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Leuprolide acetate *Lupron Injection*	DD: 7/25/1988 MA: 4/16/1993	Treatment of central precocious puberty.	Tap Pharmaceuticals, Inc. 2355 Waukegan Road Deerfield IL 60015
Levocabastine HCl ophthalmic suspension 0.05%	DD: 2/29/1988 MA:	Treatment of vernal keratoconjunctivitis.	Iolab Pharmaceuticals 500 Iolab Drive Claremont CA 94608
Levocarnitine *Carnitor*	DD: 2/28/1984 MA: 4/10/1986	Treatment of genetic carnitine deficiency.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue Gaithersburg MD 20877
Levocarnitine *Carnitor*	DD: 7/26/1984 MA:	Treatment of primary and secondary carnitine deficiency of genetic origin.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue 800 South Frederick Avenue Gaithersburg MD 20877
Levocarnitine *Carnitor*	DD: MA:	For the treatment of secondary carnitine deficiency in valproic acid toxicity.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue 800 South Frederick Avenue Gaithersburg MD 20877
Levocarnitine *Carnitor*	DD: 4/7/1997 MA:	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc. 800 S. Frederick Avenue, Suite 300 800 S. Frederick Avenue, Suite 300 Gaithersburg MD 20877
Levocarnitine *Carnitor*	DD: MA:	For the prevention of secondary carnitine deficiency in valproic acid toxicity.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue 800 South Frederick Avenue Gaithersburg MD 20877
Levocarnitine *Carnitor*	DD: 9/6/1988 MA: MA:	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue, Suite 800 South Frederick Avenue, Suite 300 Gaithersburg MD 20877
Levocarnitine *Carnitor*	DD: MA: MA:	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue 800 South Frederick Avenue Gaithersburg MD 20877
Levocarnitine *Carnitor*	DD: MA:	Treatment of pediatric cardiomyopathy.	Sigma-Tau Pharmaceuticals, Inc. 800 South Frederick Avenue Gaithersburg MD 20877
Levodopa and carbidopa *Duodopa*	DD: 1/18/2000 MA:	Treatment of late stage Parkinson's disease.	Nouvel Pharma, Inc. 11384 Strang Line Road 11384 Strang Line Road Lenexa KS 66215

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Levomethadyl acetate *Orlaam*	DD: 1/24/1985 MA: 7/9/1993	Treatment of heroin addicts suitable for maintenance on opiate agonists.	Biodevelopment Corporation 8180 Greensboro Drive, Suite 1000 8180 Greensboro Drive, Suite 1000 McLean VA 22102
Lidocaine patch 5% *Lidoderm Patch*	DD: MA: 3/19/1999 MA: 3/19/1999	For relief of allodynia (painful hypersensitivity), and chronic pain in post-herpetic neuralgia.	Teikoku Pharma USA, Inc. 745-D Camden Ave. 745-D Camden Ave. Campbell CA 95008-4146
lintuzumab *Zamyl*	DD: 9/9/2002 MA:	Treatment of acute myelogenous leukemia	Protein Design Labs, Inc. 34801 Campus Drive Fremont CA 94555
Liothyronine sodium injection *Triostat*	DD: 7/30/1990 MA:	Treatment of myxedema coma/precoma.	SmithKline Beecham Pharmaceuticals One Franklin Plaza P.O. Box 7929 Philadelphia PA 19101
lipase, amylase, and protease *TheraCLEC-Total*	DD: 1/23/2002 MA:	Treatment of pancreatic insufficiency	Altus Biologics Inc. 625 Putnam Avenue Cambridge MA 02139
Lipid/DNA human cystic fibrosis gene	DD: 4/8/1996 MA:	Treatment of cystic fibrosis.	Genzyme Corporation One Mountain Road P.O. Box 9322 Framingham MA 01701-9322
Liposomal amphotericin B *AmBisome*	DD: 12/6/1996 MA: 8/11/1997	Treatment of visceral leishmaniasis.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield IL 60015
Liposomal amphotericin B *AmBisome*	DD: MA: 8/11/1997	Treatment of cryptococcal meningitis.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield IL 60015
Liposomal amphotericin B *AmBisome*	DD: MA:	Treatment of histoplasmosis.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield IL 60015
Liposomal cyclosporin A *Cyclospire*	DD: 4/30/1998 MA: MA:	For aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation.	Vernon Knight, M.D. Baylor College of Medicine, Dept. of Baylor College of Medicine, Dept. of Molecular Phy One Baylor Plaza Houston TX 77030
Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala *ImmTher*	DD: 6/10/1998 MA: MA:	Treatment of Ewing's sarcoma.	Endorex Corp. 900 North Shore Drive Lake Bluff IL 60044

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Liposomal N-Acetylglucosminyl-N-Acetylmuramiy-L-Ala-D-isoGln-L-Ala *ImmTher*	DD: 6/10/1998 MA: MA:	Treatment of osteosarcoma.	Endorex Corp. 900 North Shore Drive Lake Bluff IL 60044
Liposomal nystatin *Nyotran*	DD: 6/13/2000 MA:	Treatment of invasive fungal infections.	Antigenics, Inc. 34 Commerce Way Woburn MA 01801
liposomal p-ethoxy growth receptor bound protein-2	DD: 12/5/2003 MA:	Treatment of chronic myelogenous leukemia	Interpath Pharmaceuticals, INc. 20651 Prince Creek Dr. Katy TX 77450
Liposomal prostaglandin E1 injection	DD: 4/25/1996 MA:	Treatment of acute respiratory distress syndrome.	Liposome Company, Inc. One Research Way Princeton NJ 08540
Liposomal-cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane-Pt (II)	DD: 9/1/1999 MA:	Treatment of malignant mesothelioma.	Antigenics Incorporated 34 Commerce Way Woburn MA 01801
Liposome encapsulated recombinant interleukin-2	DD: MA:	Treatment of brain and CNS tumors.	Biomira USA, Inc. 1002 Eastpark Boulevard Cranbury NJ 08512
Liposome encapsulated recombinant interleukin-2	DD: 6/20/1994 MA:	Treatment of cancers of the kidney and renal pelvis.	Biomira USA, Inc. 1002 Eastpark Boulevard Cranbury NJ 08512
Lisofylline	DD: 6/10/1999 MA:	Treatment of patients undergoing induction therapy for acute myeloid leukemia.	Cell Therapeutics, Inc. 201 Elliot Avenue West 201 Elliott Avenue West 2 Suite 400 Seattle WA 98119
Lodoxamide tromethamine *Alomide Ophthalmic Solution*	DD: MA: 9/23/1993	Treatment of vernal keratoconjunctivitis.	Alcon Laboratories, Inc. 6201 South Freeway Fort Worth TX 76134
Loxoribine	DD: 2/24/1992 MA:	Treatment of common variable immunodeficiency.	R. W. Johnson Pharmaceutical Research Institute Route 202, P.O. Box 300 Raritan NJ 08869

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Lucinactant *Surfaxin*	DD: MA:	Treatment of respiratory distress syndrome in premature infants.	Discovery Laboratories, Inc. 350 South Main Street 350 South Main Street Suite 307 Doylestown PA 18901
Lucinactant *Surfaxin*	DD: 7/30/1996 MA:	Treatment of meconium aspiration syndrome in newborn infants.	Discovery Laboratories, Inc. 350 South Main Street 350 South Main Street Suite 307 Doylestown PA 18901
Lucinactant *Surfaxin*	DD: 7/17/1995 MA:	Treatment of acute respiratory distress syndrome in adults.	Discovery Laboratories, Inc. 350 South Main Street 350 South Main Street Suite 307 Doylestown PA 18901
Lysine acetylsalicylate injectable	DD: 8/1/1989 MA:	Treatment of pain and fever secondary to sickle cell disease crisis.	G.D. Searle & Company
Mafenide acetate solution *Sulfamylon solution*	DD: 7/18/1990 MA: 6/5/1998 MA: 6/5/1998	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Mylan Laboratories, Inc. 781 Chestnut Ridge Road 781 Chestnut Ridge Road P.O. Box 4310 Morgantown WV 26504-4310
Mafosfamide	DD: 1/21/2003 MA:	Treatment of neoplastic meningitis	Baxter Oncology GmbH (formerly ASTA Medica Oncology) Daimlerstrasse 40 60314 franfurt/Main
Marijuana	DD: 5/25/1999 MA:	Treatment of HIV-associated wasting syndrome.	Multidisciplinary Association for Psychedelic Studies, Inc. 3 Francis St. Belmont MA 02478
MART-1 adenoviral gene therapy for malignant melanoma	DD: 3/28/1997 MA:	Treatment of metastatic melanoma.	Genzyme Corporation One Mountain Road P.O. Box 9322 Framingham MA 01701-9322
Matrix metalloproteinase inhibitor *Galardin*	DD: 12/5/1991 MA:	Treatment of corneal ulcers.	Glycomed, Inc 860 Atlantic Avenue Alameda CA 94501
MaxAdFVIII	DD: 3/3/2003 MA:	Treatment of Hemophilia A	GenStar Therapeutics Corporation 10865 Altman Row Suite 200 San Diego CA 92121-1113
Mazindol *Sanorex*	DD: 12/8/1986 MA:	Treatment of Duchenne muscular dystrophy.	Collipp, Platon J. M.D. 176 Memorial Drive Jesup GA 31545

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Mecamylamine *Inversine*	DD: MA:	Treatment of Tourette's syndrome.	Targacept, Inc. 200 East First St. Suite 300 Winston-Salem NC 27101-4165
Mecasermin *Myotrophin*	DD: 8/5/1991 MA:	Treatment of amyotrophic lateral sclerosis.	Cephalon, Inc. 145 Brandywine Parkway West Chester PA 19380-4245
Mecasermin	DD: MA:	Treatment of growth hormone insufficency syndrome.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco CA 94080
Medroxyprogesterone acetate *Hematrol*	DD: 2/22/2001 MA:	Treatment of immune thrombocytopenic purpura.	InKine Pharmaceutical Company, 1787 Sentry Parkway West 1787 Sentry Parkway West Building 18, Suite 440 Blue Bell PA 19422
Mefloquine HCl *Mephaquin*	DD: 7/22/1987 MA:	Treatment of chloroquine-resistant Falciparummalaria.	Mepha AG 4143 Dornach 4143 Dornach POSTFASH 137
Mefloquine HCl *Lariam*	DD: 4/13/1988 MA: 5/2/1989 MA: 5/2/1989	Treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110
Mefloquine HCl *Lariam*	DD: 4/13/1988 MA: 5/2/1989 MA: 5/2/1989	Prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs.	Hoffmann-La Roche, Inc. 340 Kingsland Street 340 Kingsland Street Nutley NJ 07110
Mefloquine HCl *Mephaquin*	DD: 7/22/1987 MA:	Prevention of chloroquine-resistant Falciparum malaria.	Mepha AG 4143 Dornach 4143 Dornach POSTFASH 137
Megestrol acetate *Megace*	DD: 4/13/1988 MA: 9/10/1993 MA: 9/10/1993	Treatment of patients with anorexia, cachexia, or significant weight loss (=/>10% of baseline body weight) and confirmed diagnosis of AIDS.	Bristol-Myers Squibb Pharmaceutical Research Institute 2400 West Lloyd Expressway 2400 West Lloyd Expressway Evansville IN 47721
Melanoma cell vaccine	DD: MA:	Treatment of invasive melanoma.	CancerVax Corporation 2110 Rutherford Road Carlsbad CA 92008
Melanoma vaccine *Melacine*	DD: MA:	Treatment of stage III - IV melanoma.	Ribi ImmunoChem Research, Inc. 533 Old Corvallis Road Hamilton MT 59840

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Melatonin	DD: MA: MA:	Treatment of circadian rhythm sleep disorders in blind people with no light perception.	Sack, Robert, M.D. Oregon Health Sciences University 3181 S.W. Sam Jackson Park Road Portland OR 97201
meloxicam *Mobic*	DD: MA:	Treatment of juvenile rheumatoid arthritis	Boehringer Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road P. O. Box 368 Ridgefield CT 06877-0368
Melphalan *Alkeran for Injection*	DD: 3/3/1992 MA:	For use in hyperthermic regional limb perfusion to treat metastatic melanoma of the extremity.	Glaxo Wellcome Research and Development 5 Moore Drive 5 Moore Drive PO Box 13398 Research Triangle Park NC 27709
Melphalan *Alkeran For Injection*	DD: 2/24/1992 MA:	Treatment of patients with multiple myeloma for whom oral therapy is inappropriate.	Glaxo Wellcome Inc. 5 Moore Drive 5 Moore Drive Research Triangle Park NC 27709
Meropenem *Merrem IV*	DD: 4/27/2000 MA: MA:	Management of acute pulmonary exacerbations, in cystic fibrosis patients, due to respiratory tract infection with susceptible organisms.	Zeneca Pharmaceuticals 1800 Concord Pike 1800 Concord Pike PO Box 15437 Wilmington DE 19850-5437
Mesna *Mesnex*	DD: MA: MA:	For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.	Degussa Corporation 65 Challenger Road 65 Challenger Road Ridgefield Park NJ 07660
Mesna	DD: MA: MA:	Inhibition of the urotoxic effects induced by oxazaphosphorine compounds such as cyclophosphamide.	Asta Medica , Inc. 890 East St. Tewksbury MA 01876-1496
Methionine/L-methionine	DD: 8/21/1996 MA:	Treatment of AIDS myelopathy.	Di Rocco, Alessandro M.D. Beth Israel Medical Center, Phillips Ambulatory Ca Philips Building, Suite 2R; 10 Union Square East New York NY 10003
Methotrexate *Rheumatrex*	DD: 8/23/1993 MA:	Treatment of juvenile rheumatoid arthritis.	Wyeth-Ayerst Laboratories P.O. Box 8299 Philadelphia PA 19101-8299
Methotrexate sodium *Methotrexate*	DD: MA: 4/7/1988	Treatment of osteogenic sarcoma.	Lederle Laboratories Division of American Cyanamid Company 401 N. Middletown Road Pearl River NY 10965
Methotrexate with laurocapram *Methotrexate/azone*	DD: MA:	Topical treatment of mycosis fungoides.	Durham Pharmaceuticals LLC 200 Westpark Corporate Center 4364 South Alston Avenue Durham NC 27713-2280

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Methoxsalen *Uvadex*	DD: MA: MA:	For use in conjunction with the UVAR photopheresis system to treat graft versus host disease.	Therakos, Inc. 437 Creamery Way 437 Creamery Way Exton PA 19431
methylbicyclone	DD: MA:	Treatment of cystic fibrosis	Sucampo Pharmaceuticals, Inc. 4733 Bethesda Ave. Suite 450 Bethesda MD 20814
Methylnaltrexone	DD: 6/17/1996 MA: MA:	Treatment of chronic opioid-induced constipation unresponsive to conventional therapy.	University of Chicago 5841 South Maryland Avenue MC 4028 Chicago IL 60637
metreleptin	DD: 8/22/2001 MA:	Treatment of metabolic disorders secondary to lipodystrophy	Amgen, Inc., One Amgen Center Drive Thousand Oaks CA 91320-1799
metreleptin	DD: 8/22/2001 MA: MA:	Treatment of leptin deficiency secondary to generalized lipodystrophy lipodystrophy and partial familial	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799
Metronidazole *Metrogel*	DD: MA:	Treatment of perioral dermatitis.	Galderma Laboratories, Inc. P.O. Box 331329 Fort Worth TX 76163
Metronidazole (topical) *Metrogel*	DD: MA:	Treatment of acne rosacea.	Galderma Laboratories, Inc. P.O. Box 331329 Fort Worth TX 76163
Metronidazole (topical) *Flagyl*	DD: MA:	Treatment of grade III and IV, anaerobically infected, decubitus ulcers.	Searle 4901 Searle Parkway 4901 Searle Parkway Skokie IL 60077
Microbubble contrast agent *Filmix Neurosonographic Contrast*	DD: MA:	Intraoperative aid in the identification and localization of intracranial tumors.	Cav-Con, Inc. 55 Knollwood Road 55 Knollwood Road Farmington CT 06032
Midodrine HCl *Amatine*	DD: 12/5/1996 MA: 9/6/1996	Treatment of patients with symptomatic orthostatic hypotension.	Schier Ridgewood F.K.A. (Roberts Pharmaceutical Corp.) Meridian Center III 6 Industrial Way West Eatontown NJ 07724
miglustat *Zavesca*	DD: 5/29/1998 MA: 7/31/2003	Treatment of Gaucher disease.	Actelion Pharmaceuticals Ltd Gewerbestrasse 16 CH - 4123 Allschwi

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Minocycline HCl *Minocin Intravenous*	DD: 6/19/1992 MA: MA:	Treatment of chronic malignant pleural effusion.	Lederle Laboratories Division Pearl River NY 10965
Mitoguazone *apep*	DD: 3/18/1994 MA: MA:	Treatment of diffuse non-Hodgkin's lymphoma, including AIDS-related diffuse non-Hodgkin's lymphoma.	ILEX Oncology, Inc. 4545 Horizon Hill Blvd. 4545 Horizon Hill Blvd. San Antonio TX 78229-2263
Mitolactol	DD: 7/12/1995 MA:	As adjuvant therapy in the treatment of primary brain tumors.	Biopharmaceutics, Inc. 990 Station Road Bellport NY 11713
Mitolactol	DD: 1/23/1989 MA: MA:	Treatment of recurrent invasive or metastatic squamous carcinoma of the cervix.	Biopharmaceutics, Inc. 990 Station Road Bellport NY 11713
Mitomycin-C	DD: 8/20/1993 MA:	Treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.	IOP Inc. 3100 Airway Avenue, Suite 106 Costa Mesa CA 92626
Mitoxantrone *Novantrone*	DD: 8/13/1999 MA:	Treatment of progressive-relapsing multiple sclerosis.	Immunex Corporation 51 University St. 51 University St. Seattle WA 98101
Mitoxantrone *Novantrone*	DD: 8/13/1999 MA:	Treatment of secondary-progressive multiple sclerosis.	Immunex Corporation 51 University St. 51 University St. Seattle WA 98101
Mitoxantrone *Novantrone*	DD: 8/21/1996 MA:	Treatment of hormone refractory prostate cancer.	Serono One Technology Place One Technology Place Rockland MA 02370
Mitoxantrone HCl *Novantrone*	DD: 7/13/1987 MA: MA:	Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Lederle Laboratories Division of American Cyanamid Division of American Cyanamid Company 401 N. Middletown Road Pearl River NY 10965
MN14 monoclonal antibody to carcinoembryonic antigen *Cea-Cide*	DD: MA: MA:	Treatment of pancreatic cancer.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950
MN14 monoclonal antibody to carcinoembryonic antigen *Cea-Cide*	DD: 9/18/1998 MA: MA:	For the treatment of small cell lung cancer.	Immunomedics, Inc. 300 American Rd. Morris Plains NJ 07950

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Modafinil *Provigil*	DD: 3/15/1993 MA:	Treatment of excessive daytime sleepiness in narcolepsy.	Cephalon, Inc. 145 Brandywine Parkway 145 Brandywine Parkway West Chester PA 19380
Molgramostim *Leucomax*	DD: 9/25/1989 MA:	Treatment of aplastic anemia.	Schering Corporation 2000 Galloping Hill Road Kenilworth NJ 07033
Molgramostim *Leucomax*	DD: 1/24/1989 MA:	Treatment of AIDS patients with neutropenia due to the disease, AZTor ganciclovir.	Schering Corporation 2000 Galloping Hill Road 2000 Galloping Hill Road Kenilworth NJ 07033
monarsen	DD: MA:	Treatment of Myasthenia Gravis	Medica Venture Partners Ackerstein Towers, Bldg B, 10th Floor ISRAEL
Monoclonal Ab(murine) anti-idiotype melanoma-associated antigen *Melimmune*	DD: 9/19/1994 MA: MA:	Treatment of invasive cutaneous melanoma.	IDEC Pharmaceuticals Corporation 3030 Callan Road San Diego CA 92121
Monoclonal antibodies (murine or human) to B-cell lymphoma	DD: 5/6/1986 MA:	Treatment of B-cell lymphoma.	IDEC Pharmaceuticals Corporation 11011 Torreyana Road San Diego CA 92121
Monoclonal antibodies PM-81 and AML-2-23	DD: 3/12/1990 MA:	For the exogenous depletion of CD14 and CD15 positive acute myeloid leukemic bone marrow cells from patients undergoing bone marrow transplantation.	Medarex, Inc. 67 Beaver Avenue Annandale NJ 08801-0953
Monoclonal antibody 17-1a *Panorex*	DD: 4/4/1988 MA:	Treatment of pancreatic cancer.	Centocor, Inc. 244 Great Valley Parkway Malvern PA 19355
Monoclonal antibody for immunization against lupus nephritis	DD: 1/7/1993 MA:	Treatment of lupus nephritis.	VivoRx Autoimmune, Inc. 2825 Santa Monica Blvd., Suite 200 Santa Monica CA 90404
Monoclonal antibody PM-81	DD: 6/27/1991 MA:	Adjunctive treatment of acute myelogenous leukemia.	Medarex, Inc. 519 Route 173 West Bloomsbury NJ 08804
Monoclonal antibody to cytomegalovirus (human)	DD: MA:	Treatment of cytomegalovirus retinitis in patients with AIDS.	Protein Design Labs, Inc. 2375 Garcia Avenue Mountain View CA 94043

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Monoclonal antibody to cytomegalovirus (human)	DD: 9/13/1991 MA:	Prophylaxis of cytomegalovirus disease in patients undergoing solid organ transplantation.	Protein Design Labs, Inc. 2375 Garcia Avenue Mountain View CA 94043
Monoclonal antibody to hepatitis B virus (human)	DD: 6/17/1991 MA:	Prophylaxis of hepatitis B reinfection in patients undergoing liver transplantation secondary to end-stage chronic hepatitis B infection.	Protein Design Labs, Inc. 34801 Campus Dr. Fremont CA 94555
Monoclonal antibody-B43.13 *Ovarex MAb-B43.13*	DD: MA:	Treatment of epithelial ovarian cancer.	AltaRex US Corp. 610 Lincoln Street Waltham MA 02451
Monoclonal antiendotoxin antibody XMMEn-0e5	DD: 11/4/1985 MA:	Treatment of patients with gram-negative sepsis which has progressed to shock.	Pfizer, Inc. 235 East 42nd Street New York NY 10017
Monolaurin *Glylorin*	DD: 4/29/1993 MA:	Treatment of congenital primary ichthyosis.	Glaxo Wellcome Inc. 5 Moore Drive PO Box 13398 Research Triangle Park NC 27709
Monooctanoin *Moctanin*	DD: 5/30/1984 MA:	For dissolution of cholesterol gallstones retained in the common bile duct.	Ethitek Pharmaceuticals, Inc. 7855 Gross Point Road, Unit L 7855 Gross Point Road, Unit L Skokie IL 60077
Morphine sulfate concentrate (preservative free) *Infumorph*	DD: 7/12/1990 MA: 7/19/1991 MA: 7/19/1991	For use in microinfusion devices for intraspinal administration in the treatment of intractable chronic pain.	Elkins-Sinn, Inc. 2 Esterbrook Lane Cherry Hill NJ 08003
motexafin gadolinium *Xcytrin*	DD: 1/27/2003 MA: MA:	For use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors	Pharmacyclics, Inc. 999 East Arques Avenue 999 East Arques Avenue Sunnyvale CA 94085-4521
MTC-DOX for Injection	DD: 1/3/2001 MA:	Treatment of hepatocellular carcinoma	FeRx Incorporated 4330 La Jolla Village Drive Suite #250 San Diego CA 92122
Mucoid exopolysaccharide Pseudomonas hyperimmune globulin *MEP IGIV*	DD: 11/7/1990 MA: MA:	Prevention of pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.	North American Biologicals, Inc. 12280 Wilkins Avenue Rockville MD 20852

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Mucoid exopolysaccharide Pseudomonas hyperimmune globulin	DD: 1/9/1991	Treatment of pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.	North American Biologicals, Inc. 12280 Wilkins Avenue
MEP IGIV	MA: MA:		Rockville MD 20852
Multi-vitamin infusion (neonatal formula)	DD: MA:	For establishment and maintenance of total parenteral nutrition in very low birth weight infants.	Astra Pharmaceuticals, L.P. 725 Chesterbrook Blvd. Wayne PA 19087-5677
muramyltripeptide, phosphatidyl-ethanolamine encased in multi-lamellar	DD: 6/5/2001 MA:	Treatment of children and adolescent osteosarcoma	Immuno-Designed Molecules 9 Parker Irvine CA 92618-1605
Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma	DD:	Treatment of B-cell non-Hodgkin's lymphoma.	Peregrine Pharmaceuticals, Inc. 14272 Franklin Ave.
Oncolym	MA: MA:		Suite 100 Tustin CA 92780
Murine MAb to polymorphic epithelial mucin, human milk fat globule 1	DD: 3/22/1999	Adjuvant treatment of ovarian cancer.	Antisoma plc West Africa House
Theragyn	MA: MA:		Hanger Lane Ealing
Mx-dnG1 or Rexin-G retroviral *REXIN-G*	DD: 8/15/2003 MA:	Treatment of pancreatic cancer	Epeius Biotechnologies Corporation 345 Pioneer Drive, 1803W Glendale CA 91203
Mycobacterium avium sensitin RS-10	DD: MA:	For use in the diagnosis of invasive Mycobacterium avium disease in immunocompetent individuals.	Statens Seruminstitut 5 Artillerivej DK-2300 Copenhagen S
Myelin	DD: 6/27/1991 MA:	Treatment of multiple sclerosis.	AutoImmune, Inc. 128 Spring Street Lexington MA 02173
myristoylated recombinant SCR1-3 of human complement reseptor type I	DD: 5/21/2003	Prevention of delayed graft function in solid organ transplant	Adprotech, Ltd. Chesterford Research Pk,
APT070	MA: MA:		Little Chesterford, Saffron Walden,

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea	DD: 5/13/2002 MA:	Treatment of sickle cell disease	NeuroSearch A/S 93 Pederstrupvej DK-2750 Ballerup
N-acetyl-procainamide	DD: MA: MA:	Prevention of life-threatening ventricular arrhythmias in patients with documented procainamide-induced lupus.	NAPA of the Bahamas 3560 Pennsylvania Avenue, Suite 7 Dubuque IA 52002
N-acetyl-sarcosyl-glycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl_L-prolylethyl aminde acetate	DD: 12/9/2003 MA:	For the treatment of soft tissue sarcoma	Abbott Laboratories Pharmaceutical Products Division 200 Abbott Park Road Abbott Park IL 60064
N-acetylcysteinate Lysine *Nacystelyn Dry Powder Inhaler*	DD: MA:	For the management of cystic fibrosis	Galephar Pharmaceutical Research, Inc. Road 198, No. 100 km. 14.7 Juncos Industrial Park Juncos PR 00777-3873
N-acetylcysteine	DD: 9/9/2002 MA:	Treatment of acute liver failure	William M. Lee, MD, FACP University of Texas Southwestern Medical Center at 5323 Harry Hines Blvd Dallas TX 75390-9151
N-acetylgalactosamine-4-sulfatase, recombinant human	DD: 2/17/1999 MA:	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	BioMarin Pharmaceutical, Inc. 11 Pimental Court Novato CA 94949-5608
N-acetylprocainamide *Napa*	DD: 3/23/1990 MA: MA:	To lower the defibrillation energy requirement sufficiently to allow automatic implantable cardioverter defibrillator therapy in those patients who could otherwise not use the device.	Medco Research, Inc. 8455 Beverly Blvd. 8455 Beverly Blvd. Suite 308 Los Angeles CA 90048
Nafarelin acetate *Synarel Nasal Solution*	DD: 7/20/1988 MA: 2/26/1992	Treatment of central precocious puberty.	Syntex (USA), Inc. 3401 Hillview Avenue Palo Alto CA 94303
Naltrexone HCl *Trexan*	DD: 3/11/1985 MA: MA:	For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals.	DuPont Pharmaceuticals E.I. Du Pont De Nemours & Co. E.I. Du Pont De Nemours & Co. Wilmington DE 19880
Natural human lymphoblastoid interferon-alpha	DD: 8/10/2000 MA:	Treatment of papillomavirus warts in the oral cavity of HIV positive patients.	Atrix Laboratories, Inc. 2579 Midpoint Drive Fort Collins CO 80525-4417

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Natural human lymphoblastoid interferon-alpha	DD: 1/18/2000 MA:	Treatment of Behcet's disease.	Atrix Laboratories, Inc. 2579 Midpoint Dr. Fort Collins CO 80525-4417
Natural human lymphoblastoid interferon-alpha	DD: MA:	Treatment of polycythemia vera	Amarillo Biosciences, Inc. 800 West 9th Avenue Amarillo TX 79101
NDROGE	DD: 11/1/1984 MA:	Treatment of postanoxic intention myoclonus.	WATSON Laboratories, Inc. 33 Ralph Avenue P.O. Box 30 Copiaque NY 11726-0030
Nebacumab *Centoxin*	DD: 10/1/1986 MA: MA:	Treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.	Centocor, Inc. 200 Great Valley Parkway 200 Great Valley Parkway Malvern PA 19355
Neurotrophin-1	DD: 9/13/1994 MA:	Treatment of motor neuron disease/amyotrophic lateral sclerosis.	Ericsson, Arthur Dale, M.D. 6560 Fannin, Scurlock Tower, Suite 720 Houston TX 77303
NG-29 *Somatrel*	DD: 8/8/1989 MA:	Diagnostic measure of the capacity of the pituitary gland to release growth hormone.	Ferring Laboratories, Inc. 400 Rella Boulevard, Suite 201 400 Rella Boulevard, Suite 201 Suffern NY 10901
Nifedipine	DD: 6/13/1991 MA:	Treatment of interstitial cystitis.	Fleischmann, Jonathan M.D. MetroHealth Medical Center 3395 Scranton Road Cleveland OH 44109
niprisan *Hemoxin*	DD: 8/15/2003 MA:	Treatment of sickle cell disease	Xechem International, Inc. New Brunswick Technology Center 100 Jersey Avenue, Building B, Suite 310 New Brunswick NJ 08901
nitazoxanide *Alinia*	DD: 2/14/2002 MA:	Treatment of intestinal giardiasis	Romark Laboratories, L.C. 6200 Courtney Campbell Causeway Suite 880 Tampa FL 33607
nitazoxanide *Cryptaz*	DD: MA:	Treatment for intestinal amebiasis	Romark Laboratories, L.C. 6200 Courtney Campbell Causeway Suite 880 Tampa FL 33607
Nitazoxanide *Alinia*	DD: MA:	Treatment of cryptosporidiosis.	Romark Laboratories, L.C. 6200 Courtney Campbell Causeway Suite 880 Tampa FL 33607

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Nitisinone *Orfadin*	DD: 5/16/1995 MA: 1/18/2002	Treatment of tyrosinemia type 1.	Swedish Orphan AB Drottninggatan 98 SE-111 60 Stockholm
Nitisinone *Orfadin*	DD: MA:	Treatment of alkaptonuria	Swedish Orphan AB Kungsgatan 37, 7th Floor SE-111 56
Nitric oxide *INOmax*	DD: 6/22/1993 MA:	Treatment of persistent pulmonary hypertension in the newborn.	INO Therapeutics, Inc. 54 Old Highway 22 54 Old Highway 22 Clinton NJ 08809
Nitric oxide	DD: 7/10/1995 MA:	Treatment of acute respiratory distress syndrome in adults.	INO Therapeutics, Inc. 54 Old Highway 22 Clinton NJ 08809
Nitroprusside	DD: 2/21/2001 MA:	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Thomas, MD, Jeffrey Evan Thomas Jefferson University and Wills Neurosensory 834 Walnut Street, Suite 650 Philadelphia PA 19107-5102
nolatrexed *THYMITAQ*	DD: MA:	Treatment of hepatocellular carcinoma	Zarix, Inc. 1055 Westlakes Drive Suite 200 Berwyn PA 19312
Novel Acting Thrombolytic (NAT)	DD: 1/26/2001 MA:	Treatment of peripheral arterial occlusion (PAO)	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799
NZ-1002	DD: 4/11/2001 MA:	Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.	Novazyme Pharmaceuticals, Inc. 800 Research Parkway Suite 200 Oklahoma City OK 73104
octavalent Psuedomonas aeruginosa O-polysaccaharide-toxin A *Aerugen*	DD: 5/16/2002 MA: MA:	Prevention of Psuedomonas aeruginosa infections in patients with cystic fibrosis	Orphan Europe Immeuble "Le Wilson" 70 avenue du General de Gaulle, 92046 Paris La Def
Octreotide *Sandostatin LAR*	DD: 8/24/1998 MA:	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Novartis Pharmaceuticals 59 Route 10 59 Route 10 East Hanover NJ 07936-1080
Octreotide *Sandostatin LAR*	DD: 8/24/1998 MA: MA:	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	Novartis Pharmaceuticals 59 Route 10 59 Route 10 East Hanover NJ 07936-1080

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Octreotide *Sandostatin LAR*	DD: 8/24/1998 MA:	Treatment of acromegaly.	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080
Ofloxacin *Ocuflox Ophthalmic Solution*	DD: 4/18/1991 MA: 5/22/1996	Treatment of bacterial corneal ulcers.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine CA 92713
oglufanide disodium	DD: 9/24/2001 MA:	Treatment of ovarian cancer	Cytran, Inc. 10230 NE Points Dr., NE Suite 530 Kirkland WA 98033-7869
OM 401 *Drepanol*	DD: MA:	Prophylactic treatment of sickle cell disease.	Omex International, Inc. 6001 Savoy, Suite 110 Houston TX 77036
Omega-3 (n-3) polyunsaturated fatty acid with all double bonds in the cis configuration	DD: MA:	Prevention of organ graft rejection.	Research Triangle Pharmaceuticals 4364 South Alston Avenue Durham NC 27713
Omega-3 (n-3) polyunsaturated fatty acids *Omacor*	DD: 5/4/2000 MA: MA:	Treatment of IgA nephropathy.	Pronova Biocare, AS PO Box 420 1327 Lysaker
Oncorad Ov103	DD: 4/24/1990 MA:	Treatment of ovarian cancer.	Cytogen Corporation 600 College Road East Princeton NJ 08540
Oprelvekin *Neumega*	DD: MA:	Prevention of severe chemotherapy-induced thrombocytopenia.	Genetics Institute, Inc. 87 Cambridge Park Drive 87 Cambridge Park Drive Cambridge MA 02140
oral unfractionated heparin	DD: 12/9/2003 MA:	for use in the treatment of sickle cell disease	TRF Technologies, Inc. 108 Eagle Trace Drive Half Moon Bay CA 94019
Orgotein for injection	DD: MA: MA:	Treatment of familial amyotrophic lateral sclerosis associated with a mutation of the superoxide dismutase. gene (on chromosome 21q) for copper, zinc	Oxis International, Inc. 6040 N. Cutter Circle, Suite 317 Portland OR 97217-3935
Oxaliplatin	DD: 10/6/1992 MA:	Treatment of ovarian cancer.	Debio Pharm S.A. Rue des Terreaux 17 CH-1000

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Oxandrolone *Oxandrin*	DD: 4/22/1997 MA: MA:	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Bio-Technology General Corp. One Tower Center Boulevard, 12th One Tower Center Boulevard, 12th floor East Brunswick NJ 08816
Oxandrolone *Hepandrin*	DD: 3/18/1994 MA: MA:	Treatment of moderate/severe acute alcoholic hepatitis in the presence of moderate protein calorie malnutrition.	Bio-Technology General Corp. 70 Wood Avenue South 70 Wood Avenue South Iselin NJ 08830
Oxandrolone *Oxandrin*	DD: 7/5/1990 MA:	Treatment of short stature associated with Turner's syndrome.	Bio-Technology General Corp. 70 Wood Avenue, South 70 Wood Avenue, South Iselin NJ 08830
Oxandrolone *Oxandrin*	DD: 9/6/1991 MA:	Adjunctive therapy for AIDS patients suffering from HIV-wasting syndrome.	Bio-Technology General Corp. One Tower Center Boulevard, 12 th One Tower Center Boulevard, 12 th floor East Brunswick NJ 08816
Oxandrolone	DD: 10/5/1990 MA:	Treatment of constitutional delay of growth and puberty.	Bio-Technology General Corp. 70 Wood Avenue, South Iselin NJ 08830
Oxybate *Xyrem*	DD: 11/7/1994 MA: 7/17/2002	Treatment of narcolepsy.	Orphan Medical, Inc. 13911 Ridgedale Drive Suite 250 Minnetonka MN 55305
Oxymorphone *Numorphan H.P.*	DD: 3/19/1985 MA:	For relief of severe intractable pain in narcotic-tolerant patients.	DuPont Merck Pharmaceutical Company P.O. Box 80027 Wilmington DE 19880
Oxypurinol	DD: 11/9/1998 MA:	Treatment of hyperuricemia in patients intolerant to allopurinol.	Cardiome Pharma Corp. 3650 Westbrook Mall Vancouver, B.C.
P1, P4-Di(uridine 5'-tetraphosphate), tetrasodium	DD: MA:	Treatment of cystic fibrosis.	Inspire Pharmaceuticals, Inc. 4222 Emperor Blvd., Suite 470 Durham NC 27703
p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium	DD: 3/7/2001 MA:	For the treatment of cystic fibrosis	Inspire Pharmaceuticals, Inc. 4222 Emperor Blvd. Suite 470 Durham NC 27703
Paclitaxel *Paxene*	DD: 4/15/1997 MA:	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, Inc. 4400 Biscayne Boulevard 4400 Biscayne Boulevard Miami FL 33137

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Paclitaxel *Taxol*	DD: 3/25/1997 MA: 8/4/1997	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb Pharmaceutical Research Institute 5 Research Parkway P.O. Box 5100 Wallingford CT 06492-7660
Papain, trypsin, and chymotrypsin *Wobe-Mugos*	DD: MA:	Treatment of multiple myeloma.	Marlyn Nutraceuticals, Inc. 14851 N. Scottsdale Rd. Scottsdale AZ 85254
Papaverine topical gel	DD: 2/6/1992 MA:	Treatment of sexual dysfunction in spinal cord injury patients.	Pharmedic Company 417 Harvester Court Wheeling IL 60090
Parovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) *MEDI-491*	DD: 5/7/1999 MA: MA:	Prevention of transient aplastic crisis in patients with sickle cell anemia.	MedImmune, Inc. 35 West Watkins Mill Rd. Gaithersburg MD 20878
Patul-end	DD: 2/18/1997 MA: MA:	Treatment of patulous eustachian tube.	Ear Foundation 2420 Castillo Street, Suite 100 Santa Barbara CA 93105
PEG-glucocerebrosidase *Lysodase*	DD: 12/9/1992 MA: MA:	For use as chronic enzyme replacement therapy in patients with Gaucher's disease who are deficient in glucocerebrosidase.	National Institute of Mental Health, 49 Convent Dr. MSC4405 49 Convent Dr. MSC4405 Bldg. 49, Room B1EE16 Bethesda MD 20892-4405
PEG-interleukin-2	DD: 2/1/1990 MA:	Treatment of primary immunodeficiencies associated with T-cell defects.	Chiron Corporation 4560 Horton Street Emeryville CA 94608
Pegademase bovine *Adagen*	DD: 5/29/1984 MA: 3/21/1990 MA: 3/21/1990	For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.	Enzon, Inc. 20 Kingsbridge Road 20 Kingsbridge Road Piscataway NJ 08854
Pegaspargase *Oncaspar*	DD: MA: 2/1/1994	Treatment of acute lymphocytic leukemia.	Enzon, Inc. 20 Kingsbridge Road Piscataway NJ 08854
Peginterferon alfa-2a *PEGASYS*	DD: 9/30/1999 MA:	Treatment of chronic myelogenous leukemia.	Hoffman-La Roche Inc. 340 Kingsland St. Nutley NJ 07110-1199
Peginterferon alfa-2a *PEGASYS*	DD: 7/13/1998 MA:	Treatment of renal cell carcinoma.	Hoffman-La Roche Inc. 340 Kingsland St. Nutley NJ 07110-1199

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Pegvisomant *Somavert*	DD: 6/24/1997 MA: 3/25/2003	Treatment of acromegaly.	Sensus Corporation Suite 430, 98 San Jacinto Boulevard Austin TX 78701
Pegylated arginine deiminase *Melanocid*	DD: 4/12/1999 MA:	Treatment of invasive malignant melanoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton PA 19341
Pegylated arginine deiminase *Hepacid*	DD: 3/26/1999 MA:	Treatment of hepatocellular carcinoma.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. Exton PA 19341
Pegylated recombinant human megakaryocyte growth and development factor *MEGAGEN*	DD: MA: MA:	For reducing the period of thrombocytopenia in patients undergoing hematopoietic stem cell transplantation.	Amgen, Inc. One Amgen Center Dr. Thousand Oaks CA 91320-1789
Peldesine	DD: 10/5/1993 MA:	Treatment of cutaneous T-cell lymphoma.	BioCryst Pharmaceuticals, Inc. 2190 Parkway Lake Drive Birmingham AL 35244
pemetrexed disodium *Alimta*	DD: 8/28/2001 MA:	Treatment of malignant pleural mesothelioma	Eli Lilly and Company Lilly Corporate Center Indianapolis IN 46285
Pentamidine isethionate	DD: MA:	Treatment of Pneumocystis carinii pneumonia.	Aventis Behring L.L.C. 1020 First Avenue PO Box 61501 King of Prussia PA 19406-0901
Pentamidine isethionate *Pentam 300*	DD: 2/28/1984 MA:	Treatment of Pneumocystis carinii pneumonia.	Fujisawa USA, Inc. 3 Parkway North Center 3 Parkway North Center Deerfield IL 60015
Pentamidine isethionate *Nebupent*	DD: 1/12/1988 MA: 6/15/1989 MA: 6/15/1989	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Fujisawa USA, Inc. 3 Parkway North Center 3 Parkway North Center Deerfield IL 60015
Pentamidine isethionate *Pneumopent*	DD: 10/5/1987 MA: MA:	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Fisons Corporation 755 Jefferson Rd., P.O. Box 1710 755 Jefferson Rd., P.O. Box 1710 Rochester NY 14603
Pentastarch *Pentaspan*	DD: 8/28/1985 MA: 5/19/1987 MA: 5/19/1987	As an adjunct in leukapheresis to improve the harvesting and increase the yield of leukocytes by centrifugal means.	Du Pont Pharmaceuticals E.I. Du Pont De Nemours & Co. E.I. Du Pont De Nemours & Co. Wilmington DE 19898

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Pentosan polysulfate sodium *Elmiron*	DD: 8/7/1985 MA: 9/26/1996	Treatment of interstitial cystitis.	Alza Corporation 950 Page Mill Rd. PO Box 10950 Palo Alto CA 94303-0802
Pentostatin *Nipent*	DD: 3/27/1998 MA:	Treatment of cutaneous T-cell lymphoma.	SuperGen, Inc. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
Pentostatin *Nipent*	DD: 1/29/1991 MA:	Treatment of patients with chronic lymphocytic leukemia.	SuperGen, Inc. 4140 Dublin Blvd. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
Pentostatin *Nipent*	DD: MA:	Treatment of peripheral T-cell lymphomas.	SuperGen, Inc. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
Pentostatin for injection *Nipent*	DD: 9/10/1987 MA:	Treatment of hairy cell leukemia.	SuperGen, Inc. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
Perflubron *LiquiVent*	DD: 4/26/2001 MA:	Treatment of acute respiratory distress disease (ARDS) in adults	Alliance Pharmaceutical Corp. 3040 Science Park Road 3040 Science Park Road San Diego CA 92191
Perfosfamide *Pergamid*	DD: 12/4/1989 MA: MA:	For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.	Scios Nova, Inc. 2450 Bayshore Parkway 2450 Bayshore Parkway Mountain View CA 94043
Pergolide *Permax*	DD: MA:	Treatment of Tourette's syndrome.	Sallee, Floyd R. M.D., Ph.D. Cincinnati Children's Hospital Medical Center 3333 Burnet Ave. Cincinnati OH 45229-3039
Phenylacetate	DD: 3/6/1998 MA: MA:	For use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment malignant glioma. of patients with primary or recurrent	Elan Drug Delivery, Inc. 1300 Gould Dr. Gainesville GA 30504
Phenylalanine ammonia-lyase *Phenylase*	DD: 3/8/1995 MA:	Treatment of hyperphenylalaninemia.	Ibex Technologies, Inc. 5485 Pare Montreal, Quebec
Phenylbutyrate	DD: 1/19/2000 MA:	Treatment of acute promyelocytic leukemia.	Elan Drug Delivery, Inc. 1300 Gould Dr. Gainesville GA 30504

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
phenylephrine	DD: 2/14/2002 MA:	Treatment of ileal pouch anal anastomosis related fecal incontinence	S.L.A. Pharma Unit 3, Hill Farm Industrial Estate Leavesden, Watford
Phosphocysteamine	DD: 9/12/1988 MA:	Treatment of cystinosis.	Medea Research Laboratories Port Jefferson Business Center 200 Wilson Street, Building D-6 Port Jefferson NY 11776
physostigmine salicylate **physostigmine salicylate**	DD: 1/16/1985 MA:	Treatment of Friedreich's and other inherited ataxias.	Forest Pharmaceuticals .3- .3- .30 6 150 East 58th Street New York NY 10155
Pilocarpine *Salagen*	DD: 9/24/1990 MA: 3/22/1994	Treatment of xerostomia induced by radiation therapy for head and neck cancer.	MGI Pharma, Inc. 6300 West Old Shakopee Rd. 6300 West Old Shakopee Rd. Suite 110 Bloomington MN 55438-2318
Pilocarpine HCl *Salagen*	DD: 2/28/1992 MA: 2/11/1998 MA: 2/11/1998	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	MGI Pharma, Inc. 6300 West Old Shakopee Rd. 6300 West Old Shakopee Rd. Suite 110 Bloomington MN 55438-2318
Piracetam *Nootropil*	DD: 10/2/1987 MA:	Treatment of myoclonus.	UCB Pharma, Inc. 1950 Lake Park Drive Smyrna GA 30080
Piritrexim isethionate	DD: 6/13/1988 MA: MA:	Treatment of infections caused by Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium-intracellulare.	Burroughs Wellcome Company 3030 Cornwallis Road P.O. Box 12700 Research Triangle Park NC 27709
Polifeprosan 20 with carmustine *Gliadel*	DD: MA: 9/23/1996	Treatment of malignant glioma.	Guilford Pharmaceuticals, Inc. 6611 Tributary Street Baltimore MD 21224
Poloxamer 188	DD: 8/5/1997 MA: MA:	Treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.	CytRx Corporation 154 Technology Parkway Norcross GA 30092
Poloxamer 188 *Florcor*	DD: 2/22/1990 MA:	Treatment of severe burns requiring hospitalization.	CytRx Corporation 154 Technology Parkway 154 Technology Parkway Norcross GA 30092
Poloxamer 188 *Flocor*	DD: 6/27/1989 MA:	Treatment of sickle cell crisis.	CytRx Corporation 154 Technology Parkway Norcross GA 30092

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Poloxamer 331 *Protox*	DD: 3/21/1991 MA:	Initial therapy of toxoplasmosis in patients with AIDS.	CytRx Corporation 154 Technology Parkway 154 Technology Parkway Norcross GA 30092
Poly I: poly C12U *Ampligen*	DD: 7/19/1988 MA:	Treatment of AIDS.	Hemispherx Biopharma, Inc. One Penn Center 1617 JFK Boulevard Philadelphia PA 19103
Poly I: poly C12U *Ampligen*	DD: 12/9/1993 MA:	Treatment of invasive metastatic melanoma (stage IIb, III, IV).	Hemispherx Biopharma, Inc. One Penn Center One Penn Center 1617 JFK Boulevard Philadelphia PA 19103
Poly I: poly C12U *Ampligen*	DD: 5/20/1991 MA:	Treatment of renal cell carcinoma.	Hemispherx Biopharma, Inc. One Penn Center 1617 JFK Boulevard Philadelphia PA 19103
Poly I: poly C12U *Ampligen*	DD: 12/9/1993 MA:	Treatment of chronic fatigue syndrome.	Hemispherx Biopharma, Inc. One Penn Center 1617 JFK Boulevard Philadelphia PA 19103
Poly-ICLC	DD: 3/17/1997 MA:	Treatment of primary brain tumors.	Oncovir 3202 Cleveland Avenue N.W. Washington DC 20008
Polyethylene glycol (PEG)-uricase	DD: 2/21/2001 MA:	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Bio-Technology General Corporation One Tower Center Boulevard, 12th floor East Brunswick NJ 08816
Polyethylene glycol-modified *Zurase*	DD: 9/14/1999 MA: MA:	Prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. 115 John Robert Thomas Dr. Exton PA 19341
Polyethylene glycol-modified *Zurase*	DD: MA: MA:	Treatment of tumor lysis syndrome in cancer patients undergoing chemotherapy.	Phoenix Pharmacologics, Inc. 115 John Robert Thomas Dr. 115 John Robert Thomas Dr. Exton PA 19341
polyinosinic-polycytidilic acid *Poly-ICLC*	DD: 3/3/2003 MA: MA:	Treatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever, Murray valley, and Banzai viruses	Oncovir 3203 Cleveland Ave., NW 3203 Cleveland Ave., NW Washington DC 20008-3450
polyinosinic-polycytidilic acid *Poly-ICLC*	DD: 8/2/2002 MA:	As an adjuvant to smallpox vaccination	Oncovir 3203 Cleveland Ave., NW Washington DC 20008-3450

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
polyinosinic-polycytidilic acid *Poly-ICLC*	DD: MA:	Treatment for orthopox virus infections	Oncovir 3203 Cleveland Ave., NW Washington DC 20008-3450
Polymeric oxygen	DD: 3/25/1992 MA:	Treatment of sickle cell anemia.	Capmed USA P.O. Box 14 Bryn Mawr PA 19010
Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral *NeuroCell-PD*	DD: MA: MA:	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin/Genzyme LLC One Kendall Square Cambridge MA 02139-1562
Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared for intracerebral implantation. *NeuroCell-PD*	DD: MA: MA:	Treatment of Hoehn and Yahr stage 4 and 5 Parkinson's disease.	Diacrin/Genzyme LLC One Kendall Square Cambridge MA 02139-1562
Porcine fetal neural gabaergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral *NeuroCell-HD*	DD: MA: MA:	Treatment of Huntington's disease.	Diacrin/Genzyme LLC One Kendall Square Cambridge MA 02129-1562
Porcine fetal neural gabaergic cells and/or precursors aseptically prepared for intracerebral implantation for Huntington's disease. *NeuroCell-HD*	DD: MA: MA:	Treatment of Huntington's disease.	Diacrin/Genzyme LLC One Kendall Square Cambridge MA 02139-1562
Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural *N-Graft*	DD: 6/24/1997 MA: MA:	Treatment of Hoehn and Yahr stage four and five Parkinson's disease.	Titan Pharmaceuticals, Inc. Post Office Plaza 50 Division Street, Suite 503 Somerville NJ 08876
porfimer *Photofrin*	DD: MA: 8/1/2003 MA: 8/1/2003	For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy	Axcan Scandipharm Inc. 22 Inverness Parkway 22 Inverness Parkway Suite 310 Birmingham AL 35242
Porfimer sodium *Photofrin*	DD: MA: MA:	For the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.	QLT Phototherapeutics, Inc. Lederle Laboratories Lederle Laboratories 401 North Middletown Road Pearl River NY 10965

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Porfimer sodium *Photofrin*	DD: 6/6/1989 MA: MA:	For the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.	QLT Phototherapeutics, Inc. Lederle Laboratories Lederle Laboratories 401 North Middletown Road Pearl River NY 10965
Porfiromycin *Promycin*	DD: 9/19/1995 MA:	Treatment of head and neck cancer.	Boehringer Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road PO Box 368 Ridgefield CT 06877
Porfiromycin *Promycin*	DD: 3/13/1997 MA:	Treatment of cervical cancer.	Boehringer Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road PO Box 368 Ridgefield CT 06877
Potassium citrate *Urocit-K*	DD: 9/12/1985 MA: 8/30/1985	For avoidance of the complication of calcium stone formation in patients with uric lithiasis.	University of Texas Health Science Center at Dallas 5323 Harry Hines Blvd 5323 Harry Hines Blvd Dallas TX 75235
Potassium citrate *Urocit-K*	DD: 9/16/1985 MA: 8/30/1985	Prevention of calcium renal stones in patients with hypocitraturia.	University of Texas Health Science Center at Dallas 5323 Harry Hines Blvd Dallas TX 75235
Potassium citrate *Urocit-K*	DD: 11/1/1984 MA: 8/30/1985	Prevention of uric acid nephrolithiasis.	University of Texas Health Science Center at Dallas 5323 Harry Hines Boulevard Dallas TX 75235
Potassium citrate and citric acid	DD: 2/14/1986 MA:	For the dissolution and control of uric acid and cysteine calculi in the urinary tract.	Willen Drug Company
Pr-122 (redox-phenytoin)	DD: 7/5/1990 MA:	For the emergency rescue treatment of status epilepticus, grand mal type.	Pharmos 2 Innovation Drive Alachua FL 32615
PR-225 (redox-acyclovir)	DD: 5/29/1990 MA:	Treatment of herpes simplex encephalitis in individuals afflicted with AIDS.	Pharmos 2 Innovation Drive Alachua FL 32615
PR-239 (redox penicillin G)	DD: 5/23/1990 MA:	Treatment of AIDS associated neurosyphilis.	Pharmos 2 Innovation Drive Alachua FL 32615
Pr-320 (molecusol-carbamazepine)	DD: 7/20/1990 MA:	For the emergency rescue treatment of status epilepticus, grand mal type.	Pharmos 2 Innovation Drive Alachua FL 32615

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Pramiracetam Sulfate	DD: 11/4/1991 MA: MA:	For the management of cognitive dysfunction and enhancement of electroconvulsive therapy. antidepressant activity associated with	Cambridge Neuroscience, Inc. 1 Kendall Square, Bldg. 700 Cambridge MA 02139
Praziquantel	DD: 4/18/1988 MA:	Treatment of neurocysticercosis.	EM Pharmaceuticals, Inc.
Prednimustine *Sterecyt*	DD: 6/17/1985 MA:	Treatment of malignant non-Hodgkin's lymphomas.	Pharmacia Inc. P.O. Box 16529 P.O. Box 16529 Columbus OH 43216-6529
Primaquine phosphate	DD: 7/23/1993 MA: MA:	For use in combination with clindamycin hydrochloride in the treatment of with AIDS. Pneumocystis carinii pneumonia associated	Sanofi Winthrop, Inc. 90 Park Avenue New York NY 10016
Progesterone	DD: MA: MA:	Establishment and maintenance of pregnancy in women undergoing in vitro fertilization or embryo transfer procedures.	Watson Laboratories, Inc. 311 Bonnie Circle Corona CA 91720
Propamidine isethionate 0.1% ophthalmic solution *Brolene*	DD: 3/10/1988 MA: MA:	Treatment of acanthamoeba keratitis.	Bausch & Lomb Pharmaceuticals Division 8500 Hidden River Parkway Tampa FL 33637
Prostaglandin E1 enol ester (AS-013)	DD: 6/12/1998 MA:	Treatment of Fontaine Stage IV chronic critical limb ischemia.	Mitsubishi Pharma America, Inc. 25 Independence Blvd., Suite 201 Warren NJ 07059
Prostaglandin E1 in lipid emulsion *Lipo-PGE1*	DD: 9/10/1996 MA:	Treatment of ischemic ulceration of the lower limbs due to peripheral arterial disease.	Alpha Therapeutic Corporation 5555 Valley Boulevard 5555 Valley Boulevard Los Angeles CA 90032
Protaxel	DD: 5/21/2003 MA:	Treatment of ovarian cancer	Biophysica, Inc. 3333 North Torrey Pines Court Suite 100 La Jolla CA 92037
Protein C concentrate *Protein C Concentrate (human) Vapor*	DD: 4/22/1993 MA:	For use in the prevention and treatment of purpura fulminans in meningococcemia.	Immuno Clinical Research Corp. 750 Lexington Avenue, 19th Floor 750 Lexington Avenue, 19th Floor New York NY 10022
Protein C concentrate *Protein C Concentrate (human) Vapor*	DD: 6/23/1992 MA: MA:	For replacement therapy in congenital protein C deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans.	Baxter Healthcare Corporation Hyland Division (Baxter Hyland) Hyland Division (Baxter Hyland) 550 North Brand Blvd. Glendale CA 91203

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Protein C concentrate	DD: 6/19/1992	For replacement therapy in patients with congenital or acquired protein C deficiency for the prevention and treatment of warfarin-induced skin necrosis during oral anticoagulation.	Immuno Clinical Research Corp. 750 Lexington Avenue, 19th Floor 750 Lexington Avenue, 19th Floor New York NY 10022
Protein C Concentrate (human) Vapor	MA: MA:		
Protirelin	DD: 8/24/1993	Prevention of infant respiratory distress syndrome associated with prematurity.	UCB Pharma, Inc. 1950 Lake Park Drive Smyrna GA 30080
	MA:		
Protirelin injection	DD: 1/10/1985	Treatment of amyothrophic lateral sclerosis.	Abbott Laboratories
	MA:		
Pulmonary surfactant replacement	DD: 12/5/1988	Prevention and treatment of infant respiratory distress syndrome.	Scios Nova, Inc. 2450 Bayshore Parkway Mountain View CA 94043
	MA:		
Pulmonary surfactant replacement, porcine	DD: 8/2/1993	For the treatment and prevention of respiratory distress syndrome in premature infants.	Dey Laboratories 2751 Napa Valley Corporate Drive
Curosurf	MA: MA:		Napa CA 94558
Purified extract of Pseudomonas aeruginosa	DD: 9/22/1997	Treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.	DynaGen, Inc. 99 Erie Street
ImmuDyn	MA: MA:		Cambridge MA 02139
Purified type II collagen *Colloral*	DD: 2/9/1995	Treatment of juvenile rheumatoid arthritis.	AutoImmune, Inc. 128 Spring Street Lexington MA 02421
	MA:		
pVGI.1(VEGF2)	DD: 11/9/1999	Treatment of thromboangiitis obliterans.	Vascular Genetics, Inc. 200 Westpark Corporate Center 4364 South Alston Ave. Durham NC 27713-2280
	MA:		
Pyruvate	DD: 2/21/2001	Treatment of interstitial lung disease.	Cellular Sciences, Inc 84 park Avenue P.O. Box 968 Flemington NJ 08822
	MA:		
Quinacrine hydrochloride	DD:	For prevention of recurrence of pneumothorax in patients at high risk of recurrence.	Lyphomed, Inc.
	MA:		
R-etodolac	DD: 12/9/2002	The treatment of chronic lymphocytic leukemia	Salmedix, Inc. 4330 La Jolla Village Drive Suite 250 San Diego CA 92122
	MA:		

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
rasburicase *Elitek*	DD: MA: 7/12/2002	Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research 9 Great Valley Parkway 9 Great Valley Parkway Malvern PA 19355
recombinant adeno-associated virus alpha 1-antitrypsin vector *rAAV-AAT*	DD: 1/27/2003 MA: MA:	Treatment of alpha1-antitrypsin deficiency	Applied Genetic Technologies Corp. 12085 Research Drive Suite 110 Alachua FL 32615
Recombinant bactericidal/permeability-increasing protein *Neuprex*	DD: 6/22/1998 MA: MA:	Treatment of severe meningococcal disease.	Xoma (US) LLC 2910 Seventh Street Berkeley CA 94710
Recombinant glycine2-human glucagon-like peptide-2	DD: 6/29/2000 MA:	Treatment of short bowel syndrome.	NPS Allelix Corp. 6850 Goreway Dr. Mississauga, Ontario
Recombinant human acid alpha-glucosidase	DD: 8/19/1997 MA:	Treatment of glycogen storage disease type II.	Genzyme Corporation One Kendall Square Cambridge MA 02139
recombinant human alpha 1-antitrypsin (rAAT)	DD: MA:	Treatment of cystic fibrosis	Arriva Pharmaceuticals, Inc. 2020 Challenger Drive Alameda CA 94501
recombinant human alpha-1 antitrypsin	DD: 3/6/1998 MA:	Treatment of cystic fibrosis.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh
recombinant human alpha-1 antitrypsin (rAAT)	DD: 8/28/2001 MA:	To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis	Baxter Healthcare Corporation 550 N. Brand Blvd. Glendale CA 91203
Recombinant Human Alpha-Fetoprotein (rhAFP)	DD: 2/22/2001 MA:	Treatment of myasthenia gravis	Merrimack Pharmaceuticals, Inc. 101 Binney Street Cambridge MA 02142
Recombinant human antithrombin	DD: 4/6/2000 MA:	Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.	AT III LLC c/o Genzyme Corporation 15 Pleasant St. Connector, P.O. Box 9322 Framingham MA 01701

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Recombinant human C1-esterase inhibitor	DD: 2/23/1999 MA:	Prophylactic treatment of angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel
Recombinant human C1-esterase inhibitor	DD: 2/23/1999 MA:	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Pharming N.V. Cipalstreet 3 B-2440 Geel
Recombinant human CD4 immunoglobulin G	DD: 8/30/1990 MA:	Treatment of AIDS resulting from infection with HIV-1.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco CA 94080
Recombinant human Clara Cell 10kDa protein	DD: 7/13/1998 MA:	Prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.	Claragen, Inc. 335 Paint Branch Drive College Park MD 20742
recombinant human endostatin protein	DD: 8/13/2001 MA:	Treatment of neuroendocrine tumors.	EntreMed, Inc. 9640 Medical Center Drive Rockville MD 20850
recombinant human endostatin protein	DD: 2/21/2002 MA:	Treatment of metastatic melanoma	EntreMed, Inc. 9640 Medical Center Drive Rockville MD 20850
Recombinant human gelsolin	DD: 1/12/1994 MA:	Treatment of the respiratory symptoms of cystic fibrosis.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02124
Recombinant human gelsolin	DD: 3/6/1995 MA:	Treatment of acute and chronic respiratory symptoms of bronchiectasis.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
Recombinant human highly phosphorylated acid alpha-glucosidase *TBD*	DD: 9/20/2000 MA: MA:	For enzyme replacement therapy in patients with all subtypes of glycogen storage disease type II (GSDII, Pompe Disease)	Novazyme Pharmaceuticals, Inc. 800 Research Parkway Suite 200 Oklahoma City OK 73104
Recombinant human insulin-like growth factor 1 *IGF-1*	DD: 6/7/1995 MA: MA:	Treatment of antibody-mediated growth hormone resistance in patients with isolated growth hormone deficiency Ia.	Pharmacia & Upjohn 7000 Portage Road Kalamazoo MI 49001-0199

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Recombinant human insulin-like growth factor 1 *IGF-1*	DD: 6/7/1995 MA: MA:	Treatment of growth hormone receptor deficiency.	Pharmacia & Upjohn 7000 Portage Road Kalamazoo MI 49001-0199
Recombinant human insulin-like growth factor-I *PV802*	DD: 2/16/2000 MA:	Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.	GroPep Pty Ltd. Gate 11, Victoria Dr. Adelaide SA 5000
Recombinant human insulin-like growth factor-I	DD: MA:	Treatment of post-poliomyelitis syndrome.	Cephalon, Inc. 145 Brandywine Parkway West Chester PA 19380-4245
recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3 *SomatoKine*	DD: 5/17/2002 MA: MA:	Treatment of growth hormone insensitivity syndrome	Celtrix Pharmaceuticals, Inc. a subsidiary of Insmed, Inc. 4851 Lake Brook Drive Glen Allen VA 23060
Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3	DD: 6/15/1999 MA:	Treatment of major burns that require hospitalization.	Celtrix Pharmaceuticals, Inc. P.O. Box 2400 Glen Allen VA 23058-2400
Recombinant human interleukin-12	DD: MA:	Treatment of renal cell carcinoma.	Genetics Institute, Inc. 87 CambridgePark Drive Cambridge MA 02140
Recombinant human keratinocyte growth factor	DD: MA:	Reducing the incidence and severity of radiation-induced xerostomia.	Amgen Inc. One Amgen Center Dr. Thousand Oaks CA 91320-1799
Recombinant human luteinizing hormone *LHadi*	DD: 10/7/1994 MA:	For use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061
recombinant human monoclonal antibody to hsp90 *Mycograb*	DD: 9/16/2002 MA: MA:	Treatment of invasive candidiasis	NeuTec Pharma plc 2dn floor, Clinical Sciences Bldg. Central Manchester Healthcare Trust, Oxford Rd., M
Recombinant human nerve growth factor	DD: 4/16/1999 MA:	Treatment of HIV-associated sensory neuropathy.	Genentech, Inc. 1 DNA Way South San Francisco CA 94080

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
recombinant human neutrophil inhibitor (hNE)	DD: 12/9/2003 MA:	Treatment of cystic fibrosis	Dyax Corporation 300 Technology Square Cambridge MA 02139
recombinant human porphobilinogen deaminase *Porphozyme*	DD: 9/9/2002 MA: MA:	Treatment of acute intermittent porphyria attacks	HemeBiotech A/S Roskildevej 12C 3400 Hillerod
recombinant human porphobilinogen deaminase, erythropoetic form	DD: 7/11/2002 MA:	Treatment of acute intermittent porphyria preventing attacks	HemeBiotech A/S Roskildevej 12C 3400 Hillerod
Recombinant human relaxin	DD: 11/3/1995 MA:	Treatment of progressive systemic sclerosis.	Connetics Corporation 3400 West Bayshore Road Palo Alto CA 94303
Recombinant human superoxide dismutase *Oxsodrol*	DD: 4/18/1991 MA:	Prevention of bronchopulmonary dysplasia in premature neonates weighing less than 1500 grams.	Bio-Technology General Corp. One Tower Center Boulevard, 12th floor floor East Brunswick NJ 08816
Recombinant human	DD: 9/29/1997 MA: MA:	For use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.	Genentech, Inc. 1 DNA Way South San Francisco CA 94080-4990
Recombinant humanized MAb 5c8	DD: 3/22/1999 MA:	Prevention of rejection of solid organ transplants.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
Recombinant humanized MAb 5c8	DD: MA: MA:	Prevention and treatment of Factor VIII/Factor IX inhibitors in patients with hemophilia A or B.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
Recombinant humanized MAb 5c8	DD: 3/22/1999 MA:	Prevention of rejection of pancreatic islet cell transplants.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
Recombinant humanized moncional antibody 5c8	DD: 2/3/1998 MA:	Treatment of immune thrombocytopenic purpura.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142
Recombinant humanized monoclonal antibody 5c8	DD: 2/18/1998 MA:	Treatment of systemic lupus erythematosus.	Biogen, Inc. 14 Cambridge Center Cambridge MA 02142

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
recombinant inhibitor of human plasma kallikrein	DD: 2/4/2003 MA:	Treatment of angioedema	Dyax Corp 300 Technology Square Cambridge MA 02139
Recombinant methionyl brain-derived neurotrophic factor	DD: MA:	Treatment of amyotrophic lateral sclerosis.	Amgen, Inc. One Amgen Center Dr. Thousand Oaks CA 91320-1799
Recombinant methionyl human stem cell factor	DD: MA:	Treatment of primary bone marrow failure.	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799
Recombinant retroviral vector - glucocerebrosidase	DD: MA:	For use as enzyme replacement therapy for patients with types I, II, or III Gaucher disease.	Genetic Therapy, Inc. 938 Clopper Road Gaithersburg MD 20878
Recombinant secretory leucocyte protease inhibitor	DD: 3/29/1991 MA:	Treatment of cystic fibrosis.	Amgen, Inc. 3200 Walnut Street Boulder CO 80301
Recombinant secretory leucocyte protease inhibitor	DD: 3/29/1991 MA:	Treatment of congenital alpha-1 antitrypsin deficiency.	Amgen Inc. 3200 Walnut Street Boulder CO 80301
Recombinant soluble human CD4 *Receptin*	DD: MA:	Treatment of acquired immunodeficiency syndrome.	Biogen, Inc. 14 Cambridge Center 14 Cambridge Center Cambridge MA 02142
Recombinant soluble human CD4 (rCD4)	DD: 3/23/1989 MA:	Treatment of AIDS in patients infected with HIV virus.	Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco CA 94080
Recombinant T-cell receptor	DD: 5/2/2003 MA: MA:	Treatment of multiple sclerosis patients who are both HLA-DR2 positive and autoreactive residues 35-55 to myelin oligodendrocyte glycoprotein	Virogenomics, Inc. 9020 SW Washington Square Road Suite 380 Tigard, OR 97223-4332
Recombinant urate oxidase	DD: MA:	Prophylaxis of chemotherapy-induced hyperuricemia.	Sanofi-Synthelabo Research 9 Great Valley Parkway Malvern PA 19355

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Recombinant vaccinia (human papillomavirus) *TA-HPV*	DD: 8/24/1994 MA: MA:	Treatment of cervical cancer.	Xenova Research Limited 310 Cambridge Science Park Cambridge CB4 OWG
Reduced L-glutathione *Cachexon*	DD: 2/14/1994 MA:	Treatment of AIDS-associated cachexia.	Telluride Pharmaceutical Corporation 146 Flanders Drive Hillsborough NJ 08876
Remacemide *Ecovia*	DD: 3/6/2000 MA:	Treatment of Huntington's disease.	AstraZeneca LP 725 Chesterbrook Blvd. Wayne PA 19087-5677
repertaxin	DD: 1/27/2003 MA:	Prevention of delayed graft function in solid organ transplant	Dompe s.p.a. Via Campo di Pile 67100 - L'Aquila
repository corticotropin or adrenocorticotropic hormone *H.P. Acthar Gel*	DD: 5/21/2003 MA: MA:	Treatment of infantile spasms	Questcor Pharmaceuticals, Inc. 3260 Whipple Road Union City CA 94587-1217
resiniferatoxin	DD: 5/13/2003 MA:	Treatment of intractable pain at end-stage disease	Andrew J. Mannes, Md Bldg 10/Rm 2N236 - DASS/PPCS/NIDCR/NIH 10 Convent Drive Bethesda MD 20892
Respiratory Syncytial Virus Immune Globulin (human) *Hypermune RSV*	DD: 9/27/1990 MA: MA:	Treatment of respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children.	MedImmune, Inc. 35 West Watkins Mill Road Gaithersburg MD 20878
Respiratory syncytial virus immune globulin (Human) *Respigam*	DD: 9/27/1990 MA: 1/18/1996 MA: 1/18/1996	Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.	MedImmune & Massachussetts Public Health Biologics Labs. 35 West Watkins Mill Road 35 West Watkins Mill Road Gaithersburg MD 20878
retroviral gamma-c cDNA containing vector	DD: 4/29/2002 MA:	Treatment of X linked severe combined immune deficiency disease	AVAX technologies, Inc. 9200 Indian Creek Parkway Building 9, Suite 200 Overland Park KS 66210
Retroviral vector, R-GC and GC gene 1750	DD: 5/6/1997 MA:	Treatment of Gaucher disease.	Genzyme Corporation One Mountain Road P.O. Box 9322 Framingham MA 01701-9322
Reviparin sodium *Clivarine*	DD: 6/18/2001 MA:	Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients	Knoll AG

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Reviparin sodium *Clivarine*	DD: 6/18/2001 MA:	Long-term treatment of acute deep vein thrombosis with or without pulmonary embolism in pregnant patients	Knoll AG
RGG0853, E1A lipid complex	DD: 9/15/1995 MA:	Treatment of ovarian cancer.	Targeted Genetics Corporation 1100 Olive Way, Suite 100 Seattle WA 98101
rhIGF-I/rhIGFBP-3 *SomatoKine*	DD: 12/9/2003 MA: MA:	Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)	Insmed Inc. 4851 Lake Brooke Drive 4851 Lake Brooke Drive Glen Allen VA 23060
Rho (D) immune globulin intravenous (human) *WinRho SD*	DD: 11/9/1993 MA: 3/24/1995 MA: 3/24/1995	Treatment of immune thrombocytopenic purpura.	Rh Pharmaceuticals, Inc. 104 Chancellor Matheson Road Winnipeg, Manitoba
rhuMAb VEGF[bevacizumab]) *Avastin*	DD: 11/6/2003 MA:	treatment of renal cell carcinoma	Genentech, Inc. 1 DNA Way South San Francisco CA 94080-4990
Ribavirin *Virazole*	DD: 4/12/1991 MA:	Treatment of hemorrhagic fever with renal syndrome.	Valeant Pharmaceuticals International 3300 Hyland Avenue 3300 Hyland Avenue Costa Mesa CA 92626
ribavirin *REBETOL*	DD: 4/4/2003 MA: 7/29/2003	Treatment of chronic hepatitis C in pediatric patients	Schering Corporation 2000 Galloping Hill Road 2000 Galloping Hill Road Kenilworth NJ 07033
Ricin (blocked) conjugated murine MCA (anti-B4)	DD: MA:	Treatment of B-cell leukemia and B-cell lymphoma.	ImmunoGen, Inc. 148 Sidney Street Cambridge MA 02139
Ricin (blocked) conjugated murine mca (anti-b4)	DD: 1/24/1991 MA:	For the ex-vivo purging of leukemic cells from the bone marrow of non-T cell acute lymphocytic leukemia patients who are in complete remission.	ImmunoGen, Inc. 148 Sidney Street Cambridge MA 02139
Ricin (blocked) conjugated murine MCA (anti-my9)	DD: 8/3/1989 MA:	Treatment of myeloid leukemia, including AML, and blast crisis of CML.	ImmunoGen, Inc. 148 Sidney Street Cambridge MA 02139
Ricin (blocked) conjugated murine MCA (anti-my9)	DD: 2/1/1990 MA:	For use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia.	ImmunoGen, Inc. 148 Sidney Street Cambridge MA 02139

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Ricin (blocked) conjugated murine MCA (n901)	DD: 1/25/1991 MA:	Treatment of small cell lung cancer.	ImmunoGen, Inc. 148 Sidney Street Cambridge MA 02139
Ricin (blocked) conjugated murine monoclonal antibody (CD6)	DD: 9/6/1994 MA:	Treatment of cutaneous T-cell lymphomas, acute T-cell leukemia-lymphoma, and related mature T-cell malignancies.	ImmunoGen, Inc. 148 Sidney Street Cambridge MA 02139
Rifabutin	DD: MA:	Treatment of disseminated Mycobacterium avium complex disease.	Pharmacia & Upjohn 7000 Portage Road Unit 0633-298-113 Kalamazoo MI 49001-0199
Rifabutin *Mycobutin*	DD: MA: MA:	Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.	Adria Laboratories, Inc. P.O. Box 16529 P.O. Box 16529 Columbus OH 43216
Rifalazil	DD: 4/13/1999 MA:	Treatment of pulmonary tuberculosis.	PathoGenesis Corporation 201 Elliott Avenue West Suite 150 Seattle WA 98119
Rifampin *Rifadin I.V.*	DD: 12/9/1985 MA: 5/25/1989	For antituberculosis treatment where use of the oral form of the drug is not feasible.	Hoechst Marion Roussel P.O. Box 9627 P.O. Box 9627 Kansas City MO 64134
Rifampin, isoniazid, pyrazinamide *Rifater*	DD: 9/12/1985 MA: 5/31/1994	For the short-course treatment of tuberculosis.	Hoechst Marion Roussel P.O. Box 9627 P.O. Box 9627 Kansas City MO 64134
Rifapentine *Priftin*	DD: 3/12/1996 MA: MA:	Prophylactic treatment of Mycobacterium avium complex in patients with AIDS and a CD4+ count less than or equal to 75/mm3.	Hoechst Marion Roussel, Inc. P.O. Box 9627 P.O. Box 9627 Mail Station: H3-M2516 Kansas City MO 64134-0627
Rifapentine *Priftin*	DD: 6/9/1995 MA: 6/22/1998	Treatment of pulmonary tuberculosis.	Hoechst Marion Roussel P.O. Box 9627 Mail Station: H3-M2516 Kansas City MO 64134-0627
Rifapentine *Priftin*	DD: 6/9/1995 MA:	Treatment of Mycobacterium avium complex in patients with AIDS.	Hoechst Marion Roussel , Inc. P.O. Box 9627 P.O. Box 9627 Mail Station: H3-M2516 Kansas City MO 64134-0627
Rifaximin *Normix*	DD: 2/10/1998 MA:	Treatment of hepatic encephalopathy.	Salix Pharmaceuticals, Inc. 3600 W. Bayshore Road, Suite 205 Palo Alto CA 94303

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
RII retinamide	DD: 5/6/1993 MA:	Treatment of myelodysplastic syndromes.	Sparta Pharmaceuticals, Inc. 111 Rock Road Horsham PA 19044-2310
Riluzole *Rilutek*	DD: 3/16/1993 MA:	Treatment of amyotrophic lateral sclerosis.	Rhone-Poulenc Rorer Pharmaceuticals, Inc. 500 Arcola Road, P.O. Box 1200 Collegeville PA 19426
Riluzole *Rilutek*	DD: MA:	Treatment of Huntington's disease.	Rhone-Poulenc Rorer Pharmaceuticals, Inc. 500 Arcola Road PO Box 5096 Collegeville PA 19426-0800
Rituximab *Rituxan*	DD: 6/13/1994 MA:	Treatment of non-Hodgkin's B-cell lymphoma.	IDEC Pharmaceuticals Corporation 3030 Callan Road 3030 Callan Road San Diego CA 92121
rituximab *Rituxan*	DD: 3/12/2002 MA:	Treatment of immune thrombocytopenic purpura	Genentech, Inc. 1 DNA Way 1 DNA Way South San Francisco CA 94080-4990
Roquinimex *Linomide*	DD: 7/1/1993 MA: MA:	To prolong time to relapse in leukemia patients who have undergone autologous bone marrow transplantation.	Pharmacia & Upjohn 7000 Portage Road 7000 Portage Road Kalamazoo MI 49001-0199
rSP-C lung surfactant *Venticute*	DD: 4/3/2000 MA:	Treatment of adult respiratory distress syndrome.	Byk Gulden Pharmaceuticals Byk-Gulden StraBe 2 Byk-Gulden StraBe 2 78467 Konstanz
rubitecan	DD: 7/17/2002 MA: MA:	Treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome	SuperGen, Inc. 4140 Dublin Blvd. Suite 200 Dublin CA 94568
S(-)-3-[3-amino-phthalimido]-glutar amide	DD: 3/14/2002 MA:	Treatment of multiple myeloma	EntreMed Incorporated 9640 Medical Center Dr. Rockville MD 20850
S-adenosylmethionine	DD: 4/30/1998 MA:	Treatment of AIDS-myelopathy.	Di Rocco, Alessandro M.D. Beth Israel Medical Center, Phillips Ambulatory Ca Philips Building, Suite 2Q; 10 Union Square East New York NY 10003
Sacrosidase *Sucraid*	DD: MA: 4/9/1998	Treatment of congenital sucrase-isomaltase deficiency.	Orphan Medical, Inc. 13911 Ridgedale Drive 13911 Ridgedale Drive Suite 475 Minnetonka MN 55305

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Sargramostim *Leukine*	DD: 3/6/1995 MA: 9/15/1995 MA: 9/15/1995	To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.	Immunex Corporation 51 University Street 51 University Street Seattle WA 98101
Sargramostim *Leukine*	DD: 5/3/1990 MA: 3/5/1991 MA: 3/5/1991	Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.	Immunex Corporation 51 University Street 51 University Street Seattle WA 98101
Satumomab pendetide *Oncoscint CR/OV*	DD: 9/25/1989 MA:	Detection of ovarian carcinoma.	Cytogen Corporation 600 College Road East Princeton NJ 08540
SB-408075	DD: 12/7/2000 MA:	For pancreatic cancer	SmithKline Beecham Pharmaceuticals 1250 S. Collegeville Road Collegeville PA 19426-0989
SC-1 monoclonal antibody	DD: MA:	Treatment of patients with CD55 (sc-1) positive gastric tumors	H3 Pharma, Inc. 666 Sherbrooke Street West, Suite 1400 Montreal, Quebec
SCH 58500	DD: 4/12/1999 MA:	Treatment of primary ovarian cancer.	Schering Corporation 2000 Galloping Hill Rd. Kenilworth NJ 07033
Secalciferol *Osteo-D*	DD: 7/26/1993 MA:	Treatment of familial hypophosphatemic rickets.	Teva Pharmaceuticals USA 650 Cathill Rd. 650 Cathill Rd. Sellersville PA 18960
Secretory leukocyte protease inhibitor	DD: 6/30/1992 MA:	Treatment of bronchopulmonary dysplasia.	Synergen, Inc. 1885 33rd Street Boulder CO 80301
Selegiline HCl *Eldepryl*	DD: 11/7/1984 MA: 6/5/1989 MA: 6/5/1989	As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism.	Somerset Pharmaceuticals, Inc. 777 South Harbor Island Boulevard 777 South Harbor Island Boulevard Tampa FL 33602
Sermorelin acetate *Geref*	DD: 9/14/1988 MA: 9/26/1997 MA: 9/26/1997	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	Serono Laboratories, Inc. 100 Longwater Circle 100 Longwater Circle Norwell MA 02061
Sermorelin acetate *Geref*	DD: 12/5/1991 MA:	Treatment of AIDS-associated catabolism/weight loss.	Serono Laboratories, Inc. One Technology Place One Technology Place Rockland MA 02370

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Sermorelin acetate *Geref*	DD: 2/13/1990 MA: MA:	Adjunct to gonadotropin therapy in the induction of ovulation in women with anovulatory or oligo-ovulatory infertility who fail to ovulate in response to adequate treatment with clomiphene citrate alone and gonadotropin therapy alone.	Serono Laboratories, Inc. One Technology Place One Technology Place Rockland MA 02370
Serratia marcescens extract (polyribosomes) *Imuvert*	DD: 9/7/1988 MA: MA:	Treatment of primary brain malignancies.	Cell Technology, Inc. 1668 Valtec Lane Boulder CO 80306
SGN-30 (anti-CD30 mAb)	DD: 7/18/2003 MA:	Treatment of Hodgkin's disease	Seattle Genetics, Inc 21823 30th Drive, Southeast Bothell WA 98021
Short chain fatty acid enema *Colomed*	DD: 8/19/1997 MA:	Treatment of chronic radiation proctitis.	Richard I. Breuer, M.D. 1000 Central Street, Suite 615 Evanston IL 60201
Short chain fatty acid solution *Colomed*	DD: 5/29/1990 MA: MA:	Treatment of the active phase of ulcerative colitis with involvement restricted to the left side of the colon.	Richard I. Breuer 1000 Central Street, Suite 615 1000 Central Street, Suite 615 Evanston IL 60201
Silver sulfadiazine and cerium nitrate *Flammacerium*	DD: MA: MA:	Prevention of mortality in severely burned patients.	Synthes (USA) 1690 Russell Road PO Box 1766 Paoli PA 19301
siplizumab	DD: 7/15/2003 MA:	Treatment of T-cell lymphomas	MedImmune Oncology, Inc. 35 W. Watkins Mill Road Gaithersburg Md 20878
SK&F 110679	DD: 5/23/1990 MA: MA:	For the long term treatment of children who have growth failure due to a lack of secretion. adequate endogenous growth hormone	SmithKline Beecham Pharmaceuticals One Franklin Plaza Philadelphia PA 19101
Sodium 1,3-propanedisulfonate	DD: 4/6/1999 MA:	Treatment of secondary amyloidosis.	Neurochem, Inc. 7220 Frederick Banting, Suite 100 Saint-Laurent, Quebec
Sodium dichloroacetate *Ceresine*	DD: 6/14/1999 MA:	Treatment of severe head injury.	Questcor Pharmaceuticals, Inc. 26118 Research Road Hayward CA 94545
Sodium dichloroacetate	DD: 6/11/1990 MA:	Treatment of homozygous familial hypercholesterolemia.	Stacpoole, Peter W. M.D., Ph.D. University of Florida P.O. Box 100277 Gainesville FL 32610

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
sodium dichloroacetate	DD: 7/3/2003 MA:	Use as an antidote in the management of systemic monochloroacetic acid poisoning	EBD Group 6120 Paseo del Norte Suite J2 Carlsbad CA 92009
Sodium dichloroacetate	DD: MA:	Treatment of congenital lactic acidosis.	Questcor Pharmaceuticals, Inc. 3260 Whipple Rd. Union City CA 94587-1217
Sodium dichloroacetate	DD: 6/11/1990 MA:	Treatment of congenital lactic acidosis.	Stacpoole, Peter W. M.D., Ph.D. University of Florida P.O. Box 100277 Gainesville FL 32610
Sodium dichloroacetate	DD: MA:	Treatment of lactic acidosis in patients with severe malaria.	Stacpoole, Peter W. M.D., Ph.D. University Of Florida P.O. Box 100277 Gainesville FL 32610
Sodium monomercaptoundecahydro-closo-dodecaborate	DD: MA:	For use in conjunction with a thermal or epithermal neutron beam in boron nuclear capture therapy of glioblastoma multiforme.	Theragenics Corporation
Sodium Monomercaptoundecahydro-closo-dodecaborate *Borocell*	DD: 4/15/1992 MA: MA:	For use in boron neutron capture therapy (BNCT) in the treatment of glioblastoma multiforme.	Neutron Technology Corp.& Neutron R&D Partner 877 Main Street, Suite 402 Boise ID 83702
sodium phenylbutyrate *Buphenyl*	DD: MA: 4/30/1996 MA: 4/30/1996	Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency.	Medicis Pharmaceutical Corp. 8125 N. Hayden Road 8125 N. Hayden Road Scottsdale AZ 85258
sodium phenylbutyrate	DD: 7/2/1992 MA: MA:	Treatment for sickling disorders, which include S-S hemoglobinopathy, S-C hemoglobinopathy. hemoglobinopathy, and S-thalassemia	Medicis Pharmaceutical Corp. 8125 N. Hayden Road Scottsdale AZ 85258
Sodium phenylbutyrate	DD: 4/24/1998 MA: MA:	For use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment malignant glioma. of patients with primary or recurrent	Elan Drug Delivery, Inc. 1300 Gould Dr. Gainesville GA 30504
Sodium pyruvate	DD: 3/31/2003 MA:	Treatment of cystic fibrosis	Cellular Sciences, Inc. 84 Park Avenue P. O. Box 968 Flemington NJ 08822
Sodium tetradecyl sulfate *Sotradecol*	DD: 6/10/1986 MA:	Treatment of bleeding esophageal varices.	Elkins-Sinn, Inc. 2 Esterbrook Lane Cherry Hill NJ 08003

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Soluble complement receptor type bypass	DD: 3/6/2000 Avant Immunotherapeutics, Inc. MA: MA:	syndrome in children undergoing cardiopulmonary bypass.	Prevention of post-cardiopulmonary 119 Fourth Ave. Needham MA 02494-2725
Soluble recombinant human complement receptor type 1	DD: MA:	Prevention or reduction of adult respiratory distress syndrome.	T Cell Sciences, Inc. 119 Fourth Avenue Needham Heights MA 02194
Somatostatin	DD: MA:	Treatment of bleeding esophageal varices.	UCB Pharmaceuticals, Inc. 1950 Lake Park Drive Smyrna GA 30080
Somatostatin *Zecnil*	DD: 6/20/1988 MA: MA:	Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.	Ferring Laboratories, Inc. 400 Rella Boulevard, Suite 201 400 Rella Boulevard, Suite 201 Suffern NY 10901
Somatrem for injection *Protropin*	DD: 12/9/1985 MA:	Treatment of short stature associated with Turner's syndrome.	Genentech, Inc. 460 Point San Bruno Boulevard 460 Point San Bruno Boulevard South San Francisco CA 94080
Somatrem for injection *Protropin*	DD: 12/9/1985 MA: MA:	For long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc. 460 Point San Bruno Boulevard 460 Point San Bruno Boulevard South San Francisco CA 94080
Somatropin *Nutropin*	DD: 3/6/1987 MA: MA:	For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc. 460 Point San Bruno Boulevard 460 Point San Bruno Boulevard South San Francisco CA 94080
Somatropin *Norditropin*	DD: 9/1/1987 MA: MA:	Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization	Novo Nordisk Pharmaceuticals 100 Overlook Center 100 Overlook Center Suite 200 Princeton NJ 08540
Somatropin *Biotropin*	DD: 2/12/1993 MA:	Treatment of cachexia associated with AIDS.	Bio-Technology General Corp. 70 Wood Avenue, South Iselin NJ 08830
Somatropin *Norditropin*	DD: 11/5/1987 MA:	Treatment of short stature associated with Turner's syndrome.	Novo Nordisk Pharmaceuticals 100 Overlook Center 100 Overlook Center Suite 200 Princeton NJ 08540
Somatropin *Humatrope*	DD: 5/8/1990 MA:	Treatment of short stature associated with Turner syndrome.	Eli Lilly and Company Lilly Corporate Center Lilly Corporate Center Indianapolis IN 46285

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Somatropin *Genotropin*	DD: 9/6/1994 MA:	Treatment of adults with growth hormone deficiency.	Pharmacia & Upjohn 7000 Portage Road 7000 Portage Road Kalamazoo MI 49001-0199
Somatropin (rDNA) *Saizen*	DD: 5/3/1989 MA: MA:	For the enhancement of nitrogen retention in hospitalized patients suffering from severe burns.	Serono Laboratories, Inc. One Technology Place One Technology Place Rockland MA 02370
Somatropin (r-DNA) *Serostim*	DD: 3/6/1995 MA: 12/1/2003 MA: 12/1/2003	For use alone or in combination with glutamine in the treatment of short bowel syndrome.	Serono Laboratories, Inc. One Technology Place One Technology Place Roackland MA 02370
Somatropin (r-DNA) for injection *Serostim*	DD: 3/26/1996 MA: MA:	Treatment of children with AIDS-associated failure-to-thrive including AIDS-associated wasting.	Serono Laboratories, Inc. One Technology Place One Technology Place Rockland MA 02370
Somatropin (rDNA origin) *Saizen*	DD: 3/6/1987 MA: MA:	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	Serono Laboratories, Inc. 100 Longwater Circle 100 Longwater Circle Norwell MA 02061
Somatropin (rDNA origin) *Nutropin Depot*	DD: MA: MA:	Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Genentech, Inc. 1 DNA Way 1 DNA Way South San Francisco CA 94080-4990
Somatropin (rDNA origin) injection *Norditropin*	DD: 7/10/1987 MA:	Treatment of growth failure in children due to inadequate growth hormone secretion.	Novo Nordisk Pharmaceuticals 100 Overlook Center 100 Overlook Center Suite 200 Princeton NJ 08540
Somatropin [rDNA] *Genotropin*	DD: 7/6/1999 MA: 6/20/2000	Treatment of short stature in patients with Prader-Willi syndrome.	Pharmacia & Upjohn 7000 Portage Rd. 7000 Portage Rd. 0633-298-113 Kalamazoo MI 49001-0199
somatropin [rDNA] *Genotropin*	DD: MA: 7/25/2001	Treatment of growth failure in children who were born small for gestational age.	Pharmacia and Upjohn Company 7000 Portage Road 7000 Portage Road Kalamazoo MI 49001
Somatropin for injection *Serostim*	DD: MA: 8/23/1996	Treatment of AIDS-associated catabolism/weight loss.	Serono Laboratories, Inc. 100 Longwater Circle 100 Longwater Circle Norwell MA 02061
Somatropin for injection *Humatrope*	DD: 6/12/1986 MA: 3/8/1987 MA: 3/8/1987	For the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.	Eli Lilly and Company Lilly Corporate Center Lilly Corporate Center Indianapolis IN 46285
Somatropin for injection	DD:	As replacement therapy for growth hormone	Genentech, Inc.

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Nutropin	MA:	deficiency in adults after epiphyseal closure.	460 Point San Bruno Boulevard 460 Point San Bruno Boulevard South San Francisco CA 94080
Somatropin for injection *Nutropin*	DD: 8/4/1989 MA:	Treatment of growth retardation associated with chronic renal failure.	Genentech, Inc. 460 Point San Bruno Boulevard 460 Point San Bruno Boulevard South San Francisco CA 94080
Somatropin for injection *Nutropin*	DD: 3/23/1989 MA:	Treatment of short stature associated with Turner's syndrome.	Genentech, Inc. 460 Point San Bruno Boulevard 460 Point San Bruno Boulevard South San Francisco CA 94080
Sorivudine *BRAVAVIR*	DD: 11/9/1995 MA:	Treatment of herpes zoster (shingles) in immunocompromised patients.	Bristol-Myers Squibb 5 Research Parkway 5 Research Parkway P.O. Box 5100 Wallingford CT 06492
Sotalol HCl *Betapace*	DD: 9/23/1988 MA:	Treatment of life-threatening ventricular tachyarrhythmias.	Berlex Laboratories, Inc. 300 Fairfield Road 300 Fairfield Road Wayne NJ 07470
Sotalol HCl *Betapace*	DD: 9/23/1988 MA:	Prevention of life threatening ventricular tachyarrhythmias.	Berlex Laboratories, Inc. 300 Fairfield Road 300 Fairfield Road Wayne NJ 07470
Spiramycin *Rovamycine*	DD: MA: MA:	For symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.	Rhone-Poulenc Rorer 500 Arcola Road 500 Arcola Road Collegeville PA 19426
squalamine lactate	DD: 5/11/2001 MA:	Treatment of ovarian cancer refractory or resistant to standard chemotherapy	Genaera Corporation 5110 Campus Drive Plymouth Meeting PA 19462
SS1(dsFv)-PE38	DD: 2/11/2002 MA:	Treatment of malignant mesothelioma	NeoPharm Incorporated 150 Field Drive Suite 195 Lake Forest IL 60045
SS1(dsFv)-PE38	DD: 2/11/2002 MA:	Treatment of epithelial ovarian cancer	NeoPharm, Inc. 150 Field Drive Suite 195 Lake Forest IL 60045
ST1-RTA immunotoxin (SR 44163)	DD: 8/12/1987 MA:	Treatment of patients with B-chronic lymphocytic leukemia.	Sanofi Winthrop, Inc. 9 Great Valley Parkway Malvern PA 19355
ST1-RTA immunotoxin (SR 44163)	DD: 8/12/1987 MA: MA:	Prevention of acute graft versus host disease in allogenic bone marrow transplantation.	Sanofi Winthrop, Inc. 9 Great Valley Parkway Malvern PA 19355

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Sterile talc *Steritalc*	DD: 12/8/1997 MA:	Treatment of pneumothorax.	Novatech SA Avenue du Vent des Dames - Z.I. les Paluds 13685 Aubagne
Sterile talc *Steritalc*	DD: 12/8/1997 MA:	Treatment of malignant pleural effusion.	Novatech SA Avenue du Vent des Dames - Z.I. les Paluds 13685 Aubagne
Sterile talc powder *Sclerosol Intrapleural Aerosol*	DD: 9/18/1995 MA:	Treatment of malignant pleural effusion.	Bryan Corporation 4 Plympton Street Woburn MA 01801
SU101	DD: 5/25/1995 MA:	Treatment of malignant glioma.	Sugen, Inc. 230 East Grand Ave. South San Francisco CA 94080-4811
SU101	DD: 3/12/1996 MA:	Treatment of ovarian cancer.	Sugen, Inc. 230 East Grand Ave. South San Francisco CA 94080-4811
suberoylanilide hydroxamic acid	DD: 6/12/2003 MA:	Treatment of multiple myeloma	Aton Pharma, Inc. 777 Old Saw Mill River Road Tarrytown NY 10591-6717
Succimer *Chemet capsules*	DD: 5/9/1984 MA:	Treatment of lead poisoning in children.	Bock Pharmacal Company P.O. Box 419056 Saint Louis MO 63141-9056
Succimer *Chemet*	DD: 3/22/1991 MA:	Treatment of mercury intoxication.	Sanofi Winthrop, Inc. 90 Park Avenue New York NY 10016-1389
Succimer *Chemet*	DD: 11/5/1990 MA: MA:	Prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.	Sanofi Winthrop, Inc. 90 Park Avenue 90 Park Avenue New York NY 10016-1389
Sucralfate	DD: 7/15/1993 MA: MA:	Treatment of oral mucositis and stomatitis following radiation therapy for head and neck cancer.	Fuisz Technologies, Ltd. 14555 Avion at Lakeside Chantilly VA 20151
Sucralfate suspension	DD: 3/12/1990 MA: MA:	Treatment of oral complications of chemotherapy in bone marrow transplant patients.	Darby Pharmaceuticals, Inc. 100 Banks Avenue Rockville Centre NY 11570

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Sucralfate suspension	DD: 3/4/1991 MA:	Treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa.	Darby Pharmaceuticals, Inc. 100 Banks Avenue Rockville Centre NY 11570
Sulfadiazine	DD: 3/14/1994 MA: 7/29/1994 MA: 7/29/1994	For use in combination with pyrimethamine for the treatment of Toxoplasma gondii AIDS. encephalitis in patients with and without	Eon Labs Manufacturing, Inc. 227-15 North Conduit Avenue Laurelton NY 11413
Sulfapyridine	DD: 9/10/1990 MA:	Treatment of dermatitis herpetiformis.	Jacobus Pharmaceutical Company 37 Cleveland Lane P.O. Box 5290 Princeton NJ 08540
Superoxide dismutase (human)	DD: 3/6/1985 MA: MA:	For protection of donor organ tissue from damage or injury mediated by generated during the necessary periods of oxygen-derived free radicals that are ischemia (hypoxia, anoxia), and especially reperfusion, associated with the operative	Pharmacia-Chiron Partnership 4560 Horton Street Emeryville CA 94608
Superoxide dismutase (recombinant human) *Oxsodrol*	DD: 5/17/1988 MA: MA:	Prevention of reperfusion injury to donor organ tissue.	Bio-Technology General Corp. 70 Wood Avenue, South Iselin NJ 08830
Suramin *Metaret*	DD: 5/6/1997 MA:	Treatment of hormone-refractory prostate cancer.	Warner-Lambert Company Parke-Davis Pharmaceutical Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor MI 48105-2430
Surface active extract of saline lavage of bovine lungs *Infasurf*	DD: 6/7/1985 MA: MA:	Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.	ONY, Inc. 1576 Sweet Home Road Amherst NY 14228
Surfactant (human) (amniotic fluid derived) *Human Surf*	DD: 3/25/1987 MA: MA:	Prevention and treatment of neonatal respiratory distress syndrome.	Merritt, T. Allen M.D. 2516 Stockton Boulevard Sacramento CA 95817
Synsorb Pk	DD: 7/17/1995 MA:	Treatment of verocytotoxogenic E. coli infections.	Synsorb Biotech Inc. 201, 1204 Kensington Road, N.W. Calgary, Alberta
Synthetic Human Parathyroid Hormone 1-34	DD: 1/26/2001 MA:	Treatment of hypoparathyroidism	Orphan Pharmaceuticals, U.S., Inc. 1101 Kermit Drive, Suite 608 Nashville TN 37217
Synthetic human secretin	DD: 6/16/1999 MA:	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Synthetic human secretin	DD: 3/7/2000 MA: MA:	For use in conjunction with diagnostic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176
Synthetic human secretin	DD: 6/16/1999 MA: MA:	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176
Synthetic human secretin	DD: 6/16/1999 MA:	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 1550 Gallaudet Ave. Silver Spring MD 20905-4176
Synthetic porcine secretin	DD: 6/18/1999 MA: 11/1/2002	For use in the evaluation of exocrine pancreas function.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176
Synthetic porcine secretin	DD: 6/18/1999 MA: 4/4/2002	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176
Synthetic porcine secretin	DD: 3/7/2000 MA: 4/4/2002 MA: 4/4/2002	For use in conjunction with diagnostic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176
Synthetic porcine secretin	DD: 6/18/1999 MA: MA:	For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176
T-cell depleted stem cell enriched cellular product from peripheal b lood stem cells	DD: 11/1/2001 MA:	Treatment of chronic granulomatous disease	Nexell Therapeutics Inc. 9 Parker Irvine CA 92618-1605
T4 endonuclease V, liposome encapsulated	DD: 6/27/1989 MA:	To prevent cutaneous neoplasms and other skin abnormalities in xeroderma pigmentosum.	AGI Dermatics 205 Buffalo Avenue Freeport NY 11520
Tacrolimus *Prograf*	DD: 4/6/1998 MA:	Prophylaxis of graft-versus-host-disease.	Fujisawa USA, Inc. 3 Parkway North Center Deerfield IL 60015
TAK-603	DD: 5/13/1998 MA:	Treatment of Crohn's disease.	Tap Holdings Inc. 2355 Waukegan Road Deerfield IL 60015

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Technetium Tc 99m pterotetramide carcinomas.	DD: 2/16/2000 Endocyte, Inc. MA:	For the identification of ovarian	1205 Kent Ave. Lafayette IN 47906
Technetium Tc99m anti-melanoma murine monoclonal antibody *Oncotrac Melanoma Imaging Kit*	DD: 6/2/1987 MA: MA:	For use in detecting, by imaging, metastases of malignant melanoma.	NeoRx Corporation 410 West Harrison Seattle WA 98119-4007
Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell *LymphoScan*	DD: 4/7/1992 MA:	Diagnostic imaging in the evaluation of the extent of disease in patients with histologically confirmed diagnosis of non-Hodgkin's B-cell lymphoma, acute B-cell lymphoblastic leukemia (in children and adults), and chronic B-cell lymphocytic	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950
Technetium Tc99m murine monoclonal antibody to hCG *Immuraid, hCG-Tc-99m*	DD: 8/7/1989 MA: MA:	Detection of hCG producing tumors such as germ cell and trophoblastic cell tumors.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950
Technetium Tc99m murine monoclonal antibody to human *AFP-Scan*	DD: 8/1/1989 MA: MA:	Detection of alpha-fetoprotein producing germ cell tumors.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950
Technetium Tc99m murine monoclonal antibody to human alpha-fetoprotein *Immuraid, AFP-Scan*	DD: 8/1/1989 MA: MA:	Detection of hepatocellular carcinoma and hepatoblastoma.	Immunomedics, Inc. 300 American Road Morris Plains NJ 07950
Technetium Tc99m rh-Annexin V *Apomate*	DD: 11/3/2000 MA: MA:	Diagnosis or assessment of rejection status in heart, heart-lung, single lung, or bilateral lung transplants.	Theseus Imaging Corporation 124 Mount Auburn Street 124 Mount Auburn Street Suite 200 North Cambridge MA 02138
Temoporfin *Foscan*	DD: MA: MA:	Palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy.	Scotia Pharmaceuticals Ltd. Scotia House, Castle Business Park Scotia House, Castle Business Park Stirling
Temozolomide *Temodar*	DD: 10/5/1998 MA: 8/11/1999	Treatment of recurrent malignant glioma.	Schering-Plough Research Institute 2000 Galloping Hill Rd. Kenilworth NJ 07033
Temozolomide *Temodal*	DD: MA:	Treatment of advanced metastatic melanoma.	Schering-Plough Research Institute 2000 Galloping Hill Rd. 2000 Galloping Hill Rd. Kenilworth NJ 07033

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Teniposide *Vumon for injection*	DD: 11/1/1984 MA: 7/14/1992	Treatment of refractory childhood acute lymphocytic leukemia.	Bristol-Myers Squibb Pharmaceutical Research Institute 5 Research Parkway P.O. Box 5100 Wallingford CT 06492
Teriparatide *Parathar*	DD: MA:	Treatment of idiopathic osteoporosis.	Henri Beaufour Institute USA, Inc. 27 Maple St. Milford MA 01757
Teriparatide *Parathar*	DD: 1/9/1987 MA: MA:	Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.	Rhone-Poulenc Rorer Pharmaceuticals, Inc. 500 Arcola Road 500 Arcola Road Collegeville PA 19426
Terlipressin *Glypressin*	DD: 3/6/1986 MA:	Treatment of bleeding esophageal varices.	Ferring Laboratories, Inc. 400 Rella Boulevard, Suite 201 Suffern NY 10901
Testosterone *TheraDerm Testosterone Transdermal*	DD: 9/22/1997 MA: MA:	For use as physiologic testosterone replacement in androgen deficient HIV+ patients with an associated weight loss.	Watson Laboratories Research Park Research Park 417 Wakara Way Salt Lake City UT 84108
Testosterone *Androgel*	DD: 2/5/1996 MA:	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Unimed Pharmaceuticals, Inc. Four Parkway North Four Parkway North Deerfield IL 60015-2544
Testosterone propionate ointment 2%	DD: 7/31/1991 MA:	Treatment of vulvar dystrophies.	Star Pharmaceuticals, Inc. 1990 N.W. 44th Street Pompano Beach FL 33064
Testosterone sublingual	DD: 1/16/1991 MA:	Treatment of constitutional delay of growth and puberty in boys.	Bio-Technology General Corp. 70 Wood Avenue South Iselin NJ 08830
Tetrabenazine	DD: 5/12/1998 MA:	Treatment of moderate/severe tardive dyskinesia.	Lifehealth Limited 23 Winkfield Road Windsor, Berkshire
Tetrabenazine	DD: MA:	Treatment of Huntington's disease.	Lifehealth Limited 23 Winkfield Road Doltic House Kingfisher WA Windor, Berkshire
Tetraiodothyroacetic acid	DD: 5/1/2000 MA: MA:	Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.	Danforth, Jr., MD, Elliot University of Vermont 84 Beartown Rd. Underhill VT 05489

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Tezacitabine	DD: 1/27/2003 MA:	Treatment of adenocarcinoma of the esophagus and stomach	Chiron Corporation 4560 Horton Street Emeryville CA 94608-2916
TGF(beta)2-specific phosphorothioate antisense oligodeoxynucleotide *Oncomun*	DD: 6/5/2002 MA: MA:	Treatment of malignant glioma	Antisense Pharma GmbH Josef-Engert-Str. 9 93053 Regensberg
Thalidomide	DD: 2/27/1998 MA:	Treatment of primary brain malignancies.	Celgene Corporation 7 Powder Horn Dr. Warren NJ 07059
Thalidomide *Synovir*	DD: 3/11/1996 MA:	Treatment of HIV-associated wasting syndrome.	Celgene Corporation P.O. Box 4914 P.O. Box 4914 7 Powder Horn Drive Warren NJ 07059
Thalidomide	DD: 1/12/1993 MA: MA:	Treatment of the clinical manifestations of mycobacterial infection caused by non-tuberculous mycobacteria. Mycobacterium tuberculosis and	Celgene Corporation P.O. Box 4914 7 Powder Horn Drive Warren NJ 07059
Thalidomide	DD: 9/19/1988 MA: MA:	Prevention of graft versus host disease in patients receiving bone marrow transplantation.	Pediatric Pharmaceuticals, Inc. 718 Bradford Avenue Westfield NJ 07090
Thalidomide	DD: MA:	Treatment and maintenance of reactional lepromatous leprosy.	Pediatric Pharmaceuticals, Inc. 718 Bradford Avenue Westfield NJ 07090
Thalidomide	DD: 7/29/1998 MA:	Treatment of Kaposi's sarcoma.	Celgene Corporation 7 Powder Horn Dr. Warren NJ 07059
Thalidomide *Thalomid*	DD: 7/26/1995 MA: 7/16/1998	Treatment of erythema nodosum leprosum.	Celgene Corporation P.O. Box 4914 7 Powder Horn Drive Warren NJ 07059
Thalidomide *Thalomid*	DD: MA:	Treatment of multiple myeloma.	Celgene Corporation 7 Powder Horn Dr. Warren NJ 07059
Thalidomide	DD: 9/19/1988 MA: MA:	Treatment of graft versus host disease in patients receiving bone marrow transplantation.	Pediatric Pharmaceuticals, Inc. 718 Bradford Avenue Westfield NJ 07090

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Thalidomide *Thalomid*	DD: 4/6/1999 MA:	Treatment of Crohn's disease.	Celgene Corporation 7 Powder Horn Dr. Warren NJ 07059
Thalidomide	DD: 3/5/1990 MA:	Prevention of graft versus host disease.	Andrulis Research Corporation 11800 Baltimore Avenue, Suite 113 Beltsville MD 20705
Thalidomide	DD: 5/1/1995 MA: MA:	Treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients.	Celgene Corporation P.O. Box 4914 7 Powder Horn Srive Warren NJ 07059
Thalidomide	DD: 5/15/1995 MA: MA:	Treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients.	Andrulis Research Corporation 11800 Baltimore Avenue, Suite 113 Beltsville MD 20705
Thalidomide	DD: 3/5/1990 MA:	Treatment of graft versus host disease.	Andrulis Research Corporation 11800 Baltimore Avenue, Suite 113 Beltsville MD 20705
Thymalfasin *Zadaxin*	DD: 1/8/1998 MA:	Treatment of DiGeorge anomaly with immune defects.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Blvd. 901 Mariner's Island Blvd. San Mateo CA 94404-1593
Thymalfasin *Zadaxin*	DD: 5/3/1991 MA:	Treatment of chronic active hepatitis B.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Blvd. San Mateo CA 94404-1593
Thymalfasin *Zadaxin*	DD: 3/6/2000 MA:	Treatment of hepatocellular carcinoma.	SciClone Pharmaceuticals, Inc. 901 Mariner's Blvd., Suite 205 San Mateo CA 94404
Thymoxamine HCl	DD: MA: MA:	Reversal of phenylephrine-induced mydriasis in patients who have narrow an acute attack of angle-closure glaucoma anterior angles and are at risk of developing following mydriasis.	Iolab Pharmaceuticals 500 Iolab Drive Claremont CA 91711
Thyrotropin alfa *Thyrogen*	DD: 8/3/2001 MA: MA:	Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid	Genzyme Corporation One Kendall Square One Kendall Square Cambridge MA 02139-1562
Thyrotropin alpha *Thyrogen*	DD: 2/24/1992 MA:	As an adjunct in the diagnosis of thyroid cancer.	Genzyme Corporation One Kendall Square One Kendall Square Cambridge MA 02139
Tiapride	DD: 4/21/1998 MA:	Treatment of Tourette's syndrome.	Sanofi-Synthelabo, Inc. 9 Great Valley Parkway PO Box 3026 Malvern PA 19355

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Tiazofurin (2-Beta-D-ribofuranosyl-4-thiazolec	DD: MA:	Chronic myelogenous leukemia (CML)	Ribapharm 3300 Hyland Avenue Costa Mesa CA 92626
tinidazole	DD: 4/18/2002 MA:	Treatment of giardiasis	Presutti Laboratories, Inc. 1607 N. Douglas Ave. Arlington Heights IL 60004
Tinidazole	DD: 8/20/2003 MA:	For the treatment of amebiasis	Presutti Laboratories, Inc. 1607 N. Douglas Avenue Arlington Heights IL 60004
Tiopronin *Thiola*	DD: 1/17/1986 MA: 8/11/1988	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Pak, Charles Y.C. M.D. The University of Texas Health The University of Texas Health Scienc Center at Da 5323 Harry Hines Boulevard Dallas TX 75235
tirapazamine	DD: MA:	For the treatment of head and neck cancer	Sanofi-Synthelabo Research 9 Great Valley Parkway Malvern PA 19355
Tiratricol *Triacana*	DD: 8/13/1991 MA: MA:	For use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.	Laphal Laboratoires 48 Bis, Rue des Belles-Feuilles 48 Bis, Rue des Belles-Feuilles 75116 Paris
Tizanidine HCl *Zanaflex*	DD: 1/31/1994 MA:	Treatment of spasticity associated with multiple sclerosis and spinal cord injury.	Athena Neurosciences, Inc. 800 Gateway Boulevard 800 Gateway Boulevard South San Francisco CA 94080
Tobramycin *Tobi*	DD: 6/18/1999 MA:	Treatment of bronchiectasis patients infected with Pseudomonas aeruginosa.	Chiron Corporation 201 Elliott Avenue West 201 Elliott Avenue West Suite 150 Seattle WA 98119
Tobramycin for inhalation *TOBI*	DD: MA: MA:	Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.	Pathogenesis Corporation 201 Elliott Avenue West, Suite 150 201 Elliott Avenue West, Suite 150 Seattle WA 98119
Tocophersolan oral solution (vitamin E-tpgs)	DD: 4/15/1988 MA:	Treatment of vitamin E deficiency resulting from malabsorption due to prolonged cholestatic hepatobiliary disease.	Sterling Winthrop 9 Great Valley Parkway Malvern PA 19355
Topiramate *Topamax*	DD: MA: 8/28/2001	Treatment of Lennox-Gastaut syndrome.	R. W. Johnson Pharmaceutical Research Institute Route 202, P.O. Box 300 Raritan NJ 08869-0602

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
toralizumab	DD: 3/14/2002 MA:	Treatment of immune thrombocytopenic purpura	IDEC Pharmaceuticals Corporation 3030 Callan Road San Diego CA 92121
Toremifene *Fareston*	DD: 9/19/1991 MA: 5/29/1997	Hormonal therapy of metastatic carcinoma of the breast.	Orion Corporation P.O. Box 65 P.O. Box 65 02101 ESPOO
Toremifene	DD: 8/17/1993 MA:	Treatment of desmoid tumors.	Orion Corporation P.O. Box 65 02101 Espoo
Tositumomab and iodine I 131 tositumomab *Bexxar*	DD: 5/16/1994 MA: 6/27/2003 MA: 6/27/2003	Treatment of non-Hodgkin's B-cell lymphoma.	Corixa Corporation 1124 Columbia St. Suite 200 Seattle WA 98104
Tranexamic acid *Cyklokapron*	DD: MA: MA:	Treatment of patients with congenital coagulopathies who are undergoing surgical procedures (e.g. dental extractions).	Pharmacia Inc. P.O. Box 16529 P.O. Box 16529 Columbus OH 43216
Tranexamic acid *Cyklokapron*	DD: 7/23/1987 MA: MA:	Treatment of patients undergoing prostatectomy where there is hemorrhage or risk of hemorrhage as a result of increased fibrinolysis or fibrinogenolysis.	Pharmacia Inc. P.O. Box 16529 P.O. Box 16529 Columbus OH 43216
Tranexamic acid *Cyklokapron*	DD: 9/9/1985 MA:	Treatment of hereditary angioneurotic edema.	Pharmacia Inc. P.O. Box 16529 P.O. Box 16529 Columbus OH 43216
Tranilast *Rizaben*	DD: 12/2/2003 MA:	For the treatment of maligant glioma	Angiogen Pharmaceuticals, Pty. Ltd. Level 31, ABN AMRO Tower 88 Phillip Street Sydney, N.S.W. 2000
Transforming growth factor-beta 2	DD: MA:	Treatment of full thickness macular holes.	Celtrix Pharmaceuticals, Inc. 3055 Patrick Henry Drive Santa Clara CA 95054
Transgenic human alpha 1 antitrypsin	DD: 5/19/1999 MA:	Treatment of emphysema secondary to alpha 1 antitrypsin deficiency.	PPL Therapeutics (Scotland) Limited Roslin, Edinburgh
Trastuzumab *Herceptin*	DD: MA:	Treatment of patients with pancreatic cancer that overexpress p185HER2.	Genentech, Inc. 1 DNA Way 1 DNA Way South San Francisco CA 94080-4990

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Tumor necrosis factor-binding protein II	DD: 1/6/1993 MA:	Treatment of symptomatic patients with the AIDS including all patients with CD4 T-cell counts less than 200 cells per mm3.	Serono Laboratories, Inc. 100 Longwater Circle Norwell MA 02061
Tyloxapol *Supervent*	DD: 3/8/1995 MA:	Treatment of cystic fibrosis.	Kennedy & Hoidal, M.D.'s University of Utah Health Sciences Center 50 North Medical Drive, Room 4R240 Salt Lake City UT 84132-0001
Ubiquinone *Ubi-Q-Gel*	DD: MA:	Treatment of mitochondrial cytopathies.	Gel-Tec, Division of Tishcon Corp. 30 New York Ave. PO Box 331 Westbury NY 11590
Unconjugated Chimeric (human-murine) G250 IgG monoclonal antibody	DD: 3/22/2001 MA:	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH Grillparzerstrasse 10B 81675 Munich
Uridine 5'-triphosphate	DD: 12/4/1995 MA:	Treatment of cystic fibrosis.	Inspire Pharmaceuticals, Inc. 4222 Emperor Boulevard, Suite 470 Durham NC 27703
Uridine 5'-triphosphate	DD: 6/26/1996 MA: MA:	To facilitate the removal of lung secretions in the treatment of patients with primary ciliary dyskinesia.	Inspire Pharmaceuticals, Inc. 4222 Emperor Boulevard, Suite 470 Durham NC 27703
Urofollitropin *Metrodin*	DD: MA: 9/18/1986 MA: 9/18/1986	For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.	Serono Laboratories, Inc. 100 Longwater Circle 100 Longwater Circle Norwell MA 02061
Urofollitropin *Fertinex*	DD: 12/5/1997 MA: MA:	For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism.	Serono Laboratories, Inc. 100 Longwater Circle 100 Longwater Circle Norwell MA 02061
Urogastrone	DD: 11/1/1984 MA: MA:	For acceleration of corneal epithelial regeneration and healing of stromal incisions from corneal transplant surgery.	Chiron Vision 500 Iolab Drive Claremont CA 91711
Ursodiol *URSO*	DD: 6/20/1991 MA:	Treatment of patients with primary biliary cirrhosis.	Axcan Pharma Inc. 597 Laurier Blvd 597 Laurier Blvd Mount St. Hilaire Quebec H7L 4S3
Ursodiol *Actigall*	DD: 2/19/1991 MA: MA:	Management of the clinical signs and symptoms associated with primary biliary cirrhosis.	Novartis Pharmaceuticals 59 Route 10 59 Route 10 East Hanover NJ 07936-1080

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Valine, isoleucine and leucine *VIL*	DD: 1/5/1996 MA:	Treatment of hyperphenylalaninemia.	Leas Research Products 78 Fallon Drive North Haven CT 06473
Valrubicin *Valstar*	DD: 5/23/1994 MA: 9/25/1998	Treatment of carcinoma in situ of the urinary bladder.	Anthra Pharmaceuticals, Inc. 103 Carnegie Center, Suite 102 103 Carnegie Center, Suite 102 Princeton NJ 08540
Vapreotide *Octastatin*	DD: 3/6/2000 MA: MA:	Prevention of early postoperative complications following pancreatic resection.	Debiopharm S.A. 17 rue des Terreaux 17 rue des Terreaux CH-1000 Lausanne 9
Vapreotide *Octastatin*	DD: 1/10/2000 MA: MA:	Treatment of esophageal variceal hemorrhage patients with portal hypertension.	Debiopharm S.A. 17 rue des Terreaux 17 rue des Terreaux CH-1000 Lausanne 9
Vapreotide *Octastatin*	DD: 1/10/2000 MA:	Treatment of gastrointestinal and pancreatic fistulas.	Debiopharm S.A. 17 rue des Terreaux 17 rue des Terreaux CH-1000 Lausanne 9
vapreotide pamoate *Sanvar*	DD: 11/4/2003 MA:	For the treatment of acromegaly	H3 Pharma, Inc. 666 Sherbrooke Street West, Suite 1400 Montreal, Quebec
Vasoactive intestinal peptide	DD: 3/9/2001 MA:	Treatment of Acute Respiratory Distress Syndrome.	Sami I. Said, M.D. State University of New York at Stony Brook Healt Health Sciences Center T17, 040 Stony Brook NY 11794-8172
Vasoactive intestinal polypeptide	DD: 6/23/1993 MA:	Treatment of acute esophageal food impaction.	Research Triangle Pharmaceuticals 200 Westpark Corporate Center 4364 South Alston Avenue Durham NC 27713-2280
vigabatrin *Sabril*	DD: 6/12/2000 MA:	Treatment of infantile spasms.	Aventis Pharmaceuticals Inc. P.O. Box 9627 Kansas City MO 64137
Viloxazine HCl *Catatrol*	DD: 6/11/1984 MA:	Treatment of narcolepsy.	Stuart Pharmaceuticals Division of ICI Americas Wilmington DE 19897
Viloxazine HCl *Catatrol*	DD: 6/11/1984 MA:	Treatment of cataplexy.	Stuart Pharmaceuticals Division of ICI Americas Wilmington DE 19897

FDA data supplied by DrugPatentWatch.com

LIST OF ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS

Through December 31, 2003

Generic Name/ Trade Name (if present)	*Date Designated = DD Date Approved = MA*	*Indication Designated*	*Sponsor and Address*
Virulizin *Virulizin*	DD: 2/1/2001 MA:	Treatment of pancreatic cancer.	Lorus Therapeutics Inc. 7100 Woodbine Avenue, Suite 215 Markham, ON L3R 5J2
Xenogeneic hepatocytes *HepatAssist Liver Assist System*	DD: MA:	Treatment of severe liver failure.	Circe Biomedical, Inc. 99 Hayden Ave. Lexington MA 02421-7995
Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembroyonic antigen *Cea-Cide*	DD: 8/3/1999 MA: MA:	Treatment of ovarian carcinoma.	Immunomedics, Inc. 300 American Rd. Morris Plains NJ 07950
Zalcitabine *Hivid*	DD: 6/28/1988 MA: 6/19/1992	Treatment of AIDS.	Hoffmann-La Roche, Inc. 340 Kingsland Street Nutley NJ 07110
Zalcitabine	DD: 12/9/1986 MA:	Treatment of AIDS.	National Cancer Institute, DCT NIH, Executive Plaza North, Room 7-18 Bethesda MD 20892
Zidovudine *Retrovir*	DD: 7/17/1985 MA: 3/19/1987	Treatment of AIDS.	Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park NC 27709
Zidovudine *Retrovir*	DD: 5/12/1987 MA: 3/19/1987	Treatment of AIDS related complex.	Glaxo Wellcome Inc. 5 Moore Drive Research Triangle Park NC 27709
Zinc acetate *Galzin*	DD: 11/6/1985 MA: 1/28/1997	Treatment of Wilson's disease.	Lemmon Company 1510 Delp Drive Kulpsville PA 19443
Zoledronate *Zometa, Zabel*	DD: 8/18/2000 MA: 8/20/2001	Treatment of tumor induced hypercalcemia.	Novartis Pharmaceuticals Corp. 59 Route 10 East Hanover NJ 07936-1080

FDA data supplied by DrugPatentWatch.com

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

ACETAMINOPHEN; ASPIRIN; BUTALBITAL
CAPSULE OR TABLET; ORAL
160-165MG; 160-165MG; 50MG

ACETAMINOPHEN; ASPIRIN; BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG; 325MG; 50MG

ACETAMINOPHEN; ASPIRIN; BUTALBITAL; CAFFEINE
CAPSULE OR TABLET; ORAL
160-165MG; 160-165MG; 50MG; 40MG

ACETAMINOPHEN; ASPIRIN; BUTALBITAL; CAFFEINE
CAPSULE OR TABLET; ORAL
325MG; 325MG; 50MG; 40MG

ACETAMINOPHEN; BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG; 50MG
650MG; 50MG

ACETAMINOPHEN; BUTALBITAL; CAFFEINE
CAPSULE OR TABLET; ORAL
325MG; 50MG; 40MG
650MG; 50MG; 40MG
500MG; 50MG; 40MG

AMINOPHYLLINE
TABLET; ORAL
100MG
200MG

ASPIRIN; BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG; 50MG
650MG; 50MG

ASPIRIN; BUTALBITAL; CAFFEINE
CAPSULE OR TABLET; ORAL
325MG; 50MG; 40MG
650MG; 50MG; 40MG

ASPIRIN; CAFFEINE; CARISOPRODOL
TABLET; ORAL
160MG; 32MG; 200MG

ASPIRIN; CAFFEINE; CARISOPRODOL; CODEINE PHOSPHATE
TABLET; ORAL
160MG; 32MG; 200MG; 16MG

ASPIRIN; CARISOPRODOL
TABLET; ORAL
325MG; 200MG

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE
TABLET; ORAL
325MG; 200MG; 16MG

ASPIRIN; MEPROBAMATE
TABLET; ORAL
325MG; 200MG

ASPIRIN; METHOCARBAMOL
TABLET; ORAL
325MG; 400MG

CHLOROTHIAZIDE
TABLET; ORAL
250MG

HYDROXYZINE HYDROCHLORIDE
TABLET; ORAL
10MG; 25MG; 50MG; 100MG

PREDNISONE
TABLET; ORAL
1MG; 2.5MG; 5MG; 10MG; 20MG; 25MG; 50MG

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

** 8 **

8-HOUR BAYER, ASPIRIN (OTC)
8-MOP, METHOXSALEN

** A **

0, AMOXICILLIN
A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
A-N STANNOUS AGGREGATED ALBUMIN, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
A-POXIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
A.P.L., GONADOTROPIN, CHORIONIC
A/T/S, ERYTHROMYCIN
ABELCET, AMPHOTERICIN B
ABILIFY, ARIPIPRAZOLE
ABITREXATE, METHOTREXATE SODIUM
ABREVA, DOCOSANOL (OTC)
ACCOLATE, ZAFIRLUKAST
ACCUNEB, ALBUTEROL SULFATE
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURBRON, THEOPHYLLINE
ACCURETIC, HYDROCHLOROTHIAZIDE
ACCUTANE, ISOTRETINOIN
ACEBUTOLOL HCL, ACEBUTOLOL HYDROCHLORIDE
ACEON, PERINDOPRIL ERBUMINE
ACEPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN AND BUTALBITAL AND CAFFEINE, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE #2, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE #3, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE #4, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 2, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 3, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN AND HYDROCODONE BITARTRATE, ACETAMINOPHEN
ACETAMINOPHEN AND PENTAZOCINE HCL, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE #2, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE #4, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE NO. 2, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE NO. 3, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, BUTALBITAL AND CAFFEINE, ACETAMINOPHEN
ACETAMINOPHEN, BUTALBITAL, AND CAFFEINE, ACETAMINOPHEN
ACETAMINOPHEN, BUTALBITAL, CAFFEINE, AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ACETASOL HC, ACETIC ACID, GLACIAL
ACETASOL, ACETIC ACID, GLACIAL
ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL
ACETIC ACID W/ HYDROCORTISONE, ACETIC ACID, GLACIAL
ACETIC ACID, ACETIC ACID, GLACIAL
ACETOHEXAMIDE, ACETOHEXAMIDE
ACETYLCYSTEINE, ACETYLCYSTEINE
ACHES-N-PAIN, IBUPROFEN (OTC)
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACHROMYCIN, HYDROCORTISONE
ACHROMYCIN, PROCAINE HYDROCHLORIDE
ACHROMYCIN, TETRACYCLINE HYDROCHLORIDE
ACILAC, LACTULOSE
ACIPHEX, RABEPRAZOLE SODIUM
ACLOVATE, ALCLOMETASONE DIPROPIONATE
ACTAHIST, PSEUDOEPHEDRINE HYDROCHLORIDE
ACTH, CORTICOTROPIN
ACTHAR GEL-SYNTHETIC, SERACTIDE ACETATE
ACTHAR, CORTICOTROPIN
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
ACTICORT, HYDROCORTISONE
ACTIDIL, TRIPROLIDINE HYDROCHLORIDE (OTC)
ACTIFED W/ CODEINE, CODEINE PHOSPHATE
ACTIFED, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
ACTIGALL, URSODIOL
ACTIN-N, NITROFURAZONE
ACTINEX, MASOPROCOL
ACTIQ, FENTANYL CITRATE
ACTISITE, TETRACYCLINE HYDROCHLORIDE
ACTIVELLA, ESTRADIOL
ACTONEL, RISEDRONATE SODIUM
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ACTRON, KETOPROFEN (OTC)
ACULAR LS, KETOROLAC TROMETHAMINE
ACULAR PRESERVATIVE FREE, KETOROLAC TROMETHAMINE
ACULAR, KETOROLAC TROMETHAMINE
ACUTECT, TECHNETIUM TC-99M APCITIDE
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, ACYCLOVIR SODIUM
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
ACYCLOVIR, ACYCLOVIR SODIUM
ACYLANID, ACETYLDIGITOXIN
ADAGEN, PEGADEMASE BOVINE
ADALAT CC, NIFEDIPINE
ADALAT, NIFEDIPINE

FDA data supplied by DrugPatentWatch.com

ADDERALL 10, AMPHETAMINE ASPARTATE
ADDERALL 12.5, AMPHETAMINE ASPARTATE
ADDERALL 15, AMPHETAMINE ASPARTATE
ADDERALL 20, AMPHETAMINE ASPARTATE
ADDERALL 30, AMPHETAMINE ASPARTATE
ADDERALL 5, AMPHETAMINE ASPARTATE
ADDERALL 7.5, AMPHETAMINE ASPARTATE
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
ADENOCARD, ADENOSINE
ADENOSCAN, ADENOSINE
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ADPHEN, PHENDIMETRAZINE TARTRATE
ADRIAMYCIN PFS, DOXORUBICIN HYDROCHLORIDE
ADRIAMYCIN RDF, DOXORUBICIN HYDROCHLORIDE
ADRUCIL, FLUOROURACIL
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVICOR, LOVASTATIN
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN POTASSIUM (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN POTASSIUM (OTC)
ADVIL, IBUPROFEN (OTC)
AEROBID, FLUNISOLIDE
AEROLATE III, THEOPHYLLINE
AEROLATE JR, THEOPHYLLINE
AEROLATE SR, THEOPHYLLINE
AEROLATE, THEOPHYLLINE
AEROLONE, ISOPROTERENOL HYDROCHLORIDE
AEROSEB-DEX, DEXAMETHASONE
AEROSEB-HC, HYDROCORTISONE
AEROSPORIN, POLYMYXIN B SULFATE
AFAXIN, VITAMIN A PALMITATE
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)
AGENERASE, AMPRENAVIR
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
AGGRENOX, ASPIRIN
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
AK-PENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKINETON, BIPERIDEN HYDROCHLORIDE
AKINETON, BIPERIDEN LACTATE
AKNE-MYCIN, ERYTHROMYCIN
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKPRO, DIPIVEFRIN HYDROCHLORIDE
AKRINOL, ACRISORCIN
AKTOB, TOBRAMYCIN
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
ALAMAST, PEMIROLAST POTASSIUM
ALAVERT, LORATADINE (OTC)
ALBALON, NAPHAZOLINE HYDROCHLORIDE
ALBAMYCIN, NOVOBIOCIN SODIUM
ALBENZA, ALBENDAZOLE
ALBUMOTOPE 125 I, ALBUMIN IODINATED I-125 SERUM
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL, ALBUTEROL
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALCOHOL 10% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% IN D5-W, ALCOHOL
ALCOHOL 5% IN DEXTROSE 5% IN WATER, ALCOHOL
ALCOHOL 5% IN DEXTROSE 5%, ALCOHOL
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ALDARA, IMIQUIMOD
ALDOCLOR-150, CHLOROTHIAZIDE
ALDOCLOR-250, CHLOROTHIAZIDE
ALDOMET, METHYLDOPA
ALDOMET, METHYLDOPATE HYDROCHLORIDE
ALDORIL 15, HYDROCHLOROTHIAZIDE
ALDORIL 25, HYDROCHLOROTHIAZIDE
ALDORIL D30, HYDROCHLOROTHIAZIDE
ALDORIL D50, HYDROCHLOROTHIAZIDE
ALESSE, ETHINYL ESTRADIOL
ALEVE COLD AND SINUS, NAPROXEN SODIUM (OTC)
ALEVE, NAPROXEN SODIUM (OTC)
ALFENTA, ALFENTANIL HYDROCHLORIDE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
ALINIA, NITAZOXANIDE
ALKERAN, MELPHALAN
ALKERAN, MELPHALAN HYDROCHLORIDE
ALKERGOT, ERGOLOID MESYLATES
ALLAY, ACETAMINOPHEN
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA-D, FEXOFENADINE HYDROCHLORIDE
ALLERFED, PSEUDOEPHEDRINE HYDROCHLORIDE
ALLOPURINOL, ALLOPURINOL
ALOCRIL, NEDOCROMIL SODIUM
ALOMIDE, LODOXAMIDE TROMETHAMINE
ALOPRIM, ALLOPURINOL SODIUM
ALORA, ESTRADIOL
ALOXI, PALONOSETRON HYDROCHLORIDE
ALPHA CHYMAR, CHYMOTRYPSIN
ALPHACAINE HCL W/ EPINEPHRINE, EPINEPHRINE
ALPHACAINE HCL, LIDOCAINE HYDROCHLORIDE
ALPHACAINE, LIDOCAINE
ALPHADERM, HYDROCORTISONE
ALPHADROL, FLUPREDNISOLONE
ALPHAGAN P, BRIMONIDINE TARTRATE

FDA data supplied by DrugPatentWatch.com

ALPHAGAN, BRIMONIDINE TARTRATE
ALPHALIN, VITAMIN A PALMITATE
ALPHAREDISOL, HYDROXOCOBALAMIN
ALPHATREX, BETAMETHASONE DIPROPIONATE
ALPHAZINE, PHENDIMETRAZINE TARTRATE
ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
ALREX, LOTEPREDNOL ETABONATE
ALTACE, RAMIPRIL
ALTOCOR, LOVASTATIN
ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE, ALUMINUM HYDROXIDE (OTC)
ALUPENT, METAPROTERENOL SULFATE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMARYL, GLIMEPIRIDE
AMBENYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
AMBIEN, ZOLPIDEM TARTRATE
AMBISOME, AMPHOTERICIN B
AMBODRYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
AMCILL, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMCINONIDE, AMCINONIDE
AMEN, MEDROXYPROGESTERONE ACETATE
AMERGE, NARATRIPTAN HYDROCHLORIDE
AMERSCAN MDP KIT, TECHNETIUM TC-99M MEDRONATE KIT
AMICAR, AMINOCAPROIC ACID
AMIDATE, ETOMIDATE
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, AMIKACIN SULFATE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, AMIKACIN SULFATE
AMIKIN, AMIKACIN SULFATE
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMILORIDE HCL, AMILORIDE HYDROCHLORIDE
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, AMINO ACIDS
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC, AMINOCAPROIC ACID
AMINOHIPPURATE SODIUM, AMINOHIPPURATE SODIUM
AMINOPHYLLIN, AMINOPHYLLINE
AMINOPHYLLINE DYE FREE, AMINOPHYLLINE
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, AMINOPHYLLINE
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, AMINOPHYLLINE
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSOL 5%, PROTEIN HYDROLYSATE
AMINOSYN 10% (PH6), AMINO ACIDS
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 3.5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% M IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5%, AMINO ACIDS
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 5%, AMINO ACIDS
AMINOSYN 7% (PH6), AMINO ACIDS
AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 7%, AMINO ACIDS
AMINOSYN 8.5% (PH6), AMINO ACIDS
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 10%, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5%, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5%, AMINO ACIDS

FDA data supplied by DrugPatentWatch.com

AMINOSYN II 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 7%, AMINO ACIDS
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 8.5%, AMINO ACIDS
AMINOSYN-HBC 7% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-HBC 7%, AMINO ACIDS
AMINOSYN-HF 8%, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
AMINOSYN-RF 5.2%, AMINO ACIDS
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
AMIPAQUE, METRIZAMIDE
AMITID, AMITRIPTYLINE HYDROCHLORIDE
AMITRIL, AMITRIPTYLINE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE, AMMONIUM CHLORIDE
AMMONIUM CHLORIDE 2.14%, AMMONIUM CHLORIDE
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMMONIUM CHLORIDE, AMMONIUM CHLORIDE
AMMONIUM LACTATE, AMMONIUM LACTATE
AMNESTEEM, ISOTRETINOIN
AMNESTROGEN, ESTROGENS, ESTERIFIED
AMOSENE, MEPROBAMATE
AMOXAPINE, AMOXAPINE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN AND CLAVULANATE POTSSSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
AMOXIL, AMOXICILLIN
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AMPHICOL, CHLORAMPHENICOL
AMPHOTEC, AMPHOTERICIN B
AMPHOTERICIN B, AMPHOTERICIN B
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMPICILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMRINONE LACTATE, INAMRINONE LACTATE
AMRINONE, INAMRINONE LACTATE
AMVAZ, AMLODIPINE MALEATE
AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
AN-MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
ANADROL-50, OXYMETHOLONE
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANAPROX DS, NAPROXEN SODIUM
ANAPROX, NAPROXEN SODIUM
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCEF, CEFAZOLIN SODIUM
ANCOBON, FLUCYTOSINE
ANDRODERM, TESTOSTERONE
ANDROGEL, TESTOSTERONE
ANDROID 10, METHYLTESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
ANDROID 5, METHYLTESTOSTERONE
ANDROID-F, FLUOXYMESTERONE
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANESTACON, LIDOCAINE HYDROCHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
ANEXSIA 7.5/650, ACETAMINOPHEN
ANEXSIA, ACETAMINOPHEN
ANGIO-CONRAY, IOTHALAMATE SODIUM
ANGIOMAX, BIVALIRUDIN
ANGIOVIST 282, DIATRIZOATE MEGLUMINE
ANGIOVIST 292, DIATRIZOATE MEGLUMINE
ANGIOVIST 370, DIATRIZOATE MEGLUMINE
ANHYDRON, CYCLOTHIAZIDE
ANISOTROPINE METHYLBROMIDE, ANISOTROPINE METHYLBROMIDE
ANOQUAN, ACETAMINOPHEN
ANSAID, FLURBIPROFEN
ANSOLYSEN, PENTOLINIUM TARTRATE
ANSPOR, CEPHRADINE
ANTABUSE, DISULFIRAM
ANTAGON, GANIRELIX ACETATE
ANTAGONATE, CHLORPHENIRAMINE MALEATE
ANTEPAR, PIPERAZINE CITRATE
ANTITUSSIVE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ANTIVERT, MECLIZINE HYDROCHLORIDE
ANTIZOL, FOMEPIZOLE
ANTRENYL, OXYPHENONIUM BROMIDE
ANTURANE, SULFINPYRAZONE
ANUSOL HC, HYDROCORTISONE
ANZEMET, DOLASETRON MESYLATE MONOHYDRATE
APAP W/ CODEINE PHOSPHATE, ACETAMINOPHEN
APHTHASOL, AMLEXANOX
APOGEN, GENTAMICIN SULFATE
APRESAZIDE, HYDRALAZINE HYDROCHLORIDE
APRESOLINE, HYDRALAZINE HYDROCHLORIDE
APRESOLINE-ESIDRIX, HYDRALAZINE HYDROCHLORIDE
AQUAMEPHYTON, PHYTONADIONE
AQUAPHYLLIN, THEOPHYLLINE
AQUASOL A, VITAMIN A
AQUASOL A, VITAMIN A PALMITATE
AQUATAG, BENZTHIAZIDE
AQUATENSEN, METHYCLOTHIAZIDE
ARALEN HCL, CHLOROQUINE HYDROCHLORIDE
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
ARALEN, CHLOROQUINE PHOSPHATE
ARAMINE, METARAMINOL BITARTRATE
ARAVA, LEFLUNOMIDE

FDA data supplied by DrugPatentWatch.com

ARDUAN, PIPECURONIUM BROMIDE
AREDIA, PAMIDRONATE DISODIUM
ARESTIN, MINOCYCLINE HYDROCHLORIDE
ARESTOCAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
ARESTOCAINE HCL, MEPIVACAINE HYDROCHLORIDE
ARFONAD, TRIMETHAPHAN CAMSYLATE
ARGATROBAN, ARGATROBAN
ARICEPT, DONEPEZIL HYDROCHLORIDE
ARIMIDEX, ANASTROZOLE
ARISTOCORT A, TRIAMCINOLONE ACETONIDE
ARISTOCORT, TRIAMCINOLONE
ARISTOCORT, TRIAMCINOLONE ACETONIDE
ARISTOCORT, TRIAMCINOLONE DIACETATE
ARISTOGEL, TRIAMCINOLONE ACETONIDE
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
ARIXTRA, FONDAPARINUX SODIUM
AROMASIN, EXEMESTANE
ARTANE, TRIHEXYPHENIDYL HYDROCHLORIDE
ARTHROTEC, DICLOFENAC SODIUM
ASACOL, MESALAMINE
ASBRON, THEOPHYLLINE SODIUM GLYCINATE
ASELLACRIN 10, SOMATROPIN
ASELLACRIN 2, SOMATROPIN
ASENDIN, AMOXAPINE
ASPIRIN AND CAFFEINE W/ BUTALBITAL, ASPIRIN
ASTELIN, AZELASTINE HYDROCHLORIDE
ASTRAMORPH PF, MORPHINE SULFATE
ATACAND HCT, CANDESARTAN CILEXETIL
ATACAND, CANDESARTAN CILEXETIL
ATARAX, HYDROXYZINE HYDROCHLORIDE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
ATHROMBIN, WARFARIN SODIUM
ATHROMBIN-K, WARFARIN POTASSIUM
ATIVAN, LORAZEPAM
ATNAA, ATROPINE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATRIDOX, DOXYCYCLINE HYCLATE
ATROMID-S, CLOFIBRATE
ATROPEN, ATROPINE
ATROPINE AND DEMEROL, ATROPINE SULFATE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
ATROPINE SULFATE, ATROPINE SULFATE
ATROPINE, ATROPINE
ATROVENT, IPRATROPIUM BROMIDE
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '200', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '400', AMOXICILLIN
AUGMENTIN '500', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN
AUREOMYCIN, CHLORTETRACYCLINE HYDROCHLORIDE
AVAGARD, ALCOHOL (OTC)
AVAGE, TAZAROTENE
AVALIDE, HYDROCHLOROTHIAZIDE
AVANDAMET, METFORMIN HYDROCHLORIDE
AVANDIA, ROSIGLITAZONE MALEATE
AVAPRO, IRBESARTAN
AVC, SULFANILAMIDE
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
AVENTYL HCL, NORTRIPTYLINE HYDROCHLORIDE
AVIANE-21, ETHINYL ESTRADIOL
AVIANE-28, ETHINYL ESTRADIOL
AVINZA, MORPHINE SULFATE
AVITA, TRETINOIN
AVODART, DUTASTERIDE
AXERT, ALMOTRIPTAN MALATE
AXID AR, NIZATIDINE (OTC)
AXID, NIZATIDINE
AXOTAL, ASPIRIN
AYGESTIN, NORETHINDRONE ACETATE
AZACTAM IN PLASTIC CONTAINER, AZTREONAM
AZACTAM, AZTREONAM
AZASAN, AZATHIOPRINE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZATHIOPRINE, AZATHIOPRINE
AZDONE, ASPIRIN
AZELEX, AZELAIC ACID
AZLIN, AZLOCILLIN SODIUM
AZMACORT, TRIAMCINOLONE ACETONIDE
AZO GANTANOL, PHENAZOPYRIDINE HYDROCHLORIDE
AZO GANTRISIN, PHENAZOPYRIDINE HYDROCHLORIDE
AZOLID, PHENYLBUTAZONE
AZOPT, BRINZOLAMIDE
AZULFIDINE EN-TABS, SULFASALAZINE
AZULFIDINE, SULFASALAZINE

** B **

BACI-RX, BACITRACIN
BACIGUENT, BACITRACIN
BACIIM, BACITRACIN
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE, BACITRACIN ZINC (OTC)
BACITRACIN ZINC-POLYMYXIN B SULFATE, BACITRACIN ZINC (OTC)
BACITRACIN, BACITRACIN
BACITRACIN, BACITRACIN (OTC)
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE,

FDA data supplied by DrugPatentWatch.com

BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN, BACITRACIN ZINC
BACLOFEN, BACLOFEN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BACTOCILL, OXACILLIN SODIUM
BACTRIM DS, SULFAMETHOXAZOLE
BACTRIM PEDIATRIC, SULFAMETHOXAZOLE
BACTRIM, SULFAMETHOXAZOLE
BACTROBAN, MUPIROCIN
BACTROBAN, MUPIROCIN CALCIUM
BAL, DIMERCAPROL
BALNEOL-HC, HYDROCORTISONE
BAMATE, MEPROBAMATE
BANAN, CEFPODOXIME PROXETIL
BANCAP HC, ACETAMINOPHEN
BANCAP, ACETAMINOPHEN
BANTHINE, METHANTHELINE BROMIDE
BAROS, SODIUM BICARBONATE
BARSTATIN 100, NYSTATIN
BAYCOL, CERIVASTATIN SODIUM
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN, ASPIRIN (OTC)
BECLOVENT, BECLOMETHASONE DIPROPIONATE
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
BECONASE, BECLOMETHASONE DIPROPIONATE
BEEPEN-VK, PENICILLIN V POTASSIUM
BELDIN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
BELIX, DIPHENHYDRAMINE HYDROCHLORIDE
BENADRYL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
BENADRYL, DIPHENHYDRAMINE HYDROCHLORIDE
BENDECTIN, DOXYLAMINE SUCCINATE
BENDOPA, LEVODOPA
BENEMID, PROBENECID
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENICAR, OLMESARTAN MEDOXOMIL
BENOQUIN, MONOBENZONE
BENOXINATE HCL, BENOXINATE HYDROCHLORIDE
BENSULFOID, SULFUR
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BENYLIN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
BENZACLIN, BENZOYL PEROXIDE
BENZAMYCIN PAK, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE
BENZONATATE, BENZONATATE
BENZTHIAZIDE, BENZTHIAZIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BENZYL BENZOATE, BENZYL BENZOATE
BEPADIN, BEPRIDIL HYDROCHLORIDE
BEROCCA PN, ASCORBIC ACID
BERUBIGEN, CYANOCOBALAMIN
BETA-2, ISOETHARINE HYDROCHLORIDE
BETA-HC, HYDROCORTISONE
BETA-VAL, BETAMETHASONE VALERATE
BETADERM, BETAMETHASONE VALERATE
BETADINE, POVIDONE-IODINE
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BETALIN 12, CYANOCOBALAMIN
BETALIN S, THIAMINE HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE SODIUM PHOSPHATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAPACE, SOTALOL HYDROCHLORIDE
BETAPAR, MEPREDNISONE
BETAPEN-VK, PENICILLIN V POTASSIUM
BETAPRONE, PROPIOLACTONE
BETATREX, BETAMETHASONE VALERATE
BETAXOLOL HCL, BETAXOLOL HYDROCHLORIDE
BETAXOLOL, BETAXOLOL HYDROCHLORIDE
BETAXON, LEVOBETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BETIMOL, TIMOLOL
BETOPTIC PILO, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BEXTRA, VALDECOXIB
BIAXIN XL, CLARITHROMYCIN
BIAXIN, CLARITHROMYCIN
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICILLIN, PENICILLIN G BENZATHINE
BICNU, CARMUSTINE
BILIVIST, IPODATE SODIUM
BILOPAQUE, TYROPANOATE SODIUM
BILTRICIDE, PRAZIQUANTEL
BIO-TROPIN, SOMATROPIN RECOMBINANT
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)
BIPHETAMINE 12.5, AMPHETAMINE RESIN COMPLEX
BIPHETAMINE 20, AMPHETAMINE RESIN COMPLEX
BIPHETAMINE 7.5, AMPHETAMINE RESIN COMPLEX
BIPHETAP, BROMPHENIRAMINE MALEATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BLENOXANE, BLEOMYCIN SULFATE
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BLEOMYCIN, BLEOMYCIN SULFATE
BLEPH-10, SULFACETAMIDE SODIUM
BLEPH-30, SULFACETAMIDE SODIUM

FDA data supplied by DrugPatentWatch.com

BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLEPHAMIDE, PREDNISOLONE ACETATE
BLOCADREN, TIMOLOL MALEATE
BONIVA, IBANDRONATE SODIUM
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BONTRIL, PHENDIMETRAZINE TARTRATE
BOROFAIR, ACETIC ACID, GLACIAL
BRANCHAMIN 4% IN PLASTIC CONTAINER, AMINO ACIDS
BRANCHAMIN 4%, AMINO ACIDS
BRAVELLE, UROFOLLITROPIN
BREATHTEK UBT FOR H-PYLORI, UREA, C-13
BRETHAIRE, TERBUTALINE SULFATE
BRETHINE, TERBUTALINE SULFATE
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
BRETYLIUM TOSYLATE IN DEXTROSE 5%, BRETYLIUM TOSYLATE
BRETYLIUM TOSYLATE IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
BRETYLOL, BRETYLIUM TOSYLATE
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
BREVICON 21-DAY, ETHINYL ESTRADIOL
BREVICON 28-DAY, ETHINYL ESTRADIOL
BREVITAL SODIUM, METHOHEXITAL SODIUM
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)
BRICANYL, TERBUTALINE SULFATE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BRISTACYCLINE, TETRACYCLINE HYDROCHLORIDE
BRISTAGEN, GENTAMICIN SULFATE
BRISTAMYCIN, ERYTHROMYCIN STEARATE
BROMANATE DC, BROMPHENIRAMINE MALEATE
BROMANATE DM, BROMPHENIRAMINE MALEATE
BROMANATE, BROMPHENIRAMINE MALEATE
BROMANYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
BROMATAPP, BROMPHENIRAMINE MALEATE (OTC)
BROMFED-DM, BROMPHENIRAMINE MALEATE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BROMPHERIL, DEXBROMPHENIRAMINE MALEATE (OTC)
BRONCHO SALINE, SODIUM CHLORIDE (OTC)
BRONITIN MIST, EPINEPHRINE BITARTRATE (OTC)
BRONKAID MIST, EPINEPHRINE (OTC)
BRONKODYL, THEOPHYLLINE
BRONKOMETER, ISOETHARINE MESYLATE
BRONKOSOL, ISOETHARINE HYDROCHLORIDE
BRYREL, PIPERAZINE CITRATE
BSS PLUS, CALCIUM CHLORIDE
BSS, CALCIUM CHLORIDE
BUCET, ACETAMINOPHEN
BUCLADIN-S, BUCLIZINE HYDROCHLORIDE
BUMETANIDE, BUMETANIDE
BUMEX, BUMETANIDE
BUPHENYL, SODIUM PHENYLBUTYRATE
BUPIVACAINE HCL AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HCL KIT, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HCL, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACINE HCL PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HCL, BUPRENORPHINE HYDROCHLORIDE
BUPROPION HCL, BUPROPION HYDROCHLORIDE
BUPROPRION HCL, BUPROPION HYDROCHLORIDE
BUSPAR, BUSPIRONE HYDROCHLORIDE
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
BUSULFEX, BUSULFAN
BUTABARB, BUTABARBITAL SODIUM
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
BUTABARBITAL, BUTABARBITAL SODIUM
BUTAL COMPOUND, ASPIRIN
BUTALAN, BUTABARBITAL SODIUM
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL COMPOUND, ASPIRIN
BUTALBITAL W/ ASPIRIN & CAFFEINE, ASPIRIN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE, ACETAMINOPHEN
BUTALBITAL, APAP, AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN & CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
BUTALBITAL; ACETAMINOPHEN; AND CAFFEINE WITH CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL; ACETAMINOPHEN; CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTAPAP, ACETAMINOPHEN
BUTAZOLIDIN, PHENYLBUTAZONE
BUTICAPS, BUTABARBITAL SODIUM
BUTISOL SODIUM, BUTABARBITAL SODIUM
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE

** C **

C-SOLVE-2, ERYTHROMYCIN
CAFCIT, CAFFEINE CITRATE
CAFERGOT, CAFFEINE
CALAN, VERAPAMIL HYDROCHLORIDE
CALCIBIND, CELLULOSE SODIUM PHOSPHATE
CALCIJEX, CALCITRIOL
CALCIMAR, CALCITONIN, SALMON
CALCIPARINE, HEPARIN CALCIUM
CALCITONIN-SALMON, CALCITONIN, SALMON

FDA data supplied by DrugPatentWatch.com

CALCITRIOL, CALCITRIOL
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
CALCIUM GLUCEPTATE, CALCIUM GLUCEPTATE
CALDEROL, CALCIFEDIOL
CALMURID HC, HYDROCORTISONE
CAM-AP-ES, HYDRALAZINE HYDROCHLORIDE
CAM-METRAZINE, PHENDIMETRAZINE TARTRATE
CAMILA, NORETHINDRONE
CAMOQUIN HCL, AMODIAQUINE HYDROCHLORIDE
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CANASA, MESALAMINE
CANCIDAS, CASPOFUNGIN ACETATE
CANDEX, NYSTATIN
CANTIL, MEPENZOLATE BROMIDE
CAP-PROFEN, IBUPROFEN (OTC)
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CAPITAL AND CODEINE, ACETAMINOPHEN
CAPITAL WITH CODEINE, ACETAMINOPHEN
CAPITROL, CHLOROXINE
CAPOTEN, CAPTOPRIL
CAPOZIDE 25/15, CAPTOPRIL
CAPOZIDE 25/25, CAPTOPRIL
CAPOZIDE 50/15, CAPTOPRIL
CAPOZIDE 50/25, CAPTOPRIL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CARAC, FLUOROURACIL
CARAFATE, SUCRALFATE
CARBACHOL, CARBACHOL
CARBAMAZEPINE, CARBAMAZEPINE
CARBASTAT, CARBACHOL
CARBATROL, CARBAMAZEPINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CARBOCAINE W/ NEO-COBEFRIN, LEVONORDEFRIN
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARDENE SR, NICARDIPINE HYDROCHLORIDE
CARDENE, NICARDIPINE HYDROCHLORIDE
CARDIO-GREEN, INDOCYANINE GREEN
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOGRAFIN, DIATRIZOATE MEGLUMINE
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARDIOQUIN, QUINIDINE POLYGALACTURONATE
CARDIOTEC, TECHNETIUM TC-99M TEBOROXIME KIT
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDIZEM SR, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CARDRASE, ETHOXZOLAMIDE
CARDURA, DOXAZOSIN MESYLATE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL COMPOUND, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CARMOL HC, HYDROCORTISONE ACETATE
CARNITOR, LEVOCARNITINE
CARTEOLOL HCL, CARTEOLOL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CARTROL, CARTEOLOL HYDROCHLORIDE
CASODEX, BICALUTAMIDE
CATAFLAM, DICLOFENAC POTASSIUM
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
CATARASE, CHYMOTRYPSIN
CAVERJECT, ALPROSTADIL
CECLOR CD, CEFACLOR
CECLOR, CEFACLOR
CEDAX, CEFTIBUTEN DIHYDRATE
CEDILANID-D, DESLANOSIDE
CEENU, LOMUSTINE
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFADYL, CEPHAPIRIN SODIUM
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFTIZOXIME SODIUM
CEFIZOX IN PLASTIC CONTAINER, CEFTIZOXIME SODIUM
CEFIZOX, CEFTIZOXIME SODIUM
CEFMAX, CEFMENOXIME HYDROCHLORIDE
CEFOBID IN PLASTIC CONTAINER, CEFOPERAZONE SODIUM
CEFOBID, CEFOPERAZONE SODIUM
CEFOTAN IN PLASTIC CONTAINER, CEFOTETAN DISODIUM
CEFOTAN, CEFOTETAN DISODIUM
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFOTAXIME, CEFOTAXIME SODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFPIRAMIDE SODIUM, CEFPIRAMIDE SODIUM
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
CEFTIN, CEFUROXIME AXETIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CEFUROXIME, CEFUROXIME SODIUM
CEFZIL, CEFPROZIL
CELEBREX, CELECOXIB
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELESTONE, BETAMETHASONE
CELESTONE, BETAMETHASONE SODIUM PHOSPHATE

FDA data supplied by DrugPatentWatch.com

CELEXA, CITALOPRAM HYDROBROMIDE
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A
CENTANY, MUPIROCIN
CENTRAX, PRAZEPAM
CEPHALEXIN, CEPHALEXIN
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
CEPHALOTHIN SODIUM, CEPHALOTHIN SODIUM
CEPHALOTHIN, CEPHALOTHIN SODIUM
CEPHAPIRIN SODIUM, CEPHAPIRIN SODIUM
CEPHRADINE, CEPHRADINE
CEPHULAC, LACTULOSE
CEPTAZ, CEFTAZIDIME (ARGININE FORMULATION)
CERADON, CEFOTIAM HYDROCHLORIDE
CEREBYX, FOSPHENYTOIN SODIUM
CEREDASE, ALGLUCERASE
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CEREZYME, IMIGLUCERASE
CERNEVIT-12, ALPHA-TOCOPHEROL
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CERUMENEX, TROLAMINE POLYPEPTIDE OLEATE CONDENSATE
CERVIDIL, DINOPROSTONE
CESAMET, NABILONE
CETACORT, HYDROCORTISONE
CETAMIDE, SULFACETAMIDE SODIUM
CETAPRED, PREDNISOLONE ACETATE
CETROTIDE, CETRORELIX
CHEMET, SUCCIMER
CHENIX, CHENODIOL
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CHIBROXIN, NORFLOXACIN
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL, IBUPROFEN
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHIROCAINE, LEVOBUPIVACAINE HYDROCHLORIDE
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORAMPHENICOL, CHLORAMPHENICOL
CHLORAMPHENICOL, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORDIAZACHEL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
CHLORMERODRIN HG 197, CHLORMERODRIN, HG-197
CHLOROFAIR, CHLORAMPHENICOL
CHLOROHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL, CHLORPHENIRAMINE MALEATE
CHLOROMYCETIN HYDROCORTISONE, CHLORAMPHENICOL
CHLOROMYCETIN PALMITATE, CHLORAMPHENICOL PALMITATE
CHLOROMYCETIN, CHLORAMPHENICOL
CHLOROMYCETIN, CHLORAMPHENICOL SODIUM SUCCINATE
CHLOROMYXIN, CHLORAMPHENICOL
CHLOROPROCAINE HCL, CHLOROPROCAINE HYDROCHLORIDE
CHLOROPTIC S.O.P., CHLORAMPHENICOL
CHLOROPTIC, CHLORAMPHENICOL
CHLOROPTIC-P S.O.P., CHLORAMPHENICOL
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE AND RESERPINE, CHLOROTHIAZIDE
CHLOROTHIAZIDE W/ RESERPINE, CHLOROTHIAZIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLOROTHIAZIDE-RESERPINE, CHLOROTHIAZIDE
CHLOROTRIANISENE, CHLOROTRIANISENE
CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL, CHLORPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HCL INTENSOL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CHOLAC, LACTULOSE
CHOLEBRINE, IOCETAMIC ACID
CHOLEDYL SA, OXTRIPHYLLINE
CHOLEDYL, OXTRIPHYLLINE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE
CHOLOGRAFIN SODIUM, IODIPAMIDE SODIUM
CHOLOVUE, IODOXAMATE MEGLUMINE
CHOLOXIN, DEXTROTHYROXINE SODIUM
CHOLYBAR, CHOLESTYRAMINE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CHROMALBIN, ALBUMIN CHROMATED CR-51 SERUM
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CHROMIC CHLORIDE, CHROMIC CHLORIDE
CHROMITOPE SODIUM, SODIUM CHROMATE, CR-51
CHRONULAC, LACTULOSE
CHYMEX, BENTIROMIDE
CHYMODIACTIN, CHYMOPAPAIN

FDA data supplied by DrugPatentWatch.com

CIALIS, TADALAFIL
CIBACALCIN, CALCITONIN HUMAN
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIMETIDINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CIN-QUIN, QUINIDINE SULFATE
CINNASIL, RESCINNAMINE
CINOBAC, CINOXACIN
CINOXACIN, CINOXACIN
CINTICHEM TECHNETIUM 99M HEDSPA, TECHNETIUM TC-99M ETIDRONATE KIT
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRO XR, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
CIRCANOL, ERGOLOID MESYLATES
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
CISPLATIN, CISPLATIN
CITANEST FORTE, EPINEPHRINE BITARTRATE
CITANEST PLAIN, PRILOCAINE HYDROCHLORIDE
CITANEST, PRILOCAINE HYDROCHLORIDE
CLADRIBINE, CLADRIBINE
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN, CEFOTAXIME SODIUM
CLARAVIS, ISOTRETINOIN
CLARINEX, DESLORATADINE
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLEOCIN HCL, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEOCIN, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
CLIMARA PRO, ESTRADIOL
CLIMARA, ESTRADIOL
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN HCL, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS

FDA data supplied by DrugPatentWatch.com

CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CLINORIL, SULINDAC
CLISTIN, CARBINOXAMINE MALEATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOBEX, CLOBETASOL PROPIONATE
CLODERM, CLOCORTOLONE PIVALATE
CLOFIBRATE, CLOFIBRATE
CLOMID, CLOMIPHENE CITRATE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HCL AND CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLOPRA, METOCLOPRAMIDE HYDROCHLORIDE
CLOPRA-"YELLOW", METOCLOPRAMIDE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLORPRES, CHLORTHALIDONE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
CLOXACILLIN SODIUM, CLOXACILLIN SODIUM
CLOXAPEN, CLOXACILLIN SODIUM
CLOZAPINE, CLOZAPINE
CLOZARIL, CLOZAPINE
CO-GESIC, ACETAMINOPHEN
CO-LAV, POLYETHYLENE GLYCOL 3350
COACTIN, AMDINOCILLIN
COBAVITE, CYANOCOBALAMIN
CODAMINE, HYDROCODONE BITARTRATE
CODEINE PHOSPHATE AND ACETAMINOPHEN, ACETAMINOPHEN
CODEINE, ASPIRIN, APAP FORMULA NO. 2, ACETAMINOPHEN
CODEINE, ASPIRIN, APAP FORMULA NO. 3, ACETAMINOPHEN
CODEINE, ASPIRIN, APAP FORMULA NO. 4, ACETAMINOPHEN
CODIMAL-L.A. 12, CHLORPHENIRAMINE MALEATE (OTC)
CODOXY, ASPIRIN
CODRIX, ACETAMINOPHEN
COGENTIN, BENZTROPINE MESYLATE
COGNEX, TACRINE HYDROCHLORIDE
COL-PROBENECID, COLCHICINE
COLAZAL, BALSALAZIDE DISODIUM
COLBENEMID, COLCHICINE
COLD CAPSULE IV, CHLORPHENIRAMINE MALEATE (OTC)
COLD CAPSULE V, CHLORPHENIRAMINE MALEATE (OTC)
COLESTID, COLESTIPOL HYDROCHLORIDE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)
COLISTIMETHATE, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COLONAID, ATROPINE SULFATE
COLOVAGE, POLYETHYLENE GLYCOL 3350
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COLYTE, POLYETHYLENE GLYCOL 3350
COLYTE-FLAVORED, POLYETHYLENE GLYCOL 3350
COMBIPATCH, ESTRADIOL
COMBIPRES, CHLORTHALIDONE
COMBIVENT, ALBUTEROL SULFATE
COMBIVIR, LAMIVUDINE
COMMIT, NICOTINE POLACRILEX (OTC)
COMPAZINE, PROCHLORPERAZINE
COMPAZINE, PROCHLORPERAZINE EDISYLATE
COMPAZINE, PROCHLORPERAZINE MALEATE
COMPOUND 65, ASPIRIN
COMPRO, PROCHLORPERAZINE
COMTAN, ENTACAPONE
CONCENTRAID, DESMOPRESSIN ACETATE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
CONDYLOX, PODOFILOX
CONRAY 30, IOTHALAMATE MEGLUMINE
CONRAY 325, IOTHALAMATE SODIUM
CONRAY 400, IOTHALAMATE SODIUM
CONRAY 43, IOTHALAMATE MEGLUMINE
CONRAY, IOTHALAMATE MEGLUMINE
CONSTILAC, LACTULOSE
CONSTULOSE, LACTULOSE
CONTAC 12 HOUR, CHLORPHENIRAMINE MALEATE (OTC)
CONTAC, CHLORPHENIRAMINE MALEATE (OTC)
COPAXONE, GLATIRAMER ACETATE
COPEGUS, RIBAVIRIN
COPPER T MODEL TCU 380A, COPPER
COR-OTICIN, HYDROCORTISONE ACETATE
CORDARONE, AMIODARONE HYDROCHLORIDE
CORDRAN SP, FLURANDRENOLIDE
CORDRAN, FLURANDRENOLIDE
CORDRAN-N, FLURANDRENOLIDE
COREG, CARVEDILOL
CORGARD, NADOLOL
CORLOPAM, FENOLDOPAM MESYLATE
CORMAX, CLOBETASOL PROPIONATE
CORPHED, PSEUDOEPHEDRINE HYDROCHLORIDE
CORSYM, CHLORPHENIRAMINE POLISTIREX (OTC)
CORT-DOME, HYDROCORTISONE
CORTALONE, PREDNISOLONE
CORTAN, PREDNISONE
CORTEF ACETATE, HYDROCORTISONE ACETATE
CORTEF, HYDROCORTISONE
CORTEF, HYDROCORTISONE CYPIONATE
CORTENEMA, HYDROCORTISONE

FDA data supplied by DrugPatentWatch.com

CORTICOTROPIN, CORTICOTROPIN
CORTIFOAM, HYDROCORTISONE ACETATE
CORTISONE ACETATE, CORTISONE ACETATE
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE
CORTISPORIN, HYDROCORTISONE ACETATE
CORTONE, CORTISONE ACETATE
CORTRIL, HYDROCORTISONE
CORTRIL, HYDROCORTISONE ACETATE
CORTROPHIN-ZINC, CORTICOTROPIN-ZINC HYDROXIDE
CORTROSYN, COSYNTROPIN
CORVERT, IBUTILIDE FUMARATE
CORZIDE, BENDROFLUMETHIAZIDE
COSMEGEN, DACTINOMYCIN
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COTAZYM, LIPASE
COTRIM D.S., SULFAMETHOXAZOLE
COTRIM, SULFAMETHOXAZOLE
COUMADIN, WARFARIN SODIUM
COVERA-HS, VERAPAMIL HYDROCHLORIDE
COZAAR, LOSARTAN POTASSIUM
CRESCORMON, SOMATROPIN
CRESTOR, ROSUVASTATIN CALCIUM
CRINONE, PROGESTERONE
CRIXIVAN, INDINAVIR SULFATE
CROLOM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
CROMOPTIC, CROMOLYN SODIUM
CROTAN, CROTAMITON
CRYSELLE, ETHINYL ESTRADIOL
CRYSTODIGIN, DIGITOXIN
CU-7, COPPER
CUBICIN, DAPTOMYCIN
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CUPRIC SULFATE, CUPRIC SULFATE
CUPRIMINE, PENICILLAMINE
CUROSURF, PORACTANT ALFA
CURRETAB, MEDROXYPROGESTERONE ACETATE
CUTIVATE, FLUTICASONE PROPIONATE
CYANOCOBALAMIN CO 57 SCHILLING TEST KIT, CYANOCOBALAMIN
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLACILLIN, CYCLACILLIN
CYCLAINE, HEXYLCAINE HYDROCHLORIDE
CYCLAPEN-W, CYCLACILLIN
CYCLESSA, DESOGESTREL
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOCORT, AMCINONIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPAR, TETRACYCLINE HYDROCHLORIDE
CYCLOPENTOLATE HCL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSPORINE, CYCLOSPORINE
CYCRIN, MEDROXYPROGESTERONE ACETATE
CYKLOKAPRON, TRANEXAMIC ACID
CYLERT, PEMOLINE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
CYSTADANE, BETAINE, ANHYDROUS
CYSTAGON, CYSTEAMINE BITARTRATE
CYSTEINE HCL, CYSTEINE HYDROCHLORIDE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
CYTADREN, AMINOGLUTETHIMIDE
CYTARABINE, CYTARABINE
CYTOMEL, LIOTRIX (T4;T3)
CYTOSAR-U, CYTARABINE
CYTOTEC, MISOPROSTOL
CYTOVENE IV, GANCICLOVIR SODIUM
CYTOVENE, GANCICLOVIR
CYTOXAN, CYCLOPHOSPHAMIDE

** D **

D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DACARBAZINE, DACARBAZINE
DALGAN, DEZOCINE
DALMANE, FLURAZEPAM HYDROCHLORIDE
DANAZOL, DANAZOL
DANOCRINE, DANAZOL
DANTRIUM, DANTROLENE SODIUM
DAPSONE, DAPSONE
DARANIDE, DICHLORPHENAMIDE
DARAPRIM, PYRIMETHAMINE
DARBID, ISOPROPAMIDE IODIDE
DARICON, OXYPHENCYCLIMINE HYDROCHLORIDE
DARVOCET A500, ACETAMINOPHEN
DARVOCET, ACETAMINOPHEN
DARVOCET-N 100, ACETAMINOPHEN
DARVOCET-N 50, ACETAMINOPHEN
DARVON COMPOUND, ASPIRIN
DARVON COMPOUND-65, ASPIRIN
DARVON W/ ASA, ASPIRIN
DARVON, PROPOXYPHENE HYDROCHLORIDE
DARVON-N W/ ASA, ASPIRIN
DARVON-N, PROPOXYPHENE NAPSYLATE
DAUNORUBICIN HCL, DAUNORUBICIN HYDROCHLORIDE
DAUNOXOME, DAUNORUBICIN CITRATE
DAYPRO ALTA, OXAPROZIN POTASSIUM
DAYPRO, OXAPROZIN
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DDAVP, DESMOPRESSIN ACETATE
DEAPRIL-ST, ERGOLOID MESYLATES
DECA-DURABOLIN, NANDROLONE DECANOATE
DECABID, INDECAINIDE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

DECADERM, DEXAMETHASONE
DECADRON W/ XYLOCAINE, DEXAMETHASONE SODIUM PHOSPHATE
DECADRON, DEXAMETHASONE
DECADRON, DEXAMETHASONE SODIUM PHOSPHATE
DECADRON-LA, DEXAMETHASONE ACETATE
DECAPRYN, DOXYLAMINE SUCCINATE
DECASPRAY, DEXAMETHASONE
DECLOMYCIN, DEMECLOCYCLINE HYDROCHLORIDE
DEFINITY, PERFLUTREN
DEL-VI-A, VITAMIN A PALMITATE
DELALUTIN, HYDROXYPROGESTERONE CAPROATE
DELATESTRYL, TESTOSTERONE ENANTHATE
DELAXIN, METHOCARBAMOL
DELCOBESE, AMPHETAMINE ADIPATE
DELESTROGEN, ESTRADIOL VALERATE
DELFEN, NONOXYNOL-9 (OTC)
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
DELTA-CORTEF, PREDNISOLONE
DELTA-DOME, PREDNISONE
DELTALIN, ERGOCALCIFEROL
DELTASONE, PREDNISONE
DEMADEX, TORSEMIDE
DEMAZIN, CHLORPHENIRAMINE MALEATE (OTC)
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEMI-REGROTON, CHLORTHALIDONE
DEMSER, METYROSINE
DEMULEN 1/35-21, ETHINYL ESTRADIOL
DEMULEN 1/35-28, ETHINYL ESTRADIOL
DEMULEN 1/50-21, ETHINYL ESTRADIOL
DEMULEN 1/50-28, ETHINYL ESTRADIOL
DENAVIR, PENCICLOVIR SODIUM
DENDRID, IDOXURIDINE
DEPACON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE CP, DIVALPROEX SODIUM
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
DEPEN, PENICILLAMINE
DEPINAR, CYANOCOBALAMIN
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-TESTADIOL, ESTRADIOL CYPIONATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DEPOCYT, CYTARABINE
DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
DERMABET, BETAMETHASONE VALERATE
DERMACORT, HYDROCORTISONE
DERMATOP E EMOLLIENT, PREDNICARBATE
DERMATOP, PREDNICARBATE
DESFERAL, DEFEROXAMINE MESYLATE
DESIPRAMINE HCL, DESIPRAMINE HYDROCHLORIDE
DESMOPRESSIN ACETATE PRESERVATIVE FREE, DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESOGEN, DESOGESTREL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DESONIDE, DESONIDE
DESOWEN, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
DESYREL, TRAZODONE HYDROCHLORIDE
DETROL LA, TOLTERODINE TARTRATE
DETROL, TOLTERODINE TARTRATE
DEXACEN-4, DEXAMETHASONE SODIUM PHOSPHATE
DEXACIDIN, DEXAMETHASONE
DEXACORT, DEXAMETHASONE SODIUM PHOSPHATE
DEXAIR, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE ACETATE, DEXAMETHASONE ACETATE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE, DEXAMETHASONE
DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMPEX, DEXTROAMPHETAMINE SULFATE
DEXASPORIN, DEXAMETHASONE
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DEXFERRUM, IRON DEXTRAN

FDA data supplied by DrugPatentWatch.com

DEXONE 0.5, DEXAMETHASONE
DEXONE 0.75, DEXAMETHASONE
DEXONE 1.5, DEXAMETHASONE
DEXONE 4, DEXAMETHASONE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE ASPARTATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 2.5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 25%, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 38.5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60%, DEXTROSE
DEXTROSE 7.7% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSTAT, DEXTROAMPHETAMINE SULFATE
DHC PLUS, ACETAMINOPHEN
DI-ATRO, ATROPINE SULFATE
DI-METREX, PHENDIMETRAZINE TARTRATE
DIABETA, GLYBURIDE
DIABINESE, CHLORPROPAMIDE
DIAL, HEXACHLOROPHENE
DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIAMOX, ACETAZOLAMIDE
DIAMOX, ACETAZOLAMIDE SODIUM
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIAPID, LYPRESSIN
DIASONE SODIUM, SULFOXONE SODIUM
DIASTAT, DIAZEPAM
DIATRIZOATE MEGLUMINE, DIATRIZOATE MEGLUMINE
DIATRIZOATE-60, DIATRIZOATE MEGLUMINE
DIAZEPAM INTENSOL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DIAZOXIDE, DIAZOXIDE
DIBENIL, DIPHENHYDRAMINE HYDROCHLORIDE
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM

FDA data supplied by DrugPatentWatch.com

DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DICOPAC KIT, CYANOCOBALAMIN
DICUMAROL, DICUMAROL
DICURIN PROCAINE, PROCAINE MERETHOXYLLINE
DICYCLOMINE HCL (PRESERVATIVE-FREE), DICYCLOMINE HYDROCHLORIDE
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIDREX, BENZPHETAMINE HYDROCHLORIDE
DIDRONEL, ETIDRONATE DISODIUM
DIENESTROL, DIENESTROL
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
DIETHYLSTILBESTROL, DIETHYLSTILBESTROL
DIFFERIN, ADAPALENE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
DIFLUCAN, FLUCONAZOLE
DIFLUNISAL, DIFLUNISAL
DIGOXIN PEDIATRIC, DIGOXIN
DIGOXIN, DIGOXIN
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DILACOR XR, DILTIAZEM HYDROCHLORIDE
DILANTIN, PHENYTOIN
DILANTIN, PHENYTOIN SODIUM
DILANTIN, PHENYTOIN SODIUM, EXTENDED
DILANTIN-125, PHENYTOIN
DILANTIN-30, PHENYTOIN
DILATRATE-SR, ISOSORBIDE DINITRATE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE
DILOR, DYPHYLLINE
DILOR-400, DYPHYLLINE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIMETANE, BROMPHENIRAMINE MALEATE
DIMETANE, BROMPHENIRAMINE MALEATE (OTC)
DIMETANE-DC, BROMPHENIRAMINE MALEATE
DIMETANE-DX, BROMPHENIRAMINE MALEATE
DIMETANE-TEN, BROMPHENIRAMINE MALEATE
DIMETAPP, BROMPHENIRAMINE MALEATE (OTC)
DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
DIONOSIL AQUEOUS, PROPYLIODONE
DIONOSIL OILY, PROPYLIODONE
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
DIPENTUM, OLSALAZINE SODIUM
DIPHEN, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHEN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
DIPHENHYDRAMINE HCL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
DIPHENYLAN SODIUM, PHENYTOIN SODIUM, PROMPT
DIPIVEFRIN HCL, DIPIVEFRIN HYDROCHLORIDE
DIPRIVAN, PROPOFOL
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPROSONE, BETAMETHASONE DIPROPIONATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISCASE, CHYMOPAPAIN
DISIPAL, ORPHENADRINE HYDROCHLORIDE
DISOBROM, DEXBROMPHENIRAMINE MALEATE (OTC)
DISODIUM EDETATE, EDETATE DISODIUM
DISOMER, DEXBROMPHENIRAMINE MALEATE
DISOPHROL, DEXBROMPHENIRAMINE MALEATE (OTC)
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISPERMOX, AMOXICILLIN
DISULFIRAM, DISULFIRAM
DITATE-DS, ESTRADIOL VALERATE
DITROPAN XL, OXYBUTYNIN CHLORIDE
DITROPAN, OXYBUTYNIN CHLORIDE
DIUCARDIN, HYDROFLUMETHIAZIDE
DIULO, METOLAZONE
DIUPRES-250, CHLOROTHIAZIDE
DIUPRES-500, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DIUTENSEN-R, METHYCLOTHIAZIDE
DIZAC, DIAZEPAM
DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HCL IN DEXTROSE 5%, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOBUTREX, DOBUTAMINE HYDROCHLORIDE
DOCA, DESOXYCORTICOSTERONE ACETATE
DOLENE AP-65, ACETAMINOPHEN
DOLENE, PROPOXYPHENE HYDROCHLORIDE
DOLOBID, DIFLUNISAL
DOLOPHINE HCL, METHADONE HYDROCHLORIDE
DOMEBORO, ACETIC ACID, GLACIAL
DOPAMINE HCL AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL IN DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DOPAR, LEVODOPA
DOPRAM, DOXAPRAM HYDROCHLORIDE
DORAL, QUAZEPAM
DORIDEN, GLUTETHIMIDE

FDA data supplied by DrugPatentWatch.com

DORMATE, MEBUTAMATE
DORYX, DOXYCYCLINE HYCLATE
DOSTINEX, CABERGOLINE
DOVONEX, CALCIPOTRIENE
DOW-ISONIAZID, ISONIAZID
DOXAPRAM HCL, DOXAPRAM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXIL, DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
DOXY-LEMMON, DOXYCYCLINE HYCLATE
DOXY-SLEEP-AID, DOXYLAMINE SUCCINATE (OTC)
DOXYCHEL HYCLATE, DOXYCYCLINE HYCLATE
DOXYCHEL, DOXYCYCLINE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
DRALSERP, HYDRALAZINE HYDROCHLORIDE
DRALZINE, HYDRALAZINE HYDROCHLORIDE
DRICORT, HYDROCORTISONE ACETATE
DRISDOL, ERGOCALCIFEROL
DRIXORAL PLUS, ACETAMINOPHEN (OTC)
DRIXORAL, DEXBROMPHENIRAMINE MALEATE (OTC)
DRIZE, CHLORPHENIRAMINE MALEATE
DROLBAN, DROMOSTANOLONE PROPIONATE
DROPERIDOL, DROPERIDOL
DROXIA, HYDROXYUREA
DTIC-DOME, DACARBAZINE
DTPA, TECHNETIUM TC-99M PENTETATE KIT
DUAC, BENZOYL PEROXIDE
DUO-MEDIHALER, ISOPROTERENOL HYDROCHLORIDE
DUOCAINE, BUPIVACAINE HYDROCHLORIDE
DUONEB, ALBUTEROL SULFATE
DUPHALAC, LACTULOSE
DURABOLIN, NANDROLONE PHENPROPIONATE
DURACILLIN A.S., PENICILLIN G PROCAINE
DURACLON, CLONIDINE HYDROCHLORIDE
DURADYNE DHC, ACETAMINOPHEN
DURAGESIC, FENTANYL
DURAMORPH PF, MORPHINE SULFATE
DURANEST, EPINEPHRINE
DURANEST, EPINEPHRINE BITARTRATE
DURANEST, ETIDOCAINE HYDROCHLORIDE
DURAPHYL, THEOPHYLLINE
DURAQUIN, QUINIDINE GLUCONATE
DURICEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE
DUVOID, BETHANECHOL CHLORIDE
DV, DIENESTROL
DYAZIDE, HYDROCHLOROTHIAZIDE
DYCILL, DICLOXACILLIN SODIUM
DYCLONE, DYCLONINE HYDROCHLORIDE
DYMELOR, ACETOHEXAMIDE
DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)
DYNABAC, DIRITHROMYCIN
DYNACIRC CR, ISRADIPINE
DYNACIRC, ISRADIPINE
DYNAPEN, DICLOXACILLIN SODIUM
DYRENIUM, TRIAMTERENE

** E **

E-BASE, ERYTHROMYCIN
E-GLADES, ERYTHROMYCIN
E-MYCIN E, ERYTHROMYCIN ETHYLSUCCINATE
E-MYCIN, ERYTHROMYCIN
E-SOLVE 2, ERYTHROMYCIN
E-Z PREP 220, POVIDONE-IODINE (OTC)
E-Z PREP, POVIDONE-IODINE (OTC)
E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)
E-Z SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
E-Z SCRUB, HEXACHLOROPHENE
E-Z-EM PREP LYTE, POLYETHYLENE GLYCOL 3350
E.E.S. 200, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
EC-NAPROSYN, NAPROXEN
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ECONOCHLOR, CHLORAMPHENICOL
ECONOPRED PLUS, PREDNISOLONE ACETATE
ECONOPRED, PREDNISOLONE ACETATE
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EDETATE DISODIUM, EDETATE DISODIUM
EDEX, ALPROSTADIL
EDROPHONIUM CHLORIDE PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
EDROPHONIUM CHLORIDE, EDROPHONIUM CHLORIDE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFEXOR, VENLAFAXINE HYDROCHLORIDE
EFIDAC 24 CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
EFIDAC 24 PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
EFIDAC 24 PSEUDOEPHEDRINE HCL/BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE (OTC)
EFUDEX, FLUOROURACIL
ELASE-CHLOROMYCETIN, CHLORAMPHENICOL
ELAVIL, AMITRIPTYLINE HYDROCHLORIDE
ELDECORT, HYDROCORTISONE
ELDEPRYL, SELEGILINE HYDROCHLORIDE
ELESTAT, EPINASTINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

ELIDEL, PIMECROLIMUS
ELIGARD, LEUPROLIDE ACETATE
ELIMITE, PERMETHRIN
ELIXICON, THEOPHYLLINE
ELIXOMIN, THEOPHYLLINE
ELIXOPHYLLIN SR, THEOPHYLLINE
ELIXOPHYLLIN, THEOPHYLLINE
ELLENCE, EPIRUBICIN HYDROCHLORIDE
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
ELOCON, MOMETASONE FUROATE
ELOXATIN, OXALIPLATIN
EMADINE, EMEDASTINE DIFUMARATE
EMBELINE E, CLOBETASOL PROPIONATE
EMBELINE, CLOBETASOL PROPIONATE
EMBOLEX, DIHYDROERGOTAMINE MESYLATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
EMEND, APREPITANT
EMETE-CON, BENZQUINAMIDE HYDROCHLORIDE
EMGEL, ERYTHROMYCIN
EMLA, LIDOCAINE
EMPRACET W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN
EMPRACET W/ CODEINE PHOSPHATE #4, ACETAMINOPHEN
EMTRIVA, EMTRICITABINE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENALAPRILAT, ENALAPRILAT
ENDEP, AMITRIPTYLINE HYDROCHLORIDE
ENDOSOL EXTRA, CALCIUM CHLORIDE
ENDRATE, EDETATE DISODIUM
ENDURON, METHYCLOTHIAZIDE
ENDURONYL FORTE, DESERPIDINE
ENDURONYL, DESERPIDINE
ENFLURANE, ENFLURANE
ENLON, EDROPHONIUM CHLORIDE
ENLON-PLUS, ATROPINE SULFATE
ENOVID, MESTRANOL
ENOVID-E 21, MESTRANOL
ENOVID-E, MESTRANOL
ENPRESSE-21, ETHINYL ESTRADIOL
ENPRESSE-28, ETHINYL ESTRADIOL
ENTOCORT EC, BUDESONIDE
ENULOSE, LACTULOSE
EPI E Z PEN JR, EPINEPHRINE
EPICORT, HYDROCORTISONE
EPIFOAM, HYDROCORTISONE ACETATE
EPINEPHRINE, EPINEPHRINE (OTC)
EPIPEN E Z PEN, EPINEPHRINE
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
EPITOL, CARBAMAZEPINE
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
EQUAGESIC, ASPIRIN
EQUANIL, MEPROBAMATE
EQUIPIN, HOMATROPINE METHYLBROMIDE
ERCATAB, CAFFEINE
ERGAMISOL, LEVAMISOLE HYDROCHLORIDE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERGOMAR, ERGOTAMINE TARTRATE
ERGOSTAT, ERGOTAMINE TARTRATE
ERRIN, NORETHINDRONE
ERTACZO, SERTACONAZOLE NITRATE
ERY-TAB, ERYTHROMYCIN
ERYC 125, ERYTHROMYCIN
ERYC SPRINKLES, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
ERYCETTE, ERYTHROMYCIN
ERYDERM, ERYTHROMYCIN
ERYGEL, ERYTHROMYCIN
ERYMAX, ERYTHROMYCIN
ERYPAR, ERYTHROMYCIN STEARATE
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHRA-DERM, ERYTHROMYCIN
ERYTHRO-STATIN, ERYTHROMYCIN
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN, ERYTHROMYCIN
ERYTHROMYCIN, ERYTHROMYCIN LACTOBIONATE
ERYZOLE, ERYTHROMYCIN ETHYLSUCCINATE
ESCLIM, ESTRADIOL
ESGIC, ACETAMINOPHEN
ESGIC-PLUS, ACETAMINOPHEN
ESIDRIX, HYDROCHLOROTHIAZIDE
ESIMIL, GUANETHIDINE MONOSULFATE
ESKALITH CR, LITHIUM CARBONATE
ESKALITH, LITHIUM CARBONATE
ESTAZOLAM, ESTAZOLAM
ESTERIFIED ESTROGENS, ESTROGENS, ESTERIFIED
ESTINYL, ETHINYL ESTRADIOL
ESTRACE, ESTRADIOL
ESTRADERM, ESTRADIOL
ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRADIOL, ESTRADIOL
ESTRADURIN, POLYESTRADIOL PHOSPHATE
ESTRAGUARD, DIENESTROL
ESTRASORB, ESTRADIOL HEMIHYDRATE
ESTRATAB, ESTROGENS, ESTERIFIED
ESTRING, ESTRADIOL

FDA data supplied by DrugPatentWatch.com

ESTROGENIC SUBSTANCE, ESTRONE
ESTRONE, ESTRONE
ESTROPIPATE, ESTROPIPATE
ESTROSTEP 21, ETHINYL ESTRADIOL
ESTROSTEP FE, ETHINYL ESTRADIOL
ESTROVIS, QUINESTROL
ETHAMBUTOL HCL, ETHAMBUTOL HYDROCHLORIDE
ETHAMIDE, ETHOXZOLAMIDE
ETHAMOLIN, ETHANOLAMINE OLEATE
ETHCHLORVYNOL, ETHCHLORVYNOL
ETHIODOL, ETHIODIZED OIL
ETHMOZINE, MORICIZINE HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
ETHRANE, ENFLURANE
ETHRIL 250, ERYTHROMYCIN STEARATE
ETHRIL 500, ERYTHROMYCIN STEARATE
ETHYOL, AMIFOSTINE
ETIDRONATE DISODIUM, ETIDRONATE DISODIUM
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
ETOPOSIDE, ETOPOSIDE
ETRAFON 2-10, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON 2-25, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON-A, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON-FORTE, AMITRIPTYLINE HYDROCHLORIDE
EULEXIN, FLUTAMIDE
EURAX, CROTAMITON
EUTHROID-0.5, LIOTRIX (T4;T3)
EUTHROID-1, LIOTRIX (T4;T3)
EUTHROID-2, LIOTRIX (T4;T3)
EUTHROID-3, LIOTRIX (T4;T3)
EUTONYL, PARGYLINE HYDROCHLORIDE
EUTRON, METHYCLOTHIAZIDE
EVALOSE, LACTULOSE
EVANS BLUE, EVANS BLUE
EVEX, ESTROGENS, ESTERIFIED
EVISTA, RALOXIFENE HYDROCHLORIDE
EVOXAC, CEVIMELINE HYDROCHLORIDE
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
EXELDERM, SULCONAZOLE NITRATE
EXELON, RIVASTIGMINE TARTRATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
EXNA, BENZTHIAZIDE
EXOSURF NEONATAL, CETYL ALCOHOL
EXSEL, SELENIUM SULFIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM, EXTENDED
EXTRA-STRENGTH AIM, SODIUM MONOFLUOROPHOSPHATE (OTC)
EXTRANEAL, ICODEXTRIN

** F **

FACTIVE, GEMIFLOXACIN MESYLATE
FACTREL, GONADORELIN HYDROCHLORIDE
FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK), FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FAMVIR, FAMCICLOVIR
FANSIDAR, PYRIMETHAMINE
FARESTON, TOREMIFENE CITRATE
FASLODEX, FULVESTRANT
FASTIN, PHENTERMINE HYDROCHLORIDE
FELBATOL, FELBAMATE
FELDENE, PIROXICAM
FEMARA, LETROZOLE
FEMCET, ACETAMINOPHEN
FEMHRT, ETHINYL ESTRADIOL
FEMINONE, ETHINYL ESTRADIOL
FEMOGEN, ESTROGENS, ESTERIFIED
FEMPATCH, ESTRADIOL
FEMRING, ESTRADIOL ACETATE
FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)
FEMSTAT, BUTOCONAZOLE NITRATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FENTANYL CITRATE AND DROPERIDOL, DROPERIDOL
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL, FENTANYL
FENTANYL, FENTANYL CITRATE
FERIDEX I.V., FERUMOXIDES
FERNDEX, DEXTROAMPHETAMINE SULFATE
FERNISOLONE-P, PREDNISOLONE
FERNISONE, PREDNISONE
FERRISELTZ, FERRIC AMMONIUM CITRATE
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
FERROUS CITRATE FE 59, FERROUS CITRATE, FE-59
FERTINEX, UROFOLLITROPIN
FINACEA, AZELAIC ACID
FIORICET W/ CODEINE, ACETAMINOPHEN
FIORICET, ACETAMINOPHEN
FIORINAL W/CODEINE NO 3, ASPIRIN
FIORINAL, ASPIRIN
FLAGYL ER, METRONIDAZOLE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAGYL I.V., METRONIDAZOLE HYDROCHLORIDE
FLAGYL, METRONIDAZOLE
FLAREX, FLUOROMETHOLONE ACETATE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FLAVOXATE HCL, FLAVOXATE HYDROCHLORIDE
FLAXEDIL, GALLAMINE TRIETHIODIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE

FDA data supplied by DrugPatentWatch.com

FLEXERIL, CYCLOBENZAPRINE HYDROCHLORIDE
FLEXICORT, HYDROCORTISONE
FLOLAN, EPOPROSTENOL SODIUM
FLOMAX, TAMSULOSIN HYDROCHLORIDE
FLONASE, FLUTICASONE PROPIONATE
FLORINEF, FLUDROCORTISONE ACETATE
FLORONE E, DIFLORASONE DIACETATE
FLORONE, DIFLORASONE DIACETATE
FLOROPRYL, ISOFLUROPHATE
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
FLOVENT, FLUTICASONE PROPIONATE
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER, OFLOXACIN
FLOXIN IN DEXTROSE 5%, OFLOXACIN
FLOXIN, OFLOXACIN
FLOXURIDINE, FLOXURIDINE
FLUDARA, FLUDARABINE PHOSPHATE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUDEOXYGLUCOSE F 18, FLUDEOXYGLUCOSE, F-18
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUIDIL, CYCLOTHIAZIDE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLUNISOLIDE, FLUNISOLIDE
FLUOCET, FLUOCINOLONE ACETONIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUONID, FLUOCINOLONE ACETONIDE
FLUOR-OP, FLUOROMETHOLONE
FLUORINE F-18, SODIUM FLUORIDE, F-18
FLUOROPLEX, FLUOROURACIL
FLUOROURACIL, FLUOROURACIL
FLUOTHANE, HALOTHANE
FLUOTREX, FLUOCINOLONE ACETONIDE
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLUOXYMESTERONE, FLUOXYMESTERONE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
FLURBIPROFEN, FLURBIPROFEN
FLUTAMIDE, FLUTAMIDE
FLUTEX, TRIAMCINOLONE ACETONIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FML FORTE, FLUOROMETHOLONE
FML, FLUOROMETHOLONE
FML-S, FLUOROMETHOLONE
FOAMCOAT, ALUMINUM HYDROXIDE (OTC)
FOAMICON, ALUMINUM HYDROXIDE (OTC)
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOLEX PFS, METHOTREXATE SODIUM
FOLEX, METHOTREXATE SODIUM
FOLIC ACID, FOLIC ACID
FOLICET, FOLIC ACID
FOLLISTIM, FOLLITROPIN ALFA/BETA
FOLLUTEIN, GONADOTROPIN, CHORIONIC
FOLVITE, FOLIC ACID
FOLVRON, FERROUS SULFATE
FORADIL, FORMOTEROL FUMARATE
FORANE, ISOFLURANE
FORBAXIN, METHOCARBAMOL
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
FORTAZ, CEFTAZIDIME
FORTEO, TERIPARATIDE RECOMBINANT HUMAN
FORTOVASE, SAQUINAVIR
FOSAMAX, ALENDRONATE SODIUM
FOSCAVIR, FOSCARNET SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FOVANE, BENZTHIAZIDE
FRAGMIN, DALTEPARIN SODIUM
FREAMINE 8.5%, AMINO ACIDS
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE II 8.5%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
FROVA, FROVATRIPTAN SUCCINATE
FS SHAMPOO, FLUOCINOLONE ACETONIDE
FUDR, FLOXURIDINE
FULVICIN P/G 165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G 330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN-U/F, GRISEOFULVIN, MICROCRYSTALLINE
FUNDUSCEIN-25, FLUORESCEIN SODIUM
FUNGIZONE, AMPHOTERICIN B
FURACIN, NITROFURAZONE
FURADANTIN, NITROFURANTOIN
FURALAN, NITROFURANTOIN
FUROSEMIDE, FUROSEMIDE
FUROXONE, FURAZOLIDONE
FUZEON, ENFUVIRTIDE

** G **

GABAPENTIN, GABAPENTIN
GABITRIL, TIAGABINE HYDROCHLORIDE
GALLIUM CITRATE GA 67, GALLIUM CITRATE, GA-67
GALZIN, ZINC ACETATE
GAMENE, LINDANE
GAMOPHEN, HEXACHLOROPHENE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
GANCICLOVIR, GANCICLOVIR

FDA data supplied by DrugPatentWatch.com

GANITE, GALLIUM NITRATE
GANTANOL, SULFAMETHOXAZOLE
GANTANOL-DS, SULFAMETHOXAZOLE
GANTRISIN PEDIATRIC, SULFISOXAZOLE ACETYL
GANTRISIN, SULFISOXAZOLE
GANTRISIN, SULFISOXAZOLE ACETYL
GANTRISIN, SULFISOXAZOLE DIOLAMINE
GARAMYCIN, GENTAMICIN SULFATE
GASTROCROM, CROMOLYN SODIUM
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
GASTROMARK, FERUMOXSIL
GASTROVIST, DIATRIZOATE MEGLUMINE
GAVISCON, ALUMINUM HYDROXIDE (OTC)
GEMFIBROZIL, GEMFIBROZIL
GEMONIL, METHARBITAL
GEMZAR, GEMCITABINE HYDROCHLORIDE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
GENAPAX, GENTIAN VIOLET
GENCEPT 10/11-21, ETHINYL ESTRADIOL
GENCEPT 10/11-28, ETHINYL ESTRADIOL
GENERLAC, LACTULOSE
GENESA, ARBUTAMINE HYDROCHLORIDE
GENGRAF, CYCLOSPORINE
GENOPTIC, GENTAMICIN SULFATE
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
GENOTROPIN, SOMATROPIN RECOMBINANT
GENTACIDIN, GENTAMICIN SULFATE
GENTAFAIR, GENTAMICIN SULFATE
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GENTAMICIN, GENTAMICIN SULFATE
GEOCILLIN, CARBENICILLIN INDANYL SODIUM
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GEOPEN, CARBENICILLIN DISODIUM
GEREF, SERMORELIN ACETATE
GERIMAL, ERGOLOID MESYLATES
GERMA-MEDICA "MG", HEXACHLOROPHENE
GERMA-MEDICA, HEXACHLOROPHENE
GLEEVEC, IMATINIB MESYLATE
GLIADEL, CARMUSTINE
GLIPIZIDE, GLIPIZIDE
GLOFIL-125, IOTHALAMATE SODIUM, I-125
GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLUCAGON, GLUCAGON RECOMBINANT
GLUCAMIDE, CHLORPROPAMIDE
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
GLUCOPHAGE, METFORMIN HYDROCHLORIDE
GLUCOSCAN, TECHNETIUM TC-99M GLUCEPTATE KIT
GLUCOTROL XL, GLIPIZIDE
GLUCOTROL, GLIPIZIDE
GLUCOVANCE, GLYBURIDE
GLUTETHIMIDE, GLUTETHIMIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE, GLYBURIDE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
GLYCOPREP, POLYETHYLENE GLYCOL 3350
GLYCOPYRROLATE, GLYCOPYRROLATE
GLYCORT, HYDROCORTISONE
GLYNASE, GLYBURIDE
GLYSET, MIGLITOL
GO-EVAC, POLYETHYLENE GLYCOL 3350
GOLYTELY, POLYETHYLENE GLYCOL 3350
GONAL-F, FOLLITROPIN ALFA
GONAL-F, FOLLITROPIN ALFA/BETA
GRIFULVIN V, GRISEOFULVIN, MICROCRYSTALLINE
GRIS-PEG, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
GRISACTIN ULTRA, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
GRISACTIN, GRISEOFULVIN, MICROCRYSTALLINE
GUANABENZ ACETATE, GUANABENZ ACETATE
GUANETHIDINE MONOSULFATE, GUANETHIDINE MONOSULFATE
GUANFACINE HCL, GUANFACINE HYDROCHLORIDE
GUANIDINE HCL, GUANIDINE HYDROCHLORIDE
GVS, GENTIAN VIOLET
GYNAZOLE-1, BUTOCONAZOLE NITRATE
GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)
GYNE-SULF, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
GYNIX, CLOTRIMAZOLE (OTC)
GYNODIOL, ESTRADIOL
GYNOREST, DYDROGESTERONE

** H **

H-CORT, HYDROCORTISONE
H.P. ACTHAR GEL, CORTICOTROPIN
H.R.-50, HYDROCHLOROTHIAZIDE
HABITROL, NICOTINE (OTC)
HALCION, TRIAZOLAM
HALDOL SOLUTAB, HALOPERIDOL
HALDOL, HALOPERIDOL
HALDOL, HALOPERIDOL DECANOATE
HALDOL, HALOPERIDOL LACTATE
HALDRONE, PARAMETHASONE ACETATE
HALFAN, HALOFANTRINE HYDROCHLORIDE
HALOG, HALCINONIDE
HALOG-E, HALCINONIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL INTENSOL, HALOPERIDOL LACTATE
HALOPERIDOL LACTATE, HALOPERIDOL LACTATE

FDA data supplied by DrugPatentWatch.com

HALOPERIDOL, HALOPERIDOL
HALOPERIDOL, HALOPERIDOL LACTATE
HALOTESTIN, FLUOXYMESTERONE
HALOTEX, HALOPROGIN
HALOTHANE, HALOTHANE
HARMONYL, DESERPIDINE
HC #1, HYDROCORTISONE
HC #4, HYDROCORTISONE
HC (HYDROCORTISONE), HYDROCORTISONE
HC (HYDROCORTISONE), HYDROCORTISONE (OTC)
HEAD & SHOULDERS CONDITIONER, PYRITHIONE ZINC (OTC)
HEAVY SOLUTION NUPERCAINE, DIBUCAINE HYDROCHLORIDE
HECTOROL, DOXERCALCIFEROL
HEDULIN, PHENINDIONE
HELICOSOL, UREA, C-13
HELIDAC, BISMUTH SUBSALICYLATE
HEMABATE, CARBOPROST TROMETHAMINE
HEMSOL-HC, HYDROCORTISONE ACETATE
HEP FLUSH KIT IN PLASTIC CONTAINER, HEPARIN SODIUM
HEP-LOCK U/P, HEPARIN SODIUM
HEP-LOCK, HEPARIN SODIUM
HEPARIN LOCK FLUSH IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN LOCK FLUSH PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
HEPATASOL 8%, AMINO ACIDS
HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
HEPFLUSH-10, HEPARIN SODIUM
HEPSERA, ADEFOVIR DIPIVOXIL
HEPTALAC, LACTULOSE
HERPLEX, IDOXURIDINE
HETRAZAN, DIETHYLCARBAMAZINE CITRATE
HEXA-BETALIN, PYRIDOXINE HYDROCHLORIDE
HEXA-GERM, HEXACHLOROPHENE
HEXABRIX, IOXAGLATE MEGLUMINE
HEXADROL, DEXAMETHASONE
HEXADROL, DEXAMETHASONE SODIUM PHOSPHATE
HEXALEN, ALTRETAMINE
HEXASCRUB, HEXACHLOROPHENE
HI-COR, HYDROCORTISONE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)
HIPPURAN I 131, IODOHIPPURATE SODIUM, I-131
HIPPUTOPE, IODOHIPPURATE SODIUM, I-131
HIPREX, METHENAMINE HIPPURATE
HISERPIA, RESERPINE
HISPRIL, DIPHENYLPYRALINE HYDROCHLORIDE
HISTAFED, PSEUDOEPHEDRINE HYDROCHLORIDE
HISTALOG, BETAZOLE HYDROCHLORIDE
HISTAMINE PHOSPHATE, HISTAMINE PHOSPHATE

FDA data supplied by DrugPatentWatch.com

HIVID, ZALCITABINE
HIWOLFIA, RAUWOLFIA SERPENTINA
HMS, MEDRYSONE
HOMAPIN-10, HOMATROPINE METHYLBROMIDE
HOMAPIN-5, HOMATROPINE METHYLBROMIDE
HOMATROPRINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
HUMALOG MIX 50/50, INSULIN LISPRO
HUMALOG MIX 75/25, INSULIN LISPRO
HUMALOG PEN, INSULIN LISPRO
HUMALOG, INSULIN LISPRO
HUMATIN, PAROMOMYCIN SULFATE
HUMATROPE, SOMATROPIN RECOMBINANT
HUMEGON, MENOTROPINS (FSH;LH)
HUMORSOL, DEMECARIUM BROMIDE
HUMULIN 50/50, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN BR, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN L, INSULIN ZINC SUSP RECOMBINANT HUMAN (OTC)
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN RECOMBINANT HUMAN
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN U, INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN (OTC)
HY-PAM "25", HYDROXYZINE PAMOATE
HY-PHEN, ACETAMINOPHEN
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
HYCODAN, HOMATROPINE METHYLBROMIDE
HYCOMINE PEDIATRIC, HYDROCODONE BITARTRATE
HYCOMINE, HYDROCODONE BITARTRATE
HYDELTRA-TBA, PREDNISOLONE TEBUTATE
HYDELTRASOL, PREDNISOLONE SODIUM PHOSPHATE
HYDERGINE LC, ERGOLOID MESYLATES
HYDERGINE, ERGOLOID MESYLATES
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE AND HYDROCHLORTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 100/50, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 25/25, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 50/50, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDROCHLOROTHIAZIDE AND RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL-HYDROCHLOROTHIAZIDE-RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE
HYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
HYDRAP-ES, HYDRALAZINE HYDROCHLORIDE
HYDREA, HYDROXYUREA
HYDRO-D, HYDROCHLOROTHIAZIDE
HYDRO-RESERP, HYDROCHLOROTHIAZIDE
HYDRO-RIDE, AMILORIDE HYDROCHLORIDE
HYDRO-SERP "25", HYDROCHLOROTHIAZIDE
HYDRO-SERP "50", HYDROCHLOROTHIAZIDE
HYDROCET, ACETAMINOPHEN
HYDROCHLOROTHIAZIDE INTENSOL, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE W/ HYDRALAZINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROCODONE COMPOUND, HOMATROPINE METHYLBROMIDE
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%, HYDROCORTISONE ACETATE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
HYDROCORTONE, HYDROCORTISONE
HYDROCORTONE, HYDROCORTISONE ACETATE
HYDROCORTONE, HYDROCORTISONE SODIUM PHOSPHATE
HYDRODIURIL, HYDROCHLOROTHIAZIDE
HYDROFLUMETHIAZIDE AND RESERPINE, HYDROFLUMETHIAZIDE
HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
HYDROGENATED ERGOT ALKALOIDS, ERGOLOID MESYLATES
HYDROMORPHONE HCL, HYDROMORPHONE HYDROCHLORIDE
HYDROMOX R, QUINETHAZONE
HYDROMOX, QUINETHAZONE
HYDROPANE, HOMATROPINE METHYLBROMIDE
HYDROPRES 25, HYDROCHLOROTHIAZIDE
HYDROPRES 50, HYDROCHLOROTHIAZIDE
HYDROSERPINE PLUS (R-H-H), HYDRALAZINE HYDROCHLORIDE
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXOMIN, HYDROXOCOBALAMIN
HYDROXYCHLOROQINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
HYDROXYSTILBAMIDINE ISETHIONATE, HYDROXYSTILBAMIDINE ISETHIONATE

FDA data supplied by DrugPatentWatch.com

HYDROXYUREA, HYDROXYUREA
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE
HYGROTON, CHLORTHALIDONE
HYLOREL, GUANADREL SULFATE
HYPAQUE SODIUM 20%, DIATRIZOATE SODIUM
HYPAQUE, DIATRIZOATE MEGLUMINE
HYPAQUE, DIATRIZOATE SODIUM
HYPAQUE-76, DIATRIZOATE MEGLUMINE
HYPAQUE-CYSTO, DIATRIZOATE MEGLUMINE
HYPAQUE-M,75%, DIATRIZOATE MEGLUMINE
HYPAQUE-M,90%, DIATRIZOATE MEGLUMINE
HYPERSTAT, DIAZOXIDE
HYPROTIGEN 5%, PROTEIN HYDROLYSATE
HYSERPIN, RAUWOLFIA SERPENTINA
HYTONE, HYDROCORTISONE
HYTRIN, TERAZOSIN HYDROCHLORIDE
HYZAAR, HYDROCHLOROTHIAZIDE
HYZYD, ISONIAZID

** I **

IBRIN, FIBRINOGEN, I-125
IBU, IBUPROFEN
IBU-TAB 200, IBUPROFEN (OTC)
IBU-TAB, IBUPROFEN
IBUPRIN, IBUPROFEN (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HCL, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUPROHM, IBUPROFEN
IBUPROHM, IBUPROFEN (OTC)
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDAMYCIN, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HCL PFS, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HCL, IDARUBICIN HYDROCHLORIDE
IDKIT:HP, CITRIC ACID
IFEX, IFOSFAMIDE
IFEX/MESNEX KIT, IFOSFAMIDE
IFOSFAMIDE, IFOSFAMIDE
IFOSFAMIDE/MESNA KIT, IFOSFAMIDE
ILETIN I, INSULIN PORK
ILETIN II, INSULIN PURIFIED PORK
ILOSONE SULFA, ERYTHROMYCIN ESTOLATE
ILOSONE, ERYTHROMYCIN ESTOLATE
ILOTYCIN GLUCEPTATE, ERYTHROMYCIN GLUCEPTATE
ILOTYCIN, ERYTHROMYCIN
IMAGENT, DIMYRISTOYL LECITHIN
IMAGENT, PERFLUBRON
IMDUR, ISOSORBIDE MONONITRATE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM ADVANCED, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM, LOPERAMIDE HYDROCHLORIDE
IMURAN, AZATHIOPRINE
IMURAN, AZATHIOPRINE SODIUM
INAPSINE, DROPERIDOL
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDERAL, PROPRANOLOL HYDROCHLORIDE
INDERIDE LA 120/50, HYDROCHLOROTHIAZIDE
INDERIDE LA 160/50, HYDROCHLOROTHIAZIDE
INDERIDE LA 80/50, HYDROCHLOROTHIAZIDE
INDERIDE-40/25, HYDROCHLOROTHIAZIDE
INDERIDE-80/25, HYDROCHLOROTHIAZIDE
INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
INDO-LEMMON, INDOMETHACIN
INDOCIN I.V., INDOMETHACIN SODIUM
INDOCIN SR, INDOMETHACIN
INDOCIN, INDOMETHACIN
INDOMETHACIN, INDOMETHACIN
INDOMETHEGAN, INDOMETHACIN
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
INFASURF PRESERVATIVE FREE, CALFACTANT
INFED, IRON DEXTRAN
INFLAMASE FORTE, PREDNISOLONE SODIUM PHOSPHATE
INFLAMASE MILD, PREDNISOLONE SODIUM PHOSPHATE
INFUMORPH, MORPHINE SULFATE
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC, ASCORBIC ACID
INH, ISONIAZID
INJECTAPAP, ACETAMINOPHEN
INNOFEM, ESTRADIOL
INNOHEP, TINZAPARIN SODIUM
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
INNOVAR, DROPERIDOL
INOCOR, INAMRINONE LACTATE
INOMAX, NITRIC OXIDE
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

INSPRA, EPLERENONE
INSTANT MICROSPHERES, TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT
INSULATARD NPH HUMAN, INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN (OTC)
INSULIN INSULATARD NPH NORDISK, INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
INSULIN NORDISK MIXTARD (PORK), INSULIN PURIFIED PORK (OTC)
INSULIN, INSULIN PORK (OTC)
INTAL, CROMOLYN SODIUM
INTEGRILIN, EPTIFIBATIDE
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
INTROPIN, DOPAMINE HYDROCHLORIDE
INULIN AND SODIUM CHLORIDE, INULIN
INVAGESIC FORTE, ASPIRIN
INVAGESIC, ASPIRIN
INVANZ, ERTAPENEM SODIUM
INVERSINE, MECAMYLAMINE HYDROCHLORIDE
INVIRASE, SAQUINAVIR MESYLATE
IOBENGUANE SULFATE I 131, IOBENGUANE SULFATE I 131
IODOHIPPURATE SODIUM I 131, IODOHIPPURATE SODIUM, I-131
IODOTOPE, SODIUM IODIDE, I-131
IONAMIN, PHENTERMINE RESIN COMPLEX
IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONTOCAINE, EPINEPHRINE
IOPAMIDOL, IOPAMIDOL
IOPAMIDOL-200 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-200, IOPAMIDOL
IOPAMIDOL-250 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
IOSAT, POTASSIUM IODIDE (OTC)
IPATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IPRIVASK, DESIRUDIN
IRESSA, GEFITINIB
IRON DEXTRAN, IRON DEXTRAN
IRRIGATING SOLUTION G IN PLASTIC CONTAINER, CITRIC ACID
ISMELIN, GUANETHIDINE MONOSULFATE
ISMO, ISOSORBIDE MONONITRATE
ISMOTIC, ISOSORBIDE
ISOCAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
ISOCAINE HCL, MEPIVACAINE HYDROCHLORIDE
ISOCLOR, CHLORPHENIRAMINE MALEATE (OTC)
ISOETHARINE HCL S/F, ISOETHARINE HYDROCHLORIDE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
ISOETHARINE MESYLATE, ISOETHARINE MESYLATE
ISOFLURANE, ISOFLURANE
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE E IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISONIAZID, ISONIAZID
ISOPAQUE 280, CALCIUM
ISOPAQUE 440, CALCIUM METRIZOATE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
ISOPTIN SR, VERAPAMIL HYDROCHLORIDE
ISOPTIN, VERAPAMIL HYDROCHLORIDE
ISOPTO CETAMIDE, SULFACETAMIDE SODIUM
ISOPTO CETAPRED, PREDNISOLONE ACETATE
ISORDIL, ISOSORBIDE DINITRATE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER, GENTAMICIN SULFATE
ISOTRETINOIN, ISOTRETINOIN
ISOVUE-128, IOPAMIDOL
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
IV PERSANTINE, DIPYRIDAMOLE
IVADANTIN, NITROFURANTOIN SODIUM
IVY BLOCK, BENTOQUATAM (OTC)

** J **

JANIMINE, IMIPRAMINE HYDROCHLORIDE
JANTOVEN, WARFARIN SODIUM
JUNEL 1.5/30, ETHINYL ESTRADIOL

FDA data supplied by DrugPatentWatch.com

JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL
JUNEL FE 1/20, ETHINYL ESTRADIOL
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)

** K **

K+10, POTASSIUM CHLORIDE
K+8, POTASSIUM CHLORIDE
K-DUR 10, POTASSIUM CHLORIDE
K-DUR 20, POTASSIUM CHLORIDE
K-LEASE, POTASSIUM CHLORIDE
K-TAB, POTASSIUM CHLORIDE
KADIAN, MORPHINE SULFATE
KAFOCIN, CEPHALOGLYCIN
KAINAIR, PROPARACAINE HYDROCHLORIDE
KALETRA, LOPINAVIR
KANAMYCIN SULFATE, KANAMYCIN SULFATE
KANAMYCIN, KANAMYCIN SULFATE
KANTREX, KANAMYCIN SULFATE
KAON CL, POTASSIUM CHLORIDE
KAON CL-10, POTASSIUM CHLORIDE
KAPPADIONE, MENADIOL SODIUM DIPHOSPHATE
KARIVA, DESOGESTREL
KAYEXALATE, SODIUM POLYSTYRENE SULFONATE
KEFLET, CEPHALEXIN
KEFLEX, CEPHALEXIN
KEFLIN IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
KEFLIN, CEPHALOTHIN SODIUM
KEFTAB, CEPHALEXIN HYDROCHLORIDE
KEFUROX IN PLASTIC CONTAINER, CEFUROXIME SODIUM
KEFUROX, CEFUROXIME SODIUM
KEFZOL, CEFAZOLIN SODIUM
KEMADRIN, PROCYCLIDINE HYDROCHLORIDE
KEMSTRO, BACLOFEN
KENACORT, TRIAMCINOLONE
KENACORT, TRIAMCINOLONE DIACETATE
KENALOG IN ORABASE, TRIAMCINOLONE ACETONIDE
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENALOG-H, TRIAMCINOLONE ACETONIDE
KEPPRA, LEVETIRACETAM
KERLEDEX, BETAXOLOL HYDROCHLORIDE
KERLONE, BETAXOLOL HYDROCHLORIDE
KESSO-GESIC, PROPOXYPHENE HYDROCHLORIDE
KETALAR, KETAMINE HYDROCHLORIDE
KETAMINE HCL, KETAMINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOPROFEN, KETOPROFEN (OTC)
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOZOLE, KETOCONAZOLE
KINEVAC, SINCALIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
KLARON, SULFACETAMIDE SODIUM
KLEBCIL, KANAMYCIN SULFATE
KLONOPIN RAPIDLY DISINTEGRATING, CLONAZEPAM
KLONOPIN, CLONAZEPAM
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOR-CON, POTASSIUM CHLORIDE
KLOROMIN, CHLORPHENIRAMINE MALEATE
KLOTRIX, POTASSIUM CHLORIDE
KOGLUCOID, RAUWOLFIA SERPENTINA
KONAKION, PHYTONADIONE
KOROSTATIN, NYSTATIN
KWELL, LINDANE
KYTRIL, GRANISETRON HYDROCHLORIDE

** L **

LABETALOL HCL, LABETALOL HYDROCHLORIDE
LABID, THEOPHYLLINE
LAC-HYDRIN, AMMONIUM LACTATE
LACRISERT, HYDROXYPROPYL CELLULOSE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTULOSE, LACTULOSE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL, LAMOTRIGINE
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFINE
LAMISIL, TERBINAFINE HYDROCHLORIDE
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
LAMPRENE, CLOFAZIMINE
LANABIOTIC, BACITRACIN (OTC)
LANABIOTIC, BACITRACIN ZINC (OTC)
LANIAZID, ISONIAZID
LANOPHYLLIN, THEOPHYLLINE
LANORINAL, ASPIRIN
LANOXICAPS, DIGOXIN
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
LANTRISUL, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
LANTUS, INSULIN GLARGINE
LARGON, PROPIOMAZINE HYDROCHLORIDE
LARIAM, MEFLOQUINE HYDROCHLORIDE
LARODOPA, LEVODOPA
LAROTID, AMOXICILLIN
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

LARYNGOTRACHEAL ANESTHESIA KIT, LIDOCAINE HYDROCHLORIDE
LASIX, FUROSEMIDE
LAXILOSE, LACTULOSE
LEDERCILLIN VK, PENICILLIN V POTASSIUM
LENTARD, INSULIN ZINC SUSP PURIFIED BEEF/PORK (OTC)
LENTE ILETIN II (PORK), INSULIN ZINC SUSP PURIFIED PORK (OTC)
LENTE ILETIN II, INSULIN ZINC SUSP PURIFIED BEEF (OTC)
LENTE INSULIN, INSULIN ZINC SUSP BEEF (OTC)
LENTE, INSULIN ZINC SUSP PURIFIED PORK (OTC)
LERITINE, ANILERIDINE HYDROCHLORIDE
LERITINE, ANILERIDINE PHOSPHATE
LESCOL XL, FLUVASTATIN SODIUM
LESCOL, FLUVASTATIN SODIUM
LESSINA-21, ETHINYL ESTRADIOL
LESSINA-28, ETHINYL ESTRADIOL
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUKERAN, CHLORAMBUCIL
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEUSTATIN, CLADRIBINE
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVAQUIN, LEVOFLOXACIN
LEVATOL, PENBUTOLOL SULFATE
LEVITRA, VARDENAFIL HYDROCHLORIDE
LEVLITE, ETHINYL ESTRADIOL
LEVO-DROMORAN, LEVORPHANOL TARTRATE
LEVO-T, LIOTRIX (T4;T3)
LEVOBUNOLOL HCL, LEVOBUNOLOL HYDROCHLORIDE
LEVOCARNITINE, LEVOCARNITINE
LEVOLET, LIOTRIX (T4;T3)
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL
LEVOPHED, NOREPINEPHRINE BITARTRATE
LEVOPROME, LEVOMEPROMAZINE
LEVORA 0.15/30-21, ETHINYL ESTRADIOL
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LEVOTHYROXINE SODIUM, LIOTRIX (T4;T3)
LEVOXYL, LIOTRIX (T4;T3)
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
LEXAPRO, ESCITALOPRAM OXALATE
LEXIVA, FOSAMPRENAVIR CALCIUM
LEXXEL, ENALAPRIL MALEATE
LIBRELEASE, CHLORDIAZEPOXIDE
LIBRITABS, CHLORDIAZEPOXIDE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIDEX, FLUOCINONIDE
LIDEX-E, FLUOCINONIDE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HCL 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.2% IN DEXTROSE 5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% IN DEXTROSE 5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
LIDOCATON, EPINEPHRINE
LIDOCATON, LIDOCAINE HYDROCHLORIDE
LIDODERM, LIDOCAINE
LIDOPEN, LIDOCAINE HYDROCHLORIDE
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
LIMBITROL DS, AMITRIPTYLINE HYDROCHLORIDE
LIMBITROL, AMITRIPTYLINE HYDROCHLORIDE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LINCOMYCIN HCL, LINCOMYCIN HYDROCHLORIDE
LINDANE, LINDANE
LIORESAL, BACLOFEN
LIOTHYRONINE SODIUM, LIOTRIX (T4;T3)
LIPIDIL, FENOFIBRATE
LIPITOR, ATORVASTATIN CALCIUM
LIPO GANTRISIN, SULFISOXAZOLE ACETYL
LIPO-HEPIN, HEPARIN SODIUM
LIPOSYN 10%, SAFFLOWER OIL
LIPOSYN 20%, SAFFLOWER OIL
LIPOSYN II 10%, SAFFLOWER OIL
LIPOSYN II 20%, SAFFLOWER OIL
LIPOSYN III 10%, SOYBEAN OIL
LIPOSYN III 20%, SOYBEAN OIL
LIPOSYN III 30%, SOYBEAN OIL
LIQUAEMIN LOCK FLUSH, HEPARIN SODIUM
LIQUAEMIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
LIQUAEMIN SODIUM, HEPARIN SODIUM
LIQUAMAR, PHENPROCOUMON
LIQUID PRED, PREDNISONE

FDA data supplied by DrugPatentWatch.com

LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LITHANE, LITHIUM CARBONATE
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LITHOBID, LITHIUM CARBONATE
LITHONATE, LITHIUM CARBONATE
LITHONATE, LITHIUM CITRATE
LITHOSTAT, ACETOHYDROXAMIC ACID
LITHOTABS, LITHIUM CARBONATE
LIVOSTIN, LEVOCABASTINE HYDROCHLORIDE
LO-TROL, ATROPINE SULFATE
LO/OVRAL, ETHINYL ESTRADIOL
LO/OVRAL-28, ETHINYL ESTRADIOL
LOCHOLEST LIGHT, CHOLESTYRAMINE
LOCHOLEST, CHOLESTYRAMINE
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LOCOID, HYDROCORTISONE BUTYRATE
LOCORTEN, FLUMETHASONE PIVALATE
LODINE XL, ETODOLAC
LODINE, ETODOLAC
LODOSYN, CARBIDOPA
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
LOGEN, ATROPINE SULFATE
LOMANATE, ATROPINE SULFATE
LOMOTIL, ATROPINE SULFATE
LONITEN, MINOXIDIL
LONOX, ATROPINE SULFATE
LOPERAMIDE HCL AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPID, GEMFIBROZIL
LOPRESSIDONE, CHLORTHALIDONE
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL FUMARATE
LOPRESSOR, METOPROLOL TARTRATE
LOPROX, CICLOPIROX
LOPURIN, ALLOPURINOL
LORABID, LORACARBEF
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
LORAZ, LORAZEPAM
LORAZEPAM INTENSOL, LORAZEPAM
LORAZEPAM, LORAZEPAM
LORCET-HD, ACETAMINOPHEN
LORELCO, PROBUCOL
LORFAN, LEVALLORPHAN TARTRATE
LORTAB, ACETAMINOPHEN
LOTEMAX, LOTEPREDNOL ETABONATE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
LOTREL, AMLODIPINE BESYLATE
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
LOTRIMIN, CLOTRIMAZOLE
LOTRISONE, BETAMETHASONE DIPROPIONATE
LOTRONEX, ALOSETRON HYDROCHLORIDE
LOTUSATE, TALBUTAL
LOVASTATIN, LOVASTATIN
LOVENOX, ENOXAPARIN SODIUM
LOW-OGESTREL-21, ETHINYL ESTRADIOL
LOW-OGESTREL-28, ETHINYL ESTRADIOL
LOW-QUEL, ATROPINE SULFATE
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
LOXITANE C, LOXAPINE HYDROCHLORIDE
LOXITANE IM, LOXAPINE HYDROCHLORIDE
LOXITANE, LOXAPINE SUCCINATE
LOZOL, INDAPAMIDE
LTA II KIT, LIDOCAINE HYDROCHLORIDE
LUDIOMIL, MAPROTILINE HYDROCHLORIDE
LUFYLLIN, DYPHYLLINE
LUMENHANCE, MANGANESE CHLORIDE TETRAHYDRATE
LUMIGAN, BIMATOPROST
LUNELLE, ESTRADIOL CYPIONATE
LUNGAGGREGATE REAGENT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-3, LEUPROLIDE ACETATE
LUPRON DEPOT-4, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE
LUPRON, LEUPROLIDE ACETATE
LUTREPULSE KIT, GONADORELIN ACETATE
LUVOX, FLUVOXAMINE MALEATE
LUXIQ, BETAMETHASONE VALERATE
LYGEN, CHLORDIAZEPOXIDE HYDROCHLORIDE
LYMPHAZURIN, ISOSULFAN BLUE
LYNORAL, ETHINYL ESTRADIOL
LYOPHILIZED CYTOXAN, CYCLOPHOSPHAMIDE
LYSODREN, MITOTANE

** M **

M-PREDROL, METHYLPREDNISOLONE ACETATE
M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
M-ZOLE 7 DUAL PACK, MICONAZOLE NITRATE (OTC)
M.V.C. 9+3, ASCORBIC ACID
M.V.I. PEDIATRIC, ASCORBIC ACID
M.V.I.-12 LYOPHILIZED, ASCORBIC ACID
M.V.I.-12, ASCORBIC ACID
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
MACROTEC, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
MAGNACORT, HYDROCORTAMATE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
MALARONE PEDIATRIC, ATOVAQUONE
MALARONE, ATOVAQUONE
MANDOL, CEFAMANDOLE NAFATE
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANGANESE SULFATE, MANGANESE SULFATE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, MANNITOL
MANNITOL 10%, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%, MANNITOL
MANNITOL 15%, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20%, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%, MANNITOL
MANNITOL 5%, MANNITOL
MAOLATE, CHLORPHENESIN CARBAMATE
MAPROTILINE HCL, MAPROTILINE HYDROCHLORIDE
MARCAINE HCL PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL, BUPIVACAINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
MAREZINE, CYCLIZINE LACTATE
MARINOL, DRONABINOL
MARPLAN, ISOCARBOXAZID
MATULANE, PROCARBAZINE HYDROCHLORIDE
MAVIK, TRANDOLAPRIL
MAXAIR, PIRBUTEROL ACETATE
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MAXAQUIN, LOMEFLOXACIN HYDROCHLORIDE
MAXIBOLIN, ETHYLESTRENOL
MAXIDEX, DEXAMETHASONE
MAXIDEX, DEXAMETHASONE SODIUM PHOSPHATE
MAXIPIME, CEFEPIME HYDROCHLORIDE (ARGININE FORMULATION)
MAXITROL, DEXAMETHASONE
MAXOLON, METOCLOPRAMIDE HYDROCHLORIDE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MAZANOR, MAZINDOL
MD-50, DIATRIZOATE SODIUM
MD-60, DIATRIZOATE MEGLUMINE
MD-76, DIATRIZOATE MEGLUMINE
MD-76R, DIATRIZOATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
MEASURIN, ASPIRIN (OTC)
MEBENDAZOLE, MEBENDAZOLE
MECLAN, MECLOCYCLINE SULFOSALICYLATE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MECLODIUM, MECLOFENAMATE SODIUM
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MECLOMEN, MECLOFENAMATE SODIUM
MEDIGESIC PLUS, ACETAMINOPHEN
MEDIHALER ERGOTAMINE, ERGOTAMINE TARTRATE
MEDIHALER-EPI, EPINEPHRINE BITARTRATE (OTC)
MEDIHALER-ISO, ISOPROTERENOL SULFATE
MEDIPREN, IBUPROFEN (OTC)
MEDROL ACETATE, METHYLPREDNISOLONE ACETATE
MEDROL, METHYLPREDNISOLONE
MEDROL, METHYLPREDNISOLONE ACETATE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFLOQUINE HCL, MEFLOQUINE HYDROCHLORIDE
MEFLOQUINE, MEFLOQUINE HYDROCHLORIDE
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEFOXIN, CEFOXITIN SODIUM
MEGACE, MEGESTROL ACETATE
MEGATOPE, ALBUMIN IODINATED I-131 SERUM
MEGESTROL ACETATE, MEGESTROL ACETATE
MELFIAT, PHENDIMETRAZINE TARTRATE
MELFIAT-105, PHENDIMETRAZINE TARTRATE
MELLARIL, THIORIDAZINE HYDROCHLORIDE
MELLARIL-S, THIORIDAZINE
MENADIONE, MENADIONE
MENEST, ESTROGENS, ESTERIFIED
MENOTROPINS, MENOTROPINS (FSH;LH)
MENRIUM 10-4, CHLORDIAZEPOXIDE
MENRIUM 5-2, CHLORDIAZEPOXIDE
MENRIUM 5-4, CHLORDIAZEPOXIDE
MENTAX, BUTENAFINE HYDROCHLORIDE
MENTAX-TC, BUTENAFINE HYDROCHLORIDE
MEPERGAN, MEPERIDINE HYDROCHLORIDE
MEPERIDINE AND ATROPINE SULFATE, ATROPINE SULFATE
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPHYTON, PHYTONADIONE
MEPIVACAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
MEPIVACAINE HCL, MEPIVACAINE HYDROCHLORIDE
MEPRIAM, MEPROBAMATE
MEPRO-ASPIRIN, ASPIRIN
MEPROBAMATE AND ASPIRIN, ASPIRIN
MEPROBAMATE, MEPROBAMATE

FDA data supplied by DrugPatentWatch.com

MEPRON, ATOVAQUONE
MEPROSPAN, MEPROBAMATE
MERETEK UBT KIT (W/ PRANACTIN), UREA, C-13
MERIDIA, SIBUTRAMINE HYDROCHLORIDE
MERREM I.V., MEROPENEM
MERSALYL-THEOPHYLLINE, MERSALYL SODIUM
MESANTOIN, MEPHENYTOIN
MESNA, MESNA
MESNEX, MESNA
MESTINON, PYRIDOSTIGMINE BROMIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
METAGLIP, GLIPIZIDE
METAHYDRIN, TRICHLORMETHIAZIDE
METANDREN, METHYLTESTOSTERONE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METASTRON, STRONTIUM CHLORIDE, SR-89
METATENSIN #2, RESERPINE
METATENSIN #4, RESERPINE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
METHADONE HCL INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HCL, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHAMPEX, METHAMPHETAMINE HYDROCHLORIDE
METHAMPHETAMINE HCL, METHAMPHETAMINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHDILAZINE HCL, METHDILAZINE HYDROCHLORIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHERGINE, METHYLERGONOVINE MALEATE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE LPF, METHOTREXATE SODIUM
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHOTREXATE, METHOTREXATE SODIUM
METHOXSALEN, METHOXSALEN
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYCLOTHIAZIDE AND DESERPIDINE, DESERPIDINE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND CHLOROTHIAZIDE, CHLOROTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METI-DERM, PREDNISOLONE
METICORTELONE, PREDNISOLONE ACETATE
METICORTEN, PREDNISONE
METIMYD, PREDNISOLONE ACETATE
METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE INTENSOL, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOLAZONE, METOLAZONE
METOPIRONE, METYRAPONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRA, PHENDIMETRAZINE TARTRATE
METRETON, PREDNISOLONE SODIUM PHOSPHATE
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
METRO I.V., METRONIDAZOLE
METROCREAM, METRONIDAZOLE
METRODIN, UROFOLLITROPIN
METROGEL, METRONIDAZOLE
METROGEL-VAGINAL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
METROMIDOL, METRONIDAZOLE
METRONIDAZOLE HCL, METRONIDAZOLE HYDROCHLORIDE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
METRONIDAZOLE, METRONIDAZOLE
METUBINE IODIDE, METOCURINE IODIDE
MEVACOR, LOVASTATIN
MEXATE, METHOTREXATE SODIUM
MEXATE-AQ PRESERVED, METHOTREXATE SODIUM
MEXATE-AQ, METHOTREXATE SODIUM
MEXILETINE HCL, MEXILETINE HYDROCHLORIDE
MEXITIL, MEXILETINE HYDROCHLORIDE
MEZLIN, MEZLOCILLIN SODIUM MONOHYDRATE
MIACALCIN, CALCITONIN, SALMON
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICARDIS, TELMISARTAN
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MICORT-HC, HYDROCORTISONE ACETATE
MICRAININ, ASPIRIN
MICRO-K 10, POTASSIUM CHLORIDE
MICRO-K LS, POTASSIUM CHLORIDE
MICRO-K, POTASSIUM CHLORIDE
MICRODERM, CHLORHEXIDINE GLUCONATE (OTC)
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
MICROLITE, TECHNETIUM TC-99M ALBUMIN COLLOID KIT
MICRONASE, GLYBURIDE
MICRONOR, NORETHINDRONE

FDA data supplied by DrugPatentWatch.com

MICROSUL, SULFAMETHIZOLE
MICROZIDE, HYDROCHLOROTHIAZIDE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MIDODRINE HCL, MIDODRINE HYDROCHLORIDE
MIDOL, IBUPROFEN (OTC)
MIFEPREX, MIFEPRISTONE
MIGERGOT, CAFFEINE
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MILONTIN, PHENSUXIMIDE
MILOPHENE, CLOMIPHENE CITRATE
MILPREM-200, ESTROGENS, CONJUGATED
MILPREM-400, ESTROGENS, CONJUGATED
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
MILRINONE LACTOSE IN 5% DEXTROSE, MILRINONE LACTATE
MILTOWN, MEPROBAMATE
MINIPRESS XL, PRAZOSIN HYDROCHLORIDE
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MINIRIN, DESMOPRESSIN ACETATE
MINITEC, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
MINITRAN, NITROGLYCERIN
MINIZIDE, POLYTHIAZIDE
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
MINODYL, MINOXIDIL
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL, MINOXIDIL
MINTEZOL, THIABENDAZOLE
MIOCHOL, ACETYLCHOLINE CHLORIDE
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
MIOSTAT, CARBACHOL
MIRADON, ANISINDIONE
MIRALAX, POLYETHYLENE GLYCOL 3350
MIRALUMA, TECHNETIUM TC-99M SESTAMIBI KIT
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
MIRCETTE, DESOGESTREL
MIRENA, LEVONORGESTREL
MIRTAZAPINE, MIRTAZAPINE
MISOPROSTOL, MISOPROSTOL
MITHRACIN, PLICAMYCIN
MITOMYCIN, MITOMYCIN
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER, MIVACURIUM CHLORIDE
MIVACRON, MIVACURIUM CHLORIDE
MIXTARD HUMAN 70/30, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
MOBAN, MOLINDONE HYDROCHLORIDE
MOBIC, MELOXICAM
MOCTANIN, MONOCTANOIN
MODERIL, RESCINNAMINE
MODICON 21, ETHINYL ESTRADIOL
MODICON 28, ETHINYL ESTRADIOL
MODRASTANE, TRILOSTANE
MODURETIC 5-50, AMILORIDE HYDROCHLORIDE
MOEXIPRIL HCL, MOEXIPRIL HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 5, MICONAZOLE NITRATE
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT DUAL- PAK, MICONAZOLE NITRATE
MONISTAT, MICONAZOLE
MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT-DERM, MICONAZOLE NITRATE
MONOCID, CEFONICID SODIUM
MONODOX, DOXYCYCLINE
MONOKET, ISOSORBIDE MONONITRATE
MONOPRIL, FOSINOPRIL SODIUM
MONOPRIL-HCT, FOSINOPRIL SODIUM
MONUROL, FOSFOMYCIN TROMETHAMINE
MORPHINE SULFATE, MORPHINE SULFATE
MOTOFEN HALF-STRENGTH, ATROPINE SULFATE
MOTOFEN, ATROPINE SULFATE
MOTRIN IB, IBUPROFEN (OTC)
MOTRIN MIGRAINE PAIN, IBUPROFEN (OTC)
MOTRIN, IBUPROFEN
MOXAM, MOXALACTAM DISODIUM
MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT
MPI DTPA KIT - CHELATE, TECHNETIUM TC-99M PENTETATE KIT
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MPI KRYPTON 81M GAS GENERATOR, KRYPTON, KR-81M
MPI STANNOUS DIPHOSPHONATE, TECHNETIUM TC-99M ETIDRONATE KIT
MS CONTIN, MORPHINE SULFATE
MUCINEX, GUAIFENESIN (OTC)
MUCOMYST W/ ISOPROTERENOL, ACETYLCYSTEINE
MUCOMYST, ACETYLCYSTEINE
MUCOSIL-10, ACETYLCYSTEINE
MUCOSIL-20, ACETYLCYSTEINE
MULTIFUGE, PIPERAZINE CITRATE
MUPIROCIN, MUPIROCIN
MUSE, ALPROSTADIL
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
MUTAMYCIN, MITOMYCIN
MVC PLUS, ASCORBIC ACID
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
MYBANIL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
MYCELEX, CLOTRIMAZOLE

FDA data supplied by DrugPatentWatch.com

MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
MYCELEX-7, CLOTRIMAZOLE (OTC)
MYCELEX-G, CLOTRIMAZOLE
MYCHEL, CHLORAMPHENICOL
MYCHEL-S, CHLORAMPHENICOL SODIUM SUCCINATE
MYCIFRADIN, NEOMYCIN SULFATE
MYCITRACIN, BACITRACIN
MYCO-TRIACET II, NYSTATIN
MYCOBUTIN, RIFABUTIN
MYCODONE, HOMATROPINE METHYLBROMIDE
MYCOLOG-II, NYSTATIN
MYCOSTATIN, NYSTATIN
MYDRIACYL, TROPICAMIDE
MYDRIAFAIR, TROPICAMIDE
MYFED, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
MYIDYL, TRIPROLIDINE HYDROCHLORIDE
MYKACET, NYSTATIN
MYKINAC, NYSTATIN
MYKROX, METOLAZONE
MYLARAMINE, DEXCHLORPHENIRAMINE MALEATE
MYLAXEN, HEXAFLUORENIUM BROMIDE
MYLERAN, BUSULFAN
MYLOTARG, GEMTUZUMAB OZOGAMICIN
MYMETHASONE, DEXAMETHASONE
MYMETHAZINE FORTIS, PROMETHAZINE HYDROCHLORIDE
MYOTONACHOL, BETHANECHOL CHLORIDE
MYOVIEW, TECHNETIUM TC-99M TETROFOSMIN KIT
MYPHETANE DC, BROMPHENIRAMINE MALEATE
MYPHETANE DX, BROMPHENIRAMINE MALEATE
MYPROIC ACID, VALPROIC ACID
MYSOLINE, PRIMIDONE
MYTELASE, AMBENONIUM CHLORIDE
MYTOZYTREX, MITOMYCIN
MYTREX A, NEOMYCIN SULFATE
MYTREX F, NYSTATIN

** N **

N.E.E. 1/35 21, ETHINYL ESTRADIOL
N.E.E. 1/35 28, ETHINYL ESTRADIOL
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAFAZAIR, NAPHAZOLINE HYDROCHLORIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAFTIN, NAFTIFINE HYDROCHLORIDE
NALBUPHINE HCL, NALBUPHINE HYDROCHLORIDE
NALBUPHINE, NALBUPHINE HYDROCHLORIDE
NALFON 200, FENOPROFEN CALCIUM
NALFON, FENOPROFEN CALCIUM
NALIDIXIC ACID, NALIDIXIC ACID
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NALLPEN, NAFCILLIN SODIUM
NALOXONE HCL AND PENTAZOCAINE, NALOXONE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NALOXONE, NALOXONE HYDROCHLORIDE
NALTREXONE HCL, NALTREXONE HYDROCHLORIDE
NAMENDA, MEMANTINE HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NANDROLONE PHENPROPIONATE, NANDROLONE PHENPROPIONATE
NAPHAZOLINE HCL, NAPHAZOLINE HYDROCHLORIDE
NAPHCON FORTE, NAPHAZOLINE HYDROCHLORIDE
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPRAPAC 250 (COPACKAGED), LANSOPRAZOLE
NAPRAPAC 375 (COPACKAGED), LANSOPRAZOLE
NAPRAPAC 500 (COPACKAGED), LANSOPRAZOLE
NAPRELAN, NAPROXEN SODIUM
NAPROSYN, NAPROXEN
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
NAQUA, TRICHLORMETHIAZIDE
NAQUIVAL, RESERPINE
NARCAN, NALOXONE HYDROCHLORIDE
NARDIL, PHENELZINE SULFATE
NAROPIN, ROPIVACAINE HYDROCHLORIDE MONOHYDRATE
NASACORT AQ, TRIAMCINOLONE ACETONIDE
NASACORT, TRIAMCINOLONE ACETONIDE
NASALCROM, CROMOLYN SODIUM (OTC)
NASALIDE, FLUNISOLIDE
NASAREL, FLUNISOLIDE
NASCOBAL, CYANOCOBALAMIN
NASONEX, MOMETASONE FUROATE MONOHYDRATE
NATACYN, NATAMYCIN
NATRECOR, NESIRITIDE
NATURAL ESTROGENIC SUBSTANCE-ESTRONE, ESTRONE
NATURETIN-10, BENDROFLUMETHIAZIDE
NATURETIN-2.5, BENDROFLUMETHIAZIDE
NATURETIN-5, BENDROFLUMETHIAZIDE
NAVANE, THIOTHIXENE
NAVANE, THIOTHIXENE HYDROCHLORIDE
NAVELBINE, VINORELBINE TARTRATE
NEBCIN, TOBRAMYCIN SULFATE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEFAZODONE HCL, NEFAZODONE HYDROCHLORIDE
NEGGRAM, NALIDIXIC ACID
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NEMBUTAL, PENTOBARBITAL
NEMBUTAL, PENTOBARBITAL SODIUM
NEO TECT KIT, TECHNETIUM TC-99M DEPREOTIDE
NEO-CORT-DOME, ACETIC ACID, GLACIAL
NEO-CORT-DOME, HYDROCORTISONE
NEO-CORTEF, HYDROCORTISONE ACETATE
NEO-DELTA-CORTEF, NEOMYCIN SULFATE
NEO-FRADIN, NEOMYCIN SULFATE
NEO-HYDELTRASOL, NEOMYCIN SULFATE
NEO-MEDROL ACETATE, METHYLPREDNISOLONE ACETATE

FDA data supplied by DrugPatentWatch.com

NEO-MEDROL, METHYLPREDNISOLONE
NEO-POLYCIN, BACITRACIN ZINC
NEO-POLYCIN, GRAMICIDIN
NEO-RX, NEOMYCIN SULFATE
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
NEOBIOTIC, NEOMYCIN SULFATE
NEODECADRON, DEXAMETHASONE SODIUM PHOSPHATE
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES, NEOMYCIN SULFATE
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN, GRAMICIDIN
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE, NEOMYCIN SULFATE
NEOPAP, ACETAMINOPHEN (OTC)
NEOPASALATE, AMINOSALICYLATE SODIUM
NEOPHAM 6.4%, AMINO ACIDS
NEORAL, CYCLOSPORINE
NEOSAR, CYCLOPHOSPHAMIDE
NEOSCAN, GALLIUM CITRATE, GA-67
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, BACITRACIN ZINC
NEOSPORIN, GRAMICIDIN
NEOSPORIN, NEOMYCIN SULFATE (OTC)
NEOTHYLLINE, DYPHYLLINE
NEOTRIZINE, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
NEPHRAMINE 5.4%, AMINO ACIDS
NEPHROFLOW, IODOHIPPURATE SODIUM, I-123
NEPTAZANE, METHAZOLAMIDE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NETROMYCIN, NETILMICIN SULFATE
NEURAMATE, MEPROBAMATE
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
NEURONTIN, GABAPENTIN
NEUTREXIN, TRIMETREXATE GLUCURONATE
NEXIUM, ESOMEPRAZOLE MAGNESIUM
NIACIN, NIACIN
NIACOR, NIACIN
NIASPAN TITRATION STARTER PACK, NIACIN
NIASPAN, NIACIN
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NICLOCIDE, NICLOSAMIDE
NICODERM CQ, NICOTINE (OTC)
NICOLAR, NIACIN
NICORETTE (0RANGE), NICOTINE POLACRILEX (OTC)
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICORETTE (ORANGE), NICOTINE POLACRILEX (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NICOTINE, NICOTINE
NICOTROL, NICOTINE
NICOTROL, NICOTINE (OTC)
NIFEDIPINE, NIFEDIPINE
NILANDRON, NILUTAMIDE
NILSTAT, NYSTATIN
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NIMOTOP, NIMODIPINE
NIPENT, PENTOSTATIN
NIPRIDE, SODIUM NITROPRUSSIDE
NITRO IV, NITROGLYCERIN
NITRO-BID, NITROGLYCERIN
NITRO-DUR, NITROGLYCERIN
NITROFURANTION, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN MACROCRYSTALLINE, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURAZONE, NITROFURAZONE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROGLYCERIN, NITROGLYCERIN
NITROL, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROLINGUAL, NITROGLYCERIN
NITRONAL, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
NITROSTAT, NITROGLYCERIN
NIX, PERMETHRIN
NIX, PERMETHRIN (OTC)
NIZATIDINE, NIZATIDINE
NIZORAL A-D, KETOCONAZOLE (OTC)
NIZORAL, KETOCONAZOLE
NOGENIC HC, HYDROCORTISONE
NOLUDAR, METHYPRYLON
NOLVADEX, TAMOXIFEN CITRATE
NOR-QD, NORETHINDRONE
NORCEPT-E 1/35 21, ETHINYL ESTRADIOL

FDA data supplied by DrugPatentWatch.com

NORCEPT-E 1/35 28, ETHINYL ESTRADIOL
NORCET, ACETAMINOPHEN
NORCO, ACETAMINOPHEN
NORCURON, VECURONIUM BROMIDE
NORDETTE-21, ETHINYL ESTRADIOL
NORDETTE-28, ETHINYL ESTRADIOL
NORDITROPIN, SOMATROPIN RECOMBINANT
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
NORETHIN 1/35E-21, ETHINYL ESTRADIOL
NORETHIN 1/35E-28, ETHINYL ESTRADIOL
NORETHIN 1/50M-21, MESTRANOL
NORETHIN 1/50M-28, MESTRANOL
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND MESTRANOL, MESTRANOL
NORFLEX, ORPHENADRINE CITRATE
NORGESIC FORTE, ASPIRIN
NORGESIC, ASPIRIN
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
NORINYL 1+50 21-DAY, MESTRANOL
NORINYL 1+50 28-DAY, MESTRANOL
NORINYL 1+80 21-DAY, MESTRANOL
NORINYL 1+80 28-DAY, MESTRANOL
NORINYL, MESTRANOL
NORISODRINE AEROTROL, ISOPROTERENOL HYDROCHLORIDE
NORISODRINE, ISOPROTERENOL SULFATE
NORITATE, METRONIDAZOLE
NORLESTRIN 21 1/50, ETHINYL ESTRADIOL
NORLESTRIN 21 2.5/50, ETHINYL ESTRADIOL
NORLESTRIN 28 1/50, ETHINYL ESTRADIOL
NORLESTRIN FE 1/50, ETHINYL ESTRADIOL
NORLESTRIN FE 2.5/50, ETHINYL ESTRADIOL
NORLUTATE, NORETHINDRONE ACETATE
NORLUTIN, NORETHINDRONE
NORMIFLO, ARDEPARIN SODIUM
NORMODYNE, LABETALOL HYDROCHLORIDE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
NORMOZIDE, HYDROCHLOROTHIAZIDE
NOROXIN, NORFLOXACIN
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
NORPLANT II, LEVONORGESTREL
NORPLANT SYSTEM IN PLASTIC CONTAINER, LEVONORGESTREL
NORPLANT, LEVONORGESTREL
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
NORQUEST FE, ETHINYL ESTRADIOL
NORTREL 0.5/35-21, ETHINYL ESTRADIOL
NORTREL 0.5/35-28, ETHINYL ESTRADIOL
NORTREL 1/35-21, ETHINYL ESTRADIOL
NORTREL 1/35-28, ETHINYL ESTRADIOL
NORTREL 7/7/7, ETHINYL ESTRADIOL
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
NORVASC, AMLODIPINE BESYLATE
NORVIR, RITONAVIR
NOVAFED, PSEUDOEPHEDRINE HYDROCHLORIDE
NOVAMINE 11.4%, AMINO ACIDS
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
NOVAMINE 15%, AMINO ACIDS
NOVAMINE 8.5%, AMINO ACIDS
NOVANTRONE, MITOXANTRONE HYDROCHLORIDE
NOVOCAIN, PROCAINE HYDROCHLORIDE
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN 70/30, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
NOVOLIN L, INSULIN ZINC SUSP RECOMBINANT HUMAN (OTC)
NOVOLIN L, INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
NOVOLOG MIX 70/30, INSULIN ASPART
NOVOLOG, INSULIN ASPART
NOVOTHYROX, LIOTRIX (T4;T3)
NOVRAD, LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS
NPH ILETIN I (BEEF-PORK), INSULIN SUSP ISOPHANE BEEF/PORK (OTC)
NPH ILETIN II (PORK), INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
NPH ILETIN II, INSULIN SUSP ISOPHANE PURIFIED BEEF (OTC)
NPH INSULIN, INSULIN SUSP ISOPHANE BEEF (OTC)
NPH PURIFIED PORK ISOPHANE INSULIN, INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
NUBAIN, NALBUPHINE HYDROCHLORIDE
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
NUMORPHAN, OXYMORPHONE HYDROCHLORIDE
NUPRIN, IBUPROFEN (OTC)
NUROMAX, DOXACURIUM CHLORIDE
NUTRACORT, HYDROCORTISONE
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT
NUTROPIN AQ, SOMATROPIN RECOMBINANT
NUTROPIN DEPOT, SOMATROPIN RECOMBINANT
NUTROPIN, SOMATROPIN RECOMBINANT
NUVARING, ETHINYL ESTRADIOL
NYDRAZID, ISONIAZID
NYSERT, NYSTATIN

FDA data supplied by DrugPatentWatch.com

NYSTAFORM, CLIOQUINOL
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
NYSTATIN-TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTEX, NYSTATIN
NYSTOP, NYSTATIN

** O **

OBESTIN-30, PHENTERMINE HYDROCHLORIDE
OBY-TRIM, PHENTERMINE HYDROCHLORIDE
OCL, POLYETHYLENE GLYCOL 3350
OCTOCAINE, EPINEPHRINE
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)
OCUFEN, FLURBIPROFEN SODIUM
OCUFLOX, OFLOXACIN
OCUMYCIN, BACITRACIN ZINC
OCUPRESS, CARTEOLOL HYDROCHLORIDE
OCUSERT PILO-20, PILOCARPINE
OCUSERT PILO-40, PILOCARPINE
OCUSULF-10, SULFACETAMIDE SODIUM
OCUSULF-30, SULFACETAMIDE SODIUM
OFLOXACIN, OFLOXACIN
OGEN .625, ESTROPIPATE
OGEN 1.25, ESTROPIPATE
OGEN 2.5, ESTROPIPATE
OGEN 5, ESTROPIPATE
OGEN, ESTROPIPATE
OGESTREL 0.5/50-21, ETHINYL ESTRADIOL
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
OLUX FOAM, CLOBETASOL PROPIONATE
OMEPRAZOLE, OMEPRAZOLE
OMNICEF, CEFDINIR
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 210, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 70, IOHEXOL
OMNIPEN (AMPICILLIN), AMPICILLIN/AMPICILLIN TRIHYDRATE
OMNIPEN-N, AMPICILLIN SODIUM
OMNISCAN, GADODIAMIDE
ONA MAST, PHENTERMINE HYDROCHLORIDE
ONA-MAST, PHENTERMINE HYDROCHLORIDE
ONCOVIN, VINCRISTINE SULFATE
OPCON, NAPHAZOLINE HYDROCHLORIDE
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
OPHTHAINE, PROPARACAINE HYDROCHLORIDE
OPHTHETIC, PROPARACAINE HYDROCHLORIDE
OPHTHOCHLOR, CHLORAMPHENICOL
OPHTHOCORT, CHLORAMPHENICOL
OPTICROM, CROMOLYN SODIUM
OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
OPTIMARK, GADOVERSETAMIDE
OPTIMINE, AZATADINE MALEATE
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
OPTIRAY 160, IOVERSOL
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
OPTISON, ALBUMIN HUMAN
OPTIVAR, AZELASTINE HYDROCHLORIDE
OPTOMYCIN, CHLORAMPHENICOL
ORA-TESTRYL, FLUOXYMESTERONE
ORABASE HCA, HYDROCORTISONE ACETATE
ORACORT, TRIAMCINOLONE ACETONIDE
ORAGRAFIN CALCIUM, IPODATE CALCIUM
ORAGRAFIN SODIUM, IPODATE SODIUM
ORALONE, TRIAMCINOLONE ACETONIDE
ORAMORPH SR, MORPHINE SULFATE
ORAP, PIMOZIDE
ORAPRED, PREDNISOLONE SODIUM PHOSPHATE
ORAQIX, LIDOCAINE
ORASONE, PREDNISONE
ORETIC, HYDROCHLOROTHIAZIDE
ORETICYL 25, DESERPIDINE
ORETICYL 50, DESERPIDINE
ORETICYL FORTE, DESERPIDINE
ORETON METHYL, METHYLTESTOSTERONE
ORETON, METHYLTESTOSTERONE
ORFADIN, NITISINONE
ORGARAN, DANAPAROID SODIUM
ORGATRAX, HYDROXYZINE HYDROCHLORIDE
ORINASE DIAGNOSTIC, TOLBUTAMIDE SODIUM
ORINASE, TOLBUTAMIDE
ORLAAM, LEVOMETHADYL ACETATE HYDROCHLORIDE
ORLEX HC, ACETIC ACID, GLACIAL
ORLEX, ACETIC ACID, GLACIAL
ORNADE, CHLORPHENIRAMINE MALEATE
ORNIDYL, EFLORNITHINE HYDROCHLORIDE
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
ORPHENGESIC FORTE, ASPIRIN
ORPHENGESIC, ASPIRIN
ORTHO CYCLEN-21, ETHINYL ESTRADIOL
ORTHO CYCLEN-28, ETHINYL ESTRADIOL
ORTHO EVRA, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
ORTHO-CEPT, DESOGESTREL
ORTHO-EST, ESTROPIPATE
ORTHO-N0VUM 1/80 28, MESTRANOL
ORTHO-NOVUM 1/35-21, ETHINYL ESTRADIOL

FDA data supplied by DrugPatentWatch.com

ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 1/50 21, MESTRANOL
ORTHO-NOVUM 1/50 28, MESTRANOL
ORTHO-NOVUM 1/80 21, MESTRANOL
ORTHO-NOVUM 10-21, MESTRANOL
ORTHO-NOVUM 10/11-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 10/11-28 IN PLASTIC CONTAINER, ETHINYL ESTRADIOL
ORTHO-NOVUM 2-21, MESTRANOL
ORTHO-NOVUM 7/14-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/14-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
ORUDIS KT, KETOPROFEN (OTC)
ORUDIS, KETOPROFEN
ORUVAIL, KETOPROFEN
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
OSMOVIST 190, IOTROLAN
OSMOVIST 240, IOTROLAN
OSTEOLITE, TECHNETIUM TC-99M MEDRONATE KIT
OSTEOSCAN, TECHNETIUM TC-99M ETIDRONATE KIT
OTICAIR, HYDROCORTISONE
OTOBIONE, HYDROCORTISONE
OTOBIOTIC, HYDROCORTISONE
OTOCORT, HYDROCORTISONE
OVCON-35, ETHINYL ESTRADIOL
OVCON-50, ETHINYL ESTRADIOL
OVIDE, MALATHION
OVIDREL, CHORIOGONADOTROPIN ALFA
OVRAL, ETHINYL ESTRADIOL
OVRAL-28, ETHINYL ESTRADIOL
OVRETTE, NORGESTREL
OVULEN, ETHYNODIOL DIACETATE
OVULEN-21, ETHYNODIOL DIACETATE
OVULEN-28, ETHYNODIOL DIACETATE
OXACILLIN SODIUM, OXACILLIN SODIUM
OXANDRIN, OXANDROLONE
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
OXILAN-300, IOXILAN
OXILAN-350, IOXILAN
OXISTAT, OXICONAZOLE NITRATE
OXSORALEN, METHOXSALEN
OXSORALEN-ULTRA, METHOXSALEN
OXTRIPHYLLINE PEDIATRIC, OXTRIPHYLLINE
OXTRIPHYLLINE, OXTRIPHYLLINE
OXY-KESSO-TETRA, OXYTETRACYCLINE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE 2.5/APAP 500, ACETAMINOPHEN
OXYCODONE 5/APAP 500, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN (HALF-STRENGTH), ASPIRIN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCONTIN, OXYCODONE HYDROCHLORIDE
OXYLONE, FLUOROMETHOLONE
OXYPHENBUTAZONE, OXYPHENBUTAZONE
OXYTETRACYCLINE HCL, OXYTETRACYCLINE HYDROCHLORIDE
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%, OXYTOCIN
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%, OXYTOCIN
OXYTOCIN 5 USP UNITS IN DEXTROSE 5%, OXYTOCIN
OXYTOCIN, OXYTOCIN
OXYTROL, OXYBUTYNIN

** P **

P.A.S. SODIUM, AMINOSALICYLATE SODIUM
PACERONE, AMIODARONE HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PAGITANE, CYCRIMINE HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PAMINE FORTE, METHSCOPOLAMINE BROMIDE
PAMINE, METHSCOPOLAMINE BROMIDE
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PANCURONIUM, PANCURONIUM BROMIDE
PANDEL, HYDROCORTISONE PROBUTATE
PANHEPRIN, HEPARIN SODIUM
PANIXINE DISPERDOSE, CEPHALEXIN
PANMYCIN, TETRACYCLINE HYDROCHLORIDE
PANRETIN, ALITRETINOIN
PANTOPAQUE, IOPHENDYLATE
PANWARFIN, WARFARIN SODIUM
PAPA-DEINE #3, ACETAMINOPHEN
PAPA-DEINE #4, ACETAMINOPHEN
PARACAINE, PROPARACAINE HYDROCHLORIDE
PARACORT, PREDNISONE
PARADIONE, PARAMETHADIONE
PARAFLEX, CHLORZOXAZONE
PARAFON FORTE DSC, CHLORZOXAZONE
PARAPLATIN, CARBOPLATIN
PARASAL SODIUM, AMINOSALICYLATE SODIUM
PARASAL, AMINOSALICYLIC ACID
PARATHAR, TERIPARATIDE ACETATE
PAREDRINE, HYDROXYAMPHETAMINE HYDROBROMIDE
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
PARLODEL, BROMOCRIPTINE MESYLATE
PARNATE, TRANYLCYPROMINE SULFATE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PAROXETINE HCL, PAROXETINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PAROXETINE MESYLATE, PAROXETINE MESYLATE
PARSIDOL, ETHOPROPAZINE HYDROCHLORIDE
PASER, AMINOSALICYLIC ACID
PASKALIUM, POTASSIUM AMINOSALICYLATE
PATANOL, OLOPATADINE HYDROCHLORIDE
PATHILON, TRIDIHEXETHYL CHLORIDE
PATHOCIL, DICLOXACILLIN SODIUM
PAVULON, PANCURONIUM BROMIDE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PAXIPAM, HALAZEPAM
PBZ, TRIPELENNAMINE CITRATE
PBZ, TRIPELENNAMINE HYDROCHLORIDE
PBZ-SR, TRIPELENNAMINE HYDROCHLORIDE
PCE, ERYTHROMYCIN
PEDIAMYCIN 400, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAMYCIN, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
PEDIATRIC ADVIL, IBUPROFEN (OTC)
PEDIATRIC LTA KIT, LIDOCAINE HYDROCHLORIDE
PEDIAZOLE, ERYTHROMYCIN ETHYLSUCCINATE
PEDIOTIC, HYDROCORTISONE
PEG-LYTE, POLYETHYLENE GLYCOL 3350
PEGANONE, ETHOTOIN
PEMOLINE, PEMOLINE
PEN-VEE K, PENICILLIN V POTASSIUM
PENAPAR-VK, PENICILLIN V POTASSIUM
PENBRITIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PENBRITIN-S, AMPICILLIN SODIUM
PENECORT, HYDROCORTISONE
PENETREX, ENOXACIN
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENICILLIN, PENICILLIN G POTASSIUM
PENICILLIN-2, PENICILLIN G POTASSIUM
PENICILLIN-VK, PENICILLIN V POTASSIUM
PENLAC, CICLOPIROX
PENNTUSS, CHLORPHENIRAMINE POLISTIREX (OTC)
PENTACARINAT, PENTAMIDINE ISETHIONATE
PENTACEF, CEFTAZIDIME (ARGININE FORMULATION)
PENTAM, PENTAMIDINE ISETHIONATE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PENTASA, MESALAMINE
PENTAZOCINE AND NALOXONE HYDROCHLORIDES, NALOXONE HYDROCHLORIDE
PENTAZOCINE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PENTHRANE, METHOXYFLURANE
PENTIDS '200', PENICILLIN G POTASSIUM
PENTIDS '250', PENICILLIN G POTASSIUM
PENTIDS '400', PENICILLIN G POTASSIUM
PENTIDS '800', PENICILLIN G POTASSIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PENTOTHAL, THIOPENTAL SODIUM
PENTOXIFYLLINE, PENTOXIFYLLINE
PENTOXIL, PENTOXIFYLLINE
PEPCID AC (GELTAB), FAMOTIDINE (OTC)
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE, PRECIPITATED (OTC)
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
PEPCID PRESERVATIVE FREE, FAMOTIDINE
PEPCID RPD, FAMOTIDINE
PEPCID, FAMOTIDINE
PEPTAVLON, PENTAGASTRIN
PERCHLORACAP, POTASSIUM PERCHLORATE
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERCODAN-DEMI, ASPIRIN
PERCORTEN, DESOXYCORTICOSTERONE ACETATE
PERCORTEN, DESOXYCORTICOSTERONE PIVALATE
PERGOLIDE MESYLATE, PERGOLIDE MESYLATE
PERGONAL, MENOTROPINS (FSH;LH)
PERIACTIN, CYPROHEPTADINE HYDROCHLORIDE
PERIDEX, CHLORHEXIDINE GLUCONATE
PERIOCHIP, CHLORHEXIDINE GLUCONATE
PERIOGARD, CHLORHEXIDINE GLUCONATE
PERIOSTAT, DOXYCYCLINE HYCLATE
PERMAPEN, PENICILLIN G BENZATHINE
PERMAX, PERGOLIDE MESYLATE
PERMETHRIN, PERMETHRIN
PERMETHRIN, PERMETHRIN (OTC)
PERMITIL, FLUPHENAZINE HYDROCHLORIDE
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PERSANTINE, DIPYRIDAMOLE
PERTOFRANE, DESIPRAMINE HYDROCHLORIDE
PFIZER-E, ERYTHROMYCIN STEARATE
PFIZERPEN G, PENICILLIN G POTASSIUM
PFIZERPEN VK, PENICILLIN V POTASSIUM
PFIZERPEN, PENICILLIN G POTASSIUM
PFIZERPEN-A, AMPICILLIN/AMPICILLIN TRIHYDRATE
PFIZERPEN-AS, PENICILLIN G PROCAINE
PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)
PHENAPHEN W/ CODEINE NO. 2, ACETAMINOPHEN
PHENAPHEN W/ CODEINE NO. 3, ACETAMINOPHEN
PHENAPHEN W/ CODEINE NO. 4, ACETAMINOPHEN
PHENAPHEN-650 W/ CODEINE, ACETAMINOPHEN
PHENAZINE, PHENDIMETRAZINE TARTRATE
PHENAZINE-35, PHENDIMETRAZINE TARTRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENERGAN FORTIS, PROMETHAZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PHENERGAN PLAIN, PROMETHAZINE HYDROCHLORIDE
PHENERGAN VC W/ CODEINE, CODEINE PHOSPHATE
PHENERGAN VC, PHENYLEPHRINE HYDROCHLORIDE
PHENERGAN W/ CODEINE, CODEINE PHOSPHATE
PHENERGAN W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PHENERGAN, PROMETHAZINE HYDROCHLORIDE
PHENETRON, CHLORPHENIRAMINE MALEATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PHENTERMINE RESIN 30, PHENTERMINE RESIN COMPLEX
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENTYTOIN, PHENYTOIN
PHENURONE, PHENACEMIDE
PHENY-PAS-TEBAMIN, PHENYL AMINOSALICYLATE
PHENYLBUTAZONE, PHENYLBUTAZONE
PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
PHENYTEK, PHENYTOIN SODIUM, EXTENDED
PHENYTEX, PHENYTOIN SODIUM, EXTENDED
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
PHENYTOIN, PHENYTOIN
PHENYTOIN, PHENYTOIN SODIUM
PHERAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PHERAZINE VC W/ CODEINE, CODEINE PHOSPHATE
PHERAZINE VC, PHENYLEPHRINE HYDROCHLORIDE
PHERAZINE W/ CODEINE, CODEINE PHOSPHATE
PHISO-SCRUB, HEXACHLOROPHENE
PHISOHEX, HEXACHLOROPHENE
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSLO, CALCIUM ACETATE
PHOSPHOCOL P32, CHROMIC PHOSPHATE, P-32
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PHOSPHOTEC, TECHNETIUM TC-99M PYROPHOSPHATE KIT
PHOSPHOTOPE, SODIUM PHOSPHATE, P-32
PHOTOFRIN, PORFIMER SODIUM
PHRENILIN FORTE, ACETAMINOPHEN
PHRENILIN WITH CAFFEINE AND CODEINE, ACETAMINOPHEN
PHRENILIN, ACETAMINOPHEN
PHYLLOCONTIN, AMINOPHYLLINE
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYTONADIONE, PHYTONADIONE
PILOPINE HS, PILOCARPINE HYDROCHLORIDE
PINDAC, PINACIDIL
PINDOLOL, PINDOLOL
PIPERACILLIN, PIPERACILLIN SODIUM
PIPERAZINE CITRATE, PIPERAZINE CITRATE
PIPRACIL, PIPERACILLIN SODIUM
PIROXICAM, PIROXICAM
PITOCIN, OXYTOCIN
PITRESSIN TANNATE, VASOPRESSIN TANNATE
PLACIDYL, ETHCHLORVYNOL
PLAN B, LEVONORGESTREL
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE 56 IN PLASTIC CONTAINER, MAGNESIUM ACETATE TETRAHYDRATE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLASMA-LYTE R IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLATINOL, CISPLATIN
PLATINOL-AQ, CISPLATIN
PLAVIX, CLOPIDOGREL BISULFATE
PLEGINE, PHENDIMETRAZINE TARTRATE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLENAXIS, ABARELIX
PLENDIL, FELODIPINE
PLETAL, CILOSTAZOL
PMB 200, ESTROGENS, CONJUGATED
PMB 400, ESTROGENS, CONJUGATED
PODOFILOX, PODOFILOX
POLARAMINE, DEXCHLORPHENIRAMINE MALEATE
POLOCAINE W/ LEVONORDEFRIN, LEVONORDEFRIN
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLY-PRED, NEOMYCIN SULFATE
POLY-RX, POLYMYXIN B SULFATE
POLYCILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
POLYCILLIN-N, AMPICILLIN SODIUM
POLYCILLIN-PRB, AMPICILLIN/AMPICILLIN TRIHYDRATE
POLYMOX, AMOXICILLIN
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POLYSPORIN, BACITRACIN ZINC
POLYSPORIN, BACITRACIN ZINC (OTC)
POLYTRIM, POLYMYXIN B SULFATE
PONSTEL, MEFENAMIC ACID
PORTALAC, LACTULOSE
PORTIA-21, ETHINYL ESTRADIOL
PORTIA-28, ETHINYL ESTRADIOL
POTASSIUM ACETATE IN PLASTIC CONTAINER, POTASSIUM ACETATE
POTASSIUM AMINOSALICYLATE, POTASSIUM AMINOSALICYLATE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
POVAN, PYRVINIUM PAMOATE
POVIDONE IODINE, POVIDONE-IODINE (OTC)
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
PRAMINE, IMIPRAMINE HYDROCHLORIDE
PRAMOSONE, HYDROCORTISONE ACETATE
PRANDIN, REPAGLINIDE

FDA data supplied by DrugPatentWatch.com

PRANTAL, DIPHEMANIL METHYLSULFATE
PRAVACHOL, PRAVASTATIN SODIUM
PRAVIGARD PAC (COPACKAGED), ASPIRIN
PRAZEPAM, PRAZEPAM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE
PRE-PEN, BENZYL PENICILLOYL-POLYLYSINE
PRE-SATE, CHLORPHENTERMINE HYDROCHLORIDE
PRECEDEX, DEXMEDETOMIDINE
PRECEF, CEFORANIDE
PRECOSE, ACARBOSE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE
PREDAIR FORTE, PREDNISOLONE SODIUM PHOSPHATE
PREDAIR, PREDNISOLONE SODIUM PHOSPHATE
PREDAMIDE, PREDNISOLONE ACETATE
PREDNICEN-M, PREDNISONE
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE TEBUTATE, PREDNISOLONE TEBUTATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE INTENSOL, PREDNISONE
PREDNISONE, PREDNISONE
PREDSULFAIR II, PREDNISOLONE ACETATE
PREDSULFAIR, PREDNISOLONE ACETATE
PREFEST, ESTRADIOL
PREFRIN-A, PHENYLEPHRINE HYDROCHLORIDE
PREGNYL, GONADOTROPIN, CHORIONIC
PRELAY, TROGLITAZONE
PRELONE, PREDNISOLONE
PRELUDIN, PHENMETRAZINE HYDROCHLORIDE
PREMARIN, ESTROGENS, CONJUGATED
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
PREMPHASE (PREMARIN;CYCRIN 14/14), ESTROGENS, CONJUGATED
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO (PREMARIN;CYCRIN), ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PREPIDIL, DINOPROSTONE
PRESAMINE, IMIPRAMINE HYDROCHLORIDE
PREVACARE R, CHLORHEXIDINE GLUCONATE (OTC)
PREVACID, LANSOPRAZOLE
PREVALITE, CHOLESTYRAMINE
PREVEN EMERGENCY CONTRACEPTIVE KIT, ETHINYL ESTRADIOL
PREVPAC, AMOXICILLIN
PRIFTIN, RIFAPENTINE
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PRILOSEC, OMEPRAZOLE
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
PRIMACOR, MILRINONE LACTATE
PRIMAQUINE, PRIMAQUINE PHOSPHATE
PRIMATENE MIST, EPINEPHRINE (OTC)
PRIMAXIN, CILASTATIN SODIUM
PRIMIDONE, PRIMIDONE
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE
PRINCIPEN '125', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN '250', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN '500', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN W/ PROBENECID, AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINIVIL, LISINOPRIL
PRINZIDE, HYDROCHLOROTHIAZIDE
PRISCOLINE, TOLAZOLINE HYDROCHLORIDE
PRO-BANTHINE, PROPANTHELINE BROMIDE
PROAMATINE, MIDODRINE HYDROCHLORIDE
PROBALAN, PROBENECID
PROBAMPACIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PROBEN-C, COLCHICINE
PROBENECID AND COLCHICINE, COLCHICINE
PROBENECID W/ COLCHICINE, COLCHICINE
PROBENECID, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PROCALAMINE, AMINO ACIDS
PROCAN SR, PROCAINAMIDE HYDROCHLORIDE
PROCAN, PROCAINAMIDE HYDROCHLORIDE
PROCANBID, PROCAINAMIDE HYDROCHLORIDE
PROCAPAN, PROCAINAMIDE HYDROCHLORIDE
PROCARDIA XL, NIFEDIPINE
PROCARDIA, NIFEDIPINE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROCHLORPERAZINE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE, PROCHLORPERAZINE MALEATE
PROCTOCORT, HYDROCORTISONE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
PROFEN, IBUPROFEN (OTC)
PROFENAL, SUPROFEN
PROFERDEX, IRON DEXTRAN
PROGESTASERT, PROGESTERONE
PROGESTERONE, PROGESTERONE
PROGLYCEM, DIAZOXIDE
PROGRAF, TACROLIMUS
PROHANCE MULTIPACK, GADOTERIDOL
PROHANCE, GADOTERIDOL
PROKETAZINE, CARPHENAZINE MALEATE
PROKLAR, SULFAMETHIZOLE
PROLIXIN DECANOATE, FLUPHENAZINE DECANOATE
PROLIXIN ENANTHATE, FLUPHENAZINE ENANTHATE
PROLIXIN, FLUPHENAZINE HYDROCHLORIDE
PROLOID, THYROGLOBULIN

FDA data supplied by DrugPatentWatch.com

PROLOPRIM, TRIMETHOPRIM
PROMAPAR, CHLORPROMAZINE HYDROCHLORIDE
PROMAZINE HCL, PROMAZINE HYDROCHLORIDE
PROMETA, METAPROTERENOL SULFATE
PROMETH FORTIS, PROMETHAZINE HYDROCHLORIDE
PROMETH PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHACON, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE HCL AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HCL AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE VC W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE, PROMETHAZINE HYDROCHLORIDE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
PROMETRIUM, PROGESTERONE
PROMPT PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
PRONESTYL, PROCAINAMIDE HYDROCHLORIDE
PRONESTYL-SR, PROCAINAMIDE HYDROCHLORIDE
PROPACET 100, ACETAMINOPHEN
PROPAFENONE HCL, PROPAFENONE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPARACAINE HCL, PROPARACAINE HYDROCHLORIDE
PROPECIA, FINASTERIDE
PROPHENE 65, PROPOXYPHENE HYDROCHLORIDE
PROPINE, DIPIVEFRIN HYDROCHLORIDE
PROPOFOL, PROPOFOL
PROPOXYPHENE COMPOUND 65, ASPIRIN
PROPOXYPHENE COMPOUND-65, ASPIRIN
PROPOXYPHENE HCL 65, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPOXYPHENE HCL W/ ASPIRIN AND CAFFEINE, ASPIRIN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL & HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL INTENSOL, PROPRANOLOL HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPULSID QUICKSOLV, CISAPRIDE MONOHYDRATE
PROPULSID, CISAPRIDE MONOHYDRATE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROSCAR, FINASTERIDE
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
PROSOM, ESTAZOLAM
PROSTAPHLIN, OXACILLIN SODIUM
PROSTEP, NICOTINE (OTC)
PROSTIN E2, DINOPROSTONE
PROSTIN F2 ALPHA, DINOPROST TROMETHAMINE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROTAMINE ZINC AND ILETIN II (PORK), INSULIN SUSP PROTAMINE ZINC PURIFIED PORK (OTC)
PROTAMINE ZINC AND ILETIN II, INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF (OTC)
PROTAMINE ZINC INSULIN, INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF (OTC)
PROTAMINE, ZINC & ILETIN I (BEEF-PORK), INSULIN SUSP PROTAMINE ZINC BEEF/PORK (OTC)
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTONIX, PANTOPRAZOLE SODIUM
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
PROTOPIC, TACROLIMUS
PROTOSTAT, METRONIDAZOLE
PROTROPIN, SOMATREM
PROVAL #3, ACETAMINOPHEN
PROVENTIL, ALBUTEROL
PROVENTIL, ALBUTEROL SULFATE
PROVENTIL-HFA, ALBUTEROL SULFATE
PROVERA, MEDROXYPROGESTERONE ACETATE
PROVIGIL, MODAFINIL
PROVOCHOLINE, METHACHOLINE CHLORIDE
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
PSEUDO-12, PSEUDOEPHEDRINE POLISTIREX (OTC)
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
PSEUDOEPHEDRINE HCL AND TRIPROLIDINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE
PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
PSEUDOEPHEDRINE HCL/CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
PSORCON, DIFLORASONE DIACETATE
PULMICORT RESPULES, BUDESONIDE
PULMICORT, BUDESONIDE
PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
PURIFIED CORTROPHIN GEL, CORTICOTROPIN
PURINETHOL, MERCAPTOPURINE
PYLORI-CHEK BREATH TEST, UREA, C-13
PYOCIDIN, HYDROCORTISONE
PYOPEN, CARBENICILLIN DISODIUM
PYRAZINAMIDE, PYRAZINAMIDE
PYRIDAMAL 100, CHLORPHENIRAMINE MALEATE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
PYRILAMINE MALEATE, PYRILAMINE MALEATE
PYROLITE, TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT
PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

FDA data supplied by DrugPatentWatch.com

** Q **

Q-GESIC, ASPIRIN
Q-PAM, DIAZEPAM
QUADRAMET, SAMARIUM SM 153 LEXIDRONAM PENTASODIUM
QUARZAN, CLIDINIUM BROMIDE
QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
QUELICIN, SUCCINYLCHOLINE CHLORIDE
QUESTRAN LIGHT, CHOLESTYRAMINE
QUESTRAN, CHOLESTYRAMINE
QUIBRON-T, THEOPHYLLINE
QUIBRON-T/SR, THEOPHYLLINE
QUIDE, PIPERACETAZINE
QUINACT, QUINIDINE GLUCONATE
QUINAGLUTE, QUINIDINE GLUCONATE
QUINALAN, QUINIDINE GLUCONATE
QUINAPRIL HCL, QUINAPRIL HYDROCHLORIDE
QUINATIME, QUINIDINE GLUCONATE
QUINIDEX, QUINIDINE SULFATE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
QUINORA, QUINIDINE SULFATE
QUIXIN, LEVOFLOXACIN
QVAR 40, BECLOMETHASONE DIPROPIONATE
QVAR 80, BECLOMETHASONE DIPROPIONATE

** R **

R-GENE 10, ARGININE HYDROCHLORIDE
R-P MYCIN, ERYTHROMYCIN
RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN), ALBUMIN IODINATED I-125 SERUM
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125, ALBUMIN IODINATED I-125 SERUM
RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR, FIBRINOGEN, I-125
RANICLOR, CEFACLOR
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
RAPAMUNE, SIROLIMUS
RAPLON, RAPACURONIUM BROMIDE
RAU-SED, RESERPINE
RAUDIXIN, RAUWOLFIA SERPENTINA
RAUSERPIN, RAUWOLFIA SERPENTINA
RAUTENSIN, ALSEROXYLON
RAUVAL, RAUWOLFIA SERPENTINA
RAUWILOID, ALSEROXYLON
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RAVOCAINE AND NOVOCAIN W/ LEVOPHED, NOREPINEPHRINE BITARTRATE
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN, LEVONORDEFRIN
RAXAR, GREPAFLOXACIN HYDROCHLORIDE
RBC-SCAN, TECHNETIUM TC-99M RED BLOOD CELL KIT
REBETOL, RIBAVIRIN
REDISOL, CYANOCOBALAMIN
REFLUDAN, LEPIRUDIN
REGITINE, PHENTOLAMINE MESYLATE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
REGONOL, PYRIDOSTIGMINE BROMIDE
REGROTON, CHLORTHALIDONE
REGULAR ILETIN II (PORK), INSULIN PURIFIED PORK (OTC)
REGULAR ILETIN II, INSULIN PURIFIED BEEF (OTC)
REGULAR INSULIN, INSULIN PORK (OTC)
REGULAR PURIFIED PORK INSULIN, INSULIN PURIFIED PORK (OTC)
RELA, CARISOPRODOL
RELAFEN, NABUMETONE
RELENZA, ZANAMIVIR
RELPAX, ELETRIPTAN HYDROBROMIDE
REMERON SOLTAB, MIRTAZAPINE
REMERON, MIRTAZAPINE
REMINYL, GALANTAMINE HYDROBROMIDE
REMODULIN, TREPROSTINIL SODIUM
REMSED, PROMETHAZINE HYDROCHLORIDE
RENACIDIN, CITRIC ACID
RENAGEL, SEVELAMER HYDROCHLORIDE
RENAMIN W/O ELECTROLYTES, AMINO ACIDS
RENESE, POLYTHIAZIDE
RENESE-R, POLYTHIAZIDE
RENO-30, DIATRIZOATE MEGLUMINE
RENO-60, DIATRIZOATE MEGLUMINE
RENO-DIP, DIATRIZOATE MEGLUMINE
RENOCAL-76, DIATRIZOATE MEGLUMINE
RENOGRAFIN-60, DIATRIZOATE MEGLUMINE
RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
RENOQUID, SULFACYTINE
RENORMAX, SPIRAPRIL HYDROCHLORIDE
RENOTEC, TECHNETIUM TC-99M FERPENTETATE KIT
RENOVA, TRETINOIN
RENOVIST II, DIATRIZOATE MEGLUMINE
RENOVIST, DIATRIZOATE MEGLUMINE
RENOVUE-65, IODAMIDE MEGLUMINE
RENOVUE-DIP, IODAMIDE MEGLUMINE
REPRONEX, MENOTROPINS (FSH;LH)
REQUIP, ROPINIROLE HYDROCHLORIDE
RESCRIPTOR, DELAVIRDINE MESYLATE
RESCULA, UNOPROSTONE ISOPROPYL
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RESECTISOL, MANNITOL
RESERPINE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RESERPINE AND HYDROCHLOROTHIAZIDE-50, HYDROCHLOROTHIAZIDE
RESERPINE AND HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
RESERPINE, RESERPINE
RESPORAL, DEXBROMPHENIRAMINE MALEATE (OTC)
RESTASIS, CYCLOSPORINE
RESTORIL, TEMAZEPAM
RETET, TETRACYCLINE HYDROCHLORIDE
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
RETROVIR, ZIDOVUDINE
REV-EYES, DAPIPRAZOLE HYDROCHLORIDE
REVERSOL, EDROPHONIUM CHLORIDE
REVEX, NALMEFENE HYDROCHLORIDE
REVIA, NALTREXONE HYDROCHLORIDE
REYATAZ, ATAZANAVIR SULFATE
REZIPAS, AMINOSALICYLIC ACID RESIN COMPLEX
REZULIN, TROGLITAZONE
RHINOCORT, BUDESONIDE
RID MOUSSE, PIPERONYL BUTOXIDE (OTC)
RIDAURA, AURANOFIN
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFAMPIN, RIFAMPIN
RIFATER, ISONIAZID
RILUTEK, RILUZOLE
RILUZOLE, RILUZOLE
RIMACTANE, RIFAMPIN
RIMADYL, CARPROFEN
RIMANTADINE HCL, RIMANTADINE HYDROCHLORIDE
RIMIFON, ISONIAZID
RIMSO-50, DIMETHYL SULFOXIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RIOMET, METFORMIN HYDROCHLORIDE
RISPERDAL CONSTA, RISPERIDONE
RISPERDAL, RISPERIDONE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, RITODRINE HYDROCHLORIDE
RITODRINE HCL, RITODRINE HYDROCHLORIDE
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
ROBAXISAL, ASPIRIN
ROBENGATOPE, ROSE BENGAL SODIUM, I-131
ROBIMYCIN, ERYTHROMYCIN
ROBINUL FORTE, GLYCOPYRROLATE
ROBINUL, GLYCOPYRROLATE
ROBITET, TETRACYCLINE HYDROCHLORIDE
ROCALTROL, CALCITRIOL
ROCEPHIN KIT, CEFTRIAXONE SODIUM
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
ROCEPHIN, CEFTRIAXONE SODIUM
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
ROMAZICON, FLUMAZENIL
RONDOMYCIN, METHACYCLINE HYDROCHLORIDE
ROWASA, MESALAMINE
ROXICET 5/500, ACETAMINOPHEN
ROXICET, ACETAMINOPHEN
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROXILOX, ACETAMINOPHEN
ROXIPRIN, ASPIRIN
RUBEX, DOXORUBICIN HYDROCHLORIDE
RUBIVITE, CYANOCOBALAMIN
RUBRAMIN PC, CYANOCOBALAMIN
RUBRATOPE-57 KIT, COBALT CHLORIDE, CO-57
RUBRATOPE-57, CYANOCOBALAMIN, CO-57
RUBRATOPE-60 KIT, COBALT CHLORIDE, CO-60
RUBRATOPE-60, CYANOCOBALAMIN, CO-60
RUFEN, IBUPROFEN
RUVITE, CYANOCOBALAMIN
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE
RYTHMOL, PROPAFENONE HYDROCHLORIDE

** S **

S.A.S.-500, SULFASALAZINE
SAIZEN, SOMATROPIN RECOMBINANT
SALAGEN, PILOCARPINE HYDROCHLORIDE
SALPIX, ACETRIZOATE SODIUM
SALURON, HYDROFLUMETHIAZIDE
SALUTENSIN, HYDROFLUMETHIAZIDE
SALUTENSIN-DEMI, HYDROFLUMETHIAZIDE
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SANDOSTATIN, OCTREOTIDE ACETATE
SANDRIL, RESERPINE
SANOREX, MAZINDOL
SANSAC, ERYTHROMYCIN
SANSERT, METHYSERGIDE MALEATE
SARAFEM, FLUOXETINE HYDROCHLORIDE
SARENIN, SARALASIN ACETATE
SARISOL NO. 1, BUTABARBITAL SODIUM
SARISOL NO. 2, BUTABARBITAL SODIUM
SARISOL, BUTABARBITAL SODIUM
SATRIC, METRONIDAZOLE
SCABENE, LINDANE
SCANDONEST L, LEVONORDEFRIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SCLEROSOL, TALC
SCRUBTEAM SURGICAL SPONGEBRUSH, HEXACHLOROPHENE
SEASONALE, ETHINYL ESTRADIOL
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM

FDA data supplied by DrugPatentWatch.com

SECONAL SODIUM, SECOBARBITAL SODIUM
SECREFLO, SECRETIN
SECRETIN-FERRING, SECRETIN
SECTRAL, ACEBUTOLOL HYDROCHLORIDE
SEDAPAP, ACETAMINOPHEN
SEFFIN, CEPHALOTHIN SODIUM
SELEGELINE HCL, SELEGILINE HYDROCHLORIDE
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
SELENOMETHIONINE SE 75, SELENOMETHIONINE, SE-75
SELSUN, SELENIUM SULFIDE
SEMILENTE INSULIN, INSULIN ZINC SUSP PROMPT BEEF (OTC)
SEMILENTE, INSULIN ZINC SUSP PROMPT PURIFIED PORK (OTC)
SEMPREX-D, ACRIVASTINE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SEPTI-SOFT, HEXACHLOROPHENE
SEPTISOL, HEXACHLOROPHENE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA GRAPE, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
SER-A-GEN, HYDRALAZINE HYDROCHLORIDE
SER-AP-ES, HYDRALAZINE HYDROCHLORIDE
SERAX, OXAZEPAM
SERENTIL, MESORIDAZINE BESYLATE
SEREVENT, SALMETEROL XINAFOATE
SEROMYCIN, CYCLOSERINE
SEROPHENE, CLOMIPHENE CITRATE
SEROQUEL, QUETIAPINE FUMARATE
SEROSTIM, SOMATROPIN RECOMBINANT
SERPALAN, RESERPINE
SERPANRAY, RESERPINE
SERPASIL, RESERPINE
SERPASIL-APRESOLINE, HYDRALAZINE HYDROCHLORIDE
SERPASIL-ESIDRIX #1, HYDROCHLOROTHIAZIDE
SERPASIL-ESIDRIX #2, HYDROCHLOROTHIAZIDE
SERPATE, RESERPINE
SERPIVITE, RESERPINE
SERVISONE, PREDNISONE
SERZONE, NEFAZODONE HYDROCHLORIDE
SETHOTOPE, SELENOMETHIONINE, SE-75
SEVOFLURANE, SEVOFLURANE
SHADE UVAGUARD, AVOBENZONE (OTC)
SILDAFLO, SILVER SULFADIAZINE
SILPHEN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
SILVADENE, SILVER SULFADIAZINE
SINE-AID IB, IBUPROFEN (OTC)
SINEMET CR, CARBIDOPA
SINEMET, CARBIDOPA
SINEQUAN, DOXEPIN HYDROCHLORIDE
SINGULAIR, MONTELUKAST SODIUM
SINOGRAFIN, DIATRIZOATE MEGLUMINE
SKELAXIN, METAXALONE
SKELID, TILUDRONATE DISODIUM
SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS, PERFLUOROPOLYMETHYLISOPROPYL ETHER
SLO-BID, THEOPHYLLINE
SLO-PHYLLIN, THEOPHYLLINE
SLOW-K, POTASSIUM CHLORIDE
SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE, ANHYDROUS
SODIUM AMINOSALICYLATE, AMINOSALICYLATE SODIUM
SODIUM BICARBONATE IN PLASTIC CONTAINER, SODIUM BICARBONATE
SODIUM BUTABARBITAL, BUTABARBITAL SODIUM
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.224%, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE, SODIUM CHLORIDE
SODIUM CHROMATE CR 51, SODIUM CHROMATE, CR-51
SODIUM HEPARIN, HEPARIN SODIUM
SODIUM IODIDE I 123, SODIUM IODIDE, I-123
SODIUM IODIDE I 131, KIT, SODIUM IODIDE, I-131
SODIUM IODIDE I 131, SODIUM IODIDE, I-131
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SODIUM P.A.S., AMINOSALICYLATE SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM PERTECHNETATE TC 99M, TECHNETIUM TC-99M SODIUM PERTECHNETATE
SODIUM PHOSPHATE P 32, SODIUM PHOSPHATE, P-32
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM POLYPHOSPHATE-TIN KIT, TECHNETIUM TC-99M POLYPHOSPHATE KIT
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SODIUM ROSE BENGAL I 131, ROSE BENGAL SODIUM, I-131
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM

FDA data supplied by DrugPatentWatch.com

SODIUM SUCCINATE, SODIUM SUCCINATE
SODIUM SULAMYD, SULFACETAMIDE SODIUM
SODIUM SULFACETAMIDE, SULFACETAMIDE SODIUM
SODIUM THIOSULFATE, SODIUM THIOSULFATE
SODIUM VERSENATE, EDETATE DISODIUM
SOLAGE, MEQUINOL
SOLARAZE, DICLOFENAC SODIUM
SOLATENE, BETA-CAROTENE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOMA COMPOUND W/ CODEINE, ASPIRIN
SOMA COMPOUND, ASPIRIN
SOMA, CARISOPRODOL
SOMAVERT, PEGVISOMANT
SOMOPHYLLIN, AMINOPHYLLINE
SOMOPHYLLIN-CRT, THEOPHYLLINE
SOMOPHYLLIN-DF, AMINOPHYLLINE
SOMOPHYLLIN-T, THEOPHYLLINE
SONATA, ZALEPLON
SONAZINE, CHLORPROMAZINE HYDROCHLORIDE
SONORX, SIMETHICONE-CELLULOSE
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORBITOL-MANNITOL, MANNITOL
SORBITRATE, ISOSORBIDE DINITRATE
SORIATANE, ACITRETIN
SORINE, SOTALOL HYDROCHLORIDE
SOSOL, SULFISOXAZOLE
SOTALOL HCL, SOTALOL HYDROCHLORIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SOTRET, ISOTRETINOIN
SOXAZOLE, SULFISOXAZOLE
SOY-DOME, HEXACHLOROPHENE
SOYACAL 10%, SOYBEAN OIL
SOYACAL 20%, SOYBEAN OIL
SPARINE, PROMAZINE HYDROCHLORIDE
SPECTAMINE, IOFETAMINE HYDROCHLORIDE I-123
SPECTAZOLE, ECONAZOLE NITRATE
SPECTRACEF, CEFDITOREN PIVOXIL
SPECTROBID, BACAMPICILLIN HYDROCHLORIDE
SPIRONOLACTONE + HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SPIRONOLACTONE/HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPORANOX, ITRACONAZOLE
SPRINTEC, ETHINYL ESTRADIOL
SPRX-105, PHENDIMETRAZINE TARTRATE
SPRX-3, PHENDIMETRAZINE TARTRATE
SPS, SODIUM POLYSTYRENE SULFONATE
SSD AF, SILVER SULFADIAZINE
SSD, SILVER SULFADIAZINE
STADOL PRESERVATIVE FREE, BUTORPHANOL TARTRATE
STADOL, BUTORPHANOL TARTRATE
STALEVO 100, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 50, CARBIDOPA
STANOZIDE, ISONIAZID
STAPHCILLIN, METHICILLIN SODIUM
STARLIX, NATEGLINIDE
STATICIN, ERYTHROMYCIN
STATOBEX, PHENDIMETRAZINE TARTRATE
STATOBEX-G, PHENDIMETRAZINE TARTRATE
STATROL, NEOMYCIN SULFATE
STELAZINE, TRIFLUOPERAZINE HYDROCHLORIDE
STERANE, PREDNISOLONE
STERANE, PREDNISOLONE ACETATE
STERI-STAT, CHLORHEXIDINE GLUCONATE (OTC)
STERILE UREA, UREA
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE
STERILE WATER, WATER FOR IRRIGATION, STERILE
STIE-CORT, HYDROCORTISONE
STILBESTROL, DIETHYLSTILBESTROL
STILBETIN, DIETHYLSTILBESTROL
STILPHOSTROL, DIETHYLSTILBESTROL DIPHOSPHATE
STIMATE, DESMOPRESSIN ACETATE
STOXIL, IDOXURIDINE
STRATTERA, ATOMOXETINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
STRIANT, TESTOSTERONE
STRIFON FORTE DSC, CHLORZOXAZONE
STROMECTOL, IVERMECTIN
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE, SR-89
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
SUBUTEX, BUPRENORPHINE HYDROCHLORIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUCOSTRIN, SUCCINYLCHOLINE CHLORIDE
SUCRAID, SACROSIDASE
SUCRALFATE, SUCRALFATE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUFENTA, SUFENTANIL CITRATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULAR, NISOLDIPINE
SULF-10, SULFACETAMIDE SODIUM
SULF-15, SULFACETAMIDE SODIUM
SULFA-TRIPLE #2, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFABID, SULFAPHENAZOLE
SULFACEL-15, SULFACETAMIDE SODIUM
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE

FDA data supplied by DrugPatentWatch.com

SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFADIAZINE SODIUM, SULFADIAZINE SODIUM
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFAIR 10, SULFACETAMIDE SODIUM
SULFAIR FORTE, SULFACETAMIDE SODIUM
SULFAIR-15, SULFACETAMIDE SODIUM
SULFALAR, SULFISOXAZOLE
SULFALOID, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
SULFAMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOPRIM-DS, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE & TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL, PHENAZOPYRIDINE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
SULFAMYLON, MAFENIDE ACETATE
SULFANILAMIDE, SULFANILAMIDE
SULFAPYRIDINE, SULFAPYRIDINE
SULFASALAZINE, SULFASALAZINE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
SULFATRIM, SULFAMETHOXAZOLE
SULFATRIM-DS, SULFAMETHOXAZOLE
SULFATRIM-SS, SULFAMETHOXAZOLE
SULFENTANIL CITRATE, SUFENTANIL CITRATE
SULFINPYRAZONE, SULFINPYRAZONE
SULFISOXAZOLE DIOLAMINE, SULFISOXAZOLE DIOLAMINE
SULFISOXAZOLE, SULFISOXAZOLE
SULFONAMIDES DUPLEX, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFOSE, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
SULINDAC, SULINDAC
SULLA, SULFAMETER
SULMEPRIM PEDIATRIC, SULFAMETHOXAZOLE
SULMEPRIM, SULFAMETHOXAZOLE
SULPHRIN, PREDNISOLONE ACETATE
SULSOXIN, SULFISOXAZOLE
SULSTER, PREDNISOLONE SODIUM PHOSPHATE
SULTEN-10, SULFACETAMIDE SODIUM
SULTRIN, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
SUMYCIN, TETRACYCLINE HYDROCHLORIDE
SUPPRELIN, HISTRELIN ACETATE
SUPRANE, DESFLURANE
SUPRAX, CEFIXIME
SURITAL, THIAMYLAL SODIUM
SURMONTIL, TRIMIPRAMINE MALEATE
SURVANTA, BERACTANT
SUS-PHRINE SULFITE-FREE, EPINEPHRINE
SUSTAIRE, THEOPHYLLINE
SUSTIVA, EFAVIRENZ
SYMADINE, AMANTADINE HYDROCHLORIDE
SYMBYAX, FLUOXETINE HYDROCHLORIDE
SYMMETREL, AMANTADINE HYDROCHLORIDE
SYNACORT, HYDROCORTISONE
SYNALAR, FLUOCINOLONE ACETONIDE
SYNALAR-HP, FLUOCINOLONE ACETONIDE
SYNALGOS-DC, ASPIRIN
SYNALGOS-DC-A, ACETAMINOPHEN
SYNAREL, NAFARELIN ACETATE
SYNCURINE, DECAMETHONIUM BROMIDE
SYNERCID, DALFOPRISTIN
SYNKAYVITE, MENADIOL SODIUM DIPHOSPHATE
SYNOPHYLATE, THEOPHYLLINE SODIUM GLYCINATE
SYNOVALYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
SYNTHROID, LIOTRIX (T4;T3)
SYNTOCINON, OXYTOCIN
SYPRINE, TRIENTINE HYDROCHLORIDE

** T **

T-PHYL, THEOPHYLLINE
T-STAT, ERYTHROMYCIN
TAB-PROFEN, IBUPROFEN (OTC)
TACARYL, METHDILAZINE
TACARYL, METHDILAZINE HYDROCHLORIDE
TACE, CHLOROTRIANISENE
TAGAMET HB 200, CIMETIDINE (OTC)
TAGAMET HB, CIMETIDINE (OTC)
TAGAMET HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIMETIDINE HYDROCHLORIDE
TAGAMET, CIMETIDINE
TAGAMET, CIMETIDINE HYDROCHLORIDE
TALACEN, ACETAMINOPHEN
TALC, TALC
TALWIN 50, PENTAZOCINE HYDROCHLORIDE
TALWIN COMPOUND, ASPIRIN
TALWIN NX, NALOXONE HYDROCHLORIDE
TALWIN, PENTAZOCINE LACTATE
TAMBOCOR, FLECAINIDE ACETATE
TAMIFLU, OSELTAMIVIR PHOSPHATE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TANDEARIL, OXYPHENBUTAZONE
TAO, TROLEANDOMYCIN
TAPAZOLE, METHIMAZOLE
TARACTAN, CHLORPROTHIXENE
TARGRETIN, BEXAROTENE
TARKA, TRANDOLAPRIL
TASMAR, TOLCAPONE
TATUM-T, COPPER

FDA data supplied by DrugPatentWatch.com

TAVIST ALLERGY/SINUS/HEADACHE, ACETAMINOPHEN (OTC)
TAVIST D, CLEMASTINE FUMARATE
TAVIST, CLEMASTINE FUMARATE
TAVIST-1, CLEMASTINE FUMARATE
TAVIST-1, CLEMASTINE FUMARATE (OTC)
TAVIST-D, CLEMASTINE FUMARATE (OTC)
TAXOL, PACLITAXEL
TAXOTERE, DOCETAXEL
TAZICEF, CEFTAZIDIME
TAZIDIME IN PLASTIC CONTAINER, CEFTAZIDIME
TAZIDIME, CEFTAZIDIME
TAZORAC, TAZAROTENE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE
TC 99M-LUNGAGGREGATE, TECHNETIUM TC-99M ALBUMIN AGGREGATED
TECHNECOLL, TECHNETIUM TC-99M SULFUR COLLOID KIT
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNESCAN GLUCEPTATE, TECHNETIUM TC-99M GLUCEPTATE KIT
TECHNESCAN HDP, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNESCAN HIDA, TECHNETIUM TC-99M LIDOFENIN KIT
TECHNESCAN MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN MDP KIT, TECHNETIUM TC-99M MEDRONATE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT, TECHNETIUM TC-99M ETIDRONATE KIT
TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNETIUM TC 99M HSA, TECHNETIUM TC-99M ALBUMIN KIT
TECHNETIUM TC 99M MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M MPI MDP, TECHNETIUM TC-99M MEDRONATE KIT
TECHNETIUM TC 99M SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID
TECHNETIUM TC 99M TSC, TECHNETIUM TC-99M SULFUR COLLOID KIT
TECHNETIUM TC-99M PENTETATE KIT, TECHNETIUM TC-99M PENTETATE KIT
TECZEM, DILTIAZEM MALATE
TEEBACIN, AMINOSALICYLATE SODIUM
TEGISON, ETRETINATE
TEGOPEN, CLOXACILLIN SODIUM
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TELDRIN, CHLORPHENIRAMINE MALEATE (OTC)
TELEPAQUE, IOPANOIC ACID
TEMARIL, TRIMEPRAZINE TARTRATE
TEMAZ, TEMAZEPAM
TEMAZEPAM, TEMAZEPAM
TEMODAR, TEMOZOLOMIDE
TEMOVATE E, CLOBETASOL PROPIONATE
TEMOVATE, CLOBETASOL PROPIONATE
TEN-K, POTASSIUM CHLORIDE
TENATHAN, BETHANIDINE SULFATE
TENCON, ACETAMINOPHEN
TENEX, GUANFACINE HYDROCHLORIDE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TENSILON PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
TENSILON, EDROPHONIUM CHLORIDE
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
TENUATE, DIETHYLPROPION HYDROCHLORIDE
TEPANIL TEN-TAB, DIETHYLPROPION HYDROCHLORIDE
TEPANIL, DIETHYLPROPION HYDROCHLORIDE
TEQUIN, GATIFLOXACIN
TERAZOL 3, TERCONAZOLE
TERAZOL 7, TERCONAZOLE
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TERFONYL, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
TERIL, CARBAMAZEPINE
TERRA-CORTRIL, HYDROCORTISONE ACETATE
TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN W/ POLYMYXIN, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN, LIDOCAINE HYDROCHLORIDE
TERRAMYCIN, OXYTETRACYCLINE
TERRAMYCIN, OXYTETRACYCLINE CALCIUM
TERRAMYCIN, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN-POLYMYXIN, OXYTETRACYCLINE HYDROCHLORIDE
TESLAC, TESTOLACTONE
TESLASCAN, MANGAFODIPIR TRISODIUM
TESSALON, BENZONATATE
TESTIM, TESTOSTERONE
TESTODERM TTS, TESTOSTERONE
TESTODERM, TESTOSTERONE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE, ESTRADIOL VALERATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
TESTOSTERONE, TESTOSTERONE
TESTRED, METHYLTESTOSTERONE
TESULOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
TETRACHEL, TETRACYCLINE HYDROCHLORIDE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TETRACYN, PROCAINE HYDROCHLORIDE
TETRACYN, TETRACYCLINE HYDROCHLORIDE
TETRAMED, TETRACYCLINE HYDROCHLORIDE
TETREX, TETRACYCLINE PHOSPHATE COMPLEX
TEV-TROPIN, SOMATROPIN RECOMBINANT
TEVETEN HCT, EPROSARTAN MESYLATE

FDA data supplied by DrugPatentWatch.com

TEVETEN, EPROSARTAN MESYLATE
TEXACORT, HYDROCORTISONE
THALITONE, CHLORTHALIDONE
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201
THALOMID, THALIDOMIDE
THAM, TROMETHAMINE
THAM-E, POTASSIUM CHLORIDE
THEELIN, ESTRONE
THEO-24, THEOPHYLLINE
THEO-DUR, THEOPHYLLINE
THEOBID JR., THEOPHYLLINE
THEOBID, THEOPHYLLINE
THEOCHRON, THEOPHYLLINE
THEOCLEAR L.A.-130, THEOPHYLLINE
THEOCLEAR L.A.-260, THEOPHYLLINE
THEOCLEAR-100, THEOPHYLLINE
THEOCLEAR-200, THEOPHYLLINE
THEOCLEAR-80, THEOPHYLLINE
THEOLAIR, THEOPHYLLINE
THEOLAIR-SR, THEOPHYLLINE
THEOLIXIR, THEOPHYLLINE
THEOPHYL, THEOPHYLLINE
THEOPHYL-225, THEOPHYLLINE
THEOPHYL-SR, THEOPHYLLINE
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE
THEOPHYLLINE-SR, THEOPHYLLINE
THEOVENT, THEOPHYLLINE
THERMAZENE, SILVER SULFADIAZINE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
THIOGUANINE, THIOGUANINE
THIOPLEX, THIOTEPA
THIORIDAZINE HCL INTENSOL, THIORIDAZINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOSULFIL, SULFAMETHIZOLE
THIOTEPA, THIOTEPA
THIOTHIXENE HCL INTENSOL, THIOTHIXENE HYDROCHLORIDE
THIOTHIXENE HCL, THIOTHIXENE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
THORAZINE, CHLORPROMAZINE
THORAZINE, CHLORPROMAZINE HYDROCHLORIDE
THYPINONE, PROTIRELIN
THYREL TRH, PROTIRELIN
THYRO-BLOCK, POTASSIUM IODIDE (OTC)
THYRO-TABS, LIOTRIX (T4;T3)
THYROGEN, THYROTROPIN ALFA
THYROGLOBULIN, THYROGLOBULIN
THYROLAR-0.25, LIOTRIX (T4;T3)
THYROLAR-0.5, LIOTRIX (T4;T3)
THYROLAR-1, LIOTRIX (T4;T3)
THYROLAR-2, LIOTRIX (T4;T3)
THYROLAR-3, LIOTRIX (T4;T3)
THYROLAR-5, LIOTRIX (T4;T3)
THYROSAFE, POTASSIUM IODIDE (OTC)
THYTROPAR, THYROTROPIN
TIAMATE, DILTIAZEM MALATE
TIAZAC, DILTIAZEM HYDROCHLORIDE
TICAR, TICARCILLIN DISODIUM
TICLID, TICLOPIDINE HYDROCHLORIDE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TIKOSYN, DOFETILIDE
TILADE, NEDOCROMIL SODIUM
TIMENTIN IN PLASTIC CONTAINER, CLAVULANATE POTASSIUM
TIMENTIN, CLAVULANATE POTASSIUM
TIMOLIDE 10-25, HYDROCHLOROTHIAZIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
TINDAL, ACETOPHENAZINE MALEATE
TIOCONAZOLE, TIOCONAZOLE (OTC)
TIOPRONIN, TIOPRONIN
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIS-U-SOL, MAGNESIUM SULFATE
TIZANIDINE HCL, TIZANIDINE HYDROCHLORIDE
TOBI, TOBRAMYCIN
TOBRADEX, DEXAMETHASONE
TOBRAMYCIN (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN
TOBRAMYCIN, TOBRAMYCIN SULFATE
TOBRASONE, FLUOROMETHOLONE ACETATE
TOBREX, TOBRAMYCIN
TODAY, NONOXYNOL-9 (OTC)
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOFRANIL-PM, IMIPRAMINE PAMOATE
TOLAZAMIDE, TOLAZAMIDE

FDA data supplied by DrugPatentWatch.com

TOLBUTAMIDE, TOLBUTAMIDE
TOLECTIN 600, TOLMETIN SODIUM
TOLECTIN DS, TOLMETIN SODIUM
TOLECTIN, TOLMETIN SODIUM
TOLINASE, TOLAZAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TONOCARD, TOCAINIDE HYDROCHLORIDE
TOPAMAX SPRINKLE, TOPIRAMATE
TOPAMAX, TOPIRAMATE
TOPICORT LP, DESOXIMETASONE
TOPICORT, DESOXIMETASONE
TOPICYCLINE, TETRACYCLINE HYDROCHLORIDE
TOPOSAR, ETOPOSIDE
TOPROL-XL, METOPROLOL SUCCINATE
TORA, PHENTERMINE HYDROCHLORIDE
TORADOL, KETOROLAC TROMETHAMINE
TORECAN, THIETHYLPERAZINE MALATE
TORECAN, THIETHYLPERAZINE MALEATE
TORNALATE, BITOLTEROL MESYLATE
TORSEMIDE, TORSEMIDE
TOTACILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
TOTACILLIN-N, AMPICILLIN SODIUM
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TPN SUSPENSION, NIACINAMIDE
TRACLEER, BOSENTAN
TRACRIUM PRESERVATIVE FREE, ATRACURIUM BESYLATE
TRACRIUM, ATRACURIUM BESYLATE
TRAL, HEXOCYCLIUM METHYLSULFATE
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE
TRANCOPAL, CHLORMEZANONE
TRANDATE HCT, HYDROCHLOROTHIAZIDE
TRANDATE, LABETALOL HYDROCHLORIDE
TRANMEP, MEPROBAMATE
TRANSDERM SCOP, SCOPOLAMINE
TRANSDERM-NITRO, NITROGLYCERIN
TRANXENE SD, CLORAZEPATE DIPOTASSIUM
TRANXENE, CLORAZEPATE DIPOTASSIUM
TRASICOR, OXPRENOLOL HYDROCHLORIDE
TRASYLOL, APROTININ BOVINE
TRAVAMULSION 10%, SOYBEAN OIL
TRAVAMULSION 20%, SOYBEAN OIL
TRAVASE, SUTILAINS
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 10% W/O ELECTROLYTES, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 3.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 5.5% W/O ELECTROLYTES, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 8.5% W/O ELECTROLYTES, AMINO ACIDS
TRAVATAN, TRAVOPROST
TRAVERT 10% IN PLASTIC CONTAINER, INVERT SUGAR
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRECATOR-SC, ETHIONAMIDE
TRELSTAR DEPOT, TRIPTORELIN PAMOATE
TRELSTAR, TRIPTORELIN PAMOATE
TREMIN, TRIHEXYPHENIDYL HYDROCHLORIDE
TRENTAL, PENTOXIFYLLINE
TREST, METHIXENE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

TRETINOIN, TRETINOIN
TREXALL, METHOTREXATE SODIUM
TRI-LUMA, FLUOCINOLONE ACETONIDE
TRI-NASAL, TRIAMCINOLONE ACETONIDE
TRI-NORINYL 21-DAY, ETHINYL ESTRADIOL
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRI-SPRINTEC, ETHINYL ESTRADIOL
TRIACET, TRIAMCINOLONE ACETONIDE
TRIACIN-C, CODEINE PHOSPHATE
TRIACORT, TRIAMCINOLONE ACETONIDE
TRIAD, ACETAMINOPHEN
TRIALODINE, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE DIACETATE, TRIAMCINOLONE DIACETATE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMINIC-12, CHLORPHENIRAMINE MALEATE (OTC)
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAPRIN, ACETAMINOPHEN
TRIATEX, TRIAMCINOLONE ACETONIDE
TRIAVIL 2-10, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 2-25, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-10, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-25, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-50, AMITRIPTYLINE HYDROCHLORIDE
TRIAZOLAM, TRIAZOLAM
TRICHLOREX, TRICHLORMETHIAZIDE
TRICHLORMAS, TRICHLORMETHIAZIDE
TRICHLORMETHIAZIDE W/ RESERPINE, RESERPINE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
TRICLOS, TRICLOFOS SODIUM
TRICOR (MICRONIZED), FENOFIBRATE
TRICOR, FENOFIBRATE
TRIDERM, TRIAMCINOLONE ACETONIDE
TRIDESILON, ACETIC ACID, GLACIAL
TRIDESILON, DESONIDE
TRIDIL, NITROGLYCERIN
TRIDIONE, TRIMETHADIONE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
TRIFLURIDINE, TRIFLURIDINE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRILAFON, PERPHENAZINE
TRILEPTAL, OXCARBAZEPINE
TRILITRON, PSEUDOEPHEDRINE HYDROCHLORIDE
TRIMEPRAZINE TARTRATE, TRIMEPRAZINE TARTRATE
TRIMETH/SULFA, SULFAMETHOXAZOLE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TRIMETHOPRIM, TRIMETHOPRIM
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
TRIMOX, AMOXICILLIN
TRIMPEX 200, TRIMETHOPRIM
TRIMPEX, TRIMETHOPRIM
TRINALIN, AZATADINE MALEATE
TRIOSTAT, LIOTRIX (T4;T3)
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
TRIPHASIL-21, ETHINYL ESTRADIOL
TRIPHASIL-28, ETHINYL ESTRADIOL
TRIPHED, PSEUDOEPHEDRINE HYDROCHLORIDE
TRIPLE SULFA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
TRIPLE SULFA, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TRIPLE SULFAS, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TRIPLE SULFOID, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE, CODEINE PHOSPHATE
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
TRIPROLIDINE AND PSEUDOEPHEDRINE, PSEUDOEPHEDRINE HYDROCHLORIDE
TRIPROLIDINE AND PSEUDOEPHEDRINE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE
TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE
TRISENOX, ARSENIC TRIOXIDE
TRISORALEN, TRIOXSALEN
TRITEC, RANITIDINE BISMUTH CITRATE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
TRIVORA-21, ETHINYL ESTRADIOL
TRIVORA-28, ETHINYL ESTRADIOL
TRIZIVIR, ABACAVIR SULFATE
TROBICIN, SPECTINOMYCIN HYDROCHLORIDE
TROPHAMINE 10%, AMINO ACIDS
TROPHAMINE, AMINO ACIDS
TROPICACYL, TROPICAMIDE
TROPICAMIDE, TROPICAMIDE
TROVAN PRESERVATIVE FREE, ALATROFLOXACIN MESYLATE
TROVAN, TROVAFLOXACIN MESYLATE
TROVAN/ZITHROMAX COMPLIANCE PAK, AZITHROMYCIN DIHYDRATE
TRUPHYLLINE, AMINOPHYLLINE
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
TRYMEX, TRIAMCINOLONE ACETONIDE
TRYSUL, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
TUBOCURARINE CHLORIDE, TUBOCURARINE CHLORIDE
TURGEX, HEXACHLOROPHENE
TUSSIGON, HOMATROPINE METHYLBROMIDE
TUSSIONEX, CHLORPHENIRAMINE POLISTIREX

FDA data supplied by DrugPatentWatch.com

TWINJECT, EPINEPHRINE
TYCOLET, ACETAMINOPHEN
TYLENOL (CAPLET), ACETAMINOPHEN (OTC)
TYLENOL (GELTAB), ACETAMINOPHEN (OTC)
TYLENOL W/ CODEINE NO. 1, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 2, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
TYLENOL W/ CODEINE, ACETAMINOPHEN
TYLENOL, ACETAMINOPHEN (OTC)
TYLOX, ACETAMINOPHEN
TYLOX-325, ACETAMINOPHEN
TYMTRAN, CERULETIDE DIETHYLAMINE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE
TZ-3, TIOCONAZOLE (OTC)

** U **

U-CORT, HYDROCORTISONE ACETATE
U-GENCIN, GENTAMICIN SULFATE
UCEPHAN, SODIUM BENZOATE
ULO, CHLOPHEDIANOL HYDROCHLORIDE
ULTANE, SEVOFLURANE
ULTIVA, REMIFENTANIL HYDROCHLORIDE
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRACEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE
ULTRACET, ACETAMINOPHEN
ULTRAGRIS-165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
ULTRAGRIS-330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
ULTRALENTE INSULIN, INSULIN ZINC SUSP EXTENDED BEEF (OTC)
ULTRALENTE, INSULIN ZINC SUSP EXTENDED PURIFIED BEEF (OTC)
ULTRAM, TRAMADOL HYDROCHLORIDE
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
ULTRAVATE, HALOBETASOL PROPIONATE
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 150, IOPROMIDE
ULTRAVIST 240, IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
UNASYN, AMPICILLIN SODIUM
UNI-DUR, THEOPHYLLINE
UNIPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
UNIPEN, NAFCILLIN SODIUM
UNIPHYL, THEOPHYLLINE
UNIPRES, HYDRALAZINE HYDROCHLORIDE
UNIRETIC, HYDROCHLOROTHIAZIDE
UNISOM, DOXYLAMINE SUCCINATE (OTC)
UNITENSEN, CRYPTENAMINE ACETATES
UNITENSEN, CRYPTENAMINE TANNATES
UNITHROID, LIOTRIX (T4;T3)
UNIVASC, MOEXIPRIL HYDROCHLORIDE
URACIL MUSTARD, URACIL MUSTARD
UREAPHIL, UREA
URECHOLINE, BETHANECHOL CHLORIDE
URESE, BENZTHIAZIDE
UREX, METHENAMINE HIPPURATE
URISPAS, FLAVOXATE HYDROCHLORIDE
UROBAK, SULFAMETHOXAZOLE
UROLOGIC G IN PLASTIC CONTAINER, CITRIC ACID
UROPLUS DS, SULFAMETHOXAZOLE
UROPLUS SS, SULFAMETHOXAZOLE
UROVIST CYSTO PEDIATRIC, DIATRIZOATE MEGLUMINE
UROVIST CYSTO, DIATRIZOATE MEGLUMINE
UROVIST MEGLUMINE DIU/CT, DIATRIZOATE MEGLUMINE
UROVIST SODIUM 300, DIATRIZOATE SODIUM
UROXATRAL, ALFUZOSIN HYDROCHLORIDE
URSO, URSODIOL
URSODIOL, URSODIOL
UTICILLIN VK, PENICILLIN V POTASSIUM
UTICORT, BETAMETHASONE BENZOATE
UTIMOX, AMOXICILLIN
UVADEX, METHOXSALEN

** V **

V-CILLIN K, PENICILLIN V POTASSIUM
V-CILLIN, PENICILLIN V
VAGIFEM, ESTRADIOL
VAGILIA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
VAGISTAT-1, TIOCONAZOLE (OTC)
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
VALISONE, BETAMETHASONE VALERATE
VALIUM, DIAZEPAM
VALMID, ETHINAMATE
VALNAC, BETAMETHASONE VALERATE
VALPIN 50, ANISOTROPINE METHYLBROMIDE
VALPROATE SODIUM, VALPROATE SODIUM
VALPROIC ACID, VALPROIC ACID
VALRELEASE, DIAZEPAM
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VANCENASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
VANCENASE, BECLOMETHASONE DIPROPIONATE
VANCERIL DOUBLE STRENGTH, BECLOMETHASONE DIPROPIONATE
VANCERIL, BECLOMETHASONE DIPROPIONATE
VANCOCIN HCL IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANCOCIN HCL, VANCOMYCIN HYDROCHLORIDE
VANCOLED, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
VANCOR, VANCOMYCIN HYDROCHLORIDE
VANIQA, EFLORNITHINE HYDROCHLORIDE
VANOBID, CANDICIDIN
VANSIL, OXAMNIQUINE
VANTIN, CEFPODOXIME PROXETIL

FDA data supplied by DrugPatentWatch.com

VAPO-ISO, ISOPROTERENOL HYDROCHLORIDE
VASCOR, BEPRIDIL HYDROCHLORIDE
VASCORAY, IOTHALAMATE MEGLUMINE
VASERETIC, ENALAPRIL MALEATE
VASOCIDIN, PREDNISOLONE ACETATE
VASOCIDIN, PREDNISOLONE SODIUM PHOSPHATE
VASOCON, NAPHAZOLINE HYDROCHLORIDE
VASOCON-A, ANTAZOLINE PHOSPHATE (OTC)
VASOTEC, ENALAPRIL MALEATE
VASOTEC, ENALAPRILAT
VASOXYL, METHOXAMINE HYDROCHLORIDE
VECTRIN, MINOCYCLINE HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VEETIDS '125', PENICILLIN V POTASSIUM
VEETIDS '250', PENICILLIN V POTASSIUM
VEETIDS '500', PENICILLIN V POTASSIUM
VEETIDS, PENICILLIN V POTASSIUM
VEINAMINE 8%, AMINO ACIDS
VELBAN, VINBLASTINE SULFATE
VELCADE, BORTEZOMIB
VELOSEF '125', CEPHRADINE
VELOSEF '250', CEPHRADINE
VELOSEF '500', CEPHRADINE
VELOSEF, CEPHRADINE
VELOSULIN BR HUMAN, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
VELOSULIN BR, INSULIN RECOMBINANT HUMAN (OTC)
VELOSULIN, INSULIN PURIFIED PORK (OTC)
VENOFER, IRON SUCROSE
VENTAIRE, PROTOKYLOL HYDROCHLORIDE
VENTOLIN HFA, ALBUTEROL SULFATE
VENTOLIN ROTACAPS, ALBUTEROL SULFATE
VENTOLIN, ALBUTEROL
VENTOLIN, ALBUTEROL SULFATE
VEPESID, ETOPOSIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VERCYTE, PIPOBROMAN
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERELAN, VERAPAMIL HYDROCHLORIDE
VERILOID, ALKAVERVIR
VERMIDOL, PIPERAZINE CITRATE
VERMOX, MEBENDAZOLE
VERSAPEN, HETACILLIN
VERSAPEN-K, HETACILLIN POTASSIUM
VERSED, MIDAZOLAM HYDROCHLORIDE
VERTAVIS, VERATRUM VIRIDE
VESANOID, TRETINOIN
VESPRIN, TRIFLUPROMAZINE
VESPRIN, TRIFLUPROMAZINE HYDROCHLORIDE
VEXOL, RIMEXOLONE
VFEND, VORICONAZOLE
VI-DOM-A, VITAMIN A PALMITATE
VI-TWEL, CYANOCOBALAMIN
VIADUR, LEUPROLIDE ACETATE
VIAGRA, SILDENAFIL CITRATE
VIBISONE, CYANOCOBALAMIN
VIBRA-TABS, DOXYCYCLINE HYCLATE
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VICKS FORMULA 44, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
VICODIN ES, ACETAMINOPHEN
VICODIN HP, ACETAMINOPHEN
VICODIN, ACETAMINOPHEN
VICOPRIN, ASPIRIN
VICOPROFEN, HYDROCODONE BITARTRATE
VIDEX EC, DIDANOSINE
VIDEX, DIDANOSINE
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCASAR PFS, VINCRISTINE SULFATE
VINCREX, VINCRISTINE SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINCRISTINE SULFATE, VINCRISTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
VIOCIN SULFATE, VIOMYCIN SULFATE
VIOXX, ROFECOXIB
VIRA-A, VIDARABINE
VIRAC REX, UNDECOYLIUM CHLORIDE
VIRACEPT, NELFINAVIR MESYLATE
VIRAMUNE, NEVIRAPINE
VIRAZOLE, RIBAVIRIN
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VIRILON, METHYLTESTOSTERONE
VIROPTIC, TRIFLURIDINE
VISICOL, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VISKAZIDE, HYDROCHLOROTHIAZIDE
VISKEN, PINDOLOL
VISTARIL, HYDROXYZINE HYDROCHLORIDE
VISTARIL, HYDROXYZINE PAMOATE
VISTIDE, CIDOFOVIR
VISUDYNE, VERTEPORFIN
VITAMIN A PALMITATE, VITAMIN A PALMITATE
VITAMIN A SOLUBILIZED, VITAMIN A PALMITATE
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL
VITAMIN K1, PHYTONADIONE
VITAPED, ASCORBIC ACID
VITRASERT, GANCICLOVIR
VITRAVENE PRESERVATIVE FREE, FOMIVIRSEN SODIUM
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE
VIVELLE, ESTRADIOL

FDA data supplied by DrugPatentWatch.com

VIVELLE-DOT, ESTRADIOL
VOLMAX, ALBUTEROL SULFATE
VOLTAREN, DICLOFENAC SODIUM
VOLTAREN-XR, DICLOFENAC SODIUM
VONTROL, DIPHENIDOL HYDROCHLORIDE
VOSOL HC, ACETIC ACID, GLACIAL
VOSOL, ACETIC ACID, GLACIAL
VUMON, TENIPOSIDE

** W **

WAMPOCAP, NIACIN
WARFARIN SODIUM, WARFARIN SODIUM
WELCHOL, COLESEVELAM HYDROCHLORIDE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
WELLBUTRIN, BUPROPION HYDROCHLORIDE
WELLCOVORIN, LEUCOVORIN CALCIUM
WESTADONE, METHADONE HYDROCHLORIDE
WESTCORT, HYDROCORTISONE VALERATE
WIGRAINE, CAFFEINE
WIGRETTES, ERGOTAMINE TARTRATE
WINSTROL, STANOZOLOL
WOLFINA, RAUWOLFIA SERPENTINA
WYAMINE SULFATE, MEPHENTERMINE SULFATE
WYAMYCIN E, ERYTHROMYCIN ETHYLSUCCINATE
WYAMYCIN S, ERYTHROMYCIN STEARATE
WYCILLIN, PENICILLIN G PROCAINE
WYDASE, HYALURONIDASE
WYGESIC, ACETAMINOPHEN
WYMOX, AMOXICILLIN
WYTENSIN, GUANABENZ ACETATE

** X **

X-TROZINE L.A., PHENDIMETRAZINE TARTRATE
X-TROZINE, PHENDIMETRAZINE TARTRATE
XALATAN, LATANOPROST
XANAX XR, ALPRAZOLAM
XANAX, ALPRAZOLAM
XELODA, CAPECITABINE
XENEISOL, XENON, XE-133
XENICAL, ORLISTAT
XENON XE 127, XENON, XE-127
XENON XE 133, XENON, XE-133
XENON XE 133-V.S.S., XENON, XE-133
XOPENEX, LEVALBUTEROL HYDROCHLORIDE
XYLO-PFAN, XYLOSE
XYLOCAINE 1.5% W/ DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE 5% W/ GLUCOSE 7.5%, LIDOCAINE HYDROCHLORIDE
XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYLOCAINE, LIDOCAINE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
XYLOSE, XYLOSE
XYREM, SODIUM OXYBATE

** Y **

YASMIN, DROSPIRENONE
YTTERBIUM YB 169 DTPA, PENTETATE CALCIUM TRISODIUM YB-169
YUTOPAR, RITODRINE HYDROCHLORIDE

** Z **

ZADITOR, KETOTIFEN FUMARATE
ZAGAM, SPARFLOXACIN
ZANAFLEX, TIZANIDINE HYDROCHLORIDE
ZANOSAR, STREPTOZOCIN
ZANTAC 150, RANITIDINE HYDROCHLORIDE
ZANTAC 300, RANITIDINE HYDROCHLORIDE
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
ZANTAC IN PLASTIC CONTAINER, RANITIDINE HYDROCHLORIDE
ZANTAC, RANITIDINE HYDROCHLORIDE
ZARONTIN, ETHOSUXIMIDE
ZAROXOLYN, METOLAZONE
ZAVESCA, MIGLUSTAT
ZAXOPAM, OXAZEPAM
ZEBETA, BISOPROLOL FUMARATE
ZEFAZONE IN PLASTIC CONTAINER, CEFMETAZOLE SODIUM
ZEFAZONE, CEFMETAZOLE SODIUM
ZELNORM, TEGASEROD MALEATE
ZEMPLAR, PARICALCITOL
ZEMURON (P/F), ROCURONIUM BROMIDE
ZEMURON, ROCURONIUM BROMIDE
ZERIT XR, STAVUDINE
ZERIT, STAVUDINE
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL
ZETIA, EZETIMIBE
ZIAC, BISOPROLOL FUMARATE
ZIAGEN, ABACAVIR SULFATE
ZIBA-RX, BACITRACIN ZINC
ZIDE, HYDROCHLOROTHIAZIDE
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
ZINACEF, CEFUROXIME SODIUM
ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE, BACITRACIN ZINC
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
ZINC SULFATE, ZINC SULFATE
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZIPAN-25, PROMETHAZINE HYDROCHLORIDE
ZIPAN-50, PROMETHAZINE HYDROCHLORIDE
ZITHROMAX, AZITHROMYCIN

FDA data supplied by DrugPatentWatch.com

ZOCOR, SIMVASTATIN
ZOFRAN IN PLASTIC CONTAINER, ONDANSETRON HYDROCHLORIDE
ZOFRAN ODT, ONDANSETRON
ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOLADEX, GOSERELIN ACETATE
ZOLOFT, SERTRALINE HYDROCHLORIDE
ZOLYSE, CHYMOTRYPSIN
ZOMETA, ZOLEDRONIC ACID
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
ZONALON, DOXEPIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE
ZORBTIVE, SOMATROPIN
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOSYN, PIPERACILLIN SODIUM
ZOVIA 1/35E-21, ETHINYL ESTRADIOL
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-21, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
ZOVIRAX, ACYCLOVIR
ZOVIRAX, ACYCLOVIR SODIUM
ZYBAN, BUPROPION HYDROCHLORIDE
ZYFLO, ZILEUTON
ZYLOPRIM, ALLOPURINOL
ZYMAR, GATIFLOXACIN
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE
ZYRTEC, CETIRIZINE HYDROCHLORIDE
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE
ZYVOX, LINEZOLID

FDA data supplied by DrugPatentWatch.com

FDA data supplied by DrugPatentWatch.com

** 3 **

3M
* 3M CO
SCRUBTEAM SURGICAL SPONGEBRUSH, HEXACHLOROPHENE
* 3M HEALTH CARE INC
AVAGARD, ALCOHOL (OTC)
* 3M MEDICAL PRODUCTS DIV
INSTANT MICROSPHERES, TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT
YTTERBIUM YB 169 DTPA, PENTETATE CALCIUM TRISODIUM YB-169
* 3M PHARMACEUTICALS INC
ALDARA, IMIQUIMOD
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
CIRCANOL, ERGOLOID MESYLATES
DISIPAL, ORPHENADRINE HYDROCHLORIDE
DUO-MEDIHALER, ISOPROTERENOL HYDROCHLORIDE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
LIPO-HEPIN, HEPARIN SODIUM
MAXAIR, PIRBUTEROL ACETATE
MEDIHALER ERGOTAMINE, ERGOTAMINE TARTRATE
MEDIHALER-EPI, EPINEPHRINE BITARTRATE (OTC)
MEDIHALER-ISO, ISOPROTERENOL SULFATE
METROGEL-VAGINAL, METRONIDAZOLE
MINITRAN, NITROGLYCERIN
NORFLEX, ORPHENADRINE CITRATE
NORGESIC FORTE, ASPIRIN
NORGESIC, ASPIRIN
PROVENTIL-HFA, ALBUTEROL SULFATE
QVAR 40, BECLOMETHASONE DIPROPIONATE
QVAR 80, BECLOMETHASONE DIPROPIONATE
RAUWILOID, ALSEROXYLON
SODIUM VERSENATE, EDETATE DISODIUM
TAMBOCOR, FLECAINIDE ACETATE
TEPANIL TEN-TAB, DIETHYLPROPION HYDROCHLORIDE
TEPANIL, DIETHYLPROPION HYDROCHLORIDE
THEOLAIR, THEOPHYLLINE
THEOLAIR-SR, THEOPHYLLINE
ULO, CHLOPHEDIANOL HYDROCHLORIDE
UREX, METHENAMINE HIPPURATE
VERILOID, ALKAVERVIR

** A **

AAIPHARMA
* AAIPHARMA INC
DARVOCET A500, ACETAMINOPHEN
DURACLON, CLONIDINE HYDROCHLORIDE
ORAMORPH SR, MORPHINE SULFATE
ROXICODONE, OXYCODONE HYDROCHLORIDE

AAIPHARMA LLC
* AAIPHARMA LLC
ACYCLOVIR, ACYCLOVIR
AQUASOL A, VITAMIN A PALMITATE
AZASAN, AZATHIOPRINE
BRETHINE, TERBUTALINE SULFATE
CALCITRIOL, CALCITRIOL
DARVOCET, ACETAMINOPHEN
DARVOCET-N 100, ACETAMINOPHEN
DARVOCET-N 50, ACETAMINOPHEN
DARVON COMPOUND, ASPIRIN
DARVON COMPOUND-65, ASPIRIN
DARVON W/ ASA, ASPIRIN
DARVON, PROPOXYPHENE HYDROCHLORIDE
DARVON-N W/ ASA, ASPIRIN
DARVON-N, PROPOXYPHENE NAPSYLATE
DOLOPHINE HCL, METHADONE HYDROCHLORIDE
ETODOLAC, ETODOLAC
KETOCONAZOLE, KETOCONAZOLE
M.V.I. PEDIATRIC, ASCORBIC ACID
M.V.I.-12, ASCORBIC ACID
SELEGELINE HCL, SELEGILINE HYDROCHLORIDE

AB GENERICS
* AB GENERICS LP
MORPHINE SULFATE, MORPHINE SULFATE

ABANA
* ABANA PHARMACEUTICALS INC
NORCET, ACETAMINOPHEN

ABBOTT
* ABBOTT LABORATORIES
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR SODIUM
AKINETON, BIPERIDEN HYDROCHLORIDE
AKINETON, BIPERIDEN LACTATE
ALCOHOL 5% IN D5-W, ALCOHOL
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
AMIDATE, ETOMIDATE
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, AMIKACIN SULFATE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN 10% (PH6), AMINO ACIDS
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 3.5%, AMINO ACIDS
AMINOSYN 5%, AMINO ACIDS
AMINOSYN 7% (PH6), AMINO ACIDS

FDA data supplied by DrugPatentWatch.com

AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 7%, AMINO ACIDS
AMINOSYN 8.5% (PH6), AMINO ACIDS
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN II 10%, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5%, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5%, AMINO ACIDS
AMINOSYN II 7%, AMINO ACIDS
AMINOSYN II 8.5%, AMINO ACIDS
AMINOSYN-HF 8%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
AMINOSYN-RF 5.2%, AMINO ACIDS
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMPHOTERICIN B, AMPHOTERICIN B
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATROPINE AND DEMEROL, ATROPINE SULFATE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
BIAXIN XL, CLARITHROMYCIN
BIAXIN, CLARITHROMYCIN
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
BUMETANIDE, BUMETANIDE
BUPIVACAINE HCL KIT, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HCL, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE, BUPIVACAINE HYDROCHLORIDE
BUPRENORPHINE HCL, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARTROL, CARTEOLOL HYDROCHLORIDE
CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIMETIDINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CYCLOSPORINE, CYCLOSPORINE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIAZEPAM, DIAZEPAM
DIGOXIN PEDIATRIC, DIGOXIN
DIGOXIN, DIGOXIN
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HCL IN DEXTROSE 5%, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL IN DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
EDROPHONIUM CHLORIDE, EDROPHONIUM CHLORIDE
ENALAPRILAT, ENALAPRILAT
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FUROSEMIDE, FUROSEMIDE
GENGRAF, CYCLOSPORINE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROMORPHONE HCL, HYDROMORPHONE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

FDA data supplied by DrugPatentWatch.com

IOPAMIDOL-200 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-200, IOPAMIDOL
IOPAMIDOL-250 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370 IN PLASTIC CONTAINER, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL
ISOFLURANE, ISOFLURANE
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
KALETRA, LOPINAVIR
KETAMINE HCL, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVOPHED, NOREPINEPHRINE BITARTRATE
LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIPOSYN II 20%, SAFFLOWER OIL
LIPOSYN III 10%, SOYBEAN OIL
LIPOSYN III 20%, SOYBEAN OIL
LORAZEPAM, LORAZEPAM
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MARCAINE HCL PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HCL, BUPIVACAINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER, MIVACURIUM CHLORIDE
MIVACRON, MIVACURIUM CHLORIDE
NALBUPHINE HCL, NALBUPHINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROGLYCERIN, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
NORVIR, RITONAVIR
NOVOCAIN, PROCAINE HYDROCHLORIDE
NUROMAX, DOXACURIUM CHLORIDE
OMNICEF, CEFDINIR
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
PRECEDEX, DEXMEDETOMIDINE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
QUELICIN, SUCCINYLCHOLINE CHLORIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, RITODRINE HYDROCHLORIDE
SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE, ANHYDROUS
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFENTANIL CITRATE, SUFENTANIL CITRATE
SYNTHROID, LIOTRIX (T4;T3)
TALWIN, PENTAZOCINE LACTATE
TAZICEF, CEFTAZIDIME
THIAMINE HCL, THIAMINE HYDROCHLORIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRACRIUM PRESERVATIVE FREE, ATRACURIUM BESYLATE
TRACRIUM, ATRACURIUM BESYLATE
TRICOR, FENOFIBRATE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
ULTANE, SEVOFLURANE
ULTIVA, REMIFENTANIL HYDROCHLORIDE
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
ZEMPLAR, PARICALCITOL
ZYFLO, ZILEUTON

* ABBOTT LABORATORIES HOSP PRODUCTS DIV
A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
AMIKACIN SULFATE, AMIKACIN SULFATE

FDA data supplied by DrugPatentWatch.com

AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-HBC 7%, AMINO ACIDS
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
AMRINONE, INAMRINONE LACTATE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
BRETYLIUM TOSYLATE IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
BUPIVACAINE HCL AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
CALCIJEX, CALCITRIOL
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CORLOPAM, FENOLDOPAM MESYLATE
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
DEXTROSE 25%, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DIAZEPAM, DIAZEPAM
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
ENFLURANE, ENFLURANE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
FENTANYL CITRATE AND DROPERIDOL, DROPERIDOL
FENTANYL CITRATE, FENTANYL CITRATE
HEPARIN LOCK FLUSH IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIPOSYN III 30%, SOYBEAN OIL
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NALBUPHINE HCL, NALBUPHINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PANHEPRIN, HEPARIN SODIUM
PENTHRANE, METHOXYFLURANE
PENTOTHAL, THIOPENTAL SODIUM
PHENYTOIN SODIUM, PHENYTOIN SODIUM
POTASSIUM ACETATE IN PLASTIC CONTAINER, POTASSIUM ACETATE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
RITODRINE HCL, RITODRINE HYDROCHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE

FDA data supplied by DrugPatentWatch.com

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
THAM, TROMETHAMINE
THAM-E, POTASSIUM CHLORIDE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TUBOCURARINE CHLORIDE, TUBOCURARINE CHLORIDE
UREAPHIL, UREA
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE

* ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS DIV

A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
A-POXIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, AMINOPHYLLINE
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, AMINOPHYLLINE
AMINOSOL 5%, PROTEIN HYDROLYSATE
AMINOSYN 3.5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% M IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 3.5% M, AMINO ACIDS
AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN-HBC 7% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMMONIUM CHLORIDE, AMMONIUM CHLORIDE
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BIAXIN, CLARITHROMYCIN
BRETYLIUM TOSYLATE IN DEXTROSE 5%, BRETYLIUM TOSYLATE
BUPIVACAINE HCL, BUPIVACAINE HYDROCHLORIDE
CALCIUM GLUCEPTATE, CALCIUM GLUCEPTATE
CEPHALOTHIN SODIUM, CEPHALOTHIN SODIUM
CHLOROPROCAINE HCL, CHLOROPROCAINE HYDROCHLORIDE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHOLOXIN, DEXTROTHYROXINE SODIUM
CHYMODIACTIN, CHYMOPAPAIN
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYLERT, PEMOLINE
DEPACON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE CP, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 38.5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIASONE SODIUM, SULFOXONE SODIUM
DICUMAROL, DICUMAROL
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE
DISCASE, CHYMOPAPAIN
DROPERIDOL, DROPERIDOL

FDA data supplied by DrugPatentWatch.com

E-MYCIN, ERYTHROMYCIN
E.E.S. 200, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
ENDRATE, EDETATE DISODIUM
ENDURON, METHYCLOTHIAZIDE
ENDURONYL FORTE, DESERPIDINE
ENDURONYL, DESERPIDINE
ERY-TAB, ERYTHROMYCIN
ERYDERM, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROMYCIN, ERYTHROMYCIN
EUTONYL, PARGYLINE HYDROCHLORIDE
EUTRON, METHYCLOTHIAZIDE
FENTANYL CITRATE, FENTANYL CITRATE
GEMONIL, METHARBITAL
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOTHANE, HALOTHANE
HARMONYL, DESERPIDINE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%, HEPARIN SODIUM
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYTRIN, TERAZOSIN HYDROCHLORIDE
IBU, IBUPROFEN
IBUPROFEN, IBUPROFEN
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
ISOPTIN SR, VERAPAMIL HYDROCHLORIDE
ISOPTIN, VERAPAMIL HYDROCHLORIDE
JANIMINE, IMIPRAMINE HYDROCHLORIDE
K-TAB, POTASSIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.2% IN DEXTROSE 5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% IN DEXTROSE 5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIPIDIL, FENOFIBRATE
LIPOSYN 10%, SAFFLOWER OIL
LIPOSYN 20%, SAFFLOWER OIL
LIPOSYN II 10%, SAFFLOWER OIL
LOPURIN, ALLOPURINOL
LTA II KIT, LIDOCAINE HYDROCHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 10%, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15%, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20%, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5%, MANNITOL
MAVIK, TRANDOLAPRIL
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MERIDIA, SIBUTRAMINE HYDROCHLORIDE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
METRONIDAZOLE, METRONIDAZOLE
MORPHINE SULFATE, MORPHINE SULFATE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NITROPRESS, SODIUM NITROPRUSSIDE
NORISODRINE AEROTROL, ISOPROTERENOL HYDROCHLORIDE
NORISODRINE, ISOPROTERENOL SULFATE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
NORVIR, RITONAVIR
OCL, POLYETHYLENE GLYCOL 3350
ORETIC, HYDROCHLOROTHIAZIDE

FDA data supplied by DrugPatentWatch.com

ORETICYL 25, DESERPIDINE
ORETICYL 50, DESERPIDINE
ORETICYL FORTE, DESERPIDINE
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%, OXYTOCIN
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%, OXYTOCIN
OXYTOCIN 5 USP UNITS IN DEXTROSE 5%, OXYTOCIN
PANWARFIN, WARFARIN SODIUM
PARADIONE, PARAMETHADIONE
PCE, ERYTHROMYCIN
PEDIATRIC LTA KIT, LIDOCAINE HYDROCHLORIDE
PHENURONE, PHENACEMIDE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLACIDYL, ETHCHLORVYNOL
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROSOM, ESTAZOLAM
RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR, FIBRINOGEN, I-125
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM BICARBONATE IN PLASTIC CONTAINER, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE, SODIUM CHLORIDE
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORBITOL-MANNITOL, MANNITOL
STERILE UREA, UREA
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TARKA, TRANDOLAPRIL
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THYPINONE, PROTIRELIN
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TRAL, HEXOCYCLIUM METHYLSULFATE
TRAVASE, SUTILAINS
TRICOR (MICRONIZED), FENOFIBRATE
TRIDIONE, TRIMETHADIONE
UROLOGIC G IN PLASTIC CONTAINER, CITRIC ACID
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VERCYTE, PIPOBROMAN
VICODIN ES, ACETAMINOPHEN
VICODIN HP, ACETAMINOPHEN
VICODIN, ACETAMINOPHEN
VICOPRIN, ASPIRIN

FDA data supplied by DrugPatentWatch.com

VICOPROFEN, HYDROCODONE BITARTRATE
VITAMIN K1, PHYTONADIONE

ABC HOLDING
* ABC HOLDING CORP
CAM-AP-ES, HYDRALAZINE HYDROCHLORIDE
CAM-METRAZINE, PHENDIMETRAZINE TARTRATE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRO-RESERP, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
PHENAZINE-35, PHENDIMETRAZINE TARTRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE

ABIC
* ABIC LTD
ABITREXATE, METHOTREXATE SODIUM
FLUOROURACIL, FLUOROURACIL
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
VINCRISTINE SULFATE, VINCRISTINE SULFATE

ABLE
* ABLE LABORATORIES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL; ACETAMINOPHEN; CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
CARISOPRODOL, CARISOPRODOL
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
HEMSOL-HC, HYDROCORTISONE ACETATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
INDOMETHACIN, INDOMETHACIN
LITHIUM CARBONATE, LITHIUM CARBONATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
METHOCARBAMOL, METHOCARBAMOL
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
NAPROXEN SODIUM, NAPROXEN SODIUM
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL, PHENAZOPYRIDINE HYDROCHLORIDE

ABRIKA PHARMS
* ABRIKA PHARMACEUTICALS LLLP
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE ASPARTATE

ACCESS PHARMS
* ACCESS PHARMACEUTICALS INC
APHTHASOL, AMLEXANOX

ACTELION
* ACTELION LTD
TRACLEER, BOSENTAN

ACTELION PHARMS
* ACTELION PHARMACEUTICALS US INC
ZAVESCA, MIGLUSTAT

ADAMS LABS
* ADAMS LABORATORIES INC
MUCINEX, GUAIFENESIN (OTC)

ADV CARE
* ADVANCED CARE PRODUCTS DIV ORTHO PHARMACEUTICAL CORP
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)

ADV MAGNETICS
* ADVANCED MAGNETICS INC
FERIDEX I.V., FERUMOXIDES
GASTROMARK, FERUMOXSIL

ADVANCED CARE PRODS
* ADVANCED CARE PRODUCTS
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)

AEGIS PHARMS
* AEGIS PHARMACEUTICALS INC
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE

AESGEN
* AESGEN INC
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

AGOURON
* AGOURON PHARMACEUTICALS INC
RESCRIPTOR, DELAVIRDINE MESYLATE
VIRACEPT, NELFINAVIR MESYLATE

AH ROBINS INC
* AH ROBINS INC
EXNA, BENZTHIAZIDE

AKORN

FDA data supplied by DrugPatentWatch.com

* AKORN INC
AK-PENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKPRO, DIPIVEFRIN HYDROCHLORIDE
AKTOB, TOBRAMYCIN
ALFENTA, ALFENTANIL HYDROCHLORIDE
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BAL, DIMERCAPROL
BETAXOLOL, BETAXOLOL HYDROCHLORIDE
CARDIO-GREEN, INDOCYANINE GREEN
CHLORAMPHENICOL, CHLORAMPHENICOL
COR-OTICIN, HYDROCORTISONE ACETATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
ENDOSOL EXTRA, CALCIUM CHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HEPARIN SODIUM, HEPARIN SODIUM
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
INAPSINE, DROPERIDOL
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
OCUSERT PILO-20, PILOCARPINE
OCUSERT PILO-40, PILOCARPINE
PAREDRINE, HYDROXYAMPHETAMINE HYDROBROMIDE
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDAMIDE, PREDNISOLONE ACETATE
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
SODIUM SULFACETAMIDE, SULFACETAMIDE SODIUM
SUFENTA, SUFENTANIL CITRATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULSTER, PREDNISOLONE SODIUM PHOSPHATE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TRIAMCINOLONE DIACETATE, TRIAMCINOLONE DIACETATE
TROPICACYL, TROPICAMIDE
TROPICAMIDE, TROPICAMIDE

AKORN MFG
* AKORN MANUFACTURING INC
INNOVAR, DROPERIDOL
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE

ALARA PHARM
* ALARA PHARMACEUTICAL CORPORATION
LEVO-T, LIOTRIX (T4;T3)

ALCON
* ALCON INC
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
* ALCON LABORATORIES INC
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALOMIDE, LODOXAMIDE TROMETHAMINE
AZOPT, BRINZOLAMIDE
BETADINE, POVIDONE-IODINE
BETAXON, LEVOBETAXOLOL HYDROCHLORIDE
BETOPTIC PILO, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BSS PLUS, CALCIUM CHLORIDE
BSS, CALCIUM CHLORIDE
CARTEOLOL HCL, CARTEOLOL HYDROCHLORIDE
CETAMIDE, SULFACETAMIDE SODIUM
CETAPRED, PREDNISOLONE ACETATE
CHLORAMPHENICOL, CHLORAMPHENICOL
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
DENDRID, IDOXURIDINE
ECONOCHLOR, CHLORAMPHENICOL
ECONOPRED, PREDNISOLONE ACETATE
EMADINE, EMEDASTINE DIFUMARATE
FLAREX, FLUOROMETHOLONE ACETATE
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
ISMOTIC, ISOSORBIDE
ISOPTO CETAMIDE, SULFACETAMIDE SODIUM
ISOPTO CETAPRED, PREDNISOLONE ACETATE
MAXIDEX, DEXAMETHASONE
MAXIDEX, DEXAMETHASONE SODIUM PHOSPHATE
MAXITROL, DEXAMETHASONE
MIOSTAT, CARBACHOL
MYDRIACYL, TROPICAMIDE
NAPHCON FORTE, NAPHAZOLINE HYDROCHLORIDE
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
NATACYN, NATAMYCIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
PANTOPAQUE, IOPHENDYLATE
PATANOL, OLOPATADINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PILOPINE HS, PILOCARPINE HYDROCHLORIDE
PROFENAL, SUPROFEN
STATROL, NEOMYCIN SULFATE
TOBRADEX, DEXAMETHASONE
TOBRASONE, FLUOROMETHOLONE ACETATE
TOBREX, TOBRAMYCIN
TRIFLURIDINE, TRIFLURIDINE
VEXOL, RIMEXOLONE
ZOLYSE, CHYMOTRYPSIN

ALCON UNIVERSAL
* ALCON UNIVERSAL LTD
CYCLOPENTOLATE HCL, CYCLOPENTOLATE HYDROCHLORIDE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TOBRAMYCIN, TOBRAMYCIN
TRAVATAN, TRAVOPROST
TROPICAMIDE, TROPICAMIDE

ALLEGIANCE HLTHCARE
* ALLEGIANCE HEALTHCARE CORP
POVIDONE IODINE, POVIDONE-IODINE (OTC)

ALLENDALE PHARMS
* ALLENDALE PHARMACEUTICALS
TODAY, NONOXYNOL-9 (OTC)

ALLERGAN
* ALLERGAN
ACULAR LS, KETOROLAC TROMETHAMINE
BLEPH-10, SULFACETAMIDE SODIUM
BLEPH-30, SULFACETAMIDE SODIUM
GENOPTIC, GENTAMICIN SULFATE
* ALLERGAN INC
ACULAR PRESERVATIVE FREE, KETOROLAC TROMETHAMINE
ACULAR, KETOROLAC TROMETHAMINE
ALBALON, NAPHAZOLINE HYDROCHLORIDE
ALOCRIL, NEDOCROMIL SODIUM
ALPHAGAN P, BRIMONIDINE TARTRATE
ALPHAGAN, BRIMONIDINE TARTRATE
AVAGE, TAZAROTENE
AZELEX, AZELAIC ACID
ELESTAT, EPINASTINE HYDROCHLORIDE
ELIMITE, PERMETHRIN
LUMIGAN, BIMATOPROST
OCUFLOX, OFLOXACIN
OPTICROM, CROMOLYN SODIUM
POLYTRIM, POLYMYXIN B SULFATE
RESTASIS, CYCLOSPORINE
TAZORAC, TAZAROTENE
ZYMAR, GATIFLOXACIN
* ALLERGAN PHARMACEUTICAL
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BLEPH-10, SULFACETAMIDE SODIUM
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLEPHAMIDE, PREDNISOLONE ACETATE
CHLOROPTIC S.O.P., CHLORAMPHENICOL
CHLOROPTIC, CHLORAMPHENICOL
CHLOROPTIC-P S.O.P., CHLORAMPHENICOL
ETHAMIDE, ETHOXZOLAMIDE
FML FORTE, FLUOROMETHOLONE
FML, FLUOROMETHOLONE
FML-S, FLUOROMETHOLONE
HERPLEX, IDOXURIDINE
HMS, MEDRYSONE
OCUFEN, FLURBIPROFEN SODIUM
OPHTHETIC, PROPARACAINE HYDROCHLORIDE
POLY-PRED, NEOMYCIN SULFATE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE
PREFRIN-A, PHENYLEPHRINE HYDROCHLORIDE
PROPINE, DIPIVEFRIN HYDROCHLORIDE

ALLERGAN HERBERT
* ALLERGAN HERBERT DIV ALLERGAN INC
AEROSEB-DEX, DEXAMETHASONE
AEROSEB-HC, HYDROCORTISONE
ERYGEL, ERYTHROMYCIN
ERYMAX, ERYTHROMYCIN
EXSEL, SELENIUM SULFIDE
FLUONID, FLUOCINOLONE ACETONIDE
FLUOROPLEX, FLUOROURACIL
PENECORT, HYDROCORTISONE
* ALLERGAN HERBERT SKIN CARE DIV ALLERGAN INC
FLUOROPLEX, FLUOROURACIL
NAFTIN, NAFTIFINE HYDROCHLORIDE
PENECORT, HYDROCORTISONE
TEMARIL, TRIMEPRAZINE TARTRATE

ALLIANCE PHARM
* ALLIANCE PHARMACEUTICAL CORP
IMAGENT, PERFLUBRON

ALPHA THERA
* ALPHA THERAPEUTIC CORP
SOYACAL 10%, SOYBEAN OIL

FDA data supplied by DrugPatentWatch.com

SOYACAL 20%, SOYBEAN OIL

ALPHAPHARM

* ALPHAPHARM PARTY LTD
ALPRAZOLAM, ALPRAZOLAM
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
GLIPIZIDE, GLIPIZIDE
INDAPAMIDE, INDAPAMIDE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NAPROXEN, NAPROXEN
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
TIZANIDINE HCL, TIZANIDINE HYDROCHLORIDE
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE
TRIAZOLAM, TRIAZOLAM

ALPHARMA

* ALPHARMA INC
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
SULFATRIM, SULFAMETHOXAZOLE
* ALPHARMA USPD INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETASOL HC, ACETIC ACID, GLACIAL
ACETASOL, ACETIC ACID, GLACIAL
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMINOPHYLLINE DYE FREE, AMINOPHYLLINE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BROMANATE DC, BROMPHENIRAMINE MALEATE
BROMANATE DM, BROMPHENIRAMINE MALEATE
BROMANATE, BROMPHENIRAMINE MALEATE
BROMANYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUTABARB, BUTABARBITAL SODIUM
CAPITAL AND CODEINE, ACETAMINOPHEN
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CODAMINE, HYDROCODONE BITARTRATE
CONSTULOSE, LACTULOSE
CROMOLYN SODIUM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ENULOSE, LACTULOSE
EPINEPHRINE, EPINEPHRINE (OTC)
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCET, FLUOCINOLONE ACETONIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE
HYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
HYDROCODONE COMPOUND, HOMATROPINE METHYLBROMIDE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
ISOETHARINE MESYLATE, ISOETHARINE MESYLATE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
KADIAN, MORPHINE SULFATE
LIDOCAINE HCL VISCOUS, LIDOCAINE HYDROCHLORIDE
LINDANE, LINDANE
LOMANATE, ATROPINE SULFATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
M-ZOLE 7 DUAL PACK, MICONAZOLE NITRATE (OTC)
METHDILAZINE HCL, METHDILAZINE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MYKINAC, NYSTATIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
PERMETHRIN, PERMETHRIN
PERMETHRIN, PERMETHRIN (OTC)
PHENYTOIN, PHENYTOIN
PIPERAZINE CITRATE, PIPERAZINE CITRATE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE, PROCHLORPERAZINE EDISYLATE
PROMETH FORTIS, PROMETHAZINE HYDROCHLORIDE
PROMETH PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
SERAX, OXAZEPAM
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

THEOPHYLLINE, THEOPHYLLINE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE HCL, THIOTHIXENE HYDROCHLORIDE
TRIACIN-C, CODEINE PHOSPHATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIMEPRAZINE TARTRATE, TRIMEPRAZINE TARTRATE
TRIMETH/SULFA, SULFAMETHOXAZOLE
TRIPLE SULFA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
TRIPLE SULFA, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE

ALPHARMA US PHARM
* ALPHARMA US PHARMACEUTICAL DIV
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
HYDROCORTISONE, HYDROCORTISONE
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MYKACET, NYSTATIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALNAC, BETAMETHASONE VALERATE

ALRA
* ALRA LABORATORIES INC
ACETAZOLAMIDE, ACETAZOLAMIDE
BAMATE, MEPROBAMATE
CHOLAC, LACTULOSE
COMPOUND 65, ASPIRIN
CONSTILAC, LACTULOSE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
ERYZOLE, ERYTHROMYCIN ETHYLSUCCINATE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IBU-TAB 200, IBUPROFEN (OTC)
IBU-TAB, IBUPROFEN
K+10, POTASSIUM CHLORIDE
K+8, POTASSIUM CHLORIDE
LYGEN, CHLORDIAZEPOXIDE HYDROCHLORIDE
PRAMINE, IMIPRAMINE HYDROCHLORIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
SOXAZOLE, SULFISOXAZOLE
TOLBUTAMIDE, TOLBUTAMIDE

ALTANA
* ALTANA INC
AMCINONIDE, AMCINONIDE
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN, BACITRACIN ZINC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CHLORAMPHENICOL, CHLORAMPHENICOL
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINONIDE, FLUOCINONIDE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
NYSTATIN, NYSTATIN
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TOBRAMYCIN, TOBRAMYCIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
ZIPAN-25, PROMETHAZINE HYDROCHLORIDE
ZIPAN-50, PROMETHAZINE HYDROCHLORIDE

ALZA
* ALZA CORP
ACTISITE, TETRACYCLINE HYDROCHLORIDE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
DITROPAN XL, OXYBUTYNIN CHLORIDE
DITROPAN, OXYBUTYNIN CHLORIDE
DOXIL, DOXORUBICIN HYDROCHLORIDE
DURAGESIC, FENTANYL
EFIDAC 24 CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
EFIDAC 24 PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
EFIDAC 24 PSEUDOEPHEDRINE HCL/BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE (OTC)
PROGESTASERT, PROGESTERONE
TESTODERM TTS, TESTOSTERONE
TESTODERM, TESTOSTERONE

FDA data supplied by DrugPatentWatch.com

VIADUR, LEUPROLIDE ACETATE

AM PHARM

* AMERICAN PHARMACEUTICAL PARTNERS INC
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
PIPERACILLIN, PIPERACILLIN SODIUM
VALPROATE SODIUM, VALPROATE SODIUM
VINCRISTINE SULFATE, VINCRISTINE SULFATE

AM PHARM PARTNERS

ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
AMPHOTERICIN B, AMPHOTERICIN B
BACITRACIN, BACITRACIN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
CALCITRIOL, CALCITRIOL
CALCIUM GLUCEPTATE, CALCIUM GLUCEPTATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFOTAXIME, CEFOTAXIME SODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CEFUROXIME, CEFUROXIME SODIUM
CEPHALOTHIN SODIUM, CEPHALOTHIN SODIUM
CEPHAPIRIN SODIUM, CEPHAPIRIN SODIUM
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CHROMIC CHLORIDE, CHROMIC CHLORIDE
CISPLATIN, CISPLATIN
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CUPRIC SULFATE, CUPRIC SULFATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DACARBAZINE, DACARBAZINE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE
DIAZEPAM, DIAZEPAM
DIAZOXIDE, DIAZOXIDE
DIGOXIN, DIGOXIN
DIPHENHYDRAMINE HCL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
DROPERIDOL, DROPERIDOL
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLOXURIDINE, FLOXURIDINE
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEP FLUSH KIT IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN LOCK FLUSH PRESERVATIVE FREE IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN LOCK FLUSH PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HEPFLUSH-10, HEPARIN SODIUM
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
KANAMYCIN, KANAMYCIN SULFATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LIDOCAINE HCL IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
M.V.C. 9+3, ASCORBIC ACID
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANGANESE SULFATE, MANGANESE SULFATE
MANNITOL 25%, MANNITOL
MESNA, MESNA
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE

FDA data supplied by DrugPatentWatch.com

SODIUM SUCCINATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE HCL, METRONIDAZOLE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
NALBUPHINE, NALBUPHINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NEBUPENT, PENTAMIDINE ISETHIONATE
NITROGLYCERIN, NITROGLYCERIN
OXYTOCIN, OXYTOCIN
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PROGESTERONE, PROGESTERONE
PROTAMINE SULFATE, PROTAMINE SULFATE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
RITODRINE HCL, RITODRINE HYDROCHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM HEPARIN, HEPARIN SODIUM
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
THIOTEPA, THIOTEPA
TOBRAMYCIN (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN SULFATE
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VIBISONE, CYANOCOBALAMIN
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE, VINCRISTINE SULFATE
ZINC SULFATE, ZINC SULFATE

AM THERAP
* AMERICAN THERAPEUTICS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 2, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 3, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DANAZOL, DANAZOL
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
LORAZEPAM, LORAZEPAM
MAPROTILINE HCL, MAPROTILINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHOCARBAMOL, METHOCARBAMOL
OXAZEPAM, OXAZEPAM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISONE, PREDNISONE
THIOTHIXENE, THIOTHIXENE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

AMARIN PHARMS
* AMARIN PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMEN, MEDROXYPROGESTERONE ACETATE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
MOTOFEN HALF-STRENGTH, ATROPINE SULFATE
MOTOFEN, ATROPINE SULFATE
PHRENILIN FORTE, ACETAMINOPHEN
PHRENILIN WITH CAFFEINE AND CODEINE, ACETAMINOPHEN
PHRENILIN, ACETAMINOPHEN

AMBI PHARMS
* AMBI PHARMACEUTICALS INC
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE

AMBIX
* AMBIX LABORATORIES DIV ORGANICS CORP AMERICA
HYDROCORTISONE, HYDROCORTISONE
NITROFURAZONE, NITROFURAZONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

AMERSHAM HLTH
* AMERSHAM HEALTH
AMERSCAN MDP KIT, TECHNETIUM TC-99M MEDRONATE KIT
AMIPAQUE, METRIZAMIDE
BILOPAQUE, TYROPANOATE SODIUM
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CINTICHEM TECHNETIUM 99M HEDSPA, TECHNETIUM TC-99M ETIDRONATE KIT
DICOPAC KIT, CYANOCOBALAMIN
FLUORINE F-18, SODIUM FLUORIDE, F-18
GALLIUM CITRATE GA 67, GALLIUM CITRATE, GA-67
HYPAQUE SODIUM 20%, DIATRIZOATE SODIUM
HYPAQUE, DIATRIZOATE MEGLUMINE
HYPAQUE, DIATRIZOATE SODIUM
HYPAQUE-76, DIATRIZOATE MEGLUMINE
HYPAQUE-CYSTO, DIATRIZOATE MEGLUMINE
HYPAQUE-M,75%, DIATRIZOATE MEGLUMINE
HYPAQUE-M,90%, DIATRIZOATE MEGLUMINE
IBRIN, FIBRINOGEN, I-125
INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE

FDA data supplied by DrugPatentWatch.com

ISOPAQUE 280, CALCIUM
ISOPAQUE 440, CALCIUM METRIZOATE
LUNGAGGREGATE REAGENT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
METASTRON, STRONTIUM CHLORIDE, SR-89
MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT
MPI DTPA KIT - CHELATE, TECHNETIUM TC-99M PENTETATE KIT
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MPI KRYPTON 81M GAS GENERATOR, KRYPTON, KR-81M
MPI STANNOUS DIPHOSPHONATE, TECHNETIUM TC-99M ETIDRONATE KIT
MYOVIEW, TECHNETIUM TC-99M TETROFOSMIN KIT
NEOSCAN, GALLIUM CITRATE, GA-67
NEPHROFLOW, IODOHIPPURATE SODIUM, I-123
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 210, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 70, IOHEXOL
OMNISCAN, GADODIAMIDE
OPTISON, ALBUMIN HUMAN
SELENOMETHIONINE SE 75, SELENOMETHIONINE, SE-75
SODIUM IODIDE I 123, SODIUM IODIDE, I-123
SODIUM PERTECHNETATE TC 99M, TECHNETIUM TC-99M SODIUM PERTECHNETATE
SODIUM POLYPHOSPHATE-TIN KIT, TECHNETIUM TC-99M POLYPHOSPHATE KIT
TC 99M-LUNGAGGREGATE, TECHNETIUM TC-99M ALBUMIN AGGREGATED
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT, TECHNETIUM TC-99M ETIDRONATE KIT
TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNETIUM TC 99M HSA, TECHNETIUM TC-99M ALBUMIN KIT
TECHNETIUM TC 99M MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M MPI MDP, TECHNETIUM TC-99M MEDRONATE KIT
TECHNETIUM TC 99M SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID
TECHNETIUM TC 99M TSC, TECHNETIUM TC-99M SULFUR COLLOID KIT
TECHNETIUM TC-99M PENTETATE KIT, TECHNETIUM TC-99M PENTETATE KIT
TELEPAQUE, IOPANOIC ACID
TESLASCAN, MANGAFODIPIR TRISODIUM
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
XENON XE 133, XENON, XE-133
XENON XE 133-V.S.S., XENON, XE-133

AMIDE PHARM
* AMIDE PHARMACEUTICAL INC
ACETAMINOPHEN AND PENTAZOCINE HCL, ACETAMINOPHEN
BETAXOLOL HCL, BETAXOLOL HYDROCHLORIDE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CHLORZOXAZONE, CHLORZOXAZONE
DIGOXIN, DIGOXIN
GLYBURIDE, GLYBURIDE
GUANFACINE HCL, GUANFACINE HYDROCHLORIDE
HOMATROPRINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NALOXONE HCL AND PENTAZOCAINE, NALOXONE HYDROCHLORIDE
NALTREXONE HCL, NALTREXONE HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PEMOLINE, PEMOLINE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
RIMANTADINE HCL, RIMANTADINE HYDROCHLORIDE
TIZANIDINE HCL, TIZANIDINE HYDROCHLORIDE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
URSODIOL, URSODIOL

AMPHASTAR
* AMPHASTAR PHARMACEUTICALS INC
CORTROSYN, COSYNTROPIN
DUOCAINE, BUPIVACAINE HYDROCHLORIDE

ANABOLIC
* ANABOLIC INC
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDROCORTISONE, HYDROCORTISONE
ISONIAZID, ISONIAZID
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE

ANBEX
* ANBEX INC
IOSAT, POTASSIUM IODIDE (OTC)

ANDRX

FDA data supplied by DrugPatentWatch.com

* ANDRX CORP
ALTOCOR, LOVASTATIN
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE

ANDRX PHARMS
* ANDRX PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CODRIX, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
KETOPROFEN, KETOPROFEN
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
METFORMIN HCL, METFORMIN HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NAPROXEN SODIUM, NAPROXEN SODIUM
OMEPRAZOLE, OMEPRAZOLE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE
* ANDRX PHARMACEUTICALS LLC
CODRIX, ACETAMINOPHEN
ETODOLAC, ETODOLAC

ANESTA
* ANESTA CORP
ACTIQ, FENTANYL CITRATE
FENTANYL, FENTANYL CITRATE

ANGELINI
* ANGELINI PHARMACEUTICALS INC
REV-EYES, DAPIPRAZOLE HYDROCHLORIDE

ANGUS
* ANGUS CHEMICAL CO
MYCHEL-S, CHLORAMPHENICOL SODIUM SUCCINATE
TETRACHEL, TETRACYCLINE HYDROCHLORIDE

ANTHRA
* ANTHRA PHARMACEUTICALS INC
VALSTAR PRESERVATIVE FREE, VALRUBICIN

APOTEX
* APOTEX CORP
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CARBAMAZEPINE, CARBAMAZEPINE
CEFUROXIME AXETIL, CEFUROXIME AXETIL
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
EDETATE DISODIUM, EDETATE DISODIUM
ETODOLAC, ETODOLAC
FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK), FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LISINOPRIL, LISINOPRIL
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
SOTALOL HCL, SOTALOL HYDROCHLORIDE

APOTHECON
* APOTHECON INC DIV BRISTOL MYERS SQUIBB
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, AMIKACIN SULFATE
AMIKIN, AMIKACIN SULFATE
AMOXICILLIN, AMOXICILLIN
AMPICILLIN SODIUM, AMPICILLIN SODIUM
BETAPEN-VK, PENICILLIN V POTASSIUM
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
CAPOZIDE 25/15, CAPTOPRIL
CAPOZIDE 25/25, CAPTOPRIL
CAPOZIDE 50/15, CAPTOPRIL
CAPOZIDE 50/25, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFADYL, CEPHAPIRIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEPHALEXIN, CEPHALEXIN
CLOXACILLIN SODIUM, CLOXACILLIN SODIUM
CORGARD, NADOLOL
DESYREL, TRAZODONE HYDROCHLORIDE
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DYNAPEN, DICLOXACILLIN SODIUM
ENALAPRIL MALEATE, ENALAPRIL MALEATE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FUNGIZONE, AMPHOTERICIN B
KANTREX, KANAMYCIN SULFATE
KENALOG IN ORABASE, TRIAMCINOLONE ACETONIDE
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENALOG-H, TRIAMCINOLONE ACETONIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KLOTRIX, POTASSIUM CHLORIDE
LABETALOL HCL, LABETALOL HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MUCOMYST, ACETYLCYSTEINE
MYCOLOG-II, NYSTATIN
MYCOSTATIN, NYSTATIN
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NATURETIN-10, BENDROFLUMETHIAZIDE
NATURETIN-2.5, BENDROFLUMETHIAZIDE
NATURETIN-5, BENDROFLUMETHIAZIDE
NYDRAZID, ISONIAZID
OPHTHAINE, PROPARACAINE HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
POLYCILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
POLYCILLIN-PRB, AMPICILLIN/AMPICILLIN TRIHYDRATE
POLYMOX, AMOXICILLIN
PRECEF, CEFORANIDE
PRINCIPEN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PROLIXIN ENANTHATE, FLUPHENAZINE ENANTHATE
PROLIXIN, FLUPHENAZINE HYDROCHLORIDE
PRONESTYL, PROCAINAMIDE HYDROCHLORIDE
PRONESTYL-SR, PROCAINAMIDE HYDROCHLORIDE
PROSTAPHLIN, OXACILLIN SODIUM
QUESTRAN, CHOLESTYRAMINE
RAUDIXIN, RAUWOLFIA SERPENTINA
STADOL PRESERVATIVE FREE, BUTORPHANOL TARTRATE
STADOL, BUTORPHANOL TARTRATE
STAPHCILLIN, METHICILLIN SODIUM
SUCOSTRIN, SUCCINYLCHOLINE CHLORIDE
SUMYCIN, TETRACYCLINE HYDROCHLORIDE
TEGOPEN, CLOXACILLIN SODIUM
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRIMOX, AMOXICILLIN
ULTRACEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE
VEETIDS, PENICILLIN V POTASSIUM
VELOSEF '125', CEPHRADINE
VELOSEF '250', CEPHRADINE
VELOSEF, CEPHRADINE
VESPRIN, TRIFLUPROMAZINE HYDROCHLORIDE

*** APOTHECON SUB BRISTOL MYERS SQUIBB CO**
ATENOLOL, ATENOLOL
OXACILLIN SODIUM, OXACILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENTIDS '200', PENICILLIN G POTASSIUM
PENTIDS '250', PENICILLIN G POTASSIUM
PENTIDS '400', PENICILLIN G POTASSIUM
PENTIDS '800', PENICILLIN G POTASSIUM
PRINCIPEN '125', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN '250', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN '500', AMPICILLIN/AMPICILLIN TRIHYDRATE
PRINCIPEN W/ PROBENECID, AMPICILLIN/AMPICILLIN TRIHYDRATE
TRIMOX, AMOXICILLIN
VEETIDS '125', PENICILLIN V POTASSIUM
VEETIDS '250', PENICILLIN V POTASSIUM
VEETIDS '500', PENICILLIN V POTASSIUM
VESPRIN, TRIFLUPROMAZINE

APOTHEKERNES
*** APOTHEKERNES LABORATORIUM A/S**
BACITRACIN, BACITRACIN

APPLIED ANAL
*** APPLIED ANALYTICAL INDUSTRIES**
METHAZOLAMIDE, METHAZOLAMIDE
*** APPLIED ANALYTICAL INDUSTRIES INC**
ESTRADIOL, ESTRADIOL

ARBROOK
*** ARBROOK INC**
GAMOPHEN, HEXACHLOROPHENE

ARCUM
*** ARCUM PHARMACEUTICAL CORP**
VITAMIN A PALMITATE, VITAMIN A PALMITATE

ARMENPHARM
*** ARMENPHARM LTD**
MYCHEL, CHLORAMPHENICOL

ARMOUR PHARM
*** ARMOUR PHARMACEUTICAL CO**
ACTHAR GEL-SYNTHETIC, SERACTIDE ACETATE
DEPINAR, CYANOCOBALAMIN
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
PENTACARINAT, PENTAMIDINE ISETHIONATE

ARMSTRONG PHARMS
*** ARMSTRONG PHARMACEUTICALS INC**
ALBUTEROL, ALBUTEROL

ASCENT PEDS
*** ASCENT PEDIATRICS INC**
ORAPRED, PREDNISOLONE SODIUM PHOSPHATE
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE

ASCHER
*** BF ASCHER AND CO INC**
DRIZE, CHLORPHENIRAMINE MALEATE
HY-PHEN, ACETAMINOPHEN

ASCOT
*** ASCOT HOSP PHARMACEUTICALS INC DIV TRAVENOL LABORATORIES INC**
ACETAZOLAMIDE, ACETAZOLAMIDE
AMINOPHYLLINE, AMINOPHYLLINE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

CHLORTHALIDONE, CHLORTHALIDONE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHOCARBAMOL, METHOCARBAMOL
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
SPIRONOLACTONE + HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
TOLBUTAMIDE, TOLBUTAMIDE

ASLUNG PHARM
* ASLUNG PHARMACEUTICAL LP
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

ASTA
* ASTA MEDICA INC
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE

ASTRAZENECA
* ASTRAZENECA LP
AMIKACIN SULFATE, AMIKACIN SULFATE
AQUASOL A, VITAMIN A
ASTRAMORPH PF, MORPHINE SULFATE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
CALCITONIN-SALMON, CALCITONIN, SALMON
CITANEST FORTE, EPINEPHRINE BITARTRATE
CITANEST PLAIN, PRILOCAINE HYDROCHLORIDE
CITANEST, PRILOCAINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DALGAN, DEZOCINE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
DURANEST, EPINEPHRINE
DURANEST, EPINEPHRINE BITARTRATE
DURANEST, ETIDOCAINE HYDROCHLORIDE
DYCLONE, DYCLONINE HYDROCHLORIDE
EMLA, LIDOCAINE
ENTOCORT EC, BUDESONIDE
FENTANYL CITRATE AND DROPERIDOL, DROPERIDOL
FOSCAVIR, FOSCARNET SODIUM
FUROSEMIDE, FUROSEMIDE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
M.V.I.-12 LYOPHILIZED, ASCORBIC ACID
MANNITOL 25%, MANNITOL
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
NALBUPHINE HCL, NALBUPHINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NAROPIN, ROPIVACAINE HYDROCHLORIDE MONOHYDRATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NEXIUM, ESOMEPRAZOLE MAGNESIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PRILOSEC, OMEPRAZOLE
PULMICORT RESPULES, BUDESONIDE
RHINOCORT, BUDESONIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SEROQUEL, QUETIAPINE FUMARATE
TENORMIN, ATENOLOL
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOPROL-XL, METOPROLOL SUCCINATE
XYLOCAINE 1.5% W/ DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE 5% W/ GLUCOSE 7.5%, LIDOCAINE HYDROCHLORIDE
XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYLOCAINE, LIDOCAINE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
YUTOPAR, RITODRINE HYDROCHLORIDE
* ASTRAZENECA PHARMACEUTICALS LP
ATACAND HCT, CANDESARTAN CILEXETIL
ATACAND, CANDESARTAN CILEXETIL
CEFOTAN IN PLASTIC CONTAINER, CEFOTETAN DISODIUM
CEFOTAN, CEFOTETAN DISODIUM
CRESTOR, ROSUVASTATIN CALCIUM
ELAVIL, AMITRIPTYLINE HYDROCHLORIDE
FASLODEX, FULVESTRANT
LEXXEL, ENALAPRIL MALEATE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
NOLVADEX, TAMOXIFEN CITRATE
PLENDIL, FELODIPINE
PULMICORT, BUDESONIDE
SORBITRATE, ISOSORBIDE DINITRATE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TONOCARD, TOCAINIDE HYDROCHLORIDE
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
* ASTRAZENECA UK LTD
ACCOLATE, ZAFIRLUKAST
ARIMIDEX, ANASTROZOLE
CASODEX, BICALUTAMIDE
DIPRIVAN, PROPOFOL
IRESSA, GEFITINIB

FDA data supplied by DrugPatentWatch.com

MERREM I.V., MEROPENEM
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL
ZOLADEX, GOSERELIN ACETATE

ATRIX
* ATRIX LABORATORIES INC
ATRIDOX, DOXYCYCLINE HYCLATE
ELIGARD, LEUPROLIDE ACETATE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
MOMETASONE FUROATE, MOMETASONE FUROATE

AUXILIUM A2
* AUXILIUM A2 INC
TESTIM, TESTOSTERONE

AVENTIS
* AVENTIS PHARMACEUTICAL PRODUCTS INC
ACTHAR, CORTICOTROPIN
AZMACORT, TRIAMCINOLONE ACETONIDE
AZOLID, PHENYLBUTAZONE
CALCIMAR, CALCITONIN, SALMON
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DDAVP, DESMOPRESSIN ACETATE
DORIDEN, GLUTETHIMIDE
INTAL, CROMOLYN SODIUM
LOVENOX, ENOXAPARIN SODIUM
LOZOL, INDAPAMIDE
NASACORT AQ, TRIAMCINOLONE ACETONIDE
NASACORT, TRIAMCINOLONE ACETONIDE
NICOLAR, NIACIN
PARATHAR, TERIPARATIDE ACETATE
PENETREX, ENOXACIN
PERTOFRANE, DESIPRAMINE HYDROCHLORIDE
PRESAMINE, IMIPRAMINE HYDROCHLORIDE
RILUTEK, RILUZOLE
SLO-BID, THEOPHYLLINE
SLO-PHYLLIN, THEOPHYLLINE
THYTROPAR, THYROTROPIN
TILADE, NEDOCROMIL SODIUM

AVENTIS BEHRING
* AVENTIS BEHRING LLC
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
STIMATE, DESMOPRESSIN ACETATE

AVENTIS PHARMS
* AVENTIS PHARMACEUTICALS INC
A/T/S, ERYTHROMYCIN
ACCURBRON, THEOPHYLLINE
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA-D, FEXOFENADINE HYDROCHLORIDE
AMARYL, GLIMEPIRIDE
ANZEMET, DOLASETRON MESYLATE MONOHYDRATE
ARAVA, LEFLUNOMIDE
BENDECTIN, DOXYLAMINE SUCCINATE
BRICANYL, TERBUTALINE SULFATE
CANTIL, MEPENZOLATE BROMIDE
CARDIZEM SR, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CEPHULAC, LACTULOSE
CHRONULAC, LACTULOSE
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN, CEFOTAXIME SODIUM
CLOMID, CLOMIPHENE CITRATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DECAPRYN, DOXYLAMINE SUCCINATE
DEMI-REGROTON, CHLORTHALIDONE
DIABETA, GLYBURIDE
DV, DIENESTROL
GAVISCON, ALUMINUM HYDROXIDE (OTC)
GLYBURIDE (MICRONIZED), GLYBURIDE
HEDULIN, PHENINDIONE
HIPREX, METHENAMINE HIPPURATE
HYDROXYSTILBAMIDINE ISETHIONATE, HYDROXYSTILBAMIDINE ISETHIONATE
HYGROTON, CHLORTHALIDONE
INTAL, CROMOLYN SODIUM
IPRIVASK, DESIRUDIN
LANTUS, INSULIN GLARGINE
LASIX, FUROSEMIDE
LORELCO, PROBUCOL
METAHYDRIN, TRICHLORMETHIAZIDE
METATENSIN #2, RESERPINE
METATENSIN #4, RESERPINE
NICODERM CQ, NICOTINE (OTC)
NILANDRON, NILUTAMIDE
NITRO-BID, NITROGLYCERIN
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
NOVAFED, PSEUDOEPHEDRINE HYDROCHLORIDE
ORNIDYL, EFLORNITHINE HYDROCHLORIDE
PRIFTIN, RIFAPENTINE
REGROTON, CHLORTHALIDONE
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFATER, ISONIAZID
TACE, CHLOROTRIANISENE
TAXOTERE, DOCETAXEL
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
TENUATE, DIETHYLPROPION HYDROCHLORIDE
TRENTAL, PENTOXIFYLLINE
TRICLOS, TRICLOFOS SODIUM

FDA data supplied by DrugPatentWatch.com

VANOBID, CANDICIDIN
VENTAIRE, PROTOKYLOL HYDROCHLORIDE

AVEVA
* AVEVA DRUG DELIVERY SYSTEMS INC
PROSTEP, NICOTINE (OTC)

AXCAN SCANDIPHARM
* AXCAN SCANDIPHARM INC
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
CANASA, MESALAMINE
CARAFATE, SUCRALFATE
CHENIX, CHENODIOL
PHOTOFRIN, PORFIMER SODIUM
URSO, URSODIOL

AXIOM PHARM
* AXIOM PHARMACEUTICAL CORP
BUTALBITAL, APAP, AND CAFFEINE, ACETAMINOPHEN
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
ISONIAZID, ISONIAZID
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
PREDNISOLONE, PREDNISOLONE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

AYERST
* AYERST LABORATORIES INC
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE

** B **

B BRAUN
* B BRAUN MEDICAL INC
ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ALCOHOL 10% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% AND DEXTROSE 5%, ALCOHOL
AMMONIUM CHLORIDE 2.14%, AMMONIUM CHLORIDE
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 2.5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE

FDA data supplied by DrugPatentWatch.com

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60%, DEXTROSE
DEXTROSE 7.7% IN PLASTIC CONTAINER, DEXTROSE
DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DOPAMINE HCL AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HCL AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
FREAMINE 8.5%, AMINO ACIDS
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE II 8.5%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
HYPROTIGEN 5%, PROTEIN HYDROLYSATE
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE E IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, MANNITOL
MANNITOL 10%, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%, MANNITOL
MANNITOL 15%, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%, MANNITOL
MANNITOL 5%, MANNITOL
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
METRO I.V., METRONIDAZOLE
NEPHRAMINE 5.4%, AMINO ACIDS
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL

FDA data supplied by DrugPatentWatch.com

PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC

FDA data supplied by DrugPatentWatch.com

CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCALAMINE, AMINO ACIDS
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RESECTISOL, MANNITOL
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE, SODIUM CHLORIDE
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
TROPHAMINE 10%, AMINO ACIDS
TROPHAMINE, AMINO ACIDS
UCEPHAN, SODIUM BENZOATE

BAKER NORTON
* BAKER NORTON
PROGLYCEM, DIAZOXIDE
* BAKER NORTON PHARMACEUTICALS INC
ACTICORT, HYDROCORTISONE
PACLITAXEL, PACLITAXEL
PROGLYCEM, DIAZOXIDE

BALLARD MEDCL
* BALLARD MEDICAL PRODUCTS INC
PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

BANNER PHARMACAPS
* BANNER PHARMACAPS INC
BENZONATATE, BENZONATATE
CHLOROTRIANISENE, CHLOROTRIANISENE
CLOFIBRATE, CLOFIBRATE
ETHCHLORVYNOL, ETHCHLORVYNOL
ETHOSUXIMIDE, ETHOSUXIMIDE
IBUPROFEN, IBUPROFEN (OTC)
VALPROIC ACID, VALPROIC ACID
VITAMIN A PALMITATE, VITAMIN A PALMITATE
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL

BARLAN
* BARLAN PHARMACAL CO INC
BARSTATIN 100, NYSTATIN

BARR
* BARR LABORATORIES INC
ACETOHEXAMIDE, ACETOHEXAMIDE
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMINOPHYLLINE, AMINOPHYLLINE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CAMILA, NORETHINDRONE
CEPHALEXIN, CEPHALEXIN
CEPHRADINE, CEPHRADINE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORZOXAZONE, CHLORZOXAZONE
CLARAVIS, ISOTRETINOIN
CORTISONE ACETATE, CORTISONE ACETATE
DANAZOL, DANAZOL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE ASPARTATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
E-BASE, ERYTHROMYCIN
ERRIN, NORETHINDRONE
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN, ERYTHROMYCIN
ESTRADIOL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ETHAMBUTOL HCL, ETHAMBUTOL HYDROCHLORIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM, EXTENDED
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLUTAMIDE, FLUTAMIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOLIC ACID, FOLIC ACID
GENCEPT 10/11-21, ETHINYL ESTRADIOL
GENCEPT 10/11-28, ETHINYL ESTRADIOL
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
ISONIAZID, ISONIAZID
JUNEL 1.5/30, ETHINYL ESTRADIOL
JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL
JUNEL FE 1/20, ETHINYL ESTRADIOL
KARIVA, DESOGESTREL
LESSINA-21, ETHINYL ESTRADIOL
LESSINA-28, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LITHIUM CARBONATE, LITHIUM CARBONATE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFLOQUINE, MEFLOQUINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
MIRTAZAPINE, MIRTAZAPINE
NALTREXONE HCL, NALTREXONE HYDROCHLORIDE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORTREL 0.5/35-21, ETHINYL ESTRADIOL
NORTREL 0.5/35-28, ETHINYL ESTRADIOL
NORTREL 1/35-21, ETHINYL ESTRADIOL
NORTREL 1/35-28, ETHINYL ESTRADIOL
NORTREL 7/7/7, ETHINYL ESTRADIOL
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PORTIA-21, ETHINYL ESTRADIOL
PORTIA-28, ETHINYL ESTRADIOL
PREDNISOLONE, PREDNISOLONE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RESERPINE, RESERPINE
SEASONALE, ETHINYL ESTRADIOL
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SPRINTEC, ETHINYL ESTRADIOL
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
SULFINPYRAZONE, SULFINPYRAZONE
SULFISOXAZOLE, SULFISOXAZOLE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TIZANIDINE HCL, TIZANIDINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TREXALL, METHOTREXATE SODIUM
TRI-SPRINTEC, ETHINYL ESTRADIOL
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

* BARR PHARMACEUTICALS
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

BARR PHARMS

* BARR PHARMACEUTICALS INC
REVIA, NALTREXONE HYDROCHLORIDE

BARTOR

FDA data supplied by DrugPatentWatch.com

* BARTOR PHARMACAL CO
TESTOSTERONE, TESTOSTERONE

BASF
* BASF CORP
IBU, IBUPROFEN
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LOPURIN, ALLOPURINOL
RUFEN, IBUPROFEN
SSD AF, SILVER SULFADIAZINE
SSD, SILVER SULFADIAZINE

BAUSCH AND LOMB
* BAUSCH AND LOMB INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALREX, LOTEPREDNOL ETABONATE
CARTEOLOL HCL, CARTEOLOL HYDROCHLORIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LOTEMAX, LOTEPREDNOL ETABONATE
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
SULPHRIN, PREDNISOLONE ACETATE
SULTEN-10, SULFACETAMIDE SODIUM
TIMOLOL MALEATE, TIMOLOL MALEATE
* BAUSCH AND LOMB PHARMACEUTICALS INC
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BETAXOLOL HCL, BETAXOLOL HYDROCHLORIDE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CROLOM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
DIPIVEFRIN HCL, DIPIVEFRIN HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
FLUNISOLIDE, FLUNISOLIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVOBUNOLOL HCL, LEVOBUNOLOL HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
NAFAZAIR, NAPHAZOLINE HYDROCHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
NYSTATIN, NYSTATIN
OPCON, NAPHAZOLINE HYDROCHLORIDE
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
OTICAIR, HYDROCORTISONE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROPARACAINE HCL, PROPARACAINE HYDROCHLORIDE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TROPICAMIDE, TROPICAMIDE
* BAUSCH AND LOMB SURGICAL INC
VITRASERT, GANCICLOVIR

BAXTER HLTHCARE
* BAXTER HEALTHCARE CORP
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ALCOHOL 5% IN DEXTROSE 5% IN WATER, ALCOHOL
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BRANCHAMIN 4% IN PLASTIC CONTAINER, AMINO ACIDS
BRANCHAMIN 4%, AMINO ACIDS
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
CERNEVIT-12, ALPHA-TOCOPHEROL
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS

FDA data supplied by DrugPatentWatch.com

CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER, AMINO ACIDS
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM

FDA data supplied by DrugPatentWatch.com

CHLORIDE
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
EXTRANEAL, ICODEXTRIN
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPATASOL 8%, AMINO ACIDS
IRRIGATING SOLUTION G IN PLASTIC CONTAINER, CITRIC ACID
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER, GENTAMICIN SULFATE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HCL 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
MESNEX, MESNA
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE 56 IN PLASTIC CONTAINER, MAGNESIUM ACETATE TETRAHYDRATE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLASMA-LYTE R IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

FDA data supplied by DrugPatentWatch.com

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
RENAMIN W/O ELECTROLYTES, AMINO ACIDS
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SEVOFLURANE, SEVOFLURANE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.224%, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM HEPARIN, HEPARIN SODIUM
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, WATER FOR INJECTION, STERILE
STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE
STERILE WATER, WATER FOR IRRIGATION, STERILE
SYNOVALYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIS-U-SOL, MAGNESIUM SULFATE
TRAVAMULSION 10%, SOYBEAN OIL
TRAVAMULSION 20%, SOYBEAN OIL
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 10% W/O ELECTROLYTES, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 3.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5%

FDA data supplied by DrugPatentWatch.com

IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 5.5% W/O ELECTROLYTES, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% W/ ELECTROLYTES, AMINO ACIDS
TRAVASOL 8.5% W/O ELECTROLYTES, AMINO ACIDS
TRAVERT 10% IN PLASTIC CONTAINER, INVERT SUGAR
VANCOCIN HCL IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

* BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, ACYCLOVIR SODIUM
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMPICILLIN SODIUM, AMPICILLIN SODIUM
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
CEFOXITIN, CEFOXITIN SODIUM
CEPHAPIRIN SODIUM, CEPHAPIRIN SODIUM
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE
DIAZEPAM, DIAZEPAM
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DURAMORPH PF, MORPHINE SULFATE
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HEP-LOCK U/P, HEPARIN SODIUM
HEP-LOCK, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
INFUMORPH, MORPHINE SULFATE
IOPAMIDOL, IOPAMIDOL
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
KANAMYCIN, KANAMYCIN SULFATE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
MILRINONE LACTOSE IN 5% DEXTROSE, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NALOXONE, NALOXONE HYDROCHLORIDE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROTAMINE SULFATE, PROTAMINE SULFATE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VANCOLED, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HCL, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
WYDASE, HYALURONIDASE

* BAXTER HEALTHCARE INTERNATIONAL SPECIALTY THERAPIES DIV
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

BAXTER HLTHCARE CORP

* BAXTER HEALTHCARE CORP ANESTHESIA CRITICAL CARE
AMRINONE LACTATE, INAMRINONE LACTATE
ATIVAN, LORAZEPAM
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
DOPRAM, DOXAPRAM HYDROCHLORIDE
ENLON, EDROPHONIUM CHLORIDE
ENLON-PLUS, ATROPINE SULFATE
ETHRANE, ENFLURANE
FACTREL, GONADORELIN HYDROCHLORIDE
FORANE, ISOFLURANE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LARGON, PROPIOMAZINE HYDROCHLORIDE
MEPERGAN, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
OXYTOCIN, OXYTOCIN
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

REVEX, NALMEFENE HYDROCHLORIDE
ROBAXIN, METHOCARBAMOL
ROBINUL, GLYCOPYRROLATE
SPARINE, PROMAZINE HYDROCHLORIDE
SUPRANE, DESFLURANE
WYAMINE SULFATE, MEPHENTERMINE SULFATE

BAYER
* BAYER HEALTHCARE LLC
8-HOUR BAYER, ASPIRIN (OTC)
ACTRON, KETOPROFEN (OTC)
ALEVE COLD AND SINUS, NAPROXEN SODIUM (OTC)
ALEVE, NAPROXEN SODIUM (OTC)
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN, ASPIRIN (OTC)
MEASURIN, ASPIRIN (OTC)
MIDOL, IBUPROFEN (OTC)

BAYER PHARMS
* BAYER PHARMACEUTICALS CORP
ADALAT CC, NIFEDIPINE
ADALAT, NIFEDIPINE
ANTAGONATE, CHLORPHENIRAMINE MALEATE
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
AZLIN, AZLOCILLIN SODIUM
BAYCOL, CERIVASTATIN SODIUM
BILTRICIDE, PRAZIQUANTEL
CANDEX, NYSTATIN
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRO XR, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CORT-DOME, HYDROCORTISONE
DELTA-DOME, PREDNISONE
DOMEBORO, ACETIC ACID, GLACIAL
DTIC-DOME, DACARBAZINE
HC #1, HYDROCORTISONE
HC #4, HYDROCORTISONE
LEVITRA, VARDENAFIL HYDROCHLORIDE
LITHANE, LITHIUM CARBONATE
MEZLIN, MEZLOCILLIN SODIUM MONOHYDRATE
MIXTARD HUMAN 70/30, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
MYCELEX, CLOTRIMAZOLE
MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
MYCELEX-7, CLOTRIMAZOLE (OTC)
MYCELEX-G, CLOTRIMAZOLE
NEO-CORT-DOME, ACETIC ACID, GLACIAL
NEO-CORT-DOME, HYDROCORTISONE
NICLOCIDE, NICLOSAMIDE
NIMOTOP, NIMODIPINE
NYSTAFORM, CLIOQUINOL
PRECOSE, ACARBOSE
RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN), ALBUMIN IODINATED I-125 SERUM
SOY-DOME, HEXACHLOROPHENE
STILPHOSTROL, DIETHYLSTILBESTROL DIPHOSPHATE
TRASYLOL, APROTININ BOVINE
TRIDESILON, ACETIC ACID, GLACIAL
VI-DOM-A, VITAMIN A PALMITATE

BECKLOFF
* BECKLOFF ASSOC INC
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)

BECTON DICKINSON
* BECTON DICKINSON AND CO
E-Z PREP 220, POVIDONE-IODINE (OTC)
E-Z PREP, POVIDONE-IODINE (OTC)
E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)
E-Z SCRUB, HEXACHLOROPHENE
* BECTON DICKINSON SURGICAL SYSTEM
E-Z SCRUB, CHLORHEXIDINE GLUCONATE (OTC)

BEDFORD
* BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
AMRINONE, INAMRINONE LACTATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
BLEOMYCIN, BLEOMYCIN SULFATE
BUMETANIDE, BUMETANIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CHLOROPROCAINE HCL, CHLOROPROCAINE HYDROCHLORIDE
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYCLOSPORINE, CYCLOSPORINE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HCL, DAUNORUBICIN HYDROCHLORIDE
DESMOPRESSIN ACETATE PRESERVATIVE FREE, DESMOPRESSIN ACETATE

FDA data supplied by DrugPatentWatch.com

DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DICYCLOMINE HCL (PRESERVATIVE-FREE), DICYCLOMINE HYDROCHLORIDE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOXAPRAM HCL, DOXAPRAM HYDROCHLORIDE
DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
ENALAPRILAT, ENALAPRILAT
ETOMIDATE, ETOMIDATE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLOXURIDINE, FLOXURIDINE
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
KETAMINE HCL, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVOCARNITINE, LEVOCARNITINE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OFLOXACIN, OFLOXACIN
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
THIOTEPA, THIOTEPA
VALPROATE SODIUM, VALPROATE SODIUM
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

BEDFORD LABS
* BEDFORD LABORATORIES
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
* BEDFORD LABORATORIES INC
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE

BEECHAM
* BEECHAM LABORATORIES DIV BEECHAM INC
PROBENECID AND COLCHICINE, COLCHICINE

BEL MAR
* BEL MAR LABORATORIES INC
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROXOMIN, HYDROXOCOBALAMIN
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
M-PREDROL, METHYLPREDNISOLONE ACETATE
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PROCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PYRIDAMAL 100, CHLORPHENIRAMINE MALEATE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
RUBIVITE, CYANOCOBALAMIN
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
VITAMIN A PALMITATE, VITAMIN A PALMITATE

BELL PHARMA
* BELL PHARMACAL CORP
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
RESERPINE, RESERPINE

BEN VENUE
* BEN VENUE LABORATORIES INC
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE

BERLEX
* BERLEX
FINACEA, AZELAIC ACID
* BERLEX LABORATORIES INC SUB SCHERING AG
ANGIOVIST 282, DIATRIZOATE MEGLUMINE
ANGIOVIST 292, DIATRIZOATE MEGLUMINE
ANGIOVIST 370, DIATRIZOATE MEGLUMINE
BILIVIST, IPODATE SODIUM
FLUDARA, FLUDARABINE PHOSPHATE
GASTROVIST, DIATRIZOATE MEGLUMINE
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
QUINACT, QUINIDINE GLUCONATE
SULLA, SULFAMETER

FDA data supplied by DrugPatentWatch.com

UROVIST CYSTO PEDIATRIC, DIATRIZOATE MEGLUMINE
UROVIST CYSTO, DIATRIZOATE MEGLUMINE
UROVIST MEGLUMINE DIU/CT, DIATRIZOATE MEGLUMINE
UROVIST SODIUM 300, DIATRIZOATE SODIUM
VI-TWEL, CYANOCOBALAMIN

BERLEX LABS
* BERLEX LABORATORIES INC
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAPACE, SOTALOL HYDROCHLORIDE
CLIMARA PRO, ESTRADIOL
CLIMARA, ESTRADIOL
LEVLITE, ETHINYL ESTRADIOL
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
MIRENA, LEVONORGESTREL
OSMOVIST 190, IOTROLAN
OSMOVIST 240, IOTROLAN
QUINAGLUTE, QUINIDINE GLUCONATE
REFLUDAN, LEPIRUDIN
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 150, IOPROMIDE
ULTRAVIST 240, IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
YASMIN, DROSPIRENONE

BERTEK
* BERTEK PHARMACEUTICALS INC
MENTAX-TC, BUTENAFINE HYDROCHLORIDE

BERTEK PHARMS
AVITA, TRETINOIN
MENTAX, BUTENAFINE HYDROCHLORIDE
SULFAMYLON, MAFENIDE ACETATE

BETA DERMAC
* BETA DERMACEUTICALS INC
BETA-HC, HYDROCORTISONE

BH
* BH CHEMICALS INC
HALOTHANE, HALOTHANE

BIGMAR
* BIGMAR INC
DAUNORUBICIN HCL, DAUNORUBICIN HYDROCHLORIDE
FLUOROURACIL, FLUOROURACIL
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE, METHOTREXATE SODIUM

BIO NUCLEONICS
* BIO NUCLEONICS INC
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE, SR-89

BIOCHEMIE
* BIOCHEMIE GMBH
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM

BIOCHEMIE US
* BIOCHEMIE US INC
CEFUROXIME AXETIL, CEFUROXIME AXETIL

BIOENVISION
* BIOENVISION INC
MODRASTANE, TRILOSTANE

BIOGLAN
* BIOGLAN LABORATORIES LTD
ALPHADERM, HYDROCORTISONE

BIOGLAN PHARMA
* BIOGLAN PHARMA INC
C-SOLVE-2, ERYTHROMYCIN
SOLARAZE, DICLOFENAC SODIUM

BIOGLAN PHARMS
* BIOGLAN PHARMACEUTICALS CO
ZONALON, DOXEPIN HYDROCHLORIDE

BIONICHE (CANADA)
* BIONICHE PHARMA (CANADA) LTD
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
EDETATE DISODIUM, EDETATE DISODIUM
KETAMINE HCL, KETAMINE HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE

BIOVAIL
* BIOVAIL CORP INTERNATIONAL
TIAZAC, DILTIAZEM HYDROCHLORIDE
* BIOVAIL LABORATORIES INC
ATIVAN, LORAZEPAM
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
ISORDIL, ISOSORBIDE DINITRATE
NIFEDIPINE, NIFEDIPINE
PENTOXIFYLLINE, PENTOXIFYLLINE
TECZEM, DILTIAZEM MALATE
TEVETEN HCT, EPROSARTAN MESYLATE

FDA data supplied by DrugPatentWatch.com

TEVETEN, EPROSARTAN MESYLATE
VASERETIC, ENALAPRIL MALEATE
VASOTEC, ENALAPRIL MALEATE
VASOTEC, ENALAPRILAT
* BIOVAIL TECHNOLOGIES
CEDAX, CEFTIBUTEN DIHYDRATE

BLAIREX
* BLAIREX LABORATORIES INC
BRONCHO SALINE, SODIUM CHLORIDE (OTC)

BLUE RIDGE
* BLUE RIDGE LABORATORIES INC
CARAFATE, SUCRALFATE

BLULINE
* BLULINE LABORATORIES INC
EPICORT, HYDROCORTISONE
MULTIFUGE, PIPERAZINE CITRATE

BOEHRINGER INGELHEIM
* BOEHRINGER INGELHEIM
ALUPENT, METAPROTERENOL SULFATE
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
MEXITIL, MEXILETINE HYDROCHLORIDE
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICARDIS, TELMISARTAN
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
* BOEHRINGER INGELHEIM CORP
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
* BOEHRINGER INGELHEIM PHARMACEUTICALS INC
AGGRENOX, ASPIRIN
ALUPENT, METAPROTERENOL SULFATE
ATROVENT, IPRATROPIUM BROMIDE
COMBIPRES, CHLORTHALIDONE
COMBIVENT, ALBUTEROL SULFATE
FLOMAX, TAMSULOSIN HYDROCHLORIDE
IV PERSANTINE, DIPYRIDAMOLE
MOBIC, MELOXICAM
PERSANTINE, DIPYRIDAMOLE
PRELUDIN, PHENMETRAZINE HYDROCHLORIDE
VIRAMUNE, NEVIRAPINE

BONE CARE
* BONE CARE INTERNATIONAL INC
HECTOROL, DOXERCALCIFEROL

BOWMAN PHARMS
* BOWMAN PHARMACEUTICALS INC
HISERPIA, RESERPINE
HIWOLFIA, RAUWOLFIA SERPENTINA

BRACCO
* BRACCO DIAGNOSTICS INC
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOGRAFIN, DIATRIZOATE MEGLUMINE
CARDIOTEC, TECHNETIUM TC-99M TEBOROXIME KIT
CHLORMERODRIN HG 197, CHLORMERODRIN, HG-197
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE
CHOLOGRAFIN SODIUM, IODIPAMIDE SODIUM
CHOLOVUE, IODOXAMATE MEGLUMINE
CHROMITOPE SODIUM, SODIUM CHROMATE, CR-51
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
DIATRIZOATE MEGLUMINE, DIATRIZOATE MEGLUMINE
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
HIPPUTOPE, IODOHIPPURATE SODIUM, I-131
IODOTOPE, SODIUM IODIDE, I-131
ISOVUE-128, IOPAMIDOL
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
KINEVAC, SINCALIDE
LUMENHANCE, MANGANESE CHLORIDE TETRAHYDRATE
MACROTEC, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
MINITEC, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ORAGRAFIN CALCIUM, IPODATE CALCIUM
ORAGRAFIN SODIUM, IPODATE SODIUM
PHOSPHOTEC, TECHNETIUM TC-99M PYROPHOSPHATE KIT
PHOSPHOTOPE, SODIUM PHOSPHATE, P-32
PROHANCE MULTIPACK, GADOTERIDOL
PROHANCE, GADOTERIDOL
RENO-30, DIATRIZOATE MEGLUMINE
RENO-60, DIATRIZOATE MEGLUMINE
RENO-DIP, DIATRIZOATE MEGLUMINE
RENOCAL-76, DIATRIZOATE MEGLUMINE
RENOGRAFIN-60, DIATRIZOATE MEGLUMINE
RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
RENOTEC, TECHNETIUM TC-99M FERPENTETATE KIT
RENOVIST II, DIATRIZOATE MEGLUMINE
RENOVIST, DIATRIZOATE MEGLUMINE
RENOVUE-65, IODAMIDE MEGLUMINE
RENOVUE-DIP, IODAMIDE MEGLUMINE
ROBENGATOPE, ROSE BENGAL SODIUM, I-131
RUBRATOPE-57 KIT, COBALT CHLORIDE, CO-57
RUBRATOPE-57, CYANOCOBALAMIN, CO-57
RUBRATOPE-60 KIT, COBALT CHLORIDE, CO-60
RUBRATOPE-60, CYANOCOBALAMIN, CO-60

FDA data supplied by DrugPatentWatch.com

SETHOTOPE, SELENOMETHIONINE, SE-75
SINOGRAFIN, DIATRIZOATE MEGLUMINE
SONORX, SIMETHICONE-CELLULOSE
TESULOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201

BRADLEY PHARMS
* BRADLEY PHARMACEUTICALS INC
PAMINE FORTE, METHSCOPOLAMINE BROMIDE
PAMINE, METHSCOPOLAMINE BROMIDE

BRAINTREE
* BRAINTREE LABORATORIES INC
GOLYTELY, POLYETHYLENE GLYCOL 3350
MIRALAX, POLYETHYLENE GLYCOL 3350
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350

BREATH LTD
* BREATH LTD
ALBUTEROL SULFATE, ALBUTEROL SULFATE

BRIGHTSTONE
* BRIGHTSTONE PHARMA INC
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

BRISTOL
* BRISTOL LABORATORIES INC DIV BRISTOL MYERS CO
BETAPEN-VK, PENICILLIN V POTASSIUM
BICNU, CARMUSTINE
BRISTACYCLINE, TETRACYCLINE HYDROCHLORIDE
BRISTAGEN, GENTAMICIN SULFATE
BRISTAMYCIN, ERYTHROMYCIN STEARATE
CEPHALOTHIN SODIUM, CEPHALOTHIN SODIUM
LYSODREN, MITOTANE
MEXATE, METHOTREXATE SODIUM
MUTAMYCIN, MITOMYCIN
POLYCILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
POLYCILLIN-N, AMPICILLIN SODIUM
POLYCILLIN-PRB, AMPICILLIN/AMPICILLIN TRIHYDRATE
PRECEF, CEFORANIDE
TETREX, TETRACYCLINE PHOSPHATE COMPLEX
ULTRACEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE
VEPESID, ETOPOSIDE
VERSAPEN, HETACILLIN
VERSAPEN-K, HETACILLIN POTASSIUM

BRISTOL MYERS
* BRISTOL MYERS CO
MEXATE-AQ, METHOTREXATE SODIUM
MUTAMYCIN, MITOMYCIN
PLATINOL, CISPLATIN
PLATINOL-AQ, CISPLATIN
QUESTRAN LIGHT, CHOLESTYRAMINE
QUESTRAN, CHOLESTYRAMINE
* BRISTOL MYERS PRODUCTS INC
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
NUPRIN, IBUPROFEN (OTC)

BRISTOL MYERS SQUIBB
* BRISTOL MYERS SQUIBB
AZACTAM, AZTREONAM
DELALUTIN, HYDROXYPROGESTERONE CAPROATE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
FOLLUTEIN, GONADOTROPIN, CHORIONIC
GLUCOVANCE, GLYBURIDE
HALOG, HALCINONIDE
MEGACE, MEGESTROL ACETATE
MEXATE-AQ PRESERVED, METHOTREXATE SODIUM
MONOPRIL-HCT, FOSINOPRIL SODIUM
MYCOSTATIN, NYSTATIN
ORA-TESTRYL, FLUOXYMESTERONE
PRAVACHOL, PRAVASTATIN SODIUM
STILBESTROL, DIETHYLSTILBESTROL
STILBETIN, DIETHYLSTILBESTROL
TESLAC, TESTOLACTONE
VINCREX, VINCRISTINE SULFATE
* BRISTOL MYERS SQUIBB CO
AMITID, AMITRIPTYLINE HYDROCHLORIDE
AMNESTROGEN, ESTROGENS, ESTERIFIED
AZACTAM IN PLASTIC CONTAINER, AZTREONAM
CEENU, LOMUSTINE
DROXIA, HYDROXYUREA
ESTRACE, ESTRADIOL
ETHRIL 250, ERYTHROMYCIN STEARATE
ETHRIL 500, ERYTHROMYCIN STEARATE
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
FUNGIZONE, AMPHOTERICIN B
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
HYDREA, HYDROXYUREA
KENACORT, TRIAMCINOLONE
KENACORT, TRIAMCINOLONE DIACETATE
METAGLIP, GLIPIZIDE
MYCOSTATIN, NYSTATIN
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NYDRAZID, ISONIAZID
PARAPLATIN, CARBOPLATIN
PRAVIGARD PAC (COPACKAGED), ASPIRIN
PROLIXIN DECANOATE, FLUPHENAZINE DECANOATE

FDA data supplied by DrugPatentWatch.com

PROTAMINE ZINC INSULIN, INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF (OTC)
RAU-SED, RESERPINE
REYATAZ, ATAZANAVIR SULFATE
REZIPAS, AMINOSALICYLIC ACID RESIN COMPLEX
RUBEX, DOXORUBICIN HYDROCHLORIDE
RUBRAMIN PC, CYANOCOBALAMIN
SUSTIVA, EFAVIRENZ
TERFONYL, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
TESLAC, TESTOLACTONE
TUBOCURARINE CHLORIDE, TUBOCURARINE CHLORIDE
VAGISTAT-1, TIOCONAZOLE (OTC)
VELOSEF, CEPHRADINE
VEPESID, ETOPOSIDE
VESPRIN, TRIFLUPROMAZINE HYDROCHLORIDE
VIDEX EC, DIDANOSINE
VITAMIN A, VITAMIN A PALMITATE
ZERIT XR, STAVUDINE

* BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
BLENOXANE, BLEOMYCIN SULFATE
BUSPAR, BUSPIRONE HYDROCHLORIDE
CEFZIL, CEFPROZIL
CYTOXAN, CYCLOPHOSPHAMIDE
DEAPRIL-ST, ERGOLOID MESYLATES
DOVONEX, CALCIPOTRIENE
ESTRACE, ESTRADIOL
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
GLUCOPHAGE, METFORMIN HYDROCHLORIDE
IFEX, IFOSFAMIDE
IFEX/MESNEX KIT, IFOSFAMIDE
KENALOG, TRIAMCINOLONE ACETONIDE
LYOPHILIZED CYTOXAN, CYCLOPHOSPHAMIDE
MAXIPIME, CEFEPIME HYDROCHLORIDE (ARGININE FORMULATION)
MONOPRIL, FOSINOPRIL SODIUM
PARAPLATIN, CARBOPLATIN
SERZONE, NEFAZODONE HYDROCHLORIDE
STADOL, BUTORPHANOL TARTRATE
TAXOL, PACLITAXEL
TEQUIN, GATIFLOXACIN
VIDEX, DIDANOSINE
VUMON, TENIPOSIDE
ZERIT, STAVUDINE

* BRISTOL MYERS SQUIBB MEDICAL IMAGING
DEFINITY, PERFLUTREN
GALLIUM CITRATE GA 67, GALLIUM CITRATE, GA-67
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201
XENON XE 133, XENON, XE-133

* BRISTOL MYERS SQUIBB PHARMA CO
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
COUMADIN, WARFARIN SODIUM
GLUCOSCAN, TECHNETIUM TC-99M GLUCEPTATE KIT
LODOSYN, CARBIDOPA
MIRALUMA, TECHNETIUM TC-99M SESTAMIBI KIT
NARCAN, NALOXONE HYDROCHLORIDE
OXYCODONE 2.5/APAP 500, ACETAMINOPHEN
OXYCODONE 5/APAP 500, ACETAMINOPHEN
REMSED, PROMETHAZINE HYDROCHLORIDE
SINEMET CR, CARBIDOPA
SINEMET, CARBIDOPA
SUSTIVA, EFAVIRENZ

* BRISTOL MYERS SQUIBB SPA
PENICILLIN G SODIUM, PENICILLIN G SODIUM

BRYAN

* BRYAN CORP
SCLEROSOL, TALC
TALC, TALC

BUNDY

* CM BUNDY CO
BUTABARBITAL, BUTABARBITAL SODIUM
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE

** C **

C AND M PHARMA

* C AND M PHARMACAL INC
HC (HYDROCORTISONE), HYDROCORTISONE
HC (HYDROCORTISONE), HYDROCORTISONE (OTC)
HI-COR, HYDROCORTISONE

CADEMA

* CADEMA MEDICAL PRODUCTS INC
RBC-SCAN, TECHNETIUM TC-99M RED BLOOD CELL KIT

CALGON

* CALGON CORP DIV MERCK AND CO INC
SEPTI-SOFT, HEXACHLOROPHENE

CAMALL

* CAMALL CO INC
CAM-METRAZINE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE

CARACO

* CARACO PHARMACEUTICAL LABORATORIES LTD
CARBAMAZEPINE, CARBAMAZEPINE

FDA data supplied by DrugPatentWatch.com

CLONAZEPAM, CLONAZEPAM
CLOZAPINE, CLOZAPINE
DIGOXIN, DIGOXIN
FLURBIPROFEN, FLURBIPROFEN
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
OXAPROZIN, OXAPROZIN
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HCL, TIZANIDINE HYDROCHLORIDE
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE

CARLISLE
* CARLISLE LABORATORIES INC
ALPHACAINE HCL W/ EPINEPHRINE, EPINEPHRINE
ALPHACAINE HCL, LIDOCAINE HYDROCHLORIDE
ALPHACAINE, LIDOCAINE

CARLSBAD
* CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FAMOTIDINE, FAMOTIDINE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
LOVASTATIN, LOVASTATIN

CARNRICK
* CARNRICK LABORATORIES INC DIV GW CARNRICK CO
CAPITAL WITH CODEINE, ACETAMINOPHEN

CAROLINA MEDCL
* CAROLINA MEDICAL PRODUCTS CO
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
ISONIAZID, ISONIAZID
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SPS, SODIUM POLYSTYRENE SULFONATE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE

CELGENE
* CELGENE CORP
THALOMID, THALIDOMIDE

CELL THERAP
* CELL THERAPEUTICS INC
TRISENOX, ARSENIC TRIOXIDE

CELLTECH MFG
* CELLTECH MANUFACTURING INC
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE

CELLTECH PHARMS
* CELLTECH PHARMACEUTICALS INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BIPHETAMINE 12.5, AMPHETAMINE RESIN COMPLEX
BIPHETAMINE 20, AMPHETAMINE RESIN COMPLEX
BIPHETAMINE 7.5, AMPHETAMINE RESIN COMPLEX
CORSYM, CHLORPHENIRAMINE POLISTIREX (OTC)
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
DEXACORT, DEXAMETHASONE SODIUM PHOSPHATE
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
GASTROCROM, CROMOLYN SODIUM
GLUTETHIMIDE, GLUTETHIMIDE
IONAMIN, PHENTERMINE RESIN COMPLEX
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
MYKROX, METOLAZONE
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
PSEUDO-12, PSEUDOEPHEDRINE POLISTIREX (OTC)
SEMPREX-D, ACRIVASTINE
TUSSIONEX, CHLORPHENIRAMINE POLISTIREX
ZAROXOLYN, METOLAZONE

CENCI
* CENCI POWDER PRODUCTS INC
THEOPHYLLINE, THEOPHYLLINE
* HR CENCI LABORATORIES INC
ACTAHIST, PSEUDOEPHEDRINE HYDROCHLORIDE
DIBENIL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
ELIXOMIN, THEOPHYLLINE
HISTAFED, PSEUDOEPHEDRINE HYDROCHLORIDE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
PROMETHAZINE VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE VC W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE, PROMETHAZINE HYDROCHLORIDE
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE, CODEINE PHOSPHATE

CENT PHARMS
* CENTRAL PHARMACEUTICALS INC
ACETAMINOPHEN AND HYDROCODONE BITARTRATE, ACETAMINOPHEN
AZDONE, ASPIRIN
CO-GESIC, ACETAMINOPHEN
DEXACEN-4, DEXAMETHASONE SODIUM PHOSPHATE
PHENYLPROPANOLAMINE HCL W/ CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
SYNOPHYLATE, THEOPHYLLINE SODIUM GLYCINATE

FDA data supplied by DrugPatentWatch.com

THEOCLEAR-100, THEOPHYLLINE
THEOCLEAR-200, THEOPHYLLINE
THEOCLEAR-80, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE

CENTURY PHARMS
* CENTURY PHARMACEUTICALS INC
P.A.S. SODIUM, AMINOSALICYLATE SODIUM

CEPH INTL
* CEPH INTERNATIONAL CORP
CEFACLOR, CEFACLOR
CEPHALEXIN, CEPHALEXIN

CEPHALON
* CEPHALON INC
GABITRIL, TIAGABINE HYDROCHLORIDE
PROVIGIL, MODAFINIL

CHAMBERLIN PARENTERL
* CHAMBERLIN PARENTERAL CORP
HEPARIN SODIUM, HEPARIN SODIUM

CHASE CHEM
* CHASE CHEMICAL CO LP
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL

CHASE LABS NJ
* CHASE LABORATORIES INC
NIFEDIPINE, NIFEDIPINE

CHATTEM
* CHATTEM INC
SELSUN, SELENIUM SULFIDE

CHESEBROUGH PONDS
* CHESEBROUGH PONDS INC
EXTRA-STRENGTH AIM, SODIUM MONOFLUOROPHOSPHATE (OTC)
VIRAC REX, UNDECOYLIUM CHLORIDE

CHIRHOCLIN
* CHIRHOCLIN INC
SECREFLO, SECRETIN

CHIRON
* CHIRON CORP
TOBI, TOBRAMYCIN

CIBA
* CIBA VISION CORP DIV NOVARTIS CO
CATARASE, CHYMOTRYPSIN

CIS
* CIS BIOINDUSTRIES COMPAGNIE
SODIUM IODIDE I 131, SODIUM IODIDE, I-131
* CIS US INC
AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
AN-MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
IOBENGUANE SULFATE I 131, IOBENGUANE SULFATE I 131
IODOHIPPURATE SODIUM I 131, IODOHIPPURATE SODIUM, I-131
MICROLITE, TECHNETIUM TC-99M ALBUMIN COLLOID KIT
OSTEOLITE, TECHNETIUM TC-99M MEDRONATE KIT
PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
PYROLITE, TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT
SELENOMETHIONINE SE 75, SELENOMETHIONINE, SE-75
SODIUM PERTECHNETATE TC 99M, TECHNETIUM TC-99M SODIUM PERTECHNETATE

CLAY PARK
* CLAY PARK LABORATORIES INC
AMMONIUM LACTATE, AMMONIUM LACTATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DESOXIMETASONE, DESOXIMETASONE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN, GENTAMICIN SULFATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NITROFURAZONE, NITROFURAZONE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
PERMETHRIN, PERMETHRIN
PERMETHRIN, PERMETHRIN (OTC)
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIDESILON, DESONIDE
TRIPLE SULFA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)

CLINTEC NUTR
* CLINTEC NUTRITION CO SUB CLINIQUE
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

CLONMEL

FDA data supplied by DrugPatentWatch.com

* CLONMEL HEALTHCARE
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM

CLONMEL HLTHCARE
* CLONMEL HEALTHCARE LTD
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPRAZOLAM, ALPRAZOLAM
ATENOLOL, ATENOLOL
CAPTOPRIL, CAPTOPRIL
CEFACLOR, CEFACLOR
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DIAZEPAM, DIAZEPAM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOLENE, PROPOXYPHENE HYDROCHLORIDE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
ESTRADIOL, ESTRADIOL
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FUROSEMIDE, FUROSEMIDE
GEMFIBROZIL, GEMFIBROZIL
GLYBURIDE (MICRONIZED), GLYBURIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDOMETHACIN, INDOMETHACIN
KETOPROFEN, KETOPROFEN
LORAZEPAM, LORAZEPAM
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NAPROXEN, NAPROXEN
NILSTAT, NYSTATIN
PENTOXIFYLLINE, PENTOXIFYLLINE
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRAZINAMIDE, PYRAZINAMIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
SULFASALAZINE, SULFASALAZINE
SULINDAC, SULINDAC
TOLBUTAMIDE, TOLBUTAMIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

COLGATE
* COLGATE ORAL PHARMACEUTICALS INC
ORABASE HCA, HYDROCORTISONE ACETATE
PERIOGARD, CHLORHEXIDINE GLUCONATE

COLGATE PALMOLIVE
* COLGATE PALMOLIVE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)

COLLAGENEX
* COLLAGENEX INC
PERIOSTAT, DOXYCYCLINE HYCLATE

COLLAGENEX PHARMS
* COLLAGENEX PHARMACEUTICALS INC
PERIOSTAT, DOXYCYCLINE HYCLATE

COLLEGIUM
* COLLEGIUM PHARMACEUTICALS
TRI-NASAL, TRIAMCINOLONE ACETONIDE

COLUMBIA LABS
* COLUMBIA LABORATORIES INC
STRIANT, TESTOSTERONE

COLUMBIA RES LABS
* COLUMBIA RESEARCH LABORATORIES INC
CRINONE, PROGESTERONE

COMBE
* COMBE INC
BACITRACIN, BACITRACIN (OTC)
LANABIOTIC, BACITRACIN (OTC)
LANABIOTIC, BACITRACIN ZINC (OTC)

CONNETICS
* CONNETICS CORP
LUXIQ, BETAMETHASONE VALERATE
OLUX FOAM, CLOBETASOL PROPIONATE

CONSOLIDATED MIDLAND
* CONSOLIDATED MIDLAND CORP
TEEBACIN, AMINOSALICYLATE SODIUM

CONSOLIDATED PHARM
* CONSOLIDATED PHARMACEUTICAL GROUP INC
AMOXICILLIN, AMOXICILLIN
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

FDA data supplied by DrugPatentWatch.com

PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM

CONTROLLED THERAP
* CONTROLLED THERAPEUTICS (SCOTLAND) LTD
CERVIDIL, DINOPROSTONE

COOK IMAGING
* COOK IMAGING CORP
IOPAMIDOL-200, IOPAMIDOL
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL

COPANOS
* JOHN D COPANOS AND CO INC
PENICILLIN G SODIUM, PENICILLIN G SODIUM
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE

COPLEY PHARM
* COPLEY PHARMACEUTICAL INC
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
ATENOLOL, ATENOLOL
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BROMATAPP, BROMPHENIRAMINE MALEATE (OTC)
BROMPHERIL, DEXBROMPHENIRAMINE MALEATE (OTC)
CAPTOPRIL, CAPTOPRIL
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CO-LAV, POLYETHYLENE GLYCOL 3350
DESONIDE, DESONIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
ETHOSUXIMIDE, ETHOSUXIMIDE
EVALOSE, LACTULOSE
FLUOCINONIDE, FLUOCINONIDE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
GO-EVAC, POLYETHYLENE GLYCOL 3350
GUANABENZ ACETATE, GUANABENZ ACETATE
GYNIX, CLOTRIMAZOLE (OTC)
HALOPERIDOL, HALOPERIDOL LACTATE
HEPTALAC, LACTULOSE
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1%, HYDROCORTISONE ACETATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MEBENDAZOLE, MEBENDAZOLE
MEGESTROL ACETATE, MEGESTROL ACETATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHAZOLAMIDE, METHAZOLAMIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
PEMOLINE, PEMOLINE
PIROXICAM, PIROXICAM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE, PREDNISOLONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
QUINIDINE SULFATE, QUINIDINE SULFATE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE HCL, THIOTHIXENE HYDROCHLORIDE
TRETINOIN, TRETINOIN
URSODIOL, URSODIOL
VALPROIC ACID, VALPROIC ACID

COREPHARMA
* COREPHARMA LLC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARISOPRODOL, CARISOPRODOL
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE ASPARTATE
GLYBURIDE, GLYBURIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RIMANTADINE HCL, RIMANTADINE HYDROCHLORIDE
TIZANIDINE HCL, TIZANIDINE HYDROCHLORIDE
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE

CUBIST
* CUBIST PHARMCEUTICALS INC
CUBICIN, DAPTOMYCIN

CUMBERLAND SWAN
* CUMBERLAND SWAN INC
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)

FDA data supplied by DrugPatentWatch.com

CYTOGEN
* CYTOGEN CORP
QUADRAMET, SAMARIUM SM 153 LEXIDRONAM PENTASODIUM

** D **

DAIICHI
* DAIICHI PHARMACEUTICAL CO LTD
FLOXIN, OFLOXACIN
* DAIICHI PHARMACEUTICAL CORP
EVOXAC, CEVIMELINE HYDROCHLORIDE

DAINIPPON
* DAINIPPON PHARMACEUTICAL USA CORP
ZONEGRAN, ZONISAMIDE

DANCO LABS LLC
* DANCO LABORATORIES LLC
MIFEPREX, MIFEPRISTONE

DAVIS AND GECK
* DAVIS AND GECK DIV AMERICAN CYANAMID CO
FLAXEDIL, GALLAMINE TRIETHIODIDE
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE

DEL RAY LABS
* DEL RAY LABORATORIES INC
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
DEL-VI-A, VITAMIN A PALMITATE
TRIDERM, TRIAMCINOLONE ACETONIDE

DELL LABS
* DELL LABORATORIES INC
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
HEPARIN SODIUM, HEPARIN SODIUM
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
THIAMINE HCL, THIAMINE HYDROCHLORIDE

DENTSPLY PHARM
* DENTSPLY PHARMACEUTICAL
CITANEST FORTE, EPINEPHRINE BITARTRATE
CITANEST PLAIN, PRILOCAINE HYDROCHLORIDE
DURANEST, EPINEPHRINE BITARTRATE
ORAQIX, LIDOCAINE
POLOCAINE W/ LEVONORDEFRIN, LEVONORDEFRIN
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE

DEPROCO
* DEPROCO INC
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
SCANDONEST L, LEVONORDEFRIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE

DERMIK LABS
* DERMIK LABORATORIES DIV AVENTIS PHARMACEUTICALS INC
BENZACLIN, BENZOYL PEROXIDE
BENZAMYCIN PAK, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE
CARAC, FLUOROURACIL
DERMATOP, PREDNICARBATE
HYTONE, HYDROCORTISONE
KLARON, SULFACETAMIDE SODIUM
NORITATE, METRONIDAZOLE
PSORCON, DIFLORASONE DIACETATE
* DERMIK LABORATORIES INC
DERMATOP E EMOLLIENT, PREDNICARBATE
PENLAC, CICLOPIROX
* DERMIK LABORATORIES INC SUB RORER
HYTONE, HYDROCORTISONE

DESERET
* DESERET MEDICAL INC DIV BECTON DICKINSON AND CO
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

DEXCEL LTD
* DEXCEL LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

DEXCEL PHARMA
* DEXCEL PHARMA TECHNOLOGIES LTD
PERIOCHIP, CHLORHEXIDINE GLUCONATE

DEY
* DEY LP
ACCUNEB, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CUROSURF, PORACTANT ALFA
DUONEB, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISOETHARINE HCL S/F, ISOETHARINE HYDROCHLORIDE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE

FDA data supplied by DrugPatentWatch.com

MUCOSIL-10, ACETYLCYSTEINE
MUCOSIL-20, ACETYLCYSTEINE

DHL
* DHL LABORATORIES INC
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE

DIAL
* DIAL CORP DIV GREYHOUND CO
DIAL, HEXACHLOROPHENE

DIATIDE RES LABS
* DIATIDE RESEARCH LABORATORIES DIV BERLEX LABS INC
ACUTECT, TECHNETIUM TC-99M APCITIDE
NEO TECT KIT, TECHNETIUM TC-99M DEPREOTIDE

DISTA
* DISTA PRODUCTS CO DIV ELI LILLY AND CO
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ILOSONE, ERYTHROMYCIN ESTOLATE
ILOTYCIN GLUCEPTATE, ERYTHROMYCIN GLUCEPTATE
ILOTYCIN, ERYTHROMYCIN
NALFON, FENOPROFEN CALCIUM
VALMID, ETHINAMATE

DOW PHARM
* DOW PHARMACEUTICAL CORP SUB DOW CHEMICAL CO
DOW-ISONIAZID, ISONIAZID
NEO-POLYCIN, BACITRACIN ZINC
NEO-POLYCIN, GRAMICIDIN
QUIDE, PIPERACETAZINE

DOWNSTATE CLINCL
* DOWNSTATE CLINICAL PET CENTER
FLUDEOXYGLUCOSE F 18, FLUDEOXYGLUCOSE, F-18

DPT
* DPT LABORATORIES INC
EMBELINE, CLOBETASOL PROPIONATE

DR REDDYS LABS INC
* DR REDDYS LABORATORIES INC
AMVAZ, AMLODIPINE MALEATE
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NEFAZODONE HCL, NEFAZODONE HYDROCHLORIDE
TIZANIDINE HCL, TIZANIDINE HYDROCHLORIDE

DR REDDYS LABS LTD
* DR REDDYS LABORATORIES LTD
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
OXAPROZIN, OXAPROZIN
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)

DRAXIMAGE
* DRAXIMAGE INC
DTPA, TECHNETIUM TC-99M PENTETATE KIT
SODIUM IODIDE I 131, KIT, SODIUM IODIDE, I-131
TECHNESCAN GLUCEPTATE, TECHNETIUM TC-99M GLUCEPTATE KIT
TECHNESCAN HIDA, TECHNETIUM TC-99M LIDOFENIN KIT
TECHNESCAN MDP KIT, TECHNETIUM TC-99M MEDRONATE KIT
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

DSM PHARMS
* DSM PHARMACEUTICALS INC
ALOPRIM, ALLOPURINOL SODIUM

DUNHALL
* DUNHALL PHARMACEUTICALS INC
TRIAPRIN, ACETAMINOPHEN

DURAMED
* DURAMED PHARMACEUTICALS INC
CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A

DURAMED PHARMS BARR
* DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMINOPHYLLINE, AMINOPHYLLINE
AVIANE-21, ETHINYL ESTRADIOL
AVIANE-28, ETHINYL ESTRADIOL
AYGESTIN, NORETHINDRONE ACETATE
CHLORPROPAMIDE, CHLORPROPAMIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CRYSELLE, ETHINYL ESTRADIOL
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DIAMOX, ACETAZOLAMIDE
DIAMOX, ACETAZOLAMIDE SODIUM
DIAZEPAM, DIAZEPAM
ENPRESSE-21, ETHINYL ESTRADIOL
ENPRESSE-28, ETHINYL ESTRADIOL
ESTROPIPATE, ESTROPIPATE
GLIPIZIDE, GLIPIZIDE
GYNODIOL, ESTRADIOL
HALOPERIDOL, HALOPERIDOL
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE

FDA data supplied by DrugPatentWatch.com

INDOMETHACIN, INDOMETHACIN
ISONIAZID, ISONIAZID
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPA, METHYLDOPA
METHYLPREDNISOLONE, METHYLPREDNISOLONE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PREDNISONE, PREDNISONE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPRANOLOL HCL & HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
TEMAZEPAM, TEMAZEPAM
TOLAZAMIDE, TOLAZAMIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
ZEBETA, BISOPROLOL FUMARATE
ZIAC, BISOPROLOL FUMARATE

DUSA
* DUSA PHARMACEUTICALS INC
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

DXS DEVICES
* DIAGNOSTICS AND DEVICES INC
PYLORI-CHEK BREATH TEST, UREA, C-13

DYNAPHARM
* DYNAPHARM INC
COLOVAGE, POLYETHYLENE GLYCOL 3350

** E **

E Z EM
* E Z EM CO INC
E-Z-EM PREP LYTE, POLYETHYLENE GLYCOL 3350

EASTMAN KODAK
* EASTMAN KODAK CO
CARBOCAINE W/ NEO-COBEFRIN, LEVONORDEFRIN
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
RAVOCAINE AND NOVOCAIN W/ LEVOPHED, NOREPINEPHRINE BITARTRATE
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN, LEVONORDEFRIN

ECOLAB
* ECOLAB INC
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

EDWARDS LIFESCIENCES
* EDWARDS LIFESCIENCES RESEARCH MEDICAL INC
RIMSO-50, DIMETHYL SULFOXIDE

EGIS
* EGIS PHARMACEUTICALS
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
PIROXICAM, PIROXICAM

EGIS PHARMS
* EGIS PHARMACEUTICALS LTD
CAPTOPRIL, CAPTOPRIL

EISAI MEDCL RES
* EISAI MEDICAL RESEARCH INC
ACIPHEX, RABEPRAZOLE SODIUM
ARICEPT, DONEPEZIL HYDROCHLORIDE

ELAN DRUG
* ELAN DRUG DELIVERY INC
VERELAN, VERAPAMIL HYDROCHLORIDE

ELAN PHARM
* ELAN PHARMACEUTICAL RESEARCH CORP
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
KETOPROFEN, KETOPROFEN
NIFEDIPINE, NIFEDIPINE
VERELAN PM, VERAPAMIL HYDROCHLORIDE

ELAN PHARMA
* ELAN PHARMACEUTICALS INC
NAPRELAN, NAPROXEN SODIUM

ELAN PHARMS
* ELAN PHARMACEUTICALS
FROVA, FROVATRIPTAN SUCCINATE
ZANAFLEX, TIZANIDINE HYDROCHLORIDE
• ELAN PHARMACEUTICALS INC
ZANAFLEX, TIZANIDINE HYDROCHLORIDE

ELKINS SINN
* ELKINS SINN DIV AH ROBINS CO INC
AMIKACIN SULFATE, AMIKACIN SULFATE
AMINOPHYLLINE, AMINOPHYLLINE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CHLORAMPHENICOL, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CORTISONE ACETATE, CORTISONE ACETATE
DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE
DIAZEPAM, DIAZEPAM
DIGOXIN, DIGOXIN
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE

FDA data supplied by DrugPatentWatch.com

ERYTHROMYCIN, ERYTHROMYCIN LACTOBIONATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE
METRONIDAZOLE, METRONIDAZOLE
NALOXONE, NALOXONE HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN
OXACILLIN SODIUM, OXACILLIN SODIUM
PANCURONIUM, PANCURONIUM BROMIDE
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PHENYTOIN, PHENYTOIN SODIUM
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SUCCINATE, SODIUM SUCCINATE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
VITAMIN A, VITAMIN A PALMITATE

ELKINS SINN PHARM
* ELKINS SINN PHARMACEUTICAL CO
NALOXONE, NALOXONE HYDROCHLORIDE

ENCYSIVE
* ENCYSIVE PHARMACEUTICALS INC
ARGATROBAN, ARGATROBAN

ENDO LABS
* ENDO LABORATORIES INC DIV DUPONT MERCK PHARMACEUTICAL CO
CAPTOPRIL, CAPTOPRIL
* ENDO LABORATORIES LLC
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL

ENDO PHARMS
* ENDO PHARMACEUTICALS INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
ETODOLAC, ETODOLAC
GLIPIZIDE, GLIPIZIDE
HYCODAN, HOMATROPINE METHYLBROMIDE
HYCOMINE PEDIATRIC, HYDROCODONE BITARTRATE
HYCOMINE, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
MOBAN, MOLINDONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NARCAN, NALOXONE HYDROCHLORIDE
NUBAIN, NALBUPHINE HYDROCHLORIDE
NUMORPHAN, OXYMORPHONE HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERCODAN-DEMI, ASPIRIN
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
SYMMETREL, AMANTADINE HYDROCHLORIDE
VALPIN 50, ANISOTROPINE METHYLBROMIDE

ENVIRODERM
* ENVIRODERM PHARMACEUTICALS INC
IVY BLOCK, BENTOQUATAM (OTC)

ENZON
* ENZON INC
ABELCET, AMPHOTERICIN B
ADAGEN, PEGADEMASE BOVINE

EON
* EON LABORATORIES INC
METOLAZONE, METOLAZONE
* EON LABORATORIES MANUFACTURING INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALKERGOT, ERGOLOID MESYLATES
ALPHAZINE, PHENDIMETRAZINE TARTRATE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUMETANIDE, BUMETANIDE
BUPROPION HCL, BUPROPION HYDROCHLORIDE
BUPROPRION HCL, BUPROPION HYDROCHLORIDE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM

FDA data supplied by DrugPatentWatch.com

CAPTOPRIL, CAPTOPRIL
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLONAZEPAM, CLONAZEPAM
CYCLOSPORINE, CYCLOSPORINE
DESIPRAMINE HCL, DESIPRAMINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE ASPARTATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE, DOXYCYCLINE
DRALSERP, HYDRALAZINE HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLUTAMIDE, FLUTAMIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GUANABENZ ACETATE, GUANABENZ ACETATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRAP-ES, HYDRALAZINE HYDROCHLORIDE
HYDRO-SERP "25", HYDROCHLOROTHIAZIDE
HYDRO-SERP "50", HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOCIN SR, INDOMETHACIN
ISONIAZID, ISONIAZID
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOCHOLEST LIGHT, CHOLESTYRAMINE
LOCHOLEST, CHOLESTYRAMINE
LOVASTATIN, LOVASTATIN
MEPRO-ASPIRIN, ASPIRIN
MEPROBAMATE, MEPROBAMATE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
METHADONE HCL, METHADONE HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METRONIDAZOLE, METRONIDAZOLE
MIDODRINE HCL, MIDODRINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NABUMETONE, NABUMETONE
NALTREXONE HCL, NALTREXONE HYDROCHLORIDE
NEFAZODONE HCL, NEFAZODONE HYDROCHLORIDE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NITROFURANTOIN, NITROFURANTOIN
NIZATIDINE, NIZATIDINE
NYSTATIN, NYSTATIN
OMEPRAZOLE, OMEPRAZOLE
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXAPROZIN, OXAPROZIN
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROBENECID AND COLCHICINE, COLCHICINE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPOXYPHENE COMPOUND 65, ASPIRIN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PSEUDOEPHEDRINE HCL AND TRIPROLIDINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE
RIFAMPIN, RIFAMPIN
SOTALOL HCL, SOTALOL HYDROCHLORIDE
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFASALAZINE, SULFASALAZINE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HCL, TIZANIDINE HYDROCHLORIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
WESTADONE, METHADONE HYDROCHLORIDE

* EON LABS INC
METOLAZONE, METOLAZONE

ERSANA

* ERSANA INC SUB ER SQUIBB AND SONS

FDA data supplied by DrugPatentWatch.com

VELOSEF '250', CEPHRADINE
VELOSEF '500', CEPHRADINE

ESI
* ESI PHARMACAL
CYCRIN, MEDROXYPROGESTERONE ACETATE

ESI LEDERLE
* ESI LEDERLE INC
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
CEFOXITIN, CEFOXITIN SODIUM
VINORELBINE TARTRATE, VINORELBINE TARTRATE

ESP PHARMA
* ESP PHARMA INC
BUSULFEX, BUSULFAN
DECLOMYCIN, DEMECLOCYCLINE HYDROCHLORIDE
ISMO, ISOSORBIDE MONONITRATE
SECTRAL, ACEBUTOLOL HYDROCHLORIDE
TENEX, GUANFACINE HYDROCHLORIDE

ETHITEK
* ETHITEK PHARMACEUTICALS CO
MOCTANIN, MONOCTANOIN

EVERYLIFE
* EVERYLIFE
APAP W/ CODEINE PHOSPHATE, ACETAMINOPHEN
CORTISONE ACETATE, CORTISONE ACETATE
FOLIC ACID, FOLIC ACID
HYDROCORTISONE, HYDROCORTISONE
NIACIN, NIACIN
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
STANOZIDE, ISONIAZID
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL

** F **

FALCON PHARMS
* FALCON PHARMACEUTICALS INC
TIMOLOL MALEATE, TIMOLOL MALEATE
* FALCON PHARMACEUTICALS LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIPIVEFRIN HCL, DIPIVEFRIN HYDROCHLORIDE
ECONOPRED PLUS, PREDNISOLONE ACETATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
LEVOBUNOLOL HCL, LEVOBUNOLOL HYDROCHLORIDE
MAXITROL, DEXAMETHASONE
METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBREX, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

FEI
* FEI WOMENS HEALTH LLC
COPPER T MODEL TCU 380A, COPPER

FERNDALE LABS
* FERNDALE LABORATORIES INC
ADPHEN, PHENDIMETRAZINE TARTRATE
AMOSENE, MEPROBAMATE
AQUAPHYLLIN, THEOPHYLLINE
DELAXIN, METHOCARBAMOL
DIAZEPAM, DIAZEPAM
FERNDEX, DEXTROAMPHETAMINE SULFATE
FERNISOLONE-P, PREDNISOLONE
FERNISONE, PREDNISONE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LOCOID, HYDROCORTISONE BUTYRATE
MICORT-HC, HYDROCORTISONE ACETATE
OBESTIN-30, PHENTERMINE HYDROCHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PRAMOSONE, HYDROCORTISONE ACETATE
RAUSERPIN, RAUWOLFIA SERPENTINA
STRIFON FORTE DSC, CHLORZOXAZONE

FERRANTE
* JOHN J FERRANTE
AMPHICOL, CHLORAMPHENICOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
HYDROCORTISONE, HYDROCORTISONE
OXY-KESSO-TETRA, OXYTETRACYCLINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

FERRING
* FERRING PHARMACEUTICALS INC
A.P.L., GONADOTROPIN, CHORIONIC
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
BRAVELLE, UROFOLLITROPIN
CONCENTRAID, DESMOPRESSIN ACETATE
LUTREPULSE KIT, GONADORELIN ACETATE

FDA data supplied by DrugPatentWatch.com

MENOTROPINS, MENOTROPINS (FSH;LH)
MINIRIN, DESMOPRESSIN ACETATE
REPRONEX, MENOTROPINS (FSH;LH)
SECRETIN-FERRING, SECRETIN
THYREL TRH, PROTIRELIN

FIRST HORIZON
* FIRST HORIZON PHARMACEUTICAL CORP
COGNEX, TACRINE HYDROCHLORIDE
FURADANTIN, NITROFURANTOIN
PONSTEL, MEFENAMIC ACID
ROBINUL FORTE, GLYCOPYRROLATE
ROBINUL, GLYCOPYRROLATE
SULAR, NISOLDIPINE

FISONS
* FISONS CORP
IRON DEXTRAN, IRON DEXTRAN
ISOCLOR, CHLORPHENIRAMINE MALEATE (OTC)
PENNTUSS, CHLORPHENIRAMINE POLISTIREX (OTC)
SOMOPHYLLIN, AMINOPHYLLINE
SOMOPHYLLIN-DF, AMINOPHYLLINE
SOMOPHYLLIN-T, THEOPHYLLINE
VAPO-ISO, ISOPROTERENOL HYDROCHLORIDE

FLEMING PHARMS
* FLEMING AND CO PHARMACEUTICALS INC
AEROLATE III, THEOPHYLLINE
AEROLATE JR, THEOPHYLLINE
AEROLATE SR, THEOPHYLLINE
AEROLATE, THEOPHYLLINE

FLEMINGTON PHARM
* FLEMINGTON PHARMACEUTICAL CORP
NIFEDIPINE, NIFEDIPINE

FONDA BV
* FONDA BV
ARIXTRA, FONDAPARINUX SODIUM

FOREST LABS
* FOREST LABORATORIES INC
CELEXA, CITALOPRAM HYDROBROMIDE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
LEXAPRO, ESCITALOPRAM OXALATE
NAMENDA, MEMANTINE HYDROCHLORIDE
TESSALON, BENZONATATE

FOREST PHARMS
* FOREST PHARMACEUTICALS INC
BANCAP HC, ACETAMINOPHEN
BANCAP, ACETAMINOPHEN
DURADYNE DHC, ACETAMINOPHEN
ESGIC, ACETAMINOPHEN
METRA, PHENDIMETRAZINE TARTRATE
MICROSUL, SULFAMETHIZOLE
PROKLAR, SULFAMETHIZOLE
SULFALOID, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
WOLFINA, RAUWOLFIA SERPENTINA

FORREST LABS
* FORREST LABORATORIES INC
AMBENYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
BETAPRONE, PROPIOLACTONE
DURAPHYL, THEOPHYLLINE
ELIXICON, THEOPHYLLINE
ELIXOPHYLLIN SR, THEOPHYLLINE
ELIXOPHYLLIN, THEOPHYLLINE
FORBAXIN, METHOCARBAMOL
PYOCIDIN, HYDROCORTISONE
SUS-PHRINE SULFITE-FREE, EPINEPHRINE
THYROLAR-0.25, LIOTRIX (T4;T3)
THYROLAR-0.5, LIOTRIX (T4;T3)
THYROLAR-1, LIOTRIX (T4;T3)
THYROLAR-2, LIOTRIX (T4;T3)
THYROLAR-3, LIOTRIX (T4;T3)
THYROLAR-5, LIOTRIX (T4;T3)

FOUGERA
* E FOUGERA DIV ALTANA INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE, LIDOCAINE
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE, NEOMYCIN SULFATE
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN, NYSTATIN
NYSTATIN-TRIAMCINOLONE ACETONIDE, NYSTATIN
TIMOLOL MALEATE, TIMOLOL MALEATE
TRIPLE SULFA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)

FRANKLIN PHARMS
* FRANKLIN PHARMACEUTICALS INC
SILDAFLO, SILVER SULFADIAZINE

FRESENIUS

FDA data supplied by DrugPatentWatch.com

* FRESENIUS USA INC
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

FRESENIUS KABI
* FRESENIUS KABI CLAYTON L P
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, AMINO ACIDS CYSTEINE HCL, CYSTEINE HYDROCHLORIDE
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
NEOPHAM 6.4%, AMINO ACIDS
VITAPED, ASCORBIC ACID
* FRESENIUS KABI CLAYTON R&D INC
NOVAMINE 11.4%, AMINO ACIDS
NOVAMINE 15%, AMINO ACIDS
NOVAMINE 8.5%, AMINO ACIDS
VEINAMINE 8%, AMINO ACIDS

FRESENIUS MEDCL
* FRESENIUS MEDICAL CARE NORTH AMERICA
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

FUJISAWA HLTHCARE
* FUJISAWA HEALTHCARE INC
ADENOCARD, ADENOSINE
ADENOSCAN, ADENOSINE
AMBISOME, AMPHOTERICIN B
ARISTOCORT A, TRIAMCINOLONE ACETONIDE
ARISTOCORT, TRIAMCINOLONE
ARISTOCORT, TRIAMCINOLONE ACETONIDE
ARISTOCORT, TRIAMCINOLONE DIACETATE
ARISTOGEL, TRIAMCINOLONE ACETONIDE
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFTIZOXIME SODIUM
CEFIZOX IN PLASTIC CONTAINER, CEFTIZOXIME SODIUM
CEFIZOX, CEFTIZOXIME SODIUM
CYCLOCORT, AMCINONIDE
PROGRAF, TACROLIMUS
PROTOPIC, TACROLIMUS

** G **

G AND W LABS
* G AND W LABORATORIES INC
ACEPHEN, ACETAMINOPHEN (OTC)
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
GYNE-SULF, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)
HYDROCORTISONE, HYDROCORTISONE
INDOMETHEGAN, INDOMETHACIN
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MIGERGOT, CAFFEINE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRUPHYLLINE, AMINOPHYLLINE

GALDERMA LABS
* GALDERMA LABORATORIES INC
SOLAGE, MEQUINOL

GALDERMA LABS LP
* GALDERMA LABORATORIES L P
CLOBEX, CLOBETASOL PROPIONATE
* GALDERMA LABORATORIES LP

FDA data supplied by DrugPatentWatch.com

CLINDAGEL, CLINDAMYCIN PHOSPHATE
DESOWEN, DESONIDE
DIFFERIN, ADAPALENE
FS SHAMPOO, FLUOCINOLONE ACETONIDE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE

GALEN CHEM
* GALEN CHEMICAL LTD
ESTROSTEP 21, ETHINYL ESTRADIOL
ESTROSTEP FE, ETHINYL ESTRADIOL
FEMHRT, ETHINYL ESTRADIOL
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL

GALEN LTD
* GALEN LTD
FEMRING, ESTRADIOL ACETATE

GD SEARLE LLC
* GD SEARLE LLC
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
AMINOPHYLLIN, AMINOPHYLLINE
AMMONIUM CHLORIDE, AMMONIUM CHLORIDE
ARTHROTEC, DICLOFENAC SODIUM
BEXTRA, VALDECOXIB
CALAN, VERAPAMIL HYDROCHLORIDE
CELEBREX, CELECOXIB
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
COVERA-HS, VERAPAMIL HYDROCHLORIDE
CU-7, COPPER
CYTOTEC, MISOPROSTOL
DAYPRO, OXAPROZIN
DEMULEN 1/35-21, ETHINYL ESTRADIOL
DEMULEN 1/35-28, ETHINYL ESTRADIOL
DEMULEN 1/50-21, ETHINYL ESTRADIOL
DEMULEN 1/50-28, ETHINYL ESTRADIOL
DIULO, METOLAZONE
ENOVID, MESTRANOL
ENOVID-E 21, MESTRANOL
ENOVID-E, MESTRANOL
FLAGYL ER, METRONIDAZOLE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAGYL I.V., METRONIDAZOLE HYDROCHLORIDE
FLAGYL, METRONIDAZOLE
INSPRA, EPLERENONE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LOMOTIL, ATROPINE SULFATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
NORINYL 1+80 21-DAY, MESTRANOL
NORINYL 1+80 28-DAY, MESTRANOL
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
NORQUEST FE, ETHINYL ESTRADIOL
OVULEN, ETHYNODIOL DIACETATE
OVULEN-21, ETHYNODIOL DIACETATE
OVULEN-28, ETHYNODIOL DIACETATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRO-BANTHINE, PROPANTHELINE BROMIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
SYNAREL, NAFARELIN ACETATE
TATUM-T, COPPER

GEN ELECTRIC
* GENERAL ELECTRIC CO
XENON XE 133, XENON, XE-133

GENENTECH
* GENENTECH INC
CRESCORMON, SOMATROPIN
NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT
NUTROPIN AQ, SOMATROPIN RECOMBINANT
NUTROPIN DEPOT, SOMATROPIN RECOMBINANT
NUTROPIN, SOMATROPIN RECOMBINANT
PROTROPIN, SOMATREM

GENESOFT PHARMS
* GENESOFT PHARMACEUTICALS INC
FACTIVE, GEMIFLOXACIN MESYLATE

GENPHARM
* GENPHARM INC
ACYCLOVIR, ACYCLOVIR
ALBUTEROL, ALBUTEROL
AMNESTEEM, ISOTRETINOIN
AZATHIOPRINE, AZATHIOPRINE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETIDRONATE DISODIUM, ETIDRONATE DISODIUM
ETODOLAC, ETODOLAC
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FLUTAMIDE, FLUTAMIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GUANFACINE HCL, GUANFACINE HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
LOVASTATIN, LOVASTATIN
METFORMIN HCL, METFORMIN HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NIZATIDINE, NIZATIDINE

FDA data supplied by DrugPatentWatch.com

NOVOTHYROX, LIOTRIX (T4;T3)
OXAPROZIN, OXAPROZIN
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
SOTALOL HCL, SOTALOL HYDROCHLORIDE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
* GENPHARM PHARMACEUTICALS INC
ATENOLOL, ATENOLOL
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM

GENSIA
* GENSIA LABORATORIES LTD
VECURONIUM BROMIDE, VECURONIUM BROMIDE

GENSIA AUTOMEDICS
* GENSIA AUTOMEDICS INC
GENESA, ARBUTAMINE HYDROCHLORIDE

GENSIA SICOR PHARMS
* GENSIA SICOR PHARMACEUTICALS INC
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR SODIUM
ADRUCIL, FLUOROURACIL
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMINOPHYLLINE, AMINOPHYLLINE
AMPHOTERICIN B, AMPHOTERICIN B
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BLEOMYCIN, BLEOMYCIN SULFATE
BUMETANIDE, BUMETANIDE
CALCITRIOL, CALCITRIOL
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CISPLATIN, CISPLATIN
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HCL, DAUNORUBICIN HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ETOPOSIDE, ETOPOSIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
IDARUBICIN HCL PFS, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HCL, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE/MESNA KIT, IFOSFAMIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVOCARNITINE, LEVOCARNITINE
MESNA, MESNA
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
NEOSAR, CYCLOPHOSPHAMIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPOFOL, PROPOFOL
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
THIOTEPA, THIOTEPA
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOPOSAR, ETOPOSIDE
VINCASAR PFS, VINCRISTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
ZANOSAR, STREPTOZOCIN

GENTA
* GENTA INC
GANITE, GALLIUM NITRATE

GENZYME
* GENZYME CORP
CEREDASE, ALGLUCERASE
CEREZYME, IMIGLUCERASE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
RENAGEL, SEVELAMER HYDROCHLORIDE
THYROGEN, THYROTROPIN ALFA

GILBERT LABS
* GILBERT LABORATORIES
ACETAMINOPHEN, BUTALBITAL AND CAFFEINE, ACETAMINOPHEN

GILEAD
* GILEAD SCIENCES INC
DAUNOXOME, DAUNORUBICIN CITRATE
EMTRIVA, EMTRICITABINE
HEPSERA, ADEFOVIR DIPIVOXIL
VIREAD, TENOFOVIR DISOPROXIL FUMARATE

FDA data supplied by DrugPatentWatch.com

VISTIDE, CIDOFOVIR

GLADES PHARMS
* GLADES PHARMACEUTICALS INC
E-GLADES, ERYTHROMYCIN

GLAXOSMITHKLINE
* GLAXOSMITHKLINE
ABREVA, DOCOSANOL (OTC)
ACLOVATE, ALCLOMETASONE DIPROPIONATE
ACTIDIL, TRIPROLIDINE HYDROCHLORIDE (OTC)
ACTIFED W/ CODEINE, CODEINE PHOSPHATE
ACTIFED, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
AEROSPORIN, POLYMYXIN B SULFATE
AGENERASE, AMPRENAVIR
ALBENZA, ALBENDAZOLE
ALKERAN, MELPHALAN
ALKERAN, MELPHALAN HYDROCHLORIDE
AMERGE, NARATRIPTAN HYDROCHLORIDE
AMOXIL, AMOXICILLIN
ANCEF, CEFAZOLIN SODIUM
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANSPOR, CEPHRADINE
ANTEPAR, PIPERAZINE CITRATE
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '200', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '400', AMOXICILLIN
AUGMENTIN '500', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN
AVODART, DUTASTERIDE
BACTOCILL, OXACILLIN SODIUM
BACTROBAN, MUPIROCIN
BACTROBAN, MUPIROCIN CALCIUM
BECLOVENT, BECLOMETHASONE DIPROPIONATE
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
BECONASE, BECLOMETHASONE DIPROPIONATE
BEEPEN-VK, PENICILLIN V POTASSIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFTIN, CEFUROXIME AXETIL
CEPTAZ, CEFTAZIDIME (ARGININE FORMULATION)
CLOXAPEN, CLOXACILLIN SODIUM
COMBIVIR, LAMIVUDINE
COMPAZINE, PROCHLORPERAZINE
COMPAZINE, PROCHLORPERAZINE EDISYLATE
COMPAZINE, PROCHLORPERAZINE MALEATE
CONTAC 12 HOUR, CHLORPHENIRAMINE MALEATE (OTC)
COREG, CARVEDILOL
CUTIVATE, FLUTICASONE PROPIONATE
DARAPRIM, PYRIMETHAMINE
DARBID, ISOPROPAMIDE IODIDE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DIONOSIL AQUEOUS, PROPYLIODONE
DIONOSIL OILY, PROPYLIODONE
DYAZIDE, HYDROCHLOROTHIAZIDE
DYCILL, DICLOXACILLIN SODIUM
EMGEL, ERYTHROMYCIN
EMPRACET W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN
EMPRACET W/ CODEINE PHOSPHATE #4, ACETAMINOPHEN
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
ESKALITH CR, LITHIUM CARBONATE
ESKALITH, LITHIUM CARBONATE
EXOSURF NEONATAL, CETYL ALCOHOL
FASTIN, PHENTERMINE HYDROCHLORIDE
FLOLAN, EPOPROSTENOL SODIUM
FLONASE, FLUTICASONE PROPIONATE
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
FLOVENT, FLUTICASONE PROPIONATE
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
FORTAZ, CEFTAZIDIME
HALFAN, HALOFANTRINE HYDROCHLORIDE
HISPRIL, DIPHENYLPYRALINE HYDROCHLORIDE
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL, LAMOTRIGINE
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
LAROTID, AMOXICILLIN
LEXIVA, FOSAMPRENAVIR CALCIUM
LOTRONEX, ALOSETRON HYDROCHLORIDE
MALARONE PEDIATRIC, ATOVAQUONE
MALARONE, ATOVAQUONE
MAREZINE, CYCLIZINE LACTATE
MEPRON, ATOVAQUONE
MONOCID, CEFONICID SODIUM
MYLERAN, BUSULFAN
NALLPEN, NAFCILLIN SODIUM
NAVELBINE, VINORELBINE TARTRATE
NEOSPORIN, NEOMYCIN SULFATE (OTC)
NICORETTE (ORANGE), NICOTINE POLACRILEX (OTC)
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICORETTE (ORANGE), NICOTINE POLACRILEX (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
NIX, PERMETHRIN
ORNADE, CHLORPHENIRAMINE MALEATE
OXISTAT, OXICONAZOLE NITRATE

FDA data supplied by DrugPatentWatch.com

PARNATE, TRANYLCYPROMINE SULFATE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PENTACEF, CEFTAZIDIME (ARGININE FORMULATION)
PHYTONADIONE, PHYTONADIONE
POLYSPORIN, BACITRACIN ZINC (OTC)
PYOPEN, CARBENICILLIN DISODIUM
RELAFEN, NABUMETONE
RELENZA, ZANAMIVIR
REQUIP, ROPINIROLE HYDROCHLORIDE
RETROVIR, ZIDOVUDINE
SEFFIN, CEPHALOTHIN SODIUM
SEREVENT, SALMETEROL XINAFOATE
STELAZINE, TRIFLUOPERAZINE HYDROCHLORIDE
STOXIL, IDOXURIDINE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SYNCURINE, DECAMETHONIUM BROMIDE
TAGAMET HB 200, CIMETIDINE (OTC)
TAGAMET HB, CIMETIDINE (OTC)
TAGAMET HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CIMETIDINE HYDROCHLORIDE
TAGAMET, CIMETIDINE
TAGAMET, CIMETIDINE HYDROCHLORIDE
TELDRIN, CHLORPHENIRAMINE MALEATE (OTC)
TEMOVATE E, CLOBETASOL PROPIONATE
TEMOVATE, CLOBETASOL PROPIONATE
THIOGUANINE, THIOGUANINE
THORAZINE, CHLORPROMAZINE
THORAZINE, CHLORPROMAZINE HYDROCHLORIDE
TICAR, TICARCILLIN DISODIUM
TIMENTIN IN PLASTIC CONTAINER, CLAVULANATE POTASSIUM
TIMENTIN, CLAVULANATE POTASSIUM
TOTACILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
TOTACILLIN-N, AMPICILLIN SODIUM
TRANDATE HCT, HYDROCHLOROTHIAZIDE
TRITEC, RANITIDINE BISMUTH CITRATE
TRIZIVIR, ABACAVIR SULFATE
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VASOXYL, METHOXAMINE HYDROCHLORIDE
VENTOLIN HFA, ALBUTEROL SULFATE
VENTOLIN ROTACAPS, ALBUTEROL SULFATE
VENTOLIN, ALBUTEROL
VENTOLIN, ALBUTEROL SULFATE
VONTROL, DIPHENIDOL HYDROCHLORIDE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
WELLBUTRIN, BUPROPION HYDROCHLORIDE
WELLCOVORIN, LEUCOVORIN CALCIUM
ZANTAC 150, RANITIDINE HYDROCHLORIDE
ZANTAC 300, RANITIDINE HYDROCHLORIDE
ZANTAC IN PLASTIC CONTAINER, RANITIDINE HYDROCHLORIDE
ZANTAC, RANITIDINE HYDROCHLORIDE
ZIAGEN, ABACAVIR SULFATE
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
ZINACEF, CEFUROXIME SODIUM
ZOFRAN IN PLASTIC CONTAINER, ONDANSETRON HYDROCHLORIDE
ZOFRAN ODT, ONDANSETRON
ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOVIRAX, ACYCLOVIR
ZOVIRAX, ACYCLOVIR SODIUM
ZYBAN, BUPROPION HYDROCHLORIDE

GLAXOSMITHKLINE CONS
* GLAXOSMITHKLINE CONSUMER HEALTHCARE
COMMIT, NICOTINE POLACRILEX (OTC)

GLENWOOD
* GLENWOOD INC
MYOTONACHOL, BETHANECHOL CHLORIDE
PASKALIUM, POTASSIUM AMINOSALICYLATE
RENOQUID, SULFACYTINE

GOLDLINE
* GOLDLINE LABORATORIES INC
GLYCOPREP, POLYETHYLENE GLYCOL 3350
METFORMIN HCL, METFORMIN HYDROCHLORIDE

GRAHAM CHEM
* GRAHAM CHEMICAL CO
LIDOCAINE HCL AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
MEPIVACAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
MEPIVACAINE HCL, MEPIVACAINE HYDROCHLORIDE

GRAHAM DM
* DM GRAHAM LABORATORIES INC
BUTALBITAL, ACETAMINOPHEN, CAFFEINE, ACETAMINOPHEN
COLD CAPSULE IV, CHLORPHENIRAMINE MALEATE (OTC)
COLD CAPSULE V, CHLORPHENIRAMINE MALEATE (OTC)
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PSEUDOEPHEDRINE HCL/CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
SOMOPHYLLIN-CRT, THEOPHYLLINE

GRIFFEN
* KW GRIFFEN CO
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

GRUPPO LEPETIT
* GRUPPO LEPETIT SPA SUB MERRELL DOW PHARMACEUTICALS INC
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE

GUARDIAN DRUG
* GUARDIAN DRUG CO INC

FDA data supplied by DrugPatentWatch.com

FOAMCOAT, ALUMINUM HYDROXIDE (OTC)

GUERBET
* GUERBET LLC
OXILAN-300, IOXILAN
OXILAN-350, IOXILAN

GUILFORD PHARMS
* GUILFORD PHARMACEUTICALS INC
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
GLIADEL, CARMUSTINE

GYNETICS
* GYNETICS INC
PREVEN EMERGENCY CONTRACEPTIVE KIT, ETHINYL ESTRADIOL

GYNOPHARMA
* GYNOPHARMA INC
NORCEPT-E 1/35 21, ETHINYL ESTRADIOL
NORCEPT-E 1/35 28, ETHINYL ESTRADIOL

** H **

HALLMARK PHARMS
* HALLMARK PHARMACEUTICALS
CAPTOPRIL, CAPTOPRIL

HALOCARBON
* HALOCARBON LABORATORIES DIV HALOCARBON PRODUCTS CORP
HALOTHANE, HALOTHANE

HALOCARBON PRODS
* HALOCARBON PRODUCTS CORP
ISOFLURANE, ISOFLURANE

HALSEY
* HALSEY DRUG CO INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN
ALLOPURINOL, ALLOPURINOL
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BELDIN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
BELIX, DIPHENHYDRAMINE HYDROCHLORIDE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ASPIRIN & CAFFEINE, ASPIRIN
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CODOXY, ASPIRIN
CORTALONE, PREDNISOLONE
CORTAN, PREDNISONE
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GLUTETHIMIDE, GLUTETHIMIDE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRO-D, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROPANE, HOMATROPINE METHYLBROMIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDOMETHACIN, INDOMETHACIN
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
KLOROMIN, CHLORPHENIRAMINE MALEATE
LORAZEPAM, LORAZEPAM
LOW-QUEL, ATROPINE SULFATE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
NALIDIXIC ACID, NALIDIXIC ACID
NEURAMATE, MEPROBAMATE
NIACIN, NIACIN
OXAZEPAM, OXAZEPAM
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PHENYLBUTAZONE, PHENYLBUTAZONE
PHERAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PHERAZINE VC W/ CODEINE, CODEINE PHOSPHATE
PHERAZINE VC, PHENYLEPHRINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PHERAZINE W/ CODEINE, CODEINE PHOSPHATE
PREDNISONE, PREDNISONE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPHENE 65, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
RESERPINE, RESERPINE
SARISOL NO. 1, BUTABARBITAL SODIUM
SARISOL NO. 2, BUTABARBITAL SODIUM
SARISOL, BUTABARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TEMAZEPAM, TEMAZEPAM
THEOPHYLLINE, THEOPHYLLINE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

HAMILTON PHARMS
* HAMILTON PHARMACEUTICALS LTD
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN

HANFORD GC
* GC HANFORD MANUFACTURING CO
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM

HARVEST PHARMS
* HARVEST PHARMACEUTICALS INC
ERGOMAR, ERGOTAMINE TARTRATE

HEALTHPOINT
* HEALTHPOINT LTD
AKNE-MYCIN, ERYTHROMYCIN
CETACORT, HYDROCORTISONE
CLODERM, CLOCORTOLONE PIVALATE
CORMAX, CLOBETASOL PROPIONATE
EMBELINE E, CLOBETASOL PROPIONATE
EMBELINE, CLOBETASOL PROPIONATE
NUTRACORT, HYDROCORTISONE
SANSAC, ERYTHROMYCIN

HEATHER
* HEATHER DRUG CO INC
CORTISONE ACETATE, CORTISONE ACETATE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
SULFAMETHOXAZOLE & TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
SULFISOXAZOLE, SULFISOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE

HELSINN HLTHCARE
* HELSINN HEALTHCARE SA
ALOXI, PALONOSETRON HYDROCHLORIDE

HERAN
* HERAN PHARMACEUTICAL INC
GLYCORT, HYDROCORTISONE

HERCON LABS
* HERCON LABORATORIES CORP
NITROGLYCERIN, NITROGLYCERIN

HEXCEL
* HEXCEL CHEMICAL PRODUCTS
POTASSIUM AMINOSALICYLATE, POTASSIUM AMINOSALICYLATE
SODIUM AMINOSALICYLATE, AMINOSALICYLATE SODIUM

HEYL CHEMISCH
* HEYL CHEMISCH PHARMAZEUTISHE FABRIK
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)

HI TECH PHARMA
* HI TECH PHARMACAL CO INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ERYTHRO-STATIN, ERYTHROMYCIN
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
LACTULOSE, LACTULOSE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PROMETHAZINE HCL AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HCL AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE

HIGH TECH PHARMA
* HIGH TECHNOLOGY PHARMACAL CO INC
VALPROIC ACID, VALPROIC ACID

HIKMA
* HIKMA FARMACEUTICA LDA
CEFOTAXIME, CEFOTAXIME SODIUM
* HIKMA PHARMACEUTICALS
GLYBURIDE (MICRONIZED), GLYBURIDE
NAPROXEN SODIUM, NAPROXEN SODIUM

HIKMA FARMACEUTICA
* HIKMA FARMACEUTICA PORTUGAL LDA
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM

HILL DERMAC
* HILL DERMACEUTICALS INC
DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
TRI-LUMA, FLUOCINOLONE ACETONIDE

HLR
* HLR TECHNOLOGY
ACCUTANE, ISOTRETINOIN
FORTOVASE, SAQUINAVIR
INVIRASE, SAQUINAVIR MESYLATE
ROCEPHIN KIT, CEFTRIAXONE SODIUM
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
ROCEPHIN, CEFTRIAXONE SODIUM
ROMAZICON, FLUMAZENIL
SORIATANE, ACITRETIN
VERSED, MIDAZOLAM HYDROCHLORIDE
XELODA, CAPECITABINE
XENICAL, ORLISTAT

HOLLAND RANTOS
* HOLLAND RANTOS CO INC
KOROSTATIN, NYSTATIN

HOLLISTER STIER LABS
* HOLLISTER STIER LABORATORIES LLC
PRE-PEN, BENZYL PENICILLOYL-POLYLYSINE
TWINJECT, EPINEPHRINE

HUNTINGTON LABS
* HUNTINGTON LABORATORIES INC
GERMA-MEDICA "MG", HEXACHLOROPHENE
GERMA-MEDICA, HEXACHLOROPHENE
HEXA-GERM, HEXACHLOROPHENE

** I **

IBI
* ISTITUTO BIOCHIMICO ITALIANO SPA
AMPICILLIN SODIUM, AMPICILLIN SODIUM
OXACILLIN SODIUM, OXACILLIN SODIUM

ICN PUERTO RICO
* ICN PUERTO RICO INC
FLUOROURACIL, FLUOROURACIL

IMCOR
* IMCOR DIV PHOTOGEN TECHNOLOGIES INC
IMAGENT, DIMYRISTOYL LECITHIN

IMMUNEX
* IMMUNEX CORP
LEVOPROME, LEVOMEPROMAZINE
THIOPLEX, THIOTEPA
THIOTEPA, THIOTEPA

IMP
* IMP INC
SPECTAMINE, IOFETAMINE HYDROCHLORIDE I-123

IMPAX LABS
* IMPAX LABORATORIES INC
AMINOPHYLLINE, AMINOPHYLLINE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CORTISONE ACETATE, CORTISONE ACETATE
DEXAMETHASONE, DEXAMETHASONE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE

FDA data supplied by DrugPatentWatch.com

FOLIC ACID, FOLIC ACID
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
ISONIAZID, ISONIAZID
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
NIACIN, NIACIN
OMEPRAZOLE, OMEPRAZOLE
OXYTETRACYCLINE HCL, OXYTETRACYCLINE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PIPERAZINE CITRATE, PIPERAZINE CITRATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROBENECID AND COLCHICINE, COLCHICINE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
PYRILAMINE MALEATE, PYRILAMINE MALEATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE
RILUZOLE, RILUZOLE
RIMANTADINE HCL, RIMANTADINE HYDROCHLORIDE
SULFA-TRIPLE #2, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFISOXAZOLE, SULFISOXAZOLE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THYROGLOBULIN, THYROGLOBULIN
TRIAMCINOLONE, TRIAMCINOLONE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL

IMPAX PHARMS
* IMPAX PHARMACEUTICALS
FLAVOXATE HCL, FLAVOXATE HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
SOTALOL HCL, SOTALOL HYDROCHLORIDE

INALCO
* INALCO SPA
LACTULOSE, LACTULOSE

INGRAM PHARM
* INGRAM PHARMACEUTICAL CO
DRICORT, HYDROCORTISONE ACETATE
HYDROCORTISONE, HYDROCORTISONE

INKINE
* INKINE PHARMACEUTICAL CO INC
VISICOL, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS

INO
* INO THERAPEUTICS INC
INOMAX, NITRIC OXIDE

INSIGHT PHARMS
* INSIGHT PHARMACEUTICALS CORP
NIX, PERMETHRIN (OTC)

INTERMUNE PHARMS
* INTERMUNE PHARMACEUTICALS INC
AMPHOTEC, AMPHOTERICIN B

INTERPHARM
* INTERPHARM INC
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
NAPROXEN, NAPROXEN
PREDNISONE, PREDNISONE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TOLAZAMIDE, TOLAZAMIDE

INTL MEDICATED
* INTERNATIONAL MEDICATED SYSTEMS LTD
BUPIVACINE HCL PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE

INTL MEDICATION
* INTERNATIONAL MEDICATION SYSTEM
AMINOPHYLLINE, AMINOPHYLLINE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
DIPHENHYDRAMINE HCL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPIVACAINE HCL, MEPIVACAINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

* INTERNATIONAL MEDICATION SYSTEMS LTD
AMINOPHYLLINE, AMINOPHYLLINE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEPHALOTHIN, CEPHALOTHIN SODIUM
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DIATRIZOATE-60, DIATRIZOATE MEGLUMINE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN, GENTAMICIN SULFATE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
LIDOCAINE HCL VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METRONIDAZOLE, METRONIDAZOLE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

INTL MINERALS
* INTERNATIONAL MINERALS CHEMICAL CORP
TPN SUSPENSION, NIACINAMIDE

INWOOD LABS
* INWOOD LABORATORIES INC SUB FOREST LABORATORIES INC
CARBAMAZEPINE, CARBAMAZEPINE
CORTISONE ACETATE, CORTISONE ACETATE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
THEOCHRON, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE

IOMED
* IOMED INC
IONTOCAINE, EPINEPHRINE

IPHARM
* IPHARM DIV LYPHOMED INC
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN

IPR
* IPR PHARMACEUTICALS INC
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
ZOMIG, ZOLMITRIPTAN

ISO TEX
* ISO TEX DIAGNOSTICS INC
ALBUMOTOPE 125 I, ALBUMIN IODINATED I-125 SERUM
CHROMALBIN, ALBUMIN CHROMATED CR-51 SERUM
INULIN AND SODIUM CHLORIDE, INULIN
MEGATOPE, ALBUMIN IODINATED I-131 SERUM

IVAX PHARMS
* IVAX PHARMACEUTICALS INC
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL, ALBUTEROL
ALLAY, ACETAMINOPHEN
ALPRAZOLAM, ALPRAZOLAM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
BACLOFEN, BACLOFEN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUMETANIDE, BUMETANIDE
BUTALBITAL COMPOUND, ASPIRIN
C-SOLVE-2, ERYTHROMYCIN
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEPHALEXIN, CEPHALEXIN
CEPHRADINE, CEPHRADINE
CHLORAMPHENICOL, CHLORAMPHENICOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE

FDA data supplied by DrugPatentWatch.com

CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE, CHOLESTYRAMINE
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CLOZAPINE, CLOZAPINE
CORTISONE ACETATE, CORTISONE ACETATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ESTAZOLAM, ESTAZOLAM
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUTAMIDE, FLUTAMIDE
FLUTEX, TRIAMCINOLONE ACETONIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GLIPIZIDE, GLIPIZIDE
GUANABENZ ACETATE, GUANABENZ ACETATE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 100/50, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 25/25, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 50/50, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDROCHLOROTHIAZIDE AND RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
HYDROGENATED ERGOT ALKALOIDS, ERGOLOID MESYLATES
HYDROSERPINE PLUS (R-H-H), HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISONIAZID, ISONIAZID
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOCARBAMOL, METHOCARBAMOL
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METRONIDAZOLE, METRONIDAZOLE
MIRTAZAPINE, MIRTAZAPINE
MISOPROSTOL, MISOPROSTOL
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NEFAZODONE HCL, NEFAZODONE HYDROCHLORIDE
NIACIN, NIACIN
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NOGENIC HC, HYDROCORTISONE
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
PACLITAXEL, PACLITAXEL
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PERGOLIDE MESYLATE, PERGOLIDE MESYLATE
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PHENYLBUTAZONE, PHENYLBUTAZONE
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROBENECID AND COLCHICINE, COLCHICINE
PROBENECID, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROMPT PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
PROPOXYPHENE COMPOUND 65, ASPIRIN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN

FDA data supplied by DrugPatentWatch.com

PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE SULFATE, QUINIDINE SULFATE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE AND HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
SODIUM BUTABARBITAL, BUTABARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFINPYRAZONE, SULFINPYRAZONE
SULFISOXAZOLE, SULFISOXAZOLE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TETRAMED, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIATEX, TRIAMCINOLONE ACETONIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VITAMIN A, VITAMIN A PALMITATE

IVAX RES
* IVAX RESEARCH INC
NASALIDE, FLUNISOLIDE
NASAREL, FLUNISOLIDE

** J **

J AND J
* JOHNSON AND JOHNSON CONSUMER PRODUCTS INC
ERYCETTE, ERYTHROMYCIN
GRIFULVIN V, GRISEOFULVIN, MICROCRYSTALLINE
* JOHNSON AND JOHNSON MEDICAL INC
MICRODERM, CHLORHEXIDINE GLUCONATE (OTC)
PREVACARE R, CHLORHEXIDINE GLUCONATE (OTC)

JACOBUS
* JACOBUS PHARMACEUTICAL CO
DAPSONE, DAPSONE
PASER, AMINOSALICYLIC ACID

JANSSEN
* JANSSEN PHARMACEUTICA INC
IMODIUM, LOPERAMIDE HYDROCHLORIDE
MONISTAT, MICONAZOLE
NIZORAL, KETOCONAZOLE

JANSSEN ORTHO
* JANSSEN ORTHO LLC
AXERT, ALMOTRIPTAN MALATE

JANSSEN PHARMA
* JANSSEN PHARMACEUTICA PRODUCTS LP
ERGAMISOL, LEVAMISOLE HYDROCHLORIDE
NIZORAL, KETOCONAZOLE
PROPULSID QUICKSOLV, CISAPRIDE MONOHYDRATE
PROPULSID, CISAPRIDE MONOHYDRATE
REMINYL, GALANTAMINE HYDROBROMIDE
RISPERDAL, RISPERIDONE
SPORANOX, ITRACONAZOLE

JOHNSON AND JOHNSON
* JOHNSON AND JOHNSON CONSUMER COMPANIES INC
CENTANY, MUPIROCIN
GRIFULVIN V, GRISEOFULVIN, MICROCRYSTALLINE
MECLAN, MECLOCYCLINE SULFOSALICYLATE
MONISTAT-DERM, MICONAZOLE NITRATE
RENOVA, TRETINOIN
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
SPECTAZOLE, ECONAZOLE NITRATE
* JOHNSON AND JOHNSON CONSUMER PRODUCTS WORLDWIDE
ERTACZO, SERTACONAZOLE NITRATE
* JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT
ELMIRON, PENTOSAN POLYSULFATE SODIUM
ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
RISPERDAL CONSTA, RISPERIDONE
RISPERDAL, RISPERIDONE

JOHNSON RW
* RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE
ORTHO CYCLEN-21, ETHINYL ESTRADIOL
ORTHO CYCLEN-28, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL

JONES PHARMA
* JONES PHARMA INC SUB KING PHARMACEUTICALS INC
CYTOMEL, LIOTRIX (T4;T3)
LEVOXYL, LIOTRIX (T4;T3)
METHIMAZOLE, METHIMAZOLE
SONATA, ZALEPLON

FDA data supplied by DrugPatentWatch.com

TRIOSTAT, LIOTRIX (T4;T3)
TUSSIGON, HOMATROPINE METHYLBROMIDE

JONES PHARMA INC
* JONES PHARMA INC
SKELAXIN, METAXALONE

JVL
* JVL CORP
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE

** K **

KALAPHARM
* KALAPHARM INC
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE

KENDALL IL
* KENDALL CO
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
LARYNGOTRACHEAL ANESTHESIA KIT, LIDOCAINE HYDROCHLORIDE

KENDALL LP
* KENDALL CO LP
THERMAZENE, SILVER SULFADIAZINE

KENWOOD LABS
* KENWOOD LABORATORIES DIV BRADLEY PHARMACEUTICALS
CARMOL HC, HYDROCORTISONE ACETATE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

KEY PHARMS
* KEY PHARMACEUTICALS INC SUB SCHERING PLOUGH CORP
GENAPAX, GENTIAN VIOLET
K-DUR 10, POTASSIUM CHLORIDE
K-DUR 20, POTASSIUM CHLORIDE
NITRO-DUR, NITROGLYCERIN
QUINORA, QUINIDINE SULFATE

KIEL
* KIEL LABORATORIES INC
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE

KING PHARMS
* KING PHARMACEUTICALS INC
ALTACE, RAMIPRIL
AMINOPHYLLINE, AMINOPHYLLINE
APOGEN, GENTAMICIN SULFATE
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BREVITAL SODIUM, METHOHEXITAL SODIUM
CORZIDE, BENDROFLUMETHIAZIDE
CROMOPTIC, CROMOLYN SODIUM
DELESTROGEN, ESTRADIOL VALERATE
FLORINEF, FLUDROCORTISONE ACETATE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HUMATIN, PAROMOMYCIN SULFATE
KLEBCIL, KANAMYCIN SULFATE
LORABID, LORACARBEF
MAXOLON, METOCLOPRAMIDE HYDROCHLORIDE
NALBUPHINE HCL, NALBUPHINE HYDROCHLORIDE
PREFEST, ESTRADIOL
PROCANBID, PROCAINAMIDE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
SILVADENE, SILVER SULFADIAZINE
SYNERCID, DALFOPRISTIN
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
WYCILLIN, PENICILLIN G PROCAINE

KOS
* KOS PHARMACEUTICALS INC
ADVICOR, LOVASTATIN
NIASPAN TITRATION STARTER PACK, NIACIN
NIASPAN, NIACIN

KREMERS URBAN
* KREMERS URBAN CO
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

KREMERS URBAN DEV
* KREMERS URBAN DEVELOPMENT CO
OMEPRAZOLE, OMEPRAZOLE

KRKA DD NOVO MESTO
* KRKA DD NOVO MESTO
ENALAPRIL MALEATE, ENALAPRIL MALEATE

KV PHARM
* KV PHARMACEUTICAL CO
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETIC ACID W/ HYDROCORTISONE, ACETIC ACID, GLACIAL
ACETIC ACID, ACETIC ACID, GLACIAL
AMINOPHYLLINE, AMINOPHYLLINE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE

FDA data supplied by DrugPatentWatch.com

DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
GYNAZOLE-1, BUTOCONAZOLE NITRATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
MICRO-K 10, POTASSIUM CHLORIDE
MICRO-K LS, POTASSIUM CHLORIDE
MICRO-K, POTASSIUM CHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPAFENONE HCL, PROPAFENONE HYDROCHLORIDE
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
QUINIDINE SULFATE, QUINIDINE SULFATE
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
THEOPHYLLINE, THEOPHYLLINE
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

** L **

LABS AF
* LABORATORIOS APLICACIONES FARMACEUTICAS SA DE CV
METROMIDOL, METRONIDAZOLE

LABS ATRAL
* LABORATORIOS ATRAL SARL
AMOXICILLIN, AMOXICILLIN
CEPHALEXIN, CEPHALEXIN
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

LAFAYETTE PHARMS
* LAFAYETTE PHARMACEUTICALS INC
BAROS, SODIUM BICARBONATE

LANNETT
* LANNETT CO INC
ACETAZOLAMIDE, ACETAZOLAMIDE
AMINOPHYLLINE, AMINOPHYLLINE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
BENZYL BENZOATE, BENZYL BENZOATE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BUTALAN, BUTABARBITAL SODIUM
CORTISONE ACETATE, CORTISONE ACETATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DIPHENYLAN SODIUM, PHENYTOIN SODIUM, PROMPT
FOLIC ACID, FOLIC ACID
FURALAN, NITROFURANTOIN
GLUTETHIMIDE, GLUTETHIMIDE
HYDROCORTISONE, HYDROCORTISONE
LANIAZID, ISONIAZID
LANOPHYLLIN, THEOPHYLLINE
LANORINAL, ASPIRIN
LANTRISUL, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NITROFURAZONE, NITROFURAZONE
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PHENETRON, CHLORPHENIRAMINE MALEATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PIPERAZINE CITRATE, PIPERAZINE CITRATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PRIMIDONE, PRIMIDONE
PROBALAN, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINALAN, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SERPALAN, RESERPINE
SODIUM BUTABARBITAL, BUTABARBITAL SODIUM
SODIUM P.A.S., AMINOSALICYLATE SODIUM
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFISOXAZOLE, SULFISOXAZOLE
TRICHLOREX, TRICHLORMETHIAZIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
VITAMIN D, ERGOCALCIFEROL

LEDERLE
* LEDERLE LABORATORIES DIV AMERICAN CYANAMID CO
ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN
ACHES-N-PAIN, IBUPROFEN (OTC)
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACHROMYCIN, HYDROCORTISONE
ACHROMYCIN, PROCAINE HYDROCHLORIDE
ACHROMYCIN, TETRACYCLINE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMPICILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
ARTANE, TRIHEXYPHENIDYL HYDROCHLORIDE
ASENDIN, AMOXAPINE

FDA data supplied by DrugPatentWatch.com

AUREOMYCIN, CHLORTETRACYCLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DECLOMYCIN, DEMECLOCYCLINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DOLENE AP-65, ACETAMINOPHEN
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
FOLVRON, FERROUS SULFATE
HALOPERIDOL, HALOPERIDOL
HETRAZAN, DIETHYLCARBAMAZINE CITRATE
HYDROMOX R, QUINETHAZONE
HYDROMOX, QUINETHAZONE
IBUPROFEN, IBUPROFEN
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
LEDERCILLIN VK, PENICILLIN V POTASSIUM
MEPROBAMATE, MEPROBAMATE
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
NAPROXEN, NAPROXEN
NEPTAZANE, METHAZOLAMIDE
NILSTAT, NYSTATIN
PATHILON, TRIDIHEXETHYL CHLORIDE
PREDNISONE, PREDNISONE
PROBENECID W/ COLCHICINE, COLCHICINE
PROBENECID, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
SERVISONE, PREDNISONE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFADIAZINE SODIUM, SULFADIAZINE SODIUM
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFISOXAZOLE, SULFISOXAZOLE
SUPRAX, CEFIXIME
TRIPLE SULFAS, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)

* LEDERLE PARENTERALS INC
VANCOLED, VANCOMYCIN HYDROCHLORIDE

LEE KM

* KM LEE LABORATORIES INC
MEPROBAMATE, MEPROBAMATE

LEINER

* LEINER HEALTH PRODUCTS INC
CIMETIDINE, CIMETIDINE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)

LEK PHARM

* LEK PHARMACEUTICAL AND CHEMICAL CO DD
ACYCLOVIR, ACYCLOVIR
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE

LEK PHARMS

* LEK PHARMACEUTICALS D D
0, AMOXICILLIN
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN AND CLAVULANATE POTSSSIUM, AMOXICILLIN
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
ENALAPRIL MALEATE, ENALAPRIL MALEATE
LISINOPRIL, LISINOPRIL
OMEPRAZOLE, OMEPRAZOLE

LEO PHARM

* LEO PHARMACEUTICAL PRODUCTS LTD
PINDAC, PINACIDIL

LIFE LABS

* LIFE LABORATORIES INC
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE

LIGAND

* LIGAND PHARMACEUTICALS INC
AVINZA, MORPHINE SULFATE
PANRETIN, ALITRETINOIN
TARGRETIN, BEXAROTENE

LILLY

* ELI LILLY AND CO
AEROLONE, ISOPROTERENOL HYDROCHLORIDE
ALPHALIN, VITAMIN A PALMITATE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ANHYDRON, CYCLOTHIAZIDE
AVENTYL HCL, NORTRIPTYLINE HYDROCHLORIDE
BACITRACIN, BACITRACIN
BETALIN 12, CYANOCOBALAMIN
BETALIN S, THIAMINE HYDROCHLORIDE
CALCIUM GLUCEPTATE, CALCIUM GLUCEPTATE
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CECLOR CD, CEFACLOR
CECLOR, CEFACLOR
CESAMET, NABILONE

FDA data supplied by DrugPatentWatch.com

CINOBAC, CINOXACIN
CORDRAN-N, FLURANDRENOLIDE
CRYSTODIGIN, DIGITOXIN
DECABID, INDECAINIDE HYDROCHLORIDE
DELTALIN, ERGOCALCIFEROL
DICUMAROL, DICUMAROL
DICURIN PROCAINE, PROCAINE MERETHOXYLLINE
DIETHYLSTILBESTROL, DIETHYLSTILBESTROL
DOBUTREX, DOBUTAMINE HYDROCHLORIDE
DROLBAN, DROMOSTANOLONE PROPIONATE
DURACILLIN A.S., PENICILLIN G PROCAINE
ERYTHROMYCIN, ERYTHROMYCIN
EVISTA, RALOXIFENE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FORTEO, TERIPARATIDE RECOMBINANT HUMAN
GEMZAR, GEMCITABINE HYDROCHLORIDE
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLUCAGON, GLUCAGON RECOMBINANT
HALDRONE, PARAMETHASONE ACETATE
HEPARIN SODIUM, HEPARIN SODIUM
HEXA-BETALIN, PYRIDOXINE HYDROCHLORIDE
HISTALOG, BETAZOLE HYDROCHLORIDE
HISTAMINE PHOSPHATE, HISTAMINE PHOSPHATE
HUMALOG MIX 50/50, INSULIN LISPRO
HUMALOG MIX 75/25, INSULIN LISPRO
HUMALOG PEN, INSULIN LISPRO
HUMALOG, INSULIN LISPRO
HUMATROPE, SOMATROPIN RECOMBINANT
HUMULIN 50/50, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN BR, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN L, INSULIN ZINC SUSP RECOMBINANT HUMAN (OTC)
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN RECOMBINANT HUMAN
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN U, INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN (OTC)
ILETIN I, INSULIN PORK
ILETIN II, INSULIN PURIFIED PORK
ILOSONE SULFA, ERYTHROMYCIN ESTOLATE
ILOSONE, ERYTHROMYCIN ESTOLATE
ISONIAZID, ISONIAZID
KAFOCIN, CEPHALOGLYCIN
KAPPADIONE, MENADIOL SODIUM DIPHOSPHATE
KEFLET, CEPHALEXIN
KEFLEX, CEPHALEXIN
KEFLIN IN PLASTIC CONTAINER, CEPHALOTHIN SODIUM
KEFLIN, CEPHALOTHIN SODIUM
KEFTAB, CEPHALEXIN HYDROCHLORIDE
KEFUROX IN PLASTIC CONTAINER, CEFUROXIME SODIUM
KEFUROX, CEFUROXIME SODIUM
KEFZOL, CEFAZOLIN SODIUM
LENTE ILETIN II (PORK), INSULIN ZINC SUSP PURIFIED PORK (OTC)
LENTE ILETIN II, INSULIN ZINC SUSP PURIFIED BEEF (OTC)
MANDOL, CEFAMANDOLE NAFATE
MENADIONE, MENADIONE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METUBINE IODIDE, METOCURINE IODIDE
MOXAM, MOXALACTAM DISODIUM
NEBCIN, TOBRAMYCIN SULFATE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOTRIZINE, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
NPH ILETIN I (BEEF-PORK), INSULIN SUSP ISOPHANE BEEF/PORK (OTC)
NPH ILETIN II (PORK), INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
NPH ILETIN II, INSULIN SUSP ISOPHANE PURIFIED BEEF (OTC)
ONCOVIN, VINCRISTINE SULFATE
PAGITANE, CYCRIMINE HYDROCHLORIDE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PERMAX, PERGOLIDE MESYLATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROGESTERONE, PROGESTERONE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROTAMINE ZINC AND ILETIN II (PORK), INSULIN SUSP PROTAMINE ZINC PURIFIED PORK (OTC)
PROTAMINE ZINC AND ILETIN II, INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF (OTC)
PROTAMINE, ZINC & ILETIN I (BEEF-PORK), INSULIN SUSP PROTAMINE ZINC BEEF/PORK (OTC)
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
REGULAR ILETIN II (PORK), INSULIN PURIFIED PORK (OTC)
REGULAR ILETIN II, INSULIN PURIFIED BEEF (OTC)
SANDRIL, RESERPINE
SECONAL SODIUM, SECOBARBITAL SODIUM
SEROMYCIN, CYCLOSERINE
STRATTERA, ATOMOXETINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
SULFADIAZINE, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SULFAPYRIDINE, SULFAPYRIDINE
SULFONAMIDES DUPLEX, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
SYMBYAX, FLUOXETINE HYDROCHLORIDE
TAPAZOLE, METHIMAZOLE
TAZIDIME IN PLASTIC CONTAINER, CEFTAZIDIME
TAZIDIME, CEFTAZIDIME
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE

FDA data supplied by DrugPatentWatch.com

TUBOCURARINE CHLORIDE, TUBOCURARINE CHLORIDE
V-CILLIN K, PENICILLIN V POTASSIUM
V-CILLIN, PENICILLIN V
VANCOCIN HCL, VANCOMYCIN HYDROCHLORIDE
VELBAN, VINBLASTINE SULFATE
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE
* ELI LILLY INDUSTRIES INC
DYMELOR, ACETOHEXAMIDE
NOVRAD, LEVOPROPOXYPHENE NAPSYLATE, ANHYDROUS
* LILLY RESEARCH LABORATORIES DIV ELI LILLY AND CO
CECLOR, CEFACLOR
ILOSONE, ERYTHROMYCIN ESTOLATE
PROZAC, FLUOXETINE HYDROCHLORIDE
SARAFEM, FLUOXETINE HYDROCHLORIDE

LILLY ICOS
* LILLY ICOS LLC
CIALIS, TADALAFIL

LILLY RES LABS
* LILLY RESEARCH LABORATORIES
DYNABAC, DIRITHROMYCIN

LLOYD
* LLOYD INC
THYRO-TABS, LIOTRIX (T4;T3)

LNK
* LNK INTERNATIONAL INC
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
METRONIDAZOLE, METRONIDAZOLE

LOCH
* LOCH PHARMACEUTICALS INC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
FOLIC ACID, FOLIC ACID
KANAMYCIN SULFATE, KANAMYCIN SULFATE

LOREX
* LOREX PHARMACEUTICALS
AMBIEN, ZOLPIDEM TARTRATE
KERLEDEX, BETAXOLOL HYDROCHLORIDE
KERLONE, BETAXOLOL HYDROCHLORIDE

LPI
* LPI HOLDINGS INC
N.E.E. 1/35 21, ETHINYL ESTRADIOL
N.E.E. 1/35 28, ETHINYL ESTRADIOL

LUITPOLD
* LUITPOLD PHARMACEUTICALS INC
ACETYLCYSTEINE, ACETYLCYSTEINE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
CALCITRIOL, CALCITRIOL
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXFERRUM, IRON DEXTRAN
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
FUROSEMIDE, FUROSEMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVOCARNITINE, LEVOCARNITINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
PIPERAZINE CITRATE, PIPERAZINE CITRATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
VENOFER, IRON SUCROSE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

LUPIN
* LUPIN LTD
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL

LYNE
* LYNE LABORATORIES INC
CALCITRIOL, CALCITRIOL
XYLOSE, XYLOSE

** M **

MALLARD
* MALLARD INC
MEPROBAMATE, MEPROBAMATE

MALLINCKRODT
* MALLINCKRODT CHEMICAL INC
ANEXSIA 7.5/650, ACETAMINOPHEN

FDA data supplied by DrugPatentWatch.com

ANEXSIA, ACETAMINOPHEN
BONTRIL, PHENDIMETRAZINE TARTRATE
BUCET, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE, ACETAMINOPHEN
FEMCET, ACETAMINOPHEN
HYDROCET, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LORCET-HD, ACETAMINOPHEN
LORTAB, ACETAMINOPHEN
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
METHADONE HCL, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
TENCON, ACETAMINOPHEN
TRIAD, ACETAMINOPHEN

* MALLINCKRODT INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
ANEXSIA, ACETAMINOPHEN
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE ASPARTATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
FERROUS CITRATE FE 59, FERROUS CITRATE, FE-59
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
MD-50, DIATRIZOATE SODIUM
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NALTREXONE HCL, NALTREXONE HYDROCHLORIDE
OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
OPTIMARK, GADOVERSETAMIDE
OSTEOSCAN, TECHNETIUM TC-99M ETIDRONATE KIT
OXYCET, ACETAMINOPHEN
PEMOLINE, PEMOLINE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
SELENOMETHIONINE SE 75, SELENOMETHIONINE, SE-75
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE
XENEISOL, XENON, XE-133

* MALLINCKRODT MEDICAL INC
ANGIO-CONRAY, IOTHALAMATE SODIUM
CHOLEBRINE, IOCETAMIC ACID
CONRAY 30, IOTHALAMATE MEGLUMINE
CONRAY 325, IOTHALAMATE SODIUM
CONRAY 400, IOTHALAMATE SODIUM
CONRAY 43, IOTHALAMATE MEGLUMINE
CONRAY, IOTHALAMATE MEGLUMINE
CYANOCOBALAMIN CO 57 SCHILLING TEST KIT, CYANOCOBALAMIN
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
GALLIUM CITRATE GA 67, GALLIUM CITRATE, GA-67
HEXABRIX, IOXAGLATE MEGLUMINE
HIPPURAN I 131, IODOHIPPURATE SODIUM, I-131
MD-60, DIATRIZOATE MEGLUMINE
MD-76, DIATRIZOATE MEGLUMINE
MD-76R, DIATRIZOATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
OPTIRAY 160, IOVERSOL
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
PERCHLORACAP, POTASSIUM PERCHLORATE
PHOSPHOCOL P32, CHROMIC PHOSPHATE, P-32
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125, ALBUMIN IODINATED I-125 SERUM
SODIUM CHROMATE CR 51, SODIUM CHROMATE, CR-51
SODIUM IODIDE I 123, SODIUM IODIDE, I-123
SODIUM IODIDE I 131, SODIUM IODIDE, I-131
SODIUM PERTECHNETATE TC 99M, TECHNETIUM TC-99M SODIUM PERTECHNETATE
SODIUM PHOSPHATE P 32, SODIUM PHOSPHATE, P-32
TECHNECOLL, TECHNETIUM TC-99M SULFUR COLLOID KIT
TECHNESCAN HDP, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNESCAN MAA, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNETIUM TC 99M SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
VASCORAY, IOTHALAMATE MEGLUMINE
XENON XE 127, XENON, XE-127
XENON XE 133, XENON, XE-133

MALLINCKRODT BAKER

* MALLINCKRODT BAKER INC
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE

MARCHAR

* MARCHAR LABORATORIES INC LTD
FLUOROURACIL, FLUOROURACIL

MARSAM PHARMS LLC

* MARSAM PHARMACEUTICALS LLC
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
CEFACLOR, CEFACLOR

FDA data supplied by DrugPatentWatch.com

CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DIAZEPAM, DIAZEPAM
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
ETOPOSIDE, ETOPOSIDE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FUROSEMIDE, FUROSEMIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
ISOFLURANE, ISOFLURANE
LORAZEPAM, LORAZEPAM
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NALOXONE HCL, NALOXONE HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

MARSHALL PHARMA
* MARSHALL PHARMACAL CORP
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
RESERPINE, RESERPINE
SODIUM BUTABARBITAL, BUTABARBITAL SODIUM

MARTEC
* MARTEC PHARMACEUTICALS INC
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
DIAZEPAM, DIAZEPAM
PINDOLOL, PINDOLOL
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
* MARTEC SCIENTIFIC INC
DICLOFENAC SODIUM, DICLOFENAC SODIUM

MAST MM
* MM MAST AND CO
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ONA MAST, PHENTERMINE HYDROCHLORIDE
ONA-MAST, PHENTERMINE HYDROCHLORIDE
PHENAZINE, PHENDIMETRAZINE TARTRATE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TRICHLORMAS, TRICHLORMETHIAZIDE

MATRIX MEDCL
* MATRIX MEDICAL CORP
STERI-STAT, CHLORHEXIDINE GLUCONATE (OTC)

MAYNE PHARMA USA
* MAYNE PHARMA USA INC
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
AMIKACIN SULFATE, AMIKACIN SULFATE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
BLEOMYCIN, BLEOMYCIN SULFATE
BRETYLOL, BRETYLIUM TOSYLATE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DORYX, DOXYCYCLINE HYCLATE
DROPERIDOL, DROPERIDOL
ENALAPRILAT, ENALAPRILAT
ERYC SPRINKLES, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FUDR, FLOXURIDINE
HYDROMORPHONE HCL, HYDROMORPHONE HYDROCHLORIDE
INTROPIN, DOPAMINE HYDROCHLORIDE
IOPAMIDOL, IOPAMIDOL
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
METHOTREXATE LPF, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
THEOPHYLLINE, THEOPHYLLINE
TRIDIL, NITROGLYCERIN
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINCRISTINE SULFATE, VINCRISTINE SULFATE

MAYRAND

FDA data supplied by DrugPatentWatch.com

* MAYRAND INC
SEDAPAP, ACETAMINOPHEN

MCGAW
* MCGAW INC
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE, AMMONIUM CHLORIDE
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM

MCNEIL
* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM ADVANCED, LOPERAMIDE HYDROCHLORIDE (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
MEDIPREN, IBUPROFEN (OTC)
METHOCARBAMOL AND ASPIRIN, ASPIRIN
MOTRIN IB, IBUPROFEN (OTC)
MOTRIN MIGRAINE PAIN, IBUPROFEN (OTC)
MOTRIN, IBUPROFEN
NUPRIN, IBUPROFEN (OTC)
* MCNEIL PHARMACEUTICAL CO DIV MCNEILAB INC
CLISTIN, CARBINOXAMINE MALEATE

MCNEIL CONS SPECLT
* MCNEIL CONSUMER AND SPECIALTY PHARMACEUTICALS DIV MCNEIL PCC
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
FLEXERIL, CYCLOBENZAPRINE HYDROCHLORIDE
IMODIUM ADVANCED, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM, LOPERAMIDE HYDROCHLORIDE
MOTRIN, IBUPROFEN
NIZORAL A-D, KETOCONAZOLE (OTC)
NIZORAL, KETOCONAZOLE
SINE-AID IB, IBUPROFEN (OTC)
TYLENOL (CAPLET), ACETAMINOPHEN (OTC)
TYLENOL (GELTAB), ACETAMINOPHEN (OTC)
TYLENOL, ACETAMINOPHEN (OTC)
VERMOX, MEBENDAZOLE

MD PHARM
* MD PHARMACEUTICAL INC
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DI-ATRO, ATROPINE SULFATE

MEAD JOHNSON
* MEAD JOHNSON AND CO
CAFCIT, CAFFEINE CITRATE
* MEAD JOHNSON AND CO SUB BRISTOL MYERS CO
MUCOMYST W/ ISOPROTERENOL, ACETYLCYSTEINE

MEDI FLEX HOSP
* MEDI FLEX HOSP PRODUCTS INC
CHLORAPREP, CHLORHEXIDINE GLUCONATE (OTC)

MEDICINES CO
* THE MEDICINES CO
ANGIOMAX, BIVALIRUDIN

MEDICIS
* MEDICIS PHARMACEUTICAL CORP
BUPHENYL, SODIUM PHENYLBUTYRATE
LIDEX, FLUOCINONIDE
LIDEX-E, FLUOCINONIDE
LOPROX, CICLOPIROX
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
OVIDE, MALATHION
SYNACORT, HYDROCORTISONE
SYNALAR, FLUOCINOLONE ACETONIDE
SYNALAR-HP, FLUOCINOLONE ACETONIDE
TOPICORT LP, DESOXIMETASONE
TOPICORT, DESOXIMETASONE
VECTRIN, MINOCYCLINE HYDROCHLORIDE

MEDIMMUNE ONCOLOGY
* MEDIMMUNE ONCOLOGY INC
ETHYOL, AMIFOSTINE
NEUTREXIN, TRIMETREXATE GLUCURONATE

MEDPOINTE
* MEDPOINTE HEALTHCARE INC
FELBATOL, FELBAMATE

MEDPOINTE PHARM HLC
* MEDPOINTE PHARMACEUTICALS MEDPOINTE HEALTHCARE INC
AQUATENSEN, METHYCLOTHIAZIDE
ASTELIN, AZELASTINE HYDROCHLORIDE
BEPADIN, BEPRIDIL HYDROCHLORIDE
BUTICAPS, BUTABARBITAL SODIUM
BUTISOL SODIUM, BUTABARBITAL SODIUM
COLONAID, ATROPINE SULFATE
DEPEN, PENICILLAMINE
DIUTENSEN-R, METHYCLOTHIAZIDE
DORAL, QUAZEPAM
DORMATE, MEBUTAMATE
HYZYD, ISONIAZID
LUFYLLIN, DYPHYLLINE
MEPROSPAN, MEPROBAMATE
MICRAININ, ASPIRIN

FDA data supplied by DrugPatentWatch.com

MILPREM-200, ESTROGENS, CONJUGATED
MILPREM-400, ESTROGENS, CONJUGATED
MILTOWN, MEPROBAMATE
MYLAXEN, HEXAFLUORENIUM BROMIDE
NEOPASALATE, AMINOSALICYLATE SODIUM
OPTIVAR, AZELASTINE HYDROCHLORIDE
RONDOMYCIN, METHACYCLINE HYDROCHLORIDE
SOMA COMPOUND W/ CODEINE, ASPIRIN
SOMA COMPOUND, ASPIRIN
SOMA, CARISOPRODOL
THYRO-BLOCK, POTASSIUM IODIDE (OTC)
UNITENSEN, CRYPTENAMINE ACETATES
UNITENSEN, CRYPTENAMINE TANNATES
VERTAVIS, VERATRUM VIRIDE
VOSOL HC, ACETIC ACID, GLACIAL
VOSOL, ACETIC ACID, GLACIAL
WAMPOCAP, NIACIN

MEDTRONIC
* MEDTRONIC INC
LIORESAL, BACLOFEN

MEPHA
* MEPHA AG
PIROXICAM, PIROXICAM

MERCK
* MERCK AND CO INC
ALDOCLOR-150, CHLOROTHIAZIDE
ALDOCLOR-250, CHLOROTHIAZIDE
ALDOMET, METHYLDOPA
ALDOMET, METHYLDOPATE HYDROCHLORIDE
ALDORIL 15, HYDROCHLOROTHIAZIDE
ALDORIL 25, HYDROCHLOROTHIAZIDE
ALDORIL D30, HYDROCHLOROTHIAZIDE
ALDORIL D50, HYDROCHLOROTHIAZIDE
ALPHAREDISOL, HYDROXOCOBALAMIN
AMINOHIPPURATE SODIUM, AMINOHIPPURATE SODIUM
AQUAMEPHYTON, PHYTONADIONE
ARAMINE, METARAMINOL BITARTRATE
BENEMID, PROBENECID
COGENTIN, BENZTROPINE MESYLATE
COLBENEMID, COLCHICINE
CORTONE, CORTISONE ACETATE
CUPRIMINE, PENICILLAMINE
CYCLAINE, HEXYLCAINE HYDROCHLORIDE
DARANIDE, DICHLORPHENAMIDE
DECADERM, DEXAMETHASONE
DECADRON W/ XYLOCAINE, DEXAMETHASONE SODIUM PHOSPHATE
DECADRON, DEXAMETHASONE
DECADRON, DEXAMETHASONE SODIUM PHOSPHATE
DECASPRAY, DEXAMETHASONE
DEMSER, METYROSINE
DIUPRES-250, CHLOROTHIAZIDE
DIUPRES-500, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DOLOBID, DIFLUNISAL
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EMEND, APREPITANT
FLOROPRYL, ISOFLUROPHATE
FOSAMAX, ALENDRONATE SODIUM
HUMORSOL, DEMECARIUM BROMIDE
HYDELTRA-TBA, PREDNISOLONE TEBUTATE
HYDELTRASOL, PREDNISOLONE SODIUM PHOSPHATE
HYDROCORTONE, HYDROCORTISONE
HYDROCORTONE, HYDROCORTISONE ACETATE
HYDROCORTONE, HYDROCORTISONE SODIUM PHOSPHATE
HYDRODIURIL, HYDROCHLOROTHIAZIDE
HYDROPRES 25, HYDROCHLOROTHIAZIDE
HYDROPRES 50, HYDROCHLOROTHIAZIDE
HYZAAR, HYDROCHLOROTHIAZIDE
INVANZ, ERTAPENEM SODIUM
LERITINE, ANILERIDINE HYDROCHLORIDE
LERITINE, ANILERIDINE PHOSPHATE
MANNITOL 25%, MANNITOL
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEFOXIN, CEFOXITIN SODIUM
MEPHYTON, PHYTONADIONE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MINTEZOL, THIABENDAZOLE
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
NEO-HYDELTRASOL, NEOMYCIN SULFATE
NEODECADRON, DEXAMETHASONE SODIUM PHOSPHATE
PERIACTIN, CYPROHEPTADINE HYDROCHLORIDE
PRIMAXIN, CILASTATIN SODIUM
PROSCAR, FINASTERIDE
REDISOL, CYANOCOBALAMIN
SINGULAIR, MONTELUKAST SODIUM
SYPRINE, TRIENTINE HYDROCHLORIDE
TIAMATE, DILTIAZEM MALATE
TIMOLIDE 10-25, HYDROCHLOROTHIAZIDE
* MERCK RESEARCH LABORATORIES DIV MERCK CO INC
ALDOMET, METHYLDOPA
BLOCADREN, TIMOLOL MALEATE
CHIBROXIN, NORFLOXACIN
CLINORIL, SULINDAC
COSMEGEN, DACTINOMYCIN
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COZAAR, LOSARTAN POTASSIUM

FDA data supplied by DrugPatentWatch.com

CRIXIVAN, INDINAVIR SULFATE
DECADRON-LA, DEXAMETHASONE ACETATE
INDOCIN I.V., INDOMETHACIN SODIUM
INDOCIN SR, INDOMETHACIN
INDOCIN, INDOMETHACIN
LACRISERT, HYDROXYPROPYL CELLULOSE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEVACOR, LOVASTATIN
MODURETIC 5-50, AMILORIDE HYDROCHLORIDE
NOROXIN, NORFLOXACIN
PEPCID AC (GELTAB), FAMOTIDINE (OTC)
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE, PRECIPITATED (OTC)
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
PEPCID PRESERVATIVE FREE, FAMOTIDINE
PEPCID RPD, FAMOTIDINE
PEPCID, FAMOTIDINE
PRINIVIL, LISINOPRIL
PRINZIDE, HYDROCHLOROTHIAZIDE
PROPECIA, FINASTERIDE
SINGULAIR, MONTELUKAST SODIUM
STROMECTOL, IVERMECTIN
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
VIOXX, ROFECOXIB
ZOCOR, SIMVASTATIN

MERCK RES
* MERCK RESEARCH LABORATORIES
CANCIDAS, CASPOFUNGIN ACETATE

MERETEK
* MERETEK DIAGNOSTICS INC
BREATHTEK UBT FOR H-PYLORI, UREA, C-13
MERETEK UBT KIT (W/ PRANACTIN), UREA, C-13

MERICON
* MERICON INDUSTRIES INC
HYDROCORTISONE, HYDROCORTISONE

MERIDIAN MEDCL TECHN
* MERIDIAN MEDICAL TECHNOLOGIES INC
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ATROPEN, ATROPINE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
EPI E Z PEN JR, EPINEPHRINE
EPIPEN E Z PEN, EPINEPHRINE
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
LIDOPEN, LIDOCAINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE

METABOLIC SOLUTIONS
* METABOLIC SOLUTIONS INC
HELICOSOL, UREA, C-13

METHAPHARM
* METHAPHARM INC
PROVOCHOLINE, METHACHOLINE CHLORIDE

MFG CHEMISTS
* MANUFACTURING CHEMISTS INC
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE

MGI PHARMA INC
* MGI PHARMA INC
DIDRONEL, ETIDRONATE DISODIUM
HEXALEN, ALTRETAMINE
SALAGEN, PILOCARPINE HYDROCHLORIDE

MIKART
* MIKART INC
ACETAMINOPHEN AND BUTALBITAL AND CAFFEINE, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, BUTALBITAL, AND CAFFEINE, ACETAMINOPHEN
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC, AMINOCAPROIC ACID
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTAPAP, ACETAMINOPHEN
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
ESGIC-PLUS, ACETAMINOPHEN
ETHOSUXIMIDE, ETHOSUXIMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
ISONIAZID, ISONIAZID
METHAZOLAMIDE, METHAZOLAMIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PYRAZINAMIDE, PYRAZINAMIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE

MILES
* MILES LABORATORIES INC
ALCOHOL 5% IN DEXTROSE 5%, ALCOHOL
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

FDA data supplied by DrugPatentWatch.com

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MANNITOL 10%, MANNITOL
MANNITOL 15%, MANNITOL
MANNITOL 20%, MANNITOL
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER IN PLASTIC CONTAINER, WATER FOR IRRIGATION, STERILE

MILEX
* MILEX PRODUCTS INC
MILOPHENE, CLOMIPHENE CITRATE

MILLENNIUM PHARMS
* MILLENNIUM PHARMACEUTICALS INC
INTEGRILIN, EPTIFIBATIDE
VELCADE, BORTEZOMIB

MINRAD
* MINRAD INC
ENFLURANE, ENFLURANE
ISOFLURANE, ISOFLURANE

MISSION PHARMA
* MISSION PHARMACAL CO
CALCIBIND, CELLULOSE SODIUM PHOSPHATE
EQUIPIN, HOMATROPINE METHYLBROMIDE
FOLICET, FOLIC ACID
HOMAPIN-10, HOMATROPINE METHYLBROMIDE
HOMAPIN-5, HOMATROPINE METHYLBROMIDE
LITHOSTAT, ACETOHYDROXAMIC ACID
POTASSIUM CITRATE, POTASSIUM CITRATE
TIOPRONIN, TIOPRONIN

MIZA PHARMS USA
* MIZA PHARMACEUTICALS USA INC
OCUSULF-10, SULFACETAMIDE SODIUM
OCUSULF-30, SULFACETAMIDE SODIUM
TROPICAMIDE, TROPICAMIDE

MJ PHARMS
* MJ PHARMACEUTICALS LTD
CEPHALEXIN, CEPHALEXIN

MK LABS
* MK LABORATORIES INC
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
ISONIAZID, ISONIAZID
KESSO-GESIC, PROPOXYPHENE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
NIACIN, NIACIN
RESERPINE, RESERPINE
SOSOL, SULFISOXAZOLE
VITAMIN A, VITAMIN A PALMITATE

MONARCH PHARMS
* MONARCH PHARMACEUTICALS INC
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE
CORTISPORIN, HYDROCORTISONE ACETATE
DERMACORT, HYDROCORTISONE
KEMADRIN, PROCYCLIDINE HYDROCHLORIDE
MENEST, ESTROGENS, ESTERIFIED
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, BACITRACIN ZINC
NEOSPORIN, GRAMICIDIN
NORDETTE-21, ETHINYL ESTRADIOL
NORDETTE-28, ETHINYL ESTRADIOL
PEDIOTIC, HYDROCORTISONE
POLYSPORIN, BACITRACIN ZINC
PROCTOCORT, HYDROCORTISONE
PROLOPRIM, TRIMETHOPRIM
QUIBRON-T, THEOPHYLLINE
QUIBRON-T/SR, THEOPHYLLINE
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA GRAPE, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
THALITONE, CHLORTHALIDONE
VIROPTIC, TRIFLURIDINE

MORTON GROVE
* MORTON GROVE ACQUISITION CORP
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
* MORTON GROVE PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETIC ACID, ACETIC ACID, GLACIAL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMINOPHYLLINE, AMINOPHYLLINE
BIPHETAP, BROMPHENIRAMINE MALEATE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM

FDA data supplied by DrugPatentWatch.com

CARBAMAZEPINE, CARBAMAZEPINE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIPHEN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FUROSEMIDE, FUROSEMIDE
GENERLAC, LACTULOSE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
LACTULOSE, LACTULOSE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LINDANE, LINDANE
LITHIUM CITRATE, LITHIUM CITRATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MYBANIL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
MYCODONE, HOMATROPINE METHYLBROMIDE
MYLARAMINE, DEXCHLORPHENIRAMINE MALEATE
MYMETHASONE, DEXAMETHASONE
MYPHETANE DC, BROMPHENIRAMINE MALEATE
MYPHETANE DX, BROMPHENIRAMINE MALEATE
MYPROIC ACID, VALPROIC ACID
NYSTATIN, NYSTATIN
OXTRIPHYLLINE PEDIATRIC, OXTRIPHYLLINE
OXTRIPHYLLINE, OXTRIPHYLLINE
PHENTYTOIN, PHENYTOIN
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE VC W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
THEOPHYLLINE, THEOPHYLLINE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TRETINOIN, TRETINOIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
TRIMEPRAZINE TARTRATE, TRIMEPRAZINE TARTRATE
TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE, CODEINE PHOSPHATE

MOUNT SINAI MEDCTR
* MOUNT SINAI MEDCTR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE, TL-201

MOVA
* MOVA PHARMACEUTICALS CORP
ALBUTEROL SULFATE, ALBUTEROL SULFATE

MSP SINGAPORE
* MSP SINGAPORE CO LLC
ZETIA, EZETIMIBE

MURO
* MURO PHARMACEUTICAL INC
LIQUID PRED, PREDNISONE
PRELONE, PREDNISOLONE
PROMETA, METAPROTERENOL SULFATE
VOLMAX, ALBUTEROL SULFATE

MUTUAL PHARM
* MUTUAL PHARMACEUTICAL CO INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAZOLAMIDE, ACETAZOLAMIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CARISOPRODOL, CARISOPRODOL
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE ASPARTATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FAMOTIDINE, FAMOTIDINE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
LABETALOL HCL, LABETALOL HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

LORAZEPAM, LORAZEPAM
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MINOXIDIL, MINOXIDIL
NYSTATIN, NYSTATIN
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PREDNISONE, PREDNISONE
PROPAFENONE HCL, PROPAFENONE HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
SOTALOL HCL, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFASALAZINE, SULFASALAZINE
SULINDAC, SULINDAC
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

MUTUAL PHARMA

* MUTUAL PHARMACAL CO
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE

MYLAN

* MYLAN LABORATORIES INC
ACYCLOVIR, ACYCLOVIR
CAPTOPRIL, CAPTOPRIL
ETODOLAC, ETODOLAC
IBUPROFEN, IBUPROFEN
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
* MYLAN PHARMACEUTICALS INC
ACEBUTOLOL HCL, ACEBUTOLOL HYDROCHLORIDE
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BUPROPION HCL, BUPROPION HYDROCHLORIDE
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLOROTHIAZIDE-RESERPINE, CHLOROTHIAZIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CIMETIDINE, CIMETIDINE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLORPRES, CHLORTHALIDONE
CLOZAPINE, CLOZAPINE
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
CYSTAGON, CYSTEAMINE BITARTRATE
DIAZEPAM, DIAZEPAM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ESTRADIOL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ETODOLAC, ETODOLAC
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM, EXTENDED
FAMOTIDINE, FAMOTIDINE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FUROSEMIDE, FUROSEMIDE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
GLYBURIDE (MICRONIZED), GLYBURIDE

FDA data supplied by DrugPatentWatch.com

GUANFACINE HCL, GUANFACINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL-HYDROCHLOROTHIAZIDE-RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVOTHYROXINE SODIUM, LIOTRIX (T4;T3)
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
LOVASTATIN, LOVASTATIN
MAPROTILINE HCL, MAPROTILINE HYDROCHLORIDE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEPROBAMATE, MEPROBAMATE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDODRINE HCL, MIDODRINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NADOLOL, NADOLOL
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NEFAZODONE HCL, NEFAZODONE HYDROCHLORIDE
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
NITROFURANTION, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NIZATIDINE, NIZATIDINE
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
OMEPRAZOLE, OMEPRAZOLE
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
PACLITAXEL, PACLITAXEL
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENTOXIFYLLINE, PENTOXIFYLLINE
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM, EXTENDED
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PROBENECID, PROBENECID
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RESERPINE, RESERPINE
SOTALOL HCL, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMYLON, MAFENIDE ACETATE
SULINDAC, SULINDAC
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TEMAZEPAM, TEMAZEPAM
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HCL, TIZANIDINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
ZAGAM, SPARFLOXACIN

MYLAN TECHNOLOGIES
* MYLAN TECHNOLOGIES INC
ESTRADIOL, ESTRADIOL
FENTANYL, FENTANYL
NITROGLYCERIN, NITROGLYCERIN
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE

** N **

NABI
* NABI BIOPHARMACEUTICALS
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSLO, CALCIUM ACETATE

NASKA

FDA data supplied by DrugPatentWatch.com

* NASKA PHARMACAL CO INC DIV RUGBY DARBY GROUP COSMETICS
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE, BACITRACIN ZINC (OTC)
BACITRACIN ZINC-POLYMYXIN B SULFATE, BACITRACIN ZINC (OTC)
BACITRACIN, BACITRACIN (OTC)
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
HYDROCORTISONE, HYDROCORTISONE
TRIMETH/SULFA, SULFAMETHOXAZOLE

NEIL
* NEIL LABORATORIES INC
IBUPROFEN, IBUPROFEN (OTC)

NEPHRON
* NEPHRON CORP
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BETA-2, ISOETHARINE HYDROCHLORIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
* NEPHRON PHARMACEUTICALS CORP
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE

NEW RIVER
* NEW RIVER PHARMACEUTICALS INC
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
PROFERDEX, IRON DEXTRAN
TRIAVIL 2-10, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 2-25, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-10, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-25, AMITRIPTYLINE HYDROCHLORIDE
TRIAVIL 4-50, AMITRIPTYLINE HYDROCHLORIDE

NEWTRON PHARMS
* NEWTRON PHARMACEUTICALS INC
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
TRILITRON, PSEUDOEPHEDRINE HYDROCHLORIDE

NORBROOK
* NORBROOK LABORATORIES LTD
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE

NOVARTIS
* NOVARTIS CONSUMER HEALTH INC
ASBRON, THEOPHYLLINE SODIUM GLYCINATE
CONTAC, CHLORPHENIRAMINE MALEATE (OTC)
DENAVIR, PENCICLOVIR SODIUM
FOAMICON, ALUMINUM HYDROXIDE (OTC)
HABITROL, NICOTINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFINE
LAMISIL, TERBINAFINE HYDROCHLORIDE
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
RAUTENSIN, ALSEROXYLON
TAVIST ALLERGY/SINUS/HEADACHE, ACETAMINOPHEN (OTC)
TRANSDERM SCOP, SCOPOLAMINE
* NOVARTIS PHARMACEUTICALS CORP
ACYLANID, ACETYLDIGITOXIN
ANTRENYL, OXYPHENONIUM BROMIDE
ANTURANE, SULFINPYRAZONE
APRESAZIDE, HYDRALAZINE HYDROCHLORIDE
APRESOLINE, HYDRALAZINE HYDROCHLORIDE
APRESOLINE-ESIDRIX, HYDRALAZINE HYDROCHLORIDE
AREDIA, PAMIDRONATE DISODIUM
BRETHAIRE, TERBUTALINE SULFATE
BUTAZOLIDIN, PHENYLBUTAZONE
CAFERGOT, CAFFEINE
CARBASTAT, CARBACHOL
CATAFLAM, DICLOFENAC POTASSIUM
CATARASE, CHYMOTRYPSIN
CEDILANID-D, DESLANOSIDE
CIBACALCIN, CALCITONIN HUMAN
CLOZARIL, CLOZAPINE
COMBIPATCH, ESTRADIOL
CYTADREN, AMINOGLUTETHIMIDE
DESFERAL, DEFEROXAMINE MESYLATE
DEXACIDIN, DEXAMETHASONE
DIAPID, LYPRESSIN
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
ELIDEL, PIMECROLIMUS
EMBOLEX, DIHYDROERGOTAMINE MESYLATE
ESIDRIX, HYDROCHLOROTHIAZIDE
ESIMIL, GUANETHIDINE MONOSULFATE
ESTRADERM, ESTRADIOL
EXELON, RIVASTIGMINE TARTRATE
FAMVIR, FAMCICLOVIR
FEMARA, LETROZOLE
FLUOR-OP, FLUOROMETHOLONE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FORADIL, FORMOTEROL FUMARATE
FUNDUSCEIN-25, FLUORESCEIN SODIUM
GENTACIDIN, GENTAMICIN SULFATE
GLEEVEC, IMATINIB MESYLATE
HEAVY SOLUTION NUPERCAINE, DIBUCAINE HYDROCHLORIDE
HYDERGINE LC, ERGOLOID MESYLATES
HYDERGINE, ERGOLOID MESYLATES
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INFLAMASE FORTE, PREDNISOLONE SODIUM PHOSPHATE
INFLAMASE MILD, PREDNISOLONE SODIUM PHOSPHATE
INH, ISONIAZID
ISMELIN, GUANETHIDINE MONOSULFATE
LAMISIL, TERBINAFINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

LAMPRENE, CLOFAZIMINE
LESCOL XL, FLUVASTATIN SODIUM
LESCOL, FLUVASTATIN SODIUM
LIORESAL, BACLOFEN
LIVOSTIN, LEVOCABASTINE HYDROCHLORIDE
LOCORTEN, FLUMETHASONE PIVALATE
LOPRESSIDONE, CHLORTHALIDONE
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL FUMARATE
LOPRESSOR, METOPROLOL TARTRATE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
LOTREL, AMLODIPINE BESYLATE
LUDIOMIL, MAPROTILINE HYDROCHLORIDE
MELLARIL, THIORIDAZINE HYDROCHLORIDE
MELLARIL-S, THIORIDAZINE
MESANTOIN, MEPHENYTOIN
METANDREN, METHYLTESTOSTERONE
METHERGINE, METHYLERGONOVINE MALEATE
METOPIRONE, METYRAPONE
MIACALCIN, CALCITONIN, SALMON
MIOCHOL, ACETYLCHOLINE CHLORIDE
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
NEORAL, CYCLOSPORINE
OCUPRESS, CARTEOLOL HYDROCHLORIDE
PARLODEL, BROMOCRIPTINE MESYLATE
PBZ, TRIPELENNAMINE CITRATE
PBZ, TRIPELENNAMINE HYDROCHLORIDE
PBZ-SR, TRIPELENNAMINE HYDROCHLORIDE
PERCORTEN, DESOXYCORTICOSTERONE ACETATE
PERCORTEN, DESOXYCORTICOSTERONE PIVALATE
PRISCOLINE, TOLAZOLINE HYDROCHLORIDE
REGITINE, PHENTOLAMINE MESYLATE
RESCULA, UNOPROSTONE ISOPROPYL
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SANDOSTATIN, OCTREOTIDE ACETATE
SANOREX, MAZINDOL
SANSERT, METHYSERGIDE MALEATE
SER-AP-ES, HYDRALAZINE HYDROCHLORIDE
SERENTIL, MESORIDAZINE BESYLATE
SERPASIL, RESERPINE
SERPASIL-APRESOLINE, HYDRALAZINE HYDROCHLORIDE
SERPASIL-ESIDRIX #1, HYDROCHLOROTHIAZIDE
SERPASIL-ESIDRIX #2, HYDROCHLOROTHIAZIDE
SLOW-K, POTASSIUM CHLORIDE
STARLIX, NATEGLINIDE
SULF-10, SULFACETAMIDE SODIUM
SULF-15, SULFACETAMIDE SODIUM
SYNTOCINON, OXYTOCIN
TANDEARIL, OXYPHENBUTAZONE
TAVIST D, CLEMASTINE FUMARATE
TAVIST, CLEMASTINE FUMARATE
TAVIST-1, CLEMASTINE FUMARATE
TAVIST-1, CLEMASTINE FUMARATE (OTC)
TAVIST-D, CLEMASTINE FUMARATE (OTC)
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TEN-K, POTASSIUM CHLORIDE
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TORECAN, THIETHYLPERAZINE MALATE
TORECAN, THIETHYLPERAZINE MALEATE
TRANSDERM-NITRO, NITROGLYCERIN
TRASICOR, OXPRENOLOL HYDROCHLORIDE
TREST, METHIXENE HYDROCHLORIDE
TRIAMINIC-12, CHLORPHENIRAMINE MALEATE (OTC)
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRILEPTAL, OXCARBAZEPINE
VASOCIDIN, PREDNISOLONE ACETATE
VASOCIDIN, PREDNISOLONE SODIUM PHOSPHATE
VASOCON, NAPHAZOLINE HYDROCHLORIDE
VASOCON-A, ANTAZOLINE PHOSPHATE (OTC)
VISKAZIDE, HYDROCHLOROTHIAZIDE
VISKEN, PINDOLOL
VITRAVENE PRESERVATIVE FREE, FOMIVIRSEN SODIUM
VIVELLE, ESTRADIOL
VIVELLE-DOT, ESTRADIOL
VOLTAREN, DICLOFENAC SODIUM
VOLTAREN-XR, DICLOFENAC SODIUM
ZADITOR, KETOTIFEN FUMARATE
ZELNORM, TEGASEROD MALEATE
ZOMETA, ZOLEDRONIC ACID

NOVAVAX
* NOVAVAX INC
AVC, SULFANILAMIDE
ESTRASORB, ESTRADIOL HEMIHYDRATE

NOVEN
* NOVEN PHARMACEUTICALS INC
LIDOCAINE, LIDOCAINE

NOVEX
* NOVEX PHARMA
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BETAXOLOL, BETAXOLOL HYDROCHLORIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CARTEOLOL HCL, CARTEOLOL HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CROMOLYN SODIUM, CROMOLYN SODIUM
FLUOXETINE, FLUOXETINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LACTULOSE, LACTULOSE
LEVOBUNOLOL HCL, LEVOBUNOLOL HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN, TOBRAMYCIN

NOVO NORDISK
* NOVO NORDISK PHARMACEUTICALS INC
ACTIVELLA, ESTRADIOL
GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT
INNOFEM, ESTRADIOL
INSULATARD NPH HUMAN, INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN (OTC)
INSULIN INSULATARD NPH NORDISK, INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
INSULIN NORDISK MIXTARD (PORK), INSULIN PURIFIED PORK (OTC)
INSULIN, INSULIN PORK (OTC)
LENTARD, INSULIN ZINC SUSP PURIFIED BEEF/PORK (OTC)
LENTE INSULIN, INSULIN ZINC SUSP BEEF (OTC)
LENTE, INSULIN ZINC SUSP PURIFIED PORK (OTC)
NORDITROPIN, SOMATROPIN RECOMBINANT
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN 70/30, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
NOVOLIN L, INSULIN ZINC SUSP RECOMBINANT HUMAN (OTC)
NOVOLIN L, INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
NOVOLOG MIX 70/30, INSULIN ASPART
NOVOLOG, INSULIN ASPART
NPH INSULIN, INSULIN SUSP ISOPHANE BEEF (OTC)
NPH PURIFIED PORK ISOPHANE INSULIN, INSULIN SUSP ISOPHANE PURIFIED PORK (OTC)
PRANDIN, REPAGLINIDE
REGULAR INSULIN, INSULIN PORK (OTC)
REGULAR PURIFIED PORK INSULIN, INSULIN PURIFIED PORK (OTC)
SEMILENTE INSULIN, INSULIN ZINC SUSP PROMPT BEEF (OTC)
SEMILENTE, INSULIN ZINC SUSP PROMPT PURIFIED PORK (OTC)
ULTRALENTE INSULIN, INSULIN ZINC SUSP EXTENDED BEEF (OTC)
ULTRALENTE, INSULIN ZINC SUSP EXTENDED PURIFIED BEEF (OTC)
VAGIFEM, ESTRADIOL
VELOSULIN BR HUMAN, INSULIN RECOMBINANT PURIFIED HUMAN (OTC)
VELOSULIN BR, INSULIN RECOMBINANT HUMAN (OTC)
VELOSULIN, INSULIN PURIFIED PORK (OTC)

NOVOCOL
* NOVOCOL PHARMACEUTICAL INC
ISOCAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
ISOCAINE HCL, MEPIVACAINE HYDROCHLORIDE

NUMARK
* NUMARK LABORATORIES INC
MELFIAT, PHENDIMETRAZINE TARTRATE
MELFIAT-105, PHENDIMETRAZINE TARTRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
SPRX-105, PHENDIMETRAZINE TARTRATE

NYLOS
* NYLOS TRADING CO INC
METHOCARBAMOL, METHOCARBAMOL
PREDNISONE, PREDNISONE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE

** O **

OCLASSEN
* OCLASSEN PHARMACEUTICALS INC
CONDYLOX, PODOFILOX
CORDRAN SP, FLURANDRENOLIDE
CORDRAN, FLURANDRENOLIDE
MONODOX, DOXYCYCLINE

ODYSSEY PHARMS
* ODYSSEY PHARMACEUTICALS INC
ANTABUSE, DISULFIRAM
NYSTATIN, NYSTATIN
URECHOLINE, BETHANECHOL CHLORIDE
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE

OHM
* OHM CORP
IBUPROFEN, IBUPROFEN (OTC)

OHM LABS
* OHM LABORATORIES INC
CHLORZOXAZONE, CHLORZOXAZONE
IBUPROFEN, IBUPROFEN
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUPROHM, IBUPROFEN
IBUPROHM, IBUPROFEN (OTC)
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)

ONY
* ONY INC
INFASURF PRESERVATIVE FREE, CALFACTANT

OPTOPICS
* OPTOPICS LABORATORIES CORP

FDA data supplied by DrugPatentWatch.com

OPTOMYCIN, CHLORAMPHENICOL
PARACAINE, PROPARACAINE HYDROCHLORIDE
SULFACEL-15, SULFACETAMIDE SODIUM

ORAPHARMA
* ORAPHARMA INC
ARESTIN, MINOCYCLINE HYDROCHLORIDE

ORGANICS LAGRANGE
* ORGANICS LAGRANGE INC
CORTICOTROPIN, CORTICOTROPIN

ORGANON
* ORGANON INC SUB AKZONA INC
LIQUAMAR, PHENPROCOUMON

ORGANON USA
* ORGANON USA INC
HEXADROL, DEXAMETHASONE

ORGANON USA INC
ANTAGON, GANIRELIX ACETATE
ARDUAN, PIPECURONIUM BROMIDE
CALDEROL, CALCIFEDIOL
CORTROPHIN-ZINC, CORTICOTROPIN-ZINC HYDROXIDE
COTAZYM, LIPASE
CYCLESSA, DESOGESTREL
DECA-DURABOLIN, NANDROLONE DECANOATE
DESOGEN, DESOGESTREL
DOCA, DESOXYCORTICOSTERONE ACETATE
DURABOLIN, NANDROLONE PHENPROPIONATE
FOLLISTIM, FOLLITROPIN ALFA/BETA
FUROSEMIDE, FUROSEMIDE
HEPARIN SODIUM, HEPARIN SODIUM
HEXADROL, DEXAMETHASONE
HEXADROL, DEXAMETHASONE SODIUM PHOSPHATE
HUMEGON, MENOTROPINS (FSH;LH)
LIQUAEMIN LOCK FLUSH, HEPARIN SODIUM
LIQUAEMIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
LIQUAEMIN SODIUM, HEPARIN SODIUM
LYNORAL, ETHINYL ESTRADIOL
MAXIBOLIN, ETHYLESTRENOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE SODIUM SUCCINATE
MIRCETTE, DESOGESTREL
NORCURON, VECURONIUM BROMIDE
NUVARING, ETHINYL ESTRADIOL
ORGARAN, DANAPAROID SODIUM
ORGATRAX, HYDROXYZINE HYDROCHLORIDE
PAVULON, PANCURONIUM BROMIDE
PREGNYL, GONADOTROPIN, CHORIONIC
PURIFIED CORTROPHIN GEL, CORTICOTROPIN
RAPLON, RAPACURONIUM BROMIDE
REMERON SOLTAB, MIRTAZAPINE
REMERON, MIRTAZAPINE
REVERSOL, EDROPHONIUM CHLORIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
WIGRAINE, CAFFEINE
WIGRETTES, ERGOTAMINE TARTRATE
ZEMURON (P/F), ROCURONIUM BROMIDE
ZEMURON, ROCURONIUM BROMIDE

ORIDION
* ORIDION BREATHID INC
IDKIT:HP, CITRIC ACID

ORION
* ORION CORP
COMTAN, ENTACAPONE
FARESTON, TOREMIFENE CITRATE

ORION PHARMA INC
* ORION PHARMACEUTICALS INC
STALEVO 100, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 50, CARBIDOPA

ORPHAN MEDCL
* ORPHAN MEDICAL INC
ANTIZOL, FOMEPIZOLE
CYSTADANE, BETAINE, ANHYDROUS
XYREM, SODIUM OXYBATE

ORTHO BIOTECH
* ORTHO BIOTECH PRODUCTS LP
LEUSTATIN, CLADRIBINE

ORTHO MCNEIL
* ORTHO MCNEIL PHARMACEUTICAL
DIENESTROL, DIENESTROL
HALDOL, HALOPERIDOL
HALDOL, HALOPERIDOL DECANOATE
HALDOL, HALOPERIDOL LACTATE
TOPAMAX SPRINKLE, TOPIRAMATE

ORTHO MCNEIL PHARM
* ALZA CORP
URISPAS, FLAVOXATE HYDROCHLORIDE
* ORTHO MCNEIL PHARMACEUTICAL INC
CLISTIN, CARBINOXAMINE MALEATE
ESTRADIOL, ESTRADIOL
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER, OFLOXACIN
FLOXIN IN DEXTROSE 5%, OFLOXACIN
FLOXIN, OFLOXACIN
HALDOL SOLUTAB, HALOPERIDOL
INJECTAPAP, ACETAMINOPHEN
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN

FDA data supplied by DrugPatentWatch.com

LEVAQUIN, LEVOFLOXACIN
MICRONOR, NORETHINDRONE
MODICON 21, ETHINYL ESTRADIOL
MODICON 28, ETHINYL ESTRADIOL
MONISTAT 3, MICONAZOLE NITRATE
ORTHO EVRA, ETHINYL ESTRADIOL
ORTHO-CEPT, DESOGESTREL
ORTHO-N0VUM 1/80 28, MESTRANOL
ORTHO-NOVUM 1/35-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 1/50 21, MESTRANOL
ORTHO-NOVUM 1/50 28, MESTRANOL
ORTHO-NOVUM 1/80 21, MESTRANOL
ORTHO-NOVUM 10-21, MESTRANOL
ORTHO-NOVUM 10/11-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 10/11-28 IN PLASTIC CONTAINER, ETHINYL ESTRADIOL
ORTHO-NOVUM 2-21, MESTRANOL
ORTHO-NOVUM 7/14-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/14-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-21, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
PARAFLEX, CHLORZOXAZONE
PARAFON FORTE DSC, CHLORZOXAZONE
PROTOSTAT, METRONIDAZOLE
SALPIX, ACETRIZOATE SODIUM
SULTRIN, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
TERAZOL 3, TERCONAZOLE
TERAZOL 7, TERCONAZOLE
THEOPHYL, THEOPHYLLINE
THEOPHYL-225, THEOPHYLLINE
THEOPHYL-SR, THEOPHYLLINE
TOLECTIN 600, TOLMETIN SODIUM
TOLECTIN DS, TOLMETIN SODIUM
TOLECTIN, TOLMETIN SODIUM
TOPAMAX, TOPIRAMATE
TYCOLET, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 1, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 2, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
TYLENOL W/ CODEINE, ACETAMINOPHEN
TYLOX, ACETAMINOPHEN
TYLOX-325, ACETAMINOPHEN
ULTRACET, ACETAMINOPHEN
ULTRAM, TRAMADOL HYDROCHLORIDE
VASCOR, BEPRIDIL HYDROCHLORIDE

OTSUKA
* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY, ARIPIPRAZOLE
FERRISELTZ, FERRIC AMMONIUM CITRATE
PLETAL, CILOSTAZOL
RAXAR, GREPAFLOXACIN HYDROCHLORIDE

OVATION PHARMS
* OVATION PHARMACEUTICALS INC
CHEMET, SUCCIMER
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NEMBUTAL, PENTOBARBITAL
NEMBUTAL, PENTOBARBITAL SODIUM
PEGANONE, ETHOTOIN
TRANXENE SD, CLORAZEPATE DIPOTASSIUM
TRANXENE, CLORAZEPATE DIPOTASSIUM
WINSTROL, STANOZOLOL

OXFORD PHARM
* OXFORD PHARMACEUTICAL SERVICES INC
MARPLAN, ISOCARBOXAZID

** P **

PACIFIC PHARMA
* PACIFIC PHARMA
TIMOLOL MALEATE, TIMOLOL MALEATE
* PACIFIC PHARMA INC
TIMOLOL MALEATE, TIMOLOL MALEATE

PACO
* PACO PHARMACEUTICAL SERVICES INC
LACTULOSE, LACTULOSE
* PACO RESEARCH CORP
GENTAMICIN SULFATE, GENTAMICIN SULFATE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
THIOTHIXENE HCL, THIOTHIXENE HYDROCHLORIDE

PADDOCK
* PADDOCK LABORATORIES INC
AMMONIUM LACTATE, AMMONIUM LACTATE
BACITRACIN, BACITRACIN
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
COLOCORT, HYDROCORTISONE
COMPRO, PROCHLORPERAZINE
CONDYLOX, PODOFILOX
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
ERYTHRA-DERM, ERYTHROMYCIN
ERYTHROMYCIN, ERYTHROMYCIN
HYDROCORTISONE, HYDROCORTISONE
KIONEX, SODIUM POLYSTYRENE SULFONATE
NYSTATIN, NYSTATIN
NYSTOP, NYSTATIN
PODOFILOX, PODOFILOX
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

PAL PAK
* PAL PAK INC
AMINOPHYLLINE, AMINOPHYLLINE
RAUVAL, RAUWOLFIA SERPENTINA
TRIPLE SULFOID, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)

PANRAY
* PANRAY CORP SUB ORMONT DRUG AND CHEMICAL CO INC
AMINOPHYLLINE, AMINOPHYLLINE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CINNASIL, RESCINNAMINE
CORTISONE ACETATE, CORTISONE ACETATE
HYDROCORTISONE, HYDROCORTISONE
ISONIAZID, ISONIAZID
KOGLUCOID, RAUWOLFIA SERPENTINA
PARASAL SODIUM, AMINOSALICYLATE SODIUM
PARASAL, AMINOSALICYLIC ACID
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROCAPAN, PROCAINAMIDE HYDROCHLORIDE
SERPANRAY, RESERPINE
THEOLIXIR, THEOPHYLLINE

PAR PHARM
* PAR PHARMACEUTICAL INC
ACEBUTOLOL HCL, ACEBUTOLOL HYDROCHLORIDE
ALLOPURINOL, ALLOPURINOL
AMILORIDE HCL, AMILORIDE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
CAPOTEN, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL AND ASPIRIN, ASPIRIN
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORZOXAZONE, CHLORZOXAZONE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLONIDINE HCL AND CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM, DIAZEPAM
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DISULFIRAM, DISULFIRAM
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXY-SLEEP-AID, DOXYLAMINE SUCCINATE (OTC)
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRO-RIDE, AMILORIDE HYDROCHLORIDE
HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LISINOPRIL, LISINOPRIL
LORAZEPAM, LORAZEPAM
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPROBAMATE AND ASPIRIN, ASPIRIN
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOCARBAMOL, METHOCARBAMOL
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND CHLOROTHIAZIDE, CHLOROTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MINOXIDIL, MINOXIDIL
NYSTATIN, NYSTATIN
OFLOXACIN, OFLOXACIN
ORPHENGESIC FORTE, ASPIRIN
ORPHENGESIC, ASPIRIN
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RESERPINE AND HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
SULFAMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOPRIM-DS, SULFAMETHOXAZOLE
SULFINPYRAZONE, SULFINPYRAZONE
SUMYCIN, TETRACYCLINE HYDROCHLORIDE
TEMAZEPAM, TEMAZEPAM
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TORSEMIDE, TORSEMIDE

FDA data supplied by DrugPatentWatch.com

TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
VALPROIC ACID, VALPROIC ACID

PARKE DAVIS

* PARKE DAVIS DIV WARNER LAMBERT CO
AMBODRYL, BROMODIPHENHYDRAMINE HYDROCHLORIDE
AMCILL, AMPICILLIN/AMPICILLIN TRIHYDRATE
BENADRYL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
BENADRYL, DIPHENHYDRAMINE HYDROCHLORIDE
BENYLIN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
CAMOQUIN HCL, AMODIAQUINE HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENTRAX, PRAZEPAM
CEREBYX, FOSPHENYTOIN SODIUM
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHOLEDYL SA, OXTRIPHYLLINE
CHOLEDYL, OXTRIPHYLLINE
CHOLYBAR, CHOLESTYRAMINE
COLY-MYCIN S, COLISTIN SULFATE
DILANTIN, PHENYTOIN SODIUM, EXTENDED
DILANTIN-125, PHENYTOIN
DILANTIN-30, PHENYTOIN
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
ERGOSTAT, ERGOTAMINE TARTRATE
ERYC 125, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
ERYPAR, ERYTHROMYCIN STEARATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ESTROVIS, QUINESTROL
EUTHROID-0.5, LIOTRIX (T4;T3)
EUTHROID-1, LIOTRIX (T4;T3)
EUTHROID-2, LIOTRIX (T4;T3)
EUTHROID-3, LIOTRIX (T4;T3)
EVANS BLUE, EVANS BLUE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HUMATIN, PAROMOMYCIN SULFATE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE, HYDROCORTISONE
INDOMETHACIN, INDOMETHACIN
ISOPROTERENOL HCL, ISOPROTERENOL HYDROCHLORIDE
MECLOMEN, MECLOFENAMATE SODIUM
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLTESTOSTERONE, METHYLTESTOSTERONE
MILONTIN, PHENSUXIMIDE
NARDIL, PHENELZINE SULFATE
NEURONTIN, GABAPENTIN
NITROSTAT, NITROGLYCERIN
NORLUTATE, NORETHINDRONE ACETATE
NORLUTIN, NORETHINDRONE
OXAZEPAM, OXAZEPAM
PARACORT, PREDNISONE
PARSIDOL, ETHOPROPAZINE HYDROCHLORIDE
PENAPAR-VK, PENICILLIN V POTASSIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PITRESSIN TANNATE, VASOPRESSIN TANNATE
POVAN, PYRVINIUM PAMOATE
PRE-SATE, CHLORPHENTERMINE HYDROCHLORIDE
PROCAN SR, PROCAINAMIDE HYDROCHLORIDE
PROCAN, PROCAINAMIDE HYDROCHLORIDE
PROLOID, THYROGLOBULIN
PROMAPAR, CHLORPROMAZINE HYDROCHLORIDE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SULFALAR, SULFISOXAZOLE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
UTICORT, BETAMETHASONE BENZOATE
UTIMOX, AMOXICILLIN
ZARONTIN, ETHOSUXIMIDE

* PARKE DAVIS LABORATORIES DIV WARNER LAMBERT CO
NORLESTRIN 21 1/50, ETHINYL ESTRADIOL
NORLESTRIN 21 2.5/50, ETHINYL ESTRADIOL
NORLESTRIN 28 1/50, ETHINYL ESTRADIOL
NORLESTRIN FE 1/50, ETHINYL ESTRADIOL
NORLESTRIN FE 2.5/50, ETHINYL ESTRADIOL

* PARKE DAVIS PHARMACEUTICAL RESEARCH DIV WARNER LAMBERT CO
CHLOROMYCETIN PALMITATE, CHLORAMPHENICOL PALMITATE
CHLOROMYCETIN, CHLORAMPHENICOL
CHLOROMYXIN, CHLORAMPHENICOL
DILANTIN, PHENYTOIN SODIUM
ELASE-CHLOROMYCETIN, CHLORAMPHENICOL
FEMPATCH, ESTRADIOL
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
UTICORT, BETAMETHASONE BENZOATE
ZARONTIN, ETHOSUXIMIDE

PARKEDALE

* PARKEDALE PHARMACEUTICALS INC
ACTH, CORTICOTROPIN
ANUSOL HC, HYDROCORTISONE
CHLOROMYCETIN HYDROCORTISONE, CHLORAMPHENICOL
CHLOROMYCETIN, CHLORAMPHENICOL
CHLOROMYCETIN, CHLORAMPHENICOL SODIUM SUCCINATE
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
HUMATIN, PAROMOMYCIN SULFATE
KETALAR, KETAMINE HYDROCHLORIDE
OPHTHOCHLOR, CHLORAMPHENICOL
OPHTHOCORT, CHLORAMPHENICOL

FDA data supplied by DrugPatentWatch.com

PITOCIN, OXYTOCIN
PROCAN SR, PROCAINAMIDE HYDROCHLORIDE
SURITAL, THIAMYLAL SODIUM
THEELIN, ESTRONE
VIRA-A, VIDARABINE

PARNELL
* PARNELL PHARMACEUTICALS INC
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PEDINOL
* PEDINOL PHARMACAL INC
GRIS-PEG, GRISEOFULVIN, ULTRAMICROCRYSTALLINE

PENNEX
* PENNEX PRODUCTS CO INC
ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE, ALUMINUM HYDROXIDE (OTC)

PERRIGO
* L PERRIGO CO
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ANTITUSSIVE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
CAP-PROFEN, IBUPROFEN (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CIMETIDINE, CIMETIDINE (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HCL, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
ISONIAZID, ISONIAZID
KETOPROFEN, KETOPROFEN (OTC)
LOPERAMIDE HCL AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
MEPROBAMATE, MEPROBAMATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE SULFATE, QUINIDINE SULFATE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
TAB-PROFEN, IBUPROFEN (OTC)
THEOPHYLLINE, THEOPHYLLINE
TIOCONAZOLE, TIOCONAZOLE (OTC)
* PERRIGO CO
CIMETIDINE, CIMETIDINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

PERSONAL PRODS
* PERSONAL PRODUCTS CO
DELFEN, NONOXYNOL-9 (OTC)
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 5, MICONAZOLE NITRATE
MONISTAT DUAL- PAK, MICONAZOLE NITRATE

PFIPHARMECS
* PFIPHARMECS DIV PFIZER INC
CORTRIL, HYDROCORTISONE
TETRACYN, TETRACYCLINE HYDROCHLORIDE

PFIZER
* PFIZER AGRICULTURAL DIV
ANTIVERT, MECLIZINE HYDROCHLORIDE
NORVASC, AMLODIPINE BESYLATE
* PFIZER CENTRAL RESEARCH
DIFLUCAN, FLUCONAZOLE
TROVAN, TROVAFLOXACIN MESYLATE
ZITHROMAX, AZITHROMYCIN
* PFIZER CHEMICALS DIV PFIZER INC
DIFLUCAN, FLUCONAZOLE
TROVAN PRESERVATIVE FREE, ALATROFLOXACIN MESYLATE
ZITHROMAX, AZITHROMYCIN
* PFIZER INC
ATARAX, HYDROXYZINE HYDROCHLORIDE
CEFOBID, CEFOPERAZONE SODIUM
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
EMETE-CON, BENZQUINAMIDE HYDROCHLORIDE
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GLUCOTROL XL, GLIPIZIDE
GLUCOTROL, GLIPIZIDE
LIPITOR, ATORVASTATIN CALCIUM
LITHIUM CARBONATE, LITHIUM CARBONATE
MINIPRESS XL, PRAZOSIN HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

MINIZIDE, POLYTHIAZIDE
NAVANE, THIOTHIXENE
NAVANE, THIOTHIXENE HYDROCHLORIDE
PROCARDIA, NIFEDIPINE
RENESE, POLYTHIAZIDE
RID MOUSSE, PIPERONYL BUTOXIDE (OTC)
UNASYN, AMPICILLIN SODIUM
VFEND, VORICONAZOLE
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
ZITHROMAX, AZITHROMYCIN
ZYRTEC, CETIRIZINE HYDROCHLORIDE
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE

* PFIZER LABORATORIES DIV PFIZER INC
BACITRACIN, BACITRACIN
CARDURA, DOXAZOSIN MESYLATE
CEFOBID IN PLASTIC CONTAINER, CEFOPERAZONE SODIUM
CEFOBID, CEFOPERAZONE SODIUM
CORTRIL, HYDROCORTISONE
CORTRIL, HYDROCORTISONE ACETATE
DARICON, OXYPHENCYCLIMINE HYDROCHLORIDE
DIABINESE, CHLORPROPAMIDE
FELDENE, PIROXICAM
FOVANE, BENZTHIAZIDE
GEOCILLIN, CARBENICILLIN INDANYL SODIUM
MAGNACORT, HYDROCORTAMATE HYDROCHLORIDE
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MITHRACIN, PLICAMYCIN
MODERIL, RESCINNAMINE
NEOBIOTIC, NEOMYCIN SULFATE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PERMAPEN, PENICILLIN G BENZATHINE
PFIZER-E, ERYTHROMYCIN STEARATE
PFIZERPEN G, PENICILLIN G POTASSIUM
PFIZERPEN VK, PENICILLIN V POTASSIUM
PFIZERPEN, PENICILLIN G POTASSIUM
PFIZERPEN-A, AMPICILLIN/AMPICILLIN TRIHYDRATE
PFIZERPEN-AS, PENICILLIN G PROCAINE
PROCARDIA XL, NIFEDIPINE
RENESE-R, POLYTHIAZIDE
SINEQUAN, DOXEPIN HYDROCHLORIDE
SPECTROBID, BACAMPICILLIN HYDROCHLORIDE
STERANE, PREDNISOLONE
STERANE, PREDNISOLONE ACETATE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
TAO, TROLEANDOMYCIN
TERRA-CORTRIL, HYDROCORTISONE ACETATE
TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN W/ POLYMYXIN, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN, LIDOCAINE HYDROCHLORIDE
TERRAMYCIN, OXYTETRACYCLINE
TERRAMYCIN, OXYTETRACYCLINE CALCIUM
TERRAMYCIN, OXYTETRACYCLINE HYDROCHLORIDE
TERRAMYCIN-POLYMYXIN, OXYTETRACYCLINE HYDROCHLORIDE
TETRACYN, PROCAINE HYDROCHLORIDE
TETRACYN, TETRACYCLINE HYDROCHLORIDE
TZ-3, TIOCONAZOLE (OTC)
UNASYN, AMPICILLIN SODIUM
UNISOM, DOXYLAMINE SUCCINATE (OTC)
URESE, BENZTHIAZIDE
VANSIL, OXAMNIQUINE
VIBRA-TABS, DOXYCYCLINE HYCLATE
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VIOCIN SULFATE, VIOMYCIN SULFATE
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISTARIL, HYDROXYZINE HYDROCHLORIDE
VISTARIL, HYDROXYZINE PAMOATE

* PFIZER PHARMACEUTICALS INC
TAO, TROLEANDOMYCIN
TROVAN/ZITHROMAX COMPLIANCE PAK, AZITHROMYCIN DIHYDRATE
ZOLOFT, SERTRALINE HYDROCHLORIDE

* PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
TIKOSYN, DOFETILIDE

PFIZER IRELAND

* PFIZER IRELAND PHARMACEUTICALS
RELPAX, ELETRIPTAN HYDROBROMIDE
VIAGRA, SILDENAFIL CITRATE

PFIZER PHARMS

* PFIZER PHARMACEUTICALS LTD
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
DILANTIN, PHENYTOIN
LOPID, GEMFIBROZIL
NEURONTIN, GABAPENTIN
NITROSTAT, NITROGLYCERIN
REZULIN, TROGLITAZONE

PHARM ASSOC

* PHARMACEUTICAL ASSOC INC
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE

* PHARMACEUTICAL ASSOC INC DIV BEACH PRODUCTS
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE

FDA data supplied by DrugPatentWatch.com

FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
H-CORT, HYDROCORTISONE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PREDNISOLONE, PREDNISOLONE
PROMETHAZINE HCL AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID

PHARM FORM
* PHARMACEUTICAL FORMULATIONS INC
CIMETIDINE, CIMETIDINE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HCL, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)

PHARM SPEC
* PHARMACEUTICAL SPECIALIST ASSOC
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HEPARIN SODIUM, HEPARIN SODIUM

PHARM VENTURES
* PHARMACEUTICAL VENTURES LTD
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE

PHARMA SERVE NY
* PHARMA SERVE INC SUB TORIGIAN LABORATORIES
AMINOPHYLLINE, AMINOPHYLLINE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PHARMA TEK
* PHARMA TEK INC
AMPHOTERICIN B, AMPHOTERICIN B
BACI-RX, BACITRACIN
BACIIM, BACITRACIN
COLISTIMETHATE, COLISTIMETHATE SODIUM
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE, HYDROCORTISONE
NEO-RX, NEOMYCIN SULFATE
POLY-RX, POLYMYXIN B SULFATE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN SULFATE
ZIBA-RX, BACITRACIN ZINC

PHARMACHEMIE
* PHARMACHEMIE BV
CISPLATIN, CISPLATIN
DOXORUBICIN HCL, DOXORUBICIN HYDROCHLORIDE
ETOPOSIDE, ETOPOSIDE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE

PHARMACHEMIE USA
* PHARMACHEMIE USA INC
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM

PHARMACIA
* PHARMACIA CORP
DAYPRO ALTA, OXAPROZIN POTASSIUM
MAXAQUIN, LOMEFLOXACIN HYDROCHLORIDE

PHARMACIA AND UPJOHN
* PHARMACIA AND UPJOHN
XANAX XR, ALPRAZOLAM
* PHARMACIA AND UPJOHN CO
ADRIAMYCIN PFS, DOXORUBICIN HYDROCHLORIDE
ADRIAMYCIN RDF, DOXORUBICIN HYDROCHLORIDE
ADRUCIL, FLUOROURACIL
ALBAMYCIN, NOVOBIOCIN SODIUM
ALPHADROL, FLUPREDNISOLONE
ANSAID, FLURBIPROFEN
AROMASIN, EXEMESTANE
AZULFIDINE EN-TABS, SULFASALAZINE
AZULFIDINE, SULFASALAZINE
BACIGUENT, BACITRACIN
BACITRACIN, BACITRACIN
BERUBIGEN, CYANOCOBALAMIN
CALMURID HC, HYDROCORTISONE
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CARDRASE, ETHOXZOLAMIDE
CAVERJECT, ALPROSTADIL
CLEOCIN HCL, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEOCIN, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
COLESTID, COLESTIPOL HYDROCHLORIDE
CORTEF ACETATE, HYDROCORTISONE ACETATE
CORTEF, HYDROCORTISONE
CORTEF, HYDROCORTISONE CYPIONATE
CORTISONE ACETATE, CORTISONE ACETATE
CORVERT, IBUTILIDE FUMARATE

FDA data supplied by DrugPatentWatch.com

CYKLOKAPRON, TRANEXAMIC ACID
DELTA-CORTEF, PREDNISOLONE
DELTASONE, PREDNISONE
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-TESTADIOL, ESTRADIOL CYPIONATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DETROL LA, TOLTERODINE TARTRATE
DETROL, TOLTERODINE TARTRATE
DIDREX, BENZPHETAMINE HYDROCHLORIDE
DIPENTUM, OLSALAZINE SODIUM
DIZAC, DIAZEPAM
DOSTINEX, CABERGOLINE
E-MYCIN E, ERYTHROMYCIN ETHYLSUCCINATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
ESTRING, ESTRADIOL
FEMINONE, ETHINYL ESTRADIOL
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FLORONE E, DIFLORASONE DIACETATE
FLORONE, DIFLORASONE DIACETATE
FLUIDIL, CYCLOTHIAZIDE
FOLEX PFS, METHOTREXATE SODIUM
FOLEX, METHOTREXATE SODIUM
FRAGMIN, DALTEPARIN SODIUM
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
GENOTROPIN, SOMATROPIN RECOMBINANT
GLYNASE, GLYBURIDE
GLYSET, MIGLITOL
HALCION, TRIAZOLAM
HALOTESTIN, FLUOXYMESTERONE
HEMABATE, CARBOPROST TROMETHAMINE
HEPARIN SODIUM, HEPARIN SODIUM
HYLOREL, GUANADREL SULFATE
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDAMYCIN, IDARUBICIN HYDROCHLORIDE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LONITEN, MINOXIDIL
LUNELLE, ESTRADIOL CYPIONATE
MAOLATE, CHLORPHENESIN CARBAMATE
MEDROL ACETATE, METHYLPREDNISOLONE ACETATE
MEDROL, METHYLPREDNISOLONE
MEDROL, METHYLPREDNISOLONE ACETATE
MICRONASE, GLYBURIDE
MYCIFRADIN, NEOMYCIN SULFATE
MYCITRACIN, BACITRACIN
MYCOBUTIN, RIFABUTIN
NEO-CORTEF, HYDROCORTISONE ACETATE
NEO-DELTA-CORTEF, NEOMYCIN SULFATE
NEO-MEDROL ACETATE, METHYLPREDNISOLONE ACETATE
NEO-MEDROL, METHYLPREDNISOLONE
NICOTROL, NICOTINE
NICOTROL, NICOTINE (OTC)
NORMIFLO, ARDEPARIN SODIUM
OGEN .625, ESTROPIPATE
OGEN 1.25, ESTROPIPATE
OGEN 2.5, ESTROPIPATE
OGEN 5, ESTROPIPATE
OGEN, ESTROPIPATE
ORINASE DIAGNOSTIC, TOLBUTAMIDE SODIUM
ORINASE, TOLBUTAMIDE
OXYLONE, FLUOROMETHOLONE
PANMYCIN, TETRACYCLINE HYDROCHLORIDE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PREPIDIL, DINOPROSTONE
PROSTIN E2, DINOPROSTONE
PROSTIN F2 ALPHA, DINOPROST TROMETHAMINE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROVERA, MEDROXYPROGESTERONE ACETATE
PSORCON, DIFLORASONE DIACETATE
R-GENE 10, ARGININE HYDROCHLORIDE
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOMAVERT, PEGVISOMANT
TOLINASE, TOLAZAMIDE
TRELSTAR DEPOT, TRIPTORELIN PAMOATE
TRELSTAR, TRIPTORELIN PAMOATE
TROBICIN, SPECTINOMYCIN HYDROCHLORIDE
TYMTRAN, CERULETIDE DIETHYLAMINE
U-GENCIN, GENTAMICIN SULFATE
UTICILLIN VK, PENICILLIN V POTASSIUM
VANCOR, VANCOMYCIN HYDROCHLORIDE
VANTIN, CEFPODOXIME PROXETIL
XALATAN, LATANOPROST
XANAX, ALPRAZOLAM
ZEFAZONE IN PLASTIC CONTAINER, CEFMETAZOLE SODIUM
ZEFAZONE, CEFMETAZOLE SODIUM
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZYVOX, LINEZOLID

* PHARMACIA AND UPJOHN CO NUTRITION DIV
ELLENCE, EPIRUBICIN HYDROCHLORIDE

PHARMACIA UPJOHN

* PHARMACIA AND UPJOHN CONSUMER HEALTHCARE
NASALCROM, CROMOLYN SODIUM (OTC)

PHARMADERM

* PHARMADERM DIV ALTANA INC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN, BACITRACIN ZINC

FDA data supplied by DrugPatentWatch.com

BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE, NEOMYCIN SULFATE
NYSTATIN, NYSTATIN
NYSTATIN-TRIAMCINOLONE ACETONIDE, NYSTATIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIPLE SULFA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)

PHARMAFAIR
* PHARMAFAIR INC
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BOROFAIR, ACETIC ACID, GLACIAL
CARBACHOL, CARBACHOL
CHLOROFAIR, CHLORAMPHENICOL
DEXAIR, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
GENTAFAIR, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
KAINAIR, PROPARACAINE HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
MYDRIAFAIR, TROPICAMIDE
NAFAZAIR, NAPHAZOLINE HYDROCHLORIDE
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN, GRAMICIDIN
NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE, HYDROCORTISONE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
OCUMYCIN, BACITRACIN ZINC
OTICAIR, HYDROCORTISONE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PREDAIR FORTE, PREDNISOLONE SODIUM PHOSPHATE
PREDAIR, PREDNISOLONE SODIUM PHOSPHATE
PREDSULFAIR II, PREDNISOLONE ACETATE
PREDSULFAIR, PREDNISOLONE ACETATE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFAIR 10, SULFACETAMIDE SODIUM
SULFAIR FORTE, SULFACETAMIDE SODIUM
SULFAIR-15, SULFACETAMIDE SODIUM
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE, BACITRACIN ZINC

PHARMAFORCE
* PHARMAFORCE INC
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLOSPORINE, CYCLOSPORINE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE

PHARMASEAL
* PHARMASEAL DIV BAXTER HEALTHCARE CORP
PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)

PHARMATEK
* PHARMATEK INC
NEO-FRADIN, NEOMYCIN SULFATE

PHARMATON
* PHARMATON LTD
LIDOCATON, EPINEPHRINE
LIDOCATON, LIDOCAINE HYDROCHLORIDE

PHARMAVITE
* PHARMAVITE PHARMACEUTICALS
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
ISONIAZID, ISONIAZID
MEPROBAMATE, MEPROBAMATE
PREDNISONE, PREDNISONE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE

PHARMERAL
• PHARMERAL INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL W/ ASPIRIN & CAFFEINE, ASPIRIN
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
FOLIC ACID, FOLIC ACID
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
SULFISOXAZOLE, SULFISOXAZOLE

PHARMEX PRODS
* PHARMEX PRODUCTS INC

FDA data supplied by DrugPatentWatch.com

BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE

PHARMION
* PHARMION CORP
INNOHEP, TINZAPARIN SODIUM

PHARMOS
* PHARMOS CORP
LOTEMAX, LOTEPREDNOL ETABONATE

PHOENIX LABS NY
* PHOENIX LABORATORIES INC
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
DEXAMETHASONE, DEXAMETHASONE
ISONIAZID, ISONIAZID
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE

PHYS PRODS VA
* PHYSICIANS PRODUCTS CO INC DIV INTERNATIONAL LATEX CORP
HYSERPIN, RAUWOLFIA SERPENTINA

PIERRE FABRE
* PIERRE FABRE MEDICAMENT
ETOPOSIDE, ETOPOSIDE

PIONEER PHARMS
* PIONEER PHARMACEUTICALS INC
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
INDOMETHACIN, INDOMETHACIN
METHOCARBAMOL, METHOCARBAMOL
RESPORAL, DEXBROMPHENIRAMINE MALEATE (OTC)

PLANTEX
* PLANTEX USA INC DIV IKAPHARM INC
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE

PLIVA
* PLIVA INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL, ALBUTEROL
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
ANTABUSE, DISULFIRAM
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARBAMAZEPINE, CARBAMAZEPINE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CIMETIDINE, CIMETIDINE
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOSPORINE, CYCLOSPORINE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DESIPRAMINE HCL, DESIPRAMINE HYDROCHLORIDE
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM, EXTENDED
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
GLIPIZIDE, GLIPIZIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPRIN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
INDOMETHACIN, INDOMETHACIN
KETOCONAZOLE, KETOCONAZOLE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SURMONTIL, TRIMIPRAMINE MALEATE
THEOPHYLLINE, THEOPHYLLINE
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ULTRAGRIS-165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
ULTRAGRIS-330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
URECHOLINE, BETHANECHOL CHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE

PLIVA PHARM IND
* PLIVA PHARMACEUTICAL INDUSTRY INC
TORSEMIDE, TORSEMIDE

FDA data supplied by DrugPatentWatch.com

POHL BOSKAMP
* G POHL BOSKAMP GMBH AND CO
NITRO IV, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROLINGUAL, NITROGLYCERIN
NITRONAL, NITROGLYCERIN

POINT HOLDINGS
* POINT HOLDINGS INC
ETODOLAC, ETODOLAC

POLYMEDICA
* POLYMEDICA INDUSTRIES INC
ANESTACON, LIDOCAINE HYDROCHLORIDE
NEOPAP, ACETAMINOPHEN (OTC)
PROMETHACON, PROMETHAZINE HYDROCHLORIDE

POPULATION COUNCIL
* POPULATION COUNCIL
NORPLANT, LEVONORGESTREL
* POPULATION COUNCIL CENTER FOR BIOMEDICAL RESEARCH
NORPLANT II, LEVONORGESTREL

POYTHRESS
* WILLIAM P POYTHRESS AND CO INC
BENSULFOID, SULFUR

PRAECIS
* PRAECIS PHARMACEUTICALS INC
PLENAXIS, ABARELIX

PROCTER AND GAMBLE
* PROCTER AND GAMBLE CO
DANTRIUM, DANTROLENE SODIUM
HEAD & SHOULDERS CONDITIONER, PYRITHIONE ZINC (OTC)
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
VICKS FORMULA 44, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
* PROCTER AND GAMBLE PHARMACEUTICALS INC SUB PROCTER AND GAMBL
ACTONEL, RISEDRONATE SODIUM
ASACOL, MESALAMINE
DANTRIUM, DANTROLENE SODIUM
DIDRONEL, ETIDRONATE DISODIUM
FURADANTIN, NITROFURANTOIN
IVADANTIN, NITROFURANTOIN SODIUM
LABID, THEOPHYLLINE
MACROBID, NITROFURANTOIN
NYSERT, NYSTATIN
ORLEX HC, ACETIC ACID, GLACIAL
ORLEX, ACETIC ACID, GLACIAL
SARENIN, SARALASIN ACETATE

PROF DSPLS
* PROFESSIONAL DISPOSABLES INC
HEXASCRUB, HEXACHLOROPHENE

PROMETHEUS LABS
* PROMETHEUS LABORATORIES INC
HELIDAC, BISMUTH SUBSALICYLATE
IMURAN, AZATHIOPRINE
IMURAN, AZATHIOPRINE SODIUM
RIDAURA, AURANOFIN
TRANDATE, LABETALOL HYDROCHLORIDE
ZYLOPRIM, ALLOPURINOL

PROTER
* PROTER LABORATORY SPA
OXYTETRACYCLINE HCL, OXYTETRACYCLINE HYDROCHLORIDE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

PURDUE FREDERICK
* PURDUE FREDERICK CO
ATHROMBIN, WARFARIN SODIUM
ATHROMBIN-K, WARFARIN POTASSIUM
CARDIOQUIN, QUINIDINE POLYGALACTURONATE
CERUMENEX, TROLAMINE POLYPEPTIDE OLEATE CONDENSATE
DHC PLUS, ACETAMINOPHEN
MS CONTIN, MORPHINE SULFATE
PHENY-PAS-TEBAMIN, PHENYL AMINOSALICYLATE
PHYLLOCONTIN, AMINOPHYLLINE
SULFABID, SULFAPHENAZOLE
T-PHYL, THEOPHYLLINE
UNIPHYL, THEOPHYLLINE

PURDUE PHARMA LP
* PURDUE PHARMA LP
CHIROCAINE, LEVOBUPIVACAINE HYDROCHLORIDE
OXYCONTIN, OXYCODONE HYDROCHLORIDE
SPECTRACEF, CEFDITOREN PIVOXIL

PUREPAC PHARM
* PUREPAC PHARMACEUTICAL CO DIV PUREPAC INC
ACETAMINOPHEN AND CODEINE PHOSPHATE #3, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ALLOPURINOL, ALLOPURINOL
ALPRAZOLAM, ALPRAZOLAM
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ASPIRIN AND CAFFEINE W/ BUTALBITAL, ASPIRIN
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
CAPTOPRIL, CAPTOPRIL
CARBAMAZEPINE, CARBAMAZEPINE
CARBIDOPA AND LEVODOPA, CARBIDOPA

FDA data supplied by DrugPatentWatch.com

CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEPHALEXIN, CEPHALEXIN
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CORTISONE ACETATE, CORTISONE ACETATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOLIC ACID, FOLIC ACID
GABAPENTIN, GABAPENTIN
GEMFIBROZIL, GEMFIBROZIL
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
INDAPAMIDE, INDAPAMIDE
ISONIAZID, ISONIAZID
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LORAZEPAM, LORAZEPAM
LOVASTATIN, LOVASTATIN
MEPROBAMATE, MEPROBAMATE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIRTAZAPINE, MIRTAZAPINE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NIACIN, NIACIN
NIFEDIPINE, NIFEDIPINE
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
OXYTETRACYCLINE HCL, OXYTETRACYCLINE HYDROCHLORIDE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENTOXIFYLLINE, PENTOXIFYLLINE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFISOXAZOLE, SULFISOXAZOLE
TEMAZEPAM, TEMAZEPAM
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HCL, TIZANIDINE HYDROCHLORIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIPLE SULFA, TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE;SULFAMETHAZINE)
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

PVT FORM

* PRIVATE FORMULATIONS INC
ALLERFED, PSEUDOEPHEDRINE HYDROCHLORIDE
BENZTHIAZIDE, BENZTHIAZIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DI-METREX, PHENDIMETRAZINE TARTRATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE

FDA data supplied by DrugPatentWatch.com

DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ESTERIFIED ESTROGENS, ESTROGENS, ESTERIFIED
FEMOGEN, ESTROGENS, ESTERIFIED
FOLIC ACID, FOLIC ACID
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
MEPROBAMATE, MEPROBAMATE
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROFEN, IBUPROFEN (OTC)
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

** Q **

QLT
* QLT INC
VISUDYNE, VERTEPORFIN

QOL MEDCL
* QOL MEDICAL LLC
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
SUCRAID, SACROSIDASE

QUANTUM PHARMICS
* QUANTUM PHARMICS LTD
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUTALBITAL ASPIRIN AND CAFFEINE, ASPIRIN
CLOPRA, METOCLOPRAMIDE HYDROCHLORIDE
CLOPRA-"YELLOW", METOCLOPRAMIDE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL, HYDRALAZINE HYDRÓCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
LORAZ, LORAZEPAM
MECLODIUM, MECLOFENAMATE SODIUM
MINODYL, MINOXIDIL
NYSTATIN, NYSTATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PHENTERMINE RESIN 30, PHENTERMINE RESIN COMPLEX
Q-GESIC, ASPIRIN
Q-PAM, DIAZEPAM
TEMAZ, TEMAZEPAM
TIMOLOL MALEATE, TIMOLOL MALEATE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIALODINE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ZAXOPAM, OXAZEPAM

QUESTCOR PHARMS
* QUESTCOR PHARMACEUTICALS INC
ETHAMOLIN, ETHANOLAMINE OLEATE
GLOFIL-125, IOTHALAMATE SODIUM, I-125
H.P. ACTHAR GEL, CORTICOTROPIN
NASCOBAL, CYANOCOBALAMIN

** R **

R AND D LABS
* R AND D LABORATORIES INC
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX

R AND S PHARMA
* R AND S PHARMA INC
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE

R R REGISTRATIONS
* R AND R REGISTRATIONS
THYROSAFE, POTASSIUM IODIDE (OTC)

RACHELLE
* RACHELLE LABORATORIES INC
CHLORDIAZACHEL, CHLORDIAZEPOXIDE HYDROCHLORIDE
DOXYCHEL HYCLATE, DOXYCYCLINE HYCLATE
DOXYCHEL, DOXYCYCLINE

RANBAXY
* RANBAXY LABORATORIES LTD
ACYCLOVIR, ACYCLOVIR
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CLINDAMYCIN HCL, CLINDAMYCIN HYDROCHLORIDE
DISPERMOX, AMOXICILLIN
DOXYCYCLINE, DOXYCYCLINE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
GANCICLOVIR, GANCICLOVIR

FDA data supplied by DrugPatentWatch.com

LORATADINE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
NEFAZODONE HCL, NEFAZODONE HYDROCHLORIDE
OFLOXACIN, OFLOXACIN
PANIXINE DISPERDOSE, CEPHALEXIN
RANICLOR, CEFACLOR
RANITIDINE, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
SOTRET, ISOTRETINOIN
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE

* RANBAXY PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
AVENTYL HCL, NORTRIPTYLINE HYDROCHLORIDE
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ISOTRETINOIN, ISOTRETINOIN
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
NALFON 200, FENOPROFEN CALCIUM
NALFON, FENOPROFEN CALCIUM
PENTAZOCINE AND NALOXONE HYDROCHLORIDES, NALOXONE HYDROCHLORIDE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
RIOMET, METFORMIN HYDROCHLORIDE
SECONAL SODIUM, SECOBARBITAL SODIUM

RATIOPHARM
* RATIOPHARM GMBH AND CO ARZNEIMITTEL
SUCRALFATE, SUCRALFATE

RECKITT BENCKISER
* RECKITT BENCKISER PHARMACEUTICALS INC
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
SUBUTEX, BUPRENORPHINE HYDROCHLORIDE

REED AND CARNRICK
* REED AND CARNRICK PHARMACEUTICALS DIV BLOCK DRUG CO INC
KWELL, LINDANE

RELIANT PHARMS
* RELIANT PHARMACEUTICALS LLC
AXID, NIZATIDINE
DYNACIRC CR, ISRADIPINE
DYNACIRC, ISRADIPINE
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE
RYTHMOL, PROPAFENONE HYDROCHLORIDE

REXALL
* REXALL DRUG CO
PREDNISONE, PREDNISONE
RESERPINE, RESERPINE

REXAR
* REXAR PHARMACAL
METHAMPHETAMINE HCL, METHAMPHETAMINE HYDROCHLORIDE

RHODIA
* RHODIA LTD
ISOFLURANE, ISOFLURANE

ROACO
* TJ ROACO LTD
BETADERM, BETAMETHASONE VALERATE

ROBINS AH
* AH ROBINS CO
DIMETANE-DC, BROMPHENIRAMINE MALEATE
DIMETANE-DX, BROMPHENIRAMINE MALEATE
PHENAPHEN W/ CODEINE NO. 2, ACETAMINOPHEN
PHENAPHEN W/ CODEINE NO. 3, ACETAMINOPHEN
PHENAPHEN W/ CODEINE NO. 4, ACETAMINOPHEN
PHENAPHEN-650 W/ CODEINE, ACETAMINOPHEN
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
ROBAXISAL, ASPIRIN
ROBIMYCIN, ERYTHROMYCIN
ROBINUL, GLYCOPYRROLATE
TENATHAN, BETHANIDINE SULFATE

ROCHE
* HOFFMANN LA ROCHE INC
ARFONAD, TRIMETHAPHAN CAMSYLATE
AZO GANTANOL, PHENAZOPYRIDINE HYDROCHLORIDE
AZO GANTRISIN, PHENAZOPYRIDINE HYDROCHLORIDE
BEROCCA PN, ASCORBIC ACID
BONIVA, IBANDRONATE SODIUM
BUMEX, BUMETANIDE
COACTIN, AMDINOCILLIN
COPEGUS, RIBAVIRIN
DEMADEX, TORSEMIDE
ENDEP, AMITRIPTYLINE HYDROCHLORIDE
FANSIDAR, PYRIMETHAMINE
FUZEON, ENFUVIRTIDE
GANTANOL, SULFAMETHOXAZOLE
GANTANOL-DS, SULFAMETHOXAZOLE
GANTRISIN PEDIATRIC, SULFISOXAZOLE ACETYL
GANTRISIN, SULFISOXAZOLE
GANTRISIN, SULFISOXAZOLE ACETYL

FDA data supplied by DrugPatentWatch.com

GANTRISIN, SULFISOXAZOLE DIOLAMINE
HIVID, ZALCITABINE
KLONOPIN RAPIDLY DISINTEGRATING, CLONAZEPAM
KLONOPIN, CLONAZEPAM
KONAKION, PHYTONADIONE
KYTRIL, GRANISETRON HYDROCHLORIDE
LARIAM, MEFLOQUINE HYDROCHLORIDE
LARODOPA, LEVODOPA
LIPO GANTRISIN, SULFISOXAZOLE ACETYL
LORFAN, LEVALLORPHAN TARTRATE
MENRIUM 10-4, CHLORDIAZEPOXIDE
MENRIUM 5-2, CHLORDIAZEPOXIDE
MENRIUM 5-4, CHLORDIAZEPOXIDE
NIPRIDE, SODIUM NITROPRUSSIDE
NOLUDAR, METHYPRYLON
QUARZAN, CLIDINIUM BROMIDE
RIMADYL, CARPROFEN
RIMIFON, ISONIAZID
ROCALTROL, CALCITRIOL
ROCEPHIN, CEFTRIAXONE SODIUM
SOLATENE, BETA-CAROTENE
SYNKAYVITE, MENADIOL SODIUM DIPHOSPHATE
TAMIFLU, OSELTAMIVIR PHOSPHATE
TARACTAN, CHLORPROTHIXENE
TASMAR, TOLCAPONE
TEGISON, ETRETINATE
TRIMPEX 200, TRIMETHOPRIM
TRIMPEX, TRIMETHOPRIM
VALIUM, DIAZEPAM
VALRELEASE, DIAZEPAM
VERSED, MIDAZOLAM HYDROCHLORIDE
VESANOID, TRETINOIN

ROCHE PALO
* ROCHE PALO ALTO LLC
AEROBID, FLUNISOLIDE
ANAPROX DS, NAPROXEN SODIUM
ANAPROX, NAPROXEN SODIUM
CARDENE SR, NICARDIPINE HYDROCHLORIDE
CARDENE, NICARDIPINE HYDROCHLORIDE
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CYTOVENE IV, GANCICLOVIR SODIUM
CYTOVENE, GANCICLOVIR
EC-NAPROSYN, NAPROXEN
EVEX, ESTROGENS, ESTERIFIED
FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)
FEMSTAT, BUTOCONAZOLE NITRATE
NAPROSYN, NAPROXEN
TICLID, TICLOPIDINE HYDROCHLORIDE
TORADOL, KETOROLAC TROMETHAMINE
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE

ROERIG
* ROERIG DIV PFIZER INC
ATARAX, HYDROXYZINE HYDROCHLORIDE
EMETE-CON, BENZQUINAMIDE HYDROCHLORIDE
GEOPEN, CARBENICILLIN DISODIUM
SUSTAIRE, THEOPHYLLINE

ROMARK
* ROMARK LABORATORIES
ALINIA, NITAZOXANIDE

RORER
* RORER PHARMACEUTICAL CORP SUB RORER GROUP
NITROL, NITROGLYCERIN

ROSS LABS
* ROSS LABORATORIES DIV ABBOTT LABORATORIES
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
* ROSS LABORATORIES DIV ABBOTT LABORATORIES INC
PEDIAMYCIN 400, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAMYCIN, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAZOLE, ERYTHROMYCIN ETHYLSUCCINATE
SURVANTA, BERACTANT

ROXANE
* ROXANE LABORATORIES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE NO. 4, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE NO. 2, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE NO. 3, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPRAZOLAM, ALPRAZOLAM
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AZATHIOPRINE, AZATHIOPRINE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CALCITRIOL, CALCITRIOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL INTENSOL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM INTENSOL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DICLOFENAC SODIUM, DICLOFENAC SODIUM

FDA data supplied by DrugPatentWatch.com

DIFLUNISAL, DIFLUNISAL
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DOLOPHINE HCL, METHADONE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FUROSEMIDE, FUROSEMIDE
HALOPERIDOL INTENSOL, HALOPERIDOL LACTATE
HALOPERIDOL, HALOPERIDOL
HYDROCHLOROTHIAZIDE INTENSOL, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
HYDROMORPHONE HCL, HYDROMORPHONE HYDROCHLORIDE
HYDROXYUREA, HYDROXYUREA
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
IPATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISOETHARINE HCL, ISOETHARINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LACTULOSE, LACTULOSE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
LORAZEPAM INTENSOL, LORAZEPAM
LORAZEPAM, LORAZEPAM
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METHADONE HCL INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HCL, METHADONE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE INTENSOL, METOCLOPRAMIDE HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NEFAZODONE HCL, NEFAZODONE HYDROCHLORIDE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NYSTATIN, NYSTATIN
ORLAAM, LEVOMETHADYL ACETATE HYDROCHLORIDE
OXYCODONE AND ASPIRIN (HALF-STRENGTH), ASPIRIN
PIROXICAM, PIROXICAM
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
PREDNISOLONE, PREDNISOLONE
PREDNISONE INTENSOL, PREDNISONE
PREDNISONE, PREDNISONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPRANOLOL HCL INTENSOL, PROPRANOLOL HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE
ROXICET 5/500, ACETAMINOPHEN
ROXICET, ACETAMINOPHEN
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROXILOX, ACETAMINOPHEN
ROXIPRIN, ASPIRIN
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFISOXAZOLE, SULFISOXAZOLE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
THIORIDAZINE HCL INTENSOL, THIORIDAZINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE HCL INTENSOL, THIOTHIXENE HYDROCHLORIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAZOLAM, TRIAZOLAM

ROYCE LABS
* ROYCE LABORATORIES INC
HALOPERIDOL, HALOPERIDOL
MINOXIDIL, MINOXIDIL

** S **

SABEX 2002
* SABEX 2002 INC
ARISTOCORT, TRIAMCINOLONE DIACETATE
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
DIGOXIN, DIGOXIN
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC, ASCORBIC ACID
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
REGONOL, PYRIDOSTIGMINE BROMIDE

SALIX PHARMS
* SALIX PHARMACEUTICALS INC
COLAZAL, BALSALAZIDE DISODIUM

SANDOZ
* SANDOZ INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN

FDA data supplied by DrugPatentWatch.com

ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
ALPRAZOLAM, ALPRAZOLAM
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMOXAPINE, AMOXAPINE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
ATENOLOL, ATENOLOL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUPROPION HCL, BUPROPION HYDROCHLORIDE
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
BUTAL COMPOUND, ASPIRIN
CAPTOPRIL, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL, CHLORPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CIMETIDINE, CIMETIDINE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLOFIBRATE, CLOFIBRATE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOZAPINE, CLOZAPINE
CORPHED, PSEUDOEPHEDRINE HYDROCHLORIDE
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DESIPRAMINE HCL, DESIPRAMINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLUNISAL, DIFLUNISAL
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOBROM, DEXBROMPHENIRAMINE MALEATE (OTC)
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ERCATAB, CAFFEINE
ESTERIFIED ESTROGENS, ESTROGENS, ESTERIFIED
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FUROSEMIDE, FUROSEMIDE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
GLUTETHIMIDE, GLUTETHIMIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
INVAGESIC FORTE, ASPIRIN
INVAGESIC, ASPIRIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
KETOPROFEN, KETOPROFEN
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LONOX, ATROPINE SULFATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LOVASTATIN, LOVASTATIN
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEFLOQUINE HCL, MEFLOQUINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHOCARBAMOL, METHOCARBAMOL
METHOXSALEN, METHOXSALEN
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

FDA data supplied by DrugPatentWatch.com

METHYLDOPA, METHYLDOPA
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MEXILETINE HCL, MEXILETINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
NEFAZODONE HCL, NEFAZODONE HYDROCHLORIDE
NIACIN, NIACIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
PEG-LYTE, POLYETHYLENE GLYCOL 3350
PEMOLINE, PEMOLINE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENYLBUTAZONE, PHENYLBUTAZONE
PINDOLOL, PINDOLOL
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE COMPOUND-65, ASPIRIN
PROPOXYPHENE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
RESERPINE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RIMACTANE, RIFAMPIN
SONAZINE, CHLORPROMAZINE HYDROCHLORIDE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
SULFISOXAZOLE, SULFISOXAZOLE
SULINDAC, SULINDAC
TEMAZEPAM, TEMAZEPAM
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

SANKYO
* SANKYO PHARMA INC
  BENICAR HCT, HYDROCHLOROTHIAZIDE
  BENICAR, OLMESARTAN MEDOXOMIL
  WELCHOL, COLESEVELAM HYDROCHLORIDE
* SANKYO USA CORP
  BANAN, CEFPODOXIME PROXETIL
  PRELAY, TROGLITAZONE

SANO
* SANO CORP
  NICOTINE, NICOTINE

SANOFI
* SANOFI RESEARCH DIV SANOFI INC
  ELOXATIN, OXALIPLATIN

SANOFI SYN RES
* SANOFI SYNTHELABO RESEARCH DIV SANOFI SYNTHELABO INC
  UROXATRAL, ALFUZOSIN HYDROCHLORIDE

SANOFI SYNTHELABO
* SANOFI SYNTHELABO INC
  ARALEN HCL, CHLOROQUINE HYDROCHLORIDE
  ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
  ARALEN, CHLOROQUINE PHOSPHATE
  AVALIDE, HYDROCHLOROTHIAZIDE
  AVAPRO, IRBESARTAN
  BRONKODYL, THEOPHYLLINE
  BRONKOMETER, ISOETHARINE MESYLATE
  BRONKOSOL, ISOETHARINE HYDROCHLORIDE
  BRYREL, PIPERAZINE CITRATE
  CALCIPARINE, HEPARIN CALCIUM
  DANOCRINE, DANAZOL
  DEMEROL, MEPERIDINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

DRISDOL, ERGOCALCIFEROL
INOCOR, INAMRINONE LACTATE
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
KAYEXALATE, SODIUM POLYSTYRENE SULFONATE
LOTUSATE, TALBUTAL
MYTELASE, AMBENONIUM CHLORIDE
NEGGRAM, NALIDIXIC ACID
PHISO-SCRUB, HEXACHLOROPHENE
PHISOHEX, HEXACHLOROPHENE
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLAVIX, CLOPIDOGREL BISULFATE
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
PRIMACOR, MILRINONE LACTATE
PRIMAQUINE, PRIMAQUINE PHOSPHATE
SKELID, TILUDRONATE DISODIUM
TALACEN, ACETAMINOPHEN
TALWIN 50, PENTAZOCINE HYDROCHLORIDE
TALWIN COMPOUND, ASPIRIN
TALWIN NX, NALOXONE HYDROCHLORIDE
TORNALATE, BITOLTEROL MESYLATE
TRANCOPAL, CHLORMEZANONE

SANTEN
* SANTEN INC
ALAMAST, PEMIROLAST POTASSIUM
QUIXIN, LEVOFLOXACIN

SANTEN OY
* SANTEN OY
BETIMOL, TIMOLOL

SAVAGE LABS
* SAVAGE LABORATORIES INC DIV ALTANA INC
ALPHATREX, BETAMETHASONE DIPROPIONATE
AXOTAL, ASPIRIN
BETATREX, BETAMETHASONE VALERATE
CHYMEX, BENTIROMIDE
DILOR, DYPHYLLINE
DILOR-400, DYPHYLLINE
DITATE-DS, ESTRADIOL VALERATE
ETHIODOL, ETHIODIZED OIL
FLUOTREX, FLUOCINOLONE ACETONIDE
GVS, GENTIAN VIOLET
K-LEASE, POTASSIUM CHLORIDE
KAON CL, POTASSIUM CHLORIDE
KAON CL-10, POTASSIUM CHLORIDE
MYTREX A, NEOMYCIN SULFATE
MYTREX F, NYSTATIN
NYSTEX, NYSTATIN
PANDEL, HYDROCORTISONE PROBUTATE
RUVITE, CYANOCOBALAMIN
SATRIC, METRONIDAZOLE
TRYMEX, TRIAMCINOLONE ACETONIDE
TRYSUL, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
XYLO-PFAN, XYLOSE

SAVIENT PHARMS
* SAVIENT PHARMACEUTICALS INC
BIO-TROPIN, SOMATROPIN RECOMBINANT
DELATESTRYL, TESTOSTERONE ENANTHATE
OXANDRIN, OXANDROLONE
TEV-TROPIN, SOMATROPIN RECOMBINANT

SB PHARMCO
* SB PHARMCO PUERTO RICO INC
AVANDAMET, METFORMIN HYDROCHLORIDE
AVANDIA, ROSIGLITAZONE MALEATE

SCHEIN
* SCHEIN PHARMACEUTICAL INC
INFED, IRON DEXTRAN
PROGESTERONE, PROGESTERONE

SCHERER LABS
* SCHERER LABORATORIES INC
CODEINE, ASPIRIN, APAP FORMULA NO. 2, ACETAMINOPHEN
CODEINE, ASPIRIN, APAP FORMULA NO. 3, ACETAMINOPHEN
CODEINE, ASPIRIN, APAP FORMULA NO. 4, ACETAMINOPHEN
MEPROBAMATE, MEPROBAMATE
PREDNISONE, PREDNISONE
QUINIDINE SULFATE, QUINIDINE SULFATE

SCHERER RP
* RP SCHERER CORP
NIFEDIPINE, NIFEDIPINE
* RP SCHERER NORTH AMERICA
NIFEDIPINE, NIFEDIPINE
THEOPHYLLINE, THEOPHYLLINE
VALPROIC ACID, VALPROIC ACID
* RP SCHERER NORTH AMERICA DIV RP SCHERER CORP
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
THEOPHYLLINE-SR, THEOPHYLLINE
VALPROIC ACID, VALPROIC ACID

SCHERING
* SCHERING CORP
CLARINEX, DESLORATADINE
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
GUANIDINE HCL, GUANIDINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

LOTRISONE, BETAMETHASONE DIPROPIONATE
QUINORA, QUINIDINE SULFATE
REBETOL, RIBAVIRIN
RENORMAX, SPIRAPRIL HYDROCHLORIDE
TEMODAR, TEMOZOLOMIDE
THEO-DUR, THEOPHYLLINE
UNI-DUR, THEOPHYLLINE
VALISONE, BETAMETHASONE VALERATE
VANCENASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
VANCERIL DOUBLE STRENGTH, BECLOMETHASONE DIPROPIONATE

* SCHERING CORP SUB SCHERING PLOUGH CORP
AKRINOL, ACRISORCIN
BETAPAR, MEPREDNISONE
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELESTONE, BETAMETHASONE
CELESTONE, BETAMETHASONE SODIUM PHOSPHATE
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPROSONE, BETAMETHASONE DIPROPIONATE
DISOMER, DEXBROMPHENIRAMINE MALEATE
DISOPHROL, DEXBROMPHENIRAMINE MALEATE (OTC)
ELOCON, MOMETASONE FUROATE
ESTINYL, ETHINYL ESTRADIOL
ETRAFON 2-10, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON 2-25, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON-A, AMITRIPTYLINE HYDROCHLORIDE
ETRAFON-FORTE, AMITRIPTYLINE HYDROCHLORIDE
EULEXIN, FLUTAMIDE
FULVICIN P/G 165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G 330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN-U/F, GRISEOFULVIN, MICROCRYSTALLINE
GARAMYCIN, GENTAMICIN SULFATE
HYPERSTAT, DIAZOXIDE
LOTRIMIN, CLOTRIMAZOLE
METI-DERM, PREDNISOLONE
METICORTELONE, PREDNISOLONE ACETATE
METICORTEN, PREDNISONE
METIMYD, PREDNISOLONE ACETATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRETON, PREDNISOLONE SODIUM PHOSPHATE
MIRADON, ANISINDIONE
NAQUA, TRICHLORMETHIAZIDE
NAQUIVAL, RESERPINE
NETROMYCIN, NETILMICIN SULFATE
NORMODYNE, LABETALOL HYDROCHLORIDE
NORMOZIDE, HYDROCHLOROTHIAZIDE
OPTIMINE, AZATADINE MALEATE
ORETON METHYL, METHYLTESTOSTERONE
ORETON, METHYLTESTOSTERONE
OTOBIONE, HYDROCORTISONE
OTOBIOTIC, HYDROCORTISONE
PAXIPAM, HALAZEPAM
PERMITIL, FLUPHENAZINE HYDROCHLORIDE
POLARAMINE, DEXCHLORPHENIRAMINE MALEATE
PRANTAL, DIPHEMANIL METHYLSULFATE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROVENTIL, ALBUTEROL
PROVENTIL, ALBUTEROL SULFATE
RELA, CARISOPRODOL
SODIUM SULAMYD, SULFACETAMIDE SODIUM
THEOVENT, THEOPHYLLINE
TINDAL, ACETOPHENAZINE MALEATE
TREMIN, TRIHEXYPHENIDYL HYDROCHLORIDE
TRILAFON, PERPHENAZINE
TRINALIN, AZATADINE MALEATE
UNI-DUR, THEOPHYLLINE
VALISONE, BETAMETHASONE VALERATE
VANCENASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
VANCENASE, BECLOMETHASONE DIPROPIONATE
VANCERIL, BECLOMETHASONE DIPROPIONATE

SCHERING PLOUGH

* SCHERING PLOUGH CORP
CLARINEX, DESLORATADINE
IMDUR, ISOSORBIDE MONONITRATE
NASONEX, MOMETASONE FUROATE MONOHYDRATE

* SCHERING PLOUGH HEALTHCARE PRODUCTS INC
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
DEMAZIN, CHLORPHENIRAMINE MALEATE (OTC)
DISOPHROL, DEXBROMPHENIRAMINE MALEATE (OTC)
DRIXORAL PLUS, ACETAMINOPHEN (OTC)
DRIXORAL, DEXBROMPHENIRAMINE MALEATE (OTC)
GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
LOTRIMIN, CLOTRIMAZOLE
OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)
SHADE UVAGUARD, AVOBENZONE (OTC)

SCHERING PLOUGH RES

* SCHERING PLOUGH RESEARCH INSTITUTE
LOTRISONE, BETAMETHASONE DIPROPIONATE
REBETOL, RIBAVIRIN

SCHWARZ

* SCHWARZ GMBH
MONOKET, ISOSORBIDE MONONITRATE

SCHWARZ PHARMA

FDA data supplied by DrugPatentWatch.com

* SCHWARZ PHARMA AG
EDEX, ALPROSTADIL
* SCHWARZ PHARMA INC
CO-GESIC, ACETAMINOPHEN
CODIMAL-L.A. 12, CHLORPHENIRAMINE MALEATE (OTC)
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COLYTE, POLYETHYLENE GLYCOL 3350
COLYTE-FLAVORED, POLYETHYLENE GLYCOL 3350
CORTIFOAM, HYDROCORTISONE ACETATE
DILATRATE-SR, ISOSORBIDE DINITRATE
EPIFOAM, HYDROCORTISONE ACETATE
KEMSTRO, BACLOFEN
LEVATOL, PENBUTOLOL SULFATE
PREDNICEN-M, PREDNISONE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
THEOCLEAR L.A.-130, THEOPHYLLINE
THEOCLEAR L.A.-260, THEOPHYLLINE
UNIRETIC, HYDROCHLOROTHIAZIDE
UNIVASC, MOEXIPRIL HYDROCHLORIDE

SCIOS
* SCIOS INC
NATRECOR, NESIRITIDE

SCS
* SCS PHARMACEUTICALS
ATENOLOL, ATENOLOL
CARBIDOPA AND LEVODOPA, CARBIDOPA
HALOPERIDOL, HALOPERIDOL
HALOPERIDOL, HALOPERIDOL LACTATE
PIROXICAM, PIROXICAM

SEPRACOR
* SEPRACOR INC
XOPENEX, LEVALBUTEROL HYDROCHLORIDE

SEPTODONT
* SEPTODONT INC
OCTOCAINE, EPINEPHRINE

SERONO
* SERONO LABORATORIES INC
ASELLACRIN 10, SOMATROPIN
ASELLACRIN 2, SOMATROPIN
FERTINEX, UROFOLLITROPIN
GEREF, SERMORELIN ACETATE
GONAL-F, FOLLITROPIN ALFA
GONAL-F, FOLLITROPIN ALFA/BETA
METRODIN, UROFOLLITROPIN
PERGONAL, MENOTROPINS (FSH;LH)
SAIZEN, SOMATROPIN RECOMBINANT
SEROPHENE, CLOMIPHENE CITRATE
SEROSTIM, SOMATROPIN RECOMBINANT

SERONO INC
* SERONO INC
CETROTIDE, CETRORELIX
NOVANTRONE, MITOXANTRONE HYDROCHLORIDE
OVIDREL, CHORIOGONADOTROPIN ALFA
ZORBTIVE, SOMATROPIN

SHERWOOD MEDCL
* SHERWOOD MEDICAL CO
ACTIN-N, NITROFURAZONE

SHIONOGI
* SHIONOGI USA INC
UROBAK, SULFAMETHOXAZOLE
UROPLUS DS, SULFAMETHOXAZOLE
UROPLUS SS, SULFAMETHOXAZOLE

SHIRE LABS
* SHIRE LABORATORIES INC
ADDERALL 10, AMPHETAMINE ASPARTATE
ADDERALL 12.5, AMPHETAMINE ASPARTATE
ADDERALL 15, AMPHETAMINE ASPARTATE
ADDERALL 20, AMPHETAMINE ASPARTATE
ADDERALL 30, AMPHETAMINE ASPARTATE
ADDERALL 5, AMPHETAMINE ASPARTATE
ADDERALL 7.5, AMPHETAMINE ASPARTATE
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
BANTHINE, METHANTHELINE BROMIDE
DOPAR, LEVODOPA
ETHMOZINE, MORICIZINE HYDROCHLORIDE
FURACIN, NITROFURAZONE
FUROXONE, FURAZOLIDONE
PENTASA, MESALAMINE
PRO-BANTHINE, PROPANTHELINE BROMIDE
SALURON, HYDROFLUMETHIAZIDE
SALUTENSIN, HYDROFLUMETHIAZIDE
SALUTENSIN-DEMI, HYDROFLUMETHIAZIDE
SUPPRELIN, HISTRELIN ACETATE
TOPICYCLINE, TETRACYCLINE HYDROCHLORIDE

SHIRE PHARM
* SHIRE PHARMACEUTICAL DEVELOPMENT INC
ANOQUAN, ACETAMINOPHEN

FDA data supplied by DrugPatentWatch.com

CARBATROL, CARBAMAZEPINE
FURACIN, NITROFURAZONE
PROAMATINE, MIDODRINE HYDROCHLORIDE
URACIL MUSTARD, URACIL MUSTARD

SHIRE RICHWOOD
* SHIRE RICHWOOD INC
DEXTROSTAT, DEXTROAMPHETAMINE SULFATE
OBY-TRIM, PHENTERMINE HYDROCHLORIDE
X-TROZINE L.A., PHENDIMETRAZINE TARTRATE
X-TROZINE, PHENDIMETRAZINE TARTRATE

SICOR PHARMS
* SICOR PHARMACEUTICALS INC
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
CYTARABINE, CYTARABINE
CYTOSAR-U, CYTARABINE
ETOPOSIDE, ETOPOSIDE
FLUOROURACIL, FLUOROURACIL
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

SIEGFRIED
* SIEGFRIED LTD
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE

SIGHT PHARMS
* SIGHT PHARMACEUTICALS INC
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)

SIGMA TAU
* SIGMA TAU PHARMACEUTICALS INC
CARNITOR, LEVOCARNITINE
MATULANE, PROCARBAZINE HYDROCHLORIDE

SILARX
* SILARX PHARMACEUTICALS INC
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
SILPHEN, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)

SIRIUS LABS
* SIRIUS LABORATORIES INC
TEXACORT, HYDROCORTISONE

SKYEPHARMA
* SKYEPHARMA INC
DEPOCYT, CYTARABINE

SMITH AND NEPHEW
* SMITH AND NEPHEW SOLOPAK DIV SMITH AND NEPHEW
AMINOPHYLLINE, AMINOPHYLLINE
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
FLUOROURACIL, FLUOROURACIL
FUROSEMIDE, FUROSEMIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
METHYLDOPATE HCL, METHYLDOPATE HYDROCHLORIDE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

SMITHKLINE BEECHAM
* SMITHKLINE BEECHAM CORP DBA GLAXOSMITHKLINE
LANOXICAPS, DIGOXIN
LANOXIN, DIGOXIN
LEUKERAN, CHLORAMBUCIL
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE

SOAPCO
* SOAPCO INC
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)

SOLA BARNES HIND
* SOLA BARNES HIND
ALPHA CHYMAR, CHYMOTRYPSIN
BENOXINATE HCL, BENOXINATE HYDROCHLORIDE
CYCLOPENTOLATE HCL, CYCLOPENTOLATE HYDROCHLORIDE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
GAMENE, LINDANE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROPARACAINE HCL, PROPARACAINE HYDROCHLORIDE
SODIUM SULFACETAMIDE, SULFACETAMIDE SODIUM
SULFISOXAZOLE DIOLAMINE, SULFISOXAZOLE DIOLAMINE

SOLOPAK
* SOLOPAK LABORATORIES INC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DROPERIDOL, DROPERIDOL
GENTAMICIN SULFATE, GENTAMICIN SULFATE

FDA data supplied by DrugPatentWatch.com

HALOPERIDOL, HALOPERIDOL LACTATE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
* SOLOPAK MEDICAL PRODUCTS INC
CYANOCOBALAMIN, CYANOCOBALAMIN
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
NALOXONE HCL, NALOXONE HYDROCHLORIDE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE

SOLVAY
* SOLVAY PHARMACEUTICALS
AQUATAG, BENZTHIAZIDE
ARESTOCAINE HCL W/ LEVONORDEFRIN, LEVONORDEFRIN
ARESTOCAINE HCL, MEPIVACAINE HYDROCHLORIDE
ATROPINE, ATROPINE
BALNEOL-HC, HYDROCORTISONE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
CIN-QUIN, QUINIDINE SULFATE
CORTENEMA, HYDROCORTISONE
CURRETAB, MEDROXYPROGESTERONE ACETATE
DERMACORT, HYDROCORTISONE
DEXONE 0.5, DEXAMETHASONE
DEXONE 0.75, DEXAMETHASONE
DEXONE 1.5, DEXAMETHASONE
DEXONE 4, DEXAMETHASONE
DUPHALAC, LACTULOSE
ESTRAGUARD, DIENESTROL
ESTRATAB, ESTROGENS, ESTERIFIED
GYNOREST, DYDROGESTERONE
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LACTULOSE, LACTULOSE
LITHOBID, LITHIUM CARBONATE
LITHONATE, LITHIUM CARBONATE
LITHONATE, LITHIUM CITRATE
LITHOTABS, LITHIUM CARBONATE
LUVOX, FLUVOXAMINE MALEATE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
ORASONE, PREDNISONE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PORTALAC, LACTULOSE
PROVAL #3, ACETAMINOPHEN
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
R-P MYCIN, ERYTHROMYCIN
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
RESERPINE, RESERPINE
RETET, TETRACYCLINE HYDROCHLORIDE
ROWASA, MESALAMINE
S.A.S.-500, SULFASALAZINE
SER-A-GEN, HYDRALAZINE HYDROCHLORIDE
SPRX-3, PHENDIMETRAZINE TARTRATE
SULSOXIN, SULFISOXAZOLE
SYMADINE, AMANTADINE HYDROCHLORIDE
TORA, PHENTERMINE HYDROCHLORIDE
TRANMEP, MEPROBAMATE
TRIACORT, TRIAMCINOLONE ACETONIDE
UNIPRES, HYDRALAZINE HYDROCHLORIDE
VERMIDOL, PIPERAZINE CITRATE
ZIDE, HYDROCHLOROTHIAZIDE

SOLVAY PHARMA
* SOLVAY PHARMA INC
ACEON, PERINDOPRIL ERBUMINE

SOMERSET
* SOMERSET PHARMACEUTICALS INC
ELDEPRYL, SELEGILINE HYDROCHLORIDE
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE

SORIN
* SORIN BIOMEDICA SPA
SODIUM ROSE BENGAL I 131, ROSE BENGAL SODIUM, I-131

SPEAR PHARMS
* SPEAR PHARMACEUTICALS INC
TRETINOIN, TRETINOIN

SPERTI
* SPERTI DRUG PRODUCTS INC
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE

SSL INTL
* SSL INTERNATIONAL
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

STANLABS PHARM
* STANLABS PHARMACEUTICAL CO SUB SIMPAK CORP
MEPROBAMATE, MEPROBAMATE

STAR PHARMS FL
* STAR PHARMACEUTICALS INC
VIRILON, METHYLTESTOSTERONE

FDA data supplied by DrugPatentWatch.com

STASON
* STASON INDUSTRIAL CORP
ACYCLOVIR, ACYCLOVIR
CAPTOPRIL, CAPTOPRIL
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE

STERIS
* STERIS LABORATORIES INC
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE SODIUM PHOSPHATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
COBAVITE, CYANOCOBALAMIN
CORTICOTROPIN, CORTICOTROPIN
CORTISONE ACETATE, CORTISONE ACETATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE ACETATE, DEXAMETHASONE ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM, DIAZEPAM
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DISODIUM EDETATE, EDETATE DISODIUM
DOBUTAMINE HCL, DOBUTAMINE HYDROCHLORIDE
DOXAPRAM HCL, DOXAPRAM HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
EDETATE DISODIUM, EDETATE DISODIUM
EDROPHONIUM CHLORIDE PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
EDROPHONIUM CHLORIDE, EDROPHONIUM CHLORIDE
ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRONE, ESTRONE
ETOPOSIDE, ETOPOSIDE
FENTANYL CITRATE, FENTANYL CITRATE
FLUOROURACIL, FLUOROURACIL
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN LOCK FLUSH, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE SODIUM SUCCINATE, HYDROCORTISONE SODIUM SUCCINATE
HYDROMORPHONE HCL, HYDROMORPHONE HYDROCHLORIDE
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
LIDOCAINE HCL W/ EPINEPHRINE, EPINEPHRINE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
LINCOMYCIN HCL, LINCOMYCIN HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
MANNITOL 25%, MANNITOL
MEPERIDINE HCL PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPIVACAINE HCL, MEPIVACAINE HYDROCHLORIDE
MERSALYL-THEOPHYLLINE, MERSALYL SODIUM
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MORPHINE SULFATE, MORPHINE SULFATE
MVC PLUS, ASCORBIC ACID
NALOXONE HCL, NALOXONE HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NANDROLONE PHENPROPIONATE, NANDROLONE PHENPROPIONATE
NATURAL ESTROGENIC SUBSTANCE-ESTRONE, ESTRONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES, NEOMYCIN SULFATE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OTOCORT, HYDROCORTISONE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE ACETATE, PREDNISOLONE ACETATE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE TEBUTATE, PREDNISOLONE TEBUTATE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCAINE HCL, PROCAINE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMAZINE HCL, PROMAZINE HYDROCHLORIDE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PYRIDOXINE HCL, PYRIDOXINE HYDROCHLORIDE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE, ESTRADIOL CYPIONATE
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE, ESTRADIOL VALERATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TESTOSTERONE PROPIONATE, TESTOSTERONE PROPIONATE
TESTOSTERONE, TESTOSTERONE

FDA data supplied by DrugPatentWatch.com

THIAMINE HCL, THIAMINE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE DIACETATE, TRIAMCINOLONE DIACETATE
TRIMETHOBENZAMIDE HCL, TRIMETHOBENZAMIDE HYDROCHLORIDE
TROPICAMIDE, TROPICAMIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE

STERLING
* STERLING HEALTH DIV STERLING WINTHROP INC
BRONKAID MIST, EPINEPHRINE (OTC)

STERLING WINTHROP
* STERLING WINTHROP INC
AFAXIN, VITAMIN A PALMITATE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE

STEVENS J
* JEROME STEVENS PHARMACEUTICALS INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CEPHALEXIN, CEPHALEXIN
DIGOXIN, DIGOXIN
METHOCARBAMOL AND ASPIRIN, ASPIRIN
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
UNITHROID, LIOTRIX (T4;T3)

STIEFEL
* STIEFEL LABORATORIES INC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DUAC, BENZOYL PEROXIDE
ERYTHROMYCIN, ERYTHROMYCIN
HYDROCORTISONE, HYDROCORTISONE
SCABENE, LINDANE
STIE-CORT, HYDROCORTISONE

STORZ
* STORZ OPHTHALMICS INC SUB AMERICAN CYANAMID CO
ACHROMYCIN, TETRACYCLINE HYDROCHLORIDE

STUART PHARMS
* STUART PHARMACEUTICALS DIV ICI AMERICAS
BUCLADIN-S, BUCLIZINE HYDROCHLORIDE

SUMMERS
* SUMMERS LABORATORIES INC
CROTAN, CROTAMITON

SUPERGEN
• SUPERGEN INC
DAUNORUBICIN HCL, DAUNORUBICIN HYDROCHLORIDE
ETOPOSIDE, ETOPOSIDE
MITOMYCIN, MITOMYCIN
MYTOZYTREX, MITOMYCIN
NIPENT, PENTOSTATIN

SUPERPHARM
* SUPERPHARM CORP
ACETAMINOPHEN AND CODEINE PHOSPHATE #2, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE #3, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE #4, ACETAMINOPHEN
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LOGEN, ATROPINE SULFATE
LORAZEPAM, LORAZEPAM
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFASALAZINE, SULFASALAZINE
SULFATRIM-DS, SULFAMETHOXAZOLE
SULFATRIM-SS, SULFAMETHOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE

FDA data supplied by DrugPatentWatch.com

TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL, PSEUDOEPHEDRINE HYDROCHLORIDE

SUPPOSITORIA
* SUPPOSITORIA LABORATORIES INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)

SWEDISH ORPHAN
* SWEDISH ORPHAN AB
ORFADIN, NITISINONE

SYNCOR PHARMS
* SYNCOR PHARMACEUTICALS INC
A-N STANNOUS AGGREGATED ALBUMIN, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
SODIUM IODIDE I 123, SODIUM IODIDE, I-123

SYNTHON PHARMS
* SYNTHON PHARMACEUTICALS LTD
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
PAROXETINE MESYLATE, PAROXETINE MESYLATE

SYOSSET
* SYOSSET LABORATORIES INC
E-SOLVE 2, ERYTHROMYCIN
HYDROCORTISONE, HYDROCORTISONE

** T **

TABLICAPS
* TABLICAPS INC
AMINOPHYLLINE, AMINOPHYLLINE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
FOLIC ACID, FOLIC ACID
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
NIACIN, NIACIN
PREDNISOLONE, PREDNISOLONE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE
STILBESTROL, DIETHYLSTILBESTROL

TAKEDA
* TAKEDA CHEMICAL INDUSTRIES LTD
CERADON, CEFOTIAM HYDROCHLORIDE

TAKEDA PHARMS NA
* TAKEDA PHARMACEUTICALS NORTH AMERICA INC
ACTOS, PIOGLITAZONE HYDROCHLORIDE

TAP PHARM
* TAP PHARMACEUTICAL PRODUCTS INC
CEFMAX, CEFMENOXIME HYDROCHLORIDE
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-3, LEUPROLIDE ACETATE
LUPRON DEPOT-4, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE
LUPRON, LEUPROLIDE ACETATE
NAPRAPAC 250 (COPACKAGED), LANSOPRAZOLE
NAPRAPAC 375 (COPACKAGED), LANSOPRAZOLE
NAPRAPAC 500 (COPACKAGED), LANSOPRAZOLE
PREVACID, LANSOPRAZOLE
PREVPAC, AMOXICILLIN

TARGACEPT
* TARGACEPT INC
INVERSINE, MECAMYLAMINE HYDROCHLORIDE

TARO
* TARO PHARMACEUTICAL INDUSTRIES LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
CARBAMAZEPINE, CARBAMAZEPINE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
KETOCONAZOLE, KETOCONAZOLE
TERIL, CARBAMAZEPINE
* TARO PHARMACEUTICALS INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DESOXIMETASONE, DESOXIMETASONE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
WARFARIN SODIUM, WARFARIN SODIUM
* TARO PHARMACEUTICALS USA INC
ACETIC ACID, ACETIC ACID, GLACIAL
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
AMMONIUM LACTATE, AMMONIUM LACTATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE

FDA data supplied by DrugPatentWatch.com

CLOTRIMAZOLE, CLOTRIMAZOLE
DERMABET, BETAMETHASONE VALERATE
DESONIDE, DESONIDE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOROURACIL, FLUOROURACIL
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE, HYDROCORTISONE
KETOZOLE, KETOCONAZOLE
LIDOCAINE, LIDOCAINE
NITROFURAZONE, NITROFURAZONE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
ORACORT, TRIAMCINOLONE ACETONIDE
ORALONE, TRIAMCINOLONE ACETONIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
THEOPHYLLINE, THEOPHYLLINE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
U-CORT, HYDROCORTISONE ACETATE

TARO PHARM INDS
* TARO PHARMACEUTICAL INDUSTRIES LTD
AMCINONIDE, AMCINONIDE
CARBAMAZEPINE, CARBAMAZEPINE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC

TAYLOR
* TAYLOR PHARMACEUTICALS
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
NAPHAZOLINE HCL, NAPHAZOLINE HYDROCHLORIDE

TAYLOR PHARMA
* TAYLOR PHARMACAL CO
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
MIDAZOLAM HCL, MIDAZOLAM HYDROCHLORIDE
PROPARACAINE HCL, PROPARACAINE HYDROCHLORIDE
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

TECHNILAB
* TECHNILAB INC
ACILAC, LACTULOSE
LAXILOSE, LACTULOSE

TEIKOKU PHARMA USA
* TEIKOKU PHARMA USA INC
LIDODERM, LIDOCAINE

TEVA
* TEVA PHARMACEUTICALS USA INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE #2, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE #4, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMIODARONE HCL, AMIODARONE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
BETA-VAL, BETAMETHASONE VALERATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BUPROPION HCL, BUPROPION HYDROCHLORIDE
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
CALCITRIOL, CALCITRIOL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFUROXIME, CEFUROXIME SODIUM
CEPHALEXIN, CEPHALEXIN
CEPHRADINE, CEPHRADINE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CIMETIDINE HCL, CIMETIDINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE
CINOXACIN, CINOXACIN
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLINDAMYCIN HCL, CLINDAMYCIN HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOFIBRATE, CLOFIBRATE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOXACILLIN SODIUM, CLOXACILLIN SODIUM
COPAXONE, GLATIRAMER ACETATE
COTRIM D.S., SULFAMETHOXAZOLE
COTRIM, SULFAMETHOXAZOLE
CYCLACILLIN, CYCLACILLIN
DELCOBESE, AMPHETAMINE ADIPATE
DEXAMPEX, DEXTROAMPHETAMINE SULFATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXY-LEMMON, DOXYCYCLINE HYCLATE
DRALZINE, HYDRALAZINE HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
EPITOL, CARBAMAZEPINE
ESTAZOLAM, ESTAZOLAM
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUTAMIDE, FLUTAMIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GALZIN, ZINC ACETATE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
GLUCAMIDE, CHLORPROPAMIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE, GLYBURIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HY-PAM "25", HYDROXYZINE PAMOATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROCORTISONE, HYDROCORTISONE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDAPAMIDE, INDAPAMIDE
INDO-LEMMON, INDOMETHACIN
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
LOVASTATIN, LOVASTATIN
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPRIAM, MEPROBAMATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
METHAMPEX, METHAMPHETAMINE HYDROCHLORIDE
METHAMPHETAMINE HCL, METHAMPHETAMINE HYDROCHLORIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MEXILETINE HCL, MEXILETINE HYDROCHLORIDE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MIRTAZAPINE, MIRTAZAPINE
MOEXIPRIL HCL, MOEXIPRIL HYDROCHLORIDE
MUPIROCIN, MUPIROCIN
MYCO-TRIACET II, NYSTATIN
NABUMETONE, NABUMETONE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NEFAZODONE HCL, NEFAZODONE HYDROCHLORIDE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOTHYLLINE, DYPHYLLINE
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
NIZATIDINE, NIZATIDINE
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OFLOXACIN, OFLOXACIN
ORAP, PIMOZIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
OXAPROZIN, OXAPROZIN
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN, PENICILLIN G POTASSIUM

FDA data supplied by DrugPatentWatch.com

PENICILLIN-2, PENICILLIN G POTASSIUM
PENICILLIN-VK, PENICILLIN V POTASSIUM
PENTOXIFYLLINE, PENTOXIFYLLINE
PERGOLIDE MESYLATE, PERGOLIDE MESYLATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PRELONE, PREDNISOLONE
PROBAMPACIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPACET 100, ACETAMINOPHEN
PROPOXYPHENE COMPOUND 65, ASPIRIN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PURINETHOL, MERCAPTOPURINE
QUINAPRIL HCL, QUINAPRIL HYDROCHLORIDE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RESERPINE, RESERPINE
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
SOTALOL HCL, SOTALOL HYDROCHLORIDE
STATOBEX, PHENDIMETRAZINE TARTRATE
STATOBEX-G, PHENDIMETRAZINE TARTRATE
SUCRALFATE, SUCRALFATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFANILAMIDE, SULFANILAMIDE
SULINDAC, SULINDAC
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE HCL, THIOTHIXENE HYDROCHLORIDE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HCL, TIZANIDINE HYDROCHLORIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TORSEMIDE, TORSEMIDE
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIACET, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE, TRIAMCINOLONE
TRIMETHOPRIM, TRIMETHOPRIM
TRIPHED, PSEUDOEPHEDRINE HYDROCHLORIDE
VAGILIA, TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE; SULFATHIAZOLE)
VITAMIN A SOLUBILIZED, VITAMIN A PALMITATE

THERAKOS
* THERAKOS INC

UVADEX, METHOXSALEN

TOPIDERM
* TOPIDERM INC
HYDROCORTISONE, HYDROCORTISONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TORCH
* TORCH LABORATORIES INC
H-CORT, HYDROCORTISONE

TORPHARM
* TORPHARM INC
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
CAPTOPRIL, CAPTOPRIL
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CLONAZEPAM, CLONAZEPAM
CYCLOSPORINE, CYCLOSPORINE
DILTIAZEM HCL, DILTIAZEM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
KETOCONAZOLE, KETOCONAZOLE
METFORMIN HCL, METFORMIN HYDROCHLORIDE
NIZATIDINE, NIZATIDINE
OMEPRAZOLE, OMEPRAZOLE
PAROXETINE HCL, PAROXETINE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
SELEGILINE HCL, SELEGILINE HYDROCHLORIDE
SOTALOL HCL, SOTALOL HYDROCHLORIDE
TERAZOSIN HCL, TERAZOSIN HYDROCHLORIDE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE

TRIGEN
* TRIGEN LABORATORIES INC
INDAPAMIDE, INDAPAMIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
PREDNISONE, PREDNISONE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE

TYCO HLTHCARE
* TYCO HEALTHCARE GROUP LP
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

RESTORIL, TEMAZEPAM
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOFRANIL-PM, IMIPRAMINE PAMOATE

** U **

UCB
* UCB PHARMA INC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
KEPPRA, LEVETIRACETAM
LORTAB, ACETAMINOPHEN
THEO-24, THEOPHYLLINE

UDL
* UDL LABORATORIES INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
FOLIC ACID, FOLIC ACID
HALOPERIDOL LACTATE, HALOPERIDOL LACTATE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
METHADONE HCL, METHADONE HYDROCHLORIDE
NYSTATIN, NYSTATIN
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
VALPROIC ACID, VALPROIC ACID

UNIMED
* UNIMED INC
MARINOL, DRONABINOL

UNIMED PHARMS
* UNIMED PHARMACEUTICALS INC
ANADROL-50, OXYMETHOLONE
ANDROGEL, TESTOSTERONE
PROMETRIUM, PROGESTERONE

UNITED GUARDIAN
* UNITED GUARDIAN INC
RENACIDIN, CITRIC ACID

UNITED THERAP
* UNITED THERAPEUTICS CORP
REMODULIN, TREPROSTINIL SODIUM

UNIV AZ CANCER CTR
* UNIV ARIZONA CANCER CENTER
ACTINEX, MASOPROCOL

UPSHER SMITH
* UPSHER SMITH LABORATORIES INC
DEXAMETHASONE, DEXAMETHASONE
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOR-CON, POTASSIUM CHLORIDE
METHOCARBAMOL, METHOCARBAMOL
NIACOR, NIACIN
PACERONE, AMIODARONE HYDROCHLORIDE
PENTOXIL, PENTOXIFYLLINE
PREDNISONE, PREDNISONE
PREVALITE, CHOLESTYRAMINE
SORINE, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE

US ARMY
* UNITED STATES ARMY OFFICE SURGEON GENERAL
ATROPINE SULFATE, ATROPINE SULFATE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
SODIUM THIOSULFATE, SODIUM THIOSULFATE
* US ARMY MEDICAL RESEARCH MATERIEL COMMAND
ATNAA, ATROPINE
DIAZEPAM, DIAZEPAM
SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS, PERFLUOROPOLYMETHYLISOPROPYL ETHER

US ARMY WALTER REED
* UNITED STATES ARMY WALTER REED ARMY INSTITUTE RESEARCH
MEFLOQUINE HCL, MEFLOQUINE HYDROCHLORIDE

US CHEM
* US CHEMICAL MARKETING GROUP INC
MEDIGESIC PLUS, ACETAMINOPHEN

US SURGCL
* UNITED STATES SURGICAL DIV TYCO HEALTHCARE GROUP LP
LYMPHAZURIN, ISOSULFAN BLUE

USL PHARMA
* USL PHARMA INC
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
ACETOHEXAMIDE, ACETOHEXAMIDE
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CARBAMAZEPINE, CARBAMAZEPINE
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLOFIBRATE, CLOFIBRATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DESIPRAMINE HCL, DESIPRAMINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

DIPHEN, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
ESTRADIOL, ESTRADIOL
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOXYMESTERONE, FLUOXYMESTERONE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
HYDROFLUMETHIAZIDE AND RESERPINE, HYDROFLUMETHIAZIDE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
JANTOVEN, WARFARIN SODIUM
LITHIUM CARBONATE, LITHIUM CARBONATE
LORAZEPAM, LORAZEPAM
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPROBAMATE, MEPROBAMATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
MYFED, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
MYIDYL, TRIPROLIDINE HYDROCHLORIDE
MYMETHAZINE FORTIS, PROMETHAZINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PRAZEPAM, PRAZEPAM
QUINIDINE SULFATE, QUINIDINE SULFATE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULMEPRIM PEDIATRIC, SULFAMETHOXAZOLE
SULMEPRIM, SULFAMETHOXAZOLE
TEMAZEPAM, TEMAZEPAM
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLAZAMIDE, TOLAZAMIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
VALPROIC ACID, VALPROIC ACID
WARFARIN SODIUM, WARFARIN SODIUM

** V **

VALE
* VALE CHEMICAL CO INC
AMINOPHYLLINE, AMINOPHYLLINE
SERPATE, RESERPINE

VALEANT PHARM INTL
* VALEANT PHARMACEUTICALS INTERNATIONAL
8-MOP, METHOXSALEN
AMINOPHYLLINE, AMINOPHYLLINE
ANCOBON, FLUCYTOSINE
ANDROID 10, METHYLTESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
ANDROID 5, METHYLTESTOSTERONE
ANDROID-F, FLUOXYMESTERONE
BENDOPA, LEVODOPA
BENOQUIN, MONOBENZONE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CODEINE PHOSPHATE AND ACETAMINOPHEN, ACETAMINOPHEN
DALMANE, FLURAZEPAM HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL W/ ATROPINE SULFATE, ATROPINE SULFATE
EFUDEX, FLUOROURACIL
ELDECORT, HYDROCORTISONE
FLUOXYMESTERONE, FLUOXYMESTERONE
FOLIC ACID, FOLIC ACID
LEVO-DROMORAN, LEVORPHANOL TARTRATE
LIBRELEASE, CHLORDIAZEPOXIDE
LIBRITABS, CHLORDIAZEPOXIDE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIMBITROL DS, AMITRIPTYLINE HYDROCHLORIDE
LIMBITROL, AMITRIPTYLINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
MESTINON, PYRIDOSTIGMINE BROMIDE
OXSORALEN, METHOXSALEN
OXSORALEN-ULTRA, METHOXSALEN
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SULFISOXAZOLE, SULFISOXAZOLE
TENSILON PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
TENSILON, EDROPHONIUM CHLORIDE
TESTRED, METHYLTESTOSTERONE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
TRISORALEN, TRIOXSALEN
VIRAZOLE, RIBAVIRIN

VANGARD
* VANGARD LABORATORIES INC DIV MIDWAY MEDICAL CO
ACETAZOLAMIDE, ACETAZOLAMIDE
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FOLIC ACID, FOLIC ACID
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
LO-TROL, ATROPINE SULFATE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
PAPA-DEINE #3, ACETAMINOPHEN
PAPA-DEINE #4, ACETAMINOPHEN
PREDNISONE, PREDNISONE
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFINPYRAZONE, SULFINPYRAZONE
TOLBUTAMIDE, TOLBUTAMIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE

VERSAPHARM
* VERSAPHARM INC
RIFAMPIN, RIFAMPIN

VERUM PHARMS
* VERUM PHARMACEUTICALS INC
BROMFED-DM, BROMPHENIRAMINE MALEATE

VESTAL LABS
* VESTAL LABORATORIES DIV CHEMED CORP
SEPTISOL, HEXACHLOROPHENE

VINTAGE PHARMS
* VINTAGE PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, BUTALBITAL, CAFFEINE, AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALLOPURINOL, ALLOPURINOL
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CARISOPRODOL, CARISOPRODOL
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FOLIC ACID, FOLIC ACID
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LACTULOSE, LACTULOSE
LEVOLET, LIOTRIX (T4;T3)
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PEMOLINE, PEMOLINE
PERPHENAZINE, PERPHENAZINE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PREDNISONE, PREDNISONE
PROPAFENONE HCL, PROPAFENONE HYDROCHLORIDE
PROPOXYPHENE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN
QUINIDINE SULFATE, QUINIDINE SULFATE
SOTALOL HCL, SOTALOL HYDROCHLORIDE
SULFASALAZINE, SULFASALAZINE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE

VISTAPHARM
* VISTAPHARM INC
LACTULOSE, LACTULOSE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN

VITARINE
* VITARINE PHARMACEUTICALS INC
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
AMPICILLIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
CEPHALEXIN, CEPHALEXIN
CEPHRADINE, CEPHRADINE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CORTISONE ACETATE, CORTISONE ACETATE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
GLUTETHIMIDE, GLUTETHIMIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SERPIVITE, RESERPINE
SULFISOXAZOLE, SULFISOXAZOLE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE
VITAMIN D, ERGOCALCIFEROL

VIVUS

FDA data supplied by DrugPatentWatch.com

* VIVUS INC
MUSE, ALPROSTADIL

** W **

WARNER CHILCOTT
* WARNER CHILCOTT BERMUDA LTD
CHOLEDYL SA, OXTRIPHYLLINE
DORYX, DOXYCYCLINE HYCLATE
* WARNER CHILCOTT DIV WARNER LAMBERT CO
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMITRIL, AMITRIPTYLINE HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CYCLOPAR, TETRACYCLINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DOPAMINE HCL, DOPAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DURAQUIN, QUINIDINE GLUCONATE
ERYPAR, ERYTHROMYCIN STEARATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
KANAMYCIN SULFATE, KANAMYCIN SULFATE
LORAZEPAM, LORAZEPAM
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROPOXYPHENE HCL 65, PROPOXYPHENE HYDROCHLORIDE
PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
SPIRONOLACTONE, SPIRONOLACTONE
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
* WARNER CHILCOTT INC
CARBAMAZEPINE, CARBAMAZEPINE
CYANOCOBALAMIN, CYANOCOBALAMIN
DURICEF, CEFADROXIL/CEFADROXIL HEMIHYDRATE
ERYC, ERYTHROMYCIN
ESTRACE, ESTRADIOL
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
OVCON-35, ETHINYL ESTRADIOL
OVCON-50, ETHINYL ESTRADIOL
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
SULINDAC, SULINDAC
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE

WARNER LAMBERT
* WARNER LAMBERT CO
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)

WARRICK PHARMS
* WARRICK PHARMACEUTICALS
CROMOLYN SODIUM, CROMOLYN SODIUM
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

WATSON LABS
* WATSON LABORATORIES
FOLIC ACID, FOLIC ACID
METFORMIN HCL, METFORMIN HYDROCHLORIDE
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
NORCO, ACETAMINOPHEN
OXAPROZIN, OXAPROZIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PENTAZOCINE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPAFENONE HCL, PROPAFENONE HYDROCHLORIDE
TRAMADOL HCL, TRAMADOL HYDROCHLORIDE
* WATSON LABORATORIES INC
ACEBUTOLOL HCL, ACEBUTOLOL HYDROCHLORIDE
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETOHEXAMIDE, ACETOHEXAMIDE
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
ALORA, ESTRADIOL
ALPRAZOLAM, ALPRAZOLAM
AMANTADINE HCL, AMANTADINE HYDROCHLORIDE
AMILORIDE HCL AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
AMOXAPINE, AMOXAPINE
ANDRODERM, TESTOSTERONE
ANISOTROPINE METHYLBROMIDE, ANISOTROPINE METHYLBROMIDE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BREVICON 21-DAY, ETHINYL ESTRADIOL
BREVICON 28-DAY, ETHINYL ESTRADIOL
BROMPHENIRAMINE MALEATE, BROMPHENIRAMINE MALEATE
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN

FDA data supplied by DrugPatentWatch.com

BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CAPTOPRIL, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARISOPRODOL COMPOUND, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL, CHLORPHENIRAMINE MALEATE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE W/ RESERPINE, CHLOROTHIAZIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CLINDAMYCIN HCL, CLINDAMYCIN HYDROCHLORIDE
CLOFIBRATE, CLOFIBRATE
CLOMIPRAMINE HCL, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HCL, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
COL-PROBENECID, COLCHICINE
CORDRAN, FLURANDRENOLIDE
CORTISONE ACETATE, CORTISONE ACETATE
CYCLOBENZAPRINE HCL, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HCL, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE ASPARTATE
DIAZEPAM, DIAZEPAM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIETHYLPROPION HCL, DIETHYLPROPION HYDROCHLORIDE
DIFLUNISAL, DIFLUNISAL
DILACOR XR, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISULFIRAM, DISULFIRAM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HCL, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ESTOLATE
ERYTHROMYCIN STEARATE, ERYTHROMYCIN STEARATE
ESTAZOLAM, ESTAZOLAM
ESTRADIOL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FLUOXETINE, FLUOXETINE HYDROCHLORIDE
FLUOXYMESTERONE, FLUOXYMESTERONE
FLUPHENAZINE HCL, FLUPHENAZINE HYDROCHLORIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GEMFIBROZIL, GEMFIBROZIL
GERIMAL, ERGOLOID MESYLATES
GLIPIZIDE, GLIPIZIDE
GLUTETHIMIDE, GLUTETHIMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GUANABENZ ACETATE, GUANABENZ ACETATE
GUANETHIDINE MONOSULFATE, GUANETHIDINE MONOSULFATE
GUANFACINE HCL, GUANFACINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE AND HYDROCHLORTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ HYDRALAZINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE W/ RESERPINE, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
HYDROFLUMETHIAZIDE AND RESERPINE, HYDROFLUMETHIAZIDE
HYDROFLUMETHIAZIDE, HYDROFLUMETHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE

FDA data supplied by DrugPatentWatch.com

KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HCL, LABETALOL HYDROCHLORIDE
LEVORA 0.15/30-21, ETHINYL ESTRADIOL
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LIOTHYRONINE SODIUM, LIOTRIX (T4;T3)
LISINOPRIL, LISINOPRIL
LITHIUM CARBONATE, LITHIUM CARBONATE
LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE (OTC)
LORAZEPAM, LORAZEPAM
LOW-OGESTREL-21, ETHINYL ESTRADIOL
LOW-OGESTREL-28, ETHINYL ESTRADIOL
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
LOXITANE C, LOXAPINE HYDROCHLORIDE
LOXITANE IM, LOXAPINE HYDROCHLORIDE
LOXITANE, LOXAPINE SUCCINATE
MAPROTILINE HCL, MAPROTILINE HYDROCHLORIDE
MECLIZINE HCL, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHOCARBAMOL, METHOCARBAMOL
METHYCLOTHIAZIDE AND DESERPIDINE, DESERPIDINE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLPHENIDATE HCL, METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE HCL, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MEXILETINE HCL, MEXILETINE HYDROCHLORIDE
MICROZIDE, HYDROCHLOROTHIAZIDE
MINOCYCLINE HCL, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
MIRTAZAPINE, MIRTAZAPINE
MORPHINE SULFATE, MORPHINE SULFATE
NALIDIXIC ACID, NALIDIXIC ACID
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NEFAZODONE HCL, NEFAZODONE HYDROCHLORIDE
NIACIN, NIACIN
NICARDIPINE HCL, NICARDIPINE HYDROCHLORIDE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NITROFURANTOIN MACROCRYSTALLINE, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NIZATIDINE, NIZATIDINE
NORCO, ACETAMINOPHEN
NORETHIN 1/35E-21, ETHINYL ESTRADIOL
NORETHIN 1/35E-28, ETHINYL ESTRADIOL
NORETHIN 1/50M-21, MESTRANOL
NORETHIN 1/50M-28, MESTRANOL
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND MESTRANOL, MESTRANOL
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
NORINYL 1+50 21-DAY, MESTRANOL
NORINYL 1+50 28-DAY, MESTRANOL
NORINYL, MESTRANOL
NORTRIPTYLINE HCL, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OGESTREL 0.5/50-21, ETHINYL ESTRADIOL
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXAZEPAM, OXAZEPAM
OXTRIPHYLLINE, OXTRIPHYLLINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYPHENBUTAZONE, OXYPHENBUTAZONE
PEMOLINE, PEMOLINE
PENTAZOCINE AND NALOXONE HYDROCHLORIDES, NALOXONE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PERPHENAZINE AND AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HCL, PHENTERMINE HYDROCHLORIDE
PHENYLBUTAZONE, PHENYLBUTAZONE
PHENYTEX, PHENYTOIN SODIUM, EXTENDED
PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PRAZOSIN HCL, PRAZOSIN HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PRIMIDONE, PRIMIDONE
PROBEN-C, COLCHICINE
PROBENECID W/ COLCHICINE, COLCHICINE
PROBENECID, PROBENECID
PROCAINAMIDE HCL, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE, PROCHLORPERAZINE MALEATE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROMPT PHENYTOIN SODIUM, PHENYTOIN SODIUM, PROMPT
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPOXYPHENE HCL AND ACETAMINOPHEN, ACETAMINOPHEN
PROPOXYPHENE HCL W/ ASPIRIN AND CAFFEINE, ASPIRIN
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN, ACETAMINOPHEN

FDA data supplied by DrugPatentWatch.com

PROPRANOLOL HCL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HCL, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRILAMINE MALEATE, PYRILAMINE MALEATE
QUINATIME, QUINIDINE GLUCONATE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
RANITIDINE, RANITIDINE HYDROCHLORIDE (OTC)
RAUWOLFIA SERPENTINA, RAUWOLFIA SERPENTINA
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE, HYDRALAZINE HYDROCHLORIDE
RESERPINE, RESERPINE
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SOTALOL HCL, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SPIRONOLACTONE/HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE
SULFASALAZINE, SULFASALAZINE
SULFINPYRAZONE, SULFINPYRAZONE
SULFISOXAZOLE, SULFISOXAZOLE
SULINDAC, SULINDAC
TEMAZEPAM, TEMAZEPAM
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TICLOPIDINE HCL, TICLOPIDINE HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TRAZODONE HCL, TRAZODONE HYDROCHLORIDE
TRI-NORINYL 21-DAY, ETHINYL ESTRADIOL
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRIAMCINOLONE, TRIAMCINOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAZOLAM, TRIAZOLAM
TRICHLORMETHIAZIDE W/ RESERPINE, RESERPINE
TRICHLORMETHIAZIDE, TRICHLORMETHIAZIDE
TRIFLUOPERAZINE HCL, TRIFLUOPERAZINE HYDROCHLORIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
TRIPELENNAMINE HCL, TRIPELENNAMINE HYDROCHLORIDE
TRIPROLIDINE AND PSEUDOEPHEDRINE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
TRIPROLIDINE HCL, TRIPROLIDINE HYDROCHLORIDE
TRIVORA-21, ETHINYL ESTRADIOL
TRIVORA-28, ETHINYL ESTRADIOL
VERAPAMIL HCL, VERAPAMIL HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
ZOVIA 1/35E-21, ETHINYL ESTRADIOL
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-21, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL

* WATSON LABS INC
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

WATSON LABS (UTAH)

* WATSON LABORATORIES INC
NOR-QD, NORETHINDRONE
OXYTROL, OXYBUTYNIN

WATSON PHARMS

* WATSON PHARMACEUTICALS INC
ACTIGALL, URSODIOL
FIORICET W/ CODEINE, ACETAMINOPHEN
FIORICET, ACETAMINOPHEN
FIORINAL W/CODEINE NO 3, ASPIRIN
FIORINAL, ASPIRIN

WE PHARMS

* WE PHARMACEUTICALS INC
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE

WELLSPRING PHARM

* WELLSPRING PHARMACEUTICAL CORP
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DUVOID, BETHANECHOL CHLORIDE
DYRENIUM, TRIAMTERENE

WENDT

* WENDT LABORATORIES INC
NITROFURAZONE, NITROFURAZONE

WEST WARD

* WEST WARD PHARMACEUTICAL CORP
AMINOPHYLLINE, AMINOPHYLLINE
AMITRIPTYLINE HCL, AMITRIPTYLINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL; ACETAMINOPHEN; AND CAFFEINE WITH CODEINE PHOSPHATE, ACETAMINOPHEN
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL, CARISOPRODOL
CHLORDIAZEPOXIDE HCL, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE AND RESERPINE, CHLOROTHIAZIDE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE

FDA data supplied by DrugPatentWatch.com

CORTISONE ACETATE, CORTISONE ACETATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DICYCLOMINE HCL, DICYCLOMINE HYDROCHLORIDE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HCL AND ATROPINE SULFATE, ATROPINE SULFATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ETHAMBUTOL HCL, ETHAMBUTOL HYDROCHLORIDE
FLURAZEPAM HCL, FLURAZEPAM HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDRALAZINE HCL, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
IMIPRAMINE HCL, IMIPRAMINE HYDROCHLORIDE
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LITHIUM CARBONATE, LITHIUM CARBONATE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLTESTOSTERONE, METHYLTESTOSTERONE
NIACIN, NIACIN
OXYTETRACYCLINE HCL, OXYTETRACYCLINE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE AND HYDROCHLOROTHIAZIDE-50, HYDROCHLOROTHIAZIDE
RESERPINE, RESERPINE
SODIUM BUTABARBITAL, BUTABARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SULFISOXAZOLE, SULFISOXAZOLE
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIORIDAZINE HCL, THIORIDAZINE HYDROCHLORIDE
TRIHEXYPHENIDYL HCL, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIPROLIDINE AND PSEUDOEPHEDRINE, PSEUDOEPHEDRINE HYDROCHLORIDE
VITAMIN A, VITAMIN A
VITAMIN A, VITAMIN A PALMITATE
VITAMIN D, ERGOCALCIFEROL

WESTWOOD SQUIBB
* WESTWOOD SQUIBB PHARMACEUTICALS INC
CAPITROL, CHLOROXINE
EURAX, CROTAMITON
EXELDERM, SULCONAZOLE NITRATE
FLEXICORT, HYDROCORTISONE
HALOG, HALCINONIDE
HALOG-E, HALCINONIDE
HALOTEX, HALOPROGIN
LAC-HYDRIN, AMMONIUM LACTATE
MYCOSTATIN, NYSTATIN
STATICIN, ERYTHROMYCIN
T-STAT, ERYTHROMYCIN
TACARYL, METHDILAZINE
TACARYL, METHDILAZINE HYDROCHLORIDE
ULTRAVATE, HALOBETASOL PROPIONATE
WESTCORT, HYDROCORTISONE VALERATE

WHARTON LABS
* WHARTON LABORATORIES INC DIV US ETHICALS
VITAMIN A, VITAMIN A PALMITATE

WHITBY
* WHITBY PHARMACEUTICALS INC
THEOBID JR., THEOPHYLLINE
THEOBID, THEOPHYLLINE

WHITEHALL ROBINS
* WHITEHALL ROBINS HEALTHCARE DIV AMERICAN HOME PRODUCTS CORP
BRONITIN MIST, EPINEPHRINE BITARTRATE (OTC)
PRIMATENE MIST, EPINEPHRINE (OTC)

WHITEWORTH TOWN PLSN
* WHITEWORTH TOWNE PAULSEN INC
ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN
BUTABARBITAL SODIUM, BUTABARBITAL SODIUM
CORTISONE ACETATE, CORTISONE ACETATE
DEXAMETHASONE, DEXAMETHASONE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
H.R.-50, HYDROCHLOROTHIAZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
ISONIAZID, ISONIAZID
MEPROBAMATE, MEPROBAMATE
NITROFURANTOIN, NITROFURANTOIN
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PROMETHAZINE HCL, PROMETHAZINE HYDROCHLORIDE
PROPOXYPHENE HCL, PROPOXYPHENE HYDROCHLORIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
RESERPINE, RESERPINE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM

WOCKHARDT
* WOCKHARDT AMERICAS INC
CAPTOPRIL, CAPTOPRIL
ENALAPRIL MALEATE, ENALAPRIL MALEATE
FAMOTIDINE, FAMOTIDINE
RANITIDINE HCL, RANITIDINE HYDROCHLORIDE
* WOCKHARDT LTD
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE

FDA data supplied by DrugPatentWatch.com

NIACIN, NIACIN

WOMEN FIRST HLTHCARE
* WOMEN FIRST HEALTHCARE INC
BACTRIM DS, SULFAMETHOXAZOLE
BACTRIM PEDIATRIC, SULFAMETHOXAZOLE
BACTRIM, SULFAMETHOXAZOLE
EQUAGESIC, ASPIRIN
ESCLIM, ESTRADIOL
ORTHO-EST, ESTROPIPATE
SYNALGOS-DC, ASPIRIN
SYNALGOS-DC-A, ACETAMINOPHEN
VANIQA, EFLORNITHINE HYDROCHLORIDE
WYGESIC, ACETAMINOPHEN

WOMENS CAPITAL
* WOMENS CAPITAL CORP
PLAN B, LEVONORGESTREL

WYETH AYERST
* WYETH AYERST LABORATORIES
ANSOLYSEN, PENTOLINIUM TARTRATE
ATROMID-S, CLOFIBRATE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICILLIN, PENICILLIN G BENZATHINE
CEFPIRAMIDE SODIUM, CEFPIRAMIDE SODIUM
CHLORPROMAZINE HCL, CHLORPROMAZINE HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLAPEN-W, CYCLACILLIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DIGOXIN, DIGOXIN
DIMENHYDRINATE, DIMENHYDRINATE
DIMETANE-TEN, BROMPHENIRAMINE MALEATE
DIPHENHYDRAMINE HCL, DIPHENHYDRAMINE HYDROCHLORIDE
DIUCARDIN, HYDROFLUMETHIAZIDE
EQUANIL, MEPROBAMATE
ESTRADURIN, POLYESTRADIOL PHOSPHATE
ESTROGENIC SUBSTANCE, ESTRONE
FLUOTHANE, HALOTHANE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GRISACTIN ULTRA, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
GRISACTIN, GRISEOFULVIN, MICROCRYSTALLINE
HYDROXYZINE HCL, HYDROXYZINE HYDROCHLORIDE
INDERAL, PROPRANOLOL HYDROCHLORIDE
INDERIDE LA 120/50, HYDROCHLOROTHIAZIDE
INDERIDE LA 160/50, HYDROCHLOROTHIAZIDE
INDERIDE LA 80/50, HYDROCHLOROTHIAZIDE
ISORDIL, ISOSORBIDE DINITRATE
LIDOCAINE HCL, LIDOCAINE HYDROCHLORIDE
MAZANOR, MAZINDOL
MEPERIDINE AND ATROPINE SULFATE, ATROPINE SULFATE
MEPERIDINE HCL, MEPERIDINE HYDROCHLORIDE
NALOXONE, NALOXONE HYDROCHLORIDE
OMNIPEN (AMPICILLIN), AMPICILLIN/AMPICILLIN TRIHYDRATE
OMNIPEN-N, AMPICILLIN SODIUM
ORUDIS, KETOPROFEN
PATHOCIL, DICLOXACILLIN SODIUM
PEN-VEE K, PENICILLIN V POTASSIUM
PENBRITIN, AMPICILLIN/AMPICILLIN TRIHYDRATE
PENBRITIN-S, AMPICILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PEPTAVLON, PENTAGASTRIN
PHENERGAN FORTIS, PROMETHAZINE HYDROCHLORIDE
PHENERGAN PLAIN, PROMETHAZINE HYDROCHLORIDE
PHENERGAN VC W/ CODEINE, CODEINE PHOSPHATE
PHENERGAN VC, PHENYLEPHRINE HYDROCHLORIDE
PHENERGAN W/ CODEINE, CODEINE PHOSPHATE
PHENERGAN W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PHENERGAN, PROMETHAZINE HYDROCHLORIDE
PLEGINE, PHENDIMETRAZINE TARTRATE
PMB 200, ESTROGENS, CONJUGATED
PMB 400, ESTROGENS, CONJUGATED
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROKETAZINE, CARPHENAZINE MALEATE
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
ROBITET, TETRACYCLINE HYDROCHLORIDE
SECOBARBITAL SODIUM, SECOBARBITAL SODIUM
SODIUM PENTOBARBITAL, PENTOBARBITAL SODIUM
SODIUM SECOBARBITAL, SECOBARBITAL SODIUM
SPARINE, PROMAZINE HYDROCHLORIDE
SULFOSE, TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE; SULFAMETHAZINE)
TETRACYCLINE HCL, TETRACYCLINE HYDROCHLORIDE
THIAMINE HCL, THIAMINE HYDROCHLORIDE
THIOSULFIL, SULFAMETHIZOLE
UNIPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
UNIPEN, NAFCILLIN SODIUM
WYAMYCIN E, ERYTHROMYCIN ETHYLSUCCINATE
WYAMYCIN S, ERYTHROMYCIN STEARATE
WYMOX, AMOXICILLIN
WYTENSIN, GUANABENZ ACETATE
* WYETH AYERST RESEARCH
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE

WYETH CONS
* WYETH CONSUMER HEALTHCARE
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN POTASSIUM (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN POTASSIUM (OTC)
ADVIL, IBUPROFEN (OTC)
ALAVERT, LORATADINE (OTC)
AXID AR, NIZATIDINE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)

FDA data supplied by DrugPatentWatch.com

CHILDREN'S ADVIL, IBUPROFEN
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
DIMETANE, BROMPHENIRAMINE MALEATE
DIMETANE, BROMPHENIRAMINE MALEATE (OTC)
DIMETAPP, BROMPHENIRAMINE MALEATE (OTC)
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
LORATADINE, LORATADINE (OTC)
ORUDIS KT, KETOPROFEN (OTC)
PEDIATRIC ADVIL, IBUPROFEN (OTC)

WYETH PHARMS INC
* WYETH PHARMACEUTICALS INC
ALESSE, ETHINYL ESTRADIOL
CORDARONE, AMIODARONE HYDROCHLORIDE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFEXOR, VENLAFAXINE HYDROCHLORIDE
FOLVITE, FOLIC ACID
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDERAL, PROPRANOLOL HYDROCHLORIDE
INDERIDE-40/25, HYDROCHLOROTHIAZIDE
INDERIDE-80/25, HYDROCHLOROTHIAZIDE
LEVONORGESTREL, LEVONORGESTREL
LO/OVRAL, ETHINYL ESTRADIOL
LO/OVRAL-28, ETHINYL ESTRADIOL
LODINE XL, ETODOLAC
LODINE, ETODOLAC
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MYLOTARG, GEMTUZUMAB OZOGAMICIN
NORPLANT SYSTEM IN PLASTIC CONTAINER, LEVONORGESTREL
ORUVAIL, KETOPROFEN
OVRAL, ETHINYL ESTRADIOL
OVRAL-28, ETHINYL ESTRADIOL
OVRETTE, NORGESTREL
PHENERGAN, PROMETHAZINE HYDROCHLORIDE
PIPRACIL, PIPERACILLIN SODIUM
PREMARIN, ESTROGENS, CONJUGATED
PREMPHASE (PREMARIN;CYCRIN 14/14), ESTROGENS, CONJUGATED
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO (PREMARIN;CYCRIN), ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTONIX, PANTOPRAZOLE SODIUM
QUINIDEX, QUINIDINE SULFATE
RAPAMUNE, SIROLIMUS
TRECATOR-SC, ETHIONAMIDE
TRIPHASIL-21, ETHINYL ESTRADIOL
TRIPHASIL-28, ETHINYL ESTRADIOL
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOSYN, PIPERACILLIN SODIUM

** X **

XANODYNE PHARM
* XANODYNE PHARMACAL INC
AMICAR, AMINOCAPROIC ACID
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

XCEL PHARM
* XCEL PHARMACEUTICALS INC
MIGRANAL, DIHYDROERGOTAMINE MESYLATE

XCEL PHARMS
* XCEL PHARMACEUTICALS
D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DIASTAT, DIAZEPAM
MYSOLINE, PRIMIDONE

XTTRIUM
* XTTRIUM LABORATORIES INC
DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
TURGEX, HEXACHLOROPHENE

** Y **

YAMANOUCHI
* YAMANOUCHI EUROPE BV
LOCOID, HYDROCORTISONE BUTYRATE

YOSHITOMI
* YOSHITOMI PHARMACEUTICAL INDUSTRIES LTD
CEPHALEXIN, CEPHALEXIN

** Z **

ZAMBON
* ZAMBON CORP
MONUROL, FOSFOMYCIN TROMETHAMINE

ZENITH GOLDLINE
* ZENITH GOLDLINE LABORATORIES INC
METFORMIN HCL, METFORMIN HYDROCHLORIDE
* ZENITH GOLDLINE PHARMACEUTICALS
BUSPIRONE HCL, BUSPIRONE HYDROCHLORIDE
FLUOXETINE HCL, FLUOXETINE HYDROCHLORIDE
* ZENITH GOLDLINE PHARMACEUTICALS INC
NIZATIDINE, NIZATIDINE

ZILA
* ZILA PHARMACEUTICALS INC
PERIDEX, CHLORHEXIDINE GLUCONATE

FDA data supplied by DrugPatentWatch.com

APPENDIX C

UNIFORM TERMS

DOSAGE FORMS

AEROSOL
AEROSOL, METERED
CAPSULE
CAPSULE, COATED PELLETS
CAPSULE, DELAYED REL PELLETS
CAPSULE, EXTENDED RELEASE
CONCENTRATE
CREAM
CREAM, AUGMENTED
CREAM, SUPPOSITORY
DISC
ELIXIR
EMULSION
ENEMA
FILM, EXTENDED RELEASE
FOR SOLUTION
FOR SUSPENSION
FOR SUSPENSION, EXTENDED RELEASE
GAS
GEL
GEL, AUGMENTED
GEL, METERED
GRANULE
GRANULE, DELAYED RELEASE
GRANULE, EFFERVESCENT
GUM, CHEWING
IMPLANT
INHALANT
INJECTABLE
INJECTABLE, LIPID COMPLEX
INJECTABLE, LIPOSOMAL
INSERT
INSERT, EXTENDED RELEASE
INTRAUTERINE DEVICE
JELLY
LIQUID
LIQUID, EXTENDED RELEASE
LOTION
LOTION, AUGMENTED
LOTION/SHAMPOO
N/A
OIL
OINTMENT
OINTMENT, AUGMENTED
PASTE
PASTILLE
PELLET
POWDER
POWDER, EXTENDED RELEASE
POWDER, METERED
RING
SHAMPOO
SOLUTION
SOLUTION FOR SLUSH
SOLUTION/DROPS
SOLUTION, CONCENTRATE
SOLUTION, GEL FORMING/DROPS
SPONGE
SPRAY
SPRAY, METERED
SUPPOSITORY
SUSPENSION
SUSPENSION/DROPS
SUSPENSION, EXTENDED RELEASE
SWAB
SYRUP
TABLET
TABLET, CHEWABLE
TABLET, COATED PARTICLES
TABLET, DELAYED RELEASE
TABLET, EFFERVESCENT
TABLET, EXTENDED RELEASE
TABLET, FOR SOLUTION
TABLET, ORALLY DISINTEGRATING
TAPE
TROCHE/LOZENGE

NOTE: TERMS COMPRISE CURRENTLY MARKETED PRODUCTS

FDA data supplied by DrugPatentWatch.com

APPENDIX C

UNIFORM TERMS

ROUTES OF ADMINISTRATION

BUCCAL
DENTAL
ENDOCERVICAL
FOR RX COMPOUNDING
IM-IV
IM-IV-SC
IM-SC
IMPLANTATION
INHALATION
INJECTION
INTRACRANIAL
INTRALYMPHATIC
INTRAMUSCULAR
INTRAOCULAR
INTRAPERITONEAL
INTRAPLEURAL
NTRATHECAL
INTRATRACHEAL
INTRAUTERINE
INTRAVENOUS
INTRAVESICAL
IONTOPHORESIS
IRRIGATION
IV (INFUSION)
N/A
NASAL
OPHTHALMIC
ORAL
ORAL-21
ORAL-28
OTIC
PERFUSION, CARDIAC
PERIODONTAL
RECTAL
SPINAL
SUBCUTANEOUS
SUBLINGUAL
TOPICAL
TOPICAL, VAGINAL
TRANSDERMAL
URETERAL
URETHRAL
VAGINAL

NOTE: TERMS COMPRISE CURRENTLY MARKETED PRODUCTS

ABBREVIATIONS

AMP	AMPULE
AMPICIL	AMPICILLIN
APPROX	APPROXIMATELY
BOT	BOTTLE
CI	CURIE
CSR	CAROTID SINUS REFLEX
CU	CLINICAL UNITS
DIPROP	DIPROPIONATE
EQ	EQUIVALENT TO
ELECT	ELECTROLYTE
ER	EXTENDED RELEASE
GM	GRAM
HBR	HYDROBROMIDE
HCL	HYDROCHLORIDE
HR	HOUR
INH	INHALATION
IU	INTERNATIONAL UNITS
KIU	KALLIKREIN INHIBITOR UNITS
MCI	MILLICURIE
MEQ	MILLIEQUIVALENT
MG	MILLIGRAM
ML	MILLILITER
N/A	NOT APPLICABLE
PPM	PARTS PER MILLION
REL	RELEASE
SQ CM	SQUARE CENTIMETER
U	UNITS
UCI	MICROCURIE
UGM	MICROGRAM
UMOLAR	MICROMOLAR
USP	UNITED STATES PHARMACOPEIA

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Drug Price Competition and Patent Term Restoration Act (1984 Amendments) for periods of exclusivity, during which abbreviated new drug applications (ANDAs) and applications described in Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (the Act) for those drug products may, in some instances, not be submitted or made effective as described below, and provides patent information concerning the listed drug products. Those drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the Act and those drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A are also included in this *Addendum*. This section is arranged in alphabetical order by active ingredient name. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* page. Exclusivity prevents the submission or effective approval of ANDAs or applications described in Section 505(b)(2) of the Act. It does not prevent the submission or approval of a second 505(b)(1) application. Applications qualifying for periods of exclusivity are:

(1) A new drug application approved after September 24, 1984, for a drug product all active ingredients (including any ester or salt of the active ingredient) of which had never been approved in any other new drug application under Section 505 (b) of the Act. No subsequent ANDA or application described in Section 505(b)(2) of the Act for the same drug may be *submitted* for a period of *five years* from the date of approval of the original application, except that such an application may be *submitted* after *four years* if it contains a certification that a patent claiming the drug is invalid or will not be infringed by the product for which approval is sought.

(2) A new drug application approved after September 24, 1984, for a drug product containing an active ingredient (including any ester or salt of that active ingredient) that has been approved in an earlier new drug application and that includes reports of new clinical investigations (other than bioavailability studies). Such investigations must have been conducted or sponsored by the applicant and must have been essential to approval of the application. If these requirements are met, the approval of a subsequent ANDA or an application described in Section 505(b)(2) of the Act may not be *made effective* for the same drug or use, if for a new indication, before the expiration of *three years* from the date of approval of the original application. If an applicant has exclusivity for a new application or 505(b)(2) application for the drug product with indications or use, this does not preclude the approval of an ANDA or 505(b)(2) application not covered by the exclusivity.

(3) A supplement to a new drug application for a drug containing a previously approved active ingredient including any ester or salt of the active ingredient) approved after September 24, 1984, that contains reports of new clinical investigations (other than bioavailability studies) essential to the approval of the supplement and conducted or sponsored by the applicant. The approval of a subsequent ANDA or 505(b)(2) application for a change approved in the supplement may not be *made effective* for *three years* from the date of approval of the original supplement.

FDA data supplied by DrugPatentWatch.com

The Act requires that patent information be filed with all newly submitted Section 505(b) drug applications. No NDA may be approved after September 24, 1984, without the submission of patent information to the Agency. Effective August 18, 2003, this information must be filed using FDA Form 3524a "Patent Information Submitted with the Filing of an NDA, Amendment or Supplement.

Upon approval, the patent numbers and the expiration dates, in addition to certain other information on appropriate patents claiming drug products that are the subject of approved applications, will be published in this *Addendum* or in the monthly Cumulative Supplement to this publication. Effective August 18, 2003 this information must be submitted to the agency upon approval on FDA Form 3542 "Patent Information Submitted Upon and After Approval of an NDA or Supplement". Patent information on unapproved applications or on patents beyond the scope of the Act (i.e., process or manufacturing patents) will not be published. FDA form 3542 will be the only form used for the purposes of this publication.

The patents that FDA regards as covered by the statutory provisions for submission of patent information are: patents that claim the active ingredient(s); drug product patents, which include formulation/composition patents; use patents for a particular approved indication or method of using the product; and certain other patents as detailed on FDA Form 3542. This information, as provided by the sponsor on FDA form 3542, will be included in the Cumulative Supplement to the List as it becomes available.

Since all parts of this publication are subject to changes, additions, or deletions, the *Addendum* must be used in conjunction with the most current Cumulative Supplement.

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021205 001	ABACAVIR SULFATE;TRIZIVIR	5034394	JUN 26, 2009		NCE	DEC 17, 2003
		5089500	JUN 26, 2009	U248	PED	JUN 17, 2004
		5047407	NOV 17, 2009			
		5905082	MAY 18, 2016			
		4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4828838	SEP 17, 2005			
		5034394*PED	DEC 26, 2009			
		5047407*PED	MAY 17, 2010			
		5089500*PED	DEC 26, 2009	U248		
		5905082*PED	NOV 18, 2016			
		6180639	JAN 30, 2018	U248		
		6294540	MAY 14, 2018	U65		
		6294540*PED	NOV 14, 2018	U65		
		6180639*PED	JUL 30, 2018	U248		
		6417191	MAR 28, 2016	U248		
		4837208	SEP 17, 2005			
020977 001	ABACAVIR SULFATE;ZIAGEN	5089500	JUN 26, 2009	U248	PED	JUN 17, 2004
		5089500*PED	DEC 26, 2009		NCE	DEC 17, 2003
		5034394	DEC 18, 2011			
		5034394*PED	JUN 18, 2012			
		6294540	MAY 14, 2018	U65		
		6294540*PED	NOV 14, 2018	U65		
020978 001	ABACAVIR SULFATE;ZIAGEN	5089500	JUN 26, 2009	U248	PED	JUN 17, 2004
		5089500*PED	DEC 26, 2009		NCE	DEC 17, 2003
		5034394	DEC 18, 2011			
		5034394*PED	JUN 18, 2012			
		6294540*PED	NOV 14, 2018	U65		
		6294540	MAY 14, 2018	U65		
021320 001	ABARELIX;PLENAXIS				NCE	NOV 25, 2008
020482 001	ACARBOSE;PRECOSE	4904769	FEB 27, 2007			
020482 002	ACARBOSE;PRECOSE	4904769	FEB 27, 2007			
020482 004	ACARBOSE;PRECOSE	4904769	FEB 27, 2007			
020802 001	ACETAMINOPHEN;EXCEDRIN (MIGRAINE)	5972916	JUL 14, 2017	U296		
		4943565	JUL 24, 2007			
021082 001	ACETAMINOPHEN;TAVIST ALLERGY/SINUS/HEADACHE				NC	MAR 01, 2004
019872 001	ACETAMINOPHEN;TYLENOL (CAPLET)	5004613	JUL 27, 2007			
		4820522	JUL 27, 2007			
		4968509	NOV 06, 2007			
021123 001	ACETAMINOPHEN;ULTRACET	5336691	AUG 09, 2011		NC	AUG 15, 2004
020213 001	ACETYLCHOLINE CHLORIDE;MIOCHOL-E	6261546	APR 29, 2019	U506		
019806 001	ACRIVASTINE;SEMPREX-D	4650807	MAR 26, 2008	U93		
021478 001	ACYCLOVIR;ZOVIRAX	4963555	OCT 16, 2007		NDF	DEC 30, 2005
020338 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010			
		RE34440	MAY 31, 2010	U275		
020380 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010			
		RE34440	MAY 31, 2010	U275		
020748 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010			
		RE34440	MAY 31, 2010	U275		
021449 001	ADEFOVIR DIPIVOXIL;HEPSERA	6451340	JUL 23, 2018	U470	NCE	SEP 20, 2007
		4808716	APR 25, 2006			
		5663159	SEP 02, 2014	U470		
		4724233	APR 21, 2006	U470		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019937 002	ADENOSINE;ADENOCARD	4673563	JUN 16, 2004	U38		
020059 001	ADENOSINE;ADENOSCAN	5070877	MAY 18, 2009	U116		
		5731296	MAR 24, 2015	U221		
020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U282		
		5763454	JUN 15, 2015	U282		
		6080756	JUL 05, 2016			
		6194429	JUL 23, 2018			
020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE FREE	5164402	NOV 17, 2009	U282		
		5763454	JUN 15, 2015	U282		
		6080756	JUL 05, 2016			
		6194429	JUL 23, 2018			
020899 001	ALBUMIN HUMAN;OPTISON	5573751	APR 25, 2012			
		5529766	JUN 25, 2013	U505		
		5558094	FEB 28, 2012	U505		
020949 001	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
020949 002	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
020291 001	ALBUTEROL SULFATE;COMBIVENT	5603918	JUN 09, 2015			
020950 001	ALBUTEROL SULFATE;DUONEB	6632842	DEC 28, 2021	U532	NP	MAR 21, 2004
020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA	5439670	JUL 06, 2010			
		5605674	FEB 25, 2014			
		5225183	JUL 06, 2010			
		5766573	JUN 16, 2015			
		6352684	NOV 28, 2009			
		5695743	JUL 06, 2010	U491		
020983 001	ALBUTEROL SULFATE;VENTOLIN HFA	6251368	DEC 04, 2012			
019604 001	ALBUTEROL SULFATE;VOLMAX	4751071	JUN 14, 2005			
		4777049	OCT 11, 2005			
		4851229	JUN 14, 2005			
019604 002	ALBUTEROL SULFATE;VOLMAX	4751071	JUN 14, 2005			
		4777049	OCT 11, 2005			
		4851229	JUN 14, 2005			
021074 001	ALCOHOL;AVAGARD	5897031	JUN 21, 2016		NC	JUN 07, 2004
020560 001	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012		I-309	SEP 29, 2003
		4621077	AUG 06, 2007	U114	PED	MAR 29, 2004
		5681590	DEC 02, 2012			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U303		
		6090410	DEC 02, 2012			
		6194004	DEC 02, 2012			
		4621077*PED	FEB 06, 2008	U114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 06, 2015			
		6008207*PED	DEC 06, 2015	U303		
		6090410*PED	JUN 02, 2013			
		6194004*PED	JUN 02, 2013			
020560 002	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012			
		4621077	AUG 06, 2007	U114		
		5681590	DEC 02, 2012			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U303		
		6090410	DEC 02, 2012			
		4621077*PED	FEB 06, 2008	U114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 06, 2015			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
		6008207*PED	JUN 06, 2015	U303		
		6090410*PED	JUN 02, 2013			
020560 003	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012			
		4621077	AUG 06, 2007	U114		
		5681590	DEC 02, 2012			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015	U303		
		6090410	DEC 02, 2012			
		4621077*PED	FEB 06, 2008	U114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 06, 2015			
		6008207*PED	DEC 06, 2015	U303		
		6090410*PED	JUN 02, 2013			
020560 004	ALENDRONATE SODIUM;FOSAMAX	6015801	JUL 17, 2018	U353	NS	OCT 20, 2003
		4621077	AUG 06, 2007	U114	D-61	OCT 20, 2003
		5358941	DEC 02, 2012		D-62	OCT 20, 2003
		5681590	DEC 02, 2012		PED	APR 20, 2004
		5849726	JUN 06, 2015		PED	APR 20, 2004
		6008207	JUN 06, 2015		PED	APR 20, 2004
		6090410	DEC 02, 2012			
		5994329	JUL 17, 2018			
		6225294	JUL 17, 2018			
		4621077*PED	FEB 06, 2008	U114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 16, 2015			
		5994329*PED	JAN 17, 2019			
		6008207*PED	DEC 06, 2015			
		6015801*PED	JAN 17, 2019	U353		
		6090410*PED	JUN 02, 2013			
		6225294*PED	JAN 17, 2019			
020560 005	ALENDRONATE SODIUM;FOSAMAX	6015801	JUL 17, 2018	U353	NS	OCT 20, 2003
		4621077	AUG 06, 2007	U114	D-61	OCT 20, 2003
		5358941	DEC 02, 2012		D-62	OCT 20, 2003
		5681590	DEC 02, 2012		PED	APR 20, 2004
		5849726	JUN 06, 2015		PED	APR 20, 2004
		5994329	JUL 17, 2018		PED	APR 20, 2004
		6008207	JUN 06, 2015			
		6090410	DEC 02, 2012			
		6225294	JUL 17, 2018			
		4621077*PED	FEB 06, 2008	U114		
		5358941*PED	JUN 02, 2013			
		5681590*PED	JUN 02, 2013			
		5849726*PED	DEC 06, 2015			
		5994329*PED	JAN 17, 2019			
		6008207*PED	DEC 06, 2015			
		6015801*PED	JAN 17, 2019	U353		
		6090410*PED	JUN 02, 2013			
		6225294*PED	JAN 17, 2019			
021575 001	ALENDRONATE SODIUM;FOSAMAX	4621077	AUG 06, 2007		I-309	SEP 29, 2003
		4621077*PED	FEB 06, 2008		PED	MAR 29, 2004
		5462932	MAY 17, 2014		D-61	OCT 20, 2003
		5994329	JUL 17, 2018		PED	APR 20, 2004
		5994329*PED	JAN 17, 2019			
		6015801	JUL 17, 2018			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
		6015801*PED	JAN 17, 2019			
		6225294	JUL 17, 2018			
		6225294*PED	JAN 17, 2019			
021287 001	ALFUZOSIN HYDROCHLORIDE;UROXATRAL	4661491	MAY 27, 2006		NCE	JUN 12, 2008
		6149940	AUG 22, 2017			
020886 001	ALITRETINOIN;PANRETIN				ODE	FEB 02, 2006
					NCE	FEB 02, 2004
021001 001	ALMOTRIPTAN MALATE;AXERT	5565447	MAY 07, 2015		NCE	MAY 07, 2006
021001 002	ALMOTRIPTAN MALATE;AXERT	5565447	MAY 07, 2015		NCE	MAY 07, 2006
021107 001	ALOSETRON HYDROCHLORIDE;LOTRONEX	5360800	JAN 13, 2013	DS DP U405	NCE	FEB 09, 2005
		6284770	OCT 05, 2018	U405		
021107 002	ALOSETRON HYDROCHLORIDE;LOTRONEX	5360800	JAN 13, 2013	DS DP U405	NCE	FEB 09, 2005
		6284770	OCT 05, 2018	U405		
018276 004	ALPRAZOLAM;XANAX	5061494	OCT 29, 2008			
021434 001	ALPRAZOLAM;XANAX XR				NDF	JAN 17, 2006
021434 002	ALPRAZOLAM;XANAX XR				NDF	JAN 17, 2006
021434 003	ALPRAZOLAM;XANAX XR				NDF	JAN 17, 2006
021434 004	ALPRAZOLAM;XANAX XR				NDF	JAN 17, 2006
020379 001	ALPROSTADIL;CAVERJECT	5741523	APR 21, 2015			
020379 002	ALPROSTADIL;CAVERJECT	5741523	APR 21, 2015			
020379 003	ALPROSTADIL;CAVERJECT	5741523	APR 21, 2015			
020379 004	ALPROSTADIL;CAVERJECT	5741523	APR 21, 2015			
021212 001	ALPROSTADIL;CAVERJECT				NP	JUN 11, 2005
021212 002	ALPROSTADIL;CAVERJECT				NP	JUN 11, 2005
020700 001	ALPROSTADIL;MUSE	5242391	SEP 07, 2010	U155		
		4801587	JAN 31, 2007	U155		
		5474535	DEC 12, 2012	U155		
020700 002	ALPROSTADIL;MUSE	4801587	JAN 31, 2007	U155		
		5242391	SEP 07, 2010	U155		
		5474535	DEC 12, 2012	U155		
020700 003	ALPROSTADIL;MUSE	4801587	JAN 31, 2007	U155		
		5474535	DEC 12, 2012	U155		
		5242391	SEP 07, 2010	U155		
020700 004	ALPROSTADIL;MUSE	4801587	JAN 31, 2007	U155		
		5242391	SEP 07, 2010	U155		
		5474535	DEC 12, 2012	U155		
020221 001	AMIFOSTINE;ETHYOL	5424471	JUL 31, 2012		ODE	JUN 24, 2006
		5591731	JUL 31, 2012			
		5994409	DEC 08, 2017	U305		
020221 002	AMIFOSTINE;ETHYOL	5424471	JUL 31, 2012		ODE	JUN 24, 2006
		5591731	JUL 31, 2012			
		5994409	DEC 08, 2017	U305		
020965 001	AMINOLEVULINIC ACID HYDROCHLORIDE;LEVULAN	5079262	JUL 28, 2009	U289	NCE	DEC 03, 2004
		5211938	MAY 18, 2010	U289		
		5422093	JUL 28, 2009	U289		
		5954703	OCT 31, 2017	U289		
020511 001	AMLEXANOX;APHTHASOL	5362737	NOV 08, 2011	U243		
020364 002	AMLODIPINE BESYLATE;LOTREL	4410520	AUG 11, 2003			
		4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		6162802	DEC 19, 2017	U367		
		4410520*PED	FEB 11, 2004			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020364 003	AMLODIPINE BESYLATE;LOTREL	4410520	AUG 11, 2003			
		4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		6162802	DEC 19, 2017	U367		
		4410520*PED	FEB 11, 2004			
020364 004	AMLODIPINE BESYLATE;LOTREL	4410520	AUG 11, 2003			
		4879303	MAR 25, 2007			
		4572909	JUL 31, 2006			
		6162802	DEC 19, 2017	U367		
		4410520*PED	FEB 11, 2004			
020364 005	AMLODIPINE BESYLATE;LOTREL	4410520	AUG 11, 2003		NS	JUN 20, 2005
		4572909	JUL 31, 2006		PED	DEC 20, 2005
		4879303	MAR 25, 2007			
		6162802	DEC 19, 2017	U367		
		4410520*PED	FEB 11, 2004			
019787 001	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007		NPP	JAN 08, 2007
		4572909	JUL 31, 2006		PED	JUL 08, 2007
		4879303*PED	SEP 25, 2007			
		4572909*PED	JAN 31, 2007			
019787 002	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007		NPP	JAN 08, 2007
		4572909	JUL 31, 2006		PED	JUL 08, 2007
		4879303*PED	SEP 25, 2007			
		4572909*PED	JAN 31, 2007			
019787 003	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007		NPP	JAN 08, 2007
		4572909	JUL 31, 2006		PED	JUL 08, 2007
		4879303*PED	SEP 25, 2007			
		4572909*PED	JAN 31, 2007			
020508 001	AMMONIUM LACTATE;LAC-HYDRIN				M-4	AUG 25, 2003
					PED	FEB 25, 2004
021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 10	6322819	OCT 21, 2018		NDF	OCT 11, 2004
		6605300	OCT 21, 2018			
021303 006	AMPHETAMINE ASPARTATE;ADDERALL XR 15	6322819	OCT 21, 2018		NDF	OCT 11, 2004
		6605300	OCT 21, 2018			
021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 20	6322819	OCT 21, 2018		NDF	OCT 11, 2004
		6605300	OCT 21, 2018			
021303 004	AMPHETAMINE ASPARTATE;ADDERALL XR 25	6322819	OCT 21, 2018		NDF	OCT 11, 2004
		6605300	OCT 21, 2018			
021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 30	6322819	OCT 21, 2018		NDF	OCT 11, 2004
		6605300	OCT 21, 2018			
021303 005	AMPHETAMINE ASPARTATE;ADDERALL XR 5	6322819	OCT 21, 2018		NDF	OCT 11, 2004
		6605300	OCT 21, 2018			
011522 007	AMPHETAMINE ASPARTATE;ADDERALL 10	6384020	JUL 06, 2020			
011522 012	AMPHETAMINE ASPARTATE;ADDERALL 12.5	6384020	JUL 06, 2020			
011522 013	AMPHETAMINE ASPARTATE;ADDERALL 15	6384020	JUL 06, 2020			
011522 008	AMPHETAMINE ASPARTATE;ADDERALL 20	6384020	JUL 06, 2020			
011522 010	AMPHETAMINE ASPARTATE;ADDERALL 30	6384020	JUL 06, 2020			
011522 009	AMPHETAMINE ASPARTATE;ADDERALL 5	6384020	JUL 06, 2020			
011522 011	AMPHETAMINE ASPARTATE;ADDERALL 7.5	6384020	JUL 06, 2020			
040422 005	AMPHETAMINE ASPARTATE;DEXTROAMP SACCHARATE, AMP ASPARTA				PC	SEP 15, 2003
040422 006	AMPHETAMINE ASPARTATE;DEXTROAMP SACCHARATE, AMP ASPARTA				PC	SEP 15, 2003
040422 007	AMPHETAMINE ASPARTATE;DEXTROAMP SACCHARATE, AMP ASPARTA				PC	SEP 15, 2003
050724 001	AMPHOTERICIN B;ABELCET				ODE	OCT 18, 2003

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
050740 001	AMPHOTERICIN B;AMBISOME				ODE	AUG 11, 2004
021007 001	AMPRENAVIR;AGENERASE	5723490	MAR 03, 2015	U257	NCE	APR 15, 2004
		5646180	JUL 08, 2014	U257		
		5585397	DEC 17, 2013			
021007 002	AMPRENAVIR;AGENERASE	5723490	MAR 03, 2015	U257	NCE	APR 15, 2004
		5646180	JUL 08, 2014	U257		
		5585397	DEC 17, 2013			
021039 001	AMPRENAVIR;AGENERASE	5585397	DEC 17, 2013		NCE	APR 15, 2004
		5723490	MAR 03, 2015	U257		
		5646180	JUL 08, 2014	U257		
020333 001	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
020333 002	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
020541 001	ANASTROZOLE;ARIMIDEX	RE36617	DEC 27, 2009		I-312	SEP 01, 2003
					I-363	SEP 05, 2005
019779 001	APRACLONIDINE HYDROCHLORIDE;IOPIDINE	5212196	MAY 18, 2010	U120		
021549 001	APREPITANT;EMEND	5719147	JUN 29, 2012		NCE	MAR 26, 2008
		5538982	JUL 23, 2013			
		6048859	JUN 29, 2012			
		6096742	JUL 01, 2018			
		6235735	JUN 29, 2012			
021549 002	APREPITANT;EMEND	5719147	JUN 29, 2012		NCE	MAR 26, 2008
		5538982	JUL 23, 2013			
		6048859	JUN 29, 2012			
		6096742	JUL 01, 2018			
		6235735	JUN 29, 2012			
020420 001	ARBUTAMINE HYDROCHLORIDE;GENESA	5108363	APR 28, 2009	U220		
		5234404	AUG 10, 2010	U220		
		5395970	MAR 07, 2012			
020883 001	ARGATROBAN;ARGATROBAN	5214052	MAR 13, 2012		NCE	JUN 30, 2005
		5925760	AUG 04, 2017		I-352	APR 03, 2005
021436 001	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005		NCE	NOV 15, 2007
		5006528	OCT 20, 2009		I-401	AUG 28, 2006
021436 002	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005		NCE	NOV 15, 2007
		5006528	OCT 20, 2009		I-401	AUG 28, 2006
021436 003	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005		NCE	NOV 15, 2007
		5006528	OCT 20, 2009		I-401	AUG 28, 2006
021436 004	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005		NCE	NOV 15, 2007
		5006528	OCT 20, 2009		I-401	AUG 28, 2006
021436 005	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005		NCE	NOV 15, 2007
		5006528	OCT 20, 2009		I-401	AUG 28, 2006
021436 006	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005		NCE	NOV 15, 2007
		5006528	OCT 20, 2009		I-401	AUG 28, 2006
021248 001	ARSENIC TRIOXIDE;TRISENOX				ODE	SEP 25, 2007
					NCE	SEP 25, 2005
020884 001	ASPIRIN;AGGRENOX	6015577	JAN 18, 2017	U302		
021317 001	ASPIRIN;BAYER EXTRA STRENGTH ASPIRIN FOR				NP	OCT 18, 2004
021387 001	ASPIRIN;PRAVIGARD PAC (COPACKAGED)	4346227	OCT 20, 2005			
		4346227*PED	APR 20, 2006			
		5030447	JUL 09, 2008			
		5030447*PED	JAN 09, 2009			
		5180589	JUL 09, 2208			
		5180589*PED	JAN 09, 2009			
		5622985	APR 22, 2014	U335		
		5622985*PED	OCT 22, 2014	U335		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021387 002	ASPIRIN;PRAVIGARD PAC (COPACKAGED)	4346227	OCT 20, 2005			
		4346227*PED	APR 20, 2006			
		5030447	JUL 09, 2008			
		5030447*PED	JAN 09, 2009			
		5622985	APR 22, 2014	U335		
		5622985*PED	OCT 22, 2014	U335		
		5180589	JUL 09, 2008			
		5180589*PED	JAN 09, 2009			
021387 003	ASPIRIN;PRAVIGARD PAC (COPACKAGED)	4346227	OCT 20, 2005			
		4346227*PED	APR 20, 2006			
		5030447	JUL 09, 2008			
		5030447*PED	JAN 09, 2009			
		5180589	JUL 09, 2008			
		5180589*PED	JAN 09, 2009			
		5622985	APR 22, 2014	U335		
		5622985*PED	OCT 22, 2014	U335		
021387 004	ASPIRIN;PRAVIGARD PAC (COPACKAGED)	4346227	OCT 20, 2005			
		4346227*PED	APR 20, 2006			
		5030447	JUL 09, 2008			
		5030447*PED	JAN 09, 2009			
		5180589	JUL 09, 2008			
		5180589*PED	JAN 09, 2009			
		5622985	APR 22, 2014	U335		
		5622985*PED	OCT 22, 2014	U335		
021387 005	ASPIRIN;PRAVIGARD PAC (COPACKAGED)	4346227	OCT 20, 2005			
		4346227*PED	APR 20, 2006			
		5030447	JUL 09, 2008			
		5030447*PED	JAN 09, 2009			
		5180589	JUL 09, 2008			
		5180589*PED	JAN 09, 2009			
		5622985	APR 22, 2014	U335		
		5622985*PED	OCT 22, 2014	U335		
021387 006	ASPIRIN;PRAVIGARD PAC (COPACKAGED)	4346227	OCT 20, 2005			
		4346227*PED	APR 20, 2006			
		5030447	JUL 09, 2008			
		5030447*PED	JAN 09, 2009			
		5180589	JUL 09, 2008			
		5180589*PED	JAN 09, 2009			
		5622985	APR 22, 2014	U335		
		5622985*PED	OCT 22, 2014	U335		
021567 001	ATAZANAVIR SULFATE;REYATAZ	5849911	APR 09, 2017		NCE	JUN 20, 2008
		6087383	DEC 21, 2018			
021567 002	ATAZANAVIR SULFATE;REYATAZ	5849911	APR 09, 2017		NCE	JUN 20, 2008
		6087383	DEC 21, 2018			
021567 003	ATAZANAVIR SULFATE;REYATAZ	5849911	APR 09, 2017		NCE	JUN 20, 2008
		6087383	DEC 21, 2018			
021411 001	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U494	NCE	NOV 26, 2007
		5658590*PED	JUL 11, 2015	U494	PED	MAY 26, 2008
021411 002	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U494	NCE	NOV 26, 2007
		5658590*PED	JUL 11, 2015	U494	PED	MAY 26, 2008
021411 003	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U494	NCE	NOV 26, 2007
		5658590*PED	JUL 11, 2015	U494	PED	MAY 26, 2008

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021411 004	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U494	NCE	NOV 26, 2007
		5658590*PED	JUL 11, 2015	U494	PED	MAY 26, 2008
021411 005	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U494	NCE	NOV 26, 2007
		5658590*PED	JUL 11, 2015	U494	PED	MAY 26, 2008
021411 006	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U494	NCE	NOV 26, 2007
		5658590*PED	JUL 11, 2015	U494	PED	MAY 26, 2008
020702 001	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U161	D-77	APR 22, 2005
		5273995	DEC 28, 2010	U162	I-350	OCT 18, 2005
		5686104	NOV 11, 2014	U213	PED	APR 18, 2006
		5969156	JUL 08, 2016			
		6126971	JAN 19, 2013			
		4681893*PED	MAR 24, 2010	U161		
		5273995*PED	JUN 28, 2011	U162		
		5686104*PED	MAY 11, 2015	U213		
		5969156*PED	JAN 08, 2017			
		6126971*PED	JUL 19, 2013			
020702 002	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U161	D-77	APR 22, 2005
		5273995	DEC 28, 2010	U162	I-350	OCT 18, 2005
		5686104	NOV 11, 2014	U213	PED	APR 18, 2006
		5969156	JUL 08, 2016			
		6126971	JAN 19, 2013			
		4681893*PED	MAR 24, 2010	U161		
		5273995*PED	JUN 28, 2011	U162		
		5686104*PED	MAY 11, 2015	U213		
		5969156*PED	JAN 08, 2017			
		6126971*PED	JUL 19, 2013			
020702 003	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U161	D-77	APR 22, 2005
		5273995	DEC 28, 2010	U162	I-350	OCT 18, 2005
		5686104	NOV 11, 2014	U213	PED	APR 18, 2006
		5969156	JUL 08, 2016			
		6126971	JAN 19, 2013			
		4681893*PED	MAR 24, 2010	U161		
		5273995*PED	JUN 28, 2011	U162		
		5686104*PED	MAY 11, 2015	U213		
		5969156*PED	JAN 08, 2017			
		6126971*PED	JUL 19, 2013			
020702 004	ATORVASTATIN CALCIUM;LIPITOR	4681893	SEP 24, 2009	U161	D-77	APR 22, 2005
		5273995	DEC 28, 2010	U162	I-350	OCT 18, 2005
		5686104	NOV 11, 2014	U213	PED	APR 18, 2006
		5969156	JUL 08, 2016			
		6126971	JAN 19, 2013			
		4681893*PED	MAR 24, 2010	U161		
		5273995*PED	JUN 28, 2011	U162		
		5686104*PED	MAY 11, 2015	U213		
		5969156*PED	JAN 08, 2017			
		6126971*PED	JUL 19, 2013			
021078 001	ATOVAQUONE;MALARONE	6166046	NOV 25, 2013	U406	NC	JUL 14, 2003
		5053432	OCT 01, 2008		PED	JAN 14, 2004
		6291488	NOV 25, 2013			
		5053432*PED	APR 01, 2009			
		6166046*PED	MAY 25, 2014			
		6291488*PED	MAY 25, 2014			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021078 002	ATOVAQUONE;MALARONE PEDIATRIC	6166046	NOV 25, 2013		NC	JUL 14, 2003
		5053432	OCT 01, 2008		PED	JAN 14, 2004
		6291488	NOV 25, 2013	U406	NPP	DEC 02, 2006
		5053432*PED	APR 01, 2009		PED	JUN 02, 2007
		6166046*PED	MAY 25, 2014			
		6291488*PED	MAY 25, 2014			
020259 001	ATOVAQUONE;MEPRON	4981874	AUG 15, 2009	U69		
		5053432	OCT 01, 2008			
		5053432*PED	APR 01, 2009			
		4981874*PED	FEB 15, 2010	U69		
020500 001	ATOVAQUONE;MEPRON	4981874	AUG 15, 2009	U69	ODE	JAN 05, 2006
		5053432	OCT 01, 2008		PED	JUL 05, 2006
		5053432*PED	APR 01, 2009			
		4981874*PED	FEB 15, 2010	U69		
		6649659	JUL 10, 2016	DS DP U69		
		6649659*PED	JAN 10, 2017			
019677 001	ATROPINE SULFATE;ENLON-PLUS	4952586	AUG 28, 2007	U54		
019678 001	ATROPINE SULFATE;ENLON-PLUS	4952586	AUG 28, 2007	U54		
021470 001	AZELAIC ACID;FINACEA	4713394	JAN 17, 2006	U492	NDF	DEC 24, 2005
		6534070	NOV 18, 2018			
020114 001	AZELASTINE HYDROCHLORIDE;ASTELIN	5164194	NOV 01, 2011	U207		
		5164194*PED	MAY 01, 2012			
021127 001	AZELASTINE HYDROCHLORIDE;OPTIVAR	5164194	NOV 01, 2010		PED	NOV 22, 2003
		5164194*PED	MAY 01, 2011			
021589 001	BACLOFEN;KEMSTRO	6024981	APR 09, 2018	DP		
		6221392	APR 09, 2018	DP		
021589 002	BACLOFEN;KEMSTRO	6024981	APR 09, 2018	DP		
		6221392	APR 09, 2018	DP		
020610 001	BALSALAZIDE DISODIUM;COLAZAL				NCE	JUL 18, 2005
020911 002	BECLOMETHASONE DIPROPIONATE;QVAR 40	5776432	JUL 07, 2015		NP	SEP 15, 2003
		5605674	FEB 25, 2014		NPP	MAY 10, 2005
		5695743	JUL 06, 2010			
		5683677	NOV 04, 2014			
		5766573	NOV 28, 2009	U356		
		6352684	NOV 28, 2009			
020911 001	BECLOMETHASONE DIPROPIONATE;QVAR 80	5776432	JUL 07, 2015		NP	SEP 15, 2003
		5605674	FEB 25, 2014		NPP	MAY 10, 2005
		5695743	JUL 06, 2010			
		5683677	NOV 04, 2014			
		5766573	NOV 28, 2009	U356		
		6352684	NOV 28, 2009			
019851 001	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
019851 002	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
019851 003	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
019851 004	BENAZEPRIL HYDROCHLORIDE;LOTENSIN	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
020033 001	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
020033 002	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020033 003	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
020033 004	BENAZEPRIL HYDROCHLORIDE;LOTENSIN HCT	4410520	AUG 11, 2003			
		4410520*PED	FEB 11, 2004			
020032 001	BERACTANT;SURVANTA	4397839	JUL 01, 2005			
020576 001	BETAINE, ANHYDROUS;CYSTADANE				ODE	OCT 25, 2003
019716 001	BETAMETHASONE DIPROPIONATE;DIPROLENE	4775529	MAY 21, 2007			
019555 001	BETAMETHASONE DIPROPIONATE;DIPROLENE AF	4489071	DEC 09, 2003			
020010 001	BETAMETHASONE DIPROPIONATE;LOTRISONE				NP	DEC 08, 2003
020934 001	BETAMETHASONE VALERATE;LUXIQ	6126920	MAR 01, 2016	U484		
020619 001	BETAXOLOL HYDROCHLORIDE;BETOPTIC PILO	5635172	JUN 03, 2014	U191		
019845 001	BETAXOLOL HYDROCHLORIDE;BETOPTIC S	4911920	MAR 27, 2007			
021055 001	BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015	U509	NCE	DEC 29, 2004
		5466861	NOV 14, 2012		ODE	DEC 29, 2006
		5962731	OCT 05, 2016	U475		
021056 001	BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015	U510	NCE	DEC 29, 2004
		5962731	OCT 05, 2016		ODE	DEC 29, 2006
		5466861	NOV 14, 2012			
020498 001	BICALUTAMIDE;CASODEX	4636505	OCT 01, 2008			
021275 001	BIMATOPROST;LUMIGAN	5688819	SEP 21, 2012		NCE	MAR 16, 2006
		6403649	SEP 21, 2012	U446		
020873 001	BIVALIRUDIN;ANGIOMAX	5196404	MAR 23, 2010		NCE	DEC 15, 2005
021602 001	BORTEZOMIB;VELCADE	5780454	OCT 28, 2014		NCE	MAY 13, 2008
		6083903	OCT 28, 2014	U515	ODE	MAY 13, 2010
		6297217	OCT 28, 2014	U515		
		6617317	OCT 28, 2014	DS DP		
021290 001	BOSENTAN;TRACLEER	5292740	NOV 20, 2015		ODE	NOV 20, 2008
					NCE	NOV 20, 2006
021290 002	BOSENTAN;TRACLEER	5292740	NOV 20, 2015		ODE	NOV 20, 2008
					NCE	NOV 20, 2006
020490 001	BRIMONIDINE TARTRATE;ALPHAGAN				NPP	DEC 20, 2004
					PED	JUN 20, 2005
020613 001	BRIMONIDINE TARTRATE;ALPHAGAN	6194415	JUN 28, 2015	U394	NPP	DEC 20, 2004
		6248741	JUN 28, 2015	U394	PED	JUN 20, 2005
		6194415*PED	DEC 28, 2015	U394		
		6248741*PED	DEC 28, 2015	U394		
		6465464	JUN 28, 2015	U394		
		6465464*PED	DEC 28, 2015	U394		
021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P	6194415*PED	DEC 28, 2015	U395	NP	MAR 16, 2004
		5736165	APR 07, 2015	U399	PED	SEP 16, 2004
		5736165*PED	OCT 07, 2015	U399	NPP	DEC 20, 2004
		6248741	JUN 28, 2015	U395	PED	JUN 20, 2005
		6194415	JUN 28, 2015	U395		
		6248741*PED	DEC 28, 2015	U395		
		5424078	JUN 13, 2012			
		5424078*PED	DEC 13, 2012			
		6465464	JUN 28, 2015	U395		
		6465464*PED	DEC 28, 2015	U395		
		6562873	JUL 10, 2021			
		6562873*PED	JAN 10, 2022			
		6627210	JUL 18, 2021	DP		
		6627210*PED	JAN 18, 2022			
		6641834	JUL 28, 2021	DP		
		6641834*PED	JAN 28, 2022			
		6673337	JUL 26, 2021	DP		
		6673337*PED	JAN 26, 2022			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
076260 001	BRIMONIDINE TARTRATE;BRIMONIDINE TARTRATE				PC	SEP 16, 2003
020816 001	BRINZOLAMIDE;AZOPT	5240923	AUG 31, 2010	U224		
		5378703	APR 01, 2012	U224		
		5461081	OCT 24, 2012	U225		
019672 001	BROMPHENIRAMINE MALEATE;EFIDAC 24 PSEUDOEPHEDRINE HCL/BRO	4810502	MAR 14, 2006			
		4662880	MAR 14, 2006			
		4801461	MAR 14, 2006			
021324 001	BUDESONIDE;ENTOCORT EC	5643602	JUL 01, 2014		NP	OCT 02, 2004
		5643602*PED	JAN 01, 2015		PED	APR 02, 2005
020441 002	BUDESONIDE;PULMICORT	4668218	APR 11, 2006			
		4907583	MAR 13, 2007			
		4668218*PED	OCT 11, 2006			
		4907583*PED	SEP 13, 2007			
020441 003	BUDESONIDE;PULMICORT	4668218	APR 11, 2006			
		4907583	MAR 13, 2007			
		4668218*PED	OCT 11, 2006			
		4907583*PED	SEP 13, 2007			
020929 001	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
		4787536*PED	AUG 27, 2006		PED	FEB 08, 2004
		6598603	DEC 23, 2018	U529		
		6598603*PED	JUN 23, 2019			
020929 002	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
		4787536*PED	AUG 27, 2006		PED	FEB 08, 2004
		6598603	DEC 23, 2018	U529		
		6598603*PED	JUN 23, 2019			
020929 003	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
		4787536*PED	AUG 27, 2006		PED	FEB 08, 2004
		6598603	DEC 23, 2018	U529		
		6598603*PED	JUN 23, 2019			
020746 001	BUDESONIDE;RHINOCORT	6291445	APR 29, 2017		M-22	OCT 26, 2004
		6291445*PED	OCT 29, 2017		PED	APR 26, 2005
020746 002	BUDESONIDE;RHINOCORT	6291445	APR 29, 2017		M-22	OCT 26, 2004
		6291445*PED	OCT 29, 2017		PED	APR 26, 2005
020733 001	BUPRENORPHINE HYDROCHLORIDE;SUBOXONE				NDF	OCT 08, 2005
					ODE	OCT 08, 2009
020733 002	BUPRENORPHINE HYDROCHLORIDE;SUBOXONE				NDF	OCT 08, 2005
					ODE	OCT 08, 2009
020732 002	BUPRENORPHINE HYDROCHLORIDE;SUBUTEX				NDF	OCT 08, 2005
					ODE	OCT 08, 2009
020732 003	BUPRENORPHINE HYDROCHLORIDE;SUBUTEX				NDF	OCT 08, 2005
					ODE	OCT 08, 2009
020358 001	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR	5358970	AUG 12, 2013		M-10	JUN 11, 2004
		5427798	AUG 12, 2013			
		5763493	AUG 12, 2013			
		5731000	AUG 12, 2013			
020358 002	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR	5427798	AUG 12, 2013		M-10	JUN 11, 2004
		5358970	AUG 12, 2013			
		5763493	AUG 12, 2013			
		5731000	AUG 12, 2013			
020358 003	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR	5358970	AUG 12, 2013		M-10	JUN 11, 2004
		5427798	AUG 12, 2013			
		5731000	AUG 12, 2013			
		5763493	AUG 12, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020358 004	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR	5358970	AUG 12, 2013		M-10	JUN 11, 2004
		5427798	AUG 12, 2013			
		5731000	AUG 12, 2013			
		5763493	AUG 12, 2013			
021515 001	BUPROPION HYDROCHLORIDE;WELLBUTRIN XL	6096341	OCT 30, 2018		M-10	JUN 11, 2004
		6143327	OCT 30, 2018			
021515 002	BUPROPION HYDROCHLORIDE;WELLBUTRIN XL	6096341	OCT 30, 2018		M-10	JUN 11, 2004
		6143327	OCT 30, 2018			
020711 002	BUPROPION HYDROCHLORIDE;ZYBAN	5358970	AUG 12, 2013			
		5427798	AUG 12, 2013			
		5731000	AUG 12, 2013			
		5763493	AUG 12, 2013			
020711 003	BUPROPION HYDROCHLORIDE;ZYBAN	5358970	AUG 12, 2013			
		5427798	AUG 12, 2013			
		5731000	AUG 12, 2013			
		5763493	AUG 12, 2013			
018731 001	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
					PED	JAN 19, 2005
					W	JUL 19, 2004
					W	JAN 19, 2005
018731 002	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
					PED	JAN 19, 2005
					W	JUL 19, 2004
					W	JAN 19, 2005
018731 003	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
					PED	JAN 19, 2005
					W	JUL 19, 2004
					W	JAN 19, 2005
018731 004	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
					PED	JAN 19, 2005
					W	JUL 19, 2004
					W	JAN 19, 2005
021190 001	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
		5015646*PED	NOV 14, 2008			
021190 002	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646*PED	NOV 14, 2008			
		5015646	MAY 14, 2008			
021190 003	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
		5015646*PED	NOV 14, 2008			
021190 004	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
		5015646*PED	NOV 14, 2008			
020954 001	BUSULFAN;BUSULFEX	5430057	SEP 30, 2013	U263	ODE	FEB 04, 2006
		5559148	MAY 24, 2015	U264	PED	AUG 04, 2006
		5430057*PED	MAR 30, 2014	U263		
		5559148*PED	NOV 24, 2015	U264		
020524 001	BUTENAFINE HYDROCHLORIDE;MENTAX	5021458	OCT 18, 2010	U177	I-333	JUN 06, 2004
021408 001	BUTENAFINE HYDROCHLORIDE;MENTAX-TC				NP	OCT 17, 2005
019881 001	BUTOCONAZOLE NITRATE;GYNAZOLE-1	5266329	NOV 30, 2010	U457		
020664 001	CABERGOLINE;DOSTINEX	4526892	DEC 29, 2005			
020793 001	CAFFEINE CITRATE;CAFCIT				ODE	SEP 21, 2006
020273 001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
020554 001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			
020611 001	CALCIPOTRIENE;DOVONEX	4866048	DEC 29, 2007			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020313 002	CALCITONIN, SALMON;MIACALCIN	5733569	MAR 31, 2015	U227		
		5759565	MAR 31, 2015			
018874 001	CALCITRIOL;CALCIJEX	6051567	AUG 02, 2019		PED	MAY 16, 2005
		6051567*PED	FEB 02, 2020		M-14	NOV 16, 2004
		6265392	AUG 02, 2019			
		6274169	AUG 02, 2019			
		6274169*PED	FEB 02, 2020			
		6265392*PED	FEB 02, 2020			
018874 002	CALCITRIOL;CALCIJEX	6051567	AUG 02, 2019		PED	MAY 16, 2005
		6051567*PED	FEB 02, 2020		M-14	NOV 16, 2004
		6265392	AUG 02, 2019			
		6274169	AUG 02, 2019			
		6274169*PED	FEB 02, 2020			
		6265392*PED	FEB 02, 2020			
075766 001	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
075766 002	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
075823 001	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
075823 002	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
075836 001	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
075836 002	CALCITRIOL;CALCITRIOL				PC	SEP 17, 2003
019976 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U381		
021160 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U381		
021160 002	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U381		
		6576665	APR 03, 2021			
021160 003	CALCIUM ACETATE;PHOSLO GELCAPS	4870105	APR 07, 2007	U381		
		6576665	APR 03, 2021			
020958 001	CALCIUM CARBONATE, PRECIPITATED;PEPCID COMPLETE	5229137	MAY 16, 2012	U349	NC	OCT 15, 2003
		5817340	DEC 01, 2012		PED	APR 15, 2004
		5989588	SEP 30, 2015	U349		
		5989588*PED	MAR 30, 2018	U349		
		5229137*PED	NOV 16, 2012			
		5817340*PED	JUN 01, 2013			
020577 001	CALCIUM CHLORIDE;ELLIOTTS B SOLUTION				ODE	SEP 27, 2003
020521 001	CALFACTANT;INFASURF PRESERVATIVE FREE				NCE	JUL 01, 2003
020838 001	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U3	M-21	SEP 13, 2005
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
020838 002	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U3	M-21	SEP 13, 2005
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
020838 003	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U3	M-21	SEP 13, 2005
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
020838 004	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U3	M-21	SEP 13, 2005
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011			
		5705517	APR 18, 2011			
021093 001	CANDESARTAN CILEXETIL;ATACAND HCT	5705517	APR 18, 2011	U3	NC	SEP 05, 2003
		5721263	FEB 24, 2015	U3		
		5958961	JUN 06, 2014	U3		
		5196444	JUN 04, 2012	U3		
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011	U3		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021093 002	CANDESARTAN CILEXETIL;ATACAND HCT	5705517	APR 18, 2011	U3	NC	SEP 05, 2003
		5721263	FEB 24, 2015	U3		
		5958961	JUN 06, 2014	U3		
		5196444	JUN 04, 2012	U3		
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011	U3		
020896 001	CAPECITABINE;XELODA	5472949	DEC 14, 2013	U271	I-323	APR 30, 2004
		4966891	JAN 13, 2011	U272	I-341	SEP 07, 2004
020896 002	CAPECITABINE;XELODA	5472949	DEC 14, 2013	U271	I-323	APR 30, 2004
		4966891	JAN 13, 2011	U272	I-341	SEP 07, 2004
018343 001	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U92		
018343 002	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U92		
018343 003	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U92		
018343 004	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U92		
018343 005	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U92		
018343 006	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U92		
018343 007	CAPTOPRIL;CAPOTEN	5238924	AUG 24, 2010	U92		
020712 001	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U215		
		5912013	JUN 15, 2016	U277		
020712 002	CARBAMAZEPINE;CARBATROL	5326570	JUL 05, 2011	U215		
		5912013	JUN 15, 2016	U277		
020234 001	CARBAMAZEPINE;TEGRETOL-XR	RE34990	JUL 29, 2007			
		5284662	FEB 08, 2011			
020234 002	CARBAMAZEPINE;TEGRETOL-XR	RE34990	JUL 29, 2007			
		5284662	FEB 08, 2011			
020234 003	CARBAMAZEPINE;TEGRETOL-XR	RE34990	JUL 29, 2007			
		5284662	FEB 08, 2011			
019856 001	CARBIDOPA;SINEMET CR	4900755	JUN 16, 2006			
		4832957	JUN 16, 2006			
019856 002	CARBIDOPA;SINEMET CR	4900755	JUN 16, 2006			
		4832957	JUN 16, 2006			
021485 002	CARBIDOPA;STALEVO 100	5446194	AUG 29, 2012		NCE	OCT 19, 2004
		5135950	OCT 31, 2010			
		4963590	NOV 27, 2007			
		6500867	JUN 29, 2020			
		5112861	MAY 12, 2009			
021485 003	CARBIDOPA;STALEVO 150	5446194	AUG 29, 2012		NCE	OCT 19, 2004
		5135950	OCT 31, 2010			
		4963590	NOV 27, 2007			
		6500867	JUN 29, 2020			
		5112861	MAY 12, 2009			
021485 001	CARBIDOPA;STALEVO 50	5446194	AUG 29, 2012		NCE	OCT 19, 2004
		5135950	OCT 31, 2010			
		4963590	NOV 27, 2007			
		6500867	JUN 29, 2020			
		5112861	MAY 12, 2009			
019880 001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		
019880 002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		
019880 003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		
020452 001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		
020452 002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		
020452 003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U175		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020637 001	CARMUSTINE;GLIADEL	4789724	AUG 01, 2006		ODE	SEP 23, 2003
		4757128	AUG 01, 2006		I-382	FEB 25, 2006
020297 001	CARVEDILOL;COREG	4503067	MAR 05, 2007	U3	I-343	NOV 01, 2004
		5760069	JUN 07, 2015	U233	I-388	MAR 27, 2006
		5902821	FEB 07, 2016	U313		
020297 002	CARVEDILOL;COREG	4503067	MAR 05, 2007	U3	I-343	NOV 01, 2004
		5760069	JUN 07, 2015	U233	I-388	MAR 27, 2006
		5902821	FEB 07, 2016	U313		
020297 003	CARVEDILOL;COREG	4503067	MAR 05, 2007	U3	I-343	NOV 01, 2004
		5760069	JUN 07, 2015	U233	I-388	MAR 27, 2006
		5902821	FEB 07, 2016	U313		
020297 004	CARVEDILOL;COREG	4503067	MAR 05, 2007	U3	I-343	NOV 01, 2004
		5760069	JUN 07, 2015	U233	I-388	MAR 27, 2006
		5902821	FEB 07, 2016	U313		
021227 001	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
		5378804	MAR 16, 2013		I-399	JAN 07, 2006
		5514650	MAR 16, 2013			
		5792746	MAR 16, 2013			
		6136783	MAR 28, 2017			
021227 002	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
		5378804	MAR 16, 2013		I-399	JAN 07, 2006
		5514650	MAR 16, 2013			
		5792746	MAR 16, 2013			
		6136783	MAR 28, 2017			
021222 001	CEFDITOREN PIVOXIL;SPECTRACEF	4839350	JUN 13, 2006		NCE	AUG 29, 2006
		4918068	JUN 13, 2006		I-364	AUG 21, 2005
		5958915	OCT 14, 2016			
020998 001	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U19	NCE	DEC 31, 2003
		5466823	NOV 30, 2013		I-338	OCT 17, 2004
		5563165	NOV 30, 2013			
		5972986	OCT 14, 2017	U299		
		5760068	JUN 02, 2015	U299		
020998 002	CELECOXIB;CELEBREX	5760068	JUN 02, 2015	U19	NCE	DEC 31, 2003
		5466823	NOV 30, 2013		I-338	OCT 17, 2004
		5563165	NOV 30, 2013			
		5760068	JUN 02, 2015	U299		
		5972986	OCT 14, 2017	U299		
020998 003	CELECOXIB;CELEBREX	5466823	NOV 30, 2013		NCE	DEC 31, 2003
		5563165	NOV 30, 2013		I-338	OCT 17, 2004
		5760068	JUN 02, 2015	U19		
		5760068	JUN 02, 2015	U299		
		5972986	OCT 14, 2017	U299		
020740 001	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
020740 002	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
020740 003	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
020740 004	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003
020740 005	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011		D-59	JUL 21, 2003
		5177080	NOV 26, 2011		I-303	JUL 21, 2003

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020740 006	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011		D-59	JUL 21, 2003
		5177080	JAN 26, 2011		I-303	JUL 21, 2003
					NS	JUL 21, 2003
019835 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007		NPP	OCT 21, 2005
		4525358*PED	DEC 25, 2007		PED	APR 21, 2006
019835 002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007		NPP	OCT 21, 2005
		4525358*PED	DEC 25, 2007		PED	APR 21, 2006
020346 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007		NPP	OCT 21, 2005
		4525358*PED	DEC 25, 2007		PED	APR 21, 2006
021150 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC-D 12 HOUR	4525358	JUN 25, 2007	U295		
		4525358*PED	DEC 25, 2007	U295		
		6469009	JUL 13, 2019	U295		
		6489329	APR 08, 2016			
021197 001	CETRORELIX;CETROTIDE	4800191	JUL 17, 2007		NCE	AUG 11, 2005
		5198533	JUL 17, 2007			
		6319192	APR 23, 2018	U426		
021197 002	CETRORELIX;CETROTIDE	4800191	JUL 17, 2007		NCE	AUG 11, 2005
		5198533	JUL 17, 2007			
		6319192	APR 23, 2018	U426		
020044 001	CETYL ALCOHOL;EXOSURF NEONATAL	4312860	AUG 20, 2003			
		4826821	MAY 02, 2006			
		5110806	MAY 02, 2006			
020989 002	CEVIMELINE HYDROCHLORIDE;EVOXAC	4855290	AUG 08, 2006		NCE	JAN 11, 2005
		5340821	AUG 23, 2011	U309		
		5580880	JUN 06, 2015	U310		
020832 001	CHLORHEXIDINE GLUCONATE;CHLORAPREP				NC	JUL 14, 2003
021555 001	CHLORHEXIDINE GLUCONATE;CHLORAPREP ONE-STEP SEPP				NP	OCT 07, 2005
020774 001	CHLORHEXIDINE GLUCONATE;PERIOCHIP	5002769	MAR 16, 2006			
		5023082	MAR 30, 2005			
021441 001	CHLORPHENIRAMINE MALEATE;ADVIL ALLERGY SINUS				NP	DEC 19, 2005
019746 002	CHLORPHENIRAMINE MALEATE;EFIDAC 24 CHLORPHENIRAMINE MALEA	4757330	AUG 15, 2006			
019111 001	CHLORPHENIRAMINE POLISTIREX;TUSSIONEX	4762709	AUG 09, 2005			
019574 001	CHLORTHALIDONE;THALITONE	4933360	JUN 12, 2007			
021149 001	CHORIOGONADOTROPIN ALFA;OVIDREL	5767251	JUN 16, 2015		NP	SEP 20, 2003
021159 001	CICLOPIROX;LOPROX				NDF	FEB 28, 2006
021022 001	CICLOPIROX;PENLAC	4957730	SEP 18, 2007	U379		
020638 001	CIDOFOVIR;VISTIDE	5142051	JUN 26, 2010			
020863 001	CILOSTAZOL;PLETAL				NCE	JAN 15, 2004
020863 002	CILOSTAZOL;PLETAL				NCE	JAN 15, 2004
019992 001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	DEC 09, 2003			
		4670444*PED	JUN 09, 2004			
020369 001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	DEC 09, 2003	U223		
		4670444*PED	JUN 09, 2004	U223		
019537 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	5286754	FEB 15, 2011			
		4670444	DEC 09, 2003	U36		
		4670444*PED	JUN 09, 2004			
		5286754*PED	AUG 15, 2011			
019537 002	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U36		
		5286754	FEB 15, 2011			
		4670444*PED	JUN 09, 2004			
		5286754*PED	AUG 15, 2011			
019537 003	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U36		
		5286754	FEB 15, 2011			
		4670444*PED	JUN 09, 2004			
		5286754*PED	AUG 15, 2011			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019537 004	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	4670444	DEC 09, 2003	U36		
		5286754	FEB 15, 2011			
		4670444*PED	JUN 09, 2004			
		5286754*PED	AUG 15, 2011			
020805 001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO HC	4670444	DEC 09, 2003			
		4844902	FEB 11, 2008			
		4670444*PED	JUN 09, 2004			
019847 001	CIPROFLOXACIN;CIPRO	4670444	DEC 09, 2003			
		4705789	NOV 10, 2004			
		4808583	FEB 28, 2006			
		4670444*PED	JUN 09, 2004			
		4705789*PED	MAY 10, 2005			
		4808583*PED	AUG 28, 2006			
020780 001	CIPROFLOXACIN;CIPRO	5695784	DEC 09, 2014			
		4670444	DEC 09, 2003			
		6136347	JAN 06, 2013	U362		
		4670444*PED	JUN 09, 2004			
		5695784*PED	JUN 09, 2015			
		6136347*PED	JUL 06, 2013			
020780 002	CIPROFLOXACIN;CIPRO	5695784	DEC 09, 2014			
		4670444	DEC 09, 2003			
		6136347	JAN 06, 2013	U362		
		4670444*PED	JUN 09, 2004			
		5695784*PED	JUN 09, 2015			
		6136347*PED	JUL 06, 2013			
019857 001	CIPROFLOXACIN;CIPRO IN DEXTROSE 5%	4670444	DEC 09, 2003			
		4705789	NOV 10, 2004			
		4957922	SEP 18, 2007			
		4808583	FEB 28, 2006			
		4670444*PED	JUN 09, 2004			
		4705789*PED	MAY 10, 2005			
		4808583*PED	AUG 28, 2006			
		4957922*PED	MAR 18, 2008			
019858 001	CIPROFLOXACIN;CIPRO IN SODIUM CHLORIDE 0.9%	4670444	DEC 09, 2003			
		4705789	NOV 10, 2004			
		4957922	SEP 18, 2007			
		4808583	FEB 28, 2006			
021473 001	CIPROFLOXACIN;CIPRO XR	4670444	DEC 09, 2003		NDF	DEC 13, 2005
		4670444*PED	JUN 09, 2004		PED	JUN 13, 2006
021473 002	CIPROFLOXACIN;CIPRO XR				NDF	DEC 13, 2005
					PED	JUN 13, 2006
					I-416	AUG 28, 2006
					PED	FEB 28, 2007
021537 001	CIPROFLOXACIN;CIPRODEX	4844902	FEB 11, 2008		NC	JUL 18, 2006
		6284804	AUG 10, 2020			
		6359016	AUG 10, 2020			
020210 001	CISAPRIDE MONOHYDRATE;PROPULSID	4962115	OCT 09, 2007	U79		
020210 002	CISAPRIDE MONOHYDRATE;PROPULSID	4962115	OCT 09, 2007	U79		
020398 001	CISAPRIDE MONOHYDRATE;PROPULSID	4962115	OCT 09, 2007	U79		
020767 001	CISAPRIDE MONOHYDRATE;PROPULSID QUICKSOLV	4962115	OCT 09, 2007	U79		
		5648093	JUL 15, 2014			
020551 001	CISATRACURIUM BESYLATE;NIMBEX	5453510	SEP 26, 2012	U127		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020551 002	CISATRACURIUM BESYLATE;NIMBEX PRESERVATIVE FREE	5453510	SEP 26, 2012	U127		
020551 003	CISATRACURIUM BESYLATE;NIMBEX PRESERVATIVE FREE	5453510	SEP 26, 2012	U127		
020822 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
020822 002	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
020822 003	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
020822 004	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
021046 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
021535 001	CLOBETASOL PROPIONATE;CLOBEX	6106848	SEP 22, 2017		NDF	JUL 24, 2006
021142 001	CLOBETASOL PROPIONATE;OLUX FOAM	6126920	OCT 03, 2017	U484	I-374	DEC 20, 2005
020615 001	CLONIDINE HYDROCHLORIDE;DURACLON				ODE	OCT 02, 2003
020839 001	CLOPIDOGREL BISULFATE;PLAVIX	4529596	JUL 05, 2003		I-349	FEB 27, 2005
		4847265	NOV 17, 2011			
		5576328	JAN 31, 2014	U432		
		6429210	JUN 10, 2019			
		6504030	JUN 10, 2019			
019758 001	CLOZAPINE;CLOZARIL				I-380	DEC 18, 2005
019758 002	CLOZAPINE;CLOZARIL				I-380	DEC 18, 2005
021141 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	5679717	APR 29, 2014	U323	NCE	MAY 26, 2005
		5693675	DEC 02, 2014			
		5607669	JUN 10, 2014	U323		
		5917007	APR 29, 2014	U323		
		5919832	JUN 10, 2014			
		6433026	JUN 10, 2014			
		6066678	JUN 10, 2014	U323		
021176 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	5919832	JUN 10, 2014		NCE	MAY 26, 2005
		5917007	APR 29, 2014	U323		
		5607669	JUN 10, 2014	U323		
		5693675	DEC 02, 2014			
		5679717	APR 29, 2014	U323		
		6433026	JUN 10, 2014			
		6066678	JUN 10, 2014	U323		
019722 001	CYANOCOBALAMIN;NASCOBAL	4724231	APR 16, 2005	U157		
017821 001	CYCLOBENZAPRINE HYDROCHLORIDE;FLEXERIL				D-78	FEB 03, 2006
021041 001	CYTARABINE;DEPOCYT				ODE	APR 01, 2006
020287 001	DALTEPARIN SODIUM;FRAGMIN	4303651	JAN 04, 2005		D-60	AUG 03, 2003
					I-414	DEC 10, 2006
020287 002	DALTEPARIN SODIUM;FRAGMIN				I-414	DEC 10, 2006
020287 003	DALTEPARIN SODIUM;FRAGMIN	4303651	JAN 04, 2005		D-60	AUG 03, 2003
					I-414	DEC 10, 2006
020287 004	DALTEPARIN SODIUM;FRAGMIN	4303651	JAN 04, 2005		D-60	AUG 03, 2003
					I-414	DEC 10, 2006
020430 001	DANAPAROID SODIUM;ORGARAN	5164377	OCT 03, 2010			
021572 001	DAPTOMYCIN;CUBICIN	5912226	JUN 15, 2016		NCE	SEP 12, 2008
		6468967	SEP 24, 2019			
021572 002	DAPTOMYCIN;CUBICIN	5912226	JUN 15, 2016		NCE	SEP 12, 2008
		6468967	SEP 24, 2019			
020705 001	DELAVIRDINE MESYLATE;RESCRIPTOR	5563142	OCT 08, 2013			
		6177101	JUN 11, 2018			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020705 002	DELAVIRDINE MESYLATE;RESCRIPTOR	5563142	OCT 08, 2013			
		6177101	JUN 11, 2018			
020118 001	DESFLURANE;SUPRANE	4762856	FEB 02, 2007	U67		
021271 001	DESIRUDIN;IPRIVASK	4745177	MAY 17, 2005			
		4801576	JAN 31, 2006			
		5733874	MAR 31, 2015			
021165 001	DESLORATADINE;CLARINEX	4659716	APR 21, 2004	U427	NCE	DEC 21, 2006
		4863931	SEP 15, 2008		PED	JUN 21, 2007
		4804666	FEB 14, 2006	U428		
		5595997	DEC 30, 2014	U429		
		6100274	JUL 07, 2019			
		4659716*PED	OCT 21, 2004	U427		
		4804666*PED	AUG 14, 2006	U428		
		4863931*PED	MAR 15, 2009			
		5595997*PED	JUN 30, 2015	U429		
		6100274*PED	JAN 07, 2020			
021312 001	DESLORATADINE;CLARINEX	4659716	APR 21, 2004	U427	NCE	DEC 21, 2006
		4659716*PED	OCT 21, 2004	U427	PED	JUN 21, 2007
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
		4804666	FEB 14, 2006	U428		
		4804666*PED	AUG 14, 2006	U428		
		5595997	DEC 30, 2014	U429		
		5595997*PED	JUN 30, 2015	U429		
		6100274	JUL 07, 2019			
		6100274*PED	JAN 07, 2020			
017922 001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5674850	DEC 23, 2013			
		5763407	JUN 29, 2013			
017922 002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5674850	DEC 23, 2013			
		5763407	JUN 29, 2013			
018938 001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5763407	JUN 29, 2013			
018938 002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5763407	JUN 29, 2013			
019955 001	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5047398	SEP 10, 2008			
		5674850	DEC 23, 2013			
		5763407	JUN 29, 2013			
019955 002	DESMOPRESSIN ACETATE;DDAVP	5500413	JUN 29, 2013			
		5047398	SEP 10, 2008			
		5674850	DEC 23, 2013			
		5763407	JUN 29, 2013			
017922 003	DESMOPRESSIN ACETATE;DDAVP (NEEDS NO REFRIGERATION)	5674850	DEC 23, 2013			
		5500413	JUN 29, 2013			
		5482931	JUN 29, 2013			
		5763407	JUN 29, 2013			
021090 001	DESOGESTREL;CYCLESSA	4616006	OCT 07, 2003		NP	DEC 20, 2003
		4544554	SEP 26, 2003			
		4628051	SEP 26, 2003			
020713 001	DESOGESTREL;MIRCETTE	RE35724	OCT 20, 2008			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021038 001	DEXMEDETOMIDINE;PRECEDEX	4910214	JUL 15, 2008	U421	NCE	DEC 17, 2004
021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5908850	DEC 04, 2015	U422	NP	NOV 13, 2004
		6355656	DEC 04, 2015			
021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5908850	DEC 04, 2015	U422	NP	NOV 13, 2004
		6355656	DEC 04, 2015			
021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5908850	DEC 04, 2015	U422	NP	NOV 13, 2004
		6355656	DEC 04, 2015			
020212 001	DEXRAZOXANE HYDROCHLORIDE;ZINECARD	5242901	SEP 07, 2010	U339		
		4963551	DEC 21, 2007			
020212 002	DEXRAZOXANE HYDROCHLORIDE;ZINECARD	5242901	SEP 07, 2010	U339		
		4963551	DEC 21, 2007			
019082 001	DEZOCINE;DALGAN	4605671	AUG 12, 2003			
019082 002	DEZOCINE;DALGAN	4605671	AUG 12, 2003			
019082 003	DEZOCINE;DALGAN	4605671	AUG 12, 2003			
020648 001	DIAZEPAM;DIASTAT	5462740	SEP 17, 2013		ODE	JUL 29, 2004
020648 002	DIAZEPAM;DIASTAT	5462740	SEP 17, 2013		ODE	JUL 29, 2004
020648 003	DIAZEPAM;DIASTAT	5462740	SEP 17, 2013		ODE	JUL 29, 2004
020648 004	DIAZEPAM;DIASTAT	5462740	SEP 17, 2013		ODE	JUL 29, 2004
020648 005	DIAZEPAM;DIASTAT	5462740	SEP 17, 2013		ODE	JUL 29, 2004
020607 001	DICLOFENAC SODIUM;ARTHROTEC	5601843	FEB 11, 2014			
		5698225	FEB 03, 2017	U392		
020607 002	DICLOFENAC SODIUM;ARTHROTEC	5601843	FEB 11, 2014			
		5698225	FEB 03, 2017	U392		
020809 001	DICLOFENAC SODIUM;DICLOFENAC SODIUM	5603929	NOV 16, 2014	U239		
		5653972	NOV 16, 2014	U239		
021005 001	DICLOFENAC SODIUM;SOLARAZE	5639738	JUN 17, 2014	U402	NP	OCT 16, 2003
		5792753	AUG 11, 2015			
		5852002	JUN 17, 2014	U402		
		5914322	AUG 11, 2015			
		5929048	JUL 27, 2016	U402		
		5985850	NOV 16, 2016			
020037 001	DICLOFENAC SODIUM;VOLTAREN	4960799	OCT 03, 2007			
		4829088	APR 14, 2007			
020154 002	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U248		
		5616566	AUG 29, 2006	U180		
		5254539	AUG 29, 2006	U248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		
		5880106*PED	JAN 22, 2012			
020154 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U248		
		5616566	AUG 29, 2006	U180		
		5254539	AUG 29, 2006	U248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		
		5880106*PED	JAN 22, 2012			
020154 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U248		
		5616566	AUG 29, 2006	U180		
		5254539	AUG 29, 2006	U248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020154 005	DIDANOSINE;VIDEX	5880106*PED	JAN 22, 2012			
		4861759	AUG 29, 2006	U248		
		5616566	AUG 29, 2006	U180		
		5254539	AUG 29, 2006	U248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		
020154 006	DIDANOSINE;VIDEX	5880106*PED	JAN 22, 2012			
		4861759	AUG 29, 2006	U248		
		5254539	AUG 29, 2006	U248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		
020155 003	DIDANOSINE;VIDEX	5880106*PED	JAN 22, 2012			
		5616566	AUG 29, 2006	U180		
		4861759	AUG 29, 2006	U248		
		5616566	AUG 29, 2006	U180		
		5254539	AUG 29, 2006	U248		
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		
020155 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U248		
		5616566	AUG 29, 2006	U180		
		5254539	AUG 29, 2006	U248		
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		
020155 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U248		
		5616566	AUG 29, 2006	U180		
		5254539	AUG 29, 2006	U248		
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		
020155 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U52		
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		
		5616566	AUG 29, 2006	U180		
		5254539	AUG 29, 2006	U248		
020156 001	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U248		
		5616566	AUG 29, 2006	U180		
		5254539	AUG 29, 2006	U248		
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
		5616566*PED	MAR 01, 2007	U180		
021183 001	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
021183 002	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021183 003	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
021183 004	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U248		
		5254539*PED	MAR 01, 2007	U248		
020148 001	DIHYDROERGOTAMINE MESYLATE;MIGRANAL	5169849	DEC 08, 2009	U227		
020062 001	DILTIAZEM HYDROCHLORIDE;CARDIZEM CD	5286497	MAY 20, 2011			
		4894240	JAN 16, 2007			
		5470584	MAY 20, 2011			
		5364620	NOV 14, 2011	U3		
		5439689	AUG 08, 2012	U107		
		5002776	MAR 26, 2008			
020062 002	DILTIAZEM HYDROCHLORIDE;CARDIZEM CD	5286497	MAY 20, 2011			
		5364620	NOV 14, 2011	U3		
		5470584	MAY 20, 2011			
		5002776	MAR 26, 2008			
		4894240	JAN 16, 2007			
		5439689	AUG 08, 2012	U107		
020062 003	DILTIAZEM HYDROCHLORIDE;CARDIZEM CD	5286497	MAY 20, 2011			
		5439689	AUG 08, 2012	U107		
		4894240	JAN 16, 2007			
		5002776	MAR 26, 2008			
		5364620	NOV 14, 2011	U3		
		5470584	MAY 20, 2011			
020062 004	DILTIAZEM HYDROCHLORIDE;CARDIZEM CD	5286497	MAY 20, 2011			
		4894240	JAN 16, 2007			
		5002776	MAR 26, 2008			
		5364620	NOV 14, 2011	U3		
		5439689	AUG 08, 2012	U107		
		5470584	MAY 20, 2011			
021392 001	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
		5529791	JUN 25, 2013			
021392 002	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
		5529791	JUN 25, 2013			
021392 003	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
		5529791	JUN 25, 2013			
021392 004	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
		5529791	JUN 25, 2013			
021392 005	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
		5529791	JUN 25, 2013			
021392 006	DILTIAZEM HYDROCHLORIDE;CARDIZEM LA	5288505	JUN 26, 2011		NDF	FEB 06, 2006
		5529791	JUN 25, 2013			
019471 001	DILTIAZEM HYDROCHLORIDE;CARDIZEM SR	4721619	JAN 26, 2005			
019471 002	DILTIAZEM HYDROCHLORIDE;CARDIZEM SR	4721619	JAN 26, 2005			
019471 003	DILTIAZEM HYDROCHLORIDE;CARDIZEM SR	4721619	JAN 26, 2005			
019471 004	DILTIAZEM HYDROCHLORIDE;CARDIZEM SR	4721619	JAN 26, 2005			
020092 001	DILTIAZEM HYDROCHLORIDE;DILACOR XR	4839177	DEC 09, 2006			
		5422123	JUN 06, 2012			
020092 002	DILTIAZEM HYDROCHLORIDE;DILACOR XR	4839177	DEC 09, 2006			
		5422123	JUN 06, 2012			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020092 003	DILTIAZEM HYDROCHLORIDE;DILACOR XR	4839177	DEC 09, 2006			
		5422123	JUN 06, 2012			
020939 001	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020939 002	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020939 003	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020939 004	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020401 001	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
020401 002	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
020401 003	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
020401 004	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
020401 005	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
020401 006	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013			
020507 001	DILTIAZEM MALATE;TECZEM	4968507	JUL 25, 2006			
		4880631	SEP 24, 2007			
		4983598	JAN 08, 2008			
020506 001	DILTIAZEM MALATE;TIAMATE	4880631	SEP 24, 2007			
		4968507	JUL 25, 2006			
020506 002	DILTIAZEM MALATE;TIAMATE	4880631	SEP 24, 2007			
		4968507	JUL 25, 2006			
020506 003	DILTIAZEM MALATE;TIAMATE	4880631	SEP 24, 2007			
		4968507	JUL 25, 2006			
021191 001	DIMYRISTOYL LECITHIN;IMAGENT	6280704	JUL 30, 2013		NCE	MAY 31, 2007
		6280705	JUL 30, 2013			
		6287539	JUL 30, 2013			
		5605673	FEB 25, 2014			
		5626833	MAY 16, 2014	U458		
		5639443	JUN 17, 2014			
		5695741	DEC 09, 2014	U458		
		5720938	FEB 24, 2015			
		5798091	AUG 25, 2015	U458		
020411 001	DINOPROSTONE;CERVIDIL	4931288	JAN 16, 2007			
		5269321	DEC 14, 2010	U110		
019617 001	DINOPROSTONE;PREPIDIL	4680312	JUL 14, 2004			
018723 001	DIVALPROEX SODIUM;DEPAKOTE	5212326	JAN 29, 2008			
		4988731	JAN 29, 2008			
018723 002	DIVALPROEX SODIUM;DEPAKOTE	5212326	JAN 29, 2008			
		4988731	JAN 29, 2008			
018723 003	DIVALPROEX SODIUM;DEPAKOTE	5212326	JAN 29, 2008			
		4988731	JAN 29, 2008			
019680 001	DIVALPROEX SODIUM;DEPAKOTE	5212326	JAN 29, 2008			
		4988731	JAN 29, 2008			
019794 001	DIVALPROEX SODIUM;DEPAKOTE CP	4988731	JAN 29, 2008			
		5212326	JAN 29, 2008			
019794 002	DIVALPROEX SODIUM;DEPAKOTE CP	4988731	JAN 29, 2008			
		5212326	JAN 29, 2008			
021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	4988731	JAN 29, 2008		NP	AUG 04, 2003
		4913906	APR 03, 2007			
		6419953	DEC 18, 2018			
		6511678	DEC 18, 2018			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021168 002	DIVALPROEX SODIUM;DEPAKOTE ER	4913906	APR 03, 2007		NP	AUG 04, 2003
		4988731	JAN 29, 2008			
		6511678	DEC 18, 2018			
020449 001	DOCETAXEL;TAXOTERE	4814470	MAY 14, 2010		I-379	NOV 27, 2005
		5438072	NOV 22, 2013			
		5698582	JUL 03, 2012			
		5714512	JUL 03, 2012			
020941 001	DOCOSANOL;ABREVA	4874794	APR 28, 2014		NCE	JUL 25, 2005
020931 001	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018		NCE	OCT 01, 2004
020931 002	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018		NCE	OCT 01, 2004
020931 003	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018		NCE	OCT 01, 2004
020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020624 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020624 003	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010			
		6140321	DEC 30, 2016			
		6245911	DEC 01, 2018			
		5985864	DEC 30, 2016			
		6372760	MAR 31, 2019			
020690 002	DONEPEZIL HYDROCHLORIDE;ARICEPT	4895841	NOV 25, 2010			
		6140321	DEC 30, 2016			
		6245911	DEC 01, 2018			
		5985864	DEC 30, 2016			
		6372760	MAR 31, 2019			
020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	4797413	APR 28, 2008	U103		
		4619939	OCT 28, 2003	U104		
		6248735	APR 17, 2011			
		4619939*PED	APR 28, 2004			
		4797413*PED	OCT 28, 2008			
020408 001	DORZOLAMIDE HYDROCHLORIDE;TRUSOPT	4797413	APR 28, 2008	U103		
		4619939	OCT 28, 2003	U104		
		4619939*PED	APR 28, 2004			
		4797413*PED	OCT 28, 2008			
019946 001	DOXACURIUM CHLORIDE;NUROMAX	4701460	MAR 06, 2005			
020862 001	DOXERCALCIFEROL;HECTOROL	5602116	FEB 11, 2014	U278	NCE	JUN 09, 2004
		5707980	AUG 17, 2010	U278		
		5861386	AUG 02, 2008	U278		
		5869473	AUG 02, 2008	U278		
021027 001	DOXERCALCIFEROL;HECTOROL	5602116	FEB 11, 2014	U321	NCE	JUN 09, 2004
		5707980	AUG 17, 2010	U321		
050718 001	DOXORUBICIN HYDROCHLORIDE;DOXIL				ODE	JUN 28, 2006
021098 001	DROSPIRENONE;YASMIN	5569652	OCT 29, 2013	U1	NC	MAY 11, 2004
021319 001	DUTASTERIDE;AVODART	5565467	OCT 15, 2013		NCE	NOV 20, 2006
		5846976	DEC 08, 2015	U476		
		5998427	OCT 15, 2013	U477		
020972 001	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U256	NCE	SEP 17, 2003
		5519021	MAY 21, 2013			
		5663169	SEP 02, 2014	U257		
		6238695	APR 06, 2019			
		6555133	APR 06, 2019	U248		
		6639071	FEB 14, 2018	DS		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020972 002	EFAVIRENZ;SUSTIVA	5811423	AUG 07, 2012	U256	NCE	SEP 17, 2003
		5519021	MAY 21, 2013			
		5663169	SEP 02, 2014	U257		
		6238695	APR 06, 2019			
		6555133	APR 06, 2019	U248		
		6639071	FEB 14, 2018	DS		
020972 003	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013		NCE	SEP 17, 2003
		5663169	SEP 02, 2014	U257		
		5811423	AUG 07, 2012	U256		
		6238695	APR 06, 2019			
		6555133	APR 06, 2019	U248		
		6639071	FEB 14, 2018	DS		
021360 001	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013		NCE	SEP 17, 2003
		5663169	SEP 02, 2014			
		5811423	AUG 07, 2012	U256		
		6639071	FEB 14, 2018	DS		
021360 002	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013		NCE	SEP 17, 2003
		5663169	SEP 02, 2014	U248		
		5811423	AUG 07, 2012	U256		
		6639071	FEB 14, 2018	DS		
021145 001	EFLORNITHINE HYDROCHLORIDE;VANIQA	4720489	JAN 19, 2005	U334	NP	JUL 27, 2003
		5648394	JUL 15, 2014	U334		
021016 001	ELETRIPTAN HYDROBROMIDE;RELPAX	5545644	AUG 13, 2013		NCE	DEC 26, 2007
021016 002	ELETRIPTAN HYDROBROMIDE;RELPAX	5545644	AUG 13, 2013		NCE	DEC 26, 2007
020706 001	EMEDASTINE DIFUMARATE;EMADINE	4430343	AUG 14, 2005	U403		
		5441958	DEC 08, 2013	U404		
021500 001	EMTRICITABINE;EMTRIVA	5210085	MAY 11, 2010		NCE	JUL 02, 2008
		5814639	SEP 29, 2015			
		5914331	SEP 29, 2015			
		6642245	NOV 04, 2020	U541		
020668 001	ENALAPRIL MALEATE;LEXXEL	4803081	APR 03, 2007			
		4703038	OCT 07, 2005	U3		
		4803081*PED	OCT 03, 2007			
020668 002	ENALAPRIL MALEATE;LEXXEL	4703038	OCT 07, 2005	U3		
		4803081	APR 03, 2007			
		4803081*PED	OCT 03, 2007			
018998 001	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
					PED	AUG 13, 2004
018998 002	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
					PED	AUG 13, 2004
018998 003	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
					PED	AUG 13, 2004
018998 005	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
					PED	AUG 13, 2004
021481 001	ENFUVIRTIDE;FUZEON	5464933	JUN 07, 2013		NCE	MAR 13, 2008
		6133418	JUN 07, 2013			
		6475491	JUN 07, 2015	U248		
020164 001	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	DS DP U123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012	DS DP U545		
020164 002	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	DS DP U123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012	DS DP U545		
020164 003	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	DS DP U123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012	DS DP U545		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020164 004	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	DS DP U123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012	DS DP U545		
020164 005	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	DS DP U123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012	DS DP U545		
020164 006	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	DS DP U123		
		5389618	FEB 14, 2012	DS DP U545		
020164 007	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	DS DP U123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012	DS DP U545		
020164 008	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	DS DP U123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012	DS DP U545		
020164 009	ENOXAPARIN SODIUM;LOVENOX	4692435	DEC 24, 2004	DS DP U123	I-315	NOV 17, 2003
		5389618	FEB 14, 2012	DS DP U545		
020796 001	ENTACAPONE;COMTAN	5446194	AUG 29, 2012		NCE	OCT 19, 2004
		5135950	OCT 31, 2010			
		4963590	NOV 27, 2007			
		5112861	MAY 12, 2009			
		6599530	SEP 14, 2018	DP		
021565 001	EPINASTINE HYDROCHLORIDE;ELESTAT				NCE	OCT 15, 2008
050778 001	EPIRUBICIN HYDROCHLORIDE;ELLENCE				ODE	SEP 15, 2006
021437 001	EPLERENONE;INSPRA	4559332	APR 09, 2004	U537	NCE	SEP 27, 2007
		6410054	DEC 08, 2019	U3	I-407	OCT 07, 2006
		6410524	NOV 05, 2019	U467		
		6558707	DEC 08, 2009	DP U537		
		6534093	DEC 08, 2019	U537		
		6495165	DEC 08, 2019	U537		
		6534093	DEC 08, 2019	U3		
		6410054	DEC 08, 2019	U537		
		6495165	DEC 08, 2019	U3		
021437 002	EPLERENONE;INSPRA	6410524	NOV 05, 2019	U467	NCE	SEP 27, 2007
		4559332	APR 09, 2004	U537	I-407	OCT 07, 2006
		6534093	DEC 08, 2019	U3		
		6558707	DEC 08, 2009	DP U537		
		6495165	DEC 08, 2019	U3		
		6495165	DEC 08, 2019	U537		
		6534093	DEC 08, 2019	U537		
		6410054	DEC 08, 2019	U3		
		6410054	DEC 08, 2019	U537		
021437 003	EPLERENONE;INSPRA	6410524	NOV 05, 2019	U467	NCE	SEP 27, 2007
		4559332	APR 09, 2004	U537	I-407	OCT 07, 2006
		6558707	DEC 08, 2009	DP U537		
		6410054	DEC 08, 2019	U3		
		6410054	DEC 08, 2019	U537		
		6495165	DEC 08, 2019	U3		
		6495165	DEC 08, 2019	U537		
		6534093	DEC 08, 2019	U3		
		6534093	DEC 08, 2019	U537		
020444 001	EPOPROSTENOL SODIUM;FLOLAN	4883812	MAY 12, 2006	U185	ODE	APR 14, 2007
020444 002	EPOPROSTENOL SODIUM;FLOLAN	4883812	MAY 12, 2006	U185	ODE	APR 14, 2007
020738 004	EPROSARTAN MESYLATE;TEVETEN	5656650	AUG 12, 2014	U3		
		5185351	FEB 09, 2010	U3		
020738 005	EPROSARTAN MESYLATE;TEVETEN	5656650	AUG 12, 2014	U3		
		5185351	FEB 09, 2010	U3		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020738 006	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U3		
		5656650	AUG 12, 2014	U3		
021268 001	EPROSARTAN MESYLATE;TEVETEN HCT	5185351	FEB 09, 2010	U3	NC	NOV 01, 2004
		5656650	AUG 12, 2014	U3		
021268 002	EPROSARTAN MESYLATE;TEVETEN HCT	5185351	FEB 09, 2010	U3	NC	NOV 01, 2004
		5656650	AUG 12, 2014	U3		
020718 001	EPTIFIBATIDE;INTEGRILIN	5756451	NOV 11, 2014		D-66	JUN 08, 2004
		5686570	NOV 11, 2014			
		5807825	SEP 15, 2015	U244		
		5968902	JUN 02, 2015	U453		
		5747447	MAY 05, 2015			
020718 002	EPTIFIBATIDE;INTEGRILIN	5756451	NOV 11, 2014		D-66	JUN 08, 2004
		5686570	NOV 11, 2014			
		5807825	SEP 15, 2015	U244		
		5968902	JUN 02, 2015	U453		
		5747447	MAY 05, 2015			
021337 001	ERTAPENEM SODIUM;INVANZ	5478820	FEB 02, 2013		NCE	NOV 21, 2006
		5652233	FEB 02, 2013			
		5952323	MAY 15, 2017			
021323 001	ESCITALOPRAM OXALATE;LEXAPRO	RE34712	JUN 08, 2009		NP	AUG 14, 2005
		RE34712*PED	DEC 08, 2009		PED	FEB 14, 2006
					I-366	AUG 29, 2005
					PED	MAR 01, 2006
					I-251	DEC 18, 2006
021323 002	ESCITALOPRAM OXALATE;LEXAPRO	RE34712	JUN 08, 2009		NP	AUG 14, 2005
		RE34712*PED	DEC 08, 2009		PED	FEB 14, 2006
					I-366	AUG 29, 2005
					PED	MAR 01, 2006
					I-251	DEC 18, 2006
021323 003	ESCITALOPRAM OXALATE;LEXAPRO	RE34712	JUN 08, 2009		NP	AUG 14, 2005
		RE34712*PED	DEC 08, 2009		PED	FEB 14, 2006
					I-366	AUG 29, 2005
					PED	MAR 01, 2006
					I-251	DEC 18, 2006
021365 001	ESCITALOPRAM OXALATE;LEXAPRO	RE34712	JUN 08, 2009		NP	AUG 14, 2005
		RE34712*PED	DEC 08, 2009		I-366	AUG 29, 2005
					PED	FEB 14, 2006
					PED	MAR 01, 2006
					I-251	DEC 18, 2006
019386 001	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
		6310094	JAN 12, 2021			
019386 002	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
		5017609*PED	NOV 21, 2008			
		4593119*PED	DEC 03, 2003			
019386 003	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
		5017609*PED	NOV 21, 2008			
		4593119*PED	DEC 03, 2003			
019386 004	ESMOLOL HYDROCHLORIDE;BREVIBLOC	6528540	JAN 12, 2021			
		6310094	JAN 12, 2021			
		6528540*PED	JUL 12, 2021			
		6310094*PED	JUL 12, 2021			
		4593119*PED	DEC 03, 2003			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019386 006	ESMOLOL HYDROCHLORIDE;BREVIBLOC	6528540	JAN 12, 2021			
		6310094	JAN 12, 2021			
		6528540*PED	JUL 12, 2021			
		6310094*PED	JUL 12, 2021			
		4593119*PED	DEC 03, 2003			
019386 007	ESMOLOL HYDROCHLORIDE;BREVIBLOC	6310094	JAN 12, 2021			
		6528540	JAN 12, 2021			
		6528540*PED	JUL 12, 2021			
		6310094*PED	JUL 12, 2021			
		4593119*PED	DEC 03, 2003			
019386 005	ESMOLOL HYDROCHLORIDE;BREVIBLOC DOUBLE STRENGTH	6528540	JAN 12, 2021			
		6310094	JAN 12, 2021			
		6528540*PED	JUL 12, 2021			
		6310094*PED	JUL 12, 2021			
		4593119*PED	DEC 03, 2003			
021153 001	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4738974	APR 19, 2005	U373	NP	FEB 20, 2004
		5900424	MAY 04, 2016	U373	PED	AUG 20, 2004
		4786505	APR 20, 2007	U373		
		4853230	APR 20, 2007	U373		
		5714504	FEB 03, 2015	U373		
		5877192	MAY 27, 2014	U373		
		5690960	NOV 25, 2014	U373		
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		6369085	MAY 25, 2018			
		6428810	NOV 03, 2019	U469		
		4738974*PED	OCT 19, 2005	U373		
		4786505*PED	OCT 20, 2007	U373		
		4853230*PED	OCT 20, 2007	U373		
		5690960*PED	MAY 25, 2015	U373		
		5714504*PED	AUG 03, 2015	U373		
		5877192*PED	NOV 27, 2014	U373		
		5900424*PED	NOV 04, 2016	U373		
		6147103	OCT 09, 2018			
		6147103*PED	APR 09, 2019			
		6166213*PED	APR 09, 2019			
		6191148*PED	APR 09, 2019			
		6369085*PED	NOV 25, 2018			
		6428810*PED	MAY 03, 2020	U469		
021153 002	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4738974	APR 19, 2005	U373	NP	FEB 20, 2004
		5900424	MAY 04, 2016	U373	PED	AUG 20, 2004
		4786505	APR 20, 2007	U373		
		4853230	APR 20, 2007	U373		
		5714504	FEB 03, 2015	U373		
		5877192	MAY 27, 2014	U373		
		5690960	NOV 25, 2014	U373		
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		6369085	MAY 25, 2018			
		6428810	NOV 03, 2019	U469		
		4738974*PED	OCT 19, 2005	U373		
		4786505*PED	OCT 20, 2007	U373		
		4853230*PED	OCT 20, 2007	U373		
		5690960*PED	MAY 25, 2015	U373		
		5714504*PED	AUG 03, 2015	U373		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
		5877192*PED	NOV 27, 2014	U373		
		5900424*PED	NOV 04, 2016	U373		
		6147103*PED	APR 09, 2019			
		6166213*PED	APR 09, 2019			
		6191148*PED	APR 09, 2019			
		6369085*PED	NOV 25, 2018			
		6428810*PED	MAY 03, 2020	U469		
021367 001	ESTRADIOL ACETATE;FEMRING	5855906	DEC 19, 2015	U508	NP	MAR 20, 2006
021367 002	ESTRADIOL ACETATE;FEMRING	5855906	DEC 19, 2015	U508	NP	MAR 20, 2006
020874 001	ESTRADIOL CYPIONATE;LUNELLE				NP	OCT 05, 2003
020907 001	ESTRADIOL;ACTIVELLA	RE36247	MAY 02, 2006			
020655 001	ESTRADIOL;ALORA	5122383	MAY 17, 2011		I-351	APR 05, 2005
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			
020655 002	ESTRADIOL;ALORA	5122383	MAY 17, 2011		I-351	APR 05, 2005
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			
020655 003	ESTRADIOL;ALORA	5122383	MAY 17, 2011		I-351	APR 05, 2005
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			
020655 004	ESTRADIOL;ALORA	5122383	MAY 17, 2011		I-351	APR 05, 2005
		5227169	MAY 17, 2011			
		5212199	MAY 17, 2011			
		5164190	DEC 11, 2010			
020375 001	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
020375 002	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
020375 003	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
020375 004	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
020375 005	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
020375 006	ESTRADIOL;CLIMARA	5223261	JUN 29, 2010			
021258 001	ESTRADIOL;CLIMARA PRO	5252334	OCT 12, 2010	DP	NC	NOV 21, 2006
		5770219	OCT 12, 2010	DP		
		5393529	FEB 28, 2012	DP		
		5676968	OCT 14, 2014	DP		
020870 001	ESTRADIOL;COMBIPATCH	5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
		6024976	JAN 07, 2014			
020870 002	ESTRADIOL;COMBIPATCH	5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
		6024976	JAN 07, 2014			
020847 001	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 002	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 003	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 004	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020847 005	ESTRADIOL;ESCLIM	4842864	MAR 25, 2008			
020472 001	ESTRADIOL;ESTRING	4871543	JUN 12, 2007	U306		
		5188835	JUN 12, 2007	U306		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020417 001	ESTRADIOL;FEMPATCH	4906463	MAR 06, 2007			
		5006342	APR 09, 2008			
021040 001	ESTRADIOL;PREFEST	5108995	APR 28, 2009	U311		
		5382573	JAN 17, 2012			
020323 001	ESTRADIOL;VIVELLE	4814168	MAR 04, 2008		I-254	AUG 16, 2003
		4994267	MAR 04, 2008			
		4994278	MAR 04, 2008			
		5300291	APR 05, 2011			
020323 002	ESTRADIOL;VIVELLE	4994278	MAR 04, 2008		I-254	AUG 16, 2003
		4814168	MAR 04, 2008			
		4994267	MAR 04, 2008			
		5300291	APR 05, 2011			
020323 003	ESTRADIOL;VIVELLE	4814168	MAR 04, 2008		I-254	AUG 16, 2003
		4994267	MAR 04, 2008			
		4994278	MAR 04, 2008			
		5300291	APR 05, 2011			
020323 004	ESTRADIOL;VIVELLE	4814168	MAR 04, 2008		I-254	AUG 16, 2003
		4994267	MAR 04, 2008			
		4994278	MAR 04, 2008			
		5300291	APR 05, 2011			
020323 005	ESTRADIOL;VIVELLE	4994278	MAR 04, 2008		NS	AUG 16, 2003
		5300291	APR 05, 2011		I-254	AUG 16, 2003
		4814168	MAR 04, 2008			
		4994267	MAR 04, 2008			
020538 005	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014		I-254	AUG 16, 2003
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 006	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014		I-254	AUG 16, 2003
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 007	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014		I-254	AUG 16, 2003
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 008	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014		I-254	AUG 16, 2003
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020992 001	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015		I-359	JUN 21, 2005
020992 002	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015			
020992 003	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015			
020992 004	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015			
010971 005	ESTROGENS, CONJUGATED;PMB 200	5210081	FEB 26, 2012			
010971 003	ESTROGENS, CONJUGATED;PMB 400	5210081	FEB 26, 2012			
004782 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
004782 002	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
004782 003	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012		D-82	JUL 16, 2006
004782 004	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
004782 005	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
004782 006	ESTROGENS, CONJUGATED;PREMARIN				D-82	JUL 16, 2006

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
010402 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
020216 001	ESTROGENS, CONJUGATED;PREMARIN	5210081	FEB 26, 2012			
020303 002	ESTROGENS, CONJUGATED;PREMPHASE (PREMARIN;CYCRIN 14/14)	5210081	FEB 26, 2012			
020527 002	ESTROGENS, CONJUGATED;PREMPHASE 14/14	5547948	JAN 17, 2015			
		5210081	FEB 26, 2012			
		RE36247	MAY 02, 2006			
020527 001	ESTROGENS, CONJUGATED;PREMPRO	5547948	JAN 17, 2015		D-79	MAR 12, 2006
		RE36247	MAY 02, 2006	U284		
		5210081	FEB 26, 2012			
020527 003	ESTROGENS, CONJUGATED;PREMPRO	5547948	JAN 17, 2015		D-79	MAR 12, 2006
		RE36247	MAY 02, 2006	U284		
		5210081	FEB 26, 2012			
020527 004	ESTROGENS, CONJUGATED;PREMPRO	RE36247	MAY 02, 2006		NP	MAR 12, 2006
		5547948	JAN 17, 2015		D-79	MAR 12, 2006
		5210081	FEB 26, 2012		D-81	JUN 04, 2006
020527 005	ESTROGENS, CONJUGATED;PREMPRO	5210081	FEB 26, 2012		NS	JUN 04, 2006
		RE36247	MAY 02, 2006		D-81	JUN 04, 2006
		5547948	JAN 17, 2015			
020303 001	ESTROGENS, CONJUGATED;PREMPRO (PREMARIN;CYCRIN)	5210081	FEB 26, 2012			
		RE36247	MAY 02, 2006	U284		
020130 002	ETHINYL ESTRADIOL;ESTROSTEP FE	4962098	OCT 09, 2007	U112	I-331	JUL 01, 2004
		5010070	APR 23, 2008			
020130 001	ETHINYL ESTRADIOL;ESTROSTEP 21	4962098	OCT 09, 2007	U112	I-331	JUL 01, 2004
		5010070	APR 23, 2008			
021065 001	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U283		
021065 002	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U283		
021065 003	ETHINYL ESTRADIOL;FEMHRT	5208225	MAY 04, 2010	U283		
021187 001	ETHINYL ESTRADIOL;NUVARING	5989581	APR 08, 2018		NP	OCT 03, 2004
021180 001	ETHINYL ESTRADIOL;ORTHO EVRA	5876746	JUN 07, 2015	U514	NP	NOV 20, 2004
		5972377	JUN 07, 2015	U514		
019697 001	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U66		
		4616006	SEP 26, 2003	U66		
		4628051	SEP 26, 2003	U66		
		4530839	SEP 26, 2003	U112		
		4530839*PED	MAR 26, 2004			
		4544554*PED	MAR 26, 2004			
		4616006*PED	MAR 26, 2004			
		4628051*PED	MAR 26, 2004			
019697 002	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U66		
		4616006	SEP 26, 2003	U66		
		4628051	SEP 26, 2003	U66		
		4530839	SEP 26, 2003	U112		
021241 001	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN LO	4616006	SEP 26, 2003	U112	NP	AUG 22, 2005
		6214815	JUN 09, 2019	U112	PED	FEB 22, 2006
		4530839	SEP 26, 2003	U112		
		4544554	SEP 26, 2003	U112		
		4628051	SEP 26, 2003	U112		
		4530839*PED	MAR 26, 2004			
		4544554*PED	MAR 26, 2004			
		4616006*PED	MAR 26, 2004			
		4628051*PED	MAR 26, 2004			
		6214815*PED	DEC 09, 2019			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
018985 001	ETHINYL ESTRADIOL;ORTHO-NOVUM 7/7/7-21	4530839	SEP 26, 2003			
		4544554	SEP 26, 2003			
		4616006	SEP 26, 2003			
		4628051	SEP 26, 2003			
018985 002	ETHINYL ESTRADIOL;ORTHO-NOVUM 7/7/7-28	4530839	SEP 26, 2003			
		4544554	SEP 26, 2003			
		4616006	SEP 26, 2003			
		4628051	SEP 26, 2003			
021490 001	ETHINYL ESTRADIOL;OVCON-35				NDF	NOV 14, 2006
020946 001	ETHINYL ESTRADIOL;PREVEN EMERGENCY CONTRACEPTIVE KI	6156742	DEC 05, 2020	U374		
021544 001	ETHINYL ESTRADIOL;SEASONALE	5898032	JUN 23, 2017	U1	NP	SEP 05, 2006
020584 001	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008		I-321	AUG 11, 2003
		4966768	OCT 30, 2007		PED	FEB 11, 2004
020584 002	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008		I-321	AUG 11, 2003
		4966768	OCT 30, 2007		PED	FEB 11, 2004
020584 003	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008		I-321	AUG 11, 2003
		4966768	OCT 30, 2007		PED	FEB 11, 2004
020457 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATIVE FREE	5041424	AUG 20, 2008	U135		
		RE35524	MAY 17, 2010			
020906 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATIVE FREE	5041424	AUG 20, 2008	U135		
		RE35524	MAY 17, 2010			
020906 002	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATIVE FREE	5041424	AUG 20, 2008	U135		
		RE35524	MAY 17, 2010			
020753 001	EXEMESTANE;AROMASIN	4808616	JUL 07, 2006		NCE	OCT 21, 2004
		4904650	JUL 07, 2006		ODE	OCT 21, 2006
021445 001	EZETIMIBE;ZETIA	5846966	SEP 21, 2013	U474	NCE	OCT 25, 2007
		RE37721	JUN 16, 2015	U473		
020363 001	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U96		
020363 002	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U96		
020363 003	FAMCICLOVIR;FAMVIR	5246937	SEP 21, 2010	U96		
020325 001	FAMOTIDINE;PEPCID AC	5667794	MAY 02, 2015	U205		
		5854267	DEC 29, 2015	U267		
		5667794*PED	NOV 02, 2015	U205		
		5854267*PED	JUN 29, 2016	U267		
020325 002	FAMOTIDINE;PEPCID AC				NP	SEP 23, 2006
020801 001	FAMOTIDINE;PEPCID AC	5667794	MAY 02, 2015			
		5854267	DEC 29, 2015	U267		
		5075114	DEC 24, 2008			
		5075114*PED	JUN 24, 2009			
		5667794*PED	NOV 02, 2015			
		5854267*PED	JUN 29, 2016			
020902 001	FAMOTIDINE;PEPCID AC (GELTAB)	5854267	DEC 29, 2015	U368		
		5854267*PED	JUN 29, 2016	U368		
		5667794	MAY 02, 2015	U368		
		5667794*PED	NOV 02, 2015	U368		
		4820524	FEB 20, 2007			
		4820524*PED	AUG 20, 2007			
020189 001	FELBAMATE;FELBATOL	4978680	SEP 26, 2009	U83		
		5082861	SEP 26, 2009	U83		
020189 002	FELBAMATE;FELBATOL	4978680	SEP 26, 2009	U83		
		5082861	SEP 26, 2009	U83		
020189 003	FELBAMATE;FELBATOL	4978680	SEP 26, 2009	U83		
		5082861	SEP 26, 2009	U83		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019834 001	FELODIPINE;PLENDIL	4803081	APR 03, 2007			
		4803081*PED	OCT 03, 2007			
019834 002	FELODIPINE;PLENDIL	4803081	APR 03, 2007			
		4803081*PED	OCT 03, 2007			
019834 004	FELODIPINE;PLENDIL	4803081	APR 03, 2007			
		4803081*PED	OCT 03, 2007			
021203 001	FENOFIBRATE;TRICOR	4895726	JAN 19, 2009			
		6277405	JAN 09, 2018			
		6074670	JAN 09, 2018			
		6589552	JAN 09, 2018			
		6652881	JAN 09, 2018	DP		
021203 003	FENOFIBRATE;TRICOR	4895726	JAN 19, 2009			
		6277405	JAN 09, 2018			
		6074670	JAN 09, 2018			
		6589552	JAN 09, 2018			
		6652881	JAN 09, 2018	DP		
019304 002	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009			
019304 003	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009			
019304 004	FENOFIBRATE;TRICOR (MICRONIZED)	4895726	JAN 19, 2009			
020747 001	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U253		
		4863737	SEP 05, 2006			
		5785989	SEP 05, 2006			
020747 002	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U253		
		4863737	SEP 05, 2006			
		5785989	SEP 05, 2006			
020747 003	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U253		
		4863737	SEP 05, 2006			
		5785989	SEP 05, 2006			
020747 004	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U253		
		4863737	SEP 05, 2006			
		5785989	SEP 05, 2006			
020747 005	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U253		
		4863737	SEP 05, 2006			
		5785989	SEP 05, 2006			
020747 006	FENTANYL CITRATE;ACTIQ	4671953	MAY 01, 2005	U253		
		4863737	SEP 05, 2006			
		5785989	SEP 05, 2006			
020195 001	FENTANYL CITRATE;FENTANYL	4671953	MAY 01, 2005	U87		
020195 002	FENTANYL CITRATE;FENTANYL	4671953	MAY 01, 2005	U87		
020195 003	FENTANYL CITRATE;FENTANYL	4671953	MAY 01, 2005	U87		
020195 007	FENTANYL CITRATE;FENTANYL	4671953	MAY 01, 2005	U87		
019813 001	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U43	NPP	MAY 20, 2006
		4588580*PED	JAN 23, 2005	U43	PED	NOV 20, 2006
019813 002	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U43	NPP	MAY 20, 2006
		4588580*PED	JAN 23, 2005	U43	PED	NOV 20, 2006
019813 003	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U43	NPP	MAY 20, 2006
		4588580*PED	JAN 23, 2005	U43	PED	NOV 20, 2006
019813 004	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U43	NPP	MAY 20, 2006
		4588580*PED	JAN 23, 2005	U43	PED	NOV 20, 2006
021626 001	FERRIC HEXACYANOFERRATE(II);RADIOGARDASE (PRUSSIAN BLUE)				ODE	OCT 02, 2010
					NCE	OCT 02, 2008
020416 001	FERUMOXIDES;FERIDEX I.V.	4951675	AUG 28, 2007	U143		
		5102652	FEB 06, 2009			
		5248492	SEP 28, 2010			
		4770183	SEP 13, 2005	U145		
		4827945	MAY 09, 2006	U144		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020410 001	FERUMOXSIL;GASTROMARK	5055288	OCT 08, 2008			
		5219554	JUN 15, 2010			
		5069216	MAY 09, 2006	U171		
		5219554	JUN 15, 2010			
		4827945	MAY 09, 2006	U170		
		4951675	SEP 13, 2005	U169		
		5055288	OCT 08, 2008			
		4695392	SEP 22, 2004			
		4695393	SEP 22, 2004			
		4770183	SEP 13, 2005	U169		
020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U192	M-25	MAY 12, 2006
		5855912	FEB 28, 2015		PED	NOV 12, 2006
		5738872	FEB 28, 2015			
		5932247	FEB 28, 2015			
		6037353	MAR 14, 2017	U138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U138		
		6399632	MAY 11, 2012	U468		
		5578610*PED	MAY 26, 2014	U192		
		5738872*PED	AUG 28, 2015			
		5855912*PED	AUG 28, 2015			
		5932247*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U138		
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U138		
		6399632*PED	NOV 11, 2012	U468		
020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U139	PED	AUG 25, 2003
		5932247	FEB 28, 2015		M-25	MAY 12, 2006
		5855912	FEB 28, 2015		PED	NOV 12, 2006
		6037353	MAR 14, 2017	U138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U138		
		6399632	MAY 11, 2012	U468		
		5578610*PED	MAY 26, 2014	U139		
		5855912*PED	AUG 28, 2015			
		5932247*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U138		
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U138		
		6399632*PED	NOV 11, 2012	U468		
020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U139	PED	AUG 25, 2003
		5932247	FEB 28, 2015		M-25	MAY 12, 2006
		5855912	FEB 28, 2015		PED	NOV 12, 2006
		6037353	MAR 14, 2017	U138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U138		
		6399632	MAY 11, 2012	U468		
		5578610*PED	MAY 26, 2014	U139		
		5855912*PED	AUG 28, 2015			
		5932247*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U138		
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U138		
		6399632*PED	NOV 11, 2012	U468		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U139	PED	AUG 25, 2003
		5932247	FEB 28, 2015		M-25	MAY 12, 2006
		5855912	FEB 28, 2015		PED	NOV 12, 2006
		6037353	MAR 14, 2017	U138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U138		
		6399632	MAY 11, 2012	U468		
		5578610*PED	MAY 26, 2014	U139		
		5855912*PED	AUG 28, 2015			
		5932247*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U138		
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U138		
		6399632*PED	NOV 11, 2012	U468		
020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	5578610	NOV 26, 2013		M-25	MAY 12, 2006
		5855912	FEB 28, 2015		PED	NOV 12, 2006
		6037353	MAR 14, 2017	U138		
		6039974	JUL 31, 2018			
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U138		
		6399632	MAY 11, 2012	U468		
		5578610*PED	MAY 26, 2014			
		5855912*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U138		
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U138		
		6399632*PED	NOV 11, 2012	U468		
020788 001	FINASTERIDE;PROPECIA	4760071	JUN 19, 2006			
		5571817	NOV 05, 2013	U259		
		5547957	OCT 15, 2013	U236		
		5886184	NOV 19, 2012			
020180 001	FINASTERIDE;PROSCAR	4760071	JUN 19, 2006	U262		
		5886184	NOV 19, 2012			
		5942519	OCT 23, 2018	U280		
		6046183	MAR 20, 2011			
018830 001	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
018830 002	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
018830 003	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
018830 004	FLECAINIDE ACETATE;TAMBOCOR	4642384	FEB 10, 2004			
019949 001	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
019949 002	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
019949 003	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
019949 004	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
020090 001	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
020090 002	FLUCONAZOLE;DIFLUCAN	4404216	JAN 29, 2004			
019950 003	FLUCONAZOLE;DIFLUCAN IN DEXTROSE 5%	4404216	JAN 29, 2004			
019950 005	FLUCONAZOLE;DIFLUCAN IN DEXTROSE 5%	4404216	JAN 29, 2004			
019950 001	FLUCONAZOLE;DIFLUCAN IN SODIUM CHLORIDE 0.9%	4404216	JAN 29, 2004			
019950 002	FLUCONAZOLE;DIFLUCAN IN SODIUM CHLORIDE 0.9%	4404216	JAN 29, 2004			
019950 004	FLUCONAZOLE;DIFLUCAN IN SODIUM CHLORIDE 0.9%	4404216	JAN 29, 2004			
020038 001	FLUDARABINE PHOSPHATE;FLUDARA	4357324*PED	AUG 24, 2003			
020073 001	FLUMAZENIL;ROMAZICON	4316839	OCT 10, 2004			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
018340 001	FLUNISOLIDE;AEROBID	4933168	JUN 12, 2007			
018148 001	FLUNISOLIDE;NASALIDE	4933168	JUN 12, 2007			
020409 001	FLUNISOLIDE;NASAREL	4782047	MAY 22, 2006			
		4983595	MAY 22, 2006			
		4933168	JUN 12, 2007			
019452 001	FLUOCINOLONE ACETONIDE;DERMA-SMOOTHE/FS				I-340	OCT 10, 2004
021112 001	FLUOCINOLONE ACETONIDE;TRI-LUMA				NC	JAN 18, 2005
020985 001	FLUOROURACIL;CARAC	4690825	OCT 04, 2005		NP	OCT 27, 2003
018936 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U154	NPP	JAN 03, 2006
					PED	JUL 03, 2006
018936 003	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U154	NPP	JAN 03, 2006
					PED	JUL 03, 2006
018936 004	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U154	NPP	JAN 03, 2006
					PED	JUL 03, 2006
018936 006	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U154	NPP	JAN 03, 2006
					PED	JUL 03, 2006
020101 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U154	NPP	JAN 03, 2006
					PED	JUL 03, 2006
020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U154	NPP	JAN 03, 2006
					PED	JUL 03, 2006
020974 002	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U154	I-362	JUL 29, 2005
		4626549*PED	JUN 02, 2004	U154	NPP	JAN 03, 2006
					PED	JUL 03, 2006
021235 001	FLUOXETINE HYDROCHLORIDE;PROZAC WEEKLY				NDF	FEB 26, 2004
018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM	4971998	NOV 20, 2007	U338	NP	JUL 06, 2003
		4971998*PED	MAY 20, 2008	U338	PED	JAN 06, 2004
					D-75	JUN 12, 2005
018936 008	FLUOXETINE HYDROCHLORIDE;SARAFEM	4971998	NOV 20, 2007	U338	NP	JUL 06, 2003
		4971998*PED	MAY 20, 2008	U338	PED	JAN 06, 2004
					D-75	JUN 12, 2005
021520 002	FLUOXETINE HYDROCHLORIDE;SYMBYAX	5229382	APR 23, 2011	DS DP	NC	DEC 24, 2006
		5945416	MAR 24, 2017	DS DP		
021520 003	FLUOXETINE HYDROCHLORIDE;SYMBYAX	5229382	APR 23, 2011	DS DP	NC	DEC 24, 2006
		5945416	MAR 24, 2017	DS DP		
021520 004	FLUOXETINE HYDROCHLORIDE;SYMBYAX	5229382	APR 23, 2011	DS DP	NC	DEC 24, 2006
		5945416	MAR 24, 2017	DS DP		
021520 005	FLUOXETINE HYDROCHLORIDE;SYMBYAX	5229382	APR 23, 2011	DS DP	NC	DEC 24, 2006
		5945416	MAR 24, 2017	DS DP		
021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010	U387		
		4992474	FEB 12, 2008	U211		
		5225445	FEB 12, 2008	U211		
		5126375	FEB 12, 2008			
		5290815	MAR 01, 2011	U386		
		4335121*PED	MAY 14, 2004			
021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010	U387	I-410	NOV 17, 2006
		4992474	FEB 12, 2008	U211		
		5225445	FEB 12, 2008	U211		
		5126375	FEB 12, 2008			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
		5290815	MAR 01, 2011	U386		
		4335121*PED	MAY 14, 2004			
021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010	U387		
		4992474	FEB 12, 2008	U211		
		5225445	FEB 12, 2008	U211		
		5126375	FEB 12, 2008			
		5290815	MAR 01, 2011	U386		
		4335121*PED	MAY 14, 2004			
019957 001	FLUTICASONE PROPIONATE;CUTIVATE	4335121	NOV 14, 2003			
		4335121*PED	MAY 14, 2004			
019958 001	FLUTICASONE PROPIONATE;CUTIVATE	4335121	NOV 14, 2003			
		4335121*PED	MAY 14, 2004			
020121 001	FLUTICASONE PROPIONATE;FLONASE	4335121	NOV 14, 2003		D-76	MAY 23, 2005
		4335121*PED	MAY 14, 2004		PED	NOV 23, 2005
					M-24	MAY 01, 2006
					PED	NOV 01, 2006
020548 001	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
		4335121*PED	MAY 14, 2004			
020548 002	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
		4335121*PED	MAY 14, 2004			
020548 003	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
		4335121*PED	MAY 14, 2004			
020549 001	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U409		
		4335121*PED	MAY 14, 2004	U409		
020549 002	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U409		
		4335121*PED	MAY 14, 2004	U409		
020549 003	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U409		
		4335121*PED	MAY 14, 2004	U409		
020833 002	FLUTICASONE PROPIONATE;FLOVENT DISKUS 100	4335121	NOV 14, 2003	U409		
		4335121*PED	MAY 14, 2004	U409		
020833 003	FLUTICASONE PROPIONATE;FLOVENT DISKUS 250	4335121	NOV 14, 2003	U409		
		4335121*PED	MAY 14, 2004	U409		
020833 001	FLUTICASONE PROPIONATE;FLOVENT DISKUS 50	4335121	NOV 14, 2003	U409		
		4335121*PED	MAY 14, 2004	U409		
020261 001	FLUVASTATIN SODIUM;LESCOL	5354772	OCT 11, 2011	U109	I-394	MAY 27, 2006
		5356896	DEC 12, 2011			
		5354772	OCT 11, 2011	U413		
020261 002	FLUVASTATIN SODIUM;LESCOL	5354772	OCT 11, 2011	U109	I-394	MAY 27, 2006
		5356896	DEC 12, 2011			
		5354772	OCT 11, 2011	U413		
021192 001	FLUVASTATIN SODIUM;LESCOL XL	5354772	OCT 11, 2011	U413	NDF	OCT 06, 2003
		5356896	DEC 12, 2011		I-394	MAY 27, 2006
		6242003	APR 13, 2020			
		5354772	OCT 11, 2011	U109		
020582 001	FOLLITROPIN ALFA/BETA;FOLLISTIM	5270057	MAR 20, 2011		I-306	FEB 07, 2005
		4589402	JUL 26, 2004	U206		
		5767251	JUN 16, 2015			
020582 002	FOLLITROPIN ALFA/BETA;FOLLISTIM	5270057	MAR 20, 2011		I-306	FEB 07, 2005
		4589402	JUL 26, 2004	U206		
		5767251	JUN 16, 2015			
020378 001	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U242	ODE	MAY 24, 2007
		5767251	JUN 16, 2015			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020378 002	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U242	ODE	MAY 24, 2007
		5767251	JUN 16, 2015			
020378 003	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U242	ODE	MAY 24, 2007
		5767251	JUN 16, 2015			
020696 001	FOMEPIZOLE;ANTIZOL				ODE	DEC 04, 2004
					ODE	DEC 08, 2007
					I-319	DEC 08, 2003
020961 001	FOMIVIRSEN SODIUM;VITRAVENE PRESERVATIVE FREE	5442049	AUG 15, 2012		NCE	AUG 26, 2003
		5595978	AUG 15, 2012	U522		
		4689320	OCT 15, 2004	U522		
		5264423	NOV 23, 2010	U522		
		5276019	JAN 04, 2011	U522		
021345 001	FONDAPARINUX SODIUM;ARIXTRA	4818816	AUG 19, 2003		NCE	DEC 07, 2006
					I-397	JUN 17, 2006
020831 001	FORMOTEROL FUMARATE;FORADIL	6488027	MAR 08, 2019		NCE	FEB 16, 2006
					I-342	SEP 25, 2004
					NPP	JUN 27, 2006
021279 001	FORMOTEROL FUMARATE;FORADIL				I-342	SEP 25, 2004
					NCE	FEB 16, 2006
021548 001	FOSAMPRENAVIR CALCIUM;LEXIVA	6436989	DEC 24, 2017	U257	NE	OCT 20, 2006
		6514953	JUL 15, 2019	U257		
076139 001	FOSINOPRIL SODIUM;FOSINOPRIL SODIUM				PC	APR 23, 2004
076139 002	FOSINOPRIL SODIUM;FOSINOPRIL SODIUM				PC	APR 23, 2004
076139 003	FOSINOPRIL SODIUM;FOSINOPRIL SODIUM				PC	APR 23, 2004
019915 002	FOSINOPRIL SODIUM;MONOPRIL	5006344	JUL 10, 2009		NPP	MAY 27, 2006
		5006344*PED	JAN 10, 2010		PED	NOV 27, 2006
019915 003	FOSINOPRIL SODIUM;MONOPRIL	5006344	JUL 10, 2009		NPP	MAY 27, 2006
		5006344*PED	JAN 10, 2010		PED	NOV 27, 2006
019915 004	FOSINOPRIL SODIUM;MONOPRIL	5006344	JUL 10, 2009		NPP	MAY 27, 2006
		5006344*PED	JAN 10, 2010		PED	NOV 27, 2006
020286 001	FOSINOPRIL SODIUM;MONOPRIL-HCT	5006344	JUL 10, 2009			
		5006344*PED	JAN 10, 2010			
020286 002	FOSINOPRIL SODIUM;MONOPRIL-HCT	5006344	JUL 10, 2009			
		5006344*PED	JAN 10, 2010			
020450 001	FOSPHENYTOIN SODIUM;CEREBYX	4925860	AUG 05, 2007		ODE	AUG 05, 2003
021006 001	FROVATRIPTAN SUCCINATE;FROVA	5464864	NOV 07, 2012	U436	NCE	NOV 08, 2006
		5616603	APR 01, 2014	U436		
		5637611	JUN 10, 2014	U436		
		5827871	OCT 27, 2015	U436		
		5962501	DEC 16, 2013	U436		
021344 001	FULVESTRANT;FASLODEX	4659516	OCT 01, 2004		NCE	APR 25, 2007
020235 001	GABAPENTIN;NEURONTIN	4894476*PED	NOV 02, 2008		I-311	OCT 12, 2003
		4894476	MAY 02, 2008		PED	APR 12, 2004
		6054482	APR 25, 2017		I-354	MAY 24, 2005
		6054482*PED	OCT 25, 2017			
020235 002	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		I-311	OCT 12, 2003
		4894476*PED	NOV 02, 2008		PED	APR 12, 2004
		6054482	APR 25, 2017		I-354	MAY 24, 2005
		6054482*PED	OCT 25, 2017			
020235 003	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		I-311	OCT 12, 2003
		4894476*PED	NOV 02, 2008		PED	APR 12, 2004
		6054482	APR 25, 2017		I-354	MAY 24, 2005
		6054482*PED	OCT 25, 2017			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020882 001	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		I-311	OCT 12, 2003
		4894476*PED	NOV 02, 2008		PED	APR 12, 2004
		6054482	APR 25, 2017		I-354	MAY 24, 2005
		6054482*PED	OCT 25, 2017			
020882 002	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		I-311	OCT 12, 2003
		4894476*PED	NOV 02, 2008		PED	APR 12, 2004
		6054482	APR 25, 2017		I-354	MAY 24, 2005
		6054482*PED	OCT 25, 2017			
021129 001	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		I-311	OCT 12, 2003
		4894476*PED	NOV 02, 2008		PED	APR 12, 2004
		6054482	APR 25, 2017		I-354	MAY 24, 2005
		6054482*PED	OCT 25, 2017			
020123 001	GADODIAMIDE;OMNISCAN	4687659	MAY 04, 2007	U76		
019596 001	GADOPENTETATE DIMEGLUMINE;MAGNEVIST	4647447	MAR 03, 2004			
		4963344	MAR 03, 2004			
		4957939	MAR 03, 2004			
		5362475	NOV 08, 2011			
		5560903	OCT 01, 2013			
021037 001	GADOPENTETATE DIMEGLUMINE;MAGNEVIST	5362475	NOV 08, 2011			
		5560903	OCT 01, 2013			
		4647447	MAR 03, 2004			
		4957939	MAR 03, 2004			
		4963344	MAR 03, 2004			
020131 001	GADOTERIDOL;PROHANCE	4885363	DEC 05, 2006			
		5474756	DEC 12, 2012	U480		
		5846519	DEC 08, 2015			
		6143274	DEC 12, 2012	U480		
021489 001	GADOTERIDOL;PROHANCE MULTIPACK	5474756	DEC 12, 2012	U536		
		6143274	DEC 12, 2012	U536		
		4885363	DEC 05, 2006			
		5846519	DEC 08, 2015			
020937 001	GADOVERSETAMIDE;OPTIMARK	5130120	JUL 14, 2009		NCE	DEC 08, 2004
		5137711	JUL 14, 2009			
020975 001	GADOVERSETAMIDE;OPTIMARK	5130120	JUL 14, 2009		NCE	DEC 08, 2004
		5137711	JUL 14, 2009			
020976 001	GADOVERSETAMIDE;OPTIMARK	5130120	JUL 14, 2009		NCE	DEC 08, 2004
		5137711	JUL 14, 2009			
021169 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
		6099863	JUN 06, 2017			
021169 002	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
		6099863	JUN 06, 2017			
021169 003	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
		6099863	JUN 06, 2017			
021224 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
019961 002	GALLIUM NITRATE;GANITE	4529593	JAN 17, 2005	U49		
020460 001	GANCICLOVIR;CYTOVENE	4642346	JUN 24, 2005			
020460 002	GANCICLOVIR;CYTOVENE	4642346	JUN 24, 2005			
076457 001	GANCICLOVIR;GANCICLOVIR				PC	FEB 16, 2004
076457 002	GANCICLOVIR;GANCICLOVIR				PC	FEB 16, 2004
020569 001	GANCICLOVIR;VITRASERT	5378475	JAN 03, 2012			
021057 001	GANIRELIX ACETATE;ANTAGON	4801577	FEB 05, 2007		NCE	JUL 29, 2004
		5767082	JUN 16, 2015			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021061 001	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
		5880283	DEC 05, 2015		D-69	OCT 12, 2004
					I-329	OCT 17, 2005
021061 002	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
		5880283	DEC 05, 2015		D-69	OCT 12, 2004
					I-329	OCT 17, 2005
021062 001	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
		5880283	DEC 05, 2015		D-69	OCT 12, 2004
					I-329	OCT 17, 2005
021062 002	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
		5880283	DEC 05, 2015		D-69	OCT 12, 2004
					I-329	OCT 17, 2005
021062 003	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
		5880283	DEC 05, 2015		D-69	OCT 12, 2004
					I-329	OCT 17, 2005
021062 004	GATIFLOXACIN;TEQUIN	4980470	DEC 25, 2007		NCE	DEC 17, 2004
		5880283	DEC 05, 2015		D-69	OCT 12, 2004
					I-329	OCT 17, 2005
021493 001	GATIFLOXACIN;ZYMAR	5880283	DEC 05, 2015		NDF	MAR 28, 2006
		4980470	DEC 15, 2009		NCE	DEC 17, 2004
021399 001	GEFITINIB;IRESSA	5457105	JAN 19, 2013		NCE	MAY 05, 2008
		5616582	JAN 19, 2013			
		5770599	APR 26, 2016			
020509 001	GEMCITABINE HYDROCHLORIDE;GEMZAR	4808614	MAY 15, 2010			
		5464826	NOV 07, 2012	U146		
020509 002	GEMCITABINE HYDROCHLORIDE;GEMZAR	5464826	NOV 07, 2012	U146		
		4808614	MAY 15, 2010			
021158 001	GEMIFLOXACIN MESYLATE;FACTIVE	6262071	SEP 21, 2019	U513	NCE	APR 04, 2008
		6331550	SEP 21, 2019	U511		
		6340689	SEP 14, 2019	U512		
		6455540	SEP 21, 2019	U511		
		5633262	JUN 15, 2015			
		5776944	JUN 15, 2015			
		5962468	JUN 15, 2015	U282		
021174 001	GEMTUZUMAB OZOGAMICIN;MYLOTARG	5606040	FEB 25, 2014		ODE	MAY 17, 2007
		5693762	DEC 02, 2014		NCE	MAY 17, 2005
		5739116	APR 14, 2015			
		5767285	JUN 16, 2015			
		5773001	JUN 30, 2015	U320		
		4970198	NOV 30, 2007			
		5079233	JAN 07, 2009			
		5585089	DEC 17, 2013			
020622 001	GLATIRAMER ACETATE;COPAXONE	5981589	MAY 24, 2014		ODE	DEC 20, 2003
		6054430	MAY 24, 2014			
		6342476	MAY 24, 2014	U441		
		6362161	MAY 24, 2014	U441		
		6620847	MAY 24, 2014	DS		
020622 002	GLATIRAMER ACETATE;COPAXONE	5981589	MAY 24, 2014		ODE	DEC 20, 2003
		6054430	MAY 24, 2014			
		6342476	MAY 24, 2014	U441		
		6362161	MAY 24, 2014	U441		
		6620847	MAY 24, 2014	DS		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020496 001	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U118		
020496 002	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U118		
020496 003	GLIMEPIRIDE;AMARYL	4379785	APR 06, 2005	U118		
076467 001	GLIPIZIDE;GLIPIZIDE				PC	OCT 19, 2003
020329 001	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U150		
		5024843	SEP 05, 2009			
		5091190	SEP 05, 2009	U111		
		4612008	SEP 16, 2003			
		5082668	SEP 16, 2003			
		5545413	JUL 21, 2008	U111		
020329 002	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U150		
		5082668	SEP 16, 2003			
		5091190	SEP 05, 2009	U111		
		5545413	JUL 21, 2008	U111		
		5024843	SEP 05, 2009			
		4612008	SEP 16, 2003			
020329 003	GLIPIZIDE;GLUCOTROL XL	4612008	SEP 16, 2003			
		5024843	SEP 05, 2009			
		5082668	SEP 16, 2003			
		5091190	SEP 05, 2009	U111		
		5545413	JUL 21, 2008	U111		
		5591454	JAN 07, 2014	U111		
021460 001	GLIPIZIDE;METAGLIP				NC	OCT 21, 2005
021460 002	GLIPIZIDE;METAGLIP				NC	OCT 21, 2005
021460 003	GLIPIZIDE;METAGLIP				NC	OCT 21, 2005
021178 001	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U412	NC	JUL 31, 2003
		6303146*PED	JAN 14, 2020	U412	I-368	SEP 30, 2005
					PED	JAN 31, 2004
					PED	MAR 30, 2006
021178 002	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U412	NC	JUL 31, 2003
		6303146*PED	JAN 14, 2020	U412	I-368	SEP 30, 2005
					PED	JAN 31, 2004
					PED	MAR 30, 2006
021178 003	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U412	NC	JUL 31, 2003
		6303146*PED	JAN 14, 2020	U412	I-368	SEP 30, 2005
					PED	JAN 31, 2004
					PED	MAR 30, 2006
020051 001	GLYBURIDE;GLYNASE	4916163	APR 10, 2007			
		4735805	APR 05, 2005			
020051 002	GLYBURIDE;GLYNASE	4735805	APR 05, 2005			
		4916163	APR 10, 2007			
020051 003	GLYBURIDE;GLYNASE	4735805	APR 05, 2005			
		4916163	APR 10, 2007			
020051 004	GLYBURIDE;GLYNASE	4916163	APR 10, 2007			
		4735805	APR 05, 2005			
019726 001	GOSERELIN ACETATE;ZOLADEX	5366734	NOV 22, 2011			
		4767628	AUG 30, 2005			
020578 001	GOSERELIN ACETATE;ZOLADEX	4767628	AUG 30, 2005			
		5366734	NOV 22, 2011			
020239 001	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U89	I-369	AUG 16, 2005
		6294548	MAY 04, 2019			
		5952340	SEP 14, 2016	U519		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020239 002	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U89	I-369	AUG 16, 2005
		6294548	MAY 04, 2019			
		5952340	SEP 14, 2016	U519		
020305 001	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U105		
020305 002	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 20, 2007	U105		
021238 001	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U105		
020695 001	GREPAFLOXACIN HYDROCHLORIDE;RAXAR	5563138	OCT 08, 2013			
021282 001	GUAIFENESIN;MUCINEX	6372252	APR 28, 2020	U489		
021282 002	GUAIFENESIN;MUCINEX	6372252	APR 28, 2020	U489		
019967 001	HALOBETASOL PROPIONATE;ULTRAVATE	4619921	DEC 16, 2004			
019968 001	HALOBETASOL PROPIONATE;ULTRAVATE	4619921	DEC 16, 2004			
020125 001	HYDROCHLOROTHIAZIDE;ACCURETIC	4743450	FEB 24, 2007			
		4743450*PED	AUG 24, 2007			
020125 002	HYDROCHLOROTHIAZIDE;ACCURETIC	4743450	FEB 24, 2007			
		4743450*PED	AUG 24, 2007			
020125 003	HYDROCHLOROTHIAZIDE;ACCURETIC	4743450	FEB 24, 2007			
		4743450*PED	AUG 24, 2007			
020758 001	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011			
		5994348	JUN 07, 2015			
020758 002	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011			
		5994348	JUN 07, 2015			
020758 003	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011			
		5994348	JUN 07, 2015			
021532 002	HYDROCHLOROTHIAZIDE;BENICAR HCT	5616599	APR 01, 2014	U500	NC	JUN 05, 2006
					NCE	APR 25, 2007
021532 003	HYDROCHLOROTHIAZIDE;BENICAR HCT	5616599	APR 01, 2014	U500	NC	JUN 05, 2006
					NCE	APR 25, 2007
021532 005	HYDROCHLOROTHIAZIDE;BENICAR HCT	5616599	APR 01, 2014	U500	NC	JUN 05, 2006
					NCE	APR 25, 2007
020818 001	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U3		
		6294197	JUN 18, 2017	U3		
020818 002	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U3		
		6294197	JUN 18, 2017	U3		
020818 003	HYDROCHLOROTHIAZIDE;DIOVAN HCT	5399578	MAR 21, 2012	U3		
		6294197	JUN 18, 2017	U3		
020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	5153197	OCT 06, 2009	U538	I-415	SEP 30, 2006
		5138069	AUG 11, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010			
		5153197*PED	APR 06, 2010	U538		
		5608075*PED	SEP 04, 2014			
		5153197	OCT 06, 2009	U3		
		5153197*PED	APR 06, 2010	U3		
020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5138069	AUG 11, 2009		I-415	SEP 30, 2006
		5153197	OCT 06, 2009	U538		
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010			
		5153197*PED	APR 06, 2010	U538		
		5608075*PED	SEP 04, 2014			
		5153197	OCT 06, 2009	U3		
		5153197*PED	APR 06, 2010	U3		
021162 001	HYDROCHLOROTHIAZIDE;MICARDIS HCT	5591762	JAN 07, 2014	U3	NC	NOV 17, 2003
		6358986	JAN 10, 2020			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021162 002	HYDROCHLOROTHIAZIDE;MICARDIS HCT	5591762	JAN 07, 2014	U3	NC	NOV 17, 2003
		6358986	JAN 10, 2020			
020729 001	HYDROCHLOROTHIAZIDE;UNIRETIC	4743450	FEB 24, 2007			
020729 002	HYDROCHLOROTHIAZIDE;UNIRETIC	4743450	FEB 24, 2007			
020729 003	HYDROCHLOROTHIAZIDE;UNIRETIC	4743450	FEB 24, 2007			
020716 001	HYDROCODONE BITARTRATE;VICOPROFEN	4587252	DEC 18, 2004	U55		
		6348216	JUN 10, 2017			
		6599531	JUN 10, 2017			
020769 001	HYDROCORTISONE BUTYRATE;LOCOID LIPOCREAM	5635497	JUN 03, 2014			
020453 001	HYDROCORTISONE PROBUTATE;PANDEL	4794106	AUG 28, 2006			
016295 002	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
016295 003	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
016295 004	HYDROXYUREA;DROXIA				ODE	FEB 25, 2005
021455 001	IBANDRONATE SODIUM;BONIVA	4927814	JUL 09, 2007	U520	NCE	MAY 16, 2008
		6143326	APR 21, 2017	U520		
		6294196	OCT 07, 2019			
019771 001	IBUPROFEN;ADVIL COLD AND SINUS	4552899	APR 09, 2004			
		4552899*PED	OCT 09, 2004			
021374 001	IBUPROFEN;ADVIL COLD AND SINUS	5071643	DEC 10, 2008			
		5071643*PED	JUN 10, 2009			
		5360615	DEC 10, 2008			
		5360615*PED	JUN 10, 2009			
019833 002	IBUPROFEN;CHILDREN'S ADVIL	4788220	NOV 29, 2005			
		4788220*PED	MAY 29, 2006			
020589 001	IBUPROFEN;CHILDREN'S ADVIL	4788220	JUL 08, 2007			
		4788220*PED	JAN 08, 2008			
021373 001	IBUPROFEN;CHILDREN'S ADVIL COLD				NP	AUG 01, 2003
					PED	FEB 01, 2004
020516 001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011			
		5374659*PED	JUN 20, 2012			
020601 001	IBUPROFEN;CHILDREN'S MOTRIN	5215755	JUN 01, 2010			
		5215755*PED	DEC 01, 2010			
020603 001	IBUPROFEN;CHILDREN'S MOTRIN	5374659	DEC 20, 2011			
		5374659*PED	JUN 20, 2012			
021128 001	IBUPROFEN;CHILDREN'S MOTRIN COLD	6211246	JUN 10, 2019		NP	AUG 01, 2003
021472 001	IBUPROFEN;IBUPROFEN	6251426	JUN 25, 2018			
020601 003	IBUPROFEN;JUNIOR STRENGTH MOTRIN	5215755	JUN 01, 2010			
		5215755*PED	DEC 01, 2010			
019842 001	IBUPROFEN;MOTRIN	5374659	DEC 20, 2011			
		5374659*PED	JUN 20, 2012			
020135 001	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
		5320855	JUN 14, 2011			
		5215755*PED	DEC 01, 2010			
		5320855*PED	DEC 14, 2011			
020135 002	IBUPROFEN;MOTRIN	5215755	JUN 01, 2010			
		5320855	JUN 14, 2011			
		5215755*PED	DEC 01, 2010			
		5320855*PED	DEC 14, 2011			
020491 001	IBUTILIDE FUMARATE;CORVERT	5155268	DEC 28, 2009			
021321 001	ICODEXTRIN;EXTRANEAL	6248726	JUN 19, 2018	U495	ODE	DEC 20, 2009
		4761237	AUG 02, 2005	U495		
		4886789	DEC 12, 2006	U495		
		6077836	JUN 20, 2017	U495		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019763 001	IFOSFAMIDE;IFEX	4882452	MAR 03, 2008			
019763 002	IFOSFAMIDE;IFEX	4882452	MAR 03, 2008			
019763 003	IFOSFAMIDE;IFEX/MESNEX KIT	4882452	MAR 03, 2008			
019763 004	IFOSFAMIDE;IFEX/MESNEX KIT	4882452	MAR 03, 2008			
021335 001	IMATINIB MESYLATE;GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
					ODE	MAY 10, 2008
					ODE	FEB 01, 2009
					I-376	DEC 20, 2005
					I-392	MAY 20, 2006
021335 002	IMATINIB MESYLATE;GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
					ODE	MAY 10, 2008
					ODE	FEB 01, 2009
					I-376	DEC 20, 2005
					I-392	MAY 20, 2006
021588 001	IMATINIB MESYLATE;GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
					I-376	DEC 20, 2005
					ODE	FEB 01, 2009
					ODE	MAY 10, 2008
					I-392	MAY 20, 2006
021588 002	IMATINIB MESYLATE;GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
					I-376	DEC 20, 2005
					ODE	FEB 01, 2009
					ODE	MAY 10, 2008
					I-392	MAY 20, 2006
020367 001	IMIGLUCERASE;CEREZYME	5549892	AUG 27, 2013	U252		
020367 002	IMIGLUCERASE;CEREZYME	5549982	AUG 27, 2013	U252		
020723 001	IMIQUIMOD;ALDARA	4689338	AUG 25, 2009	U172		
		5238944	AUG 24, 2010			
020685 001	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U132		
		6645961	MAR 04, 2018	DP		
020685 003	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U132		
		6645961	MAR 04, 2018	DP		
020685 005	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U132		
		6645961	MAR 04, 2018	DP		
020685 006	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U132		
		6645961	MAR 04, 2018	DP		
020986 001	INSULIN ASPART;NOVOLOG	5618913	APR 08, 2014		NCE	JUN 07, 2005
		5866538	JUN 20, 2017		NR	DEC 21, 2004
021172 001	INSULIN ASPART;NOVOLOG MIX 70/30	5547930	SEP 28, 2013		NC	NOV 01, 2004
		5834422	SEP 28, 2013	U471		
		5948751	JUN 19, 2017			
		5840680	SEP 28, 2013	U471		
		5618913	APR 08, 2014			
021081 001	INSULIN GLARGINE;LANTUS	5656722	SEP 12, 2014		PED	OCT 20, 2005
		5656722*PED	MAR 12, 2015		NCE	APR 20, 2005
					D-80	MAY 01, 2006
020563 001	INSULIN LISPRO;HUMALOG	5474978	JUN 16, 2014	U534		
		5514646	MAY 07, 2013	U534		
021018 001	INSULIN LISPRO;HUMALOG MIX 50/50	5461031	JUN 26, 2014			
		5474978	JUN 16, 2014			
		5514646	MAY 07, 2013			
		5747642	JUN 16, 2014			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021017 001	INSULIN LISPRO;HUMALOG MIX 75/25	5474978	JUN 16, 2014			
		5747642	JUN 16, 2014			
		5461031	JUN 16, 2014			
		5514646	MAY 07, 2013			
020563 002	INSULIN LISPRO;HUMALOG PEN	5474978	JUN 16, 2014	U534		
		5514646	MAY 07, 2013	U534		
020351 001	IODIXANOL;VISIPAQUE 270	5349085	SEP 20, 2011			
020808 001	IODIXANOL;VISIPAQUE 270	5349085	SEP 20, 2011			
020351 002	IODIXANOL;VISIPAQUE 320	5349085	SEP 20, 2011			
020808 002	IODIXANOL;VISIPAQUE 320	5349085	SEP 20, 2011			
021425 001	IOPROMIDE;ULTRAVIST (PHARMACY BULK)	4364921	MAR 06, 2005	U498		
021425 002	IOPROMIDE;ULTRAVIST (PHARMACY BULK)	4364921	MAR 06, 2005	U498		
020220 004	IOPROMIDE;ULTRAVIST 150	4364921	MAR 06, 2005	U113		
020220 003	IOPROMIDE;ULTRAVIST 240	4364921	MAR 06, 2005	U113		
020220 002	IOPROMIDE;ULTRAVIST 300	4364921	MAR 06, 2005	U113		
020220 001	IOPROMIDE;ULTRAVIST 370	4364921	MAR 06, 2005	U113		
020316 001	IOXILAN;OXILAN-300	4954348	DEC 21, 2009			
020316 002	IOXILAN;OXILAN-350	4954348	DEC 21, 2009			
020394 001	IPRATROPIUM BROMIDE;ATROVENT				I-327	OCT 27, 2003
020757 001	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011		I-373	SEP 17, 2005
		6342247	JUN 07, 2015			
020757 002	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011		I-373	SEP 17, 2005
		6342247	JUN 07, 2015			
020757 003	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011		I-373	SEP 17, 2005
		6342247	JUN 07, 2015			
020571 001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR	4604463	AUG 20, 2007			
		6403569	APR 28, 2020	U449		
040024 001	IRON DEXTRAN;DEXFERRUM	5624668	SEP 29, 2015			
021135 001	IRON SUCROSE;VENOFER				NP	NOV 07, 2003
018662 002	ISOTRETINOIN;ACCUTANE				M-12	MAY 02, 2005
					PED	NOV 02, 2005
018662 003	ISOTRETINOIN;ACCUTANE				M-12	MAY 02, 2005
					PED	NOV 02, 2005
018662 004	ISOTRETINOIN;ACCUTANE				M-12	MAY 02, 2005
					PED	NOV 02, 2005
019546 001	ISRADIPINE;DYNACIRC	4466972	AUG 21, 2003	U3		
019546 002	ISRADIPINE;DYNACIRC	4466972	AUG 21, 2003	U3		
020336 001	ISRADIPINE;DYNACIRC CR	4816263	OCT 02, 2007	U3		
		4466972	AUG 21, 2003	U3		
		4783337	SEP 16, 2003	U3		
		4946687	AUG 07, 2007			
		5030456	JUL 09, 2008			
		4950486	AUG 21, 2007			
020336 002	ISRADIPINE;DYNACIRC CR	4816263	OCT 02, 2007	U3		
		4783337	SEP 16, 2003	U3		
		4946687	AUG 07, 2007			
		4466972	AUG 21, 2003	U3		
		4950486	AUG 21, 2007			
		5030456	JUL 09, 2008			
020083 001	ITRACONAZOLE;SPORANOX	5633015	MAY 27, 2014			
020657 001	ITRACONAZOLE;SPORANOX	5707975	JAN 13, 2015		I-332	MAY 09, 2004
		4727064	FEB 23, 2005			
		6407079	JUN 18, 2019			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020966 001	ITRACONAZOLE;SPORANOX	4727064	FEB 23, 2005		I-332	MAY 09, 2004
		6407079	JUN 18, 2019			
020310 001	KETOCONAZOLE;NIZORAL A-D	5456851	APR 07, 2014			
019700 001	KETOROLAC TROMETHAMINE;ACULAR	5110493	MAY 05, 2009	U75	M-16	FEB 08, 2005
		5110493*PED	NOV 05, 2009	U75		
021528 001	KETOROLAC TROMETHAMINE;ACULAR LS	5110493	MAY 05, 2009		NP	MAY 30, 2006
		5110493*PED	NOV 05, 2009			
020811 001	KETOROLAC TROMETHAMINE;ACULAR PRESERVATIVE FREE				M-16	FEB 08, 2005
021066 001	KETOTIFEN FUMARATE;ZADITOR				NCE	JUL 02, 2004
020857 001	LAMIVUDINE;COMBIVIR	4837208	SEP 17, 2005			
		5047407*PED	MAY 17, 2010			
		5905082*PED	NOV 18, 2016	U248		
		6113920	OCT 23, 2017	U257		
		4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4833130	SEP 17, 2005			
		5047407	NOV 17, 2009			
		5859021	MAY 15, 2012	U248		
		5905082	MAY 18, 2016	U248		
		6180639	JAN 30, 2018	U248		
		6180639*PED	JUL 30, 2018	U248		
020564 001	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009		D-2	JUN 24, 2005
		5905082	MAY 18, 2016			
		5905082*PED	NOV 18, 2016			
		5047407*PED	MAY 17, 2010			
		6180639	JAN 30, 2018	U248		
		6180639*PED	JUL 30, 2018	U248		
020564 003	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009		NS	JUN 24, 2005
		5047407*PED	MAY 17, 2010		D-2	JUN 24, 2005
		5905082	MAY 18, 2016			
		5905082*PED	NOV 18, 2016			
		6180639	JAN 30, 2018	U248		
		6180639*PED	JUL 30, 2018	U248		
020596 001	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009		D-2	JUN 24, 2005
		6004968	MAR 20, 2018			
		6004968*PED	SEP 20, 2018			
		5047407*PED	MAY 17, 2010			
		6180639	JAN 30, 2018	U248		
		6180639*PED	JUL 30, 2018	U248		
021003 001	LAMIVUDINE;EPIVIR-HBV	5047407	NOV 17, 2009		I-339	AUG 16, 2004
		5532246	JUL 02, 2013	U250	PED	FEB 16, 2005
		5905082	MAY 18, 2016			
		5047407*PED	MAY 17, 2010			
		5532246*PED	JAN 02, 2014	U250		
		5905082*PED	NOV 18, 2016			
021004 001	LAMIVUDINE;EPIVIR-HBV	5047407	NOV 17, 2009		PED	FEB 16, 2005
		5532246	JUL 02, 2013	U250	I-339	AUG 16, 2004
		6004968	MAR 20, 2018			
		5047407*PED	MAY 17, 2010			
		5532246*PED	JAN 02, 2014	U250		
		6004968*PED	SEP 20, 2018			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020241 001	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U106	ODE	AUG 24, 2005
					I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020241 002	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U106	ODE	AUG 24, 2005
					I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020241 003	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U106	ODE	AUG 24, 2005
					I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020241 004	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U106	ODE	AUG 24, 2005
					I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020241 005	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U106	ODE	AUG 24, 2005
					I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020241 006	LAMOTRIGINE;LAMICTAL	4602017	JUL 22, 2008	U106	ODE	AUG 24, 2005
					I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020764 001	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
		4602017	JUL 22, 2008	U106	I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020764 002	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
		4602017	JUL 22, 2008	U106	I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020764 003	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		ODE	AUG 24, 2005
		4602017	JUL 22, 2008	U106	I-387	JAN 17, 2006
					I-404	JUN 20, 2006
020764 004	LAMOTRIGINE;LAMICTAL CD	5698226	JAN 29, 2012		I-387	JAN 17, 2006
		4602017	JUL 22, 2008	U106	I-404	JUN 10, 2006
					ODE	AUG 24, 2005
020406 001	LANSOPRAZOLE;PREVACID	5093132	SEP 03, 2008		I-316	NOV 30, 2003
		5045321	SEP 03, 2008		M-12	JUL 31, 2005
		4689333	JUL 29, 2005	U126		
		5026560	JUN 25, 2008			
		4628098	MAY 10, 2009			
		5433959	SEP 03, 2008			
		5013743	FEB 12, 2010	U452		
020406 002	LANSOPRAZOLE;PREVACID	4689333	JUL 29, 2005	U126	I-316	NOV 30, 2003
		5026560	JUN 25, 2008		M-12	JUL 31, 2005
		5045321	SEP 03, 2008			
		5093132	SEP 03, 2008			
		4628098	MAY 10, 2009			
		5433959	SEP 03, 2008			
		5013743	FEB 12, 2010	U452		
021281 001	LANSOPRAZOLE;PREVACID	4628098	MAY 10, 2009		I-316	NOV 30, 2003
		4689333	JUL 29, 2005	U126		
		5013743	FEB 12, 2010	U452		
		5026560	JUN 25, 2008			
		5045321	SEP 03, 2008			
		5093132	SEP 03, 2008			
		5433959	SEP 03, 2008			
021281 002	LANSOPRAZOLE;PREVACID	4628098	MAY 10, 2009		I-316	NOV 30, 2003
		4689333	JUL 29, 2005	U126		
		5013743	FEB 12, 2010	U452		
		5026560	JUN 25, 2008			
		5045321	SEP 03, 2008			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
		5093132	SEP 03, 2008			
		5433959	SEP 03, 2008			
021428 001	LANSOPRAZOLE;PREVACID	4628098	MAY 10, 2009			
		4689333	JUL 29, 2005	U126		
		5013743	FEB 12, 2010	U452		
		5026560	JUN 25, 2008			
		5045321	SEP 03, 2008			
		5093132	SEP 03, 2008			
		5433959	SEP 03, 2008			
		5464632	NOV 07, 2012			
		6123962	FEB 13, 2007			
		6328994	MAY 17, 2009			
021428 002	LANSOPRAZOLE;PREVACID	4628098	MAY 10, 2009			
		4689333	JUL 29, 2005	U126		
		5013743	FEB 12, 2010	U452		
		5026560	JUN 25, 2008			
		5045321	SEP 03, 2008			
		5093132	SEP 03, 2008			
		5433959	SEP 03, 2008			
		5464632	NOV 07, 2012			
		6123962	FEB 13, 2007			
		6328994	MAY 17, 2009			
020597 001	LATANOPROST;XALATAN	5296504	MAR 22, 2011	U260	I-375	DEC 20, 2005
		5422368	MAR 22, 2011	U260		
		4599353	JUL 28, 2006	U260		
		6429226	SEP 06, 2009	U260		
020905 001	LEFLUNOMIDE;ARAVA				NCE	SEP 10, 2003
					I-395	JUN 13, 2006
					PED	MAR 10, 2004
					PED	DEC 13, 2006
020905 002	LEFLUNOMIDE;ARAVA				NCE	SEP 10, 2003
					I-395	JUN 13, 2006
					PED	MAR 10, 2004
					PED	DEC 13, 2006
020905 003	LEFLUNOMIDE;ARAVA				NCE	SEP 10, 2003
					I-395	JUN 13, 2006
					PED	MAR 10, 2004
					PED	DEC 13, 2006
020807 001	LEPIRUDIN;REFLUDAN	5180668	JAN 19, 2010		ODE	MAR 06, 2005
020726 001	LETROZOLE;FEMARA	4978672	JUN 03, 2011	U203	I-318	JAN 10, 2004
021343 001	LEUPROLIDE ACETATE;ELIGARD	5599552	FEB 04, 2014		NP	JAN 23, 2005
		5733950	OCT 03, 2008			
		5739176	OCT 03, 2008			
		4938763	OCT 03, 2008			
		5278201	JAN 11, 2011			
		5324519	OCT 20, 2011			
021379 001	LEUPROLIDE ACETATE;ELIGARD	5599552	FEB 04, 2014		NP	JUL 24, 2005
		5733950	OCT 03, 2008			
		5739176	OCT 03, 2008			
		4938763	OCT 03, 2008			
		5278201	JAN 11, 2011			
		5324519	OCT 20, 2011			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021488 001	LEUPROLIDE ACETATE;ELIGARD	4938763	OCT 03, 2008		NP	FEB 13, 2006
		5278201	JAN 11, 2011			
		5324519	OCT 20, 2011			
		5599552	FEB 04, 2014			
		5733950	OCT 03, 2008			
		5739176	OCT 03, 2008			
019732 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4652441	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		4917893	NOV 01, 2004			
		5330767	NOV 01, 2004			
		5476663	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5575987	SEP 02, 2013			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			
020011 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631020	NOV 01, 2004			
		5631021	MAY 20, 2014			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		4917893	NOV 01, 2004			
		5330767	NOV 01, 2004			
		4652441	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		5716640	SEP 02, 2013			
020517 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5643607	JAN 02, 2013			
		5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4728721	MAY 01, 2006			
		5476663	NOV 01, 2004			
		5575987	NOV 19, 2013			
		5480656	JAN 02, 2013			
		4849228	JUL 18, 2006			
		5330767	NOV 01, 2004			
		5716640	SEP 02, 2013			
		5814342	FEB 01, 2011			
		6036976	DEC 13, 2016			
020263 002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4652441	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		5330767	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		4849228	JUL 18, 2006			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020263 003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4917893	NOV 01, 2004			
		4652441	NOV 01, 2004			
		4677191	JUL 03, 2005			
		5330767	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5575987	SEP 02, 2013			
		5476663	NOV 01, 2004			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			
020263 004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4652441	NOV 01, 2004			
		5476663	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5575987	SEP 02, 2013			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			
020263 005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4652441	NOV 01, 2004			
		5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		5476663	NOV 01, 2004			
		4849228	JUL 18, 2006			
		5575987	SEP 02, 2013			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			
020263 006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4652441	NOV 01, 2004			
		5330767	NOV 01, 2004			
		4917893	NOV 01, 2004			
		4677191	JUL 03, 2005			
		4728721	MAY 01, 2006			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		4849228	JUL 18, 2006			
		5716640	SEP 02, 2013			
		6036976	DEC 13, 2013			
020708 001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	5631020	MAY 20, 2014			
		5631021	NOV 01, 2004			
		4728721	MAY 01, 2006			
		4849228	JUL 18, 2006			
		4954298	NOV 01, 2004			
		5330767	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5480656	JAN 02, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	5575987	NOV 19, 2013			
		5643607	JAN 02, 2013			
		5716640	SEP 02, 2013			
		5814342	FEB 01, 2011			
		6036976	DEC 13, 2016			
		5631021	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5480656	JAN 02, 2013			
		5575987	NOV 19, 2013			
		5330767	NOV 01, 2004			
		5643607	JAN 02, 2013			
		4728721	MAY 01, 2006			
		4849228	JUL 18, 2006			
		5631020	MAY 20, 2014			
		5716640	SEP 02, 2013			
		5814342	FEB 01, 2011			
		6036976	DEC 13, 2016			
021088 001	LEUPROLIDE ACETATE;VIADUR	5728396	JAN 30, 2017	U316		
		5932547	JUN 13, 2017			
		5985305	JAN 30, 2017			
		6113938	JUL 24, 2018			
		6124261	JUN 13, 2017			
		6132420	JAN 30, 2017			
		6156331	JAN 30, 2017			
		6235712	JUN 13, 2017			
		6375978	DEC 17, 2018			
		6395292	JAN 30, 2017			
020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U332	I-347	JAN 30, 2005
		5547994	AUG 20, 2013	U332		
		5760090	JAN 05, 2010	U332		
		5844002	JAN 05, 2010	U332		
		6083993	JAN 05, 2010	U332		
		6451289	MAR 21, 2021			
020837 002	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U332	I-347	JAN 30, 2005
		5547994	AUG 20, 2013	U332		
		5760090	JAN 05, 2010	U332		
		5844002	JAN 05, 2010	U332		
		6083993	JAN 05, 2010	U332		
		6451289	MAR 21, 2021			
020837 003	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U332	I-347	JAN 30, 2005
		5547994	AUG 20, 2013	U332		
		5760090	JAN 05, 2010	U332		
		5844002	JAN 05, 2010	U332		
		6083993	JAN 05, 2010	U332		
		6451289	MAR 21, 2021			
020035 001	LEVAMISOLE HYDROCHLORIDE;ERGAMISOL	4584305	JUN 18, 2004	U42		
021035 001	LEVETIRACETAM;KEPPRA	4943639	AUG 06, 2009		NCE	NOV 30, 2004
		4837223	JUN 06, 2006			
021035 002	LEVETIRACETAM;KEPPRA	4943639	AUG 06, 2009		NCE	NOV 30, 2004
		4837223	JUN 06, 2006			
021035 003	LEVETIRACETAM;KEPPRA	4943639	AUG 06, 2009		NCE	NOV 30, 2004
		4837223	JUN 06, 2006			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021505 001	LEVETIRACETAM;KEPPRA	4943639	AUG 06, 2009		NCE	NOV 30, 2004
		4837223	JUN 06, 2006			
021114 001	LEVOBETAXOLOL HYDROCHLORIDE;BETAXON	4911920	MAR 27, 2007	U369		
		5540918	JUL 30, 2013			
020997 001	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U276		
020997 002	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U276		
020997 003	LEVOBUPIVACAINE HYDROCHLORIDE;CHIROCAINE	5708011	OCT 13, 2014	U276		
020219 001	LEVOCABASTINE HYDROCHLORIDE;LIVOSTIN	4369184	DEC 07, 2004			
020182 001	LEVOCARNITINE;CARNITOR	6335369	JAN 18, 2021	U433	ODE	DEC 15, 2006
		6429230	JAN 18, 2021	U433		
020634 001	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-372	OCT 30, 2005
					I-393	MAY 23, 2006
					D-83	OCT 23, 2006
020634 002	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-372	OCT 30, 2005
					I-393	MAY 23, 2006
					D-83	OCT 23, 2006
020634 003	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-372	OCT 30, 2005
					I-393	MAY 23, 2006
					D-83	OCT 23, 2006
020635 001	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-372	OCT 30, 2005
					I-393	MAY 23, 2006
					D-83	OCT 23, 2006
020635 004	LEVOFLOXACIN;LEVAQUIN	5053407	DEC 20, 2010		I-393	MAY 23, 2006
					I-372	OCT 30, 2005
					D-83	OCT 23, 2006
020635 002	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE 5%	5053407	DEC 20, 2010		I-372	OCT 30, 2005
					I-393	MAY 23, 2006
					D-83	OCT 23, 2006
020635 003	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE 5%	5053407	DEC 20, 2010		I-372	OCT 30, 2005
					I-393	MAY 23, 2006
					D-83	OCT 23, 2006
020635 005	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE 5%	5053407	DEC 20, 2010		I-393	MAY 23, 2006
					I-372	OCT 30, 2005
					D-83	OCT 23, 2006
021199 001	LEVOFLOXACIN;QUIXIN	4382892	SEP 02, 2003		NDF	AUG 18, 2003
		5053407	DEC 20, 2010			
		4551456	NOV 14, 2003			
021225 001	LEVONORGESTREL;MIRENA				NP	DEC 06, 2003
021342 001	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 002	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 003	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 004	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 005	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 006	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 007	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 008	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 009	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 010	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 011	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021301 001	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
021301 002	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
021301 003	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021301 004	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
021301 005	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
021301 006	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
021301 007	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
021301 008	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
021301 009	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
021301 010	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
021301 011	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
021301 012	LEVOTHYROXINE SODIUM;LEVOXYL	6555581	FEB 15, 2022			
020575 001	LIDOCAINE;LIDOCAINE	5446070	FEB 27, 2011			
		5234957	FEB 27, 2011			
		5332576	JUL 26, 2011			
020575 002	LIDOCAINE;LIDOCAINE	5332576	JUL 26, 2011			
		5234957	FEB 27, 2011			
		5446070	FEB 27, 2011			
020612 001	LIDOCAINE;LIDODERM	5589180	MAR 17, 2009	U485	ODE	MAR 19, 2006
		5411738	MAY 02, 2012			
		5827529	OCT 27, 2015	U486		
		5709869	MAR 17, 2009	U485		
		5601838	MAY 02, 2012	U488		
021451 001	LIDOCAINE;ORAQIX				NDF	DEC 19, 2006
021130 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U319	NCE	APR 18, 2005
		6559305	JAN 29, 2021		NPP	DEC 19, 2005
		6514529	MAR 15, 2021	DP	I-402	JUL 22, 2006
021130 002	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U319	NCE	APR 18, 2005
		6559305	JAN 29, 2021		NPP	DEC 19, 2005
		6514529	MAR 15, 2021	DP	I-402	JUL 22, 2006
021131 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U319	NCE	APR 18, 2005
		6559305	JAN 29, 2021		NPP	DEC 19, 2005
					I-402	JUL 22, 2006
021132 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U319	NCE	APR 18, 2005
		6559305	JAN 29, 2021		NPP	DEC 19, 2005
					I-402	JUL 22, 2006
019558 001	LISINOPRIL;PRINIVIL				NPP	MAY 29, 2006
					PED	NOV 29, 2006
019558 002	LISINOPRIL;PRINIVIL				NPP	MAY 29, 2006
					PED	NOV 29, 2006
019558 003	LISINOPRIL;PRINIVIL				NPP	MAY 29, 2006
					PED	NOV 29, 2006
019558 004	LISINOPRIL;PRINIVIL				NPP	MAY 29, 2006
					PED	NOV 29, 2006
019558 006	LISINOPRIL;PRINIVIL				NPP	MAY 29, 2006
					PED	NOV 29, 2006
019777 001	LISINOPRIL;ZESTRIL				PED	AUG 07, 2003
					PED	NOV 29, 2006
					NPP	MAY 29, 2006
019777 002	LISINOPRIL;ZESTRIL				PED	AUG 07, 2003
					PED	NOV 29, 2006
					NPP	MAY 29, 2006
019777 003	LISINOPRIL;ZESTRIL				PED	AUG 07, 2003
					PED	NOV 29, 2006
					NPP	MAY 29, 2006

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019777 004	LISINOPRIL;ZESTRIL				PED	AUG 07, 2003
					PED	NOV 29, 2006
					NPP	MAY 29, 2006
019777 005	LISINOPRIL;ZESTRIL				PED	AUG 07, 2003
					PED	NOV 29, 2006
					NPP	MAY 29, 2006
019777 006	LISINOPRIL;ZESTRIL				PED	AUG 07, 2003
					PED	NOV 29, 2003
					NPP	MAY 29, 2006
020191 001	LODOXAMIDE TROMETHAMINE;ALOMIDE	5457126	OCT 10, 2012	U117		
020013 001	LOMEFLOXACIN HYDROCHLORIDE;MAXAQUIN	4528287	FEB 21, 2006	U36		
020448 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM A-D	5489436	FEB 06, 2013			
020606 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5248505	JUL 28, 2010			
		5612054	SEP 28, 2010			
		5489436	FEB 06, 2013			
		5679376	OCT 21, 2014			
		5716641	MAY 21, 2012	U226		
021140 001	LOPERAMIDE HYDROCHLORIDE;IMODIUM ADVANCED	5612054	SEP 28, 2010			
		5248505	SEP 28, 2010	U434		
		6103260	JUL 17, 2017			
021226 001	LOPINAVIR;KALETRA	5914332	DEC 13, 2015	U351	NC	SEP 15, 2003
		5635523	JUN 30, 2014	U352		
		5541206	JUL 30, 2013	U348		
		5674882	OCT 07, 2014	U344		
		5886036	DEC 29, 2012	U345		
		6037157	JUN 26, 2016	U346		
		5846987	DEC 29, 2012	U350		
		5648497	JUL 15, 2014			
		6232333	NOV 07, 2017			
		6284767	FEB 14, 2016	U401		
		6458818	NOV 07, 2017			
		6521651	NOV 01, 2017			
021251 001	LOPINAVIR;KALETRA	5541206	JUL 30, 2013	U348	NC	SEP 15, 2003
		5914332	DEC 13, 2005	U351		
		5635523	JUN 03, 2014	U352		
		5846987	DEC 29, 2012	U350		
		5648497	JUL 15, 2014			
		5674882	OCT 07, 2014	U344		
		5886036	DEC 29, 2012	U345		
		6037157	JUN 26, 2016	U346		
		6284767	FEB 14, 2016	U401		
019658 001	LORATADINE;CLARITIN	4659716	APR 21, 2004	U142		
		4863931	SEP 15, 2008			
		4659716*PED	OCT 21, 2004	U142		
		4863931*PED	MAR 15, 2009			
019658 002	LORATADINE;CLARITIN	4659716	APR 21, 2004	U142		
		4659716*PED	OCT 21, 2004	U142		
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
020641 001	LORATADINE;CLARITIN	4659716	APR 21, 2004	U142		
		4863931	SEP 15, 2008			
		4659716*PED	OCT 21, 2004	U142		
		4863931*PED	MAR 15, 2009			
		6132758	JUN 01, 2018			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020641 002	LORATADINE;CLARITIN	4659716	APR 21, 2004	U142		
		4659716*PED	OCT 21, 2004	U142		
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
		6132758	JUN 01, 2018			
020704 001	LORATADINE;CLARITIN REDITABS	4659716	APR 21, 2004	U142		
		4863931	SEP 15, 2008			
		4659716*PED	OCT 21, 2004	U142		
		4863931*PED	MAR 15, 2009			
020704 002	LORATADINE;CLARITIN REDITABS	4659716	APR 21, 2004	U142		
		4659716*PED	OCT 21, 2004	U142		
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
019670 001	LORATADINE;CLARITIN-D	4659716	APR 21, 2004	U142		
		4863931	SEP 15, 2008			
		4659716*PED	OCT 21, 2004	U142		
		4863931*PED	MAR 15, 2009			
019670 002	LORATADINE;CLARITIN-D	4659716	APR 21, 2004	U142		
		4659716*PED	OCT 21, 2004	U142		
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
020470 001	LORATADINE;CLARITIN-D 24 HOUR	4659716	APR 21, 2004	U142		
		5314697*PED	APR 23, 2013			
		4863931	SEP 15, 2008			
		4659716*PED	OCT 21, 2004	U142		
		4863931*PED	MAR 15, 2009			
		5314697	OCT 23, 2012			
020470 002	LORATADINE;CLARITIN-D 24 HOUR	4659716	APR 21, 2004	U142		
		4659716*PED	OCT 21, 2004	U142		
		4863931	SEP 15, 2008			
		4863931*PED	MAR 15, 2009			
		5314697	OCT 23, 2012			
		5314697*PED	APR 23, 2013			
075209 001	LORATADINE;LORATADINE				PC	JUL 21, 2003
075822 001	LORATADINE;LORATADINE				PC	AUG 09, 2003
075706 001	LORATADINE;LORATADINE AND PSEUDOEPHEDRINE SU				PC	NOV 29, 2003
076050 001	LORATADINE;LORATADINE AND PSEUDOEPHEDRINE SU				PC	JUL 30, 2003
020386 001	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009		I-383	SEP 17, 2005
		5153197	OCT 06, 2009	U3		
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010			
		5153197*PED	APR 06, 2010	U3		
		5608075*PED	SEP 04, 2014			
		5210079	MAY 11, 2010	U496		
		5210079*PED	NOV 11, 2010	U496		
020386 002	LOSARTAN POTASSIUM;COZAAR	5153197	OCT 06, 2009	U3	I-383	SEP 17, 2005
		5138069	AUG 11, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010			
		5153197*PED	APR 06, 2010	U3		
		5608075*PED	SEP 04, 2014			
		5210079	MAY 11, 2010	U496		
		5210079*PED	NOV 11, 2010	U496		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020386 003	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009		I-383	SEP 17, 2005
		5153197	OCT 06, 2009	U3		
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010			
		5153197*PED	APR 06, 2010	U3		
		5608075*PED	SEP 04, 2014			
		5210079	MAY 11, 2010	U496		
		5210079*PED	NOV 11, 2010	U496		
020803 001	LOTEPREDNOL ETABONATE;ALREX	4996335	MAR 09, 2012			
		5540930	OCT 25, 2013			
020583 001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	MAR 09, 2012			
		5540930	OCT 25, 2013			
020841 001	LOTEPREDNOL ETABONATE;LOTEMAX	4996335	FEB 26, 2008			
		5540930	OCT 25, 2013			
021249 001	LOVASTATIN;ADVICOR	6080428	MAY 27, 2017	U447	NC	DEC 17, 2004
		6129930	SEP 20, 2013	U448		
		6406715	OCT 31, 2017	U450		
021249 002	LOVASTATIN;ADVICOR	6080428	MAY 27, 2017	U447	NC	DEC 17, 2004
		6129930	SEP 20, 2013	U448		
		6406715	OCT 31, 2017	U450		
021249 003	LOVASTATIN;ADVICOR	6080428	MAY 27, 2017	U447	NC	DEC 17, 2004
		6129930	SEP 20, 2013	U448		
		6406715	OCT 31, 2017	U450		
021316 001	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JUN 26, 2005
		6080778	MAR 23, 2018	U456		
021316 002	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JUN 26, 2005
		6080778	MAR 23, 2018	U456		
021316 003	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JUN 26, 2005
		6080778	MAR 23, 2018	U456		
021316 004	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JUN 26, 2005
		6080778	MAR 23, 2018	U456		
019643 002	LOVASTATIN;MEVACOR				PED	AUG 14, 2005
					I-350	FEB 14, 2005
019643 003	LOVASTATIN;MEVACOR				PED	AUG 14, 2005
					I-350	FEB 14, 2005
019643 004	LOVASTATIN;MEVACOR				PED	AUG 14, 2005
					I-350	FEB 14, 2005
019832 003	MAFENIDE ACETATE;SULFAMYLON				ODE	JUN 05, 2005
020652 001	MANGAFODIPIR TRISODIUM;TESLASCAN	4933456	NOV 27, 2011			
		4992554	FEB 12, 2008			
		5091169	FEB 25, 2009			
		5223243	JUN 29, 2010	U237		
		4647447	MAR 03, 2004	U238		
019940 001	MASOPROCOL;ACTINEX	4695590	APR 17, 2008			
		5008294	APR 15, 2008	U68		
019591 001	MEFLOQUINE HYDROCHLORIDE;LARIAM	4579855	OCT 01, 2004			
020264 001	MEGESTROL ACETATE;MEGACE	5338732	AUG 16, 2011			
020938 001	MELOXICAM;MOBIC				NCE	APR 13, 2005
020938 002	MELOXICAM;MOBIC				NCE	APR 13, 2005
020207 001	MELPHALAN HYDROCHLORIDE;ALKERAN	4997651	NOV 18, 2008			
021487 001	MEMANTINE HYDROCHLORIDE;NAMENDA	5061703	APR 11, 2010	U539	NCE	OCT 16, 2008
		5614560	MAR 25, 2014	U539		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021487 002	MEMANTINE HYDROCHLORIDE;NAMENDA	5061703	APR 11, 2010	U539	NCE	OCT 16, 2008
		5614560	MAR 25, 2014	U539		
021487 003	MEMANTINE HYDROCHLORIDE;NAMENDA	5061703	APR 11, 2010	U539	NCE	OCT 16, 2008
		5614560	MAR 25, 2014	U539		
021487 004	MEMANTINE HYDROCHLORIDE;NAMENDA	5061703	APR 11, 2010	U539	NCE	OCT 16, 2008
		5614560	MAR 25, 2014	U539		
020922 001	MEQUINOL;SOLAGE	5194247	MAR 16, 2010	U294	NC	DEC 10, 2004
		5470567	MAR 19, 2010	U294		
		6353029	AUG 24, 2020			
019651 001	MESALAMINE;ASACOL	5541170	JUL 30, 2013	U141		
		5541171	JUL 30, 2013	U141		
019618 001	MESALAMINE;ROWASA	4657900	APR 14, 2004			
		RE33239	MAY 12, 2004			
019884 001	MESNA;MESNEX	5696172	OCT 06, 2013			
020855 001	MESNA;MESNEX	5252341	JUL 16, 2011		NDF	MAR 21, 2005
		5262169	JUL 16, 2011			
013217 001	METAXALONE;SKELAXIN	6407128	DEC 03, 2021	U189		
013217 003	METAXALONE;SKELAXIN	6407128	DEC 03, 2021	U189		
021410 001	METFORMIN HYDROCHLORIDE;AVANDAMET	5002953	AUG 30, 2008	U493	NCE	MAY 25, 2004
		5741803	APR 21, 2015	U493		
		6288095	FEB 11, 2017	U493		
		5965584	JUN 19, 2016	U493		
		6166042	JUN 19, 2016	U493		
021410 002	METFORMIN HYDROCHLORIDE;AVANDAMET	5002953	AUG 30, 2008	U493	NCE	MAY 25, 2004
		5741803	APR 21, 2015	U493		
		6288095	FEB 11, 2017	U493		
		5965584	JUN 19, 2016	U493		
		6166042	JUN 19, 2016	U493		
021410 003	METFORMIN HYDROCHLORIDE;AVANDAMET	5002953	AUG 30, 2008	U493	NCE	MAY 25, 2004
		5741803	APR 21, 2015	U493		
		6288095	FEB 11, 2017	U493		
		5965584	JUN 19, 2016	U493		
		6166042	JUN 19, 2016	U493		
021410 004	METFORMIN HYDROCHLORIDE;AVANDAMET				NCE	MAY 25, 2004
021410 005	METFORMIN HYDROCHLORIDE;AVANDAMET				NCE	MAY 25, 2004
020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					M-6	APR 19, 2004
					W	DEC 15, 2003
					W	JUN 15, 2004
020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					M-6	APR 19, 2004
					W	DEC 15, 2003
					W	JUN 15, 2004
020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					M-6	APR 19, 2004
					W	DEC 15, 2003
					W	JUN 15, 2004
020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					M-6	APR 19, 2004
					W	DEC 15, 2003
					W	JUN 15, 2004

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					M-6	APR 19, 2004
					W	DEC 15, 2003
					W	JUN 15, 2004
021202 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE XR	6475521	MAR 19, 2018		NDF	OCT 13, 2003
		6660300	MAR 19, 2018	U542		
021202 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE XR	6475521	MAR 19, 2018		NDF	OCT 13, 2003
		6660300	MAR 19, 2018	U542		
020969 001	METHOXSALEN;UVADEX	4845075	APR 11, 2009			
		5036102	JUL 30, 2008	U273		
		4999375	MAR 12, 2008			
021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003		NP	AUG 01, 2003
		4783337	SEP 16, 2003	U372		
		4612008	SEP 16, 2003			
		5082668*PED	MAR 16, 2004			
		4612008*PED	MAR 16, 2004			
		4783337*PED	MAR 16, 2004			
021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003		NP	AUG 01, 2003
		4783337	SEP 16, 2003	U372		
		4612008	SEP 16, 2003			
		5082668*PED	MAR 16, 2004			
		4612008*PED	MAR 16, 2004			
		4783337*PED	MAR 16, 2004			
021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	5082668	SEP 16, 2003		NP	AUG 01, 2003
		4783337	SEP 16, 2003	U372		
		4612008	SEP 16, 2003			
		5082668*PED	MAR 16, 2004			
		4612008*PED	MAR 16, 2004			
		4783337*PED	MAR 16, 2004			
021121 004	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4612008	SEP 16, 2003		NP	AUG 01, 2003
		4783337	SEP 16, 2003	U372		
		5082668	SEP 16, 2003			
		5082668*PED	MAR 16, 2004			
		4612008*PED	MAR 16, 2004			
		4783337*PED	MAR 16, 2004			
021259 001	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD	6344215	OCT 27, 2020		NDF	APR 03, 2004
021259 002	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD	6344215	OCT 27, 2020		NDF	APR 03, 2004
021259 003	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD	6344215	OCT 27, 2020		NDF	APR 03, 2004
021284 001	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	MAY 15, 2016		NP	JUN 07, 2005
		6228398	MAY 01, 2019	U472		
021284 002	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	MAY 15, 2016		NP	JUN 07, 2005
		6228398	MAY 01, 2019	U472		
021284 003	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	MAY 15, 2016		NP	JUN 07, 2005
		6228398	NOV 01, 2019	U472		
019786 003	METOPROLOL FUMARATE;LOPRESSOR	4892739	JAN 09, 2007			
019786 004	METOPROLOL FUMARATE;LOPRESSOR	4892739	JAN 09, 2007			
019962 001	METOPROLOL SUCCINATE;TOPROL-XL	5001161	MAR 19, 2008		I-194	FEB 05, 2004
		4957745	SEP 18, 2007	U107		
		5081154	MAR 19, 2008			
		4927640	MAY 22, 2007			
019962 002	METOPROLOL SUCCINATE;TOPROL-XL	5001161	MAR 19, 2008		I-194	FEB 05, 2004
		4957745	SEP 18, 2007	U107		
		5081154	MAR 19, 2008			
		4927640	MAY 22, 2007			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019962 003	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	U107	I-194	FEB 05, 2004
		5001161	MAR 19, 2008			
		5081154	MAR 19, 2008			
		4927640	MAY 22, 2007			
019962 004	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	U107	NS	FEB 05, 2004
		5001161	MAR 19, 2008	U107	I-194	FEB 05, 2004
		5081154	MAR 19, 2008	U107		
		4927640	MAY 22, 2007			
019737 001	METRONIDAZOLE;METROGEL	4837378	JUN 06, 2006			
020208 001	METRONIDAZOLE;METROGEL-VAGINAL	5536743	JUL 16, 2013	U137		
		4837378	JUN 06, 2006			
		5840744	JAN 15, 2008	U370		
020968 001	MICONAZOLE NITRATE;MONISTAT DUAL- PAK	5514698	MAR 21, 2014			
021308 001	MICONAZOLE NITRATE;MONISTAT 1 COMBINATION PACK	6153635	NOV 28, 2020			
		5514698	MAR 21, 2014			
019815 001	MIDODRINE HYDROCHLORIDE;PROAMATINE				ODE	SEP 06, 2003
019815 002	MIDODRINE HYDROCHLORIDE;PROAMATINE				ODE	SEP 06, 2003
019815 003	MIDODRINE HYDROCHLORIDE;PROAMATINE				ODE	SEP 06, 2003
020687 001	MIFEPRISTONE;MIFEPREX	4626531	OCT 12, 2004		NCE	SEP 28, 2005
020682 001	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U111		
020682 002	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U111		
020682 003	MIGLITOL;GLYSET	4639436	JAN 27, 2009	U111		
021348 001	MIGLUSTAT;ZAVESCA	5472969	MAY 13, 2013		NCE	JUL 31, 2008
		5525616	JUN 11, 2013		ODE	JUL 31, 2010
					M-18	APR 09, 2005
020415 001	MIRTAZAPINE;REMERON				M-18	APR 09, 2005
020415 002	MIRTAZAPINE;REMERON				M-18	APR 09, 2005
020415 003	MIRTAZAPINE;REMERON				M-18	APR 09, 2005
021208 001	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		M-18	APR 09, 2005
021208 002	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		M-18	APR 09, 2005
021208 003	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		M-18	APR 09, 2005
019297 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE	4820738	APR 11, 2006	U98	ODE	NOV 13, 2003
		4617319	JUN 13, 2005	U390	I-324	OCT 13, 2003
					ODE	OCT 13, 2007
020098 001	MIVACURIUM CHLORIDE;MIVACRON	4761418	JAN 22, 2006			
020098 002	MIVACURIUM CHLORIDE;MIVACRON IN DEXTROSE 5%	4761418	JAN 22, 2006			
020717 001	MODAFINIL;PROVIGIL	4927855	MAY 22, 2007	U255	ODE	DEC 24, 2005
		RE37516	OCT 06, 2014	U255	NCE	DEC 24, 2003
020717 002	MODAFINIL;PROVIGIL	4927855	MAY 22, 2007	U255	ODE	DEC 24, 2005
		RE37516	OCT 06, 2014	U255	NCE	DEC 24, 2003
					PC	SEP 21, 2003
076204 001	MOEXIPRIL HYDROCHLORIDE;MOEXIPRIL HCL				PC	SEP 21, 2003
076204 002	MOEXIPRIL HYDROCHLORIDE;MOEXIPRIL HCL					
020312 001	MOEXIPRIL HYDROCHLORIDE;UNIVASC	4743450	FEB 24, 2007			
020312 002	MOEXIPRIL HYDROCHLORIDE;UNIVASC	4743450	FEB 24, 2007			
020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	5837699	JAN 27, 2014	U249	I-360	JUL 17, 2005
		6127353	OCT 03, 2017		PED	JAN 17, 2006
		5837699*PED	JUL 27, 2014	U249		
		6127353*PED	APR 03, 2018			
019625 001	MOMETASONE FUROATE;ELOCON	4808610	OCT 02, 2006			
		4808610*PED	APR 02, 2007			
019796 001	MOMETASONE FUROATE;ELOCON	4775529	MAY 21, 2007			
		4775529*PED	NOV 21, 2007			
020829 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U228	PED	AUG 20, 2003
		5565473*PED	AUG 03, 2012	U228	I-378	DEC 31, 2005

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020830 001	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U228	PED	AUG 20, 2003
		5565473*PED	AUG 03, 2012	U228	I-378	DEC 31, 2005
020830 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U228	PED	SEP 03, 2003
		5565473*PED	AUG 03, 2012	U228	PED	AUG 20, 2003
					PED	SEP 03, 2003
					I-378	DEC 31, 2005
021409 001	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012		NDF	JUL 26, 2005
		5565473*PED	AUG 03, 2012		PED	JAN 26, 2006
					PED	AUG 20, 2003
					I-378	DEC 31, 2005
021260 001	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
021260 002	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
021260 003	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
021260 004	MORPHINE SULFATE;AVINZA	6066339	NOV 25, 2017		NP	MAR 20, 2005
020616 001	MORPHINE SULFATE;KADIAN	5202128	APR 13, 2010			
		5378474	MAR 23, 2010			
020616 002	MORPHINE SULFATE;KADIAN	5378474	MAR 23, 2010			
		5202128	APR 13, 2010			
020616 003	MORPHINE SULFATE;KADIAN	5202128	APR 13, 2010			
		5378474	MAR 23, 2010			
021085 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX	4990517	JUN 30, 2009	U298	NCE	DEC 10, 2004
		5607942	MAR 04, 2014	U298	I-329	APR 27, 2004
		5849752	DEC 05, 2016	U298	I-385	FEB 28, 2006
021277 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX IN SODIUM CHLORIDE 0.8%	4990517	JUN 30, 2009	U298	NCE	DEC 10, 2004
		5607942	MAR 04, 2014	U298	NDF	NOV 30, 2004
		5849752	DEC 05, 2016	U298	I-329	APR 27, 2004
					I-385	FEB 28, 2006
021598 001	MOXIFLOXACIN HYDROCHLORIDE;VIGAMOX	4990517	JUN 30, 2009		NDF	APR 15, 2006
		5607942	MAR 04, 2014		PED	OCT 15, 2006
		5849752	DEC 05, 2016		NCE	DEC 10, 2004
		4990517*PED	DEC 30, 2009		PED	JUN 10, 2004
		5607942*PED	SEP 04, 2014			
		5849752*PED	JUN 05, 2017			
020353 001	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
020353 002	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
020353 003	NAPROXEN SODIUM;NAPRELAN	5637320	JUN 10, 2014			
020763 001	NARATRIPTAN HYDROCHLORIDE;AMERGE	4997841	JUL 07, 2010	U232		
020763 002	NARATRIPTAN HYDROCHLORIDE;AMERGE	4997841	JUL 07, 2010	U232		
021204 001	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006		NCE	DEC 22, 2005
		5463116	OCT 21, 2012		I-411	OCT 20, 2006
		5488150	JAN 30, 2013			
		6559188	SEP 17, 2019			
		6641841	NOV 14, 2017	DP U214		
021204 002	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006		NCE	DEC 22, 2005
		5463116	OCT 21, 2012		I-411	OCT 20, 2006
		5488150	JAN 30, 2013			
		6559188	SEP 17, 2019			
		6641841	NOV 14, 2017	DP U214		
021009 001	NEDOCROMIL SODIUM;ALOCRIL	4474787	OCT 02, 2006	U304		
		4760072	JUL 26, 2005			
019660 001	NEDOCROMIL SODIUM;TILADE	4474787	OCT 02, 2006			
		4760072	JUL 26, 2005			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020152 001	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317*PED	SEP 16, 2003			
020152 002	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317*PED	SEP 16, 2003			
020152 003	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317*PED	SEP 16, 2003			
020152 004	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317*PED	SEP 16, 2003			
020152 005	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317*PED	SEP 16, 2003			
020152 006	NEFAZODONE HYDROCHLORIDE;SERZONE	4338317*PED	SEP 16, 2003			
020778 001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013			
		5952343	OCT 07, 2013	U257		
		6162812	OCT 07, 2013	U248		
		5952343*PED	APR 07, 2014	U257		
		5484926*PED	APR 07, 2014			
		6162812*PED	APR 07, 2014	U248		
020779 001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013			
		5952343	OCT 07, 2013	U257		
		6162812	OCT 07, 2013	U248		
		5484926*PED	APR 07, 2014			
		5952343*PED	APR 07, 2014	U257		
		6162812*PED	APR 07, 2014	U248		
021503 001	NELFINAVIR MESYLATE;VIRACEPT	5484926	OCT 07, 2013			
		5484926*PED	APR 07, 2014			
		5952343	OCT 07, 2013	U257		
		5952343*PED	APR 07, 2014	U257		
		6162812	OCT 07, 2013	U248		
		6162812*PED	APR 07, 2014	U248		
020920 001	NESIRITIDE;NATRECOR	5114923	MAY 19, 2009		NCE	AUG 10, 2006
020636 001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011	U167		
		5366972*PED	MAY 22, 2012			
020933 001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011			
		5366972*PED	MAY 22, 2012			
020381 001	NIACIN;NIASPAN	6080428	MAY 27, 2017	U331		
		6129930	SEP 20, 2013	U354		
		6406715	OCT 31, 2017	U450		
020381 002	NIACIN;NIASPAN	6080428	MAY 27, 2017	U331		
		6129930	SEP 20, 2013	U354		
		6406715	OCT 31, 2017	U450		
020381 003	NIACIN;NIASPAN	6080428	MAY 27, 2017	U331		
		6129930	SEP 20, 2013	U354		
		6406715	OCT 31, 2017	U450		
020381 004	NIACIN;NIASPAN	6080428	MAY 27, 2017	U331		
		6129930	SEP 20, 2013	U354		
		6406715	OCT 31, 2017	U450		
020381 005	NIACIN;NIASPAN TITRATION STARTER PACK	6080428	MAY 27, 2017	U331		
		6406715	OCT 31, 2017	U450		
		6129930	SEP 20, 2013	U354		
019734 001	NICARDIPINE HYDROCHLORIDE;CARDENE	4880823	NOV 14, 2006			
		5164405	NOV 17, 2009			
020005 001	NICARDIPINE HYDROCHLORIDE;CARDENE SR	5198226	MAR 30, 2010			
020005 002	NICARDIPINE HYDROCHLORIDE;CARDENE SR	5198226	MAR 30, 2010			
020005 003	NICARDIPINE HYDROCHLORIDE;CARDENE SR	5198226	MAR 30, 2010			
021330 001	NICOTINE POLACRILEX;COMMIT	5110605	AUG 21, 2010		NDF	OCT 31, 2005
021330 002	NICOTINE POLACRILEX;COMMIT	5110605	AUG 21, 2010		NDF	OCT 31, 2005
020076 001	NICOTINE;HABITROL	4597961	JAN 23, 2005	U56		
		5016652	MAY 21, 2008			
		5834011	MAY 01, 2007	U355		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020076 002	NICOTINE;HABITROL	4597961	JAN 23, 2005	U56		
		5016652	MAY 21, 2008			
		5834011	MAY 01, 2007	U355		
020076 003	NICOTINE;HABITROL	4597961	JAN 23, 2005	U56		
		5016652	MAY 21, 2008			
		5834011	MAY 01, 2007	U355		
020076 004	NICOTINE;HABITROL	5834011	MAY 01, 2007	U355		
		4597961	JAN 23, 2005	U56		
		5016652	MAY 21, 2008			
020076 005	NICOTINE;HABITROL	5834011	MAY 01, 2007	U355		
		4597961	JAN 23, 2005	U56		
		5016652	MAY 21, 2008			
020076 006	NICOTINE;HABITROL	5834011	MAY 01, 2007	U355		
		4597961	JAN 23, 2005	U56		
		5016652	MAY 21, 2008			
020165 004	NICOTINE;NICODERM CQ	5004610	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5364630	JUN 14, 2008			
		5462745	JUN 14, 2008			
		5508038	APR 16, 2013			
		6165497	JUN 14, 2008	U388		
		5633008	JUN 14, 2008	U389		
020165 005	NICOTINE;NICODERM CQ	5004610	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5364630	JUN 14, 2008			
		5462745	JUN 14, 2008			
		5508038	APR 16, 2013			
		5633008	JUN 14, 2008	U389		
		6165497	JUN 14, 2008	U388		
020165 006	NICOTINE;NICODERM CQ	5004610	JUN 14, 2008			
		5344656	JUN 14, 2008			
		5342623	JUN 14, 2008			
		5364630	JUN 14, 2008			
		5462745	JUN 14, 2008			
		5508038	APR 16, 2013			
		5633008	JUN 14, 2008	U389		
		6165497	JUN 14, 2008	U388		
020385 001	NICOTINE;NICOTROL	5656255	AUG 12, 2014			
020536 001	NICOTINE;NICOTROL	5501236	JUN 08, 2010			
		6098632	JUN 08, 2010			
020714 001	NICOTINE;NICOTROL	5400808	JUN 08, 2010			
		4917120	APR 17, 2007			
		4800903	JAN 31, 2006			
		4793366	DEC 27, 2005			
		5167242	JUN 08, 2010			
		5501236	JUN 08, 2010			
		6098632	JUN 08, 2010			
019983 001	NICOTINE;PROSTEP	4946853	AUG 07, 2007	U56		
019983 002	NICOTINE;PROSTEP	4946853	AUG 07, 2007	U56		
019983 003	NICOTINE;PROSTEP	4946853	AUG 07, 2007	U56		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019983 004	NICOTINE;PROSTEP	4946853	AUG 07, 2007	U56		
020198 001	NIFEDIPINE;ADALAT CC	4892741	JUN 08, 2008			
		5264446	NOV 23, 2010			
020198 002	NIFEDIPINE;ADALAT CC	4892741	JUN 08, 2008			
		5264446	NOV 23, 2010			
020198 003	NIFEDIPINE;ADALAT CC	4892741	JUN 08, 2008			
		5264446	NOV 23, 2010			
019684 001	NIFEDIPINE;PROCARDIA XL	4765989	SEP 16, 2003			
		5264446	NOV 23, 2010			
		4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
019684 002	NIFEDIPINE;PROCARDIA XL	4765989	SEP 16, 2003			
		5264446	NOV 23, 2010			
		4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
019684 003	NIFEDIPINE;PROCARDIA XL	4765989	SEP 16, 2003			
		5264446	NOV 23, 2010			
		4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
020356 001	NISOLDIPINE;SULAR	4892741	JUN 08, 2008			
		4703038	OCT 07, 2005	U3		
020356 002	NISOLDIPINE;SULAR	4892741	JUN 08, 2008			
		4703038	OCT 07, 2005	U3		
020356 003	NISOLDIPINE;SULAR	4892741	JUN 08, 2008			
		4703038	OCT 07, 2005	U3		
020356 004	NISOLDIPINE;SULAR	4892741	JUN 08, 2008			
		4703038	OCT 07, 2005	U3		
021498 001	NITAZOXANIDE;ALINIA	5387598	FEB 07, 2012	U524	NCE	NOV 22, 2007
		5578621	SEP 08, 2014	U525	ODE	NOV 22, 2009
		5965590	JUL 03, 2017	U523		
		5968961	MAY 07, 2017			
		6020353	SEP 08, 2014			
		6117894	MAY 07, 2017			
021232 001	NITISINONE;ORFADIN	5006158	APR 09, 2008		NCE	JAN 18, 2007
		5550165	AUG 27, 2013		ODE	JAN 18, 2009
021232 002	NITISINONE;ORFADIN	5006158	APR 09, 2008		NCE	JAN 18, 2007
		5550165	AUG 27, 2013		ODE	JAN 18, 2009
021232 003	NITISINONE;ORFADIN	5006158	APR 09, 2008		NCE	JAN 18, 2007
		5550165	AUG 27, 2013		ODE	JAN 18, 2009
020845 002	NITRIC OXIDE;INOMAX	5485827	JAN 23, 2013	U297	ODE	DEC 23, 2006
		5873359	JAN 23, 2013	U297	NCE	DEC 23, 2004
020845 003	NITRIC OXIDE;INOMAX	5485827	JAN 23, 2013	U297	ODE	DEC 23, 2006
		5873359	JAN 23, 2013	U297	NCE	DEC 23, 2004
020064 001	NITROFURANTOIN;MACROBID	4772473	JUN 16, 2006			
		4798725	JUN 16, 2006			
020145 001	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 002	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 003	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 004	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 005	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
020145 006	NITROGLYCERIN;NITRO-DUR	5186938	FEB 16, 2010			
018705 002	NITROGLYCERIN;NITROLINGUAL PUMPSPRAY	5186925	FEB 16, 2010			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021134 001	NITROGLYCERIN;NITROSTAT	6500456	SEP 16, 2018			
021134 002	NITROGLYCERIN;NITROSTAT	6500456	SEP 16, 2018			
021134 003	NITROGLYCERIN;NITROSTAT	6500456	SEP 16, 2018			
019757 001	NORFLOXACIN;CHIBROXIN	4551456	NOV 14, 2003	U57		
019384 002	NORFLOXACIN;NOROXIN	4639458	JAN 22, 2005			
019667 001	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	MAY 19, 2015			
019667 002	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	MAY 19, 2015			
019667 003	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	MAY 19, 2015			
019667 004	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	MAY 19, 2015			
021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U268	ODE	NOV 25, 2005
		5538739	JUL 23, 2013			
		5639480	JUN 17, 2014			
		5922338	JUL 13, 2016			
		5922682	JUL 13, 2016			
		6395292	JAN 30, 2017			
021008 002	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U268	ODE	NOV 25, 2005
		5538739	JUL 23, 2013			
		5639480	JUN 17, 2014			
		5922338	JUL 13, 2016			
		5922682	JUL 13, 2016			
021008 003	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5688530	NOV 18, 2014	U268	ODE	NOV 25, 2005
		5538739	JUL 23, 2013			
		5639480	JUN 17, 2014			
		5922338	JUL 13, 2016			
		5922682	JUL 13, 2016			
019735 001	OFLOXACIN;FLOXIN	4382892	SEP 02, 2003			
019735 002	OFLOXACIN;FLOXIN	4382892	SEP 02, 2003			
019735 003	OFLOXACIN;FLOXIN	4382892	SEP 02, 2003			
020799 001	OFLOXACIN;FLOXIN	5401741	MAR 27, 2012	U407	D-84	SEP 30, 2006
019921 001	OFLOXACIN;OCUFLOX	4382892	SEP 02, 2003		PED	NOV 22, 2003
		4551456	NOV 14, 2003	U80		
		4382892*PED	MAR 02, 2004			
		4551456*PED	MAY 14, 2004	U80		
020592 001	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U149	I-313	NOV 09, 2003
					I-400	JUL 10, 2006
020592 002	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U149	I-313	NOV 09, 2003
					I-400	JUL 10, 2006
020592 003	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U149	I-313	NOV 09, 2003
					I-400	JUL 10, 2006
020592 004	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U149	I-313	NOV 09, 2003
					I-400	JUL 10, 2006
020592 005	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U149	I-313	NOV 09, 2003
					I-400	JUL 10, 2006
020592 006	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U149	I-313	NOV 09, 2003
					I-400	JUL 10, 2006
021086 001	OLANZAPINE;ZYPREXA ZYDIS	5229382	APR 23, 2011	U324		
021086 002	OLANZAPINE;ZYPREXA ZYDIS	5229382	APR 23, 2011	U324		
021086 003	OLANZAPINE;ZYPREXA ZYDIS	5229382	APR 23, 2011	U324		
021086 004	OLANZAPINE;ZYPREXA ZYDIS	5229382	APR 23, 2011	U324		
021286 002	OLMESARTAN MEDOXOMIL;BENEVAS	5616599	APR 01, 2014	U500		
021286 001	OLMESARTAN MEDOXOMIL;BENICAR	5616599	APR 01, 2014	U500	NCE	APR 25, 2007
021286 003	OLMESARTAN MEDOXOMIL;BENICAR	5616599	APR 01, 2014	U500	NCE	APR 25, 2007

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021286 004	OLMESARTAN MEDOXOMIL;BENICAR				NCE	APR 25, 2007
020688 001	OLOPATADINE HYDROCHLORIDE;PATANOL	5641805	JUN 06, 2015	U184		
		4871865	OCT 03, 2006			
		4923892	MAY 08, 2007	U174		
		5116863	DEC 18, 2010			
019715 001	OLSALAZINE SODIUM;DIPENTUM	4559330	JUL 31, 2004	U58		
021229 001	OMEPRAZOLE MAGNESIUM;PRILOSEC OTC	4738974	APR 19, 2005		RTO	JUN 20, 2006
		5900424	MAY 04, 2016			
		4786505	APR 20, 2007			
		4853230	APR 20, 2007			
		5690960	NOV 25, 2014			
		5817338	OCT 06, 2015			
		5753265	JUN 07, 2015			
		6403616	NOV 15, 2019			
		6428810	NOV 03, 2019			
		4786505*PED	OCT 20, 2007			
		4853230*PED	OCT 20, 2007			
019810 001	OMEPRAZOLE;PRILOSEC	4786505	APR 20, 2007	U108	M-19	JUL 12, 2005
		4853230	APR 20, 2007	U108	PED	JAN 12, 2006
		6150380	NOV 10, 2018			
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4786505*PED	OCT 20, 2007	U108		
		4853230*PED	OCT 20, 2007	U108		
		6147103*PED	APR 09, 2019			
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2019			
		6191148*PED	APR 09, 2019			
019810 002	OMEPRAZOLE;PRILOSEC	4786505	APR 20, 2007	U108	M-19	JUL 12, 2005
		4853230	APR 20, 2007	U108	PED	JAN 12, 2006
		6150380	NOV 10, 2018			
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4786505*PED	OCT 20, 2007	U108		
		4853230*PED	OCT 20, 2007	U108		
		6147103*PED	APR 09, 2019			
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2019			
		6191148*PED	APR 09, 2019			
019810 003	OMEPRAZOLE;PRILOSEC	4853230	APR 20, 2007	U108	M-19	JUL 12, 2005
		4786505	APR 20, 2007	U108	PED	JAN 12, 2006
		6150380	NOV 10, 2018			
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4786505*PED	OCT 20, 2007	U108		
		4853230*PED	OCT 20, 2007	U108		
		6147103*PED	APR 09, 2019			
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2019			
		6191148*PED	APR 09, 2019			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020007 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U44		
		4695578	JAN 25, 2005			
		5578628	FEB 16, 2005	U44		
020103 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U44		
		4695578	JAN 25, 2005			
		5578628	FEB 16, 2005	U44		
		5344658	SEP 06, 2011			
020103 002	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U44		
		4695578	JAN 25, 2005			
		5578628	FEB 16, 2005	U44		
		5344658	SEP 06, 2011			
020103 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5344658	SEP 06, 2011			
		5578628	FEB 16, 2005	U44		
		4753789	JUN 24, 2006	U44		
		4695578	JAN 25, 2005			
020403 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U44		
		4695578	JAN 25, 2005			
		5578628	FEB 16, 2005	U44		
020605 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5578628	FEB 16, 2005	U44		
		4753789	JUN 24, 2006	U44		
		4695578	JAN 25, 2005	U183		
020007 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN PRESERVATIVE FREE	5578628	FEB 16, 2005	U44		
		4695578	JAN 25, 2005			
		4753789	JUN 24, 2006	U44		
020781 001	ONDANSETRON;ZOFRAN ODT	5955488	NOV 14, 2015			
		6063802	NOV 14, 2015			
		5578628	FEB 16, 2005	U330		
		4695578	JAN 25, 2005	U330		
		4753789	JUN 24, 2006	U330		
020781 002	ONDANSETRON;ZOFRAN ODT	5955488	NOV 14, 2015			
		6063802	NOV 14, 2015			
		5578628	FEB 16, 2005	U330		
		4695578	JAN 25, 2005	U330		
		4753789	JUN 24, 2006	U330		
020766 001	ORLISTAT;XENICAL	4598089	JUN 18, 2009		NCE	APR 23, 2004
		6004996	JAN 06, 2018		PED	OCT 23, 2004
		4598089*PED	DEC 18, 2009		M-29	DEC 12, 2006
		6004996*PED	JUL 06, 2018		PED	JUN 12, 2007
021087 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5763483	DEC 27, 2016		NCE	OCT 27, 2004
		5866601	FEB 02, 2016		I-317	NOV 17, 2003
		5952375	FEB 02, 2016			
021246 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5763483	DEC 27, 2016	U376	I-317	NOV 17, 2003
		5866601	FEB 02, 2016		NDF	DEC 14, 2003
		5952375	FEB 02, 2016		NCE	OCT 27, 2004
021492 001	OXALIPLATIN;ELOXATIN	5420319	APR 07, 2013		NCE	AUG 09, 2007
		5338874	APR 07, 2013			
		5290961	JAN 12, 2013			
021492 002	OXALIPLATIN;ELOXATIN	5420319	APR 07, 2013		NCE	AUG 09, 2007
		5338874	APR 07, 2013			
		5290961	JAN 12, 2013			
020776 001	OXAPROZIN POTASSIUM;DAYPRO ALTA	6030643	MAY 16, 2017	U497	NE	OCT 17, 2005
015539 002	OXAZEPAM;SERAX	4620974	NOV 04, 2003			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
015539 004	OXAZEPAM;SERAX	4620974	NOV 04, 2003			
015539 006	OXAZEPAM;SERAX	4620974	NOV 04, 2003			
021014 001	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
021014 002	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
021014 003	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
021285 001	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
017577 001	OXYBUTYNIN CHLORIDE;DITROPAN				M-28	APR 15, 2006
					PED	OCT 15, 2006
018211 001	OXYBUTYNIN CHLORIDE;DITROPAN				M-28	APR 15, 2006
					PED	OCT 15, 2006
020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	4783337	SEP 16, 2003		NPP	APR 15, 2006
		5674895	MAY 22, 2015		PED	OCT 15, 2006
		5082668	SEP 16, 2003			
		5840754	MAY 22, 2015			
		4612008	SEP 16, 2003			
		5912268	MAY 22, 2015			
		6124355	MAY 22, 2015	U378		
		6262115	MAY 22, 2015	U393		
		4783337*PED	MAR 16, 2004			
		4612008*PED	MAR 16, 2004			
		5082668*PED	MAR 16, 2004			
		5674895*PED	NOV 22, 2015			
		5840754*PED	NOV 22, 2015			
		5912268*PED	NOV 22, 2015			
		6124355*PED	NOV 22, 2015	U378		
		6262115*PED	NOV 22, 2015	U393		
020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	5840754	MAY 22, 2015		NPP	APR 15, 2006
		5674895	MAY 22, 2015		PED	OCT 15, 2006
		5082668	SEP 16, 2003			
		4783337	SEP 16, 2003			
		4612008	SEP 16, 2003			
		5912268	MAY 22, 2015			
		6124355	MAY 22, 2015	U378		
		6262115	MAY 22, 2015	U393		
		4783337*PED	MAR 16, 2004			
		4612008*PED	MAR 16, 2004			
		5082668*PED	MAR 16, 2004			
		5674895*PED	NOV 22, 2015			
		5840754*PED	NOV 22, 2015			
		5912268*PED	NOV 22, 2015			
		6124355*PED	NOV 22, 2015	U378		
		6262115*PED	NOV 22, 2015	U393		
020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	5912268	MAY 22, 2015		NPP	APR 15, 2006
		4612008	SEP 16, 2003		PED	OCT 15, 2006
		5840754	MAY 22, 2015			
		5674895	MAY 22, 2015			
		5082668	SEP 16, 2003			
		4783337	SEP 16, 2003			
		6124355	MAY 22, 2015	U378		
		6262115	MAY 22, 2015	U393		
		4783337*PED	MAR 16, 2004			
		4612008*PED	MAR 16, 2004			
		5082668*PED	MAR 16, 2004			
		5674895*PED	NOV 22, 2015			
		5840754*PED	NOV 22, 2015			
		5912268*PED	NOV 22, 2015			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
		6124355*PED	NOV 22, 2015	U378		
		6262115*PED	NOV 22, 2015	U393		
021351 002	OXYBUTYNIN;OXYTROL	5164190	DEC 11, 2010		NDF	FEB 26, 2006
		5601839	APR 26, 2015			
		5834010	APR 26, 2015			
020553 001	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
		4861598	AUG 29, 2006			
		5549912	OCT 26, 2007			
		5508042	APR 16, 2013	U443		
		5656295	OCT 26, 2007	U443		
020553 002	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
		5549912	OCT 26, 2007			
		4861598	AUG 29, 2006			
		5508042	APR 16, 2013	U443		
		5656295	OCT 26, 2007	U443		
020553 003	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4861598	AUG 29, 2006			
		4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
		5549912	OCT 26, 2007			
		5508042	APR 16, 2013	U443		
		5656295	OCT 26, 2007	U443		
020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5508042	APR 16, 2013	U443		
		5656295	OCT 26, 2007	U443		
		4861598	AUG 29, 2006			
		4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
		5549912	OCT 26, 2007			
020553 005	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4861598	AUG 29, 2006			
		4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
		5549912	OCT 26, 2007			
		5508042	APR 16, 2013	U443		
		5656295	OCT 26, 2007	U443		
020262 001	PACLITAXEL;TAXOL				ODE	AUG 04, 2004
021372 001	PALONOSETRON HYDROCHLORIDE;ALOXI	5202333	APR 13, 2010	U528	NCE	JUL 25, 2008
020036 001	PAMIDRONATE DISODIUM;AREDIA	4711880	JUL 29, 2005		D-68	AUG 20, 2004
020036 003	PAMIDRONATE DISODIUM;AREDIA	4711880	JUL 29, 2005		D-68	AUG 20, 2004
020036 004	PAMIDRONATE DISODIUM;AREDIA	4711880	JUL 29, 2005		D-68	AUG 20, 2004
020987 001	PANTOPRAZOLE SODIUM;PROTONIX	4758579	JUL 19, 2010		NCE	FEB 02, 2005
		5997903	DEC 07, 2016		I-330	JUN 12, 2004
					I-356	APR 19, 2005
020987 002	PANTOPRAZOLE SODIUM;PROTONIX	4758579	JUL 19, 2010		I-356	APR 19, 2005
		5997903	DEC 07, 2016		I-330	JUN 12, 2004
					NCE	FEB 02, 2005
020988 001	PANTOPRAZOLE SODIUM;PROTONIX IV	4758579	JUL 19, 2010		NDF	MAR 22, 2004
					NCE	FEB 02, 2005
					I-337	OCT 19, 2004
020819 001	PARICALCITOL;ZEMPLAR	5246925	APR 17, 2012	U314		
		5587497	DEC 24, 2013			
		6136799	APR 08, 2018			
		6361758	APR 08, 2018	DP		
		5246925*PED	OCT 17, 2012			
		5587497*PED	JUN 24, 2014			
		6136799*PED	OCT 08, 2019			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
		6361758*PED	OCT 08, 2018			
					PC	MAR 06, 2004
075356 001	PAROXETINE HYDROCHLORIDE;PAROXETINE HCL				PC	MAR 06, 2004
075356 002	PAROXETINE HYDROCHLORIDE;PAROXETINE HCL				PC	MAR 06, 2004
075356 003	PAROXETINE HYDROCHLORIDE;PAROXETINE HCL				PC	MAR 06, 2004
075356 004	PAROXETINE HYDROCHLORIDE;PAROXETINE HCL					
020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U12	I-326	APR 13, 2004
		5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		PED	OCT 13, 2004
		5789449	JAN 06, 2009	U285	PED	JUN 14, 2005
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U286		
		6133289	MAY 19, 2015	U358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U431		
		4721723*PED	JUN 29, 2007	U12		
		5789449*PED	JUL 06, 2009	U285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U286		
		6121291*PED	SEP 17, 2017	U431		
		6133289*PED	NOV 19, 2015	U358		
		6172233*PED	JUL 15, 2018			
020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U12	I-326	APR 13, 2004
		5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		PED	OCT 13, 2004
		5789449	JAN 06, 2009	U285	PED	JUN 14, 2005
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U286		
		6133289	MAY 19, 2015	U358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U431		
		4721723*PED	JUN 29, 2007	U12		
		5789449*PED	JUL 06, 2009	U285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U286		
		6121291*PED	SEP 17, 2017	U431		
		6133289*PED	NOV 19, 2015	U358		
		6172233*PED	JUL 15, 2018			
020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-326	APR 13, 2004
		5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		PED	OCT 13, 2004
		5789449	JAN 06, 2009	U285	PED	JUN 14, 2005
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U286		
		6133289	MAY 19, 2015	U358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U431		
		4721723*PED	JUN 29, 2007	U12		
		5789449*PED	JUL 06, 2009	U285		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U286		
		6121291*PED	SEP 17, 2017	U431		
		6133289*PED	NOV 19, 2015	U358		
		6172233*PED	JUL 15, 2018			
		6080759	MAY 19, 2015			
		4721723	DEC 29, 2006		I-326	APR 13, 2004
		5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		PED	OCT 13, 2004
		5789449	JAN 06, 2009	U285	PED	JUN 14, 2005
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6133289	MAY 15, 2015	U358		
		6121291	MAR 17, 2017	U286		
		6121291	MAR 17, 2017	U431		
		6172233	JAN 15, 2018			
		4721723*PED	JUN 29, 2007	U12		
		5789449*PED	JUL 06, 2009	U285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U286		
		6121291*PED	SEP 17, 2017	U431		
		6133289*PED	NOV 19, 2015	U358		
		6172233*PED	JUL 15, 2018			
020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006	U12	I-326	APR 13, 2004
		5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		PED	OCT 13, 2004
		5789449	JAN 06, 2009	U285	PED	JUN 14, 2005
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U286		
		6133289	MAY 15, 2015	U358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U431		
		4721723*PED	JUN 29, 2007	U12		
		5789449*PED	JUL 06, 2009	U285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U286		
		6121291*PED	SEP 17, 2017	U431		
		6133289*PED	NOV 19, 2015	U358		
		6172233*PED	JUL 15, 2018			
020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-345	DEC 14, 2004
		5811436	SEP 22, 2015		I-326	APR 13, 2004
		5872132	MAY 19, 2015		PED	JUN 14, 2005
		5900423	MAY 19, 2015		PED	OCT 13, 2004
		5789449	JAN 06, 2009	U285		
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U286		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
		6133289	MAY 19, 2015	U358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U431		
		4721723*PED	JUN 29, 2007			
		5789449*PED	JUL 06, 2009	U285		
		5811436*PED	MAR 22, 2016			
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U286		
		6121291*PED	SEP 17, 2017	U431		
		6133289*PED	NOV 19, 2015	U358		
		6172233*PED	JUL 15, 2018			
020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		I-326	APR 13, 2004
		5789449	JAN 06, 2009	U285	PED	JUN 14, 2005
		4721723	DEC 29, 2006	U12	PED	OCT 13, 2004
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U286		
		6133289	MAY 19, 2015	U358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U431		
		4721723*PED	JUN 29, 2007	U12		
		5789449*PED	JUL 06, 2009	U285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U286		
		6121291*PED	SEP 17, 2017	U431		
		6133289*PED	NOV 19, 2015	U358		
		6172233*PED	JUL 15, 2018			
020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		I-326	APR 13, 2004
		5789449	JAN 06, 2009	U285	PED	JUN 14, 2005
		4721723	DEC 29, 2006	U12	PED	OCT 13, 2004
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U286		
		6133289	MAY 19, 2015	U358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U431		
		4721723*PED	JUN 29, 2007	U12		
		5789449*PED	JUL 06, 2009	U285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U286		
		6121291*PED	SEP 17, 2017	U431		
		6133289*PED	NOV 19, 2015	U358		
		6172233*PED	JUL 15, 2018			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		I-326	APR 13, 2004
		5789449	JAN 06, 2009	U285	PED	JUN 14, 2005
		4721723	DEC 29, 2006	U12	PED	OCT 13, 2004
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U286		
		6133289	MAY 19, 2015	U358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U431		
		4721723*PED	JUN 29, 2007	U12		
		5789449*PED	JUL 06, 2009	U285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U286		
		6121291*PED	SEP 17, 2017	U431		
		6133289*PED	NOV 19, 2015	U358		
		6172233*PED	JUL 15, 2018			
020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		I-326	APR 13, 2004
		5789449	JAN 06, 2009	U285	PED	JUN 14, 2005
		4721723	DEC 29, 2006	U12	PED	OCT 13, 2004
		6062927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U286		
		6133289	MAY 19, 2015	U358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U431		
		4721723*PED	JUN 29, 2007	U12		
		5789449*PED	JUL 06, 2009	U285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U286		
		6121291*PED	SEP 17, 2017	U431		
		6133289*PED	NOV 19, 2015	U358		
		6172233*PED	JUL 15, 2018			
020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		I-358	FEB 12, 2005
		4839177	JUN 13, 2006		PED	AUG 12, 2005
		5422123	JUN 06, 2012		I-405	AUG 28, 2006
		4721723	DEC 29, 2006			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U286		
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U286		
		6133289	MAY 19, 2015	U286		
		6172233	JAN 15, 2018			
		4721723*PED	JUN 29, 2007			
		4839177*PED	DEC 13, 2006			
		5422123*PED	DEC 06, 2012			
		5789449*PED	JUL 06, 2009	U286		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U286		
		6133289*PED	NOV 19, 2015	U286		
		6172233*PED	JUL 15, 2018			
		6548084	JUL 19, 2016			
		6548084*PED	JAN 19, 2017			
020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		I-358	FEB 12, 2005
		4839177	JUN 13, 2006		PED	AUG 12, 2005
		5422123	JUN 06, 2012		I-405	AUG 28, 2006
		4721723	DEC 29, 2006			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U286		
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U286		
		6133289	MAY 19, 2015	U286		
		6172233	JAN 15, 2018			
		4721723*PED	JUN 29, 2007			
		4839177*PED	DEC 13, 2006			
		5422123*PED	DEC 06, 2012			
		5789449*PED	JUL 06, 2009	U286		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U286		
		6133289*PED	NOV 19, 2015	U286		
		6172233*PED	JUL 15, 2018			
		6548084	JUL 19, 2016			
		6548084*PED	JAN 19, 2017			
020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	4721723	DEC 29, 2006		I-358	FEB 12, 2005
		4839177	JUN 13, 2006		PED	AUG 12, 2005
		5422123	JUN 06, 2012		I-405	AUG 28, 2006
		5789449	JAN 06, 2009	U286		
		5872132	MAY 19, 2015			
		5900423	MAY 19, 2015			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U286		
		6133289	MAY 19, 2015	U286		
		6172233	JAN 15, 2018			
		4721723*PED	JUN 29, 2007			
		4839177*PED	DEC 13, 2006			
		5422123*PED	DEC 06, 2012			
		5789449*PED	JUL 06, 2009	U286		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U286		
		6133289*PED	NOV 19, 2015	U286		
		6172233*PED	JUL 15, 2018			
		6548084	JUL 19, 2016			
		6548084*PED	JAN 19, 2017			
021299 001	PAROXETINE MESYLATE;PAROXETINE MESYLATE	5874447	JUN 10, 2017	U286		
		5874447	JUN 10, 2017	U518		
		5874447	JUN 10, 2017	U46		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021299 002	PAROXETINE MESYLATE;PAROXETINE MESYLATE	5874447	JUN 10, 2017	U286		
		5874447	JUN 10, 2017	U518		
		5874447	JUN 10, 2017	U46		
021299 003	PAROXETINE MESYLATE;PAROXETINE MESYLATE	5874447	JUN 10, 2017	U286		
		5874447	JUN 10, 2017	U518		
		5874447	JUN 10, 2017	U46		
021299 004	PAROXETINE MESYLATE;PAROXETINE MESYLATE	5874447	JUN 10, 2017	U286		
		5874447	JUN 10, 2017	U518		
		5874447	JUN 10, 2017	U46		
021106 001	PEGVISOMANT;SOMAVERT	6057292	SEP 21, 2015	U507	NCE	MAR 25, 2008
		5849535	SEP 21, 2015		ODE	MAR 25, 2010
		5958879	SEP 27, 2011	U507		
		5350836	SEP 27, 2011	U507		
		5681809	SEP 27, 2011	U507		
		6583115	SEP 27, 2011	U507		
021106 002	PEGVISOMANT;SOMAVERT	6057292	SEP 21, 2015	U507	NCE	MAR 25, 2008
		5849535	SEP 21, 2015		ODE	MAR 25, 2010
		5958879	SEP 27, 2011	U507		
		5350836	SEP 27, 2011	U507		
		5681809	SEP 27, 2011	U507		
		6583115	SEP 27, 2011	U507		
021106 003	PEGVISOMANT;SOMAVERT	6057292	SEP 21, 2015	U507	NCE	MAR 25, 2008
		5849535	SEP 21, 2015		ODE	MAR 25, 2010
		5958879	SEP 27, 2011	U507		
		5350836	SEP 27, 2011	U507		
		5681809	SEP 27, 2011	U507		
		6583115	SEP 27, 2011	U507		
021079 001	PEMIROLAST POTASSIUM;ALAMAST	5034230	DEC 23, 2008	U184	PED	MAR 24, 2005
		5034230*PED	JUN 23, 2009	U184	NCE	SEP 24, 2004
020629 001	PENCICLOVIR SODIUM;DENAVIR	5075445	SEP 24, 2010		NPP	OCT 10, 2006
		6469015	OCT 22, 2019	U501		
		6573378	SEP 24, 2010			
		6579981	JUN 17, 2020	U501		
020193 001	PENTOSAN POLYSULFATE SODIUM;ELMIRON	5180715	JAN 19, 2010	U159	ODE	SEP 26, 2003
021084 001	PERFLUOROPOLYMETHYLISOPROPYL ETHER;SKIN EXPOSURE RED	5607979	MAY 30, 2015		NCE	FEB 17, 2005
021064 001	PERFLUTREN;DEFINITY	5527521	APR 05, 2011		NCE	JUL 31, 2006
		5547656	APR 05, 2011			
		5769080	JUL 20, 2010			
019385 001	PERGOLIDE MESYLATE;PERMAX	4797405	OCT 26, 2007			
		5114948	OCT 19, 2009			
019385 002	PERGOLIDE MESYLATE;PERMAX	4797405	OCT 26, 2007			
		5114948	OCT 19, 2009			
019385 003	PERGOLIDE MESYLATE;PERMAX	4797405	OCT 26, 2007			
		5114948	OCT 19, 2009			
020184 001	PERINDOPRIL ERBUMINE;ACEON	4508729	AUG 21, 2006			
		5162362	NOV 10, 2009	DS DP U531		
020184 002	PERINDOPRIL ERBUMINE;ACEON	4508729	AUG 21, 2006			
		5162362	NOV 10, 2009	DS DP U531		
020184 003	PERINDOPRIL ERBUMINE;ACEON	4508729	AUG 21, 2006			
		5162362	NOV 10, 2009	DS DP U531		
020237 001	PILOCARPINE HYDROCHLORIDE;SALAGEN				ODE	FEB 11, 2005
021302 001	PIMECROLIMUS;ELIDEL	5912238	JUN 15, 2016		NCE	DEC 13, 2006
		5912238*PED	DEC 15, 2016		PED	JUN 13, 2007
		6352998	OCT 26, 2015			
		6352998*PED	APR 26, 2016			
		6423722	JUN 26, 2018			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6423722*PED	DEC 26, 2018			
		4687777	JAN 17, 2011		NCE	JUL 15, 2004
		6211205	JUN 19, 2016	U410		
		6271243	JUN 19, 2016	U411		
		6303640	AUG 09, 2016	U425		
		6166042	JUN 19, 2016	U414		
		6166043	JUN 19, 2016	U415		
		6172090	JUN 19, 2016	U416		
		5965584	JUN 19, 2016	U417		
		6150383	JUN 19, 2016	U418		
		6150384	JUN 19, 2016	U419		
		6329404	JUN 19, 2016	U430		
021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4687777	JAN 17, 2011		NCE	JUL 15, 2004
		6211205	JUN 19, 2016	U410		
		6271243	JUN 19, 2016	U411		
		6303640	AUG 09, 2016	U425		
		6166042	JUN 19, 2016	U414		
		6166043	JUN 19, 2016	U415		
		6172090	JUN 19, 2016	U416		
		5965584	JUN 19, 2016	U417		
		6150383	JUN 19, 2016	U418		
		6150384	JUN 19, 2016	U419		
		6329404	JUN 19, 2016	U430		
021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	4687777	JAN 17, 2011		NCE	JUL 15, 2004
		6211205	JUN 19, 2016	U410		
		6271243	JUN 19, 2016	U411		
		6303640	AUG 09, 2016	U425		
		6166042	JUN 19, 2016	U414		
		6166043	JUN 19, 2016	U415		
		6172090	JUN 19, 2016	U416		
		5965584	JUN 19, 2016	U417		
		6150383	JUN 19, 2016	U418		
		6150384	JUN 19, 2016	U419		
		6329404	JUN 19, 2016	U430		
020014 001	PIRBUTEROL ACETATE;MAXAIR	4664107	MAY 12, 2004			
020529 001	PODOFILOX;CONDYLOX	4680399	JUL 14, 2004			
		5057616	OCT 15, 2008			
020698 001	POLYETHYLENE GLYCOL 3350;MIRALAX	5710183	JUL 14, 2015	U265		
		6048901	APR 20, 2019	U343		
020744 001	PORACTANT ALFA;CUROSURF				NCE	NOV 18, 2004
020451 001	PORFIMER SODIUM;PHOTOFRIN	4866168	MAR 10, 2004		I-391	AUG 01, 2006
		5028621	MAR 10, 2004		ODE	AUG 01, 2010
		5438071	AUG 01, 2012			
		4649151	MAR 10, 2004			
		4932934	JUN 12, 2007	U128		
		5145863	DEC 15, 2009	U129		
019439 002	POTASSIUM CHLORIDE;K-DUR 10	4863743	SEP 05, 2006	U99		
019439 001	POTASSIUM CHLORIDE;K-DUR 20	4863743	SEP 05, 2006	U99		
074726 003	POTASSIUM CHLORIDE;KLOR-CON M15				PC	DEC 24, 2003
020667 001	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
		4843086	NOV 23, 2007	U231		
020667 002	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
		4843086	NOV 23, 2007	U231		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020667 003	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
		4843086	NOV 23, 2007	U231		
020667 004	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
		4843086	NOV 23, 2007	U231		
020667 005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
		4843086	NOV 23, 2007	U231		
020667 006	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
		4843086	NOV 23, 2007	U231		
019898 002	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		D-70	DEC 18, 2004
		5180589	JUL 09, 2008		PED	DEC 09, 2003
		5030447	JUL 09, 2008		PED	JUL 18, 2003
		5622985	APR 22, 2014	U335	PED	JUL 18, 2003
		4346227*PED	APR 20, 2006		PED	AUG 10, 2003
		5180589*PED	JAN 09, 2009		PED	JUN 18, 2005
		5622985*PED	OCT 22, 2014	U335	PED	JUL 18, 2003
		5030447*PED	JAN 09, 2009		I-370	OCT 29, 2005
					PED	APR 29, 2006
019898 003	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		D-70	DEC 18, 2004
		5030447	JUL 09, 2008		PED	DEC 09, 2003
		5180589	JUL 09, 2008		PED	JUL 18, 2003
		5622985	APR 22, 2014	U335	PED	JUL 18, 2003
		4346227*PED	APR 20, 2006		PED	AUG 10, 2003
		5180589*PED	JAN 09, 2009		PED	JUN 18, 2005
		5622985*PED	OCT 22, 2014	U335	PED	JUL 18, 2003
		5030447*PED	JAN 09, 2009		I-370	OCT 29, 2005
					PED	APR 29, 2006
019898 004	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		D-70	DEC 18, 2004
		5030447	JUL 09, 2008		PED	DEC 09, 2003
		5180589	JUL 09, 2008		PED	JUL 18, 2003
		5622985	APR 22, 2014	U335	PED	JUL 18, 2003
		4346227*PED	APR 20, 2006		PED	AUG 10, 2003
		5180589*PED	JAN 09, 2009		PED	JUN 18, 2005
		5622985*PED	OCT 22, 2014	U335	PED	JUL 18, 2003
		5030447*PED	JAN 09, 2009		I-370	OCT 29, 2005
					PED	APR 29, 2006
019898 008	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		NS	DEC 18, 2004
		5030447	JUL 09, 2008		D-70	DEC 18, 2004
		5180589	JUL 09, 2008		PED	JUN 18, 2005
		5622985	APR 22, 2014	U335	PED	JUN 18, 2005
		4346227*PED	APR 20, 2006		PED	DEC 09, 2003
		5180589*PED	JAN 09, 2009		PED	JUL 18, 2003
		5622985*PED	OCT 22, 2014	U335	PED	JUL 18, 2003
		5030447*PED	JAN 09, 2009		PED	AUG 10, 2003
					PED	JUL 18, 2003
					I-370	OCT 29, 2005
					PED	APR 29, 2006
019775 001	PRAZOSIN HYDROCHLORIDE;MINIPRESS XL	4783337	SEP 16, 2003			
		4612008	SEP 16, 2003			
		4765989	SEP 16, 2003			
		5082668	SEP 16, 2003			
019775 002	PRAZOSIN HYDROCHLORIDE;MINIPRESS XL	4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
		4765989	SEP 16, 2003			
		5082668	SEP 16, 2003			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020545 001	PROCAINAMIDE HYDROCHLORIDE;PROCANBID	5656296	AUG 12, 2014			
020545 002	PROCAINAMIDE HYDROCHLORIDE;PROCANBID	5656296	AUG 12, 2014			
020701 001	PROGESTERONE;CRINONE	4615697	OCT 07, 2003	U208		
		5543150	SEP 15, 2013	U209		
020701 002	PROGESTERONE;CRINONE	4615697	OCT 07, 2003	U208		
		5543150	SEP 15, 2013	U209		
021416 001	PROPAFENONE HYDROCHLORIDE;RYTHMOL SR	5681588	OCT 28, 2014		NDF	SEP 04, 2006
021416 002	PROPAFENONE HYDROCHLORIDE;RYTHMOL SR	5681588	OCT 28, 2014		NDF	SEP 04, 2006
021416 003	PROPAFENONE HYDROCHLORIDE;RYTHMOL SR	5681588	OCT 28, 2014		NDF	SEP 04, 2006
019627 002	PROPOFOL;DIPRIVAN	5714520	MAR 22, 2015		I-322	FEB 20, 2004
		5714520*PED	SEP 22, 2015		PED	AUG 20, 2004
		5731355	MAR 22, 2015	U217		
		5731355*PED	SEP 22, 2015	U217		
		5731356	MAR 22, 2015	U218		
		5731356*PED	SEP 22, 2015	U218		
		5908869	MAR 22, 2015	U270		
		5908869*PED	SEP 22, 2015	U270		
019536 001	PROPRANOLOL HYDROCHLORIDE;INDERAL	4600708	JUL 19, 2005			
021438 001	PROPRANOLOL HYDROCHLORIDE;INNOPRAN XL	6500454	DEC 31, 2022		NP	MAR 12, 2006
021438 002	PROPRANOLOL HYDROCHLORIDE;INNOPRAN XL	6500454	DEC 31, 2022		NP	MAR 12, 2006
020021 002	PSEUDOEPHEDRINE HYDROCHLORIDE;EFIDAC 24 PSEUDOEPHEDRINE HCL	RE01461	MAR 14, 2006			
020639 001	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
020639 002	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
020639 003	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
020639 005	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
019885 001	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U210		
		5747504	APR 10, 2005	U210		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U210		
		5747504*PED	OCT 10, 2005	U210		
019885 002	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U210		
		5747504	APR 10, 2005	U210		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U210		
		5747504*PED	OCT 10, 2005	U210		
019885 003	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U210		
		5747504	APR 10, 2005	U210		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U210		
		5747504*PED	OCT 10, 2005	U210		
019885 004	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U210		
		5747504	APR 10, 2005	U210		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U210		
		5747504*PED	OCT 10, 2005	U210		
020973 001	RABEPRAZOLE SODIUM;ACIPHEX	5035899	APR 04, 2009	U385	NCE	AUG 19, 2004
		5045552	MAY 08, 2013	U385	I-346	FEB 12, 2005

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020973 002	RABEPRAZOLE SODIUM;ACIPHEX	5045552	MAY 08, 2013	U385	NCE	AUG 19, 2004
		5035899	APR 04, 2009	U385	I-346	FEB 12, 2005
					I-371	NOV 08, 2005
020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	5393763	JUL 28, 2012	U114		
		5457117	JUL 28, 2012	U114		
		5478847	MAR 02, 2014	U114		
		5811120	MAR 02, 2014			
		5972383	MAR 02, 2014	U287		
		6458811	MAR 10, 2017			
019901 001	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
		5061722	OCT 19, 2008			
		5403856	APR 04, 2012	U71		
019901 002	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
		5061722	OCT 19, 2008			
		5403856	APR 04, 2012	U71		
019901 003	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
		5061722	OCT 19, 2008			
		5403856	APR 04, 2012	U71		
019901 004	RAMIPRIL;ALTACE	5061722	OCT 19, 2008		I-310	OCT 04, 2003
		4587258	JAN 27, 2005			
		5403856	APR 04, 2012	U71		
020559 001	RANITIDINE BISMUTH CITRATE;TRITEC	5629297	MAY 13, 2014	U186		
		5008256	JUL 17, 2009			
		5256684	OCT 26, 2010	U199		
		5403830	APR 04, 2012	U200		
		5407688	APR 04, 2012	U201		
		5601848	FEB 11, 2014	U202		
		5456925	OCT 10, 2012			
019090 001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004			
		4585790*PED	NOV 11, 2004			
019593 001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004			
019593 002	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004			
		4585790*PED	NOV 11, 2004			
019675 001	RANITIDINE HYDROCHLORIDE;ZANTAC	4585790	MAY 11, 2004			
		5068249	NOV 26, 2008			
		5068249*PED	MAY 26, 2009			
		4585790*PED	NOV 11, 2004			
020095 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5028432	FEB 22, 2010			
		5028432*PED	AUG 22, 2010			
020251 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5102665	JUN 23, 2009			
		5102665*PED	DEC 23, 2009			
020251 002	RANITIDINE HYDROCHLORIDE;ZANTAC 150	5102665	JUN 23, 2009			
		5102665*PED	DEC 23, 2009			
020095 002	RANITIDINE HYDROCHLORIDE;ZANTAC 300	5028432	FEB 22, 2010			
		5028432*PED	AUG 22, 2010			
020520 001	RANITIDINE HYDROCHLORIDE;ZANTAC 75	4880636	MAY 13, 2008			
		4880636*PED	NOV 13, 2008			
020984 001	RAPACURONIUM BROMIDE;RAPLON	5418226	APR 14, 2013		NCE	AUG 18, 2004
020984 002	RAPACURONIUM BROMIDE;RAPLON	5418226	APR 14, 2013		NCE	AUG 18, 2004
020630 001	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583*PED	AUG 15, 2009			
		5466700	AUG 30, 2013	U156		
		5019583	FEB 15, 2009			
		5466700*PED	MAR 01, 2014	U156		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020630 002	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583	FEB 15, 2009			
		5466700	AUG 30, 2013	U156		
		5019583*PED	AUG 15, 2009			
		5466700*PED	MAR 01, 2014			
020630 003	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583	FEB 15, 2009			
		5466700	AUG 30, 2013	U156		
		5019583*PED	AUG 15, 2009			
		5466700*PED	MAR 01, 2014	U156		
020741 001	REPAGLINIDE;PRANDIN	5312924	SEP 05, 2006		I-367	OCT 21, 2005
		6143769	SEP 05, 2006			
		RE37035	MAR 14, 2009			
020741 002	REPAGLINIDE;PRANDIN	5312924	SEP 05, 2006	U214	I-367	OCT 21, 2005
		6143769	SEP 05, 2006			
		RE37035	MAR 14, 2009			
020741 003	REPAGLINIDE;PRANDIN	5312924	SEP 05, 2006	U214	I-367	OCT 21, 2005
		6143769	SEP 05, 2006			
		RE37035	MAR 14, 2009			
021511 001	RIBAVIRIN;COPEGUS				NP	DEC 03, 2005
020903 001	RIBAVIRIN;REBETOL	5767097	JAN 23, 2016	U235	M-26	MAR 06, 2005
		5914128	DEC 22, 2017		ODE	JUL 29, 2010
		6051252	DEC 22, 2017		PED	JAN 29, 2011
		6063772	JAN 23, 2016	U375		
		6172046	SEP 21, 2017	U377		
		5767097*PED	JUL 23, 2016	U235		
		5914128*PED	JUN 22, 2018			
		6051252*PED	JUN 22, 2018			
		6063772*PED	JUL 23, 2016	U375		
		6172046*PED	MAR 21, 2018	U377		
		6335032	DEC 22, 2017			
		6335032*PED	JUN 22, 2018			
		6337090	DEC 22, 2017			
		6337090*PED	JUN 22, 2018			
		6177074	NOV 01, 2016	U454		
		6177074*PED	MAY 01, 2017	U454		
		6461605	NOV 01, 2016	U478		
		6461605*PED	MAY 01, 2017	U478		
		6472373	SEP 21, 2017	U479		
		6472373*PED	MAR 21, 2018	U479		
		6524570	NOV 01, 2016	U499		
		6524570*PED	MAY 01, 2017	U499		
		6335032	DEC 22, 2017		M-26	MAR 06, 2005
020903 002	RIBAVIRIN;REBETOL	6335032*PED	JUN 22, 2018		ODE	JUL 29, 2010
		5767097	JAN 23, 2016	U235	PED	JAN 29, 2011
		5767097*PED	JUL 23, 2016	U235		
		5914128	DEC 22, 2017			
		5914128*PED	JUN 22, 2018			
		6051252	DEC 22, 2017			
		6051252*PED	JUN 22, 2018			
		6063772	JAN 23, 2016	U375		
		6063772*PED	JUL 23, 2016	U375		
		6172046	SEP 21, 2017	U377		
		6172046*PED	MAR 21, 2018	U377		
		6337090	DEC 22, 2017			
		6337090*PED	JUN 22, 2018			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021546 001	RIBAVIRIN;REBETOL	6472373	SEP 21, 2017	U521	NDF	JUL 29, 2006
		6472373*PED	MAR 21, 2018	U521	PED	JAN 29, 2007
		6461605	NOV 01, 2016	U521	ODE	JUL 29, 2010
		6461605*PED	MAY 01, 2017	U521	PED	JAN 29, 2011
		6172046	SEP 21, 2017	U521		
		6172046*PED	MAR 21, 2018	U521		
		6063772	JAN 23, 2016	U521		
		6063772*PED	JUL 23, 2016	U521		
		5767097	JAN 23, 2016	U521		
		5767097*PED	JUL 23, 2016	U521		
018859 001	RIBAVIRIN;VIRAZOLE	6150337	NOV 21, 2017	U400		
021024 001	RIFAPENTINE;PRIFTIN				ODE	JUN 22, 2005
020599 001	RILUZOLE;RILUTEK	5527814	JUN 18, 2013			
020474 001	RIMEXOLONE;VEXOL	4686214	JUL 22, 2008	U100		
020835 001	RISEDRONATE SODIUM;ACTONEL	5583122	DEC 10, 2013	U222		
		6096342	NOV 22, 2011			
		6165513	JUN 10, 2018			
020835 002	RISEDRONATE SODIUM;ACTONEL	5583122	DEC 10, 2013	U222		
		6096342	NOV 22, 2011			
		6165513	JUN 10, 2018			
020835 003	RISEDRONATE SODIUM;ACTONEL	5994329	JUL 17, 2018	U353	D-73	MAY 17, 2005
		6015801	JUL 17, 2018	U353	D-74	MAY 17, 2005
		5583122	DEC 10, 2013	U222		
		6096342	NOV 22, 2011			
		6165513	JUN 10, 2018			
020272 001	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U90	M-15	MAR 03, 2005
					I-412	DEC 04, 2006
					I-413	DEC 04, 2006
020272 002	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U90	M-15	MAR 03, 2005
					I-412	DEC 04, 2006
					I-413	DEC 04, 2006
020272 003	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U90	M-15	MAR 03, 2005
					I-412	DEC 04, 2006
					I-413	DEC 04, 2006
020272 004	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U90	M-15	MAR 03, 2005
					I-412	DEC 04, 2006
					I-413	DEC 04, 2006
020272 005	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U90	M-15	MAR 03, 2005
					I-412	DEC 04, 2006
					I-413	DEC 04, 2006
020272 007	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U90	M-15	MAR 03, 2005
					I-412	DEC 04, 2006
					I-413	DEC 04, 2006
020272 008	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U90	M-15	MAR 03, 2005
					I-412	DEC 04, 2006
					I-413	DEC 04, 2006
020588 001	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U90	M-15	MAR 03, 2005
		5453425	JUL 11, 2014		I-412	DEC 04, 2006
		5616587	JUL 11, 2014		I-413	DEC 04, 2006
021444 001	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U516	M-15	MAR 03, 2005
		5648093	JUL 15, 2014		I-412	DEC 04, 2006
		6224905	JUN 10, 2017	U516	I-413	DEC 04, 2006

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021444 002	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007	U516	M-15	MAR 03, 2005
		5648093	JUL 15, 2014		I-412	DEC 04, 2006
		6224905	JUN 10, 2017	U516	I-413	DEC 04, 2006
021444 003	RISPERIDONE;RISPERDAL	4804663	DEC 29, 2007		M-15	MAR 03, 2005
		5648093	JUL 15, 2014		I-412	DEC 04, 2006
		6224905	JUN 10, 2017	U516	I-413	DEC 04, 2006
				U516		
021346 001	RISPERIDONE;RISPERDAL CONSTA	4804663	DEC 29, 2007		NDF	OCT 29, 2006
		5688801	NOV 18, 2014			
		5770231	NOV 19, 2013			
		5965168	NOV 19, 2013			
		6110921	NOV 19, 2013			
		5792477	MAY 02, 2017			
		5916598	MAY 02, 2017			
		6110503	MAY 02, 2017			
		6194006	DEC 30, 2018			
		6264987	MAY 19, 2020			
		6596316	DEC 30, 2008	DP		
		6379703	DEC 30, 2018	DP		
		6379704	MAY 19, 2020	DP		
		6534092	MAY 19, 2020	DP		
		6544559	NOV 19, 2013			
		6368632	NOV 19, 2013	U543		
		6403114	MAY 02, 2017			
021346 002	RISPERIDONE;RISPERDAL CONSTA	4804663	DEC 29, 2007		NDF	OCT 29, 2006
		5688801	NOV 18, 2014			
		5770231	NOV 19, 2013			
		5965168	NOV 19, 2013			
		6110921	NOV 19, 2013			
		5792477	MAY 02, 2017			
		5916598	MAY 02, 2017			
		6110503	MAY 02, 2017			
		6194006	DEC 30, 2018			
		6264987	MAY 19, 2020			
		6596316	DEC 30, 2008	DP		
		6379703	DEC 30, 2018	DP		
		6379704	MAY 19, 2020	DP		
		6534092	MAY 19, 2020	DP		
		6544559	NOV 19, 2013			
		6368632	NOV 19, 2013	U543		
		6403114	MAY 02, 2017			
021346 003	RISPERIDONE;RISPERDAL CONSTA	4804663	DEC 29, 2007		NDF	OCT 29, 2006
		5688801	NOV 18, 2014			
		5770231	NOV 19, 2013			
		5965168	NOV 19, 2013			
		6110921	NOV 19, 2013			
		5792477	MAY 02, 2017			
		5916598	MAY 02, 2017			
		6110503	MAY 02, 2017			
		6194006	DEC 30, 2018			
		6264987	MAY 19, 2020			
		6596316	DEC 30, 2008	DP		
		6379703	DEC 30, 2018	DP		
		6379704	MAY 19, 2020	DP		
		6534092	MAY 19, 2020	DP		
		6544559	NOV 19, 2013			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
		6368632	NOV 19, 2013	U543		
		6403114	MAY 02, 2017			
020659 001	RITONAVIR;NORVIR	5635523	JUN 03, 2014	U190		
		5484801	JAN 28, 2014			
		5541206	JUL 30, 2013	U140		
		5648497	JUL 15, 2014			
		5846987	DEC 29, 2012	U190		
		6037157	JUN 26, 2016			
		5674882	OCT 07, 2014			
		5886036	DEC 29, 2012			
020680 001	RITONAVIR;NORVIR	5635523	JUN 03, 2014	U190		
		5541206	JUL 30, 2013	U140		
		5648497	JUL 15, 2014			
		5846987	DEC 29, 2012	U190		
		5948436	SEP 13, 2013			
020945 001	RITONAVIR;NORVIR	5648497	JUL 15, 2014			
		5846987	DEC 29, 2012	U347		
		5541206	JUL 30, 2013	U348		
		5635523	JUN 03, 2014	U347		
		6232333	NOV 07, 2017			
020823 003	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U322		
020823 004	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U322		
020823 005	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U322		
020823 006	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U322		
021025 001	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U322		
020864 001	RIZATRIPTAN BENZOATE;MAXALT	5298520	JUN 29, 2012	U240		
		5602162	FEB 11, 2014			
020864 002	RIZATRIPTAN BENZOATE;MAXALT	5298520	JUN 29, 2012	U240		
		5602162	FEB 11, 2014			
020865 001	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JUN 29, 2012	U240		
		5602162	FEB 11, 2014	U240		
		5457895	OCT 01, 2013			
020865 002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JUN 29, 2012	U240		
		5602162	FEB 11, 2014	U240		
		5457895	OCT 01, 2013			
020214 002	ROCURONIUM BROMIDE;ZEMURON	4894369	APR 13, 2008			
020214 001	ROCURONIUM BROMIDE;ZEMURON (P/F)	4894369	APR 13, 2008			
021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U266	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U266	M-27	AUG 06, 2006
		6239173	JUN 24, 2013			
021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U266	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U266	M-27	AUG 06, 2006
		6239173	JUN 24, 2013			
021042 003	ROFECOXIB;VIOXX	6239173	JUN 24, 2013		NCE	MAY 20, 2004
		5474995	JUN 24, 2013	U266	I-353	APR 11, 2005
		5691374	MAY 18, 2015		M-27	AUG 06, 2006
		6063811	MAY 06, 2017			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021052 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U266	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U266	M-27	AUG 06, 2006
		6239173	JUN 24, 2013			
021052 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U266	NCE	MAY 20, 2004
		5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U266	M-27	AUG 06, 2006
		6239173	JUN 24, 2013			
020658 001	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
		4824860	MAY 19, 2008	U212		
020658 002	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
		4824860	MAY 19, 2008	U212		
020658 003	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
		4824860	MAY 19, 2008	U212		
020658 004	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
		4824860	MAY 19, 2008	U212		
020658 005	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
		4824860	MAY 19, 2008	U212		
020658 006	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
		4824860	MAY 19, 2008			
020658 007	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
		4824860	MAY 19, 2008			
020533 001	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4870086	SEP 24, 2010		D-64	NOV 02, 2003
		4695576	SEP 22, 2004			
020533 003	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4695576	SEP 22, 2004		D-64	NOV 02, 2003
		4870086	SEP 24, 2010			
020533 004	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4695576	SEP 22, 2004		D-64	NOV 02, 2003
		4870086	SEP 24, 2010			
020533 005	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN	4695576	SEP 22, 2004		D-64	NOV 02, 2003
		4870086	SEP 24, 2010			
021071 002	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U329	NCE	MAY 25, 2004
		5741803	APR 21, 2015	U329	I-384	FEB 27, 2006
		6288095	FEB 11, 2017	U420		
021071 003	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U329	NCE	MAY 25, 2004
		5741803	APR 21, 2015	U329	I-384	FEB 27, 2006
		6288095	FEB 11, 2017	U420		
021071 004	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U329	NCE	MAY 25, 2004
		5741803	APR 21, 2015	U329	I-384	FEB 27, 2006
		6288095	FEB 11, 2017	U420		
021366 002	ROSUVASTATIN CALCIUM;CRESTOR	RE37314	JUN 12, 2012		NCE	AUG 12, 2008
		6589959	DEC 23, 2019			
		6316460	AUG 04, 2020			
021366 003	ROSUVASTATIN CALCIUM;CRESTOR	RE37314	JUN 12, 2012		NCE	AUG 12, 2008
		6589959	DEC 23, 2019			
		6316460	AUG 04, 2020			
021366 004	ROSUVASTATIN CALCIUM;CRESTOR	RE37314	JUN 12, 2012		NCE	AUG 12, 2008
		6589959	DEC 23, 2019			
		6316460	AUG 04, 2020			
021366 005	ROSUVASTATIN CALCIUM;CRESTOR	RE37314	JUN 12, 2012		NCE	AUG 12, 2008
		6589959	DEC 23, 2019			
		6316460	AUG 04, 2020			
019414 001	RUBIDIUM CHLORIDE RB-82;CARDIOGEN-82	4562829	MAY 01, 2004	U503		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020772 001	SACROSIDASE;SUCRAID				ODE	APR 09, 2005
020236 001	SALMETEROL XINAFOATE;SEREVENT	4992474	FEB 12, 2008			
		5225445	FEB 12, 2008	U182		
		5126375	FEB 12, 2008			
020692 001	SALMETEROL XINAFOATE;SEREVENT	4992474	FEB 12, 2008		I-348	MAR 22, 2005
		5225445	FEB 12, 2008	U211		
		5126375	FEB 12, 2008			
		5290815	MAR 01, 2011	U386		
020570 001	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM;QUADRAMET	4898724	FEB 06, 2007	U187		
020628 001	SAQUINAVIR MESYLATE;INVIRASE	5196438	NOV 19, 2010			
020828 001	SAQUINAVIR;FORTOVASE	5196438	NOV 19, 2010			
		6352717	NOV 16, 2019			
		6008228	JUN 06, 2015			
021136 001	SECRETIN;SECREFLO				NP	APR 04, 2005
					ODE	APR 04, 2009
					I-408	NOV 01, 2005
021209 001	SECRETIN;SECREFLO				NP	APR 04, 2005
					ODE	APR 04, 2009
019863 001	SERMORELIN ACETATE;GEREF	4703035	DEC 28, 2004	U47		
020443 001	SERMORELIN ACETATE;GEREF	4703035	DEC 28, 2004		ODE	SEP 26, 2004
020443 002	SERMORELIN ACETATE;GEREF	4703035	DEC 28, 2004		ODE	SEP 26, 2004
021385 001	SERTACONAZOLE NITRATE;ERTACZO				NCE	DEC 10, 2008
019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U12	M-11	AUG 06, 2004
		4962128*PED	MAY 02, 2010	U152	PED	FEB 06, 2005
		4962128	NOV 02, 2009	U152	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U12	I-261	FEB 07, 2006
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U461		
		5789449	JAN 06, 2009	U460		
019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U12	M-11	AUG 06, 2004
		4536518*PED	JUN 30, 2006	U12	PED	FEB 06, 2005
		4962128	NOV 02, 2009	U152	I-355	MAY 16, 2005
		4962128*PED	MAY 02, 2010	U152	I-261	FEB 07, 2006
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U461		
		5789449	JAN 06, 2009	U460		
019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U12	PED	FEB 06, 2005
		4536518*PED	JUN 30, 2006	U12	M-11	AUG 06, 2004
		4962128	NOV 02, 2009	U152	I-355	MAY 16, 2005
		4962128*PED	MAY 02, 2010	U152	I-261	FEB 07, 2006
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U461		
		5789449	JAN 06, 2009	U460		
019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U12	PED	FEB 06, 2005
		4536518*PED	JUN 30, 2006	U12	M-11	AUG 06, 2004
		4962128	NOV 02, 2009	U152	I-355	MAY 16, 2005
		4962128*PED	MAY 02, 2010	U152	I-261	FEB 07, 2006
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U461		
		5789449	JAN 06, 2009	U460		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U12	M-11	AUG 06, 2004
		4536518*PED	JUN 30, 2006	U12	PED	FEB 06, 2005
		4962128	NOV 02, 2009	U152	I-355	MAY 16, 2005
		4962128*PED	MAY 02, 2010	U152	I-261	FEB 07, 2006
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U461		
		5789449	JAN 06, 2009	U460		
020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U286	M-11	AUG 06, 2004
		4536518*PED	JUN 30, 2006	U286	PED	FEB 06, 2005
		5248699	AUG 13, 2012		I-355	MAY 16, 2005
		5248699*PED	FEB 13, 2013		I-261	FEB 07, 2006
		5744501	JAN 06, 2009	U461		
		5789449	JAN 06, 2009	U460		
020926 001	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U246	NCE	OCT 30, 2003
		5667775	SEP 16, 2014	U246		
		6509013	AUG 13, 2013			
021179 001	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U246	NCE	OCT 30, 2003
		5667775	SEP 16, 2014	U246		
		6509013	AUG 13, 2013			
021179 002	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U246	NCE	OCT 30, 2003
		5667775	SEP 16, 2014	U246		
		6509013	AUG 13, 2013			
020478 001	SEVOFLURANE;ULTANE	5990176	JAN 27, 2017		M-17	MAR 30, 2004
		6074668	JAN 09, 2018		PED	SEP 30, 2004
		5990176*PED	JUL 27, 2017			
		6074668*PED	JUL 09, 2018			
		6288127	JAN 27, 2017			
		6288127*PED	JUL 27, 2017			
		6444859	JAN 27, 2017			
		6444859*PED	JUL 27, 2017			
020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007		D-65	FEB 16, 2004
		4929629	MAY 29, 2007		M-9	FEB 16, 2004
		5436272	JUL 25, 2012	U439		
020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007		D-65	FEB 16, 2004
		4929629	MAY 29, 2007		M-9	FEB 16, 2004
		5436272	JUL 25, 2012	U439		
020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA	4746680	JUN 11, 2007		D-65	FEB 16, 2004
		4929629	MAY 29, 2007		M-9	FEB 16, 2004
		5436272	JUL 25, 2012	U439		
020895 001	SILDENAFIL CITRATE;VIAGRA	5250534	MAR 27, 2012			
		6469012	OCT 22, 2019	U155		
020895 002	SILDENAFIL CITRATE;VIAGRA	5250534	MAR 27, 2012			
		6469012	OCT 22, 2019	U155		
020895 003	SILDENAFIL CITRATE;VIAGRA	5250534	MAR 27, 2012			
		6469012	OCT 22, 2019	U155		
019766 001	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U59	I-350	OCT 18, 2005
		RE36481	JUL 10, 2007	U300	PED	APR 18, 2006
		RE36520	MAY 26, 2009	U300	I-390	APR 16, 2006
		4444784*PED	JUN 23, 2006	U59		
		RE36481*PED	JAN 10, 2008	U300		
		RE36520*PED	NOV 26, 2009	U300		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019766 002	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U59	I-350	OCT 18, 2005
		RE36481	JUL 10, 2007	U300	PED	APR 18, 2006
		RE36520	MAY 26, 2009	U300	I-390	APR 16, 2006
		4444784*PED	JUN 23, 2006	U59		
		RE36481*PED	JAN 10, 2008	U300		
		RE36520*PED	NOV 26, 2009	U300		
019766 003	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U59	I-350	OCT 18, 2005
		RE36481	JUL 10, 2007	U300	PED	APR 18, 2006
		RE36520	MAY 26, 2009	U300	I-390	APR 16, 2006
		4444784*PED	JUN 23, 2006	U59		
		RE36481*PED	JAN 10, 2008	U300		
		RE36520*PED	NOV 26, 2009	U300		
019766 004	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U59	I-350	OCT 18, 2005
		RE36481	JUL 10, 2007	U300	PED	APR 18, 2006
		RE36520	MAY 26, 2009	U300	I-390	APR 16, 2006
		4444784*PED	JUN 23, 2006	U59		
		RE36481*PED	JAN 10, 2008	U300		
		RE36520*PED	NOV 26, 2009	U300		
019766 005	SIMVASTATIN;ZOCOR	4444784	DEC 23, 2005	U59	I-350	OCT 18, 2005
		RE36481	JUL 10, 2007	U300	PED	APR 18, 2006
		RE36520	MAY 26, 2009	U300	I-390	APR 16, 2006
		4444784*PED	JUN 23, 2006	U59		
		RE36481*PED	JAN 10, 2008	U300		
		RE36520*PED	NOV 26, 2009	U300		
021083 001	SIROLIMUS;RAPAMUNE	5100899	JUN 06, 2009	U290	NCE	SEP 15, 2004
		5212155	MAY 18, 2010	U291	I-386	APR 11, 2006
		5308847	MAY 03, 2011	U292		
		5403833	APR 04, 2012	U293		
		5536729	SEP 30, 2013			
021110 001	SIROLIMUS;RAPAMUNE	5100899	JUN 06, 2009	U290	NCE	SEP 15, 2004
		5212155	MAY 18, 2010	U291	I-386	APR 11, 2006
		5308847	MAY 03, 2011	U292		
		5403833	APR 04, 2012	U293		
		5989591	MAR 11, 2018			
021110 002	SIROLIMUS;RAPAMUNE	5100899	JUN 06, 2009	U290	NCE	SEP 15, 2004
		5212155	MAY 18, 2010	U291	I-386	APR 11, 2006
		5308847	MAY 03, 2011	U292		
		5403833	APR 04, 2012	U293		
		5989591	MAR 11, 2018			
020955 001	SODIUM FERRIC GLUCONATE COMPLEX;FERRLECIT				NCE	FEB 18, 2004
020231 001	SODIUM FLUORIDE;COLGATE TOTAL	5288480	JUL 16, 2008			
		4894220	JAN 16, 2007	DP		
		5037635	JAN 16, 2007	DP		
		5156835	OCT 20, 2009	DP		
		5344641	MAR 09, 2010	DP		
		5538715	JAN 16, 2007	DP		
		5776435	JAN 16, 2007	DP		
021196 001	SODIUM OXYBATE;XYREM				ODE	JUL 17, 2009
					NCE	JUL 17, 2007
020572 001	SODIUM PHENYLBUTYRATE;BUPHENYL	4457942	AUG 20, 2004	U136		
020573 001	SODIUM PHENYLBUTYRATE;BUPHENYL	4457942	AUG 20, 2004	U136		
021097 001	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS;VISICOL	5616346	MAY 18, 2013	U359	NP	SEP 21, 2003

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019107 001	SOMATREM;PROTROPIN	4658021	APR 14, 2004			
020280 006	SOMATROPIN RECOMBINANT;GENOTROPIN	4968299	JUN 28, 2008		ODE	OCT 31, 2004
		5633352	MAR 10, 2015		ODE	JUN 20, 2007
					I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN	4968299	JUN 28, 2008		ODE	JUN 20, 2007
		5633352	MAR 10, 2015		I-334	JUL 25, 2004
					ODE	JUL 25, 2008
					ODE	OCT 31, 2004
020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		6152897	JUN 11, 2018		ODE	JUL 25, 2008
		5633352	MAR 10, 2015		ODE	OCT 31, 2004
020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		6152897	JUN 11, 2018		ODE	JUL 25, 2008
		5633352	MAR 10, 2015		ODE	OCT 31, 2004
020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		6152897	JUN 11, 2018		ODE	JUL 25, 2008
		5633352	MAR 10, 2015		ODE	OCT 31, 2004
020280 004	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5633352	MAR 10, 2015		ODE	OCT 31, 2004
					ODE	JUN 20, 2007
					I-334	JUL 25, 2004
					ODE	JUL 25, 2008
020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		6152897	JUN 11, 2018		ODE	JUL 25, 2008
		5633352	MAR 10, 2015		ODE	OCT 31, 2004
020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		6152897	JUN 11, 2018		ODE	JUL 25, 2008
		5633352	MAR 10, 2015		ODE	OCT 31, 2004
020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		6152897	JUN 11, 2018		ODE	JUL 25, 2008
		5633352	MAR 10, 2015		ODE	OCT 31, 2004
020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		5633352	MAR 10, 2015		ODE	JUL 25, 2008
					ODE	OCT 31, 2004
020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5716338	FEB 10, 2015		ODE	JUN 20, 2007
		5435076	APR 16, 2013		I-334	JUL 25, 2004
		5633352	MAR 10, 2015		ODE	JUL 25, 2008
					ODE	OCT 31, 2004
020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		5633352	MAR 10, 2015		ODE	JUL 25, 2008
					ODE	OCT 31, 2004
020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVATIVE FREE	5435076	APR 16, 2013		ODE	JUN 20, 2007
		5716338	FEB 10, 2015		I-334	JUL 25, 2004
		5633352	MAR 10, 2015		ODE	JUL 25, 2008
					ODE	OCT 31, 2004

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019640 001	SOMATROPIN RECOMBINANT;HUMATROPE				ODE	DEC 30, 2003
					I-398	JUL 25, 2006
019640 004	SOMATROPIN RECOMBINANT;HUMATROPE				ODE	DEC 30, 2003
					I-398	JUL 25, 2006
019640 005	SOMATROPIN RECOMBINANT;HUMATROPE				ODE	DEC 30, 2003
					I-398	JUL 25, 2006
019640 006	SOMATROPIN RECOMBINANT;HUMATROPE				ODE	DEC 30, 2003
					I-398	JUL 25, 2006
019640 007	SOMATROPIN RECOMBINANT;HUMATROPE				ODE	DEC 30, 2003
					I-398	JUL 25, 2006
019721 001	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
019721 002	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
021148 001	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
		5849700	DEC 15, 2015	U340		
		5849704	DEC 15, 2015			
021148 002	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
		5849700	DEC 15, 2015	U340		
		5849704	DEC 15, 2015			
021148 003	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
		5849700	DEC 15, 2015	U340		
		5849704	DEC 15, 2015			
019676 001	SOMATROPIN RECOMBINANT;NUTROPIN				ODE	OCT 29, 2004
019676 002	SOMATROPIN RECOMBINANT;NUTROPIN				ODE	OCT 29, 2004
020168 001	SOMATROPIN RECOMBINANT;NUTROPIN				ODE	DEC 30, 2003
020168 002	SOMATROPIN RECOMBINANT;NUTROPIN				ODE	DEC 30, 2003
021075 001	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5656297	JUL 25, 2014			
		5654010	AUG 05, 2014			
		6051259	DEC 02, 2012	U340		
		5912015	MAR 12, 2012			
021075 002	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5656297	JUL 25, 2014			
		5654010	AUG 05, 2014			
		6051259	DEC 02, 2012	U340		
		5912015	MAR 12, 2012			
021075 003	SOMATROPIN RECOMBINANT;NUTROPIN DEPOT	5656297	JUL 25, 2014			
		5654010	AUG 05, 2014			
		6051259	DEC 02, 2012	U340		
		5912015	MAR 12, 2012			
020604 001	SOMATROPIN RECOMBINANT;SEROSTIM				ODE	AUG 23, 2003
020604 002	SOMATROPIN RECOMBINANT;SEROSTIM				ODE	AUG 23, 2003
020604 004	SOMATROPIN RECOMBINANT;SEROSTIM				ODE	AUG 23, 2003
021597 001	SOMATROPIN RECOMBINANT;ZORBTIVE				NP	DEC 01, 2006
					ODE	DEC 01, 2010
021597 002	SOMATROPIN RECOMBINANT;ZORBTIVE				NP	DEC 01, 2006
					ODE	DEC 01, 2010
021597 003	SOMATROPIN RECOMBINANT;ZORBTIVE				NP	DEC 01, 2006
					ODE	DEC 01, 2010
021597 004	SOMATROPIN RECOMBINANT;ZORBTIVE				NP	DEC 01, 2006
					ODE	DEC 01, 2010
019865 001	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
019865 002	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019865 003	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
019865 004	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
019865 005	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
					M-13	OCT 01, 2004
021151 001	SOTALOL HYDROCHLORIDE;BETAPACE AF				PED	AUG 22, 2003
021151 002	SOTALOL HYDROCHLORIDE;BETAPACE AF				PED	AUG 22, 2003
021151 003	SOTALOL HYDROCHLORIDE;BETAPACE AF				PED	AUG 22, 2003
021151 005	SOTALOL HYDROCHLORIDE;BETAPACE AF				PED	AUG 22, 2003
021151 006	SOTALOL HYDROCHLORIDE;BETAPACE AF				PED	AUG 22, 2003
021151 007	SOTALOL HYDROCHLORIDE;BETAPACE AF				PED	AUG 22, 2003
020677 001	SPARFLOXACIN;ZAGAM	4795751	FEB 04, 2010	U160		
020240 001	SPIRAPRIL HYDROCHLORIDE;RENORMAX	4470972	SEP 11, 2003	U3		
020240 002	SPIRAPRIL HYDROCHLORIDE;RENORMAX	4470972	SEP 11, 2003	U3		
020240 003	SPIRAPRIL HYDROCHLORIDE;RENORMAX	4470972	SEP 11, 2003	U3		
020240 004	SPIRAPRIL HYDROCHLORIDE;RENORMAX	4470972	SEP 11, 2003	U3		
020412 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U94		
		4978655*PED	DEC 24, 2008	U94		
020412 002	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U94		
		4978655*PED	DEC 24, 2008	U94		
020412 003	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U94		
		4978655*PED	DEC 24, 2008	U94		
020412 004	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U94		
		4978655*PED	DEC 24, 2008	U94		
020412 005	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U94		
		4978655*PED	DEC 24, 2008	U94		
020413 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008			
		4978655*PED	DEC 24, 2008			
021453 001	STAVUDINE;ZERIT XR	4978655	JUN 24, 2008	U248	NDF	DEC 31, 2005
		4978655*PED	DEC 24, 2008	U248	PED	JUL 01, 2006
021453 002	STAVUDINE;ZERIT XR	4978655	JUN 24, 2008	U248	NDF	DEC 31, 2005
		4978655*PED	DEC 24, 2008	U248	PED	JUL 01, 2006
021453 003	STAVUDINE;ZERIT XR	4978655	JUN 24, 2008	U248	NDF	DEC 31, 2005
		4978655*PED	DEC 24, 2008	U248	PED	JUL 01, 2006
021453 004	STAVUDINE;ZERIT XR	4978655	JUN 24, 2008	U248	NDF	DEC 31, 2005
		4978655*PED	DEC 24, 2008	U248	PED	JUL 01, 2006
007073 002	SULFASALAZINE;AZULFIDINE EN-TABS				I-308	AUG 18, 2003
020080 001	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
020132 001	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		6368627	MAR 02, 2012	U444		
		5863559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
020132 002	SUMATRIPTAN SUCCINATE;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008	U72		
		6368627	MAR 02, 2012	U444		
		5863559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		
020132 003	SUMATRIPTAN SUCCINATE;IMITREX	5037845	AUG 06, 2008	U72		
		4816470	DEC 28, 2006	U72		
		6368627	MAR 02, 2012	U444		
		5863559	JAN 26, 2016	U72		
		6020001	MAR 02, 2012	U444		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020626 001	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011	U232		
020626 002	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011	U232		
020626 003	SUMATRIPTAN;IMITREX	4816470	DEC 28, 2006	U72		
		5037845	AUG 06, 2008			
		5307953	DEC 02, 2012			
		5554639	SEP 10, 2013	U232		
		5705520	DEC 10, 2011	U232		
020070 001	TACRINE HYDROCHLORIDE;COGNEX	4631286	OCT 25, 2004	U97		
		4816456	SEP 09, 2007			
020070 002	TACRINE HYDROCHLORIDE;COGNEX	4631286	OCT 25, 2004	U97		
		4816456	SEP 09, 2007			
020070 003	TACRINE HYDROCHLORIDE;COGNEX	4631286	OCT 25, 2004	U97		
		4816456	SEP 09, 2007			
020070 004	TACRINE HYDROCHLORIDE;COGNEX	4631286	OCT 25, 2004	U97		
		4816456	SEP 09, 2007			
021368 001	TADALAFIL;CIALIS				NCE	NOV 21, 2008
021368 002	TADALAFIL;CIALIS				NCE	NOV 21, 2008
021368 003	TADALAFIL;CIALIS				NCE	NOV 21, 2008
020587 001	TALC;SCLEROSOL				ODE	DEC 24, 2004
017970 001	TAMOXIFEN CITRATE;NOLVADEX				M-20	AUG 30, 2005
					PED	MAR 01, 2006
020579 001	TAMSULOSIN HYDROCHLORIDE;FLOMAX	4868216	SEP 19, 2006	U181		
		4731478	OCT 27, 2004			
		4703063	OCT 27, 2009			
		4772475	FEB 27, 2006			
021184 003	TAZAROTENE;AVAGE	5089509	JUN 13, 2011	U481	NP	SEP 30, 2005
020600 001	TAZAROTENE;TAZORAC	5089509	JUN 13, 2011	U193		
		5089509	JUN 13, 2011	U481		
		5914334	JUN 07, 2014	U517		
		6258830	JUN 07, 2014	U517		
020600 002	TAZAROTENE;TAZORAC	5089509	JUN 13, 2011	U193		
		5089509	JUN 13, 2011	U481		
		5914334	JUN 07, 2014	U517		
		6258830	JUN 07, 2014	U517		
021184 001	TAZAROTENE;TAZORAC	5089509	JUN 13, 2011	U481	NDF	SEP 29, 2003
021184 002	TAZAROTENE;TAZORAC	5089509	JUN 13, 2011	U481	NDF	SEP 29, 2003
					I-344	OCT 11, 2004
020887 001	TECHNETIUM TC-99M APCITIDE;ACUTECT	5508020	APR 16, 2013		NCE	SEP 14, 2003
		5645815	JUL 08, 2014			
		5443815	AUG 22, 2012			
020256 001	TECHNETIUM TC-99M BICISATE KIT;NEUROLITE	5279811	NOV 23, 2008	U101		
		5431900	JUL 11, 2012	U336		
021012 001	TECHNETIUM TC-99M DEPREOTIDE;NEO TECT KIT				NCE	AUG 03, 2004
019829 001	TECHNETIUM TC-99M EXAMETAZIME KIT;CERETEC	4615876	OCT 07, 2003			
		4789736	DEC 06, 2005			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019981 001	TECHNETIUM TC-99M RED BLOOD CELL KIT;ULTRATAG	4755375	JUL 05, 2005	U51		
019785 001	TECHNETIUM TC-99M SESTAMIBI KIT;CARDIOLITE	4452774	DEC 21, 2004			
		4894445	JAN 16, 2007	U337		
		5324824	JAN 16, 2007			
		4885100	SEP 11, 2007			
		4988827	JAN 29, 2008			
019785 003	TECHNETIUM TC-99M SESTAMIBI KIT;MIRALUMA	4452774	DEC 21, 2004			
		4894445	JAN 16, 2007	U337		
		5324824	JAN 16, 2007			
		4885100	SEP 11, 2007			
		4988827	JAN 29, 2008			
019928 001	TECHNETIUM TC-99M TEBOROXIME KIT;CARDIOTEC	4705849	NOV 10, 2004			
020372 001	TECHNETIUM TC-99M TETROFOSMIN KIT;MYOVIEW	5045302	AUG 14, 2008		I-396	FEB 28, 2006
021200 001	TEGASEROD MALEATE;ZELNORM	5510353	APR 26, 2013	U466	NCE	JUL 24, 2007
021200 002	TEGASEROD MALEATE;ZELNORM	5510353	APR 26, 2013	U466	NCE	JUL 24, 2007
020850 001	TELMISARTAN;MICARDIS	5591762	JAN 07, 2014	U3	NCE	NOV 10, 2003
		6358986	JAN 10, 2020			
020850 002	TELMISARTAN;MICARDIS	5591762	JAN 07, 2014	U3	NCE	NOV 10, 2003
		6358986	JAN 10, 2020			
020850 003	TELMISARTAN;MICARDIS	5591762	JAN 07, 2014	U3	NCE	NOV 10, 2003
		6358986	JAN 10, 2020			
018163 003	TEMAZEPAM;RESTORIL	5030632	JUL 09, 2008	U70		
		5326758	JUL 09, 2008	U70		
		5211954	MAY 18, 2010			
021029 001	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
		5260291*PED	MAY 09, 2011		ODE	AUG 11, 2006
					PED	FEB 11, 2005
					PED	FEB 11, 2007
021029 002	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
		5260291*PED	MAY 09, 2011		ODE	AUG 11, 2006
					PED	FEB 11, 2005
					PED	FEB 11, 2007
021029 003	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
		5260291*PED	MAY 09, 2011		ODE	AUG 11, 2006
					PED	FEB 11, 2005
					PED	FEB 11, 2007
021029 004	TEMOZOLOMIDE;TEMODAR	5260291	NOV 09, 2010		NCE	AUG 11, 2004
		5260291*PED	MAY 09, 2011		ODE	AUG 11, 2006
					PED	FEB 11, 2005
					PED	FEB 11, 2007
021356 001	TENOFOVIR DISOPROXIL FUMARATE;VIREAD	5977089	JUL 25, 2017	U248	NCE	OCT 26, 2006
		6043230	JUL 25, 2017	U248	NPP	AUG 15, 2006
		5935946	JUL 25, 2017	U248		
		4808716	APR 25, 2006	U248		
		6057305	MAY 02, 2017	U248		
		5922695	JUL 25, 2017	U248		
019057 001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5412095	APR 29, 2013			
		5212176	JUN 29, 2010			
		5294615	APR 29, 2013	U165		
				U3		
019057 002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5412095	APR 29, 2013			
		5212176	JUN 29, 2010			
		5294615	APR 29, 2013	U165		
				U3		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019057 003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5412095	APR 29, 2013			
		5212176	JUN 29, 2010			
		5294615	APR 29, 2013	U165		
				U3		
019057 004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5412095	APR 29, 2013			
		5212176	JUN 29, 2010			
		5294615	APR 29, 2013	U165		
				U3		
020347 001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5212176	JUN 29, 2010			
		5412095	APR 29, 2013			
		5294615	APR 29, 2013	U165		
				U3		
020347 002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5212176	JUN 29, 2010			
		5412095	APR 29, 2013			
		5294615	APR 29, 2013	U165		
				U3		
020347 003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5212176	JUN 29, 2010			
		5412095	APR 29, 2013			
		5294615	APR 29, 2013	U165		
				U3		
020347 004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5212176	JUN 29, 2010			
		5412095	APR 29, 2013			
		5294615	APR 29, 2013	U165		
				U3		
020192 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006	U73		
020539 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006	U73		
		4680291	JUL 14, 2004	U281		
020749 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4755534	DEC 30, 2006			
		6121314	MAY 18, 2012	U502		
020980 001	TERBINAFINE HYDROCHLORIDE;LAMISIL	4680291	JUL 14, 2004	U73		
		4755534	DEC 30, 2006	U73		
021124 001	TERBINAFINE HYDROCHLORIDE;LAMISIL AT	4680291	JUL 14, 2004	U73		
		4755534	DEC 30, 2006	U73		
		5681849	OCT 28, 2014			
		6121314	MAY 18, 2012	U504		
020846 001	TERBINAFINE;LAMISIL	4755534	DEC 30, 2006	U445		
		4680291	JUL 14, 2004	U445		
021318 001	TERIPARATIDE RECOMBINANT HUMAN;FORTEO				NP	NOV 26, 2005
020489 001	TESTOSTERONE;ANDRODERM	4863970	NOV 14, 2006			
		4983395	NOV 12, 2007			
		5152997	DEC 11, 2010	U490		
		5164190	DEC 11, 2010			
		4849224	NOV 12, 2007			
		4855294	SEP 06, 2008			
020489 002	TESTOSTERONE;ANDRODERM	4849224	NOV 12, 2007			
		4855294	SEP 06, 2008			
		4863970	NOV 14, 2006			
		4983395	NOV 12, 2007			
		5152997	DEC 11, 2010	U490		
		5164190	DEC 11, 2010			
021015 001	TESTOSTERONE;ANDROGEL	6503894	AUG 30, 2020	U490		
021543 001	TESTOSTERONE;STRIANT	4615697	OCT 07, 2003		NP	JUN 19, 2006
		6248358	AUG 23, 2019	U527		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021454 001	TESTOSTERONE;TESTIM	5023252	JUN 11, 2008	U483	NP	OCT 31, 2005
019762 001	TESTOSTERONE;TESTODERM	4704282	NOV 03, 2004			
		4725439	FEB 16, 2005			
		4867982	FEB 16, 2005			
		5840327	AUG 15, 2016			
019762 002	TESTOSTERONE;TESTODERM	4704282	NOV 03, 2004			
		4867982	FEB 16, 2005			
		4725439	FEB 16, 2005			
		5840327	AUG 15, 2016			
020791 001	TESTOSTERONE;TESTODERM TTS	6348210	NOV 10, 2019	U440		
020785 001	THALIDOMIDE;THALOMID	6045501	AUG 28, 2018	U371	NCE	JUL 16, 2003
		6315720	OCT 23, 2020	U442	ODE	JUL 16, 2005
		6561977	OCT 23, 2020	U371		
		6561976	AUG 28, 2018	U371		
020785 002	THALIDOMIDE;THALOMID	6045501	AUG 28, 2018	U371	ODE	JUL 16, 2005
		6315720	OCT 23, 2020	U442	NCE	JUL 16, 2003
		6561977	OCT 23, 2020	U371		
		6561976	AUG 28, 2018	U371		
020785 003	THALIDOMIDE;THALOMID	6045501	AUG 28, 2018	U371	ODE	JUL 16, 2005
		6315720	OCT 23, 2020	U442	NCE	JUL 16, 2003
		6561977	OCT 23, 2020	U371		
		6561976	AUG 28, 2018	U371		
020898 001	THYROTROPIN ALFA;THYROGEN	5674711	AUG 31, 2010		ODE	NOV 30, 2005
		5602006	FEB 11, 2014		NCE	NOV 30, 2003
		5658760	AUG 19, 2014			
		5240832	AUG 31, 2010			
		6114144	NOV 24, 2015			
		5840566	NOV 24, 2015			
020646 001	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
		5354760	MAR 24, 2012			
		5958951	JUN 10, 2017			
		5866590	APR 29, 2016			
020646 002	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
		5354760	MAR 24, 2012			
		5958951	JUN 10, 2017			
		5866590	APR 29, 2016			
020646 003	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
		5354760	MAR 24, 2012			
		5958951	JUN 10, 2017			
		5866590	APR 29, 2016			
020646 004	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
		5354760	MAR 24, 2012			
		5958951	JUN 10, 2017			
		5866590	APR 29, 2016			
020646 005	TIAGABINE HYDROCHLORIDE;GABITRIL	5010090	SEP 30, 2011			
		5354760	MAR 24, 2012			
		5958951	JUN 10, 2017			
		5866590	APR 29, 2016			
020707 001	TILUDRONATE DISODIUM;SKELID	4876248	JAN 30, 2010			
		4980171	APR 06, 2009			
020963 001	TIMOLOL MALEATE;TIMOLOL MALEATE	6174524	MAR 26, 2019			
020963 002	TIMOLOL MALEATE;TIMOLOL MALEATE	6174524	MAR 26, 2019			

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020330 001	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	SEP 25, 2006			
020330 002	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	SEP 25, 2006			
020439 001	TIMOLOL;BETIMOL	5231095	JUL 27, 2010			
020439 002	TIMOLOL;BETIMOL	5231095	JUL 27, 2010			
020484 001	TINZAPARIN SODIUM;INNOHEP				NCE	JUL 14, 2005
020912 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U230		
		5658929	MAR 08, 2011			
		5733919	OCT 23, 2016			
		5880136	SEP 27, 2010	U254		
		5965581	OCT 23, 2016			
		5972967	OCT 23, 2016			
		5978698	OCT 08, 2017			
		6136794	JAN 29, 2019			
020913 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	5292756	MAY 14, 2012	U230		
		5658929	MAR 08, 2011			
		5733919	OCT 23, 2016			
		5880136	SEP 27, 2010	U254		
		5965581	OCT 23, 2016			
		5972967	OCT 23, 2016			
		5978698	OCT 08, 2017			
		6136794	JAN 29, 2019			
021447 001	TIZANIDINE HYDROCHLORIDE;ZANAFLEX	6455557	NOV 28, 2021			
021447 002	TIZANIDINE HYDROCHLORIDE;ZANAFLEX	6455557	NOV 28, 2021			
021447 003	TIZANIDINE HYDROCHLORIDE;ZANAFLEX	6455557	NOV 28, 2021			
050753 001	TOBRAMYCIN;TOBI				ODE	DEC 22, 2004
020697 001	TOLCAPONE;TASMAR	5236952	JAN 29, 2012			
		5476875	DEC 19, 2012	U219		
020697 002	TOLCAPONE;TASMAR	5236952	JAN 29, 2012			
		5476875	DEC 19, 2012	U219		
020771 001	TOLTERODINE TARTRATE;DETROL	5382600	MAR 25, 2012			
		5559269	NOV 05, 2013	U318		
		5382600*PED	SEP 25, 2012			
		5559269*PED	MAY 05, 2014			
020771 002	TOLTERODINE TARTRATE;DETROL	5382600	MAR 25, 2012			
		5559269	NOV 05, 2013	U318		
		5382600*PED	SEP 25, 2012			
		5550269*PED	MAY 05, 2014			
021228 001	TOLTERODINE TARTRATE;DETROL LA	5382600	MAR 25, 2012		NDF	DEC 22, 2003
		5559269	NOV 05, 2013	U318	PED	JUN 22, 2004
		5382600*PED	SEP 25, 2012			
		5559269*PED	MAY 05, 2014			
		6630162	NOV 11, 2019	DP U544		
		6630162*PED	MAY 11, 2020			
021228 002	TOLTERODINE TARTRATE;DETROL LA	5382600	MAR 25, 2012		NDF	DEC 22, 2003
		5559269	NOV 05, 2013	U318	PED	JUN 22, 2004
		5382600*PED	SEP 25, 2012			
		5559269*PED	MAY 05, 2014			
		6630162	NOV 11, 2019	DP U544		
		6630162*PED	MAY 11, 2020			
020505 001	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004		ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 002	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004		ODE	AUG 28, 2008
					I-335	AUG 28, 2004

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020505 003	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004		ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 004	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004		ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 005	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004		ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 006	TOPIRAMATE;TOPAMAX	4513006	SEP 26, 2004		ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020844 001	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2004		ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020844 002	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2004		ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020844 003	TOPIRAMATE;TOPAMAX SPRINKLE	4513006	SEP 26, 2004		ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020671 001	TOPOTECAN HYDROCHLORIDE;HYCAMTIN	5004758	MAY 28, 2010			
		5004758*PED	NOV 28, 2010			
020497 001	TOREMIFENE CITRATE;FARESTON	4696949	SEP 29, 2009	U196	ODE	MAY 29, 2004
020136 001	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
020136 002	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
020136 003	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
020136 004	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
020137 002	TORSEMIDE;DEMADEX	RE34672	AUG 11, 2006			
		4861786	JUL 08, 2007			
020281 001	TRAMADOL HYDROCHLORIDE;ULTRAM	6339105	OCT 12, 2019	U435		
		6339105*PED	APR 12, 2020	U435		
020281 002	TRAMADOL HYDROCHLORIDE;ULTRAM	6339105	OCT 12, 2019	U435		
		6339105*PED	APR 12, 2020	U435		
020528 001	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
		5744496	APR 28, 2015	U229		
020528 002	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
		5744496	APR 28, 2015	U229		
020528 003	TRANDOLAPRIL;MAVIK	5744496	APR 28, 2015	U229		
		4933361	JUN 12, 2007			
020591 001	TRANDOLAPRIL;TARKA	4933361	JUN 12, 2007			
		5721244	FEB 24, 2015			
020591 002	TRANDOLAPRIL;TARKA	4933361	JUN 12, 2007			
		5721244	FEB 24, 2015			
020591 003	TRANDOLAPRIL;TARKA	4933361	JUN 12, 2007			
		5721244	FEB 24, 2015			
020591 004	TRANDOLAPRIL;TARKA	4933361	JUN 12, 2007			
		5721244	FEB 24, 2015			
021257 001	TRAVOPROST;TRAVATAN	6011062	DEC 22, 2014	U382	NCE	MAR 16, 2006
		5631287	DEC 22, 2014	U382	M-23	FEB 13, 2006
		5849792	DEC 22, 2014	U383		
		5889052	AUG 03, 2013	U383		
		6235781	JUN 15, 2019	U382		
021272 001	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U455	NCE	MAY 21, 2007
					ODE	MAY 21, 2009
021272 002	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U455	NCE	MAY 21, 2007
					ODE	MAY 21, 2009
021272 003	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U455	NCE	MAY 21, 2007
					ODE	MAY 21, 2009

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021272 004	TREPROSTINIL SODIUM;REMODULIN	5153222	OCT 06, 2009	U455	NCE	MAY 21, 2007
					ODE	MAY 21, 2009
020404 003	TRETINOIN;AVITA	4971800	NOV 20, 2007	U178		
		5045317	SEP 03, 2008	U179		
019963 001	TRETINOIN;RENOVA	4603146	JUL 29, 2003	U131		
		RE36068	JUL 29, 2003	U131		
021108 001	TRETINOIN;RENOVA	RE36068	JUL 29, 2003	U131	NP	AUG 31, 2003
		4603146	JUL 29, 2003	U131		
		6531141	MAR 07, 2020			
020475 001	TRETINOIN;RETIN-A MICRO	4690825	OCT 04, 2005	U134		
		5955109	SEP 21, 2016	U134		
020475 002	TRETINOIN;RETIN-A MICRO	4690825	OCT 04, 2005	U134	NS	MAY 10, 2005
		5955109	SEP 21, 2016	U134		
019798 001	TRIAMCINOLONE ACETONIDE;NASACORT	4767612	JAN 23, 2007	U85		
020468 001	TRIAMCINOLONE ACETONIDE;NASACORT AQ	5976573	JUL 03, 2016	U295		
		6143329	JUL 03, 2016			
074973 001	TRIMETHOPRIM HYDROCHLORIDE;PRIMSOL	5763449	AUG 07, 2016			
		5962461	AUG 07, 2016			
020326 001	TRIMETREXATE GLUCURONATE;NEUTREXIN	4694007	MAY 20, 2006	U91		
		4376858	MAY 09, 2004			
		6017922	MAY 18, 2018			
020326 002	TRIMETREXATE GLUCURONATE;NEUTREXIN	6017922	MAY 18, 2018			
021288 001	TRIPTORELIN PAMOATE;TRELSTAR	5225205	JUL 20, 2010		NP	JUN 29, 2004
					NCE	JUN 15, 2005
020715 001	TRIPTORELIN PAMOATE;TRELSTAR DEPOT	5225205	JUL 20, 2010		NCE	JUN 15, 2005
		5776885	JUL 07, 2015			
020719 001	TROGLITAZONE;PRELAY	4572912	NOV 09, 2008			
		5602133	SEP 15, 2013	U173		
		5859037	NOV 13, 2017	U251		
		6011049	NOV 13, 2017	U301		
		6046202	SEP 15, 2013	U317		
020719 002	TROGLITAZONE;PRELAY	4572912	NOV 09, 2008			
		5602133	SEP 15, 2013	U173		
		5859037	NOV 13, 2017	U251		
		6011049	NOV 13, 2017	U301		
		6046202	SEP 15, 2013	U317		
020719 003	TROGLITAZONE;PRELAY	5602133	SEP 15, 2013	U173		
		4572912	NOV 09, 2008			
		5859037	NOV 13, 2017	U251		
		6011049	NOV 13, 2017	U301		
		6046202	SEP 15, 2013	U317		
020720 001	TROGLITAZONE;REZULIN	5602133	SEP 15, 2013	U173		
		4572912	NOV 09, 2008			
		5859037	NOV 13, 2017	U251		
		6011049	NOV 13, 2017	U301		
		6046202	SEP 15, 2013	U317		
020720 002	TROGLITAZONE;REZULIN	5602133	SEP 15, 2013	U173		
		4572912	NOV 09, 2008			
		5859037	NOV 13, 2017	U251		
		6011049	NOV 13, 2017	U301		
		6046202	SEP 15, 2013	U317		
020720 003	TROGLITAZONE;REZULIN	5602133	SEP 15, 2013	U173		
		4572912	NOV 09, 2008			
		5859037	NOV 13, 2017	U251		
		6011049	NOV 13, 2017	U301		
		6046202	SEP 15, 2013	U317		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020759 001	TROVAFLOXACIN MESYLATE;TROVAN	5164402	DEC 18, 2011	U282		
		5763454	JUN 15, 2015	U282		
		6187341	JAN 20, 2019			
020759 002	TROVAFLOXACIN MESYLATE;TROVAN	5164402	DEC 18, 2011	U282		
		5763454	JUN 15, 2015	U282		
		6187341	JAN 20, 2019			
021214 001	UNOPROSTONE ISOPROPYL;RESCULA	5001153	SEP 19, 2008		NCE	AUG 03, 2005
		5151444	MAR 19, 2008	U333		
		5166178	NOV 24, 2009	U333		
		5212200	MAY 18, 2010	U333		
		5208256	MAY 21, 2011	U333		
		5221763	JUN 22, 2010			
020586 002	UREA, C-13;BREATHTEK UBT FOR H-PYLORI	4830010	OCT 27, 2009	U147		
		5140993	AUG 24, 2009	U148		
020586 001	UREA, C-13;MERETEK UBT KIT (W/ PRANACTIN)	4830010	OCT 27, 2009	U147		
		5140993	AUG 24, 2009	U148		
020617 001	UREA, C-14;PYTEST	4830010	MAY 15, 2006	U195		
020617 002	UREA, C-14;PYTEST KIT	4830010	MAY 15, 2006	U195		
021289 001	UROFOLLITROPIN;BRAVELLE				NP	MAY 06, 2005
					I-377	DEC 19, 2005
019415 004	UROFOLLITROPIN;FERTINEX	5767067	JUN 16, 2015			
		4845077	JUL 04, 2006	U408		
		4725579	FEB 21, 2005	U408		
		4589402	JUL 26, 2004	U482		
019415 005	UROFOLLITROPIN;FERTINEX	5767067	JUN 16, 2015			
		4845077	JUL 04, 2006	U408		
		4725579	FEB 21, 2005	U408		
		4589402	JUL 26, 2004	U482		
020675 001	URSODIOL;URSO	4859660	AUG 22, 2006		ODE	DEC 10, 2004
020487 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX	4957924	JUN 23, 2009	U530	D-67	JUN 25, 2004
		5879706	JAN 19, 2016	U530	I-381	SEP 09, 2005
		6107302	JAN 19, 2016	U530	I-403	AUG 29, 2006
					I-389	APR 01, 2006
020487 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX	5879706	JAN 19, 2016	U530	D-67	JUN 25, 2004
		6107302	JAN 19, 2016	U530	I-381	SEP 09, 2005
		4957924	JUN 23, 2009	U530	I-403	AUG 29, 2006
					I-389	APR 01, 2006
021341 002	VALDECOXIB;BEXTRA	5633272	FEB 13, 2015	U462	NCE	NOV 16, 2006
021341 003	VALDECOXIB;BEXTRA	5633272	FEB 13, 2015	U462	NCE	NOV 16, 2006
021304 001	VALGANCICLOVIR HYDROCHLORIDE;VALCYTE	6083953	JUL 28, 2014	U384	NE	MAR 29, 2004
					I-406	SEP 12, 2006
020593 001	VALPROATE SODIUM;DEPACON				D-72	JAN 24, 2005
020892 001	VALRUBICIN;VALSTAR PRESERVATIVE FREE				NCE	SEP 25, 2003
					ODE	SEP 25, 2005
020665 001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U3	I-365	AUG 14, 2005
020665 002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U3	I-365	AUG 14, 2005
021283 001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		I-365	AUG 14, 2005
		6294197	JUN 18, 2017	U3		
021283 002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		I-365	AUG 14, 2005
		6294197	JUN 18, 2017	U3		
021283 003	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		I-365	AUG 14, 2005
		6294197	JUN 18, 2017	U3		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021283 004	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		I-365	AUG 14, 2005
		6294197	JUN 18, 2017	U3		
021400 001	VARDENAFIL HYDROCHLORIDE;LEVITRA	6362178	OCT 31, 2018	DS DP U533	NCE	AUG 19, 2008
021400 002	VARDENAFIL HYDROCHLORIDE;LEVITRA	6362178	OCT 31, 2018	DS DP U533	NCE	AUG 19, 2008
021400 003	VARDENAFIL HYDROCHLORIDE;LEVITRA	6362178	OCT 31, 2018	DS DP U533	NCE	AUG 19, 2008
021400 004	VARDENAFIL HYDROCHLORIDE;LEVITRA	6362178	OCT 31, 2018	DS DP U533	NCE	AUG 19, 2008
020151 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020151 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020151 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020151 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020151 005	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020151 006	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		4535186*PED	JUN 13, 2008		PED	NOV 02, 2004
020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		6274171	MAR 20, 2017		PED	NOV 02, 2004
		5916923	JUN 28, 2013	U398	I-261	FEB 11, 2006
		6403120	MAR 20, 2017	U451		
		6419958	MAR 20, 2017	U459		
		6444708	JUN 28, 2013	U398		
		4535186*PED	JUN 13, 2008			
		5916923*PED	DEC 28, 2013	U398		
		6274171*PED	SEP 20, 2017			
		6403120*PED	SEP 20, 2017	U451		
		6419958*PED	SEP 20, 2017	U459		
		6444708*PED	DEC 28, 2013	U398		
		6419958	MAR 20, 2017	U535		
		6419958*PED	SEP 20, 2017	U535		
		6403120	MAR 20, 2017	U535		
		6403120*PED	SEP 20, 2017	U535		
020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		6274171	MAR 20, 2017		PED	NOV 02, 2004
		5916923	JUN 28, 2013	U398	I-261	FEB 11, 2006
		6403120	MAR 20, 2017	U451		
		6419958	MAR 20, 2017	U459		
		6444708	JUN 28, 2013	U398		
		4535186*PED	JUN 13, 2008			
		5916923*PED	DEC 28, 2013	U398		
		6274171*PED	SEP 20, 2017			
		6403120*PED	SEP 20, 2017	U451		
		6419958*PED	SEP 20, 2017	U459		
		6444708*PED	DEC 28, 2013	U398		
		6419958	MAR 20, 2017	U535		
		6419958*PED	SEP 20, 2017	U535		
		6403120	MAR 20, 2017	U535		
		6403120*PED	SEP 20, 2017	U535		
020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		6274171	MAR 20, 2017		PED	NOV 02, 2004
		5916923	JUN 28, 2013	U398	I-261	FEB 11, 2006
		6403120	MAR 20, 2017	U451		
		6419958	MAR 20, 2017	U459		
		6444708	JUN 28, 2013	U398		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
		4535186*PED	JUN 13, 2008			
		5916923*PED	DEC 28, 2013	U398		
		6274171*PED	SEP 20, 2017			
		6403120*PED	SEP 20, 2017	U451		
		6419958*PED	SEP 20, 2017	U459		
		6444708*PED	DEC 28, 2013	U398		
		6419958	MAR 20, 2017	U535		
		6419958*PED	SEP 20, 2017	U535		
		6403120	MAR 20, 2017	U535		
		6403120*PED	SEP 20, 2017	U535		
020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-325	MAY 02, 2004
		6274171	MAR 20, 2017		PED	NOV 02, 2004
		5916923	JUN 28, 2013	U398	I-261	FEB 11, 2006
		6403120	MAR 20, 2017	U451		
		6419958	MAR 20, 2017	U459		
		6444708	JUN 28, 2013	U398		
		4535186*PED	JUN 13, 2008			
		5916923*PED	DEC 28, 2013	U398		
		6274171*PED	SEP 20, 2017			
		6403120*PED	SEP 20, 2017	U451		
		6419958*PED	SEP 20, 2017	U459		
		6444708*PED	DEC 28, 2013	U398		
		6419958	MAR 20, 2017	U535		
		6419958*PED	SEP 20, 2017	U535		
		6403120	MAR 20, 2017	U535		
		6403120*PED	SEP 20, 2017	U535		
020552 001	VERAPAMIL HYDROCHLORIDE;COVERA-HS	4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
		5190765	AUG 14, 2007			
		5160744	JUN 27, 2011			
		5252338	JUN 27, 2011			
		5232705	AUG 31, 2010			
		5200196	JAN 22, 2008			
		5141752	JUN 27, 2006			
		5082668	JAN 21, 2009			
		5030456	NOV 07, 2008			
		4946687	OCT 02, 2007			
		5785994	OCT 22, 2009	U315		
		6096339	APR 04, 2017	U365		
		6146662	AUG 14, 2007	U366		
020552 002	VERAPAMIL HYDROCHLORIDE;COVERA-HS	4612008	SEP 16, 2003			
		4783337	SEP 16, 2003			
		5190765	AUG 14, 2007			
		5160744	JUN 27, 2011			
		5252338	JUN 27, 2011			
		5232705	AUG 31, 2010			
		5200196	JAN 22, 2008			
		5141752	JUN 27, 2006			
		5082668	JAN 21, 2009			
		5030456	NOV 07, 2008			
		4946687	OCT 02, 2007			
		5785994	OCT 22, 2009	U315		
		6096339	APR 04, 2017	U365		
		6146662	AUG 14, 2007	U366		

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019614 001	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007	U3		
019614 002	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007	U3		
019614 003	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007	U3		
019614 004	VERAPAMIL HYDROCHLORIDE;VERELAN	4863742	JUN 19, 2007			
020943 001	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
020943 002	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
020943 003	VERAPAMIL HYDROCHLORIDE;VERELAN PM	4863742	JUN 19, 2007			
021119 001	VERTEPORFIN;VISUDYNE	5707608	AUG 02, 2015		NCE	APR 12, 2005
		6074666	FEB 05, 2012		I-336	AUG 22, 2004
		4920143	APR 24, 2007			
		5095030	APR 24, 2007			
		5214036	MAY 25, 2010			
		5770619	JAN 06, 2015	U357		
		5798349	AUG 25, 2015	U357		
		5756541	MAR 11, 2016	U357		
		4883790	JAN 20, 2007			
		5283255	JAN 20, 2007	U357		
014103 003	VINCRISTINE SULFATE;ONCOVIN	4619935	OCT 28, 2003			
021266 001	VORICONAZOLE;VFEND	5116844	AUG 11, 2009	DP U540	NCE	MAY 24, 2007
		5364938	NOV 15, 2011	DS	I-409	NOV 14, 2006
		5567817	OCT 22, 2013	DS DP U540		
		5773443	JAN 25, 2011	DS DP U540		
021266 002	VORICONAZOLE;VFEND	5116844	AUG 11, 2009	DP U540	NCE	MAY 24, 2007
		5364938	NOV 15, 2011	DS	I-409	NOV 14, 2006
		5567817	OCT 22, 2013	DS DP U540		
		5773443	JAN 25, 2011	DS DP U540		
021267 001	VORICONAZOLE;VFEND	5773443	JAN 25, 2011	DS DP U540	NCE	MAY 24, 2007
		5116844	AUG 11, 2009	DP U540	I-409	NOV 14, 2006
		5364938	NOV 15, 2011	DS		
		5567817	OCT 22, 2013	DS DP U540		
		6632803	JUN 02, 2018	DP		
		5376645	JAN 23, 2010	DP		
		5134127	JAN 23, 2010	DP		
020547 001	ZAFIRLUKAST;ACCOLATE	5612367	MAR 18, 2014	U189		
		5583152	SEP 26, 2010			
		4859692	SEP 26, 2010			
		5319097	DEC 11, 2011			
		5294636	DEC 11, 2011			
		5482963	JAN 09, 2013			
		6143775	DEC 11, 2011			
020547 003	ZAFIRLUKAST;ACCOLATE	4859692	SEP 26, 2010			
		5294636	DEC 11, 2011			
		5319097	DEC 11, 2011			
		5482963	JAN 09, 2013			
		5583152	SEP 26, 2010			
		5612367	MAR 18, 2014	U189		
		6143775	DEC 11, 2011			
020199 001	ZALCITABINE;HIVID	5028595	JUL 02, 2008	U65		
		4879277	NOV 07, 2006	U65		
020199 002	ZALCITABINE;HIVID	4879277	NOV 07, 2006	U65		
		5028595	JUL 02, 2008	U65		
020859 001	ZALEPLON;SONATA	4626538	JUN 06, 2008		NCE	AUG 13, 2004
					M-8	FEB 22, 2004

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020859 002	ZALEPLON;SONATA	4626538	JUN 06, 2008		NCE	AUG 13, 2004
					M-8	FEB 22, 2004
021036 001	ZANAMIVIR;RELENZA	5360817	NOV 01, 2011		NCE	JUL 26, 2004
		5648379	JUL 15, 2014	U274		
		6294572	DEC 15, 2014			
019655 001	ZIDOVUDINE;RETROVIR	4724232	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4837208	SEP 17, 2005			
019910 001	ZIDOVUDINE;RETROVIR	4833130	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4837208	SEP 17, 2005			
		4724232	SEP 17, 2005			
019951 001	ZIDOVUDINE;RETROVIR	4833130	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4724232	SEP 17, 2005			
		4837208	SEP 17, 2005			
020518 001	ZIDOVUDINE;RETROVIR	4828838	SEP 17, 2005			
		4837208	SEP 17, 2005			
		4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4833130	SEP 17, 2005			
020518 002	ZIDOVUDINE;RETROVIR	4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4837208	SEP 17, 2005			
020471 001	ZILEUTON;ZYFLO	4873259	DEC 10, 2010	U168		
020471 003	ZILEUTON;ZYFLO	4873259	DEC 10, 2010	U168		
020458 001	ZINC ACETATE;GALZIN				ODE	JAN 28, 2004
020458 002	ZINC ACETATE;GALZIN				ODE	JAN 28, 2004
020825 001	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
		6150366	MAY 27, 2019			
020825 002	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
		6150366	MAY 27, 2019			
020825 003	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
		6150366	MAY 27, 2019			
020825 004	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
		6150366	MAY 27, 2019			
020919 001	ZIPRASIDONE MESYLATE;GEODON	6399777	APR 01, 2017		NCE	FEB 05, 2006
		4831031	MAR 02, 2007		NDF	JUN 21, 2005
		6110918	MAR 26, 2017			
		6232304	APR 01, 2017			
021223 001	ZOLEDRONIC ACID;ZOMETA	4939130	NOV 13, 2007	U53	NCE	AUG 20, 2006
		4777163	JUL 24, 2007		ODE	AUG 20, 2008
					I-361	FEB 22, 2005
021223 002	ZOLEDRONIC ACID;ZOMETA	4777163	JUL 24, 2007		NCE	AUG 20, 2006
		4939130	NOV 13, 2007	U53	I-361	FEB 22, 2005
					ODE	AUG 20, 2008

FDA data supplied by DrugPatentWatch.com

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnote for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020768 001	ZOLMITRIPTAN;ZOMIG	5466699	NOV 14, 2012			
		5863935	NOV 14, 2012			
		5466699*PED	MAY 14, 2013			
		5863935*PED	MAY 14, 2013			
020768 002	ZOLMITRIPTAN;ZOMIG	5466699	NOV 14, 2012			
		5863935	NOV 14, 2012			
		5466699*PED	MAY 14, 2013			
		5863935*PED	MAY 14, 2013			
021450 004	ZOLMITRIPTAN;ZOMIG	5466699	NOV 14, 2012	U436	NDF	SEP 26, 2006
		5466699*PED	MAY 14, 2013		PED	MAR 26, 2007
021231 001	ZOLMITRIPTAN;ZOMIG-ZMT	5466699	NOV 14, 2012		NDF	FEB 13, 2004
		5466699*PED	MAY 14, 2013		PED	AUG 13, 2004
021231 002	ZOLMITRIPTAN;ZOMIG-ZMT	5466699	NOV 14, 2012		NDF	FEB 13, 2004
		5466699*PED	MAY 14, 2013		PED	AUG 13, 2004
019908 001	ZOLPIDEM TARTRATE;AMBIEN	4382938	OCT 21, 2006	U74		
019908 002	ZOLPIDEM TARTRATE;AMBIEN	4382938	OCT 21, 2006	U74		
020789 001	ZONISAMIDE;ZONEGRAN				NCE	MAR 27, 2005
020789 002	ZONISAMIDE;ZONEGRAN				NCE	MAR 27, 2005
020789 003	ZONISAMIDE;ZONEGRAN				NCE	MAR 27, 2005

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(c)(3)(5).

2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
   DS = Drug Substance claim
   DP = Drug Product claim
   U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at http://www.fda.gov/cder/orange/patex.htm

3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT & EXCLUSIVITY ABBREVIATIONS

D	NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES)
I	NEW INDICATION (SEE INDIVIDUAL REFERENCES)
M	MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY
PC	PATENT CHALLENGE
PED	PEDIATRIC EXCLUSIVITY
RTO	RX TO OTC SWITCH OR OTC USE
U	PATENT USE CODE (SEE INDIVIDUAL REFERENCES)
W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE ANNUAL EDITION SECTION 1.8 WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN
D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY
D-28	USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
D-29	INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS
D-30	5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS
D-31	CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY DOSING SCHEDULE

D-32	REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS
D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS
D-34	EVERY FOUR MONTHS DOSAGE REGIMEN
D-35	FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS
D-36	FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY
D-37	DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)
D-38	CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
D-39	CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "..1/2 TO 1 HOUR BEFORE EATING" TO ".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..."
D-40	ONCE-A-DAY DOSING REGIMEN
D-41	DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
D-42	TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
D-43	INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
D-44	IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
D-45	ONCE DAILY DOSING FOR MAINTENANCE ONLY
D-46	NEW DOSING REGIMEN OF 80MG DAILY
D-47	PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
D-48	ADIMISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL
D-49	PEDIATRIC DOSING GUIDELINES
D-50	INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
D-51	OPTIONAL STARTING DOSE OF 40MG/DAY
D-52	ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
D-53	USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
D-54	USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
D-55	ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
D-56	ADDITION OF POSTPRANDIAL DOSING
D-57	3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
D-58	CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
D-59	REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY
D-60	ADDITION OF A POST-OPERATIVE DOSING REGIMEN
D-61	ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-62	ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-63	TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
D-64	INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML
D-65	CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
D-66	DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
D-67	SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
D-68	CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY DOSING SCHEDULE

D-69	SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
D-70	80MG ONCE DAILY DOSING REGIMEN
D-71	EIGHT WEEK DOSING REGIMEN
D-72	INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
D-73	ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-74	ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-75	INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
D-76	FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
D-77	ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)
D-78	USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
D-79	NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
D-80	CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
D-81	NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS
D-82	USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-83	750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
D-84	ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS

EXCLUSIVITY INDICATION

I-1	DYSMENORRHEA
I-2	CHOLANGIOPANCREATOGRAPHY
I-3	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-4	PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)
I-5	HYSTEROSALPINGOGRAPHY
I-6	TREATMENT OF JUVENILE ARTHRITIS
I-7	BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN
I-8	ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY
I-9	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-10	PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY
I-11	RELIEF OF MILD TO MODERATE PAIN
I-12	TREATMENT OF CUTANEOUS CANDIDIASIS
I-13	URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI
I-14	SEBORRHEIC DERMATITIS
I-15	PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
I-16	STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM
I-17	MANAGEMENT OF CONGESTIVE HEART FAILURE
I-18	ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
I-19	HERNIOGRAPHY
I-20	KNEE ARTHROGRAPHY
I-21	HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
I-22	RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY INDICATION

I-23	SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-24	TREATMENT OF RHEUMATOID ARTHRITIS
I-25	ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS
I-26	TREATMENT OF LIVER FLUKES
I-27	ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE
I-28	SELECTIVE ADULT VISCERAL ARTERIOGRAPHY
I-29	METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION
I-30	TREATMENT OF TINEA PEDIS
I-31	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES
I-32	PEDIATRIC MYELOGRAPHY
I-33	ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN
I-34	ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT
I-35	PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING
I-36	ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS
I-37	RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS
I-38	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)
I-39	TREATMENT OF ACUTE MYOCARDIAL INFARCTION
I-40	PRIMARY NOCTURNAL ENURESIS
I-41	MIGRAINE HEADACHE PROPHYLAXIS
I-42	HERPES ZOSTER
I-43	HERPES SIMPLEX ENCEPHALITIS
I-44	MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY
I-45	ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS
I-46	USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING
I-47	TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
I-48	PEDIATRIC ANGIOCARDIOGRAPHY
I-49	TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI
I-50	FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER
I-51	TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS
I-52	PEDIATRIC EXCRETORY UROGRAPHY
I-53	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-54	RENAL CONCENTRATION CAPACITY TEST
I-55	HYPERTENSION
I-56	EROSIVE GASTROESOPHAGEAL REFLUX DISEASE
I-57	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER
I-58	INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS
I-59	ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE
I-60	SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE
I-61	FEMALE ANDROGENETIC ALOPECIA
I-62	PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-63	ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION
I-64	PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS
I-65	PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
I-66	UNCOMPLICATED GONORRHEA
I-67	TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
I-68	CENTRAL PRECOCIOUS PUBERTY

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY INDICATION

I-69	SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
I-70	USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
I-71	VARICELLA INFECTIONS (CHICKENPOX)
I-72	PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE
I-73	INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
I-74	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-75	TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS
I-76	PREVENTION OF OSTEOPOROSIS
I-77	DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM
I-78	CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY
I-79	MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM
I-80	DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE
I-81	PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS
I-82	TREATMENT OF TRAVELERS' DIARRHEA
I-83	ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN
I-84	INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION
I-85	TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
I-86	TREATMENT OF SECONDARY CARNITINE DEFICIENCY
I-87	RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88	MANAGEMENT OF ENDOMETRIOSIS
I-89	EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90	INTENSIVE CARE UNIT SEDATION
I-91	MONOTHERAPY USE FOR HYPERTENSION
I-92	ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94	USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
I-95	TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-96	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
I-97	ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT
I-98	TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY
I-99	PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100	TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102	TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
I-103	PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104	TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105	TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106	TREATMENT OF ACROMEGALY
I-107	VAGINAL CANDIDIASIS
I-108	EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
I-109	TYPHOID FEVER
I-110	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY INDICATION

I-111	TREATMENT OF PAGET'S DISEASE OF BONE
I-112	MANAGEMENT OF MODERATE TO SEVERE PAIN
I-113	TREATMENT OF PROSTATITIS
I-114	USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE
I-115	USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK
I-116	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-117	TO SLOW THE PROGRESSION FO CORONANY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118	PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY
I-119	TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
I-120	MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
I-121	EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS
I-122	PSORIASIS OF THE SCALP
I-123	RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
I-124	LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
I-125	EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
I-126	ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
I-127	TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
I-128	IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...
I-129	TREATMENT OF ALCOHOL DEPENDENCE
I-130	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-131	PERIPHERAL ARTERIOGRAPHY
I-132	TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
I-133	MANAGEMENT OF CHRONIC STABLE ANGINA
I-134	HEART FAILURE POST MYOCARDIAL INFARCTION
I-135	BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
I-136	IDIOPATHIC CHRONIC URTICARIA
I-137	PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
I-138	TREATMENT OF ACUTE RECURRENT GENITAL HERPES
I-139	PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN
I-140	PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE
I-141	TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
I-142	LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION□
I-143	EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS□
I-144	ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
I-145	0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
I-146	CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS
I-147	PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
I-148	TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO2) IS LESS THAN OR EQUAL TO 55 TORR
I-149	TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
I-150	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
I-151	PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
I-152	SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY INDICATION

I-153	MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN]
I-154	PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
I-155	TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT
I-156	ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
I-157	TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES
I-158	TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER
I-159	FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES
I-160	TREATMENT OF BACTERIAL CORNEAL ULCERS
I-161	TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY
I-162	FOR USE IN PATIENTS 6-11 YEARS OF AGE
I-163	TREATMENT OF PHOTOPHOBIA
I-164	CHRONIC BACTERIAL PROSTATITIS
I-165	MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
I-166	TREATMENT OF BULIMIA
I-167	COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS
I-168	MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)
I-169	USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER
I-170	PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS
I-171	RELIEF OF SYMPTOMS OF THE COMMON COLD
I-172	TREATMENT OF INITIAL EPISODE OF GENITAL HERPES
I-173	PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY
I-174	PELVIC INFLAMMATORY DISEASE
I-175	TREATMENT OF TINEA CORPORIS AND TINEA CRURIS
I-176	TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
I-177	TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178	TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179	NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
I-180	TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
I-181	TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182	TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183	MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
I-184	TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG)
I-185	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-186	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187	PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-188	TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
I-189	TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
I-190	PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
I-191	ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY INDICATION

I-192	THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
I-193	TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
I-194	CONGESTIVE HEART FAILURE
I-195	FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER
I-196	ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-197	MAINTENANCE OF HEALING OF DUODENAL ULCER
I-198	FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER
I-199	MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES
I-200	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
I-201	EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
I-202	SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA
I-203	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-204	USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-205	INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS
I-206	TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
I-207	FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-208	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
I-209	PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
I-210	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
I-211	FOR USE IN PEDIATRIC POPULATION
I-212	TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213	TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
I-214	TREATMENT OF OSTEOPOROSIS
I-215	PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216	FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-217	PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-218	USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)
I-219	USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
I-220	TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
I-221	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
I-222	PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
I-223	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
I-224	FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-225	USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
I-226	FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
I-227	SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD)

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY INDICATION

I-228	PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL
I-229	PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
I-230	IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
I-231	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
I-232	TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
I-233	PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSUFSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
I-234	FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER
I-235	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
I-236	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-237	MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-238	ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS
I-239	TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
I-240	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS
I-241	USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER
I-242	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS
I-243	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS
I-244	REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
I-245	TREATMENT OF ACUTE SINUSITIS
I-246	TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
I-247	USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG
I-248	INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM
I-249	TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY
I-250	PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C
I-251	TREATMENT OF GENERALIZED ANXIETY DISORDER
I-252	NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN
I-253	COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN
I-254	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)
I-255	PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)
I-256	USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY
I-257	TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION
I-258	FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE
I-259	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY INDICATION

I-260	EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)
I-261	TREATMENT OF SOCIAL ANXIETY DISORDER
I-262	TREATMENT OF PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12
I-263	TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY
I-264	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION
I-265	TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER
I-266	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES
I-267	USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES
I-268	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE
I-269	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
I-270	ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
I-271	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-272	TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
I-273	ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-274	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
I-275	USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES
I-276	USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
I-277	TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA
I-278	TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)
I-279	TREATMENT OF POST-TRAUMATIC STRESS DISORDER
I-280	USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
I-281	INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-282	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
I-283	TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS
I-284	TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE
I-285	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER
I-286	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III
I-287	USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH
I-288	CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE
I-289	USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL
I-290	PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-291	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
I-292	TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-293	TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY INDICATION

I-294	TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS
I-295	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS
I-296	LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY
I-297	SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-298	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA
I-299	USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM
I-300	PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE
I-301	TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS
I-302	TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME
I-303	INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS
I-304	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV
I-305	TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
I-306	INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE
I-307	NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES
I-308	TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMOTOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS
I-309	INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-310	REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES
I-311	ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS
I-312	FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-313	EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE
I-314	TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES
I-315	THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
I-316	TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID
I-317	PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER
I-318	FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-319	USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS
I-320	TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)
I-321	JUVENILE RHEUMATOID ARTHRITIS
I-322	USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
I-323	COLORECTAL CANCER
I-324	REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
I-325	PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
I-326	GENERALIZED ANXIETY DISORDER
I-327	SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
I-328	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
I-329	UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY INDICATION

I-330	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD
I-331	TREATMENT OF MODERATE ACNE VULGARIS
I-332	EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN)
I-333	TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
I-334	LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
I-335	ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
I-336	EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
I-337	PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME
I-338	MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
I-339	TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
I-340	ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
I-341	BREAST CANCER COMBINATION THERAPY
I-342	USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-343	USE OF COREG FOR SEVERE HEART FAILURE
I-344	ACNE VULGARIS
I-345	TREATMENT OF POSTTRAUMATIC STRESS DISORDER
I-346	TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
I-347	TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE
I-348	LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
I-349	ACUTE CORONARY SYNDROME
I-350	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
I-351	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
I-352	ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
I-353	TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
I-354	MANAGEMENT OF POST HERPETIC NEURALGIA
I-355	PREMENSTRUAL DYSPHORIC DISORDER
I-356	TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
I-357	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-358	TREATMENT OF PANIC DISORDER
I-359	TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE
I-360	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE
I-361	TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
I-362	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-363	ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
I-364	TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
I-365	TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
I-366	PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY INDICATION

I-367	COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS:METFORMIN,SULFONYLUREAS,REPAGLINIDE,OR THIAZOLIDINEDIONES
I-368	USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
I-369	PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
I-370	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
I-371	HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
I-372	NOSOCOMIAL PNEUMONIA
I-373	TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
I-374	SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS
I-375	FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
I-376	TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
I-377	USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
I-378	RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-379	USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION
I-380	TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
I-381	TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
I-382	FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
I-383	TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
I-384	USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
I-385	MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD"INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML TO STREPTOCOCCUS PNEUMONIAE
I-386	RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
I-387	ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE
I-388	TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-389	SUPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
I-390	USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE,DIABETES,PERIPHERAL VESSEL DISEASE,STROKE HISTORY,OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH,REDUCE NONFATAL MI & STROKE.....
I-391	ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY
I-392	TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL
I-393	CHRONIC BACTERIAL PROSTATITIS
I-394	USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES
I-395	TO IMPROVE PHYSICAL FUNCTION
I-396	EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
I-397	EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY INDICATION

I-398	IDIOPATHIC SHORT STATURE
I-399	TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS
I-400	USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-401	LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
I-402	DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
I-403	USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE
I-404	MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
I-405	TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN
I-406	PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
I-407	IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION
I-408	STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE INDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP)
I-409	ESOPHAGEAL CANDIDIASIS
I-410	USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS
I-411	EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS
I-412	MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-413	ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-414	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
I-415	SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY
I-416	THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS

EXCLUSIVITY MISCELLANEOUS

M-1	INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
M-2	APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
M-3	ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN
M-4	CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD
M-5	INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION
M-6	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION
M-7	CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
M-8	ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
M-9	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

EXCLUSIVITY MISCELLANEOUS

M-10	INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
M-11	USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
M-12	NEW LANGUAGE FOR PEDIATRIC USE
M-13	INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
M-14	ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
M-15	LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
M-16	CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
M-17	INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
M-18	INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
M-19	INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
M-20	LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
M-21	COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
M-22	CHANGE IN TIME TO ONSET OF ACTION
M-23	INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
M-24	INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
M-25	ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT
M-26	INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
M-27	INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY
M-28	INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION
M-29	LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS

PATENT USE

U-1	PREVENTION OF PREGNANCY
U-2	TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
U-3	TREATMENT OF HYPERTENSION
U-4	PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS
U-5	METHOD OF PRODUCING BRONCHODILATION
U-6	METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS
U-7	INCREASING CARDIAC CONTRACTILITY
U-8	ACUTE MYOCARDIAL INFARCTION
U-9	CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT
U-10	DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS
U-11	TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS
U-12	METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION
U-13	A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT
U-14	ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES
U-15	METHOD OF LOWERING INTRAOCULAR PRESSURE
U-16	USE IN LUNG SCANNING PROCEDURES
U-17	TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
U-18	METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
U-19	TREATMENT OF INFLAMMATION
U-20	A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-21	TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS
U-22	METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS
U-23	METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE
U-24	METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST
U-25	REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS
U-26	REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-27	DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-28	CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY
U-29	CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY
U-30	CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY
U-31	INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY
U-32	PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN
U-33	TREATING VIRAL INFECTIONS IN A MAMMAL
U-34	TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL
U-35	TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION
U-36	METHODS OF TREATING BACTERIAL ILLNESSES
U-37	METHOD OF TREATING GASTROINTESTINAL DISEASE
U-38	TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
U-39	ANGINA PECTORIS
U-40	METHOD OF TREATMENT OF BURNS
U-41	METHOD OF TREATING CARDIAC ARRHYTHMIAS
U-42	ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER
U-43	MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-44	RELIEF OF NAUSEA AND VOMITING
U-45	TREATMENT OF INFLAMMATION AND ANALGESIA
U-46	TREATMENT OF PANIC DISORDER
U-47	STIMULATION OF THE RELEASE OF GROWTH HORMONE
U-48	ANALGESIA
U-49	SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
U-50	USE IN TREATING INFLAMMATORY DERMATOSES
U-51	BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
U-52	TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-53	HYPERCALCEMIA OF MALIGNANCY
U-54	REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS
U-55	TREATMENT OF PAIN
U-56	AID TO SMOKING CESSATION
U-57	OPHTHALMIC USE OF NORFLOXACIN
U-58	METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
U-59	METHOD OF TREATING HYPERCHOLESTEROLEMIA
U-60	NASAL ADMINISTRATION OF BUTORPHANOL
U-61	CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD
U-62	CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY
U-63	ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE
U-64	TREATMENT OF VIRAL INFECTIONS
U-65	METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
U-66	TRIPHASIC REGIMEN
U-67	METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL
U-68	TREATMENT OF ACTINIC KERATOSIS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-69	TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS
U-70	TREATMENT OF TRANSIENT INSOMNIA
U-71	METHOD OF TREATMENT OF HEART FAILURE
U-72	TREATMENT OF MIGRAINE
U-73	METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES
U-74	METHOD OF PROVIDING HYPNOTIC EFFECT
U-75	RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
U-76	USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
U-77	TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-78	ULCERATIVE COLITIS
U-79	SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD
U-80	METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
U-81	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS
U-82	TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE
U-83	TREATMENT OF SEIZURES
U-84	A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
U-85	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-86	METHOD OF TREATING CERTAIN FORMS OF EPILEPSY
U-88	TREATMENT OF MODERATE PLAQUE PSORIASIS
U-89	TREATMENT OR PROPHYLAXIS OF EMESIS
U-90	TREATMENT OF PYSCHOTIC DISORDERS
U-91	ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS
U-92	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY
U-93	USE AS AN ANTIHISTAMINE/DECONGESTANT
U-94	TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED
U-95	SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS
U-96	METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS
U-97	A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT
U-98	A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL
U-99	METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM
U-100	METHOD OF TREATING OCULAR INFLAMMATION
U-101	ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED
U-102	METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN
U-103	TREATMENT OF OCULAR HYPERTENSION
U-104	TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE
U-105	EMESIS
U-106	TREATMENT OF EPILEPSY
U-107	TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
U-108	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS
U-109	ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE
U-110	USE AS A RETRIEVABLE PERSSARY
U-111	DIABETES
U-112	CONTRACEPTION
U-113	METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE
U-114	USE FOR INHIBITING BONE RESORPTION

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-115	USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS
U-116	METHOD OF MYOCARDIAL IMAGING
U-117	TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES
U-118	METHOD OF LOWERING BLOOD SUGAR LEVEL
U-119	TREATMENT OF NASAL HYPERSECRETION
U-120	CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES
U-121	METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS
U-122	A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS
U-123	METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS
U-124	TREATMENT OF ACNE
U-125	TREATMENT NEUROGENERATIVE DISEASES
U-126	TREATMENT OF GASTRITIS
U-127	METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE
U-128	METHOD FOR TREATMENT OF TUMORS
U-129	METHOD TO DESTROY OR IMPAIR TARGET CELLS
U-130	MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS
U-131	PHOTODAMAGED SKIN
U-132	INHIBITING HIV PROTEASE
U-133	MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET
U-134	TREATMENT OF ACNE VULGARIS
U-135	ANTITUMOR AGENT
U-136	PROCESS FOR WASTE NITROGEN REMOVAL
U-137	METHOD OF TREATING BACTERIAL VAGINOSIS
U-138	TREATMENT OF ALLERGIC RHINITIS
U-139	TREATMENT OF ALLERGIC REACTIONS
U-140	USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION
U-141	TREATMENT OF ULCERATIVE COLITIS
U-142	METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE
U-143	BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING
U-144	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS
U-145	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS
U-146	METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS
U-147	DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2
U-148	DEVICE FOR COLLECTING A BREATH SAMPLE
U-149	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES
U-150	METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE
U-151	RELIEF OF SYMPTOMS OF THE COMMON COLD
U-152	METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER
U-153	TREATMENT OF INITIAL EPISODE GENITAL HERPES
U-154	METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER
U-155	TREATMENT OF ERECTILE DYSFUNCTION
U-156	METHOD OF PROVIDING ANESTHESIA
U-157	TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY
U-158	ANGINA
U-159	TREATMENT OF INTERSTITIAL CYSTITIS
U-160	TREATMENT OF BACTERIAL INFECTIOUS DISEASE
U-161	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-162	METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
U-163	METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
U-164	METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
U-165	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
U-166	TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER
U-167	METHOD FOR TREATING HIV-1 INFECTION
U-168	METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
U-169	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
U-170	METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
U-171	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
U-172	TREATMENT OF GENITAL WARTS
U-173	ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
U-174	USE AS AN ANTIHISTAMINE AGENT
U-175	METHOD OF TREATING MALIGNANT TUMORS
U-176	METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES
U-177	FUNGICIDE
U-178	FACILITATED ADHERENCE OF AGENTS TO SKIN
U-179	ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
U-180	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-181	PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
U-182	USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-183	TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
U-184	TREATING ALLERGIC EYE DISEASES IN HUMANS
U-185	METHOD OF TREATING HYPERTENSION
U-186	METHOD FOR TREATING GI DISORDERS CAUSED BY H.RYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
U-187	THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
U-188	TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER
U-189	ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
U-190	USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
U-191	METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
U-192	USE IN TREATING ALLERGIC REACTIONS
U-193	PSORIASIS
U-194	TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE
U-195	METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON
U-196	TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
U-197	USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
U-198	TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA
U-199	METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT
U-200	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-201	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-202	METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
U-203	TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-204	USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-205	METHOD FOR TREATING HEARTBURN
U-206	METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION
U-207	USE AS NASAL SPRAY
U-208	VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
U-209	VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION
U-210	METHOD OF TREATING CONGESTIVE HEART FAILURE
U-211	USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-212	METHOD OF TREATMENT OF PARKINSON'S DISEASE
U-213	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
U-214	USE AS A BLOOD GLUCOSE-LOWERING AGENT
U-215	TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
U-216	TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE
U-217	METHOD OF PRODUCING ANESTHESIA
U-218	METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
U-219	TREATMENT OF PARKINSON'S DISEASE
U-220	METHOD OF DIAGNOSIS
U-221	SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
U-222	METHOD OF TREATING PAGET'S DISEASE USING ACTONEL
U-223	TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
U-224	CONTROLLING INTRAOCULAR PRESSURE
U-225	MEHTOD FOR DELIVERY
U-226	METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
U-227	NASAL ADMINISTRATION
U-228	ASTHMA
U-229	CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
U-230	PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
U-231	USE IN PARKINSON'S DISEASE
U-232	METHOD OF TREATING MIGRAINE
U-233	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-234	METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
U-235	METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
U-236	TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY
U-237	METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
U-238	IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....
U-239	TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
U-240	TREATMENT OF ACUTE MIGRAINE ATTACKS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-241	FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-242	USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
U-243	TOPICAL ADMINISTRATION
U-244	PLATELET AGGREGATION INHIBITORS
U-245	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-246	PHOSPHATE BINDING
U-247	TREATMENT OF RHEUMATOID ARTHRITIS
U-248	TREATMENT OF HIV
U-249	METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE
U-250	TREATMENT OF HEPATITIS B INFECTION
U-251	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
U-252	METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE
U-253	ORAL TRANSMUCOSAL USE
U-254	USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
U-255	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
U-256	TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
U-257	TREATMENT OF HIV INFECTION
U-258	TREATMENT OF NEURODEGENERATIVE DISEASES
U-259	TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE
U-260	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
U-261	TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
U-262	TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
U-263	METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN
U-264	METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN
U-265	USE AS LAXATIVE
U-266	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA
U-267	PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
U-268	ACROMEGALY
U-269	EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
U-270	METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
U-271	METHOD OF TREATING TUMORS
U-272	METHOD OF TREATING CARCINOMA
U-273	CUTANEOUS T-CELL LYMPHOMA
U-274	ZANAMIVIR FOR INHALATION
U-275	METHOD OF USE OF THE DRUG SUBSTANCE
U-276	METHOD OF USE OF LEVOBUPIVACAINE
U-277	NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
U-278	METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
U-279	METHOD OF USE OF THE APPROVED PRODUCT
U-280	TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
U-281	ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-282	METHOD OF TREATING BACTERIAL INFECTIONS
U-283	METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
U-284	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
U-285	DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
U-286	DEPRESSION
U-287	TREATMENT OR PREVENTION OF OSTEOPOROSIS
U-288	THERAPY OF INFLUENZA
U-289	TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
U-290	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
U-291	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN
U-292	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE
U-293	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
U-294	TREATMENT OF HYPERPIGMENTARY DISORDERS
U-295	TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-296	TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY
U-297	PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS
U-298	METHOD OF COMBATING BACTERIA IN A PATIENT
U-299	TREATMENT OF ADENOMATOUS POLYPS
U-300	INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
U-301	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
U-302	TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
U-303	METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS
U-304	A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION
U-305	METHODS FOR USING THE DRUG PRODUCT
U-306	TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY
U-307	CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
U-308	CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA
U-309	TREATING SJOEGREN SYNDROME
U-310	TREATMENT OF XEROSTOMIA
U-311	HORMONE REPLACEMENT
U-312	PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER
U-313	TREATMENT OF CONGESTIVE HEART FAILURE
U-314	METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
U-315	METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
U-316	METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
U-317	METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
U-318	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
U-319	TREATMENT OF MICROBIAL INFECTIONS
U-320	INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA
U-321	REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
U-322	TREATMENT OF ALZHEIMER'S DEMENTIA

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-323	USE AS A BILE ACID SEQUESTRANT
U-324	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE
U-325	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
U-326	METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
U-327	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE
U-328	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH
U-329	USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-330	TREATMENT OF NAUSEA AND VOMITING
U-331	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-332	TREATMENT OR PREVENTION OF BRONCHOSPASM
U-333	METHOD OF TREATING OCULAR HYPERTENSION
U-334	TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
U-335	USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
U-336	DIAGNOSTIC RADIOIMAGING
U-337	USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
U-338	METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
U-339	PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN
U-340	THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN
U-341	METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
U-342	METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER
U-343	REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION
U-344	METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR
U-345	RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION
U-346	METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR
U-347	METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
U-348	METHOD OF USE FOR INHIBITING HIV INFECTION
U-349	METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION
U-350	PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-351	INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR
U-352	INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-353	PREVENTION AND TREATMENT OF OSTEOPOROSIS
U-354	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-355	METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING
U-356	DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
U-357	USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
U-358	DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
U-359	METHOD OF USE OF VISICOL

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-360	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-361	MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY
U-362	USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS
U-363	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011
U-364	TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-365	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION
U-366	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION
U-367	TREATMENT OF CARDIOVASCULAR DISORDERS
U-368	HEARTBURN
U-369	METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE
U-370	INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS
U-371	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
U-372	METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
U-373	GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-374	KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
U-375	METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
U-376	TREATMENT OF INFLUENZA
U-377	METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
U-378	METHOD FOR TREATING INCONTINENCE
U-379	METHOD OF TREATING ONYCHROMYCOSIS
U-380	COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
U-381	TREATMENT OF HYPERPHOSPHATEMIA
U-382	METHOD OF STABLIZING PROSTAGLANDIN
U-383	METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
U-384	TREATMENT OF CMV RETINITIS
U-385	TREATMENT OF PEPTIC ULCERS
U-386	TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
U-387	TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
U-388	SMOKING CESSATION AID APPLIED TO THE SKIN
U-389	SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
U-390	METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
U-391	USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER
U-392	TREATMENT OF PATIENTS FOR INFLAMMATION
U-393	MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
U-394	METHOD OF USE OF ALPHAGAN
U-395	METHOD OF USE OF ALPHAGAN P

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-396	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
U-397	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
U-398	TREATMENT OF GENERALIZED ANXIETY DISORDER
U-399	IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS
U-400	USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESPONSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS
U-401	USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
U-402	TREATMENT OF ACTINIC KERATOSES
U-403	ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES
U-404	TREATMENT OF ALLERGIC CONJUNCTIVITIS
U-405	FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)
U-406	METHOD OF USE OF ATOVAQUONE AND PROGUANIL
U-407	METHOD OF TREATING OTOPATHY
U-408	FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION
U-409	METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE
U-410	METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-411	METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION
U-412	TREATMENT OF TYPE 2 DIABETES
U-413	USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS
U-414	A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-415	A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-416	A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-417	COMBINATION USE OF AD-4833 WITH A BIGUANIDE
U-418	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-419	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-420	METHOD OF TREATMENT OF TYPE II DIABETES
U-421	USE FOR SEDATION
U-422	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-423	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
U-424	FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
U-425	METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-426	PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
U-427	METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
U-428	METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
U-429	METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
U-430	METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
U-431	POSTTRAUMATIC STRESS DISORDER

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-432	REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
U-433	USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
U-434	CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS
U-435	A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
U-436	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
U-437	METHOD OF USE EQUAL TO PROCESS OF PREPARATION
U-438	TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
U-439	TREATMENT OF OBESITY
U-440	METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
U-441	METHOD OF TREATING MS BY ADMINISTERING COPAXONE
U-442	METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
U-443	MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
U-444	METHOD OF TREATING
U-445	USE AS AN ANTIMYCOTIC AGENT
U-446	TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
U-447	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-448	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-449	USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
U-450	INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
U-451	TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-452	USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
U-453	TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
U-454	METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
U-455	TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
U-456	METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
U-457	METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
U-458	METHOD OF USE OF IMAGENT
U-459	TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-460	METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
U-461	METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
U-462	SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
U-463	VENOGRAPHY
U-464	PERIPHERAL ARTERIOGRAPHY
U-465	CT IMAGING OF THE HEAD
U-466	TREATMENT OF IRRITABLE BOWEL SYNDROME
U-467	USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-468	METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
U-469	TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE
U-470	THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
U-471	METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
U-472	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
U-473	TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
U-474	TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN
U-475	TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-476	METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
U-477	METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
U-478	METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
U-479	METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
U-480	CONTRAST AGENT FOR MRI
U-481	DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY
U-482	METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....
U-483	METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND
U-484	METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
U-485	METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
U-486	EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE
U-487	METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
U-488	METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA
U-489	EXPECTORANT
U-490	TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-491	METHOD OF DELIVERING A DRUG TO THE LUNG
U-492	METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID
U-493	TREATMENT OF TYPE 2 DIABETES MELLITUS
U-494	TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
U-495	PERITONEAL DIALYSIS SOLUTION
U-496	METHOD FOR TREATING CHRONIC RENAL FAILURE
U-497	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
U-498	INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
U-499	METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
U-500	USE AS AN ANTIHYPERTENSIVE AGENT
U-501	TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
U-502	PITYRIASIS VERSICOLOR
U-503	GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-504	TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
U-505	ULTRASOUND CONTRAST AGENT
U-506	PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
U-507	ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
U-508	METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
U-509	TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEIOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-510	TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
U-511	USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
U-512	USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA
U-513	METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA
U-514	PREVENTION OF OVULATION IN A WOMAN
U-515	TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
U-516	METHOD OF TREATING A PSYCHOTIC DISEASE
U-517	STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
U-518	OBSESSIVE COMPULSIVE DISORDER
U-519	POST OPERATIVE NAUSEA AND VOMITING
U-520	PREMENOPAUSAL OSTEOPOROSIS
U-521	METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-522	TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA
U-523	METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL
U-524	METHOD OF TREATING DIARRHEA
U-525	METHOD OF TREATING PARASITIC INFECTIONS
U-526	METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION
U-527	METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE
U-528	PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
U-529	ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
U-530	TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES
U-531	TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES
U-532	TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR
U-533	ERECTILE DYSFUNCTION
U-534	HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA
U-535	TREATMENT OF SOCIAL ANXIETY DISORDER
U-536	CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING
U-537	TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE
U-538	FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS
U-539	TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-540	TREATMENT OF FUNGAL INFECTIONS
U-541	METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1
U-542	METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION

FDA data supplied by DrugPatentWatch.com

PATENT AND EXCLUSIVITY TERMS

PATENT USE

U-543	TREATMENT OF SCHIZOPHRENIA
U-544	TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
U-545	METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT
U-546	USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE

FDA data supplied by DrugPatentWatch.com